Methods and compositions for modulating a genome

ABSTRACT

Methods and compositions for modulating a target genome are disclosed.

RELATED APPLICATIONS

This application is a continuation of International Application No. PCT/US2021/020948, filed Mar. 4, 2021, which claims priority to U.S. Ser. No. 62/985,285 filed Mar. 4, 2020, U.S. Ser. No. 63/035,627 filed Jun. 5, 2020, and U.S. Ser. No. 63/067,828 filed Aug. 19, 2020, the entire contents of each of which is incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 14, 2022, is named V2065-700620_SL.xml and is 4,442,008 bytes in size.

BACKGROUND

Integration of a nucleic acid of interest into a genome occurs at low frequency and with little site specificity, in the absence of a specialized protein to promote the insertion event. Some existing approaches, like CRISPR/Cas9, are more suited for small edits that rely on host repair pathways, and are less effective at integrating longer sequences. Other existing approaches, like Cre/loxP, require a first step of inserting a loxP site into the genome and then a second step of inserting a sequence of interest into the loxP site. There is a need in the art for improved compositions (e.g., proteins and nucleic acids) and methods for inserting, altering, or deleting sequences of interest in a genome.

SUMMARY OF THE INVENTION

This disclosure relates to novel compositions, systems and methods for altering a genome at one or more locations in a host cell, tissue or subject, in vivo or in vitro. In particular, the invention features compositions, systems and methods for inserting, altering, or deleting sequences of interest in a host genome.

Features of the compositions or methods can include one or more of the following enumerated embodiments.

ENUMERATED EMBODIMENTS

1. A system for modifying DNA comprising:

-   -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence (e.g., a CRISPR         spacer) that binds a target site (e.g., a second strand of a         site in a target genome), (ii) optionally a sequence that binds         the polypeptide, (iii) a heterologous object sequence, and (iv)         a 3′ target homology domain.         2. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain;     -   wherein:     -   (i) the polypeptide comprises a heterologous targeting domain         (e.g., in the DBD or the endonuclease domain) that binds         specifically to a sequence comprised in the target site; and/or     -   (ii) the template RNA comprises a heterologous homology sequence         having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%         homology to a sequence comprised in a target site.         3. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the RT domain comprises a sequence of Table 1 or 3 or a         sequence of a reverse transcriptase domain of Table 2 or a         sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,         98%, or 99% identity thereto.         4. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the RT domain comprises a sequence of Table 1 or 3, or a         sequence of a reverse transcriptase domain of Table 2,     -   wherein the RT domain further comprises a number of         substitutions relative to the natural sequence, e.g., at least         1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100         substitutions.         5. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the system is capable of producing an insertion into the         target site of at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90,         95, or 100 nucleotides.         6. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the system is capable of producing an insertion into the         target site of at least 1, 2, 3, 4, 5, 10, 20, 30, 40, or 44         nucleotides.         7. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the heterologous object sequence is at least 74, 75, 76,         77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,         93, 94, 95, 96, 97, 98, 99, 100, 120, 140, 160, 180, 200, 500,         or 1,000 nts in length.         8. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the heterologous object sequence is at least 1, 2, 3, 4,         5, 10, 20, 30, 40, 50, 60, 70, or 73 nucleotides in length.         9. The system of any of the preceding embodiments, wherein one         or more of: the RT domain is heterologous to the DBD; the DBD is         heterologous to the endonuclease domain; or the RT domain is         heterologous to the endonuclease domain.         10. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the system is capable of producing a deletion into the         target site of at least 81, 85, 90, 95, 100, 110, 120, 130, 140,         150, 160, 170, 180, 190, or 200 nucleotides.         11. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the system is capable of producing a deletion into the         target site of at least 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60,         70, or 80 nucleotides.         12. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein the system is capable of producing nucleotide         substitutions, e.g., transitions and/or transversions, into the         target site of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10         nucleotides.         13. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   wherein (a)(ii) and/or (a)(iii) comprises a TAL domain; a zinc         finger domain; or a CRISPR/Cas domain chosen from Table 4 or a         functional variant (e.g., mutant) thereof.         14. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence (e.g., a CRISPR         spacer) that binds a target site (e.g., a second strand of a         site in a target genome), (ii) optionally a sequence that binds         the polypeptide, (iii) a heterologous object sequence, and (iv)         a 3′ target homology domain,     -   wherein the endonuclease domain, e.g., nickase domain, cuts both         the first strand and the second strand of the target site DNA,         and wherein the cuts are separated from one another by at least         2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 30 nucleotides.         15. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) a sequence that specifically binds the RT         domain, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain.         16. The system of any of the preceding embodiments, wherein the         template RNA further comprises a sequence that binds (a)(ii)         and/or (a)(iii).         17. A system for modifying DNA comprising:     -   (a) a first polypeptide or a nucleic acid encoding the first         polypeptide, wherein the first polypeptide comprises (i) a         reverse transcriptase (RT) domain and (ii) optionally a         DNA-binding domain,     -   (b) a second polypeptide or a nucleic acid encoding the second         polypeptide, wherein the second polypeptide comprises (i) a         DNA-binding domain (DBD); (ii) an endonuclease domain, e.g., a         nickase domain; and     -   (c) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds the         second polypeptide (e.g., that binds (b)(i) and/or         (b)(ii)), (ii) optionally a sequence that binds the first         polypeptide (e.g., that specifically binds the RT domain), (iii)         a heterologous object sequence, and (iv) a 3′ target homology         domain.         18. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, and (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain;     -   (b) a first template RNA (or DNA encoding the RNA) comprising         (e.g., from 5′ to 3′) (i) a sequence that binds the polypeptide         (e.g., that binds (a)(ii) and/or (a)(iii)) and (ii) a sequence         that binds a target site (e.g., a second strand of a site in a         target genome), (e.g., wherein the first RNA comprises a gRNA);     -   (c) a second template RNA (or DNA encoding the RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds the         polypeptide (e.g., that specifically binds the RT domain), (ii)         a heterologous object sequence, and (iii) a 3′ target homology         domain.         19. The system of any of the preceding embodiments, wherein the         second template RNA comprises (i).         20. The system of any of the preceding embodiments, wherein the         first template RNA comprises a first conjugating domain and the         second template RNA comprises a second conjugating domain.         21. The system of any of the preceding embodiments, wherein the         first and second conjugating domains are capable of hybridizing         to one another, e.g., under stringent conditions, e.g., wherein         the stringent conditions for hybridization includes         hybridization in 4×sodium chloride/sodium citrate (SSC), at         about 65° C., followed by a wash in 1×SSC, at about 65° C.         22. The system of any of the preceding embodiments, wherein the         first and second conjugating domains may be joined covalently,         e.g., by splint ligation, e.g., by the method described by         Moore, M. J., & Query, C. C. Methods in Enzymology, 317,         109-123, 2000.         23. The system of any of the preceding embodiments, wherein         association of the first conjugating domain and the second         conjugating domain colocalizes the first template RNA and the         second template RNA.         24. The system of any of the preceding embodiments, wherein the         reverse transcriptase (RT) domain is from a retrotransposon, or         a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or 99%         identity thereto.         25. A system for modifying DNA comprising:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain from a retrotransposon, or a sequence having at         least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity         thereto, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence (e.g., a CRISPR         spacer) that binds a target site (e.g., a second strand of a         site in a target genome), (ii) optionally a sequence that binds         the polypeptide, (iii) a heterologous object sequence, and (iv)         a 3′ target homology domain.         26. The system of any of the preceding embodiments, wherein the         template RNA comprises (i).         27. The system of any of the preceding embodiments, wherein the         template RNA comprises (ii).         28. The system of any of the preceding embodiments, wherein the         template RNA comprises (i) and (ii).         29. The system of any of the preceding embodiments, wherein the         reverse transcriptase domain comprises an amino acid sequence         according to a reverse transcriptase domain of any of Table 30,         Table 31, Table 41, Table 44, or Table 50, or a sequence having         at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%         identity thereto, or a functional fragment thereof.         30. A template RNA (or DNA encoding the template RNA) comprising         a targeting domain (e.g., a heterologous targeting domain) that         binds specifically to a sequence comprised in the target DNA         molecule (e.g., a genomic DNA), a sequence that specifically         binds an RT domain of a polypeptide, and a heterologous object         sequence.         31. A template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds a         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds an endonuclease         and/or a DNA-binding domain of a polypeptide, (iii) a         heterologous object sequence, and (iv) a 3′ target homology         domain.         32. The template RNA of any of the preceding embodiments,         wherein the template RNA comprises (i).         33. The template RNA of any of the preceding embodiments,         wherein the template RNA comprises (ii).         34. A template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) a sequence that binds a target site         (e.g., a second strand of a site in a target genome), (ii) a         sequence that binds an endonuclease and/or a DNA-binding domain         of a polypeptide, (iii) a heterologous object sequence, and (iv)         a 3′ target homology domain,     -   wherein (i) comprises a nucleic acid sequence with         complementarity to a sequence of a gene of any of Tables 9-12 or         with no more than 1, 2, 3, 4, or 5 differences from said         sequence having said complementarity.         35. A template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) a sequence that binds a target site         (e.g., a second strand of a site in a target genome), (ii) a         sequence that specifically binds an RT domain of a         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain.         36. The template RNA of any of the preceding embodiments,         further comprising (v) a sequence that binds an endonuclease         and/or a DNA-binding domain of a polypeptide (e.g., the same         polypeptide comprising the RT domain).         37. The template RNA of any of the preceding embodiments,         wherein the RT domain comprises a sequence selected of Table 1         or 3 or a sequence of a reverse transcriptase domain of Table 2         or a sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%,         96%, 97%, 98%, or 99% identity thereto.         38. The template RNA of any of the preceding embodiments,         wherein the RT domain comprises a sequence selected of Table 1         or 3 or a sequence of a reverse transcriptase domain of Table 2,         wherein the RT domain further comprises a number of         substitutions relative to the natural sequence, e.g., at least         1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100         substitutions.         39. The template RNA of any of the preceding embodiments,         wherein the sequence of (ii) specifically binds the RT domain.         40. The template RNA of any of the preceding embodiments,         wherein the sequence that specifically binds the RT domain is a         sequence, e.g., a UTR sequence, of Table 1 or from a domain of         Table 2, or a sequence having at least 70, 75, 80, 85, 90, 95,         or 99% identity thereto.         41. A template RNA (or DNA encoding the template RNA) comprising         from 5′ to 3′: (ii) a sequence that binds an endonuclease and/or         a DNA-binding domain of a polypeptide, (i) a sequence that binds         a target site (e.g., a second strand of a site in a target         genome), (iii) a heterologous object sequence, and (iv) a 3′         target homology domain.         42. A template RNA (or DNA encoding the template RNA) comprising         from 5′ to 3′: (iii) a heterologous object sequence, (iv) a 3′         target homology domain, (i) a sequence that binds a target site         (e.g., a second strand of a site in a target genome), and (ii) a         sequence that binds an endonuclease and/or a DNA-binding domain         of a polypeptide.         43. The system or template RNA of any of the preceding         embodiments, wherein the template RNA, first template RNA, or         second template RNA comprises a sequence that specifically binds         the RT domain.         44. The system or template RNA of any of the preceding         embodiments, wherein the sequence that specifically binds the RT         domain is disposed between (i) and (ii).         45. The system or template RNA of any of the preceding         embodiments, wherein the sequence that specifically binds the RT         domain is disposed between (ii) and (iii).         46. The system or template RNA of any of the preceding         embodiments, wherein the sequence that specifically binds the RT         domain is disposed between (iii) and (iv).         47. The system or template RNA of any of the preceding         embodiments, wherein the sequence that specifically binds the RT         domain is disposed between (iv) and (i).         48. The system or template RNA of any of the preceding         embodiments, wherein the sequence that specifically binds the RT         domain is disposed between (i) and (iii).         49. A system for modifying DNA, comprising:     -   (a) a first template RNA (or DNA encoding the first template         RNA) comprising (i) sequence that binds an endonuclease domain,         e.g., a nickase domain, and/or a DNA-binding domain (DBD) of a         polypeptide, and (ii) a sequence that binds a target site (e.g.,         a second strand of a site in a target genome), (e.g., wherein         the first RNA comprises a gRNA);     -   (b) a second template RNA (or DNA encoding the second template         RNA) comprising (i) a sequence that specifically binds a reverse         transcriptase (RT) domain of a polypeptide (e.g., the         polypeptide of (a)), (ii) a heterologous object sequence,         and (iii) 3′ target homology domain.         50. The system of any of the preceding embodiments, wherein the         nucleic acid encoding the first template RNA and the nucleic         acid encoding the second template RNA are two separate nucleic         acids.         51. The system of any of the preceding embodiments, wherein the         nucleic acid encoding the first template RNA and the nucleic         acid encoding the second template RNA are part of the same         nucleic acid molecule, e.g., are present on the same vector.         52. The system of any of the preceding embodiments, wherein the         system is capable of producing an insertion into the target site         of at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100         nucleotides.         53. The system of any of the preceding embodiments, wherein the         heterologous object sequence is at least 74, 75, 76, 77, 78, 79,         80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,         96, 97, 98, 99, 100, 120, 140, 160, 180, 200, 500, or 1,000 nts         in length.         54. The system of any of the preceding embodiments, wherein the         system is capable of producing a deletion into the target site         of at least 81, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160,         170, 180, 190, or 200 nucleotides.         55. The system of any of the preceding embodiments, wherein one         or both of the template RNA and the RNA encoding the polypeptide         of (a) comprises chemically modified mRNA, e.g., mRNA comprising         a chemically modified base, e.g., mRNA comprising         5-methoxyuridine.         56. The system of any of the preceding embodiments, wherein one         or both of the template RNA and the RNA encoding the polypeptide         of (a) comprises chemically modified RNA, e.g., RNA comprising a         chemically modified base, e.g., RNA comprising 2′-o-methyl         phosphorothioate.         57. The system of any of the preceding embodiments, wherein one         or both of the template RNA and the RNA encoding the polypeptide         of (a) comprises chemically modified RNA, e.g., RNA comprising a         chemically modified base, e.g., 2′-o-methyl phosphorothioate, at         one or both of the 3, 4, or 5 bases at the 5′ or 3′ end of the         RNA.         58. A polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain; wherein the DBD and/or the endonuclease         domain comprise a heterologous targeting domain that binds         specifically to a sequence comprised in a target DNA molecule         (e.g., a genomic DNA).         59. A polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain, wherein the RT         domain has a sequence of Table 1 or 3 or a sequence of a reverse         transcriptase domain of Table 2, or a sequence having at least         70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity         thereto.         60. A polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain, wherein the RT         domain has a sequence of Table 1 or 3 or a sequence of a reverse         transcriptase domain of Table 2, wherein the RT domain further         comprises a number of substitutions relative to the natural         sequence, e.g., at least 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60,         70, 80, 90, or 100 substitutions.         61. The polypeptide of any of the preceding embodiments, wherein         the polypeptide is encoded by an mRNA, e.g., a chemically         modified mRNA, e.g., an mRNA comprising a chemically modified         base, e.g., an mRNA comprising 5-methoxyuridine.         62. The polypeptide of any of the preceding embodiments, wherein         the polypeptide is encoded by an mRNA, e.g., a chemically         modified mRNA, e.g., an mRNA comprising a chemically modified         base, e.g., an mRNA comprising N1-Methyl-Psuedouridine.         63. A system for modifying DNA, comprising:     -   (a) a first polypeptide or a nucleic acid encoding the         polypeptide, wherein the polypeptide comprises a reverse         transcriptase (RT) domain, wherein the RT domain has a sequence         of Table 1 or 3 or a sequence of a reverse transcriptase domain         of Table 2, or a sequence having at least 70%, 75%, 80%, 85%,         90%, 95%, 96%, 97%, 98%, or 99% identity thereto; and optionally         a DNA-binding domain (DBD) (e.g., a first DBD); and     -   (b) a second polypeptide or a nucleic acid encoding the         polypeptide, wherein the polypeptide comprises (i) a DBD (e.g.,         a second DBD); and (ii) an endonuclease domain, e.g., a nickase         domain.         64. A system for modifying DNA, comprising:     -   (a) a first polypeptide or a nucleic acid encoding the         polypeptide, wherein the polypeptide comprises a reverse         transcriptase (RT) domain, wherein the RT domain has a sequence         of Table 1 or 3 or a sequence of a reverse transcriptase domain         of Table 2, wherein the RT domain further comprises a number of         substitutions relative to the natural sequence, e.g., at least         1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100         substitutions; and optionally a DNA-binding domain (DBD) (e.g.,         a first DBD); and     -   (b) a second polypeptide or a nucleic acid encoding the         polypeptide, wherein the polypeptide comprises (i) a DBD (e.g.,         a second DBD); and (ii) an endonuclease domain, e.g., a nickase         domain.         65. The system of any of the preceding embodiments, wherein the         nucleic acid encoding the first polypeptide and the nucleic acid         encoding the second polypeptide are two separate nucleic acids.         66. The system of any of the preceding embodiments, wherein the         nucleic acid encoding the first polypeptide and the nucleic acid         encoding the second polypeptide are part of the same nucleic         acid molecule, e.g., are present on the same vector.         67. A reaction mixture comprising:     -   a cell and any system, polypeptide, template RNA, or DNA         encoding the same of any preceding embodiment.         68. A reaction mixture comprising:     -   a DNA comprising a target site and any system, polypeptide,         template RNA, or DNA encoding the same of any preceding         embodiment.         69. A kit comprising:     -   the system, polypeptide, template RNA, or DNA encoding the same         of any preceding embodiment;     -   instructions for using the system, polypeptide, template RNA, or         DNA encoding the same; and     -   one or both of a cell or a DNA comprising a target site.         70. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the DBD comprises a TAL         domain.         71. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the DBD comprises a zinc         finger domain.         72. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the DBD comprises a         CRISPR/Cas domain.         73. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the endonuclease domain is a         nickase domain.         74. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the endonuclease domain         comprises a CRISPR/Cas domain.         75. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the CRISPR/Cas domain         comprises a domain or polypeptide from Table 4, or a functional         variant (e.g., mutant) thereof.         76. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the CRISPR/Cas domain         comprises a domain or polypeptide from genus/species from Table         4.         77. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the endonuclease domain         comprises a type IIs nuclease (e.g., FokI), a Holliday Junction         resolvase, or a double-stranded DNA nuclease comprising an         alteration that abrogates its ability to cut one strand (e.g.,         transforming the double-stranded DNA nuclease into a nickase).         78. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain comprises a         reverse transcriptase or functional fragment or variant thereof         chosen from Table 1 or 3 or a sequence of a reverse         transcriptase domain of Table 2.         79. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain comprises one         or more mutations (e.g., an insertion, deletion, or         substitution) relative to a naturally occurring RT domain or an         RT domain or functional fragment chosen from Table 1 or 3 or a         sequence of a reverse transcriptase domain of Table 2, or         sequence listing SEQ ID NO: 1-67 from WO2018089860A1,         incorporated herein by reference.         80. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the one or more mutations are         chosen from D200N, L603W, T330P, D524G, E562Q, D583N, P51L,         S67R, E67K, T197A, H204R, E302K, F309N, W313F, L435G, N454K,         H594Q, L671P, E69K or D653N in the RT domain of murine leukemia         virus reverse transcriptase or a corresponding mutation at a         corresponding position of another RT domain.         81. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the one or more mutations are         chosen from WO2018089860A1, incorporated herein by reference         (e.g., a C952S, and/or C956S, and/or C952S, C956S (double         mutant), and/or C969S, and/or H970Y, and/or R979Q, and/or R976Q,         and/or R1071S, and/or R328A, and/or R329A, and/or Q336A, and/or         R328A, R329A, Q336A (triple mutant), and/or G426A, and/or D428A,         and/or G426A,D428A (double mutant) mutation, and/or any         combination thereof, positions relative to WO2018089860A1 SEQ ID         NO: 52), in the RT domain of R2Bm retrotransposase or a         corresponding mutation at a corresponding position of another RT         domain.         82. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the DBD and/or the         endonuclease domain (e.g., a CRISPR/Cas domain) comprises a         domain or polypeptide from Table 4, or a functional variant         (e.g., mutant) thereof.         83. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the DBD and/or the         endonuclease domain (e.g., CRISPR/Cas domain) comprises a domain         or polypeptide from Table 4.         84. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain and the DBD         and/or the endonuclease domain (e.g., CRISPR/Cas domain) are         fused via a peptide linker, e.g., a linker of Table 42.         85. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the linker is about 6-18,         8-16, 10-14, or 12 amino acids in length.         86. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the linker is comprises         glycine and serine, e.g., wherein the linker comprises solely         glycine and serine residues, e.g., wherein the linker comprises         a sequence of GSSGSS (SEQ ID NO: 1736).         87. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the linker comprises a         sequence according Table 42, e.g., linked 10 as disclosed in         Table 42 to or a sequence having no more then 1, 2, or 3         substitutions relative thereto.         88. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the CRISPR/Cas domain         comprises Cas9, e.g., wild-type Cas9 or nickase Cas9.         89. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain is positioned         C-terminal of the DBD in the polypeptide.         90. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain is positioned         C-terminal of the nickase domain in the polypeptide.         91. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain is positioned         N-terminal of the DBD in the polypeptide.         92. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the RT domain is positioned         N-terminal of the nickase domain in the polypeptide.         93. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the polypeptide comprises a         linker, e.g., positioned between the RT domain and the DBD or         the RT domain and the nickase domain.         94. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the linker is between 2-50,         e.g., 2-30, amino acids in length.         95. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the linker is a flexible         linker, e.g., comprising Gly and/or Ser residues.         96. The system, kit, template RNA, or reaction mixture of any of         the preceding embodiments, wherein the 3′ target homology domain         is complementary to a sequence adjacent to a site to be modified         by the system, or comprises no more than 1, 2, 3, 4, or 5         mismatches to a sequence complementary to the sequence adjacent         to a site to be modified by the system.         97. The system, kit, template RNA, or reaction mixture of any of         the preceding embodiments, wherein the 3′ target homology domain         is more than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,         18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45,         50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140,         150, 160, 170, 180, 190, or 200 nucleotides long, (e.g., 4, 5,         6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,         23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long).         98. The system, kit, template RNA, or reaction mixture of any of         the preceding embodiments, wherein the 3′ target homology domain         is no more than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,         17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40,         45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130,         140, 150, 160, 170, 180, 190, or 200 nucleotides long.         99. The system, kit, template RNA, or reaction mixture of any of         the preceding embodiments, wherein the heterologous object         sequence is complementary to a site to be modified by the system         except at the position or positions to be modified.         100. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence is complementary to a site to be modified by the system         except at positions encoding a sequence to be inserted to the         site.         101. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence is complementary to a site to be modified by the system         except the heterologous object sequence does not comprise         nucleotides encoding a sequence to be deleted at the site.         102. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence is more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,         15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or         30 nucleotides long, (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,         14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,         or 30 nucleotides long).         103. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence is no more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,         14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,         or 30 nucleotides long.         104. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence substitutes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10         nucleotides for non-target site nucleotides.         105. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence inserts at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20,         25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or         100 nucleotides, or at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,         0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8,         8.5, 9, 9.5 or 10 kilobases into the target site.         106. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence deletes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20,         25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 81, 85, 90, 95,         100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200         nucleotides.         107. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the heterologous object         sequence is separated from the sequence that binds the         polypeptide (e.g., that binds the endonuclease domain and/or DBD         domain) by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25,         or 30 nucleotides.         108. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds         the polypeptide (e.g., that binds the endonuclease domain and/or         DBD domain) is at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90,         95, 100, 110, 120, or 130 nucleotides long (and optionally no         more than 150, 140, 130, 120, 110, 100, 90, 85, or 80         nucleotides long).         109. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds         the polypeptide binds the endonuclease domain and/or DBD domain.         110. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds         the polypeptide comprises a sequence according to one or both of         a predicted 5′ UTR and a predicted 3′ UTR of Table 3 or Table         41, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%,         96%, 97%, 98%, or 99% identity thereto, or functional fragment         thereof.         111. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds         the polypeptide (e.g., that binds the endonuclease domain and/or         DBD domain) comprises a gRNA.         112. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         target site (e.g., a second strand of a site in a target genome)         is at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35,         40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120,         or 130 nucleotides long (and optionally no more than 150, 140,         130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26,         25, 24, 23, 22, 21, or 20 nucleotides long), e.g., is 17, 18,         19, 20, 21, 22, 23, or 24 nucleotides long.         113. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         target site is complementary to the second strand of the target         site, or comprises no more than 1, 2, 3, 4, or 5 mismatches to a         sequence complementary to the second strand of the target site.         114. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         target site (e.g., a second strand of a site in a target genome)         is separated from the sequence that binds the polypeptide (e.g.,         that binds the endonuclease domain and/or DBD domain) by at         least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30         nucleotides.         115. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, further comprising a second         strand-targeting gRNA that directs the endonuclease domain         (e.g., nickase) domain to nick the second strand (e.g., in the         target genome).         116. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the template RNA further         comprises the second strand-targeting gRNA.         117. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the second         strand-targeting gRNA is disposed on a separate nucleic acid         from the template RNA.         118. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the gRNA directs the         endonuclease domain (e.g., nickase) domain to nick the second         strand (e.g., in the target genome) at a site that is at least         10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,         90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150         nucleotides 5′ or 3′ of the target site modification (e.g., the         nick on the first strand).         119. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the gRNA specifically         binds the edited strand.         120. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the polypeptide         comprises a heterologous targeting domain that binds         specifically to a sequence comprised in the target DNA molecule         (e.g., a genomic DNA).         121. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         targeting domain binds to a different nucleic acid sequence than         the unmodified polypeptide.         122. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the polypeptide         does not comprise a functional endogenous targeting domain         (e.g., wherein the polypeptide does not comprise an endogenous         targeting domain).         123. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         targeting domain comprises a zinc finger (e.g., a zinc finger         that binds specifically to the sequence comprised in the target         DNA molecule).         124. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         targeting domain comprises a Cas domain (e.g., a Cas9 domain, or         a mutant or variant thereof, e.g., a Cas9 domain that binds         specifically to the sequence comprised in the target DNA         molecule).         125. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the Cas domain is         associated with a guide RNA (gRNA).         126. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         targeting domain comprises an endonuclease domain (e.g., a         heterologous endonuclease domain).         127. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the endonuclease         domain comprises a Cas domain (e.g., a Cas9 or a mutant or         variant thereof).         128. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the Cas domain is         associated with a guide RNA (gRNA).         129. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the endonuclease         domain comprises a Fok1 domain.         130. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the template         nucleic acid molecule comprises at least one (e.g., one or two)         heterologous homology sequence having at least 85%, 90%, 95%,         96%, 97%, 98%, 99%, or 100% homology to a sequence comprised in         a target DNA molecule (e.g., a genomic DNA).         131. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein one of the at least         one heterologous homology sequences is positioned at or within         about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45,         50, 60, 70, 80, 90, or 100 nucleotides of the 5′ end of the         template nucleic acid molecule.         132. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein one of the at least         one heterologous homology sequences is positioned at or within         about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45,         50, 60, 70, 80, 90, or 100 nucleotides of the 3′ end of the         template nucleic acid molecule.         133. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         homology sequence binds within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10         nucleotides of a nick site (e.g., produced by a nickase, e.g.,         an endonuclease domain, e.g., as described herein) in the target         DNA molecule.         134. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         homology sequence has less than 50%, 40%, 30%, 20%, 10%, 5%, 4%,         3%, 2%, or 1% sequence identity with a nucleic acid sequence         complementary to an endogenous homology sequence of an         unmodified form of the template RNA.         135. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         homology sequence has having at least 85%, 90%, 95%, 96%, 97%,         98%, 99%, or 100% homology to a sequence of the target DNA         molecule that is different the sequence bound by an endogenous         homology sequence (e.g., replaced by the heterologous homology         sequence).         136. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         homology sequence comprises a sequence (e.g., at its 3′ end)         having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%         homology to a sequence positioned 5′ to a nick site of the         target DNA molecule (e.g., a site nicked by a nickase, e.g., an         endonuclease domain as described herein).         137. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the heterologous         homology sequence comprises a sequence (e.g., at its 5′ end)         suitable for priming target-primed reverse transcription (TPRT)         initiation.         138. The system, method, kit, template RNA, or reaction mixture         of any of any of the preceding embodiments, wherein the         heterologous homology sequence has at least 85%, 90%, 95%, 96%,         97%, 98%, 99%, or 100% homology to a sequence positioned within         about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45,         50, 60, 70, 80, 90, or 100 nucleotides of (e.g., 3′ relative to)         a target insertion site, e.g., for a heterologous object         sequence (e.g., as described herein), in the target DNA         molecule.         139. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the template         nucleic acid molecule comprises a guide RNA (gRNA), e.g., as         described herein.         140. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the template         nucleic acid molecule comprises a gRNA spacer sequence (e.g., at         or within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80,         90, or 100 nucleotides of its 5′ end).         141. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein an RNA of the         system (e.g., template RNA, the RNA encoding the polypeptide of         (a), or an RNA expressed from a heterologous object sequence         integrated into a target DNA) comprises a microRNA binding site,         e.g., in a 3′ UTR.         142. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments wherein the microRNA binding         site is recognized by a miRNA that is present in a non-target         cell type, but that is not present (or is present at a reduced         level relative to the non-target cell) in a target cell type.         143. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the miRNA is         miR-142, and/or wherein the non-target cell is a Kupffer cell or         a blood cell, e.g., an immune cell.         144. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the miRNA is         miR-182 or miR-183, and/or wherein the non-target cell is a         dorsal root ganglion neuron.         145. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the system         comprises a first miRNA binding site that is recognized by a         first miRNA (e.g., miR-142) and the system further comprises a         second miRNA binding site that is recognized by a second miRNA         (e.g., miR-182 or miR-183), wherein the first miRNA binding site         and the second miRNA binding site are situated on the same RNA         or on different RNAs of the system.         146. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the template RNA         comprises at least 2, 3, or 4 miRNA binding sites, e.g., wherein         the miRNA binding sites are recognized by the same or different         miRNAs.         147. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the RNA encoding         the polypeptide of (a) comprises at least 2, 3, or 4 miRNA         binding sites, e.g., wherein the miRNA binding sites are         recognized by the same or different miRNAs.         148. The system, method, kit, template RNA, or reaction mixture         of any of the preceding embodiments, wherein the RNA expressed         from a heterologous object sequence integrated into a target DNA         comprises at least 2, 3, or 4 miRNA binding sites, e.g., wherein         the miRNA binding sites are recognized by the same or different         miRNAs.         149. A system comprising:     -   an mRNA encoding the polypeptide or system of any of the         preceding embodiments, and     -   a template RNA of any preceding embodiment.         150. The system of any of the preceding embodiments, wherein the         mRNA encoding the polypeptide or system of any preceding         embodiment and the template RNA of any preceding embodiment are         disposed on different nucleic acid molecules.         151. A system comprising an RNA molecule comprising:     -   a template RNA (or RNA encoding the template RNA) of any         preceding embodiment, and     -   a sequence encoding the system or polypeptide of any preceding         embodiment.         152. The system of any of the preceding embodiments, wherein the         RNA molecule comprises an internal ribosome entry site, e.g.,         operably linked to the sequence encoding the system or         polypeptide.         153. The system of any of the preceding embodiments, wherein the         RNA molecule comprises a cleavage site, e.g., situated between         the template RNA (or RNA encoding the template RNA) and the         sequence encoding the system or polypeptide.         154. The system or polypeptide of any of the preceding         embodiments, wherein the polypeptide comprises a split intein,         e.g., two or more (e.g., all) of the RT domain, DBD,         endonuclease (e.g., nickase) domain, or combinations thereof are         translated as separate proteins which combine into a single         polypeptide by protein splicing.         155. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the system comprises one or         more circular RNA molecules (circRNAs).         156. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the circRNA encodes the Gene         Writer polypeptide.         157. The system of any of the preceding embodiments, wherein the         circRNA comprises a template RNA.         158. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein circRNA is delivered to a         host cell.         159. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the circRNA is capable of         being linearized, e.g., in a host cell, e.g., in the nucleus of         the host cell.         160. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the circRNA comprises a         cleavage site.         161. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the circRNA further comprises         a second cleavage site.         162. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the cleavage site can be         cleaved by a ribozyme, e.g., a ribozyme comprised in the circRNA         (e.g., by autocleavage).         163. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the circRNA comprises a         ribozyme sequence.         164. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme sequence is         capable of autocleavage, e.g., in a host cell, e.g., in the         nucleus of the host cell.         165. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is an inducible         ribozyme.         166. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is a         protein-responsive ribozyme, e.g., a ribozyme responsive to a         nuclear protein, e.g., a genome-interacting protein, e.g., an         epigenetic modifier, e.g., EZH2.         167. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is a nucleic         acid-responsive ribozyme.         168. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the catalytic activity (e.g.,         autocatalytic activity) of the ribozyme is activated in the         presence of a target nucleic acid molecule (e.g., an RNA         molecule, e.g., an mRNA, miRNA, ncRNA, lncRNA, tRNA, snRNA, or         mtRNA).         169. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is responsive to         a target protein (e.g., an MS2 coat protein).         170. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the target protein localized         to the cytoplasm or localized to the nucleus (e.g., an         epigenetic modifier or a transcription factor).         171. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme comprises the         ribozyme sequence of a B2 or ALU retrotransposon, or a nucleic         acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or         99% sequence identity thereto.         172. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme comprises the         sequence of a tobacco ringspot virus hammerhead ribozyme, or a         nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%,         98%, or 99% sequence identity thereto.         173. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme comprises the         sequence of a hepatitis delta virus (HDV) ribozyme, or a nucleic         acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, or         99% sequence identity thereto.         174. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is activated by         a moiety expressed in a target cell or target tissue.         175. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is activated by         a moiety expressed in a target subcellular compartment (e.g., a         nucleus, nucleolus, cytoplasm, or mitochondria).         176. The system, kit, polypeptide, or reaction mixture of any of         the preceding embodiments, wherein the ribozyme is comprised in         a circular RNA or a linear RNA.         177. A system comprising a first circular RNA encoding the         polypeptide of a Gene Writing system; and     -   a second circular RNA comprising the template RNA of a Gene         Writing system.         178. The system of any of the preceding embodiments, wherein the         nucleic encoding the polypeptide of (a) comprises a coding         sequence that is codon-optimized for expression in human cells.         179. The system of any of the preceding embodiments, wherein the         template RNA comprises a coding sequence that is codon-optimized         for expression in human cells.         180. A lipid nanoparticle (LNP) comprising the system, template         RNA, polypeptide (or RNA encoding the same), or DNA encoding the         system, template RNA, or polypeptide, of any preceding         embodiment.         181. A system comprising a first lipid nanoparticle comprising         the polypeptide (or DNA or RNA encoding the same) of a Gene         Writing system (e.g., as described herein); and     -   a second lipid nanoparticle comprising a nucleic acid molecule         of a Gene Writing System (e.g., as described herein).         182. The system, kit, polypeptide, or reaction mixture of any         preceding embodiments, wherein the system, nucleic acid         molecule, polypeptide, and/or DNA encoding the same, is         formulated as a lipid nanoparticle (LNP).         183. The LNP of any of the preceding embodiments, comprising a         cationic lipid.         184. The LNP of any of the preceding embodiments, wherein the         cationic lipid having a following structure.

185. The LNP of any of the preceding embodiments, further comprising one or more neutral lipid, e.g., DSPC, DPPC, DMIPC, DOPC, POPC, DOPE, SM, a steroid, e.g., cholesterol, and/or one or more polymer conjugated lipid, e.g., a pegylated lipid, e.g., PEG-DAG, PEG-PE, PEG-S-DAG, PEG-cer or a PEG dialkyoxypropylcarbamate. 186. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the system, polypeptide, and/or DNA encoding the same, is formulated as a lipid nanoparticle (LNP). 187. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle (or a formulation comprising a plurality of the lipid nanoparticles) lacks reactive impurities (e.g., aldehydes), or comprises less than a preselected level of reactive impurities (e.g., aldehydes). 188. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle (or a formulation comprising a plurality of the lipid nanoparticles) lacks aldehydes, or comprises less than a preselected level of aldehydes. 189. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle is comprised in a formulation comprising a plurality of the lipid nanoparticles. 190. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation is produced using one or more lipid reagents comprising less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. 191. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation is produced using one or more lipid reagents comprising less than 3% total reactive impurity (e.g., aldehyde) content. 192. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation is produced using one or more lipid reagents comprising less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. 193. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation is produced using one or more lipid reagent comprising less than 0.3% of any single reactive impurity (e.g., aldehyde) species. 194. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation is produced using one or more lipid reagents comprising less than 0.1% of any single reactive impurity (e.g., aldehyde) species. 195. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation comprises less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. 196. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation comprises less than 3% total reactive impurity (e.g., aldehyde) content. 197. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation comprises less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. 198. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation comprises less than 0.3% of any single reactive impurity (e.g., aldehyde) species. 199. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the lipid nanoparticle formulation comprises less than 0.1% of any single reactive impurity (e.g., aldehyde) species. 200. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. 201. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 3% total reactive impurity (e.g., aldehyde) content. 202. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. 203. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 0.3% of any single reactive impurity (e.g., aldehyde) species. 204. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 0.1% of any single reactive impurity (e.g., aldehyde) species. 205. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the total aldehyde content and/or quantity of any single reactive impurity (e.g., aldehyde) species is determined by liquid chromatography (LC), e.g., coupled with tandem mass spectrometry (MS/MS), e.g., according to the method described in Example 26. 206. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the total aldehyde content and/or quantity of reactive impurity (e.g., aldehyde) species is determined by detecting one or more chemical modifications of a nucleic acid molecule (e.g., as described herein) associated with the presence of reactive impurities (e.g., aldehydes), e.g., in the lipid reagents. 207. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the total aldehyde content and/or quantity of aldehyde species is determined by detecting one or more chemical modifications of a nucleotide or nucleoside (e.g., a ribonucleotide or ribonucleoside, e.g., comprised in or isolated from a nucleic acid molecule, e.g., as described herein) associated with the presence of reactive impurities (e.g., aldehydes), e.g., in the lipid reagents, e.g., as described in Example 41. 208. The system, kit, polypeptide, or reaction mixture of any of the preceding embodiments, wherein the chemical modifications of a nucleic acid molecule, nucleotide, or nucleoside are detected by determining the presence of one or more modified nucleotides or nucleosides, e.g., using LC-MS/MS analysis, e.g., as described in Example 41. 209. A lipid nanoparticle (LNP) comprising the system, polypeptide (or RNA encoding the same), nucleic acid molecule, or DNA encoding the system or polypeptide, of any preceding embodiment. 210. A system comprising a first lipid nanoparticle comprising the polypeptide (or DNA or RNA encoding the same) of a Gene Writing system (e.g., as described herein); and

-   -   a second lipid nanoparticle comprising a nucleic acid molecule         of a Gene Writing System (e.g., as described herein).         211. The system, kit, polypeptide, or reaction mixture of any         preceding embodiment, wherein the system, nucleic acid molecule,         polypeptide, and/or DNA encoding the same, is formulated as a         lipid nanoparticle (LNP).         212. A system comprising:     -   a first lipid nanoparticle comprising the polypeptide (or DNA or         RNA encoding the same) of a system or polypeptide of any         preceding embodiment; and     -   a second lipid nanoparticle comprising the template RNA (or DNA         encoding the same) of a system or template RNA of any preceding         embodiment.         213. A virus, viral-like particle, fusosome, or virosome         comprising the system, template RNA, polypeptide (or RNA         encoding the same), or DNA encoding the system, template RNA, or         polypeptide, of any preceding embodiment.         214. A system comprising:     -   a first virus, viral-like particle, fusosome, or virosome         comprising the polypeptide (or DNA or RNA encoding the same) of         a system or polypeptide of any preceding embodiment; and     -   a second virus, viral-like particle, or virosome comprising the         template RNA (or DNA encoding the same) of a system or template         RNA of any preceding embodiment.         215. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present is greater than         100, 125, 150, 175, or 200 nucleotides long, or at least 0.3,         0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,         5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 kilobases long (and         optionally less than 15, 10, 5, or 20 kilobases long, or less         than 500, 400, 300, or 200 nucleotides long).         216. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present contains a polyA         tail (e.g., a polyA tail that is at least 5, 10, 20, 30, 40, 50,         60, 70, 80, 90, or 100 nucleotides in length (SEQ ID NO: 3663)).         217. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present contains:     -   a 5′ cap, e.g.: a 7-methylguanosine cap (e.g., a O-Me-m7G cap);         a hypermethylated cap analog; an NAD+-derived cap analog (e.g.,         as described in Kiledjian, Trends in Cell Biology 28, 454-464         (2018)); or a modified, e.g., biotinylated, cap analog (e.g., as         described in Bednarek et al., Phil Trans R Soc B 373, 20180167         (2018)), and/or     -   a 3′ feature selected from one or more of: a polyA tail; a         16-nucleotide long stem-loop structure flanked by unpaired 5         nucleotides (e.g., as described by Mannironi et al., Nucleic         Acid Research 17, 9113-9126 (1989)); a triple-helical structure         (e.g., as described by Brown et al., PNAS 109, 19202-19207         (2012)); a tRNA, Y RNA, or vault RNA structure (e.g., as         described by Labno et al., Biochemica et Biophysica Acta 1863,         3125-3147 (2016)); incorporation of one or more         deoxyribonucleotide triphosphates (dNTPs), 2′O-Methylated NTPs,         or phosphorothioate-NTPs; a single nucleotide chemical         modification (e.g., oxidation of the 3′ terminal ribose to a         reactive aldehyde followed by conjugation of the         aldehyde-reactive modified nucleotide); or chemical ligation to         another nucleic acid molecule.         218. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the template RNA comprises         one or more modified nucleotides, e.g., selected from         dihydrouridine, inosine, 7-methylguanosine, 5-methylcytidine         (5mC), 5′ Phosphate ribothymidine, 2′-O-methyl ribothymidine,         2′-O-ethyl ribothymidine, 2′-fluoro ribothymidine, C-5         propynyl-deoxycytidine (pdC), C-5 propynyl-deoxyuridine (pdU),         C-5 propynyl-cytidine (pC), C-5 propynyl-uridine (pU), 5-methyl         cytidine, 5-methyl uridine, 5-methyl deoxycytidine, 5-methyl         deoxyuridine methoxy, 2,6-diaminopurine,         5′-Dimethoxytrityl-N4-ethyl-2′-deoxycytidine, C-5         propynyl-f-cytidine (pfC), C-5 propynyl-f-uridine (pfU),         5-methyl f-cytidine, 5-methyl f-uridine, C-5 propynyl-m-cytidine         (pmC), C-5 propynyl-f-uridine (pmU), 5-methyl m-cytidine,         5-methyl m-uridine, LNA (locked nucleic acid), MGB (minor groove         binder) pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), or         5-methoxyuridine (5-MO-U).         219. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present contains one or         more modified nucleotides.         220. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA remains intact (e.g.,         greater than 100, 125, 150, 175, or 200 nucleotides long, or at         least 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5,         4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 kilobases         long) after a stability test.         221. The system, kit, or reaction mixture of any of the         preceding embodiments, wherein at least 1% of target sites are         modified after the system is assayed for potency.         222. The system, kit, template RNA, polypeptide, or reaction         mixture of any of the preceding embodiments, wherein the system,         polypeptide, template RNA, and/or DNA encoding the same, is         formulated as a lipid nanoparticle (LNP).         223. The system, kit, template RNA, polypeptide, or reaction         mixture of any of the preceding embodiments, wherein the DNA         encoding the system, polypeptide, and/or template RNA are         packaged into a virus, viral-like particle, virosome, liposome,         vesicle, exosome, or LNP.         224 The system, kit, template RNA, polypeptide, or reaction         mixture of any of the preceding embodiments, wherein the DNA         encoding the system, template RNA, or polypeptide is packaged         into an adeno-associated virus (AAV).         225. The system, kit, template RNA, polypeptide, or reaction         mixture of any of the preceding embodiments, wherein the system,         template RNA, polypeptide, lipid nanoparticle (LNP), virus,         viral-like particle, or virosome is free or substantially free         of pyrogen, virus, fungus, bacterial pathogen, and/or host cell         protein contamination.         226. A virus, viral-like particle, or virosome comprising:     -   the system, template RNA, or polypeptide of any of the preceding         embodiments, or DNA encoding any of the same, and     -   an adeno-associated virus (AAV) capsid protein.         227. The system, kit, template RNA, polypeptide, virus,         viral-like particle, or virosome of any of the preceding         embodiments, wherein the system, template RNA, and/or         polypeptide is active in a target tissue and less active (e.g.,         not active) in a non-target tissue.         228. The system, kit, template RNA, polypeptide, virus,         viral-like particle, or virosome of any of the preceding         embodiments, further comprising one or more first         tissue-specific expression-control sequences specific to the         target tissue, wherein the one or more first tissue-specific         expression-control sequences specific to the target tissue are         in operative association with the template RNA, the polypeptide         or nucleic acid encoding the same, or both.         229. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the endonuclease domain,         e.g., nickase domain, nicks the first strand of the target site         DNA and nicks the second strand at a site a distance from the         first nick.         230. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the nicks are made in an         outward orientation.         231. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the nicks are made in an         outward orientation.         232. The system, kit, template RNA, or reaction mixture of any         of embany of the preceding embodiments,     -   wherein the sequence that binds a target site specifies the         location of the nick to the first strand,     -   wherein the system further comprises an additional nucleic acid         comprising a sequence that binds a site a distance from the         target site, and wherein the sequence that binds a site a         distance from the target site specifies the location of the nick         to the second strand.         233. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional nucleic         acid further comprises a sequence that binds the polypeptide         (e.g., that binds the endonuclease domain and/or DBD), e.g.,         wherein the additional nucleic acid comprises a gRNA.         234. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         site a distance from the target site (e.g., binds to the first         strand of a site in a target genome) is at least 15, 16, 17, 18,         19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70,         75, 80, 85, 90, 95, 100, 110, 120, or 130 nucleotides long (and         optionally no more than 150, 140, 130, 120, 110, 100, 90, 80,         70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or 20         nucleotides long), e.g., is 17, 18, 19, 20, 21, 22, 23, or 24         nucleotides long.         235. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         site a distance from the target site is complementary to the         first strand of the target site, or comprises no more than 1, 2,         3, 4, or 5 mismatches to the first strand of the target site.         236. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the DBD and/or         endonuclease domain comprise a CRISPR/Cas domain.         237. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the CRISPR/Cas domain and         the template RNA bind to the target site, and wherein the first         strand of the target site comprises a first PAM site.         238. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the CRISPR/Cas domain and         the additional nucleic acid bind to the site a distance from the         target site, and wherein the second strand of the site a         distance from the target site comprises a second PAM site.         239. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first PAM site and         second PAM site are positioned between the location of the nick         to the first strand and the location of the nick to the second         strand.         240. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the location of the nick         to the first strand and the location of the nick to the second         strand are positioned between the first PAM site and second PAM         site.         241. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, further comprising an additional         polypeptide comprising an additional DNA-binding domain (DBD)         and an additional endonuclease domain, e.g., an additional         nickase domain.         242. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional         endonuclease domain, e.g., the additional nickase domain,         comprises an endonuclease or nickase domain described herein,         e.g., a CRISPR/Cas domain, a type IIs nuclease (e.g., FokI), a         Holliday Junction resolvase, a meganuclease, or a         double-stranded DNA nuclease comprising an alteration that         abrogates its ability to nick one strand (e.g., transforming the         double-stranded DNA nuclease into a nickase).         243. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional DBD binds a         site a distance from the target site.         244. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the endonuclease domain         of (a) or (b) nicks the first strand and the additional         endonuclease domain (e.g., additional nickase domain) nicks the         second strand.         245. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the nicks are made in an         outward orientation.         246. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the nicks are made in an         inward orientation.         247. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the DBD and optionally the         template RNA (e.g., the sequence that binds the polypeptide)         specifies the location of the nick to the first strand, and the         additional DBD specifies the location of the nick to the second         strand.         248. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the polypeptide (e.g., the         DBD) comprises a TAL effector molecule.         249. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the polypeptide (e.g., the         DBD) comprises a zinc finger molecule.         250. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the polypeptide (e.g., the         DBD) comprises a CRISPR/Cas domain.         251. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional polypeptide         (e.g., the additional DBD) comprises a TAL effector molecule.         252. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional polypeptide         (e.g., the additional DBD) comprises a zinc finger molecule.         253. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional polypeptide         (e.g., the additional DBD) comprises a CRISPR/Cas domain.         254. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the polypeptide and the         additional polypeptide bind to sites on the target DNA between         the location of the nick to the first strand and the location of         the nick to the second.         255. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the location of the nick         to the first strand and the location of the nick to the second         strand are between the sites where the polypeptide and the         additional polypeptide bind to the target DNA.         256. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein, on the target DNA, the         location of the nick to the second strand is positioned on the         opposite side of the binding sites of the polypeptide and         additional polypeptide relative to the location of the nick to         the first strand.         257. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein, on the target DNA, the         location of the nick to the second strand is positioned on the         same side of the binding sites of the polypeptide and additional         polypeptide relative to the location of the nick to the first         strand.         258. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the CRISPR/Cas domain of         the polypeptide and the template RNA bind to the target site,         and wherein the first strand of the target site comprises a PAM         site.         259. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the PAM site and the site         at a distance from the target site are positioned between the         location of the nick to the first strand and the location of the         nick to the second strand.         260. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the location of the nick         to the first strand and the location of the nick to the second         strand are positioned between the PAM site and the site at a         distance from the target site.         261. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, further comprising an additional         nucleic acid (e.g., a gRNA) comprising a sequence that binds a         site a distance from the target site, and wherein the sequence         that binds a site a distance from the target site specifies the         location of the nick to the second strand.         262. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the additional nucleic         acid further comprises a sequence that binds the additional         polypeptide (e.g., the CRISPR/Cas domain), e.g., wherein the         additional nucleic acid comprises a gRNA.         263. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         site a distance from the target site (e.g., to the first strand         of a site in a target genome) is at least 15, 16, 17, 18, 19,         20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,         80, 85, 90, 95, 100, 110, 120, or 130 nucleotides long (and         optionally no more than 150, 140, 130, 120, 110, 100, 90, 80,         70, 60, 50, 40, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or 20         nucleotides long), e.g., is 17, 18, 19, 20, 21, 22, 23, or 24         nucleotides long.         264. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the sequence that binds a         site a distance from the target site is complementary to the         first strand of the target site, or comprises no more than 1, 2,         3, 4, or 5 mismatches to the first strand of the target site.         265. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the site a distance from         the target site comprises a PAM site.         266. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the PAM site and the         target site are positioned between the location of the nick to         the first strand and the location of the nick to the second         strand.         267. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the location of the nick         to the second strand (e.g., relative to the nick to the first         strand) is such that DNA polymerization by the RT domain         proceeds toward the location of the nick to the second strand.         268. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the location of the nick         to the second strand (e.g., relative to the nick to the first         strand) is such that DNA polymerization by the RT domain         proceeds away from the location of the nick to the second         strand.         269. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first nick and the         second nick are at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,         70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170,         180, 190, or 200 nucleotides apart.         270. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first nick and the         second nick are no more than 25, 30, 35, 40, 45, 50, 55, 60, 65,         70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170,         180, 190, 200, or 250 nucleotides apart.         271. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first nick and the         second nick are 20-200, 30-200, 40-200, 50-200, 60-200, 70-200,         80-200, 90-200, 100-200, 110-200, 120-200, 130-200, 140-200,         150-200, 160-200, 170-200, 180-200, 190-200, 20-190, 30-190,         40-190, 50-190, 60-190, 70-190, 80-190, 90-190, 100-190,         110-190, 120-190, 130-190, 140-190, 150-190, 160-190, 170-190,         180-190, 20-180, 30-180, 40-180, 50-180, 60-180, 70-180, 80-180,         90-180, 100-180, 110-180, 120-180, 130-180, 140-180, 150-180,         160-180, 170-180, 20-170, 30-170, 40-170, 50-170, 60-170,         70-170, 80-170, 90-170, 100-170, 110-170, 120-170, 130-170,         140-170, 150-170, 160-170, 20-160, 30-160, 40-160, 50-160,         60-160, 70-160, 80-160, 90-160, 100-160, 110-160, 120-160,         130-160, 140-160, 150-160, 20-150, 30-150, 40-150, 50-150,         60-150, 70-150, 80-150, 90-150, 100-150, 110-150, 120-150,         130-150, 140-150, 20-140, 30-140, 40-140, 50-140, 60-140,         70-140, 80-140, 90-140, 100-140, 110-140, 120-140, 130-140,         20-130, 30-130, 40-130, 50-130, 60-130, 70-130, 80-130, 90-130,         100-130, 110-130, 120-130, 20-120, 30-120, 40-120, 50-120,         60-120, 70-120, 80-120, 90-120, 100-120, 110-120, 20-110,         30-110, 40-110, 50-110, 60-110, 70-110, 80-110, 90-110, 100-110,         20-100, 30-100, 40-100, 50-100, 60-100, 70-100, 80-100, 90-100,         20-90, 30-90, 40-90, 50-90, 60-90, 70-90, 80-90, 20-80, 30-80,         40-80, 50-80, 60-80, 70-80, 20-70, 30-70, 40-70, 50-70, 60-70,         20-60, 30-60, 40-60, 50-60, 20-50, 30-50, 40-50, 20-40, 30-40,         or 20-30 nucleotides apart.         272. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         double-stranded breaks (e.g., at least 100, 90, 80, 70, 60, 50,         40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% fewer) when         modifying DNA than an otherwise similar system wherein one or         more of a PAM site, target site, or site a distance from the         target site is not situated between the location of the first         strand nick and the location of the second strand nick.         273. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         double-stranded breaks (e.g., at least 100, 90, 80, 70, 60, 50,         40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% fewer) when         modifying DNA than an otherwise similar system wherein the         polypeptide and the additional polypeptide bind to sites on the         target DNA not between the location of the nick to the first         strand and the location of the nick to the second.         274. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         double-stranded breaks (e.g., at least 100, 90, 80, 70, 60, 50,         40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% fewer) when         modifying DNA than an otherwise similar system wherein, on the         target DNA, the location of the nick to the second strand and         the location of the nick to the first strand are located between         the binding sites of the polypeptide and additional polypeptide.         275. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         double-stranded breaks (e.g., at least 100, 90, 80, 70, 60, 50,         40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% fewer) when         modifying DNA than an otherwise similar system wherein the         location of the nick to the second strand (e.g., relative to the         nick to the first strand) is such that the RT domain initiates         reverse transcription away from the location of the nick to the         second strand.         276. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         deletions not encoded by the heterologous object sequence (e.g.,         at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5,         4, 3, 2, or 1% fewer) when modifying DNA than an otherwise         similar system wherein one or more of a PAM site, target site,         or site a distance from the target site is not situated between         the location of the first strand nick and the location of the         second strand nick, e.g., as measured by PacBio long read         sequencing, e.g., as described in Example 29.         277. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         deletions (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20,         10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than         an otherwise similar system wherein the polypeptide and the         additional polypeptide bind to sites on the target DNA not         between the location of the nick to the first strand and the         location of the nick to the second, e.g., as measured by PacBio         long read sequencing, e.g., as described in Example 29.         278. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         deletions not encoded by the heterologous object sequence (e.g.,         at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5,         4, 3, 2, or 1% fewer) when modifying DNA than an otherwise         similar system wherein, on the target DNA, the location of the         nick to the second strand and the location of the nick to the         first strand are located between the binding sites of the         polypeptide and additional polypeptide, e.g., as measured by         PacBio long read sequencing, e.g., as described in Example 29.         279. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         deletions not encoded by the heterologous object sequence (e.g.,         at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5,         4, 3, 2, or 1% fewer) when modifying DNA than an otherwise         similar system wherein the location of the nick to the second         strand (e.g., relative to the nick to the first strand) is such         that the RT domain initiates reverse transcription away from the         location of the nick to the second strand., e.g., as measured by         PacBio long read sequencing, e.g., as described in Example 29.         280. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         insertions not encoded by the heterologous object sequence         (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8,         7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than an         otherwise similar system wherein one or more of a PAM site,         target site, or site a distance from the target site is not         situated between the location of the first strand nick and the         location of the second strand nick, e.g., as measured by PacBio         long read sequencing, e.g., as described in Example 29.         281. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         insertions not encoded by the heterologous object sequence         (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8,         7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than an         otherwise similar system wherein the polypeptide and the         additional polypeptide bind to sites on the target DNA not         between the location of the nick to the first strand and the         location of the nick to the second, e.g., as measured by PacBio         long read sequencing, e.g., as described in Example 29.         282. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         insertions not encoded by the heterologous object sequence         (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8,         7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than an         otherwise similar system wherein, on the target DNA, the         location of the nick to the second strand and the location of         the nick to the first strand are located between the binding         sites of the polypeptide and additional polypeptide, e.g., as         measured by PacBio long read sequencing, e.g., as described in         Example 29.         283. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         insertions not encoded by the heterologous object sequence         (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8,         7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than an         otherwise similar system wherein the location of the nick to the         second strand (e.g., relative to the nick to the first strand)         is such that the RT domain initiates reverse transcription away         from the location of the nick to the second strand., e.g., as         measured by PacBio long read sequencing, e.g., as described in         Example 29.         284. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces more         desired Gene Writing modifications (e.g., at least 500, 400,         300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6,         5, 4, 3, 2, or 1% more) when modifying DNA than an otherwise         similar system wherein one or more of a PAM site, target site,         or site a distance from the target site is not situated between         the location of the first strand nick and the location of the         second strand nick, e.g., as measured by PacBio long read         sequencing, e.g., as described in Example 29.         285. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces more         desired Gene Writing modifications (e.g., at least 500, 400,         300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6,         5, 4, 3, 2, or 1% more) when modifying DNA than an otherwise         similar system wherein the polypeptide and the additional         polypeptide bind to sites on the target DNA not between the         location of the nick to the first strand and the location of the         nick to the second, e.g., as measured by PacBio long read         sequencing, e.g., as described in Example 29.         286. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces more         desired Gene Writing modifications (e.g., at least 500, 400,         300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6,         5, 4, 3, 2, or 1% more) when modifying DNA than an otherwise         similar system wherein, on the target DNA, the location of the         nick to the second strand and the location of the nick to the         first strand are located between the binding sites of the         polypeptide and additional polypeptide, e.g., as measured by         PacBio long read sequencing, e.g., as described in Example 29.         287. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces more         desired Gene Writing modifications (e.g., at least 500, 400,         300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6,         5, 4, 3, 2, or 1% more) when modifying DNA than an otherwise         similar system wherein the location of the nick to the second         strand (e.g., relative to the nick to the first strand) is such         that the RT domain initiates reverse transcription away from the         location of the nick to the second strand., e.g., as measured by         PacBio long read sequencing, e.g., as described in Example 29.         288. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first nick and the         second nick are at least 100, 110, 120, 130, 140, 150, 160, 170,         180, 190, 200, 220, 240, 260, 280, 300, 350, 400, 450, or 500         nucleotides apart, e.g., at least 100 nucleotides apart, (and         optionally no more than 500, 400, 300, 200, 190, 180, 170, 160,         150, 140, 130, or 120 nucleotides apart).         289. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the first nick and the         second nick are 100-200, 110-200, 120-200, 130-200, 140-200,         150-200, 160-200, 170-200, 180-200, 190-200, 100-190, 110-190,         120-190, 130-190, 140-190, 150-190, 160-190, 170-190, 180-190,         100-180, 110-180, 120-180, 130-180, 140-180, 150-180, 160-180,         170-180, 100-170, 110-170, 120-170, 130-170, 140-170, 150-170,         160-170, 100-160, 110-160, 120-160, 130-160, 140-160, 150-160,         100-150, 110-150, 120-150, 130-150, 140-150, 100-140, 110-140,         120-140, 130-140, 100-130, 110-130, 120-130, 100-120, 110-120,         or 100-110 nucleotides apart.         290. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         insertions not encoded by the heterologous object sequence         (e.g., at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8,         7, 6, 5, 4, 3, 2, or 1% fewer) when modifying DNA than an         otherwise similar system wherein the location of the nick to the         second strand is less than 100 nucleotides away from the         location of the nick to the first strand (and optionally at         least 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides away), e.g.,         as measured by PacBio long read sequencing, e.g., as described         in Example 29.         291. The system, kit, template RNA, or reaction mixture of any         of the preceding embodiments, wherein the system produces fewer         deletions not encoded by the heterologous object sequence (e.g.,         at least 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5,         4, 3, 2, or 1% fewer) when modifying DNA than an otherwise         similar system wherein the location of the nick to the second         strand is less than 100 nucleotides away from the location of         the nick to the first strand (and optionally at least 20, 30,         40, 50, 60, 70, 80, or 90 nucleotides away), e.g., as measured         by PacBio long read sequencing, e.g., as described in Example         29.         292. Any above-numbered system, which does not comprise DNA, or         which does not comprise more than 10%, 5%, 4%, 3%, 2%, or 1% DNA         by mass or by molar amount.         293. A method of making a system for modifying DNA (e.g., as         described herein), the method comprising:     -   (a) providing a template nucleic acid (e.g., a template RNA or         DNA) comprising a heterologous homology sequence having at least         85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% homology to a         sequence comprised in a target DNA molecule, and/or     -   (b) providing a polypeptide of the system (e.g., comprising a         DNA-binding domain (DBD) and/or an endonuclease domain)         comprising a heterologous targeting domain that binds         specifically to a sequence comprised in the target DNA molecule.         294. The method of any of the preceding embodiments, wherein:     -   (a) comprises introducing into the template nucleic acid (e.g.,         a template RNA or DNA) a heterologous homology sequence having         at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% homology to         the sequence comprised in a target DNA molecule, and/or     -   (b) comprises introducing into the polypeptide of the system         (e.g., comprising a DNA-binding domain (DBD) and/or an         endonuclease domain) the heterologous targeting domain that         binds specifically to a sequence comprised in the target DNA         molecule.         295. The method of any of the preceding embodiments, wherein the         introducing of (a) comprises inserting the homology sequence         into the template nucleic acid.         296. The method of any of the preceding embodiments, wherein the         introducing of (a) comprises replacing a segment of the template         nucleic acid with the homology sequence.         297. The method of any of the preceding embodiments, wherein the         introducing of (a) comprises mutating one or more nucleotides         (e.g., at least 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60,         70, 80, 90, or 100 nucleotides) of the template nucleic acid,         thereby producing a segment of the template nucleic acid having         the sequence of the homology sequence.         298. The method of any of the preceding embodiments, wherein the         introducing of (b) comprises inserting the amino acid sequence         of the targeting domain into the amino acid sequence of the         polypeptide.         299. The method of any of the preceding embodiments, wherein the         introducing of (b) comprises inserting a nucleic acid sequence         encoding the targeting domain into a coding sequence of the         polypeptide comprised in a nucleic acid molecule.         300. The method of any of the preceding embodiments, wherein the         introducing of (b) comprises replacing at least a portion of the         polypeptide with the targeting domain.         301. The method of any of the preceding embodiments, wherein the         introducing of (a) comprises mutating one or more amino acids         (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30,         40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, or         more amino acids) of the polypeptide.         302. A method for modifying a target site in genomic DNA in a         cell, the method comprising contacting the cell with:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and         -   (b) a template RNA (or DNA encoding the template RNA)             comprising (e.g., from 5′ to     -   3′) (i) optionally a sequence that binds the target site (e.g.,         a second strand of a site in a target genome), (ii) optionally a         sequence that binds the polypeptide, (iii) a heterologous object         sequence, and (iv) a 3′ target homology domain,     -   wherein:     -   (i) the polypeptide comprises a heterologous targeting domain         (e.g., in the DBD or the endonuclease domain) that binds         specifically to a sequence comprised in or adjacent to the         target site of the genomic DNA; and/or     -   (ii) the template RNA comprises a heterologous homology sequence         having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%         homology to a sequence comprised in or adjacent to the target         site of the genomic DNA;         -   thereby modifying the target site in genomic DNA in a cell.             303. A method for manufacturing an template RNA, comprising:     -   (a) providing an template RNA of any preceding embodiment, and     -   (b) assaying one or more of:         -   (i) the length of the template RNA, e.g., whether the             template RNA has a length that is above a reference length             or within a reference length range, e.g., whether at least             80, 85, 90, 95, 96, 97, 98, or 99% of the template RNA             present is greater than 100, 125, 150, 175, or 200             nucleotides long;         -   (ii) the presence, absence, and/or length of a polyA tail on             the template RNA, e.g., whether at least 80, 85, 90, 95, 96,             97, 98, or 99% of the template RNA present contains a polyA             tail (e.g., a polyA tail that is at least 5, 10, 20, or 30             nucleotides in length (SEQ ID NO: 3664));         -   (iii) the presence, absence, and/or type of a 5′ cap on the             template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97,             98, or 99% of the template RNA present contains a 5′ cap,             e.g., whether that cap is a 7-methylguanosine cap, e.g., a             O-Me-m7G cap;         -   (iv) the presence, absence, and/or type of one or more             modified nucleotides (e.g., selected from dihydrouridine,             inosine, 7-methylguanosine, 5-methylcytidine (5mC), 5′             Phosphate ribothymidine, 2′-O-methyl ribothymidine,             2′-O-ethyl ribothymidine, 2′-fluoro ribothymidine, C-5             propynyl-deoxycytidine (pdC), C-5 propynyl-deoxyuridine             (pdU), C-5 propynyl-cytidine (pC), C-5 propynyl-uridine             (pU), 5-methyl cytidine, 5-methyl uridine, 5-methyl             deoxycytidine, 5-methyl deoxyuridine methoxy,             2,6-diaminopurine,             5′-Dimethoxytrityl-N4-ethyl-2′-deoxycytidine, C-5             propynyl-f-cytidine (pfC), C-5 propynyl-f-uridine (pfUJ),             5-methyl f-cytidine, 5-methyl f-uridine, C-5             propynyl-m-cytidine (pmC), C-5 propynyl-f-uridine (pmU),             5-methyl m-cytidine, 5-methyl m-uridine, LNA (locked nucleic             acid), MGB (minor groove binder) pseudouridine (Ψ),             1-N-methylpseudouridine (1-Me-Ψ), or 5-methoxyuridine             (5-MO-U)) in the template RNA, e.g., whether at least 80,             85, 90, 95, 96, 97, 98, or 99% of the template RNA present             contains one or more modified nucleotides;         -   (v) the stability of the template RNA (e.g., over time             and/or under a pre-selected condition), e.g., whether at             least 80, 85, 90, 95, 96, 97, 98, or 99% of the template RNA             remains intact (e.g., greater than 100, 125, 150, 175, or             200 nucleotides long) after a stability test;         -   (vi) the potency of the template RNA in a system for             modifying DNA, e.g., whether at least 1% of target sites are             modified after a system comprising the template RNA is             assayed for potency; or         -   (vii) the presence, absence, and/or level of one or more of             a pyrogen, virus, fungus, bacterial pathogen, or host cell             protein, e.g., whether the template RNA is free or             substantially free of pyrogen, virus, fungus, bacterial             pathogen, or host cell protein contamination.             304. A method for manufacturing a system for modifying DNA,             comprising:     -   (a) providing a system for modifying DNA of any preceding         embodiment, and     -   (b) assaying one or more of:         -   (i) the length of the template RNA, e.g., whether the             template RNA has a length that is above a reference length             or within a reference length range, e.g., whether at least             80, 85, 90, 95, 96, 97, 98, or 99% of the template RNA             present is greater than 100, 125, 150, 175, or 200             nucleotides long;         -   (ii) the presence, absence, and/or length of a polyA tail on             the template RNA, e.g., whether at least 80, 85, 90, 95, 96,             97, 98, or 99% of the template RNA present contains a polyA             tail (e.g., a polyA tail that is at least 5, 10, 20, or 30             nucleotides in length (SEQ ID NO: 3664));         -   (iii) the presence, absence, and/or type of a 5′ cap on the             template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97,             98, or 99% of the template RNA present contains a 5′ cap,             e.g., whether that cap is a 7-methylguanosine cap, e.g., a             O-Me-m7G cap;         -   (iv) the presence, absence, and/or type of one or more             modified nucleotides (e.g., selected from pseudouridine,             dihydrouridine, inosine, 7-methylguanosine,             1-N-methylpseudouridine (1-Me-Ψ), 5-methoxyuridine (5-MO-U),             5-methylcytidine (5mC), or a locked nucleotide in the             template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97,             98, or 99% of the template RNA present contains one or more             modified nucleotides;         -   (v) the stability of the template RNA (e.g., over time             and/or under a pre-selected condition), e.g., whether at             least 80, 85, 90, 95, 96, 97, 98, or 99% of the template RNA             remains intact (e.g., greater than 100, 125, 150, 175, or             200 nucleotides long) after a stability test;         -   (vi) the potency of the template RNA in a system for             modifying DNA, e.g., whether at least 1% of target sites are             modified after a system comprising the template RNA is             assayed for potency;         -   (vii) the length of the polypeptide, first polypeptide, or             second polypeptide, e.g., whether the polypeptide, first             polypeptide, or second polypeptide has a length that is             above a reference length or within a reference length range,             e.g., whether at least 80, 85, 90, 95, 96, 97, 98, or 99% of             the polypeptide, first polypeptide, or second polypeptide             present is greater than 600, 650, 700, 750, 800, 850, 900,             950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400,             1450, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids long             (and optionally, no larger than 2500, 2000, 1500, 1400,             1300, 1200, 1100, 1000, 900, 800, 700, or 600 amino acids             long);         -   (viii) the presence, absence, and/or type of             post-translational modification on the polypeptide, first             polypeptide, or second polypeptide, e.g., whether at least             80, 85, 90, 95, 96, 97, 98, or 99% of the polypeptide, first             polypeptide, or second polypeptide contains phosphorylation,             methylation, acetylation, myristoylation, palmitoylation,             isoprenylation, glipyatyon, or lipoylation;         -   (ix) the presence, absence, and/or type of one or more             artificial, synthetic, or non-canonical amino acids (e.g.,             selected from ornithine, β-alanine, GABA, δ-Aminolevulinic             acid, PABA, a D-amino acid (e.g., D-alanine or D-glutamate),             aminoisobutyric acid, dehydroalanine, cystathionine,             lanthionine, Djenkolic acid, Diaminopimelic acid,             Homoalanine, Norvaline, Norleucine, Homonorleucine,             homoserine, O-methyl-homoserine and O-ethyl-homoserine,             ethionine, selenocysteine, selenohomocysteine,             selenomethionine, selenoethionine, tellurocysteine, or             telluromethionine) in the polypeptide, first polypeptide, or             second polypeptide, e.g., whether at least 80, 85, 90, 95,             96, 97, 98, or 99% of the polypeptide, first polypeptide, or             second polypeptide present contains one or more artificial,             synthetic, or non-canonical amino acids;         -   (x) the stability of the polypeptide, first polypeptide, or             second polypeptide (e.g., over time and/or under a             pre-selected condition), e.g., whether at least 80, 85, 90,             95, 96, 97, 98, or 99% of the polypeptide, first             polypeptide, or second polypeptide remains intact (e.g.,             greater than 600, 650, 700, 750, 800, 850, 900, 950, 1000,             1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500,             1600, 1700, 1800, 1900, or 2000 amino acids long (and             optionally, no larger than 2500, 2000, 1500, 1400, 1300,             1200, 1100, 1000, 900, 800, 700, or 600 amino acids long))             after a stability test;         -   (xi) the potency of the polypeptide, first polypeptide, or             second polypeptide in a system for modifying DNA, e.g.,             whether at least 1% of target sites are modified after a             system comprising the polypeptide, first polypeptide, or             second polypeptide is assayed for potency; or         -   (xii) the presence, absence, and/or level of one or more of             a pyrogen, virus, fungus, bacterial pathogen, or host cell             protein, e.g., whether the system is free or substantially             free of pyrogen, virus, fungus, bacterial pathogen, or host             cell protein contamination.             305. A method for modifying a target site in genomic DNA in             a cell, the method comprising:     -   contacting the cell with:         -   (a) a polypeptide or a nucleic acid encoding the             polypeptide, wherein the polypeptide comprises (i) a reverse             transcriptase (RT) domain, (ii) a DNA-binding domain (DBD);             and (iii) an endonuclease domain, e.g., a nickase domain;             and         -   (b) a template RNA (or DNA encoding the template RNA)             comprising (e.g., from 5′ to 3′) (i) optionally a sequence             that binds the target site (e.g., a second strand of a site             in a target genome), (ii) optionally a sequence that binds             the polypeptide, (iii) a heterologous object sequence,             and (iv) a 3′ target homology domain,     -   thereby modifying the target site in genomic DNA in a cell.         306. A method for modifying a target site in genomic DNA in a         cell, the method comprising:     -   contacting the cell with a system, polypeptide, template RNA, or         DNA encoding the same of any preceding embodiment,     -   thereby modifying the target site in genomic DNA in a cell.         307. The method of any of the preceding embodiments, wherein a         system, polypeptide, template RNA, or DNA are delivered to the         target site by electroporation, e.g., nucleofection.         308. The method of any of the preceding embodiments, which does         not comprise contacting the cell with DNA, e.g., or which         comprises contacting the cell with a composition that not         comprise more than 10%, 5%, 4%, 3%, 2%, or 1% DNA by mass or by         molar amount.         309. The method of any of the preceding embodiments, which does         not comprise contacting the cell with protein, e.g., or which         comprises contacting the cell with a composition that not         comprise more than 10%, 5%, 4%, 3%, 2%, or 1% protein by mass or         by molar amount.         310. The method of any of the preceding embodiments, which         comprises contacting a target cell or population of target cells         with at least two template RNAs and/or at least two GeneWriter         polypeptides, such that at least two target sites (a first         target site and a second target site) are modified in a target         cell.         311. The method of any of the preceding embodiments, wherein the         first target site and the second site are each independently         edited at a frequency of at least 5%, 10%, or 15% of copies of         the site in a cell population.         312. The method of any of the preceding embodiments, wherein the         first target site and the second site are each independently         edited at a frequency of at least 50%, 60%, 70%, or 80% of the         level of editing obtained in an otherwise similar cell         population contacted with an otherwise similar system targeting         only one of the target sites.         313. The method of any of the preceding embodiments, wherein the         resulting cell population comprises no more than 5%, 10%, or 20%         unwanted indels compared to the unwanted indels obtained in an         otherwise similar cell population contacted with an otherwise         similar system targeting only one of the target sites.         314. The method of any of the preceding embodiments, wherein the         cell is a primary cell.         315. The method of any of the preceding embodiments, wherein the         cell is a T cell.         316. A method for modifying a target site in genomic DNA in a         cell, the method comprising: contacting the cell, e.g., by         nucleofection or lipid particle delivery, with:     -   (a) a polypeptide or a nucleic acid encoding the polypeptide,         wherein the polypeptide comprises (i) a reverse transcriptase         (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an         endonuclease domain, e.g., a nickase domain; and     -   (b) a template RNA (or DNA encoding the template RNA) comprising         (e.g., from 5′ to 3′) (i) optionally a sequence that binds the         target site (e.g., a second strand of a site in a target         genome), (ii) optionally a sequence that binds the         polypeptide, (iii) a heterologous object sequence, and (iv) a 3′         target homology domain,     -   thereby modifying the target site in genomic DNA in a cell,     -   wherein the cell is euploid, is not immortalized, is part of a         tissue, is part of an organism, is a primary cell, is         non-dividing, is haploid (e.g., a germline cell), is a         non-cancerous polyploid cell, or is from a subject having a         genetic disease.         317. The method of any of the preceding embodiments, wherein the         template RNA comprises (i).         318. The method of any of the preceding embodiments, wherein the         template RNA comprises (ii).         319. The method of any of the preceding embodiments, wherein the         template RNA comprises (i) and (ii).         320. A method for treating a subject having a disease or         condition associated with a genetic defect, the method         comprising:     -   administering to the subject:         -   (a) a polypeptide or a nucleic acid encoding the             polypeptide, wherein the polypeptide comprises (i) a reverse             transcriptase (RT) domain, (ii) a DNA-binding domain (DBD);             and (iii) an endonuclease domain, e.g., a nickase domain;             and         -   (b) a template RNA (or DNA encoding the template RNA)             comprising (e.g., from 5′ to 3′) (i) optionally a sequence             that binds the target site (e.g., a second strand of a site             in a target genome), (ii) optionally a sequence that binds             the polypeptide, (iii) a heterologous object sequence,             and (iv) a 3′ target homology domain,     -   thereby treating the subject having a disease or condition         associated with a genetic defect.         321. The method of any of the preceding embodiments, wherein the         template RNA comprises (i).         322. The method of any of the preceding embodiments, wherein the         template RNA comprises (ii).         323. The method of any of the preceding embodiments, wherein the         template RNA comprises (i) and (ii).         324. A method for treating a subject having a disease or         condition associated with a genetic defect, the method         comprising:     -   administering to the subject a system, polypeptide, template         RNA, or DNA encoding the same of any preceding embodiment,     -   thereby treating the subject having a disease or condition         associated with a genetic defect.         325. The method of any of the preceding embodiments, wherein the         disease or condition associated with a genetic defect is an         indication listed in any of Tables 9-12, and/or wherein the         genetic defect is a defect in a gene listed in any of Tables         9-12.         326. The method of any of the preceding embodiments, wherein the         subject is a human patient.

Definitions

Domain: The term “domain” as used herein refers to a structure of a biomolecule that contributes to a specified function of the biomolecule. A domain may comprise a contiguous region (e.g., a contiguous sequence) or distinct, non-contiguous regions (e.g., non-contiguous sequences) of a biomolecule. Examples of protein domains include, but are not limited to, an endonuclease domain, a DNA binding domain, a reverse transcription domain; an example of a domain of a nucleic acid is a regulatory domain, such as a transcription factor binding domain.

Exogenous: As used herein, the term exogenous, when used with reference to a biomolecule (such as a nucleic acid sequence or polypeptide) means that the biomolecule was introduced into a host genome, cell or organism by the hand of man. For example, a nucleic acid that is as added into an existing genome, cell, tissue or subject using recombinant DNA techniques or other methods is exogenous to the existing nucleic acid sequence, cell, tissue or subject.

First/Second Strand: As used herein, first strand and second strand, as used to describe the individual DNA strands of target DNA, distinguish the two DNA strands based upon which strand the reverse transcriptase domain initiates polymerization, e.g., based upon where target primed synthesis initiates. The first strand refers to the strand of the target DNA upon which the reverse transcriptase domain initiates polymerization, e.g., where target primed synthesis initiates. The second strand refers to the other strand of the target DNA. First and second strand designations do not describe the target site DNA strands in other respects; for example, in some embodiments the first and second strands are nicked by a polypeptide described herein, but the designations ‘first’ and ‘second’ strand have no bearing on the order in which such nicks occur.

Genomic safe harbor site (GSH site): A genomic safe harbor site is a site in a host genome that is able to accommodate the integration of new genetic material, e.g., such that the inserted genetic element does not cause significant alterations of the host genome posing a risk to the host cell or organism. A GSH site generally meets 1, 2, 3, 4, 5, 6, 7, 8 or 9 of the following criteria: (i) is located >300 kb from a cancer-related gene; (ii) is >300 kb from a miRNA/other functional small RNA; (iii) is >50 kb from a 5′ gene end; (iv) is >50 kb from a replication origin; (v) is >50 kb away from any ultraconservered element; (vi) has low transcriptional activity (i.e. no mRNA +/−25 kb); (vii) is not in copy number variable region; (viii) is in open chromatin; and/or (ix) is unique, with 1 copy in the human genome. Examples of GSH sites in the human genome that meet some or all of these criteria include (i) the adeno-associated virus site 1 (AAVS1), a naturally occurring site of integration of AAV virus on chromosome 19; (ii) the chemokine (C-C motif) receptor 5 (CCR5) gene, a chemokine receptor gene known as an HIV-1 coreceptor; (iii) the human ortholog of the mouse Rosa26 locus; (iv) the rDNA locus. Additional GSH sites are known and described, e.g., in Pellenz et al. epub Aug. 20, 2018 (https://doi.org/10.1101/396390).

Heterologous: The term heterologous, when used to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described. For example, a heterologous polypeptide, nucleic acid molecule, construct or sequence refers to (a) a polypeptide, nucleic acid molecule or portion of a polypeptide or nucleic acid molecule sequence that is not native to a cell in which it is expressed, (b) a polypeptide or nucleic acid molecule or portion of a polypeptide or nucleic acid molecule that has been altered or mutated relative to its native state, or (c) a polypeptide or nucleic acid molecule with an altered expression as compared to the native expression levels under similar conditions. For example, a heterologous regulatory sequence (e.g., promoter, enhancer) may be used to regulate expression of a gene or a nucleic acid molecule in a way that is different than the gene or a nucleic acid molecule is normally expressed in nature. In another example, a heterologous domain of a polypeptide or nucleic acid sequence (e.g., a DNA binding domain of a polypeptide or nucleic acid encoding a DNA binding domain of a polypeptide) may be disposed relative to other domains or may be a different sequence or from a different source, relative to other domains or portions of a polypeptide or its encoding nucleic acid. In certain embodiments, a heterologous nucleic acid molecule may exist in a native host cell genome, but may have an altered expression level or have a different sequence or both. In other embodiments, heterologous nucleic acid molecules may not be endogenous to a host cell or host genome but instead may have been introduced into a host cell by transformation (e.g., transfection, electroporation), wherein the added molecule may integrate into the host genome or can exist as extra-chromosomal genetic material either transiently (e.g., mRNA) or semi-stably for more than one generation (e.g., episomal viral vector, plasmid or other self-replicating vector).

Inverted Terminal Repeats: The term “inverted terminal repeats” or “ITRs” as used herein refers to AAV viral cis-elements named so because of their symmetry. These elements promote efficient multiplication of an AAV genome. It is hypothesized that the minimal elements for ITR function are a Rep-binding site (RBS; 5′-GCGCGCTCGCTCGCTC-3′ (SEQ ID NO: 1538) for AAV2) and a terminal resolution site (TRS; 5′-AGTTGG-3′ for AAV2) plus a variable palindromic sequence allowing for hairpin formation. According to the present invention, an ITR comprises at least these three elements (RBS, TRS and sequences allowing the formation of an hairpin). In addition, in the present invention, the term “ITR” refers to ITRs of known natural AAV serotypes (e.g. ITR of a serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 AAV), to chimeric ITRs formed by the fusion of ITR elements derived from different serotypes, and to functional variant thereof. By functional variant of an ITR, it is referred to a sequence presenting a sequence identity of at least 80%, 85%, 90%, preferably of at least 95% with a known ITR, allowing multiplication of the sequence that includes said ITR in the presence of Rep proteins.

Mutation or Mutated: The term “mutated” when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference (e.g., native) nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. A nucleic acid sequence may be mutated by any method known in the art.

Nucleic acid molecule: Nucleic acid molecule refers to both RNA and DNA molecules including, without limitation, cDNA, genomic DNA and mRNA, and also includes synthetic nucleic acid molecules, such as those that are chemically synthesized or recombinantly produced, such as RNA templates, as described herein. The nucleic acid molecule can be double-stranded or single-stranded, circular or linear. If single-stranded, the nucleic acid molecule can be the sense strand or the antisense strand. Unless otherwise indicated, and as an example for all sequences described herein under the general format “SEQ. ID NO:,” “nucleic acid comprising SEQ. ID NO:1” refers to a nucleic acid, at least a portion which has either (i) the sequence of SEQ. ID NO: 1, or (ii) a sequence complimentary to SEQ. ID NO:1. The choice between the two is dictated by the context in which SEQ. ID NO:1 is used. For instance, if the nucleic acid is used as a probe, the choice between the two is dictated by the requirement that the probe be complimentary to the desired target. Nucleic acid sequences of the present disclosure may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more naturally occurring nucleotides with an analog, inter-nucleotide modifications such as uncharged linkages (for example, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (for example, phosphorothioates, phosphorodithioates, etc.), pendant moieties, (for example, polypeptides), intercalators (for example, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (for example, alpha anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of a molecule. Other modifications can include, for example, analogs in which the ribose ring contains a bridging moiety or other structure such as modifications found in “locked” nucleic acids. In various embodiments, the nucleic acids are in operative association with additional genetic elements, such as tissue-specific expression-control sequence(s) (e.g., tissue-specific promoters and tissue-specific microRNA recognition sequences), as well as additional elements, such as inverted repeats (e.g., inverted terminal repeats, such as elements from or derived from viruses, e.g., AAV ITRs) and tandem repeats, inverted repeats/direct repeats (e.g., transposon inverted repeats, e.g., transposon inverted repeats also containing direct repeats, e.g., inverted repeats also containing direct repeats), homology regions (segments with various degrees of homology to a target DNA), UTRs (5′, 3′, or both 5′ and 3′ UTRs), and various combinations of the foregoing. The nucleic acid elements of the systems provided by the invention can be provided in a variety of topologies, including single-stranded, double-stranded, circular, linear, linear with open ends, linear with closed ends, and particular versions of these, such as doggybone DNA (dbDNA), close-ended DNA (ceDNA).

Gene expression unit: a gene expression unit is a nucleic acid sequence comprising at least one regulatory nucleic acid sequence operably linked to at least one effector sequence. A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if the promoter or enhancer affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be contiguous or non-contiguous. Where necessary to join two protein-coding regions, operably linked sequences may be in the same reading frame.

Host: The terms host genome or host cell, as used herein, refer to a cell and/or its genome into which protein and/or genetic material has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell and/or genome, but to the progeny of such a cell and/or the genome of the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. A host genome or host cell may be an isolated cell or cell line grown in culture, or genomic material isolated from such a cell or cell line, or may be a host cell or host genome which composing living tissue or an organism. In some instances, a host cell may be an animal cell or a plant cell, e.g., as described herein. In certain instances, a host cell may be a bovine cell, horse cell, pig cell, goat cell, sheep cell, chicken cell, or turkey cell. In certain instances, a host cell may be a corn cell, soy cell, wheat cell, or rice cell.

Operative association: As used herein, “operative association” describes a functional relationship between two nucleic acid sequences, such as a 1) promoter and 2) a heterologous object sequence, and means, in such example, the promoter and heterologous object sequence (e.g., a gene of interest) are oriented such that, under suitable conditions, the promoter drives expression of the heterologous object sequence. For instance, the template nucleic acid may be single-stranded, e.g., either the (+) or (−) orientation but an operative association between promoter and heterologous object sequence means whether or not the template nucleic acid will transcribe in a particular state, when it is in the suitable state (e.g., is in the (+) orientation, in the presence of required catalytic factors, and NTPs, etc.), it does accurately transcribe. Operative association applies analogously to other pairs of nucleic acids, including other tissue-specific expression control sequences (such as enhancers, repressors and microRNA recognition sequences), IR/DR, ITRs, UTRs, or homology regions and heterologous object sequences or sequences encoding a transposase.

Pseudoknot: A “pseudoknot sequence” sequence, as used herein, refers to a nucleic acid (e.g., RNA) having a sequence with suitable self-complementarity to form a pseudoknot structure, e.g., having: a first segment, a second segment between the first segment and a third segment, wherein the third segment is complementary to the first segment, and a fourth segment, wherein the fourth segment is complementary to the second segment. The pseudoknot may optionally have additional secondary structure, e.g., a stem loop disposed in the second segment, a stem-loop disposed between the second segment and third segment, sequence before the first segment, or sequence after the fourth segment. The pseudoknot may have additional sequence between the first and second segments, between the second and third segments, or between the third and fourth segments. In some embodiments, the segments are arranged, from 5′ to 3′: first, second, third, and fourth. In some embodiments, the first and third segments comprise five base pairs of perfect complementarity. In some embodiments, the second and fourth segments comprise 10 base pairs, optionally with one or more (e.g., two) bulges. In some embodiments, the second segment comprises one or more unpaired nucleotides, e.g., forming a loop. In some embodiments, the third segment comprises one or more unpaired nucleotides, e.g., forming a loop.

Stem-loop sequence: As used herein, a “stem-loop sequence” refers to a nucleic acid sequence (e.g., RNA sequence) with sufficient self-complementarity to form a stem-loop, e.g., having a stem comprising at least two (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) base pairs, and a loop with at least three (e.g., four) base pairs. The stem may comprise mismatches or bulges.

Tissue-specific expression-control sequence(s): As used herein, a “tissue-specific expression-control sequence” means nucleic acid elements that increase or decrease the level of a transcript comprising the heterologous object sequence in the target tissue in a tissue-specific manner, e.g., preferentially in an on-target tissue(s), relative to an off-target tissue(s). In some embodiments, a tissue-specific expression-control sequence preferentially drives or represses transcription, activity, or the half-life of a transcript comprising the heterologous object sequence in the target tissue in a tissue-specific manner, e.g., preferentially in an on-target tissue(s), relative to an off-target tissue(s). Exemplary tissue-specific expression-control sequences include tissue-specific promoters, repressors, enhancers, or combinations thereof, as well as tissue-specific microRNA recognition sequences. Tissue specificity refers to on-target (tissue(s) where expression or activity of the template nucleic acid is desired or tolerable) and off-target (tissue(s) where expression or activity of the template nucleic acid is not desired or is not tolerable). For example, a tissue-specific promoter (such as a promoter in a template nucleic acid or controlling expression of a transposase) drives expression preferentially in on-target tissues, relative to off-target tissues. In contrast, a micro-RNA that binds the tissue-specific microRNA recognition sequences (either on a nucleic acid encoding the transposase or on the template nucleic acid, or both) is preferentially expressed in off-target tissues, relative to on-target tissues, thereby reducing expression of a template nucleic acid (or transposase) in off-target tissues. Accordingly, a promoter and a microRNA recognition sequence that are specific for the same tissue, such as the target tissue, have contrasting functions (promote and repress, respectively, with concordant expression levels, i.e., high levels of the microRNA in off-target tissues and low levels in on-target tissues, while promoters drive high expression in on-target tissues and low expression in off-target tissues) with regard to the transcription, activity, or half-life of an associated sequence in that tissue.

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of the Gene Writing™ genome editing system.

FIG. 2 is a schematic of the structure of the Gene Writer™ genome editor polypeptide.

FIG. 3 is a schematic of the structure of exemplary Gene Writer™ template RNAs.

FIGS. 4A and 4B are a series of diagrams showing examples of configurations of Gene Writers using domains derived from a variety of sources. Gene Writers as described herein may or may not comprise all domains depicted. For example, a GeneWrite may, in some instances, lack an RNA-binding domain, or may have single domains that fulfill the functions of multiple domains, e.g., a Cas9 domain for DNA binding and endonuclease activity. Exemplary domains that can be included in a GeneWriter polypeptide include DNA binding domains (e.g., comprising a DNA binding domain, e.g., of a Table herein; a zinc finger; a TAL domain; Cas9; dCas9; nickase Cas9; a transcription factor, or a meganuclease), RNA binding domains (e.g., comprising an RNA binding domain of B-box protein, MS2 coat protein, dCas, or an element of a sequence of a Table herein), reverse transcriptase domains (e.g., comprising a reverse transcriptase domain of an element of a sequence of a Table herein; other retrotransposases (e.g., as listed in a Table herein); a peptide containing a reverse transctipase domain (e.g., as listed in a Table herein)), and/or an endonuclease domain (e.g., comprising an endonuclease domain of an element of a Table herein; Cas9; nickase Cas9; a restriction enzyme (e.g., a type II restriction enzyme, e.g., FokI); a meganuclease; a Holliday junction resolvase; an RLE retrotranspase; an APE retrotransposase; or a GIY-YIG retrotransposase). Exemplary GeneWriter polypeptides comprising exemplary combinations of such domains are shown in the bottom panel.

FIG. 5 is a diagram showing the modules of an exemplary GeneWriter RNA template. Individual modules of the exemplary template can be combined, re-arranged, and/or omitted, e.g., to produce a Gene Writer template. A=5′ homology arm; B=Ribozyme; C=5′ UTR; D=heterologous object sequence; E=3′ UTR; F=3′ homology arm.

FIG. 6 is a table listing the modules of an exemplary Gene Writer RNA template. Individual modules can be combined, re-arranged, and/or omitted, e.g., to produce a Gene Writer template. A=5′ homology arm; B=Ribozyme; C=5′ UTR; D=heterologous object sequence; E=3′ UTR; F=3′ homology arm.

FIGS. 7A and 7B are diagrams showing an exemplary second strand nicking process. (FIG. 7A) A Cas9 nickase is fused to a Gene Writer protein. The Gene Writer protein introduces a nick in a DNA strand through its EN domain (shown as *), and the fused Cas9 nickase introduces a nicks on either top or bottom DNA strands (shown as X). (FIG. 7B) A Gene Writer is targeted to DNA through its DNA biding domain and introduces a DNA nick with its EN domain (*). A Cas9 nickase is then used the generate a second nick (X) at the top or bottom strand, upstream or downstream of the EN introduced nick.

FIGS. 8A and 8B. The linker region at the C-terminus of the DNA-binding domain of R2Tg can be truncated and modified. Deletions in the Natural Linker from the myb domain at A or B to positions 1 or 2 along with replacement by 3GS (SEQ ID NO: 1024) or XTEN synthetic linkers were constructed (FIG. 8A). Integration efficiency was measured in HEK293T cells by ddPCR (FIG. 8B).

FIG. 9 . Landing pads designed for testing target site mutations of R2Tg Gene Writer.

FIG. 10A. ddPCR assay measuring percentage of integrations from all lentiviral integrated landing pads per cell.

FIG. 10B. Amplicon-sequencing and NGS analysis of indels present at landing pads sites.

FIG. 11 . AAVS1 ZFP replacement of DNA binding domain of a Retrotransposase Gene Writer. This Figure discloses “3GS Linker” as SEQ ID NO: 1024.

FIG. 12 . Cas9 or Cas9 nickase replacement of DNA binding domain of Retrotransposase GeneWriters with or without active EN domain (*=mutant)

FIG. 13 . AAVS1 ZFP fusion to a Retrotransposase Gene Writer with or without functional DNA binding domain.

FIGS. 14A and 14B. Schematic of nickaseCas9-GeneWriter fusions. (FIG. 14A) Schematic of nickaseCas9 fused to Gene Writer protein. (FIG. 14B) Schematic of 3′ extended gRNA.

FIGS. 15A and 15B. Schematic of nickaseCas9-GeneWriter fusions. (FIG. 15A) Schematic of nickaseCas9 fused to Gene Writer protein. (FIG. 15B) Schematic of donor transgene flanked by UTRs and homology to the cut site.

FIGS. 16A-16C. Schematic of constructs. (FIG. 16A) Schematic of Gene Writer protein. (FIG. 16B) Schematic of donor transgene flanked by UTRs and homology to the cut site. (FIG. 16C) Schematic of Cas9 constructs used.

FIGS. 17A and 17B. The schematics for mRNA encoding Gene Writer (FIG. 17A). The native untranslated regions (UTRs) were replaced by 5′ and 3′ UTRs optimized for the protein expression (shown as 5′ UTRexp and 3′ UTRexp). The Gene Writer protein expression was assayed by HiBit assay by probing HiBit tag expression (FIG. 17B). This Figure discloses “3GS” as SEQ ID NO: 1024.

FIG. 18 . Genome integration induced by Gene Writer protein with its native UTRs and UTRs optimized for the protein expression. The Gene Writing activity with non-native UTRs is stimulated by the presence of the RNA template bearing the retrotransposon native UTRs.

FIG. 19 . Delivery of Gene Writer system using mRNA encoding the polypeptide and plasmid DNA encoding the RNA template for retrotransposition.

FIG. 20 . Diagrams of example 5′UTR engineering strategies. HA=homology arm; K=Kozak sequence; pA=poly A signal; AMa=A. maritima; Rx=other species of retrotransposon.

FIG. 21 . Possible location of an intron (or introns) within the RNA template. Introns are shown by curved lines. 5′HA: 5′ homology arm; 3′ HA: 3′ homology arm; 5′ UTR: Retrotransposon-specific 5′UTR; 3′ UTR: Retrotransposon-specific 3′ UTR; GOI gene of interest. Orange blocks correspond to the sequence designed to be expressed from the genomic location harboring its own cell specific promoter, poly(A) signal and UTRs for the protein expression (5′ and 3′ UTR_(exp)). The sequence can be oriented in the sense (shown above) or the antisense orientation related to retrotransposon UTRs and homology arms. The intron can be located within GOI, or within UTR_(exp).

FIG. 22 . Genome integration in HEK293T cells as reported by 3′ ddPCR assay. The Gene Writer mRNA at 0.5 μg/well was co-transfected with the RNA templates with or without enzymatically added cap 1 and the poly(A) tail. The Gene Writer mRNA to RNA transgene ratio was 1:1.

FIG. 23 . Genome integration detected by 3′ ddPCR induced by expression of Gene Writer mRNA produced with either unmodified (G0) or modified nucleotides (pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), 5-methoxyuridine (5-MO-U) or 5-methylcytidine (5mC)). 1 ug of Gene Writer mRNA per well was used. The non-modified RNA template was used. The Gene Writer RNA to the RNA template were co-transfected in 1:8 molar ratio.

FIG. 24 . Construct diagram of driver and transgene plasmids. Homology arms (HA) and stuffer sequences are variable in this set of experiments.

FIGS. 25A-25C. (FIG. 25A) Timeline of experiment. (FIG. 25B) Schematic of R2Tg and transgene construct configurations. (FIG. 25C) Western Blot against Rad51 shows loss of Rad51 protein expression at day 3.

FIGS. 26A and 26B. U2OS cells were treated with a non targeting control siRNA (ctrl) or siRNA against Rad51, along with R2Tg Wt or control RT and EN mutants. ddPCR at the 3′ (FIG. 26A) or 5′ (FIG. 26B) junction was used to assess integration efficiency on day 3.

FIGS. 27A and 27B. (FIG. 27A) Sequence map of Ribozyme of R2 element from Taeniopygia guttata (R2Tg) in context of modules of Gene Writer transgene molecule RNA. The Ribozyme features are denoted as: P, based paired region; P′, based pair region complement strand; L, loop at end of P region; J, nucleotides joining base paired regions. Figure discloses SEQ ID NO: 1734. (FIG. 27B) Prediction of ribozyme secondary structure of R2Tg. Shaded box indicates a predicted catalytic position that could be used to inactivate the ribozyme. Figure discloses SEQ ID NO: 1734.

FIG. 28 . Sequence map of Ribozyme of R2 element from Taeniopygia guttata (R2Tg) in context of modules of Gene Writer transgene molecule RNA. The Ribozyme features are denoted as: P, based paired region; P′, based pair region complement strand; L, loop at end of P region; J, nucleotides joining base paired regions. Figure discloses SEQ ID NO: 1734.

FIG. 29 . Prediction of ribozyme secondary structure of R2 element from Taeniopygia guttata. Figure discloses SEQ ID NO: 1734.

FIG. 30 . Gene Writing system for treating an exemplary repeat expansion disorder. Figure discloses SEQ ID NOS 1645, 1599, 1645, 1635-1636, 1645 and 1686-1688, respectively, in order of appearance.

FIG. 31 . An illustration of two orientations of second strand nicking in an exemplary Gene Writing system.

FIGS. 32A and 32B. An illustration of the orientation and position of second strand nicking in an exemplary Gene Writing system and their effect on editing.

FIG. 33 . Shows generation and expression of Cas9-RT fusion proteins. To assess expression of novel Gene Writer polypeptides in human cells, U2OS cells were transfected with Cas-RT expression plasmids harboring various RT domains from Tables 1 and 30 fused to a wild-type (WT) or Cas9(N863A) nickase. Cell lysates were collected on day 2 post-transfection and analyzed by Western blot using a primary antibody against Cas9. A primary antibody against GADPH was included as a loading control.

FIG. 34 . Shows improving expression of Cas-RT fusions through choice of linker sequence. To assess how linkers can alter the expression of novel Gene Writer polypeptides in human cells, U2OS cells were transfected with Cas-RT expression plasmids harboring various linkers from Table 42 fusing the Cas9(N863A) nickase to the RT domain of an RNA-binding domain mutated R2Bm retrotransposase. Cell lysates were collected and analyzed by Western blot using a primary antibody against Cas9. A primary antibody against vinculin (left) or GADPH (right) was included as a loading control. Cas9 controls on the left represent titration of a Cas9 expression plasmid. Empty arrows indicate the original linker tested, while the filled arrow represents a linker (Linker 10) found to substantially improve expression of the fusion polypeptide. Sample numbers correspond to linker sequence identifiers in Table 42.

FIG. 35 . Shows Cas/gRNA DNA targeting activity is preserved in Cas-RT fusions. Various RT domains were fused to Cas9(WT) and electroporated into U2OS cells. Genomic DNA was harvested and analyzed for mutational signatures by next generation sequencing. Mutations in the RNA or DNA-binding domains (RBD or DBD) of R2 retrotransposase domains is indicated, where relevant. Indel frequency is used here as a proxy for Cas activity preservation in the context of the RT fusion.

FIGS. 36A and 36B Disclose application of mutations improving reverse transcriptase domains. Conserved reverse transcriptase domains from the retrovirus genera Betaretrovirus, Deltaretrovirus, Gammaretrovirus, Epsilonretrovirus, and Spumavirus were aligned and compared to mutations previously shown to improve RT activity (Anzalone et al Nat Biotechnol 38(7):824-844 (2020); Baranauskas et al Protein Eng Des Sel 25(10):657-668 (2012); Arezi and Hogrefe Nucleic Acids Res 37(2):473-481 (2009)). FIG. 36A shows a set of 3 core mutations was identified and applied to RTs from these genera as indicated in. FIG. 36B discloses additional mutations were applied with first priority from the set of T306K/W313F, or alternately from L139P/E607K where neither of the first set were deemed transferrable. Selected mutations are shown in Table 45. FIGS. 36A and 36B disclose SEQ ID NOS 3610, 3623, 3637, 3611, 3624, 3638, 3611, 3624, 3639, 3612, 3625, 3640, 3613, 3626, 3641, 3611, 3627, 3642, 3614, 3628, 3643, 3615, 3629, 3644, 3616, 3630, 3645, 3617, 3630, 3645, 3618, 3631, 3646, 3619, 3632, 3647, 3620, 3633, 3648, 3621, 3634, 3649, 3622, 3635, 3650, 3622, 3636, 3651, 3652, 2060, 2738, 3653, 2086, 2758, 3653, 2086, 2759, 3654, 2087, 2773, 3655, 2088, 2775, 3653, 2086, 2863, 3656, 2103, 3046, 3657, 2104, 3080, 3658, 2120, 3081, 3658, 2175, 3081, 3659, 2221, 3082, 3660, 2279, 3102, 3661, 2525, 3103, 3662, 2704, 3122, 1850, 2736, 3125, 1905, 2737, and 2123, respectively, in order of appearance.

FIG. 37 . U2OS cells were nucleofected with various Cas-RT fusion vectors in which the RT domain was selected from a database of monomeric retroviral reverse transcriptase domains. Editing of a HEK3 locus using a Template described in Table 43 was assessed by amplicon sequencing and analysis of precise editing vs indel signatures. Data are represented here as Activity Ratios, which are calculated as the ratio of the frequency of reads with the precisely intended edit (CTT insertion at the target nick site) to the frequency of reads with any other mutations (indels). Three Template RNA configurations assayed resulted in similar outcomes, so the results for a single template (Template P2 from Table 43) are shown.

FIG. 38 . shows targeting multiple loci simultaneously results in efficient Gene Writing activity. HEK293 cells were nucleofected with Gene Writing systems comprising different compositions of Template plasmids to enable targeting of: 1) HEK3 alone, 2) HBB alone, or 3) both HBB and the HEK3 locus. Percent of editing is indicated for each locus upon delivery of one or both locus-specific Template RNA expression plasmids. Filled bars represent Perfect Writing events, while unfilled bars represent the frequency of indels. Target-locus-specific editing was seen when delivering either Template independently, and highly efficient and specific edits were seen at both loci when co-delivering the Templates.

FIG. 39 . Shows effect of length on Gene Writing activity. HEK293T cells were nucleofected with all-RNA Gene Writing systems comprising various Template RNAs (Table 48) to test editing efficiency of the DNA-free approach at the HEK3 locus. Template 4, which encoded the same edit as Template 1, but with an addition of 20 nt at the 3′ end of the RT template, showed an approximately 3.1-fold drop in precise Writing activity and an approximately 2.4-fold drop in the ratio of precise corrections to indels.

FIG. 40 . Shows effect of all-RNA delivery of Gene Writer using different mRNA compositions. Nucleofection of various Cas9-RT(MMLV) mRNAs (Table 49) into HEK293T using Template 1 (Table 48A). No strong effects were observed here in varying capping and UTR compositions.

FIG. 41 . HEK293T cells were nucleofected with a Gene Writing system using a set Template (Template 1, Table 48) for editing the HEK3 locus and two different Cas-RT constructs. Sequence analysis indicated that both Cas-RT fusions made edits in a very precise and efficient manner. In both systems, there was an increase in efficiency under conditions including the optional secondary nick. These data show successful cloning and Precise Writing by the PERV RT domain in the context of these Cas-RT fusions.

FIG. 42 . Shows the effect of all-RNA delivery of Gene Writer employing modified nucleotides. mRNA molecules encoding the Cas-RT(MMLV) polypeptide were varied in composition to determine effects (Table 49). Here, Template 1 is used to edit the HEK3 locus after incorporating modified nucleotides in the mRNA component. Gene Writing activity with a 5moU-modified mRNA component was found to both high and precise.

FIGS. 43A-43C show the effect of all-RNA delivery of Gene Writer using different mRNA compositions delivered into the cell via lipid particles. FIG. 43A shows all-RNA lipofection of various Cas9-RT(MMLV) mRNAs into HEK293T was performed using Template 1 (Table 48) and delivering via Lipofectamine 3000. FIG. 43B shows all-RNA lipofection of various Cas9-RT(MMLV) mRNAs into HEK293T was performed using Template 1 (Table 48) and delivering via MessengerMax reagent. These data indicated higher precise editing efficiencies with the MessengerMax reagent. FIG. 43C shows assay of two Templates differing in total length using MessengerMax reagent. No major changes in efficiency of editing were found to be associated with the template change in this experiment. Where included head-to-head, the addition of the second-nick gRNA resulted in an increase in efficiency of the system.

FIG. 44 . shows all-RNA delivery of Cas-RT using lipid-based systems. The Cas9-RT(MMLV) and Cas9-RT(PERV) were delivered into HEK293T cells with Template 1 (Table 48) using MessengerMax lipid reagent. Here, activity for both enzymes was around 5% Precise Writing.

FIGS. 45A and 45B show expression of all-RNA Gene Writer system in primary human CD4+ T cells. FIG. 45A shows Gene Writer protein expression from mRNAs with varying doses delivered into primary human CD4+ T cells at day 1 post-nucleofection. Gene Writer was detected by an antibody targeting a Cas9 part of the polypeptide. GAPDH, a housekeeping gene, was detected by an antibody against GAPDH. Increasing expression levels were observed with increasing doses of nucleofected mRNA encoding the polypeptide were delivered, e.g., 0, 2.5, 5, and 10 μg Gene Writer mRNAs. Data for the detection of protein expression shown comprised 2 replicate. FIG. 45B shows Cell viability after nucleofection of 6 Template RNAs. Viability of primary CD4+ T cells after RNA delivery of the Gene Rewriter system at day 3 post nucleofection. Cell viability was assessed by flow cytometry after live/dead staining of harvested T cells (mean±s.d., n=2 replicates). [Gate: Live cells in a singlet population of cell population selected by FSC/SSC size plot]

FIGS. 46A and 46B show Gene Writing in primary human CD4+ T cells. FIG. 46A shows precise editing of the HEK3 genomic locus by a Gene Writer system in primary human CD4+ T cells, without addition of second-nick gRNA. FIG. 46B shows precise editing of the HEK3 genomic locus by a Gene Writer system in primary human CD4+ T cells. Genomic DNA was extracted from cells at day 3 post-nucleofection. Genome editing of HEK3 was examined by PCR-based amplicon-sequencing assay. DNA amplicons containing the expected genomic alteration were identified as Precise Write events, whereas amplicons with unintended editing (e.g. insertion, deletion) were counted as Indels. The percentage of each was calculated based on total reads per condition (mean±s.d., n=2 replicates).

FIGS. 47A and 47B show use of a second-nick gRNA for Gene Writing in primary human CD4+ T cells. The data generated in FIG. 46 are shown here for a direct comparison of potential effects of second-nick gRNA on efficiency. FIG. 47A shows in this experiment, the addition of a second-nick gRNA did not result in an enhanced precise writing signal. FIG. 47B shows rather, the use of a second-nick gRNA may have increased the frequency of indels. Thus, in some embodiments, a second nick gRNA sequence may be absent from a system described herein. Precise editing of HEK3 genomic site by the Gene Writer system in primary human CD4+ T cells, without (FIG. 47A) or with addition of second-nick gRNA (FIG. 47B). Genomic DNA was extracted from cells at day 3 post-nucleofection. Genome editing of HEK3 was examined by PCR-based amplicon-sequencing assay. DNA amplicons containing the expected genomic alteration by Gene Writer system were identified as Precise Write events, whereas amplicons with unintended editing (e.g. insertion, deletion) were counted as Indels. The percentage of each was calculated based on total reads per condition (mean±s.d., n=2 replicates).

FIG. 48 . shows screening construct design for retrotransposon-mediated integration in human cells. A driver plasmid comprising a retrotransposase (Driver) expression cassette is transfected together with a template plasmid comprising a retrotransposon-dependent reporter cassette. Whereas expression from the template plasmid results in a non-functional GFP because of an interrupting antisense intron, transcription of the template molecule from the template plasmid results in the generation of an RNA with the intron removed by splicing that can then be reverse transcribed and integrated by the system. Expression of the reporter cassette will thus only occur from the integrated reporter cassette (Integrated gDNA, bottom) and not from the template plasmid. HA=homology arm, where applicable; CMV=mammalian CMV promoter; HiBit=HiBit tag for quantification of protein expression; T7=T7 RNA polymerase promoter; UTR=untranslated sequence, e.g., native retrotransposon UTRs; pA=poly A signal; SD-SA is used to indicate the splice-donor and splice-acceptor sites of an antisense intron in the GFP coding sequence.

FIG. 49 . Screening of candidate retrotransposons identifies 25 candidates working to integrate a trans payload in human cells. A total of 163 retrotransposon systems were assayed for activity in human cells as described in Example 39. Integration as measured by ddPCR is shown as copies/genome for each retrotransposon driver/template system. The height of each bar indicates the average value of two replicates.

FIGS. 50A and 50B show luciferase activity assay for primary cells. LNPs formulated as according to Example 44 were analyzed for delivery of cargo to primary human (A) and mouse (B) hepatocytes, as according to Example 45. The luciferase assay revealed dose-responsive luciferase activity from cell lysates, indicating successful delivery of RNA to the cells and expression of Firefly luciferase from the mRNA cargo.

FIG. 51 discloses LNP-mediated delivery of RNA cargo to the murine liver. Firefly luciferase mRNA-containing LNPs were formulated and delivered to mice by iv, and liver samples were harvested and assayed for luciferase activity at 6, 24, and 48 hours post administration. Reporter activity by the various formulations followed the ranking LIPIDV005>LIPIDV004>LIPIDV003. RNA expression was transient and enzyme levels returned near vehicle background by 48 hours. Post-administration.

DETAILED DESCRIPTION

This disclosure relates to compositions, systems and methods for targeting, editing, modifying or manipulating a DNA sequence (e.g., inserting a heterologous object sequence into a target site of a mammalian genome) at one or more locations in a DNA sequence in a cell, tissue or subject, e.g., in vivo or in vitro. The heterologous object DNA sequence may include, e.g., a substitution, a deletion, an insertion, e.g., a coding sequence, a regulatory sequence, or a gene expression unit.

More specifically, the disclosure provides reverse transcriptase-based systems for altering a genomic DNA sequence of interest, e.g., by inserting, deleting, or substituting one or more nucleotides into/from the sequence of interest. This disclosure is based, in part, on a bioinformatic analysis to identify reverse transcriptase sequences, for example in retrotransposons from a variety of organisms (see Table 1 or 3).

The disclosure provides, in part, Gene Writer™ genome editors comprising a polypeptide component and a template nucleic acid (e.g., template RNA) component. In some embodiments, a Gene Writer™ genome editor can be used to introduce an alteration into a target site in a genome. In some embodiments, the polypeptide component comprises a writing domain (e.g., a reverse transcriptase domain), a DNA-binding domain, and an endonuclease domain (e.g., nickase domain). In some embodiments, the template nucleic acid (e.g., template RNA) comprises a sequence that binds a target site in the genome (e.g., that binds to a second strand of the target site), a sequence that binds the polypeptide component, a heterologous object sequence, and a 3′ target homology domain. Without wishing to be bound by theory, it is thought that the template nucleic acid (e.g., template RNA) binds to the second strand of a target site in the genome, and binds to the polypeptide component (e.g., localizing the polypeptide component to the target site in the genome). It is thought that the endonuclease (e.g., nickase) of the polypeptide component cuts the target site (e.g., the first strand of the target site), e.g., allowing the 3′homology domain to bind to a sequence adjacent to the site to be altered on the first strand of the target site. It is thought that the writing domain (e.g., reverse transcriptase domain) of the polypeptide component uses the 3′ target homology domain as a primer and the heterologous object sequence as a template to, e.g., polymerize a sequence complementary to the heterologous object sequence. Without wishing to be bound by theory, it is thought that selection of an appropriate heterologous object sequence can result in substitution, deletion, or insertion of one or more nucleotides at the target site.

In embodiments, the disclosure provides a nucleic acid molecule or a system for retargeting, e.g., of a Gene Writer polypeptide or nucleic acid molecule, or of a system as described herein. Retargeting (e.g., of a Gene Writer polypeptide or nucleic acid molecule, or of a system as described herein) generally comprises. (i) directing the polypeptide to bind and cleave at the target site; and/or (ii) designing the template RNA to have complementarity to the target sequence. In some embodiments, the template RNA has complementarity to the target sequence 5′ of the first-strand nick, e.g., such that the 3′ end of the template RNA anneals and the 5′ end of the target site serves as the primer, e.g., for target-primed reverse transcription (TPRT). In some embodiments, the endonuclease domain of the polypeptide and the 5′ end of the RNA template are also modified as described.

Gene Writer™ genome editors Gene Writer™ genome editors are systems that are capable of modifying a host cell's genome and can be applied for the mutation, deletion, or other modification of a genomic target sequence, including the insertion of heterologous payloads. In some embodiments, these systems take inspiration from a group of naturally evolved mobile genetic elements known as retrotransposons. Gene Writer™ polypeptides can also comprise RT domains derived from sources other than retrotransposons, e.g., from viruses.

Non-long terminal repeat (LTR) retrotransposons are a type of mobile genetic elements that are widespread in eukaryotic genomes. They include two classes: the apurinic/apyrimidinic endonuclease (APE)-type and the restriction enzyme-like endonuclease (RLE)-type. The APE class retrotransposons are comprised of two functional domains: an endonuclease/DNA binding domain, and a reverse transcriptase domain. The RLE class are comprised of three functional domains: a DNA binding domain, a reverse transcription domain, and an endonuclease domain. The reverse transcriptase domain of non-LTR retrotransposon functions by binding an RNA sequence template and reverse transcribing it into the host genome's target DNA. The RNA sequence template has a 3′ untranslated region which is specifically bound to the transposase, and a variable 5′ region generally having Open Reading Frame(s) (“ORF”) encoding transposase proteins. The RNA sequence template may also comprise a 5′ untranslated region which specifically binds the retrotransposase.

In some embodiments, as described herein, the elements of such non-LTR retrotransposons can be functionally modularized and/or modified to target, edit, modify or manipulate a target DNA sequence, e.g., to insert an object (e.g., heterologous) nucleic acid sequence into a target genome, e.g., a mammalian genome, by reverse transcription. Such modularized and modified nucleic acids, polypeptide compositions and systems are described herein and are referred to as Gene Writer™ gene editors. A Gene Writer™ gene editor system comprises: (A) a polypeptide or a nucleic acid encoding a polypeptide, wherein the polypeptide comprises (i) a reverse transcriptase domain, and either (x) an endonuclease domain that contains DNA binding functionality or (y) an endonuclease domain and separate DNA binding domain; and (B) a template RNA comprising (i) a sequence that binds the polypeptide and (ii) a heterologous insert sequence. For example, the Gene Writer™ genome editor protein may comprise a DNA-binding domain, a reverse transcriptase domain, and an endonuclease domain. In some embodiments, the DNA-binding function may involve an RNA component that directs the protein to a DNA sequence, e.g, a gRNA. In other embodiments, the Gene Writer™ genome editor protein may comprise a reverse transcriptase domain and an endonuclease domain. In certain embodiments, the elements of the Gene Writer™ gene editor polypeptide can be derived from sequences of non-LTR retrotransposons, e.g., APE-type or RLE-type retrotransposons or portions or domains thereof. In some embodiments the RLE-type non-LTR retrotransposon is from the R2, NeSL, HERO, R4, or CRE clade. In some embodiments the Gene Writer™ genome editor is derived from R4 element X4_Line, which is found in the human genome. In some embodiments the APE-type non-LTR retrotransposon is from the R1, or Tx1 clade. In some embodiments the Gene Writer™ genome editor is derived from Tx1 element Mare6, which is found in the human genome. The RNA template element of a Gene Writer™ gene editor system is typically heterologous to the polypeptide element and provides an object sequence to be inserted (reverse transcribed) into the host genome. In some embodiments the Gene Writer™ genome editor protein is capable of target primed reverse transcription. In some embodiments, the Gene Writer genome editor protein is capable of second strand synthesis. Table 50 shows exemplary Gene Writer proteins and associated sequences from a variety of retrotransposases, identified using data mining. Column 1 indicates the family to which the retrotransposon belongs. Column 2 lists the element name. Column 3 indicates an accession number, if any. Column 4 lists an organism in which the retrotransposase is found. Column 5 lists the predicted 5′ untranslated region, and column 6 lists the predicted 3′ untranslated region; both are segments that are predicted to allow the template RNA to bind the retrotransposase of column 7. (It is understood that columns 5-6 show the DNA sequence, and that an RNA sequence according to any of columns 5-6 would typically include uracil rather than thymidine.) Column 7 lists the predicted retrotransposase amino acid sequence. Column 8 lists the predicted RT domain present based on sequence analysis, column 9 lists the start codon position, and column 10 lists the stop codon position.

Lengthy table referenced here US20230272430A1-20230831-T00001 Please refer to the end of the specification for access instructions.

In some embodiments the Gene Writer™ genome editor is combined with a second polypeptide. In some embodiments the second polypeptide is derived from an APE-type non-LTR retrotransposon. In some embodiments the second polypeptide has a zinc knuckle-like motif. In some embodiments the second polypeptide is a homolog of Gag proteins.

Inspired by the success of retrotransposons in nature, it is further discussed here that the natural function of a retrotransposon can be recapitulated using functional parts derived from completely independent systems. For example, a functional Gene Writer™ can be made up of unrelated DNA binding, reverse transcription, and endonuclease domains. This modular structure allows combining of functional domains, e.g., dCas9 (DNA binding), MMLV reverse transcriptase (reverse transcription), FokI (endonuclease). In some embodiments, multiple functional domains may arise from a single protein, e.g., Cas9 nickase (DNA binding, endonuclease), R2 retrotransposon (DNA binding, reverse transcription, endonuclease).

In some embodiments, a Gene Writer™ system is capable of producing an insertion into the target site of at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides (and optionally no more than 500, 400, 300, 200, or 100 nucleotides). In some embodiments, a Gene Writer™ system is capable of producing an insertion into the target site of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides (and optionally no more than 500, 400, 300, 200, or 100 nucleotides). In some embodiments, a Gene Writer™ system is capable of producing an insertion into the target site of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 kilobases (and optionally no more than 1, 5, 10, or 20 kilobases). In some embodiments, a Gene Writer™ system is capable of producing a deletion of at least 81, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nucleotides (and optionally no more than 500, 400, 300, or 200 nucleotides). In some embodiments, a Gene Writer™ system is capable of producing a deletion of at least 81, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nucleotides (and optionally no more than 500, 400, 300, or 200 nucleotides). In some embodiments, a Gene Writer™ system is capable of producing a deletion of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nucleotides (and optionally no more than 500, 400, 300, or 200 nucleotides). In some embodiments, a Gene Writer™ system is capable of producing a deletion of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 kilobases (and optionally no more than 1, 5, 10, or 20 kilobases). In some embodiments, a Gene Writer system is capable of producing a substitution into the target site of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 or more nucleotides. In some embodiments, the substitution is a transition mutation. In some embodiments, the substitution is a transversion mutation. In some embodiments, the substitution converts an adenine to a thymine, an adenine to a guanine, an adenine to a cytosine, a guanine to a thymine, a guanine to a cytosine, a guanine to an adenine, a thymine to a cytosine, a thymine to an adenine, a thymine to a guanine, a cytosine to an adenine, a cytosine to a guanine, or a cytosine to a thymine.

Polypeptide Component of Gene Writer™ Gene Editor System

Domains and Functions:

In some embodiments, the Gene Writer™ polypeptide possesses the functions of DNA target site binding, template nucleic acid (e.g., RNA) binding, DNA target site cleavage, and template nucleic acid (e.g., RNA) writing, e.g., reverse transcription. In some embodiments, each functions is contained within a distinct domain. In some embodiments, a function may be attributed to two or more domains (e.g., two or more domains, together, exhibit the functionality). In some embodiments, two or more domains may have the same or similar function (e.g., two or more domains each independently have DNA-binding functionality, e.g., for two different DNA sequences). In other embodiments, one or more domains may be capable of enabling one or more functions, e.g., a Cas9 domain enabling both DNA binding and target site cleavage. In some embodiments, the domains are all located within a single polypeptide. In some embodiments, a first domain is in one polypeptide and a second domain is in a second polypeptide. For example, in some embodiments, the Gene Writer™ polypeptide may be split between a first polypeptide and a second polypeptide, e.g., wherein the first polypeptide comprises a reverse transcriptase (RT) domain and wherein the second polypeptide comprises a DNA-binding domain and an endonuclease domain, e.g., a nickase domain. As a further example, in some embodiments, the first polypeptide and the second polypeptide each comprise a DNA binding domain (e.g., a first DNA binding domain and a second DNA binding domain). In some embodiments, the first and second polypeptide may be brought together post-translationally via a split-intein.

Writing Domain:

In certain aspects of the present invention, the writing domain of the Gene Writer™ system possesses reverse transcriptase activity and is also referred to as a reverse transcriptase domain (a RT domain). In some embodiments, the RT domain comprises an RT catalytic portion and RNA-binding region (e.g., a region that binds the template RNA).

In certain aspects of the present invention, the writing domain is based on a reverse transcriptase domain of an APE-type or RLE-type non-LTR retrotransposon. A wild-type reverse transcriptase domain of an APE-type or RLE-type non-LTR retrotransposon can be used in a Gene Writer™ system or can be modified (e.g., by insertion, deletion, or substitution of one or more residues) to alter the reverse transcriptase activity for target DNA sequences. In some embodiments the reverse transcriptase is altered from its natural sequence to have altered codon usage, e.g. improved for human cells. In some embodiments the reverse transcriptase domain is a heterologous reverse transcriptase from a different retrovirus, LTR-retrotransposon, or non-LTR retrotransposon. In certain embodiments, a Gene Writer™ system includes a polypeptide that comprises a reverse transcriptase domain of an RLE-type non-LTR retrotransposon from the R2, NeSL, HERO, R4, or CRE clade, or of an APE-type non-LTR retrotransposon from the R1, or Tx1 clade. In certain embodiments, a Gene Writer™ system includes a polypeptide that comprises a reverse transcriptase domain of a non-LTR retrotransposon, LTR retrotransposon, group II intron, diversity-generating element, retron, telomerase, retroplasmid, retrovirus, or an engineered polymerase listed in Table 1 or Table 3. In some embodiments, a Gene Writer™ system includes a polypeptide that comprises a reverse transcriptase domain listed in Table 2. In embodiments, the amino acid sequence of the reverse transcriptase domain of a Gene Writer™ system is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% identical to the amino acid sequence of a reverse transcriptase domain of a non-LTR retrotransposon, LTR retrotransposon, group II intron, diversity-generating element, retron, telomerase, retroplasmid, retrovirus, or an engineered polymerase whose DNA sequence is referenced in Table 1 or Table 3, or of a peptide comprising an RT domain referenced in Table 2. In some embodiments, the RT domain has a sequence selected from Table 1 or 3, or a sequence of a peptide comprising an RT domain selected from Table 2, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the RT domain comprising a Gene Writer polypeptide has been mutated from its original amino acid sequence, e.g., has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 substitutions. In some embodiments, the RT domain is derived from the RT of a retrovirus, e.g., HIV-1 RT, Moloney Murine Leukemia Virus (MMLV) RT, avian myeloblastosis virus (AMV) RT, Rous Sarcoma Virus (RSV) RT. In some embodiments, the RT domain is derived from the RT of a Group II intron, e.g., the group II intron maturase RT from Eubacterium rectale (MarathonRT) (Zhao et al. RNA 24:2 2018), the RT domain from LtrA, the RT TGIRT (or trt). In some embodiments, the RT domain is derived from the RT of a retron, e.g., the reverse transcriptase from Ec86 (RT86). In some embodiments, the RT domain is derived from a diversity-generating retroelement, e.g., from the RT of Brt. In some embodiments, the RT domain is derived from the RT of a retroplasmid, e.g., the RT from the Mauriceville plasmid. In some embodiments, the RT domain is derived from a non-LTR retrotransposon, e.g., the RT from R2Bm, the RT from R2Tg, the RT from LINE-1, the RT from Penelope or a Penelope-like element (PLE). In some embodiments, the RT domain is derived from an LTR retrotransposon, e.g., the reverse transcriptase from Ty1. In some embodiments, the RT domain is derived from a telomerase, e.g., TERT. A person having ordinary skill in the art is capable of identifying reverse transcription domains based upon homology to other known reverse transcription domains using routine tools as Basic Local Alignment Search Tool (BLAST). In some embodiments, the reverse transcriptase contains the InterPro domain IPR000477. In some embodiments, the reverse transcriptase contains the pfam domain PF00078. In some embodiments, the RT contains the InterPro domain IPR013103. In some embodiments, the RT contains the pfam domain PF07727. In some embodiments, the reverse transcriptase contains a conserved protein domain of the cd00304 RT_like family, e.g., cd01644 (RT_pepA17), cd01645 (RT_Rtv), cd01646 (RT_Bac_retron_I), cd01647 (RT_LTR), cd01648 (TERT), cd01650 (RT_nLTR_like), cd01651 (RT_G2_intron), cd01699 (RNA_dep_RNAP), cd01709 (RT_like_1), cd03487 (RT_Bac_retron_II), cd03714 (RT_DIRS1), cd03715 (RT_ZFREV_like). Proteins containing these domains can additionally be found by searching the domains on protein databases, such as InterPro (Mitchell et al. Nucleic Acids Res 47, D351-360 (2019)), UniProt (The UniProt Consortium Nucleic Acids Res 47, D506-515 (2019)), or the conserved domain database (Lu et al. Nucleic Acids Res 48, D265-268 (2020)), or by scanning open reading frames for reverse transcriptase domains using prediction tools, for example InterProScan. The diversity of reverse transcriptases has been described in, but not limited to, those used by prokaryotes (Zimmerly et al. Microbiol Spectr 3(2):MDNA3-0058-2014 (2015); Lampson B. C. (2007) Prokaryotic Reverse Transcriptases. In: Polaina J., MacCabe A. P. (eds) Industrial Enzymes. Springer, Dordrecht), viruses (Herschhorn et al. Cell Mol Life Sci 67(16):2717-2747 (2010); Menendez-Arias et al. Virus Res 234:153-176 (2017)), and mobile elements (Eickbush et al. Virus Res 134(1-2):221-234 (2008); Craig et al. Mobile DNA III 3rd Ed. DOI:10.1128/9781555819217 (2015)), each of which is incorporated herein by reference.

In some embodiments, the reverse transcriptase (RT) domain exhibits enhanced stringency of target-primed reverse transcription (TPRT) initiation, e.g., relative to an endogenous RT domain. In some embodiments, the RT domain initiates TPRT when the 3 nt in the target site immediately upstream of the first strand nick, e.g., the genomic DNA priming the RNA template, have at least 66% or 100% complementarity to the 3 nt of homology in the RNA template. In some embodiments, the RT domain initiates TPRT when there are less than 5 nt mismatched (e.g., less than 1, 2, 3, 4, or 5 nt mismatched) between the template RNA homology and the target DNA priming reverse transcription. In some embodiments, the RT domain is modified such that the stringency for mismatches in priming the TPRT reaction is increased, e.g., wherein the RT domain does not tolerate any mismatches or tolerates fewer mismatches in the priming region relative to a wild-type (e.g., unmodified) RT domain. In some embodiments, the RT domain comprises a HIV-1 RT domain. In embodiments, the HIV-1 RT domain initiates lower levels of synthesis even with three nucleotide mismatches relative to an alternative RT domain (e.g., as described by Jamburuthugoda and Eickbush J Mol Biol 407(5):661-672 (2011); incorporated herein by reference in its entirety).

In some embodiments, the RT domain forms a dimer (e.g., a heterodimer or homodimer). In some embodiments, the RT domain is monomeric. In some embodiments, an RT domain, e.g., a retroviral RT domain, naturally functions as a monomer or as a dimer (e.g., heterodimer or homodimer). In some embodiments, an RT domain naturally functions as a monomer, e.g., is derived from a virus wherein it functions as a monomer. Exemplary monomeric RT domains, their viral sources, and the RT signatures associated with them can be found in Table 30 with descriptions of domain signatures in Table 32. In some embodiments, the RT domain of a system described herein comprises an amino acid sequence of Table 30, or a functional fragment or variant thereof, or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. In embodiments, the RT domain is selected from an RT domain from murine leukemia virus (MLV; sometimes referred to as MoMLV) (e.g., P03355), porcine endogenous retrovirus (PERV) (e.g., UniProt Q4VFZ2), mouse mammary tumor virus (MMTV) (e.g., UniProt P03365), Mason-Pfizer monkey virus (MPMV) (e.g., UniProt P07572), bovine leukemia virus (BLV) (e.g., UniProt P03361), human T-cell leukemia virus⁻¹ (HTLV-1) (e.g., UniProt P03362), human foamy virus (HFV) (e.g., UniProt P14350), simian foamy virus (SFV) (e.g., UniProt P23074), or bovine foamy/syncytial virus (BFV/BSV) (e.g., UniProt 041894), or a functional fragment or variant thereof (e.g., an amino acid sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto). In some embodiments, an RT domain is dimeric in its natural functioning. Exemplary dimeric RT domains, their viral sources, and the RT signatures associated with them can be found in Table 31 with descriptions of domain signatures in Table 32. In some embodiments, the RT domain of a system described herein comprises an amino acid sequence of Table 31, or a functional fragment or variant thereof, or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. In some embodiments, the RT domain is derived from a virus wherein it functions as a dimer. In embodiments, the RT domain is selected from an RT domain from avian sarcoma/leukemia virus (ASLV) (e.g., UniProt AOA142BKH1), Rous sarcoma virus (RSV) (e.g., UniProt P03354), avian myeloblastosis virus (AMV) (e.g., UniProt Q83133), human immunodeficiency virus type I (HIV-1) (e.g., UniProt P03369), human immunodeficiency virus type II (HIV-2) (e.g., UniProt P15833), simian immunodeficiency virus (SIV) (e.g., UniProt P05896), bovine immunodeficiency virus (BIV) (e.g., UniProt P19560), equine infectious anemia virus (EIAV) (e.g., UniProt P03371), or feline immunodeficiency virus (FIV) (e.g., UniProt P16088) (Herschhorn and Hizi Cell Mol Life Sci 67(16):2717-2747 (2010)), or a functional fragment or variant thereof (e.g., an amino acid sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto). Naturally heterodimeric RT domains may, in some embodiments, also be functional as homodimers. In some embodiments, dimeric RT domains are expressed as fusion proteins, e.g., as homodimeric fusion proteins or heterodimeric fusion proteins. In some embodiments, the RT function of the system is fulfilled by multiple RT domains (e.g., as described herein). In further embodiments, the multiple RT domains are fused or separate, e.g., may be on the same polypeptide or on different polypeptides.

In some embodiment, a GeneWriter described herein comprises an integrase domain, e.g., wherein the integrase domain may be part of the RT domain. In some embodiments, an RT domain (e.g., as described herein) comprises an integrase domain. In some embodiments, an RT domain (e.g., as described herein) lacks an integrase domain, or comprises an integrase domain that has been inactivated by mutation or deleted. In some embodiment, a GeneWriter described herein comprises an RNase H domain, e.g., wherein the RNase H domain may be part of the RT domain. In some embodiments, an RT domain (e.g., as described herein) comprises an RNase H domain, e.g., an endogenous RNAse H domain or a heterologous RNase H domain. In some embodiments, an RT domain (e.g., as described herein) lacks an RNase H domain. In some embodiments, an RT domain (e.g., as described herein) comprises an RNase H domain that has been added, deleted, mutated, or swapped for a heterologous RNase H domain. In some embodiments, mutation of an RNase H domain yields a polypeptide exhibiting lower RNase activity, e.g., as determined by the methods described in Kotewicz et al. Nucleic Acids Res 16(1):265-277 (1988) (incorporated herein by reference in its entirety), e.g., lower by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to an otherwise similar domain without the mutation. In some embodiments, RNase H activity is abolished.

In some embodiments, an RT domain is mutated to increase fidelity compared to an otherwise similar domain without the mutation. For instance, in some embodiments, a YADD (SEQ ID NO: 1539) or YMDD (SEQ ID NO: 1540) motif in an RT domain (e.g., in a reverse transcriptase) is replaced with YVDD (SEQ ID NO: 1541). In embodiments, replacement of the YADD (SEQ ID NO: 1539) or YMDD (SEQ ID NO: 1540) or YVDD (SEQ ID NO: 1541) results in higher fidelity in retroviral reverse transcriptase activity (e.g., as described in Jamburuthugoda and Eickbush J Mol Biol 2011; incorporated herein by reference in its entirety).

In some embodiments, the reverse transcriptase domain is one selected from an element of Table 1 or Table 3.

Table 1: Exemplary reverse transcriptase domains from different types of sources. Sources include Group II intron, non-LTR retrotransposon, retrovirus, LTR retrotransposon, diversity-generating retroelement, retron, telomerase, retroplasmid, and evolved DNA polymerase. Also included are the associated RT signatures from the InterPro, pfam, and cd databases. Although the evolved polymerase RTX can perform RNA-dependent DNA polymerization, no RT signatures were identified by InterProScan, so polymerase signatures are included instead.

TABLE 2 InterPro descriptions of signatures present in reverse transcriptases in RT Protein Type Accession UniProt Sequence signatures MarathonRT Group CBK92290.1 D4JMT MDTSNLMEQILSSDNLNRAYLQVVR IPR000477 II 6 NKGAEGVDGMKYTELKEHLAKNGET PF00078, intron IKGQLRTRKYKPQPARRVEIPKPDG cd01651 GVRNLGVPTVTDRFIQQAIAQVLTP IYEEQFHDHSYGFRPNRCAQQAILT ALNIMNDGNDWIVDIDLEKFFDTVN HDKLMTLIGRTIKDGDVISIVRKYL VSGIMIDDEYEDSIVGTPQGGNLSP LLANIMLNELDKEMEKRGLNFVRYA DDCIIMVGSEMSANRVMRNISRFIE EKLGLKVNMTKSKVDRPSGLKYLGF GFYFDPRAHQFKAKPHAKSVAKFKK RMKELTCRSWGVSNSYKVEKLNQLI RGWINYFKIGSMKTLCKELDSRIRY RLRMCIWKQWKTPQNQEKNLVKLGI DRNTARRVAYTGKRIAYVCNKGAVN VAISNKRLASFGLISMLDYYIEKCV TC (SEQ ID NO: 1542) TGIRT, Group AAT72329.1 Q6DKY2 MALLERILADRNLITALKRVEANQG IPR000477 trt II APGIGDVSTDQLRDIYRAHWSTIRA PF00078, intron QLLAGTYRPAPVRRVGIPKGPGGTR cd01651 QLGITPVVDRLIQQIALQELTPIFD PDFSPSSFGFRPGRNAHDAVRQAQG YIQEYGRYVVDMDLKEFFDRVNHDL IMSRVARKVDKKRVLKLIRYALQAG VMIEGVKVQTEEGTQPGGPLSPLLA NILLDDLDKELEKRGLKFCYRADDC NIYVSKLRAGQRVKQSIQRFLEKTL KLKVNEEKSVADRPWKRAFGLFSFT PERKARIRLAPRSIQRLKQRIRQLT NPNWSISMPREIHRVNQYVGMWIGY FRLVTEPSVLQTIEGWIRRRLRLCW QLQWKRVRTRIRELRALGLKETAVM EIANRTKGAWRTTKPQTLHQALGKY TWTAQGLKTSLQRYFELRQG (SEQ ID NO: 1543) LtrA Group AAB06503.1 P0A3U0 MKPTMAILERISKNSQENIDEVFTR IPR000477, II LYRYLLRPDIYYVAYQNLYSNKGAS PF00078, intron TKGILDDTADGFSEEKIKKIIQSLK cd01651 DGTYYPQPVRRMYIAKKNSKKMRPL GIPTFTDKLIQEAVRIILESIYEPV FEDVSHGFRPQRSCHTALKTIKREF GGARWFVEGDIKGCFDNIDHVTLIG LINLKIKDMKMSQLIYKFLKAGYLE NWQYHKTYSGTPQGGILSPLLANIY LHELDKFVLQLKMKFDRESPERITP EYRELHNEIKRISHRLKKLEGEEKA KVLLEYQEKRKRLPTLPCTSQTNKV LKYVRYADDFIISVKGSKEDCQWIK EQLKLFIHNKLKMELSEEKTLITHS SQPARFLGYDIRVRRSGTIKRSGKV KKRTLNGSVELLIPLQDKIRQFIFD KKIAIQKKDSSWFPVHRKYLIRSTD LEIITIYNSELRGICNYYGLASNFN QLNYFAYLMEYSCLKTIASKHKGTL SKTISMFKDGSGSWGIPYEIKQGKQ RRYFANFSECKSPYQFTDEISQAPV LYGYARNTLENRLKAKCCELCGTSD ENTSYEIHHVNKVKNLKGKEKWEMA MIAKQRKTLVVCFHCHRHVIHKHK (SEQ ID NO: 1544) R2Bm non- AAB59214.1 V9H052 MMASTALSLMGRCNPDGCTRGKHVT IPR000477 LTR AAPMDGPRGPSSLAGTFGWGLAIPA PF00078, retro- GEPCGRVCSPATVGFFPVAKKSNKE cd01650 transposon NRPEASGLPLESERTGDNPTVRGSA GADPVGQDAPGWTCQFCERTFSTNR GLGVHKRRAHPVETNTDAAPMMVKR RWHGEEIDLLARTEARLLAERGQCS GGDLFGALPGFGRTLEAIKGQRRRE PYRALVQAHLARFGSQPGPSSGGCS AEPDFRRASGAEEAGEERCAEDAAA YDPSAVGQMSPDAARVLSELLEGAG RRRACRAMRPKTAGRRNDLHDDRTA SAHKTSRQKRRAEYARVQELYKKCR SRAAAEVIDGACGGVGHSLEEMETY WRPILERVSDAPGPTPEALHALGRA EWHGGNRDYTQLWKPISVEEIKASR FDWRTSPGPDGIRSGQWRAVPVHLK AEMFNAWMARGEIPEILRQCRTVFV PKVERPGGPGEYRPISIASIPLRHF HSILARRLLACCPPDARQRGFICAD GTLENSAVLDAVLGDSRKKLRECHV AVLDFAKAFDTVSHEALVELLRLRG MPEQFCGYIAHLYDTASTTLAVNNE MSSPVKVGRGVRQGDPLSPILFNVV MDLILASLPERVGYRLEMELVSALA YADDLVLLAGSKVGMQESISAVDCV GRQMGLRLNCRKSAVLSMIPDGHRK KHHYLTERTFNIGGKPLRQVSCVER WRYLGVDFEASGCVTLEHSISSALN NISRAPLKPQQRLEILRAHLIPRFQ HGFVLGNISDDRLRMLDVQIRKAVG QWLRLPADVPKAYYHAAVQDGGLAI PSVRATIPDLIVRRFGGLDSSPWSV ARAAAKSDKIRKKLRWAWKQLRRFS RVDSTTORPSVRLFWREHLHASVDG RELRESTRTPTSTKWIRERCAQITG RDFVQFVHTHINALPSRIRGSRGRR GGGESSLTCRAGCKVRETTAHILQQ CHRTHGGRILRHNKIVSFVAKAMEE NKWTVELEPRLRTSVGLRKPDIIAS RDGVGVIVDVQVVSGQRSLDELHRE KRNKYGNHGELVELVAGRLGLPKAE CVRATSCTISWRGVWSLTSYKELRS IIGLREPTLQIVPILALRGSHMNWT RFNQMTSVMGGGVG (SEQ ID NO: 1545) LINE-1 non- AAC51271.1 O00370 MTGSNSHITILTLNVNGLNSPIKRH IPR000477 LTR RLASWIKSQDPSVCCIQETHLTCRD PF00078, retro- THRLKIKGWRKIYQANGKQKKAGVA cd01650 transposon ILVSDKTDFKPTKIKRDKEGHYIMV KGSIQQEELTILNIYAPNTGAPRFI KQVLSDLQRDLDSHTLIMGDFNTPL SILDRSTRQKVNKDTQELNSALHQT DLIDIYRTLHPKSTEYTFFSAPHHT YSKIDHIVGSKALLSKCKRTEIITN YLSDHSAIKLELRIKNLTQSRSTTW KLNNLLLNDYWVHNEMKAEIKMFFE TNENKDTTYQNLWDAFKAVCRGKFI ALNAYKRKQERSKIDTLTSQLKELE KQEQTHSKASRRQEITKIRAELKEI ETQKTLQKINESRSWFFERINKIDR PLARLIKKKREKNQIDTIKNDKGDI TTDPTEIQTTIREYYKHLYANKLEN LEEMDTFLDTYTLPRLNQEEVESLN RPITGSEIVAIINSLPTKKSPGPDG FTAEFYQRYKEELVPFLLKLFQSIE KEGILPNSFYEASIILIPKPGRDTT KKENFRPISLMNIDAKILNKILANR IQQHIKKLIHHDQVGFIPGMQGWFN IRKSINVIQHINRAKDKNHVIISID AEKAFDKIQQPFMLKTLNKLGIDGM YLKIIRAIYDKPTANIILNGQKLEA FPLKTGTRQGCPLSPLLFNIVLEVL ARAIRQEKEIKGIQLGKEEVKLSLF ADDMIVYLENPIVSAQNLLKLISNF SKVSGYKINVQKSQAFLYNNNRQTE SQIMGELPFTIASKRIKYLGIQLTR DVKDLFKENYKPLLKEIKEDTNKWK NIPCSWVGRINIVKMAILPKVIYRF NAIPIKLPMTFFTELEKTTLKFIWN QKRARIAKSILSQKNKAGGITLPDF KLYYKATVTKTAWYWYQNRDIDQWN RTEPSEIMPHIYNYLIFDKPEKNKQ WGKDSLLNKWCWENWLAICRKLKLD PFLTPYTKINSRWIKDLNVKPKTIK TLEENLGITIQDIGVGKDFMSKTPK AMATKDKIDKWDLIKLKSFCTAKET TIRVNRQPTTWEKIFATYSSDKGLI SRIYNELKQIYKKKTNNPIKKWAKD MNRHFSKEDIYAAKKHMKKCSSSLA IREMQIKTTMRYHLTPVRMAIIKKS GNNRCWRGCGEIGTLVHCWWDCKLV QPLWKSVWRFLRDLELEIPFDPAIP LLGIYPKDYKSCCYKDTCTRMFIAA LFTIAKTWNQPNCPTMIDWIKKMWH IYTMEYYAAIKNDEFISFVGTWMKL ETIILSKLSQEQKTKHRIFSLIGGN (SEQ ID NO: 1546) Penelope non- AAL14979.1 Q95VB5 MERSPEPSININGRHAVCTATNMSY IPR000477, LTR AKIKTKYKDSKRTINKFQLTLVKLT PF00078, Retro- KLKSSLKFLLKCRKSNLIPNFIKNL cd00304 transp TQHLTILTTDNKTHPDITRTLTRHT oson HFYHTKILNLLIKHKHNLLQEQTKH MQKAKTNIEQLMTTDDAKAFFESER NIENKITTTLKKRQETKHDKLRDQR NLALADNNTQREWFVNKTKIEFPPN VVALLAKGPKFALPISKRDFPLLKY IADGEELVQTIKEKETQESARTKFS LLVKEHKTKNNQNSRDRAILDTVEQ TRKLLKENINIKILSSDKGNKTVAM DEDEYKNKMTNILDDLCAYRTLRLD PTSRLQTKNNTFVAQLFKMGLISKD ERNKMTTTTAVPPRIYGLPKIHKEG TPLRPICSSIGSPSYGLCKYIIQIL KNLTMDSRYNIKNAVDFKDRVNNSQ IREEETLVSFDVVSLFPSIPIELAL DTIRQKWTKLEEHTNIPKQLFMDIV RFCIEENRYFKYEDKIYTQLKGMPM GSPASPVIADILMEELLDKITDKLK IKPRLLTKYVDDLFAITNKIDVENI LKELNSFHKQIKFTMELEKDGKLPF LDSIVSRMDNTLKIKWYRKPIASGR ILNFNSNHPKSMIINTALGCMNRMM KISDTIYHKEIEHEIKELLTKNDFP PNIIKTLLKRRQIERKKPTEPAKIY KSLIYVPRLSERLTNSDCYNKQDIK VAHKPTNTLQKFFNKIKSKIPMIEK SNVVYQIPCGGDNNNKCNSVYIGTT KSKLKTRISQHKSDFKLRHQNNIQK TALMTHCIRSNHTPNFDETTILQQE QHYNKRHTLEMLHIINTPTYKRLNY KTDTENCAHLYRHLLNSQTTSVTIS TSKSADV (SEQ ID NO: 1547) M- Retro ADS42990.1 P03355 TLNIEDEHRLHETSKEPDVSLGSTW IPR000477 MLV virus [660- LSDFPQAWAETGGMGLAVRQAPLII PF00078, RT 1330] PLKATSTPVSIKQYPMSQEARLGIK cd03715 PHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDI HPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDP EMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDD LLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKE GQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLY PLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQG YAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGK LTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPV VALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDG SSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEG KKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALF LPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLL (SEQ ID NO: 1548) RSV Retro AAC82561.1 P03354 TVALHLAIPLKWKPDHTPVWIDQWP IPR000477 RT virus [709- LPEGKLVALTQLVEKELQLGHIEPS PF00078, 1567] LSCWNTPVFVIRKASGSYRLLHDLR cd01645 AVNAKLVPFGAVQQGAPVLSALPRG WPLMVLDLKDCFFSIPLAEQDREAF AFTLPSVNNQAPARRFQWKVLPQGM TCSPTICQLVVGQVLEPLRLKHPSL CMLHYMDDLLLAASSHDGLEAAGEE VISTLERAGFTISPDKVQREPGVQY LGYKLGSTYVAPVGLVAEPRIATLW DVQKLVGSLQWLRPALGIPPRLMGP FYEQLRGSDPNEAREWNLDMKMAWR EIVRLSTTAALERWDPALPLEGAVA RCEQGAIGVLGQGLSTHPRPCLWLF STQPTKAFTAWLEVLTLLITKLRAS AVRTFGKEVDILLLPACFREDLPLP EGILLALKGFAGKIRSSDTPSIFDI ARPLHVSLKVRVTDHPVPGPTVFTD ASSSTHKGVVVWREGPRWEIKEIAD LGASVQQLEARAVAMALLLWPTTPT NVVTDSAFVAKMLLKMGQEGVPSTA AAFILEDALSQRSAMAAVLHVRSHS EVPGFFTEGNDVADSQATFQAYPLR EAKDLHTALHIGPRALSKACNISMQ QAREVVQTCPHCNSAPALEAGVNPR GLGPLQIWQTDFTLEPRMAPRSWLA VTVDTASSAIVVTQHGRVTSVAVQH HWATAIAVLGRPKAIKTDNGSCFTS KSTREWLARWGIAHTTGIPGNSQGQ AMVERANRLLKDRIRVLAEGDGFMK RIPTSKQGELLAKAMYALNHFERGE NTKTPIQKHWRPTVLTEGPPVKIRI ETGEWEKGWNVLVWGRGYAAVKNRD TDKVIWVPSRKVKPDITQKDEVTKK DEASPLFAG(SEQ ID NO: 1549) AMV Retro HW606680.1 — TVALHLAIPLKWKPNHTPVWIDQWP IPR000477, RT virus LPEGKLVALTQLVEKELQLGHIEPS PF00078, LSCWNTPVFVIRKASGSYRLLHDLR cd01645 AVNAKLVPFGAVQQGAPVLSALPRG WPLMVLDLKDCFFSIPLAEQDREAF AFTLPSVNNQAPARRFQWKVLPQGM TCSPTICQLIVGQILEPLRLKHPSL RMLHYMDDLLLAASSHDGLEAAGEE VISTLERAGFTISPDKVQREPGVQY LGYKLGSTYVAPVGLVAEPRIATLW DVQKLVGSLQWLRPALGIPPRLMGP FYEQLRGSDPNEAREWNLDMKMAWR EIVQLSTTAALERWDPALPLEGAVA RCEQGAIGVLGQGLSTHPRPCLWLF STQPTKAFTAWLEVLTLLITKLRAS AVRTFGKEVDILLLPACFREDLPLP EGILLALRGFAGKIRSSDTPSIFDI ARPLHVSLKVRVTDHPVPGPTVFTD ASSSTHKGVVVWREGPRWEIKEIAD LGASVQQLEARAVAMALLLWPTTPT NVVTDSAFVAKMLLKMGQEGVPSTA AAFILEDALSQRSAMAAVLHVRSHS EVPGFFTEGNDVADSQATFQAY (SEQ ID NO: 1550) HIV Retro AAB50259.1 P04585 PISPIETVPVKLKPGMDGPKVKQWP IPR000477, RT virus [588- LTEEKIKALVEICTEMEKEGKISKI PF00078, 1147] GPENPYNTPVFAIKKKDSTKWRKLV cd01645 DFRELNKRTQDFWEVQLGIPHPAGL KKKKSVTVLDVGDAYFSVPLDEDFR KYTAFTIPSINNETPGIRYQYNVLP QGWKGSPAIFQSSMTKILEPFRKQN PDIVIYQYMDDLYVGSDLEIGQHRT KIEELRQHLLRWGLTTPDKKHQKEP PFLWMGYELHPDKWTVQPIVLPEKD SWTVNDIQKLVGKLNWASQIYPGIK VRQLCKLLRGTKALTEVIPLTEEAE LELAENREILKEPVHGVYYDPSKDL IAEIQKQGQGQWTYQIYQEPFKNLK TGKYARMRGAHTNDVKQLTEAVQKI TTESIVIWGKTPKFKLPIQKETWET WWTEYWQATWIPEWEFVNTPPLVKL WYQLEKEPIVGAETFYVDGAANRET KLGKAGYVTNRGRQKVVTLTDTTNQ KTELQAIYLALQDSGLEVNIVTDSQ YALGIIQAQPDQSESELVNQHIEQL IKKEKVYLAWVPAHKGIGGNEQVDK LVSAGIRKVL (SEQ ID NO: 1551) Tyl LTR AAA66938.1 Q07163- AVKAVKSIKPIRTTLRYDEAITYNK IPR013103 Retro- 1 DIKEKEKYIEAYHKEVNQLLKMKTW PF07727 transposon [1218- DTDEYYDRKEIDPKRVINSMFIFNK 1755] KRDGTHKARFVARGDIQHPDTYDSG MQSNTVHHYALMTSLSLALDNNYYI TQLDISSAYLYADIKEELYIRPPPH LGMNDKLIRLKKSLYGLKQSGANWY ETIKSYLIQQCGMEEVRGWSCVFKN SQVTICLFVDDMVLFSKNLNSNKRI IEKLKMQYDTKIINLGESDEEIQYD ILGLEIKYQRGKYMKLGMENSLTEK IPKLNVPLNPKGRKLSAPGQPGLYI DQDELEIDEDEYKEKVHEMQKLIGL ASYVGYKFRFDLLYYINTLAQHILF PSRQVLDMTYELIQFMWDTRDKQLI WHKNKPTEPDNKLVAISDASYGNQP YYKSQIGNIYLLNGKVIGGKSTKAS LTCTSTTEAEIHAISESVPLLNNLS YLIQELNKKPIIKGLLTDSRSTISI IKSTNEEKFRNRFFGTKAMRLRDEV SGNNLYVYYIETKKNIADVMTKPLP IKTFKLLTNKWIH (SEQ ID NO: 1552) Brt Diversity- NP_ Q775D8 MGKRHRNLIDQITTWENLLDAYRKT IPR000477, Generating 958675.1 SHGKRRTWGYLEFKEYDLANLLALQ PF00078, retro- AELKAGNYERGPYREFLVYEPKPRL cd01646 element ISALEFKDRLVQHALCNIVAPIFEA GLLPYTYACRPDKGTHAGVCHVQAE LRRTRATHFLKSDFSKFFPSIDRAA LYAMIDKKIHCAATRRLLRVVLPDE GVGIPIGSLTSQLFANVYGGAVDRL LHDELKQRHWARYMDDIVVLGDDPE ELRAVFYRLRDFASERLGLKISHWQ VAPVSRGINFLGYRIWPTHKLLRKS SVKRAKRKVANFIKHGEDESLQRFL ASWSGHAQWADTHNLFTWMEEQYGI ACH (SEQ ID NO: 1553) Tyl LTR AAA66938.1 Q07163- AVKAVKSIKPIRTTLRYDEAITYNK IPR013103 Retro- 1[1218- DIKEKEKYIEAYHKEVNQLLKMKTW PF07727 transposon 1755] DTDEYYDRKEIDPKRVINSMFIFNK KRDGTHKARFVARGDIQHPDTYDSG MQSNTVHHYALMTSLSLALDNNYYI TQLDISSAYLYADIKEELYIRPPPH LGMNDKLIRLKKSLYGLKQSGANWY ETIKSYLIQQCGMEEVRGWSCVFKN SQVTICLFVDDMVLFSKNLNSNKRI IEKLKMQYDTKIINLGESDEEIQYD ILGLEIKYQRGKYMKLGMENSLTEK IPKLNVPLNPKGRKLSAPGQPGLYI DQDELEIDEDEYKEKVHEMQKLIGL ASYVGYKFRFDLLYYINTLAQHILF PSRQVLDMTYELIQFMWDTRDKQLI WHKNKPTEPDNKLVAISDASYGNQP YYKSQIGNIYLLNGKVIGGKSTKAS LTCTSTTEAEIHAISESVPLLNNLS YLIQELNKKPIIKGLLTDSRSTISI IKSTNEEKFRNRFFGTKAMRLRDEV SGNNLYVYYIETKKNIADVMTKPLP IKTFKLLTNKWIH (SEQ ID NO: 1552) Brt Diversity- NP_ Q775D8 MGKRHRNLIDQITTWENLLDAYRKT IPR000477, Generating 958675.1 SHGKRRTWGYLEFKEYDLANLLALQ PF00078, retro- AELKAGNYERGPYREFLVYEPKPRL cd01646 element ISALEFKDRLVQHALCNIVAPIFEA GLLPYTYACRPDKGTHAGVCHVQAE LRRTRATHFLKSDFSKFFPSIDRAA LYAMIDKKIHCAATRRLLRVVLPDE GVGIPIGSLTSQLFANVYGGAVDRL LHDELKQRHWARYMDDIVVLGDDPE ELRAVFYRLRDFASERLGLKISHWQ VAPVSRGINFLGYRIWPTHKLLRKS SVKRAKRKVANFIKHGEDESLQRFL ASWSGHAQWADTHNLFTWMEEQYGI ACH (SEQ ID NO: 1553) RT86 Retron AAA61471.1 P23070 MKSAEYLNTFRLRNLGLPVMNNLHD IPR000477, MSKATRISVETLRLLIYTADFRYRI PF00078, YTVEKKGPEKRMRTIYQPSRELKAL cd03487 QGWVLRNILDKLSSSPFSIGFEKHQ SILNNATPHIGANFILNIDLEDFFP SLTANKVFGVFHSLGYNRLISSVLT KICCYKNLLPQGAPSSPKLANLICS KLDYRIQGYAGSRGLIYTRYADDLT LSAQSMKKVVKARDFLFSIIPSEGL VINSKKTCISGPRSQRKVTGLVISQ EKVGIGREKYKEIRAKIHHIFCGKS SEIEHVRGWLSFILSVDSKSHRRLI TYISKLEKKYGKNPLNKAKT (SEQ ID NO: 1554) TERT Telomerase AAG23289.1 014746 MPRAPRCRAVRSLLRSHYREVLPLA IPR000477 TFVRRLGPQGWRLVQRGDPAAFRAL PF00078, VAQCLVCVPWDARPPPAAPSFRQVS cd01648 CLKELVARVLQRLCERGAKNVLAFG FALLDGARGGPPEAFTTSVRSYLPN TVTDALRGSGAWGLLLRRVGDDVLV HLLARCALFVLVAPSCAYQVCGPPL YQLGAATQARPPPHASGPRRRLGCE RAWNHSVREAGVPLGLPAPGARRRG GSASRSLPLPKRPRRGAAPEPERTP VGQGSWAHPGRTRGPSDRGFCVVSP ARPAEEATSLEGALSGTRHSHPSVG RQHHAGPPSTSRPPRPWDTPCPPVY AETKHFLYSSGDKEQLRPSFLLSSL RPSLTGARRLVETIFLGSRPWMPGT PRRLPRLPQRYWQMRPLFLELLGNH AQCPYGVLLKTHCPLRAAVTPAAGV CAREKPQGSVAAPEEEDTDPRRLVQ LLRQHSSPWQVYGFVRACLRRLVPP GLWGSRHNERRFLRNTKKFISLGKH AKLSLQELTWKMSVRDCAWLRRSPG VGCVPAAEHRLREEILAKFLHWLMS VYVVELLRSFFYVTETTFQKNRLFF YRKSVWSKLQSIGIRQHLKRVQLRE LSEAEVRQHREARPALLTSRLRFIP KPDGLRPIVNMDYVVGARTFRREKR AERLTSRVKALFSVLNYERARRPGL LGASVLGLDDIHRAWRTFVLRVRAQ DPPPELYFVKVDVTGAYDTIPQDRL TEVIASIIKPQNTYCVRRYAVVQKA AHGHVRKAFKSHVSTLTDLQPYMRQ FVAHLQETSPLRDAVVIEQSSSLNE ASSGLFDVFLRFMCHHAVRIRGKSY VQCQGIPQGSILSTLLCSLCYGDME NKLFAGIRRDGLLLRLVDDFLLVTP HLTHAKTFLRTLVRGVPEYGCVVNL RKTVVNFPVEDEALGGTAFVQMPAH GLFPWCGLLLDTRTLEVQSDYSSYA RTSIRASLTFNRGFKAGRNMRRKLF GVLRLKCHSLFLDLQVNSLQTVCTN IYKILLLQAYRFHACVLQLPFHQQV WKNPTFFLRVISDTASLCYSILKAK NAGMSLGAKGAAGPLPSEAVQWLCH QAFLLKLTRHRVTYVPLLGSLRTAQ TQLSRKLPGTTLTALEAAANPALPS DFKTILD (SEQ ID NO: 1555) Mauriceville Retro NC_0015 Q36578 MPNHRLPNCVSYLGENHELSWLHGM cd00304 RT plasmid 70.1 FGLLKRSNPQTGGILGWLNTGPNGF VKYMMNLMGHARDKGDAKEYWRLGR SLMKNEAFQVQAFNHVCKHWYLDYK PHKIAKLLKEVREMVEIQPVCIDYK RVYIPKANGKORPLGVPTVPWRVYL HMWNVLLVWYRIPEQDNQHAYFPKR GVFTAWRALWPKLDSQNIYEFDLKN FFPSVDLAYLKDKLMESGIPQDISE YLTVLNRSLVVLTSEDKIPEPHRDV IFNSDGTPNPNLPKDVQGRILKDPD FVEILRRRGFTDIATNGVPQGASTS CGLATYNVKELFKRYDELIMYADDG ILCRQDPSTPDFSVEEAGVVQEPAK SGWIKQNGEFKKSVKFLGLEFIPAN IPPLGEGEVKDYPRLRGATRNGSKM ELSTELQFLCYLSYKLRIKVLRDLY IQVLGYLPSVPLLRYRSLAEAINEL SPKRITIGQFITSSFEEFTAWSPLK RMGFFFSSPAGPTILSSIFNNSTNL QEPSDSRLLYRKGSWVNIRFAAYLY SKLSEEKHGLVPKFLEKLREINFAL DKVDVTEIDSKLSRLMKFSVSAAYD EVGTLALKSLFKFRNSERESIKASF KQLRENGKIAEFSEARRLWFEILKL IRLDLFNASSLACDDLLSHLQDRRS IKKWGSSDVLYLKSQRLMRTNKKQL QLDFEKKKNSLKKKLIKRRAKELRD TFKGKENKEA (SEQ ID NO: 1556) RTX Engineered QFN49000.1 — MILDTDYITEDGKPVIRIFKKENGE IPR006134 polymerase FKIEYDRTFEPYLYALLKDDSAIEE PF00136, VKKITAERHGTVVTVKRVEKVQKKF cd05536 LGRPVEVWKLYFTHPQDVPAIMDKI REHPAVIDIYEYDIPFAIRYLIDKG LVPMEGDEELKLLAFDIETLYHEGE EFAEGPILMISYADEEGARVITWKN VDLPYVDVVSTEREMIKRFLRVVKE KDPDVLITYNGDNFDFAYLKKRCEK LGINFALGRDGSEPKIQRMGDRFAV EVKGRIHFDLYPVIRRTINLPTYTL EAVYEAVFGQPKEKVYAEEITTAWE TGENLERVARYSMEDAKVTYELGKE FLPMEAQLSRLIGQSLWDVSRSSTG NLVEWFLLRKAYERNELAPNKPDEK ELARRHQSHEGGYIKEPERGLWENI VYLDFRSLYPSIIITHNVSPDTLNR EGCKEYDVAPQVGHRFCKDFPGFIP SLLGDLLEERQKIKKRMKATIDPIE RKLLDYRQRAIKILANSLYGYYGYA RARWYCKECAESVIAWGREYLTMTI KEIEEKYGFKVIYSDTDGFFATIPG ADAETVKKKAMEFLKYINAKLPGAL ELEYEGFYKRGLFVTKKKYAVIDEE GKITTRGLEIVRRDWSEIAKETQAR VLEALLKDGDVEKAVRIVKEVTEKL SKYEVPPEKLVIHKQITRDLKDYKA TGPHVAVAKRLAARGVKIRPGTVIS YIVLKGSGRIVDRAIPFDEFDPTKH KYDAEYYIEKQVLPAVERILRAFGY RKEDLRYQKTRQVGLSARLKPKGTL EGSSHHHHHH (SEQ ID NO: 1557)

TABLE 1 Signature Database Short Name Description cd00304 CDD RT like RT_like: Reverse transcriptase (RT, RNA-dependent DNA polymerase)_like family. An RT gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. RTs occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. These elements can be divided into two major groups. One group contains retroviruses and DNA viruses whose propagation involves an RNA intermediate. They are grouped together with transposable elements containing long terminal repeats (LTRs). The other group, also called poly(A)-type retrotransposons, contain fungal mitochondrial introns and transposable elements that lack LTRs. [PMID: 1698615, PMID: 8828137, PMID: 10669612, PMID: 9878607, PMID: 7540934, PMID: 7523679, PMID: 8648598] cd01645 CDD RT Rtv RT_Rtv: Reverse transcriptases (RTs) from retroviruses (Rtvs). RTs catalyze the conversion of single-stranded RNA into double-stranded viral DNA for integration into host chromosomes. Proteins in this subfamily contain long terminal repeats (LTRs) and are multifunctional enzymes with RNA-directed DNA polymerase, DNA directed DNA polymerase, and ribonuclease hybrid (RNase H) activities. The viral RNA genome enters the cytoplasm as part of a nucleoprotein complex, and the process of reverse transcription generates in the cytoplasm forming a linear DNA duplex via an intricate series of steps. This duplex DNA is colinear with its RNA template, but contains terminal duplications known as LTRs that are not present in viral RNA. It has been proposed that two specialized template switches, known as strand-transfer reactions or “jumps”, are required to generate the LTRs. [PMID: 9831551, PMID: 15107837, PMID: 11080630, PMID: 10799511, PMID: 7523679, PMID: 7540934, PMID: 8648598, PMID: 1698615] cd01646 CDD RT_Bac_retron I RT Bac retron I: Reverse transcriptases (RTs) in bacterial retrotransposons or retrons. The polymerase reaction of this enzyme leads to the production of a unique RNA-DNA complex called msDNA (multicopy single-stranded (ss)DNA) in which a small ssDNA branches out from a small ssRNA molecule via a 2′- 5′ phosphodiester linkage. Bacterial retron RTs produce cDNA corresponding to only a small portion of the retron genome. [PMID: 1698615, PMID: 16093702, PMID: 8828137] cd01648 CDD TERT TERT: Telomerase reverse transcriptase (TERT). Telomerase is a ribonucleoprotein (RNP) that synthesizes telomeric DNA repeats. The telomerase RNA subunit provides the template for synthesis of these repeats. The catalytic subunit of RNP is known as telomerase reverse transcriptase (TERT). The reverse transcriptase (RT) domain is located in the C-terminal region of the TERT polypeptide. Single amino acid substitutions in this region lead to telomere shortening and senescence. Telomerase is an enzyme that, in certain cells, maintains the physical ends of chromosomes (telomeres) during replication. In somatic cells, replication of the lagging strand requires the continual presence of an RNA primer approximately 200 nucleotides upstream, which is complementary to the template strand. Since there is a region of DNA less than 200 base pairs from the end of the chromosome where this is not possible, the chromosome is continually shortened. However, a surplus of repetitive DNA at the chromosome ends protects against the erosion of gene-encoding DNA. Telomerase is not normally expressed in somatic cells. It has been suggested that exogenous TERT may extend the lifespan of, or even immortalize, the cell. However, recent studies have shown that telomerase activity can be induced by a number of oncogenes. Conversely, the oncogene c-myc can be activated in human TERT immortalized cells. Sequence comparisons place the telomerase proteins in the RT family but reveal hallmarks that distinguish them from retroviral and retrotransposon relatives. [PMID: 9110970, PMID: 9288757, PMID: 9389643, PMID: 9671703, PMID: 9671704, PMID: 10333526, PMID: 11250070, PMID: 15363846, PMID: 16416120, PMID: 16649103, PMID: 16793225, PMID: 10860859, PMID: 9252327, PMID: 11602347, PMID: 1698615, PMID: 8828137, PMID: 10866187] cd01650 CDD RT_nL RT_nLTR: Non-LTR (long terminal repeat) TR_like retrotransposon and non-LTR retrovirus reverse transcriptase (RT). This subfamily contains both non-LTR retrotransposons and non-LTR retrovirus RTs. RTs catalyze the conversion of single-stranded RNA into double-stranded DNA for integration into host chromosomes. RT is a multifunctional enzyme with RNA- directed DNA polymerase, DNA directed DNA polymerase and ribonuclease hybrid (RNase H) activities. [PMID: 1698615, PMID: 10605110, PMID: 10628860, PMID: 11734649, PMID: 12117499, PMID: 12777502, PMID: 14871946, PMID: 15939396, PMID: 16271150, PMID: 16356661, PMID: 2463954, PMID: 3040362, PMID: 3656436, PMID: 7512193, PMID: 7534829, PMID: 7659515, PMID: 8524653, PMID: 9190061, PMID: 9218812, PMID: 9332379, PMID: 9364772, PMID: 8828137] cd01651 CDD RT_G2 intron RT_G2_intron: Reverse transcriptases (RTs) with group II intron origin. RT transcribes DNA using RNA as template. Proteins in this subfamily are found in bacterial and mitochondrial group II introns. Their most probable ancestor was a retrotransposable element with both gag- like and pol-like genes. This subfamily of proteins appears to have captured the RT sequences from transposable elements, which lack long terminal repeats (LTRs). [PMID: 1698615, PMID: 8828137, PMID: 12403467, PMID: 11058141, PMID: 11054545, PMID: 10760141, PMID: 10488235, PMID: 9680217, PMID: 9491607, PMID: 7994604, PMID: 7823908, PMID: 3129199, PMID: 2531370, PMID: 2476655] cd03487 CDD RT_Bac_retron_II RT Bac retron IL Reverse transcriptases (RTs) in bacterial retrotransposons or retrons. The polymerase reaction of this enzyme leads to the production of a unique RNA-DNA complex called msDNA (multicopy single-stranded (ss)DNA) in which a small ssDNA branches out from a small ssRNA molecule via a 2′- 5′ phosphodiester linkage. Bacterial retron RTs produce cDNA corresponding to only a small portion of the retron genome. [PMID: 1698615, PMID: 8828137, PMID: 11292805, PMID: 9281493, PMID: 2465092, PMID: 1722556, PMID: 1701261, PMID: 1689062] cdO3715 CDD RT_ZFREV_like RT_ZFREV_like: A subfamily of reverse transcriptases (RTs) found in sequences similar to the intact endogenous retrovirus ZFERV from zebrafish and to Moloney murine leukemia virus RT. An RT gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. RTs occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. These elements can be divided into two major groups. One group contains retroviruses and DNA viruses whose propagation involves an RNA intermediate. They are grouped together with transposable elements containing long terminal repeats (LTRs). The other group, also called poly(A)-type retrotransposons, contain fungal mitochondrial introns and transposable elements that lack LTRs. Phylogenetic analysis suggests that ZFERV belongs to a distinct group of retroviruses. [PMID: 14694121, PMID: 2410413, PMID: 9684890, PMID: 10669612, PMID: 1698615, PMID: 8828137] cdO5536 CDD POLBc_B3 DNA polymerase type-B B3 subfamily catalytic domain. Archaeal proteins that are involved in DNA replication are similar to those from eukaryotes. Some members of the archaea also possess multiple family B DNA polymerases (B1, B2 and B3). So far there is no specific function(s) has been assigned for different members of the archaea type B DNA polymerases. Phylogenetic analyses of eubacterial, archaeal, and eukaryotic family B DNA polymerases are support independent gene duplications during the evolution of archaeal and eukaryotic family B DNA polymerases. Structural comparison of the thermostable DNA polymerase type B to its mesostable homolog suggests several adaptations to high temperature such as shorter loops, disulfide bridges, and increasing electrostatic interaction at subdomain interfaces. [PMID: 10997874, PMID: 11178906, PMID: 10860752, PMID: 10097083, PMID: 10545321] cd05780 CDD DNA_polB_Kod1_like_exo The 3′-5′ exonuclease domain of archaeal family-B DNA polymerases with similarity to Pyrococcus kodakaraensis Kod1, including polymerases from Desulfurococcus (D. Tok Pol) and Thermococcus gorgonarius (Tgo Pol). Kodl, D. Tok Pol, and Tgo Pol are thermostable enzymes that exhibit both polymerase and 3′-5′ exonuclease activities. They are family-B DNA polymerases. Their amino termini harbor a DEDDy-type DnaQ-like 3′-5′ exonuclease domain that contains three sequence motifs termed ExoI, ExoII and ExoIII, with a specific YX(3)D pattern at ExoIII. These motifs are clustered around the active site and are involved in metal binding and catalysis. The exonuclease domain of family B polymerases contains a beta hairpin structure that plays an important role in active site switching in the event of nucleotide misincorporation. Members of this subfamily show similarity to eukaryotic DNA polymerases involved in DNA replication. Some archaea possess multiple family- B DNA polymerases. Phylogenetic analyses of eubacterial, archaeal, and eukaryotic family-B DNA polymerases support independent gene duplications during the evolution of archaeal and eukaryotic family-B DNA polymerases. [PMID: 18355915, PMID: 16019029, PMID: 11178906, PMID: 10860752, PMID: 10097083, PMID: 10545321, PMID: 9098062, PMID: 12459442, PMID: 16230118, PMID: 11988770, PMID: 11222749, PMID: 17098747, PMID: 8594362, PMID: 9729885] PF00078 Pfam RVT 1 A reverse transcriptase gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. Reverse transcriptases occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. [PMID: 1698615] PF00136 Pfam DNA_pol B This region of DNA polymerase B appears to consist of more than one structural domain, possibly including elongation, DNA-binding and dNTP binding activities. [PMID: 9757117, PMID: 8679562] PF07727 Pfam RVT 2 A reverse transcriptase gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. Reverse transcriptases occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. This Pfam entry includes reverse transcriptases not recognised by the Pfam:PF00078 model. [PMID: 1698615] IPR000477 InterPro RT_dom The use of an RNA template to produce DNA, for integration into the host genome and exploitation of a host cell, is a strategy employed in the replication of retroid elements, such as the retroviruses and bacterial retrons. The enzyme catalysing polymerisation is an RNA- directed DNA-polymerase, or reverse trancriptase (RT) (2.7.7.49). Reverse transcriptase occurs in a variety of mobile elements, including retrotransposons, retroviruses, group II introns [PMID: 12758069], bacterial msDNAs, hepadnaviruses, and caulimoviruses. Retroviral reverse transcriptase is synthesised as part of the POL polyprotein that contains; an aspartyl protease, a reverse transcriptase, RNase H and integrase. POL polyprotein undergoes specific enzymatic cleavage to yield the mature proteins. The discovery of retroelements in the prokaryotes raises intriguing questions concerning their roles in bacteria and the origin and evolution of reverse transcriptases and whether the bacterial reverse transcriptases are older than eukaryotic reverse transcriptases [PMID: 8828137], Several crystal structures of the reverse transcriptase (RT) domain have been determined [PMID: 1377403], IPR006134 InterPro DNA- DNA is the biological information that instructs cells how dir_DNA_pol_B_multi_dom to exist in an ordered fashion: accurate replication is thus one of the most important events in the life cycle of a cell. This function is performed by DNA- directed DNA- polymerases 2.7.7.7) by adding nucleotide triphosphate (dNTP) residues to the 5′ end of the growing chain of DNA, using a complementary DNA chain as a template. Small RNA molecules are generally used as primers for chain elongation, although terminal proteins may also be used for the de novo synthesis of a DNA chain. Even though there are 2 different methods of priming, these are mediated by 2 very similar polymerases classes, A and B, with similar methods of chain elongation. A number of DNA polymerases have been grouped under the designation of DNA polymerase family B. Six regions of similarity (numbered from I to VI) are found in all or a subset of the B family polymerases. The most conserved region (I) includes a conserved tetrapeptide with two aspartate residues. It has been suggested that it may be involved in binding a magnesium ion. All sequences in the B family contain a characteristic DTDS motif (SEQ ID NO: 1558), and possess many functional domains, including a 5′-3′ elongation domain, a 3′-5′ exonuclease domain [PMID: 8679562], a DNA binding domain, and binding domains for both dNTP's and pyrophosphate [PMID: 9757117], This domain of DNA polymerase B appears to consist of more than one activities, possibly including elongation, DNA-binding and dNTP binding [PMID: 9757117], IPR013103 InterPro RVT_2 A reverse transcriptase gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. Reverse transcriptases occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. This entry includes reverse transcriptases not recognised by IPR000477 [PMID: 1698615],

Table 3 (below) shows exemplary Gene Writer™ proteins and associated sequences from a variety of retrotransposases, identified using data mining. Column 1 indicates the family to which the retrotransposon belongs. Column 2 lists the element name. Column 3 indicates an accession number, if any. Column 4 lists an organism in which the retrotransposase is found. Column 5 lists the predicted 5′ untranslated region, and column 6 lists the predicted 3′ untranslated region; both are sequences that are predicted to allow the template RNA to bind the retrotransposase of column 7. (It is understood that columns 5-6 show the DNA sequence, and that an RNA sequence according to any of columns 5-6 would typically include uracil rather than thymidine.) Column 7 lists the predicted retrotransposase amino acid sequence.

TABLE 3 Exemplary Retrotransposon Sequences 5. 6. 7. 1. 2. 3. 4. Predicted Predicted  Predicted Amino Family Element Accession Organism 5′UTR 3′UTR Acid Sequence R2 R2- . Taeniopygia GTCTAGTTACAACTGGGCAT TTCAGGTTATTTAGATGCTT MASCPKPGPPVSAGAMSLES 1_TG guttata CGCTGCAGAGATCGCACCTC AGTTTTTGTACCTTTCTTGT GLTTHSVLAIERGPNSLANS CTCGTGGTCCCGCTGGTAGC TTTGTTTAGGATTTTGATAG GSDFGGGGLGLPLRLLRVSV CCTTCGAAGGGTGACTAAGT TGTTAGTATTTTTATATTTT GTQTSRSDWVDLVSWSHPGP CGATCTCTGCCCCAGGTACG TGTACGATTGCATAATGTTC TSKSQQVDLVSLFPKHRVDL GAGCCGTTGGGACTCACCAG TTTTTTATACAGTTCTGTTT LSKNDQVDLVAQFLPSKFPP TCCAACGTAACTCCTGCCTA TAATAAAATAGACGATAGCT NLAENDLALLVNLEFYRSDL AATTCGGTGAAACAAATTCC AGAGACGTTAGGGCAGCCAC HVYECVHFAAHWEGLSGLPE TCGGTAAAAAGCCCC AAGCCAGTTAGGTAGCGGAT VYEQLAPQPCVGETLHSSLP (SEQ ID NO: 1140) AGTAGGTAGGAACAGACTTT RDSELFVPEEGSSEKESEDA TACTATTTCATAACGCGTCA PKTSPPTPGKHGLEQTGEEK ATTACCACCTGATTTGGACC VMVTVPDKNPPCPCCGTRVN AATTCACGGGATTTGTCCAA SVLNLIEHLKVSHGKRGVCF GGTGGACGGGCCACCTTTAC RCAKCGKENSNYHSVVCHFP TTAACCCGGAAAAGGAACAT KCRGPETEKAPAGEWICEVC ATATAATTTATGTGTGTTCG NRDFTTKIGLGQHKRLAHPA ATAAA VRNQERIVASQPKETSNRGA (SEQ ID NO: 1263) HKRCWTKEEEELLIRLEAQF EGNKNINKLIAEHITTKTAK QISDKRRLLSRKPAEEPREE PGTCHHTRRAAASLRTEPEM SHHAQAEDRDNGPGRRPLPG RAAAGGRTMDEIRRHPDKGN GQQRPTKQKSEEQLQAYYKK TLEERLSAGALNTFPRAFKQ VMEGRDIKLVINQTAQDCFG CLESISQIRTATRDKKDTVT REKHPKKPFQKWMKDRAIKK GNYLRFQRLFYLDRGKLAKI ILDDIECLSCDIPLSEIYSV FKTRWETTGSFKSLGDFKTY GKADNTAFRELITAKEIEKN VQEMSKGSAPGPDGITLGDV VKMDPEFSRTMEIFNLWLTT GKIPDMVRGCRTVLIPKSSK PDRLKDINNWRPITIGSILL RLFSRIVTARLSKACPLNPR QRGFIRAAGCSENLKLLQTI IWSAKREHRPLGVVFVDIAK AFDTVSHQHIIHALQQREVD PHIVGLVSNMYENISTYITT KRNTHTDKIQIRVGVKQGDP MSPLLFNLAMDPLLCKLEES GKGYHRGQSSITAMAFADDL VLLSDSWENMNTNISILETF CNLTGLKTQGQKCHGFYIKP TKDSYTINDCAAWTINGTPL NMIDPGESEKYLGLQFDPWI GIARSGLSTKLDFWLQRIDQ APLKPLQKTDILKTYTIPRL IYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAIL YSSTRDGGLGITKLAGLIPS VQARRLHRIAQSSDDTMKCF MEKEKMEQLHKKLWIQAGGD RENIPSIWEAPPSSEPPNNV STNSEWEAPTQKDKFPKPCN WRKNEFKKWTKLASQGRGIV NFERDKISNHWIQYYRRIPH RKLLTALQLRANVYPTREFL ARGRQDQYIKACRHCDADIE SCAHIIGNCPVTQDARIKRH NYICELLLEEAKKKDWVVFK EPHIRDSNKELYKPDLIFVK DARALVVDVTVRYEAAKSSL EEAAAEKVRKYKHLETEVRH LTNAKDVTFVGFPLGARGKW HQDNFKLLTELGLSKSRQVK MAETFSTVALFSSVDIVHMF ASRARKSMVM (SEQ ID NO: 1016) R2 R2- . Geospiza AGACTTAAGTGAGTTTGGTT GGTAGATAATCTTTGTATAG VGLCPSPGVDGTHQPNDSFQ 1_ fortis ACAACTGGGCATAGCTGCAG TGGGGGGGGATCTCATGTAC NFGETNFSVQVARLVTRNLA Gfo AGACCGCGCCTCCTCGCGGC CGGGTTTCTTTTATTTGATT PRSVRGNGFGSGMATHPVPA CCCGCTGGTAAGCCCTTAAC TTCAATAAAACAGACGGTAG DESGHESDPFLVGRSCGQPA AGGGTGACTAA CTAGGTTCGCAAGGCAGCCA RLTRQSVGTQTSRDDILPSK (SEQ ID NO: 1141) CAAGCCAAAGATAGGTAGGG TTKLTENELDLLVNFSLELY TGCTCATAGTGAGTAGGGAC RSDLQGFVQEGIHFSVNREV AGTGCCTTTTGATTCACAAC LEGFPEVYEQPAPQPAVGDD GCGTCAATACCATCTGACAC LNTSLPPDNNICVLEKGSSE GGATACCCTTACCGGACTTG AVEDGTPEVAHPVPETQGKE TCATGATCTCCCAGACTTGT SPNNIVMVTLPNKNPPCPCC CCAAGGTGGACGGGCCACCT RVRLHSVLALIEHLKGSHGK TTACTTAACCCGGAAAAGGA KRACFRCVKCGRENFNYHST ACATATATTAATTATATGTG VCHIAKCKGPKVEKAPVGEW TTCGGAAAA ICEVCGRDFTTKIGLGQHKR (SEQ ID NO: 1264) LAHPLVRNQERIDASQPKET SNRGAHKRCWTKEEEEMLIK LEVQFEGHRNINKLIAEHLT TKTSKQISDKRRLLPRKQLT DLSKGVAGQKVLDPGLSHQP QLGVVDNGLGGGHLPGGPAA EGRTIEPLGHHLDKDNGHRE IADQHKAGRLQAHYRKKIRK RLSEGMISNFPEVFEQLLDC QEAQPLINQAAQDCFGCLDS ASQIRKALRKQNTQKDQGDQ PKRPAQKWMKKRAVKRGHFL RFQKLFHLDRGKLAKIILDD VECLSCDIPPSEIYSVFKAR WETPGQFAGLGDFEINRKAN NKAFRDLITAKEILKNVREM TKGSAPGPDGIALGDIRKMD PEYTRTAELFNLWLTSGEIP DMVRGCRTVLIPKSSKPERL KDINNWRPITIGSILLRLFS RIITARLTKACPLNPRQRSF ISAAGCSENLKLLQTIIRTA KNEHRPLGVVFVDIAKAFDT VSHQHIIHVLQRRRVDPHII GLVKNMYKDISTVITTKKNT YTDKIQIQVGVKQGDPLSPL LFNLAMDPLLCKLEEHGKGF HRGQSKITAMAFADDLVLLS DSWEDMNANIKILETFCDLT GLKTQGQKCHGFYIKPTKDS YTVNNCAAWTINGTPLNMIN PGESEKYLGLQFDPWVGIAK TSLPEKLDFWLERIDRAPLK PFQKLDILKTYTIPRLTYVA DHSEMKAGALEALDRTIRSA VKDWLHLPSSTCDAILYTSM KDGGLGVTKLVGLIPSVQAR RLHRIAQSPEETMKDFLEKA QMEKMYEKLWVQAGGKRKRM PSIWEALPEVVPSIDTATTS EWEAPNPKSKYPRPCNWRRK EFKKWTKLIAQGWGIRCFKG DKISNNWIRHYRYIPHRKLL TAIQLRASVYPTREFLARGR EDNCVKSCRHCEAAEESCAH IIGMCPVVRDARIKRHNRIC ERLMEEAGKRDWTVFQEPHI RDVTKELYKPDLIFVKEGLA LVVDVTIRFESTKTTLEEAA AEKVNKYKHLETEVRNLTNA KDVIFMGFPLGARGQWYNKN FELLDTLGLPRSRQDIIAKT LSTDALISSVDIIHMFASRG RRQHA (SEQ ID NO: 1386) R2 R2- . Zonotrichia CGACTTGAGAAGGTCTGGTT GTAGTCACATTGCACTTTCT NKFLGKSRVAYCLKPGPPVS 1_ZA albicollis ACAACTGGGCATAGCTGCAG GTAACTTGCACTGGGTGTGG DRGKEFGSGLTTHPEPESES AGATCGCGCCTCCTCGTGGC GATGTGGGCCTGGGGTGTGG GHDPTVPNPGPSLGAGEGAQ CCCGCTGGTAAGCCCTTAAC GTTATGGGGTATATATGTGG PLPLLRVSVGTQTCEEDFIT AGGGTGACTAAGTCGATCTC GATATTCTGGTGGGAATGTC SRPTKLPGIESELGPLVKFS TGCCCCAGTCCAGGAGCCGC CATTCACTGTATGCCTATCT LEVYRSDLKGDVQFEGIHFP TGGGTTTCACCAGCCCAGCG TTTTAATAAAAAGACGGTAG DNWGVLEGFPEVYEQLAPQP ATTCCTTCCAAATTCGGTGA CTAGGTTCGCGAAGCAGCCA NGGDELNHSLPGDREGDVLE (SEQ IDNO: 1142) CAAGCCAATAGCCAGTTAGG KDSSEKEKEAAPEALPSVQR TAGCTCATAGTGGGTAGGTG ARSEQLPDNIVKVTVPDKNP ACAGGAACCTTTGACTCAGA PCPCCGVRLNSVLALIEHLK ACGCGTCCATTAACATCTAG GSHGRRRVCFRCAKCGRENF AACGGACCAAACTTCGGACA NHHSTVCHYAKCKGPQIERP TGCACCGATTAACCGGATTT PVGEWICEVCGRDFTTKIGL GTCCAAGGTGGACGGGCCAC GQHKRHMHAMVRNQERIDAS CTTTACTTAACCCGGAAAGG QPKETSNRGAHKRCWTKEEE GAACATATATAGTTATATGT ELLMKLEVQFENHKNINKLI GTTCGTAATA AEQLTTKTAKQISDKRRMLL (SEQID NO: 1265) KKGRGTTGNLETEPGMSHQS QAKVKDNGLGGDHLPGGPVV DKGTIGKPGQHLDTDNSHQI TAGKKKGGGLQARYRRRIMK RLAAGTINIFPKVFKELIND QEARPLINQTTEDCFGLLDS ACQIRTALREKGKSQEERPR KQYQKWMKKRAIKRGDYLRF QRLFHLDRGKLARIILDNTE SLSCDISPSEIYSVFKARWE TPGHFNGLGDFEIKGKANNK AFRDFITAKEIEKNVREMSK GSAPGPDGIALGDIKKMDPG YSRTAELFNLWLTAGDIPDM VRGCRTVLIPKSTTPERLKD INNWRPITIGSILLRLFSRI ITARMTKACPLNPRQRGFIS APGCSENLKLLQSIIRTAKN EHKPLGVIFVDIAKAFDTVS HQHIIHVLQQRRVDPHIVGL VNNMYKDISTYVTTKKNTHT DKIQIRVGVKQGDPLSPLLF NLAMDPLLCKLEESGKGFHR GQSSITAMAFADDLVLLSDS WENMKENIKILETFCNLTGL KTQGQKCHGFYIKPTKDSYT INNCPAWTINGTPLNMINPG ESEKYLGLQIDPWTGVAKYD LSTKLKIWLESIDRAPLKPL QKLDILKTYTIPRLTYLADH SEMKAGALEALDQQIRTAVK DWLHLPSCTCDAILYVSTRD GGLGVTKLAGLIPSVQARRL HRIAQSPDETMKDFLEKAQM EKMYEKLWVQAGGKKKGMPS IWEALPMTVPPTNTGNLSEW EAPNPKSKYPKPCDWRRKEL KKWTKLESQGRGVKNFRNDT ISNDWIQYYRRIPHRKLLTA IQLRANVYPTREFLARGRGD NYVKFCRHCEADLETCGHII GFCPVTKDARIKRHNRICDR LCEEAAKREWVVFKEPHLRD ATTELFKPDVIFVKEDRALV VDVTVRYESAKTTLEAAAME KVDKYKHLEAEVKELTNAKD VVFMGFPLGARGKFYKGNFN LLETLGLPKTRQLSVAKTLS TYALMSSVDIVHMFASRSRK PNV (SEQ ID NO: 1387) R2 R2Dr AB097 Danio AATCCCCCCTACCCAATCCC AAATCCCAGCGGGATACAGC MESTAKGKSYWMARRPVEGA 126 rerio CCCGTCGTGACCTCCAGGCC AAGAAGGTATCGGATCTAAT TEGSLGRVPFVTRDPKRKPE AGGAATCACGAGCGTACGAC AAGGTTGAGCGAGGAGAGGG AKRTLTHGLGLRECSVVLTR AGTGGCCATCCGGCAATGAC TGGAGATCCTTTGGGGGGGG LIEGRRGRDHTPSGWNAQRG AATAGCGTGACTAACGACAA TCGGGCTAAGTTCCCCTCTC MPNDESSVEEPNGPIPSNPI TGAGTCAGATCCATGACCCT GGGTCCTCCCACGGTGACGC PTGTQALPEPMADGEQGEHP TGGAGTGGGTTAACCTCCGC TCTACCCCTCCCTCCTCGCT GVVVTLPLRDLNCPLCGGSA CTCTTTAAAAAC CGTAGAACCCAACGGTGAAC STAVKVQRHLAFRHGTVPVR (SEQ ID NO: 1143) ACGGTTGGCAGGATGAAGTG FSCESCGKTSPGCHSVLCHI ACGTGAGGGGTAAGACATGC PKCRGPTGEPPEKVVKCEGC GTACGTGAGCGCGCATTTTT SRTFGTRRACSIHEMHVHSE GCTGTTCTCTGGACTGGGTT IRNRKRIAQDRQEKGTSTDG TCGTCCCCCTCACAACCATC EGRAGVERADAGEGPSGEGI ACTTACACTATAGGGGCACA PPKRPRRARTPREPSEPPAN GCGGCTCCTACCTCCCTCCC PPILSPQPDLPPGGLRDLLR TATGACCCCCCCTTCCCATA EVASGWVRAARDGGTVIDSV CCGATCCATGGCTGTTCTAG LAAWLDGNDRLPELVDAATQ TCTGGACCGAGGGTCGGACG RTLQGLPAGRLARRPATFVA GGGCATTTGAAGGTAGCTGG PNRRRGRWGRRLKLLAKRRA AATCCTCCGCTGCTGCGAGC YHDCQIRFRKDPARLAANIL CTGAGGTCGATGGTTAGAGG DGKSETSCPINEQAIHEHFR TGAAATACTTGGGAGGAGAC NKWANPSPFGGLGRFGTENR ACAGCCTCCGGAGAGCCCCT ANNAHLLGPISKSEVQTSLR CCCGGGTGGTCATCATGGCA NASNASTPGPDGVGKRDISN ACCGGGTGAAACCTTACGGT WDPECETLTQLFNMWWFTGV TTCACTTACGAAACAGCACC IPSRLKKSRTVLLPKSSDPG ATAACAGCGCCGTAATAGCG AEMEIGNWRPITIGSMVLRL CACCGGTGTGACTACTGTCC FTRVINTRLTEACPLHPRQR AGTGCTGATATTCTCATCTG GFRRSPGCSENLEVLECLLR GAGAATACAACACGGGTAAT HSKEKRSQLAVVFVDFAQAF GGCAGAGTATTCAAAACCCA DTVSHEHMLSVLEQMNVDPH AATGTTTACGATCGACCAAC MVNLIREIYTNSCTSVELGR GGAGTCGTTCCCTTGCATCT KEGPDIPVRVGVKQGDPLSP AGGCCGGACCCGAAACTGCC LLFNLALDPLIQSLERTGKG GTAATTGCCCGTCCCCAAGG CEAEGHKVTALAFADDLALV TAGCCTCTTAGAAAACCGAA AGSWEGMAHNLALVDEFCLT GCCCGGTCGGGGCGGTGGTT TGLTVQPKKCHSFMVRPCRG GCGGCGGCGCTGCGGGGGCC AFTVNDCPPWVLGGKALQLT TGCTGCTCGGGCGGCGTCGG NIENSIKYLGVKVNPWAGIE TGTGCCGCGGTGGTTGCGGT KPDLTVALDRWCKRIGKSLL GGTGCGGCGGGGATCTCGGT KPSQKVYILNQFAIPRLFYL CCTTGCGGTGCCGCTGTGCC ADHGGAGDVMLQNLDGTIRK GCCGCGGTCGCGTCGGTGGC AVKKWLHLPPSTCNGLLYAR GCTGGGGTGGTGGCCCGAGT NCNGGLGICKLTRHIPSMQA GGCGTCGGCGTGCCACTGCC RRMFRLANSSDPLMKAMMRG CATAGTCGCCCGCGGGGGCG SRVEQKFKKAWMRAGGEESA ACCGATCTGGAGGGGCGAGG LPRVFGANQYQEGEEVANDL GGGCTCGCGGGACTTTAACG VPRCPMPSDWRLEEFQHWMG AGAAACGGAACGCAACTTCT LPIQGVGIAGFFRNRVANGW CGCATCGCTCCCGGGACTTT LRKPAGFKERHYIAALQLRA CCCCCCTCGTTCAGCCGAGG CVYPTLEFQQRGRSKAGAAC GATGCCAAAAGGCATGAAAG RRCSSRLESSSHILGKCPAV GTAAGTACCATACCGGTCCG QGARIRRHNKICDLLKAEAE CAAAACTCTCTTCTGACTCG TRGWEVRREWAFRTPAGELR GTTCTCTGTTGGTTTTCTAG RLDLVLILGDEALVIDVTVR AGTAACAACGAGGTGGAGGA YEFAPDTLQNAGKDKVSYYG GAGGGACATGGCAGGGACTC PHKEAIARELGVRRVDIHGF CCATTCGTGCCAGCGGGTGG PLGARGLWLASNSKVLELMG GGACAGATCGAAGGAACGGT LSRERVKVFSRLLSRRVLLY TCGAGGGCGTAACAGACGAG SIDIMRTFYATLQ AGGGAATCCGGTCACACATT (SEQ ID NO: 1388) GATGCCATGCCTAAATAGGC GAGGTTTGTATTTCTACTTT GTGGGTTCAGTATAGTCGGA GCATATGGTCGGTTGTCCCG TTGTTTTCACGGCGGGCAAG CGACTATCATGATAAAGTAG AATGGGAGACGGGCTCCCTG ACAAACCCGGAAAGGCGCCC CCCCGTGGTTCGTAGCAGCT GACGGATCACGCTCGAAGAA AAATGAGTGAGAGGGGACGC CGCAACCAC (SEQ ID NO: 1266) R2 R2- . Gasterosteus CATATTGGGGTCTCAGGAGG GGAGGGGAGTAGGTCTCTAC MLRGGVGTPPAGGAGAVGPG 1_GA aculeatus AGACACAGGGTCTGTTGCGG TCTGACCCGAAGGGCCCCCC MASPGGCSVRFSPGGRRLLG CTCCGGTAAACGGTACCGGA CGTTTCAGACCTGATTCTAG HRTGGLSPSVSWRLKRLSVS GTCGGTTAAGCATCGTTTGG GCTACCTGTGCCTAATTGGG LRRWSGPGLLGADGAGGGAA GCCCGCCTCCACGTGGTGGT GGGGTCCCAAAGAGATGTTG VASPRGTQVLGSGAGRRWLG CCGCGGTAACACCAATAGGG TCTGTTGTAGAAGGGTTTGC HGSRGSSPSAARGLRRLTVR TGGCTAAGAGGCCCAGTAAT GCCACTGACTGCACGGAAGG LKRLSGGLLSPKACRDAEEG TTCCCCGAATTGTCTTCCCC GTGGGCCTCGACAGGTAGGG SSSSPGFRNPKGLGGRGLTP CCCGCGCGGGGGGGACCCCC GTTACATGACTCCGTGCTGC LGSRRFCRLTVSLNRWRGSL CTTTAGTGTCGGAGCGGTCG TCAGCAGACCCGCGCCTCTG VKLNASSRASGRRTPVKPAC CGCCTCCGCGTTTGGGGTGT AGACCGGGTAGGGCTACTTG DSRAGRGSEHAEGGGVSAAP CGCAGGCGTGAGCCTTCGTC AACAAGCGACGCCCTGGTGT MVLRSRRKLTFSVDGDSNSG CCCTTAAGTTCAGACGGTCC ATGTCCGTATCCTAACCTGG DRARSGSVSAARPGHLLVDG CGGCTTCTTGCCGGGCCAAC TTTGGGAAAGCCGATACCGG ESASSRSGPAGDARLAGPST CCCCGGTGCAGCGTTCTCCC CAATGCCCGCCACAGGTGTC RSRRKGCLPPVDFENPKKRT ATGTTGGATCGGCACCCAGC GCGCACCCCACGGGATGACG RLMAKMTNGNPTSHVPCPAP CCCGGGTGCCATGCGAGTTC TATGGGCCCCGGGGGACCTC CSNGHEGGGRVAVIEGRLPE AGACATTTTGTTTATGTATC ATGGATACTCCACTGGACTT LSGSRISGIQPALPVETSFV GTCTGCGTGGTTGACTTGCT GCACAATCCTGGTGTACTGG GQSTGRGADGDANANSSPPS AAGCTCATTTCCTCCTCTCA ATGCAGCGACGTTGGTGACA PNLGGSVGMVPAVRDGTPPL CTGCGTCCCCCCAGGTGCTG TAAGCAATCGCTAAGTCGGG GRPGEDHSRECAGGNTPLWM ATCGGTTGAAGAGGATTCGT GTAGGGGAGGTGGGGACCTC LEDSFRCDYCPREFGTRAGR CGTTGACCTCGGCGGTGAAT GGCACGGCTGTAGGAACGGG SLHMRRAHLAEYDGAGFCWG TTGGGATTGTATTATACAGG TGTATGGGCTCCGGCAGCCG ERLSEFAATRLWSTEETKKL TAGGTATAGAGGGCGTGCGG TCGTCACTCCCATACAACAC AVFCERGVPSPSECRAIAAS (SEQ ID NO: 1144) AGGGGCTGCATCCTGGTGGC LGAGKTHHQVRSKCRLVFEA CGGTGCTAGTTGGTTCTGGA IRRRELLEVAAATERLEKSA AGCCCGCCCGGGCTGGTTCG RRKQPAVPPAPVHGVRGVLR CAGAAGCAGGGTGCGCCCAG GLLGKRVPREGGTTGSTSAR GGTAGGTTTGGTATATCTGG IVRRDDCRQGAVASASLNLI GTCCGGTGCGATACCTATCG RRLGRKATGRSGRRRVLGRP ATGGGCAGCGAGGGCCGCCT PRMDVRRSVRMRRMRRFLYR CGTGACGCGCTGTGTGGAGC LARLGWAKLAMFVLDGQMGA TGGAGCCGGCCTGGGTATGA SCPVPLVEVSAVFRERWSIV ACAGTTCTTGCGGATGTGGC RAFLGLGQFGGFGTADNAGF GTAGCTAGATAGTACCCGTG GKLIDPAEVRAHLQSIKNRS GTTGTGGGCGTGGTGTCGAC SPGPDGITKVALSKWDPEGI CAAATGTTGTCCTGTGTGCA KLAHMYSTWLVSAGIPKVFK CATAGGCCAAGGGTTACGTG KCRTTLIPKTGDVSLHGDVG GGTGGCAGTCAGAAGCACCC QWRPITIASLVLRLYSRILT GCACCTGGAAGTGATTGCCC ERMTVACPSHPRQRGFIASP CGGGATCCCGGCTCTCTGTG GCSENLMLLEGCMSLSKAGN AAGAGCTACCTTGAGGAAAG GSLAVVFVDFAKAFDTVSHE GTGTTCCGCTGGAACTCAAG HLLSVLVQKGLDQHMVELIK ACCCTACAGTAGGGGATATC DSYENSVTKVHCQEGCSTDI AACTGGCTTTGAGGTGCTGT AMKVGVKQGDSMSPLLFNLA GATTCCGGAACCAGGGCGAG LDPLIQQLEREGRGFPVNGK GGCGAGTACTTAGAGCATGT SITAMAFADDLAIVSDSWEG CCAAAAGCCCGGGGAACGTT MRANLDILVDFCELTGMRTQ CCGGGGGCCTGCTTGGGTCG PSKCHGFLIEKSGSRSYKVN TTGGACCCACATCCGTAAAA RCEPWLLNDTALHMVGPKES CGATGGATCTCGCGTCGGCG IKYLGVQVNPWTGIFAEDTV CTCGGGAGAACTTCCCGCAT AKLRQWVVAISKTPLRPLDK GAACGCTGATTGCATGTGAG VSLLCQFAVPRVIFVADHCM AACGCCCCCACGGCGGCGGG LSAKALTEMDRSIRQAVKRW GCAGGCGCTCCCCCTGGGTG LHLARCTTNGLLYSRKSSGG TAAGGCTCGGGGGGGTCACG LGIPKLSMIVPAMQARRLLG GCTCCGCTCTAAAAG LSRSKDETVRWMFLETTDHV (SEQ ID NO: 1267) AFERAWLRAGGSPDEVPELG PDLVEGSPAEGNADPVSTVR PRKRIVPCDWRQVEFDRWAG QLVQGKGIRTFEADKISNCW LYDYPPNKLKPGDFTAAVQL RANVYPTRELAGRGRTDTID VCCRHCGEAPETCWHILALC PKVKRCRIQRHHKVCQVLVA EAERHGWEVEREKRWMLPSG ECVAPDLICWLDELALIVDV TVRYEFDEESLERARIEKEC KYRPLIPVIRASRVQTKKVT VYGFPLGARGKWPAKNELLL ADLGLSKARTRSFAKLLSRR VLLHSLDVMRTFMR (SEQ ID NO: 1389) R2 R2_B AB076 Bomby GGGCGATACGCATAATTTTA GCCTTGCACAGTAGTCCAGC MMASTALSLMGRCNPDGCTR M 841 x mori ATTTCCCGATTGAAATCCAG GGTAAGGGTGTAGATCAGGC GKHVTAAPMDGPRGPSSLAG TCGTCTTAATCTGGTGACCA CCGTCTGTTTCTTCCCCGGA TFGWGLAIPAGEPCGRVCSP GTGGCGCGGTCACCAGTATA GCTCGCTCCCTTGGCTTCCC ATVGFFPVAKKSNKENRPEA GTGCACAGGACGTGAATGGC TTATATTTAACATCAGAAAC SGLPLESERTGDNPTVRGSA TCCGAGGCTGGCGGAGTCAC AGACATTAAACATCTACTGA GADPVGQDAPGWTCQFCERT TCACTATAAGTGTGAGAGAC TCCAATTTCGCCGGCGTACG FSTNRGLGVHKRRAHPVETN GATGTCCTGTGCCAAGTATA GCCACGATCGGGAGGGTGGG TDAAPMMVKRRWHGEEIDLL CGTCCAACCCTAACGGGTTA AATCTCGGGGATCTTCCGAT ARTEARLLAERGQCSGGDLF AGTGAAATTAGTTGCTCATA CCTAATCCATGATGATTACG GALPGFGRTLEAIKGQRRRE ACAGGGACGGTGTACCTGTT ACCTGAGTCACTAAAGACGA PYRALVQAHLARFGSQPGPS TGCTCGTGGCTGGCTATCGA TGGCATGATGATCCGGCGAT SGGCSAEPDFRRASGAEEAV ATGGACGGGACCAATACACC GAAAA  EERCAEDAAAYDPSAVGQMS CCCCTGTTAGTAATGGGGTA (SEQ ID NO: 1268) PDAARVLSELLEGAGRRRAC AGAGAGAGCGGTCTGAAACT RAMRPKTAGRRNDLHDDRTA ATGGCCGAAATCACGACGCC SAHKTSRQKRRAEYARVQEL CCACTCCTACCCATAACCTG YKKCRSRAAAEVIDGACGGV CACGTGGTACCGCCGCACAT GHSLEEMETYWRPILERVSD TGACCGATACGGGAGGAGGG APGPTPEALHALGRAEWHGG GCAGCACTTGAATCACGTAG NRDYTQLWKPISVEEIKASR TCTTGGTGTAGCCATTGCGG FDWRTSPGPDGIRSGQWRAV GACTACAGCCCTCGTAAGTG PVHLKAEMFNAWMARGEIPE CCGCCTTAGAACGCAACGGG ILRQCRTVFVPKVERPGGPG GCAATAGGTGGGCCGGGGCG EYRPILIASIPLRHFHSILA CTAGCGGGGGGGAGTAATCT RRLLACCPPDARQRGFICAD CCCCTGTTGGCGTGCACCGC GTLENSAVLDAVLGDSRKKL ACTGCTCCCACTGGGGGCAG RECHVAVLDFAKAFDTVSHE TGTCATCCGGAAACAGGTGG ALVELLRLRGMPEQFCGYIA GCCGGGGCGCCACCAGGGGG HLYDTASTTLAVNNEMSSPV GAGCAATCCCTCCTG KVGRGVRQGDPLSPILFNVV (SEQ ID NO: 1145) MDLILASLPERVGYRLEMEL VSALAYADDLVLLAGSKVGM QESISAVDCVGKQMGLRLNC RKSAVLSMIPDGHRKKHHYL TERTFNIGGKPLRQVSCVER WRYLGVDFEASGCVTLEHSI SSALNNISRAPLKPQQRLEI LRAHLIPRFQHGFVLGNISD DRLRMLDVQIRKAVGQWLRL PADVPKAYYHAAVQDGGLAI PSVRATIPDLIVRRFGGLDS SPWSVARAAAKSDKIRKKLR WAWKQLRRFSRVDSTTQRPS VRLFWREHLHASVDGRELRE STRTPTSTKWIRERCAQITG RDFVQFVHTHINALPSRIRG SRGRRGGGESSLTCRAGCKV RETTAHILQQCHRTHGGRIL RHNKIVSFVAKAMEENKWTV ELEPRLRTSVGLRKPDIIAS RDGVGVIVDVQVVSGQRSLD ELHREKRNKYGNHGELVELV AGRLGLPKAECVRATSCTIS WRGVWSLTSYKELRSIIGLR EPTLQIVPILALRGSHMNWT RFNQMTSVMGGGVG (SEQ ID NO:1390) R2 R8Hm- . Hydra TTCAAGTGGATGAAGCTGGG TAAATGCCAAAAGTTGCTTG MNLLIVTSSIKESDVPSSGK A vulgaris AAGGTAATCTGTAGTTGGTT GGCTAAATGATACGTACGCT GGVAVNNITAGASGKDTCVI GAGTTGGTTGCAGATTACTG AGAAAAAGCGACTTGCTGCA IHPGTDGIWCCTECVEIHNS CTGTCGATTTTGCTTTCTAT CGGATGACGGTTCATCAGAG GKDLKRHLAKRHPSVTISGY TGAAAGCCTGTCTCTACGGG CCCGATATGTGCATGTCAAG KCNLCPFVSERQLSVGTHLR TCCTGAAGCTTGAATTTTGG GCGGCAGGGAGAATCACTAG YCRGVKEVVKREFACASCSF TAGCTATAGTTTTGTGGGAG TGTAGCTGTTCTTTCCATTA SSDTFSGLQVHMQRKHIAEW GAAAGTGGAATTTTGTACCA CGACTTACGCGGTTAACGTG NDQLKEKTEFAWTDRELREL TCTTTTGTCTCTCGTATCTA GCACGATAGATTTACACCAG AEKELTTPSFRYNKIFYAAL CTATAGTAAATCCGGTCATG GAAATAATACGTGAAGGGTT GTSRTYDAVRKIRYNDRYKS CAGCCTCTACGCGGCGCAAC CCACCATATACTGGAGTTTA AIAEMRSQIADAAAAAQERD TAGAAACTTGGATCAGTGAT GATCTATGAGGGAAACATTT VERGLVSAHSDRGKEMLPVV CAAGGCTAATGCATGCCGGG GTAATAAGTCAGTCTGGTAA ETKSDIQVNNDIKKDIELTP TCTCCTCAGATTAGGAGTAT CCTGGCGCCGCTGTTGAGTC NSRQKQTNLALARPAVIEVE AATACAAATCTGACTTCATC AAATTAACTATGTCAATACT EDLGRQDVKQYLASLRQDDY ACTAAGAGGCTATGGGGCTA CATTAAGTTATCGACTTTGA TSPAERSIFAYCREETNWSA ACGATCCTATAGTCTCG TATGGCATGGGGTGATTCCG TKRQVLKISRTTRGLRQPKK (SEQ ID NO: 1146) CGTTATATCAAAGTCAAACA VRPFEFPEGFKPNRNMRKWR TGATGATTGCAATGAGAAAC KYRFLQECYREKRAETVSKI TACCACGCTTGGTCACGTTT LDGTFIDEPEEEIRPELEEV GTGAGGAGAACATCTCATTC QRMYIDRLEKRTQLDTTKIV AAGCCTCCCGGATGTCGGCA QTDEVFCLQSYGRITIGEVR CCCGCTGACATCTTCTGGCT DALGASKKDSASGPDGLLLQ TATGAAAATTTTCATTAATT DVRRLGPLLLCNIFNMWYLH TTTGTAAGTCATGGGCGGCT GIPVEENRCRTILLYKSGDR TGAAAGC HLASNYRPVTIGNMLNRLYA (SEQ ID NO: 1269) KIWDKRIRKNVRLHVRQKAF IPVDGCFENVKTIQCVLQSY RKRKLEHNVVFIDLAKAFDT VLHDSIRKALWRKGVPSGVV KVVDSLYAGAVTSISVGKTK TRSICINSGVKQGCPLSPLL FNLILDELAERIEATGCGLD LDGHVLSSMAFADDYVLLAK DSVEMNELIRVCSTFFKEKG LSVNPGKCQSLRVLPVKEKK RSMKVLVRPHRWWRIKDQDV DIPSMTYDSLGKYLGVSIDP TGKIALPIEEWKNWMTKLKE CKLKPEQKVKILKEVVCSRV NYVLRMSECGISELRSWTRF VRNWAKNIIHLPTWCSSDWI HSIKGLGIPDVSKGIVIQRM RASEKMSTSEDGIVRVVGAR LVQKNRVLWEKAGFEGIELK AARRHCEVERLNNIGNITNG VALKTIAAVSSVNRYWMIED NLKSGNKILVWKAMAGAIPT KINLSRGVADQTLKKCRRCG LTAETDGHILAGCHTSSDAY SKRHNMLCDKLAKELKLNGG PNRRVWRERTCFTSTGRRYR PDIIVKDDSKITVIDMTCPY EKSEGHLIQCESAKVTKYEP LKLDKYWTRELEGANGIVAE KVELMGLAIGAIGTIMRSTL RKLCELKSGRIVRRLQMIAC NNSAQIIKGHLSRATRRNLR (SEQ ID NO: 1391) R2 R8Hm- . Hydra CTTGGGGTCACTGACACATT ATGCCCGAGGTAGTTGGGAT MSNRITIGDVPSVGKGGLTV B vulgaris TTTCGGTAGCCATAGTTTTT AATGATGCACAAGCTCGTAA NKQTAGADGAEACVVIHPGA TGAGAGGAAGAGTGGAAGTT GGCGACTTGCTGCACGTATG KGIWSSPACLRKFTIGKELR TTTCCATGAGTCGTCTCTCG CCGCTAAACGCTTAGCTCGA AHLAQIHKLAPSAVRYRCNK TATAAACTGTGGTAAATCCG TGAGTGCATGTCAAGACGGT CPYEGDVQLSVGTHLRYCKG GCCATCCAGCCTCTACGCGG CGGGAGTATGATCAGTGGAG IAGVVEEKKQFACAICNFSS CGCAACTAGAAACTTGGATC CTGACTTTCCAGACAACTCA DTFSGLQVHKQRKHVVEWNE AGTGATCAAGGCTAATGGAT CGCGGATTCGCGTGCGGTGG QLKEKTEFAWTDRELRELAV GACGGGACTCCATGGATAAG ATACAACACCTGGTATAACA KEVTIPFSVVNTETFAVLDI GAGATATAAAGATCTTATTT TATGAAGGGTTCCATCTAGT TTRTKDAVRKIRYTDRYKSI GAACGCATCTTAAGGGGTTA ACAGGGATAACGATCCATGG LAEVRAQVNAVAEEAPQASD TGGGGCTAACACCCCCTTAA GAGCAAACTAATTAGTTGGA ESQITLLVNTGRGAELQPAV TTCTGGTGCACATTTATTGA GGTAATCCAACGCCGCTGTT INITDSIELVTDVNEVEMVT CCGTT GAGTCAGTTTTTAACCGCCA SNSTNEEQPINAPVEPAVIE (SEQ ID NO: 1147) GTCAACTCTTGTAGGTTATC ADLGRQDAKLYLASLRQSDC GGTCTTCGGCAGACCTTGGA TNASDRWTLAYCRGEVDWCK CCGCCTAGCGCCGGCCAACA TKSRLFKVSRHARGLRQPQR GTTTGTCGTCGACTAACATG VENWEFPEGFRPNRNLRKWR ATGATTTGCGAGAGAAACCC KYSFLQSCYRTKKKETVSKI ACGCTTTGTCACTTATGTGA LDGTFKDTPEEEIRPELEEV GGATAAAATCTCTTGTCCAT QRVYVDRLEVRTQLDTTRTV ATGATCCTTTGAAGGGAACA HIDERFDLVSYGRITIREVQ GCGCTTTGAGCTTGCTCGGC DAISASKKDASGGPDGLLLQ GTTGGCACCTTTAGTCTGTA DVKKASPRQLCIIFNMWYLH ATATTTTCTTGATATTATGG GIPVVENRCRTILLHKGGEK ACGAAAAAGGTAGTATGGTT HLTSNYRPVTIGNMLNRVYA GCA (SEQ ID NO:1270) KIWDRRIRKNLQLHVRQKAF VPLDGCFENVKTIQCILQSY RRSRREHNVVFVDLAKAFDT ILHDSIEKALLRKGIPRSVI KVVDSLYAGAVTSITVGKTK TRPICINSGVKQGCPLSPLL FNLVIDELAERLEATGCGLD LEGHVISSMAFADDYVLLAK DSVEMNVLMNVCNTFFEEKG LAVNPAKCQSLRVLPVKGKR SMKVLTRTHRWWKINNQDVE IPSMTYESVGKYLGVMIDPA GKIALPIEEWKLWLTRLREC KLKPDQKVKVLKEVVCARAN YVLRMSGCGICELRKWSRFV RGWVKSIIHFPAWCNSEWMH SSKGLGIPDVVSGIVIQRMR AAEKMAKSTDGVVRVVGARI VQTNRVLWKRAGLAGIELDA ARKFCEVKRVNKIGNQTNGG ALKTIAESSVSRHWLLEKNI RPGNKILVWKAMAGVIPTKI NLSRGVADQTLKKCRCCGLT AETDCHILAGCPTSRDAYSK RHNLLCDKLAKELRLNGGPS RRVWRERMCLSGNGRRYKPD IVVKDDGVITVIDMACPYEK SERHLSQCEDAKVAKYEPLR LDRSWTQELEGNNGRSANEI SVVGIAVGAIGTITRKTQRI LSKLKLAKVGRPLQIIACNE SAQIIRRHLSGSRLRNLR (SEQ ID NO: 1392) R2 R9Av GQ39 Adineta GAAATAGTTTGCAATGGTAG ACTAGTCTCCTTCTTCTATT MNLPIREHAVSVHNINKFNY 8057 vaga GTGTATGGCGCCTCTGTGTC AGTCAGTCTAATTAATTTTT LCQLCSKSYDTINSVKAHYV TCTCTTTCGCTGGATATAGT CTTACATTCTACATCTAGTT ACRRQKNASSTTAVPTNVIN TTGACGATTTTGTACCAGGT CCATTATTAAATTGGTATGA NNQLAINTNQVISRNPLQCV ATCTGTTTCTTGTGAGTTCA TCAGTGCTATCTCTGCTACA ECLMKQVDFYAKDTKALVTH GCACCAGTTTGAACAGGCTT CTCAATGCTTAATCGTATGT MRTKHAAAYEESKKVATRRV AGCGATAGACCTTCGAACTT TATTGACAGTCTGACACTTG AWSPDEDQILAELEVKLKKI GAAACACTGTTGTGAAGCTG ATTACTCTTACGACATATGC QKGQLLSRLVVEYNKCADKS GCTGGGCCCCTGCAGATTTT ACTGTTTGCTTCAGAGAAAC KAPSRSKDAIRTRRQQHDYK CTCGATTAGAACGTGAGTGT CACTGTTCATATAGTGAAGT LLLRSLQSQQPPVGSEDSDS TACGTCCAGAATGACCCACC TCCTCAGTTTTCTGTTGATA DISSSNNNPLTTTHNVTPTP AGTGGTTAGTTCTACGTTGC TATTCTTCTTTCATTCTCGC DSSNVVLLIQKIRESVDSIV CCTGGAAAGGAGAAAAGTTG TTCTCCTTTTCTACTGTGTT KITNLKLNTNMLNAASAFIN AGCTAAAATCGCACGGCCTA CTTTTTATCAGTTTTTTGTG QNNNMDPLELSMRGIEEDVK GTTGTTTATCAAATAGGCAC GAAAAATTGAGAATAAATAA AIRDKELQKPTRNVPSSTTS GGTGAGGAACTCTTCTATGT AGT RKPTRNAKRLEKSKKYGYYQ ACCCTGACTAAAGTACTCAC (SEQ ID NO: 1271) HLYYNNKKKLVAEILDGETS TTGTGCGCTGGGTTTGCTCC GAKPPPMNLVEDYYRNIWSR CCCTCGCATTGACTTATCTG STIDDSPVNNIKTVNSDSIF ATCGCACTACCCACCAAACG APISRDEIKLALSNTKKDSA AAACATAAACTTAGCTCGTG AGPDAVTIKEAKAIIDNLYV GTATCAGTCCACAGCGTGTG AYNIWLGVQGIPEQLKLNKT CAGTCGGATTCAGGGGAGCG ILIPKGNSDLSLLKNWRPIT TGTTAGTGACAAGCAGGATA ISSIILRVYNRLLAYRMNKI ATATTAACATAGTTAATGTT FKTNDKQVGFKPVNGCGINI AAGGCGTTCAACATTCCTTA SWLHSLLKHARLNKNSIYAC TCCAATTGGAAGAGTTGACT LVDVSKAFDSVSHQSIVRAL GTGAAGTTTGTCATGAAGAC TMNGAPSLLVKLIMDQYTNV ATTGGACAA NTVITCSGSISNKINISSGV (SEQ ID NO: 1148) KQGDPLSSLLFNLVIDELFD VIKDQYGYTIDNIGTTNARC FADDLTLISSSRMGMNKLLE LTTKFFKERGLNVNPSKCMS IGMSKGYKGKKSKIESEPLF SITDAQIPMLGYIDKTTRYL GVNFTSIGAIDAKRIKKDLQ DTLDKLEHLKLKAQCKMDLL RTYMIPRFMFQLIHTELYPK LLIKMDILIRKLAKRILHLP ISTSSEFFYLPFKEGGLQLT SLKEAVGLAKIKLHKKIMSS NDPMLCYLIESQRSRIVEHF MKDLKLGDSLTLNEMNNIKE CFMKEKRISFAQKIHGVGFE VFSSSPLTNQWINGEIKTMT TKTYINSIKLRTNTLETRVT TSRGLNIIKTCRRCHVADES LMHVLQCCSSTKGLRYSRHH KICAKVANKLVMNGYGVFRE KSYPDPNNSGSYLRPDIIAV KNGHVIVLDVTVVYEVTGAT FINAYQTKINKYNAIMVQIE QMFNCVNGELHGLVIGSRGS IHHSQLHIWHQMGFSSIELK YVAIGCMEDSLRIMSTFSKA IT (SEQ ID NO: 1393) R2 R2Ol LC349 Oryzias CGCACAGGGGACACAGAGCC GGGGGACAGCTGGGAGTCTC MGTDTVYVGQDYPSGLSKRV 444 latipes TGCCCAAGTACCGCTCCCGA GGCATGATTACAAATCTTGC PARLVAGPMLRERSCHAHVF GGGAGCGGGAAACGGGGGGG GCTGCACTCGGATGTCGTCC RAGHMWNWRTSLPSGRWDQP TGACTATCCCCTGGGGTCCG CCGTGACGGACACATTAATC ALEKSRVLTRSVATATDPEI GCGAGAGCGCTGGTCTACGG CGGAAAGCGAGTGGTGACTC TSYPGKSVSTSTQVQEEDWC ACCAGGGGTGGCTGTGGGCA GCCTCAAG SRESGWISPGLAPEEPSVVS GGCTGCTCCTCAGGCCAGTT (SEQ ID NO: 1272) EITASMVATMRVATEEVVLE GATTAGTTACGCATGGGCTG PQPEQVVTILPEHGRNVPPG TACCTCCACGTGGTCCCGCT LAEQDTASPIEVSVLLPDLA GGTAACGACTTGTCGGCTAA ENCPLCGVPSGGLRLLGKHF ATCAGCCCGCCCACCATCTG AVRHAGVPVTYECRKCAWRS GGATATGGTTGACCGTCTAA PNSHSISCHVPKCRGRARMP CCCCAGTACTCAGGTCACAA SGDPGIACDLCEARFATEVG ACAAA VAQHKRHVHPVEWNKVRLER (SEQ ID NO: 1149) RGARGGGIKATKLWSVAEVE TLIRLIREHGDSGATYQLIA DELGRGKTAEQVRSKKRLLR IDTASNSPDDAEVEEERLES LAVRSSSRSPPSLVATRVRE AVARGESEGGEEIRAIAALI RDVDQNPCLIETSASDIISK LGRRVDGPKRPRPVVREQTQ EKGWVRRLARRKREYREAQY LYSRDQARLAAQILDGAASQ ECALPVDQVYGAFREKWETV GQFHGLGEFRTGARADNWEF YSPILAAEVKENLMRMANGT APGPDRISKKALLDWDPRGE QLARLYTTWLIGGVIPRVFK ECRTKLLPKSSDPVELQDIG GWRPVTIGSMVTRLFSRILT MRLTRACPINPRQRGFLASS SGCAENLLIFDEIVRRSRRD GGPLAVVFVDFARAFDSISH EHILCVLEEGGLDRHVIGLI RNSYVDCVTRVGCVEGMTPP IQMKVGVKQGDPMSPLLFNL AMDPLIHKLETAGTGLKWGD LSIATLAFADDLVLVSDSEE GMGRSLGILEKFCQLTGLRV QPRKCHGFFMDKGVVNGCGT WEICGSPIHMIPPGESVRYL GVQVGPGRGVMEPDLIPTVH TWIERISEAPLKPSQRMRVL NSFALPRIIYQADLGKVTVT KLAQIDGIVRKAVKKWLHLS PSTCNGLLYSRNRDGGLGLL KLERLIPSVRTKRIYRMSRS PDIWTRRMTSHSVSKSDWEM LWVQAGGERGSAPVMGAVEA APTDVERSPDYPDWRREENL AWSALRVQGVGADQFRGDRT SSSWIAEPASVGFAQRHWLA ALALRAGVYPTREFLARGKE KSGAACRRCPARLESCSHIL GQCPFVQANRIARHNKVCVL LATEAERFGWTVIREFRLED AAGGLKIPDLVCKKADTVLI VDVTVRYEMDGETLKRAASE KVKHYLPVGQQITDKVGGRC FKVMGFPVGARGKWPASNNT VLAELGVPAGRMRTFARLVS RRTLLYSLDILRDFMREPAG RGTRVALIPAATGAAN (SEQ ID NO: 1394) R2 R2_LP AF015 Limulus TGGGAGGAGACCCAAACTAT ATTTTGTCTCTTTCCCCAAT GIDGYMFGYARASGSTSVSI 814 polyphemus CCTAGGATGGGGCGGAACCG GATGTCTACTAGCACGCTGC QSSSMTEGETNERATPRASD ACCATATGAGCCATATTAAC CGAAGCTAGATAGATTGAGG SSSVSIQSSCVTEGECLPPT ATTGCCCACACTATCCTCTG AATCTGCGTAATCTGTAATG DNCNPSVENQLPCVTEGRFE GAGGTACCTCCTCGTGGTAC ATTACGCCTCATGGGCATCT RVGSLVTVRLPFRKVACDLC GGCTGGATATAGGTAAATCC ATCGGTAGCGTCGACCCTGA SKEFLTYSKFAVHQANFHNS TGTAACCAAATCCTCCAACC CGTTAAATTGGGTAATAAGA ETQACCTYCGKSDGNHHSIA CGTGAAGGAGAACACTAAAA AATATCGA CHVPKCPWRRTVTFAANLSN CCCATATAGTGGCCTCGCCA (SEQ ID NO: 1273) FLCDLCNDSFKTKSGLSQHK ACCACTATATGTCCAACGGC RHKHPCSRNAERILSLGVRT AGGAGAAGCTATCTCCCGGA PSARPRQVVWSEEETRTLRE TGGGAAGGAAAACCCTAAAC VEVVYSGQKNINVLCAGHLP CGTGATGGGAACTTACCGGC GKTSKQVSDKRRDLHRIRSS CCCATCAGCTATTGGGTACC NVHGTPTTQSRGDPVEQVEE CGGTAGGGACTTGCAACCCT YEELDWEGMHPFPDPDSKFC ACCCTGTATTTGCATTTTAT SYLDQLRDQKGLTEPVWQEI AGGGAACCGGTCGGCCCTAT EIVAQEWVENLAHVQSSWNH ATCAGAGTAGACCGTTTATT ERTTKQVPENNTPARRPFKR AAATATGGGTGAAAATATTA RLHRVERYKRFQRMYDLQRK ACAGTAAAAGCTATGGTTTG RLAEEILDGREAVTCNLKKE GCGTCCGTGTGGTGCCAGGG EIKDHYDQVYGVSNDRVSLD CGGCGGCCAAACCCGAGCTA DCPRPPGANNTDLLKPFTPT CTTGGCACCAACTGGGGATG EVMDSLQGMKNGAPGPDKIT GTAGCTTCCGAGCGATTCCC LPFLQKRLKNGIHVSLANVF TGGCGACGTGGGACCGATCG NLWQFSGRIPECMKSNRSVL ACGATGGAGTCCAAACATCC IPKGKSNLRDVRNWRPITIS GGAATAGAGGAATTGAGAAA SIVLRLYTRILARRLERAVQ TACCTATTCCACCACCGGCT INPRQRGFVPQAGCRDNIFL CACATACCCAAGGTGAACCC LQSAMRRAKRKGTLALGLLD GGTGCAACTAGAGTACAACC LSKAFDTVGHKHLLTSLERF TATCTGTGGCGGTAGGTGCC AVHPHFVRIVEDMYSGCSTS GAACCACTCAGGTGACGGGC FRVGSQSTRPIVLMRGVKQG TTGTTTATTGATGTCTCCCT DPMSPILFNIALDPLLRQLE ACGAGACACGAATTGTGACA EESRGFMFREGQAPVSSLAY AATCCACTCCGGTGGACAAT ADDMALLAKDHASLQSMLGT TACCCGATCTATGAACCTGT VDKFCSGNGLGLNIAKSAGL TACCGATATTAGACAAGAAA LIRGANKTFTVNDCPSWLVN ATAAAGAACTGACAACGCCT GETLPMIGPEQTYRYLGASI AGAGCTTCAGGCAGCATGTC CPWTGINSGPVKPTLEKWIA TGTAAGTATCCAGTCATCGA NITESPLKPHQRVDILCKYA GCGTGACTGAGGGCGAAATT LPRLFYQLELGTLNFKELKE GATAATAACTCTGAAACTGA LDSMVKQAVKRWCHLPACTA (SEQ ID NO: 1150) DGLLYSRHRDGGLAVVKLES LVPCLKIKTNLRLVHSTDPV ISSLAESDGLVGAIEGIAQK AGLPIPTPDQRSGTYHSNWR DMERRSWERLALHGQGVELF KGSRSANHWLPRPVGMKPHH WVKCLAMRANVYPTKRGLSR GNLSKNKDSAKCRGCTSMRE TLCHLSGQCPKLKSMRIRRH NKICEHLIAEASFKGWKVLQ EPTLVTDNGERRRPDLIFHR DDKAVVVDVTVRYEISKDTL REAYASKVRRYGCLTEQIKD LTGATSVVFHGFPMGARGAW FPESSDVMADLNIRSKYFEE FLCRRTILYTLDLLWKSNNE QYLERLAP (SEQ ID NO: 1395) NeSL NeSL- Z82058 Caenor GCTCACTTTCTATCGTGTTA CCTCCAGGGCACGCCGCACG MLRRKGRHRMVMVNSVKWQP 1 habditis ACCGTACGTTTACACTCCCA CCAAAAGTCCTGGCATAACT SAHAEAIGTGKSWAPQRSQA elegans GTGAGTGTAATAAAGGTTAT CTGCAAATAACATCAAACGT SEHGWQSNAMFDPPNRILFA TCGATAGAGGGTGTCTCCCT CAATCAACTCCACAAACTCT RDSWSLNQSTHLQNQRSGSG CTTTCTTGGGTAATTCTTCG CCACTCTCTTCAAGTCTTCT LGIRPGQVRNNMVGGGPHRA GCGGTCCGGGGTCTCTCCCT CGGTGCTTCCAACACCACAA GDPKRRVELVSIQGSEVTVR CGTCTTTTTTTTAAACTTTT TGGTGAAAGCTCCTTCACCT TIYPSDEIFSCYSKSCDIKT CTTTCTCATCCACTCTTTTG TTTCCCTCCAAAATTCTTCC KAGYGPEDLKHLTRHIKNEH CTCCTTTTTACTAACTCTTG CATGTGGGGAAGTCCTGTTC GLKARWAYQCGLCNEKSDPS TACTCTATAGTCTTTTCTCA TTGTAAGCTCTCCGGAGGCT VSEGHKWMEAHMVAVHQSSA TCCCCCATCCGCCGTTGGGC GCAAGAGCAGAAGAAATTCT EKRIKSYQKCTGARVAEQLQ AAAGTTTATTTACTTTGTTA TCTTTCTGACAAGGTCAGAA AAAPSLTVPGKHKSGSRDAA AATCCATATTTTATCTCTCT GGAAGTCCTGTTCTTGAGGC KDSMTPTKDDDPKTRIYQTR CACCCGTACAGAAAGCGTCT GTCCATCCCGGGCGTCATAG SVVKKSTQKTAEPTDEGSRG CCTTCTCAAACGCTTTTCTG GAGAGATCAGATGCACCTTC PKYASIFQKSVKARKSLALL TACTTTTTCTTATATTTTCA TAGCAGGAGCTAGAAGGGCT CELSSPKPMNPLPTNELTLK TTAACATATTTTTCCTGTTT GCCCTGTCTTGAGATCCCCA EGNSRELAKEEAPSEGIDDI ATACTAACCTAACCTCCATT CGGGGGTCAATAGACGGGAG VIIDLDESEESPPRRKRFNT GTCAATTACTAACTAACTTG GGGCTGCTGGCTTTCTCTTT WCLDHESSREAWLDDTAIFW TACAACGGATTTCG TTAAGAGGAAGCACCAATCC YISYLCRGSTKYSALDPCLW (SEQ ID NO: 1151) GGAGATCCTTAGGGGTCAAA SMYKVKGSRYILDRLESSIT GGATTAAAAGGCAGCAGGTC YFFPICEEDHWTLLVLKDNS CAATTCTCCTCACTGACTTC YYYANSLHQEPRGPVRDFIN GGTCAGAGAGGAGTCCCGCC DSKRARKEFKVQVPLQRDSF TTGGAGACCTCCCCGGGGAG NCGVHICLMTNSIMAGGKWH GTTGCTGAAGAGGCGGAAGC SEEDVRNFRKRLKKTLQEEG TCCTTCTAGCAAGAGCTAGA YELYSVNSLGIPFQAPTTEQ GGGAGTTCCCAGTCCTGAAA MDYKETRCKRSYASVLTQIS CCCTTGCGGTTGATGATGGA PPAKRPDCKPDNNIFVPTKD ATGGAAGAGTACTTCGGTAC CAAEGNPQEKGRNESPEEIN TGCTCGTTGCTCTCTCTGCG TEHIVVAGKPANNISPRCRS TTTTACTGCCGAGGGCCGGA TSEMLFEMVKATTSSGRSSL TTTGCTCGAATCGCGAAAGG GTMTQDEFIRTSTIAEAVPL TCTCAATCGACCATTCAAGA MSIKLPPMELPRKILPPIPP TGACGGCTTATCTAAGGTCC RKPTQTNGGQKGKQQRVPTG GAAAGCAGTTGGGAGAGTAA KPDTLNAKVRNWENNQLESY CGTGTTCTCCTACCTTTCAA AMEGRSFQRLEWLTEVLTAS GTTGAATGGTCGTTTTACTG IQKAAAGDEGIVDIICKRNP TTTGGGATAGCTGACTTGAT PLEVAKGEMCTQTENKRKTT GCTAGTACGCTTCATCTGTG NNAARIADPIQSSKGAGDVK GATGACGCTCCCCAAGCAGT ASYWKERARTYNRIIGSKEE CAAGTAGACTTGAAAGGTGC LCKIPIDQLEDFFKKSTSRT CCTCGCCCTAGTTAGCTCTT NVQESIMKEKSSKIPALKIG AGACCTTATGGGTCGCCATG NWMEKKFIGKEVAFALRKTK GTTGTGGACGGGTATGCTTG DTAQGADGLRYHHLQWFDPS CCGGAGCCGAGTCGTGTTTC GELLAKVYNECQRHRKIPKH TTAGAACCAACCTCGACGAG WKEAETILLFKNGDQSKPEN GCGAAAGCTTGCACAAGTTA WRPISLMPVIYKLYSSLWNR GCACAATTGTGGTAGGGCCG RIRAVPNVLSKCQRGFQERE ACTAGAAAATGAGTCCCTTA GCNESLAILRTAIDVAKGKR GGGGGTTACGCCTTGGCGAA RNLAVAWLDLTNAFGSIPHE AGTGAGGACAATTGGCATTG LIEYALTAYGFPQMVVDVVK ACGGGTGCTTCGGCACTAGG DMYQGASMRVKNATEKSDRI CAAAGGCGCCACCACACTGT PIMSGVKQGDPISPTLFNIC CCAATCTCTAAAAAGTTCAC LETVIRRHLESANGHQCLKT ATTCATCGAAGAACTACCGG RIKVLAFADDMAILTDSPDQ AACCAACCACACATGTGTTG LQRELSKLDNDCTPLNLIFK AAACCTACACGGTGGAAGGG PAKCASLVIQKGVVRSASIK AAAGGAAAGCTTCGCTGGAA LKGNAIRCLDENTTYKYLGV CGAAAAGAACGGATAGGTTC QTGSAARISAMDLLEKVTKE CCCTTCTTGATGGCTGTGAG LECVVKSDLTPPQKLDCLKT GCTTAGGATGGACGGGAAGG FTLSKLTYMYGNSIPLITEI CCGTGAGGCCTCAGGCGGGT KMFANIVIRGVKVMHRIPVR AACTCGGCCAGACGCTAGTT GSPLEYIHLPVKDGGLGVAC GATCTTCGGATCACGACAGC PKTTCMITFLVSTLKKLWSD CCTGGCTAAGAGGAACCCTG DEYIKTLFTSLAEEVVKKES GATGGAGTGTGAAGGATGGG KKSTVTMDDIADYLNVEERI CGGGTAGGGGGTTAAGCCTG NRSEFGYNSITRLRDVMRNL TTGACAGACCACCGACTGCA AITGDSPLYRLKMVVKNGKI GTCACAAAATCAGTGATTAT ALLVQATSESMERIYTEEDA GCGGGTGGACCAATCTGTTG KKLQRSLKDQVNKALKHRFN GCGGGTGTTTCCCTCTACCT TTKVVKSKVVRVVQQHPASN GACCCCGCAATATGGTATGT RFVTKGGNLSLACHRFVHKA ACGATCCTCGGATCTAAAAT RLNLLACNYNNYDKSKSKVC TCATAATGGCCCACCACAAC RRCGKDLETQWHILQNCPFG CATAAACCTCCCTAGCAGCT FSKKITERHDAVLHKVKTLI GGTGGTCCCGATAATTCGGG ESGGKKNWTMKIDEELPGFS TTCTTGCCACTACTGCGACC RLRPDICLKSPDEKQIILAD CAGGCTCGCC VACPYEHGVEAMERSWQAKI (SEQ ID NO: 1274) DKYETGFAHLRKSGTKLTVL PIIIGSLGSWWKPTGDSLKE LGIKGSVINSAIPELCATVL EHSKNTYWNHIFGEAYIPNP MRNGHAKPAGNGWKKERLQK APVRPTN (SEQ ID NO: 1396) CRE Cnl1 . Cryptococcus CCCTCTTAATACCCCATAAC TGAGGAAGAGGAGGTTGGAT MSLQRAKNARGDPGRCNLCS neoformans ACATAACAACCCCCTAATCA TATTTTTTCTTTTCTTTAAT ADYRDLKDHLNKQHSTHFFV ACGTTCTCTGCACCTTAAAC AAGTTGTTTATTTAAGTAGT PSDLRGSSLVACPRCGTPCS ACCACCAAC TTCTTTCATTCGGGCAACCC AGTGLSRHQSRYCGLTAPRI (SEQ ID NO: 1152) ACACGACAACCCAATAAATT RRNRVGNSTNTSRCPPSNTA AAACAACGAAAAATGCAACC ASPIVPSPSPERPSPPQPAE TCTATAACCC VVASLEPLSEAEEVLEVAQV (SEQ ID NO: 1275) DAETVDTLEGTRRAPESVPR SAEEGSTRVRELNMTAPEEE HRGEEESSHTNPTAPAGLEN AVSSTLGPSPGTLPSLLPSQ ECANERFLYLAHLPVRSKPL PNNLVTDFMDAAERCALAYI AQPSDSTLLAFLALPKVGLT QALAPEQPLRPSTFLKQFPH IPWPEQPPARRPPSNIRPDT TKQVIKLVENGRLGAAERVL EEDASVAELDQGVIDQLITK HPKGPSCPFGNAVGPTPGKA PDIDTIQKALDSFKPDTAPG VSGWSVPLLKTAAKREPVKQ FLQLLCAAIANNTAPGRSML RTSRLIPLKKDDGSIRPIAV GELIYRLCAKALIISHFQPD FLLPFQLGVKSIGGVEPIVR LTERVLEGSAGAEFSFLASL DASNAFNRVDRAEMAAAVKT HAPTLWRTCKWAYGDSSDLV CGDKILQSSQGVRQGDPFGP LFFSITLRPTLNALSQSLGP STQALAYLDDIYLFSNDSQV LSKTTQFLADKQHIIKLNEK KCKLISFDEIRQEGFKMLGT MVGGKEKRAEFLEGRIRKEM AKVGKLKDLPHQHALLLLRF CIQQNLRHLQRSLRSDDLVD LWERLDTMLWEEVKRMRMRQ REDTAEEEALGRSLTKLPAR LGGLGLLSFKDVAPLAYRSA AEASDTLLDNLGLLSSPEEP PTPIPQRTRCAELWESQQEA ILHNLGDTERKRLTENASRL GRSWLSVIPYLQPLRLSNVE IASGLHDRTLVGSSIPVCRF CGSDSPLGHDELCRARNPWT QRRHNAINRVIYQHLKQIQG ATVEIEPHTLSGQRRNDLRV RGSSALAFTDYDLKVYSLGD RDARSTVTPCAPNGKLADFC LDRCVNWLDKVGQVVSKNAP KVTGGVFKPIILSTGGLMSR STADEWKDWRDAMPVGGFEK MEKRIGVELVKARARTLVL (SEQ ID NO: 1397) CRE CRE- . Chondrus ACGCCCCCTATCCATTTCTG TAAGTCCTTGACGCCTGCCC MSQPNISSAETPLSQLPTPV 12_CC crispus CCAGCCTCCCATCGGCTCGC CGTGATACAGCATCGGTACC PTPPSPSNPSLSLPTVRDLL ri CGTCTCCGCAACCCCTCTTC CCTAGCATTTGAATAAAAAA LCPIRSSHVYSSIPSSCLHS CTCGGCTGTACCAGTTCCGC (SEQ ID NO: 1276) FTMLLIKTVRAASATMTPTE TCCCACAACCTCCCTCGCCA SHRAFIHLHILPIAVLRRSF CA RGETGWRSRTGQHHALRQRI (SEQ ID NO: 1153) RRASSGRHWAALWHEALAAH QVDLDYRTRHSRRYQASATS RHRIGRAMRLAADAQYGRAM SALKAKPLPDLHAAATRDTL TALHPPPASPVQPLSPTDLP PVPEITEGQVLRAARALNPT SAAGPDHLSPRILQLLARTT ISPEAGVTGLSALTNLVRRL ARGDIPDRTAPLLAAATLIP LQPRPHKIRPIAVGQALRRL VTKVLLPPAIQDTRDHLLPE QLANSVASGMDAIVHDTRML MHRHGRNPDYIMVSVDARNA FNTFSRQSLLDRLPLQTPSL ARFLNLIYGRTVPDLVLPSS PRFLMKSQEGTQQGDPASML LFSLAIQPLLRRLTRECRLD LNRWYADDGTLVGPISEVIK ALRILRDDGPQSGFHVNINK CRAYWPTVMPEKLSELLRIF PLHVECGEGGVALLGAPLGT DAFVRRHLMNKVQSCHASLS LLDEIPDARTRFHLHRVTGS VCKVEHVFRLTPPHLSLPAA TKFDEQQIAAYSRLNDVAVS TSMATQIGLPFRLGGHGFTP LSPFIHASYAASLIEAAPVR VKGPHNPSESFYRRMARRHI VHVLGALNPEVRTRGILGTH SPLGPFEPEALLSRPERVHH TLIQAMQGATSRLYWEHTAW DLDPLPRNHSAASVRRRARY NSLRAPGAASFLCSHPSLTS RVPSAVWSCMLRRHLDTPVY CDSIRPLICSHCCKPMDARG DHAAICRHGFGVVHRHNTVR NLLARHAFRAAGLCCDLEVP SLLPNTANRPADILVQPAPP PSGALPDRPTAYDVTVRSPY CRSTMSLAAKGLAGAAEAAD LDKLRVHSRTVRDAFHLQPD SPLPLLDWHFVPLAFDTLGA TSSRTMAVLEYLAHRIANRT YSSYGTAKIRLLORISFAVW SSLASATLSRMPYHGAALSS PAQV (SEQ ID NO: 1398) CRE CRE- . Chondrus CNCCAGCCAMCGATCCCGCC TAATTCACCTTCATATCTGC MAXXPXISPPGAPPAPLRYR 13_CC crispus GCCACTCGCMGCCCGGCCGT TAGTGTCTCTGTAAGCGCAC MLQCPPPLPKXXXXPVPHPM ri CTCGACCGCCACCTCCCCGA CCCTCATGCATTGATAAAAT SSPIRXRLPHRXMRGPPSXT SGCCCCAGCCCATC TACCCCCCA PPRDMHRPHGTPGPHSHRXC (SEQ ID NO: 1154) (SEQ ID NO: 1277) GRPPXHCTHASXQPRXAXHX LQXPKLRSPPPHPHVSPLIL CXGPLPTPMTQPRMKRALSX SAKAPPTKRPSASQGPAASS HDXPRTPPPXPPRPPPYRFP PPTLDQHXFALSXAYPHPXP RRPPSPXRXLRHSFPPRFGX QTFSSIPGPRLHSTVLLLIR LVRAATAANTPETTTLXSCT FTCSRLPFFERPSXAXLAGG PRAVNFMLSACXYGERVXDE SGXSYXXKXHCITSHPPRPR RYSRQHSRNHHTXFLHLHLL PTAXLREAFRGEXGWRSSRG QLHALRLXIRRACTGREWGL LXXEALDAHSXRTEWQHTHA RRPSPPVSPSARAARAMRLA SQAQYGRAMRTFTNPPLADL NDPATMERLQALHPTPTVPV VPLPPSAQPRPPEVTXEAVX RAVRRLNPNSAAGPDRMSPK LLHLLAHTPISPEAGVTGLS ALTNLVSRLARGSLPPCTIP LASAATLLPLQPRPGKIRPI AIGQALRRLVTKXLLPAAID DCRDHLAPEQXANGIPNGID AIVHDARMLVRRHGNDPHYX MVSIDASNAFNNFSRQQVLD QLPTRAPSLSRYLDMVYARA PSPLVLPSXPPTILHSRXGS QQGDPASMLLFSLALQPLTR LISRECXLXMNRWYADDGTI IGRIDEVXKALDIITKEGPR FQFFLNPSKTRVFWPSRQXD LLSPLMTVGPLRVIDEGGVX LLGAPIGSPSXMAQYIREXL NTCKTALAHLDHIPEARMRF HLHRVSASACRLQHLFRLVP PDFAXPFAQQFDRDQLXAYX RFNSVTMSPRIVPKYGCXFX TXATASPHWHLPYTPXTLLA SSIPLQHGYKVPTFPPSLSI SVLHEARCGSFFEIYLHSXN PHTSRCDYVAKNRAQIRLXF SHGGHGLTSLASTIHASYAA SLIDTAPARLQGPHFPAVSQ YQRFARGPLRVVLRNLPSFV QPAHFSMTEXDLGCLEPXAL LARPERIHTFLLQAQYSAAA SSYWQXPLWESFPNPGDHSA ASLRKRVRYNSLLAPGATSF LTAHPAATSRVHNATWSTML RRHLDAPVTNDSISPLRCXH CSKPMDARGDHAXIXSHGFG TLHRHNTVRNVLARQLFRVA GLAYSLEVPFLIPNTAARPA DILVQPPPPAPGLPPDXPTA YDVTICSPFRRGMLYHAARH RGGAADAASVRKXKALERTI RXALLIEDDNXPPPLDWHFQ PLSFDALGAPSQSTVHVIED HAKLMALRNSCTIATAKSRI QQRLSFAIWSSAAAAILSRL PTHAADISYPIEV (SEQ ID NO: 1399) CRE CRE- . Acanthamoeba TAACCCTAACCCTCTCCCTC TAAGCCGCGCGACGAGGACG MATTTISRSPSSSSSSSSAR 1_ACas castellanii GGCCCCTCTACCCTAAAGCG GCCAGGACGACCAGGACGAC SRASASTSASVASIPRLFRD CCCTAATCGACCGGCGACGC GGCGACGGCGACCACCTAGC GRFHCPLAHCQTRTSTWQDL CCTAATCGCTACCCTCTACG ACCGCACGCGCCACGACATA SAHLTRMHDGDVPRDVAAAC CCCTAATCGACTTTGGCGCC TTGTCGCGCGCTGTACAGGC GIVQCLHEGCRKWFRGAAGL AAAGCGACTTTCCCCGGCCG GGCTAGGTCGAGCCCAGCCG ASHRGKARHAPPPAPRAALA ATTTTCTTCCTGCCTTTTTC ACCGTTCTGAGCCTCAGTCG VAAVPRADSRGRTPAPTPSV TTTTCTCTCCAAGCGACGCG GCTTGAGCCCCCGGCTTCCC APPXAGPPPRAAPRAAPSPL CCTTTTACTTTGCCGCCGTT AAGGCCTACCGGGGCGGCTC PCPPALPHPPPSASPPTSSV CTGTTTTTTCTTTTCTCTTT TTTTTCGCCCTGGTTTTTGC TSPCSPPTTPPSQPSPDLFS GCACTTCGCTTCTACTTCAC CGGCCTGTTTTTTCTCTCCC GFANAPTTPSPPSTPXSSPA ACCTCCTCCTCCTCCTTCTC CCTTTTCCCCCCTTTTCCAT GSPIPAARRFVLPVATPYPA GACCCGCGCGGCCTCGAGCG TTGTACTTAGTTTTTCCTTC PAPRANRPKLSPVARPFVPK ACTTGCTGCAGCGGCTCCCG GGCCGCGGCAGCTTGTTGCC ARAGAIPEASSPVTPQDRAV GCCTCCCCCACGCGGCCTGC CGGCATAGTGTTAATATGTT SRREDAAAAPSSAPGLGLAD TACTCCCGCTTTCTAGACGC TAAAAAACGTGTAAATAAAT EHEDDDTYGGDTIALTAPHA CCCCGGTCTTGCTCTCAGTC AACTGTTTAACCCTAACCCT PRETRAPFEFEACFLEEEAP TCCCGCATCGAAGCGGTAGT AACCCTAA ATAGDLPPYARAFLACPSAR CGGGGTACGTGCTCAAGTGA (SEQ ID NO: 1278) LQEIPRRLKSAWQAAAKTIA CTCAAGCCTCTTTTCAGCCT EAALDCHTAGDTQGYNAHLR CGGCGCTCTCTCAATCCGCC LFIELPARGLAVPTNCRGAA TCAGTCTTAGCCTTTCAAGT RTKLQRERLLDIAAGRIPAI TGCTCGATTACGCTCTCGAA PDPPCDAPGADDALRGFPVS TCGCTCTCTCTCTCAGTCTC GTTAGDVSNDDDSGGVHDRP AGTCTCAGTCTCAATCTCGA AATASARQAKRLVEQGLSSR TCTTGCCTTCGCCTTCGTCT ALRALERGEPAVASADTLGR CGACGCCTTGCTCTCGWAAT LEALHPPNPTDRGLWPGAPK CGCTGCCACTACGTGCCAGC AAIPRVTAKHLAQVAKELPR TTTTTCGTGCCTTGTCTTCG GSAPGPSGWTFELVQAAIDR TGTCGACCCGGACCGTTTGC QPTGTVAAFLIDMAQRALRG AAGCCCTCGCCTTCGTACCC TLHWRGLLTASRLVALKKPD CGCTCTCGTAGCCGTTCTCA GGVRPIAVGEALYRVIGRLV TCGCTGAAGCGTTCTACGCG LKADRVMSSADATQYVGRHQ CTGGCAGCAAGCCTCGGCCC YGVAYPGGVEAPVHAVRELH TAGCTTGTAGCGCCGCCGGT DSGQLRAVVSLDWRNAFNSL GGCCGCTCGCCAAC DRVHTALLIADRAPALARLY (SEQ ID NO: 1155) EWSYREDSVLVLPRAFEKAG LPASLLSQAGVRQGDVLGPL FFAIGAAPVLDEIDAIPYVT PRAYLDDIFVTIPHGVTDAA TKAAVAATFATAEREGAAAG LRLNRCKSAVWAADAEALLP PHAAGAREDVESCAPVREGL KILGAPVGSPAFVAKSLDGI IKRAIGTLDLVADAELPLQH KLVLLRQCVAQIPTFWARAV PDAGPALAVWDTALLRRTGA LVGLDVRDGSLQADIARLPV RLGGLGLRSMKDTAPRAFVA SILFAAALANTRRSELTCSA STARRLRAALPELARTDACN DEAAWRRSIARGVFPDVDKL GTTQLQRVLQGMADSKSAHR TRRQVPFLFAAVFEDAATPG SGAWLAAIPSDPTLVLPDAE LAEAVRIKLLTTTANAAGVC PACHKTGIDPSHAYTCVSLS HLRTARHDVVVRRVELACKT EKPVREHVLAIPPVAPTDNN NNGDEDGSPVTTADDNADGH AVATKRRPETRASARAAAAA ATAAAAAAIINDNSLLSDDD DDDDHDDNCHGEERGEGERN VTCPGHYTATPFAADDTLDN SDEDNEDNAHEDDDEDGKDD NDDDVYNNCNSSSSDGDEGG DDLDYEYSDQSVTRSVDAAT GESPNPERPTTPTRALLRAD LWLPATSTAVDVMVAAACRR SRAKAFDRAVSRKAAKYGPA VADGSIAKVVPFVVSPFGVL SRPAKAFLKRAMGDTTAAKQ AKARLRLAVAAVRGTARLSY AWGACAALIVGGN (SEQ ID NO: 1400) CRE Cre- . Fragilariopsis ATCAATCTAATACTGAAGGC TAGCACCACCATCTATTCAT MAPLPWNAATSSPPSPVPLT 1_FCy cylindrus AATACCAAACTCAACCCGAA ATCCACACACTGACCACCTC NDKKKDSTLPTATSKNLSKN ATCAAAATCGTTAGAATCAA CACCTTCACAACTCCACTCT NNNKNNNTNRINNIKNNDNT TATACGACCCCCGCTGCTGT CAATTCCCCTGACTACTAAG NDGSNKINLKLPPAAVKITN ACATGTCCAGCCGGATCTCG AAATATTTCATGGTGGTTAC PYKNKKKNKKKNNAGKSNPK TTGTAAAGAAGATTGCAGCT ATTGGAGGTATCCCAACACC TNQNPNSSPLSDNDDDDTDS GTAAAAAAGTTGGACTTCTT AAGCACAAAATGAACCCACT SNITINRRLKFGTDDLAPPN TGTTCTTCCTGTGAAGAAGT AACCCTCTCATCCTATCCAC PPSNTNTIGTATAATAATAT TGATTGTGGCTGTTCAAATT GGGGACCACCTTTGAGCAGA TTATAATATTATNTTTTTTT CTTTTCATAATAAAGAATTA ACACCATTCATATTACAACC TNNTTGDNLASNINNNNNNN (SEQ IDNO: 1156) TTTAGCTAGATTAAGATAAT NSGSNNSNTNNINNTDGNGS TATTTAGTACATATTTTATA NNRPPPRVYTVDPRSDLPGA CTATTAAAAAAAAAAAAAAA EISAANKMLDEVYGDHVHDN A (SEQ ID NO:1279) PGSHLSGLISSSQDQLWQGY FRRLIPHNQSLYDCPKGKLG KDITNEYSNLFEAIMNGKCN MEKLLVFPVVVLQRRHGVTK NADVKRRLLSRLTAWKEGKF KYLVEDTHRDLIAKQSKARG DTTPAHRAKVYSSKLMRGHL QSAVNYITDREGGGILYPYD VDEKSGHTVSRVLQDKHPSM RDPGPTAMPAYESVPELPTL EITADTVEIVAGKLSGGAGL SGVDSIQLKHLLLHHGQASQ RLRNVCAKFGRWLANEHPPW ASYRAMLANRLIALDKMPGI RPVGIGDTWRRFFAKLVLAV SMSYATDCCGSDQLCAGLRA GVDGAIHGLSAMWREMESEE NTGFVLIDADNAFNEVSRIN MLWTIRHEWPAGARFAFNCY RHHSLLVVRNPGGKPFTFFS KEGVTQGDPFAMIAYGVALL PLIRKLKELNVLLVQSWYAD DASAAGKFDEILRLFQDLLR MGPDFGYFPNASKSILITHP DNVVAAHHFFNETHGLGFKI STGSRFLGGFIGDTTSRDEY VSTKIADWIHGTKELAAVAR LKYPHAAYTGITKCLQHKWS FTQRVIPGIDDLFQPLEDEL TNNLLPALFGDPPSTMDDKL RLLTALPVKHAGLALPNPVT SSATNYKNSTLMSSHLLLAV QGKINFSLQDHRDTCQSSLS ASRELRQTENDSSLTNLLAA LPPAAAGQPSTTRAIKRAGE TGLWLTTIPNHINGNILGCD EFIDAIRLRYQKVPHNLPAK CDGCGSAFDVGHALQCKSGG LIIRRHDELNLELASLAKMA LRESAIRAEPEINPSASIMD SPTTITAIDTNGDRGDLLIK GFWDNGMDAIIDVRITDTDA KSYRTRDPKKVLQSQEKEKK KKYLDQCLLQRRAFTPFVVS VDGLIGYEASNVLKQLSKRL ADKWNKPYSVTCGIVRSRIS IACARASNQCLRGSRIPFKT MSRQIQWEDGAGAGLYRIVR (SEQ ID NO: 1401) CRE Cre- . Hydra TTTCTAATGTTACGTGATAT TAACTTGTATTTTTAAATTG MNMVSICKRCDRSFTTLKGL 1_HM vulgaris GATATGGTTAGTTCATGGTT TTTTATTAGTTT NIHKGQCKIFVSNTNKQINN AGTTTATGTTTATGCTTAGT (SEQ ID NO: 1280) VVNNELTTPNKNKVEINTIL TTATGGAAAATCGTTTATTT NCDEISVEHYSTNTPYLPKI ATGGCACAATATTGTTTGCT NICESIIDPNDYLWGHMPFS GTTTTTAAATTTATGTAACG FLLNHVNTIYDEIVFYHKNL TGTGCATTTGATGTATATTC FKVPSGKGGKMFIEELTFWL TTGAACTTTTTAATCTGAAT KQFNNRTKLNGIAMKCFMIV TTTTACTTGGTTTAATACGT PSLMLQKPSIRSKAKEHAEC TTATTATATTCTTCGATTGA LVRRITLWRNGNFSELMREI GCAATTTATCCTATCAAAGC RYIQSKINTSKKKRTFEDIS AATTTATCCTTCGATTCGAG RIFAKLMMEGKVAAALKVLD CAATTTATCCTTCGATTCGA RESSGILQCSESVLKELKSK GCAATTTATCCTTCGATTGA HPDETPVQDNCLLYGPLQNT GCAATTTATCCTATCAAAAT PECLFDSIDEISIFNSALQT TAGCATATATACTGCAATTT KGSAGPSGMDADLYRRVLCS TCAAATAATCTACGAAATAA KCFGPSCKTLREEIATFTKN GTTCACTTACTGAAAATCAT IATKSYQPDIVQPYIACRLI TAAGTAAAAGAAGAAAGGAA PLDKNPGIRPIGIGEVLRRI GAAAAAATAAAAATAAAAAG VGKTISHHCQKEIKEAAGPL TAGTAAATCCTTTCATAACA QTCAGHGAGAEAAIHAMQKI ATAATCATTCTATTATTAAA FHQEDTDGVLLIDARNAFNC TTTAAAGGAATATTTTGGTT LNRSVALHNIQITCPILAMY TTGTACTAAATCATGCGTTC LVNTYRKPAKLFIYGGETIF ATATTTCACCGAAGAAGGGG SKEGTTQGDPLAMPWYSLST GCTGCTATATTTTTGTTTGA VTIINTLKLVIPDVKQVWLA AGTTGTTTATCTTAAAACTT DDATAAGKLQSLKKWYKCLE TAAACTTGTGTTCAACCAAC DVGGLYGYYVNQSKCWLIVK CGTAAACATTAGTTCGCTGT SDNQAEEAKLIFGNSINITT TCGCTCAAATTATCTACAAT QGKRHLGAALGSEAYKKVYC ATAAAATTTATCAATCTTTI EDLVSKWSKELNNLCEIATT TTCGTTACGGTAAACAATAA QPQAAYSAFIKGYRSKFTYF ACAATAAAATAACTATAGTT LRTIEAFENFVTPVEKILSE ATTTTATTGTTTACCGCATA KLLPVLFGTDCSIIKENRDL TTGTTTAACTATAGTTAAAC LALNPSEGGLGICNLITEAK AAAGTATTTGTTTATGGAAC EQHTASKKITNLHIKSILDQ ATTACCAGTATCTCTTGTTA SDVMKEKDDFGKTFSEIKTK AGGTAAACAACAAAACATAG TNMDKSKKKKEEVKKIHAGL ACGGCATCTCTTTTTAAGGT PENLKLLVEQACDKGASSWL AATTAAGTATACGGCTAATA NTLPIKEQHLDLNKEEFKDA ATAAAAATATACAGCTAATA LRLRYNVPLANLPSYCACGE ATAAAATCTTCA KFDELHAMSCKKGGFVCNRH (SEQ ID NO: 1157) DNIRDLLTVCLNKVCTDVQA EPHLIPLTNEKFNFKTANTN DEARLDIKAKGFWRKGETAF FDVRVTHVNSKSSKKQPTKH IFRRHEDAKKREYLERVLEV EHGTFTPLIFGTNGGFGDEC KRFTALLAQKLSLKMGERYG AVINWLRTRLSMEITRASLL CLRGSRTPFRHYNTDDVGLE NVQCGLI (SEQ ID NO: 1402) CRE CRE- . Lactuca ACATTAAATTAGAGAGGTTG TGAACTATATTTTATATATT MASSSTSSSDICLCPFRSFH 1_LSa sativa ATGTTTCAATGGAAGAAGAT AAAAAAA CCPNGEVGSKGIXRMISHIK GAAATTCCAAGAAGCTATTT (SEQ ID NO: 1281) RHHLLTEDRKCVLREALSSD TTGTTGCCCACCAAGTGTTT VGLFMAVEETLKAFGQWMCG GATAAAATGTCCAAACTAAT KCMTLHALSRYCHHPDGRVX TTTTCTCTTGTTGCAGCTTT FVTGADGSSRYIVGILKPST ATTGTTCAAGATAATGTAGT KESVTNALGGLVFDVGLLDR TTGCTTAGTTTGAGCGTTCC VFKEPITTVKSIPHSCRLAF TTGTGCACACCAACAGTGTG SQALKTALYKVIAQPGSVDA TTGGTGTGCCATTTCCTTTC WICLLLLPRCTLQVFRPKNR CTTCCTTTTTAACTATTGCT QECRSGNRKSLQQSSILKSL TCATAGCTTAAGCTTCATCT DTWGKEDGIRKLVQNMLDNP CGAGGCTTGTTCTCTTGT EVGAMGQGGGILQKESTSSN (SEQ ID NO: 1158) TNIRQCLRKVADGHFTAAVK VLCSSGVAPYNGDTIKALED KHPFRPPPSMPSPIISEPPL VADFDCVFGCIKSFPKGTSC GRDGLRAQHXLDALCGEGSA IATDLIRAITSVVNLWLAGR CPTILAEFVASAPLTPLIKP DNGIRPIAVGTIWRRLVSKV AMKGVGKEMAKYLNDFQFGV GVSGGAEVVLHSANRVLSEH HADGSLAMLTVDFSNAFNLV DRSALLHEVKRMCPSISLWV NFLYGQAARLYIGDQHIWSA TGVQQGDPLGPLLFALVLHP LVHKIRDNCKLLLHAWYLDD GTVIGDSEEVARVLNIIRVN GPGLGLELNIKKTEIFWPSC DGRKLRADLFPTDIGRPSLG VKLLGGAVSRDAGFISGLAM KRAVNAVDLMGLLPQLCDPQ SELLLLRSCMGIAKLFFGLR TCQPVHIEEAALFFDKGLRR SIEDMVVCGGPFFGDIQWRL ASLPIRFGGLGLYSAYEVSS YAFVASRAQSWALQDHILRD SGICGMDSDYLCAMTRLRDT IPGFDCSGFTNKDTPPKSQK ALACALFSKIVKDMEVDFDM TVRQKAVFECLRAPHAQDFL LTIPIDGLGQHMSPVEYRTI LRYRLMIPLFPIDEICPVCR KACLDTFGEHAVHCRELPGF KYRHDVVRDVLFDACRRAGI SAKKEAPVNFLTDPQDGRST LRPADILVFGWVGGKHACVD LTGVSPLVGLRSGGFTAGHA ALKAAACKVAKHENACIENQ HVFVPFAFDTFGFLAPEAVE LLNRVQRVMHSNVISPRSTD VVFKRISFAIQKGLAAQLVA RLPSIDMY (SEQ ID NO: 1403) CRE Cre- . Monosiga CATCTTGGCGTGAACCACGT TAGGTAGGCACCGTCTCGGG MATESGGEDSWTQVRGAKRP 1_MB brevicollis TGTCAGACAAAATCTGCAAC GGTCCCTCTGTGGGGATCCC SAESPPSNTTTSPSQTHRSA CCCGCTCTTTGCGGCCCGCG TGTGTGCACCTGTCGCTCCC KHTKHGSARHDRNHVFPDPM TTTTGGCGGCGCCCTCGCTC TAGGTGGTTCCTCGTTGTGT TTPLRPHARHSVPTARASSH CCACCGTGTCCGCTCGCTTG CTTTTGATGGCTTGACTTGT VPSTSPAAGATESSARAVVP CTCGCTTGCTTGCCCCGCGG ATTTTTGTTTTAATTTTGCT AAEPVTRTSNGGGEQHPIIG AC TTAATTTTTGCTGTATTTGT NTSNASPRTPRTPSSPRSFA (SEQ ID NO: 1159) GTGGTATTTTTGCTGAATTT QVAAAMPAAATATSSAPMTE TTGTAAGGTCCTTTGTATGA DLSASVPSEPNGSGEQQPSP TGTCTTTGTCTTCTGTGGTC ESTGQTHHSIPNTPSDFLTM GGTTGTTTTCCTCAATCCGA SSDESDSPPRSTALRAPTPI CGTTGTGTCTCGTTGGATGT APPAHDGDGDTNGSATPEPL GAGCGTGCCGTGGTGTTCTT VQSPTPAQMVLPYPSGTQQT TGTGTTTGTGCTGTGATGGC HSDPSPPSASPPATTILPAA TTGTAGTTGTGATGTGTGAC ISHPVEHSEHANSAPLGEVS TGCCTTTTTGGGTGTCTTGT ESETHNTAGEHSESEQDVLL GTTTGAAATGGCCGTATCTC SDPAPPIAANVLDAQRKVLL TGGTTATACTTGGTCGTTTT KTSGHRQLLACPFGLCKCKG GTACGATTTTTGTTTCTATG PRLDRKAWVNHVLREHPYDE TGCGTGATTCTTCGCGCTTG QATDLVKQVMEAKLVAQCNK TACTTCTTGGCATGATAGAA CHLFFEAAGISQHRSRCGAN GCCAATGAATGTGTCTTGTT LKRATEALFHAAGHDLLEIM CTCTTGTGTTGTTTTGCGTG RGAWPQQCVGSRISVCELLK CCGTCGTGATTTTGATGTCG LARHPLMQRSRYPSNATETK GGGTTGCACAGCTTTGCTTT LMAATLSQLYWSAVHSDYTA CAGCTCTGAGGTTCAAACAC EEREMCWALILALPSMLLSA CTAATTTA PSTALSTIDLRNMFHDRLRW (SEQ ID NO: 1282) LVTGQLGRVVDAMRKAVARK QSRRGQLNAGAGAHPNDAVD QSLRSLVRDPDLADEAWANH VTNRLNRGQIAKAFDADKAR AVIGNSEVQAVRDLLVPPGL TPYIASTPASTSTLAPATAV SSPTVSFTKGELPKALAATK GVTDPYGWSGELLASIYRIK EHFSQVLGPRQGSTSDPTAP SDGDAPQGPTTATGGPQVAL NKIFHHIANNTVPESIRHAL CSINYTILEKANGKFRPVGT DSIFNKVVNRALLEQQQPHI AHLLQASPELAVGVKDGISA AVGMAFGELQACESTPGWTM LSLDFKSAFNYTDRARLHEI VADKVPGLLRAFERHYARPT THCIVDKFFKVIDIDVGQGI VQGNELSPFFFALYSCEVLG LLDATTDYRCKVIKYLDDIV LMGPAEDVAADVEIVKARAE SAGLHLQPSKSRFYMPRHHS ASITAIKSVLPDAVRETANT GMTVLGTPIGRREWMKKQLN DKAKHIAGKLNDMLTTGVSL QALLTAMQYVPSLINHLYTL PPSLTSGLSELLNRACKDTF VKAFFAKVNLSAPAGAEGHD VTLEQLLEARLFTRANTGGF GLHDLVERGPVAYVCNMAKL ATRYPRVYDRLLEDASRAAD FEAHVORAGFQMATVKDAAT QRPAEIIALRSKAALDDLMA KCALDLQQAYLASREWGVST VLTMRGRDKLRRLSDTTFAI AVVSMMGFGLHELINVKPTD KCPLCSSKTPQPRLTREHLL TCRPIKRHNALRDEMGRLLR YATLSHVWVEKSGYNANGQS CRIDLHCRNPFPGGALGPAL PDLGIDVTVRTAQPPTTSQA CIKVGAALRRAEKEKRDYYT GFNHGKTLIVPAAMTTTGGF ASSFVDLLGQLARCAEARGV YQPGLDEAFVPRWKGRFAAL VHQMNADHIQRHFGGVCLRS S (SEQ ID NO: 1404) CRE CRE- . Hydra AATTTAAAAAAAAAAAATCG TGAGCTCTTATAAATTTATA MSSCKVTIPHVCPYCKVELK 2_HMa vulgaris TTTATTTATGGCATAATACT TTATAGCATTTTGTTTTA TICGINRHILKCKKNPLQIP GTTTGTAATTTTTGAAAATT (SEQ ID NO: 1283) SLQKTNTSLTLEPNTKVIPS CGTGCAACAACTGCAGTTAA ITKQNDIIIASTSSNNLAFN ATTGAAGAGCTGAAATTTAA QKKDYTLTPTYSRKTTPVSI GATCTGAGCTTTTCAATCAG LSSMKMTPISITSHIVRRKL AGTTTTTTACCCTAAAACAT PELPSQTTNHLFNENFINVP TAAATTTTATCATAACAAAA FLPEIMNHLPVPNNNVMWGV ATCGTTCTAATATTATTAAA YSYQQFKLFVDSTYDEIVNY CTTAAAGAAATTCGTTCTTA RRNIFNIPSGKAGKEFIEEL TATCAAATCTTATTTCAGTG TFWLRKFNSTSSLNSIALKV TTTCACAGACGAAGGGTTTT TMILPNLLLQKPSAKSKSKE ACTAGATTTTTATTTTTTCA HTLCLTRRIDLWKKGDTSLL ACTTTTGAATTTGTTTATTA LKEVRNIQKKFVNSKXKRSM TAAAACTGTAAACTAGTGTG DDISRIFAKLIMEGKITAAL CAACCAACCGTAAAAAWTAG KFLEKEASSGILPLSDNTLK TTAGCTGTTCACCCAAAATA DLKSKHPEPSRVEDYSLLFG TTATTCAGTATGAAAATATT PIDLIPKCFFDCIDEQLVMK TAATCTTCTTTATTCGCAGT AAFATKGSAGPSGMDADIYR AAACAATAAAATATCTAGTT RILCSKNFIKEGKELRKEIA AAACAAAATATTTCTTAATA KMTQNLLTETYEPTFLEAFT ATAAAAAACAAAAACTTTTT ACRLIPLDKNPGIRPIGVGE CTTAACAAGTACA VLRRIIGKVISWSFNSEIKE (SEQ ID NO: 1160) AAGPLQTCAGHGAGAEAAVH AMKEIFDNVQTDAILLIDAK NAFNCMNRQVALHNIQIICP LISIYLINTYRNPSRLFVAG GKEISSQEGTTQGDPLAMPW YSCNTTIIIEHLLVNYPQVK QVWLADDAAASGSIANLHSW YQHLIDEGCKHGYYVNQSKC WLIVKSPSLAENAGIVFGKS VNITTEGQRHLGSVIGSQNF KNKYCTEKVAKWLTELKQLC KVAETQPQAAFIAFTKGFRS KFTYFLRTIPKFEQYLAPVD EILSHLLLPTLFGKDTPFED HIRKLFTLTPRDGGLGIPIL VEEAPHQFLSSVKLTKNLVQ QIIDQDKILKTKNSSGNVLE DLEKILTTDRLKHRKEKIIA VDSMQPDSMLRNIQQTRSEC ASTWLNALPLENQGFVLNKE EFRDALCLRYNFDLKNIPRI CECGEPFNVTHALSCKKGGF ISSRHDNIRNLFTTLLKRVC INVQSEPHLIPLDNENFYFH TANKSNQARLDIKANGFWRN GQTAFFDVRVTHVNSMSNKN LDIAAIFRKHEKEKKREYGE RVREVEHGSLTPLVFGTNGG MGKECHRFVRRLAEKLAEKQ NEKYSVVMTWLRTKLSFEIL RSTILCLRGSRTPWTKKNDF EIGVDFKMDALEARI (SEQ ID NO: 1405) CRE MoTe JQ747 Magnaporthe CCCGAACCCGAACCCAAACC TAATAGGTAACGTCCCTATT MVCPTCNGVYADYNDHIRKK R1 487 oryzae CAAACCCAAACCCAAACCCA TTTGTCTTTGGTTTTGTTTT HPDERYTALQLQPLGLTPCP AACCCAAACCCAAACCCAAA TATCTTTGTTTTTGTTTTTG ICKTACKNDLGVKTHLSKIH CCCGGAGGGTTCCCAAGTCG TTTTCGTTTTTGTTTTTGTT KISGASKISTQPRIRTENTD CCTAAACCCGAAGGGTTTAG TTCGTTTTTGTTTTTTTTTT NTNSVPTSSFNPVLPEIQTL GATATTATTTCGTTTATTAG TGTTTTTGTTTTTGTTTTTG TPGLNNSRWADNPRKRRADT AATTGGATAATTATTTACCC CCTTTGTTTTTGTTTTTATC PSPTRGRNTRPRRFSYTDID CTGTTGGACAGGGGGGTTGC TTTATTTTTGTTTTTGTTTT LTNDEPADNPRANNPRVNNP AGGGGTTAAATTAAGGTTTT TACTTTGTTTTATTTGTTTT RVNNEPPSSPNSLPSISEFH TTATTATTTATGCGCCGTTT ATATTTACCTTTTGATTTTT TPGTLPLTNSNISLKDQHDK ATTTGTTTACCCCCCCAAAT TCTATTTTTCCCACCCTTAT ITGPILQKPLIQKLIEYSKI ATTATAAAAGCGCGTTCCAT TATTATAACCCCAACCTACT PIPEHHLHARQAKIFADAAN CCTCTTAGGAAAAGCGAAGC AATATTTTTTCTTTTTTCTT RIAKNFIQSPTEKTLFNLLI TTTTCCTTGTAAAAGTCGCT TTTTCTTTTTACGGTTTTAT LPRIFGIGLINGKVTKIMQN AGACTTTTACTATAAAAGTC TTTCCCGTTTGTTTTTTCTA FPSQIPPIPKIDFPSEKTDS GCTAGACTTTTATACCAATC TTTTATTTGTACGACAAAAC DPVLNAKKLLEKGYIGRAAK TTTTAACAAAAAGCGTAGCT CCTTAGCAAATAAGCTTAGA AIIDPTPVAPETPESLNILR TTTTGTTGCCAATCTATTAA ATATAATAAAGCGCGAATTA EKHPIGQNNPFNTKSQPISG AAAAAGCGGAGCTTTTTTTA AAA RQITEKAILLAISSIGREKA ACTTTTTCTTTTTTTTTTTT (SEQ ID NO: 1284) PGLSGWTRSLLDAAIKIPTQ TTTTCTTTTTTTTTTTTTTT NDVIPALRLLTDMIRQGTAP TTTCTTTTTTTTTTTTTTTT GRELLCASRLIGLSKPDGGV TTTTTTATATATATTATTAT RPIAVGDLLYKIAFKAILNT TATTATTATTAGCGGTGGGG LWSPNCLLPYQLGVNSIGGV CTATTTATGCGCTTTAATTT EPAIFTLEEAIMGPNINGIK GTGCGGGGCTATTTATGCGC SITSLDLKNAFNSVSRAAIA TTTAATTTGTGCGGGGCTAT SSVAKYAPTFYRSTCWAYNQ TAATGCGCTTTAACTTTACA PSILITENGSVLASAQGIRQ AATTTTATTTATGCGCTTTA GDPLGPLLFSLAFRPTLETI ATTGCTGCGGGCCTGTTAAT QKSLPYTYIAAYLDDVYILS GCGCTTTAATTTACAAATTT KTPVKDKIAKIIEKSPFTLN CATTAATGCGCTTTAACTTT SAKTTETDIDTLKTNGLKTL TATATTTACTAATGCGTTAT GSFIGPTELRKEFLQNKIQN TTATATAATTGCTATTATTA FESSINALKKLPKQYGLLIL TCGTTGCTATTATTATTATT RKSTQLLLRHLLRTLNSQDL GCTATTATTATCGTTATTAT WELWEKTDKLIADFVINLTV TATTGCAATTTTATTATATA TKRKKRPITDFVTPLITLPI AACCCTCGTTTGTCCCTCGA KDGGFGLLRHNGIAQDIYFA TTTATCCCGTTTCTTTTCCA AKDLTTEIRHKIQRISNDFP TCCCATCGCGCGTTTTCGTA QNQSPTATEILHLLHNGVLA AGCTTTGGTTTTCGTAGGAT DCKNGLTNAQLNALTENASY TTGCTTTCGTAGGCTTTGCT LGRKWLNILPIQKSNRLTDW TTCGTAGGCTTTCGTCAGCT EMAEAVRLRLLAPVKPLTHP TTTACCTGCTTTTATTTTTT CNHCGNRTNINHEDVCKGAV CTTTTTCTTTTTATTCCCCC RKYTARHDQINRSFVNSLKS CCCTTTTTTTTACCTGGTTT RPEIDVEIEPDLNNENNVNN ATTAGCGGTTTACCTGCTTT ANTTTENPTPSPNGQNDTGC TATTACCTGGTTCCCCTTTA LFTTPIRSGTRNGQNGLRAD CCTGTTTTATTAGCGGTTTA FAVINGVSKYYYDVQIVAIN CCTGCTTTTATTACCTGGTT KDSGNTNPLNTLADAANNKR CCCCTTTACCTACTTTATAA RKYQFLDPFFHPIIISAGGL GCGGTTTACCTGCTTTTATT MEKDTAQAYKQIQKLIGPVA ACCTGGTTCCCCTTTACCTG AHWLDTSISLILLRSRTTAA TTTTATTAGCGGTTTACCTG ISIAKNRPRA CTTTTATTACCTGGTTCCCC (SEQ ID NO: 1406) TTTACCTGTTTTATTAGCGG TTTACCAGCTTTTATTACCT GGTTCCCCTTTACCTACTTT ATTAGCGGTTTACCCGTTTC TATTAGTGGGCATTTATTTC CCGTTTTTATTAGCAGTTAA ATTTACCCTTTTAAGGTTAT TTACCTGCTTTTATTCACAG GGCACCCCTGTTTTTACTAG CAGTTAAATTTACCTTTTTA AGGTTATTTACCTGCTTTTA TTCACAGGGCACCCCTGTTT TTACCAGCAGTTAAATTTAC CTTTTTAAGGTTATTTACCT GCTTTTATTAACAACCCTTT ATTTTTTCCTATTAACGGGT ATTTATTTACCTGTTTTATT GGAATTCACCCGTTGGACGG C (SEQ ID NO: 1161) HERO HERO- . Branchiostoma TTTTCAGTCTGGCTCAGCCA TGATTAAAGACCCGAAACAC MNAVCVCGKVCKNQRGLRIH 2_BF floridae GTGACCGCCGGGAAAGTCCG CCAATGACCCCGGGTTCATC QTKMACLRRVQAEHRSGAVA GCTGACTACCACGAATAGGG ACTGATGATGTGTCCCTGTT TTVEPVLSASAPGQTEEDQG TGGTGACAGCTGGATAGACA CGCACTACCAGAGTGTATTC PEAPHSARNLRATPAPPQGR GACGACAGCTCGGAAAGACG TAGAG KSDHHRVKWPAANSKEWSQF GCATTGGGGCAGTATGGGTT (SEQ ID NO: 1285) DEDVDMILESVSRGSTDQKL GGCACCCCTAACTGCATCTC QSMCTVIMSMGAERFGTIGQ CCCTAGGAGAGCATCCCGCA RKPTDTMKPNRREVKIRQLR ACACGCTACAAAGAACCACA QELKSLRRSFKASTSGEERA AAGAGCAATACCCCCAGGGA ALAELTHHLREKLRTLRRAE TGCCCGAGAGGGGGGGAGGA WHKKKGKERARKRSAFITNP TGAGCATCCCATTCGGACGG FGFTKRLLGQKRSGNLTCPV TCCAATCGGTATTGACCCCA EEINLHLSNTFSDASRDVDL GCAAACGGAGAATCGACA GPCPLLVTSPEPEVHFDISE (SEQ ID NO: 1162) PTLKEVRETVKAARSSSAPG PSGVVYKVYKHCPRLVVRLW RILKVVWRRGKVAADWRQAE GVWIPKEEESSKVDQFRLIS LLSVEGKIFFKIVAQRLIKY LLDNQYIDTSVQKGGVPGVP GCLEHTGVVTQLIREAKENR GDLAVLWLDLANAYGSIPHK LVETALTRHHVPESIQNLIL DYYSNFWLRAGSSTATSAWQ RLEKGIITGCTISVPLFALA MNMIVKGAEAGCRGPVSRSG TRQPPIRAFMDDLTVMTATV PVCRWLLQGLERLITWARMS FKPAKSRSLVLKKGKVAERF RFTLGGTQIPTVSEKPVKSL GKVFNSSLKDTASVQQTRSD LTTWLEGIDKTGLPGSFKAW MFQHGVLPRVLWPLLVYEVP MTMVEQLERTISRFLRKWLG LPRSLSNIALYGRSTKLQLP LSGLTEEFKVTRAREVLMYR DSSDSKVSSAGIHVRTGRKW KAQEAVDQAEARLRHSVLVG SVAVGRAGLGSCPKPRYDKV SGKEKRLLIQDEIRAGEEED RRCRMVGMRKQGAWTRWEHA DSRKVTWPELCRAEPSRIKF LISSVYDVLPSPANLHVWGL AETPSCQLCQRRGTLEHILS CCPKALGEGRYRWRHDQVLR VLADTVSNAIQSSRSQQPPK KSIVFVRAGEKTRQQPTSAG GLLSTARDWQLLVDLGRQLK FPEHIVATSLRPDMVLVSES TRQVVLLELTVPWEERISEA NERKRAKYAELVVQSQSNGW RARCVPVEVGCRGFAGQSLA YVLKLLGVRGFRLRKSIRDI LEAAEKASRWLWFRRGEPWK PHGHRSGNDQPRLGRPGEGV W (SEQ ID NO: 1407) HERO HERO- . Danio TTCAAGCCTGGCGCAGCCAG TGATCAACCCCGGCTGGGTC MTHANEQTTNKIYVTCICGK 2_DR rerio TGACTCCTAGGAATAGACTA ACCTGGGTGAGAGTGTATGA LCKNHWGLKIHQARMKCLEQ GGTGGCAACCAAGAATAGTT TGTTGAGAGACCCGAAACAC ESKVQRTGPEPGETQEEPGP TGGTCGACTACTGGAGAGAC TCAATGATCCCAGGATACAT EATHRAKSLHVPEPQTPSEV AGTTGACGGCACGGAAAGAC CACTGATGATGTGTCCCAAA VQQRIKWPPASKGSEWLQFD GGCACTTGGGACAGTATGGG TGCATCCATGAGATGTTTCT EDVSNIIQAIAKGDADSRLK TTAGCACCCCAGCCTGTGTC TGCATAA TMTTIIFSYALERFGCIEKG TTTCGTGAGAGAGAACCCAA (SEQ ID NO: 1286) KTKPTTPYTMNRRATQIHHL ACAAGCTACGGAAAGCCCCA RQELRSLKKLYKKATDEEKQ CAGAGATATACCCCCAGGAG PLAELKNILRKKLMILRRAE ATCCCGAGAGGGGGGGAGGA WHRRRGRERARKRAAFITNP TGAGATCTCCAATCGGACGG FGFTKQLLGDKRSGRLECSI ATCAAAGGTTA EEVNRFIEETVSDPLREQEL (SEQ ID NO: 1163) EPNKALISPTPPAREFSLRG PSLKEVKEIIKASRSASTPG PSGIPYLVYKRCPGLLLHLW KILKVIWQRGRVAEQWRCAE GVWIPKEENSKNINQFRIIS LLSVEGKVFFSIVSRRLTEF LLENNYIDPSVQKGGIPGAP GCLEHTGVVTQLIREAHENR GDLVVLWLDLANAYGSIPHK LVELALHRHHVPSKIKDLIL DYYNNFKMRVTSGSETSSWH RIGKGIITGCTISVILFALA MNMVVKSAEVECRGPLTKSG VRQPPIRAYMDDLTITTTTV PGSRWILQGLERLIAWARMS FKPSKSRSMVLKKGKVVDKF HFSISGSVIPTITEQPVKSL GKLFDSSLKDSAAIQKSKKE LGAWLAKVDKSGLPGRFKAW IYQHSILPRVLWPLLIYAVP MSTVESLERKISGFLRKWLG LPRSLTSAALYGTSNTLQLP FSGLTEEFMVVRTREALQYR DSRDGKVSSACIEVRTGRKW NAGKAVEVAESRLQQKALVG TVATGRAGLGYFPKTLVSQV KGKERHHLLQGEVRASVEEE RVSRVVGLRQQGAWTRWNTL QRRITWANILQADFQRVRFL VQAVYDVLPSPSNLHVWGKN ETPSCLLCSGRGSLEHLLSS CPKALADGRYRWRHDQVLKA IAASLASAINTSKNHRAPRK AVHFIKAGEKPRALPQLTTG LLHKASDWQLEVDLGKQLRF PHHIAATRLRPDIIAISEAS RQLIILELTVPWEERIEEAN ERKRAKYQELVEECRERGWR TYYEPIEIGCRGFAGRSLCK VLSRLGITGVAKKRAIRSAS EAAEKATRWLWIKRADPWTA VGTQVGT (SEQ ID NO: 1408) HERO HERO- . Branchiostoma CTGACCAGCAGACGGGAAGC TAGAAACCCACAAGGCTGAG MALPAVRSGPASTWTLLITL 3_BF floridae CCGCGACCAACTAGTCTCCG AAATGTAGAGCATCTGTATG VIVAAKGTDGFMSFKLPLLS CAAATATTGCACACAGGGCG GACAATATTGATGATTGAAA TDTWSGYNNDVKTLLGPLHH ACCCTATGGAGCTGATTCAG TGTTGTGATTTTAGATCAAA ELATNEMSPKLAGEGFSDIM TCAAATTTCCTCTGAGATAT TTTAGAAATATGAAAACCGA CDFMASKPEFSHTTEESHSE ACCGATAACTATCTACAGAA ACTAAACTAAATATAATGTT GYISHEPQSLAQVKRLKNKL ACTGCACAGTTAGTTTGGAA TTTTTTAAAGTAATGATAAG RKKAFRADATPEDRKAFRDA AGAGCTTTTCTACTGAAAGA CAATACCCACATTGTGCAAT IKTYSFMKRQQKRKETTKSA CAGCAAAATCCGCCACTTTA ACTATCTATGTTATGTCCTT AHQEKEYHKNFWKFAGKCAK GACGAGCGTCAAGACTGCCC TGTCCCCCCTGCATGTTTGG GQLDIPPVKPAFSVYYANEY TCCCCATAACCAAT TCAATAATGACCATCGTGTC YKNKYSHPTRVDFNKLLWFP (SEQ ID NO: 1164) CTGGGCTCCGTGTACCTTTC HLPVEEQLPANSFDMSPVRP TTTACTATGAATAAAGAATG KDIKAVLSKRCATSAPGPDG ATTTTACTAC IMYGHLKHLPACHLFLSTLF (SEQ ID NO: 1287) SKLLESGDPPTSWSSGNVSL IHKDGSPEAAENFRMICLTS CVSKIFHQILSERWAKYMTC NDLIDPETQKAFLTGINGCV EHVQVMREILAHAKKNRRTV HITWFDLADAFGSVEHELIY YQMERNGFPPIITTYIKNLY SRLKGKVKGPGWESDPFPFG RGVFQGDNLSPIIFLTVFQP ILQHLKGVEQQHGYNLNDKH YVTLPFADDFCLITTNKRQH QKLITQISSNTKSMNLKLKP RKCKSMSIVSGKPSDISFTI DGDPVKTTKDAPEKFLGGYI TFLSKTKETYDILAKTIETT VENINKSAIRNEYKLRVYME YAFPSWRYMLMVHDLTDTQL QKLDSIHTKAIKTWLRMQPS ATNAILYNTRGLNFKSISDL YLEAHALAYSRSVLKADEKV KHALQAKLDRESQWTRKMQK WGIGKCHTIHQQAIHVAKDS EWTSVRKHVKQQVTDMRHDV WTKHQENLLQQGQMLQLLEE EKCDLTWRSAMYNLPRGILS FAVRASIDALPTLCNLTTWG KRNTDKCKLCGNRETLHHVL NHCGVALQQGRYTFRHNSVL KHITDTIIESIDTSRINATI YADIQGYTTNGGTIPVHTIP TTQKPDLIIYLPEQKTLHIH ELTVPFEKNIKTSHDRKVNK YSTLAADLETAGISATLTCF EVGSRGLVTPENKTRLRTLF KIVKAKPPKTLFTDISRIAM LSSYAIWNSRHEPYWESETL L (SEQ ID NO: 1409) HERO HERO . Danio AAAGCAGTAGAG TAGCATGCCACTTGGACACA MTTHRAEVTTSGKTQEEPGP Dr rerio (SEQ ID NO: 1165) GGCCGGGGTCTGATCAGCCT EATHSAQSLLVSPTPAAGRS CGGTCGGGTCGCCTGGAGGA PATQSCPQVTAAHNSPQSPQ GGGTGTCTGTTGCAAGACCC SQQVAVTRSDCVPLAQPRIQ GAAACACCCTGTGAGCCCAG WPQSSKKAEWLQFDKDVNQI GAAACAACACTGATGATGTG LEVTGKGGVDQRLSTMTTLI TCCAAGGTTGTGCATCAGGA VNIAAERFGTVTPKPTPSTY GATGTTTCTGTAAC TPSHRVKEIKRLRKELKLLK (SEQ ID NO: 1288) RQYKAAGEVERAGLEDLRGI LRKQLVNLCRAEYHRKRRRE RARKRAAFLANPFKLTKQLL GQKRTGKLTCSKEAINNHLK ATYSDPNREQPLGPCGALLT PPEPTSEFNMKEPCRSEVEE VVRRARSSSAPGPSGVPYKV YKNCPKLLHRLWKALKVIWR RGKIAQPWRYAEGVYIPKEE KSENIDQFRVISLLSVESKI FFSIVAKRLSNFLLSNKYID TSMQKGGIPGVPGCLEHTGV VTQLIREAREGRGDLAVLWL DLTNAYGSIPHKLVEVALEK HHVPQKVKDLIIDYYSKFSL RVSSGQLTSDWHQLEVGIIT GCTISVTLFALAMNMMVKAA ETECRGPLSKSGVRQPPIRA FMDDLTVTTTSVPGARWILQ GLERLVAWARMSFKPAKSRS LVLRKGKVRDEFRFRLGQHQ IPSVTERPVKSLGKAFNCSL NDRDSIRETSTAMEAWLKAV DKSGLPGRFKAWVYQHGILP RLLWPLLIYEVPMTVVEGFE QKVSSYLRRWLGLPRSLSNI ALYGNTNKLKLPFGSVREEF IVARTREHLQYSGSRDAKVS GAGIVIRTGRKWRAAEAVEQ AETRLKHKAILGAVAQGRAG LGSLAATRYDSASGRERQRL VQEEVRASVEEERTSRAVAM RQQGAWMKWEQAMERNVTWK DIWTWNPLRIRFLIQGVYDV LPSPSNLYIWGRVETPACPL CSKPGTLEHILSSCSKALGE GRYRWRHDQVLKSIAEAISK GIKDSRYRQATAKVIQFIKE GQRPERTAKNCSAGLLSTAR DWVMTVDLERQLKIPPHITQ STLRPDIILVSEATKQLILL ELTVPWEERMEEAQERKRGK YQELVEQCRANGWRTRCMPV EVGSRGFASYTLSKAYGTLG ITGTNRRRALSNNVEAAEKA SRWLWLKRGEQWGQ (SEQ ID NO: 1410) HERO HEROFr . Takifugu AGACTAGGTGACAACCAAGA TGATCACCCCGGCTGGGTCG MTPAMEMTTTVTCICSKLCK rubripes ACAGTTWGGTCGACTACTGG CCTGGGCGAGGGTGTATGAT NQRGLKIHQARMKCLEREVE AAAGACAGTTGGCAGCTCGG GTCGTGAGACCCGAAACACC VQRTGPGPGETQEEPGQEAT AAAGACGGCACCCGGGACAG CTATGAACCCAGGATACATC HRSQSLHVPEPPNPNRVVQQ TATGGGTTAGCACCCCAGCC CTGACGATGTGTCCCAGTGC QRIKWPPANRRSEWLQFDED TGTATCTTTCGCGAGAAGGA ATCCAGGAGATGTAKCTTTA VSNIIQATAKGDVDSRLQAI ACCCAAACAAGCTACGGAAA AGT STIIVSYGSERFGRIEKGNT GCCCTACAGAGAAACACCCC (SEQ ID NO: 1289) ETTSYTMNRRSFKIHQLRKE CAGGAGATCCCGAGAGGGGG LRTLKKQFKRAXDGDKQALK GGAGGATGAGATCTCCAATC ELYNILRKKLKTLRRAEWHR GGACGGACCTAACGTTA RRGRERARKRAAFIANPFRF (SEQ ID NO: 1166) SKQLLGDKRSGRLECSREEV NRFLQNTMSDPLRGQDLGPN RALISPAPPSAEFKLAEPSL KEVEEVIKAARSASSPGPSG VPYLVYKRCPEILRHLWKAL KVIWRRGRVADQWRCAEGLW IPKEEDSKNINQFRTISLLS VEGKVFFSIVSRRLTEFLLK NNYIDTSVQKGGIPGVPGCL EHNGVVTQLIREAHESKGEL AVLWLDLTNAYGSIPHKLVE LALHLHHVPSKIKDLILDYY NNFRLRVTSGSVTSDWHRLE KGIITGCTISVVLFVLAMNM VVKAAEVECRGPLSRSGVRQ PPIRAYMDDLTVTTTSVPGC RWILQGLERLILWARMSFKP TKSRSMVLKKGKVVDKFRFS ISGTVIPSITEQPVKSLGKL FDSSLKDTAAIQKSTEELGG WLTKVDKSGLPGRFKAWIYQ YSILPRVLWPLLVYAVPVTT VESFERKISSFLRRWLGLPR SLNSAALYGTSNTLQLPFSG LTEEFKVARTREALQYRDSR DCKVSSAGIEVKTGRKWKAE KAVXVAESRLRQKALVGAVA TGRTGLGYFPKTQVSHARGK ERNHLLQEEVRAGVEEERVG RAVGLRQQGAWTRWESALQR KVTWSNIMQADFHRVRFLVA AVYDALPSPANLHAWGKSET PTCSLCSGRGSLEHLLSSCP KSLADGRYRWRHDQVLKAVA ESIALAISTXKHHHAPKKAI SFIKAGERPRAGPQITTGLL HTAXDWQLHVDLGKQLIFPQ HIATTSLRPDMIIISEASKH LIMLELTVPWEERIEEANER KRAKYQELVEECRGRGWRTF YEPIEVGCRGFAGRSLCKAF GRLGVTGTAKKRAIKXASEA AERATRWXWLKRADPWVATG TQAGS (SEQ ID NO: 1411) HERO HEROTn . Tetraodon AGATTGGTCTGGCTAAGCCA TGATCACTCCCAGTCGGGTC MATTQASVKPTAVATCVCGK nigroviridis GTGACGTCCAGGAACAGACT GCCTGGGTGAGGGGGTCTGA ICKNPRGLKIHQTKMGCLAS GGCTGACGACCACGAATAGA TGTTGAAAGACCCGAAACCC VQPEQRARFSLSESREVPAR GTGGTGACAGCTTGGATAGA CCGATGACCCCAGGTACTAT AEPYGPQQPHSPEALGETQE CAGCTGACAGCAGGGAAAGA CACTGACGATGTGTCCAAGA ERGQESPHSAQNLRAQVAQA CGGCAACCGGGGCAGGAAGG CATGCATCAATAGGTGTATT PDNPQHHRRVKWPPASKVSE GCTAGCAACCCAGCCTGCAT TAGAAATC WQQLDEDLEGILESTAKGGV CTTCCGTGAGGAAGAACCCA (SEQ ID NO: 1290) DRKLQTMTTLVISFATERYG AAACTTGCTACGAAGAGCCC TMEKRAAPEKYTKNRRAEKI GAAGCAAAGATACCCCCAGG SQLRQELRVLKKQFKGASED GGAGCCCGAGAGGGGGGGAG QKPGLAELRCTLRKKLLTLR AATGAGCTCCCCAAACGGAC RAEWHRRRAKERAKKRAAFL GGATAAC ANPFGFTKQLLGQKRSAHLE (SEQ ID NO: 1167) CAKEEVDSYLHDTFSDAERE NSLGECRVLISPPEPACSFN TKAPTWKEIQTVVRAARNNS APGPNGVPYLVYKRCPKLLA RLWKILRVIWRRGKVAHQWR WAEGVWVPKEEKSTLIEQFR TISLLNVEGKIFFSILSHRL SDFLLKNQYIDSSVQKGGIP GVPGCLEHCGVVTQLIREAR EGRGSLAVLWLDLANAYGSI PHKLVEMALARHHVPGPIKT LIMDYYDSFHLRVTSGSVTS EWHRLEKGIITGCTISVIIF ALAMNMLAKSAEPECRGPIT KSGIRQPPIRAFMDDLTVTT TSVPGCRWILQGLERLMTWA RMRFKPGKSRSLVLKAGKVT DRFRFYLGGTQIPSVSEKPV KSLGKMFDGSLKDAASIRET NDQLGHWLTLVDKSGLPGKF KAWVYQHGILPRILWPLLVY EFPISTVEGLERRVSSCLRR WLGLPRSLSSNALYGNNNKL TLPFSSLAEEFMVTRAREVL QYRESKDPKVALAGIEVRTG RRWRAQEAVDQAESRLHHKE LVGAVATGRAGLGTTPTTHL SRLKGKERRDQVQLEVRASI EEQRASQWVGLRQQGAWTRW EEAMARKISWPELWRAEPLR IRFLIQSVYDVLPSPSNLFL WGKVESPSCPLCQGRGTLEH ILSSCPKALGEGRYRWRHDQ VLKAIAESISSAMEYSKRLP LPGRGVRFVRAGEQPPPQPR AQPGLLATARDWQLRVDLGK QLKFPENIVETNLRPDIVLH SQSSKQVILLELTVPWEERM EEAYERKAGKYAELVEDCRR AGWRSRCLPIEVGGRGFAGK SLCKAFSLLGITGMRRRKAI CAASEAAERASRWLWIQRDK PWTSASWTQAGN (SEQ ID NO: 1412) NeSL LIN9_SM . Schmidtea AAACGACATCATGAACGCTT TAAAATGGCAAAAAGATATT MMDSRQLNTPKIRKYQNPKM mediterranea GGCCGCAACAATCCAGTTAT TCAAGATGAATTGTGGACTC TNDIMKSYNYAVLSDVTPQE CCCTGCGGTAACATTGTGGA ATCTAAAAAATGACCACCTT TTQTTTHLNVDIDNETTQPK ACTCATAAGACAAGTACTAA GAGTCCAAATATGCCTAGCT QPLTKSGKPKSKPIAVSYKF AAGAAGAATTAGAAAAATTA ATCATGGTTGCTGATGGAAA KDATFIWDTTPQTNPPRDCT GAAGAAAAAATTGAAAATAA CAGTAAGGCACCTGATAGCT KLIDKTRPRKTIFKKSAFQS TTTATTTATAAAATTTAAAA AACTTTTCACTGTGAATATC YLKKELSNETFVEVKTFLMA ATTTAAATAAATTTAAAAAT TTCAGATATTCACAGTGACA THKYRFKDENSRLLAYRIIN TTAAATTTAAATTTAAATGA CGAAAGGACACCACTAGTAA RYVMETANEFKETEFDMARF AGATAAAAATTTATTTAATC AAACCACTAGTTTTTTCTGA AKFFTIPENWLKHLKPYSTA CAATAAATAATCAAGAAAAT CACCTCTTGCTACAAACTCT TETSPADRIKVQKLVDLTCR CAAGAAA GTAAAAATCAAAAGGATCGA YPFKTQEEQTSVANFLHFFT (SEQ ID NO: 1168) TAGGCCGCGCTTTCACGGTC QRSIIGISRDYKFQKFIPFM TGTATTCGTACTGAAAATCA ARKNTRPETTSTMVTTSPTE AGATCAAGGAAGCTTTTCCC QNRLPMVIITPLEEPKSEHR CTTTTAGTCAACACCAGGTT RPEKRGASNDTIVLSDEEFP TCTGTCCTAGTTGAGCTTCC LLKRRTLPTRKSKNPTGAGN CTTGGGACATCTGCGTTACC VPTETECTDEVKFILNNEYQ ATTTGACAGATGTACCGCCC IECKECGKVWENVRNGLNHL CAGTCAAACTCCCCACCTGA RQKHDFPNRTDVMVSCVRCE CACTGTCCTCAAAACAGTTC VPIKGAECVNHIKNHKKDDK AATTGCATCCGAAGATCGCA EESEAGSLVANTQDIPNESS ATTTTTTCACTAAAATAAAT LSQAAIEVYLRNILKMKENQ TAACAAAAGTTAATTATACT ERNIQYLEPSTANFLINRNL GCTTCATTGAGTAAGTAGAA RAFYQNVKIEKLIGWEQVIW AAACAATC LIHWNKCHWIVYLANCDSKT (SEQ ID NO: 1291) SVILDSDNQMTLQQRCNIKA KFDKFLEGTFEEKTVLGTLE RKVPQQPNNFDCGIYVIQYI SDFLKDPQRIDYHTPDSKRI RKEIGELILEEMKNPASKIK NPNKEIQSLLOKFRLLQINV NDVFHWFAAEYQKSLPKIRT KRDGKLNKLSCSYQIQRLFG LAPKRAVKEIYFQETSTADL ETRVLNEHFKKDESTMKECK IKNGNHYQDWITKAQIDNKE ILEALKNSTDSAPGEDNIPL RQWIIWNNDGVLFDMFNYIK RTHDIPDMWKNYTTTLLIKP GKSQESNIPANWRPISILPT SYRIFMKVLNKRVLEWANRG ELISKWQKAVDKANGCDEHS YVIQALIEKANRSYYKNEQC HLAFLDLADAFGSIPFQVIW HTLKNMGMDEETINLLKEIY KDCSTKYKCGKNESEKIKIT KGVRQGCPLSMTLFSLCIQY LIQGIAEKKKGATIAGQEVC ILAYADDLVIVANTAKDMQM LLTTIENLAKQADLIFKPAK CGYYRDPRDKKSMMKIYGKE ISIVDEKNVYTYLGVRIGDT KKKDLNVRFEEVKKKTTAIF KSKLRSDQKLEAYNIFCQSK FVYILQGEDIAKTKIETYDE EIKKMIKEDILKLQDKSPFT DFVIYSPREKGGLGITKIID EQTIQTINRTAKLLNSSHRA IRAIIYEELIQVANLRGEKE INTIEEALKWLEGTNKYKKN SNAKTTWITRVREAFQTLEK KHKIKVRFVPKENCIGYKIK CDTQEKIVELDNSKELSKSL HWMIKEAYYKEWKALKCQGY IISLKTSEFMEWKMPRGLPD PDWRFLTKVKANMLDVNMKQ ANQGGRLGSTKCRKCEDKES ASHVINHCASGNWSRVEKHN QVQNELAKELTKRNISFEKD SIPKETKESLRPDLVIRLKD KIMIVDIKCPFDEESAIESA RNKNIDKYRELAKEIQAKTG LQTTVSTFVVCSLGTWDKRN NELLRQMGIRYEESKEMRIN MIQKAIHGSRKTYDHHRNFN NG (SEQ ID NO: 1413) NesL NeSL- . Caenor AAGGACGCTGGTTTAAGGCC TAAACCCACACGAGAMCTAC MPLXISDCVHLVSAEGDTMN 1_CBre habditis GAATTCGTTCGTTCTTTTTC GACGCCATAAGATCAGGCAT GRSTCGPLSRSSSVVSRSRS brenneri TGGCGGTCTTGCTTTGAGCT GTACGGATGTGAATGAGACT SPSPSVPPHPSPSIGPDTGL TGGTTTCCGATCCT GATGAACGGAATGAGCACGT SAGIIGTSRGCSLWLPEVDN (SEQ ID NO: 1169) GCCCATAAGATCGGGTATKA ALSQWLRKGLERDHEVLVCG AAGAWCAGAGACGATCCCTA FEAAKPLSLSKARLLRKTPR MCATCGGGAAAACACGAGTT NTGVVRHILEFDGRLVHTNC ATACTGCTTCACTGAMCTCG NETECVLSTLXSXXAVEVVR CTAAGCTCTCATAATGACCG ISLKCEPREPCEPKCVLSIL AACTTGTTCGCAACTGCCTC CSDKIVXISFECETREPFPF CTAACCGGGCGGGTGTGAGA FXDRKFREPIPFVFERMYDP AGGGAGGTCGCCTTGAGGCG RDPIPSFICWMYDLRQRMTP GACGCAATGAGGGATGTGTG GTLPXNPLSXENKDSWGRPA CAGGTTCCCCCTCTTGAGAT VIKNEIRSMRSYLEENVKEN CCGAAAGTCTAAAAGTACTA RLNLLRRLRGGGEGKKMIRK GACCGAAAGATCGAGGACGG LVAEKKSDTEAVCRILYPLD ACGGGATGGCCGCGAGGCAC DRYECFVDGCETTSTMGYGS ACGGCGGGTAACACAGCCAG SDLKYMTTHIKKEHGVKVQW ATAACCTAGTAGATCTTCGG TYECSLCNKQAPFMGGAASK ATCTCGTCGGCCTGGAGATA WVTAHMATKHTETVKLKLKP TGTGGAACCCTGGGAAAGGA SISTTAKVAAKLDEIAVSLP GAAAGTTGTTTGTTGGGCTG KPRQVRVLRDPDEVKEKVAK GCAAGAGTGAAGTTTGAATG PTLASTREEVKRNALRNMAP TGAACCACCGTCATGCAACC LVELSSQNQLTGAERPEETS ACTAAACCAGTGGCGATGCG EAMRLEECRTPEKIAELEGK GGTGGAGTCATCACAGGAAA IQTRTVTKKLSALKESMEKR ATGTTTCTGTTGCTTGACTT TREEKVGKPSLAPIHEEVKK ATCAGTGTTTGATATCGCCC TARRSLAPLVEPSTFTHLTG TCAGGCACAAGTATGAAGGC ASRLQAVRDAFSKANKDAAA CCCCACCCACATAAACTCCC KRRSSLAKPARLSEIMNTTF TAGCAACTGGTAGTCCAGCA TKETVNETKEPVNDTDESIA AGCGCTGGTWCTTGCTACTA TIQPQVRVYRFNTWCLDHET TTGCGCCCCAGGCTCGCCC TREAWLTGEVVDWFMGKVTE (SEQ ID NO: 1292) KKDQYRVFDSLVWSMYKFHG VGYVLDLMRDPLTYFLPICE HDHWVLLVIDEKGIWYGDSK GAEPCREIAKFIEETKRERR MFPVPVPLQRDGVNCGVHIC LMVKSIVNGEPWYTEEEVKV FRRNVKRGLKEFGFELYSER IVYVGDDSIKVNDEHDDDVV FLSEETNNTTFTIEQAEDPA EEDAQHLESPVKPVKLMELK IPKIEIKKKEIRRKPKQQIE KKRKVPTGKPDELLVRVRLW LEREVQSYFDSGKRFQRLEW ILDVLTAAIHKATAGDEQAI ERIEKRSPPLEVEEGEMSTQ TEPKKRERKEKESGCEMKAS HKEMYFKNRSKAFNVIIGKD SKQCEIPIETLQKFFEGTTA ETNVPAEVLKEMGSRLPKLE ALDWMEANFIESEVSDAMKK TKDTAPGVDGLRYHHLKWFD PEYKMLTLLYNECKNHRKIP SHWKEAETILLYKGGDETRP DNWRPISLMPTIYKLYSSLW NRRIRSVGGVMSKCQRGFQE REGCNESIGILRTAIDVAKG KRRNLSVAWLDLTNAFGSVP HELIKSTLESYGFPEMVTEI VMDMYRGASIRIKSKNEKSE QIVIKSGVKQGDPISPTLFN MCLENVIRRHLDSASGHRCI KTKVKVLAFADDMAILAENR DQLQTELNKLDKECESLNLI FKPVKCASLIIERGMVNKNA EVVLRGKPIRNLDENGSYKY LGVHTGIATRVSTMQLLESV TKEMDLVNQSGMAPFQKLDC LKTFVLPKLTYMYANAIPKL TELKVFANLTMRMVKEIHEI PIKGSPLEYVQLPPSQGGLG VACPKITALITFLVNVMKKL WSSDSYIRKLYRDYLDEVAE TETGMEEMTKEDIAKYLSGD VPIDKKAFGYNTFTRVRDVC NSLTXIXGAPLHKLKIVERD GDFAILVQATKEGMEKIFTC AQEKKLQQLLKAEVNTALAH RFFTEKPVKSAVMSVMRQYP QSNAFVKNGKNVSIAVHSWI HKARLNALHCNFNTYGENKS KVCRRCGKDVETQLHILQXC EYGLPKLINERHDAVLHVVR NLIRKGSKKDWKLKIDETVS SCNQLRPDIYMCSPDGKEVI MADVTCPYESGMQAMQESWN RKVTKYEGGFSHFXKMGKKF TVLPIVVGSLGTWWKPTTNS LVQLGIEKXTIRRVIPELCS MTMEYSKDVYWNHIFGDTFR KPPMRFGVEKPKGNSWKKEG SEPKGAASSD (SEQ ID NO: 1414) NeS NeSL- . Caenor GCGCCCCGGGTTACATTGTC TAAAAGCCAAAAGCCACGGA WRRPAPKQTKNSSLHHLGHE L 1_CJap habditis GGGGCCACCTTTCTCTTGGA GCATCGGGAAAGAAAAATGG VKRIARLKPGIFEFHAKPKN japonica GTAGAGTACAGTCTACTAAT AAAAGGACTGAAAACGAGAC SSLHHLGHGVKRXARLKPGI TTTTTGATAAGCTAGTCGGG TGAAAAATCCCAAACAAAAC FEFHAKXKNSSLHHLGHEVK TCCGAACCACTAGAGTTTGC AAATCCAAAACAAACTGAAA RIARLKPGIFEFHAKPKNSS TTGAAAATGCGTCAAACCAG AAAAAAAAAAAACAAAACAA LHHLGHEVRRNSRLKPGIFG CATTTTAGAACTCGCCCAAA AAACTGGACAGACACTGGAA FYQKSKNSSLHHLGHEVRRI AGTTCGGCCCCGACCCCCAA ACAGTGTCAGGCAAAGTCGC ARLKPGILEFHAKNRIKSGL ACAAATGGGACCTTCTTGAC CGATTATACTGTTCCACGCC KVTFLSDLXAHAGALACSRF GATTTTCCCTGAAAATCGGA TTAAAAGTCCCGAAATGGCG LASTLKTEHCRQKSFKPVGF GGATGGAATGGTCCCCTATT CAAAACAACCTGAATCTATC LLHFLKNSSINEVASLRNVK CTTGTAAATAGKACTGTGCA TGAAAGTGCTCCAAACCACG KXFLEFFSGKPIGGMASFSR ATACCCCTTCGTCATCTGTG CACAACTCGGAGAAAATCAG TKITFFKLCLKNFVLSAENP GGGAACAGATGACACGTGAC GGACAAGTTGCTTCACGCAA PIIRQKTNONKASXVQIARG GTCATCCGTGTAGACGTCAC CGGGCTGGGACAGGTACCCC GHLSDCLPSQKMAGVLGRLF GTTTTCCCGTGCCTGCGGGA CTCCTGAAACCGCGAGGTTG LSVQSTLSHRPFDTLLRSDD GCCCCCAATCGAGCAATTTT AGGATGGACGGGAAGGCCGC DKRGRKTIKLQFFIKENLVT TGCTCTTTTGAGTGTCTGGA GAGGCTTATGGCGGGTAACT PXVARDVKILXKQTKNNSGN ACGCTTGAAACCCCAGACAA CGGTTGGTGTGCTAGTAGAT SDSNSETKNFSKNKVSRQNG ATCAGGCCCAGTCGTCGGAA GATTTATATCCGACAGCCCC PLIGGGNHKKIGENQITRTL AATTTCTTTTTGAAATTTTT AACTAAGAGGAATCCTGGGA EIESKSDDNKVLVLRILYPT TGGCGCCTGCGAAAAAAATT AAGGAAAACTTGAAAAAGTT NDWYKCYSQWCQHKSLVGYG TTTTAACCGCCACAAACCCC TTTACAGGGCTGGTAATAGT AHDLKYLTDHIKSTHSKKVE CGGGAGGCGCGGWTAGGGAT TCAGCACAATTGTAGTCTAC WSYQCSICDAKAEGTGTKAA ATCGATGTCATCGACTCGTC TGTCTTGCAACCACAACAAA RWITAHMPKVHGIEATHRIK GGTGATCTTTGATTTTCTCT CCAGTGGTTCTGCGGGTAGA QNSEKTTNVKTANSLQEMAL CTGCGTCTCCTATTTTGGAA TCAAACTATAATTTGTGTGT SLQKPKNGPKKVVMATSTTP CAGTCTCGACCAAAAAACCG TTTCTTTTACTTGACCCGGG EKKISELESKIQTREVAKQL GGCCTGGCAACCCACCGAAT CAACACATTATACCACGTCC SALKESAQKNQQGNKTKNVK CCGGATGTCGGAGGGATTTG ACAAGGACGAATTCATAATG SSLKTIAENTNETKKISARK GCAAGAAATGTTGGAAATAA GCCCCTCCCTAAATAAACTC SLINYLKPEDVLNHIPKEPK CGAAATTTCGTTATTTTCAG CCTAGCAACTGGTGGTCCGG PASAKXGLQELTGAQRLQET CACAATTGTCAAACCGGCAA CGAAGCCGGTTCTTGCCACT RRRFMAGNRRDSIARRESLS GAAAACTGGATGGACAAGAC ATTGCGCCCCAGGCTCGCCC LGKISNSFKIELKNAPEKTT ACACAATTTACCGGAAATTG LKKPAVTQKQNTSQNVSSST TGCTTGTTACGTCGAATTTC (SEQ ID NO: 1293) VVKENKTGNDVITIDDTETV CCAATTTTGAAAAAATTCCT KRKINTWCLDHESTENAWMA CGTTCCACTGGTCGGGACGC DDIIFWYIQKQIEISLDNKK GAGGTCAGACGATCTGCACG FKVIDPLIWTTYRIYGVECV TCTGAAACCCAAAATCTTCG QDELVGFEKYFFPICENGHW GATTTTATGCAGTAG VLLIIDDKRVWYSDSLADKP (SEQ ID NO: 1170) IEVIEDLINKLNRTQGKFNQ TVPKQKDGFNCGVHVCLVAK SVITENFWYTEKDVNDFRKT VKLWLFSEGFELYSEPYKQI QNKNISVNSEKNQISDNEKN WGDKTQTVNESTLKERDEDI FLLRPHISVGVALKTEDEKN QKAENLKAPQKLKAIRRLKI LKTCLKKLTAVKGKPEETER AAIPNLMAIKLKTPPKVEPV RRNPEKGENYXKSQPNKKRQ IPTGKPDELVKKVREWFEIQ FQAYFEDGKSFQRLEWXTGL LTAAIHKASAGDEQAVGKII KRCPPLEIEEGEMATQTETK QKPKNQKSTKGANSSSSIRE AYAENRARTFNKIIGKDDKC EIPIEKIEKFFENTTSNTNV PTETLARITSDLPKLEIGSW IEEEFREKEVAEALKKTKDT APGVDGLRYHHLSWFDPKXK LLTKLYNECREHKKIPGHWK EAETVLLYKGGDETQAENWR PISLMPTICKLYSSLWNKRI KSVTGVLSKCQRGFQEREGC NESIAILRTAIEAAKGTKKS LSIAWLDLTNAFGSVPHESI EATLIAYGFPGMVTEVIKDM YNGASIRVKTKNEKSKQILI KSGVKQGDPISPTLFNICLE SVIXRHLKSADGHKCIXSNI KLLAFADDMAILSDSKTKLQ QELQKMDDDCTPLNLIFKPA KCASLIIEWGKVQKDQKIKL KGQFIRSLAEQDTYKYLGVQ TGIETRVSAMQLMKKTVSEL DKINCSALAXWQKLDAVKTF VLPKMTYMYANTVPKLSELK EFANITMRAIKVMQNIPVKG SPLEYVOLPIGKGGLGVACP KTTALITYLVSTMKKLWSTD DYIRKLHTDYLKMVAIKETK TKEVTLEDLASYLSDDKTVC KKAVGYNSFTRVREICKTLS KNKGALLSQLKIIAKDGKLA ILVQAXKDGKTKIFTHDHVK TLQKXLKKEINEALLHRFTT EKRVKSEVVRVVQEYPQCNS FVRDGGKVSIGAHRFVHKAR LNLLACNYNTWQDAATKQCR RCGYEKETQWHILSSCPKSM GGKITERHDSVLKTVKEMIQ TGSLKNWKLKLDHELPGSTR LRPDIYLRSPNGSEIILGDV TIPYEHGIEAMQTAWQKKIE KYEEGFKYLRSTGKKLTIVP IVVGALGSWWKPTTDSLVSL GIDKNTVKRAIPEICSTVLE YSKNIYWNHIFGDSYQKVPM FFGGEKPKGQSWKKVKPPEG KTASNHEPPG (SEQ ID NO: 1415) NeS NeSL- . Caenor CGCGAACCAGTCAT TAGCCGATCGTAAAAGAAAC MTVFIDRGIGERGQMAVCSL L 1_CRe habditis (SEQ ID NO: 1171) CGAGCCGTAACAACAAGCAA HRYFSFSPFSPIPPYVNNGS m remanei AGTAAACAAAAGAAAAATCA FGENGCGTDKSLLPVIEVVV ATAAAAAGGAAGGTTGACCT REVKINWSENILVVECLIMV CAGACCCCGAGGAGGGAAGA KSGERVVVKRQNLEKVIQNL GAGACACCSAGAAAAAGAGA ARINSTLFSNLGNQIFCVVP GACGCAGAGAAAAGGAGAGA RIKDSTNKEQGYRKEKQXKF CACCTCTCATAAGGAGAGGT HVSFRSIKSQVPPYLRGGGD AGGTCAATCCAAATGTAAAC VMEDTEIRGIRKLEPEAQLD AGAAAAAACCAGTGGGGAGG SSKPLICRVLYPTQGYMYKC AAAGAAAGACTGATTTCACC FYPKCKGHSNGSTDLRSLKK CACTAAAATGAATTTGGAAA HMVDKHFTNIEFAYKCATCM CAGAATTTGGAAGAGAAAAG FLTTGKSATALKSIKAHMAS AGAAAGGGAAACCTAAAGAA HHKVTMEPGKKSLVQKLNAR AATAGTTCTCTTGCCAAAAT LEEAAPSLPMPRNRSKVIQL TCTGTAGAGGAATACTTTGT TPEKSISELEKKKQTRSVAK CAAAACATGATAGAAACCAG QLSTLKESAQKKEEEVKIAE TAATCTGGTACGAAAGACAA VKKREPRLSIIPESNVRRSL GTAAGACCTGAACTGACAAG AAGLEQCINPEQSVAQRIRE AAGGAAGTCAGAAAGAAATA KREEYAKASREAAAKRRSSL CCGCTCACAAAGCCTGTGAT AMKPARLPDKENEITLQETK CGATTCTCTTACCTACTGAA KIDDPIVIDLEKECILTTVL CTTGTTCTCTTGGCCTCGTA QVPRNQFNSWCLEHETTIDA ACCGGCTAAAGGGAGAAGGA WLTDEVIHMYMCTITENRKY ATGTTAATTGGAGATAGACA FMAIDPVLWPVYVRNGAEDL TAAAGATAGGTGGAGTGAAG LRRTSCPGTFFFPICESNHW GTCCTGTTCTTGAAACTAGG VLLVIEHDVYWYLDPKGEEP AGGAATGTGGAAAGAGCAGA KGNVEILLESMKRKRQYYEF AGGCCGCGAGGCTTTAGACG PPPSQRDNVNCGVHVCLMAK GGTAACTCAGTCAGTTGCTA SIVDECGYNWYSEEDVRSFR GTGGTCTTCGGATCCAACGG TNMKDILKSKGYELCPEPYN CTTCGGACATAGTGAGGAAC RQNLLKTEKQKEVILEEMID CCTGGGTACGGAGAAGAAAT SFVVEDDMTFTVHRDSDHGD GGAAAAGAGATAGGGCGGGC DEVEHLKTIEQEPENEISEI AAAGGCTAAGTTCATACACT ENVEGSVDSVIPKLMEMRVQ GTCATGCAACCACTAAACCA TPPVINEKRGKKRVSAKEKP GTGGGATCTGCGGGTGAATC RKQKEKEQKVPTGKPDELVK ACTTTCGAAAAGAAGTGAAT RVRVWFEKEFKSYVEDGKSF GGACGTGCTGATGTCTGACT QRLEWXTDVLTAAIQKASAG TTAAAGAAGTCTGAAATTAA DEKAVELIEKRCPPLEXEEG AAAAACAGATATAAAGGCCC EMCTQTEKKKKPKSGKGNGG CTCACTATAAACTCCACAGC QESMKSLMASYSENRAKTYN AACAGGTGGTCCGGCGAGGC RIIGKHSKQCEIPIAKVQKF CGGTTCTTGCCACCATTGCA FEGTTAETNVPKETLKEMCS CCCCAGGCTCGTC RLPKVEVGTWIEGEFSESEV (SEQ ID NO: 1294) TEALKKTKDTAPGVDGLRYH HLKWFDPELKMLSQIYNECR EHRKIPKHWKEAETILLYKG GDESKXDNWRPISLMPTIYK LYSSLWNRRIRAVKGVMSKC QRGFQEREGCNESIGILRTA IDVAKGKKRNIAVAWLDLTN AFGSVPHELIKETLESYGFP EIVVDVVEDMYRDASIRVTT RTEKSDQIMIKSGVKQGDPI SPTLFNMCLESVIRRHLDRS VGHRCLKTKIKVLAFADDMA VLAESSEQLQKELTAMDADC SALNLLFKPAKCASLILEKG IVNRLNEVVLRGKPIRNLME NETYKYLGVQTGTETRVSIM DHITEVSREIDLVNMSQLAM HQKLDILKAFILPKMTYMYQ NTTPKLSELKVFANLVMRSV KEFHNIPLKGSPLEYVQLPV GKGGLGVACPKNTALLTFLV TIMKKLWSSDSYIRKLYTDY LEEVAKVEIGKFEVNLNDLA EFLSDERAVDSKLFGFNAFT RVREVVRSLCKNKDSPLHSL KIIEREGKLAISVQATEESI EKIFTEDQEKKLMYLLKGEL NTALQHRFFTQKVFKSEVMR VVQQHPQSNSFVRNGGKMSF SAQRFVHPGRLNQLPCNYNT WAKGRTKLCRRCAKNENETQ SHILQVCDYSIGNIIKERHD AVLYKFRELIKRGSKGHWLE RTDRTVPNTGSQLKPDLYLE SPDGKHVILADVTVPYERGI EGMQKAWNEKINKYTDGYKE IFRRQGKSLVVLPLVVGSLG TWWKPTEESLIKLGVEKTTV RRIIPETCGMVAEYSKNCYW RHIYGEKYVQTPMINGGKKP EGNDWKKCEKGIEVPKVTN (SEQ ID NO: 1416) NeS NeSL- . Trichomonas GGGTGAGTAGTCTAGTGGT TAAGAAGAGATAAGACGAGT MIPVLGTGGPEKLPLQSYVY L 1_TV vaginalis (SEQ ID NO: 1172) GAGAAGAACAGAAGCATAGT CGNTAITDSFTPTAKTILKP AGGATTGGCAGAGCTTAAGC EEQNLDIVLKNIAALNPENY GATGTCACTCGGTACGAAAC SDLIRSLSKMEFRLDYPKEI GTGTACCAAACACCGGATTC ENYWISEKLFSQSIASLPIS CGTGCTAGGAATCACAAGCC LLVASMFSPEDRDLSTEPFH AAAATAAAAGAGACACCACG CNADGCNFHCDNCERMVEHI AAAATTACTCACCCTCCCTC REHHNTDPMINTFETTEDTF AAACAGATAATAATATTAAC RRITAIKIDKTGIEELNPLK CTCCCATCCATCAGTCCGTA YRCSYCDELFTEAEDHAIHM TGGTCTGATAACAGACTAGC ISHLTEKLSPDISFFFNDIL ACCACATCCATGATACACTC RLYKTIDKPTVQNLFPETQV ATTGGAGTGAAAACCACCAA AIFDTLEETNRFRLIVGREA CAACAAATCCACCTAGACCA IETIEEAFPPSPPGTDRKPS AATCCTGCCCCACCTCCACC IIITDTCQLRFVPCMDEPPK CAAGTAGCTCGCTTCGCTCG GDLGILTLLLRDFSAHNIPI CTCACCTAAAACTTTGCTCG KSLNNKELIADKDIDYSPDF CTCGCTTCGCTCGCTCGTCT VEGALANAEEHDTTNSQNNN TAACCCTTTCCGAATAAACA GRYINSAEKLTEFLIQCEDY CTTACAATTCCCGGCTCGCC LTNIKTLEDLERFYTTIKDY CCATTTTTT RVNKEVIAEDTPIFVYFLVE (SEQ ID NO: 1295) EGKLPKPGLRCPLESYEGHE DKAFESLRKLCDHFKGEIAK TSFDPKVHTIDIWVEFLAQA YGTGTFVYKDENGNIDLDTH VFKCPYADCSYTNNDRSKLM DHMKTKKHAKNVYIERYGFF WGIVIEGVNRPKGIVYPTLK DIKEHACRKCPEAGCNTYVT ELSDIKEHLKKKHKSTTAGV DGEIAHTDATYCWITKEELD ALHAERARERAEQVDNTPVQ QIINADNNEENNENQEDNGN NEEADALDPPNNTTETEDEA VHAVIINPPATEEEEVAIIA EARRNIPELQQAEERGCVTP KMTSLVRLKLLKGGGELFNK KLTPLATRYAATGNTEADKI KVDYLTLKCNAALREMIYTN NHSESKFMTAENGEDTAPPP RISEDTRDRIQKAANEIKGT LIKVVKHISHARCLKDSTRD DEHNKFVEMIAKIKNDLRDN KFEQYNIEEIFQGPISDQSI LNIVNTEDNNEFIKKMDYIN RILGTPQDASPYARKKLQAC FADNPTKTLRNIILADKVPQ QSLKPSEYLDYYGPQWANEA EGYENFLHHDYALPERYGQV FANDFLDFMTNESKIIEVIR NKNHLSAHGLDGIPNSVYML FPVSAAKFLSILFRSIIISG HIPDCWKLSKTVMLFKKDDP SLAKNWRPIGITSCTYRIFM TLVNKALQMIPMFHAMQKGF VRGATLSEHIAVANEVLCQS TRTQSEMFQTAIDFTNAFGT VPHQLIFDSLEAKKVPDSII NLLKDLYKGARTAIYTRHAH SEIVPVRRGVIQGCPLSPIL FNCCLDPLLYAVQRRHFEDG YRFQDKAGQYSIAIQAYADD VLVISPTHEGMQRILNTVDE FQKIAKLKVAPQKCVTLAKT STAIQPFRIGPDEIPIKTSM DNITYLGIPISGTKTSRFAA ATGILEKVKAQIRVVFASHL ALSQKIIALRVFILPQLDFY MFHNVFRVNDLKATDQMIRG LIDKEAPTSNIPVSFFYMPK NKGGFGLVKLELRQPQLVLT KFARLWLSQQAETKAFFHTM AQEEKSFRKVVEDQENGFLG IKMENGKIVQKNERSKRTNC FITQAAKAADKLEVRFKEWD KGGIQVRGVGENATDWYRSK HIGQISPLIGRVIQQRQYEE FKKDETHSHTFCEPAALAES HDIMKRPQAVPNNLYSAAIA LRTNTAPTPANMHFHNPEVL ANCPLCGCQSCTLFHTLNMC RNRFSLYKWRHNIICDDIYQ FIHDHYPGVTIKCSARITSD GYQTTGPELDDTVKDLLPDL VVYDEANKMIKIIEVTCPYG TDNNVGNSLDAAYDKKVNKY KSLAEQTERLFNWTTTLSII VVSSLGVIPLRTKLDALRIS PADHIQLLKRLSMHAIAASA CIVFEKVPEFFGMRCRPLPG RVTAPNAAIPPNNNENNNDT DHGQENQQATSEEQPTNNGN AQEDNGQGEQINNSTEQTIS VDQIIEEDAENNAIEQALDQ PDEDEFLN (SEQ ID NO: 1417) Nes NeSL- . Caenor GACTCGCCTTGGGGAAGGTW TAAACCGGCTCCTCTGGGAG MRYHXSNXPAXRTSDNXWRS L 2_CBr habditis TTTCAGGGGKSAATTGCCGM GAGGTATGTCAGAGGACATT IXKDVRRPDPSTIEEKSRYN e brenneri AGGCAAGGCAGCCCCCSMMT CTCCGTGGGCGGATGGGAGG RSIGIPDSLKXRSSAVRSXS AGCTTACAAAGTAAGTACMC AGTAGGGTAACGACCCGTCA SXPPSGPQDVRLXNSPSLDD ATTTTCATTTCTTGTGAATT TTCTGGATGCCTAAACCACC RRRLVDCETTLGSYREWTDK CTTTAAACATATTTTTCTTG ACAATCTGTCAAGGCAAAGT PMMGKMTYAAVTKRAPPRPQ TTTTTTGATTTCTTTTTTCT GCCCCAAAAGCACACGCGTG TGGARLSTNLLADEMEIKYR CTACCTTCCCCCAATTCTTC GATCGGTTTGGATGCCGACT DTNDIRLVIDLPNPHLIKCP CCCTCATCTTGTGTATACAT GAGCCAGAGGGCAAAGTCGA LCKSCISARGRGANALKYMK CCCCCTCCTCCAACCAATCA AGGCCGGTAGGCTCCCGGCG RHIADAHHLNADFVYKCSRC ATACATTGACCTCTCTCTTC GGTTGTCCGTCATAGTCAGT QEHEPENVCGAKWIVNHLKR TGTCAAAAAATCAATACTAG GGTGCGCCTACACCCAACTG VHGYTLEDAVSTAKPSTRQQ TATATTGTCCCTTGTATAGT CTATGACACACAAGGACAAC IANAFNDSAPFIDARKTSDV ATTATTTGACGTCGTCTTTG CCAAAATAAATAAGCCAAGG PEKKSREAGLEKFLAPTKSE TATTAGGAGTAGGTAACAAW CGGCGTTAGCTTCGAGCTAA DTREKTPPSTRKSSESSEAS CTGTGTATGGCTTCAAAAAG CAAGCTCCCCGAGAGGATGG IQSTIQETLSESSDTLTVQE CATGCACAAACWCCTGTCAA TTGCCACAGGGCACCATCCT IINISSEDEMDEEPPKRRVN AAAGTAWTTCCCATCMTGTG GGGGAACGACCCGATCTTTC VWALIHENGKDAWIDSDLMV AATAGCTCAACGACWKGAAG GGATGCCCAACCACCGCCAA IFLESRARGYESCSIIDPLN MCCAATGAT TCTGTCAGGCAACGTGCCCC FICTDMSYLTTIVRRRMEEG (SEQ ID NO: 1173) AAAAGCACACGTGCGGAGCG YKKIIFPLCANDHWTLVTIT GTTGGATGCCGACTGAGCCA GSTATFYDPMGNEPTETVKK GAGGGCAAAGTCGTAGGCCG MIDELDLEMQLAPSNSPRQR GTAGGCTCCCGGCGGGTTCT DSWNCGVFVMKMAEAYIKDT CCGTCGTAGTCAGTGGTGTG QWDLTDVDTDVKTFRRSLLT CCTACACCTAACTGCTATGA ELKAKFNIFAEDIQTYRPPS CAAGCGTATAGGAGGCCCGG RKALTRNSQSPVVVCHKCSR AAAAACAAGCCAAGGCGGCG PATPIQDVSRMEVEEAPVLV TTAGCTGAGAGCTAACAAGC PTPEEPPQEWTFVGKNRKRG TTCTCGTGGATGGGTGCCAG VTSRTPNTSPEAKRPAFPPV AGGGCACCATCCTGGTGGGT PLKPSANRWHFPEEETEKME GGATGGGGGGAGCTTGGGAA VSSADEVKNSTPPKPPKIPN CGTCCCGATCCTTCGGATGC LLAMKIASPVPLKRGNPSKK CCAGACCACCGCAATCTGTC HGKGHMMNTARKGPTKKEMP AAGGCACCGTGCTCCAAAAG KGEPANLIVKIRSWFDEQLK CACACGCGCGGGTTGGTTTG MYKDEGSNLQRLTWLSDSLT GATGCCGACTGAGCCAGAGG AAIGKAFNGNKYIVDQIIKR GCAAAGTCGTAGGCCGGTAG NPPPLVEKGAMSTQTSRKRD GCTCCCGGCGGGCTCTCCGT EFKPRERMAQEPNEPLRIQY CATAGTCAGTGGTGTGCCTT AKNRQKTFFKIIGKQSEQCT CACCCAACTGCTATGACATG INIETVEQHFRKTLKAPVVS CGTACAGGAGGCCCGGAAAA ENAIKTVCGSIKKVLMPKTI ATAAGCCAAGGCGGCGTTAG EDPISSVEVKSILTKVKDTS CATAGGGCTAACAAGCTTCT PGTDGVKYSNLRWFDPEGER CGTGGATGGGTGCCAGAGGG LAKLFEECRKHREIPSHWKE CACCATCCTGGTGGGTGGAT AETILLPKDCSDEEKKKPEN GGGGGGAGCTTGGGAACGTC WRPIALMATIYKLYSAVWSR CCGATCGTTCGGATGCCCAA RISGVQGVISPCQRGFQSLD CCACCGCAATCTGCCAGGCA GCNESIGILRMCIDTASVLN ACGTGCTTCGGAWGGTCATT RNLSCSWLDLTNAFGSVPHE GGTTCTAGACTTGTAATAGA LIRRSLESFGYPQSVIQIVT CCATTGGCCGGAAGAGCACA DMYKGATMKVKTADQKTQSI CGCGCGGTTGGTTGGATGCC KIEAGVKQGDPISPTLFNIC GACCGAGCCTAGAGGGTGCA LEGIIRMHQMREKGYDCVGH AACCTGAAGGGCGAGGTCGA KVRCLAFADDLAILTNNKDE AGGCCGTGAGGCTCCCGGCG MQEVIDKLDADCRSVSLIFK GGAAACTCCGTCATAGTTAG PRKCASLTIVRGAVDKYAKI TGGTGTGCCTACACCCGACG RINGDAIRTMADRDTYRYLG ACTATGACACATAGGAGGAA VKTGVGGRASETEALIQVVK TCCTGATCTGATATGATCAT ELQKVHETDLAPHQKLDILK GTATATAGGGAGGGCGAAGG TFLLPRLQHLYRNATPKLSE TAAATAGTCAGKGTCAAAGT LREFENVVMKSVKRYHNIPI CCACGTGGCAGCTACTCCCC KGSPVEYVQIPVKKGGLGVL AGCATAGTAGTGATGCGAGT SPRLTCLITFLTSTLCKLWS GGAWCCAACTTTGACACTGA DDPFISSIHKDALSRITVKA TGTTCCCTGAGCCTGACCCA MGLTTQSATIKETCEYLNTR TCTGCACAAATCCAACAGTG KAVTKGGYSLFCRMNESLRT TATGATGGCCCACACACTGA LSVIQGAPLKSMEFIPVNNE GGACGAGTATCACTTGTGAT IGIAVQATKDSEIKVFTKAD ACTCAGAGGTGTCCCCCATG SLKLMSKLKDLVRSAMLKRF ATCAACCAATATCACAGCTA LEEKSVKSRVTQVLQHHPQS GCGGACCTACCGTGAGGTAG NRFVRDGRNCSIAAQRFVHP ACCCCCGCCGCTGTAGCAGG ARLNLLSCNANTYDVNHPKG CTCGCCTC CRRCQADFESQQHILQNCHY (SEQ ID NO: 1296) SLAGGITQRHDRVMNRILQE IGNGRKAHYKIMVDMETGAT RERPDIIMEERDGPEVLLAD VTVPYENGVQAVERAWDKKI EKYKHFLDYYRKIGKKATIL PLVVGSLGTYWPDTSHSLKM LGLSDGQIRNVIPEICQIAL ESSKNIYWKHILGDSYKTVE GLFCQRNNKEVRFEGKGEKH HVSQRFQPLKCEKVRTMKST KEEGRSRSNAKKGPNWRRSK SESDGRSVSKGRYWRDPSNK PPHSKMTQSALAKR (SEQ ID NO: 1418) NeS NeSL- . Caenor CCAACTCTCATCGTATTAAC TGAATACCGTCAGATAAGCC MTNVYLKPVNDNQTNKTGDN L 2_CRe habditis CTACGGTATTCACTCCTAGT CCCAACATAAAAATAAAAGT SRNTMSNSQCEMTWKPVART m remanei GAGTGTAATAAAGGTTAATT CGGCGTTAGCTAACCACTAA YAQAASTNPADDKTVTVLGC ACGTTTTCTCTTGCMAGAGA ACCGGCTCCTCATTGGGGGA KYNLLKLGNTPQTSKRSPPK AAAAGAAAATTCGAATCCTT GAGTATCATTCCGGTGCTCT PSRGGARISSVYTLTDELEI TTTGTGTAACTCACAAACTG CCGTTTGGGCGGTAGGGAGG THREEGKITFAIDLPNKNNI ACAGAGACCTATCGAATTTC AGTTGGGTAGCGACCCGGAA LCPLCRECTQTRGRGSSFTK CTTTGTTTCGTATATAGGAA GTATGGATGCCCAACCACCG HMKLHVKEKHQLDATFIYKC TAGTCACTCTGGACCACGAA CAATCTGATCTGGCATTGTG SMCNEYEPEKKCGTKWIQTH GTGGACAGTTGTCGGCGGAC TTTCGGATGGTCTCTGTCTC LQKVHNYKYDESAIVVPVPP TTCCAGAGTGGAGAGAAAAG TAGATCTGAAATAGAGCTCT NTRQQIANELNNAAPFVDIR GTGTGAAGAGAGGAGGTCTA GGCCTGAAGAACACACGCGC KPKAAAVEEKKTENGALLKF GAAACACTTCGGCTGTCTAG GGACCGGTTGGATGCCGACT LTKSNKDDQVKSPSXDIPDA GACCAGTTCCTGAGTGGAAA CGATCTGGAGGGTGCAAACC ESPEKETQALTIDPKGNNSP GAGGAAGGTCTAGAAACACT TGAAAGGGAAAGTTGAAGGC SKSSIRSSQSSASSVCQEIQ TCGGCTGTCTAGGACCAGTT CGTGAGGCTCCTGGCGGGAA EIITLSEDEDPKGARPKPGI CGTGAGATCTCTCGTGGAGA ACTCCGTCAT NVWSUNETGKDAYIDTDIMM GTTGAAAACAGTCAGCTGAG AGTCAGTGGTGTGCCAACAC AFLKMRVENCDSVNIIDPLN GCTACTGTATTTCTTGATAG CCGACGACTATGACATAGTT YQFPARVDLVPUQRNLEDGK CCCCGCCCCCAATCCCCCTC GGAGGAATCCTGATCTGATA KRWFPICADEHWTLLTISNG CCCCCCCCCTCGACAGATTT ATAATCATTGTTCATATAAG IAAFYDPTGSRMSSYIEELV TTCTGTTTGACCTCCTGGAA GGAGGGGGATGGTAAATACC NELGLIIPKEQDEQPRQRDS TTTGCGAGGAGTGCGCGAGA CAGGGTCCGAAACCATCAAA YNCGVFVMKMAEAFIQDTEW ATTTTCGAATTCTTCGCGCG GCAGCTACTGACCAGCATAG EMEEVEEDVKNFRRNLLEEL TTTTCTCGAAATTTTCCAGA TAGTGATGAACACATAGACC KPNYEIFAEKIKYYNSPGKS AGATTCGAGCGGAGAATCTT CTGGGGTTCCCTGAACTCGA FAQSRPTSRSSQCAVCPTCS CGAGAAAGTGAGCTGAATTT CCCATCTGCACAAACCCACT RSATPMMDVGNMEVDPVPQQ CGCGCGAATTTTCCGCGATT TTGTACAAATGAACCAAACT QETPKSREPEQDEGWKVVGK TTCAAATTATCGATTTTTGT GATGAAGAGTTTAATGATTT ARKRGWTERSPNISPEAKRQ CGGAAAATTTATTTTCTGGC CTTACATCACAGCTAGCGGA FTGPEIKWSPGKFHPLVGET AAAATTTGATTGAGTTCACG CCTACCGTGAGGTAGACTCC EEMEVTCDSPPTKEPTTEPK CGGGAGAGAAGGAATTGTTG CGCCGCTGTAGCAGGCTCGC VTPSLPAMKIASPEVTKKQT GAAAAGGGTATTGATTTTTG CATTG SKKKGKYGKKKQXTKKAQPP TGGCGGAGGAAACTCCCACT (SEQ ID NO: 1297) KGEPTKKAQPKGEPAKLIEQ GAATCAATAACTCTCAAAGG VRTWFDKQMKSYQEQGSNIQ AGAACTCATCGAACAACCTC TLTWIADSLTAAIFKANSGN GGGTGACCTGAATCTTGGGC KYLVDKITARCPPPLLNEGE GAAATTTTCGCATTGACACA MATQTSRRTEAVKPKDRFVK AGATAAMACAAATTACTGTK ESNEPLRIQYAKNRAKTFNV GAAAATAAATCAGAACAAAC IIGKHSARCEIDINVVENHF TGTCAAAAAGAGAGACAAAA RQTLKAQPVTEEALNTVCSG AGTATTGATTAACAACATC IKKAKVDPSIEGPISSGEVK (SEQ ID NO: 1174) AILAKIKDTSPGTDGVKYSD LKWFDPEGERLALLFDECRQ HGKIPSHWKEAETVLLPKDC TEEERKKPENWRPISLMATV YKLYSSVWNRRISSVKGVIS DCQRGFQAIDGCNESIGILR MCIDTATVINRNLSCSWLDL TNAFGSVPHELIRRSLAAFG YPESVINIISDMYNGSSMRV KTAEQKTQNIMIEAGVKQGD PISPTLFNICLEGIIRRHQT RKTGYNCVGNDVRCLAFADD LAILTNNQDEMQDVLNQLDK DCRSVALIFKPKKCASLTIK KGSVDQYARIKIHGMPIRTM SDGDTYKYLGVQTGNGGRAS ESESLTQIAAELQMVHDTDL APNQKLDVLKAFILPRLQHM YRNATPKLTELKEFENTVMK SVKMYHNIPIKGSPLEYVQI PVKNGGLGVMSPRFTCLITF LASTLFKLWSDDEYISSIHK KALSRITAKVMGLKTQKATL QEQCEYLNTKKAITKGGYSL FSRMNEAIRTLSVNLGAPLK SMQFIPENGEIALEVQASEN SQIKVFSKADSMKLVTKLKD LVKSAMLKNFLENKKVKSKV VQVLQHHPQSNKFVNDGKNX SISSQKFVHPARLSQLVCNG NSYSKDLPKNCRWCGYECES QAHILQHCTYSLSSGITQRF IDRVLNRILXEVIKGRKNND YYDIMVDTEPGPTRERPDII MIQKDGPEVLLADVTVPYEN GWAIEAAWDWKMEKYSHFID YFARLGKRAVILPLWGSLGT YWPDTSNSLRMLGLSDGQIR NLIPDISMIALESSKQIYWR HIFGDSYRIVSDLYCRKDQQ EIRFGDEPMENVQVSDRFQP FKTREREKKSEEEKKRRSKS KKGKTWRGSKKQTDSRQSGK SNQNQGFQRSVGQGVSR (SEQ ID NO: 1419) NeS NeSL- chrUn Caenor CCCTTTTCTATCGTATTAAC TAACATGCCTTGGAAGGCAC MTKTEWSWRHRSRSRSVGIV L 4_CRe habditis TACGATAACCGCTCATTTGA CACGCCAAAAGTCCTGGCAA VKIDTSDYANVRVHVAADLS m remanei GTGTAAAAAAGGTTCCCCCC CTGATTTGAATAATGTATAA NEDGHTSHNNGIILPIPMKP TCCTCGCCTGCCTTACCCAC AAGTAACTGGAACCAAATGC SVDRFCQIQYPPRGYYVPHP GCATCTCTGCCTCTGGGAAG CCGATAGGTAGGGCGGGAGA QSQKGHDAKPSRHWNEEAQP GCGGAGGGTCAACTTGCGGG AAATGACCTAGAAAACACAA PYYHNNNHGRRGRSAKPSGR TCTGTGGATTTCCTTTCCTA AGTCCCAAGCCCCCGGATTC RPPRKPILQEESLAAHPQIP TCCACCGCCCATATTCTCTG GAAAGACCTATAGGAAGTCA GDTASAVPLYSDVVNNENKS TCGAAAGCCTACCTAGATCA GTGAATAGAGAGAAATATCA QGKPPQGSHRRSGRPGTKPS GCCGGGAGTTTTTCCTATCC AACAAATCTCACCCATTCAC VPVGEAEQETNSRPIAPEPI CATTCAGGCGATCGCTCAAG AAGGACTTACTGGTCGAGTA VKFKHDKHGWTTVQGSHSSG GCTGTTTTATCGACACTCCT GAAAACAAGCCAAAACATCA RPVPKPSVPVVSEANRFQLL TCTTGACAAGTATTTATTTC AGCACGACGCAAAAAGGGGT QEGDFPPLTTSESSQEEIKV TTGACAAATTCTATTTTTCC AACTTTGGGCAACTAATTAA PNYQRIVSPIPLPSEEDSKL TTTTATCGATTTTCTCTTAT CGGATACCTCCGTGTATCAG PTKSNYRAPKGRKSRNYKKP TTATCGATTCTTGTGAAAAT GCAAAGCCGCCACCAACAGC QQQNPKKYQQRLPYQPKVNN (SEQ ID NO: 1175) AAATTACTGCCCGATAGGTA APTDRMAPEQLKGGGGKTAH GGGCGTGAGAAAATGACCTA NDIEEMEIEEDTDEKIIQVK CAACCTCCAAGACCCGAGCC RIKIVNKLTPHHFVCMMTYP CACGGAATCGAAAGACCTAT TDNIYRCFVKGCTATSQGGW AGGAAGTCAGTGAATTGATG GAEDLKYLTVHIRQEHKIKV GAAATACAAAACCAAATTTC EWTYECGICGDLSGGAGKHI TTCCATTCACAAGGACTTAC SKWIKPHMRKKHNRDAPTNF TGGTCGAGTAGAGCACAAGC KMGSRSSGKPKITELLEESA CAAAATATCAAGTATGACGC PSCSNPRRKTLNQKKTAIIT AAAAATGGGTAACCTTGGGC QVTPEKLKTGYQTRSVTKAL ATCCAATCAACGGATACCTC SVLKESRQKELEVLREEEKA TGCGTATCAGGCAAAGTCGC NAKQKSKLHPFFTKAPHIDG CACCAAACTGTACTACTCCG VKPTVRRELSKMITPGGEHK AAAAAACCAAGAAACATGAT GTKIPMVHTKRGLIQKINRK TTTCCCACTCCGTTAAAGCA AKKAKPMHLDESTIIEASQL TCTCAACCAAGCTAAAGCGG DVITIDDDDEDDNMTPMRRR TAAGGTTATCATGTCAAAAG FNTWCLDHETTQEAWLTDDV GTGTAGCTACAGCAACCTAA INWYLKDLCFGNEQYMLVDP AGCCCGAAAGGTAGGGCCGT LVWLIYKMGGMAGVEQRFKS ATAAAAAGACCTACACCCTC KKTCLFPICEADHWILLVFD CAAGACCTAAACCCACGAAC ETNLCYANSLGSQPNGQVKN TCGAACGACCTACAGGAAGT FIQQLNRKLCSFEKEVPLQK CCGTGAATGGAGAGAAATAT DSVNCGVHVCLIAKSIVNGQ CTCACCAAATCTCTTCCATT FWYDDSDVRTFRTNAKAALK CACAAAGGCTAACTGGTCAA AQGYELFSEAPKQIENPDSS GTAGAGCACAAGCTAAGCCT HREDIKENSMEMCSESLMIV CCAAGCACGAAGTGATATGG ATPQRSEAPMELVDTEPSDL GTAATTTAGGCAACCAATCA ESPKSDRVVYEDCITALSDV ACGGATACCTCCGTGTATCA SEPRMTPEKSETPEVPVVEE GGCAAAGTCGCCACAAACAC RDLDWPKLESPKSDRVVYED TGTACTACTCCGTTACTCCC CITDLSDVSEQRMTPEKCET AAACACATGGATCTCCTTCT PEAPLVVECVELERLPKDLP CTCACCAAAAAGCTTTATAA VTDRSTVVAIPEAVKLEEKS CCAAGCTAACGGTGGAAAGG EVVIPRLMELSYTVPPEPSP ACATCATGTCACGAGGAGTA VVEYTQPYTHTHTKPKVKAT GCTACAGTAACCTCTCTCTT CQMGKKRKVPTGKPDELIQI GAGACTGCAAAGTCGAGGAT VRQWFEKEFNDYVTEGRNFQ GGATTGGGAAGGCCGCGAGG RLEWLTNLLTAAIQKASAGD CAAAAGGCGGGTAACTCGGC EETIEKIRKRCPPPEVRENE CAGACGCTAGTGATCTTCGG MSTQTSQRQKPTTTNQKKRS ATCCGACAGCCCTGGCCTTA RNTTQSDTQANTYWRNRAKT GAGGAACCCTGGGATAAGGA YNQIIGQDFKQCDIPIAILE GCACGACGGGAAGGATGTTC EFYKKTTSVTNVPQETLVKV CGCAAGGATTTCCCTTCCCA TSRLPRLDIGKWIEDPFTEQ TTAGTCAGGGCTGGCAGTTG EVFGALKKTKDTAPGTDGLR GTAATATAGCCTTTCTACAC YYHLQWFDPDCKMLSSIYNE ACCACCGTCTTGCACCCACT CQHHLKIPAQWKEAETILLF AAACCAGTGGGATATGCGGG KSGDESKPDNWRPISLMPTI TGGACTCAATGTAGAAAGGT YKLYSSLWNRRIRTVKGIMS GTTCCCACTGCCTGACTCGC KCQRGFQEREGCNESIGILR CAACTTTATATGTCTTGTCA SAIDVAKGKRSHLSVAWLDL ACATAATGGCCCCTCACTAT TNAFGSVPHELIESTLSAYG AAACTCCCTAGCAACTGGTG FPEMVVHIVKDMYKDASIRV GTCCGGCGAAGCCGGTTCTT KNRTEKSEQIMIKSGVKQGD GCCACTATTGCGCCCCAGGC PISPTLFNMCLETVIRRHLK TCGCC ESSGHKCIDTRIKLLAFADD (SEQ ID NO: 1298) MAVLAESKEQLQKELTEMDE DCTPLNLIFKPAKCASLIIE FGKVRTHEQIMLKREPIRNL NDDGTYKYLGVHTGADARTS EEELIISVTKEVDLVNRSAL TPPQKLDCLKTFTLPKMTYM YANAIPKLTELSAFANMVMR GVKIIHYIPVRGSPLEYIQI PTGKGGLGVPCPRITALITF LVSTMKKLWSDDEYIRKLYN SYLKKVVEAETGIVEVSTKD LAEYLSNKVPSRKHEFGYNC YSRIREVCNGLALNQAAPLY KLEFIEQDNELAVVVQPTEE SKERIFTKDHVKKLQSLLKA SVNDALLHRFLTTKPVKSEV VQVLQQHPQSNSFVRMGGKV SISVHVWIHRSRLNQLTCNY NIFDPKQPKNCRRCGYKNET QWHILQDCTYGWAKLIRERH DAVHHKVVTMICAGAKKNWG RKIDQELPGFTSLRPDICLT SPDGKEVIFADVCVPYSRTR NIEFAWKEKIRKYTEGYSHL VAQGIKVTVLPIAIGSLGTW WTPTNESLYQLGISKSDIRS AIPLLCSTVMEYSKNAYWNH IYGNSYTSVPLRYGHQKPDG DDWKKELSCEPVLALQQ (SEQ ID NO: 1420) NeS NeSL- . Schmidtea TTAAATCATTTTTAAATGTG TGAGTGTGCTACGAGGCAGC MNVDLDATIKSIGMNTKETT L 4_SM mediterranea TTTGAATATCTTAAATTATC GCTGGTAATTGCATCGGCGT YPNSQLRVETTPCTSTTIMH AAATCATATTAATATCAATG TGCAGATTTGTGTACGATAG ASCNTTSTISYSPLPSAVSL CTAAAAAAAAATCGTGCKCA ATAAAAACCAATAGTAATAA PESPASSITITTTDDNCDII TCAGGCGCACGAAAATAATG ATGCTGAGCCTAGCTCGCAT ETPYPLPQTNGDLSEILKDI GACACAACTCGTCGACCTGC ATCTAAGCCGAAAGGCAGCA EANKDTTMSNKVLDCDSDSG TGTCGACTCACAGAGAACCT TATATATGAGACAATTTAAA DDRDMIIENDRESDMDLFSQ CAATTTGGAAGAATGGGAAG AAAAAA SLLNTNQSDERREKNLTENA CCTATAATGCTACAATTCCG (SEQ ID NO: 1299) PTEITTEKSYFDIISKASDN CCAACCCCTATTTGAATGAC TTSKKLLNVKNELTAGLPPM AGATAGTCAAATATCAAAAA PPVTNTAKFIRNVRPEDIAD ATATACAAACTGCTGTCAAG PTLYRLDSRGKLGCRTQYKK CGTGACTCACTTCCTTCCAA PGCGDIAVYDYEAIVEHAAF TCGAAAAATAGGAAKATGTA IHTIPFNEQNNVDCQPCHPK AGAAACATGAAAGTCAAGCT KGKDVHTIVLIKYADIFNHI GAAAAACCAATAATATGTCC EAHSHVVQTAITDNMKTYLR TAAAATAAAACAATTTGAAA LTKENXFYCSYRNNKKKNKC ATATGCAAAAAATACCTATA KKAFNLESNMMDITEHMKTH AAATCACAGCCGAATAAATT TGYSFDXNLNILCYCGIWKP CCCATCCGTTCTAAGCAGAA FTELIAHIKTEHLQEYINSI ACCGCTACGAACTACTGCAA PNKENIHNTTTIVSPLNFAG GAATCGGATCAAGTATATTA ILASGETQNIPDEEIIKPRD ATTTCCCCCCMGGGGGAAAT LPENLAFNRNIENELSWSQH TAATATACTTGTTAKAAAAT LVKAYIFSYAVKTSTIFINP TAATTTTTTAATAAAAATAA YTCNALIQCNYKTFFETFPF ATAAATCGAATAAATATAAA KDFAKWNEIVLPIHNNTSSW ATAAAAATAAATCAAATTAA SFFFLNKKKRVAMIIDPTAD ACTTTTATTAACAATAAAAT DSHTLHFELATDILRTILNV CGCAGTAAGTAAATTTCCAC QNIFEDLNFPLTEVEYPVCH TGTTATTAAATTTAAAACAA EANLSAFXVCHFLKCLMSDL AATTCCTTTAAAAATGCCTC PIDIPDIDHMKETMRPIIRK TCTTTTTCAGTAATAACACC YNCAKFPESDVRNYRVLIED TTTTCTTGCTTTTATTACTA LIYQLNLDTITCEEILCEIE TTTCTTGTGTACTGTACAAA RINGRLNPKRYFKESKPKTD TCGAGCACAGTTATTGCAAA IIHLQKKKSAELLCVKRLKF TAGGACATAGAAATTCCTTT QISQKTEIGKIWENDDVDHR TTAAGTAAATTTAAATCCAT PPMARFLKTFASQDCPVSNT GAGAAATAAAATAAAATCCT SSINLPYYMDTDTDXCTDCE TTTGATTCAAAGTTTCTATG NLSHIMKNLDSSAPGMDLIT TTGCTTTCTAATAGAATGGT GGDWKKISPKHELITAICNC GTAAGCATTAATGGGTCTTG ILRNKVCPEKWKLFRTVLIL ATTTTTATAAATTAAATATA KPGKMSESFRANSWRPLAIM TTTAATCTATTAAATTAATA DTAYRIFTTLLNNRLLQWIR TGTTTTTATTAATTATTAAT NGNLISPNQKAIGIPDGCAE TTTTATAGTGGGGGGAAATT HNATLHFAIDRAKRCKTELH AATATACTTGATCCCAAGAA IVWLDIADXFGSLPHDLIWY TCAACTGATGATGAAGAATA TLANMGLKNETLTLIKELYK TGTTATTTCAAAATACATAC DVKTIFDCQGTLSEPVPITK AAGAAGCTGGAAAAAACAAA GVKQGCPLSMTLFCLSIDYI TCAATCGCTACA LKSILTNYPFLLHDLNISIL (SEQ ID NO: 1176) AYADDLVLLSDSYLEIKKSL ESTVELAAFANLKFKPSKSG YLSINNVNSDILKLHLYNEE IPTISENNKYRYLGVDFSYK RNQDVDGRLGSALALTRSLF KSYLHPAQKLNAYKTFIHSK LIFSLRNCVIGHRILDCDRN RVTQGREKQLGFDQEIKALL KTMIGDKFQAXNNYFPYTHC KLGGLGITSAIDEYLIQSIT GITRLFHSSNLSFRKMLITE LAHSRGGKNFEAGLKWLNCE VNKAFPNTSFFVKFQKSALA LKRKFCICVNLKFVEDNFSL EMTYKKRTSYVNHQNLSTLS KELHDFVGLYYAEQXCQMRV QGHIATAIGDSITAKYLIAS DILNDAQYYFLVRARNNLLN LNYNAYRLKYNIGTKCRLCH LDEETQAHXFNHCRAKPNAR RVKHENVLVSIVAFLEKIGF EIDVEKSPKYISIPTKLKPD MVIRSKRNKDIHVLDLKVPY DSGEGFEKAREDNYVKYKDL AIEIGKAFNQKATISAVVIG CLGTWDKKNNAALSKIGLTK TEIISLARIACPNAVIACYH IYREHVSFTKSAMALPFSLA (SEQ ID NO: 1421) NeS R5 AY216701 Girardia GTAGGTAACTATGACTGCAA TGATCCGTGTGTTTGTGTCG TTGRNLGQWSCYSRSIQQSN L tigrina AATAATAATTCTACACCTAT TATGATTGTTTCCGTGTGTG YSFKLSSTEVGELVEQSPAP TGTTGATAACTCATCTCGTG TCTATATTTTTCTTTTTTAT LQSPQFSNNYNNLNINNNLY CGCAAACGGAGCATGTTATT ACTTTCAATTACCTCGTTGT YSLNTFNQSNNLCCLVNIEF TCTAATCATTTCGTCACACA AATGTTATAACTTCATATGG FPTQHLLGDIVNSGCINYMN GGATTCTTCTAATTCTGATA AATATATGTAATTTAGTTTA NYNNFDNINLYINSNVLSYN GTAATATTATAGATAGAGAT GTTTAGTTAGTTTAGTTTAG NYNHSFLASPYTTNITEHAD AGGAACCTTGTTGATTTAGA TTTAGTTTAGTTTAGTTAGT INMHVQEVNMQQDNNTQHAI TGCGTCAATAACTTCTCCTA TTAGTTAGTTTAGTTAGT TQQVSLQATSLQHTLDEMIV CTATTATACAGCCAGAGGAT (SEQ ID NO: 1300) QFNTAVRLKKKHKVAKIFRG AGTAAGATATCTGAGGATGA HNHRKDLPTLPAREQYKTKP GGACTTCATCTTAGTCAATA KLAIREVLHRKTTATSSPSE GGAAAAAGAGCAAAAATAAG NAIKAFFSSYSRPAELFTGQ AAAAAATCTAAGAAAACAAC ELLESSWFPVHPEDDFEFRI TGAAAATAAAAATGAAATTC PGRDQIAKYIKFASKSAAGL CTATTCAAAAGAGTAAAGAT DWITYEDIKLGDPSGEILQP AAGAAAAAGAAGTCTAAAAT IFEYIVQNNICPSEGKASRT TAATACCGAAAAACTAACTG IMIPKPGKSDYSDPSSWRPI AAAATATTACTACTTCTGAA TITSAVYRLLMKYLTWELYN ATACCACTTGAAATTGCTCC WILLNQMLSRSQKSLGKFEG TTCCATACCTTTACCTTCAG CHDHNAMLNMLIQDVRRQTN CAAGTACCTCGGGTTCTCAA PSNPINKNKRLYIVFLDFTN CAACCGGCCAATCCTCCAGA AFGSVPLDTLMYVPQRFGLG AGACGCTACTCTAAGTGATA TSALTLIKNLYLDNYTNVTC CGGATCTCTTCCTTACACAG GESKIENVKLNKGVKQGCPL GATGATCCCGATAGTCTTAT SMLLFNIFINIIIRAIEAMP TCTTTCTGGAAGTACTCAAC DVHGYPLGDMDIRILAYADD CAACCTTTGTTGACCTCAAC IALISDSHKDLQEMVYKAEY CCTTCACAGCAATCGGAACT IGRILGLLFNPSKCALMDIP TCCTTCAAATACTGACAGCC HDKKRTPPILVNGEMIKCVG AAAGATTTGAGGCGGGTGAA KADPYKYLGTFRSWFRKLDI ACACCCAAAATCATAACTTC KELLQMMMDETKLITESNLH TTACAGGGATGACCTTTTCT PHQKIHAYETFIHSQLPFHL ACTCTACAGTCCTTCACTAC RHSRIPFSDFITNRKTNKTT AACTCAGATACAGGTTACGG NNSNDSEKSIQKAYDPESGQ TATAAGTGTTGACAATGGGG LFLNTFALPSGCAKDFFYIT AGCAGAGGTTTCGAATTCTT KDAGGPQLTSGLDEYLIQSI GCTAGGAATCTTGTCAGGAA MYIFRLLGSEDPTLNSAIKH AACCAAGGATAAGTTCCCCT DLISHLNLKGFVNINFSQAI CTTTATATGCTGGACAAGTA SIFNSNFTDRTDHFSHLSRT ATTAGACACACAGTCTTCTT EWARLQLARKKLKSTLAIQT CAATCACTTCAACCAGGCAT NVCLINGHLVLTLSLENNVL ACTACGCCAATAATATAACT LIDSKEKGDVKKIHASLMGF GATAGTAAAGGTAATCTAAT LRLAHLIRLQKHGWSKLLFS TGAGTTTTCTGATGATAAGC ATTHHEILNKRILNGHVPYK CTTTTCAAAGTATACCGACT IWYFIHRARLGLLPTKLFSV GACCCAAAAACTGAACTAGA SNLCRKCGGKKETMSHALVN GCAAATTAGGAGAGAGAGAC CPMMQTLINERHDALEISLV AACATCTAGTTGATAGAGCT QILSSKFQGTVIRQKTYVNE CTTAGACATAATCAGTTACG LRPDITMESDTQYYLVEVKC GGAAACTTATATTTTAAATA PFDTKMSFELRTQQTTDKYN AACTTAATAATAATAATGGG IIIEILEDVHPGKEVRLVTF GGGGGTGGCGAACATTTGAA IVGTLGSWGPQNSDFLRDLG AAGGAAAAAGATCAAAGTCA FSKDEIDQVKTRLMLQNINS ATACGGATGATGTCTCCAGC SCEQWKRFVQYAPTITPGPI AATGATGGAGACAGAAAACA PDAESEDDQGTSDNGPTAAT TAG VQGPVIGDEEEELQIYDSGL (SEQ ID NO: 1177) DESSDDEPDPDDAELLFTID IEQYLNSVITD (SEQ ID NO: 1422) NeS Utopia- . Chrysemys GTTTAATTCCTTCTGATGGA TAACCGAGACCGCCGACCAG MESPAXIFEKIDAALXIYSA L 1B_CP picta CATCTGCAACACCCGTCCTG GGAAATAACCCACTTCCTTC AAXLXXNSLSLSPXXAXXSX B bellii AAG CCTGACGAACCAAGGGACGC XAAPASSTPQKTQXKPIPXT (SEQ ID NO: 1178) ACCCCACCCATGTACTTATT TLGASRKXRTTXKDEXIXXW CGCTACACCGATACTGACTT XKKAPVDTSXGRXSTRRTAL GGACTCCTTATACATTCCAT RDLTSRSXNIXXALQEEDPR GGGTGGCGTACCCGAGCCCA RTPPXSRDQDAERRPAAPEK CTTATCCACTGACACTTTAA AATRGAPPTIQDQDADRCPA AAACTCTTGCACCCCAATCT GRDATGGAPRRPRTRMLXAA GGGTCTATGCCGGTTATGCG PLGRMPPEEPPPTTRDQDAD ATATGTATGTATCTCTTCAT RRPAAPERDAPEGTTSSTPD CCTTGCAACCGATACCTGTA PETTYHPPVRRRAAPRGTHS ATCCCTCATAACCCAAGCCT XAXDLDAARCPSGQRDIVAS GACCCCAGATGTACAGTACC ESSTPPGATSPPQASLPDXE TTCCCTCTTAACTCGTGTAT ESPAESAGTTEVRPTEGEAG ATTTAATTTTAAACATTAAC EDDCIYLQYPXPTGLLLCPF TTTAATAAAATTTTTAAA CLPXHGVQTLGALSKHVRKA (SEQ ID NO: 1301) HNKRIAFRCSRCDAPFETQK KCKXHXATCKGPLTTAKVNP TDTLRVPTPTPTDGPASAPQ PASPEPQXVRGDQPPTEGSA TPASRTDDATKRTSPASRIP TLDPAVRGITATSQVSDLTR CLSDLIKTIRHNTDTRRXSA PPQVTSCRPAVGATSTAPQA ARRDPANGGASRSPQIPRPD PAPGRPNTSSKVTQRDSDRQ KPHAPPRTPQPDTTRRRTRT IPSASKHDRAPTKPNTGVSR TPLPPGRSSAASETPRAAPP PPHQDPRLKTHLNTAPQSEG QQGHRLSPQHLNPRRQRSRR NDGREQRVATPWQSAWMEEL AKAEDFETFDTLMDRLTAEL SAEITARRREPQEASRATRR FPAPTRNNTAREGRRGDVGR RYDPAAASRIQKLYRTNRTK AMREILDGTSSYCAIQPERL YSYFKDVFDHEAQTNLQRPE CLLPLPRINLTEDLERDFSP QEVQARLMRTKNTAPGKDGI RYHLLKKRDPGCLVLAAIFT KCKQFHRVPRSWKKSMTVLI HKKGERDDPGNWRPISLCST IYKLYASCLAARITDWSVCG GAVSSVQKGFMSCEGCYEHN FLLQTAIQEARRSKRQCAVA WLDLTNAFGSIPHHHIFATL GEFGMPETFIQILRDLYKDC TTTIRATDGETDAIPIRRGV KQGCPLSPIIFNLAMEPLIR AISSGPTGFDLHGKKISILA YADDLALVADSSESLQQMLD VTSQAAEWMGLRFNPKKCAS LHVDGGARALVRPSRFLIQG EPMASLEEGEVYQHLGTPTG VRVRQTPEDTIAEILRDAAQ IDSSLLAPWQKINALNTFLI PRISFVLRGSAVAKVPLNKA DSTIRQLVKKWLYLPQRAST DIIYISHRQGGANVPRMGDL CDVAVMTHAFRLLTCPDPTV RSIAQEAVRDVVRKRIARAP SEQDIATYLSGSLEAEFGRE GGDLSSLWSRARNASRRLGK RIGCCWKWCEERRELGILVP RIKTPDHTIVTPTARAMLER TLKDAIRCHYAENLKRKPDQ GKVFEVSSKWDASNHFLPGG SFTRFADWRFVHRARLNCVP LNGAIRHGNRDKRCRKCGYA NETLPHVLCGCKQHSGAWRH RHNAIQNRLVKAIPPSLGKI TLDSAIPGTDSRLRPDIVVT DAEKKKVLMVDVTVPFENRS PAFHEARARKALKYTPLAET LRAQGYEVQIHALIVGALGS WDPHNEPVLRACGVGRRYAR LMRQLMVSDTIRWSRDIYTE HITGHRQYHTE (SEQ ID NO: 1423) NeS Utopia- . Acanthamoeba CCCGTCAAGGGTGCTCCACG TAACAACCATGTATGGTGAA MAAKSVACPHDGCANKYASE L 1_ACa castellanii AGATCCCTGTCGCTAGCCGA CCACACCTCTCTCGATCTTG ASLRRHIKNKHATDEEGDET CCGGTTTTACCACCCCACCC TATTCTGTGATTGGACATCA SHSCPHCHRPFSTARGLSVH CGCCCGGACAACCACGGACC GAGTTCCTGCGAAGGGATAC IGKSHRQAPPEPTRPPPAPA CTGCTCCGCAGCAGGACCCC ACTCTGCCAATCTCGTGGGT PADPGLDPDPGPTVTPPSRD ACGCACG TGTAATAAATCCACACCTTC DEDREEPDDDPVEIADLSCP (SEQ ID NO: 1179) AACA HCAQALPSAHGLANHLRACK (SEQ ID NO: 1302) DHRVPAPGAPRSGPPSSRYW TAVEHHRYVEAMARFADHPD LLARAAAHIGTRTYKQVDSH RTKVIAAEREGRPVRTLDPT MDWRMRPYCASTTARWLAEQ GRSPVAPRSPCPEPHAPPPA AALLYIPATPPAPTPRAPVA PPKLAPPAESTVPATPDGNP EAPAPPFSAPGPPTPKALPP PPPSRRNLRPHLVPKDAWQG VADAVAPAASRLLRTPLAHL STEQWATFEAALAGLEATLH HAARSAEAVPTRCASRARED AERQLREARKTREIFGKAAA LYAAGKDPTATIERIPPEVR LHLPTPGSAEWPARAAAARR VIRRAVARADRLRKRMGILD SDRDLQRLFNANQKKAVRQI LAPSTKAPRCQLDPAAVEEA YIQTLAKPPPIDPSPPWKNS VQWPRPPTAADDGGSPFSVA EVRAQLRRLPNGSAPGIDGI PYEAYKRTKLDATLAHVFEV VRLNARLPARWDVARTVLLY KKGDPNDTGNWRPISLQVTI YKIFTAALSKRLISWAGKHN TFSASQKGFLPAEGCHEHAF VLRSVLDDARRHKQNVYLAW YDLRNAFGSVSHDLIAWCAA MLGLPRYLRDAIGAIYRHSA LFVQVGDQETTGVIPMRCGV KQGCPLSPLLFNLCVEPALR CLRRTTGYKFYGTSITVEGQ AYADDLLTAAPSAYHAARQV ATIEEWANWAGVSFVVQALS LDAPAGKCAALAINFEGGLM HSIDPALKVQGAAIPAMSRN NVYRYLGVHVGLTDALGQAN ELLEKASRDARTICASGLEP WQKVVAIKTFILSRLPFFFH NGKIQRGRCQQFDRELRENL RAALRLPVCTTNAFFHSRVA SGGLGILPIAEEQQVYLAAH VFKLLTSPDLSIRAIARHQL AEVTHARHTTPVQDGEASPF FGWLMRGQEVASTTPSGDVS SIWFAAAGAYSRMGWSVRDA LHPTLTVGPGVQFEGRFORA NVIPALRASAFSRHAVEWSA LRTQGRAAAYQHAVHPATHH WVHNSAGLTTKEYRFAIKCR LGLLPTRAAPHHRNGPTACR ACSYARETANHVLGHCPATK AEVIARHNRICRALAQAAEA SWTSVLEDVPIPGVDSPLRP DIYCSRPGQCAIIEVAVSYE DAFNASMEGRAKQKTDKYAG LAATVEEQLRLQTRHAAFVV GFSGVVLPASVTATATSLDL PPKTWNVLLKRCVAASIKGS YTAWRRFRRSTP (SEQ ID NO: 1424) NeS Utopia- . Acromyrmex GGTGCACAACGGATGCATCA TAAATTATTTTGTCTTTGTC VCSVRGCRREDSRRFYKFKF L 1_AEc echinatior TACGTGTACCGGAGCATACG TTGGCCCCCCCTTTTTAAAC PLNFVKVPKTIVIGSAFQKS GGCTGTCACGGCGGCTGCAT CAAGCAGGAGAGAGTGGCCC SVSARSQNHSRSTRVPKTRQ GCGCGATCTAGCTCGGAGAT AATGCCCAACTATTATATAT PRTSNTIGRYTAASANNYLT TTTATTTATTTATTTATTAA TAACTATTTACTGTGATATT VIITGNYTVFAQWICYRECT TTTATTTATTTATTCATCGA TATTATTTGACTGTTGGGCG WLLSKFVNFFLTIIGYFFQL GTGTGAGTGTTCGCGTTTTG GGCCCCTCTCTGCTGGTTTT RLVVIYEGPVILDTFSNCGS CCGAGAAGCGATTTTCGTTA ATTTATATATATTTTTTACT SLFMRGQXSKALLVRLNRSA AGTGATACGCGCCGCGTTCA CGCGTACTTTTTGTACTACT LAMADPQVHYIDYPLPPRVK TAGGTTAG CTATTTTTCTTTTTATTTTA CVKCFGAEGAGKVKGEYSDP (SEQ ID NO: 1180) GCTATGCTATTTTTATCTCT PHLAKHLKKCHPGDTLNYKC TTCTTTGTCTCTATTTTCTT SICDLRGTGKYPLRDVKAHY TCTTTTTTTCTTTCCTTTTC AECHVSPAVDAAGPSTRGSL TTTTCTTTCTTTTATTCTTC GECSGAGQPTASRAAKATTR TTTTATTTATCTTTTTTTCT LAETVGGTDKRRAATSGSRQ TTTCTGTTGTGGGGCCCTGA LTLPFAATPSPSTAAGEARA CCGTCCGAGTGTGAATGCCG PRSXSTTPTSRSPSYAAVTA CGAAAAACAATATTATGTTT GPPSMRSTTTSTTARSKTVA TATACGAGTGTGCATGTGCG KGAAPNTTTTTTARRSGEAA TGATATATTTATCTATTTTA ATRKPPTTATVSKPRVLSVE TTTTATTTATTTATTATAAT TVRLPVDDIQRAGVQNAAKP TTATTGCCGCGCGCGCTCCT ARAPSRPPQRTSPEAGGPRT CCGGGACTTTTATTCGTTGA TGAKEKCGEGAYKKLPANSG CAATACTGTGATATTTTTCT NPISTRTRRATSVPVEKSEG GCKCAGGCTGGGGGGGCTTG TARRERVSPHPPPKGIDIIL CCCCCCAGCCCCTTAGTTTT SSTSEEEGTPYQPGGVGRLR AATTGCCTATGCGGGGGGGG LRRKKVTGPPPKMTPREGVV CTTTTGTCCCCCGCAAATGT TRARRSTSAPVEKSALDARL ATATATATATATATTTAGCG TALDRTSSRATGNPTSQIAG CGCGGCTTAGCCGCTTTTGT GLYTSRGQPERTPPARLPSL TTGTATTACCCCAGAGGGGA SPTTRGSPSGSLGEIRTPIS ATTGTCCCTCTGGGGAAAAA PATSLPATLTTCTVTTTTCG AAATGATTGGAAAAATAAAG SPITSTGFTGGVGRLITPPS TGAGCTAA LPQTNILPTIGEEGTSPCVA (SEQ ID NO: 1303) VVTTHPRPTGEDAPCEAPQP VSDHQRQSIGEPRRDTDTHL ACDVATGNAHHLHGDDDHLW KPHNIHGLHRWRGEADNTXE PPPNEHPPDHRGGRNVTVRG GRHHPSLGGRSTSPLILPRP TTPEPERGQEERRLEGAAQP PTTPVVEGDNQWDGQWTVSV RRRARRQQLNDTSPSNSESP PTAGPSRSPRIAPLSALIAA STSRHETSLNLNCTNGNICM DRTPPRNILPVXAERRRETS PQDRVEGDIGYGAGKVSAEH PSAPVNVRGVMSRGRATASS IVPPRANRGEGGRQHHSRRR PDAPVGQPSRDHPAPATVAR QRRRERVAARDALLDRAKDV ATIADLEAFAASVAAFFGED ASATGAAARARDRSVRSREA GARRGVKGGERPEREGAGRP GSAPADPGASGEARGDWVRE AKRLQALYRANRRKAVREVL QGPADQCQVPKRQVQEYFER LYSGGEDLAGAGVEAERPDP SSPREVSAVLGPLAEREVDR RLRRMNNSAPGPDGVSYRDL RGADRGARLLTALYNICLRL EAVPASWKTSNTVLIHKKGD RGMLENWRPLALGDTVPKLF AALLADRLTDWAVTRGKLCS AQKGFLRDEGCYEHNFVLQE VLTHAKRSKRQAVVAWLDLS NAFGSIPHATIRRALIRSAV PRGLIAIWDSMYDGCTTRVR TAEGHTAPIPIRSGVRQGCP LSPIIFNLAIDSVVRVAAEX NDGYSLHGNTWSALAYADDI ALLAQTPEGMERMLASVEAE AASVGLRFNPAKCATLHVGA GNGGRVLPTSFQIQGETINP LAQGESYTHLGVPTGFSVDQ TPYAAVGDIVSDLRAVDRSL LAPWQKIEMLGTFILSRLDF LLRGARVFKGPLTAVDLNIR RHVKSWLNLPQRASAEGVYM PPRWGGCGLLPLSDLADVLT VAHAYRMLTVRDGAVRELAW ESLRGVVGRRIGHAPSCEDI ASFLSGSLDGRMRGGGEASL WSSARNAALRQSERLSLRWR WVEATEEMTLECRGPRGAAI KIPPEARGQVVNRLRSAVAE HYASRLLSKPDQGKVFEVSS RSRVSNHFIRGGSFTRFADW RFIHKARLDVLPLNGARRWE ANDKRCRRCGEVSETLPHVL CHCGIHSAAIQLRHDAVLHR LWKATRLPGVVRVNQRVEGV SDELGALRPDLVVRHEPSKS VVICDVTVPFENRWTAFEDA RARKIAKYSPLAEELQRRGY RVVVTAFVVGALGSWDPRNE AVLRLLRVGNQYAAMMRRLI VSDTIRWSRDIYVEHVSGTR QYLAPSRPSGDLATPPRAVR RRWLAEERSAQDAARRGSDS VSVA (SEQ ID NO: 1425) NeS Utopia . Alligator TGCTGGAAAGACGGAGAACC TGAACCCCCCCTCTGCACCA CHHAGLRPGTPNRTRRPDQT L - mississippiensis GCTTCCTTTTTCCCTGCGCC GATGGACCTTCACTTCGAGA APLPDPRGHPMPPNRRGSRS 1_AMi TGGCCTGGTATTGCAGTACC GGATTCTTCAGCAATGGACG RPEEPSRREPPXPRACQGLR TCCAGGATTAGCGCCAACTA ACCCCGCTCCACCCGAAGAG VWSPPQQRMPTPWQTLWLEE GTCCGGCAGACTGTCGGAAT GACCCCCGCGATGAGACTCT LSRATTFKAFEASVARLTEE ACAGCAATAGAAAGWGAGCT ATATGGACTGAGACACTTTT LSAAARPGQPRGGNNRPATR GACTAGCAGCTTGCTTTCCT TCTTCGAACCACTTCCTCCA RDHRLQPQRRPRRQRYDPAA TCCTCCGGTGCAGCATGGGT CCATTGCGGACCATTGTAAC ASRIQKLYRANRPKAVREIL TCTCGTCAGTCMTGACGGGC GGGTTTGTGTGTATCTATCT EGPSAFCQVPRETLFNYFSR TAGGGAAGGCGGTGCTGCCA TCTTTCTCTCTCAGCGTCGC VFNPPAEAAAPRPATVEALT GTACGTCCGAAAGAGTGCCG GAACCCCCTCCCTCCCCTTC PVPPAEGFEDAFTPQEVEAR GTTGCGCAAGCGACCGCGCC CCCTCCCCCTCCCCCCCACC LKRTRDTAPGRDGIRYSLLK ACTCAGGTGAGTAGCCAAGG CCCGGGCTTAGTTGGCTAAC KRDPGCLVLSVLFNRCREFR GTCTTACAGTTCACCGGACC ATTGTATCTCCTGTAACCTA RTPTTWKRAMTVLIHKKGDP CGAWAACGCGAAAACCCCAA GTTGCGTTCCCCTCCTCACC TDPGNWRPIALCSTVAKLYA CTCGGGCTAGTAGCCGAAGA CCCATCCCTCTATTGTTAGT SCLAARITDWAVTGGAVSRS CCTGGGTCCCCCCCMGGTCA CCCTCGCTCGGGCGCTCTGT QKGFMSTEGCYEHNFTLQMA GAGTAGGCGAACGCCWGKGC ATTTCCCTACCGGCTTTGTC LDNARRTRKQCAVAWLDISN TCAGAGGACGGAACGCGGAA ATCTTTTTTGGATTCACAAT AFGSVPHRHIFGTLRELGLP AACACCCCCAGGTCCCAAGG CCTAAACATCTACTAATAAA DGVIDLVRELYHGCTTTVRA ACGCCCTGATCCACTGACAA AGTCAATC TDGETAEIPIRSGVRQGCPL GAACGCTCGAGGCACGCCAG (SEQ ID NO: 1304) SPIIFNLAMEPLLRAVAGGP GAGACCCCCAGCTAGGGTGG GGLDLYGQKLSVLAYADDLV ACCGCCGACTGCAGGTCCGG LLAPDATQLQQMLDVTSEAA AGGACCCTCCCAGGAGGGTG RWMGLRFNVAKCASLHIDGR GACCAGCGAACCCAAGTTGG QKSRVLDSTLTIQGQAMRHL CGACGAACCCTGACGCACCC RDGEAYCHLGTPTGHRAKQT CCCACGATGTCAGGACCCCG PEETINGIVQDAHKLDSSLL ACAGGCGGCGGTGGACCACT APWQKIDAVNTFLIPRVAFV GACCATCGACCGACCCCCAG LRGSAVPKTPLKKADAEIRR AGGCAGAGAGACTCTCAGAG LLKKWLHLPLRASNEVLHIP CCCGGAACCCCGGCTGACGA YRQGGANVPRMGDLCDIAVV GAGCCGCCTCCCGGCGGAGG THAFRLLTCPDXTVSIIAAS ACCCCGGAGCCTGAGGATGC ALEETARKRIGRQPTRRDLA CCCCCGGATGACGGCGGAGC TFLSGSLEGEFSRDGGDFAS GCCCCGAGCGACAGCGGACC LWSRARNATRRLGKRIGCAW CCTCCGGACCCCCACGGCCC TWTEERRELGVSLQPAPHAD CTCGGTGACGATGGCGGGCC RVTVTPRTRTFLERFLKDAV CCGAACGACGACGACCCCCG RNKYAGDLRAKPDQGKVFDV GACCCCGGCGGTCCCGAGGA TSKWDSSNHFMPSGSFTRFA CGCCCCCCCCGAGGGTCTCC DWRFLHRARLNCLPLNGAVR CCACGCTGGTGGAGGAGCCC FGHRDKRCRRCGYVAETLPH CGGACCCCCCCGACACCGGA VLCSCKPHARAWQLCHNAVQ CCCCCCCACGGACGACCCAG DRLVRAIPAAAGEISVNRTV GCGAAGGCGTAGACATGACA PGCESQMRPDIVITNEEAKK GCACTCACGTTCCTCCCCTT VVIVDVTIPFENRRQAFTDA CCCCCTCCCGGCGAAGCTGT RARKREKYAPLADILRGRGY TCTGCCCGACCTGCCACCCG DVTVDALIVGTLGAWDPSNE CCAAGACAGTACAGGTCGCA SVLHACRVSRRYAKLMRCLM CGGCGACATGAACAAGCACC VSDTIRWSRDIYVEHITGHR TACGGCGCTTCCACCAGCTG QYTDPTRRTAAGPDPEGTA CGCCTAGCCTTCTACTGCGC (SEQ ID NO: 1426) CCTCTGCGGCACCGAGTACG AGGCCCTGAAGCTCCTGAAG AACCACCAGAAGGGATGCGA GGGCCACGGAGCCGAGAGGA GACCCGGCACGCTGGTGAGG TCCGCTGCCCCGGCCCGCCG GACCCAGGCCGCGGTGCGAA GGCCCGCCAGACTGGCCACC CCGCCGACAACCCCACCGGA CCAGACCTCCAGGGACCACC CGACGGAGAGACCTGCCCCA GTGA (SEQ ID NO: 1181) NeS Utopia- . Chelonia CTCTTCTTATGAATACTTGC TGAGCCGGTACGACATCGTG MTTKKVLGASTTLQTSSTKG L 1_CMy mydas AACACCTGCACTGAAGATGG CATCAACTATGAGAAAGGGA KNSGCSKDPLRDAVPGRSWI ATTCTCCGGCTGCTATTTTT CTGAGAGACTTTTTCCATTG LRPACRDITTRRNIPPAPQQ GAAAAACTGATGCTGCTTTG GACCATATGAACTGGAACCA QQPPMESPPTLQLQDALRRP AAGGTGTATTCTGCTGCTGC TAAACTCACTGAACATTAAA SPTPAAAQVADAGGALAALH TACCTTGGAAGGAAATTCTC TCTCACCAAATGAGGGTAAA TIKRGISVDWTSISPKXXQR TCTCTGCTCCTGAGACATCC TCCATCCTCATCATCGTATC XTSASPDACPASETTQRDXR CCAGCTGCACCGTGTACCAC CACTCATTATACTCCACACC XLLDARPAGPLDPTRPHQDE CACCACCACTGCTGCTGCTC TGAACATAGCCATTATATGA PASDTADAAGTPLLQGNEDT CACAGAAGGTTTCTCGGACA ACAACATACCCCCATATCTC IYLQYPLAADMLICPICSPP (SEQ ID NO: 1182) AATGTCTGTACTTTGACCCG QSFHLLGVVTRHLKRCHSKR TTAACCTTTTACCCCCAATC VAFSCALCSLPFETQKQCKM GGGGATATTGCAGATTATGT HQVACRKCLKGTTQSPAPAP ATTCCTTACGCCACCCGATC SPPAARRPAAPEPQRRKXTS CTAAACCGAATTTCGCACCC QAAVKKPAPVARPAERDAAI CTTGATAATCTGTACCTTAT EKVPAASGNITQVLASRRPV TCCCTGATAACCAGAAACTT SPSHVAKXISMLRRLSAASP CTATGCTTAAACTCTGTACC PVQHVPVPRRISAPPRIAAR GTTTTTTTTTATTTCAACAT DPVAGRASAAPQTALRTPAA CATCTTAATAAAATTATTAA GGASTTPQTALRTPTAGGAS A AMPQTTLPXPRRPDWRNQPR (SEQ ID NO: 1305) SHSKAPGLHRQTDQHGPQVH SAGHCLREISRSSSNRLGSS HSAAATHRRTGGVPATPEPD RVSPTTSNAXIPPEIPPQHP TEGNPDPRDRRQADHTAGSE PAPDEVEDXEGQRPMVRAAT PWQTAWTEELQAAASFDDFD LLVDRLTRELSAEIAPRRSS NQENAPPAHRTPAPNHNTTT RGARSRDASRRYDPAAASRI QKLYRANRSKAMREILDGPS PYCTIPSERLYSYFKDVFDR IARNDAQRPECLRPLPRVDE AGVLETDXTPKEVMARLSKT KNTAPGKDGIPYSLLKKRDP GCLVLATLFNQCKRFCRTPS SWKKAMTVLVYKKGERDDPS NWRPISLCSTMYKLYASCLA SRITEWSVSGGAISSIQKGF MSCEGCYEHNFVLQTTIETA RRARRQCAVAWLDLANAFGS MPHHHIFATLQEFGMPENFL RVIREVYEGCSTTIRSVEGE TAEIPIRSGVKQGCPLSPII FNLAMEPLLRAISNGTDGFN LHGERVSVLAYADDLVLTAD DPESLQGMLDATSRAADWMG LRFNAKKCATLHIDGSKRDS VQTTGFQIQGEPVIPLAEGQ AYQHLGTPTGFRVRQTPEDT IQEILQDAAKIDASLLAPWQ KINALNTFLIPRISFVLRGS AVAKVPLNKADKIVRQLVKK WLFLPQRASNELVYIAHRHG GANVPRMGDLCDIAVITHAF RLLTCPDAMVRNIAANALHD ATKKRIGRAPSNQDIATFLS GSLDGEFGRDGRDIASLWSR ARNATRRLGKRIGCRWEWCE ERQELGVLVPQIRSNDNTIV TPSARGMLERTLKAAIHSLY VETLKRKPDQGKAFELTSKW DASQPLPRRGRLHPFRRLAV HPPCPAQLRPAQRSRPPREP RQALQEVRLLQRDPAPRPVQ LQAPLQSLAAAPQCHPEPPG ESHRTAPGGGRRELRHPRYP ASGTPANHFLAGGGFTRFAD WRFIHRARLNCVPLNGAVRH GNRDKRCRKCGYSNETLPHV LCSCKPHSRAWQLRHNAIQN RLVKAIAPRLGEVAVNCAIP GTDSQLRPDVVVTDEAQKKI ILVDVTVSFENRTPAFREAR ARKLEKYAPLADTLRAKGYE VQMDALIVGALGAWDPCNER VLRTCGIGRRYARLMRRLMV SDTIRWSRDIYIEHITGHRQ YQEV (SEQ ID NO: 1427) NeS Utopia- . Chrysemys TTTTTTCTGATGCTTGACTG TGAGCCAGAGTGACATCGTT MTQDQDADCCPAGKDATRGA L 1_CPB picta CAAACACCCATCCAGAAGAT CTCCCACTACGAGAAAGGGA PPMTQDQDADRCPAAPERDA bellii GGAATCTCCTGCAGCCATTT CCAAGTGACCTTCTCCGTTG PEGTTSSTPDPKTTYHPAVR TTGAAAAAATTGATGCTGCT GATCATATGAACTGGAACCA RRAARRGMHLRAQDLDAARC TTAAAGATATACTCCATTCT TAAACTCCCTGAACATTAAA PSGQRDNVASESSAPPRATS CCTWKTTTGKAAGAAAACTC TCTCACCAAATGAGGGTCAA PPQASLPDPEESPGESAGTT TTTTTCAGCTTCAGCTATTC TCCATCCTCATCATCATATC EIRPTEGEAGEEDRIYLQYP TGTCATCGGCTGCTGCTGTT CACTCATTATAMTCCACACC LPTGLLLCPFCLPVHGVQTL CCTGCTTCCCAGAAAGCTCA CGAACACAGCCACTCTATGA AALSKHVRKTYNKRIAFRCS GCMAAAACCTATCCTGAAGA ACTTCATACCCTCATATCTC RCDLPFETQKKCKFHQATCR CCWCCCTTGGTGCCTCACGG AATGTCTGTACTTTGACCCA GPPTTAKVNPTDILRVPTLT AAGACCCGGASCACCTGCAA TCAACCTTTTACCCCCAATC PTDDLASAPQPASPESQQIR GAACCAAAACATTAGGAGCT GGGGATATTGCAGATTATGT GDQPPTEGSVTPASRTDDAT GGCTGAAGAAACCCCCCGTG ATTCCTCATGCCACCTGATC KRTSPVSRIPTLDPAVRGTT GATACCTCWGCAGGGAGACC TTAAACCAAACTTTGCACCC ATSQVNNLTRRLSDLIKTIR TGGSTCCAGMAGGACAKCTC TCGATAATCTGTATGTTATT HNTDTRRCSAPPQVTSCRPA TTCGGGACCTCMCATCSAGG CCCTGATAACCAGAAACTTC VGATSIVPQAARRDPANGGA AGCAAGAATATCTCAACAGC TATGCTCAAACTCTGTTCAC SRSPQIPQPDPAPGRPNTSS TCTTCAGGAGGGGGACCCCC TATTTTTTTTAACATCATCT KVTQRASDRQKPHAPPRTHQ GGAGAACCCTGCCCGCTTCC TAATAAAATTTTTAAATCTG PDAARRRTRTIPSASKHDRA CAGAACCAGGATGCTGATCG TT PTKPSTGASRTPLPPGRSSA CCGCCCCACCGGGAAGGATG (SEQ ID NO: 1306) ASETPRAALPTTPGPPPQDP CCACCGCAGGAGCCCCCCCA PEHRSTVRGTTRPQTVPAAP (SEQ ID NO: 1183) EPAETTQQEERRPRARVATP WQSAWMEELAKAEDFENFDT LMDRLTAELSAEITARRREP QEAARATRRFPAPSRNNTAR EGRRGDVGRRYDPAAASRIQ KLYRMNRTKAMREILDGTSS YCAIQPERLYSYFKDVFDHE AQTNLRRPECLSPLPRIDLT EDLERDFSPQEVQARLSRTK NTAPGKDGIRYPLLKKRDPG CLVLAAIFNKCKQFHRVPRS WKKSMTVLIHKKGXRDDPGN WRPISLCSTIYKLYASCLAA RITDWSVCGGAVSSVQKGFM SCEGCYEHNFLLQTAIQEAR RSKRQCAVAWLDLTNAFGSI PHHHIFATLGEFGMPETFIQ ILRDLYKDCTTTIRATDGET DAIPIRRGVKQGCPLSPIIF NLAMEPLIRAISSGPTGFDL HGKKLSILAYADDLVLTADD PESLQGMLDATSRATDWMGL RFNAKKCATLHIDGSKRDSV QTTGFQIQGEPVIPLAEGQA YQHLGTPTGFRVRQTPEDTI QEILQDAAKIDASLLAPWQK INALNTFLIPRISFTLRGSA VAKVPLNKADKIIRKLVKKW LFLPQRASNELVYIAHRHGG ANVPRMGDLCDVAVITHAFR LLTCPDATVRNIAANALRDA TEKRIGRAPSNQDIATFLSG SLDGEFGRDGRDIASLWSRT RNATRRLGKRIGCRWEWCEE RQELGIRVPQIRSDDNTIVT PTARGLLERTLKAAIRSLYV ETLKRKPDQGKAFELTSKWD ASNHFLDGGGFTRFADWRFI HRARLNCVPLNGAVRHGNRD KRCRKCGYPNETLPHVLCSC KPHSRAWQLRHNAIQNRLVK AIAPRLGEISVNCTIAGTDS QLRPDVVVTDEAQKKIILVD VTVSFENRTPAFREARARKL EKYAPLADTLRAKGYEVQMD ALIVGALGAWDPCNERVLRT CGIGRRYARLMRRLMVSDAI RWSRDIYIEHITGHRQYQEA (SEQ ID NO: 1428) NeS Utopia- . Drosophila AAAGTGTAGTTCTTTTCTGT TAAAAAATTAAAATGCCTTA YAPGYEAAQSPCGREPPRDH L 1_DYa yakuba TTTAGTGTAGTGGGAAGTCT AAAATAAATAAATATATCAA HRRPRDACGSSHSPEPCLTT k GTTTCTTTTTATTATGTTTT AATTTAAAAAAAAAAACGAG PRLLPETVSAEPCDDESQRT TTACGAAAAAGTCCTGGTCT GAACAAATAAACACAAATTC RYASPHKQARTLHDAEPRDA TTGAAATTCATTGTCTAAAT TGAAAGATTTATATAATTTA SREHAPSCAEPRCHRCQWTH TTTAAATAAAATTATAAAAT AAAWATAAATCGAAAATAAA WKDCCPHSTNTTDGPEGTDR TTAAAAAGAAAATTAATTAA TGTTGAAAACAAAAAAAAAA CADTITSPATAACPQRSPCP AGAAGCGATGAAATATCTCT TAATAATAATAATAAAAACA LGSSNGCDETAPEKRQPAAD GAAATTCAATCAATCAATTA CAATAACACTCACCCGGCCT LVHTAPFAVLVRAGPFADLV ATCATGGCGTCTCAGCGAGT GCCCCAGAGGCAGGTAAACA RAGPFADHHQDDDPLPHRSG GCACGTATTTGCCTACCCCT TTTACTGGCCATATGGCTTT SLGPLCSKQKDPRKTHQHRH TCGTGGGACCATTCCGGTGC TTTTTTAA SGQAGNQTHTDIPRAAPSRR TCCGTATGCATGGATGCGTC (SEQ ID NO: 1307) AAICLMANAAATREDLLRAA CGGGATGCATCCCACTAGGT TSLSEMAAANQPTRSPTGGG CGCTGGGCGAATACGGCACA EPTSQGRRGPQALADAAKRI TACGCTGCGGCATATCAGCA QQIYRTNIPRAMRKVLRTLL CATAACCCGGCGCCACCCAC TAVFSACLRTGHVPDLCKKS AAGTGGTTATTACATACCGT RTVLIHKKGDRTDLSNWRPL TGCCGGGTCTGTGGCGCTGA SMGDTIPKLFAAVMADRLTA (SEQ ID NO: 1184) FLTNGGRLSEEQKGFLQHEG CHEHNFVLGQVLEESRRQGK DLVMGWLDLSNAFGSIPHAT IMDAVAGMGIPSRIRTIIHQ LATGAATTAKTIDGMSEEIP IEAGVRQGCPASPILFNIAI ERVLRKIKTVNAGYLLYGSR ISPLAYADDLVLIASSPEEM RSLLRAADDAAIEAGLHFNP KKCATLHLTGKKSSRRAVQT GFLVRGTPIPAMTEGDAYEY LGIPLGLKKNQTPRAAMEAI VGDIAKIDDSLLAPWQKIDA ARTFVAPKLDFVLRSGATLR APLRHLDTVIKKHIKKWLYL PQRASAEVVYTPLKKGGAGI LPSSILADVLTIAQAHRMVS CPGEVVSRIASEGLREAVKR KINREPSGDEMAHFLSGSTL SGETASFGDAGFWSRVRMAT KRQAVHLGVRWAWRGGELLV ESRGQRNRPVATDSNSRSQL IQRLRCAAQDEFLTILINKP DQGKVAKLSTLTPVSNAFIR DGSFTRFADWRFIHRARLGV LPLNGAIRWGSGDKRCRVCG YQLESVPHVLCHCMHHSNAM QQRHNAVMDRLAKAGSRLGT PRVNCRVEGVAEDMAALRPD LVWRDERSRKIVIVDVTVPF ENGAEAFDNARGEKEEKYRP LAEALRAMGYQVKLEAFIVG ALGSWDPKNERVLKTLGVSR FYAGLMRRLMVADTIRWSRD IYVEHVSGIRQFTLPSGAPS N (SEQ ID NO: 1429) NeS Utopia- . Gavialis CGCTGGAAAGACGGAGAACC TGAACCGCCCCCCCTCCGCG MSGPRQAAADPRPSTDPRRQ L 1_Gav gangeticus GCTTCTTTTTCCTGCGCCCG CCAGACGGACCTTCACTTCA RDSQSPEPRLTRAASRRRTP GCCTGGTATTGCACTTCCTC CTCCGAGAGGATTCTTCGAC DPEDAPRTTAEHPERRRTPP CAGGACCAGCGCCAACCTAG CACGGACGACCCCGCTCCAC DPRGPSATTAGPERRRPPDP TCCGGCAGACTGCCGGAATA CCGAAGAGGACCCCCGCGAT GGPEDDPPEGLPTLVEEPRT ATAGCCTCAGAAAGAGAGCT GAGACTCTATACGGACTGAG PPTPDPPDGRPRRGCRRGSA GGCTAGCAGCCCTCTTTTCT GCACTTCCTTCGAACCACTT HVPPLPPPCEAAVPDLPPAK TTCCTCCGGTGCAGCGTGGG CCTCCACCATTGCGGACCAT AVQVAQRHEQTPTALPPAAP TTCTTGTCAGTCCTGATGGG TGTAACGGGTTTGTGTGTAT SVLLLPLRHRVRGPEAPEEP CTAGGGAAGGCGGTGCCGCC CTATCTCCTTTCTCTCTCAG PQGMPGPRGREETRHAGEVR AGTACGTCCGAAAGAGCGCC CGTCGCGAACCCCCTCCCCC RPTTRAAARRPARPAAPPAT GGTTGCGCGAGCGACCGCGC ACCCCCCACCCCCGGGCTTA PPDQTSGDRPTERPAPATPP CGCTCAGGCGAGTAGCCCAA GTTGGCTAACATTGTATCTC RRSAPRDPRPDVTPRPDGPP GGGTCTTACGGTTCGCCGGA CTGTAACCTAGTCGCGTTCC PGPPGPPDAPDPPRIPEPPG CCCGATAACGCGAAAGCCCC CCTCCTCACCCCCATCCCTC EPEPPGALQLPSVPGSPGAE GACTCGGGCCAGTAGCCGAA TATTGTTAGTCCCTCGCTCG TSAQQRMPTPRQALWLEELS GACCNTGGGCCTCCCTCCCC GGCGATCTGTATTTCCCTAT RATAFEAFEASVARLTEELS AGGTCGGAGTAGGCGAACGC CGGCTTTGTCATCTTTTTTC AAARPGQPRRGADNGPTTRR CCGTGCTCGGAGGACGGAAC TGGATTCCCGATCCTAAACA DHRPQPQRRPRRQRYDPAAA GTGGACAAAACACCCCCAGG TTTACTAATAAAAGTCAATC SRIQKLYRANRPKAAREILE TCCCAATGACGCCCTGATCC TGTTCTTT GPSAFCQVPRETLFNYFSRV ACTGACAAGAACGCTCGAGG (SEQ ID NO: 1308) FNPPAEAAAPRPATVEALTP CACNCCAGGAGACCCCCAGC VPPAEGFEEAFTPREVEARL TAGGGCAGACCGCCGACCAC KRTRDTAPGRDGIRYGLLKK GGGTCGCGGAGGACCCTCCC RDPGCLVLSVLFNRCREFRR AGGAGGGTGGACCAGCGAAC TPAAWKRAMTVLIHKKGDPT CCGAGTCGGCGACGAACCCC DPGNWRPIALCSTVAKLYAS GACGCACCCCCCCCGCG CLAARITDWAVTGGAVSRSQ (SEQ ID NO: 1185) KGFMSTEGCYEHNFTLQMAL DNARRTRKQCAVAWLDISNA FGSVPHRRIFGTLRELGLPD GVIDLVRELYHGCTTTVRAT DGETAEIPIRSGVRQGCPLS PIIFNLAMEPLLRAVAGGPG GLDLYGQKLSVLAYADDLVL LAPDATQLQQMLDVTSEAAR WMGLRFNVAKCASLHIDGRQ KSRVLDSTLTIQGQAMRHLR DGEAYCHLGTPTGHRAKQTP EETINGIVQDAHKLDSSLLA PWQKIDAANTFLIPRVAFVL RGSAVPKTPLKKADAEIRRL LKKWLHLPLRASNEVLHIPY RQGGANVPRMGDLCDIAVVT HAFRLLTCPDATVSIIAASA LEETARKRIARQPTGRDLAT FLSGSLEGEFGRDGGDFASL WSRARNATRRLGKRIGCAWT WTEECRELGVSLQPAPHADR VTVTPRTRTFLERFLKDAVR NKYAGDLRAKPDQGKVFDVT SKWDASNHFMPSGSFTRFAD WRFLHRARLNCLPLNGAVRF GHRDKRCRRCGYAAETLPHV LCSCKPHARAWQLRHNAVQD RLVRAIPAAAGEISVNRTVP GCESQMRPDIVITNEEAKKV VIVDVTIPFENRRQAFTDAR ARKREKYAPLADTLRGRGYD VTVDALIVGTLGAWDPSNES VLRACRVSRRYAKLMRCLMV SDTIRWSRDIYVEHITGHRQ YSDPTRRAAAGPDPEGTA (SEQ ID NO: 1430) NeS Utopa AGCV0 Lytechinus ATCTACTATC TGAATAGCATTTATATTGTG MSCPREGSDHLGPDPETPAL L -1_LV 1358106 variegatus (SEQ ID NO: 1186) TTCCAAACAACATACTCATT HQGSDIRVTSSRLRGSRGKS ATTATATCTAAACATTTTTT SRQPSSRHQVPASEASATAQ TTTCTGTTCCTGACAATCTA QTAANECQVCGSSFATSSGL CGTAAAGTCTGCTAACCAAC RRHMARLHRAASADPEGAAP TGGCATGATGAAATAAGATA ASITEIFDYPLPSRWKCSAC AAATCCCCTTACACATTAAT SENFFNQQTLKRHQTRHHPA TTCTTGTCACATCATAATGC TTFAYAFRCSSCRSEFDSAR TTTGTCAAAGCAATGTCCTA RAANHWQVHKKERSQLSGTE CATAATATCTCGATGTCACC PQASSQARVSMAHSPPPLPN CCAATTAATTTTACATCCTT TSWAELASNPAEIPSFVWES CGGTAACCTTTATACCGTTG PPKNRPSVEEFGSSLPTDVT GATCAACATATATGATTTGT MMSQSPPPQVQSSPVPALTP AAAACTGTTATTTCTGAGTT LSPAATASSSPPGAARQLTP TTTTCTATGCTAATAAA PTQTNTPVTQRARLQPEADV (SEQ ID NO: 1309) VPELPPSVTEHPVSDAQHWV DAVSSASDWSEFEAVCDQFV IHAVAVSRPNLARPQQQDRQ RSGDHPPRQQRGQHRPTFDV REASRIQKLYRTSKKRAIRH ILKEKSPSFSGSESDVLDFF REVYSAKEVDEEAVGKLASS LFDVPQGDDSATSLSLPTSA KEIGARLSRMTNSAPGKDRL EYRHIRRADGSFSISEAIFN KCLAEGRIPAPWKTASTILL HKAGPTDDPANFRPIALQSC LYKLFMAVLADRLTKWACEN QYLSPEQKSARPCEGCFEHS FLLSAALKDCRRNQKTICIG WLDLRNAFGSIPHPVIKIVL SSLGVPDSLVTLLMDAYNGA STSFTLTGGQTDTVPIRSGV KQGCPMSPILFNLAIELIIR AVKKNASDNHLGVTVQGKNL SILAYADDLVLLSRDTEGLQ SLLQVAGSSASTLQMQFKPQ KCATLTLDCKRGTNVRQSAH HIQGAAIPSLTEEERYRYLG VPIGLPRLTSLQESSRKLSS DIETISSSLLAPWQKLDAIK TFVIPILQYTLRATEYLKSD LKPLRAAIIKHVKKICHLPV RSSNAFVFASRPSGGLAFVD PGVDADILVVTQAVRTLASD DDTVRAVALGQLTSVVHRTV HSAPSDDCIDKFLSGSSEGP LANSGNSGQASSLWSRTRAA SRRLKIRIVGASSGDIKVES GGRAIPSKKVTAGLRSDHHN EMSEKLRSLPDQGKVARALS LDSFANATSWLTSGSFIRFC DWRFIHRARLNCLPTNAAVR RWKQNANTKCRRCDHQLETL PHIINNCRPNMVPIRRRHNS IQERLVKAIHYGDIYQDQHV PGDPNPRERPDITVVEGNKV TIVDITIPFDNGPDALSTAA NAKVMKYDTLRQELASRGMD VEVHAFVIGSLGSWHGDNER VLGRLGISRRYRTLMRRLCC IDAIKGSRDIYIEHVTGHRQ Y (SEQ ID NO: 1431) NeS Utopa- . Nasonia CCATTCCTTCGTACGGGTTT TAGTGGGGCCATAACACCTA SGXTGREVKCITVNVLMEQQ L 1_NVit vitripennis TCGTGCCGGCATAGCCGGGT GGCCCCACAGTGTGGCGATG PHTKAIREGDFIVILLPQSD GGGAGACTCGCGCGGGGGAG TCCATGTGTGTCGTCCTTAC DETLCCPLCVGRGRYSGKTR GTCATATCTCACCACCATCC TTATTTATTTATTTGTCCTG VECLNRHVKEVHPDLTTTFR TCGAGCTTTTTGCTGCACCT TCGAGCTGTTTAATCTATTC CWGCGFAAPGDKKYPRKIVT GA ATATGTATGTGTTGTGTGTG QHCATCVPEVSSAPSGRVDG (SEQ ID NO: 1187) TCGTCCCTCGTAGCAGTTTT ERRVNTRRRLGIAAATEASP ATTCCGTCCAACCAGAGGTC VRRTRRNGLASPPVEQNISQ GACCAATATTAAAATAAGCA SAAPPEPARVPQHPEIVALG TGGCTTGAAGCAGGCCAAGC ESADDEVFRSPVNSPPRDWR GCCGTGTTCTAACCCCGTTT AAAPQQAASSSPXAVPGITA TAGGGGAAGTTACTTAACCT ATPSNTTRTGNGSAXSILAE AAAAATACAACTTTTCC HPIPAPPPTNTTEANGRADI (SEQ ID NO: 1310) PRSGRAPPPGXQAARRRAPT TEQRRIVGLLEAATGREQLE EATTQAMLFLARLTGRRPEP RNAIRPGXRQRHPAQGDVQA QAPDRIXEAKKLQRLYRTSK KRAVQKILAGPXMNCQIDKN TITAHFVELAARRDGGEDWP DVFDREEPTAASGEALCTPI TREEVFRRLKGRNNTSPGPD GITYRDLAKAXPGAHVLAAL YNXIWRIEATPALWGVSNTT LIYKKGDAMDISNWRPISLG DTVPKLFAAILADRIKRWAV ANGRYSASQKGFLEFEGCYE HNFVLQEAIREAKGGRKELV VAWLDLASAFTSVPHSSILQ ALEGHGLPSKARNIISSLYT GMTTRFHTAEGPTDPILIQS GVRQGCPLSPDVFNLTLEVV LREIQRTGEGYTIEGRRISH LAYADDVAILADSPAGMRRL LFAAERGARAVGLTFNPAKC ATLHIAGRGEEAVRPTEFSV QGTPVRALASGEAYEHLGIP TGYQVRQTPINTLRDLLADI GSIDRSLLAXWQKLDAVGTF LLPRLDFTMQGAHIDKGFLT EADKIIKKAAKSWLSLPQRA SAELVFLPPSQGGGGLLTVA HSYKMLYSSDVTVSTIAGST LRRTVSERLKKRASNIDIAR FLSGDLDLPRSTSPSTFWTK VRSAALRIKTKLGLRWSWCQ GGEVLLMACGDPRAPGTRVS PQTKHLVTTSLRRCLNRHYA ESLLAKKDQGKVFEVTRRSG QSNHFLRSGSFTRFCDWRFI HRARLDVLPLNAAKRWQRGM DKRCRRCGSDLETLPHVLSH CGPHSAARQKRHNNIQDRLV KAASRCPGTISVNQTVVGVR GPDAALRPDIVVRDDVNRRV TIVDVAVPFENRLEAFDGVR EAKIAKYTPLARQLTDSGYT VTVEAFVVGALGAWDPRNER VLSLLSISRYYAILMRRLMV SDTIRWSRDIYVEHVSGIRQ YRE (SEQ ID NO: 1432) NeS Utopia- . Phytophthora GCCCGCCGGTGGAGTAGCCA TAGACGGCACAGTTCTGGCC MVVSRITARLEATPAPRWDP L 1_PCa capsici TGTTGGCCACCACCGCCCAA CACGTAGGCCGAAAGGGCCC PLPRRVIASRIADRLVPATA GTCTCCGCCGCAGCTGCGAC CACCCATGTAGGGAACCGCC PCRSALNAAFPSPSRDTVTE TGCTGCTGCTCATCGAGTCG CTCGGGAAATCCATTCCGGT SFTQEDRQLEPLTRHVDEET CAGTAGTCGCAGCTGCACAA GTTCGACTGAAGAGATGCTC KDSELPGRAPTVLDEESKDN GCACCACCTCCTGCCGGACG CTTCGCCTTGACGGAGGTAC DATAGEWLLRFDGACRANPG CGCCGCCGTGGAGCACCACG ATCTCGACAGTCGAACTTCA PGGAGAVLFNPSGAASWTCS CGCGCGCTGAGCCGTACCAA ACTCGCAACATATCCGATAC HFMPGATETNNTAEYTAFLL GACCAAGGNTTCCAGGCTCG AGTTACAAACCACAGTTAGA GARAAADHGATLLRVQGDSQ CGCGCGCGTGGMGCTCCCAG TATCAGATAGGAACCTTCCT LVLRQVKGIYGAKSTRLRRL CCAGCGACGCGTTCAGCAGC TTAGGAAGCTAACGGGTACA RDAVRAELARVGQFSLHHID AGGGTCGGCTGCGGCAGCTC CTGGATGGTAAATACACATA RQDNAHADRLANRALDMKST GACGCTGCACGGGGACGGCA CATTTC LVECATHPGRNACTTTLTTS GCGACGGCAGGCACCAAGAC (SEQ ID NO: 1311) AAAESPASPPPVGARDTPMA CACGACGACCAAGCCGTCGC DAGEERLADVDDGEVYAAMR TGCCGTCCCCATGGACGTCG LGPGEVPERRPRLRLRQLSD ACCAAGGTGCTCGGTGGCCG EELEAASEMVERLGAALSAK ACAGCGGATCAMCACCCGCT ITDAEDWASAEGYITALPYM GTCGCCGCCACCGGAGCTCC LYDKLQSYSQAPRGPQQPVL GAGTCGGCGGCAAGCGCCGC TRSPRGDDRPASSEPNASST CGCCTGAACGACGGCGACGA TGGVASEHQPRRRRRRGRRK CGAAGACATCCGCGAGCTGG GRRQRRNPRRSGREGATGGH CCGAGCTTCTGCTGCCCGAC QQHKKHKPRPPRETQHHREH GAGGAGGAGGCCGACGACCA RLDEALDELHALERTDPHNR CAAACCAGCGCCCAGGTTAC PAIAKARRRVGRIRSAINQQ CCGCGACCAGCGCTCATCCG LLRHKFDTDEKACVDGILST GCCTCCGTCCTCGCTGTGTA ARAERAARAATPSPPASGAP CGCGCACAACGCGCAGCGCT TTTVSAPGAIVTNDDGTCPI TCAACTGCACGTTGTGCGTG PSDKLWRHFDAVNTPRLDFD TACACGGCTGCCAGCTTCGC AEAPGSAAFRAAMDHLPAAT TGCTCTTACGCGACACAGGG RLLDLLKEAPSTDEIETQLQ ACTCTCGGCACCGGCGCGTG HVKASSSPGLDGVGYDVYKR ACCTTCCTGGACAGGTTCTC FTIQLLPVLRAAFRCCWLYK GGCGGGTTGCGCGTGCGGCA KVPQSWKLGVVRLLHKKGPR AACCTTTTGCCTCGAGGCTG EDPANWRPICLQQAIYKLYT GCCGCAGCAAGACACGCACA GILARRLTRWMDANDRHAPG AACGTGCGCCAGCCTCAGCA QKGFRAVNGCGEHNFLAATL CCACACTGGTCGCGGTTTCG IDNARRKHRPLYEVWYDFRN ACGACAGGAGGAGCATCAAG AFGSVPFALLWDSLQRLGVP CCACACTGTCGTCGGAGCCA PDYVDMCKGLYNQASFVVGN ACACCACCGTCGCCACGGCG AVDGSTAPVEQRVGVFQGCP GTCACCGCCGAACCCCCCCT LSPQLFNAAISPLLYALRRL GCTCCACCATCAAGCCTCGG PDTGVQLSSVDRPGASAYAD AACTCACTGTGCCCCCCCCC DLKIFSGTKAGITQQHELVA ACGTGTGAGTTCCCCCGACG TFLRWTGMQANPAKCRSMGV TCGATGTGCAGCTGCACAGT RRNTNGAVEADNVHLELDDT CCGCCACAGGAAGATCAGCA PIPSMTHMQSYTYLGIGDGF CGAGGACGCCACCCANCACC DHVRRRVELAPKLKTLKHDV CGGAGAGCACGCAACACCAA TALVESGLAPWQVVKAVKVY CCTCCTGAGGCAACCCGCTG LYPRVEYALRHLRPDDQHLE GGGTTCGCCGCTCGCGCCCA SFDLHLRRGLRHLLRLPKNA CGCTCGTTGCCTCCAGGATT TNEFFYAPVSRGGLGLLPLV GCTCAGCGACTCGGCGAGCT ELHAALQIAHGWQTLHSPDP GGAACCTCCACGCTGGGGCC AIRRVAREQLYQIADARHRL CACCATTACCCCGCGCG DKDHWPHRREELCELLLNGE (SEQ ID NO: 1188) LGTSAHAPPKRRNGDIGSLW VDVRKNLKTFGLKVATAPAN QETGVPAQPLQLRVPHHAEW LDHGNVLRHVKLHIKNLHWQ TWCALSDQGKTARVHGGVGS AFLTRPRGMWESDYRFAVAA RLNVVDTVNTLSRRRLRAHD RCRYPACRWKETLAHVLNHC PGTMDAVRGRHDDALKEIEH TLRASSGDRRELRVNQTVPG LPGPPLRPDIQVYNHDKRTV AVVDLAVAFDEQPSEDPESS GLAKAVQIKKAKYAGIKEHL ENQGWKVHLSAIVYGSLGSV AASNHKVYTEHLGLLKRDAK RLDRQLSSACIQSSRRIWNF HCAKHRARQHEHQAPPSQAT RGRRVTETGGNPSRTDRR (SEQ ID NO: 1433) Nes Utopia . Phytophthora AGCTCGGCCTCGCGGCTGCC TAAGCTGGTCATCATGACCG MLADPAALAAGLARAPPPPS N -1_PI infestans TTCCCAGGCGCCGCCGACTT ACAGGGCACTACCCAGGTAG APQDPSPAFPAGPAGQNPRA L CGCGCTCTGGCGCGGCCCAC GGAACCGCCCTTAAAAAACC AAPARVEVHTVVAPPGRAGG ACGCCGCCGCCGAGCCTCCA CAGGAAGACACAAACACCCT MLPDPGLVEEPIQATYAHDA AGCGCGCCCGTTGGCTTTCG CCACTTAGTGACATACATAT AQFECALCPYVAESMAVLVQ CAGACGCAGGGCTCGCGGCG TTTAGCCTAGATTTCAGTTA HRRSAHRGTRFKDIFTSGCQ ACGGCCCTCGCCAGCCCCCA CGGAGAGGTTACTAACTGGT CSLVFYARIVAASHAVACAR AGACCCCCCCTACGATGTGG AAATACGAACACATATTCTG RNQRAVPPAPTPVAPTRPEA CACCACCCGGCAGGGCGGCC TTCTAATCAGTGTGAAAACT TPQPTGYLAAAMTAAAAAAS GGCAGGCTGCCCGACTCGGT GGTTTTCGCCTTTTGGCGGA SDTVVAAATNMQSAVPAAAK ATCGCCGGGTGCTACACTCT CTTTTTCACTCGCATTTTTG TTGLQLVPPELEPALPQRAS CAGCCGCCACAGCTCGGGCC GGCAATCGTCTGCGGCTAGC CHAGKRRRLNADEAVTPCTP TTGGCGGTCCGCCATTGGCC TTGCTAGCGGCGGACGAGCG TARVSPQTEVAMAPHDAPQD CTTGGAGCTCGACAGCGACA GTCTCCGGGGGCGTTCACCT DTVLQREAAEPQPDPAATPG GCAGCGACGACGAGGACGCT TTCCCCCGCGAGGCCAACTA AQVQRVEDTTAAQDDTVQQD CAAGACCCCCACGCCGCCGC CACCGATCTTCTCTACACTT HDADTAQVSPPRRTPTRWGP CCCAGAACCCCCAGAAGACG TTCTAATTCGCCTCCGTCTT RPSSTQEPSPMTGEPAATLA TCGCGAGTGTGCTTGCCCCA CGGTCTTCGGTTGTCGGGCT ARRPLTPAATGTRATRWGPC CCCGGCAGGGCAGGCAGC TTTTTCTTTTTGACCAATCA HRAIGAAAIARLVTGLSTEP (SEQ ID NO: 1189) GAGCGCGCCATGCGCCTCTT AQPQRRQPPPPQEPPSQPEP CTGGCCAATCAGAGACCGGG LAAAATAAADIAATVAADIA CCCTGTCCTCGGACAGCGAG AAAANAAMDVDGGPAADETW GCCTCCACGGCCAGCCAATC LLRFDGACRRNPGPGGAGAA GAGTCTCGGCAGCGACGCGT LFAPSGAVVWTCSHYMPSRS CTTTCTATAGCGCAGCTGAC ETNNTAEYTALLLGVQSAVH GAGGCCGATCTGGCGGCCCC HGASHLEVEGDSSLVIAQVK CGATTGGTCCGACTTTCGGC GTFACRNARLRQLRNRVRHA CAATCAGCGACGACGAGGGG LRSVDTHKLRHIDRQANAHA GCAGGGGTTTACACTTTTGC DRLANRALDQRRTSSECGTH CCCCGTTTCGACTTCAACTT GSCMDSCLAVPTALAAQETP CAGGCCAAAATGGCGATTTG PAAPPSTSATPAEGNAMDDI GACCCTCCACGCGCCGTGCC AAEIAARDEGETFPVLPIGP ACTGCTCGGCACCGGCGGCG GSAPERQPRLRLRQLSDEER ATTCAGCGGGTGCAACTTCG DAAADALQELADTMASKIED GGCACGTGTGCAACACATGC ADSWTSGEGYISSIPERIRE AGCGCCCATTGCACGCCAAG VLQPYATAPPQPGRSRRQQR CGGCATCGCGGGACGACGCC RRPPRVTRNQREHRLDEALD TCGGCCGCCCAAGCGCAGCC DMAATQQATPRDQRAVRRAR CCGCCCTTCCAGCACGACCT RRVGRVRASMAQQELRHEFA CGCGCCGTTTGGCGGATCGC KDESKCVAKILKTASTETAA CATCAAGACGTGCGAGAGCC EDEHPETCPIDAATLHAHFT AGGCGGGGTCGGGCAAAATA GVNAPRTDFDYDATSGREFR TACTTACTCTAAGTATGCCC AAMSDLPPATVEIDAFDAEL GAATCCCTGCCCTCTCAGGC TIDEVEDQLTRAAKTSSPGH TGAACGCGGCCCCATACTTG DGIDYGIYSRFAAQLVPLLH ATCTAAGTATGGGAGGATCC AVFQFCWRHRRVPRLWKVGI CTGGCCTCTCAGGCTGTACG VRLIHKKGDPRQPTNWRPIC CGAGACCC LQPTIYKLYSGLLAHRLSRW (SEQ ID NO: 1312) LEGNDRLPMAQKGFRAFNGC HEHNFMATTLLDQTRRQHRK LYQVWYDLRNAFGSLPQQLM WRVLRHLGVDSGFIDRCRDI YRDSAFVVANAADGATDPVR QEVGVYQGCPLSPLLFVAAL VPLVRRLEKLDGVGVPLADG VRPCTTAYADDLKVFSDSAA GIRKCHDTVAGFLAWTGLRA NPGKCASLAVTTNARGNPTR DSSMRLEVHDAAITTLSLHE SYRYLGVGDGYDHVRHRLQL EPKLKQLKREAVALLTSGLA PWQVVRALKVYVYPKVEYAL RHLRPLQSQLQAFDRVVSKG LRHLLSLPRSATSEVLYAPT SSGGLGLQPLVELHRALQLA HAWQMLHSKDPAIQAVARAQ ACQVVRKRYRLQEDHWRGRD DELVRSFLNSELAASPHAEV LRRNGDIASLWSDVQRWLRI YHLRFEHCDETEAHGPLSFR VPHHNKWLTHKTVLRHVKLH LKIRHQTRWKGMVDQGKTVR VHGGVGAKFMTTGAGLSDDD YRFGVKGRLNQVDTNSVLKR KRLRAHTTCRDPTCSSAETL AHVLNHCESNMDAIRQRHDD ALEQIGSKIRGALDRAKSPT ELRLNQTVPEYTGAALRPDI VLRNVAAKTMVIADLAVTFE DQAARARHSSLQLSHDHKTL KYQPIVAELQHKGWRVQTAA IVYGTLGSVQPSNFKAYTEK FKLHKREARQLDLQLSSHCI RASHRIWGWHCRQHRDRQRS GTASRASRGSGGAPRRTSQA PARR (SEQ ID NO: 1434) NeS Utopia- . Patiria CTGATGTGGATACCTTGGAA GATTAGCGAACACTAATATC MCLKSFSSTSGLRRHMARLH L 1_PMi miniata TTACTCAACCGTGTCGGAGT CTGCCMTAGACGTGATTGCT RQPSPDASTPSTMTEVFPYP CTTTTGTCTTTTGCGCCCAA AATCCGCAAACCAACCGGAT LPKVWPCVVCRENFYHNQTL CACCTCATGGATACCATGCT CTACAGCCTGAACACTGAAC KRHQKNFHPNVDLTTVYQCS TGTCGCTGGAGCGACGTTAC TTTAATCTTCACCCATGTCA VCGQEFVTGRKASFHFKVHR AAGCGTGAGGGCGCCCTCCA CATCTGGACACTAGGTTTTT RMSASAIPTPSAMPSSPMDL TGCCGGACAGCTGGTCTGTG GCTCTGTTTGTGTTTTCCTG IRGLVGEPLPPSPARTPPPL CC CCTTTWCMTTGGAWCTTTCG ARYISPAPRSSFSPPWNPSP (SEQ ID NO: 1190) CMCTGGAATTTATTTGTCGC PPRSPTPLPRPLTPPPRSPS TTGGATTATTTTTTTTCTCA PPPRSPTPPPPVTLTTAPVT CAATTTGGATCTATTTTCGT EPAVPVALTTAQVTEPSAPA TTGTTCACTTCGAACTCTAG VHTAAPVTLSNAPVTEPATP CTGCCCTTTCTTCGGACACT ATDPATPVTRLHSPVTHISC GAACTTTAATCTTCGCCATG SISFTASHAPYSCAAPTSPS GCTGTCAGTCGCCGGTTCAC VYACSPRRRQCSSTIAAVCN TTGCTGCGGTGGGATCCTGT SEASSGNPCLLALPVHRHHL TGTGATAATCCCCGTGCATT PDTSPQRPGLLFHHPGIPPH GCCCATGGATTTATTTCCGC RPGRPPHCHGHSLHRHDHRA CTTAGTTGTTCCTAACCTTG RRPGRQHHLPRSPSPPPRSP GATTTATTGCTGTGGGTGAT SPPSRSPSPPPRSPSPPPRP GCCCGGGTTTTGTTTACATC STPPPRSPSPTPRSPSPPPR GGGATCCCGCTGCGGCTCGG PPILPPRSPDSTHRSLTSHA TGTTCCATGCGACTGGCAGC RSPSRPATPPIPVQPRHLRP CCCTTTGTTTACTCTSGACT STPAHPGVDNAVPPSQQSAI CTATTCATTGTTGTATTTCT DVWLAELSRSADFESFEDVC TCCACACTGGCCAGTGATCA DRFVEFAAAEGRNNGRPARP CACTGCTGTGTTTCCCGGGA AHQPPRDRGNQGPRPQRPPR AGATATCCTCTGCGGTTTTC PHRPGLGPEFDAQEASRLQK ACGCTCTGGGTGTCTCCCCG LYRTSKKRAIRTILTGSDVR GGCAACGCACTGGTTGCTTG YSGYRGPHPALMSDTAATEV CTGCGCCATCACCCTTTTCG LTSGFLSLEVFSAREVDTDT TTTATATTCATTTTCAGTCT IATDTSLLFPNSAQARESGQ GCCGTTATCTTGGCCAGCGC DLLRPVTQREVSLRLGRMSN TCATTCTTTTGTGATGGCCG SAPGKDRLEYRHIRQVDGAF TGGACTGACCCTCTGCGGTT RVTLEIFNRCLRESRVPSSW TTCTGCGGTCASCACTCTCG KTATTVLIHKKGDATDPANF GTGAATGCTGTGCCACCATT RPIALQSCLYKLLMAILSDR TTTCATTTGTTTACTTTTTC VTTWALDNDLISSSQKSARP AGCTACAATTATCCTGGCCA GEGCYEHTFLLSTVVKDARR GCTTTCACTCTTTTGTGATG NQKNMYAAWLDLQNAFGSIP GCCGTGGACGGACCCTCTGC HDAMFTVLTSIGAPEGLVSL TGGTTTTCACGCTCCGGGTT VRDVYTDASTDFVTPTGRTA TGTCTGCGGTCAGCACCCTT AVPIHSGVKQGCPISPVLFN GGTGAGTGCTGGTCGTTTGT LTLELIIRAVNASATRDRSA TTGCTCATTTTGCTTAGTTC PVVHGQAVPILAYADDLVIL ACCATTATCTTTMTTCTCTT SRSSDGLQSLLTTASIMATK TTGTWTGGTTTTCCTAGCGG IQLKFKPAKCASLSLECRRG TTGTCTGGGAGTTGAGCTGC TKVRPLEFNVQDKIIPALTE AGTTGTCTGGTCTTGGTTTT EQHYRYLGVPIGLYRTDDSL ACCCCCATTTGTTTTCTTTT ETLVAKMTDDIQRIDSSLLA AACGCGGGGCGTATTGCCTT PWQKLDAIRTFVQPCLAYTL GACCGGCCGTCTCAGCTTTT RAGDCAKKHLKRLRGQLVKT CTCCTAGAGCAACCTTCCGT ARKVCNLPTRATTNYIFADR TCATCCAACTTTTAGTTTTC RAGGLGFIDPNVDADIQIIT TCAGTTCTTGGCCATTCCGG QAVRMLSSPDDITRAIATGQ TTGGTTAATTTTTATTTATA LSSVVHRTIHRAPTQEETDE CTTAATTTTATGTTTACATT FLSASMEGDFANSGNSGQAS TTCTGGTTGGAGACCATTTT SLWSRARAAARRLKVTISGS AGCTTGTTTTAATAGCTTTT LSGSVITKSTENREMAAKSI CTTCTTTAATTAATACCCTC TTALRAQSRAHYTHRLLSLP TGCCATTGAGGGTTTTTATT DQGKVGQSLNQDQYMNSSSW ACTATTAATTTTGTTTACTC MSSGSYILFCDWRFIHRARL TTTGTAACTTGTTTGATTGA NTLPTNATAQRWKPNTSPAC ATATTTTAATAAACCAC RRCQHPQETLPHILNHCPPN (SEQ ID NO: 1313) MVPIRRRHNLVQQRIVSAVR HGRVFVDQHVPEDPNPRERP DITVVEGDKVTIIDVCCPFD NGRDALMTAAAAKETKYADL KQALVAAGKDVEVFGFAVGS LGSWLPSNERALRRLGIAKR FRTLMRKLLRIDAIKGSRDV YIEHMCGHRQYT (SEQ ID NO: 1435) NeS Utopia- . Phytophthora AGACGAGCAACGCGCTGGGG TGAAGCTGCACAAGCGCGAG MDVDGGPAMPEPWVLRFDGA L 1_PS sojae CCCAAGACCTGGCACGAACG GCTCGACAGCTGGACCTTCA CRRNPGPGGAGAALFKPCGT ACACTGCCCAGGCTGTGAAC GCTGTCGAGCCACTGCATCC VAWTCSHYMPNSSETNNTAE GACGAGCACGCTGCTAACCC GCGCCAGCCACCGCACCTGG YTALLLGVQSAVHHGASHLE GGCAGCGCACCGGCCTCTGG GGCTGGTACTGCCGGCGCCA IEGDSHLVVAQVKGTFACRN GCTCCGCTGCACCGGTTACC CCGCGAAGGACAACGGAGCG PRLRQLRNRVRHALRAVTSL GGTGCAACACGGTGGGGTCC GCAACGCCTCGCGAGCGCCG TLKHIDRKANAHADRLANRA ACGTCACGGCGCGATCGGGG CGTGGGTCTGGGGGGGGCCC LDLKRSLAECGEHQGAMESC CAGCGGCTGTAGCTCGCCTG GCGGCGCACATCGCAGGCTC LHMNPAAQRQREQPAPPARP CTCACAGGCCTACCCACGGC GGGCACGGCGGTAAGCTGGT ACAPTRAESASDHDEDIDAE ACCAGCACCAGCTACGCGCC CATTTGACCAACAGGGCACT IAARDGGEAFPTLPIGPGTA GGCCTGCTTCGGCTCGGCGC ACCCAGGTAGGGAACCGCCC PARQPRLRLRQLTEDEQEAA TGCCCAGACCCGCCCGCTCC TTCAAAAACCCAGGAAGACA ASALQAMAEELACKIEDADS CCCCGCGGCCACGACGACAG CAAACACCCTCCCTTTAGTG WTSGDGYISAIPSRIRQLLQ CCCCCGATGCG ACATGCATATTTTAGCCTAC PFTAAQPHPRPPLQQQRQRP (SEQ ID NO: 1191) ATTTCAGTTACGGAGAGGTT PRVTRTQREHRLDEALDEMA ACTAACTGGTAAACACGAAC AVQQERPTSRSAVRRARRRV ACACAT GRIRASMRQQQLRHDFARNE (SEQ ID NO: 1314) SKCVEDILRAASAETAAEEH PETCPIDSGTLHEHFTAVNS PRINFLPDEACGALFREAMA DVGTPQERRSALTDELTMDE VEDQLMQAATNSSPGHDGVG YDIYKKFAAQLVPLLHAAFQ SCWRHHRVPALWKVGFVRLI HKKGDPNDPANWRPICLQTA IYKLYSGLLARRLSAYLEAN GLLLMAQKGFRAYNGCHEHN FVATTLLDQTRRMRRRLYQV WYDLRNAFGSVHQDMLWYVL RLLGVERAFVERCDDIYEDS YFVVGNAADGATEPVRQEVG VYQGCPLSPLLFIAALVPLL RALEKLDGVGVALADGVRPC TTAYADDLKVFSDSAAGITR CHAVVEKFLEWTVLOANPGK CAFLAVTRNARGNPAHDKDM KLSLHDEEVSSIKLHDSYRY LGVGDGFDHVRHRLQLEPKL QQIKREAVALMQSGLAPWQV VKALKTYVYPKVEYALRHLR PLQSQLQGFDRVVAKGLRHL LRLPRSATNEVLYAPTSSGG LGLQPLVEMHRALQIAHAWQ MLHSKDPAIREVARAQVWQV ARKRHRLREEHWRERDDELV RCFLNSELAASPHAEALRRH GDIGSLWSDVQRWLRIYHLS LVVQDDRNGLDPLGLRVPHH AKWLDHKSVLRHVKLHLKIR HQTRWKGLADQGKTVRAHGG VGAKFMSTWAGLSDDDYRFG VKARLNQIDTNAVLKRKRLR SHKTCRDPTCSSAETLAHVL NHCESNMDAIRQRHDDALEQ IGSKIRNALKRGKSTAELRL NQTVPEYTGAALRPDIVLRI VAAKKMVIADLAVTFEEHAA GARHSSLQLSHDHKTLKYQP IVAELQLKGWQVQTAAIVYG SLGSVQPSNSTPTRKS (SEQ ID NO: 1436) NeS Utopia- ADOS01001 Pythium GCGGTGTACGCGCACAACGC TGATGCGGGTCATATTGACC MGTQSARERGAPSAPHSHTL N 1_PU 321 ultimum CGCGCTCTTCGAGTGCACGT GAAAGGGCACCATCCACGTA GPRTPPRPPACSKHGELESA L TGTGCGCGCACACCGCGCGG GGACACCGCCCTCAAAAACC AGGRDGQCSDGAERERDAER GATCTCGCCGCGCTCCAGCA CAGTTCAGTTTATTGACACC DIRANERDCNGDGDGDDADS GCATCGGCGCTCCGCGCACC CTCCACTTAGTGACATGCAT DSDDRNDARRRSRRPRATAT GCAGCGTCCGCTTTGTGGAT ATTCAAACCGATACATATTC TTTSAPTTTTTTTTSATTSA CACTTCCACAGCGGATGCGC GTTAGGAGAGGTTACTAACT TTPATDSSPWVLRFDGACRR GTGCGGCGTGAGCTTCCACT GGTAATATATCACCATTTC NPGPGGAGAALFEPGGAVVW CGCGTGCGGCGGCAACCAAG (SEQ ID NO: 1315) TVSHYLPGSETNNTAEYSAM CACGCGCGCGAATGTCCAGA LLGVRSAIHHGATRLRVEGD GAGCGCGTTCTCGGTCGCCG SHLALSQVRGTFACTNRRLR CCGCCGCGCGCACTGCAGCG KLRNRVQAALRELGDYRLVH GCCAACACCGCAGGTATGTC IDRQANAHADRLANRALDLR TCTCGGCGCCGACGAACGCG KTKVDCGPHATTTDACVQPA ACCACCTCGCGTCCGTCGGC EILAPTARLSSSSSSSSSSS GCCTTGCATGATGTTGCATC SDEPMPGLEEPAADDETDAD CCCCGCTTTTGGCAACATTT AEADIAMRDGGEIFPTLQIG TGCCGGTTGCGTTTGCGACC PGSAPAQQPRLRLRQLSDDE GCGGCAGACGCATCAAGCGC SEAAARTLEHFANDMASKIA CACCGTGATCGCAGACGCAG DADDWRSGEGYISAIPVRLR CCATGCAGCACAGTGCTGTG ELLAPYAVPIRSPPRNASSR CCCTCTGCTGCCGCCCAATC PPRPQSRPPRPPRVTRHQRE CCCTCGGCGTGCGCACGTCC HRLDEALDDLAAAQRSTSTD CCCCCGTGCCGCGCGCCACC QRSIRNARRRVGRIRTAQAQ ACGACACCATCCGCGCTGCG SDLRSQFATNERACVESILR GATTGGTGGCAAACGCCGCC AAKPDGTEPQASAGTCPIDR GCCTGAACGACGACGGCGAC ATLHAHFAGVNTPRERFDFD AACGAAAACAGCGACGGCCG DALGADFRAALDVLPPPDQA CGACGCCGACATCGAGATGC ADAFADELSLGEVEDQLDRV GCGCCGACGACACCGACGCA VASSSPGLDGVGYDVFKRFR CCAGCGCCGACCAACCCCGC LQLLPLLHAAYQCCWRHRRV GACCAGTGCGGCTGCAACGC PATWKVGLVRLLHKKGDRAE CCGCGCGCACAGCACCAGCA PNNWRPICLQQAIYKVYSGL CCAACGGATGCCGCGACCGC LARRLSRWLEANERFTTAQK GCGCCGCCGCCACACGCG GFREFNGCHEHNFVASSLLD (SEQ ID NO: 1192) QTRRLHRKLYAVWYDLRNAF GSMPQPLMWRVLARLGVDTA FLQRCEDIYADSFFVVGNAA DGATDPVRQEVGVYQGCPLS PLLFISALIPLLRALQRLPG VGVPLADGVRPCTTAYADDL KVFSDSAAGIQQCHGTVARF LRWTGLRANASKCALLPVTT TARGNPAIDDTLQLELHGDA IARLTLQSSYAYLGVGDGFD HVQHRVQLAPKLAELKRDAV ALLRSGLAPWQVLKAIKVYL YPRIEYALRHLRPLQSQLEG FDRAVAKGFRHLLRLPANAT NELLYAPVSSGGLGLLPLVE LHKALQIAHGWQMLHSKDAA VQAIARAQVRQVVQKRYTLD ADHWQGRDDELVQLFLNSEL AASPHATIKRRNGDIGSLWS DVQRHLKTLQLRLETREPTA DAPDSPNGLLHLRVPHHRKW LSHKTVLRHMKLHIRLCHKH KWQSMSDQGRTVRAHGQAGS HFVSRGVGLWDADYRFALQA RLNQLDTNSTLKRRRQRTNA TCRAPNCSRTETLAHVLNHC ETNMDVIRQRHDGALEQIGA AINAAIKGRRTDTEVRLNQT VPEFNGPAWRPDIQVRDARS KTMVIADLAITFEDQPNDQS ASSSLQHSREHKIAKYQPIA AALERQGWRVHTSAIVYGSL RSVHPSNFTVYTELLGLLKR DARRLNTTLSCHCIRSSRRV WNWHCGQHRARQHQRCQEGR AHGSGGNQRAEGGTATT (SEQ ID NO: 1437) NeS Utopia . Strigamia GGAGTGTTCTTTTCGGAGAC TGATGGGAGAGTGAGGAATC MATVRLKYPYPPEGILCGPC L -1_SM maritima GCCGCCTACTTTAGAGGAGA TTCTCCACTGTGCAAAACCA AANTNAPQTRPYSDKSGLAK GAATCCCCACGGGCATCCTC TACAGTCAGAAGATGCTAAC HLKLYHKATLWECRHCGHEE ATTTGATCTGATCCATCGAG TACTAGTTTGATACCCTGTG SDLRKMKKHISTNHPVAAAA TATCTGCGAATAGTCGGCGC CCCCCTGCAATGTCCCGCGT APTVPPRLGPTAPPPPRVIL ACTCCTTTTGCCATGATCCC GTCGTACCCAAGCCCGGCTG RPRFIPRPRTPSPSSSSSSA GGGGGTCTCATGGTAAAAAG GCATTGAGACACATTAGGCT SSPASSRRSVSLPPASPPVS GTTTGTGGCACGGCTTAGTT CTCGCTCCCCCGTATACTCT SASSPAARSGRNSPDSQGTA GACGCCCCTCTTCCACGTCA CATAATTTCGTGTACGCTAA PVTPIGTVRNSPAGSPALSY CTCGGCCTGCATCGATCGAC TCCTACCCTACCCCTCCCTT STASPIASTITTPRHLSPAS TGCTCTCTCCTCTTCCTCCC TGACCACTCACCCAACCATG PALSAGPGSLGASPPVSPTA TCCCTCCTCTTCACGCTCTC TGTATAGCTGTGCTGGTGAT ATVPPAPPATVPAVMAATVP TTCACGTGACCCCTTCCCAT CCCGGGGCGGTTATTCACTG FVAATTVPSVGSSTVPQRPA CCCGCCCCTCGGCTTTTGGC GTTATCATATCATTCTAAAA GPRRPPPFPIDDWIGRIARV AAAGATCTGTGTGTCCTCCA TGATCTTTGATCTCTCAATT SSLPELDAVSRLLEDEWKRR AAGCACCCATCTACCATTTG AACAACTAACTTATTTCTGT PPDPNARPASLHPTRRPPPP CTCGAGTTGCGATTGGTCGA TTGTTTCATTGTTTCACCTC STRPRPCHGTGGTSVSLAAL AGCTGCCACGCCACTCGTCT GTAAGAGGAAGTTCATTGTG TSSCIREDHRGSLPLLCTSG ACTCTGCCTCTCTGACCCCT CGATAAATCAA WDSPWPLSPSPSSHCPSSNP TCCCCCCTCTCTCCCTCTGC (SEQ ID NO: 1316) CPSSSTPPSSLLGPPRHSHL CGCCCTCGCCTCTCGGGTCC TWRGSGSTTPSHRHCSRARY CTTCCCATCTCCCTCCTCCC HHLLWRLPYPSSPRLPYPPS ATCCACGTGCTCCCTCCTCT ALARYPSVPPALDDPLPSLS CGTCACGTGATCGTTGCGGC TIGSEGSPECHLCRNWTPSQ TCGAC GCSRMKWSRDAPLTPTPDPP (SEQ ID NO: 1193) HSIRHAALPLHLLALVPAMG PAELQSLWRRSRPRAFAKIT EGASPFCALPVGTVHGHFLQ VHQATAHLPTPVPLPPLRPP RSSDPLVTPISPGEVLDRLR RATDTAPGPDTIIYSEWRAI DPTGRLLSSLFQKVQTFGAP TRWKESTTTLIHKGGDHTAM SSWRPIALLSTVAKIYGSIL SHRLTTWAVQNGRLSLSQKG FLPFRGCLDQNYLVQSCLQD ARRNKKTLSLAFLDLKNAFG SIPHLTIRHSLEWLGLAPSS IDILEASFLGSSTRVRTETG LTPPISLDTGWQGAPLSPIL FNLAIEPLLRTVPSAHSGFS LHGHWSWAYADDLAILAPST PALQSQLDAISGMADWAGLS FNPAKCATVTLTGKDNSRDT LSLQGSPVPSISDGDAYKHL GVPTGTTTFPSGTDAIKKMT TDLQAIDHSDLAPAQKLDAL RTFIMPQLSFHLSHGSVPKA PLTQLDKKIKRAAKHWLFLP QRASNEILYMSHLHGGQSLL PLSVLADIGQVTHAVALLQS RDPAVADLALRTCREVASKR AKKTVNGPELAQYLSGSTDG IYCTPTSDIPSLWTTARAAT RRLSSTLPLTWTSPLPSGVP FLSINGSPLSPFRVQSTLTN AIRHNHLSTLIAKRDQGNSY RTSHDPDPSNYWVKGGDFLR FCDWRFIHRARLNLLPVNGA RRWDANSIKTCRRCGAPNET LAHVLNVCPVGLPEMKKRHD AIHARIKKALRPSPHTWHHD RTVPGCGPLRPDILRISERD KSVAIVDIHVPFDNGTDAVE RAHETKRAKYELIRRHYEHQ GYRVTFDSLVVTALGRLWRG SEAALQALQISSQYSKLLRK LLVADAIHGSRNVYAHHMTG MVM (SEQ ID NO: 1438) NeS Utopia AAGJ0 Strongy AAGGCTCAAACCAGGCTGCC TGACGAAATGTTCAATATAT MSHSITEVFDYPLPSRWKCT L -1_SP 21405 locentrotus AACCAAGCTGCCAGCTTAGG GACATTCTAATGTTCATGTA VCLENFFNQQTLKRHQARHH 37 purpuratus CACCAACCAAGCTGCCAGTC TTTTTTGTTTGCTTGACAAA QTTSFLYVFRCSACQAEFDS CAGGCTCCAACCAGGCTGCC GCTAGATGAATATATTCCCT ARKASNHWQSHKRKPILSQP CACCAATCTGCCAGCTTAGG GTCCTACTACATACATCTCG AVNEIPSSGLDPSPPRSRPP CTCCAACCAAGCTGCCCACC ATGTGCCCTTGCTAGACGAT VEVIGSSFPDDVSMLSEPST TAGCTGCCAGCTTAGGCACC CCATTGGTAACCATGATATC PSTSLQMDPEVVHPPSRSIS AACCAAGCTGCCAGCCGAGG AATGGATTAACACATGATCT FSPMHLSPTQPASPIQIGVE ATCCAACCAGGCTGCCCACC GTAAACAATATATGATTTAC VSFNSSSSLQMDPEVVQPPS TAGCTGCCAGCTTAGGCTCC ACAATGTATTTATTGTTTCA PSISFSPMHLSPTQPASPIQ AACCAAGCCGCCAGCCCAGG ATAAATCTGTTCTTTTCACT IGVEVSFNSSGSLQMDPEVV CTCCAACCAGGTTGCCACCC TTAATACATGAAACATGACT QPPSPSISFSPMHLSPTQPV GAAAGTCTGCCAGTTTAGGC GTGCCTTCTCCAACTGGAGA SPIQIGIEVSFTSSSPLQMD ACCAACCAAGCTGCCAGCCG CCTACATAATTTGTTAAAAT PEVVQPPSPSMSYSPMHLSL AGGCTCCAACCAGGCTGCCA GATATAAATATTTCGAAGAT TQPDSPIPVDIDVIPAAEVP CTCGAGGCTCCAACCAGGCT GAAATTATTATTAATAA LPDIEIPPSPDRHPAAEVPL TTCACCCGAAGCATTACCCA (SEQ ID NO: 1317) PDIEIPPSPDRHPVAEVPLP GGCTGCCCGTTTAGGCACAA DIEIPPSPDRHPQSPPRPVM ACCAGGCTGCCAGCCGAGGC MEQPVHTPPPADTQQANGPQ TCCAACCAAGCAACCAGCCC HWVTVLANATNWEDFGRVCV AGGTTCCAATCAAGCTGCCA EFANHAVEAARSRQDAPQVR GCCGAGGCTCCAAGTAAGCT PAAQRQPRRPTRPRQPTFDV GCCAGCCGAGGCTCCAACCA REASRLQKLYKRSKKRAVRH GGCTGCCACTCGAGGCTCCA ILRDDAPSFSGSNEQLLDYF ACCAGGCTTTCACCCGAAGC KEIYAPPEIDENRAQQLAES ATTACCCAGGCTGCCCGTTT LFTDLEEAKESAAALMSPIS AGGCACAAACCAAGCTGCCA QQEISTRLSRMSNSAPGKDR GCCGAGGCTCCAACCAAGCA LEYRHIRQADGACRVTHIMF ACCAGCCCAGGTTCCAATCA NRCLQEHRIPSAWKEATTIL AGCTGCCAGCCGAGGCTCCA IHKSGTTDDPANFRPIALQS ACCAAGCTGCCAGCCGAGGC CLYKLFMGILSDRMTQWACN TCCAACCAGGCTGCCCACCA HNLLSPEQKSARPCEGCHEH AGCTGCCAACTTAGGCTCCA TFLLSSVIKDTKRNQKTANI ACCAAGCTGCCAGCCCAGGC AWLDLRNAFGSIPHQAIHAV TCCAACCAGGTTGCCACCCG LTTIGAPVSLVMLLKDTYTG AATCTCTGCCAGTTTAGGCA ASTSFLSTSGETDPIQIQSG CCAACCAAGCTGCCAGCCTA VKQGCPMSAILFNLTIELII GGCTCCAACCAGGCTGCCAC RAVKKKATDDGLGLVVHGQR TCGAGGCTCCAACCAGGCTT LSIMAYADDLVLMSKTPEGL TCACCCGAAGCATCACCCAG DAILSVASEQAETLRLAFKP GCTGCCCTTTTAGGCACAAA TKCASLSLSCRHGTSVLPRE TCAAGCTGCCAGCCGAGGCT YTVQGHLMPALDEEEQYRYL CCAACCAAGCAACCAGCCCA GVPFGLPRFTNLKDLIGKLK GGTTCCAATGAAGCTACCAG GNIETIASSLLAPWQKLDAI CCGAGGCTCCAACCAAGCTG KTFVQPGLSFVLRAADYLKS TCAGCCGAGGCTCCAACCAG DLRSLKSAITTNVKKICQLP GCTGCCCACCAAGCTGCCAG LRAANAYIFAAKESGGLAFI CTTAGGTACCAACCAAGCTG DPNVDADIQVITQAVRVLSS CCAGCCCAGGCTCCAACCAG DDEVVQTIATSQLKSVVHRT GTTGCCACCCGAAACTCTGC IHAVPTEEDIDNYLSGSNEG CAGTTTAGGCACCAACCAAG LLANSGNSGQASSLWSRTRS CTGCCAGCCGAGGCTCCAAC AARRLHLTLRATTSGTVVVN CAGGCTGCCACTCGAGGCTC QQADIDHTRDILPASITRGL CAACCAGGCTTTCACCCCAA RLIQRTTNAEKLKSLPDQGK GCATCAACCAGGCTGCCCGT VARSLSNDPFANGSSWHATG TTAGGCACAAACCAAGCTGC KFIRFCDWRFIHRARLNCLP CAGCCGAGGCTCCAACCAGG TNVATKRWKANANGKNGHQQ CCTCCAACCAAGCTACCAGC ETLPHVLNHCLPNMVPIRRR CGAAGCTCTGCCAGATTAGG HDNIQQRLVTAIRHGDVFVN CACCAACCAAGCTGCCACCG QHVPGDPNPRERPDITVIEG TTAGAGGCCCAGAGCCCACC NKVTVIDISVPFDNGPNACT AATCCCATAACGTGTGAGAT TAAQAKVEKYSALRQALRDM ATGTGAAGCTTCCTTCCACA GRDVEVHGFIVGALGTWHQG CCTCCGCCGGTCTCCGTCGC NERALGRLGVSRWYRTLMRK CACACGGCCAGGCTTCATCG LCCIDAIQASRDIWVEHVTG CACCACTGCTGAACACACTG HRQYE ACGACAGC (SEQ ID NO: 1439) (SEQ ID NO: 1194) NeS Utopia . Trichinella TTTCTGGTATGAATCCCAAG TGATCCGTCCCGAACCAACG MCSAKTPALKSGRRRGKEVN L -1_TSP spiralis CGGATTCGTTACGAAATTTG GAACCACATTGCCGCATGAC YEGQIVRVERRRGSRSSTSA CATAAGTTTTTGAAAAAATA TTCGATTTCGCTTTTGCTCT TDLGTRMVTRGRKKLMEASV GGCATTTGGTCGAGTGCTCG TTTTGTATTTAATTTTGCTA REAGHHGGESASTVDVDVVE CACCACCATTTGTCGCGGGT TTAACAATTCAGTTTGTTAA SKKITGKTARRNRRAPSGDG CGTCCTGATATTGCACTACA CTGTTTTGTATTCATTTGAA KRRESCGAECGQAVCGNAVA TTCAGGAACGGCCTATTCCC GATCCAAATAAAAC DRSEASSPRTPNVSKSGRDK TTCGGGGAATTGTGTTTTAG (SEQ ID NO: 1318) CGQPTIKASTPSPPKRKPTT GAATTGGAATCGGTTTGGTT SSSPRTPCLSKRGARSKIPS ACGATCGGTCGAGTGGTTCG TPDTPSTSGGSGKQRVLVSP TGAGATCGAGTGACAGCCGG LLRTEKLPDLEVLQRTEEQV GTGGCAGCGACA TVRATFPIAQAVVCPLGCEK (SEQ ID NO: 1195) PYTAVRPDGQFAHQTLTRHF MRVHNCHSVQWHYRCRNCNT DFLPADHRYPLRVVNTHVRS CVSRWEITRKLGESEDLHGV RCDLCDYVGVSKRAVGLHRR RHANENIMQNTGTAAQIEAL SKQVGEIRVAGDYSQFKFGK RVRQYVAPTQRRDGLDEEEV HEAEEEEVPAESRTILGEPS TATAIGAEEISATGPVRADT AAQQMICRIGQWCVWPQDYH SIPAPQCWTDTLMDLMIEQI VLQRYPDGAGVSVMSCSAVS AAIHHEISAEFAAQVMSSHD ASLYCIIPVNVRNHWQMIVL DVAERVVHYYCSLREHNTVV LSSLLSLVELSGKHTGCTSW KIETHDGAPVQTNAFDCGPF SCLFLKHLLHGIDMNFGDRE SAALRTDLKFMIDAVSTPVV PATDKLKKKPDGSATQLTQF QQKFLSASDNWQSPDVDLQA VYDEVVESIVSGHNEPSSRN TSRLQKKSPGKGGKGQVRRR SAVTRDPAWLKSASAVQKAF NSAPARTVNAILRRPNACPS FTATQVADHYFNLRPAVTSL APEVIDILPPPATDHSMLVA ELSESEVWEKMQKAPNSAPG ADRITIRMVRMADPGAMILT RFYRACLLRKWVPLQWKQSV CKLLYKDGDKERLANWRPIA LEPVLQRVLSAVVASRVTNW ARANGLISLEAQKGFQPADG TSEHNFVMEVAIQEARRTNA QLAISWLDISNAFGTVSHQL LFSLLERYGLDPTFTSFIQN LYKDATIVVKGANGTHVTAR WSVGVRQGDPCSGILFCLFV EPLLRSVLPSLPCEAETTAV NVLGQPITALAYADDIALFA PSIGVMQQQLCKIQGMASAM GFRFNPKKCASLYLNRAVVN AATFTISGEEIPALVHGDTF RYLGVAAGLGKPQTPFSLLR ENLREAELIFRSKLAPWQKM DAYRTYVLPRLTFQLMIAKF NNIKQSAGQYDRAILRLVKR CFQLPVETSTDFIRAPRQCG GLGVPSLRELYATAKVSRAL KMLWSPCRVVSSLAASQLQR VASAYFAKRLRDVEAADLST FMNAARSTPLDRSGYPTCLW MDARKQMSYLTKVAGVDCYF LVGEAGTSFFIRNGLGQTVS VLSPLRKNKVMSVLGGAIQT RHLDAWLQCKRQGKTASCIV LDRSSSRFITTGRYTSFAAM RFALPARLDLLPCRARSSMR SYQNCRRCGYDRETLPHILQ HCRQFSAPAYQARHDAVQGR LETVMRRRFPNLRVNRALPE IGSNKRPDLVVVDEEKRLVI LLDIAIVFENTAAAFVDART RKWAHYEKEILAYRLRGYSV TYDAIVVGALGTWDPKNDAI LKRIGVVSQRYLRLMKVLVV SEMLEHSSRIYRKHLGLRDL LPDTGTKRRPVGTTETDPPG GDLRQKKRNTISARASGGKC LERRFTSPVGTPSQRGELQC QPCPGPRRPALAGIAPNPPS LQPRKPPPRQHQKPVTKSTA H (SEQ ID NO: 1440) NeS Utopia- . Chelonia GGCAGAAACTGCACSTTCTA TGAGCTGGAGTGCCGATGAG MLQLRLPTPQTLRLLHPSQL L 2_CMy mydas GAAGACTCACTGCCTATCCT AAGCGCAGTCGGGAAAGTAA PQSHSTKRWSNIYEERARAP GAGGAAGACTACCGCTTTGG CTGAAATACTTTCCTCATGG KDTTIERVSAASKIPKLDPA AGATGGATTCTACTGCCGCT ATTGTATTTTCTAAATGGAC KRRIGAPLQLMQGNSISRQL GCTTCAAAAGAAAATCTTCA AACCTACCTAATTCTCAATT SASSQYVQHNAWRRVSAPPH TGCTGCTTCGGAGGCTCCAG ACTGAGGGACAATCTCCACT TGNFTGSCRRKLALPHRPPS GACAGASTGAGAAGATGATC CATTGATATATTTTGCTT ETQPAESYLHCWTTQRDPTL GCTCCCTCGCCGATTCCACA TCCACAACCAAATCTC ADQHGLQDHPTGLPPEGSHC GAAACCTTCAACTGCCGCTC TGTACAACTTTTCATGAGTG IKDPRQNSSTEGQRRSGNSQ GGACCGCTGCTGCTCCACGG ATGTACCCGAGTACTTGGAT ARRIPKRASTAASKTVLPKR AGCGCCCATCGGGGAACAGC TCTAATATCTAAACTGTATT TSAALKSVREDTALVLEDPA CTCTAAGAGACCCTCAGCGC GTTAAATCTATTCACCTAAA KWSSQHREGXRQQANPTAVF TTCCAGGACATCGCAGATGA TTTGGGTTATTGCTGATTAT QPEPAEIEQQPXVRAATPWQ GCAGCATCGATTGGAAAAGC GTACTCTATGTATCATATGA AAWMEELARTASFXDFDLLV AGCGCCTCCCTGAAGAAAAC CTTTTAAAAACAAACTTTGT DRLTKDLSAEIVSGRKGTQE CCGTGGAGATGCTGCTGCAG ATTTGTGGATAATCTAAGCA NTPTAHRQNQNNMREARRRN GGAWATCTTGCACCTCGAGG CTATACCCAGATGTACAGAC ISRCYDPAAASRIQKLYRSN ACGGCCTCCCAGGACATCGC ACTCTTTTCCCAACCTATGT RPKAMREILDGPSSYCAIPS AGCCAGGACAAACATCATCT ATTATATTTTTTTAACATTA ERLFLYFKGVFDRVAQNDMQ CGCCTGCTCTTCAGGASAAG GCTTTAATAAAATTTTTAAA RPECLXPXPRVDYAEDXEQD GATGCCMSAAGAACTTMTCC FTSWEVEARLTKTKNTAPGK CACCTCCTCMACTGCCCAGG (SEQ ID NO: 1319) DGIRYNFLKKRDPGCLVLTA ATCCTSATGCTGGTCGTCGT IFNKCKQFRRTPSSWKKSMM CCTGCTGTGCTGGAAGMKAC VLVYKKGKQDNPNTRRPISL CCCAACTGGCGAGACCTCAG CSTMYKLYASCLAARITDWS AAACCACCCAGMWGGACCKC VNGGAISSIQKGFMSCKGCY AACATCTCACTAGATGCCTG EHNFVLQTAIHMARRAWRQC CCCAGCCGAACCTCTCCATG AIAWLDLANAFGSMPHQHIF CWACTCTCCCAGAGCAACSA DMLREFGMPENFLQLVRELY GAACCATCCAGMGAATCCGC EGCTTTICSMEGETPEIPIR TGATATGACTGAAGCCMATC SGVKQGCPLSPIVFNLAMEP CAACAGAGGGAGAAGGAAAG LIRAISSGLGGFDLYDNRVN GAGAATGACTGCATCTATCT ILAYADDLVLIADNPESLQQ CCAGTATCCCCTCCCTACGG MLDITSQAANWMGLRFNARK ACACGCTCCTCTKCCCCTTC CASLHIDGSRRDSVQATSFQ CGCTATCCGAGGGTTCCAGT IQGEPMIFLEDGQAYQHLGT ACATTGGCAGTCTCAGCAMA PTGFRVQQTPEDTIAEILRD CACCTCAAGAGAATCCATAS VARIDSSLLAPWQKINALNT CAAGCGGATCACCTTCCGGT FLIPRISFVLRGSAMVKVPL GTGCCCTCTSCGACCTGCCT NKADNTIRQLVKKWMFLPQR TTCGAGACGCAGATGAAATG ASNELVYISHRQGGANVPRM TAAGTCTCATCAAGTCACCT GDLCDVAVITHAFRLLTCPD GCAAAGGACATCTCGAACTG AMVRNIAESALQDAVKKRIA GAAGAGTCCAACTTTACCAG RTPSNQDVATYLSGSLEGEF TCTATGTTGCCGCCACCCCA GRDGGDFASLWTRARNATRR TCTCTGCTCCGAAAGCAGAA LEKRIGCHWTWCEERQELGV ACACCAC LVPQVKNTDHTIITPRARTM (SEQ ID NO: 1196) LERTLKDAIRCQYVENLKRK PDQGKAFEVTCKWDASNHFL PGGSFTRFADWRFIHRARLN CVPLNGAVRHGNRDKRCRKC GYANETLPHVLCSCKPHSRA WQLRHNAIQDRLARAIPPPV GKVAVNSAIPGTDSQLRPDI VITNEDRKKIIMVDVTVPFE NRTPAFHDARARKVEKYAPL AETLRAKGYQVQTHALIVGA LGAWDPSNERVLRECGIGQR YARLMRQLMVSDAIRWSRDI YIEHITGHRQYQEG (SEQ ID NO: 1441) NeS Utopia . Phytophthora ACCGCCCAAGTCTCCACCGC TAAGCTGGTCATTTGACCGA MQDMEEELLLDVEMETETTE L 2_PCa capsici AGCTGCGACTGCTGCTGCTC CAGGGCACTACCCAGGTAGG PQTSTAXDATTTTDRPTRWG ATCGAGCCGCAGTAGTCGCA GAACCGCCCTTCAGAAACCC PHPRAVAAAAIAQLVTGEXA GCTGTACAAGCACCACCTCC AGGAAGACACAAACACCCTC XPALPSRQDRRPAPRSHAPT TACCGGACGCGCCGTCGTGG CCTTTAGTGACATACATATT RSRWGPRHQAVGAAAIASLA AGCACCACGCGCGCGCTGAG TTAGGCTACATTTCAGTTAC TGLPASAAPVSRATKHGEGR CCGCNTCAAGACCAAGAATT GGAGAGGTTACTAACTGGTA RRLQTRWGPRVSIPRAARRP CCAGGCTCGCGCGCGCGTGG AATAAAAAGCACTTT GSRWGPPRAAGASGQLPASA CGCTTCAAGATGGCGACGCG (SEQ ID NO: 1320) SGATGOLPEHVEAITTTPRV ACCAGCAGGAGTGGCCGCTC ASDADEGPTPPDPWILRFDG TACTGACGGCGGAGACGAGG ACRRNPGPGGAGAALFKPSG CCAAGACCGAGGACAGCGAC AVVWTCSHYMPSSNETNNTA GCGGACGCAGCCAAGCGCCA EYTALLLGVQSAVHHGATRL AGCCGCTCAAGCAGCACCGA DIEGDSSLVIAQVKGTFACR GACCCCATACCCMGGACACC NAKLRQLRNRVRHALRSVEK GCGCCGTACGACGGCCACAG YTLRHIDRKANAHADRLANR GGACTCGGTGCTGGCTGTGT ALDRRSSSSECEPHGSCMER ACGCACACAACGCACCTGCA CCGTDTTPAVQGPTPQAAAA TTCACCTGCGCGTTGTGTGT VPVQVWPQWQRQTMVAWTTS GTACACAGCACGCAACTTCG HGGRCRDCSTRCGRSLPSLA CCGAGCTGACCAAGCATCGC HRPRLSPRRQPRLRLRQLSD CATGCAGCGCATCGTCACAC EERDXAADALQELSDVMASK CCGCTTCGTGGATCACTTCC IVDADSWDTGEGYISSIPER ACAGCGGGTGCACGTGTGGC IREVLQPYTTRPPRPGHQQQ ATCGGCTTCCAGTCGCGCGC QRRRPPRVTRNQREHRLDEA GGCAGCTACGCGACACGCTC LDDMQATQQAAPRDQRAIHR AAGCCTGTGCAGACAGCACA ARRRVGRVRASMAKQELRQA CACGCCACCGTAGCTGCCTC FAKDESKCVSKILAGASAET GCGCGACCCGGCMNCCASTG AAEEHVDECPIDAATLHAHF CSSCCSGNGCCGGMAGCGAS TGTNAPRTDFDYDAACGQEF GAGGAGGACCNCGCACCCCC RGALDSMQPPTVATDAFEEE CGGTCCTCTSSTCGCGGCAG LTIDEVEDQLTRAAKTSSPG CATCTGCAGCTGCAGCAGCC HDGIGYDIYSRFAAQLVPLL GCATCAAGCGCCACTCCAGC HAAYQFCWLHRRVPALWKLG TGCAGATACTGCCACCACGC IVRLIHKKGDPMQPTNWRPI AGAGCGCCGTGCCCATCGCT CLQPAIYKIYSGLLARRLSR ACTCCTGGGCCCCAGTACGC WMEQNQRLPMAQKGFRAFNG CCCCCACGTGCTGGAGCCAC CHEHNFVATTLLDQTRRSHR CTCCAGAGCTCCGAGTTTCC RLYQVWYDLRNAFGSLPQQL GGCAAACGCCGMCGCCTCAA MWSVLRHLGVDASFIARCKN CACGCCGATCGACCTGCAGC IYQDSAFVVANAVDGATDPV CGCTGGACGTGGACGCGCTG RQEVGVYQGCPLSPLLFISA (SEQ ID NO: 1197) LVPLIRRLEKLDGVGVPLAE GVRPCATAYADDIKVFSDSA AGIRKCHDAVTRFLEWTGLR ANPGKCASLAVTTNARGNPV RDDGVHLELQGEVIAPLSLH DSYRYLGVGDGFDHVRHRLQ LEPKLQQIKREAVALMQSGL AGWQVVKALKTFVYPKVEYA LRHLRPLQSQLQGFDRAVVR GLRHLLRLPQSATTEFFYTP TSGGGLGLQSLVEMHQALQV AHAWQMLHSKDAAVVAVAKE QVCQVARKRYRLQEEHWRGR GDELVRLFLNSELAASPFAD CLRRNGDIGSLWTDVQRTLR LHHLSLTAQDDRDGQDPLAL RVPHHTKWLDHKTVLRHVKL HMKIRHQTRWKGLVDQGKTV RVHGGLGAKFVSTGAGLSDD AYRFGVKARLNQVDTNAVLK RKRLRSSKTCRDPTCSSAET LAHALNHCASNMDAIRQRHD DALEQIGSKIRGALERAKST TELRLNQTVPEYTGAALRPD IVLRNVAAKKMVIADLAVTF EDHAAGARHSSLQLSHDHKT LKYQPIVAELRVQGWQVQTA AIVYGSLGSVQPSNFKTYTE KLKLHKREARQLDLQLSSHC IQASHRIWGWHCRRHREGQR SGNTSRASRGSGGTPRRTSQ VRARR (SEQ ID NO: 1442) NeS Utopia- . Phytophthora GCTCGGCCTCGCGGCTGCCT TAGGCGGAAACCAGGCCCAA MLADPAALAAGLARAPPPPS L 2_PI infestans TCCCAGGCGCCGCCGACTTC GACGGCCGACAGGGCCCCAC APQDPSPAFPAGPAGQNPRA GCGCTCTGGCGCGGCCCACA CCAGGTAGGGAACCGCCCTA AAPARVEVHTVVAPPGRAGG CGCCGCCGCCGAGCCTCCAA GAAACCCATTTCGGTGGTCG MLPDPGLVDSSPAAATAATP GCGCGCCCGTTGGCTTCCGC ACTCGAAGGCCTTACCTATT APVAATATTARAAARVAVEH AGACGCAGGGCTCGCGGCGA TTTTCCTTAGACATTCAATT HAHAEPNQEHLPMARVLVEP CGGCCCTCGCCAGCCCCCAA AGGTAGCGACCAAATTACAA MQVDECSSCDRSTLTADDGS GACCCCCCCTACGATGTGGC ATTTGGTAACGAGTAAGCCA GDDVAAPSSMLSNDVAAPMD ACCACCCGGCAGGGCGGCCG AATGGTAATACACAAAACTT VDSGTSCPPTLQQPLQRPRA GCAGGCTGCCCGACTCGGTA TTCTGTTCTAATCAGTGTGA LHVGSKRRRLDADDGEEAHQ TCGCCGGGTGCTACACTCTC AAACTGGTTTTCGCCTTTTG LQEEEEAGIHAPALRLSAAS AGCCGCCACAGCTCGGGCCT GCGGACTTTTTCACTCGCAT AQPASVLAVYTHNASRFDCT TGGCGGTCCGCCATTGGCCC TTTTGGGCAATCGTCTGCGG LCAYTAGSFASLLTHRNSRH TTGGAGCTCGACAGCGACAG CTAGCTTGCTAGCGGCGGAC RRTAFLDRFSAGCACGVPFA CAGCGACGACGAGGACGCTC GAGCGGTCTCCGGGGGCGTT SRLAAARHAQACASLSSAPS AAGACCCCCACGCCGCCGCC CACCTTTCCCCCGCGAGGCC AEASSAAGTSSPTADGADST CCAGGACCCCCCGCAGACGT AACTACACCGATCTTCTCTA VSAVAHAEPGLPHHNDTELT CGCGAGTGTGCTTGCCCCAC CACTTTTCTAATTCGCCTCC ASPPLVSSSDVEVQATKTEA CCGGCAAGGCAGGCAGC GTCTTCGGTCTTCGGCTGTC TDNRWGAPLPRVLVASRIAG (SEQ ID NO: 1198) GGATTTTTTTCTTTTTGACC RLAQVPPPRWGPPLPRTTIA AATCAGAGCGCGCCATGCGA ARIATRLAATPAPRWDPPLP CTCTTCTGGCCAATCAGAGA RSLVVSRIAARLLPALPDAP CCGGGCCCTGTCCTCGGACA ACEEEAKDSDTMDWAPTWTN GCGAGGCCTCCACGGCCAGC EETKESEPHDEAPGQVDEET CAATCAAGTCTCGGCAGCGA IDDADGEWLLRFDGACRANP CGCGTCTTTCTATAGCGCAG GPGGAGAALFKPSGPVVWTC CTGACGAGGCCGATCTGGCG SHYDPSTTATNNTAEYTALL GCCCCCGATTGGTCCGACTT LGARAAADHGVTKLRIEGDS TCGGCCAATCAGCGACGACG TLVIQQVRGIFATRSTRLRA AGGGGGCAGGGGTTTACACT LRNKVKLELARVGSFSLHHI TTTGCCCCCGTTTCGACTTC DRQANGHADRLANAGLDRRR AACTTCAGGCCAAAATGGCG TKLECSVHPDGRGCTNTSVA ATTTCGACCCTCCACGCGCC TAAPTAPAAPLPSARPPAST GTGCCACTGCTCGGCACCGG AAPSPDDDHSDQGDIDDGEV CGGCGATTCAGCGGGTGCAA YAAMCISPDAVPHRRPRLRL CTTCGGGCACGTGTGCAACA RRLTDEESEEAGNVVERLAA CATGCAGCGCCCATTGCACG SLAAKIADAPDWETAEGYIT CCAAGCGGCATCGCGGGACG ALPYALYDKLQPYSQSQHQP ACGCCTCGGCCGCTCAAGCG PRQQQQQQRQRPRQQQQTRQ CAGCCCCGCCCTTCCAGCAC RRQRRCKRGGGSQHRQRKTR GACCTCGCGCCGTTTGGCGG RRRPPRVTRHHREHRIDEAL ATCGCCATCAAGACGTGCGA DDLHALESRRPQDRTAISKA GAGCCAGGCGGGGTCGGGCA RRRVGRIRSALDQHQLRHRF AAATATACTTACTCTAAGTA DTDEKACVDGILAAARDKDR TGCCCGAATCCCTGCCCTCT AASVTTTAQTAAPPHSAPAS CAGGCTGAACGCGGCCCCAT APSSAVDDGICPIPGDLLHA ACTTGATCTAAGTATGGGAG FFTDVNTPRTEFDADSPIGA GGATCCCTGGCCTCTCAGGC RFREALAQLPAAIAATELLM TGTACGCGAGACCCGTACGG EPPSPDEVEDQLQRVRGTSS CCGAATCCCCTGGCCTCTCA PGLDGVGYDVYKTFTQQLLP GCCTGTACGCGGGGC ALHAAFSRCWTDQRVPQSWK (SEQ ID NO: 1321) LGVVRLLFKKGDRQDPANWR PICLQQAVYKLYAGILAHRF TRWLDANTRHADAQKGFRAV NGCGEHNFLAATLTDNARRR RRELHVVWYDIKNAFGSVPH ELLWEVLRRMGVPAQFIACC QGIYDAAAFTVGNAADGTTA PIQLRLGVFQGCPLSPHLFT AVISPLLHALKRLPGTGVQL SAVDRPGASAYADDLKVFSD TKDGITRQHQLVTDFLRWTG MVANPSKCSTMSVQRDNRGV LKTANLTLQLDGAQIPALGM TEAYAYLGIGDGFDHVRRRV ELAPKLRELKADTTALMQSG LAPWQVVKALKVYIYPRVEY ALRHLRPFQQQLQGFDRHLA RGLRHLLRLPTSATTEFLYA PTSRGGLGLLPLTEVHGALQ IAHAWQTLHSPDPAIRRIAR VQLRQVADARHRLDAEHWKE RGEELCERLLNSQLGTSAHA PPKRRNCDIGSLWVDVQRHL RSLGLQLQTAPADTHTGAPA QPLQLRVPHHDKWLTHKDVL RHVKLHIKNNHWHRWTSMRD QGKTARAHGGEGSGFLTQPR GMWEADYRFAVAGRLNQVDT YSVLKRRRLRSHDRCRQPGC HRAETLAHVLNHCPGTMDAV RGRHDGALKRIERELHASAT DRRDRVELRVNQTVPSLAGP ALRPDLQLYNHTKKTVAVVD LAVAFEEQASDDASSSALSL IASHKRAKYDRIKRHLERQG WKVHLSALVYGSLGAVASGN YQVYTTHLGLLKRDAKRLDR QLSVECIQSSRRIWNLHCSQ HRTRQHQARPSQGPRGSRAT ETGGTPSQTSRR (SEQ ID NO: 1443) NeS Utopia- . Phytophthora TCAAGCCCCGCCGCCAAGCC TGAGCACCTTGGGTTGCTCA MSGDVVSSDGSSRTTDASGD L 2_PR ramorum CAGCTGCGGCTGTTGCCGCC AGCGTGATGCGAAGCGGCTG GDDGAGSSDAAGDVGVVAMD CCTCCAGCAGCAGCAGTCGC GACCGGCAGCTCTCGGTGGC VDQGARRQQPPWQRVGGKRR AGCTGAACCTACAGCCCCTC GTGCATCCAGTCCAGCCGCC RLNDVDDEDTRELAELLLEE CTGCTGATCGCGCCGCCGTG GCATCTGGAACCTGCACTGC EDEAGDHAPAPRLSAASARP GAGCCCCGCGCGCGCGCCGA AGCCAGCACCGCGCGCGCCA ASVLSVYAHNAQRFQCTLCT GCCGCCCCAAGAACAAGCAC GCACCAAGCACCAGGGGGAA YTAASFASLKRHRDSRHRRT CCCCAGCTAGCGCGCGCGTG GTCGGGCGGCGGAGACCGGG AFLDRFSAGCACGAPFASRL GAGCCC GGGACTCCGCCGCGCACCGG AAANHAHACASLNRTLSVAA (SEQ ID NO: 1199) CCGCCGCTAGACGGCACACA TPAAGELSPTAGAANATVKA GGCCCACAGCGGCCGACAGG ATVTPDSPRQDPPELAASPP GCCACACCCAGGTAGGGAAC LASSPDVAVQAADMQAPTRW CGCCCTCAAACCCCGCCGGT DPPLPRTLVATRVASRLTDL ACATTATGGTCCGACACCTA TPPRWGPPLPRATVVSRIAA TGAGGTGCAACCTGTACACA RLEAAPTPRWGPPLPRVVVA AGTTACACACCACATAGCGA SRIAERLAPPELAADDETKD CTACCAGGTATTTACTACCT GEEDQSFTEPVAAARSXGGE GGAAGCCAAGGATTAACCGG DANGEWLLRFDGACRANPGP TCGGTAATACACATAACTTT GGAGAALFKPSGPVVWTCSH YMPSSSETNNTAEYTALLLG (SEQ ID NO: 1322) MRAAADHGATRVHVEGDSTL VIQQVRGIFATRSTRLRGLR KSVKAEMARMEHVTLHHIDR QANGHADRLANAALDRRKTK LECGLHPDGQGCSSTAATTA VPSVVPDRPPSSTAAAPTPS AEPDETEQGDIDDGEVYAAM CIGPDSIPERRPRLRLRQLS ETEEEEAGAIVERLAATLAG KITDASDWATAEGYITALPY TLYDKLQPFAQHRHQPRPQH RQQPQRDPPLGTHDGDHGQP STSRSRRRRRRAKDRLRRRP PRITRHHREHRLDEALDDLR AVEHASPHDRPAVARARRRV GRVNSAIAQQQLRHKFDKDE KACVDGILAAARASRGLATP SASASRHPPPVPSTAADDGS CPIPSDELHAFFTAVNTPAG TFEPMAPVGAPFRSAVAHLP AATSQPELLSDAPTTDDIED QLQRARGSSSPGLDGVGYDI YKAFAAQLLPALHAAFACCW RHKQVPQSWKVGVVRLLFKK GERTEPANWRPICLQQAIYK LYAGVLARRLTRWLDANGRH ADTQKGFRAMNGCGEHNFLA ATLVDQARRKRRELHVVWYD FANAFGSVPHDLLWEALERQ GVPSPFIACCRGLYADAVFT VGNAADGTTAPIALRVGVFQ GCPLSPHLFTAAIAPLLHAL KRLPDTGVQLSRVDCLGASA YADDLKIFSGTEGGTKRQHA LVADFLRWTGMRANPAKCCT MSVQRDTRGVLKACNLGLQL DGAPIPALTMSASYAYLGIG DGFDHVRRRIELAPKLQELK HDATALLQSGLAPWQVVKAV KVYLYPRVEYALRHLRPFHQ QLEGFDRHLVRGLRHLLRLP ANATTAFFYAPVSRGGLGLL PLTELHAALQVAHGWQMLNS KDPAIRRIARVQLRQIADAR HRIDAQAWQDREEELAQLLL NSQLGASTGAPPKRRNGDIG SLWVDVQRHLRHLSLKLETA PACAETGTAAAMLQLRVPHH DKWLDHKTVLRHVKLHYKNK HWARWAAMXDQGKTARTHGG AGSGFLTRPRGMWEADYRFA VAARLNQLDTHSVLKRRRLR XHDRCRQPGCTQGGDAGARA QPLRRHHGRGPRPPRRRPQA HRARAARVVAGRPGPRRAPG QPDGAVARRPRATARPPAVQ PHQEDGGGGRPGRGVRGAGE RRPGELGAGTHRRTQAREVC RRQATPRAPRVEGPPLGARV RLARRGAGRQPQGAY (SEQ ID NO: 1444) NeS Utopia . Pythium TGACTGGTGTTTGATCACGA TAAGCGGGGGGTCCAGACCC MDYDDSEFFDAICIPDEDAD L -2_PU ultimum TCAATGAGGTGATTAACATG CACAAGAGAGAAGCAGGAAT VLDDGDEGDEGGNDDESSEP AGCCGGAGCAGGCCCCTTAC CATGGTCCGCATGGACCAGT LPLAITNAPSAPLHATMLCG ACGCTGGTGCTGTAATGGTT AGGGCACGCTCCACAAAGGT TVTQPWLLRFDGACRRNPGP CAGGAATGCTCTTATGAGTA TATCGCCCTCAAACCCATCA AGAGATLTRPNGIILWTHYR ACTCCACAGTATAATTTTTG CACGAAGGATCTAAAAAGAA YIPDKTATNNVAEYEALLDG TTAGCGGGGGTGAGCGCGTG AGCAACAATCGAAATAGTAA LRCAAHHGVKHLRIEGDSNL CGCCGCCCCCACCTTTCTCT ATAGTAAATAGCTTAGAAAG VIEQVKGIFACSTSLRPRRD TTTCGTTTGTATTTGGTTCC GTCAACATGCGAAATGCATG QVREILRHFETYSFRHIDRA TCTGGAGCGACTTCCGTGGC AGGAACGTAAGATGGTAATA LNRQADRLANQALDLLKTVS TTTTGTCGCGCGCTATCGCG CATTTTTATA VCALSQTRVQDDTGAAHGCW CCCGGCATGAGGATCGTCGC (SEQ ID NO: 1323) HWTPPDASPTDDASTSILTQ TCCTGACGCCATGTGCGCCA DVPVPMDIDDYDPDEPMNAA GTATATCGGAGCCCCGTGCT DDPVSINAEREGGTVYPVLR CCGCTTGGGTGTGTGTTCCG LGPNVVPERQKRLQIPWLPP CCACGACGCCACGCGATTTG REMQKLEKKIEVLGETFASR CGTGCACGGCATGCGCTGGC IRDAPDWFSAEGYITALTSE GACTTCCGCTCAGTGCGCGA LATLIRQSTAATTGPNAARP ACTCGCGGTGCATCGTCGAC CERTISKEKRRARRTTPLQR GTGCGCACCGGTCTCTGGCC ALAEAKHELQIIQPDASRKS TTCCAGGACTGGTATGAGTC VRKAARRVKRISQAQQRHDL GTCGTGCGCGTGCAGAGCGC RRLFSTNERRCVEKILRDPP TCTTCACCGCCCGTCTCGAC VGPSSTSSSLPATDDDRCTI GCGTTCGTTCATTCGAGCCG DPADLFAYFQTQATAPTNFD TTGCGACCACAATGCGAACC FDDEGGELFRSVLDELPRAD AATCAGCGAACGCCGTCCCC QEVHLLEDEITRDEIEDQLS TCGTCCGCCGCCTCGACAAC RISKSTAPGLDGITNAVYVR GAGAGCGGACGCGGATGCGA FKLQLLDALQAAFNACWRYN CGGCCCCCCCTCCCGCTATC RVPSMWKAAFVRLIYKKGNR TCTCTTCCGCGGACGGGCTT AVPSNWRPICLQQTVYKLYT CCCCCGCCCCTGTCCTAGTT AILASRLQRWMDANARFTMS GCGCCGCTCTCCTTCTGGAT QKGFRAFNGCHEHNFVATCL GCGGCAACTTGGACGACCCA HDQTRRLRKKLAIVWYDLRN CGTGCACGCG AFGSLPHEYLWRVLARLGMP TGCGCTGCCGCCAGTGCGAC PQFVARVRQLYADASFTVES GGCGTTGATCCAGCGTCATC RDGTTDPVQLERGVYQGCPL TACACGCCGTTCCTCCCGTA SPYLFIAALIPLVRALHKLK TCGACAGCAACCGATCTCAA DQHGIVLAPGVTDCVSAYAD CGGCGATGATAGCCAACCTC DIKIFARSGTGAKALHEIVV CAGACCCGCGTGCCAACATC RFLSWTNMAANPAKCALMVT CAACAGCTTCCAGCCATCCA DGARGGDDTDASMTLSIEGE TTCGACAACGACAACGACAA TIPRLTGKEGYVYLGVEDGL CGACAACGACGACGACCCGC AHERRATCLRDSLKAASADV TGCTCGACGACGTGCTC VRLLRSDLAPWQIVRAIKSH (SEQ ID NO: 1200) VLSRFDYVLRHLRPFLSLFD GFDKMLVRGIKRLCQLPQTA TSEFLFSPTSAGGLGFLPLK ELFAALQIVHALQMLHSKDA NVRAIARHQALQVVRKRYAL QSDHWSDREEELLEEFFNGT LERSPFALAKKVSGDIASLW TDVRVNLTKYGLKFGEAHGR RLQPLVSHTDKQLAPQQWAS AIKTHMRLRHLKRWTTLVDQ GKTARMHERIGSAFLTRPSG VYDASYAFAVRARLNQVDTR SALKRKRIVNNSRCRVSGCS ELETLAHVLNHCRFGSDSIR ARHAETLLLIKTTMERELTR PGRQHQRLLVDATVPEARDP VPSNDAAESNIGAMAPSISH LRPDIQLYDNKTMEAVIIDL AVAFEDQSTDDAASSSSFAR VKGVKTKKYEVIKQFLEYKG YTVHVAALVYGSLGSVDTGN FAVYTERLGLRKGAVRRLEC SLSARHINFAHRMWRRHAIA HTTGLRLIGTNSVQQQGVQR APAEKQQHQRPVQRPSRAQA PRDQPSQQQQSQQSFQQQSQ QSQQSQQSQQSQQSRQRHAP TPTPVPVPVPVPVSTPTLTP TPTPTRRPKPAPSSTQPQQG APAQRRQQREQKKQPACRRR HATAVRETPPAAPTAARTAT PTARPTATTRSTSTTRSTAT ATSTTRSSAPTSRPSAPRPR SSAPRPRSSAPTTRSAAPTT RSAAPTAIATTSVYKSRRTT NAISGATTRRSASSKRAPMQ PRTALTPTQQQQRQ (SEQ ID NO: 1445) NeS Utopia . Phytophthora GTACGGCCGAATCCCTGGCC TAGACGGCAAAGTTCTGGCC MPRSLASEPVHSSASRLPSQ L -3_PI infesta TCTCAGCCTGTACGCGGGGC CGCGTAGGCCGAAAGGGCCC APPTSRSGAAHTPPPSLQAR TATACTTGGTCTAAGT CGCCCAGGTAGGGTAACGCC PLASADAGLAATALASPQDP (SEQ ID NO: 1201) CTCGGGAAAACCATTCTGGT PYDVAPPGRAAGRLPDSVSP GTTTGGCTGTTTTTCAACAG GATLSAATARALAVRHWPLE TCGAACTTCAACTCGGAGCA LDSDSSDDEDAQDPHAAAPG TATCAGATACACTTACTCAC PPADVASVLAPPGRAGSMLA ACATTTAGATATCAGATAGG DPAALAAGLARAPPPPSAPQ GAACCTTTATTAGGGAGATA DPSPALPAGPAGQNPRAAAP ACGGGTACACCGGATGGTAA ARVEVHTVVAPPGRAGGMLP ATATACAAAACCTTCTCTGT DPGLVDSSPAAATAATPAPV TCTAATCAGTGTGAAAACTG AATATTARVAVEHHAHAEPN GTTTTCGCCTTTTGGCGGAC QEHLPMARVLVEPMQVDECS TTTTTCACTCGCATTTTTGG SCDRSTLTADDGSGDDVAAP GCAATCGTCTGCGGCTAGCT SSMLSNDVAAPMDVDSGTSC TGCTAGCGGCGGACGAGCGG PPTLQQPLQRPRALHVGSKR TCTCCGGGGGCGTTCACCTT RRLNADDGEEAHQLQEEEEA TCCCCCGCGAGGCCAACTAC GIHAPALRLSAASAQPASVL ACCGATCTTCTCTACACTTT AVYTHNASRFDCTLCAYTAG TCTAATTCGCCTCCGTCTTC SFASLKTHRNSRHRRTAFLD GGTCTTCGGTTGTCGGGCTT RFSAGCACGVPFASRLAAAR TTTTCTTTTTGACCAATCAG HAQACASLSSAPLAEASSAA AGCGCGCCATGCGACTCTTC GASSHTVDGADSTVSAAGHA TGGCCAATCAGAGACCGGGC EPDLPRHNATELTASPPLVS CCTGTCCTCGGACAGCGAGG STDVEVQATETEATENRWGT CCTCCACGGCCAGCCAATCA PLPRVLVASRIAGRLAQVPP AGTCTCGGCAGCGACGCGTC PRWGPPLPRTTIAGRIATRL TTTCTATAGCGCAGCTGACG AATPAPRWSPPLPRSLVASR AGGCCGATCTGGCGGCCCCC IAGRLLPALPDAPACEDEAK GATTGGTCCGACTTTCGGCC DSDEMDWEASEPHVEAPGPV AATCAGCGACGACGAGGGGG DEETIDDADGEWLLRFDGAC CAGGGGTTTACACTTTTGCC RANPGPGGAGAALFKPSGPV CCCGTTTCGGCTTCAACTTC VWTCSHYDPSTTATNNTAEY AGGCCAAAATGGCGATTTGG TALLLGARAAADHGVTKLRV ACCCTCCACGCGCCGTGCCA EGDSTLVIQQVRGIFATRST CTGCTCGGCACCGGCGGCGA RLRALRNKVKLELARVGSFS TTCAGCGGGTGCAACTTCGG LHHIDRQANGHADRLANAGL GCACGTGTGCAACACATGCA DRRRTQLECSVHPDGRGCTN GCGCCCATTGCACGCCAAGC TSVATAAPTASAAPSTPTRP GGCATCGCGGGACGACGCCT PATTAAPFHSDQGHIDEDDE CGGCCGCTCAAGCGCAGCCC RRADIDDGEIYAPMTLGPDE CGCCCTTCCAGCACGACCTC VPARRPRLRLRQLSDEELEA GCGCCGTTTGGCGGATCGCC AGAIVERLSASLSAKITDAE ATCAAGACGTGCGAGAGCCA DWGTAEGYITALPHLLYDKL GGCGGGGTCGGGCAAAATAT LPYSRTAPRHQRPPRPSRNQ ACTTACTCTAAGTATGCCCG QDHPQPRRDQPQRNVDEQQH AATCCCTGCCCTCTCAGGCT AESQQGEDQRQQQPPTRRRR GTACGCGGCCCCATACTTGA RRGKRRGRRQRRHPRQPGQS CCTAAGTATGGGAGGATCCC TRASQQSRQRRPRPPRVTRH TGGCCTCTCAGGCTGTACGC HREHRIDEALDELHTLERAR GRGGACCAAGTACAGCCGAA PQDRSAIDKARRRVGRVRGA TCCCTGGCCTCTCAGCCTGT INQHLLRHRFDTDEKACVAD ACGCGGGGCTATACTTGGTC ILEKAHAARAARTAQAAGAA TAAGTATGCCCCGGTCGCTG TSTGGAATAPTQQAATSALG GCCTCTGAGCCCGTACGC DADDGTCPILADELWQYFTG (SEQ ID NO: 1324) TNTPRWEFNPATPVGEAFRT AMARLPPATRLRELLTEAPT ADEIETQLQHVRGSSSPGLD GIGYDVYQRFAQQLLPVLTA SFKRCWTAKMVPQSWQVGVV RLLYKKGAHDDPANWRPICL QQAIYKLYTGVLARRLVRWL DVNDRHAPGQKGFRAVNGCG EHNFLAATLIDQARRKRRSL YEVWYDFRNAFGSVPFQLLW DSLQRLGAPADFIDMCKGLY HQAAFVIGNAADGPTAAIRQ QVGVFQGCPLSPQLFNVAIS PLLFALRRLPETGVQLSGDD RVGVSAYADDLKTFSSTKAG ATKQHELVAAFLAWTGMKAN AAKCSSMGVRRNSNGATEAD NLDLALDGTPIPSMTHMQSY TYLGIGDGFDHVHRRIELAP KLKTLKQDTTALLESGLAPW QVVKAVKVYLYPRVEYALRH LRPEDQLLESFDLHLRAGLR HLLRLPKNANNDFFYSPVSR GGLGLLPLVELHAALQIAHG WQMLNSTDPATRRIAREQLH QIADARHRLDKAHWKERGDE LCQLFLNLDLGTSAHAPPKR RNCDIGSLWVDVRKNLQAFG LKLETAPADAESGTPALPLQ LRVPHHEKWLTHRDVLRHVK QHLKNKHWRAWCAFQDQGRT ARAHGGVGSSFITRPRGMWE SDYRFAVAARLNMVDTSATL ARRRLRAHDRCRYPGCRWKE SLEHVLNHCPGTMDAVRGRH DGVLREIEHALRAPSGARRE LRVNQTVPGLPGPALRPDIQ VYNHDQRTVAVVDLAVAFDR QDRDDPETSGLAKAAAEKKA KYTGIQRHLERQGWKVHLSA LVYGSLGSVAPNNYKVYTEH LGLLKRDAKRLDRTLSVACI QSSRRIWNLHCAKHRARQHQ TPSQSRGRRVTETGGAPSRT DRR (SEQ ID NO: 1446) NeS Utopia . Phytophthora TGCGCGGCAGACCAAGACGC TAGACGGCAACACTCTGGCC MQDQVDAEQQARNRWGPPLP L -3_PR ramorum GCAGCCAACAACAGACCGTG CGCGTCGGCCGAAAGGGCCC RPLVASRVAARLGEVPPPRW CAGCGTGCGGGTGGAAAGCG CACCCACGTAGGGAACCGCC GPPLPRGVVVSRIAARLEAV CCGCCGCCTGAACGCTGGTG CTCGGGAAACCCAGTCTGGT PVPRGGPPLPRSFVATRIAD ACGATGAAGACCAGCGAGAG GTTCGGCCAAGAAATGCACC RLAPPSPDLSLLDEEMKESE CTGGCCGAGCTCCTGCTCGT ACCACCACGGCGGAGGTGCA PPDPTHHSADEDSTDAETAD GGACGAGGACAAGGCTGGCG TTTCGACAGTCGAACTTCAA AVMEPAFVSDPPTATPREWR CCGAACACCCCGCGCTCAGG CCCGCCACATATCGGATATA LQFDGACRGGPNPGGAGALL CTGCCCACGGCCAGCGCTCA GTTACAGCTCTAGTTAGACA YNPEGAVVWTGSHYMPGAKE TCCGGCCTCCGTCCTCTCCG TCGGATAGGAACTTCTTAGA TNNSAEYTALLIGARAAADH TGTACGCGCACGCTGCAACT AAATTAACGGGTATACCGGA GARQLRIEGDSLLVIRQVKG CGCTTCGACTGCACGCTGTG TGGTAAATAAAATAAAAACT LYATKSTRLRQLRNAVRHEL CACGTACACGGCTGCCAGCC TC ARVGQHSLHHIDRQGNAFAD TCGCTTCGCTCAAGCGCCAC (SEQ ID NO: 1325) RLANRALDLKSDKVECKEHP CGCTCGTCTCGGCACCGACG VAGACTTCMGSPSAGPPATP CACGGCCTTCCTCGACAAGT PPTTADIEMADAGSDDELRA TCTTGGCGGGCTGCGCGTGC DIDDGEVYAPMRLEPGVIPT GGCACGCCCTTCGCATCGAG RRSRLRLRQLTDDEMEAAGE GTTGGCCGCAGCCAGACACG VVERLSAGLSAKIADADDWE CGCAAGCGTGCGCCAACCTC TAEGYITALPYMLYDKLQQY TGCACCACCTCGGCGACGAC TQVRHGTARSPAPHPQRRDV TTCGACGGCAGCAAAGGCAT QGQVETHREPRHETIGQPDQ CAAGCCCCACTGCTGCCGGA PGEPSPTRRRRRGKRKGRRQ GGCAGACCCACCGTCCGTGC RRHPRRTNCGGGGRQQRKQR AGTGGTCACCGCCGCGCCCG HPRPPRGTRHHREHRIDEAI ACCTGCCCCGCCAGTATCCC DELHALERARPQARPAIAKA TCGGAGCTCGTTGCGTCCCC RRRVGRIRSAIDQQLLRHRF CCCGCAGCCGAGCTCCACCA DTAEKECVDGILAAARTARD ACGTTGCA ARTTVRAAAATGTTATPETA (SEQ ID NO: 1202) VTSGTEQQDDNGTCPIPSEV LWRHFDSVNTPQRDFDPEAP EGAAFRSAMARLPAATRFME LLKEEPSTDGIEVQLQHASS TSSPGLDGVGYDVYKRFASQ LLPVLKAAFKCCWTHKQVPQ SWKLGVVRLLYKKGDREDPA NWRPICLQQAIYKIYTGVLA RRLTRWQDANDRHAPGQKGF RPVNGCGEHNFLAAMLIDHA RRKHRPLYEVWYDFRNAFGS VPLGLLWDALERTGVPAEYI AAVQGLYDHAAFMVGNAVDG STAPILQRVGVFQGCPLSPP LFSAAISPLLHALQLLPSSG VQLSGDDRPGVSAYADDLKT FSGTKAGVTEQHELVAMFLR WTGMADGFDHVRRRVALAPK LKLLKQDATALMESGLAPWQ VVKAVKGYLYPRVEYALRHL RPDDQLLESFDLHLRRGLRH LLRLPKSANNDFVYAPVSRG GLGFLPLVELHAALQIAHGW QMINSPDPAIRRIAREQLHQ VADARHRLDKDHWKQRGDEL CELLLNGELGTSAHAPPKRR NGDIGSLWVDVRKNLKAFGL KLATAPADPESGAPAKPLQL CVPHHAEWLDHRNVLRHVKQ HMKNKRWRAWCSHVDQGRTA RAHGGVGSGFLTRPRGMWES DYRFAVAARLNMLDTVNVLA RRRLRAHDRCRHPGCRWKET LAHVLNHCPGTMDSIRGRHD DALKEIERTLHASSGDRQGR TELRTNQTVPGLAGPALRPD LQVYNHDQRTVAVVDLAIAF DEQPRDDPESSGLAKAAAEK KAKYAGIKRHLERQGWKVHL SALVYGSLGSVAPSNYKVYT EHLGLLKRDAKRLDRQLSVA CIQSSRRIWNLHCAQHRARQ HQDQPAPRGRRVTETGGTPS RTDRR (SEQ ID NO: 1447) Nes Utopia AATU0 Phytophthora AGCTCGGCCTCGCGGCTGCC TAAACGGGTCACTTGACCGA MLADPAALAAGLARAPPPPS L -4_PI 10012 infestans TTCCCAGGCGCCGCCGACTT CAGGGCACCACCCAGGTAGG APQDPSPAFPAGPAGQNPRA 81.1 CGCGCTCTGGCGCGGCCCAC GAACCGCCCTTTAAAACCCA AAPARVEVHTVVAPPGRAGG ACGCCGCCGCCGAGCCTCCA GGAAGACACAAACACCCTCC MLPDPGLVEEPIQATYAHDA AGCGCGCCCGTTGGCTTTCG ACATAGTGACATACATATTT AQFECALCPYVAESMAVLVQ CAGACGCAGGGCTCGCGGCG TAGCCTAGATTTCAGTTACG HRRSAHRGTRFKDIFTSGCQ ACGGCCCTCGCCAGCCCCCA GAGAGGTTACTAACTGGTAC CSLVFYARIVAASHAVACAR AGACCCCCCCTACGATGTGG ATAAAATTACACATTCTGTT RNQRAVPPAPTPVAPTRPEA CACCACCCGGCAGGGCGGCC CTAATCAGTGTGAAAACTGG TPQPTGYLAAAMTAAAAAAS GGCAGGCTGCCCGACTCGGT TTTTCGCCTTTTGGCGGACT SDTVVAAATNMQSAVPAAAK ATCGCCGGGTGCTACACTCT TTTTCACTCGCATTTTTGGG TTGLQLVPPELEPALPQRAS CAGCCGCTACAGCTCGGGCC CAATCGTCTGCGGCTAGCTT CHAGKRRRLNADEAVTPCTP TTGGCGGTCCGCTATTGGCC GCTAGCGGCGGACGAGCGGT TARVSPQTEVAMAPHDAPQD CTTGGAGCTCGACGGCGACA CTCCGGGGGCGTACACCTTT DTVLQREAAEPQPDPAATQG GCAGCGACGACGAGGACGCT CCCCCGCGAGGCCAACTACA AQVQRVEDTTAAQDDTVQQD CAAGACCCCCACGCCGCCGC CCGATCTTCTCTACACTTTT HDADTAQVSPPRRTPTRWGP CCCAGAACCCCCAGAAGACG CTAATTCGCCTTCGTCTTCG RPSSTQEPSPMTGEPAATLA TCGCGAGTGTGCTTGCCCCA GTCTTCGGCTGTCGGATTTT ARRPLTPAATGTRATRWGPC CCCGGCAGGGCAGGCAGC TTTCTTTTTGACCAATCAGA HRAIGAAAIARLVTGLPTEP (SEQ ID NO: 1203) GTGCGCCATGCGACTCTTCT AQPQRRQPPPPQEPPLQPEP GGCCAATCAGAGACCGGGCC QAAAATVAADIAATVAADIA CTGTCCTCGGACAGCGAGGC AAAANAAMDVDGGPAADETW CTCCACGGCCAGCCAATCAA LLRFDGACRRNPGPGGAGAA GTCTCGGCAGCGACGCGTCT LFAPSGAVVWTCSHFMPSRS TTCTATAGCGCAGCTGACGA ETNNTAEYTALLLGAQSAVH GGCCGATCTGGCGGCCCCCG HGAKRLNIEGDSHLILSQVR ATTGGTCCGACTTTCGGCCA GAFACNNKRLRSLRNRVQAS ATCAGCGACGACGAGGGGGC LRQLDWYRLQHIDRKANQHA AGGAGTTTACACTTTTGCCC DRLANRALDLRRTVTECGPH CCGTTTCGACATCAACTTCA AETRNRCFQTPQPLVEPGET GGCCAAAATGGCGATTTCGA HCVPGSDEVLAANTAMEDAT CCCTCCACGCGCCGTGCCAC AVPTEDDEAEVAARDGGEVF TGCTCGGCACCGGCGGCGAT PTIAIGPDSAPAKQPRLRLK TCAGCGGGTGCAACTTCGGG KLDEDDFDAAAAAVTRVSEE CACGTGTGCAACACATGCAG LASKIVDAGDWTSGEGYISA CGCCCATTGCACGCCAAGCG IPERLRAALRPFALPTQPAR GCATCGCGGGACGACGCCTC PQPREPRMQQPPRRPPRVTR GGCCGCTCAAGCGCAGCCCC DHLEHRLDEALDTMENVQRS GCCCTTCCAGCACGACCTCG TPQNQKAVRRARRRVGRLRS CGCCGTTTGGCGGATCGCCA AMDRTRLRKKFATHERECVA TCAAGACGTGCGAGAGCCAG EILRRASTEEAANPSQEKCP GCGGGGTCGGGCAAAATATA IDRATLHEYFTATSTORTPF CTTACTCTAAGTATGCCCGA DYDSAKGTEFRTFLEVMSTP ATCCCTGCCCTCTCAGGCTG SHETSALTAEPTLDEIEDQL TACGCGGCCCCATACTTGAT AHVKAGSSPGHDGVGYDVYR CTAAGTATGGGAGGATCCCT RFQVQLLPLLHAAFRFCWRH GGCCTCTCAGGCTGTACGCG RRVPALWKVGFVRLLHKKGD AGACCCGTACGGCCGAATCC PQQPNNWRPICLQTAIYKLY CTGGCTTCTCAGCCTGTACG SGLLARRLSKFLEANELLPM CGGGGCTATACTTGGTCTAA AQKGFRAFNGCHEHNFVATT GTATGCCCCGGTCGCTGGCC LLDQTRRMHRRLYQVWYDLR TCTGAGCCCGTACACA NAFGSLPQQLMWGVLRQLGV (SEQ ID NO: 1326) TEEFVARCSGIYEDSYFVVG NASDGATEPVRQEVGVYQGC PLSPLLFITALVPLLRALEN QDGVGVPLADGVRPCATAYA DDIKVFCDSATGIQRCHALV TRFLEWTGLQANPAKCAFLP VTRSQHSNPTRDRDIELRIH GEAIATLGLQESYRYLGVGD GFDHVRHRLQLEPKLKQIKR EAVALLHSELVPWQILKALK VYIYPKVEYALRHLRPLKSQ LQGFDSAIVRGLRHLLRLPE NSHDGLFFSPTSAGGLGLLS LVELHEALQVAHAWQMLHSK DPAIRAIARTQVGQVARKRF KLVEEHWRGREDDLAQRFLN TELAASPHATETRRNGDIGS LWNDVRDTLQTLGLKFAAGD EEEAPGLLQLRVPHHTKWLS HSTVLRHVKLHMKLRRMDTW KSKVSQGTTVREHGGVGSRF ITAGAGLSDAEYRFAIAPRA HLIDTNSTLKRRRLRANDTC RAPGCSYTEPPAHILNKCSP NMDAIRKRHDDALERIADAL RRKVEKSGGRLEVAINKTVP EYDGAALRPDIVLRNTETKR AIIADLAITHENQPTDATTS SALQQSRDNKITKYQTVAAA MMRAGWRVRVTGIVYGSLGS VLPSNFKVYTELLALLKRDA RRLNRQLSSHCIRASARIWS AHCRRHRERQRSGNASRASR GSGGAPRRTSQASARR (SEQ ID NO: 1448) NeS Utopia . Phytophthora CCAGGAATCACCCCCGCCGC TAGACGGCACACAGGCCCAC MSGDVVSSDGSSRTTDASGD L -4_PR ramorum CCCCAAGCGCTCCGCCGCCG AGCGGCCGACAGGGCCACAC GDDGAGSSDAAGDVGVVAMD AGCCCAGCTGCGGCTGCTGC CCAGGTAGGGAACCGCCTTC VDQGARRQQPPWQRVGGKRR CGCCCCACTGGTGACGGCAG AAACCCGGCCGGTACATTAT RLNDVDDEDTRELAELLLEE TCGCAGCTGCCCCTGCCACC GGTCCGACACCTATGAGGTG EDEAGDHAPAPRLSAASARP TCTCCTGTTGGCCGCGCCGC CAACCGGTACACAAGTTACA ASVLSVYAHNAQRFQCTLCT CGTGGAGCCCCGCGCGCGCG CACCACATAGCGACTACCAG YTAASFASLKRHRDSRHRRT CCGAGCCGCCCCAAGAACAA GTATTTACTACCTGGAAGCC AFLDRFSAGCACGVPFASRL GCACCCCCAGCTAGCGCGCG AAGGATTAACCGGTCGGTAA AAANHAHACDSLNRTFSVAA CGTGGAGCCC TACACATAACTTT APAAGELSPTAGAANATVKA (SEQ ID NO: 1204) (SEQ ID NO: 1327) ATVTPDSPRQDPPKLAATPP LASSALVVDPDHAEQQARER WGPPLPRTLVAGRVAARLSE VPAPRWGPPLPRGVVAFRIG HRVLPPEMTSDEETKDDSSV QDGDRQDYPVAAMDVDSGMS GEWLLRFDGACRANPGPGGA GAALSQPDGSVVWTCSHYMP SSSETNNTAEYTALLLGTRA AADHGTTTLRVEGDSTLVIQ QVRGIFATRSVTLRHLRDQV KLELARVGRFSLHHIDRQAN AHADRLANRALDLRRTVSEC GVHPDGNGCTPTAIDDRPLA PTQQPPDAPPPPPAADIEME DPDDEDLADIDDGEVYAAMR VGPNATPQRRRRGRSGTAKK HRRQRPPRVTRHHREHRLDE ALDDLHAVERSTPSDRTTVR RARRRVGRVNSAIEQQRLRH RFDTDEKACVTDILAKACAT REAARTTASGGDPPAGPATP AAGSADDGTCPILGEELWRF FDSVNTPRQEFAPDAPVGAA FRSALARLPAATSCKELLTA APSAGEVEDQLQHVRGASSP GLDGVGYDVYQHFAAQLLPA LTAAFKACWTAKRVPQSWKL GVVRLLHKKGAREDPANWRP ICLQQAIYKLYTGLLARRLV RWLDANDRHAPGQKGFRAVN GCGEHNFLAATLVDQARRKR RTLFEVWYDFRNAFGSVPFA LLWDALARLGVPDDYVTMCK GLYESAAFVVGNAIDGTTDP IALRVGVFQGCPLSPQLFNA AISPLLFALQRLPATGVQLS GDDCPGASAYADDLKIFSGT EDGIKRQHALVADFLRWTGM AANPNKCCTMSVQRDGRGVL KTDDLQLDLAGTPIPALSMS ASYTYLGIGDGFDHVRRRVE LAPALKQLKDDATTLLQSGL APWQVVKAVKTYLYPRVEYA LRHLRPFQQQLEGFDRHLAR GLRHLLRLPGNATAECFYAP VSRGGLGLLPLTELHAALQV AHGWQLLNSKDPAIRRIARV QLRQIADARHRIDSRAWEGR DEELCELLLNSQLGTSPDAP PKRRNGDIGSLWVDVQRHLR TLGLKFATAPACADAGSAAT TLQLRVPHHDKWLDHRTVLR HVKLHVKHRHWSKWAAMRDQ GKTARAHGGAGSGFLTRPRG MWEADYRFAVAARLNQLDTH SVLKRRRLRAHDHCRQPGCS RAETLAHVLNHCAGTMDAVR GRHDDALKHIERALHASSPG GQDRVELRVNQTVPSLAGPA LRPDLQLYNHTKKMVAVVDL AVAFEEQASDDPESSALARI AAHKRAKYAGVKRHLERQGW KVHLSALVYGSLGAVPAGNH KVLTEHLGLLKRDAKRLDRQ LSVACIQSSRRIWNLHCSQH RARQHQAPGGSRAAETGGTP PRTGRR (SEQ ID NO: 1449) NeS Utopia . Phytophthora CTCAAGCCTAGCAGCGGCTA TGACGCACCGTGACATAGTG MARVLVEPMQVDECSSCDRS L -5 PI infestans CCGCAGCTACTCCAGCTCCG CGGCACGTGAAGATGCACAT TLTADDGSGDDVAAPSSLNS GTAGCTGCTACTGCTACAAC GAAGCTCCGACACTGGGCCA NDVAAPMDVDSGTDCPPALQ TGCTCGCGCTGCTGCTCGCG AGTGGGCGGCCATGCGCGAC QPPQRPRALHVGSKRRRLDA TCGCCGTGGAGCACCACGCG CAAGGCAAGACAGCTCGTGC DDEEEARQLQEEEEAGIHAP CACGCTGAACCGAACCAAGA ACATGGTGGGGTTGGTAGTG ALRLSAASAQPASVLAVYTH ACATCTACCG GCTTCCTCACACGGCCGCGA NASRFDCTLYAYTAGSFASL (SEQ ID NO: 1205) GGCCTGTGGGAAGCCGACTA KTHRNSRHRRTAFLDRFSAG CCGGTTCGCGGTGGCCGGCC CACGVPFASRLAAARHAQAC GCTTAAACCAGGTAGACACG ASLSSAPLAEASSAAGASSH CACAGTGTCCTCAAGCGCCG TVDEADSTVSAAGHTEPDLP GCGCCTCCGAGCACATGACA RHNATELTASPPLVSSPDVE GGTGCAGACACCCAGGATGC VQAPETEATENRWGTPLPRV ACGCGCTCCGAGACGCTGGC LVASRIAGRLAQVPPPRWGP GCATGTGCTTAACCACTGCG PLPRTTIAGRIATRLAATPA ACGGAACCATGGACGCAGTC PRWDPPLPRSLVVSRIAARL CGTGGCCGGCCATGACGCCG LPALPDAPACEEEAKDSDTM CACTCAAGATTATTGAGCGT DWAPTWTNEETKDSEPHDEA GCGCTCCTCGCATCGTCGGC PGQVDEETIDDADGEWLLRF CGACCAGCAGGACCGTGCTG DGACRANPGPGGAGAALFKP AGCTCCGCGTGAACCAGACC SGPVVWTCSHYDPSTTATNN GTGCCGTCACTCGCCGGCCC TAEYTALLLGARAAADHGVT CGCGCTACGGCCCGACCTTC KLRVEGDSTLVIQQVRGIFA AGCTCTACAACCACACCAAG TRSTRLRALRNKVKLELARV AAGACGGTGGCGGTGGTCGA GSFSLHHIDRQANGHADRLA CCTGGCCGTGGCGTTGAGGA NAGLDRRRTKLECSVHPDGR GCAGGCGAGTGACGACGCGA GCTNTSVATAAPTAPAAPLP GTAGCTCGGCACTGTCCCGG PARPPATTAAPSHDDDHSVQ ATCGCCAACCACAAGCGAGC GDIDDGEVYAAMCIGPDAVP CAAGTACGACCACATCAAGC HRRPRLRLRHLTDEESEEAG TACACCTCGAGCGCCAAGGA DVVERLAASLAAKIADAPDW TGGAAGGTACACCTCTCGGC ETAEGYITALPYALYDKLQP ACTCGTGTACGGGTCGCTTG YSQAQPQPPSQQQQQQQQRP GGGCGGTCGCTAGTGGCAAC RQQQQTRQRRQRRGKRGGGS TACCAGGTGTACACCACACA QRRQRKTRRRRPPRVTRHHR CCTGGGGCTACTCAAGCGCG EHRIDEALDDLHAIESRRPQ ATGCAAAGCGGCTGGACCGG DRTAISKARRRVGRIRSALD CAGCTGTCTGCCTAATGCAT QHQLRHRFDTDEKVCVDAIL CCAGTCCAGCCGCCGCATCT AGARASQGATTAPPSATTDP AGAATCTACACTGCAGCCAG PAPMDDSRCPIPGDDLWRFF CACCGGACTCGCCAACACCA DSVNTPRRSFDAEAPDGAAF GGCGAGGCCCAGCCAAGGAC REAMACLPAATRAQELLTEA CAAGAGGCAGCCGGGCGACG PTVDEVEDQIQHARASSSPG GAGACCGGGGGGACTCCGTC LDGVGYDIYKQFAAHLLPAL CCAGACAAGCCGCCGCTAGG HTAFVCCWNHKRVPQSWKLG CGGAAACCAGGCCCAAGACG VVRLLHKKGDRQDPANWRPI GCCGACAGGGCCCCACCCAG CLQQTIYKLYAGILSRRFVR GTAGGGAACCGCCCTAGAAA WLDANARHAEAQKGFRAMNG CCCATTTCGGTGGTCGACTC CGEHNFLAATLVDHARRKRK GCAAGCCTTACCTATATTTT ELHVVWYDLANAFGSVPHDL AGACGTAGCGACCAAATTAC LWETLARQGVPPTFVDCCRG AAATTTGGTAACGAGTAAGC IYSDAAFTIGNAADGTTAPI CAAATGGTAATACACAAAAC RLRVGVFQGCPLSPHLFTAA TTT IAPLLHALKRLPVTGVQLTG (SEQ ID NO: 1328) VDRPGAAAYADDLKTFSSSV DGIKRQHELVATFLRWTGMA ANLSKCSAMSVQRDSRGVLK TGDLCLKLNDAEIPALSMTA SYAYLGIGDGFDHVRRRLEL APMMKQLKHDATALMQSGLA SWQVVKAVKVYLYPRIEYAL RHLRPFKQQLEAFDEHLRRG LRHLLRLPTNATSAFFSAPT SRGGLGLLPLTELHAALQIA HGWQILNSPDGATQRIAREQ LREIPDARHRLDTAHWRNRD AELCELLLNSQLGQSSHAPP KRRNCDIGSLWIDIRRQLGT LGLKFETAPGRRSHQPARPA IAAFACRTTTSG (SEQ ID NO: 1450) NeS Utopia . Phytophthora CCAGGCATCACCCCCGCCGC TGATGCCCGCCAACTACAAG MSGDWSSDGSSRTTDVSGDG L -5_PR ramorum CCCCAAGCGCTCCGCCGCCG GTGCTTACTGAGCACCTTGG DDGADGAGSSDAAGDVGVVA AGCGCAGCTGCGGCTGCTGC GCTGCTCAAGCGTGATGCGA MDVDQGARRQRPPWQRVGGK CGCCCCACTGGTGACGGCAG AGCGGCTGGACCGGCAGCTG RRRLNDVDDEDTRELAELLL TCGCAGCTGCCCCTGCCACC TCGGTGGCGTGCATCCAGTC EEEDEVGAQAPALRLFAASA TCTCCTGTTGGCCGCGCCGC CAGCCGCCGCATCTGGAACC HPASVLSVYAHNAQRFVCTL CGTGGAGCCCCGCGCGCGCG TGCACTGCGCGCAGCATCGA CAYTAASFASLKRHRDSRHR CCGAGCCGCCCCAAGAACAA GCACGGCAGCACCAGGGCCA RVSFVDKFSAGCACGTPFGS GCACCCCCAGCTAGCGCGCG AGCGCCAAGGGGCAGTCGGG RLAAARHAQACASLSIPRTV CGCGGAGCCC CGGCGGAGACCGGGGGGACT TAPAAAGDLSPTATGANATA (SEQ ID NO: 1206) CCGCCACAGAGCGGCCGCCG SAAATSPDLPRPASPELAAS CTAAGCGGACATCGGGCCCG PPQTSPFDVAIQADAAEQTA TAGCGGCCGACAGGGCCACA WTRWDPPLTRAAVAARVASR CCCATGTAGGGAACCGCCCT LAWPAPRWGPPLSRTLVASR CTAAACCCGCCCGGTACATT IAARLDAQTSRWGPPLPPAM ATGGTCCGACACCTATGAGG VASRIASRLAAMPAPRWGPP TGCAACCGGTACACAAGTTA LLRTVIASRIADRLLPPELA CACACCACATAGCGACTACC ADEETKDDDVHMDNAASVDV AGGTATTTACTACCTGGAAG DEESEVADVVMTDHDGEWLL CCAAGGATTAACCGGTCGGT RFDGACRANPGPGGAGAALF AATACACATAACTTT KPSGPWWACSRYMPSSSATN (SEQ ID NO: 1329) NTAEYTALLLGARAAADHGA THLRVEGDSTLVIQQVRGIF AARSTRMRALRNQVQSELAR VGSFSLHHIDRQDNAHADRL ANRALDLRRTVIECGIHCDG VGCTATTTEVQSSSAPEIPT RPVADDHDEHEWDVVDVCGV CGVCGDRGTCGVCDVSGDI DDGEVYAAMRTGPDAVPARR PRLRLRKLTDEEQEEAGTLA ERLGATLAAKIADARDWESA EGYITALPYLLYDKLLPYSQ GPARSLPVRQHQRQQQQPDG QFQRPTQSRSAARRQRRQRH RARRRPPRVTRHHREHRLDE ALDDLHAVERATPSDRRSIR RARRRVGRVNSAVEQQRLRH HFDTNEKGCVEILLAKARAQ RSTTVARTAVGEPNSGAAED DGTCPIPSERLHRHFTEVNT PGSSFDAMAPVGAPFRAALA HLPAATEASELLTEAPTPDE IEDQLQRAKGTTSPGLDGVG YDVYKAFSTQLLPVLHAAFQ CCWQHHRVPQSRKQGIVRLL YKKGPREDPANWRPICLQQV IYKTYAGVLARRFTRWLAAN GRHADAQKGFRTVNGCGEHN FLASTLIDHARRSRRELHMV WYDLKNAFGSVPQELLWEVL QRMGVPPAFVEVCQGLYQDA AFTVGNAADGPTDLVRQLVG VFQGCPLSPHLFTAAISPLL HALDRLKDTGVRLSADDRPG ASAYADDLKIFSGTADGVKR QHALVADFLRWTGMVANPNK CCTMSVQRDGRGVLKACDLE LQLDGARIPSLIMNASYAYL GTGDGFDHVRRRIELVPALM QLKDDATALLQSGLAPCQVV KAVKTYLFPRVEYALRHLRP FQQQLEGFNRHLVCGLRHLL RLPVSATTSFFFVPVSRGGL GLLPLTELHAAPADRRPAPP PRPRPLEGAGGENMRAADQL AARDVGPRPTQAPQRRHRLV VGRRPAPPPRTRPQARDRAG VRGDRHRGGDAAASRAAPRE VAGPPHGPAAGEAAHEEQAL AAVGRDEGPRQDRPHPWWCR ERLPHAASRPMGDRLPLCSG GSAQPAGHAQRAEAPAPPRA RPVSTAGLLPCRDTGTRAES LRRHHGRGPRPPRRCAQDHR ARAHRVVRAARTAPSSGSTR PCPRSPAPRCGPTSSSSTTP RRRWRWSTWPWRSRSRRATT PRALRWRASPRTSEPSTPAS SGTSSAKGGRSTSRRSCTAR WAR (SEQ ID NO: 1451) NeS YUREC . Ciona ATCAACCCACTACTACACCC TAGCCAAAAGATTTGGTGTT MATSSSSVSSGNVQTEVRCV L i intestinalis TCTACAAAGAACCCACTACA CTTGGCGAGCTGCAGTCCCG YHGKGDLLLECPVAHCPSIH GCAAGATCTTGGCGACCAAC GCAGAGTAGGCGAGATCGTG PTVATITKHLKKHHTPQFEQ TACACCTGCAGCCTCCCGTC AGCTCTACACCGCTTCACGA ITTKNLTITYTCSQCSFSTT GACTCTTCACCACCTGCGCA TTTGACGAGTTCTTCTTGAG GLTQHHISKHYKTCKGVGAV CCTCCCTCCGACTCCAAGCG TCGATCCCCAACGGCAACGC QEGNKGRFCCPACGTRWALL GCAGACAGTGGCACCACCAG ACTCCAAATTTAACGACCGC CKARHHFNNVHFEYDTPPIA CACTCCAAGGGTCCACAGCC ATGGCGACGCCACTGATCTC AFSGTPYKLKKRKFTIINKA AGAAGAGTGCACCCCCCACT CCAGTCATCCGTGCTCCGAG LTYSCPLPLNQLLCPLWSCS GCTAGGAAGAGCTAGGCCAT GGCACTTAAGGGGAACCGAT LTILNKPLSSVQQETAHGDG TGCCCGCTGTGGGCCTTGTG TCACTGATGCTGCAAGTTGG SQGQSYVPTQLRQVLRARCH CTGGCTGTCTGCCGCTGATT CGGGGGCGCACTCACCAATG CGNPPIGKGHWASCQGKRPL GGCACGTTAGGGAGTGTGCG GAAGATGAGGGAGCCCAACG SSPKGGRSSPTPPANLTLHF CTGAGCACGATAGGGAGGCT ATGCCCCGAACTACCGCACC LNYLPFQLPSQSSSPQSSTL GCTGAAGCCGAAGAACCCGC GTCCCCAGCACCGTGTCCTT DPTACKARVPIPSFLRGDCE GCCGGGGACTTTAGGACTTT GTGAGTAATTATTTTCACTA VTFFIIPSVNFYRPYLSYPL AACTAAAATCTGTAACACTA ATCCAGGGACGGGGCCATGA RMFWRNRTSSGHCSLHRWRG AAATTGGAATACTGGATTAC ACTGAACTATGTCTGCACGC FVRERLVPHPRSKSPARTPL TATTGGATTACTACTGGACA TGCCCCGCCTAGCCTCGGCC EFLCEFRLAGVFPDPGKVAS ATAACCTGATCTACAACAAC ACAAATAAATAGTCAAGCCG LRPVPAPLTLCLSPPVAGPM CAATTGGATTACAGAACCAA GGGCGTACTACCAATTGATT ISCEDHSAPPSVRSSSPIPN ATTACAATCTCAACTACAAA CGGATTTGGCGGGGCCCATC SPASVSSVEAHLSDLLDKVS CAAAAAGTGAGTCCCCGGCC ACGCGCCTCCGCCCCCACAC SGELRPLSPTLPSSGFFGPL GGGTTTCTATATTACCCAAT ACAAAAACACTTTTAAACTC LPPTPPPRPTPSAEKASPSG TACTGTTTTTACAATTTTAA TTCGGTTCCCCAACCACTAC LSYLPCREVKIASIARPSPA AATTTTATAGTATTTTACTA AACAAAGCGAGCGGCCCCTC SQRVGCDADRTGPSLNPNYQ ATTTTTCCGCCCCGCTAGCA TTAGATCCAATTTTAAAATT QTSPPSTPSFSPIVRPPKFP CTTAAATTGGCACCCCCCCC TTAAATCAGTGCACTCAACT RSGAKVNSKSKPPGVRPRRA CCCCSTCCAAAAAAAAATAG TTTTTACGTGTTGTGTTTTI KPIEPGTESASPVDVDTISS ATAACCCTCCACCACCTAAA IGTATTTTTTCCCACAGATT SVQEPCTPENRTPEFFYERK CCCCGGTCACCCCCTCAGAA TTGTATTTTTATATTATATT WLVSILNIHEREGSNFFQFN CTAATTGGAACCCGGATCTT TTATATACACAACACTAITT RDLEYWTQLLSGSQKGGRAK TTCCCTCTATCAAATTTCCG TIATACACTACCTTGCACTG RASYNRGAANQAMKNRDSGR GTTCAGTTTGGCTTAATTAC TCCCACITTTTGTAATTATC KDFDPRPVAGHSSGGGTELG CTAAAACCCGTCTTTATTTT ACCTTTTACCTTTTATGCCG SRPRYPKGARLRADFWRDMK ATCCCTTTATTGCCCCTTAA CTCGCTGAGCTCCTTGCACG GTVRKLLDGSNGERRCGIPL ACCAAATTATTCAAATTGAA GATGACCAGACAAACTTTTA DIIERKFRQVSMPGWIDHRR ATCCGGCCAAATTGCCTTGC TAAAATTATAACATTGTTTT YAAGASPSLVTQAETDVAIT TGAACCACCATTTTTGTTTT AATTGTCGCGGGGTATCAGT SEEVEAVLSGLNVQSAPGSD TCTTATAAAAGTAAATTTTT GGCGCCCCCTTGCGGCCGTG GLSYRFWKGLDPSGRLLSCL CAACAACCCAAAATCATAAA AAAGCCCTTTTCACCTTAAT FEIVRRHGRIPGAWPTCSVI ATTAAAACTGTTATCTGATT TCGCCCCTTAGTCCAAATTT LLCKDAQGDVQDVGNWRPIT AGTCTAAATTCTGTTATTGA TTCCCCATTGCCTGTAAAAG ICRTLYKLYAAVIARRIQTW CAAAAACCTCCATACCAACC TGCGTTGCCGTCGACTCGAA AKQGGVLSRLQKGFMPVEGV TTAATCTTATCATTATCTTC CTCGTCCTTTTTACCGCCTC FEHVFMLDTVLSDAKLRRKN ACCCAGACTGCTCAATCTAG TCTGTTACTGAACTATGACC LLAVFLDVRNAFGSVRHECL TTCTTTTTTCAATCAATAAG AGCTTGGCTGTTGAAGTCGG LKVLRHFDAPHYLVELVRDI GAGGTGTTTTCTTTGGTCTG CTTTAATTCGCCGGCTTCAC YTGATCRVRSSVGETGDIPC TTGTTTTATAGTTTACCGTT ATTATATTTTTTTGTTGGGT DRGVRQGYPLSGILFNLVTE ATAATAGTCTGTTGTCCTAT AATCTGTTTTTTTTCATATA VLIPGLSAGNDGYRMACLGG AGTTTTCCGTGGTGTATTTC TAAAACCATTCGGCTTAAAA KLTQVLAYADDLVWTENRDQ TGGTCTACTATAGTTGGTGC TCACCAATCCCCATCATCCA MLRQLGVCEEFGRWAGLAFN CTCTAAAACATTATTATACC CCCTGGTCACCCATTGAAAC QRKCGLIGWRTLRGGRRVAL GAAGAGTGCTAGCGATTTCT ATCTCTTTTTAGTCAATTAT EDPLLLNGVEIPLLRPGEHY ATTATTAACTCACCCACCAG TTTTTCAGATTACCCCTCCC KYLGAMTGVMSVPRTGSQLI TACTGCTGTGCATCCACGCA AAATTGTCATATAGTTTAAC KDFRARLQRLFTSFLTPHQK GCACCACGCCTGCCATCACG ACCCCGTTTGCCAAGTTGGT LIALKRFLLPSLSFHLRVRP TACAGTGCGCTTGCTGCCTT CTTTTCCCCATCCCCTTCTG IARSELIALDRRVRECLRVA GTGTTTTGTTTTGCAGACAC TCCTTCCGGTAATCCCATAA FRLTKPSCQAVFHTPTDMDG CACTGGACGATAG CATTTTATTCTTTAATTCGG LGVPSVCSESSILTIAQGFK (SEQ ID NO: 1207) CCCCATAAATAGTGTAATCT VLTSPDGTVSATASARVKLY TAAGACGAAGTCCCCAGAGG AAKFGGLTEAGPSDWARYLS CCCGGTCCCCCCCTTCTTTG GDDVNGNSTRKPGANLPSGL TCATGGACCGGGCCAGCCCC WTRVRCASRQLGAVWRVCPE CCTGTTACCACAACAACCCA NGITVRVRNSVITSRDRRKL CCATTTTATTCTTTCTTTCT IRSFHDCSNQQWKEQWMQHP TTTTATTAGTATTTATTTAT NQEKTAAAHMAYADANRWVK ATTGCCGCCCAACTGTCGTG QPSVMEPHTYFFALRARLNL TCGTGGCGCAGGGGGGTTCC LPTRVSRAIYSRDQHPDILC CTCTGTCGGCCCAGTGGACG RRCGASVESLPHVLNHCPPN ACCGTCTAAAAAACAGGCAC MSIILGRHNLVLQEVLNAVD AGGCAGCAGGCACTTATCAC KTQFKEISVDRTVPEHMSET CCGGTACCTCCGGGTACCGG GEALRPDIVARRNDGSWVVD AGGCTGGTTTTCAGCGCACT VACPFDQKANFDEAAKRKLL GTACGTGATGGCCAATTTTA KYDKLCCNIAASTGKPVECH TTCATTGCATTTTATCCGCG SIWGSLGSLAEGLSTSLRAL TCGTGGTGTTTGCGTGGATG GITDFARSKLVACHQG CATTAATAAAAGATGAAATT (SEQ ID NO: 1452) CC (SEQ ID NO: 1330) R2 PERER BN000 Schistosoma ATCTCACGTTTTAATTTATT TAACGGCTGAACGAATAGCC MPVSTGAETDITSSLPIPAS E-9 800 mansoni TTTGAACTACTGCAGTCTGA CCCTTCACTCTTAGACATTC SIVSPNYTLPDSSSTCLICF GTGCTTCTAACGACCCGAAG CCCCACTGTTGTTGCTTATC AIFPTHNILLSHATAIHHIS GCTCAGAAACTACCCACTTC TTCATGCTCTTGTGTTAATT CPPTPVQDGSQQMSCVLCAA TTGAACTGCTACTTTTTGCT GACTGCTCTCTTCTGGGTTG AFSSNRGLTQHIRHRHISEY GTTTATCCACAACAACAGTT ACGTCTGATTGTCTCTCTCT NELIRQRIAVQPTSRIWSPF GTGATTCTATTCTCCANATA CTTTCCATATTGCTTGCTCT DDASLLSIANHEAHRFPTKN TTCCTTGTGCTTTTGTCAAC GCCCGCTTACTTCCAATAGT DLCQHISTILTRRTAEAVKR ATTATTCTATACCAACTGTA TGTCATATTATGTCTTTGTT RLLHLQWSRSPTAITTSSNN CCACCTACTTCTTCATCTCA TACTTGCCATGTCTAACGAC HTITDIPNTEARYIFPVDLD CGTTTTAATTCTGGTCTTAT AATTACTTTATCTACCTTAG EHPPLSDATTPNASTHPLPE TTTCTCATCATTAGTCACGG TTTGTCCTCTTGGTTTCGAT LLVILTPLPSPTRLQNISES AGAGGGCCTATGAACGGTCC TGCCTTCATATGTTCATGGC QTSHESNKNSMHTPPTYACD GTGACGCGAAATTCTATCCG GGAATCTGATGTTTATAATG PDETLGATPSSTIPSCFHSY CGATTTCGACCTCTCCTGCT ACTATTCCTATTACCACCAC QDPLAEQRGKLLRASASLLQ AGTGGTCCCCGAAGTACGGT TACAACTACTATTATTATTT SSCTRIRSSSLLAFLQNEST TCCTCTGGCCTGTCAGTTGT TCATTACTATTAACATTATT LMDEEHVSTFLNSHAEFVFP GTTAAAACTATATAATAACG ATAAACATTATTACTATTAT RTWTPSRPKHPSHAPANVSR (SEQ ID NO: 1208) TATTATTACTATTATTACTT KKRRKIEYAHIQRLFHHRPK CTACAATTAATATTATGGCT DASNTVLDGRWRNPYVANHS ACTCCTCTCAGCACACCAAT MIPDFDCFWTTVFTKTNSPD AAAATATCAATCAAACATCT SREITPIIPMTPSLIDPILP CAATTATATCCACCTATTAA SDVTWALKEMHGTAGGIDRL ACTCTCTCTATTTCCCCTGA TSYDLMRFGKNGLAGYLNML GTTATAAACTTACAATTCAG LALAYLPTNLSTARVTFVPK TCTAACCGAATATCTCTCTT SSSPVSPEDFRPISVAPVAT TTACAAATCTTAAGTATGTA RCLHKILAKRWMPLFPQERL ATTTTGTGCCAAACCCATTT QFAFLNRDGCFEAVNLLHSV GGGTCTGTACAATTTGATAC IRHVHTRHTGASFALLDISR TTAAAAATAAATGTTATTAG AFDTVSHDSIIRAAKRYGAP CC ELLCRYLNNYYRRSTSCVNR (SEQ ID NO: 1331) TELHPTCGVKQGDPLSPLLF IMVLDEVLEGLDPMTHLTVD GESLNYIAYADDLVVFAPNA ELLQRKLDRISILLHEAGWS VNPEKSRTLDLISGGHSKIT ALSQTEFTIAGMRIPPLSAA DTFDYLGIKFNFKGRCPVAH IDLLNNYLTEISCAPLKPQQ RMKILKDNLLPRLLYPLTLG IVHLKTLKSMDRNIHTAIRK WLRLPSDTPLAYFHSPVAAG GLGILHLSSSVPFHRRKRLE TLLSSPNRLLHKLPTSPTLA SYSHLSQLPVRIGHETVTSR EEASNSWVRRLHSSCDGKGL LLAPLSTESHAWLRYPQSIF PSVYINAVKLRGGLLSTKVR RSRGGRVTNGLNCRGGCAHH ETIHHILQHCALTHDIRCKR HNELCNLVAKKLRRQKIHFL QEPCIPLEKTYCKPDFIIIR DSIAYVLDVTVSDDGNTHAS RLLKISKYGNERTVASIKRF LTSSGYIITSVRQTPVVLTF RGILDRASSQSLRRLCFSSR DLGDLCLSAIQGSIKIYNTY MRGT (SEQ ID NO: 1453) R2 R2- . Bombus TCAATAGTTACTCGGGGGCA TGAAAACACGATAACGATTA IAKFDNNTNSASDAAPLSPG 1_BTe terrestris GGCGGGATATTGGTCTTGCC TGAATCAAAATAAGAAAGTA GAVADLSASEGTTDNDQAMS TTGCCCAAGTCACACTCCTA AACATCCCAGAAATTGTCTA PAMSLXTVPLVGNRVACPXC CCTCCTCGTGGTACCGCCGG CGTCTTATTTGTTATCTATT EKREANLFFLNLSDLDRHLT TAACACGCGCACGTCCACAT TATTTGTTTA QHHPDAPIXWSCIDCAKCFP CAGCGAGGGGCGTACTCCCC (SEQ ID NO: 1332) KLHGARCHIPKCGGASSQAR CGGATGTGGCGGCGCGTGGC TGEFQCEACPMSFGSRRGLS TAAACGGAGTGTGGCGACGA THERHAHPAVRNIKRRGADP AGGAGCGAAAGACTAACAAC PEENTKSWKVEXVARLKGLW TATAACGGTCTTCCGTAACG EIFKDHKYPNKEISKFLTTK GCTACTTGGAGCCGTGAATA TVDXXKYQRKKLNLIGXESP ATGGAGCCTATATTAAACCC QEATSLATEGGCDLVSSGNA TGGAACTCGTTCCTTCGTTC SFGSPVGRNENEEELIHEWK TGTTGACGACTGGAACGGCA LSLKNEINKPTEVPPILKEV AAGGACATGATTTGGATAAC YNRLMLIWEEHQDDRDSLTE AATTGGAAACTTAATATCGA SLDHFIRTALYELINKINKN ATTCACAATTAA QTDLKTKRAAKTKSPKNNRN (SEQ ID NO: 1209) SRKRFSYARCQELFHECPRR LADAVVNNDQAYLEPARQPP GSEEVRGLYEKLWGQVGSTY VPAPVTRVPKLSLSEIFPPI AAEDVGERIGKIRKKAAAGP DGLQRDHLTIPGLPIIMAKI YNILVYCSYFPSAWKENRTT LIPKINKPCSLVENWRPITI SPILGRIFSSIIDGRIRRGT VLNMRQKGFTSENGCKINIE LLNSALNYSKRNSGGIFTIV DISKVFDTVPHAALKPCLAK KGVPALIVDLIDEMYKNVKT TIKTKDGGVEIMIRRGVKQG DPLSPLLFNLCLEPLLEEIE EQASGINVSEHRKVSVLAFA DDIVLLGADAREAQHQINVL TDYLQSLMMNLSIEKCQTFE VVAKKDTWFIKEPGLKIGNQ IMPTVDPDEAFKYLGAKIGP WKGVHCGVIVPELLSVVKRV RKLSLKPGQKVELLTKYIFP RYIYHLLVSPPSDTVLKLLD SEVRQEVKTILHLVPSTATG FFYTPKACGGIGIPRFEHII KLGTLKSAIKIANSIDPAVA GLIDDAAIKKLKQTANSLRI NWPASLEDIEKARKRLRKEH ISQWADLKCQGQGVPDFIKN KTGNLWLEDHSLLKPSRLID ALRLRTNTFGTRSVLARADK NIDVTCRRCRAQPETLGHIL GLCQHTKGLRIKRHDEVKSL LEGRLKSKKNNEVFVEPTIK AGGSLFKPDLVIKNGERVLV VDVTVRYENKNYLALAEKEK IEKYRPCLRALKEIFNAKGG EILPVVLGSRGTITPNTEKV LKRLGIANNDIKTILLNVLR SSIELCNIFIDD (SEQ ID NO: 1454) R2 R2- . Crocodylus AGGCGTCTCCTTTAAGGGCA TGAATCCCACTCTGGGGACC VPPGAEARGRYHHPRXEXAR 1_Crp porosus ACGGTCTGGTTACGCGGTCG CCCAAAAATTAGAAAAACCC QGEPPSXRVFLVXLPDSNPP CAGCAGKCTTGCKCCAGGTA AAAACAGTTGTGTTTAAGTG CPICGDHVXXXSVLALHCVE CCTCCWCGTGGTTCCCGCCG TGTTCTTGTTTGTCCCTTTG GHXWAXVQYQCTHCGILCHI GGTGCCGMAGMCCCAGGSCT GCTTCACCTCCAAGTTGCGA PRCQGRVXEXTGKDXXCPEC GTCGGTAGCTCGATCCTGGC TCCCCCATCTCCCCTGCGCT PASFDEKAGLSQHKRHTVTX ACAGTAMGGCCAGGGGAGTK GTCTTTCTGAATGACCAGTG SXERVAGXLLRAXLRHGCWS CTTCCTTGCTGCWGGTGCCC GTGTTGAGGCTGGTGTGACC VEEEETLTRLDAMFXGARNI CACAAGCGTKTGGCAGSMCM TCGGTCACCTCCAAGGCCAA NQLIAAEXVSKMXKQISDKW CCTGCTTCWTCGCAAMAATM GTGCCCTGGCCCCGAGTAGG RXLXLXPEQTTXGGXAESAS ASAGKGTSMTCAGTAGTCGG ACCAGGTGGCCCAGCTTGCT VVXXESMTPEMEAQSPAXPP CCCCGCCGCTAGCCAAAACT GGGCACCCGTCACCGCCCAG GKIRKIFTGQDGHAGGXAWE GTTCGCCACSCAGTTACAGA GGCAAATGGAAGGGATCTAT NQEDFHWTRWARRWLKRGQX TGGTGCCTGTGCTGACCKGK CCTGACCACTACCAGGCTAA LSDKVQEVLGXWVEGQPRIX KGCCCCGTGGGCTCGGWGGT GTGTGGTGCTGCCTAGCCTG AWVDXVSLDVLTLFLGVPPG GCAGGGGWGGCCGGCCCATG CCGTAAGGTCAAGCGCCCTG PQRAPSKKGPXEGGKPTSWM GCTGGGCCAGACSTGGGCCK CTGCCGCTCGGGTAKCAGTC NKRAIKWGTFLRYQHLFGAN TGGAGCCCGCTCCCAMCCCA CTCGTTCACTCGTCCCTCCT RKLLAAXILDGAXRNQXTLL GAGTTCCCCCTCAAMGCCGC AGTACCCTCCGCMTCTGCGC LEEVXQXYXGKWEAEPPFEG CAGGKCAGMAMCAKCCGGGG TTCTGCTATCCACTGTGGCC LGRFGXXRDVDSFAFEALIT AGKGMCACGGCCCCGGCCGT GGWGATGCCGAGGWTGSWMC XEEAVKHMMXMAXXSAPGPD GA AWCCTCGACACCTCCAGGGC KLTLRDLRRADPEGDALAEL (SEQ ID NO: 1210) CAAGCGCCTTGGCCMCAGGT FSLWXITGVVPDRLKEXQXV AGGACCTGGCACCTGCCCAG LIPKAVDFEKLRQLGNWRPI GGGGCCAGACACTGCCTGCG TIXSIVLQLXSRVLTARLTA GCAAGGGAAAGGGAGCCGTC ACPIXPHQQGFISAPXCAEN CCTGACCGTTACCGGGCTTG LKXPELIXRKVKXDRRPLGV ATGGTGCTGGCTAGCCCGCC AFVDXARAFDSVSHDXISWV GTATGTCAAGCACTCCACAG LKAKGVDQHIVNLIEDSYQK CTGCTCGAGTTCGCTGGCTT VTMRVQVFSGSTPPISIKXG CACCTTCATCCCWCCTAGTG VKQGDPMSPLLFNIAMDPLI CCTTCCGCCTCTGCGCTATT XKLKTVRQGVKVGSASLTTL TTCGTCCCGACTCGTACCTC AFADGLXLLXDSWEGMQHNI CCCACCTCTGCGCTACMGCT TTSXTPGRACNTTSRHPRGL ATCCCTGMAAGGACCAAGTG LQPHGPTSATXKMXGVLLES GGCAGGGGSGTTCGCCCCCC XMRLLYGEQLRGLEDXRPXX GCCCGCAGGAGGCTCGGCGT HDAXARRADTISGLEXRSLG ATCCGTGGCKTCWTGCCTCC WDXQTRFGYATXLLAREDGD ACCGTCTTGTGCCGCTAGAG CXAQTNAEALCWXSXPFPGC GGGTACCTCMGAGACCGGCG AXRPXYANXGWVASEALDSM CAACACGACCTTGACGSTTA SRRXVKEWFHLPACTDXLLX GACAGTAGGGTGMAACAKCC SRHRDGGLGLLRLARXXLAA CTGCTGCAGGCSTGAAGGGC XVRRPIRVATSSDEVTRKVS CAAACGGCTGTGCCATGAGA YACGISDEVERLXLAXGGDX GGGGAACCTTGAAGACCGGG SNVPRFEDPXAPKSXXVQGP SCAGTCAGCCAGTTAGTCAG HEAAQETPRVVRTQAIPWPS TTGGGCGAAACAATCCCAGC NWRAEEHSKWAQLSCQGERV TGCAGGCCCAMMAGGGCTGT ELFCNDPVSNGWINSRGQLA CAGGTGAGGGGGTATCCCCA ERLWIMALKLRSNIYPTREF WCCACCCCCCGCCGCCGACT LGRGQAGTNIGCRHCTHPRE ACGGAGGCAKGAAGTCCCTA TLGHILGICPAMQEARILRH GTGACTTCKGACCCCCACGT NKLCKILAAEGKNCEWTVYY CTTGTGCCGGGAGAGGGGAA EPHLHNAAGELRKPDLIFVR CCTTGAAGATCGGGGCAAGC DGTALVVDITVWYEGGPATL CGCACTTGATAGTTAGCCAG LSTTAEKATKYLDLNTQIQE TCKGGTGAAACAATCCCAGC LTGAEQVTYFGFPIGARGKW TGCGGGTCCGAAAGGGCCGA HADNWRVLSELGLSNSRKER CTWCCAGGCGAGGGGGGCCT VTRLLSWRALLGSVDMVNIF GCGGAAAMCCCCCTCCATGG VSKHRQENLLDEHCTPAEQV TACGGAGKTCTGGCGTCCTM VSSYAS ACCGACWCCTTGCCACCAAC (SEQ ID NO: 1455) GTCTTGTGCCGGGAGAGGGG AACCTTGAAGATCGGGSCAA GCTGCACTTGATGGTTAGTC AGTCGGGTGAAATAATCCCA GCWGCCCCCGCTGTGACTGC TAAGMCWGGTCCCCAAGGGG CATGAGGCATSTGCGCTGAG CCGGSAGGGGTGACACMCGG CGATCGGCGCAGCACAKAST GAAGGGAGGCACTTGCTGAG ACTGCTTCTGAGGCCCCAGA CTTGGGGTGGTGCAGCCTTG TCTGGGGTATGGTACAGCAC CCTACTGCTCCCTTTGGKCA GCAGAATTCGTCCCGACCTC TTACCCACCCGAGTCTGCGC CTTGTTCCGCTATCCTGCAT CTCCGATCCACCTCGCTGTC TCCCCGCTGCGCTGCTTTTC TCTCAAGTGGGTTAAATCTT GTCATGATTACCTCCCACGT TTCCGCTCAAGGGCAATGCC CAAMATGACGGGGATCGCTG GTGCATGGCAGTCATGAGAC CATCCGGACCCTCCGGTGGT CGCTATAGTCATTTTKTGTT GCATGGGGCATSCTGAGTCA CTTAACCGAAAGACTCWAAA TAACTCAAAAGAGGKAMCCT CTGSGGTTCGGTAAA (SEQ ID NO: 1333) R2 R2- . Drosophila GAAGCTGGGTCGGATGAGCG TAGATGTACTAACCTCTAGC FERRSNSWGYRPLEPRSVGT 1_DWi willistoni CAGAAGGGGTGTTCTTTGGA TTTTCTTATACTTTTGCCTG ESNNNSPRSNITITSATSRP ACACTGTAATTCATAAGTCG CTACCTTGGCATTACATCTA GDQPREAIAVVNLAGEIPCA TAAGTCTGATCAAGTCGACT AAAAGGTACAAACATCGCAT VCGRLFNTRRGLGVHMSHQH CGAAACCTCCTCGTGGTGTT TGTCATAAAGAGGTGGTTTT KDELDTQRQREDVKLRWSEE TCCTGGGTGCTGTTGAGTTC AGTACGTAGGCGCTGTGGGA EAWMMARKEVELEASGNLRF CTAGTCTCTAGGTTCTTTTC CTTCATTGTCCCGGTGATGC PNKKLAEVFTHRSSEAIKCF AGTAGCTAA AGTGAATCGTGCATACGAGA RKRGEYKAKLEQIRGQSTPT (SEQ ID NO: 1211) TTGTCCAGTAGTTGGTTGCT PEALDSITSQPRPSLLERNH CGTATCTTTAGAAGATTTCC QVSSSEAQPINPSEEQSNWE TTCCTCGGCGATCAAAAAAA IMRILQGYRPVECSPRWRAQ AAAAAAAAAAAAAAAA VLQTIVDRAQAVGKETTLQC (SEQ ID NO: 1334) LSNYLLEVFPLPNEPHTIGR SNLRRPRTRRQLRQQEYAQV QRRWDKNTGRCIKSLLDGTD ESVMPNQEIMEPYWKQVMTN PSTCSCDNTRFRMEHSLETV WSAITPRDLRENKLKLSSAP GPDGITPRTARSVPLGIMLR IMNLILWCGKIPFSTRLART IFIPKTVTANRPQDFRPITV PSVLVRQLNAVLASRLASKV NWDPRQRGFLPTDGCADNAT LVDLILREHHKRWKSCYLAT VDVSKAFDSVSHQAIIKTLQ AYGAPTNFVSFIEEQYKGGG TSLNGAGWSSEVFIPARGVK QGDPLSPLLFNLIIDRLLRS YPREIGAKVGNTMTSAAAFA DDLVLFAETPMGLQTLLDTT VGFLASVGLSLNADKCFTVS IKGQAKQKCTVVERRSFCVG ERECPSLKRTEEWKYLGIRF TADGRARYSPADDLGPKLLR LTRAPLKPQQKLFALRTVLI PQLYHQLTLGSVMIGVLRKC DRLVRQFVRRWLDLPLDVPV AYFHAPHTCGGLGIPSIRWI APMLRLKRLSNIKWPHLEQS EVASSFIDDELQRARDRLKA ENVQLCSRPEIDSYFANRLY MSVDGCGLREAGHYGPQHGW VSQPTRLLTGKEYLHGVKLR INALPSKSRTTRGRHELERR CRAGCDAPETTNHILQKCYR THGRRVARHNSVVNAVKRGL ERKGCVVHVEPSLQCDSGLN KPDLVGIRQNHIYVIDVQVV TDGHSLDQAHQRKVERYDRA DIRSQMRRFFGATGEIEFHS VTLNWRGIWSGQSVKRLIAK DLLIAEDTKLISVRAVNGGV TSFKYFMYCAGYTRS (SEQ ID NO: 1456) R2 R2- . Gavialis AGGCATCTCCTTKAAGGGTA TGAGAAGTTGCGAGTTCTTA PAAPRAWGAVEAGPWPGRTR 1_Gav gangeticus ATGGTCTGGTTACATGGTCA TGCAAGTTGAATACCACTCT AVEPAPSPESSPSEAARAAP TAGCAGGTTTGTGTCAGGTA KGKGACCCCAAAAAAWWAAA AGEGHGPGHESPSVQRPEAD CCTCCCAGTGGTTCCCGCCG CCCCAAAACAGTTGTGTTTA TTAPGVSAPTREGEPPSTRV GGTGSCAMAGCCCCAGGGCT AGTGTGTTCTTGTTCGTCCC FLVRLPDSNPPCPICRDHVG GTCGGTAGCTCGATCCTGGT TTTGGCTTCACCTCSAAGTT KPSALALHCVESHAWADVQY ACAGTACGGCCAAGGGAGTT GCGATCCCCCCATCTCCCCT QCTHCKKVSANKHSILCHIP CTTCCTTGCTGTCGGGTGCC GCGCTGCCTTTCAGAACGGC CCQGRVPEWTGKDWACPECP TCGCAAGCACKTGGCAGCCC CGGTGGTGTCGAGGCTGGCG ASFNKKVGLSQHKRHVHPVT CAATCGCTTCATTGCGAAAA CGACCTCGGTCACCTCCAAG RNVERVAGSLSRAGLRPQTR ACACAAACGTCCTAAGGGGA GCCAAGTGCCCTGGCCCCGA RGCWSVEEEETLTCLDAMFR TGATCAGCTAGTCAGTTCTG GTAGGACTGAGTGGCCCAGC GARNINQLIAAEMVTKMPKQ CCGCTAGCCAAAACTGTTTG TCGCTGGGCACCCGTCACCA ISDKRRQLGLCPEQTTLGGD CCACCCAGTTACAGATAGCG TCTGGGGCAAATGGAAGGGA AESTSVVEEESMTPEMETQS TCTGTGCTGA TCTGTCCTGACCACTACCAG PINPPGKIRKILAQRARRWL (SEQ ID NO: 1212) GCTAAGTGTGGTGCGGCCTA KKGQGLSDKVREVLGAWVEG GCCTGCCGTAAGGTCAAGCG QPRIHAWVDSVSLDVLTLFL CCCTGCTGCCACTCAGGTAT GVPSGPQRAPNKKRPKEGGK CAGTCCTCGTTCACTTGTCC PTSWMNKCAVKWGTFLRYQH CTCCTAGTACCCTCTGCCTC LFGANRKLLVAIVLDGADRN TGCTCTTTTGCTATCCACTA QCTLLLEEVFQAYREKWGLE TGGCCAGTGATGTTGAGGTT EVLRAYRGKWEVESSFEGLG GGTGCATCCTTGGTCACCTC RFGVRRDADNFAFKALITPE CAGGGCCAAGCGCCTTGGCC EVVKHMMAMASKSAPGPDKL ACAGGTAGGACCTGGCACCT TLRDLRRADPEGDALAELFS GCCCAGGGGGCCAGACACTG LWLITGTVPDGLKECRSVLI CCTGTGGCAAGGGAAAGGGA PKTVDREKLGQLGNWRPITI GCCGTCCCTGACCGTTACCA GSIVLRLFSRVLTARLAAAC GGCTTGAGATGGTGCTGGCT PINPRQRGFIAAPGCAENLK AGCCCACCATATGTCAAGCA VLELLLRKRKRDRQPLGVVF CTCCACAGCTGCTTGAGTTT VDLARAFDSVSHDHISWVLK GTTGGCTTCACCTTCATCCC AKGVDEHIVNLIEDSYQKVT ACCTAGTGTCTTCTGCCTCT TRVQVFNGVTPPISIKTGVK GCACTATTTTCATCCCAACT QGDPMSPLLFNIAMDPLIAK CGTACCTCCCCATCTCTGCG LETDGQGVKVGSASLTTLAF CTCCTGCTATCCCTGCAAGG ADDLVLLSDSWEGMLKNISI ACCAAGTAGGCAGGGGGGTT LEDFCNLTGLRVQPKKCQGF CATCCCCCTACCTGCAGGAG FLNPTCDSFTVNNCEAWKIA ACTCAGCATATCCATGACTT GREITMLGPGESTRYLGLNV CTTGCCTCCACCGTCTTGTG GPWVGIDKPDLGTQLSSWLE GCGCTAGAGGGGTACCTCAG RIGTAPLKPMQKLSLLVQYA AGACCGGCACAACATGACCT IPRLNYQADYAGIGRVALEA TGACGGTTAGACAGTAGGGT LDSMNRRKVKEWFHLPACTS CAAACAACCCTGCTGCAGGC DGLLHSRHRDGGLGLPRLAK CCAAAGGGCCAACAGCTGTG AIPEAQVRRLIRVATSSDEV CCACGAGAGGGGAACCTTGA TRKVSYACGISDEVERLWLA AGACTGGGGCAGTCTGACCA RGGDMSSVPRFEDPEAPRSP TGCTGGTTAGTCAGTTGGGT GVQGPCEAAQEIPSVVRKLA GAAATAATCCCAGCTGCAGG IPRPSNWRSKKHSKWAQLSC CCCAAAAGGGCTGACAGTCA QGEGMELFCNDPVSNGWNNS GGTGAGGGGGTATCTCCATC RGQLAEHLQIVALKLRSNIY TGCTCCCCACTGCCAACTAC PTREFLGRSQASTNVGCRHC GGAGGCATGAAGTCCGTAGT THPHETLGHILGICPAVQEA GACTTCTGACCCCCACGTCT RIIRHNKLCKILAAEGKKCE TGTGCCATGAGAAGGGAACC WTVYYELQLLNAAGELCKPD TTGAAGATTGGGACAAACCG LIFVRDGTXLVVNVTVGYEG CACTTGAAAGTTACTCAGCC GPAXLLSTAAEKATKYLDXN GGGTGAAAATAAGTCCCAGT AQIQELTGAEQVTYFGFPIG TGCGGGCCCCTCGGGGCTGA ARGKWHADNXRVLSELGLSN CAGTCAGGTGAGGAGGGCTG SRKERVARLLXWRALLGSVD CAAAGCCCATCTCCTGACTC MVNIFASKHRQENLSDXALS CAGAGGCCTGGCGTCCTAAC PS CGACTTCTTGCCACCAATGT (SEQ ID NO: 1457) CTTGCGCCAGGAGAGGGCAA CCTTGAAGATCGGGGCAAGC CGCACTTGATAGTTAGCCAG TCGAGTGAAACAATCTCAGC TGCGGGTCCGAAAGGACTGA CTTCCAGGCGAGGGGGGGGC CTGCGGAAAACCCCCTCCAT GGTACGGAGGTCTGGCATCC TAACCGACACCTTGCCACCA ATGTCTTGTGCCAGGAGAGG GGAACCTTGAAGACTGGGGC AAGCCGCAGTTGATGGTTAG TCAGTCGGGTGAAATAATCC CGGCTGCACCCTGCTGTGAC TGCTAAGCCCGGTCCCCAAG GGGCATGAGGCATGTGCGCT GAGACGGGAGGGGTGACATC TGGCGATCAGCACAGCACAG ACTGAAGGGAGGCACTTGCC GAGAATGCTTCTGAGGCCCC AGACTTGGGGTGGTGCAGCT TTGTCTCGTGTATAGTACAG CACCCTACTGCTCCCTTTGG GCAGCAGAATTTGTCCTGAC CTCTTACCCACCCGAGTCTG CGCTTTTGTTCCACCTCGCT GTCTCCCTGCTGTGCTGTTT TTCTCTCAAGTGGGTTAAAT CTCAACATGATTATCTCCCA CGTTTCCGCTCAAGGGCAAT GCCCAACATGACGGAGATCG TTGGTGCATGGTAGTCACGA GACCATCCGGACCCTCCAGT GGTCGCTATAGTCATTTTGT GTTGCATGGGGCATGCTGAG TCACTTAACCGAAAGACTGT AAATAACTCAAAAGAGGTAC CCTCCGGGGTTCGGTAAA (SEQ ID NO: 1335) R2 R2- . Ixodes GTTCCAAAGGAAGGCACTCC TAGTGTGACGGAGTCCTCAA MQCTSRLADAPRFARVGVEG 1_IS scapularis TTTGGTTCGTGATGAGATGT GCCCCCACAAGTGCCTGCCA EGVGASGNGTDAQLWYGCTG TCATGGTGCTTGCCTAGCTG GGTGGCAGGAAAGGGCAACT CDEAFSSLRGLRIHAAQKKH GAGAAATCCGACTCACACCT ACTGGTGAGCGACCCAAGCA GNQDGLLRLPAGRPRKRRVG GCACGTGGTCCCTGCCGCCT AGGCGGAGCCAAGACCAAGC KSTTAGASDRVTTDPVPAPV GCCAGTATGCCGAGGAAACG TGGAGCCAAGAGCAACTCCA PESPGLLPGLPGPSLPGCSD GGTGCAACTTAATCCGTGGA GGAGGCAGGGGTGGATATCA LPPGVLPGGWSASPGPLSWP TACTGGTAGCAACGTGAGCA AGAGCAACCCCAAGGGACAC PSLDAGPLPGPSRVSPGPSR ACGGTACGGTCCTTCGCGGA AGACCACGGGCAACTACTGG PSPGKPTGPPSLDAGPLPGP CCACCCTGGGCGTTCGGGTT TGAGCGCCCAAGACAGGGGT SRVSPGPSRPSPGKPPGTPE GCCAGCCCGTTCGCCCGAAA GGATATTAAGAACAGCCCCA PLPGSPGGRRGVSPGQPGSR TATCTTGGCCCTGAAACTAA CAAAGTGTTACCTATATTAA TDPSSSAGAGHFVCPQCSRA AAGAAAA CAATAAAGTTGAAGCCTCAA FSSKIGMSQHQKHAHLEEYN (SEQ ID NO: 1213) CCACGCATTGCGGGTTAGAT AGINITRTKARWDPEETYLL GGCGTGGCTTGGCCCGCCGC ARLEATLNPDHKNINQTLHA CATGATGAGCTGGAACCCTC ALPRGSCRTLESIKAHRKQA CACCTGGTGGGCCGCACGAG AYRDLVTSLRSARESSEAQH ACCACCGGCTCTTTCTACTA VPDRPLETPEPQTPANPQRD AGGCCGGTCTCCGTGACTGC SKQAVIEALQSLIGRAPPGS GGTTGGGATAAACTCCAAGC FQGARLWDIARQATRGTNIL ACTGAGCGGTAAAAAAAAAA PLLNSYLRDVFTLPTKPTRK AAAAAAAAAAAAAAAAA KPAVRPARSRRKQKKQEYAR (SEQ ID NO: 1336) TQDLFRKKQSDCARAVLDGP TSSSVPGTGAFLQTWREIMT GPSPALEAPPLPTRGEVDLF FPATAQEIQSAEIAVNSAAG PDGFSARLLKSVPALLLRVM VNLLLLVRRVPAALRDARTT FIPKVPDAVDPSQFRPITVA SVLQRLLHRILAKRALEAIP LNFRQRAFQPVDGCAENIWL LSTALNEARTRRRPLHMASV DLTKAFDRVTTDAILRGARR AGLSGEFIGYLKELYTTSRT LLQFQGESLLVEPTTGVRQG DPLSPILFNLVLDEYLSSLD PDISFVSGDLRLDAMAFADD LIVFASTPAGLQDRLDALVE FFDPRGLRVNVKKSFTLSLQ PGRDKKVKVVCDQIFTIGGT PLPASKVATPWRYLGMTFTP QGSINKGTSEQLDLLLTRTS KAPLKPQQRLVVLRNYLLPR LYHRLVLGPWSAALLLKMDT TIRGAIRRWMDLPHDTPLGF FHAPVTEGGLGINSLRASIP AMVLQRLDGLHFSTHPGAEV AIQLPFLTGLHRRAEAAAQY QGQRLLSKADVHRMWSARLH GSCDGRPLRESKRVPAAHRW AAEGTRLLSGRDFISITKLK INALPTLERTSRGQHKDIQC RAGCQAVESLGHVLQACHRG HRGRIRRHDNIARYVCGRLT QIGWAVKWEPHYSVAGRTLK PDIVAHRGAETVVLDAQVVG TSMRLGFHHAQKKEKYSLPD LLHQVCEGRRDAARVSTITL NFRGVWAPESAQDLKSLGLT DNDLKLLTVRCLQGGAQCFR LHRRMTTVVKATGDEANALP AHSGLPPTQLGGRTLGPSAH NQSARTT (SEQ ID NO: 1458) R2 R2- . Mnemiopsis TGGGGGCCCCTTGGACTTGC CCATGCTCTTACCAGGCCAC MSNTSHSKLNLKMDNKLKTS 1_MLe leidyi TCCCTGGGGCAGGACACCAG TTGACGGCGCTACACCGGTC LETPSGVRADSIITRVRTSS TGAAAGGAGATCCTCAAGAC TGTAGGAGGGTATCTCAGCG NRGEHSNGVTYPRCEQGVAP AGGACAGAGAGACAGGCACA ACTTGGACAAAATGGATCTT LDTHGGICDAPPQVTVPATE CCAACCCTTCGAACCTGAGG GACTGCCTGAGGGCGCTTAT TDKQKKCEYCEFTYLKPRQI AGACACCCAGATCTGGTTAC CGAGTGACCCAGAGTAAGCT GTHMRKRHPQEWNDIKRTKF CCCATTCCTGTAACCATGGT GGTAGGAAGAATCTTGCAGT LSEKRQKRWLDEDFELLCIG TGCTCTCCGTGCGCTGTTAA TGAGAGGGCTAGTAGGGCCA QEEYLVLSSIGKQGKGINQY GGAAACCCAGCCTAGTACCC GCCTCTGCTCGTCAACTGTC IQTKYFPTLSTDAIKSQRKS TCGGGGAAAGGTTGCGTAGT CTAGGCGTTAACGTGTGCCT RRFSEYSEKRSRELQPCNTS ACTTAGCAGTGTGCGGATCA CCCTATGAGGTAACCGTGAA SDPEELPNEAVTENSPLSFD AACCTCTACCGGTCTCTCTA GTATTACTTGTTTCCCTGTA PLDRDVVKKISSKDHGDQIL GCGATGAAAGTTTCTCCGAC GAGACCATATAACTAGCTGA LVQEHLINGRYQEANTLAKA TGGAACTTGAGGGACTGGCT GAAACGCCCTGCGGGTTAAT IFEKLSGKFPNLKTGDHRPG AGCCCAGCTAGCCTGTAGAG ATATAGTGACGAGAAAAGTC KQQTARKVGKKRVRGSGKKL CAATGCGTATACGATGCCTT GCTTTATCCTTACATAACAG SPSKQNRRELYAIVQKQWRT GGCGACAATGGCGACCGCTG TGTGATAGTCATCCTTATCA KKRSKVINQILTGNLNKEQS CTTAGCAGACGGAGGTTAGT CAACTGTCCTGGCGAACAAA YTHTPDQLAQFWSTLFGRVS GAAAGGGCGACTTGCTGTTC ATGGCAGAGGGATAGTACTC PRDDRPINHRRSVIPELDKP ATAGTCACGTGAGTCGTCTA GGTCCAACCAGAAGGAAGCC LSVEEVEAALKGAKDAATGI GAAACTTATACGCACCCAGA CACACGATGCCAAACTTGCT DGVPISHLKHLGSAALTILY GACTGCACCGATGCTGCCCT GTAACCCACGTGAGCGGAAA NGLYVTGSIPDPWKRARTIL CTGTTCCAGGAGAAGGACAG ACATCCTCCGAGTATAGTAT IPKSNPPASPGDYRPISISS TGGAGGACTAAATCGTAGCG GATGGAAGGATACAGGATGT YFYRIYTSAISKRLASAVSL CGAGCGGTGTT GGACCGCTCTAGGCGGCGGA DDRQKGFIKEDGIRDNLSLI (SEQ ID NO: 1214) CGGTGTAGACGGCGACCTTA DTLINETKAGSKSLFMTFMD CCATAGCTGCGACTGCTGTG VKKAFDSVSHYAIARSLEWA CGATCCGGAACGGGCCTTTC GVPDGMRSVIADLYQDCTTD TCACTTACCTCAAGCACCGT ICGRSVKVTRGVKQGDPLSS GTCGGATCGCGGGGTGGGCG TLFNLVIEMVMSNVPERLGI CGGGATTCCTGCTGGGAAGT QFQGHRLFYLAFADDLVLLT TGTCTGCACCCAAGTCGTCA RGPTANQKLVSLVHEQLARV GCTAACTGTCGGTCAGTTAC GLELHPGKCKSIAIMADPKR CGCCGTCCTGCATCCCCGAG KTTFVDQGSSVLIGGEPVSS TTGTGACCAGCGTACAGCCA LGPQEWYKYLGIKLGSGGMP TGTACCACGGCACTTCCAGC QGIYRDQLADLLAKTDSAPL ATTCTCTGGTCTAAGAATGT KPQQRLYILRSHILPKFNHR ATCAGCTGGCCCGCCGAAAG LMFERVTCQTLEGLDKLIRT ATAGAGCGACCCCGCCTCTA HVRKWLKLPKDTPGPAFYAD TCACTAGAGTAAGCAGGCAC KGSGGLGLITLRYRVPLLKL GCGAAATATATGCAGGACGC RRHKKMADSPDPVIRLIPNA CTTGGCTCAGTAGCTCTGGT EPTISLLARWTKMCSLYGKQ ACTGAGTATAGCATGGCTGA YQHKSELSKIIRDKYWTMCD ACGCCCCTTTAAGTTCGGTG GKGLRTEVPPDTAKKTLSLL GCCCAGAGACTCTCCGAGAC FEDRTPLKPGQLIGAIGVRL TTCCCAGTCCTGGAGAGGGT NTLGTPARNNRAKGYSPEAN ACACCTTTACCAGAACTTTC ICDKCPGNRQATLGHISQTC TGTGGTCGGTTG PATHGRRVKRHDKIVNRIAK (SEQ ID NO: 1337) ALKERGSVKNILTEPHLRHD KLPLRKPDLIVHTEKSVEII DVQVVADQGISRHEDEDQQK KIVKYDVDGYKRAAYKMLGI DYGSIPCNVSAFTITWRGNL APHSLKLASRLQFSPVLKYI VADSLVDTWGAFLIWGKTS (SEQ ID NO: 1459) R2 R2- . Petromyzon CTATTAATGGGATGAAGAAG TAATTTAAGGTAAAATCGTG MNERLTDELTTEFILSDMFL 1_PM marinus GGGGACACGAGTTTGTGTGT GGATTGTTTTGATGGCAATC WDYPCTDQNKCYPCNLVFLD GCATCCAGTTTCCATGGTGC TGCCTAGTCGCGGCCTTCCA HRTWSSHMARVHPHANKTYK ATGCAGGAGTGGTGGTTTAA TTTTGGGTAGGCAGCAGACC CRICNRTADSIHKIASHYGR ATGGCGAGACTCTACAGGGC CATCTATATAACAAACTACT TCKSLIGKTNAITTTIDETL TTCCATGGCTACACGGGATG TTGCCTTTCATAGGGGTACC FSCLHCSRGFTTKTGLGVHT CAAGGCATCAGACATTTTGG CGACCCTACCAACTTTCGGG RRTHPTEHEAILQQNTPGRK CACAGGCAATCCTTTTGGTC GAAGTAAAAGAAA VRWGEEEVEIMAHKEAQQKD TCTACCGCAATCATGTCTTA (SEQ ID NO: 1338) EDINMNQLIQNSVMPHRTLE GACCTCAGTAGCGACCACTA AIKGKRRNIKYKELVRTLKE CAACCACAGTGGTGACTGCT TTYKVENQCLVNLVLPTTSE GTTGAGTGAAGGACGACTGA ITTTPSEGDQPAIRAEKEQS GCGCTGGATAACAACTTTCT PTAAEDLQVIINDLKSQNFS TGCGTGGCCCAACATCGAAG HNQALLLLNSHVEKFLNRSK CAACCACTTCGGAGCTGGCA PIKRKDHVNQQEIDENRHRR CAAGGCAAGAGGGCAGCCCA QSKQTKYRRYQYLYHTNKKA AGGTGTGAATCATCTCAACT LLDEITSDRSGPSIYPTEES TCACTGCAGGAAGAAATGCT IRGTFVTLFESNSPPDNIPS GTGCAAGGATGAGTGTGAAC KLKNDQSCIDIVKAITLDEL GACACCAACGGGATTGTTGC IKTLAIMKDKSPGQDNITLS TGACCAGGAGGTGCCAACCA DLRTLPIKYLLDILNIILYI AATTTGAATGGATTGACTTT QDIPQIWKQHRTRLIPKTKE GGGCCTGGTTTCTCCTGCGT ELEKPSNWRPITISSIVIRL GTATTGCACGGAAAAACAAG LHKILSYRLGQQLKLNYRQK TGGCTACACGTGTGGCCGTC AFLPVDGCFENSALLHFIIH GTGTCCTGGGGTTTCGCAAC NARQKHENTQIVSIDLSKAF ACAACTCCACAAGATCGACA DSVSHESIIRALNRFNLSKE ACTATGAGGATGACAATGTA SITYLTNIYKCNLTDIVFGS CTTAAAGAACAAAGAGACTG TIMRNINLKRGVKQGDPLSP ACGCCAAAGGGGATTTAAAC LLFNMIMDELLDNLPTYIGV CGCCAAATCGTACATTGGGT NVGNQKVNSMMFADDLILFA CTCACTACAATTTTTTTACG ETECGMNKLLDITTKFLDDR TGTATTTATTTTCCTAAGTG HLKININKCNSLRFIKYGKQ TCTGTACTTGCCATTCTTCG KTFSVATTSSYFINNEPINP CTGCTTTTTCTGCATTAATT VSYVKGFKYLGIEFDPRGKR GCATATCGTATGCAAATAAG SISCNLLAAMLNKLTRAPLK CGAATTAACCACCACCGTGC PEKKVYLINNNLIPRIIHQL AACTATATGCAGATGTTACA VLGKVTKGLLMSLDSEIRKT GCTGAGCCCTCTATCATACC VKLLLRLPHDTPDSFFYTSV GGTGTACTAATCTGGTATGG SNGGMGIRNLCDSVALSIIN TGTTGGCATGCTATGCTTGC RHNKLITSDDLVIRALSQQS GTAACGACCTTTGCTGATTG YTIATLKQAHIIAGSKFPSK GTTCAGTCGGCTGATGGTGG SLNQNKWSNKLYQTTDGRGL GTTCAGGCGAAACATTTGTA VYCQSQTENNSWITGNHRTI TATTGGTTTAATCAAACCGA KSYNYIDMVKLRINALPTKS AACACTAAAATTTTGAACAC RCNRGTLETKQCRFKCRSIN AGTTTTCCATTACACCAGTT NQISEETLAHILQKCDRSHY GTATTGCTAGAAGTGCAAAT SRIARHDSLVQFLATAAQKL CGAAGGAGTCAATTTTGACC NWEVIKEPTLPSDTNKAKPD GACGATTAGCTGCCGATGTG LILVRDSHVLIVDVAVPWES CGGTGAAAAAGCTGATCACA RSLAHAYDFKVKKYATDKKM ATAGCATACACTTGGGCCGA QAYLKTIYPEKEIRTEALII CAACCCCGTGTGCTATAAAC SARGGWCALNNMVTKKVGLS GTAAGTCGCGAATTATAAAG SAWVKLALIKVMEGSVKIWR AAAACAAACCGGACGGACTA SWSKG CTCGGTGACGAACTAACATC (SEQ ID NO: 1460) GCTC (SEQ ID NO: 1215) R2 R2- . Schmidtea CAGTGCTATTCGAATGTCAA GGCCACGCGCGTCGTCCTTG MKKVLNNETEKLPGSNLTFM 1_SM mediterranea TGTGAAGAAATTCAACTAAG TTTGATCACTAGTGGATCAA CGFCDREFDTARGRGVHESR CTCTGGTTAACGGCGGGAGT CCTTCGACTCCCCGGAACTG GHLVERDAAVQSRVKAVVSK AACTATGACTCTCTTAAGGA TGGGAGTGGCGGAAGAAAGG KYYYSNEEDVALAKMQLXHA ATTAAGAATTTACCTGCCKT CCAGAGGATGTCCTGAAACC DLAKSEXLEAMYLALGKGRT AKTAAAARTGAAATCMGTTG ATATATTTATTTATAGAAGT REAIEQHIRKSLRYKGVLEE TTCATWGCAAGTGGTATTGT TTTACTTCATCCTATTTACG QRKLLETARGNVRQNNVGVP ACACCTTCCCGCGGTGCTAG TATTTCAGTATGAAAATGAG ASNATKNLORFLESLPLGTN TCGTTTAAAACTAAGTTACA TAAAGTTCTCGACTCGATGA RREERLDRIIRSNSIESQRL AACCACGAGGGGCGTCCTGA GTTGGGGGCAACCATTGGGG ELIHYCNDMCQDFVQLDCQX CGGACTGSAAAAGCATTGAG GTCCTGAAGAGAGGCTCTCA NPINAIRRRNPKRLSKKQLK RGTCMTGAAGAGAGGCTCTT CTGTAAAAAATCTCTTCGTG RAKFSALQRLWIRDRKAAAQ ATTGTACGAATCTCTTCAAC TCTGTTTATTCCTAGGCACN LVLKDKLDSLLSNKEDSKDL GATCGAAGTCTGGACCGATA TGCTGCATTATGAAGCGGWG GSYWQQVFERESELDRRPIP TGAGAACTAATACATTAGTT AAAGTAAAGTTAGAGCTGAG QVVENEELNSPVLEKEVEWA GACAGGTGAAAAATACTGTT AGATAGGTACTTGCTGCATT VKNIKKSTAAGPDGLTALAL GATTACTTAGTTCTCAGTCA ATGAAGCGGAGAAAGGCCTC KKIPYSELVKLFNIILLVGF TGTGGTATATTGCCAGTCAA GAATAAATAGGGTGTTAGAG LPDVLKNSRTILIPEVDNPQ TTACTACATWAATATTAGTG TTATTGATGGAGAGTATACT GGGDYRPISINSVLTRTLNK TGGCTCTCAAAGGAACACGA AGTAAGCTTAAGCTGCGCCT ILAKRVSEGDFGINGQKGFK TTGRTCGGCAGTCCAATGCG CGCGCGGTGCCCAAAAATAT SVDGCLENLATVESILADAR CGACTGGCGGGCTTGTTGTT ACTTAATGAGAGCAATAACT MKKNKLAVVFLDMSKAFDSV TGCATTTGTTACCGGCTACT CAAGGNGAGTTTAATTCATA NHESIVRAGEIKGYPKLLMT TGAAAAGGTTATATATAGCA TGCGCATGCGGCACCAAGGT YVKECYNDATTNVAGVTAKF GACGCTTAAAGCGCGACTGT GCTGAATGGCATCGATTAAA NRGVKQGDPLSPALFNNVID AATTTACATYTCATTGCCCA CCTCTCCTGTTGTAGAAGCA LAIERVSGTGIGYNMGGKKY GTATTTGTCTTTTGTCAGAT GGTCATAAATGGAGGRGGGC SVVAYADDLVLFGESREGLQ TTAGCAAAATTTCATATTTT AACCACTGAAACTTATGAGC IALTALLEELKLNGLTPNPA GTTAATTACCTTAACTGGTT CAGAAGAAGCTTAACTACAW KSASLTFERSGPHWFASTDT AAACGATCCCATAATTGCTT AAGTTTTAGGCAATTACTGA VTALGDQIPAMGNIETYKYL GCAATTATTATAAAGTAATT ACGGAGTTAACTGTTAGTTA GIKFNSCGVVKGSLPGIYTK CAGGTAAAAATTACATATCT ACACTACCATGTAGTTGTTT KLELISKAPLKPQQRLAMLT GGCTGATCCTGCCAGTAGTC ATAAAGCAAATATCAGGTTT DFLIPGVLHQAVFGQTNAGD ATTTTACTTCCGCCGCGCTA CAGTCTATATACTAAAAGTA LRSLDKRTRRAVRSWCHLPS TAAAACAGTTTAAAAACTGA TTTTTTGATACCGTGGTATA DTSTAFIHAKAKDGGMGIPS ATAGGAATCAAAAAGAACAT TAGGCAACTAGTTAGGAAAT IRAEVQFGKLDRFGKLPNVK GGCAAGCGACTATATGTAAC AGTAACATATGGTGGTGCCT DERSKVLADNAHIKKKMLEK TGGGCATTCAACATTCCCTA GGGGGGATGACGCATTGTCT LGVGIPIKGVRCKNKLEFYN TTAGTATCACCAGTCATGGT CGTCTGTTTTATATAATGGG KMREELIKSNDGIGLKEASL GCCATATCTTTKGATAAAGA TCTTTATGGTACTGAGGAAA VPSANTWLKLSDLHMSGRTF TACAGTTTAAAACTGCGATG CTTATCGACTCGCGAGTACC VGCLKTRGNLMATVTRTSRG ATACTAATAGAGATCCTCTT CGGGAAGTGGATCTGGATGA GQNPGIELNCKKGCQYQGSL AGACCTTCGTAAAGAAGTGG AACCCGTAAACCGATCGATY NHIVQKCPVVKGLRIKRHDE GGATTGATGACATTAGCATT TAGCCTATAAGTACCAGCGA VVKYVEEITKKAGWSATMEP GGAAGAATTAAATCTCCAAG CAGTTAAACCATCTTACGCG IIPFEGSHRKPDLVLVRGDL GAAATGGAGTAACTTCAATG AGGGGTAAAACCTGAGGACC GKVVDIQIVSDHCGLDEKNS AAGTCCCACAACCCCGTTGA GATTATGGTATAACTTCTCA CKIGKYDNDIIRNYVRGLGP AGGGCTGGGTTCGAGTATCG AGATTAGCACAAAATGCGAG SRVEVAAITLNWRGVWSRDS AGAGAAAACTCTAAATTCTC TGCAACTTGAGGAGGAGGAT FNLIKRLGMTEMDAKIISMR TTCGGTTMTGTCCAACGGAG TTGAGTGTTAATTCATAATG VLASTAKMFKTCKKVLEPVC GGGACATTACTGTAAAATAT TACTAATCTAATTAAACTGT RTKTADCDGYGPEETSARPC CCTCTAAAAACAACT GACGGGAATTGCAGCTTCGG HELNLKESSGT* (SEQ ID NO: 1216) CTGTAATTACTTTGAGGCCT (SEQ ID NO: 1461) ATCACGGATTGTAAGGAACA TATTGACACCGTAAGTCTAA CGTGTTCCCGATTTCCAACC AGGTCATATGAAGGGCTGCC CTTGATAAGGCGGATTTGAC CCAATTCTTCATATGAGAGG CTTATTCCAGCCTTCCCGTA GTACCGTGAGGTTTTCCCGC CTCGAACGGAACAATGTTGC AGGGTAATTAAGTACATCGG GCTATATMGCGATATTTAAC GTTTTA (SEQ ID NO: 1339) R2 R2- . Strongy TCTCGCGACGCGTTCTTCTG TAAACCTTGCCTCCCCGGGC MENSFAWEGTSSAEGRTTVE 1_SP locentrotus CCTGATGAAGTCACGTCAGG CCCCCTCAGTGACTAAGACA DSPSSSDDFVSNVGFKVAKA purpuratus TAATAGACTTAGAAGGTTGA ACTTTCACCGTAATAATCAT DPTVWEEANMSEDNTIIEDP TGAGCGTTCCTCTCCTGGAC ATATTTGTATACCATGTATT PSSSDDFANNVGFKVTRADP CGGGGGTGAGGATGTGTTCT AATCTAGGTAACAATTGAAA TAWEEASTSTETEDLPSSSN ACTGAATCATCGTTCCGGTT GTAACATTGAACCGTATTCA FIDNVETQIDMAGPTAWEDA GTGAGGTCCGCTGCAAATAG TACTTTAATGAGTACAATAG DSNEDNIDEGTPNNINNNLA GCCTTGGGGTGGTCTACCTC TGAAGGGAACTGTATATTAC IVRGRADAYACSCCERNFIS CGGGTCGCTACTCCTTTTGA ATACCTCGAGATAGAGGTTT LKAIGTHLKETHNKKVVFEC GCTAGTCGATCCAGGTGAGA TTGTACCTTAAGGGTTCGTG AKCQHTFVKAHGLACHVPKC GTCGGGGAAGCCCACTTAGG AGAATCCATACTGCATAAAG KEDADTPMLNRLLHGCGECG TGGGCCAGCTAAGCAGATCA GGGTTAACTTGTAACTCAAC LAFNTRRGLSQHERHRHPSA CCCCCCCAGCACGACAGTGC CCCAGGGAGACAAGCCGACA CLSTRRRSRLDGIARKKSLR GCTGTAATATAGCCTGTTGA AATTCGGCATTACTATGTGA NRRDIWTNDEIRLLKQLMIQ GAGTGCACCCATTTATAA GGGTCATAAGTGTTAAAGGA YEHAKKINIKIAEHFNHKNA GTTATAAAAGTATAAATGGT CCCATTGTATATAACTTGTA KQVMHKRRSLREKDMALGAP TCTTAGCTAACCTATCCAAT AATGTACAGAGAATTCGAGT HDAPPPLAEEPIIEVVEGAR GATTTTTATTGTTATGTATA TGAGTTCGAAGAATAAACAA EELEQAPVDVILPDLEALTV ATACTGACCACTTTAGTCTA ACAAAAAAGAAAACAAAGAG NDGRGGGSPVLTEGGESTRD GTGTCATGTAAGGATCCGAG AATTCGTTCGTCCATAGAAG MEENGGTDTRSPSPREERAG ACAATAGCCTATGTCTCTAG CGGAAAAAGCGCAAAAAGGC STPWERGWQPRVDRGRGEYK TCTAGCAATAACACAAGAGG GTCCTAACCTCACGGTCTAA GYGGERGDRHTVSLSQRGES GATAATCCACCTCCCTACTC CCCAGAAACATTTAAGGGGG GVDPLTPGGVVEDYDDSYLE CAGCCACCACCTTTACCTTT GAAGGAGCTCATTACTCCAA DYFPGWDEDEHMHIIGRLDL CTTATCTTCCATATAGATGC TCCAAAACCACGTTCCCTAG SDESEQGEAAVSPRLGSFGD CAACCAGACGGGTCGATGGG CCCAAAAGCGCGCTTCAATG LLEEVNAMEGKDNLSEALAE CAGTGAGAAACAAGAATGGG AGGGAGCCGATATTGGAGGA TLGLVLHEGHRVEYIKEKMN GATAATTTGGAATTTGACAT CAGAGTTCATCAAAAGCCAC INVKQMATEILAHGANKGNP TCTTTCCTAAAGCAGACCTG CTGTAAGTAGGCCCATTTCT KRRKEAVAAKRNPGTRLDRA AAGGGTTAAGAGTCACAAGC GCCAAGGACATGCGCAAAAG QRDNQAKAKAKEKKRIFSET GGAGTCCGGACTGTCTTTAT GAAGCAGATTATCAAACCAG QTQYKKNPHRLVEKLLDGKG AAACAGACAATATTTTCTTA TCAAACAAGCACAAACATTG DERCSVSLEVIQRTYMNRFS TTTTACCACCTATATGGGGA GGGGGATGGGATAACCCCGG RESKEVDIGAYVDPETVEDN TATTTCCCAACTCGTAATAT AAAGAGAGGGATCTTTAGAT QGIVDPISKAEIERAISTTK AGGGCCCACTGTCAAGTGGC AGTGGATGGAAGGGGTGGGA KGSAPGPDGVTYDALKAYGN TGGTATAAGTTACCCTGTGG CGTTGAATCCAACCATGCCG CQLYLLIMYNTWLAMGKVPS GTAACAAATAAATTCAAACA TTTTTATGTTCCCGATAAAG EAKTYRSILIPKGQGDPMDI AAGA AAGGATAAGGTCACTCCAGC NNFRPLTLANVISRLYSKIL (SEQ ID NO: 1217) CTGACACACAAAGTGGGGTA TRRLDGAVSVCPRQRGFTHK AAAGAACTCCGCTCGTACGG ASIEDNTLILRELIMKSKRN ACTCCAAATAGAA KECLAVVLLDLAKAFDTVSH (SEQ ID NO: 1340) DLIIKALRRHRVHEHLISVI MDLYEGGTTSFTTDEGTTCP IAIRSEVKQGDSLSPVLFNL ALDPLLATLEQRGKGVEIGG HTFVSLAYADDTALVSSSHL DMTANLDITVEYLNATGLSL NVRKCQGFLLTPINKSFLVN EAESWVVEREAIPWVEPGDT AKYLGVQVGPWSRPWPSIQP VIKRLTAYCESIDKAALKPR QRIHILTTYIAPRIAFEIAE GGYSTLVDCRGGIQYTRIRE VDMTIRNYVRKWLFLPACLS NSFLYTRRGEGGLGLVSFYD YVPTERMRKLVRVCDSEDPV IAGAAASLGLRERAAKISAQ TGLPVPVKPKGAHNAWRKVQ KKKWKAQPTQGKGVSCYQHR LGNKWLGAPSFLTENDYIWA IKLRTNLVPTREAMGRGIIG RNQVECRHCHTTIETMGHIS GYCQMVLDIRLIRHNRICKA LIKAATATGLRVTEEPRIVG TDGKNYLPDLIFSAGAGEPC YVVDPTVVWDDDPKNLREAW RGKVRKYTPIIPAVEAMLHP SSVQIFGFVCGARGTWCPMN DDIAKIVGLKNSGISRTLQI VLCDTIRMVKAFMAR (SEQ ID NO: 1462) R2 R2- AGKD Salmo AATCTTTAACCCCGGACTCT TAGATCCGTTTGTTATGATT MSGKRIVEMSGCDEKICQNK 1_SSa 01072 salar TGGGGTTCTTACGACTCTGT GGAGGGAGCCTGCCGAGTGG HCLKRRWAWISGPKGETSPP 455 ATGAGGAACAGTCGAAGAGA TATGAGCGCTCCAACTATTG RKRGTCENVSFQDKSHASDP GGGCGCTACCAATCCAAGTA AACCCATATGATTCCCGAGG DPLKAPEAREDAGSVAPQWV TATGTCCCAAGAGGGCTGGG CCTGGCCAGACGCCTAGATG GEIKTPSLTSRDGVSEVVLP ACAGGGTGGAAGAGTGCACC CCTGCCACAATTGAACGCAG PQPVHAEGVSPASDSKDKAT TCGCGATCTGGGGCAGGGAA CCCTAGCTTGCTAGGAGATC KITLLISLPVCDLRCGRCER GGAATGGAGAGAAGTCGAAG CATAGGAACTGGCCTATGGG PLETVGKAVRHFAVAHPTVS AAGGCTTGTAGAGAAGGGGC GCGTCATGACGGTTGAAGTT VVFKCQKCEKSSKNSHSISC TCTCCTAGATCCTAACCTGT CCTCCATAGCGTGCTTGGGA HIPKCKGMTETRTDVEGDHG ATGACGCCCGTAAAACGGTG GGGGACGACAATGACGAGTC CDHCQEKFTTAMGLTQHKRH ACCCCAGTAGCGAATAAAGG ATGACGTACCGAGAGAACCC RHIVQYCKEKEGEMTARRKG AGGCAGGTGACAATAGAGGG CAACCCAGGTTGGGGGAGAG EVEAVKWSEWEESEVARLSD CAGGGCCGACTTCCCAGGTT AGCCAGCAAGAGCGGAGATG GLAGLKMINRRIADSLGTGK TACATTGTTGTACTTGTCAA CTTGGTATACCAAGCTAGCA TAEQVRQKRRRMRPEKVRCD CATAAAGAGGTGTCTCAATA GAGAGAGGGTTGAAGAGGAT KPKEAKDKSNLIKMLSIPSA GTTTGAATCAACAAGGGAGA GACTACTGGGCTCAGAGTCA TPTPQTGLKGFLLGELNGVA GGAATACCGACCTGCTCCCT TCTCACCCTAAAAGGCGGTG TKGEVQIGGVTLSLRGVEQD TGGGGCGGGGGTACTGGTCT GGGCATCGGTTGAACACCTA SALLNTSALELQRLLGGRAG TAGCCCGGTTCCCCGCAAGT CCCATACCGGGATGGGAGGT SANPLSLQRERETTLPSERR TTCCTTTGCCTGGGATGTGC GGTAGGCCGAAAAAGAACAG KTKQGEYRRVQKMFRSNEKK CTGACTGGCTCCATCCCCTT GAAGATGGTGGAGTAAGTTG IAKYILDGNGDGEAASPPLE TCCCCATTAGGCACGGCTAG AGAGCGGTTGCTCGGGAAGT IALAFKSRWEEVETFHGLGQ ATGACGCACCGATGGGCGGG TATGTTGTGATAACTCCATT FYSRGEADGVVFRSLISMSE TGTGTAGGTCGCTACCGAAG AAGGCCGGTGGGCATGGTGC VCENLGAIKNNTAAGPDGIT GGGACTGGGGGTGTCCGGTG GGATAATGGAAACTATAAAA KPALLEWDPTGAKLAAIFSI AACCAGGACTTCCCAAAATG ACAATAAAAAGAAAGACCAA WLTSGTLPGPFKKCRTTLIP GTCTCACATTTTTAAGCGGC AAAAATGTTCTGTTATGATG KTDDPILLTQVAGWRPLTIG TTGAGTATCGCCCAGTATCC CCTTACACATGTCTGGGAGA SVVLRLYSRILTHRLERACP TCGCGCGGCACTGGGAACCC CCCCATAAGGGTCTCCCCTT INPRQRGFISSPGCSENLMI AGTCAACCGCTCTGTGCCCC ATACTTCACTGGGAAACCCC LGGLIKRSWAKGERLAVVLV GGCGCAGGCGGGGGTTTAAT ATAAGGGTATCCCCCTATAT DFARAFDSVSHSHILEILRQ GTCTCCCCGGCTTCACCGGC TTACTGGGAGACCCCATAAG RGLDEHIIGIVGDSYTDVTT GCTTCGGCGACGACGCAGAG GGTCTCCCCCTATAGATGTA TITVSGEQSPPIDMRVGVKQ GAGCACCCGGAGGCCCCCAT GAGCGTAAGGGGTCTCCAAA GDPMSPLLFNLALDPMIDTL GAACTTAAACCAACCTATCT GTACCGGCCGATATGGCCTT ERYGLGYRMGEQQITALAFA TGAAATATGGCCTCTCGTTC ATGGCAAACTCTGGTGGTAG DDLVLVSDSWEGMACNIRIL GGGTGAAGGGCAGGTGGGAA GGACAAGGAGGTAAGGGCAG EEFCRLTGLRIQPRKCHGFL GAGAGGGCTGCCTCACGATA TGCCAACCCCTACTTGATCG IQKIQRARSVNLCKPWIVCG AACACCTAGTCAATAGCCAG GGACCATCCAGGGAATGCCA EELHMVGPEESVSYLGMKVS TCGGGAAAAATGTGGAATGT TCCTCCCGCGAAGGTGATGT PWHGIMEPDPVERLCNWISS TAGGACAGGGAGGTAAGGGA GGTGAGGTAAGGGGGGAGCC IGRSPLKPSQKVRMLNVYAA GGCGGCTTTTTCGTAAGGCT CGTCTTCGAGTTTCCCCAAC PRMTYQADHGGLGPIVLNVL CCTTCAACCCCTACCTGTAG CCCTACCCACAGGTGAGAGG DGMIRKAVKVWLHLPLCTCD TCCACCTATTGCAGGTGTTG AGGAGAAGAGGAATCTGTCC GLLYSRCQDGGLGIVKLACQ ACAACATGCAAGATGACCTG CCAACGGGAGGAGGGTGAGG IPSIQARRVYRLWHSKEAIT CCTCGTTACGGGTCGCGTAT TGTAAGGGGGAGACCTTCTA RVVTRRTVEAEEYRGMWLRA CATTGCTACAGGTCGTGTGC GTAGGGTCTTCTCAGTCGCC GGSEAGLPPLEDREEGAVQC CGCTTCTAAGAGGATAGTAA TGACGTCCTGACTGTGGGGT TDTAGSVKPKNPVIPDWRRA GGAGAGGTTATAGGGAGGTC GGATCAGTACCCTACAGGTG EFLKWQNLTAQGVGVQVFGG CTGTTAGGGCTTCCTCAACC AGACCGGTGAGGTAAGGGTG DKNSNHWMANPETLGSKERH CCTCTCTATGCGATTCCTTA TGGCCCTCTTGAGGGCTGCG YIAGLQLRANVYPTREALSR CAGGAGTGGATCGAGAAGTC CCAACCCCTACTCGAGGTAA GRPDLPKVCRQCLAGTESCA CCGGACGTAATACACCCTGG CCTGAGGGAGTGGTGGAATG HILGQCPAVKDSRIRRHHKL AGGTAAGGGAGTGGCCTTCT GCGGCATGTTAGTGCTGGGA CDLLASEAESAGWTVIREMC AGTAGGGCTGCTTCAACCCC CTTGATTGCGAGGGTTTAAT CRTRAGALRRPDLVFVKTGF TCTGATGGGAGTGTACCGGG GAGAGTGGCCTGCTGAGAGC ALVVDVTVRYEMAYDTLMGA AACCTCGACTTGTAAGCACA AACACTTGTGGTGCTTAAAG AAEKVARYTPITPYVAMTLK GGTTAGTATGGGAGCAGAAG CGGGGCGGCCCATGACCACC ARRVKVFGFPLGARGKWPGS GGGGAGCCGTAATGGGCTTC GTGAGATAGGACACTGCACA NDRLLKAMGVGGGRRKQLAK TCTTTCACCTGCTTACATAA GTGCAGCCATGAGGTTCCTG LFSRRALLYSLDVLRDFYRA TACCTGTGGTGCATGTATCT GAGGATGATGCGATGAGGTG EGETGDLDDESVDDHL AGGTCTTGGCGGGAGAGTAC GGGGCCTCATCAGCCCCTCC (SEQ ID NO: 1463) TGAGAGACAAGGTTGAGACC TGGCAGGGCGTCGGCCAGGG CCAAGATTGGGTCTCCCTAG AAACTAAATGTCTCTAGCAT CCTCTATAGCTGCGACTCTT GTCAGTGCAGTGAGGTAAGG AGCGGGGATATGGAGTAACA GGAGAGCACTCTAGTAGGGC TGTACCAAGGGAGTGAATAA TCTTCCAACCCCTACCTGTA TAAAGGAATTGACGGGGTAC GGTCACCTGGTCCAGGTGTC AAGTGACTGTTGGCCCGAAT GATGATGTGAAAACAAGAGC CCTAGCCACTTGATGACCAG TACTTTGGTACCGGTCTGTT GGATATATTACAGACTGAGA GCAAAAAGGGTTCTGCAGAG GCGAATCTAGAGACGTGAGA GACGACGGCTATCCCTATCG ATAAAGTGAGAATTGGTTGA GGAGGGAATAGTCGGTCCCA GCGAATACAGAGGAAG GGTAGTGGAAAATGGGGCTT (SEQ ID NO: 1218) TCCACTGAGCATGAAAATGT GGTAGAGGTTGCGTCCAACC CAATGATTTGCAGCAGAGCT CTTGGACACGAAGTCTGTAT AGTCCCATGCAGGCAGCCAA CCAGAGAATGGTGGCAAGAC CCCAGCTCCGTATGGGAGGG GAGGGCCAAGATATACGGAA CGGCTGCTAAAGCGTTCTGC CGGTGTCAGTCTAATCACAG ACAGCTGTGACGAAACAAAG TATGGGTTCCGACATGCTTG GTCAGCTCTTAGCCGCAAGG CTTAAATCGAACGCAGCCCG CCGAGAGTGAACATTAAACG GGGATGGAATGTGTCTAGCG GTTACGTACTACCAGGGCTC AGGTTCGCCTGAGCCGAGGC TCTACACGTCATGGTGGGAG TTCTCCCCACGCTCGTGAGG GCATGTAGTGGGATGGCATG TGGCGGACCATCAGCTGGCA CTACCAGGCCTCGGGCTTGC CCGAGTGCGGGACCTCACAC ATTGTAGGTGTGCTTGTCCC CCCTACGTTCGAAGACTTGA GGCGGAGAATACTCATAGGC CCCACGGCAAAGGGACACAA CACGGAGGCTTGTGTCCGAC GAGCCGTGGACTCCTATAGA CAGCCCGGGATATCACTGGG CACGCTCATACTGAAGAAAT TCGATGAACCGGGCCTACCG GAGCAAATGCACTCTAATCG CCTTTGTGGGCGACTGTGGC CCCCTCATGCGAGTGAGGAA TATCATAAACTGCAATGGTT CAAAAAGTGATTCCTATGGC TCGTCGGGGAGGGCTGACTG GGGCAAGCAAATGATTGAAA GGGGAAGAACCTTTTTCAAC TGTTTCTTGCCAAGCCCGGT TGATGGTGGCGCTAGTAATT GCGACGGGAAAATGCGGTTT AAGTCTCCGAAGTAGTGCGT AGCACCGGATGTCGACCGGG TGTAAAAGCCCTTCGTAAAG TCCCTGGGGAGGTCAGTCCT GGGGCTACTGATGCGCAGTA TGTAATTCGCAGAATAGGGC CATCGATACCGCCTGCGTGA CTCGACTGGGTTTCCACTTG AGGATATCCGACCGTAGCGT GCACCCTCTTGTAGTTGCGC CGGAAACGGCTGTGTTCCCT CACGTATGTGAGGAAACTCA ACAATGTGAGTGGGTAAACG GCGGGACGAACTATGGCTCT CGT (SEQ ID NO: 1341) R2 R2- . Tribolium AGTCATAGAGCCAGAACCTC TGAAAAGAGTGGCAGTTGTG MSRRPGKSNEPPVRSRAMGL 1_TCa castaneum CTCGTGGTCCCGCTGGGCAC GAGACTTCCTTCGGACGTCG TTLSGTKTSNSGAQGPSTSA s AGGGATTAATTTTTCTGTGG GGTCGGATTTTCGGACGCCA PMQNMAGGFVCDCGRSYALK CAAATTTGACTGGCTTCAGA GGGTACCTCCACCGCTGGGT TSLARHKKECGKNNAECRWC GAGCGTTTTTCGAAGTGGWC TCACAAACTAGGCGAACATC GTRFNTLAGTRQHERKAHFV TGTGTGACTGCGTTCCCCCC TGCCGATACCCTCTTTAGGT QYQSDLAKALPQPESELMEK TTAGTTGCTATWTCCGCTKM CATAGGACCACATGTCTCTG IAIVEARSXNGIFYKEMMAS GATTAACATCTCACCTCGAC CACGAGATTAACCCA TGLTHQQVRSRREKPEYKGF GTWTAAGATCATT (SEQ ID NO: 1342) LERARRSLAQTNIRAGSISP (SEQ ID NO: 1219) ASTXAGSLESASPKAGCSSS ASPGPTTRSRAPTKGVPXRS SNSARIVVEAQVHTRAPPNT GETEVALRESRRTVPRLGXN PSRPCGISPLMAIAIDEDSV LGGLRVQAGPSPTAVHSVEA FPGTSSMTPMETDRVHNKSG IDPILEHNGTRQVRREESST REDPVEQWSPNYPKTPVTMP NITTTADAXXTSYNRTPQTL PGNRRRRSRSLPPVQRKSAS DXLESVDSLGPWAVFLQDQV DAGSLSGNDSLADLVRVALT KSDRGVLNDAVNRYLAQRAE SLRIRKRGSKGKRKSKTGRH YGQTTSGSGQRAALFKKHQD LFLKNRRGLAETILSGKEDF GPRPEPPVTSVEEFYGGIFE SPSPPDNEPFEVRATGVEDP PPLTSPWTKRTLRSPCYWRR RPPPTYITMDEIKAARAGWQ ISAPGSDQIPVAAVKTMSEL ELAILFNIILFRNVQPSAWG VLRTTLVPKDGDLRNPANWR PITISSALQRLLHRVLAARL SKLVSLSSSQRGFTEIDGTL ANALILHEYLQYRRQTGRTY XVVSLDVRKAFDTVSHCSVS RALGRFGIPSVIREYILATF GAQTTIKCGSVTTRPIRMLR GVRQGDPLSPVLFNLVMDEL LEKVNEKYEGGSLOSGERCA IMAFADDLILIADRDQDVPA MFDDVSTFLERRGMSVNPAK CRALIAGAVSGRSVVRTGSS YKIHNTPIPNVDALDAFKYL GLEFGHKGVERPTIHNLSVW LNNLRRAPLKPDQKCLFIRQ YVIPRLLYGMQNPQVTSRVL READRLIRRHLKTYYHLNVH TPDSLIHASVSDGGLGIMEL RKAIPRIFLGRLVKLLNKNK DSVLSSVLQSNRVRTLMGKL STMAGEVPESTFWRNQIASG PLSKGLEQAAEDSASRLWIS EKPSGWSGRDHVRAVQLRTG NLPTKAIPSVPVGQRRCRHG CACDESISHVLQMCPLTHAD RIRRHDEVVKKVARHCTSRG WTVEVEPHIRSRCGRLFKPD LAVHQPGGAIVIADVQVSWD SESLTVPYERKRAKYDVPQF HQAAQHAWPGKALTFAPVIV GARGIWPRINNDRSAALQIP PVVRRACVNSVVKWGSSIHA TFMRSVWANRLNPRPLRA (SEQ ID NO: 1464) R2 R2- . Tinamus CTGGGGACCGTGGTTACAAC TAGGGGGCTTGGCATTTCTC MGSWIVNFVSVATQTGEFPV 1_TGu guttatus CCGGGCTTAGCTGCAGAGAC ATTGCCTGCTCCTGAAAGGA DTARRAPVPVTSYPESECHX t AGTACCTCCCCGTGGTTCCC TATGGGTCCTGCGTCGCGTG PLPLTFCNSDVTIWGGVRPE GCCGGACCCCGTAACATCGG GTAGGCAGACCCATTCGTCC PVDCLGDLPEXYDALPGVAG GTGACTGAATCTGTCTCTGC GAGTAGGGGGCTTGGCAGTN PREXVGGSPPGEGVRSPGIA CCCGGGAGTAGTTCCTCCTT TCCATTGCCTGTGCCCGAAA SPSGTAVQHDFGSPILVPGA GCCCTATTGACCAGCGGTCG GGACGTGGGTCATCTGGTCT EAAEVSTPVVKVPQDHPACP CCGGCTGCTCAATAGTATTC GTCTGCCTACACCTCTCTAG CCGTRVVKVTALSEHLRRAH TAGGCGTGAAATATAGCGAT ACTTGTAACATCTAGTCTGT GRKRVLFQCSRCGRMNEKHH AGTCCTAGTGGTTGTCTTAC CAACAAGATCAAAATTCTTC SIACHFPKCRGPPVEEGPLG TGGGCCATAGCCCCTTGCTT ACACAGACGACCGAGCTTGC APEWCCEECGQKFNTKSGLS CAGGGGTCATTCGCGAAGTC TCAGTCTTCCTGTACCCGCA QHKRSVHPLTRNVERIEAAR TCTCAGGAGAACTGGGGGTG GAATTTTGCTCTTGCTCTCC PKGKGKRGAHKGCWTEAEVA GTGTTCTTCTGGGTATAGCT TTTGGCTGTGTCCTGGACGT QLIELEGRFKNQRFINKLIA AAACCCCCTAGACTGTGTCC GGGACTATTCCATCTCGTCC EHLPSKSAKQISDKRRQLAA GATCC CAAATGCCGCGTCCAATTAT ATKTSSPEKRVTSSTSGESS (SEQ ID NO: 1220) ACCGGATTTGACAAAGCGGA PEVEKVEGIKREYRRRVGEW CGGCCCGCTTTATAAGCCGG LCAGSLXDQTSFQKILEDVE AAAAGGTGCCTTGTAAAATT SGSEIVTGPLEELASFARGK GCAAGGTTCATTAAATAG LAAARVRHHRKHPAEAVPAR (SEQ ID NO: 1343) EEQRWMKRRVGRRGLYLRFQ RLFALDRRKLAGIILDDVES IKCPLPMEEVADVFRRRWEE VAPFTGSGSFRSLGKADNGA FKPMISAKEVMKNVXEMSRR SAXGPDGLSLRDLMKIDPQG SRMAELFNLWLLAGRVPDQV KAGRTVLIPKSADPGKIGNI DNWRPITIGSVXLRMFSRIL SARLRRACPINRRQRGFIAA PGCSENLKLLQALIKSAKRD HRTLGVVFVDLAKAFDSVNH QHIFQVLVQKGVDGHIIDIL RDLYTNAGTYLESGSQRSGF IKILRGVKQGDPLSPILFNL ALDPLLCRLEDRGLGYKYGD QQIXSLAFADDLALLSDSWE GMQQSIRVVEEFCQRTGLRV QAPKCHGFLIRPTKESYTIN DCDPWTIADMQLDMIDPGSS EKYLGLGIDPWIGLSRPELS EVLTRWVKNIGGAPLKPLQK VDILRSYALPRLLFIADHAG LSATCLHSLDLSIRSAVKGW LHLPPSTCDAIIYVSYKDGG LGLPRLASLIPNVQARRLVR IAQSEDDVIRSVVLQEGIQE EIRKVWISAGGRPEKVPSVT GEFPVMEAQAADEALSEWER RAPRTIYPIPCKWRKREMEN WTNLKSQGHGIRNFENDRIS NDWLLHYGRIPHRKLITAIQ LRANVYPTREFLARGLGEGA PRGCRHCPAEWESCSHIIGY CPAVQEARIKRHNDICGVLA EEARKLGWVIFIEPHLRDNT NELFKPDLVLVKGSCAKVVD VTIRYESGLTTLSDAAAEKA RKYQHLAGEVRALTSATTVD FLGFPIGARGKWYVGNNGLL SDLGFSTSRVVRIARALSKK ALLSSVDIIHIFASRARQAQ TSE (SEQ ID NO: 1465) R2 R2- . Trichinella CTCCTGACTAACCTGATTTC TGAGGTTTTTGTTTTCTTTT MSNRLANTAAAGGVPEKTSG 1_TSP spiralis GTCCGTGCGGCGGCGTTTTC TTCCTTTTACCATTCTTGTT TLDIPGQPSSSGEKRAISYP TTTTCGCTCTCCGCTCGTCG CCATTGTTGTTATTTGCTTT GPFGCNSCSFTSTTWLSLEL AAATTTGCTGTAGTTGATTC AATCCTGTATTTTACCGCCG HFKSVHNIRDFVFLCSKCKK GCTTTTCTTTGCGTTTTCTT GCAATTCCATTGTTATTATT SWPSINSVASHYPRCKGSVK CTACTTTCGCAGTTTTTTCT ACTGTTACTGTTATTATTGT AAVVPTSLANTCTTCGSSFG GCATTGCCACG TACTATTGTTTTTACTTTTA TFSGLQLHRKRAHPDVFAAS (SEQ ID NO: 1221) CTTACTACTGTTATTATACT CSKKTKARWSNDEFTLLARL TTAATTCGTTAACTTACGTT EAGLDPACKNINQVLAERLM ATTGTTACCACTACTTACTT EYNITRGVEMIKGQRRKDQY TGCTCTCTCGCAAACGTTCG KALVRQLRSNSETQQCVGLA TTGTTGTTTCTTTTGGACCA GSMDSNVPANDTSSSVASEV GGTTTAGAGAAATCGCACGC SITYPEYGAVMSCDLIKEAT ACAGCGGAACTGGACCGCTT GMAIVDINELQSNLRKAFLS AAGCCAGAAATAGTAAAGTA GRKLPMKFHGARETAQKKMA ACAA NPRVAKFKRFQRLFRSNRRK (SEQ ID NO: 1344) LASHIFDKASLEQFGGSIDE ASDHLEKFLSRPRLESDSYS VISGDKSIGVAHPILAEEVE LELKASRPTAVGPDGIALED IKKLNTYDIASLFNLWLKAG DLPASVKASRTIFLPKSDGT TDISNCRPITIASAMYRLFS RIITRRLAARLELNVRQKAF RPEMNGVFENSAILYALIKD AKVRSREICVTTLDLAKAFD TVPHSRILRALRKNNVDPES VDLISKMLTGTTYAEIKGLQ GKLIPIRNGVRQGDPLSPLL FSLFIDEIIGRLQACGPAYD FHGEKICILAFADDLTLVAD SAAGMKILLKAACDFLEESG MSLNAEKCRTLCITRSPRSR KTFVNPAAKFIISDWKTGIS SEIPSLCATDTFRFLGHTFD GEGKIHIDTEEIRSMLKSVK SAPLKPEQKVALIRSHLLPR LQFLFSTAEADSRKAWLIDS IIRGCVKEILHSVKAGMCTD IFYIPSRDGGMGFTSLGEFS LFSRQKALAKMAGSSDPLSK RVAEFFIERWNIARDPKVIE AARRVYQKKRYQRFFQTYQS GGWNEFSGNTIGNAWLTNGR ARGRNFIMAVKFRSNTAATR AENLRGRPGTKECRFCKSAT ETLAHICQRCPANHGLVIQR HDAVVTFLGEVARKEGYQVM IEPKVSTPVGALKPDLLLIK ADTAFIVDVGIAWEGGRPLK LVNKMKCDKYKTAIPAILET FHVGHAETYGVILGSRGCWL KSNDKALASIGLNITRKMKE HLSWLTFEIIFITQISRIYN SFMKK (SEQ ID NO: 1466) R2 R2- scaffold_ Tetranychus CTCTCTTATTTTAACATATT TGATGTATCCCTTCAATATA MCILGGLTSHSREGGLSRGS 1_TUr 6 urticae CGATGTACTCGTACATTGAA TTGTAATCCTCATTCGTCCC SQLKTVKPQNEEDNGTTQLK TATGCTTTTATTTTTTTTCA TATCCTTTCATTTGATAAAA AGSADSFPRPSGDLNPEEPL AAGTTTTTTGGGTGCATACC GAAACTTTGTTGCTCCTTTT SIDICPVCFROMKSYLGVRV CCTGGAAAATTCTGAGATGT AATAGTTGGTCCCTCCTGTC HMQKMHLEEYNASIPDPVVS ATAAATCTCCCATCAGCTTT CCTTTTCTGGAACCTGGTTG HTRWSDEEAAQLAFTEAKIE GGCTGAAACGTTGGCTAAGT TATCGATTATTGAAAGTTGC VDKLLPRGKGINKFLLELLP TTTGTAGGTTGTTTGCCCCC AATAAACGGATTTAA GRTLESIKSHRKRQSHKDLV TACTACTTAGTCGCAAATGG (SEQ ID NO: 1345) RKYVKEFVDTLAADNDDDTI TATTTGCTAACAGTTGTTAA ICQDNGDIFNDPIVGATDSQ ATTGTTACATTTACAAGTCC SETETVADPAEFKTFIELAD TATCCAGTGCCTCCTCGTGG DPTKPKVVAKLRNLIKDKPK CGCTACCCGGTAACACTTAG SEILGSDILVRILRRTLHGL AGTAATCTGAGTGGCTAAAC PVEDELDQYLEVYFTGKIKQ TGGAAGGGCGGAAAATGCAA RRSKTQTALSKKQIKQRDYG ACAGGCGGTTGGTAGATGCT RLQELYSRSRKRCANEILNP TCGGCATTTTGCCAAAAATC TSMSGGFGHQELSEFWTKTF CACGGCTTTTTAGCCCAACA GPDEQPTLGEVEIIPKENCW ACATCAGGGTGATGGACCCG WDIFSPISSDEIKASYPSIG CCAGCTTGTGGTCAGGATCC KAAGPDNFSAYQLRKVPVWH CATCCATGAATAAAGCATGG LECLYNIFAFYKDIPSRLKD CTCTGCTTCTGGTGCATCCT AKTILIPKKDNAESPGDFRP CAACGGGATCGGCTTCGGCT ITLSSIITRHFHKILATRVN GGATGTAAGTCTTGCGGAGG NFVRFHPMQRGFIQSDGCLE C NTALIQTVIREAKVRRKQVH (SEQ ID NO: 1222) ITFCDVRKAFDSVRYDSIIA AIAKKGAPGSFIMYLSNLYR GNKTTLLTAGGETRITPTRG VRQGDPLSPILFNCVMDQIL TALPSRTGFTLSAGDESVNV NCLAFADDIILISKTKNGHQ ELLDVTQRILKENGLDLNPD KCCSLSLIPHSKTKKIKVVR ADFVVNGVKVRSMSIGDSTC YLGVSINVTGQVAPVKMYQA LCEKLDSAAIKPHQRLYILK HFVITKMFHPLILSTIAAHK IKNLDLISRRYVRKWLHLPH DCGSGMIHAKVSDGGLGVPL LFRTIADLKVRRKEKLQVHE NPIFRILAKLSTVSKELENC KKIASKTTDIQEKTFKEMLA TYDGLSLKEARAVPEVHKWV DSYDKRYKFAGRDFVQVIQA RFNALPTRSRVWRGRGADEK SLRCRAGCNARETLNHVSQS CFRTHRVRTARHDKILDFIC ERLDVVGVKYVREKPISFPG KKLIPDLIVENTDQALVLDL QIVGDNSELPLDERGKNKVI KYNCSEMQELYKRKKKTLAV KALTLHYKGLMAPETSNILR SFGFKSKDLEKMAYMALFGT VAAWGIFNRSTETMRSVANW PRPEEL (SEQ ID NO: 1467) R2 R2- . Drosophila GAAGCTGGGAAGCTGGGTCG TAGATGTACTAACCTCTAGT FERRSNSWGYQNLEPSNVGQ 2_DWi willistoni GATGAGCGCAGAAGGGGTGT TTCTCTATACTTTTGCCTGC DMNTVPRINNTTTTPATSRP TCTTCGGAGCACTGTAATTC TACCTTGGCATTACATCTAA GDQPREAIAVVNLAGEIPCA ATAAGTCGTAAGTCTGATCA AAAGGTACAAACATCGCATT VCGRLFNTRRGFGVHMSHQH AGTCGACTCGGAACCTCTTC GGCAAAAAGAGGTGGTTTTA KDELDTQRQREDVKLRWSEE GTGGTGTTTCCTGGGTGCTG GTACATAGGCGCTGTGGGAC EAWMMARKEVELEASGNLRF TTGAGTTCCTAGTCTCTAGG TTCATTGTCCCGATGATGCA PNKKLAEVFTHRSSEAIKCF TTCTCTCCAGTAGCTAA GCGAATCGTGCATACGAGAT RKRGEYKAKLEQIRGQSTPT (SEQ ID NO: 1223 TGTCCAGTAGTTGGTTGCTC PEALDSITSQPRPSLLERNH GTATCTTTAGAAGATTTCCT QVSSSEAQPINPSEEQSNWE TCCTCGGCGATCAAAANAAA IMRILQGYRPVECSPRWRAQ AAAAAAAAAAAAAAA VLQTIVDRAQAVGKETTLQC (SEQ ID NO: 1346) LSNYLLEVFPLPNEPHTIGR SNLRRPRTRRQLRQQEYAQV QRRWDKNTGRCIKSLLDGTD ESVMPNQEIMEPYWKQVMTN PSTCSCENTRFRMEHSLETV WSAITPRDLRENKLKLSSAP GPDGITPRTARSVPLGIMLR IMNLILWCGKIPFSTRLART IFIPKTVTANRPQDFRPITV PSVLVRQLNAVLASRLASKV NWDPRQRGFLPTDGCADNAT LVDLILREHHKRWKSCYLAT VDVSKAFDLVSHQAIIKTLQ AYGAPTNFVSFIEEQYKGGG TSLNGAGWSSEVFIPARGVK QGDPLSPLLFNLIIDRLLRS YPREIGAKVGNTMTSAAAFA DDLVLFAETPMGQTLLDTTL GFLASVGLSLNADKCFTVSI KGQAKQKCTVVERRSFCVGE RECPSLKRTEEWKYLGIRFT ADGRAQYSPADDLGPKLLRL TRAPLKPQQKLFAHRTVLIP QLYHQLTLGSVMIGVLGKCD RLVRQFVRRWLDLPLDVPVA YFHAPHTCGGLGIPSIRWIA PMLRLKRLSNIKWPHLEQSE VASSFIDDELQRARDRLKAE NVQRCSRPEIDSYFANRLYM SVDGCGLREAGHYGPQHGWV SQPTRLLTGKEYLHGVKLRI NALPSKSRTTRGRHELERRC RAGCDAPETTNHILQKCYRT HGRRVARHNSVVNAVKRGLE RKGCVAHVEPSLQCDSGLNK PDLVGIRQNHIYVIDVQVVT DGHSLDQAHQRKVERYDRAD IRSQMRRFFGVTGEIEFHSV TLNWRGIWSGQSVKRLIAKD LLIAEDTKLISVRAVNGGVT SFKYFMYCAGYTRS (SEQ ID NO: 1468) R2 R2- . Petromyzon CGGTGCGTTCCCTTGGGTAA TGAGAATAATGAGGTGCTAA RPQTKLMTDKLKFSSQLARG 2_PM marinus GGAACACGAGTCTTAGTGGC CCTCCCTGGGCCTGACCAAA LAKQRAMDGARVGDPPITVR CTTGACCTCCACGTGGTCCC CCCAGAACACATCACTGGCC PTETDLCNTEGSWGRRPMKL GCTGGTAACATCATCTCTTG AAGATGATTTCCCGCAGCAC LFVSVSTQTQNEDALWASDV ATGATGGCTAACAAGGCTAA GTTGCTTTTCTCTCTCGATA AKPMASRSALKMTSIPSMTF TGCACCCATTCCATCTCCTA CCCGAGAATGTTCTGCGGAA HNSSLEKEEEMNYDFYEQIK TCTCGCATGGAGGCCGCTAT CTACGCAGTCTATGAACAGT SLVESDDSSDDFTEDDEDVE GCGTGATTACTAG CACAGACAACCTCTGATCCA ESFLDISAEEPVLGKFPIDT (SEQ ID NO: 1224) AG KGTITVVLPSLEYICVICKQ (SEQ ID NO: 1347) HMGKASELVAHFNIKHRDIP LVFKCAKCDKTNSNHRSIAC HAPKCGGIKLTEESLPMVCE CCQARFATLSGLSQHKRHAH PVTRNEERIKDGIKGTSQRG VHRSCWSLKEVEQLALLELQ FQGKKNINKIIAEALGTKTN KQVSDKRRDLSKKTGAPMSD SLHFSSRPLETLSPPPNVTT GTSSILAQAAERLTNENSGT LEKPAMEAIKAWLNGEGQHD ALVETATALMLCPMRLVKNK GKRSKPENDIIKPRILPTRS WMKKRAEKRGSFMKHQKLFF KNRSLLASLVLDGTERHECR IPNADVYRFYCEKWEKVLPF NGLGQFKSSGVANNEYFEPL ISVEEVQTAIRAIKPTSAAG PDGLTRAAICAADPEGRTLT ALFNAWMITGIIPKELKKNR TILIPKVMDDEKLKELGNWR PITIGSMILRLFSRIMTARL ARACPLNPRQRGFIAASGCS ENLKVLQDLMRHAKKLHRPL AVMFIDIAKAFDSVSHAHIL WVLRHKKVDEHVVGIIQNAY DRCTTSFKSNGESTREISIR VGVKQGDPMSPLLFNLAMDP LICTLESHGVGYSIDTDHVT ALAFADDLVLVSESWVGMAA NLAILESFCGLSGLEVQARK CQGFMISPTKDSYTVNNCDP WTIKNKDVHMIQPDESTKYL GLKICPWTGIIRSDLHVQLK TRISKIDEAPLKPTQKVELL NAYALPRLLYPADHSDCKQS TLRVLDQEIIKAVKGWLHLP ASTCDGLLYARARDGGLAIL KLENAIPSVQVRRLQRIANS SDAIARNIASSQGVEEEYRS LWVRAGGDSEAIPTFFLRGS ESKEPVYPRPCDWRKRESRR RCEKPVQGRGIVNFAQDRIS NAWLGPRCGFKQCFFIAALQ LRANIYPTRESINRGRDGAS RSCRKCSARLESLSHILGQC PAVQKFKDCATQTEAEMVPH GPAGNALPGWSLSRTFLVNV PQYKNSRIARRNKISDILAD EAARLGWWVYKEPRFTSEAG ELRKPALVFAKGEEALVIDV TVRFELSRKTSSEAASHQVA YYTPPCDQVKVLTKASNVTF FGFQVGARGKVAP (SEQ ID NO: 1469) R2 R2- . Schmidtea AGTCATAGGGTGAACTGCAA TAGAAGGGAAACAAAGGAAA RKELVTIKNLFEESGATAPA 2_SMe mediterranea TTCTGACACGATGACCGAGC AACGAAATGACTGGAAACTA PVPLEVAVEVHQSSSVPEIT d TGTGTCAGTTTGCAGCTAGT TGAAGGATATAGCTGAAAGC DESTTTQEGSYSEPPIHRCE CGCTAAAGACTCGATCAGTC CGCAAGGAAGGCTAAGTCCT NCGREFRTRAGVQQHRRKAH CGCCAAGTGAGGTGGCCGGG GAAACCGATCTACATCTTCG TNEFMEEKEKAAPTKKLRWT TATCTGCAGCACTAGAGCCA ATCCCAAGAGGAACTGTGGG DEEKEILIESEIKIIKEGSL CTGGTATCAAGAGCAGAGAT TTAAGCTTGAGCCGACGGAA KEQHEINKILASRMPGRSQD ACGCGAGTGGAAGTTGAGTA AAAGCGAATGCATGTTAGAC GIAKIRQKQEHKAEIQRRLH CGACTACCTTCACGGGGTCC GACGAGGTACAGTCACCTCC GTVTTNETRGNRTSEITEPI TCCTGATAACCACAGTGGAC TCGTGGTATTTGGCGGGCAA RSLPINTKTWSEDEMKRMLA TGTGGGAACTAAATGTGTGC TGCTCACTAAATTAACTGTG EEVKLRTKNEKDINKKLAEI TCAGCGTTCCCTACTTTCTC AGTAGCTGAGAACTGTATGT FPNRTMGSIKSKRTKDKDYQ GTAGGGTAAAGGGTATGATA GTATCATGAAAAAAAAA DLVKLTMQTISENPDNETDF ACCCAGAGAATATCCCATGG (SEQ ID NO: 1348) NTSNTENNSTDAEKEVKNYL GAGATATCCATGGAAAAAGC NMLLLTINEEEWLTSTLKEA ACCACGTTAGACAATCCGAT ATLALQGKKTEASEKLNEYA GGTCTAACTCGGCTCCGAGG SKTLFPGLKITNQTRKREKK GGCTAACTATCCCAAAGGGC ISKRETRRQEYAEIQKLYKK TTAA NISSAAEKAINGKWSIKPEE (SEQ ID NO: 1225) EYHNNKDLIKAWKPILEAPP FSDCRPIENIKEMDYALMEI STAEIFLAIRAMGKTAPGPD GIKYSKLKKNIQSMAILFNT CLLTSFLPLPLKIARTILIP KQENPGILDYRPLTIASVVT RVFHSILAKKLDNNAQLSQR QKGFRKCDGVAENIVILETI LTNSRSEKRPLCMAFVDLRK AFDSVGHESIIRGAKRVGVP PMLLEYISSSYQNASTNLFG EILNSRRGVRQGDPLSPILF NFVIDEALENLNRNIGYLLK EEKVSCLAFADDIVLIAETK GGLENHIEKLLEKLNGAGLE LNASKCATLMVMKNGKEKST YISTKAIKIKENDIPTMKAT ETYKYLGLOMGFKAREQNAN EVITEGLENITRAPLKPQQR IHILRDFLIPRLIHKLVLGR VAKKSLKRIDQNIRKKVRNW LHLPKDTTAAFIHADAGDGG LGVPALEHTIPLLKRERITN LRKSNDPVTKECLRMEYTKQ VLGKWSRPTKIGETLATNKS QLKEAFRKQMLITLDGKGLK DHHETPTIHKWIRRGENMTG KQFITAVKIRGNLVATKSRN SRGRPEQEKLCEAQCGRPDS LGHILQGCWRTHGMRVERHN NICRRIKAIMKGKESEVVEE PRLQTNEGLRKPDLLICHKG KIIICDAQVVADSSNCSLES ENQRKIDYYKKDSVVSEARK LIGRVDEDIIIMAVTFNWRG AISKTSIRDLDMLLDIKSKE VIKMSRKIIRDNSIMVEMHR NRTEKRR (SEQ ID NO: 1470) R2 R2- . Tribolium TGGAAGACCCCGCCCATGAG TGATGCTCCTTTGGTTTTAC MKSRSFRRIGDCAAGSSRRG 2_TCas castaneum GCTTGGAGAGTGTGATCCTG CATCTGTGGGGGCATCGGTC VRLTGKAGREGRFAASPHLS ATCACACTTGAAAAGTTATG CTCACGGTTTCCTCGGGTTT PRYLAGSVSGNVPSVPPGPG CTGAGTACGTCGTGAGAGTC CCTATTGTTTTTCCTAAACC LGAGAPAFAAGRNADGGPAQ GGTAACTGTCCCAGGATGGT CGACAAGGAGCCCTTTGGCC NPCPYCARSFTTANGRGLHI CTGGGATAGGCTAAACCTCA CTCCTCCTTAAACACCTCTC RRAHPDEANNAIDIERIHAR GCAGGGGAAAGTTGTAGGGG CTTCATCCTSTTAGTCCATT WSHEETAMMARLEAGAIQRG CCTGCCACCCCTACACTTTT CCGGCTAAAATGATGAAGAC GVRFMNQFLVPRMPGRTLEA ATAGATATGGCATTCGATAC CGAGGAGTGTCACTCTCTTG VKSKRRDATYKALVQRFLQA CTCAAATAGAGCCTCGGACT GCGGGGTTAACCCGTCCAAG PQINLPELRDGDAPRQPDPQ TGGAGGAGCATGGTTCCCCT TGTAAATGTGACCTCGCCAT QENPPEPPSFDGAIRGAVAD CCTCCTCGTACTAGACCTGG TCGGGCTCTGATA LVGGVDWQRLGFQGDRLCNI AACCAACGGTCTTGACAACC (SEQ ID NO: 1349) ARRACDGGDVSGQLLGWLRD CCATTGGACCTACGGGAGCG VFPVKRVSTRGDQSDLDVDG GACCATGCTCATGGACATGG ALVSRRTARTREYARVQELY ATTCCGAAGACGAAGCGGGG RKEPKACLARILGDRREGAN GAACACGGACCCCCCGCCGA RAPNRDPAFIDFWRGVFSEA TAATGCTCACTTAACGTCAG SAEVEGWAEEVSDHGELARR GCGAACCCATCGAAATCATC VWDPISVEEVGRSRVRNGAA TTGATGTTACCCTTTCAAAG PGPDGIAVSVWNKLPPEAAA CAGGTCATGCGGCATATGTC LLFNVLLLGRCLPAELTRTR TCAATGCCGGAAAGGGTGGC TVFIPKTDAPRTPADYRPIS TCCCGGGCGTAACGGACATC IASVVARHFHRVLSARVQRI TATCGCTGATGGAASCTAGC PDLFTKYQRGFLSGVDGIAD TCGCTCTTGAAGAACGGCGG NLSVLDTMLTMSRRCCKHLH ACGGGGACTTGGAATCGTGG LAALDVSKAFDTVSHFAIVR TGTGGTTCTGATGTAAGTCC ACRSIFGSAETVLEEGGRRH TGAAATTATGGCGTGATGGC FVQVRXGVRQXDPLSPLLFN CCGCCCGCCCGACCGGAGGG LVLDRALKRLSTDVGFRLTD ACTTAGAACCCCCTTCCGCG ATKVTALAFADDVVLCATTA AGGGTCCTGTCTGTAGGTCC RGLQTNLDVLEAELRLAGLL WCCATCTCCGTAAAACGAGT LNPNKCQALSLVASGRDHKV TGGAGGAAACCGCAGACGGG KLVTKPTFKVGQNTIHQVDA G SSIWKYLGIQFRGSGMCGCG (SEQ ID NO: 1226) SEGVAAGLKRITCAPLKPQQ RMHLLRVFFLPKFYHAWTFG RLNAGVLRRLDVVVRTSVRT WLRLPHDIPVGYFHAPTKSG GLGIPQLSRFIPFLRLKRFD RLGRSAVDYVRECAFTDIAD RKIRWCRERLSGIVDQVAGG RDALDAYWTAQLHQSVDGRA LRESASVASSTQWLRCSTRA IPASDWLHYTAVHIGALPSR VRTSRGRRGGQDVSCRGGCL LDETPAHCIQVCHRTHGGRV LRHDAIAKRISADLMELGWI VTREVSFRTTAGVFRPDMVA VKEGVTVILDVQIVSPAPTL DEAHRRKVAKYRDRADLARY LAEAAVARGRAPPANIRFAS ATISWRGVWSAESVGSLREL GLSARHFDRYTTMALCGSWR NWVRFNASTASRMGRGRGDA SPRRHENQQ (SEQ ID NO: 1471) R2 R2- . Megachile TCTAGTTAGCAAGCGGCCCC TAAATGTCGAACCGAATTTT SGPATSTFGETKSRLCEPTS 7_MR rotundata CTCTAA GGGTAACGTGCACCCCACCA ALGCRPGAVVIQWAQIHKEK (SEQ ID NO: 1227) TCCTTAATCGGCAGCACGCA RKRIVGWPLGHLGSPTSLKL ATAAAGCCGTGGGCAGTGGT RHPRLQAKRIVPVLAELMQC TTTAGTGGGTAGTCATTAGG LCARHVSGRSPQKSAWAFTL AGTCCCACAGTACCCAGCGA EERTSACGVDAMFVCSTCQR ACATCTTAGTGGGTCTGCGT SFATKIGLGVHVRRAHVEVA AAACGCATTTCCACTGCCTA NAAISVERVKDRWSEEERRI TCCTCCGGGAAAAAAAAAAA MAAVEVRGVLSGARFINEYI AAAAAAAAAAAAAAAAAAAA MSHLQTSRTLESVKGTRKNP AAAAAAAAAAAAAA KYKELVATLLEEARTSVREE (SEQ ID NO: 1350) SPRSAVNDSATQPSGPSDTR SLRTEHLFTESTEPFEHRIR ELIGDLEGVTDFRAELLVSI AEQQLQGDEVAESLTRWLGE VFKPENQQQQVQRKRRRQRK APVSGQLPKWRERRRDYAAM QTLFHRNPSLAAGRVLDGKN ESRPPDLPEMTAFWEPILTE QSAEHRAVGPASEKSELCSV WGPVEKEELLSSVPPLDTAV GPDGVTARQWRAVLPAVRAL LYNIILKRGSFPASMLESRT VFLPKKQHSVNPADFRPISI ASVVVRQLHKILAMRLRRTN LVDERQRCMDDGCAENITVL ASLLDDARHGLKELHLVSLD CAKAFDSVSHHAIDATLKEC GLPAGFVQYISRTYSDSSTR LEVGRNRSEPIKTNRGVRQG DPLSTLIFCLCFDRVARTLS PHIGYDLNNTRISTLLYADD AFLVSTTAPGMNILLRSVEE SAGEVGLSFNTSKCSALSLI PSGKEKKMKVGTTPTFKTSQ GFITQITPSQEWRYLGVDFQ YSGPKKASRSLKIELERISK APLKPQQRLLILRVYLLPRY YHHLVLSRTTLGHLRGLDLQ VRAAVRRWLSLPRDIPIAYF HTTAKEGGLGLPAFETSIPC LMLARLRSMETSTCKAARAA VQGFWVQKRIHWATAALTKN GEALTCKADVDRWWASRLHK SVDGRELRECSGVGSSSTWV NSALNITGRDYVQYHHVRIN SLPTRIRTSRGVRREGMEVT CRAGCQVTETAAHVIQSCHR THGGRILRHNAVCKVLASGL RDKGWEVREEPKLRTRQGLR KPDIVAIKDGVARVIDAQVV SGSGPLDEAHETKRKYYSDN GDVTAAIARECNIAPSNVAY SSCTISWRGVWSPRSAADLL QVGLSKKLLGFITLRVLRGS HLNWTRWNKMTTMRVHHQRT GIG (SEQ ID NO: 1472) R2 R2Amel . Apis TGGTAATCAAATGCCTCGCT TGATCGTTAAAAGTAAAAAT MSSNEEGASDTGAPGPGVPV mellifera ATTTTAGTAGCGGTAGCGCT CTATTTATTTATTTTTATTC ADVSAADGRATYDDHGMSTD CCGCCCGCGCAGGAACCATT CTATATTATAACACATTATT YEKQTIELPLNGQIQCLWCH GACGCCGCCGTAGTGTGGGT TATTTATTTACTTATTGTTT IEGRNQRFLQESQYLKHKDT GATTTTATATCCAACCAATC TAAAGATGACGAAGCCGCAA QHPKGEIIWRCAACQKEFEK ACGTCAACTACGATCATTTG GGCCAATCCAAATTTAACAA LHGCRCHLPKCKGRKEAKGV TAATCACCGACGGTACTTGG AAGAACGAGACTACTGGTCG AKFKCDSCEESFLTQRGLSM TAGGGGTACCACATGGGCAT ACATTAAAAAGACGAAGCAG HELHRHPAIRNLKRTQGTSR TCTTGCTCATTCCACAACGC CTGCCAGCTGATAAACAACA GNTRPINRASVWSKEETDLL CGCCTCCATCATGGCAACAA GAGCCCGTCTCGGCCTTTAC IKLNERYKHLKQPNVALKEY TTTAAAATATATATAAATTC ACCGAGCGGTGCAAGTCCTG FPDKTLKQISDKRRLLPVQE TTAAGGTTTGACCGTATTCA ACGTACTATTGTACGTCTAG PEDVATTDETGPPPSDSSEE TATATATATATATATATTTA GGCGCGGGGCAGATTCTACC SIYESATEDEGGGDMQQTAP ATATTACAACCATAAATCTT GTGTAGAATCTGGGGCGACG NDSWKEPFIQSIRTNHLEEE ATATCGAGCCTTCTATTTGG CCTCCGCGAGGCACTCCCTG DSLRKVEEAIERMAMNEGVT TCTCAAAAGCAATACGTTGT GACAACGTACGCTAAAGCGT EQEVGTLLEQFVDSLTQSPT CAGATCTTGTAGAACATCAG ACGGCTAAGTGCGCCTCCCG TERKGSRRKSQKTTKRKTTH GAGTGAGCGGTGCGCTGTGG AAAGGGTCCCCGTTCCTAAT NNRKKFLYAKHQELYKKSPR TATCCGTGCTTTGTGCCGCG TTTTCCGAGCCCGCGGGCAG RLLELALSGESSSGREVVNL GCGACAAACCAATACGCTGC ATCTCGTGGCAGTGACGCTA PEADSVGPLYKSLWGQIGPE TGCCTGTCGCAAAGCAATAC GAAAGTTAAGTCCGCGGACA KTHRNQPMCNNIDMSEIWTP GCTGCTGATTCTCGGATGCG TATAAAATTACAGCCTTAAA IALESLVEKFKKIKSDTAAG GGTGTCGACGGTCACGCAAA TAATGAACCCCACGAAGGAG ADQIKKFHLRKKGALHVFAK GCGATACGCTGGTGGGGTTT GTATCCTCGAAATTCCGCCA LCNLLMLHRIYPAQWKTNRT CAAAACAATACGGCGCTGGT CGATCCTTCTGATCGTAGGC TLIPKPGKSAEEVENWRPIT GCTAAAAAGCATTATGCCGC GCAAAACA IGSLLGRIYSAMIDRKLRSK TAACGGCTGGATTGTCGATC (SEQ ID NO: 1351) IKQHIRQKGFTQEDGCKNNI GCCGCTGCGGGGGCTAGTGG AILSSALTKMKEDSGGIITI CGCACCCAGAGAGGTGCGAC IDISKAFDTVPHGEISQSLM GCGCAAGCATTGGTTCTGTG NKGVPSPICEYIQKMYIGCK CGAAGCGGAGTTCTTGAGAG TIIYCRDKKTLPVDILRGVK TAATGGTTGCTGGGGGCACA QGDPLSPLLFNLIIDPIIGT AAGCGCAACATATAGCCTCT LDETTEGIKLENENISVLAF TATGCCTCAAGTCGTAGTTC ADDLVLLAKDKETADKQNRL GTACCTCCACGTGGTCCCGC INEYLDDLKMKVSAEKCTTF TGGAATGCCTATCGACTCCT EIKRQNKTWFLGDPQLTLGQ CCCCGGAGGATCATAGAGTT QRIPYADPEAAIKYLGTNFN CGAAACCGGCTACGGCGAGG PWRGLCKTSIKEIIDAARTV CAAGGGCGGTGAGGTGCACA KQLKLKPHQKINLIRTYLLP CCGATGGGGAGCAGCGACCC RYIHKLVANPPPLGTLDLID CACCTACCCTTAGCTAAGAG KELKTIIKEILHLHPSTTDG AGCAGGCGATCCGCCAACTG LIYTDKSHGGLGIQRVANIV TCAGCACGAAATAAACTAAT KLAKLKHSILMTRSEDNAVK CATATGTATACGAGGGAGAA IALNGQEGMVKRYATSIGLQ TTTACAACGGGTACCTTGTG WPCGIEEIEETRKKLKRADT CCCGAACCGCCTGTAGGTAT NKWKTLISQGQGIKEFFGDK CACCTACAGGTGTTAAAATG TGNAWLYNPEMLRPSRYLDA AATCTGATAGCTGGCGGATC LKLRTNTYGTKAALHRAKRD GTCGACCCTCTTTGATGGCT IDINCRRCGVQVETLGHILG CTGCGCCAACGACTGGAAAG LCTHTKNKRIKRHDEICDLI AATAGGAACGGAAGTCTAAT AKNVSKEYVIFREPEVEVNG GGAAGGAAAGTGTCGGGAGC DRRKPDMVIKDHDKVYVVDV ACTATAAATTCCCAAAGAAG TVRYENNDSLNKAYKEKENK AAAAGAAAAGAAAAAAAATA YKETAEIMRRDLKAKESRVL AAAAACCCAAATTAA PVVIGSRGAVPRATIENLKV (SEQ ID NO: 1228) LGLQTKHALTASLIALRSSI EMANEFLDYDHTT (SEQ ID NO: 1473) R2 R2B . Nasonia GACTAGACTATGGGTTCAGT TGACCTGAACAAAACGTGTT TFAPTHPMVRSGPCRKTKRP _N vitripennis CAGTCCCAAATAGCCGATCC GTCTTGTCTTGTCTAAAACT GSDYRESLIMDSGNNVASEP Vi TGGCGCGTCCGGCAGTAATG ATTTATTCGAAATAAGGGGA RGAVDVTSAAPIGAELNAEP CCACGTATGAGTCGGTTACC GGCTAACTGCCTGCAAGTTG CEGRNORREAALSAQTRRRN CATCTCTAAACGCGTAGAGG AACGCGAAAGTTAGACCTTC XARRARNAQQADEPGDDEEI TGGGGAGCTAAAGGCCAGGC CCACCTAAAGCCCAAAAGTG ETHGPLTIRTXEPMEIVAIA GGTTTACCCGACGTCGAATT ATCGGGGAATGAATCCGCGG KNPQACPKCLQGGTQLLCMG TCTCCAGGTCTGTGTCAGTC GTGACCCCAGAGTTGGGTAA SWELSRHINKEHPSVDVTWV GACGGAATAAAGGTACTACA ACCCTTGAAACGTTGGAGAA CGACQRRCTTLRSWSCHVLH ACATCTACTATCTATCGGGA GCGGAAGAGAGTCCCGCCAC CKGRQEPKDLPFKCEHCSLS TCGGAAGACGCCTTACAGCG CGAGCATCGAGTGCTGCGGC FDSQIGLSQHERHVHPEVRN TTTTCCGATTTTTGCTCTTT GCCCGAATGAAACCGATCGC DKRAAEANKPKGKSGRRPSI GAGCATTTTTCTTCAAATTG GGATGGTGCAAGTCGTAGGA WSDEDLLLIRELESEYHGAR CGATAACCGACCCGATCACG CGGGGCACGACCTAAGCCTC NINEKIAEHFPDRTGRQVSD CGGGGCTTTGACAAAGCAAT TGTCACGGCGGCGAAGCCAG ARRRKDYAALRGRGGPQGPA GCGTGGTCGGTAAGATGGTT GAATCACCATGCAAAGGTGT EGVEAIEEVDEGEIPEGEEL GCAATCTTTTCCACCTCGTT GAACTGGGGCGGATACCTCC VATDGAALESGPPENGGSAP TCTTTTACGGAACGAAAGCA ACGGGGTTTCCCTGGGCATC AEQVNAPALESSSQQDRECS ATGCGTGTGGGGAACGTTAA GCGCGAGCGATGGCCAAAGT PAVGSDEQIEDSSDDDEFSD AAACTCCCTTCATGCATCCC CCGCTTTCTCAGCTACAAAA ALGEISLPEPLSVERTTISP AGGATTTATCCTGCTTACTG CAAAAATGGTATGAGACTTC PPRDDWKGPMRWEICNASEE CAAAGCAATGCGTGTGGAGC GTTAACACTAATTTTTCCGA AGSYANWVTGLQELVRNNAL GACTTTACCACGAGTCGCTC GCCTAGCAGGCTCCCTTGAC SEIGLDSLYDQLIQIMRHPS CACCGCAAAGCAATGCGTAT AACGCTTATGAATCTGGAAA DDNEQDRLQLNARGPPRRGH CGCGCAAAAGCAATGCGTGT AGGACACAAAGTGGAAAAAG RKNRRRRRLTAADRKRFAFA GGGGGACTTGTCAAAGATCC CGCTGATGGTGGACAAAAGT RCQDLWNNNPKKLAELVIAN CCCGCCGCAAAGCAATGCGT CAGTTGAGACTTGATATCAG DLSILQRRQAPGRTETQTLY GTCGGCACCACGTAGAGCAA TTGTTTTGACTAAGAATTTT NELWGRVGPNIEAPRRTEDP AGCGTGTAGGCAGACTTTGT ATTATCGTTGACTTTTAAAT IPVSRIFTPITPQEIMGRIR CAAAAGTAGTTCTGCCGCAA ATTTTATTATTGACTGTTAA RIKNDSAAGPDGVTKDDLRG AGCAATGCGTGTGGAGATCT TATACTGACTTGGGACCAAG RGVSIALSKLFNSILLAGYY TCGCCGGTGAAAGCAATACG TCATCTCTGTTACCCGGTAC PKAWRENRTTLLPKPEKDPA TGTGGGCGAACTTAG CGGTTCCTGTCATCAAACCG DVKNWRPITISSMVSRVYSG (SEQ ID NO: 1229) GAAAGTCCGTCCCACGTAAT LLDQRVRAVIKQCDRQKGFT GTGGTAGACGCAGGAG EENGCFSNIQLLDDAVSNAK (SEQ ID NO: 1352) KAGGVITILDVSKAFDTVPH AVIQGCLEKKGIPETVAAYI SSMYRDCSTAIRTRSGDVKI GMKRGVKQGDPLSPLIFNLV LEPLLERLQETSGVEIEGMN LSCAAFADDIVCFANTAPEA GRQLRMVADYLGRLDMSLSV SKCIAVEYVPHRKTWYTKNP GLEVNGNAVPSISPSETFKY LGAKVSPWKGLLEGFESDAF REVISRVQRLPLKPMQKVDL LQMYIFPRYTYGLITSPPAK AVLKTIDRIIRTRIKEILHL PESVSSSFLYTPRKQGGLGL LEVEKMVLIAALRNGLRARQ SHDPVTRAAMNSNAADDRLK SYADALRLHWPLTTKELDTY KYQLRLSYAQKWAEQKWQGQ GVEEFAQDPVGNSWLQRYDL LPASRYIDAIKLRTNTYPTR ALMKIIDGRVDSSCRKCQGS SETLGHILGRCRYTKDKRIS RHNEIKDLLKARLAKNHQVM DEPQITVRGQRFKPDLVVKT NEGRVHVIDVTVRYEHRTYL DEGRTEKIGKYRQILSTLRR DLHSNAEEVIPIVIGSRGAI PRETRKALSKLGIGKSDWLT ISLIALRSSLEIVNAFMDD (SEQ ID NO: 1474) R2 R2Ci-B AB097 Ciona CGACGGTGAACCACCTTGTC TGACAGTAATATGAAAACAT MGEWPWVSWSLTVLVEKWRP 122 intestinalis GCGGTGTAAGAGCTTTAGTG CACATCTGACCGGCACAGAA FTILQPYPMPGQLRVDVYLP TCTCGAACAAGAAATAGCTT TCACCATGCCGTAATGCACC RKTSYLMDKNIYENTTSPGG GTGTGCTGTCCTTCTGGGCG CAACTAAGGATTCCAATGGG GPLCGEKTHRSDVIIPPPGF GTGCACATACTTCTTAACCT TAAAAAAAAAAAAAAAAAAA APSTDTASNTLGENVDASAT CCCGAGGCCATGCCGGCGGG AAAAAAAAAAAAAAAAAAAA TSSANPLSQEPGWCESCSKL GGCTTTAGCCCCCGGCAGGT AA FKSQRGLRVHQRSKHPELYH TTTACCATGCCGGACGGGTT (SEQ ID NO: 1353) SQNQPLPRSKARWSDEEMVI CGAGAGGTAGAGGCCAAACT FAREEIANRKIRFINQHLHK AAGAGTTCACCAGCAGACTT VFPHRTLESIKGLRGKNVRY CGCACGCGGCTGGCCACTGG ARIMADLEAEMTSQPEAATS CCGAAGTTTAAACAACAGGG LCTETSENLASSNVLPQTRG CCGCATCTTCCCAAACTCAA WAENLVENIDTAHLANLGPL TATATGGTGTTAAGTGAACC SQFEPGKPSSSTKEAINTEY GTGCCG NDWISKWLPSGAAHRERRAN (SEQ ID NO: 1230) PPSTKLNARATRRLQYSRIQ NLYKLNRSACAQEVLSGAWK VQSGELNLKEVQPFWEKMFR KESAKDRRKPKPTGEVLWGL MEPLTIAEVGSTLKSTTPSA PGPDKLTLDGVKRIPIAELV SHYNLWLYAGYQPEGLREGI TTLIPKIKGTRDPAKLRPIT VSSFICRIFHRCLAQRMETS LPLGERQKAFRKVDGICHNI WSLRSLIHNSKDNLKELNIT FLDVRKAFDSISHKSLGIAA ARLGLPPPLITYISNLYPNC STKLKVNGKISKPIEVRRGV RQGDPLSPLLFNAVMDWALS ELDPRVGVQIGEQRINHLAF ADDIILVSSTKIGMVSSINT LSRHLAKSGLEISAGKEGKS ASMAIVVDGKKKMWTVDPLP RFKVNSQKIPALSITQQYKY LGINIDAQGARNDAARILTE GLAELSRAPLKPQQRLYLLR VHLLPKLQHGLVLSSCAKRA LTYLDKSVRSAIRRWLTLPK DTPTAFYHAKACDGGLGITR LEHTIPILKRNRMMKLTLSE DPVIMELVKLTYFTNLLHKY SNVKLLNSWPVTDKDSLARA EASMLHTSVDGRGLSNCSDV PRQSDWVTNGASLLSGRDFI GAIKVRGNLLPTKVSAARGR QREITCDCCRRPESLGHILQ TCPRTWGPRISRHDSLLKRV RNQACLKNWTPIIEPSIPTN IGLRRPDLVLAKGNIAFLVD ATVVADNANMQLQHEAKVEK YNNSDIKEWIKVHCPGVDEV RVTSLTANWRGCLYGGSASF LTEDLGLPKAELSLLSAKIN EKGYYLWCAHYRGTARLWNR PLRS (SEQ ID NO: 1475) R2 R2C_N . Nasonia CGGGTTCCCCCGACTTCGGC TAGCGGACTGGACTGTCTGG WVTSPRRPRYVGPQKKKASD Gi giraulti TTGCCGTGGTCTGGGGCTCA AGGAGTGTTTAACTCGGGTT GNDGRAAARAEPTNPGGPDR CTGCTTTTTGTGGAGTCATG CTCATGGGAACCCGACAACG ADDDEGDVKFWCEFPGCDRF GTTACATGGTGACCCTGGTT TTGTTATCTTGTATGACAAT FMTRSGRGLHHKKGHPDWND CCTCGCACCCCCGCTGGAAA TCATAAAAAAAAAAAAAAAA QRNLAGKQHRKEIWSEEERL CTATCTGGGGAGGCCATGAT AAAAAAAAAAAA LLAKKEAELAISGARFINVE TGGGTAACGATAAAGGTCCT (SEQ ID NO: 1354) LRDFTARSLDAIKGQRKRPD GGTCGTGTCCTCCTGAGATA YKILVEKFVRELRVRGIRQG GGCTGAATGGGTCACTAAGT VASRSQQARAMAVAGAPAAT GGCACCTAA SSGAPPVATQPPPSGRVLRS (SEQ ID NO: 1231) QVVEAPAMEIPVAESEGDSS GDELFEDVEPVRLSDLPPDR FTIYFAGLEIPGTEDIYAHR LHTICLMTTWRTKEEVRLEL GLFLKDLFPSKGSQERPERT NLPDPRNRIERRRGEYKKCQ DLWRRNKSTCVQRILKEDLS QGECLPRELMEPFWNATFTQ NPGTAPVLPPPTEVYSSVWE PIRPENIKGNYPPQNTAAGI DGLTVGDLKGVSREMLARIF NLFMWCGKLPEHLCASRTIL LPKKPGAKVPGEFRPITVTS VLIRTFHKVLAERLKVVPLD PRQRGFRESDGCAENVMLLD MTIRYHHERRRKMFLALLDM AKAFDSVSFESMREVLTTKG IPTPFIEYFMTHLEDSFTVL QHGNWQSGKIHPTCGVKQGD PLSPPIFNFIMDEMLKRLPK EIGVNLDGLFVNAMAFADDL SLVANTEQGLQILIDEATSF LGLCGLRANPNKCVTLAIKT IPKEKKTAIDPSSHFRIGNA VIPSLKRTDEWVYLGIKFNS NGRLISDAKPKLIKDLELLT KAPLKPQQRLWALKVIVIPG ILYRGTLGSSTAGYLRSLDC VIRAYVRRWLRLPGDCPNGY FHAAVADGGLGVHPIRYKAM VDRLARLRKLEKSAYITGPE AARYLQRQVSIAENRLRDGA NRIMSDASMLREFLRELLYK SFDGRPLENSSKVPGQHRWV EEPTRFLSGADYMNCIRARI AALPTAARCARGRLKDKHCR AGCGNVETLNHVLQFCHRTH GTRIGRHDAVVKYVVGGLKK RGYAVKEEPKIVLQDVVYKP DMVATKEGKTLILDAQVLGD QRDMRLAHEDKLRKYGAPEF KRKIRSETGSATIKSLSVTL SWRGLWGPDSVKGLLEEGVI LKKDLKILSTRVLIGALAGW RRFNERTSMATSGRREEVTT RMVRRWKRRERVGVG (SEQ ID NO: 1476) R2 R2La JN937 Lepidurus GGGGTAGCAATTGATCGATT TGATAATCGCTCCATCCTGC MSGKSSKPRTVSSGSSSQET 617 arcticus CCCGCTTCCTCGTGGCGCTA AACTAATTATGAATGCAAAT PPSGSNACDICGKCFMKPVG CCCTGGGTAATACTATGAGG CTGTTAAGTGACATTAGTGA LSRVHPSQYHARLEKNQPKA AATTGATCACACCGTAGCGA TACTTACCTGATACTTACCC KKFRWTDEDLYFLAKKEAEL ACGTCATCAGTCACAGCTGC TGGTATTTATTTGACCTATA LHLGSIKFVNKELAEFFPEK ACGAATCCAGATAGAAATAT CTTACCCTGGTATCTACCTG SVDQIRGQRRSETYKQQVLS AACAGACGAGTAATTCTTTT ACATATATTTATCTAACCAC IHSELLKLQTVADSPPPSRI AAAAGCTCGTCAGTAATCTT CTACCTATGATGACTCCCGC PAKEVSAWLDFFLALPKTKN CCCAG GGAAACTCTCACTTACCTTA KFSEDKLDQLIRTAQDGTLI (SEQ ID NO: 1232) TTACCCACTTGGTCTTTTAT LDDLDLYLREVLVQPTSQGE TTTCTCGTTCCTTATTACTT KQAKLLPPPKSSREKRDREY TGTTCCTTTGGTGTAGGGTT ARAQNLYRKNKTACVNAILD CTCTGGTTTTTGGAACGGCT GNKKCENKIPDIDDFWKTIF TCCTTAGCCGGAATTTTGTC ESHSPPDAEPVCYVVDEEPT TGATGTATCTTGCTTGTGTC NIWSWISFFEMNHNYPDSST CTTGAAATATACGACCCAGG SPGPDGVTARMLRSIPARVL CTTGCGTCATTTAGGCTCTG NKLLNLLLFIEDLPAVFKCH GGAAA RTVLIPKIDNPTSPGEFRPI (SEQ ID NO: 1355) TISSIVVRQLNKIIAARVSE GVPINPRQKAFRQIDGCAEN VFLLDFILRDAKTKIKSLSL ATVDIKKAFDSVSHHSIFRA IRGARCPENLVNYIQNSYSG CTTQISVGGSISASKIPMNR GVKQGDPLSPVLFNLVINEI IRKLPASIGYPINSELSINC IAYADDLILVTNTREGLKLL LGLLNEELPKRGLELNASKC FGLSLTALGKLKKTHLCTSD QLDLHGTLIKNLTAEESWVY LGVPFSHIGRSKSFSPDLEA LLNKLQKSPLKLQQKLFALR VYLIPRLLHGLVLSRVAIGE LKIMDKLILKHLRVWLRLPK DTPLGFFYSPVKLGGLGIKN LRTNVLKCRKQRIERMLVSP DDVVRLVAESEIFLKETDKL KDLLTINGMCLDXRNVPRTG KNNKFWSERLYTSFDGKTLA YSEYFTQGGGWIREDKILQP AHVFAECIKLRINALPTKSR VAHGRPTKDRSCRAGCLDVQ KVPTIETINHIAQVCPRTHG ARIKRHDRLVQFLSLNLRKN PKRNVLVEYNFRTVAGIRKP DIIVIEDTRAVILDVQVVGD SSNLEMEYLEKSRKYSNDAN FINALQKLYPTVTNLTFHAV TFNNRGLIAKSTVAALRMLG VPPRCIMILCVISLEKTLEV WRMFNQSTASARK (SEQ ID NO: 1477) R2 R2LcA . Lepidurus TTTGGGGTAGCAATTGATCG TAGTGCTTGAGTGATGCCTA MSEESRPKQTASKRGAAVEK couesii ATTCCCGCCTCCTCGTGGCG TCCTTTCTTTGATTAACTCT TMMSGTYVCTLCGRSFEKSV CTACCCCGGGATAGCCTCAA TACCATATACTTACCAGTTC GLSLHTNRMHPEAYNKLKEA AGAAATTTGACGGTAAAGCA TTACCCGTACTTACCCTGTA KKPVLKKARWSEEEVFLLAQ AAGAGGAATTGATCACCCAA TACTTACCTGTGTGCGTACC KEAELSFIGGIKFMNIELHK GGCAGTACATCGGCCTTCCT TGTGTACTTGTCCTTTAGCC IFPERELEGIKGQRKNPTYK GCAGGAGCTCTGATAAAGAT GCCTTGTGTTTTTACCATTG AQVVSLLAEIRESKANDSSS ATTAGTGAGTTATTCTGTTG GTACTTACCTTGTGTGGTTG SSSSSSSCDSASLGISNWLE AAGCTCGCTATTTCATTCCC CCCGATACTTACCTTGTATT FLLALPKTSNQFQEGRLDRL CTG TGCCTTGTAATTCTGCATGA ISDALRGVDVLENLDAYLLE (SEQ ID NO: 1233) TATTTATTGTGTAGGTTCCT VFAKPMAQNPCPKPPPPAKN GATGCTTACCTGATTTGTCC SRERRDREYSRVQNFYKKNR CCCTCATCATCTTTAGTTTC SACINSILDGNTRSQNVIPG GTTCTATTTCACTCCATTAT LTKFWTETFEKNSPPDDEAP GGAGTTCCGTTTGTTTTTTG DQFVADEPRDMYKWITFYEM GTGGAGGTACAGCACCCTTT SQDYLDSSTAPGVDGFSAKQ AAGCTGGAATTGAGTGAGTT LRSMSPRVLNKILNLLLLSE TATGTACTTTGGATGGTTGT NLPNSFKMHKTVLIPKIDDP AATAAACTACCCGGAGGCAT KSPGDFRPITISPVLARLLN (SEQ ID NO: 1356) KILAARLSKLVPISQRQKAF LPVDGCGENIFLLDYILRSS KKSSKSVAMAVLDVKKAFDS VSHHSILRALNEAKCPINFI NFVRNSYDGCTTKLTCGGTS FPDSVRMNRGVKQGDPLSPV LFNLIIDSAIRKLPDSIGYV IRDGLKINCLAYADDLILVA SSRAGLKTLLNIVAEHLSLR GLDLNAAKCHGLSIIASGKA KTTYVSAADSLDLDGQPIKN LGVLDTWTYLGIPFSHLGRA EKVSPDLTNLLNKLQKAPLK LQQKLYAVRNFVIPRALHGL ILSKTNLKELNTLDRAIRVF LRTLLYLPKDTPLGFFHSPI KSGGLGITCFRTSVLKCRLQ RIARMRSSCDGVIQAVAESD IFADEYAKLRDLIRINGNVL DTTESIKRYWAQRLHSSVDG KTLAYMDYFPQGNLWMSEDK VSQRSYVFADCVKLRINAIP TRVRVSRGRPNKEMCCRAKC FDSQRMPAFESLNHITQVCP RTHGSRIQRHDKIAKFLFKN LNNCPSRSVLYEPHFVTVDG LRKPDIIIYDDSHMVVLDVQ VVSDSANLEKEFECKAKKYA NDVALRSAMLIKYPFIKSFS FVAATYNNRGLIAKSSVQVL RQLGLSPRSIMVSILICLEG TLETWRIFNQSTMNAH (SEQ ID NO: 1478) R2 R2LcB JN937 Lepidurus TTTTGGGGTAGCAATTGATC TGATAATCGCTCCATCCTGC MSGKSSKPRTVSSGSSSQET 619 couesii GATTCCCGCCTCCTCGTGGC AACTAATTATGAATGCAAAT PPSGSNACDICGKCFMKPVG GCTACCCTGGGATAACCTCA CTGTTAAGTGACATTAGTGA LSLHMSKVHPTQYHARLEKN AAGAAATTTGACGGTAAAGC TACTTACCTGATACTTACCC QPKAKKFRWTDEDLYFLAKK TAAGAGGAATTGATCACACC TGGTATTTATTTGACCTATA EAELLLLGGIKFMNKELAEF GTGACGAATATCATCAGTCA CTTACCCTGGTATCTACCTG FPEKSVDQIKGQRRSETYKQ CAGCTGCACGAATCCAGATA ACATATATTTATCTAACCAC QVVSIHSELLKLQAVADSPP GATATATAACAGGCGAGTAA CTACCTATGATGACTCCCGC PSRIPAKEVSAWLDFLLALP TTCTTTTCGAAGCTCGTCAG GGAAACTCTCACTTACCTTA KTKNKFSEDKLDQLIRTAQE TAATCTTCCCAG TTACCCACTTGGTCTTTTAT GTPVLNDLDLYLREVLVQPT (SEQ ID NO: 1234) TTTCTCGTTCCTTATTACTT RQGERQAKPLPPPKSSREKR TGTTCCTTTGGTGTAGGGTT DREYARVQNFYRKNKTACVN CTCTGGTTTTTGGAACGGCT AILDGNKKCENKIPDIDEFW TCCTTAGCCGGAATTTTGTC KAIFESQSPPDAEPVSYVVD TGATGTATCTTGCTTGTGTC EEPKNIWSWISFFEMNRNYP CTTGAAATATACGACCCAGG DTSTSPGPDGVTARMLRSIP CTTGCGTCATTTAGGCTCTG ARVLNKLLNLLLFIEDLPAV GGAAA FKCHRTVLIPKVDNPALPGE (SEQ ID NO: 1357) FRPITISSIIVRQLNKIIAA RVSEGVPINPRQKAFRQIDG CAENVFLLDFILRDAKTKIK SLSLATVDIKKAFDSVSHHS IFRAIRGARCPENLVNYIQN SYSGCTTQISVGGSISTTKI LMNRGVKQGDPLSPVLFNLV INEIIRKLPASIGYPINSEL SINCIAYADDLILVANTREG LKLLLNLLNEELPKRGLELN ASKCFGLSLTALGKLKKTHL CTSDQLDLHGTLIKNLTAEE SWVYLGVPFSHIGRSKSFSP DLEALLNKLQKSPLKLQQKL FALRVYLIPRLLHGLVLSRV AIGELKIMDKLILKHLRVWL RLPKDTPLGFFYSPVKLGGL GIKNLRTNVLKCRKQRIERM LVSPDDVVRLVAESEIFLKE TDKLKDLLTINGMCLDXRNV PRTGKNNKFWSERLYTSFDG KTLAYSEYFTQGGGWIREDK ILQPAHVFAECIKLRINALP TKSRVAHGRPTKDRSCRAGC LDVQKVPAIETINHIAQVCP RTHGARIKRHDRLVQFLSLN LRKNPKRNVLVEYNFRTVAG IRKPDIIVIEDTRAAILDVQ VVGDSSNLEMEYLEKSRKYS NDATLSMRINALQKLYPTVT SLTFHAVTFNNRGLIAKSTV AALRMLGVPPRCIMILCVIS LEKTLEVWRMFNQSTASARK (SEQ ID NO: 1479) R2 R2Nve . Nematostella GGTTGGGGCCTTCTCGTGGC TGATGGTGGGTTACTCGCCT MLRGTGNMNDKRDGSATADP c-A vectensis GGAGTCGTGAGTAAGGGGTA CTGTGTAACAGGCAAATGAA TSALLGAVGDGSLVCNLCGL TAGGGGTAAGGGACACCACG AGCTGCGCAAGCAGTCGATG ACKSRGGLSIHRRSKHATVY GACCGAGAACGGTTACCGCT AGCCAAAGCCGCACAGCCCC HAERQPAPRAKARWTNDEMI CAAGGCGAGTGGTGGAAGGC CGACTGGGGTACAGGGCAGC LVARKQIASEKSRCSAVVEG ATAAAATCGTAACGCCGCCC CCTGGGCTATGCCCGAAGTC MREAVPHRTFDAVKSLKTKN TCCGACCTGCTCCTGAAACT TTTTGACAGGTCCAAACTTC RNYTRILEQIRAECSEEEVI AATGCCAACCAACTGACTGT ACCCTTGCCGCCAGTAGGGC ESGVLKDRTENVCVQTTSNV GGGGCTAACCTCCCCAGAGT ACCAGGGCCAGGTGCAGGTG PGSAGRAASVELEGNIQVGH CAGG GGCGCTTTGTTCTATTTGGT QLAQKTMAGNNSRKQPANHT (SEQ ID NO: 1235) TTCGCTTAATTTTTGTTAAA NWAEFNIEEGNITLRKSKRK TTTTTCCCGTGCGCCCACCC ANGMPDATHRPGPPTVDSLK TTTTTAACCCTTTTAACACC HPVCLLQGAADKRDEPHTVE AATTTTTTTTACAACCCTCT QLYYNIEEGMPLAEEQQWSE ACTCAATAATCCAAATGAAT KLFDAIDSSLLSVEVELGRI AAAAGCGGCATAACAGGTGA VPGCPDEETRQLIDREFLDF ACAC IHSYSREKPPQRGLAKSKPP (SEQ ID NO: 1358) PKGPKSLRRQQYRQLQRLWD KNRSAAAEQALTGKWQEVRT AAGVPLSLMEVPWREIFETP STTDVREPAPAGPVLWQLLR PVTIAEVEDAISSKKSASGP DGVPCAALQTMGAASLAAHF NLWLLAGTQPKRLTECRTIF VPKEVNTHLPLHHRPITIGS VVVRLFHQILGKPMEAVLPL GSGQRGFRKGDGICQNIWLL HTLIRRSTDLLRPLKLVFLD VKKAFDSVSHESLLIAAKRL GVPGPLLTYINELYSRSETV FEVGGESSGSVKVSQGVKQG DPLSSTLFNCVIDWAVSDLD PHIGVLLGESRVSFLAYADD LVLLSETEAALTSQLNSIEK SLAHCGLKLSTGDSGKSASL NIVIDGKAKRWVVNPTPFLR ASGGEIRSLVANETYKYLGI NIGAQGVKAAEYNAFKEALD NLSRAPLKPQQRLFLLKTYL LPQLHHSLVLSRTTGKLLNS LDALVRKAVRGWLKLPHDTH RAFFYAHQADGGLNVPSLYH LIPLLRRSRYERLTRVEDPE IREVSRTDYFKRVLGAAAAA TTVAGHRIDSKVTLRLAWRE ALYASADGRGLSQCPLVPEV HSWVTDVSGLQTGSQYISAV RLRGALLPTAVRKSRGRGGV NSNCDCCGRGQPEFLGHVLQ TCPRTWGSRISRHNHVLSLI AKACRSRRWQVLEEPIIQTP AQLLKPDLVIWNHQAAYVVD VSVPGDNTPLSTCHNRKVAY YSGESVREWVRSKTGHNPTV SSVVINWRGAMAKESYRLLT KDLRLAKTLPRLLVLRVLEG GHGIWLNFHRSTFAVGVT (SEQ ID NO: 1480) R2 R2Sm- . Schistosoma ATGTTTTAATTTATTTTTGA TTGCTTATCTTCATGTTTTT MPVSTGAETDITSSLPIPAS A mansoni ACTACTACTGTCTGAGTGCT GTGTTAATTGACTGCTCTCT SIVSPNYTLPDSSSTCLICF TCTTACAACCTGAAGGCTCA TCTGGGTTGATGTCTGATTG AIFPTHNILLSHATAIHHIS GAAACTACCCACTTTTTGCT TCTCTCTCTCTTTCCATATT CPPTPVQDGSQQMSCVLCAA GTTTATCCACAACAACAGTT GCTTGCTCTCCCCGCTTACT AFSSNRGLTQHIRHRHISEY GTGAATCTATTCTCCAAATA TCCAATAGTTGTCATATTAT NELIRQRIAVQPTSRIWSPF TTCCTTGTGCTTTTGTCAAC GTCTTTGTTTACTTGCCATG DDASLLSIANHEAHRFPTKN ATTATTCTATACCAACTGTA TCTAACGACAATTACTTTAT DLYQHISTVLTRRTAEAVKR CCACCTACTTCTTCATCTCA CTACCTTAGTTGGTCCTCTT RLLHLQWSRSPTAITTSSNN CGTTTTAATTCTGGTCTAAT GGTTTGGTTGCCTTCATGTG HTTTDIPNTEARYIFPVDLD TTTCTCATCATTAGTCACGG TTCATGGCGGAATCTGATGT EHPPLSDATTPDASTHPLPE AGAGGGCCTATGAACGGTCC TTATAATGACTATTCCTACT LLVILTPLPSPTRLQNISES GTGACGCGAAATTCAATCCA ACCACCATTACAACTATTAT QTSHESNRNSMHTPPTYACD CGAATTCGTCCTCTTCTGCT TATTATCACTATTATTAACA SDESLGVTPSSTIPSCFHSY AGTGGTCCCCGAAATACGGT TTATTATTACTTCTACAATT RDPLAEQRSKLLRASASLLQ TCCTCTGGCCTGTCAGTTGT AGTATTATGGCTACTCCTTT SSCTRIRSSSLLAFLQNAST GTTAAAACTATATAATAACG CAGCACACCAATAAAATCTC LMDEEHVSTFLNSHGEFVFP (SEQ ID NO: 1236) AATCAAACATCTCACTTATT RTWTPSRPKHPSHAPANVSR AAACTCTCTATTTCCCCTTC KKRRKIEYAHIQTLFHHRPK GTTATAAACTTACAATTCAG DAANTVLDGRWRNPYVANHS TTTAACCGAATATCTCTCTT MIPDFDCFWTTVFTKTNSPD TTACAAATCTTAAGTATGTA SREITPIIPMTPSLIDPILP ATTTTGTGCCAAGCCCATTT SDVTWALKEMHGTAGGIDRL GGGTCTGTACAATTTGATAC TSYDLMRFGKNGLAGYLNML TTAAAAATAAATGTTAT LALAYLPTNLSTARVTFVPK (SEQ ID NO: 1359) SSSPVSPEDFRPISVAPVAT RCLHKILAKRWMPLFPQERL QFAFLNRDGCFEAVNLLHSV IRHVHTRHAGASFALLDISR AFDTVSHDSIIRAAKRYGAP ELLCRYLNNYYRRSTSCVNR TELHPTCGVKQGDPLSPLLF IMVLDELLEGLDPMTHLTVD GESLNYIAYADDLVVFAPNA ELLQRKLDRISLLLHEAGWS INPEKSRTLDLISGGHSKIT ALSQTEFTIAGMRIPPLSAA DTFDYLGIKSNFKGRCPVAH IDLLNNYLTEISCAPLKPQQ RMKILKDNLLPRLLYPLTLG IVHLKTLKSMDRNIHTAIRK WLRLPSDTPLAYFHSPVAAG GLGILHLSSSVPFHRRKRLE TLLSSPNRLLHKLPTSPTLA SYSHLSQLPVRIGHETVTSR EEASNSWVRRLHSSCDGKGL LLAPLSTESHAWLRYPQSIF PSVYINAVKLRGGLLSTKVR RSRGGRVTNGLNCRGGCAHH ETIHHILQHCALTHDIRCKR HNELCNLVAKKLRRQKIHFL QEPCIPLEKTYCKPDFIIIR DSIAYVLDVTVSDDGNTHAS RLLKISKYGNERTVASIKRF LTSSGYIITSVRQTPVLTFR GILERASSQSLRRLCFSSRD LGDLCLSAIQGSIKIYNTYM RGTQRLNE (SEQ ID NO: 1481) R2 R2Tc EU854 Triops TTTTTGGTCTGGCATTTGAT TAGATGACTGCCCTACCCCT MSQKRRPEKAVPDEGATAHD 578 cancriformis CGTTTCCGCCTCCTCGTGGC TTGCTGCCGAAGAACTACTG VAQPDKSKCSVCGETFKGPA GCCAGACTGGGTAAGCTGAT AAGACTATTGAACTAACCAA SVTMHMVKKHPVEFNELKMA TTATCAGTGAGCTAAGAGAA CTGTGTTAAGTAAGAACTAA KKPVPKKVRWSEEEIFQLAR ACGATCACCGCAGGAGTCCA TGCCTCTTTTTCCCTGCATG TEAELTLQGVRFINVELQKI TCTACCTGCGCTGCACGTGA TATCCCCTGATCAGTGACTT FPAREIEGIKGQRKLAKYKE TTTCATTGTGCACTTGGCGA ATTTTCTTTTCCTGTTGCGC LVKDQLDEIGRAPNPPEQEI GTTATCCCTTGTGGAGCTCG CCTTTGTTTAGTTATTTCCT GEDVPSPFKAWLELLLALPK CTCGTTAGCTTTTGAG TTAATTACTAGAATTATCTT TPNDFLEHKLDNIIVQALKE (SEQ ID NO: 1237) TTCGTTCTCCGTCTAATTGC DVNSDQVFNDLNSYLKLILE TTT PSGRAKSVPGEIIHGDPSGS TTCGGTGTAGGAACGGCTAC AKTSVTKAPKPATVSSSRKK CTAAAGCTGGAAGTGGGAAG RRDAEFARIQRLYRKNRTSC TGTTTTCAATGTACTTTGTG INTILDGNTREHEAPKNMEG ATTATAGAAATATATGACCC FWREIFERESPDDPDDPDIF GAGGTGCATTGTTTGGCATT LEEEASDIWKYISFYEMCNL TCCTCGAGAAA YPPPSTAPGPDGFSSKDLRR (SEQ ID NO: 1360) MTPRVLNKILNLLLHLRDLP QILKSHRTVLIPKTDLPTKP GDFRPITISNILVRHLNKIL ANRVSHLIPINERQKAFLPI DGCAENIFTLDFILHHARTK IKSLSMAILDISKAFDSVSH HSIFRALREARCPIGFIKFI ENCYGGCFTKLFCGGVKYPS EVSMNRGVKQGDPLSPVLFN LVIDGLIRQIPSALGFNVSD QVKVSCIAYADDLILIATTR AGLKTLLDLTNSYLAKRGLS LNPDKCSALSIVASGKQKLV YIASSEHFDLAGQKMRNLNV GDSWRYLGIQFSHLGRAEKV TPDLTCLINRLQKAPLKLQQ KLYALRIYLIPRLIHGLTLS KTNLGELKTLDKLIRKYIRA WLHLPDDTPMGYFYTPLKAG GLGLPSLRLVILNNRLERIL RMKASQDIIVRTIAESETLG VEIRKLHDLLSIDGTILDTS VKIHSFWAERLYSSYDGKCL CNSANFPPGNKWIGEDSLNQ RSHIFADCLKLRINALPTRS RTARGRPLKDKPCRAGCRNS DGVKVIETLNHITQVCERTH GARVKRHDRLVDFAVKGLQR PHRVVLKEPHYKTVNGVRKP DIVIKIPDHTYICDFQVVSD TSCLELEFRKKALKYAEDKG LCDQLTRDHPGELSFTAITF NTRGLIAKSSVTALRKLGMP PRSIMTLQKICMEGSLEIWR IFNQTTAMARN (SEQ ID NO: 1482) R2 R2_DA . Drosophila AGAATATGGATTTGATTGTG TAGCCAATGCACGGGTTCCA FERRKDPWGYRPPGTLKQIG n ananassae CAGAGGGGGTGCTATACCGT GATTAAGCTTGCTGCCGAAG ATENNEPRNLNRFVRGESTA AACTCGTAAGCCATGCAATC CATACCATCAAAATCGGCAT SSLESTQFGTSAEVNLAGRV AGATCAAGTCGACTCAAAAC AAAATTCGCTTAATAAAGGA PCTICEMTFSSKRGLGVHMS CTCCTCGTGGTATTCTCTGG GGTGGTTTTAGTACGTAGGC HRHKDDLDAQRLRVDKKARW GTGCCAGTATTTACTGGTAG GTCCCGGGACTTGTCTCGGG SEEETLMMARKEVELAASGV CTGA ATGAATCGTGCATGCGTATA RFLNKKLAEIFTHRSADAIS (SEQ ID NO: 1238) ATTGGGATCGATAACAAATA SYRKRSEYKAKLEQIRGQSV CCAACTAAGTTATTACTAAT PTPEAEEINTTQRRPSNSEQ ATATCGAAATACATAAATAT NRRVPRSEGGPIAPTEQTNN CCCGTCCTTACGTATCTTTG EILRVLQGLAPVVCLPRWRA AAGATTTCCATCCTCAGCGA EVLQNIVDNAQVSGQETTLQ ACAAAAAAAAAAAAAA SLSSYLMEIFPPRNEPHILT (SEQ ID NO: 1361) RPRTEPRNMRQRRRQQYARV QRNWDKHPGRCIKSLLEEDD ESVMPNQEVMEPYWRRVMTQ PSSSSIKRDMFNMEHSLERV WSAVNQRDLRATKVKLSSSP GPDGITPKTARSVPEGIMLR IMNLILWCGNLPYSIRLART IFIPKKATANQPQDYRPISV PSVIVRQLNAILASRLSAAI NWDTRQRGFLPTDGCADNTT IVDLVLREHHKRFKSCYIGT LDVSKAFDAVAHEAVYNTLA SYGAPKGFINYLRKAYEGGG TMLAGNGWVSEAFIPARGVK QGDPLSPILFNLVIDRLLRS LPSEIGAKVGNAMTNAAAFA DDIVLFAETPMGLQKLLDTT VCFLSSVGLTLNTDKCFTVS IKGQAKQKCTVVERRSFLIG GRECPSLKRTDEWKYLGIKF TAEGRARYDPAEDLGPKLLR LTRAPLKPQQKLFALRTVLI PQLYHKLTLGSVTIGVLKKF DKLVRYTARKWLGLPVDVPV SFFHAPHKSGGLGLPSLRWT APMLRLKRLSNIKWPHLERS EVASSFVEEEMRRARDRLQA GSEELLTRSQVDSYLANRLH MSVDGCGLREAERFAPQHGW VSQPTRLLTGKEYTDGIKLR INALPSRSRTTRGRHELERR CRAGCDAPETTNHILQQCYR THGRRIARHNGVVNFLKRGL ERRGCVVHVEPSLQGETGLN KPDLVAIRQNRIYVIDTQIV TDGHSLDQAHQRKVGKYDTP DIRTNLRRSFGAFDIEFHSA TVNWRGIWSGQSVKRLIASD LLSSGDSNIISVRVISGGLW SWRQFMYLSGYTRDWT (SEQ ID NO: 1483) R2 R2_DM X5196 Drosophila TTGGGGATCATGGGGTATTT TAGCTAAATCGTTTGGTTCA MTTRPSVDIFPEDQYEPNAA 7 melano GAGAGCAGAGGGGGAGTATT AAACATTTGCTTGCTGTCTT ATLSRVPCTVCGRSFNSKRG gaster CTTCTGTAATTCGTAAGTCA GGCATAACATCAATAAAGGC LGVHMRSRHPDELDEERRRV TATCATATGATGTGCGGAAG ATAAACATCGCAAAATAATG DIKARWSDEEKWMMARKEVE GGGAATTTTACTCTGTAACT GTTATAATTAAATGGCTATG LTANGCKHINKQLAVYFANR CACAAGTCTCTCCTTTACTC AGGATGGTTTTAGTACGTAG SVEAIKKLRQRGDYKEKIEQ AAGTCGACTCAAAACCTCCT GCGTTGCGGAACTTCGGTTC IRGQSALAPEVANLTIRRRP CGTGGTGGTCCCGGTAATGC ATATAGAGCAATGAATCGTG SRSEQDHQVTTSETTPITPF TAAACTCGTTTAGCAGCTAA CATGCTAGGAAAACTGACCA EQSNREILRTLRGYSPVECH TTTGAGCGGAAAAACTTTTC CACACAGTGTTGGCAGACCT SKWRAQELQTIIDRAHLEGK CGATGGGCTGGTTCCCCAGA AGTATCTTTCGAAGATTTCC ETTLQCLSLYLLGIFPAQGV GGAAATTTATTCATATTGGA ATACCTCCGCGATCAAAAAA RHTLTRPPRRPRNRRESRRQ ACTACAAGCACAAATAACGA AAAAAAAAAAAAAAAA QYAVVQRNWDKHKGRCIKSL GCCTCGGATACCTTTACACA (SEQ ID NO: 1362) LNGTDESVMPSQEIMVPYWR ATCTG EVMTQPSPSSCSGEVIQMDH (SEQ ID NO: 1239) SLERVWSAITEQDLRASRVS LSSSPGPDGITPKSAREVPS GIMLRIMNLILWCGNLPHSI RLARTVFIPKTVTAKRPQDF RPISVPSVLVRQLNAILATR LNSSINWDPRQRGFLPTDGC ADNATIVDLVLRHSHKHFRS CYIANLDVSKAFDSLSHASI YDTLRAYGAPKGFVDYVQNT YEGGGTSLNGDGWSSEEFVP ARGVKQGDPLSPILFNLVMD RLLRTLPSEIGAKVGNAITN AAAFADDLVLFAETRMGLQV LLDKTLDFLSIVGLKLNADK CFTVGIKGQPKQKCTVLEAQ SFYVGSSEIPSLKRTDEWKY LGINFTATGRVRCNPAEDIG PKLQRLTKAPLKPQQRLFAL RTVLIPQLYHKLALGSVAIG VLRKTDKLIRYYVRRWLNLP LDVPIAFVHAPPKSGGLGIP SLRWVAPMLRLRRLSNIKWP HLTQNEVASSFLEAEKQRAR DRLLAEQNELLSRPAIEKYW ANKLYLSVDGSGLREGGHYG PQHGWVSQPTRLLTGKEYMD GIRLRINALPTKSRTTRGRH ELERQCRAGCDAPETTNHIM QKCYRSHGRRVARHNCVVNR IKRGLEERGCVVIVEPSLQC ESGLNKPDLVALRQNHIDVI DTQIVTDGHSMDDAHQRKIN RYDRPDIRTELRRRFEAAGD IEFHSATLNWRGIWSGQSVK RLIAKGLLSKYDSHIISVQV MRGSLGCFKQFMYLSGFSRD WT (SEQ ID NO: 1484) R2 R2_ DP . Drosophila AAGATATGGATCTGAATAAT TAGCCTATACACTATGTTGG SSFGLIVTNLNSETVLWGCQ e persimilis AGCGTAGAAGGGGAGTCATT AGAGAAGACGCTTGCTACCT PLGQFSLIGTNMQNTTPRII CCGTAATTCGTAAATCGTAA AGGCAAAATGTGAAATTAGG NTNSLTNQIPTVSSLGAQSE AAATCAGATCAAGTTGATTC TATAAACATCGTGGTTGTAA HSAQVNPNSGYQCTICESSF AAGACCTCCTCGTGGTATCT AACTTGAGGTGGGTTTTTAG RSKSGLGVHMSRRHKDEFDQ TCTGGATGCTATTAGACTGA TACGTATGCGTGATTACTTC LRLRTDRKAQWSEEELSMMA (SEQ ID NO: 1240) GTAATCATGAATCGTGCATG RKEIELAANGERYLNKKLAE CTAGTGGGGTTTGGCCTCCA VFTNRSVDAIKKCRORERYK CTAGTATCTTTGAAGATTTT TKIEQLKGQAVPLPEALESE CCTTCCTCAGCGATCAAAAA TIQRRPSIRERDLLVTPPNT AAA LGTTPTELSNSEILAVLQGY (SEQ ID NO: 1363) PPVVCNDQWRVEVLQSIVDG AQASGKEITLQRLSTYLMEV FPSQNDRPIQTRPPRRPRNR RQGRRQQYALTQRNWDKHKG RCIKAILDGTEGTATMPSQG IMGSYWRQVMTQTSPTYSGT NTTFRTEHPLEGVWSPITLG DLRVHRVSLTKSPGPDGITP RTVRSIPSGVMLRIMNLILW CGKLPVSIRQARTIFIPKVG NASRPQDFRPITVQSVMVRI LNAILASRLTSSVDWDPRQR GFLPTDGCADNTTIVDLILR DHHKRCKSLYIATLDISKAF DSVSHAAVSATLTAYGAPKE FVDYVQNSYEVCGTTLNGDG WRSEEFIPARGVRQGDPLSP IIFNLIIDQLLRSYPNEIGA TIGDHTTNAAAFADDIVLFA ETRLGLQTMLDTTVDFLSSV GLTLNSDKCFTVGIKGQPKQ KCTVVIPETFRIGSRSCPAL KRTDEWKYLGITFTAQGRTR YSPADDLGPKLLRLTRSPLK PQQKLFALRTVLIPQLYHKL TLGSVMIGVLRKCDILVRST VRKWLGLPLDVSTAFFHAPH TYGGLGIPSVRWVAPMLRMK RLSNIKWAHLAQSEAASSFL TDELNKARGRTLAGLNELTS RTEIETYWANRLYMSVDGRG LREAGLFRPQHGWVCQPTRL LTGQDYRNSIKLRINALPSR SRTTRGRNELERQCRAGCDA PETTNH ILQNCYRTHGRRVARHNCVV NNLKRILEEKGHTVHVEPSL QLETSVSKPDLVCIRDNHAC VIDAQIITDGLFLDDVHHRK VEKYKRPEVISALRREFGVS GNVEVLSATLNWRGIWSNQS VRRLIAKGLISSGDSNVISA RVVTGGLYCFRQFMYLAGYT RDWT (SEQ ID NO: 1485) R2 R2_DP . Drosophila CAATTGGAAAGATATGGGTC TAGCCTATACACTATGTTGG SSFGLIVTNLNSETVLWGCQ s pseudoobscura TGAATAATAGCGTAGAAGGG AGAGAAGACGCTTGCTACCT PLGQFSLIGTNMQNTTPRII GAGTCATTCCGTAATTCGTA AGGCATAATGTGAAATTAGG NTNSLTNQIPTVSSLGAQSE AATCGTAAAAATCAGATCAA TATAAACATCGTGGTTGTAA HSAQVNPNSGYQCTICESSF GTTGATTCAAGACCTCCTCG AACTTGAGGTGGGTTTTTAG RSKSGLGVHMSRRHKDEFDQ TGGTATCTTCTGGATGCTAT TACGTATGCGTGATTACTTC LRLRTDRKAQWSEEELSMMA TAGACTGA GTAATCATGAATCGTGCATG RKEIELAANGERYLNKKLAE (SEQ ID NO: 1241) CTAGTGGGGTTTGGCCTCCA VFTNRSVDAIKKCRORERYK CTAGTATCTTTGAAGATTTT TKIEQLKGQAVPLPEALESE CCTTCCTCAGCGATCAAAAA TIQRRPSIRERDLLVTPPNT AAAAAAAAAAAAAAAAAAA LGTTPTELSNREILAVLQGY (SEQ ID NO: 1364) PPVVCNDQWRVEVLQSIVDG AQASGKEITLQRLSTYLMEV FPSQNDRPIQTRPPRRPRNR RQGRRQQYALTQRNWDKHKG RCIKAILDGTEGTATMPSQG IMGSYWRQVMTQTSPTYSGT NTTFRTEHPLEGVWSPITLG DLRVHRVSLTKSPGPDGITP RTVRSIPSGVMLRIMNLILW CGKLPVSIRQARTIFIPKVG NASRPQDFRPITVQSVMVRI LNAILASRLTSSVDWDPRQR GFLPTDGCADNTTIVDLILR DHHKRCKSLYIATLDISKAF DSVSHAAVSATLTAYGAPKE FVDYVQNSYEVCGTTLNGDG WRSEEFIPARGVRQGDPLSP IIFNLIIDQLLRSYPNEIGA TIGDHTTNAAAFADDIVLFA ETRLGLQTMLDTTVDFLSSV GLTLNSDKCFTVGIKGQPKQ KCTVVIPETFRIGSRSCPAL KRTDEWKYLGITFTAQGRTR YSPADDLGPKLLRLTRSPLK PQQKLFALRTVLIPQLYHKL TLGSVMIGVLRKCDILVRST VRKWLGLPLDVSTAFFHAPH IYGGLGIPSVRWVAPMLRMK RLSNIKWAHLAQSEAASSFL TDELNKARGRTLAGLNELTS RSEIETYWANRLYMSVDGRG LREAGLFRPQHGWVCQPTRL LTGQDYRNGIKLRINALPSR SRTTRGRNELERQCRAGCDA PETTNHILQNCYRTHGRRVA RHNCVVNNLKRILEEKGHTV HVEPSLQLETSVSKPDLVCI RDNHACVIDAQIITDGLFLD DVHHRKVEKYKRPEVISALR REFGVSGNVEVLSATLNWRG IWSNQSVRRLIAKGLISSGD SNVISARVVTGGLYCFRQFM YLAGYTRDWT (SEQ ID NO: 1486) R2 R2_DS . Drosophila GGGATCAGGGGTAATTGCGA TAGCTAAAACGTTTGGTTCA FERQNFSDGLVPQRKFIHIG e sechellia GCAGAGGGGGAGTATTTTTC AAACATTTGCTTGCTGTCTT TTNRNNEPRSNLRNLMTTRP TGTAATTCGTAAGTCATATC GGCATAACATCAATAAAGGC SVDIFPEDQYEPNAAATLSR ATATGGTGTGCGGAAGGGGA ATAAACATCGCAAATAATGG VPCTVCGRSFNSKRGLGVHM ATTTTACTCTGTAACTCACA TAATATATAAATTGGCTATG RSRHPDELDEERRRVDIKAR AGTCTCTCCTTTACTCAAGT AGGATGGTTTTAGTACGTAG WSEEEKWMMARKEVELTANG CGACTCAAAACCTCCTCGTG GCGTTGCGGAACTTCGGTTC HKHINKQLAVYFANRSVEAI GTGGTCCCCGGTAATGCTAA AGATAGAGCAATGAATCGTG KKLRQRGDYKEKIEQIRRQS ACTTGTTTAGCAGCTAA CATGCTAGGAAACTGAAGTG ALVPEVANLTIRRRPSRSEQ (SEQ ID NO: 1242) TTGACAGACCTAGT NHQVTTSETTPITPFEQSNR ATCTTTCGATAGATTTCCAT EILRTLRGYSPVECHSKWRA ACCTCCGCGATCAAAAAAAA QELQTIIDRAELEGKETTLQ AAAAAAAAAAAAA CLSLYLLGIFPAQGVRHTLT (SEQ ID NO: 1365) RPPRRPRNRRESRRQQYAVV QRNWDKHKGRCIKSLLNGTD ESVMPSQEVMVPYWREVMTQ PSPSSCSREVIQMDHSLERV WSAITEHDLRASRISLSSSP GPDGITPKTAREVPSGIMLR IMNLILWCGNLPHSIRLART VFIPKTVTAKRPQDFRPISV PSVLVRQLNAILATRLNSSI NWDPRQRGFLPTDGCADNAT IVDLVLRHSHKHFRSCYIAN LDVSKAFDSLSHASIYDTLR AYGAPKGFVDYVQNTYEGGG TSL NGDGWSSEEFVPARGVKQGD PLSPILFNLVMDRLLRNLPS EIGARVGNAITNAAAFADDL VLFAETRMGLQVLLDRTLDF LSLVGLKLNADKCFTVGIKG QPKQKCTVLEAQSFYVGSRE IPSLKRTDEWKYLGINFTAT GRVRCNPAEDIGPKLQRLTK APLKPQQRMFALRTVLIPQL YHKLALGSVAIGILRKTDKL IRYYVRRWLNLPLDIPIAFI HAPPKSGGLGIPSLRWVAPM LRLRRLSNIKWPHLTQNEVA SSFLEAEKQRARDRLLAEQN ELLSRPAIEKYWANKLYLSV DGSGLREAGHWGPQHGWVNQ PTRLLTGKEYIDGIRLRINA LPTKSRTTRGRHELERQCRA GCDAPETTNHIMQKCYRSHG RRIARHNCVVNRIKRGLEER GCVVIVEPSLQCESGLNKPD LVALRQNHIDVIDIQIVTDG HSMDDAHQRKINRYDRPDIR TELRRRFEAAGDIEFHSATL NWRGIWSGQSVKRLIAKGLL SKYDSHIISVQVMRGSLGCF KQFMYLSGFSRDWT (SEQ ID NO: 1487) R2 R2_ . Drosophila GGGATCTGGGGTAATTGCGA TAGCTAAAACGTTTGGTTCA TCLAANLSGKNFSDGLVTQR DSi simulans GCAGAGGGGGAGTATTTTTC AAACATTTGCTTGCTGTCTT KFTHIGTTNTNNEPRISLHN TGTAATTCGTAAGTCATATC GGCATAACATCAATAAAGGC LMTTRPSVDIFPEDQYEPNA ATATGGTGTGCGGAAGGGGA ATAAACATCGCAAAATAATG AATLSRVPCTVCGRSFNSKR ATTTTACTCTGTAACTCACA GTTATATATAAATGGCTATG GLGVHMRSRHPDELDEERRR AGTCTCTCCTTTACTCAAGT AGGATGGTTTTAGTACGTAG VDIKARWSEEEKWMMARKEV CGACTCAAAACCTCCTCGTG GCGTTGCGGAACTTCGGTTC ELTANGHKHMNKQLAVYFAN GTGGTCCCCGGTAATGCTAA AGATAGAGCAATGAATCGTG RSVEAIKKLRQRGDYKEKIE (SEQ ID NO: 1243) CATGCTAGGAAAACTGACCA QIRGQSALVPEVANLTIRRR CACGCAGTGTTGGCAGCCCT PSRSEQNHQVTTSETTPITP AGTATCTTTCGATAGATTTC FEQSNREILRTLRGYSPVEC CATACCTCCGCGATCAAAAA HSKWRAQELQTIIDRAELEG AAAAAAAAAAAAAAAAAA KETTLQCLSLYLLGIFPAQG (SEQ ID NO: 1366) VRHTLTRPPRRPRNRRESRR QQYAVVQRNWDKHKGRCIKS LLNGTDESVMPSQEVMVPYW REVMTQPSPSSCSGEVIQMD HSLERVWSAITEHDLRASRI SLSSSPGPDGITPKSAREVP SGIMLRIMNLILWCGNLPHS IRLARTVFIPKTVTAKRPQD FRPISVPSVLVRQLNAILAT RLNSSINWDPRQRGFLPTDG CADNATIVDLVLRHSHKHFR SCYIANLDVSKAFDSLSHAS IYDTLRAYGAPKGFVDYVQN TYEGGGTSLNGDGWSSEEFV PARGVKQGDPLSPILFNLVM DRLLRNLPSEIGAKVGNAIT NAAAFADDLVLFAETRMGLQ VLLDKTLDFLSLVGLKLNAD KCFTVGIKGQPKQKCTVLEA QSFYVGSREIPSLKRTDEWK YLGINFTATGRVRCNPAEDI GPKLQRLTKAPLKPQQRMFA LRTVLIPQLYHKLALGSVAI GVLRKTDKLIRYYVRRWLNL PLDVPIAFIHAPPKSGGLGI PSLRWVAPMLRLRRLSNIKW PHLTQNEVASSFLEAEKQRA RDRLLAEQNELLSRPAIEKY WANKLYLSVDGSGLREAGHW GPQHGWVNQPTRLLTGKEYI DGIRLRINALPTKSRTTRGR HELERQCRAGCDAPETTNHI MQKCYRSHGRRVARHNCVVN RIKRGLEERGCVVIVEPSLQ CESGLNKPDLVALRQDHIDV IDIQIVTDGHSMDDAHQRKI NRYDRPDIRTELRRRFEAAG DIEFHSATLNWRGIWSGQSV KRLIAKGLLSKYDSHIISVQ VMRGSLGCFKQFMYLSGFSR DWT (SEQ ID NO: 1488) R2 R2_ . Drosophila CATAAGTCTTGCCTTTACTC TAGCTTAAAACGTTTGGTTC FERRIFPKGLVPLTKDNHIG DYa yakuba AAGTCGACTCAAAACCTCCT ACATACATCTGCCTGCTGCC TTNLQNEPRIFTNDLLTTRP CGTGGTGTTTCCCGGTAATG TTGGCACAATATCAAAAAGG SVDHVPEDQYEPNAAATLSR TTAAACTTGTTTAGCAGCTA CATAAACATCGCACATATTG VPCTVCDRSFNSKRGLGVHM A GTTATTTACGGCTATGAGGA RSRHPDELDEERRRVDIKAR (SEQ ID NO: 1244) TGGTTTTAGTACGTAGGCGT WSEEEKWMMARKEVELMANG TGCGGAACTTCGGTTCGGAT FKHINKQLAVYFANRSVEAI AGAGCAATGAATCGTGCATG KKLRQRGDYKEKIEQIRGQS CTAGGAACTGACCAAATAAC ALAPEVANLTIRRRPSRSEQ AGCAGCCCTAGTATCTTTCG DHQVPTSEASPITPLEQSNR AAGATTTCCATACCTTTGCG EILRTLRGYSPVVCPSKWRA ATCAAAAAAAAAAAAAAAAA QELQTIIDRAEFEGKETTLQ AA CLSLYLQGIFPVQGVRHTLT (SEQ ID NO: 1367) RPPRRPRNRRESRRQQYAVI QRNWDKHKGRCIKSLLNGTD ESVMPSREFMEPYWREVMTQ PSPSSCNGEVIRTDHSLETV WSAITEQDLRASRVSLSSSP GPDGVTPKTAREVPSGIMLR IMNLILWCGNLPHSIRLART IFIPKTVTAKRPQDFRPISV PSVLVRQLNAILATRLTSSI DWDPRQRGFSPTDGCADNAT IVDLVLRHSHKYFKSCYIAN LDVSKAFDSLSHAAIYGTLR AYGAPKGFVDYVQKTYEGGG ISLNGEGWCSEEFVPARGVK QGDPLSPILFNLVIDRLLRA LPSEIGTKVGNAMINAAAFA DDLVLFAETRMGLQTLLDKT VDFLSTVGLKLNADKCFTVG IKGQPKQKCTVLEAQSFCVG SREIPTLKRTDEWKYLGIHF TASGRVRCNPAEDIGPKLQR LSEAPLKPQQRLFALRTVLI PQLYHKLSLGSVTIGVLRKT DKLIRFYVRRWLNLPSDVPI AFVHAPPKCGGLGIPSLRWV APMLRLRRLSNIKWPHLVQS EEASSFIEAEKQRARGRLIA EQNELLSRPAIEKYWANRLY LSVDGGGLREAGHYGPQHGW VSQPTRLLTGKEYLDGIRLR INALPTKSRTTRGRHELERQ CRAGCDAPETTNHIMQKCYR SHGRRVARHNCVVNRIKRGL EERGCVVIAEPSLQCESGLN KPDLVVLRQNHIDVIDVQVV TDGHSMDEAHQRKINRYDRP DIRTELRRRFEAAGDIEFHS ATLNWRGIWSGQSVKRLIAK GLLSKYDSHIISVQVMRGSL GCFRQFMYLSGFSRDWT (SEQ ID NO: 1489) R2 R2_KF GU949 Kalotermes GAGAGGTCACTGTTGCTGAT TAATGTCCCTTTTGGCTTGC MEVPLTSSLGSGATQAPGTP 558 flavicollis CAGCTGGACACCTAGCTGAC CCCCACCTGCTTAAAGGAAC ELLGEHTVERPGLDQGHSYG TGCGTGCATGCGTGCACGCC TGGCAGGAAAGAGAGTGATC LLMDDVELPVRLPFFGPLIC GCGCGCCGCCTCCTCGTGGT CGTGCCATAGAAATATGGTT PGCRTLLTSEETISSHHRRV ACCGCTGGTAACGCAGGGTC ATCCGGGGCAAGTCACTAGC HPDARTRWVCYGCDSPFMTY ACTGAGACTACCTGCGGCTA AATATGGGACTTCTCCGGGT RAIKCHLPKCSGRKVVTGDH AAGGCGCGCGCGAGGGATTG CCGTGCGGTCCTTCCAACAT ICNGCTKRFESQRGLSLHKR TAAGTCCACCACCTCCACGT GAGCTGGACGTAGTCCACTC RAHPGLRNEEMLEPPVRAER GGTTCCCCGCGGGCAACGGC TATGACTTGAACGATACGGG RPNAHKSSIWSIDEIRILEQ ATAGTTCATCTGCCGGCCAA GGCGTATCTCCCCCGGAAGA YEAAYVGDLHINMKIAAHLP GCGTGCCGTTCCCTCGATCC GGTCGCCTAGGCGACTTAGA FKTNKQVSNYRNDRRKKSRT TCCTCTGATTAGGGATAGGA A ATDASQQGLGPNDGNRGIVP GGGGGGCGGTGGCTCCCGCC (SEQ ID NO: 1368) SGQSSPLFLEGSDAEGDEDV GACGACCTGGCAAACACCTT FNVLVPPTLGGLEPAGQVHS GGACACGCTAAGATAATAGG LSEGETSPLVGEADPCFMGG CCGTCCTCCGGGCCGGCCGA TPSAGEASGSTLLGPDPTPA ATCATAAGCACACA DGYSLVRKDLQLSVQTSPLL (SEQ ID NO: 1245) AVGSVGTESVQFERGVLSCG TPPEFLHPEQFAHCANNDPV LNASEEQVHAPLGEEANDLP DNNHPSELGVDPEDPTCSPA TEQVQPSSEEEADDPFAQFK AWRRRVASYALKIETGVLPA QVDDLLRRLRDGDTQSKVTC EEVEEVVLSLTRTILGGTAP KKRVEGRTKWTYKSRTNHEA RKRIMYARCQDLYRRRPQRP VERAVGYQAEESLLDNQDER PSHGAFETFYTGLWGKSGQC NITMPPGVPRHTGHVLREVT PKDIYSRLRKLKKDYAPGPD GVTKLKVQSMGAYPSLLAKV YNLVMLTGYFSSCWKEHKTS LIPKDRGSPMDVSNWRPITI GSLLSRIYTGLIERRLRTVS DIHQRQVGFMPVNGCAANLF IFDECIRQAKKEGTIVGSLI DVAKAFDTVPHEAILRALSS QGVDEHTMAHIRDMYSGIRT RINGKGSDIPLVRGVKQGDP LSPMLFNMVMDPLIRDLQRK GFRIGGHEIGALAFADDIVL LADSIDGAQDHVDQVGRYMN KLGMTLNPRKSSSFLITAMR KTWICRDPGLSIGETKVPGA RPSSALKYLGVNYTLSEGLE SGALIDKLMQAVNRARGLAL KPLQKVNLILERIIPKFLYG IILGGPSLTRLHAADKCVRM AVKEILHLHPSTTDHVLYAR KKDGGMGIPRLAHLVRLASL RSGLALLASGDVAVQAAGMA GDLEGRCKKVANDLRLNWPV TLRDVVRASNKFKSQESKDW ERLASQGHGVKDFRNDRLGN CWLYDPTVLSSSRYTDALRL RTNTFGVNVALRRADKDLEV NCRRCHGKPETLGHVLGECV AGKGMRIQRHDKMAAFVATK CEEKGYQTTREQLFSIEQGK LKPDLVVIDGERALIVDVTV RFESGNALSRGASEKIEKYQ PLADYFVSQGAVREANVLPI VVGSRGAITQATLKSLATLG LDVERVGKYLAICAVASSVE IACMHLDYT (SEQ ID NO: 1490) R2 R2_RL GU949 Reticulitermes CTCACTGCTGTCATGCCATT TGAGTTAGATATATATGACG MMADYNNSVDHALEDNTRLI 555 lucifugus GTTAATGCGTTGGGTGATGG ACTGATTCTTCCCTAACTAA FARDAVLARVCGPFDNLECG CGGGTGATGGGAGACGAGTT AATATAATTTGGAATGTGCA LCGVLLTSLQGVREHCHRAH ACAGCAGAGCTGGCTTCACG TTACTTATACTTTATTGTAT HNLDLTFQCTKCDKGFSSYR GGGGGGGCTGTAGTTGCCCG TTATTGACATCCGTAGTAGT GICCHFSKCIGARISVSEGP AACCAGTCTGCTTCTGAGTG CTGTTTAGTGGATTTAGATC LSCSECEREFDSKRALSTHE CCTCCACGTGGCCTCGCTGG GTTAACCATTCTGTGACGTC RHMHPGIRNAKRLKDFNPRG AAACGTCGGAGCTGCTTACG GCTGATGTCTATATGTACCA GGGKTIHGNTKWTEEEVQLL GCTAACCCGTAGACAACTCC GTGGCAGAATGCTGACTAAG VSLSKRFEGYKSINKEISLI GGCGGCCAAACTCAGAAAAC AACAAAATAATTTTAAACAA LTSKTCKQISDKRRYLNLHN GGCCTTACTACCAGGGTCAT TAGACAGCACTAAGAAATTC GNGGLAAAEAVLEFCEDSHP CCCTCGCGGCGGCGCTAAGA TGCAAACTGGAACGTGGCCC EVTESDGAVLSEIMDEECHQ CCTTACTGTATGTACTACGG ACGGTAGGCCAATATACCGG SSVTMRSSIVHGDIGREVQG ACTACAGTTGAGTAGCGCGG AAAGGGAAAATGACACATCC KELVRIPPDNSVMGNCVVLL GAGAGCACTTGATGTGAGGG CCCCTTAAA RKLATDKRSDLDLSKDKELR TAGCAACTTGTTGCTACTTC (SEQ ID NO: 1369) IDIEKATKANRESADGRVIQ GACTGTCTCCCTGAAGATTT SVAGNEIDPDTFQWKELLLG CCGAAGGGGTGCCGCAAGTC QVRGFPRVDENSELFDLDDK CATGGGGGCGGTCCTGCTGT LTKELSSDSPVWNDNCELIV GGGAGTTATCTTGCACCCGG SDLCQVLCKKKYELGRQHHV GAAGCCCTCAGTGGATAAAT RKGKRHRGIHHKREKFRECQ ACTCCAAAATGGCTTAGCCA KIFRKSPRKLAEYLYRDKDL CCTCACGTGGAGAGAGGGGA SHISKDASTPQGIEQYYSQL ATTAGGGGTTTACTCCTAAG WGEPELLESNTIEEKLPSSS GGCCGATGCCTCCAATCGGA LFDCLPPITPEEVEGRIHKI TTTCCCCGGGCAACGGCTAT RPSSAPGLDGVRKIHLVGKG TATCAGCCGGCTAAGTTCGG ITLVLVKLYNLLFLTGGYPE ACCCTCATCTACTGATGGGA CWKRNRTVFIPKIGKDLSEV TACTCTCTCTCCCCCCGCCT GGWRPLTIGSLLARMYSAFL GCGTGATTAGTTGGGAATGC ERRIRRVTSLSLSQRGFTNI ACGCGGGCGGGTGATTCTGA QGCHVNLTILKEGIRQAKVK CAAGCCCAGCCCAAAAGTTC NGGVIVSVDIEKAFDTIPHS TTACCACGACGTACCCGGGG VIFSRLASQGVPPLLRKIIS GTGTCACCCGAACTAATATA NMYKDVYTVIEGQCIPIKRG TTTTCCGCCGATCGGTTCGC VKQGDPLSPLLFNIAIDPVL TGTGGGGGGATGTCGGGGCC RSLEEFQGGLPLGNSAIKIL TGGTGGCCGGGAACCGTCAG AFADDIILGASSAGQAQQMV CCGCTCTTTGAGTGTCCTGC DMLGIGLTSCGLGVSHRKCF GTAACCCGGAGGCGGTGACG GFQIVNKNKTWTIVDPMITL TCGAAGGGCTAGGCTAGCAC NGSSLPFSGPEDRLPYLGVD GGTCCAGACCCCTGAACGCC INPWDRKSRYDAGQRLISAA TGGGGAGACGGGCCCACCAC KRGSQLSLKPQQKINLITAF CTGAGTAGGAGTGGGTCCTT LLPKFLYILIEDPPSPAYLK TACCTCATTTGAGGTGTCTC SIDHDLRQIYKNILHLPNCV CTCGTTCTTGTAGGGGGCGA STAFMYSPKRDGGLGLPRLS AGGACGAGGAATGCATCCGT CLVPLAHLKAGIKLGSLQDS CCCTCCAGGATGCTGGTGGT LVREITTSDRFVRTMGSVAH TTCCGTCTGGTGGGCTCATG SLWASWSLTLQDIYKLKSAL CTGAAACGCGCAGGTGCCGA KRREAKAWESCVSQGQGAAQ TTTGTCGAAGAGGACATATG FRGDSIGNNWLHNPGTYRPG GGGTAACCCATAGAACCTAG QYIEALKLRANLTGVRVNLK GCAGGAGTAATCCCTTAGCT RSGYNVPITCRFCKDIPETQ GGGGGGGTCAGCTGGTGGGT AHVLGLCPKTKGMRIQRHDS CCTGTCAATTTATCCTCCCC IVNRVRDKLKTKSPVALMHE TCCATGCCAGAGCCGGTCCG QNFTVEEGQVFKPDIVTILG AGGTTAGAGACGGACTCATT EVGYVIDVTVRYDDRDYIKD TTCTCCTTTTTATATGTC ASVEKIRKYEALKGYLKDLY (SEQ ID NO: 1246) PQLNKVEVLPLVFGSRGAVP GSTVHNMGLLGFTKREMVHI SRKVIADSLIISNFLEVY (SEQ ID NO: 1491) R2 R2_RU GU949 Reticulitermes CACACTGCTGTCATGCCATT TGAGTTAGATATATATAACG MMADYNNSVDHALEDDTRFI 554 urbis GTTAATTCGTTGGGTGATGG ACTGATTCTTCCCTAACTAA FARDSVLARVCGHFDNLKCE CGGGTGATGGGAGACGAGTT AATATAATTTGGAATGTGCA LCGVLLTSLQGVREHCHRSH ACAGCAGAGCTGGCTTCACG TTACTTATACTTTATTGTAT HNLDLTFQCTKCDKGFSSYR GGGGGGCTGTAGTGGCCCGA TTATTGACATCCGTAGTAGT GICCHFSKCRGARISVSEGP ACCAGTCTGCTTCTGAGTGC CTGTTTAGTGGATTTAGATC LSCSECERKFDSKRALSTHE CCCCAAGTGGCCTCGCTGGA GTTAACCATTCTGTGACGTC RHMHPGIRNAKRLKDFNPRG AACGTCGGAGCTGCTTACGG GCTGATGTCTACATGTACCA GGKTIHGNTKWTEEEVQLLV TTAACCCGTAGACAACTCCG GTGGCAGAATGCTGACTAAG SLSKRFEGYKSINKEISLIL GCGGCCAAACTCAGAAAACG AACAAAATAATTTTAAACAA TSKTCKQISDKRRYLNLHNG GCCTTACTACCAGGGCCATC TAGACAGCACTAAGAAATTC NGGLAAAEAVLVFCDDSHLE CCTTGCGGTTGCGCTAAGAC TGCAAACTGGAACGTGGCCC VTDSDGAVLSEIMDEEYYQS CTTACTGTATGTACTACGGA ACGGTAGGCCAATATACCGG SLTMRSSIVHGDIGREVQGK CTACAGTTGAGTAGCGCGGG AAAGGGAAAATGACAAATCC DLVRIPPDNSVMGNCVVLLR AGAGCACTCGATGTGAGGGT CCCCTTAAA KLATEKRSDLDLSKDKELRI AGCAACTTGTTGCTTCTTCG (SEQ ID NO: 1370) DIEKATKANRESADGRVIQS ACTGTCTCCCTGAAGAGTTC VADNEIDPDTFQWKELLLGQ CGAAGAGGTGCCGCAAGTCC VRGFPRVDENSELFDLDDKL ATGGGGGCGACCCGGCTGTG TSELSSDSPVWNDNCELIVS GGAGTTATCCTGCACCCGGG DLCHVLCKNKYELGRQHHVR AAGCCCTCAGTGGATAAATA KGKRHRGIHHKREKFRECQK CTCCAAAATGGCTTAGCCAC IFRKSPRKLAEYLYRDKDLS CTCACGTGGAGAGAGGGGAA HISKDVSTPQGIEQYYSQLW TTAGGGGTTTACTCCTAAGG GKPELLESNTTEEMLPSSSL GCCGATGCCTCCAATCGGAT FDCLPPITPEEVEGRIHKIR TTCCCAGGGCAACGGCTATT PSSAPGLDGVGKIHLVGKGI ATCAGCCGGCTAAGTTCGGA TLVLAKLYNLLFLTGGYPEC CCCTCATCTACCGATGGGAT WKRNRTVFIPKIGKDLSEVG ACTCTCTCTCCCCCCGCCTG GWRPLTIGSLLARMYSAFLE CGTGATTAATTGGGAATGCA RRIRRVTSLSSSQRGFTNIQ CGAGGGCGGGTGATTCTGAC GCHVNLTILKEGIRQAKVKN AAGCCCAGCCCAAAAGTTCT GGVIVSVDIEKAFDTIPHSV TACCACGACGTACCCGGGGG IFSRLASQGVPPLLRKIISN TGTCACCCGAACTAATATAT MYKDVYTVIEGQCIPIKRGV TTTCCACCGATCGGTTCGCT KQGDPLFPLLFNIAIDPVLR GTGGGGGGATGTCGGGGCCT SLEEFQGGLPLGNSAIKILA GGTGGCCAGGAACCGTCAGC FDDDIILGASSAGQAQQMVD CGCTCTTTGAGTGTCCTGCG MLGIGLTSCGLGVSHRKCFG TAACCCGGAGGCGGTGACGT FQIVNKNKTWAIVDPMITLN CGAAGGGCTAGGCTAGCACG GSSLPFSGPEDRLPYLGVDT GTCCAGACCCCTGAACGCCT NPWDRKSRYDAGQRLISAAK GGGGAGACGGGCCCACCACC RGSQLSLKPQQKINLITTFL TGTGTAGGAGTGGGTCCTTT LPKFLYILIEDPPSPAYLKS ACCTCATTTGAGGTGTCTCC IDHDLRQIYKNILHLPNCVS TCGGTCTAGTAGGGGGCGAA TAFMYSPKRDGGLGLPRLSC GGACGAGGGATGCATCCGTC LVPLAHIKAGIKLGSLQDSL CCTCCAGGATGCTGGTGGTT VREITTSDRFVRTMGSVSHS TCCGTCTGGTGGGCTCATGC IGASWPLTLQDIYKLKSALK TGAAACCCGCAGGTGCCGAT RREAKAWESCVSQGQGAAQF TTGTCGAAGAGGACATATGG RGDSIGNNWLHNPGTFRPGQ GGTAACCCATAGAACCTAGG YIEALKLRANSTGVRVNLKR CAGGAGTAATCCCTTAGCTG SGYNVPITCRFCKDIPETQA GGGGGGTCAGCTGGTGGGTC HVLGLCPKTKGMRILRHDSI CTGTCAATTTATCCTCCCCT VNRVRDKLKTKSPVALMHEQ CCATGCCAGAGCCGGTCCGA NFTVEEGQVFKPDIVTILGE GGTTAGAGACGGACTCATTT VGYVIDVTVRYEDRDYIKDA TCTCCTTTTTATATGTC SVEKIRKYEALKGYLKDLYP (SEQ ID NO: 1247) QLNKVEVLPLVFGSRGAVPG STVHNMGLLGFTKREMVHIS RKVITDSLIIISNFLEVY (SEQ ID NO: 1492) R2 RaR2 FJ461304 Rhynchosciara CAGAACGTGGAGAAACGGAA TAGAAATGTGTGCGATAAGG MSNYNETNTSGGDNPRMATQ americana TAACTACCCAGATCCGTTGG TGTGAATAGAAGGGTTCACC TTGSLSSGPINQHTCELCCR TTAACCGGTGGCAAAGTTAA AAGAGGGAGACCTAGTTTGG TFGTRAGLGQHVRKTHPIES TCAAGGTTGCCATAGGCTTA ACCTCAGAAATGGGGTCATA NQSINVERKKRRWSPEEIRR ATAACCCTATGGAAATGTTT GGAGTGATAGGTTGTAAAGC MANMEAQATINNIKHLTQYL CCACACACCTCCACGTGGTG CGTTGGGGAATCCGGCTACA ATYLPQRTLNAIKGRRRDAE CCTGCCGGAAATTGTTCTAG CATGGTATCTCAGGAGCCAT YKELVTGIIANLRSNSSTQQ GGTGAACAAGCTAAGTIGTG TCATGCGCTGATCTCATTAA TNQVCNESEMSQRSKILQSI AGAAACGGGCTCCACCACAA GGCGTAATAAACTGTGAAAC RESVRDLRSRRNKYAKALQE TATGGAGCCTGCCAGGGCGC AGATCCTGATAATGCCGTGC LGEAALCGKMLNEEQLIHCI GAGACTCAGGACTCTCCATG TACCAAATGATGTAACGAGG KSMFNTAKCPKGPRFRKTAT TACAAAGTGGTTAGTTGCAA CGGAAATAAAATTAATCTGG HSGTNKQQRQQRYARVQKLY AAAGAGTGCGCCTAGCATGA GGCGTTCTGCGGAATGACTA KMNRKVAAKMVLEETDKIQI CTGATAATTTTTCACTGAAA CTAAATATAGCGATGCTATA KLPDHDPMFKFWESEFKEGE TAACGTTGAACTTTATCTGT TATACAAACGACTGATGGTA GMPERMPKDLKESPDLKAIW GTCATGTGCACAACACTATG ACACCGGCCTTA DPVTEEEVRKAKVANNTAAG GTGTCTGATCAAGCACCATC (SEQ ID NO: 1371) PDGIQPKSWNRISLKYKTLI AGTGGTGGACCTGCTAATGT YNLLLYYEKVPHKLKVSRTV ATTAGTAGAACGTGTCCAGG FIPKKKDGSSDPGEFRPLTI CGATAATGCACACACGGCCT CSVVLRGFNKILVQRLVSLY CCGGGCCCATCGCTTTTTTT KYDERQTAYLPIDGVGTNIH GAGATTCCCTAGAAACTTCA VLAAILNDSNTKLSELHVAL GTGTGTGCGACAACTGTATA LDITKAFNRLHHTSIIKSLV ACCCATAAGGGATGGACAAA GKGFPYGFITFIRRMYTGLQ GGTTATACTAGGGGGTAAAA TMMQFEGHCKMTQVNRGVYQ ACCCTAATCGGCTAATGGCA GDPLSGPIFLLAIEKGLQAL AATGGGATGTAGAAATGCCA DKEVGYDIGDVRVNAGAYAD AAGATTACTCGCACCGAATA DTDLVAGTRLGLQDNINRFS ATGGTGGCCGAAAAGCGGGT STIKQVGLEVNPRKSMTLSL AATCGAATGAAATGGTAATG VPSGKEKKMKVETGKPFRAN CTGTAGCGGAAACATGATCA DVPLKELSINDFWRYLGISY CATTCTGTGACAGTAAACCA TNEGPERLSLTIEQDLERLT TTAGACCTAGGGGGAACTAT KAPLKPQQRIHMLNAYVIPK GATTAACAAGATACCAGCTT YQDKLVLSKTTAKGLKRTDR ACATGGAAGCAATGAAATGT QIRQYVRRWLKLPHDVPIAY AAGTCACAGTAGTGATAAGT LHAPVKSGGLNIPCLQYWIP GGTGAAGAGTCTTGTAATCA LLRVNRVNKITESQRSVLAA CCGTAACTAGGCCAGGTTCT VGKTALLTSTVYKCNQSLAT GGGGATGCCATGAACTTAGG LGGNPTMLAYRTYWEKELYA GGGAGTATGGTTAGCAGATC KVDGKDLQNARDDKASTRWN TACCAGCTAACACTATTACT GMLHSDISGEDYLNYHKLRT GATAATATGTAAGCCGCAGT NSVPTKVRTARGRPQKETSC AGCGCTAAGTGGTGTACAGA RGGCKSTETLQHVVQQCHRT TTTGCAACCACCGTAACTAA HGGRTLRHDRIVGLLQHELR GTTCTGTTTCGATGGACTAG RDYNVLAKQELKTGIGLRKP GGGGAATCATGATTAACAAG DLVLIKDDTAHIVDVQVARC ATACCAACTTACATGGAAGT SKLNESHVRKRSKYDKKEIE TATGAAATGTAAGTCACAGT VEVKSRYRVSKVMYEACTIS AGTGATAAGTGGTGAAGAGT YKGIWDKQSVMSMRRLGVSE CTTGTAATCACCGTAACTAG YCLFKIVTSTLRGTWLCWKR GCCAGATGTAGTCAAAGCAC FNMITSVRS ATGTTTAGGGGGAACAAGGT (SEQ ID NO: 1493) TAACATTGGTAAAAGACCAA TGCAACCTCCGTAACTAAAC GTGAAGGCACAAAACTAAAA GTCCAGTGGATGACAGGTGA GGTCATCACTGGACCCAAAT GTTTTAAGCTCATCATAACA ACACGGTGAAAAATCCAGCA TTTATTTGCCTGATTGAGTA GCTTCCACACTATTCCAAAG CCGAACCTATCTGGGTTTTT CTTGAAAGGCCGTATAGGGC ATATGTCGAGAAATAAGTCC AAGGTGAGGTAGTGTGGCCC TGTACCCAGGGGTAAGGTAC TATACGGTCGAGTGGCTCAG TAGGCCTAACTAGCCACTGA GTCACTATAATGACTAGTT (SEQ ID NO: 1248) R2 YURE- . Ciona CCAAAATTACTTCCAGCACC TAAGATCCGCGGCTGTGGCG MAGHKITMSEGKLLEVAVRY 2_Cis savignyi TCCACAGCAGACGAACGAAG CCGAACGAGCACCTGCCCAT GGVRNVSYECPVPDCTKTFS AAAGAAGACTTACGAAATAA TCTTCTTGTAGGGACTTTTT QANNLIRHLNNFGNTKHRAH GAATAAGCAGTTTAAAGACG CACCCTCACTCCCCCCAATA NFTYFFTCEKCKIQIHSNTK AAGCAGACGAACACCACTCC GTTTTTTTTCGTTTTTTCGT HNISNHYKQCCATGGGPSCE ACCAACGACGCTCTGCAGCT TTTTTCACCCCCACCCCACT TGQYFCPACEQAGLGNLESA ACACCACCACCATCTCGCCG CGCCTCTGGGCTGCACATCC LRHFQSSHPEFNLPPRSQFS CAACAAGAAGAATTTTCCGC CACACGTAGGGACCTGTTTA KSHPNSYTLSLKPKDHLMKI TGCTCTCCACTCTGCTCCAA TATTATTTGCCTTTTATATG LYSGPLTPGQLVCPIKICLR CACCACCTCTCCTGCTCTGT TACCACTTTTTAAATATATT SSAARLFHDVSKLRKHMLVD GGACTGCTGCCTTGCTGCTG TTTGTACCCCACAAGATGCT HNRTLVYETTCGKCLRPVDT GACCAACCTCTACCCGAAGG TTTCGCCAAAAAAAAAAAAT SKNMRKTTSHFEKCSGESFI AACCCTTCGAACCCAGCAGC TTTTGTATCACATTTTTATA SSPSPIPQKTYKLDLPSTST AAGGTACGTGTCACCACCTC TTTTGTAAAACACAGATTTT PPPRKSPKLQPYKPIRTFKN TCCACAGAGCCAAGGCCAGA TATAAACTTTGCACTATTTT PLTKSSQSKSDNPPKPTPFF GTGGATAGAGCAGCGGCCTC TATATAAACTTCGCACTTAT SPRTLERSASWPALSEVVDP TACAACCAAGTTCTCCACTC TTAAAATGAATCGCATCTTT LPKLKEKHPSLPCALDKCPP CGACGACAAAACACCTGCCT TTTATATACACCAACACAAA SPRIKPSTLVPPCHTANNSP CGTGGCCAGAGTCCTGCCGA CAGGATGTGCAGCTCAGGGG KPTSPESPSTLKPLPRPIRP AGAAGAATCTTCGACCCCAA AACCAATCCTGCGTCCCTCC SKPLEDWLTVRSVGPDREIV CACCGTCTCGGCAGGGCTCC TAGCGGCGGGAGGGGCGCCC LNIGPRPRPGPAAGSRTTSP AAGCAACGACATCAGCCACG ACCTACCCCCACGCTCCTCT PSTAPAKRVAANPIAAPLSG AGTGCCCACCGGAGTGGACG TGAGCACCAACAGGGACTCC EPGATLDCGQTGRKVQPPKK CGGCGAACCCGAGGACCGCT CTTCCGGAGCCCCTGCACCC RPTESAGSLPPPAEPATDLL GTCGCCAAGAACAATAACAT TCAACTTTTCTTATTTTTAA TGREGLARLVEEYHLSGDFG CACCGCCTGCAGCAGCTACC AAAAAAAAAATCATATATAT AFCRDLERWTALSSTNRRPK AAACAAAGGTTAGTCTCCTA TGATCTTGACGACGGGGGCT PRRGRYNRGAAARATRNRGR CCTCACCTACAAACTCGTCT ACATTCAGCCCCCAAAAACC DDRQDPQDRDDQGGPGPVTC GAATAGACGCCCCCGCGTGG CACCCACCATCCCCAACGAG GRPQRYKRAAALRSAFGRDM GAGCTAACCTTGGTAGCTAG TGCCGGGGCATTGAAGAGCT KATVRRIIDGERGDARCEID CTGCAGTGCCCTGCGACAGC CCGGCACAATTAGCACTTAG PKTIEGRFRDELSPPVREGP GGCCTCGAAGAGCTGCAGAG CTTATTTATTATTTTTTGTC ECSLPPWMAEAQAGEHAPSN CGTCAGCCTGCTTCGACCTC AACATTTTTGTTTTTTCAAA DSQPGDAYDGPITALEVEMV GCTTGTTCTCATTTCAACCT ITTTTTCACCCCTCACCCCC LSTLNVGSAPGSDGLSYGFW ACTCCGTCCTGTGGAATCAA ACCCTAATAGGTCCCTCGGG RALDPKGLVLSELFEVCRIE AAGAGCCCCACTAACAATTA CTTGGGCCCCTTTTTCGTGC RRVPGPWKSSRVTLICKDAE CATTCATAAAATCTAGCAAG TCGAGAAGCGTCACATCGCC GDLDDLGNWRPISICQTVYK AACGAAGAGAAGCGACCAAC CCACTGACCACGACCTTCCC IYAAVLARRLQSWALDGGVI TTTTAATCCATAACTTTTAG CGACATTGGAGTCCTTGGCG SRSQKGFMPFEGVYEHVFLL ATCTTTTTATTTATTAC TCTCCCAGGTCGAAACAGTC DSVVADARATRRSLAVCWLD TGTTTTTAAG CCAAGTGATAGCACCTAATG LRNAFGSVDHTTIVEALSRF CCCTAAGCATATTGCCTTTT CTCGACTTGTTTCGGCCTGG GAPAGLVEMISDIYTGGSCR TTTAGATCTTATAATTATAA GCCGCCGAGGATTCCCAGAA IRTRAGFTPDIPVGRGVRQG AAATAGATTCAAAGTTAACA CGACCATTCTTCTAAATAAT CPLSGIIFNLVMEVLLRGVE CCACCAGGCCGCTACAGAGC ATTTATATTTCAGAATAAAA ANNACGYRLSCAGGASVRVL ATTTTATTTAATCAATTTGT CTATATATATATCGTTGGCG AYADDVALVGSSRAEXKIQL TACCGACCTCCTGCTGCTTC GGACTTGTCCCGCCTCGATA GVCERFAAWAGFSFNNKKCA TTTTTACTTTCTCCAGACTA CCGAGTGCTGCAGAGCGGCA AMVLKHQRGGRRLLDSAPLR CTACCCGGATACAACCCTTG AAATAAAGAAGAAACCGACG LCGEEVAILGPDSFYKYLGA GAAACGAGAGGA TCGCTCTGCAGCCAAGGACC HTGYGRQTGGQLVDRVERQV (SEQ ID NO: 1249) ACCCAAACTCAAGCCAGCAC VRLFTSFLTPTQKLSALKRI CGTCGACAACCAACATCCTC VLPAMSFHLRVRPCAEGHLR AAGTCGGCGGTTGCTGGAAC RLDNTVRRCVKTALRLPKGS AACTCATAACATCTTCAANA CRAFFHTSPDAGGLGITSVV TAAATTATCACCCTGTGCAG AECDILTVTQAFKMLSSPDH CAGGAGGCCGTGCTTTTAAA LVSLVAKGRLGMHAARMGRS ACTACTCTGTAGTGGCTCAT ETASACAMADYLSGDSVMGH GATAATATTTCGCTCCTTTT XSWKTGYRMPADLWTATRAA TTGCCCCGTGTAAACTTAGT SRRLSLRFSPQPQGEFGLES NGATGCGAATAAAATCAGTT GTFKIAPRERRSLTRRLHHR GAATCA QNLWWRNQWAALPNQGKTVA (SEQ ID NO: 1372) AHSAYAASNNWVKGPSSLAP QALFFGLKARLNQMPTRSVK ACYSRAPNYDKSCRRCGAEV ETLPHVLNHCPKSMKSILER HDSVLAEVLAAIPRGTFASV DVDRTSREHFRRVGEALRPD IVARRHDGSVVVADVTCPFE SCASALDTAAARKIEKYDQL CANLRQLYRKPVESHALVVG SLGSWGRTNNTALAALGIRG AVRSRLAKQLVNLSVEGSHN IWLRWSGGIPKDLVR (SEQ ID NO: 1494) R4 Dong . Bomby GCTAGCTCCCTAAAATCCTA TAAAAACTAGCATAATTATT MLRRGRIFLPASTKAGKTRG x mori CCTTACGTCCGAGGCGAACA AACTCATAACTAATGTATAT RMKWSREVNLFIMRTYYYVT TCTGTCCACGTGGGGAGCGG TACTTGGCCAAAAGCCCGTA KLETDLTIYRKKLHEHFSLK AAACGCGTACTATCGAAACT TATACAGTTCCACCGGCTCT YPNVIISQQRISDQKRAIER TACGCGGCTAACAAGGTAAA GTCGACAGACTGAACTGAGA NKLLSQETLDRLKEEVRKQL GGTAACCCATTAATATGGAG AAGGGGAAACATATGGAAAT EDEQTNNVENEKLNSETYSH ACAAGACTAAAAAGAAAATT AATAATAA EYTTLTPQTILTKKTQQHTN GAGAGGGCCGCTTCCCGGGG (SEQ ID NO: 1373) IISSTQTSHSSTQTESITLL GCGATCGCCGGGGCACACCT LENEVDILNTNPTEGATQTQ GGAGCTGGCGCTGGGTGTTC EVKDKFETNLTMYSGMDPKA CAGCATAGGATCCGTCAGCG RPPLPKLKYSSKLNELIRLF GCGGAGAGTTGAGCAGGCGG NNDILVDYISPDTQLSDVHT GCTCTCGCCGGGGATTTACA LTYCTAVTISEQLKYKIIAI ACCCGAAAATGCTACAGCCG EGNARHKKNFKPPWQQRLEK CCAACAGAAATCACGATGTA DIAKLRADIGKLTQYINNNR GAAAGTAGGAGCAATAGCCC SKKVVQSVEQIFKNTKIHTS ATGTGAACCTTACAGCCCGA HENGNKKSQEFLDTLKQKLA GTACCGGTTCATACAACCCC LKAHRLKRYNNSQKRKNENT TCGGTACAATCATCACCATC IFLTNEKLFYRNLIKPKTDR ATCCTCGGGTCATAGAGGCT DNSNIDIPTAEQLEMYWARL CACCAACGTCGACTATGG WENSAKHNDKANWITEEKER (SEQ ID NO: 1250) WDTIEEMQFDDVTEEEITTI TARLHNWKSPGIDKIHNFWF KKLICLHKTIAKNLTDIISG NQSIPEFIATGITYMIPKGD FSIEASQYRPITCLPTIYKI LTTVITKKINSHIEHNNILA EEQKGCRRGHMGCKEQLIID STIMKHATTKNRNLHCTYID YKKAFDSIPHSWLIQVLEIY KINPIIISFLRNIMTHWQTT LKLKNPPNFVTTRQIAIKKG IYQGDSLSPLWFCLALNPLS HQLHNDRAGYRIKQQDNTET IISHLIYMDDIKLYAKNDKE MKKLIDTTTIFSNDISMQFG LDKCKTVHIIKGKVQPGDYT IDDTNTITAMEPSDLYKYLG FQQLKGLDHITIKQSLTSEY KKRINAICKTKLSGKHLIKA LNTYAIPILTYSFGIIKWSK TDIEQIERITRTTLTKHNNL HPKSAIERLTIKRQDGGRGM IDIWHLWRKQIHSLKTFFYI KSDLSEIHRAIAQNDNNYTP LNLKQKELIDNTENLRNRNP QKDMEENWKKKALHGRHPHD LSQSHIDSKASNMWLKTGSL FPETEGFLIAIQDQVINTKN YRKYIIKDPTIRDDKCRKCN TQPETIQHITGACSTLTQTD YTHRHNQLANIIHQQLALKH KLIQNTNTPYYNYKPQTVLE NDSCKLYYDRAILTDRTIHY NRPDITLQDKNNKVTYIIDI AVPNTHNIQKTFTEKMTKYT ELKEEIVRIWKQKKAYIVPI IISTTGVVPNHIHNSLKLLD LKDNIFISLQKAAILNTCRI VRKFMQLEENQTYYTQ (SEQ ID NO: 1495) R4 DongA AB097 Anopheles GAAGGCTAACCACAATA TAACATCCGGTGCAAACTCA METRSMRKRTTRLPEEGAPT G 127 gambiae (SEQ ID NO: 1251) TTAACATTAAGAAAAGAGAG GAGPGTGDRASIQRLEDEMV AGGAGAAATGAGAATGAGAT QERSFSQRALPVPRTQNRNG TCATTCACCTTTGGCATTTG SPINHQGNAASANVAVADRQ AATAGCCCGGGGTAGGTGAA QSLILAGGRRQRIMWTREMN AAGTTCCCAGCATATTGCTG HYVIRCYYVYTRMETDMPGR AGAAGTGACAAAATTCGGAT VKMLGMFNDRFPRFAHQLDL AATAATAATAATAATAATAA SKLYIRQRAIILPEELEFIK TAATAATAATAATAATAATA LEVRREFGEEEAGWRESSRI ATAATAATAATATGCATAAT SARLNTIDQNTSRASEDRDL AATA DEPTAPGLSVDIQHQMATAV (SEQ ID NO: 1374) TQFHGTDPLSRHRLPKLHYS YRLKTAVSIINQDVLPQYLD SVGSIEDLQLIVYSAAVAVV RTLWLRTYPQGDSEGRPCSK AEKPAWMRRLENRINATRTK IGRMQEYQRGNSSMKVVRQI AEMVKPKELRDLTDANITEV LDIHLQRLSALAKRLRRYAE CSKRKEQNRMFNINEREFYN WIRNDKPNFREGLPDIGDFT QFWANLCEKPVQHNSEGMRL AEDERFSDGIEDMPVLVVNA QDIREATQYTRNGAAPGPDF VYNFWYKKLITIHEQIAACF NTVLEDSRKLPKFITGGVTY FLPKDQNTKNPAKYRPLTCL SNLNKVLSSVITQKVKDHCD TNNVMTEEQTGRRKNTQGCK DQVIIDAVIVGQAAKKQRNL DMAYIDYKKAYDSVPHSYLL KVLQLYKVDGNVIKLMQHAM GMWSTSLHVTDGKVVLRSRS LNIRRGIFQGDTFSTLWFCL AMNPLSRTLNQQCNFGYLLK SEEISTRITHTFFMDDLKLF AETVQKMHHLLKNVQGFSND IKMEFGIGKCRSIHLHRGQV LDADSFRANEQEEIRHMVQG ETYKFLGFLQLRGIHYAVIK KELQDKFLHRVSCILKSFLS VGNKVKAINTFAVALLTYSF GVMKWSNTDLEALERTIRVV STKHQMRHPKASVERVILPR KIGGVGIIDIQALCISQIHQ LRSYFVESQNRHELYRTVYK ADHGLSALHLAQQDYQLNCN IKTVDGKGATWKQKELHGTH THQLNLEHIDKVSSSTWLVR CDLFCETEGFMVAIQDRVIA TWNYRRCILREDVEDRCRKC NSGGESIEHVIAGCPVLAGS AYLDRHNDVAKIVHQQLALR HKLVERFLPCYRYLPDPVQE NDCIKLYWDREIITDILIRA NRPDILVYEKRKKRATIDID IAVTLDHNVQTTFSTKVMKY HDLAEELKQTWYLEDIRIVP VIISATGIVPMALLRSLDEL ELQRELPRIQKAVILRTCST LRRFLNPYN (SEQ ID NO: 1496) R4 R4- CADV0 Bursaphelenchus GGGATCCTGGGTTCCTACTA TAAGAAAAGCATGAAATAAT MTCNNAVVFPPADGNPAGTA 1_BX 1008175 xylophilus CCTCGCTCCACCTCCTCGCG AAGAAATCAGATAAGAATAA DRNFAIRFPSSEPPGPSGIR ATGGATCCTGGGGAAGTCTC CAAGAATACTAATAAGTATA PSEPLDGRTGIGDVEHAQAG CGGACTGAGCTAAGAGAGCG TCATGTAACTATGACAAAAA NGGFLVDVLEYKEAHRYGSK TTAAAGTAGAGGGTGACGGC GAACGCACCAATAAGAACAT CEFCYVQTKGTVCSKPRTDA GTAAGTACCTCCAAGTTGCG GCTTGAGTGGCCAGCTCTGC WLKCEILFLLHHAYTANQNK GTGGAGCGGAACATCTACTC AGGCAAAAGTCGAATTTGGA SIELAESAFRRAGITRRSKA TTCGGAGAGAGGGGAAGCTC ACAGCCGGTAATGGAAGACC TIAKRWSLIQRGKGTDYKEY TATGGCGGCGTTAGAAAGGT TGCAACAAACGTGGGGTAGC WDEYFEKFRYECNPTPIVRR TGGACTACGGCAACGCCAGG AGGCAATATGTAACTATGAC KRNRLAAGLQSPSSVPNGYE GAGATGGGGAAGGTTCATCA AGACCAAAACTCCGAAACTC FERKRTCETPLDTKASSLPL GGTGATACTAGTTCGCTACT TGGTAATGAGCCCGTGCCCC ICNLLTGIVGVENVEENMSV GTCATTCGATGTATCCGGAA CCAAGCATGTGGTCTCGTTC ECTEPKELSGTANSSVPGLA CCATACTCGCCAAGTTGTGA GATGTAGTTAGGAACAGTTC EGVYERRHNNVNEPAAGCPQ ACTATGTGAAAGTCTGGATC TCTTTAACCCGTGATGATTA DVPVANNLIDSPTTNDRLEA CAATCCAAGACCACGGGGCG CGCCCTGTCTTAAATGGCAG EFKAQLDRAERSYMRRRLPR CAATTAAAAGGTGTGAAGCA GTGCCACCAAATACCGAACA LKNLSPDERMWIGTTVERLR GCTTGCTGGTGATCACCACG CTCGTTGAGGTATGGTGGTC LETVSEPVCEQWRLANAGLY GTGGTACCTACACCGGCGGG CGAATGTGAAGCTGGGAGTA AAIRSIAVMRPLDAAREAHK GGAACATCTTTAATGCCGAG CAATTTGGTACGAGAGCACC TWLLNMKMTERKLRQQIGWV ATGACCGCGCGAATAATAGG AGCGCCCCCGATCTAAGTGA ETTRRTKNEARTERQEIVYR GAGCCGGCAAAAGCCGAGCG TGACGCATGCGTCGGAACAA KVAKLRRERFPEMDLDSVSV TAAGTGGAAAGGATACAGAA TGAAGACGGCTGGCAAACAT HLKRKLELLKGRIQVRTAER ATTTGCTCAAAAGTATACCA TCAGGAGTCGCAAA LRRDTREAAGPYGKTALRGQ ACCCGCCACTTATAAAAGAC (SEQ ID NO: 1375) GFAPNVKDATQYWSGLAQPS CGAGAAAAGGGTACCACTAG GQKCSENSAILSDWKELVEC AGCTCATTATAAAACATCT NLSSLPDQMEPLVVQGISRA (SEQ ID NO: 1252) SPWKSPGPDGIFNYYWRQDF IVDWLKQLMLDSLRTGHYPW KLSSGRTVLLYKDGDPTKAE NYRPITCLNGCFKMINSVVS EVILKRVENTIALPIEQMAL RRKVWACVESQIWDQIKQRK LSDRTQKCKVAWVDFSKAYD SLNHDAIKFVIGVLKLPTGI NNYLLDSMQNWSTHLELKSS GKVVRGPSYPIKRGVLQGDS LSPTLFVVVTSIIVRHIKTI ESSDIQMYMDDIKLYGKDQE TLTRLIKELQTVSNKLGLCM NLKKCAILGDDLPEEINGIE HLKESYKYLGVPQREITQVR ATMAALEKKILTEVDTSLGA AELSYRQRISRVNSKIAPLV RFVVQSMLVTPRDVLKVYNR LGGIDVEIRRRLVKYEIRYK KSNVARLYLDRKVGGIGFVN LCRIMVEAVAARAVYCRLAP SFNEFQDFLAEQNTSPITAA QTILDKCGINIELSTSTLGD VKKIVRNHYHELWLTAWKNT GLYKRWENDHVDIKRSSLWI NRGNLSANNARIGIGIQDNS IFCRGFVGNKCDTKYCRLCG DGIESVSHIVTGCPTHRTNL YIERHDCVARNVYAYLAIRY GIPVPHYTQRVKTIEKNGDQ SVELYWNYKFPCTRALEACR PDIVLIDKVSKRTHIIEVAV SWRGRLQEMVDRKVYKYTVN GEYEADGSSRGWNIVRELND QYGFPVEVYTLVIGAGGEIL PCTVKDVERLTGGAATDNLI ERMERSAVLGSCRIIKRHLA L (SEQ ID NO: 1497) R4 R4- . Heterodera TGGCGATACTCGGAACCTCC TGAGGACTCANAATTGACAA MISCDLERETLTQMALFRAR 1_HG glycines GGGGAGCCTGGTAGGAGTTG TACACCTCAGA SDKTPTHAGIPAPDEVREGG GCCTACAGGTCGCGAAAGTC (SEQ ID NO: 1376) CGQNRTNPAAPRGKAAAIQR CCTAGGTGCTGCACGGGTTG QNGITIPIXACAQSGLVRTQ CGCTAATCCGAGGGCGCTGG RVQQWSAVEESALKDVVVRN GTTACCTTCCCATCGGCCAA TDDRGLINWAKGVLPEWQRL AAACGTCTGGGCCTTCTTAG CQLNPTMYMARSSPSLSNKW CCGCGGGTCCAGTATTTCTG ASLRRTHVGPGCPSKEGSGP TTGAGCCTGACAGTTCTTCC SQDLSDVKIQPARLAHDTVA CGGATATGGCGAAAGATTAC ELPQRTVPCGTDGHGVIDSD AGGGCGGTATTTCGTGAAAC ETETALAEVSRSSPFGEREP CTAAAAAWGGTCGGGCCGAA LDLGATERITRKRLRNAVRD TGGCACGGACAGACTCACTT VVPPRKRRVPSTPSRKEQDL CGGAGTGAGCTCG VPEVDGPAPTDVLTHPPTES GGGGCATCCGTGTGTTACCC EPEPMLDPLSLVQLVRPQLG CGCTGCACCACGCCGAAGCT RAMGWAAEEMELGNVVMDVE GTCATAGCGAGCCCGAAGGG LKREFNREVRRVGRTPPDQM GAATGGCCATGGAGACTCCA YKRGAGPPLPQKREPERVAL GCCTCACCCTGTAACTCGAA LEQLIAARVERGINRGLDWF CCTAAGTCCAGGCCCCTTTC LELNVAVFAAARVLSRRERV TGGTGTTGGCTCGCACTGGT ETLADRLHINDSATLSEVSR TAGGAACACGACAGTCTCGT RRAKAERKLRCAREQPWMSR GTAATCCCACACGCACCGAA RIRXLGVRVERLKQLADLVR AGCCCTAGCCCTCGTAGGCG QRIAGRGNRSSYEGPRRRFR AAGGCTGCGTTGCTGGTTTC LRPSLRSVTEAPVNPPLNGN AGAACTGTGAGCWAGTGGGG EVYTFWHSLWAQSLRANTDD TTCGGATGGCCGAGTGTACC CQLREFKNQLSAARHTDLTS AACCTGCTTGCTAACAGGTA VGTSSLVQMFSAALRKMKKG GCATAGAGTAATATGCTAGT KAPGPDGIRAAWWGVFRRIA AAGCAGGGCACGAGAAAGGG PYVATWVVRVIRGAEPVANW CCGTAAAGGCTCCGGCTATG ICNGLTVLLPKSSDNADPSN AAGGACCTTGCGACCACGCG YRPITCLNTCYKLFTAVIAQ TGTGTCTCCCACGTGCGGAT ITASYVDVLGGLPRQQVALR TCTTGAAGCCAGAGTCTTGC KGVWGTSVSLMIDALTVADA ACTGCGCGCAGGATGGAGCC RRAKRPLGVCWFDFKKA TGTGCAACTCCTCCCTCGCT FDSVPHNLIRWILRVIGLPP GATCGCAGGAGTGGAGGATC VILSVIVSVMDQWATRLKIG ACCACTCTTTTTACCTTGCT GKVMPKTIPVRTGVFQGDTL AGCTTGGGGTACCACCTTGA SPLLFCLSVWPISFALDQFP GCTGGGGCCGGCCTTGCTAG QYQFRCANHLQQGFSVGHVF CTTGGGGTACGACCCTTTGA YMDDLKCYCPDREVLTAVIQ GCTGGGGCTGGCCTTACTAG QVQKSASALGLTIHYKKSAW CTTGGCGCGCCACCCTTGGA LDQDGGKSGKAVLGVPXLVG GCTGGGGTGGCGCAAGATCA TYKYLGMHERFMIVSKDSLE CTTGTATACGGTCTAACCAA SVRGKFMGRLKTLWTSKLTF TACATTTGAAAAGCGATCAA GQAMLGTKSXCMPVVRYVLQ AGCGAA NLFLPKSEFNQTRLVLREWD (SEQ ID NO: 1253) RQIRDLLDECNIRQVFRSKT ELYVSREEGGWGLPSMEDAL EEEVVTKLAILVARQETEPL FRVCEALERKRCPTPLSLGL QILKDWGVGVELQGRTLLLN GNTVGPSQATRKLTGELVLR REAERLSRWRSKVKPGCGMT GGAWRDVPGIDVHLSNRWLV KGALSPTVVSNSLAIRANTV ILRGSGGGYTKGTLLRCRGC GNTGETRRHIVSACSLGRQK GAASRRHDNVCRILVRAICH KLNIEPPNSANFPHVVVLEG SGAKMWIDFPFVVPHKIRHT RPDIVVLFEWNGVRRLSVIE VAVSDVANMQTQHIRKSHRY GTNSTEPFVAGVTPTYRNDC LAAQLRAKFKAQQVDVIPII VGTTGETLDGEFGRIRKGLP MLTKLQMPRLWSEIQRAVIL GSYRILVEHLALPKGGA (SEQ ID NO: 1498) R4 R4- . Parhyale CCGACCGCCAGCGGGATAAC TGAGCCTTAGGTCGCGGGAT MKMSHNRDTPSNGVKGTSVR 1_PH hawaiensis TGGCAAACCCTGTCTCGACC GTGACCCGGCGCCAGAGTGT LGTSLVRSPVGEAGAVRERG ACCGGCCCGTGAATCCATCG AGAGCTGAACATCGCTCAAC THPSESVSQDSDASVNATGE GGGCGTATGAGTCTGACACA CGATCCAATTTGGGTCGTGA GSVREQAPLSPPGAEEATVP GGGGGGTGTTTAAGGTGACC AATCCCCTCGATAATAATAA TQRRTRHKWSREDRVVLWEC CTGTTGCGAGGAAATGCGCA TAATAA FVASKREGPGYLKRLKQLWD GCAAAAGCCGGATGAGCCTT (SEQ ID NO: 1377) ERGIPGNFPQASLSGQIRQI AGAACATCGAAGGCCAACGA CSKNLLSEEERLQIAARMEA CAACCTGCCGAAAGACTGGC QVASPSADEPARQVPTRPVT GACTAATCCAGTCAACCTCC PPRSPPVEPARRPSIPSEET TGTAGGTCACCGGCTGGTCA PDLGAVPSEIDSADPNRSPS TGCTGAATCTCAGCTTAACC RGPRHLPAHNMSQSESEDDV AGGCGTACGAACTTACAGTT TDPDVSDQQRSDSLEPRDLL GGAGGGTCGAGCACCCCTGA RNSSVESTPGHPNQELSDTL TGGCTGAAAAGGACCATCAA LSNYVPSEIDSDDPNQSPRR AGTCGAAGGTAGCCAACGAG GPRHLPAHDMSLSDSMDEET AAGACCAACGGCTGATTCAG EPDLSDQQRSDLLELRDLLR GCGGAAGAGTCAACTCGTTG NSSVETTPKGHPSLRHLPEP AATGCGTTCGACAGCTTGGG KIRAAAFRVNSVIGKIHTNN GTAGATGGAACTCCTAAGCC ITETNALIKAGADLAVRILE CTGAAAGGCAGTCCATCTTC VQPRPQRTQRKKDPPWKHRL GCAGACGCTAAGGTGCCCCG EKNIAEIRKHLSWISEWRRG CCGCCTGAGGGTTATCAGGC NLHDEEKKTLLESRYRCLEV CCCGCCGCCTGAGGGTTACC GLTNLEDTLKQRLSAKRSKV AGGCAACC RRFEARVAGFHQNQLFNTNQ (SEQ ID NO: 1254) KRLYQTLRGEETSSDSPNAE ESIRFWSDIWSKEVRHNNTA EWLHDVKEKNVAADPDLTIT SQQLKKQLSKTKNWKAPGPD MVQGYWIKTFTSLHSRIAAQ LNHCLQRGTVPTWMTTGKTV LIQKDKAKGTEVSNYRPITC LPLMWKVLTGIIYERVYQHL DSKKLLPDEQKGCRRNTRGT KDHLLVDKLLTKDARSKKKN LSMAWVDYKKAFDMVPHSWI LECLDIYGIAGNIRNLIATT MPNWKTQLTSANKHLGEVSI KRGIFQGDSLSPLLFVLTMI PLSETLNKAGQGYNYSRTMK LNHLLYMDDLKLYAKSKDQV EQLLNIVHQYSQDIKMQFGV SKCGVLNIERGEVTASEGIT IEEGTIKDIEEAGYKYLGVM EYNTILHRTMKDSIRKEYLT RLRLILKSHLNGGNTIKAIN TWAVPVVRYSAGIINWTKKD CTDMDIKTRKLMTIYRALHP RSCVDRLYINRREGGRGLIS VEDCVEAEKRALSQHFRESD DPWARCLVEAKLLKETETAD QFKERRRLDRTNKWKSMKMS GQYLEAVQDKIVPDSWNWLL RGELKRETEGTILAAQEQAL RTRYIQNKIDKRNVPSTCRI CRSSDETINHVISECGVLAQ KEYKRRHDKVARHLHWTLLR IHNFPVSERWYEHEPAPVVE NEAVQIYWDKRMETDRVLHA NRPDIVVKDKQEKSAKLIDI SIPFDSRIVDKEAEKKEKYR DLAIELQRLWQMKVDVVPVV IGALGAMSKNLKTALRELKC GHLHPGTLQKSALLGTAHII RKVL (SEQ ID NO: 1499) R4 R4- CADV0 Bursaphelenchus GAGGATCCTGGGTTCCTACT TAACAAGTGTAATAAAAACC MVFNNCKPKHLCPAIRPTGQ 2_BX 10090 xylophilus ACCCTGCTCCATCTCCTCGC ACCCATGCGTAGTAAACCGA QETNGGSEGTAEPTAGPSRP 48 GATGGATCCTTGGGGAAGTC TCAATTATCTAGCAAAATCG AVSEDAAQPVPLFEEGEYIR TCCGGACTGAGCTAAGAGAG CAGGTCAGAAGACCAAAGAA AHRDKTCPYCEVLWIGARSS CGTTAAAGTAGAGGGTGGCG CCGACCCAGAGGAATAGGAC KARSDSWPLCQILYLMKRND GCGTAGTGACTTCCAAGTTG CAGAGCTGAAACTCTCAGAT DLRGQRTRYPLLESSLRAAG CGATGGGGCGGAACATCTAC ACGCCAACGGTCCTAATAAA IARTKFAIIKCIRNVLRDRY TCTTCTGAGAGAGGGAAAGC ACGTCGTTAAGTAAAGCATC VPNGPYSEHWKIYRANSGEV CCTATGGCGGCGGTAGAAAG GTTAAGTACAAAACAAAAGC PQGATITKGKRSARVAGLPS GTTGGGCTACGGCAACACTT ACTGTAAACGCGAGGCCCCC PSQSGHHTKRIQAGTGIETE GCCATGATCAGATTCGATCA TCTTTGCCAAACTCCGGTAA TTVTETNTTPEVSHEHRDPC AAATTAGCCTCTGGGGCTGG TCCTCGTAGTACGGTGCTTT GEPETSAANVDKVTELTEDG CAACCCTACAACGGATTGTA TTCCCGCTTCACGAATCAGA SETRGTANVANGGVSVSDPG AACTGAACTATGCTATGCAA ACGCTGCCAGATCTTGTCCG RKRQSSSQNRGNIETTNPEL AATGAAAATAAAAAATGGGG ACATGGGCCGTAGGGTTTGG VGMWEDMFGVQLDGAMRTTE GCTTTACAATCTAAGGTGTT GAGTACCAGCGTGGGGCGGA RPRLPKLKHLSEPERLWIRA GGCAGATCACGAAAACTGCC GAGCGTACCTGGGTACACTG KLEQAWLQCVSYDVEQQWLN CGTCGATGAGGGTGAGATAA CATAATCGGGTCTCAGAAAA ANAVLYAAIRSVAASRPCKE CATCCTACGGAACAGCCCCT CCACCTATGGTTTATTATTC AREAQKTWLDNKKKDEAKLR GCTGGACCAAACCAAATCAT TGTCTCCCATCTGCAGGGTA RLIGRISSVHSMPKGDRTPR CCACAAATTGGAGGGTTTTC GCTTTTCGTTGGGCCATAGG EKKLVKNITKLKNTHYPDMD TTGGTAGTTTCCCTTGGCAC AGCCTAGGGGCAAGAGTGCA WGGLLNHFKVKLSQLKEKIS GTCTTGTTTCATAAGCCAGA TGTAGTCTTCAACGGCCATG VRVAEHKRKVNRNAAGQYGK ATAAAAACGATACCATACAG CCAGGGAAACTTGTGAGAGG SVAGSAGLAPDVVSATAYWS ACATGAGGCTGGGTACCTGC TGAGGGATAACTAGCATCAG GLAQPGPKKFKASSPIFQTW CAGCCGCGACACGGAAAACC ATAATATCAGTCATGAAATT KDDVAKNLNTEPVLLYPIIK GGTAGGTGCAACCGGAGACA AGTAACAACCAACGTTCACC ECIRKPSPWKAPGPDGIYNY GCTAGGGGAAAGAAAATAGT GTCGTTGGCAAAACACCGAC YWQQEFVAQWIQTLVKRTLD AAAGTGTCGAAAACAAAACA TAACGATGCTAGTTAGAAAG IGRFPTALMCGRTVLLFKSG GGTAGCCCCTGGCTAGAGGG AGTCGGGTCTTCCCAAAGTT DKSMPQNYRPITCLNGCFKI AATGGGACATTGTCCGATTA AGGTGCTTGCACCGAAGCCG TNAVLTKVILQRVQDTCALP GGTTGCCTTGACCCAATGAA ATCCGCTCTACCCACAGCTC REQMALKPKVWSCMEAQLRD AGCCAACCGGGTTTACATTA TGCCCAGCGTT QALQSEIGDDCKTAWIDFSK TCGGTCTACCAAGGGCAATG (SEQ ID NO: 1378) AYDSLDHDALRFVIQTIALP ACCAGAGAAACTGCGACTAT AGMEEYLLKSLDSWRTQLVL GCCGTAACCCTTCGCAGATT SDAGKVVSGKPYPIKRGVLQ GCCGATGAGAACCATCGATC GDSLSPALFVLTTSPIVAHL GTAAGTCGAAGCCAAGCGGA QRTCPTGRIQLYMDDIKLYG TTGACCAGTGGAGGGTTATC KTESDLCMLIKETQRVANKL CCGACAACAGC GLNINLKKCALFGKSIKQSI (SEQ ID NO: 1255) AGFDPLGDRTYKYLGIPQRD VADIKQAYDELKAKTVQTIG ETMACDYLTTRQVINRLNSK IPPVVRFVTQSALCSAPMTR GLYNKITELDNVSRAELRKV LIYKATNVSRFYLATKEGGF GYASLQQVFVEAVVSRAIYC LRAPSLCDIREFILSKFDPV KVARIALARSKIDMDIERMD MASATRTIRQHYQAKWKTLF QQSKLYQKWVQHKIDIPNSS RWLQRGEISPRNCRIAVAVQ DNTLLCRGFVGSKDPNKQCR LCNAGIETASHIVTECSTHR VHMYIERHDSVARNIYAVLA KNCGFWIPHYSQKIPTVKIT KSYELYWNYKFPCTQALEAC RPDIVLIDRAKKRILVVEVA VSYVTRLEQMTQRKLYKYGV NGEYQADGETRGWNICRELV QKYNMRIDLCIVVIGACGEI LPCMVKEIEKISKVSGRQLL ERCQRSAVLGTVRTVRRHLA N (SEQ ID NO: 1500) R4 R4- ABLAO Heterodera TGTGGCGATACTCGGAACCT TAGTCGTAGCCCAGATGTCG MRKSFLQHIPELSSHIAMSV 2_HG 10003 glycines CCGGGGAGCCTGGTAGGAGT ACAGCCCCTACACCGGTAGA PARNYPKMCSLAQGSSGTLS 89 TGGCCTACAGGTCGCGAAAG TGGAAGGAGGTATGTATCTA HNGKGVAMHRCPSDDCAGKD TCCCTAGGTGCTGCACGGGT AGCCCACGGCAAGCCACCAG PPQRGSQKGNLRSVRWTPSE TGCGCTAATCCGAGCCCCTT TGGAAACGGTGACCACCTCT EKAVFEYWSRLEQHAMLNGS CCGGTGTTGGCTAGCACTGG GTTCGCGGAAATGCCCCGTA EARGTCAITRSQFLIHWDGE AGGGGGGGGGGTCCAAAGAA GAGTATATGAAGGTCGGAGC RESRSLSDGVPEYPMRTERA TACGTGAAGCGGACCCTGTG ATTGAAGCACAAGTGAGAAC YYERVRLLRQRGWQWDCANE TTTTCTCTGACCTCATACGG CCTGGAAGTATGGTGGTGA CLVIGQCAEPCRKPNVVAIK GTATATCCCGATGATATCTA GCTGGT ADKGMKRSLVKGKLLSLPHV TACAGTGTTCATTTTCATTT AACCTCGAATTCCTCCTATG MGEINQVSVQVEVPLPSVPA CTTAACCTGCTTTTTCCTCA GGTGCTTGCGCCCGTAGGTC SVPQVEGVESKGFTETEPSN AGAGAAATATGACCACATTC ATTTGTGTATGTAGGGATGG KPSLEGNPAEEGLRKPERVN GTTTGCCATTTCGAAGGTGC AAGGAATCTCGATAGCGCAA VPVHGIISDSERKDLKDRFW GACTTTTGAGGGAGTTCTCA ATCGGGATACCGCACTGGCG SAYKTAKRSVGFRPALKIEP GGGACATCAAGCTGTTCATG ATCATGCTGCCAGTGGGCCC NRVNRAQWEVLDSCVVEVLK GACGGCTTGACGGCTCGTGG TGCTGAGTTGGGCGGGTTAG KRETSNGYRGCVLRHLNVAV CGGCACGCAGCCGCGCGGGC CAACCCGTCCAGGGACGCAG YAAGYVLAEGNKERRQVIRR CAGTTAGGGCTGGTGCCAAT ATGCCAAAAGCCTGGTGACA QSAEWLLRQKSEINNIRRHI GAGGCAGCGAAGAAGTCTCT CTCTAAAGGGAGTCTACGGC GWITDELTRRRTGKNPTSRQ GAAACGCCAAAAGCAGCGGG GACGAGAACATCCCCTAAGT LSNFAWLQRRYQVLGKPVRE AGAAGAGAGAGAAAGCGGGG C TRDLEVQRERLVSRLRLAQD ACGGGTTAGAGATAATAGCA (SEQ ID NO: 1379) RINSSMDREERVRKRMLPLR TGATTGACGGCGAAGCAATA RKLEEPLGDSKLDTKQARTF CTTTGACTTCCAGGTACGGA WASLIGERKEFGKIPELENW GGACGGCGGCAAAAAGCAAA AEEVRSKVTDGQGFASDHVD AAGGGGACGAAACCGATGGC QTVWKKILGKARPLKAPGPD ATTGCCAAAGGGGCCGAAAC GIPNLLWKRLPSANQALFKW CATTGAGCTGGACGCTGATG LMGIKRKQLSVPSWLTKGRV GGCCGTCTGCCGCGCAAAAG VLLPKGGDPVDPANYRPIAC GAGGGGGGAGCCCCTCCGTC LNTQYKLVTGMVTAWVSEHL TGGGAAGAAGGTGCGGCGCC TTYSILPIEQRAMVSGTWGC ATTCGTCCAACAAACCGGAA THAMVIDRAITSYAEATGLP TAGATCTTGATGATCTCAGC LYVGFVDFAKAFDSVSQPWI AATTGATCATATTGATCTCT RYALKVAGVHKRIRCLIGIL TTTTCCAGTTGTTGCGATAA MKCWSVRYEVFKSGRVLRSA ATTATCGTGCATTATTTCTT PLAVKNGVLQGDTLSPLLFC CGATTTCTCCAAAGCTTAAC LSVAVVSSAVGSLFDFEVTI TCCTTTCCTAATACCTACTC PGRGVMQQQNHLFYMDDFKG ATGTATACGTTAGTAGGCAT FAPSEASLTRMLVTLERTAS GTTTTATGCAGGTAAAGATA ALGLKINKRKCALVHPRERE GACCTGGTGCCCCCGGGCGA NEETGSDIPVLGLRDTYKYL CTTGGGATGTGGATGATGGT GIEERFGIVFEDAWDRVRTK TGGCGGAGAGTTCTGATGAC MFERMRTLLCTEHTFGELRA GCCGTAGTTCCGGAGGAACA AFASTIAPVARYLFLNVIVG GTTCCTACTAGTGCCAGCCT GPSWSETLTKAKDMDLRIRR GGGCTAGTGGAGCTGGTCTG LLWERRDNEPGWRFKHCSAD GCGAGTGCTTTGCTCGTCAG RLYLRVQYGGLGFVSVEDTL ATAAGGGGTGGTTGGGGTGG SESIIYCWAYVQCRPELELA TACCTCTGGAATGATGTGTC RELFGTLNRSARSGIKQSIA GGATAAGCACTCTGCCTTAT KGARKVFRSYALLSKNSAQR AAAGCTGTCGTTCTGCCCAG VSDLDGDASPGFRVGEMIFM GTTTCTCCTAACCAGGTTGA EPTRGARAIVKILRKENDSR ACTTGTAATGAGCCTTTGGG RLAAWKGRPMGGRVVSLPEL TATCTGGTCGGGGTCTGCGC DQVHSYHWLIRARIGRRSFR GGAGATAGCTCGTGAGGAGC DCIAAQEGQLKARELMCPHI TGTTATTACATTATTGGTTG NAKAKWCRRCGDGRVETEQH AACGCTTTTGGGTCGTACTG ILSGCAWSRTGTMLDRHNGV CACAGATAAAT VRQVHTALCRKYGLPVSSHV (SEQ ID NO: 1256) VPLHAVIENEHAKILYDVAL HTSPAGVLPREDGSTSYTGL RSTRPDMVIFDKKARTILIV EISVPWRENLVKQELIKWRK YAINSMIEPLELAEAEIPGP NLKHALGLAYGTSFPTVKVV PIVVGSCGEVLPNITKRLSE LGIPKRGIPSLLESIQRAAI IGSGHVIRAHLSVPRSESET (SEQ ID NO: 1501) R4 R4- CACX0 Strongyloides CGTCAGAAGAGCAGGTGTTT TAATTAGATTTATATGTGCC MQKFSVPKDSSQIFLVDSIL 2_SRa 10020 ratti TTCAAAGCAAAGACTTATTC ACTTTACCTCAAAGATATAT NKHICSTKNKVKDVIKRRSI 06 TACGAAGGGGAAAGATGATC TAATACTAACTTAATTATAA IKTLICAAGLTLRKLVCGKL AAACATGCAGATTTGGCTGC TTTATTATGAATTATAATAT GNNKYNSKINQLWKKERKII AATGAAATAGAATCAAACTA AATAAGTTTTAAAATAAAA NCIEDLKHLIETNKRRHNFG CCATGTGGTGACATCTTGCA (SEQ ID NO: 1380) KRLRNAKVSPSEMLKDYYNK AATACCATTCATACACAAGA LRYIKNEITACLDEHKKAIL AGACACGATATGGTTGTGTA RTKFKLTPSIKIISNIQNHN CAATATATTAAAAAGACTAA DEEAELPKEEEFVKYYKELF AAGAAAAGTATAAGTTAGAT TNKDGDDKETPHLDNWLKKF GGTGATTTACAATATGGTAG SKTLIVDWTINDKEILEALK ATCAGTATTTAATGGGAAGA YCGNFKAPGSDMVMKVCYKW AGGAAAAAATTAGGATCAGA FKSAQNYLIRWIKSTWYGEY TCTGGCCATAAGTTTTTGAC TINKKDTNAVTFMIWKRDGK TGAACAACCGTTAGTAAACA PKNDVKSYRPISCLNCDFKL ATAAACCGGATATTGTTATA LNKLIANKIYESIEKILPIN ACGATGAAAGAAGGGAAAAA QMAVIKNKHGTCEALLLYKS AAAGATAACGTACATACTAG LVQSMKFRRTKDVKEIWCSW AGATGTCGATACCACATATC IDFSKCYDSISHKCLKKMIQ TAGAACTTGAAGATGCAAGA SIKAPPIIHKLILDGIDSWN AAGAATAAAGTATAAAAAAT ISICNGKNISKTKIPVKSGI ATTGTGTGAGCTCCATGGTA LQGKVASSLYFVLLTGEISY AAAATAACGAATGATAATGT ALNKEEQVPIETITPSNTLK TGATTCGATAGCTCGTGATT INHISFIDDYQLYATSQKKV TTAATCTACTAAATTTAATG EKLTIKLREIAEEMNLKLNP GAAAGAAAAGAAAGGTGTAA QKCGIYGTDDLGKRLMLKES GATAAAGTTTGGATCATTTG SLNFPYTSEYKYLGLVENSL TATTTGGCTGTTATGGAGAA DLKDINIQLFKDKILSKYST TATGTCTTGACTGAATCTGC IFESRLTTHQKRKVFNSTIS TCTAAGAACACAGAAAATCC PCAAYYLGNLITNKCSIQEL TGATTGAATTGGGATTCTCC LNECKKFDQMVRNQLVNQNI AAAAAAGAGATGGATAGCTT KKLQVSNSRIYLPKEYNSLG GATCAAAGAGTGTTCTTACA LNEIEIEVAANIIRKACYIK GTTAAATGAATGAGACAGCA KRETLRGVDKLYIAMSKNGH AGAATTATTATGAAACATCT RNTLSDALYITKKYSNFQIN AGAAGGCGAAAAGAATCAAG WNIMGMVKDQNNILLDAKKI ATGAAATCAGCCATTAATAA IENIKEKRRNLWLEHWKKGN CTTTTATTTACCCAATTATT MTYANEAIKKEFHLPDLNID TATTGCGTTAACTTGATTAT SKYLMLCYAGSEEQUIYNGH ATGATATTTATTGTATATTT VSLVNQSSPSSRLCRKCNKL ATTGTTTAATTTAGTTTCAT EETSYHVASVCEFHKKNLHL AGTACAAATAAAAGAATATA MRHNSAVYHIITELCRIMKV CTACGATTCTTTACTTTTAA KCTLRYPEASGIIKSGNMKI GTTCTACGAGAACGTTGTTT AAGVKYTFGTAKIYHNKPDL TAGAATATTTTAATAATATT VWYTPEVIYVIEVSISSLKN TCTACTACAATTAAGTAATT AKSQMKMKTARYAVNSTKKL AGAAGAAATCAACGAAAGCA ENFAALNNLKKGENFVEILS GCTAAACTTACTCGCAAAAT HKANFKRVHFMPLVFCTFGE TCGTTGATCGAGGCTGGAAT IPKETMKYLEKLNFSNEKIK GGCACCAACTAATATACTAA TIASPIARYTGRTLKAHFTN CCAACAATAGAAAAAAAAAG AAGAACTTCAGTGGACTTCA (SEQ ID NO: 1502) AATAAAATAAAATTATTGGT AGAATTGTATGATAAAACTG AGAAAATTTGACTAAAACAA AAAGATTAGAGCAAATATGT CATCATTTTCCTAATCATAC AATTAAAGCGATGATGACGA AATTGAGAGAATTTGAAAGA GAAAAAAGGGAAAATTGTGA AATTAAAATGAGGGAAAATG AGGAAAAACCTGAGGAAAAA TTAAATTTTGACAACTATGA AGAAGCAAAATTGAAAAGAG GAATTAAGTGTAAAAAAGAA GTAAAACCAATTGTTATTGA AAACAAGGATTAGGAATTTT TGAAAACGGAAAAATTATTT CTCAAGTTTGTCAACACAAT CAATTACCAAAGAAAGAAGG GTAAATCAACCAGA (SEQ ID NO: 1257) R4 R4- CADV0 Bursaphelenchus GGGTCCTCGGTTCTTACTAC TGAGACCACCCATGCGCAGA MISRSQADRPVEGQPVTAMS 3_BX 10088 xylophilus CGTGCTCCACCTCCTCGCGA GTATCCGAATCAGTGAAAGT FHNLEPNNLYPENLRPTGSQ 32 TGGACCCTGGGGTAGGCCTC CCAAGTTTCAGGACAGAAAC DANRGVADIAEEVTGPSGLV CGGGCTGAGCTAAGCAGAGC GTCAGATAAGTCCAAGAGAA TNEEAARAPPLFVEGEYKRA ATTAAAGTAAAGAGTGACGG ACGAGAAAACAAGTTCAAGT HCGGGKCHYCRVLWIGARSS CGCAGTTGCTTCCAAGTTGC ATGCAAGAGTTAATCAATAA KARTDSWNLCEILFLINKCM GGTGGGGCGGAACATCTACT GAGAGTACCGTAAATGTATG ELGNVRRIYSPLESSLKEAG CTTCTGAGAGAGGGGAAGCC ACCCCCCCCTTTGCCAAGTC INRTRHAIVKCRLAVMRDRF CTATGGCGGCGTTAGAAAGG GACAACTGTCATGCAGGTGT VDNAPYSEHWRLYNACAENR TTGGACTGCGGCAACACTAG CTCTCTTTTCACCCGCCATA AVVVPMDSATTVKKRTARQA CCATGATCAGATTCGATCAA TGGACCAAACGCTATCCAGC GLESPSQIGVAGKRVHEAET AATAGCCTCTGGGGCTGGCG CTCGCTCAGAAGAGCCTTAG GTDRINAVIETNTTPLEDID ACCCTATAACGGATTGTAAA GGCTGGGGAGTACCACATGT LSPETPEGLAELPSTVEIME CTGAACTATGCTAACCTGTC GGCGGAAACTGAATCTGGAT LTEDGSRSRGTANDADGGVS AGTAAAGACAGAACGGGGGC GCGATGCATACCGGGAGCGC ISDPLRNRPSSSQESRNVPE TTTGCAATCTAAGGTGTTGG AGCGAAATCACTTAACGCTG QVDPDGELVWESLYGAQLRG CAGACCACTAAAACTGCCCT GTGCACCTCCTGCTATCGTA AMRTTDRPRLPKLTKFSAAE TTGATGAGGGTGAGATAACA GTACTTCCTAGATAGATGAG QLWIKSKVEKARLECVSYGI TCCTACGGAACAGCCCCTGC TAGGGTGGGCTAAAGGTAGT EQQWLRASAVLYATIKTVAA TGATCCAAACAAAATCATCC CGTCTTCAATGGCAATACCG CRPYNKAREAHKVWLENKRA ACAAATCGGAGGGTTTTCTT AGGGGTCTCGTGACAGGTGA EEKRVRRIIGRIETVRTMPK GGTAGTTTCCCTTGGCACGT GGGATAACTAGTATCAGATA GKRTDKQIRLARKINRLKRV CTTGTTTCAAAAGCCAGAAT ATATCAGTCATGAAATTAGC SFPEMDWHGFLNHFKAKLDL ATAAAACAATACCGAAGTAC AACAACCAACGTCACCGTCG LKKLISVRVAEHERKISRKI AGAATGGCTGGAACCTAACA TTGGCAAAACACCGACTAAC AGTYGKSVSGQSGFTPDVVA GCCATGGCACAGAAAACCGG GATGCTAGTTAGAAAGAGTC ATTFWSGLAQPGPKKFKKNS TGGGTGCACACCGGAGACAG GGGTCTTCCCAAAGTTAGGT LIFQTWKDSVVENMNTEPVL CAGGGGAAAGATTGCAAAGT GCTTGCACCGAAGCCGATCC LHPLIIECMNKPSPFKATGP GCCGTAAATAAAGATGGTAG GCTCTACCCACAGCTCTGCC DGIFNSYWRQGFIANWVKSL CTCTCTGACCTGAGGGAATG CAGCGTT IQRTIQTGEFPASLMCGRTV GGACACTGTCCGATTAATGC (SEQ ID NO: 1381) LLYKNGDTAKPENYRPITCL CTTATCCCGAAGACGGTCAA NGCFKMTNAVITKVIVQRVQ GGTTCTATCTTATCGGTCTC DTCALPGEQMALKPKVWACM CAAAGGGCTCTGGCCATAGA EAQLRDQALQSEIGNDCKTA AGCTGCGAGGAAGCCGTAAC WIDFSKAYDSLDHDAIRFVI CCTACGCAGATTGCCGCCGT ETLALPDGMEKYLLKSLESW GC KTKLVLSNRGKVATGRPYKI (SEQ ID NO: 1258) KRGVLQGDSLSPALFVIATS PIVSHLKRVCPSGRIQLYMD DIKLYGKSETELRMLIKEVQ KVANKLGLQMNLKKCSTYGA GLTESIAGFDPLGDRAYKYL GVPQRSVADTNLAFGELEGK VIRSIEETMACEYLTMRQVV TRLNSVIGPLVRFVAQSVLT SQAKVSWIYNKISDLDSKIR AKLAQTGLRYKKSNVARLYL SKSKNGIGLVNVQQVLVEAL VSRAIYCLRAPSLVEIREHI LTAEFDPVGAARTVLRRSRI QLEIERVEMASAISAIKTNY QARWMTKFTQSKLYQKWVHH DIDLANSNLWLERGEISPQN ARIAVAAQDNTLLCRGFVGN RESEKQCRMCNMGIETCSHI LTECSYHRAHMYIERHDSVA RNIYAVLAKDHGLWIPHYSQ PVSSVTKTPTCELYWNYKFP CTRALEACRPDIVLIDRAKR TILIVEVAVSYVTRLKQMVS RKVYKYGVNGEKGADGESRG WNMIRELSEVYNMKVNLCAV VIGASGEVLPCTVKAIQSIS SKTSSRQLLERCQRSAVLGS TRVVKRHLAEFH (SEQ ID NO: 1503) R4 R4- . Bursaphelenchus TGCCAGCGGTGTTGATTAGG TAATTAGGCAGTGCTCCTAG MEILWEDLRLKIEDRYGVTL 4_BX xylophilus TCCAAGTTCTTTGGCCAAAG CGGAGTGCCGTGAAGTGGTG PQRSASSLKNQYPKVILRGL ATCCGCCCTCGGTTTAGCAG TCAGTACCCGTCGTGTGGAA PDSGLPWAGVQVNDTGQVVV TACCGAACGAGTATACCTTC AGCCCAGGAGGGTTAGTACC VDHAEAATLRGSSPAAVDGE AAGTGGTGGCACTGAATTAG GACAGTGGGAAACCCGCTGC AEEPVVPPLPAAEVVESAAD ACTGAATACTCTGAACTGTA ACGCAACCTAAAGACATTTG AAVPDPQSEIVADQGVETRP GACTTTTGTGCAACTGTGTA CCCTTCGGGGGAGAGGTATG VENPPANSRETETEPVEVEP TGGTGTGGAAGACTTGTTTG AGACCACACTAGTCATGGTT YLEGQYKFFVSKILGKSMWR TACCACTATCAGCTTTATTG GCTTGCGCAAGCATGACTCA KPIKYPRRVPETLWRQANEL GGGCTCGTTACTGTTTCATA TTCATTGTAAGTTCGTATTA IERSIRQGEVSIQSLNCMVY CAGGTAGATGTCCCCTTTAG TGAGGCCTCGCGGAATGCGA AAGCAVKSSLDKKDQEAKRR AGATTTCCCTGCAGTTTGCG AAGTCCAAGAGCGCCAACTT ESEWYACRKAEIKALERYLN CTCCAAGTCGCTAGCCTCTT GTCTCTTTGGGAGGTTCCTC FIDLELKRRSASRPLTSRQR GCGTGTAGTCAAAGGAATAC CGGGTTCCTTAGGGTTGGCG QNLGVLITKYGRARVRSGVR ATTCGCCGTCGGTGACAGGG TACCATGCTTCGTGTGAGAC LSELQAMLRDALVGIRKCMA CTATACCCGGCGACTACGGA CTAGGCCGCTTGGACCTAGA KRSADKKRKQGKFVPIQRYL CTTGTTTATTACGTAGTGCA GTTAAGCTGTTGCATGTTTG EPSSAEPRLSPDTVRAYWND GCCTCGTTTAAGACGAATGT AGGATGCCTTAGGCGGACGC IVGSSQQSTSDSTIQDWSSN GAAAAGAAGGTGTGATTACT CATG LSVPSQELNASKIMGWWRAA AAGCGTTATGAGTCGGGTTA (SEQ ID NO: 1382) VSKSKPNKAAGPDGIPGVLW TCTGGAAACTCCGCCCCGCC KRFRSASEWVCTWLYRLLQK GCAATGGCTTCAAGGGTCAA RRIITPRWLSVGRVVLLPKK ACTGCTAACATTTTAAACCA GPLEDPANYRPIACLNTVYK ATATTTGGCAGCAGCAGACT LITSVVEMAVREQIQACPGL ATGATGTCAGAGTGCCGGGG VPYEQIANRKGVWGCTHASI GTCTATCGATATAAGACTGA VDRMITGASREGKGGGFPDL AAGCGATAGACGTGGAGTGA RVLFYDCKKAFDSVNRDHMF AAGGATTCCCTTTGTTAAGA AVLRVANVNVKVVHLLHTLS GAATCGGTAGAATTCACTTT QQWCVRYELRRNNRVERSSP TTACTTATTCAAGAACTTAA LRVKRGLLQGDTLSPTWFCL CAGCAACAAGCACTCGCGAG CMAPISASIKTLNPGPTLRP GATTACCGCCCCAGATTCGG NMGNGRNRGQVAIQVSHVFY TCGGCGGTACTTCACCTGCT MDDLKVYCPRVADQRRMEQN TTCTTCCACTTTCGGAATCT IPQLFGEIGLSINASKSAAA GGCATCCTGGCTTTCAGTGT AAVGRYVESELPVLGTKDEY GGTGATGGCCGGCTTGAGTT KYLGIESGFVVNEVAALDRM TTCTTGAGTCGTGCGAGTGC QAVLLNRVEAILSVKEHTVG CTCATCTGGGACGTCCGGAC QRRDAIRAKAIPGGAYILGH CGATTGATGGAGTCTGCAGT IILSDLDPRGAAERMRRLDI GGACGAGGACTTGATGGACC EIRRLVKSAGILHDKCSTAR GTAACCATAGTATATCCCTC IHLSCEQGGLAWPSMERAYY ATGCGTCTTCTCGACTCGAG VAVAYSASYLLTSQDETISR GGGGTAGCTTGCACTACCCA ARDYFVSGRLSNKFTVYKHL CCCTTCTCTTCTCCGATTGG TSIVDSLGLSVELPDPNGLP GATTTAGACCTAGCCCTCTG TGQPSVLARTIARAIDAKLE GTGTGTCTCGACCCGCGATA AQWKETLLTYQRAGRVERAD TCAGATTCCTGAATCGACTG PTVVDHANSYHWLRKAWINE TGAGAAATGTCTACGCGCAA KAYQHAVSVMEGTLLEGVNP AGATCGACCCATTGCCACCC HGVLTMCRACKAPSASIAHI GGCTATGTGGATCGGGCTCT ITGCAELRKSHMKVRHDGVT TGACTGCTTATCTCCGGCTT RWLYNALTEVDGSLPKFHYT TAATCGCTTGAGGAAAGGGG QQIPAEMRGERLTVRYDSDI GGTGTCGCCCGAAAGGGTTA VTPNKPRHNRPDLVVFDSTR CGCGATCATCCGATTCCTAC KVIYIVEVSVTWLSVLQKQY CGTAAAAACGTAGTTGAAGT DNKLNRYAVNSNHEFSESIP AGGATTGAACCTGAGTACCA YPPGVNLANEIRVLYPQFTG AGTGAAAAGAGTGGCTATAA GVKVFPMIISPTGEVHMQFV TGCTCCATGGTATACCCTAG PHLAELLENPNIPRILEKIQ GGATAACCGTGTCGAGCGCA RSVVLGTDYIIRSYFAM CTGCTCAATACCCTGATTTG (SEQ ID NO: 1504) TTAGTGTAGGTATGTCTAGT GGCTGCCTAGGCAGATTCGC CTATTCACTACGTAAAATCT GGGTGAGTACCATAAGAACC TCCTGTAGGGCCAGGAGTCA AACTAGTCCAGGTTCGGTAT GCTTCGGTATACTCTCTCAC GGGCTAGTCACCTAAGAGTT AAGAACCGCCTTTTTCTGCA CTGTGAATAGAAAAAGAAGG GCGGGAGAATATACGGGCGA GGTAAGCACGTCGGAACGGG GTGTGCCCAACTCGTACCGT ACGCCCGGACAAGGACCATC TTTCGTACCCCGTTCACCCG GCACAAGTCCGATTGTCTCT CCCGAGAGGCGTCGGCGGAG GTTGGCTAACGCCGTCTCTC CAACCATCGGTTTGGGTTTA AGTAACGCCCCAGTGGCCGG TAGCCAAACTGATGGAGGCA GAAATGCCGGTCCGTTGCTA AATGCGGGAACGGACCAAAA CGCCGGTGTGGTGGATACAG GTGGAAGAGTCTTTTGGTCT ACGCAAGAAAAGACCAGGCT CAAGTACGAATACGACCGTC TTCGTGAACGACGCCGTCGA GACAAAGTTCGAAATCCTAC GGTCGATAAGGCC (SEQ ID NO: 1259) R4 R4_AL U2944 Ascaris GGGGCCGGTGGGTTTACTCA TAGTCGCTAAGGGGTCCGGA MPCSTNSFFERGTPEPHREP 5 lumbricoides CTTCTGACCCACCACCAACG AATGGTCCGGTCCTGCGCTA ISGTDSSESLGMGTHRSPRL GAACGAGGGAAAGCAGAGCT CCCGGTTCTGGTAGCACGTT NDDEVINGPKGHESDPVHVV GGGGCCCTCTTCCGATTGGC CAAGCGCTCAATCGCCTGCC RAPRTLHPRRLELPIGVNNL ATGGAACCGACCTCCACGTG TTGTAGGCAGTCCATCTGTG GEASQLRQDSAIAEEAQLES GTGGCCCTGGGCAACGGAAT GAAGTCGCGCTCTTGATACA TENHDGRRPPLRGGRKLWSE TCAAGAGAGGATTTAATCCT GATGTGGACGGATGGAAGCA KEIATLRRLCEAYGNRQVCW CTCTATCATTTGCAAGATGG GATGATAGAGCCGGTGACGG KEVQRKFADFHEERTVAALA ATGAGATCGAGGTATCCGGC CCCTACTAGCCAAACGC TKWGALKRPRAPMVGAPPTP AAACAGGTTCCAAGTGAGCA (SEQ ID NO: 1383) DHDPERGPAGEGDGGTTSQE CCTTTCCCATAGCTGGGAAT NVPTDDPIPANGPTEGKESD ATGGGTTAGGCGTCCTCTGA VRPAVACRCTEPEEQLMESD CATATAAGAGGAATCAGACT VRPPAVVRLADPEQHTMKSG CGTTCGCGCCCGGTCATTAA VKPVALDGSADLEERPKEKD CATCGATCAGCGGGAGGGCC IEQMGVDFEGEPRFRAFRKA GGACTGAAGTAAATTTCCTG FYGYFRWAVNSFDREPVKRV TTGGCCCGAGTGCAGGTGGA RRDCPKVFYAYADYLIATGS GCTCGGACCCGAAAAACGAT SKALGPNQSRIGRLNGLVYA CCCTAAGAGGACCACAACCC AARTIHQFWREEVGHRQQGE GAAGGGATGGACGCAGTCGC KGWYTKTKATREDLQMLISM CCCGGCACGTTTGGTGTTGG MESELARRKEKRKPGAKELE TTATCCTGGAGTGTTGTGGG NIHKLVARLGTRSTSGIVRR ACGAATAGCT LEMTRQRLKLLEDRISLHEQ (SEQ ID NO: 1260) EKRRKRLRKQFAETPSLKLL TKGAKDRGDTMVTMKSVMDF WRPIIGRRVTSNPDQLQVLR DWRDEQKKAYPADLDLEKAD LEEKYEGAIRRIQPWKAPGP DGLHAHWWKALPSAKRLLGE LVVDWLTTGKVTTGWMCRGR TILIPKKGDRGDPSNYRPIT CLNTCYKVLTSVMNSVILSH LSRGEALPMNQRAMRKREWG CTHAMVLDRAMVMDAMAQKK HSLSVAWLDYRKAYDSVSHE YIRWAINSVNIPRSVQLTLK RLMSDWETRFESTQCRPKLR SDKMKVLNGIFQGDSLSPTL FVLCIAPISYALNKGVGQCQ SSSGWSAGYGFEIGHQFYMD DLKLYARTPAMLDSQIQVVS EVSEAMGLHLNLSKCAKAHY APHGAGGAQEAVEGAEGSRK GEIPILGLRSTYKYLGVEQR LLPMEVALKEFEDKFMDRAE TIFASELTWGQMATAYNTIA IAGLRYVYSNTNGASPKLLE ALKRAATLDTRIRDLLRRHK CRFRNSFVERLYIPRECGGY GLKSVEDTLRESILATWSYI ATNPHLAGQQYFFERLAARG KRTPMADGVKILLDLGVEPQ VDLKRRTVTVDGIVFEDPTK LHRYLVGKLLKARTEARIRR WKEASLAGRLVNDTSIDMRL SCLWMKKGFVSARNLRDALA VQEGSLLTRACPALKGKGGQ EVCRCCHAAPETAEHITSAC RYWLPSLYVERHDSVARNLY YVICCRYGITPVHYSNRVSP LSENSQCRVLWNMDMQTRTP MKHRKPDIVVFDLKREKILM FEVSIAHASGLLKQREIKIN RYTVNSEELPDETITPYPPG PNLAADLAATYGWQVEFAPV VVGTCGEHVPAVKEDLQRTL DLKPHQVEALLERISRSAVI GTARVVRAHLACS (SEQ ID NO: 1505) R4 R4_H . Heliconius ATAAATAATAATAATAATAA TAACTTATTGTCAGAATTCC ITYTANMALVTLFMENMENK mel melpomene TAATAATAAGCCCCCTAAAA TTACTAGTAATAATAATTAT RYNLRPLPGGRRGASGANAG TCCAACCATACGTCCGAGTC CGCTGAAAATCTCCACCCAA CHSMRTVGDGGLSRRVPLEK GAACATCTGATTCTCGTGGG ATATTGCTTGGCTATATGCT NVTAEQSSSPLTSSSSHSPV GGGCGGACACGTGAAAATAA CGCAATTTTTGGTTAACGTA SSIPSPSSTRTLLNSPNSSP (SEQ ID NO: 1261) CCCCAATGATTTGGGAGAAC TSSHSSLVIRSADVVQEALA AAAAATGGTAAAACTATAAT NYPAPTAGSIRARKKWTDIM AATAATAATTATATTAATAT NRYIWRTYLIITKCETTLLN (SEQ ID NO: 1384) NYLEPLHQEFSSKFPEMQVT RQRIGDQRRAIIRNKLLSDD TLAQILIEVKELLQIGDQPL TQNNIHSTQLSHSNTRIKWS NELNEEIVKCYFEVTLLEVN KTSYRKNLYSLFISRNPHLS HLTEQRIADQRRLIFMNKSV HNDRIIELKREVEIKLANSN SLTKNITESNSPSSQTNEIN DSAYVQSNLQPVEPLDQHCI NRHNLIEKHYVEQEFNNALI QFNNTNPETRPYIPRQKSSR KFSQIVSFLNSEVLPKHLNN ELDFNALHNIIYTAXYTASL CNGTKFSFIDNYRPRNSKPS WQRRLESRIDKYRLQIGRLT QYISGNRNRKILKTVEEIKT QYKIHSHHEEPNTELPHFLD TLKQKLNATSNRLRRYLTCT KRKQQNNTFVNNEKHFYRTL SSTNQNTTTQLXEHPTENNL QQYWANIWETSIEHNADAEW LNKIPDXEINXMKFKDISIE TFNQUIQRTHNWKAPGTDNI HNYWYKKLTCTHSLLLKHIN QFIQSPCTLPLFITNGITYM LPKGLDPTNPANYRPITCLQ TIYKIITACITDIIYKHIDQ NNILAEQQKGCRKNSQGCKE QLTIDAIVMKQAHNKNXNTM YIDYRKAFDSVPHSWLLYIL KKYKIHPILITFLSSVMLSW KTRLKLINNNETLITDWIKI QRGIFQGDALSPLWFCLALN PLSELLNNTNTGFKLKHNNT YHIISHLMYMDDIKLYASNN KELKILADLTQSFSTDIRME FGIEKCKVHSIKRGKSQQNT YILNTGEQIESMDENSTYKY LGFQQAKQIQQKQTKIELTN KFKFRLNQILRSQLNSRNII KAINTYAIPILTYSFAIINW SQTDLSNLQRIINTHMTTHR KHHPKSCIQRLTISRLDGGR GLIDIRNLHNNLVTKFRNYF YAKAEISELHKFIVNIDNKY TPLNLNDRNIQLNQTLITKQ QKIEAWSLKSLHGRHLADLS QTHVDKVASNEWLRRGDLFP ETEAFMMAIQDQVIDTRNYQ KHIIKRPNMVNDLCRRCYSS PETIQHITGACKTIVQTDYK HRHDQVAAIIHQHLAFKHSL ITQAQKTPYYKYSPQAILES TNFKLYWDRTIITDKTVHYN RPDILLHDKVKXSVYLIDIA IPNTHNLASTFSNKIDKYTD LTIELKSQWKVQSVTTVPIV LSTTGVVPHTLHTSLETLGI HRLSYILLQKAAILNTCRIV RKFLSSNN (SEQ ID NO: 1506) R4 Rex6 Takifugu TTCTATGCGCCTTATGCGAC TAGAGGACCCGAGTCTGAAG MSGTXTDRVIPARTSPGSTR rubripes TGGATAGGCCAGTGGTTTAC GAAGGAGGCACCGCCCAGGA SASGVGEPGPPDVKLATGTR GCCGCTGACTTTGGTGCGGA GGGCGAGGAAGAGATTTTTT HSWSRAENVVLMECYYGSNP AGGTTGTCGGTTCGAATCCA TTTATATATATATATATATA SERGYMQRMWEKWVLRNPTS GGCGAGCCCTTAGGCAAGGC TATA SLTKKQLLAQCSNIRNKKLL TCCTTACGCATATATGCCTA (SEQ ID NO: 1385) SQLEIDEARRCASPTVQICY CACCTCGGT GKGEPGRQVSXGVISSSPPN (SEQ ID NO: 1262) IEIGYKAPMTDGLGTRAADL RERIMKSWGNSTTSLPRLTH KVPDQSLLEDMNTALSTIPT TTITETNQLMYAAATVILQM LGYKMKSMNSQKEQMAPWRR RLEAKIMATRREVSLLTELS RGVNLRTEXPKKYNKLSTTE ALETAKQRLTALATRLKRYT REVEARRINKVFSTNPAKVY SQWQGNKMTTDPPRAETEQY WKSIWEKEATHNTXAQWLQD LQTEHSQLPEQDPVVITLAD IQTRVSKMKSWTAPGPDKIH AYWLKKLTALHERLAAQMNQ LLTSGNHPEWLTQGRTVLIM KDPQKGTIPSNYRPITCLST TWKLLSGIIAAKISRHMDQY MSRAQKGIGNNTRGAKHQLL VDRAIAQDCRTRHTNLCTAW IDYKKAYDSMPHTWILECLK LYNINRTLREFIQNSMKLWN TTLEANSKPIARVSIRCGIY QGDALSPLLFCIGLNPLSQI ITKSGYGYQFRSGTTVSHLL YMDDIKLYAKNERDIDSLIH LTRIYSKDIGMSFGLDKCGR MISRRGKVIATDGVELPEGN ITDVQDSYKYLGIPQANGNH EEAARRSATAKYLQRLRQVL KSQLNGKNKIQAINTYALPV IRYPAGIIPWPLEEIQATDI KTRKLNGKHKIQAINTYALP VIRYPAGIIPWPLEEIQATD IKTRKLLTMHGGFHPKSSVL RLYTKRKEGGRGLVSVRTTV QEETTSLREYIKKMAPTDRL LSECLRQQKPTKEEEPEGLS WKDKPLHGMYHRQIEEVADI EKTYQWLEKAGLKDSTEALL MAAQEQALSTRAIEARVYHT RQDPRCRLCGDAPETVQHIT AGCKMLAGKAYMERHNQVAG IVYRNICTEYGLEVPGSRWE TPPKVLENKQAKILWDFQIQ TDKMVVANQPDIVVVDKHQK TVVVIDVAIPSDSNIRKKEH EKLEKYQGLKEEMERMWGMK ATVVPVVIGTLGAVTPKLSR WLQQIPGTTSEISVQKSAVL GTAKILRRTLRLPGLW (SEQ ID NO: 1507)

TABLE 30 Exemplary monomeric retroviral reverse transcriptases and  their RT domain signatures RT Name Accession Organism Sequence Signatures Q4VF Q4VFZ2 Porcine MGATGQQQYPWTTRRTVDLGVGRVT IPR043502, Z2_9 endogenous HSFLVIPECPAPLLGRDLLTKMGAQISF SSF56672, GAM retrovirus EQGKPEVSANNKPITVLTLQLDDEYRL IPR000477, R- YSPLVKPDQNIQFWLEQFPQAWAETA PF00078, resi- GMGLAKQVPPQVIQLKASATPVSVRQ cd03715 dues YPLSKEAQEGIRPHVQRLIQQGILVPVQ only SPWNTPLLPVRKPGTNDYRPVQDLRE VNKRVQDIHPTVPNPYNLLCALPPQRS WYTVLDLKDAFFCLRLHPTSQPLFAFE WRDPGTGRTGQLTWTRLPQGFKNSPTI FDEALHRDLANFRIQHPQVTLLQYVDD LLLAGATKQDCLEGTKALLLELSDLGY RASAKKAQICRREVTYLGYSLRDGQR WLTEARKKTVVQIPAPTTAKQVREFLG TAGFCRLWIPGFATLAAPLYPLTKEKG EFSWAPEHQKAFDAIKKALLSAPALAL PDVTKPFTLYVDERKGVARGVLTQTL GPWRRPVAYLSKKLDPVASGWPVCLK AIAAVAILVKDADKLTLGQNITVIAPH ALENIVRQPPDRWMTNARMTHYQSLL LTERVTFAPPAALNPATLLPEETDEPVT HDCHQLLIEETGVRKDLTDIPLTGEVLT WFTDGSSYVVEGKRMAGAAVVDGTR TIWASSLPEGTSAQKAELMALTQALRL AEGKSINIYTDSRYAFATAHVHGAIYK QRGLLTSAGREIKNKEEILSLLEALHLP KRLAIIHCPGHQKAKDPISRGNQMADR VAKQAAQGVNLLPMIETPKAPEPGRQ YTLEDWQEIKKIDQFSETPEGTCYTSD GKEILPHKEGLEYVQQIHRLTHLGTKH LQQLVRTSPYHVLRLPGVADSVVKHC VPCQLVNANPSRIPPGKRLRGSHPGAH WEVDFTEVKPAKYGNKYLLVFVDTFS GWVEAYPTKKETSTVVAKKILEEIFPR FGIPKVIGSDNGPAFVAQVSQGLAKILG IDWKLHCAYRPQSSGQVERMNRTIKET LTKLTAETGVNDWIALLPFVLFRVRNT PGQFGLTPYELLYGGPPPLVEIASVHSA DVLLSQPLFSRLKALEWVRQRAWRQL REAYSGGGDLQIPHRFQVGDSVYVRR HRAGNLETRWKGPYHVLLTTPTAVKV EGISTWIHASHVKPAPPPDSGWKAEKT ENPLKLRLHRVVPYSVNNFSS (SEQ ID NO: 1559) POL_ P23074 Simian MDPLQLLQPLEAEIKGTKLKAHWDSG IPR043502, SFV1- foamy ATITCVPEAFLEDERPIQTMLIKTIHGEK SSF56672, resi- virus  QQDVYYLTFKVQGRKVEAEVLASPYD IPR000477, dues type 1 YILLNPSDVPWLMKKPLQLTVLVPLHE PF00078 only YQERLLQQTALPKEQKELLQKLFLKY DALWQHWENQVGHRRIKPHNIATGTL APRPQKQYPINPKAKPSIQIVIDDLLKQ GVLIQQNSTMNTPVYPVPKPDGKWRM VLDYREVNKTIPLIAAQNQHSAGILSSI YRGKYKTTLDLTNGFWAHPITPESYW LTAFTWQGKQYCWTRLPQGFLNSPAL FTADVVDLLKEIPNVQAYVDDIYISHD DPQEHLEQLEKIFSILLNAGYVVSLKKS EIAQREVEFLGFNITKEGRGLTDTFKQK LLNITPPKDLKQLQSILGLLNFARNFIPN YSELVKPLYTIVANANGKFISWTEDNS NQLQHIISVLNQADNLEERNPETRLIIK VNSSPSAGYIRYYNEGSKRPIMYVNYIF SKAEAKFTQTEKLLTTMHKGLIKAMD LAMGQEILVYSPIVSMTKIQRTPLPERK ALPVRWITWMTYLEDPRIQFHYDKSLP ELQQIPNVTEDVIAKTKHPSEFAMVFY TDGSAIKHPDVNKSHSAGMGIAQVQFI PEYKIVHQWSIPLGDHTAQLAEIAAVE FACKKALKISGPVLIVTDSFYVAESAN KELPYWKSNGFLNNKKKPLRHVSKW KSIAECLQLKPDIIIMHEKGHQQPMTTL HTEGNNLADKLATQGSYVVHCNTTPS LDAELDQLLQGHYPPGYPKQYKYTLE ENKLIVERPNGIRIVPPKADREKIISTAH NIAHTGRDATFLKVSSKYWWPNLRKD VVKSIRQCKQCLVTNATNLTSPPILRPV KPLKPFDKFYIDYIGPLPPSNGYLHVLV VVDSMTGFVWLYPTKAPSTSATVKAL NMLTSIAIPKVLHSDQGAAFTSSTFAD WAKEKGIQLEFSTPYHPQSSGKVERKN SDIKRLLTKLLIGRPAKWYDLLPVVQL ALNNSYSPSSKYTPHQLLFGVDSNTPF ANSDTLDLSREEELSLLQEIRSSLHQPT SPPASSRSWSPSVGQLVQERVARPASL RPRWHKPTAILEVVNPRTVIILDHLGN RRTVSVDNLKLTAYQDNGTSNDSGTM ALMEEDESSTSST (SEQ ID NO: 1560) POL_ P07572 Mason- MGQELSQHERYVEQLKQALKTRGVK IPR043502, MPM Pfizer VKYADLLKFFDFVKDTCPWFPQEGTID SSF56672, V- monkey IKRWRRVGDCFQDYYNTFGPEKVPVT IPR000477, resi- virus AFSYWNLIKELIDKKEVNPQVMAAVA PF00078, dues QTEEILKSNSQTDLTKTSQNPDLDLISL cd01645, only DSDDEGAKSSSLQDKGLSSTKKPKRFP PF06817, VLLTAQTSKDPEDPNPSEVDWDGLED IPR010661 EAAKYHNPDWPPFLTRPPPYNKATPSA PTVMAVVNPKEELKEKIAQLEEQIKLE ELHQALISKLQKLKTGNETVTHPDTAG GLSRTPHWPGQHIPKGKCCASREKEEQ IPKDIFPVTETVDGQGQAWRHHNGFDF AVIKELKTAASQYGATAPYTLAIVESV ADNWLTPTDWNTLVRAVLSGGDHLL WKSEFFENCRDTAKRNQQAGNGWDF DMLTGSGNYSSTDAQMQYDPGLFAQI QAAATKAWRKLPVKGDPGASLTGVK QGPDEPFADFVHRLITTAGRIFGSAEAG VDYVKQLAYENANPACQAAIRPYRKK TDLTGYIRLCSDIGPSYQQGLAMAAAF SGQTVKDFLNNKNKEKGGCCFKCGKK GHFAKNCHEHAHNNAEPKVPGLCPRC KRGKHWANECKSKTDNQGNPIPPHQG NRVEGPAPGPETSLWGSQLCSSQQKQP ISKLTRATPGSAGLDLCSTSHTVLTPEM GPQALSTGIYGPLPPNTFGLILGRSSITM KGLQVYPGVIDNDYTGEIKIMAKAVN NIVTVSQGNRIAQLILLPLIETDNKVQQ PYRGQGSFGSSDIYWVQPITCQKPSLTL WLDDKMFTGLIDTGADVTIIKLEDWPP NWPITDTLTNLRGIGQSNNPKQSSKYL TWRDKENNSGLIKPFVIPNLPVNLWGR DLLSQMKIMMCSPNDIVTAQMLAQGY SPGKGLGKKENGILHPIPNQGQSNKKG FGNFLTAAIDILAPQQCAEPITWKSDEP VWVDQWPLTNDKLAAAQQLVQEQLE AGHITESSSPWNTPIFVIKKKSGKWRLL QDLRAVNATMVLMGALQPGLPSPVAI PQGYLKIIIDLKDCFFSIPLHPSDQKRFA FSLPSTNFKEPMQRFQWKVLPQGMAN SPTLCQKYVATAIHKVRHAWKQMYII HYMDDILIAGKDGQQVLQCFDQLKQE LTAAGLHIAPEKVQLQDPYTYLGFELN GPKITNQKAVIRKDKLQTLNDFQKLLG DINWLRPYLKLTTGDLKPLFDTLKGDS DPNSHRSLSKEALASLEKVETAIAEQF VTHINYSLPLIFLIFNTALTPTGLFWQD NPIMWIHLPASPKKVLLPYYDAIADLII LGRDHSKKYFGIEPSTIIQPYSKSQIDW LMQNTEMWPIACASFVGILDNHYPPN KLIQFCKLHTFVFPQIISKTPLNNALLVF TDGSSTGMAAYTLTDTTIKFQTNLNSA QLVELQALIAVLSAFPNQPLNIYTDSAY LAHSIPLLETVAQIKHISETAKLFLQCQ QLIYNRSIPFYIGHVRAHSGLPGPIAQG NQRADLATKIVASNINTNLESAQNAHT LHHLNAQTLRLMFNIPREQARQIVKQC PICVTYLPVPHLGVNPRGLFPNMIWQM DVTHYSEFGNLKYIHVSIDTFSGFLLAT LQTGETTKHVITHLLHCFSIIGLPKQIKT DNGPGYTSKNFQEFCSTLQIKHITGIPY NPQGQGIVERAHLSLKTTIEKIKKGEW YPRKGTPRNILNHALFILNFLNLDDQN KSAADRFWHNNPKKQFAMVKWKDPL DNTWHGPDPVLIWGRGSVCVYSQTYD AARWLPERLVRQVSNNNQSRE (SEQ ID NO: 1561) POL_ P03365 Mouse MGVSGSKGQKLFVSVLQRLLSERGLH IPR043502, MMT mammary VKESSAIEFYQFLIKVSPWFPEEGGLNL SSF56672, VB- tumor QDWKRVGREMKRYAAEHGTDSIPKQ IPR000477, resi- virus AYPIWLQLREILTEQSDLVLLSAEAKSV PF00078, dues TEEELEEGLTGLLSTSSQEKTYGTRGT cd01645, only AYAEIDTEVDKLSEHIYDEPYEEKEKA PF06817, DKNEEKDHVRKIKKVVQRKENSEGKR IPR010661 KEKDSKAFLATDWNDDDLSPEDWDD LEEQAAHYHDDDELILPVKRKVVKKK PQALRRKPLPPVGFAGAMAEAREKGD LTFTFPVVFMGESDEDDTPVWEPLPLK TLKELQSAVRTMGPSAPYTLQVVDMV ASQWLTPSDWHQTARATLSPGDYVL WRTEYEEKSKEMVQKAAGKRKGKVS LDMLLGTGQFLSPSSQIKLSKDVLKDV TTNAVLAWRAIPPPGVKKTVLAGLKQ GNEESYETFISRLEEAVYRMMPRGEGS DILIKQLAWENANSLCQDLIRPIRKTGT IQDYIRACLDASPAVVQGMAYAAAMR GQKYSTFVKQTYGGGKGGQGAEGPV CFSCGKTGHIRKDCKDEKGSKRAPPGL CPRCKKGYHWKSECKSKFDKDGNPLP PLETNAENSKNLVKGQSPSPAQKGDG VKGSGLNPEAPPFTIHDLPRGTPGSAGL DLSSQKDLILSLEDGVSLVPTLVKGTLP EGTTGLIIGRSSNYKKGLEVLPGVIDSD FQGEIKVMVKAAKNAVIIHKGERIAQL LLLPYLKLPNPVIKEERGSEGFGSTSHV HWVQEISDSRPMLHIYLNGRRFLGLLD TGADKTCIAGRDWPANWPIHQTESSLQ GLGMACGVARSSQPLRWQHEDKSGII HPFVIPTLPFTLWGRDIMKDIKVRLMT DSPDDSQDLMIGAIESNLFADQISWKS DQPVWLNQWPLKQEKLQALQQLVTE QLQLGHLEESNSPWNTPVFVIKKKSGK WRLLQDLRAVNATMHDMGALQPGLP SPVAVPKGWEIIIIDLQDCFFNIKLHPED CKRFAFSVPSPNFKRPYQRFQWKVLPQ GMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMI QALNKHGLVVSTEKIQKYDNLKYLGT HIQGDSVSYQKLQIRTDKLRTLNDFQK LLGNINWIRPFLKLTTGELKPLFEILNG DSNPISTRKLTPEACKALQLMNERLST ARVKRLDLSQPWSLCILKTEYTPTACL WQDGVVEWIHLPHISPKVITPYDIFCTQ LIIKGRHRSKELFSKDPDYIVVPYTKVQ FDLLLQEKEDWPISLLGFLGEVHFHLP KDPLLTFTLQTAIIFPHMTSTTPLEKGIV IFTDGSANGRSVTYIQGREPIIKENTQN TAQQAEIVAVITAFEEVSQPFNLYTDSK YVTGLFPEIETATLSPRTKIYTELKHLQ RLIHKRQEKFYIGHIRGHTGLPGPLAQG NAYADSLTRILTALESAQESHALHHQN AAALRFQFHITREQAREIVKLCPNCPD WGHAPQLGVNPRGLKPRVLWQMDVT HVSEFGKLKYVHVTVDTYSHFTFATA RTGEATKDVLQHLAQSFAYMGIPQKIK TDNAPAYVSRSIQEFLARWKISHVTGIP YNPQGQAIVERTHQNIKAQLNKLQKA GKYYTPHHLLAHALFVLNHVNMDNQ GHTAAERHWGPISADPKPMVMWKDL LTGSWKGPDVLITAGRGYACVFPQDA ETPIWVPDRFIRPFTERKEATPTPGTAE KTPPRDEKDQQESPKNESSPHQREDGL ATSAGVDLRSGGGP  (SEQ ID NO: 1562) POL_ P03355 Moloney MGQTVTTPLSLTLGHWKDVERIAHNQ IPR043502, MLV murine SVDVKKRRWVTFCSAEWPTFNVGWP SSF56672, MS- leukemia RDGTFNRDLITQVKIKVFSPGPHGHPD IPR000477, resi- virus QVPYIVTWEALAFDPPPWVKPFVHPKP PF00078, dues PPPLPPSAPSLPLEPPRSTPPRSSLYPALT cd03715 only PSLGAKPKPQVLSDSGGPLIDLLTEDPP PYRDPRPPPSDRDGNGGEATPAGEAPD PSPMASRLRGRREPPVADSTTSQAFPL RAGGNGQLQYWPFSSSDLYNWKNNN PSFSEDPGKLTALIESVLITHQPTWDDC QQLLGTLLTGEEKQRVLLEARKAVRG DDGRPTQLPNEVDAAFPLERPDWDYT TQAGRNHLVHYRQLLLAGLQNAGRSP TNLAKVKGITQGPNESPSAFLERLKEA YRRYTPYDPEDPGQETNVSMSFIWQSA PDIGRKLERLEDLKNKTLGDLVREAEK IFNKRETPEEREERIRRETEEKEERRRTE DEQKEKERDRRRHREMSKLLATVVSG QKQDRQGGERRRSQLDRDQCAYCKE KGHWAKDCPKKPRGPRGPRPQTSLLT LDDQGGQGQEPPPEPRITLKVGGQPVT FLVDTGAQHSVLTQNPGPLSDKSAWV QGATGGKRYRWTTDRKVHLATGKVT HSFLHVPDCPYPLLGRDLLTKLKAQIH FEGSGAQVMGPMGQPLQVLTLNIEDE HRLHETSKEPDVSLGSTWLSDFPQAW AETGGMGLAVRQAPLIIPLKATSTPVSI KQYPMSQEARLGIKPHIQRLLDQGILV PCQSPWNTPLLPVKKPGTNDYRPVQD LREVNKRVEDIHPTVPNPYNLLSGLPPS HQWYTVLDLKDAFFCLRLHPTSQPLFA FEWRDPEMGISGQLTWTRLPQGFKNSP TLFDEALHRDLADFRIQHPDLILLQYV DDLLLAATSELDCQQGTRALLQTLGN LGYRASAKKAQICQKQVKYLGYLLKE GQRWLTEARKETVMGQPTPKTPRQLR EFLGTAGFCRLWIPGFAEMAAPLYPLT KTGTLFNWGPDQQKAYQEIKQALLTA PALGLPDLTKPFELFVDEKQGYAKGVL TQKLGPWRRPVAYLSKKLDPVAAGWP PCLRMVAAIAVLTKDAGKLTMGQPLV ILAPHAVEALVKQPPDRWLSNARMTH YQALLLDTDRVQFGPVVALNPATLLPL PEEGLQHNCLDILAEAHGTRPDLTDQP LPDADHTWYTDGSSLLQEGQRKAGAA VTTETEVIWAKALPAGTSAQRAELIAL TQALKMAEGKKLNVYTDSRYAFATA HIHGEIYRRRGLLTSEGKEIKNKDEILA LLKALFLPKRLSIIHCPGHQKGHSAEAR GNRMADQAARKAAITETPDTSTLLIEN SSPYTSEHFHYTVTDIKDLTKLGAIYDK TKKYWVYQGKPVMPDQFTFELLDFLH QLTHLSFSKMKALLERSHSPYYMLNR DRTLKNITETCKACAQVNASKSAVKQ GTRVRGHRPGTHWEIDFTEIKPGLYGY KYLLVFIDTFSGWIEAFPTKKETAKVV TKKLLEEIFPRFGMPQVLGTDNGPAFV SKVSQTVADLLGIDWKLHCAYRPQSS GQVERMNRTIKETLTKLTLATGSRDW VLLLPLALYRARNTPGPHGLTPYEILY GAPPPLVNFPDPDMTRVTNSPSLQAHL QALYLVQHEVWRPLAAAYQEQLDRP VVPHPYRVGDTVWVRRHQTKNLEPR WKGPYTVLLTTPTALKVDGIAAWIHA AHVKAADPGGGPSSRLTWRVQRSQNP LKIRLTREAP  (SEQ ID NO: 1563) POL_ P03362 Human T- MGQIFSRSASPIPRPPRGLAAHHWLNFL IPR043502, HTL1 cell QAAYRLEPGPSSYDFHQLKKFLKIALE SSF56672, A- leukemia TPARICPINYSLLASLLPKGYPGRVNEIL IPR000477, resi- virus 1 HILIQTQAQIPSRPAPPPPSSPTHDPPDS PF00078 dues DPQIPPPYVEPTAPQVLPVMHPHGAPP only NHRPWQMKDLQAIKQEVSQAAPGSPQ FMQTIRLAVQQFDPTAKDLQDLLQYL CSSLVASLHHQQLDSLISEAETRGITGY NPLAGPLRVQANNPQQQGLRREYQQL WLAAFAALPGSAKDPSWASILQGLEEP YHAFVERLNIALDNGLPEGTPKDPILRS LAYSNANKECQKLLQARGHTNSPLGD MLRACQTWTPKDKTKVLVVQPKKPPP NQPCFRCGKAGHWSRDCTQPRPPPGP CPLCQDPTHWKRDCPRLKPTIPEPEPEE DALLLDLPADIPHPKNLHRGGGLTSPP TLQQVLPNQDPASILPVIPLDPARRPVI KAQVDTQTSHPKTIEALLDTGADMTV LPIALFSSNTPLKNTSVLGAGGQTQDH FKLTSLPVLIRLPFRTTPIVLTSCLVDTK NNWAIIGRDALQQCQGVLYLPEAKRPP VILPIQAPAVLGLEHLPRPPQISQFPLNP ERLQALQHLVRKALEAGHIEPYTGPGN NPVFPVKKANGTWRFIHDLRATNSLTI DLSSSSPGPPDLSSLPTTLAHLQTIDLRD AFFQIPLPKQFQPYFAFTVPQQCNYGP GTRYAWKVLPQGFKNSPTLFEMQLAH ILQPIRQAFPQCTILQYMDDILLASPSHE DLLLLSEATMASLISHGLPVSENKTQQ TPGTIKFLGQIISPNHLTYDAVPTVPIRS RWALPELQALLGEIQWVSKGTPTLRQP LHSLYCALQRHTDPRDQIYLNPSQVQS LVQLRQALSQNCRSRLVQTLPLLGAIM LTLTGTTTVVFQSKEQWPLVWLHAPL PHTSQCPWGQLLASAVLLLDKYTLQS YGLLCQTIHHNISTQTFNQFIQTSDHPS VPILLHHSHRFKNLGAQTGELWNTFLK TAAPLAPVKALMPVFTLSPVIINTAPCL FSDGSTSRAAYILWDKQILSQRSFPLPP PHKSAQRAELLGLLHGLSSARSWRCL NIFLDSKYLYHYLRTLALGTFQGRSSQ APFQALLPRLLSRKVVYLHHVRSHTNL PDPISRLNALTDALLITPVLQLSPAELHS FTHCGQTALTLQGATTTEASNILRSCH ACRGGNPQHQMPRGHIRRGLLPNHIW QGDITHFKYKNTLYRLHVWVDTFSGAI SATQKRKETSSEAISSLLQAIAHLGKPS YINTDNGPAYISQDFLNMCTSLAIRHTT HVPYNPTSSGLVERSNGILKTLLYKYF TDKPDLPMDNALSIALWTINHLNVLTN CHKTRWQLHHSPRLQPIPETRSLSNKQ THWYYFKLPGLNSRQWKGPQEALQEA AGAALIPVSASSAQWIPWRLLKRAACP RPVGGPADPKEKDLQHHG  (SEQ ID NO: 1564) POL_ P14350 Human MNPLQLLQPLPAEIKGTKLLAHWDSG IPR043502, FOA spumaretro- ATITCIPESFLEDEQPIKKTLIKTIHGEK SSF56672, MV- virus QQNVYYVTFKVKGRKVEAEVIASPYE IPR000477, resi- YILLSPTDVPWLTQQPLQLTILVPLQEY PF00078 dues QEKILSKTALPEDQKQQLKTLFVKYDN only LWQHWENQVGHRKIRPHNIATGDYPP RPQKQYPINPKAKPSIQIVIDDLLKQGV LTPQNSTMNTPVYPVPKPDGRWRMVL DYREVNKTIPLTAAQNQHSAGILATIV RQKYKTTLDLANGFWAHPITPESYWL TAFTWQGKQYCWTRLPQGFLNSPALF TADVVDLLKEIPNVQVYVDDIYLSHDD PKEHVQQLEKVFQILLQAGYVVSLKKS EIGQKTVEFLGFNITKEGRGLTDTFKTK LLNITPPKDLKQLQSILGLLNFARNFIPN FAELVQPLYNLIASAKGKYIEWSEENT KQLNMVIEALNTASNLEERLPEQRLVI KVNTSPSAGYVRYYNETGKKPIMYLN YVFSKAELKFSMLEKLLTTMHKALIKA MDLAMGQEILVYSPIVSMTKIQKTPLP ERKALPIRWITWMTYLEDPRIQFHYDK TLPELKHIPDVYTSSQSPVKHPSQYEGV FYTDGSAIKSPDPTKSNNAGMGIVHAT YKPEYQVLNQWSIPLGNHTAQMAEIA AVEFACKKALKIPGPVLVITDSFYVAES ANKELPYWKSNGFVNNKKKPLKHISK WKSIAECLSMKPDITIQHEKGISLQIPVF ILKGNALADKLATQGSYVVNCNTKKP NLDAELDQLLQGHYIKGYPKQYTYFL EDGKVKVSRPEGVKIIPPQSDRQKIVLQ AHNLAHTGREATLLKIANLYWWPNM RKDVVKQLGRCQQCLITNASNKASGPI LRPDRPQKPFDKFFIDYIGPLPPSQGYL YVLVVVDGMTGFTWLYPTKAPSTSAT VKSLNVLTSIAIPKVIHSDQGAAFTSST FAEWAKERGIHLEFSTPYHPQSGSKVE RKNSDIKRLLTKLLVGRPTKWYDLLPV VQLALNNTYSPVLKYTPHQLLFGIDSN TPFANQDTLDLTREEELSLLQEIRTSLY HPSTPPASSRSWSPVVGQLVQERVARP ASLRPRWHKPSTVLKVLNPRTVVILDH LGNNRTVSIDNLKPTSHQNGTTNDTAT MDHLEKNE (SEQ ID NO: 1565) POL_ P03361 Bovine MGNSPSYNPPAGISPSDWLNLLQSAQR IPR043502, BLVJ- leukemia LNPRPSPSDFTDLKNYIHWFHKTQKKP SSF56672, resi- virus WTFTSGGPTSCPPGRFGRVPLVLATLN IPR000477, dues EVLSNEGGAPGASAPEEQPPPYDPPAIL PF00078 only PIISEGNRNRHRAWALRELQDIKKEIEN KAPGSQVWIQTLRLAILQADPTPADLE QLCQYIASPVDQTAHMTSLTAAIAAAE AANTLQGFNPKTGTLTQQSAQPNAGD LRSQYQNLWLQAGKNLPTRPSAPWSTI VQGPAESSVEFVNRLQISLADNLPDGV PKEPIIDSLSYANANRECQQILQGRGPV AAVGQKLQACAQWAPKNKQPALLVH TPGPKMPGPRQPAPKRPPPGPCYRCLK EGHWARDCPTKATGPPPGPCPICKDPS HWKRDCPTLKSKNKLIEGGLSAPQTIT PITDSLSEAELECLLSIPLARSRPSVAVY LSGPWLQPSQNQALMLVDTGAENTVL PQNWLVRDYPRIPAAVLGAGGVSRNR YNWLQGPLTLALKPEGPFITIPKILVDT SDKWQILGRDVPSRLQASISIPEEVRPP VVGVLDTPPSHIGLEHLPPPPEVPQFPL NLERLQALQDLVHRSLEAGYISPWDGP GNNPVFPVRKPNGAWRFVHDLRATNA LTKPIPALSPGPPDLTAIPTHPPHIICLDL KDAFFQIPVEDRFRFYLSFTLPSPGGLQ PHRRFAWRVLPQGFINSPALFERALQE PLRQVSAAFSQSLLVSYMDDILYASPT EEQRSQCYQALAARLRDLGFQVASEK TSQTPSPVPFLGQMVHEQIVTYQSLPTL QISSPISLHQLQAVLGDLQWVSRGTPTT RRPLQLLYSSLKRHHDPRAIIQLSPEQL QGIAELRQALSHNARSRYNEQEPLLAY VHLTRAGSTLVLFQKGAQFPLAYFQTP LTDNQASPWGLLLLLGCQYLQTQALS SYAKPILKYYHNLPKTSLDNWIQSSED PRVQELLQLWPQISSQGIQPPGPWKTLI TRAEVFLTPQFSPDPIPAALCLFSDGAT GRGAYCLWKDHLLDFQAVPAPESAQK GELAGLLAGLAAAPPEPVNIWVDSKY LYSLLRTLVLGAWLQPDPVPSYALLYK SLLRHPAIVVGHVRSHSSASHPIASLNN YVDQLLPLETPEQWHKLTHCNSRALS RWPNPRISAWDPRSPATLCETCQKLNP TGGGKMRTIQRGWAPNHIWQADITHY KYKQFTYALHVFVDTYSGATHASAKR GLTTQTTIEGLLEAIVHLGRPKKLNTD QGANYTSKTFVRFCQQFGVSLSHHVP YNPTSSGLDERTNGLLKLLLSKYHLDE PHLPMTQALSRALWTHNQINLLPILKT RWELHHSPPLAVISEGGETPKGSDKLF LYLLPGQNNRRWLGPLPALVEASGGA LLATDPPVWVPWRLLKAFKCLKNDGP EDAHNRSSDG  (SEQ ID NO: 1566) O4189 O41894 Bovine MPALRPLQVEIKGNHLKGYWDSGAEI IPR043502, 4_9RE foamy TCVPAIYIIEEQPVGKKLITTIHNEKEHD SSF56672, TR- virus VYYVEMKIEKRKVQCEVIATALDYVL IPR000477, resi- VAPVDIPWYKPGPLELTIKIDVESQKHT PF00078 dues LITESTLSPQGQMRLKKLLDQYQALW only QCWENQVGHRRIEPHKIATGALKPRPQ KQYHINPRAKADIQIVIDDLLRQGVLR QQNSEMNTPVYPVPKADGRWRMVLD YREVNKVTPLVATQNCHSASILNTLYR GPYKSTLDLANGFWAHPIKPEDYWITA FTWGGKTYCWTVLPQGFLNSPALFTA DVVDILKDIPNVQVYVDDVYVSSATE QEHLDILETIFNRLSTAGYIVSLKKSKL AKETVEFLGFSISQNGRGLTDSYKQKL MDLQPPTTLRQLQSILGLINFARNFLPN FAELVAPLYQLIPKAKGQCIPWTMDHT TQLKTIIQALNSTENLEERRPDVDLIMK VHISNTAGYIRFYNHGGQKPIAYNNAL FTSTELKFTPTEKIMATIHKGLLKALDL SLGKEIHVYSAIASMTKLQKTPLSERK ALSIRWLKWQTYFEDPRIKFHHDATLP DLQNLPVPQQDTGKEMTILPLLHYEAI FYTDGSAIRSPKPNKTHSAGMGIIQAKF EPDFRIVHLWSFPLGDHTAQYAEIAAF EFAIRRATGIRGPVLIVTDSNYVAKSYN EELPYWESNGFVNNKKKTLKHISKWK AIAECKNLKADIHVIHEPGHQPAEASP HAQGNALADKQAVSGSYKVFSNELKP SLDAELEQVLSTGRPNPQGYPNKYEYK LVNGLCYVDRRGEEGLKIIPPKADRVK LCQLAHDGPGSAHLGRSALLLKLQQK YWWPRMHIDASRIVLNCTVCAQTNST NQKPRPPLVIPHDTKPFQVWYMDYIGP LPPSNGYQHALVIVDAGTGFTWIYPTK AQTANATVKALTHLTGTAVPKVLHSD QGPAFTSSILADWAKDRGIQLEHSAPY HPQSSGKVERKNSEIKRLLTKLLAGRP TKWYPLIPIVQLALNNTPNTRQKYTPH QLMYGADCNLPFENLDTLDLTREEQL AVLKEVRDGLLDLYPSPSQTTARSWTP SPGLLVQERVARPAQLRPKWRKPTPIK KVLNERTVIIDHLGQDKVVSIDNLKPA AHQKLAQTPDSAEICPSATPCPPNTSL WYDLDTGTWTCQRCGYQCPDKYHQP QCTWSCEDRCGHRWKECGNCIPQDGS SDDASAVAAVEI (SEQ ID NO: 1567) POL_ Q7SVK7 Murine MGQTVTTPLSLTLEHWGDVQRIASNQ IPR043502, MLV leukemia SVGVKKRRWVTFCSAEWPTFGVGWP SSF56672, BM- virus QDGTFNLDIILQVKSKVFSPGPHGHPD IPR000477, resi- QVPYIVTWEAIAYEPPPWVKPFVSPKL PF00078, dues SLSPTAPILPSGPSTQPPPRSALYPAFTP cd03715 only SIKPRPSKPQVLSDDGGPLIDLLTEDPPP YGEQGPSSPDGDGDREEATSTSEIPAPS PMVSRLRGKRDPPAADSTTSRAFPLRL GGNGQLQYWPFSSSDLYNWKNNNPSF SEDPGKLTALIESVLTTHQPTWDDCQQ LLGTLLTGEEKQRVLLEARKAVRGND GRPTQLPNEVNSAFPLERPDWDYTTPE GRNHLVLYRQLLLAGLQNAGRSPTNL AKVKGITQGPNESPSAFLERLKEAYRR YTPYDPEDPGQETNVSMSFIWQSAPAI GRKLERLEDLKSKTLGDLVREAEKIFN KRETPEEREERIRRETEEKEERRRAGDE QREKERDRRRQREMSKLLATVVTGQR QDRQGGERRRPQLDKDQCAYCKEKG HWAKDCPKKPRGPRGPRPQTSLLTLD DQGGQGQEPPPEPRITLTVGGQPVTFL VDTGAQHSVLTQNPGPLSDRSAWVQG ATGGKRYRWTTDRKVHLATGKVTHSF LHVPDCPYPLLGRDLLTKLKAQIHFEG SGAQVVGPKGQPLQVLTLGIEDEYRLH ETSTEPDVSLGSTWLSDFPQAWAETGG MGLAVRQAPLIIPLKATSTPVSIQQYPM SHEARLGIKPHIQRLLDQGILVPCQSPW NTPLLPVKKPGTNDYRPVQDLREVNK RVEDIHPTVPNPYNLLSGLPPSHQWYT VLDLKDAFFCLRLHPTSQPLFAFEWRD PGMGISGQLTWTRLPQGFKNSPTLFDE ALHRDLADFRIQHPDLILLQYVDDILLA ATSELDCQQGTRALLQTLGDLGYRAS AKKAQICQKQVKYLGYLLREGQRWLT EARKETVMGQPVPKTPRQLREFLGTA GFCRLWIPGFAEMAAPLYPLTKTGTLF SWGPDQQKAYQEIKQALLTAPALGLP DLTKPFELFVDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRM VAAIAVLTKDAGKLTMGQPLVILAPH AVEALVKQPPDRWLSNARMTHYQAM LLDTDRVQFGPVVALNPATLLPLPEEG APHDCLEILAETHGTRPDLTDQPIPDAD HTWYTDGSSFLQEGQRKAGAAVTTET EVIWAGALPAGTSAQRAELIALTQALK MAEGKRLNVYTDSRYAFATAHIHGEI YRRRGLLTSEGREIKNKSEILALLKALF LPKRLSIIHCLGHQKGDSAEARGNRLA DQAAREAAIKTPPDTSTLLIEDSTPYTP AYFHYTETDLKKLRDLGATYNQSKGY WVFQGKPVMPDQFVFELLDSLHRLTH LGYQKMKALLDRGESPYYMLNRDKT LQYVADSCTVCAQVNASKAKIGAGVR VRGHRPGTHWEIDFTEVKPGLYGYKY LLVFVDTFSGWVEAFPTKRETARVVSK KLLEEIFPRFGMPQVLGSDNGPAFTSQ VSQSVADLLGIDWKLHCAYRPQSSGQ VERINRTIKETLTKLTLAAGTRDWVLL LPLALYRARNTPGPHGLTPYEILYGAPP PLVNFHDPDMSELTNSPSLQAHLQALQ TVQREIWKPLAEAYRDRLDQPVIPHPF RIGDSVWVRRHQTKNLEPRWKGPYTV LLTTPTALKVDGISAWIHAAHVKAATT PPIKPSWRVQRSQNPLKIRLTRGAP (SEQ ID NO: 2453)

TABLE 31 Exemplary dimeric retroviral reverse transcriptases and their RT domain signatures RT Name Accession Organism Sequence Signatures Q8313 Q83133 Avian RATVLTVALHLAIPLKWKPN IPR043502, 3_AVI myeloblastosis- HTPVWIDQWPLPEGKLVALT SSF56672, MA associated QLVEKELQLGHIEPSLSCWN IPR000477, virus type TPVFVIRKASGSYRLLHDLR PF00078, 1 AVNAKLVPFGAVQQGAPVLS cd01645, ALPRGWPLMVLDLKDCFFSI PF06817, PLAEQDREAFAFTLPSVNNQ IPR010661 APARRFQWKVLPQGMTCSPT ICQLIVGQILEPLRLKMPSL RMLHYMDDLLLAASSHDGLE AAGEEVISTLERAGFTISPD KVQREPGVQYLGYKLGSTYV APVGLVAEPRIATLWDVQKL VGSLQSVRPALGIPPRLMGP FYEQLRGSDPNEAREWNLDM KMAWREIVQLSTTAALERWD PALPLEGAVARCEQGAIGVL GQGLSTHPRPCLWLFSTQPT KAFTAWLEVLTLLITKLRAS AVRTFGKEVDILLLPACFRE DLPLPEGILLALRGFAGKIR SSDTPSIFDIARPLHVSLKV RVTDHPVPGPTVFTDASSST HKGVVVWREGPRWEIKEIAD LGASVQQLEARAVAMALLLW PTTPTNVVTDSAFVAKMLLK MGQEGVPSTAAAFILEDALS QRSAMAAVLHVRSHSEVPGF FTEGNDVADSQATFQAYPLR EAKDLHTALHIGPRALSKAC NISMQQAREVVQTCPHCNSA PALEAGVNPRGLGPLQIWQT DFTLEPRMAPRSWLAVTVDT ASSAIVVTQHGRVTSVAAQH HWATAIAVLGRPKAIKTDNG SCFTSKSTREWLARWGIAHT TGIPGNSQGQAMVERANRLL KDKIRVLAEGDGFMKRIPTS KQGELLAKAMYALNHFERGE NTKTPIQKHWRPTVLTEGP PVKIRIETGEWEKGWNVLVW GRGYAAVKNRDTDKVIWVPS RKVKPDITQKDEVTKKDEAS PLFAGISDWAPWEGEQEGLQ EETASNKQERPGEDTPAANE S (SEQ ID NO: 1568) POL_ P05896 Simian MGARNSVLSGKKADELEKIR IPR043502, SIVM immuno- LRPGGKKKYMLKHVVWAANE SSF56672, 1 deficiency LDRFGLAESLLENKEGCQKI IPR000477, virus LSVLAPLVPTGSENLKSLYN PF00078, TVCVIWCIHAEEKVKHTEEA PF06817, KQIVQRHLVMETGTAETMPK IPR010661, TSRPTAPFSGRGGNYPVQQI PF06815, GGNYTHLPLSPRTLNAWVKL IPR010659 IEEKKFGAEVVSGFQALSEG CLPYDINQMLNCVGDHQAAM QIIRDIINEEAADWDLQHPQ QAPQQGQLREPSGSDIAGTT STVEEQIQWMYRQQNPIPVG NIYRRWIQLGLQKCVRMYNP TNILDVKQGPKEPFQSYVDR FYKSLRAEQTDPAVKNWMTQ TLL1QNANPDCKLVLKGLGT NPTLEEMLTACQGVGGPGQK ARLMAEALKEALAPAPIPFA AAQQKGPRKPIKCWNCGKEG HSARQCRAPRRQGCWKCGKM DHVMAKCPNRQAGFFRPWPL GKEAPQFPHGSSASGADANC SPRRTSCGSAKELHALGQAA ERKQREALQGGDRGFAAPQF SLWRRPVVTAHIEGQPVEVL LDTGADDSIVTGIELGPHYT PKIVGGIGGFINTKEYKNVE IEVLGKRIKGTIMTGDTPIN IFGRNLLTALGMSLNLPIAK VEPVKSPLKPGKDGPKLKQW PLSKEKIVALREICEKMEKD GQLEEAPPTNPYNTPTFAIK KKDKNKWRMLIDFRELNRVT QDFTEVQLGIPHPAGLAKRK RITVLDIGDAYFSIPLDEEF RQYTAFTLPSVNNAEPGKRY IYKVLPQGWKGSPAIFQYTM RHVLEPFRKANPDVTLVQYM DDILIASDRTDLEHDRVVLQ LKELLNSIGFSSPEEKFQKD PPFQWMGYELWPTKWKLQKI ELPQRETWTVNDIQKLVGVL NWAAQIYPGIKTKHLCRLIR GKMTLTEEVQWTEMAEAEYE ENKIILSQeqegcyyqeskp leatviksQdnqwsYKIHQE DKILKVGKFAKIKNTHTNGV RLLAHVIQKIGKEAIVIWGQ VPKFHLPVEKDVWEQVVWTD YWQVTWIPEWDFISTPPLVR LVFNLVKDPIEGEETYYVDG SCSKQSKEGKAGYITDRGKD KVKVLEQTTNQQAELEAFLM ALTDSGPKANIIVDSQYVMG IITGCPTESESRLVNQIIEE MIKKTEIYVAWVPAHKGIGG NQEIDHLVSQGIRQVLFLEK IEPAQEEHSKYHSNIKELVF KFGLPRLVAKQIVDTCDKCH QKGEAIHGQVNSDLGTWQMD CTHLEGKIVIVAVHVASGFI EAEVIPQETGRQTALFLLKL ASRWPITHLHTDNGANFASQ EVKMVAWWAGIEHTFGVPYN PQSQGVVEAMNHHLKNQIDR IREQANSVETIVLMAVHCMN FKRRGGIGDMTPAERLINMI TTEQEIQFQQSKNSKFKNFR VYYREGRDQLWKGPGELLWK GEGAVILKVGTDIKVVPRRK AKIIKDYGGGKEMDSSSHME DTGEAREVA (SEQ ID NO: 1569) POL_ P03354 Rous MEAVIKVISSACKTYCGKTS IPR043502, RSVP sarcoma PSKKEIGAMLSLLQKEGLLM SSF56672, virus SPSDLYSPGSWDPITAALSQ 1PR000477, RAMILGKSGELKTWGLVLGA PF00078, LKAAREEQVTSEQAKFWLGL cd01645, GGGRVSPPGPECIEKPATER PF06817, RIDKGEEVGETTVQRDAKMA IPR010661 PEETATPKTVGTSCYHCGTA IGCNCATASAPPPPYVGSGL YPSLAGVGEQQGQGGDTPPG AEQSRAEPGHAGQAPGPALT DWARVREELASTGPPVVAMP VVIKTEGPAWTPLEPKLITR LADTVRTKGLRSPITMAEVE ALMSSPLLPHDVTNLMRVIL GPAPYALWMDAWGVQLQTVI AAATRDPRHPANGQGRGERT NLNRLKGLADGMVGNPQGQA ALLRPGELVAITASALQAFR EVARLAEPAGPWADIMQGPS ESFVDFANRLIKAVEGSDLP PSARAPVIIDCFRQKSQPDI QQLIRTAPSTLTTPGEIIKY VLDRQKTAPLTDQGIAAAMS SAIQPLIMAVVNRERDGQTG SGGRARGLCYTCGSPGHYQA QCPKKRKSGNSRERCQLCNG MGHNAKQCRKRDGNQGQRPG KGLSSGPWPGPEPPAVSLAM TMEHKDRPLVRVILTNTGSH PVKQRSVYITALLDSGADIT IISEEDWPTDWPVMEAANPQ IHGIGGGIPMRKSRDMIELG VINRDGSLERPLLLFPAVAM VRGSILGRDCLQGLGLRLTN LIGRATVLTVALHLAIPLKW KPDHTPVWIDQWPLPEGKLV ALTQLVEKELQLGHIEPSLS CWNTPVFVIRKASGSYRLLH DLRAVNAKLVPFGAVQQGAP VLSALPRGWPLMVLDLKDCF FSIPLAEQDREAPAFTLPSV NNQAPARRFQWKVLPQGMTC SPTICQLVVGQVLEPLRLKH PSLCMLHYMDDLLLAASSHD GLEAAGEEVISTLERAGFTI SPDKVQREPGVQYLGYKLGS TYVAPVGLVAEPRIATLWDV QKLVGSLQWLRPALGIPPRL MGPFYEQLRGSDPNEAREWN LDMKMAWREIVRLSTTAALE RWDPALPLEGAVARCEQGAI GVLGQGLSTHPRPCLWLFST QPTKAFTAWLEVLTLLITKL RASAVRTFGKEVDILLLPAC FREDLPLPEGILLALKGFAG KIRSSDTPSIFDIARPLHVS LKVRVTDHPVPGPTVFTDAS SSTHKGVVVWREGPRWEIKE IADLGASVQQLEARAVAMAL LLWPTTPTNVVTDSAFVAKM LLKMGQEGVPSTAAAFILED ALSQRSAMAAVLHVRSHSEV PGFFTEGNDVADSQATFQAY PLREAKDLHTALHIGPRALS KACNISMQQAREVVQTCPHC NSAPALEAGVNPRGLGPLQI WQTDFTLEPRMAPRSWLA VTVD TASSAIVVTQHGRVTSVAVQ HHWATAIAVLGRPKAIKTDN GSCFTSKSTREWLARWGIAH TTGIPGNSQGQAMVERANRL LKDRIRVLAEGDGFMKRIPT SKQGELLAKAMYALNHFERG ENTKTPIQKHWRPTVLTEGP PVKIRIETGEWEKGWNVLVW GRGYAAVKNRDTDKVIWVPS RKVKPDITQKDEVTKKDEAS PLFAGISDWIPWEDEQEGLQ GETASNKQERPGEDTLAANE S (SEQ ID NO: 1570) POL_ P15833 Human MGARGSVLSGKKTDELEKVR IPR043502, HV2D immuno- LRPGGKKKYMLKHVVWAVNE SSF56672, 2 deficiency LDRFGLAESLLESKEGCQKI IPR000477, virus type LKVLAPLVPTGSENLKSLFN PF00078, 2 IVCVIFCLHAEEKVKDTEEA PF06817, KKIAQRHLAADTEKMPATNK IP010661, PTAPPSGGNYPVQQLAGNYV PF06815, HLPLSPRTLNAWVKLVEEKK IPR010659 FGAEVVPGFQALSEGCTPYD INQMLNCVGEHQAAMQIIRE IINEEAADWDQQHPSPGPMP AGQLRDPRGSDIAGTTSTVE EQIQWMYRAQNPVPVGNIYR RWIQLGLQKCVRMYNPTNIL DIKQGPKEPFQSYVDRFYKS LRAEQTDPAVKNWMTQTLLI QNANPDCKLVLKGLGMNPTL EEMLTACQGIGGPGQKARLM AEALKEALTPAPIPFAAVQQ KAGKRGTVTCWNCGKQGHTA RQCRAPRRQGCWKCGKTGHI MSKCPERQAGFLRVRTLGKE ASQLPHDPSASGSDTICTPD EPSRGHDTSGGDTICAPCRS SSGDAEKLHADGETTEREPR ETLQGGDRGFAAPQFSLVVR RPVVKACIEGQSVEVLLDTG VDDSIVAGIELGSNYTPKIV GGIGGFINTKEYKDVEIEVV GKRVRATIMTGDTPINIFGR NILNTLGMTLNFPVAKVEPV KVELKPGKDGPKIRQWPLSR EKILALKEICEKMEKEGQLE EAPPTNPYNTPTFAIKKKDK NKWRMLIDFRELNKVTQDFT EVNWVFPTRQVAEKRRITVI DVGDAYFSIPLDPNFRQYTA FTLPSVNNAEPGKRYIYKVL PQGWKGSQSICQYSMRKVLD PFRKANSDVIIIQYMDDILI ASDRSDLEHDRVVSQLKELL NDMGFSTPEEKFQKDPPFKW MGYELWPKKWKLQKIQLPEK EVWTVNAIQKLVGVLNWAAQ LFPGIKTRHICKLIRGKMTL TEEVQWTELAEAELQENKII LEQEQEGSYYKERVPLEATV QKNLANQWTYKIHQGNKVLK VGKYAKVKNTHTNGVRLLAH VVQKIGKEALVIWGEIPVFH LPVERETWDQWWTDYWQVTW IPEWDFVSTPPLIRLAYNLV KDPLEGRETYYTDGSCNRTS KEGKAGYVTDRGKDKVKVLE QTTNQQAELEAFALALTDSE PQVNIIVDSQYVMGIIAAQP TETESPIVAKIIEEMIKKEA VYVGWVPAHKGLGGNQEVDH LVSQGIRQVLFLEKIEPAQE EHEKYHGNVKELVHKFGIPQ LVAKQIVNSCDKCQQKGEAI HGQVNADLGTWQMDCTHLEG KIIIVAVHVASGFIEAEVIP QETGRQTALFLLKLASRWPI THLHTDNGANFTSPSVKMVA WWVGIEQTFGVPYNPQSQGV VEAMNHHLKNQIDRLRDQAV SIETVVLMATHCMNFKRRGG IGDMTPAERLVNMITTEQEI QFFQAKNLKFQNFQVYYREG RDQLWKGPGELLWKGEGAVI IKVGTEIKVVPRRKAKIIRH YGGGKGLDCSADMEDTRQAR EMAQSD (SEQ ID NO: 1571) POL_ P03369 Human MGARASVLSGGELDKWEKIR IPR043502, HV1A immuno- LRPGGKKKYKLKHIVWASRE SSF56672, 2 deficiency LERFAVNPGLLETSEGCRQI IPR000477, virus type LGQLQPSLQTGSEELRSLYN PF00078, 1 TVATLYCVHQRIDVKDTKEA cd01645, LEKIEEEQNKSKKKAQQAAA PF06817, AAGTGNSSQVSQNYPIVQNL IPR010661, QGQMVHQAISPRTLNAWVKV PF06815, VEEKAFSPEVIPMFSALSEG IPR010659 ATPQDLNTMLNTVGGHQAAM QMLKETINEEAAEWDRVHPV HAGPIAPGQMREPRGSDIAG TTSTLQEQIGWMTNNPPIPV GEIYKRWIILGLNKIVRMYS PTSILDIRQGPKEPFRDYVD RFYKTLRAEQASQDVKNWMT ETLLVQNANPDCKTILKALG PAATLEEMMTACQGVGGPGH KARVLAEAMSQVTNPANIMM QRGNFRNQRKTVKCFNCGKE GHIAKNCRAPRKKGCWRCGR EGHQMKDCTERQANFLREDL AFLQGKAREFSSEQTRANSP TRRELQVWGGENNSLSEAGA DRQGTVSFNFPQITLWQRPL VTIRIGGQLKEALLDTGADD TVL EEMNLPGKWKPKMIGGIGGF IKVRQYDQIPVEICGHKAIG TVLVGPTPVNIIGRNLLTQI GCTLNFPISPIETVPVKLKP GMDGPKVKQWPLTEEKIKAL VEICTEMEKEGKISKIGPEN PYNTPVFAIKKKDSTKWRKL VDFRELNKRTQDFWEVQLGI PHPAGLKKKKSVTVLDVGDA YFSVPLDKDFRKYTAFTIPS INNETPGIRYQYNVLPQGWK GSPAIFQSSMTKILEPFRKQ NPDIVIYQYMDDLYVGSDLE IGQHRTKIEELRQHLLRWGF TTPDKKHQKEPPFLWMGYEL HPDKWTVQPIMLPEKDSWTV NDIQKLVGKLNWASQIYAGI KVKQLCKLLRGTKALTEVIP LTEEAELELAENREILKEPV HEVYYDPSKDLVAEIQKQGQ GQWTYQIYQEPFKNLKTGKY ARMRGAHTNDVKQLTEAVQK VSTESIVIWGKIPKFKLPIQ KETWEAWWMEYWQATWIPEW EFVNTPPLVKLWYQLEKEPI VGAETFYVDGAANRETKLGK AGYVTDRGRQKVVSIADTTN QKTELQAIHLALQDSGLEVN IVTDSQYALGIIQAQPDKSE SELVSQIIEQLIKKEKVYL AWVPAHKGIGGNEQV DKLVSAGIRKVLFLNGIDKA QEEHEKYHSNWRAMASDFNL PPVVAKEIVASCDKCQLKGE AMHGQVDCSPGIWQLDCTHL EGKIILVAVHVASGYIEAEV IPAETGQETAYFLLKLAGRW PVKTIHTDNGSNFTSTTVKA ACWWAGIKQEFGIPYNPQSQ GVVESMNNELKKIIGQVRDQ AEHLKTAVQMAVFIHNFKRK GGIGGYSAGERIVDIIATDI QTKELQKQITKIQNFRVYYR DNKDPLWKGPAKLLWKGEGA VVIQDNSDIKVVPRRKAKII RDYGKQMAGDDCVASRQDED (SEQ ID NO: 1572) POL_ P16088 Feline KEFGKLEGGASCSPSESNAA IPR043502, FIVPE Immuno- SSNAICTSNGGETIGFVNYN SSF56672, deficiency KVGTTTTLEKRPEILIFVNG IPR000477, virus YPIKFLLDTGADITILNRRD PF00078, FQVKNSIENGRQNMIGVGGG PF06817, KRGTNYINVHLEIRDENYKT IPR010661, QCIFGNVCVLEDNSLIQPLL PF06815, GRDNMIKFNIRLVMAQISDK IPR010659 IPVVKVKMKDPNKGPQIKQW PLTNEKIEALTEIVERLEKE GKVKRADSNNPWNTPVFAIK KKSGKWRMLIDFRELNKLTE KGAEV0LGLPHPAGLQIKK QVTVLDIGDAYFTIPLD PDYAPYTAFTLPRKNNAGPG RRFVWCSLPQGWILSPLIYQ STLDNIIQPFIRQNPQLDIY QYMDDIYIGSNLSKKEHKEK VEELRKLLLWWGFETPEDKL QEEPPYTWMGYELHPLTWTI QQKQLDIPEQPTLNELQKLA GKINWASQAIPDLSIKALTN MMRGNQNLNSTRQWTKEARL EVQKAKKAIEEQVQLGYYDP SKELYAKLSLVGPHQISYQV YQKDPEKILWYGKMSRQKKK AENTCDIALRACYKIREESI IRIGKEPRYEIPTSREAWES NLINSPYLKAPPPEVEYIHA ALNIKRALSMIKDAPIPGAE TWYIDGGRKLGKAAKAAYWT DTGKWRVMDLEGSNQKAEIQ ALLLALKAGSEEMNIITDSQ YVINIILQQPDMMEGIWQEV LEELEKKTAIFIDWVPGHKG IPGNEEVDKLCQTMMIIEGD GILDKRSEDAGYDLLAAKEI HLLPGEVKVIPTGVKLMLPK GYWGLIIGKSSIGSKGLDVL GGVIDEGYRGEIGVIMINVS RKSITLMERQKIAQLIILPC KHEVLEQGKVVMDSERGDNG YGSTGVFSSWVDRIEEAEIN FIEKFHSDPQYLRTEFNLPK MVAEEIRRKCPVCRIIGEQV GGQLKIGPGIWQMDCTHFDG KIILVGIHVESGYIWAQIIS QETADCTVKAVLQLLSAHNV TELQTDNGPNFKNQKMEGVL NYMGVKHKFGIPGNPQSQAL VENVNHTLKVWIQKFLPETT SLDNALSLAVHSLNFKRRGR IGGMAPYELLAQQESLRIQD YFSAIPQKLQAQWIYYKDQK DKKWKGPMRVEYWGQGSVLL KDEEKGYFLIPRRHIRRVPE PCALPEGDE (SEQ ID NO: 1573) POL_ P03371 Equine TAWTFLKAMQKCSKKREARG IPR043502, EIAVY infectious SREAPETNFPDTTEESAQQI SSF56672, anemia CCTRDSSDSKSVPRSERNKK IPR000477, virus GIQCQGEGSSRGSQPGQFVG PF00078, VTYNLEKRPTTIVLINDTPL PF06817, NVLLDTGADTSVLTTAHYNR IPR010661, LKYRGRKYQGTGIIGVGGNV PF06815, ETFSTPVTIKKKGRHIKTRM IPR010659 LVADIPVTILGRDILQDLGA KLVLAQLSKEIKFRKIELKE GTMGPKIPQWPLTKEKLEGA KETVQRLLSEGKISEASDNN PYNSPIFVIKKRSGKWRLLQ DLRELNKTVQVGTEISRGLP HPGGLIKCKHMTVLDIGDAY FTIPLDPEFRPYTAFTIPSI NHQEPDKRYVWKCLPQGFVL SPYIYQKTLQEILQPFRERY PEVQLYQYMDDLFVGSNGSK KQHKELIIELRAILQKGFET PDDKLQEVPPYSWLGYQLCP ENWKVQKMQLDMVKNPTLND VQKLMGNITWMSSGVPGLTV KHIAATTKGCLELNQKVIWT EEAQKELEENNEKIKNAQGL QYYNPEEEMLCEVEITKNYE ATYVIKQSQGILWAGKKIMK ANKGWSTVKNLMLLLQHVAT ESITRVGKCPTFKVPFTKEQ VMWEMQKGWYYSWLPEIVYT HQVVHDDWRMKLVEEPTSGI TIYTDGGKQNGEGIAAYVTS NGRTKQKRLGPVTHQVAERM AIQMALEDTRDKQVNIVTDS YYCWKNITEGLGLEGPQNPW WPIIQNIREKEIVYFAWVPG HKGIYGNQLADEAAKIKEEI MLAYQGTQIKEKRDEDAGFD LCVPYDIMIPVSDTKIIPTD VKIQVPPNSFGWVTGKSSMA KQGLLINGGIIDEGYTGEIQ VICTNIGKSNIKLIEGQKFA QLIILQHHSNSRQPWDENKI SQRGDKGFGSTGVFWVENIQ EAQDEHENWHTSPKILARNY KIPLTVAKQITQECPHCTKQ GSGPAGCVMRSPNHWQADCT HLDNKIILHFVESNSGYIHA TLLSKENALCTSLAILEWAR LFSPKSLHTDNGTNFVAEPV VNLLKFLKIAHTTGIPYHPE SQGIVERANRTLKEKIQSHR DNTQTLEAALQLALITCNKG RESMGGQTPWEVFITNQAQV IHEKLLLQQAQSSKKFCFYK IPGEHDWKGPTRVLWKGDGA VVVNDEGKGIIAVPLTRTKL LIKPN (SEQ ID NO: I574) POL_ P19560 Bovine MKRRELEKKLRKVRVTPQQD IPR043502, BIV29 Immuno- KYYTIGNLQWAIRMINLMGI SSF56672, deficiency KCVCDEECSAAEVALIITQF IPR000477, virus SALDLENSPIRGKEEVAIKN PF00078, TLKVFWSLLAGYKPESTETA PF06817, LGYWEAFTYREREARADKEG IPR010661 EIKSIYPSLTQNTQNKKQTS NQTNTQSLPAITTQDGTPRF DPDLMKQLKIWSDATERNGV DLHAVNILGVITANLVQEEI KLLLNSTPKWRLDVQLIESK VREKENAHRTWKQHHPEAPK TDEIIGKGLSSAEQATLISV ECRETFRQWVLQAAMEVAQA KHATPGPINIHQGPKEPYTD FINRLVAALEGMAAPETTKE YLLQHLSIDHANEDCQSILR PLGPNTPMEKKLEACRVVGS QKSKMQFLVAAMKEMGIQSP IPAVLPHTPEAYASQTSGPE DGRRCYGCGKTGHLKRNCKQ QKCYHCGKPGHQARNCRSKN REVLLCPLWAEEPTTEQFSP EQHEFCDPICTPSYIRLDKQ PFIKVFIGGRWVKGLVDTGA DEVVLKNIHWDRIKGYPGTP IKQIGVNGVNVAKRKTHVEW RFKDKTGIIDVLFSDTPVNL FGRSLLRSIVTCFTLLVHTE KIEPLPVKVRGPGPKVPQWP LTKEKYQALKEIVKDLLAEG KISEAAWDNPYNTPVFVIKK KGTGRWRMLMDFRELNKITV KGQEFSTGLPYPPGIKECEH LTAIDIKDAYFTIPLHEDFR PFTAFSVVPVNREGPIERFQ WNVLPQGWVCSPAIYQTTTQ KIIENIKKSHPDVMLYQYMD DLLIGSNRDDHKQIVQEIRD KLGSYGFKTPDEKVQEERVK WIGFELTPKKWRFQPRQLKI KNPLTVNELQQLVGNCVWVQ PEVKIPLYPLTDLLRDKTNL QEKIQLTPEAIKCVEEFNLK LKDPEWKDRIREGAELVIKI QMVPRGIVFDLLQDGNPIWG GVKGLNYDHSNKIKKILRTM NELNRTVVIMTGREASFLLP GSSEDWEAALQKEESLTQIF PVKFYRHSCRWTSICGPVRE NLTTYYTDGGKKGKTAAAVY WCEGRTKSKVFPGTNQQAEL KAICMALLDGPPKMNIITDS RYAYEGMREEPETWAREGIW LEIAKILPFKQYVGVGWVPA HKGIGGNTEADEGVKKALEQ MAPCSPPEAILLKPGEKQNL ETGIYMQGLRPQSFLPRADL PVAITGTMVDSELQLQLLNI GTEHIRIQKDEVFMTCFLEN IPSATEDHERWHTSPDILVR QFHLPKRIAKEIVARCQECK RTTTSPVRGTNPRGRFLWQM DNTHWNKTIIWVAVETNSGL VEAQVIPEETALQVALCILQ LIQRYTVLHLHSDNGPCFTA HRIENLCKYLGITKTTGIPY NPQSQGVVERAHRDLKDRLA AYQGDCETVEAALSLALVSL NKKRGGIGGHTPYEIYLESE HTKYQDQLEQQFSKQKIEKW CYVRNRRKEWKGPYKVLWDG DGAAVIEEEGKTALYPHRHM RFIPPPDSDIQDGSS (SEQ ID NO: 1575) A0A1 A0A142B KH1 TVALHLAIPLKWKPDHTPVW IPR043502, 42BK Avian IDQWPLPEGKLVALTQLVEK SSF56672, H1_A leukosis ELQLGHIEPSLSCWNTPVFV IPR000477, LV and IRKASGSYRLLHDLRAVNAK PF00078, sarcoma LVPFGAVQQGAPVLSALPRG cd01645, virus WPLMVLDLKDCFFSIPLAEQ PF06817, DREAFAFTLPSVNNQAPARR IPR010661 FQWKVLPQGMTCSPTICQLV VGQVLEPLRLKHPSLRMLHY MDDLLLAASSHDGLEAAGEE VISTLERAGFTISPDKIQRE PGVQYLGYKLGSTYVAPVGL VAEPRIATLWDVQKLVGSLQ WLRPALGIPPRLMGPFYEQL RGSDPNEAREWNLDMKMAWR EIVQLSTTAALERWDPALPL EGAVARCEQGAIGVLGQGLS THPRPCLWLFSTQPTKAFTA WLEVLTLLITKLRASAVRTF GKEVDVLLLPACFREDLPLP EGILLALRGFAGKIRSSDTP SIFDIARPLHVSLKVRVTDH PVPGPTVFTDASSSTHKGVV VWREGPRWEIKEIADLGASV QQLEARAVAMALLLWPTTPT NVVTDSAFVAKMLLKMGQEG VPSTAAAFILEDALSQRSAM AAVLHVRSHSEVPGFFTEGN DVADSQATFQAYPLREAKDL HTALHIGPRALSKACNISMQ QAREVVQTCPHCNSAPALEA GVNPRGLGPLQIWQTDFTLE PRMAPRSWLAVTVATASSAI VVTQHGRVTSVAARHHWATA IAVLGRPKAIKTDNGSCFTS KSTREWLARWGIAHTTGIPG NSQGQAMVERANRLLKDKIR VLAEGDGFMKRIPTGKQGEL LAKAMYALNHFERGENTKTP IQKHWRPTVLTEGPPVKIRI ETGEWEKGWNVLVWGRGYAA VKNRDTDKIIWVPSRKVKPD ITQKDELTKKDEASPLFAGI SDWAPWKGEQEGL (SEQ ID NO: 1576) 

TABLE 32 InterPro descriptions of signatures present in reverse transcriptases in Table 30 (monomeric viral RTs) and Table 31 (dimeric viral RTs). Signature Database Short Name Description cd01645 CDD RT_Rtv RT_Rtv: Reverse transcriptases (RTs) from retroviruses (Rtvs). RTs catalyze the conversion of single-stranded RNA into double-stranded viral DNA for integration into host chromosomes. Proteins in this subfamily contain long terminal repeats (LTRs) and are multifunctional enzymes with RNA-directed DNA polymerase, DNA directed DNA polymerase, and ribonuclease hybrid (RNase H) activities. The viral RNA genome enters the cytoplasm as part of a nucleoprotein complex, and the process of reverse transcription generates in the cytoplasm forming a linear DNA duplex via an intricate series of steps. This duplex DNA is colinear with its RNA template, but contains terminal duplications known as LTRs that are not present in viral RNA. It has been proposed that two specialized template switches, known as strand-transfer reactions or “jumps”, are required to generate the LTRs. [PMID: 9831551, PMID: 15107837, PMID: 11080630, PMID: 10799511, PMID: 7523679, PMID: 7540934, PMID: 8648598, PMID: 1698615] cd03715 CDD RT_ZFREV_like RT_ZFREV_like: A subfamily of reverse transcriptases (RTs) found in sequences similar to the intact endogenous retrovirus ZFERV from zebrafish and to Moloney murine leukemia virus RT. An RT gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. RTs occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. These elements can be divided into two major groups. One group contains retroviruses and DNA viruses whose propagation involves an RNA intermediate. They are grouped together with transposable elements containing long terminal repeats (LTRs). The other group, also called poly(A)- type retrotransposons, contain fungal mitochondrial introns and transposable elements that lack LTRs. Phylogenetic analysis suggests that ZFERV belongs to a distinct group of retroviruses. [PMID: 14694121, PMID: 2410413, PMID: 9684890, PMID: 10669612, PMID: 1698615, PMID: 8828137] PF00078 Pfam RVT_1 A reverse transcriptase gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. Reverse transcriptases occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. [PMID: 1698615] IPR000477 InterPro RT dom The use of an RNA template to produce DNA, for integration into the host genome and exploitation of a host cell, is a strategy employed in the replication of retroid elements, such as the retroviruses and bacterial retrons. The enzyme catalysing polymerisation is an RNA-directed DNA-polymerase, or reverse trancriptase (RT) (2.7.7.49). Reverse transcriptase occurs in a variety of mobile elements, including retrotransposons, retroviruses, group II introns [PMID: 12758069], bacterial msDNAs, hepadnaviruses, and caulimoviruses. Retroviral reverse transcriptase is synthesised as part of the POL polyprotein that contains; an aspartyl protease, a reverse transcriptase, RNase H and integrase. POL polyprotein undergoes specific enzymatic cleavage to yield the mature proteins. The discovery of retroelements in the prokaryotes raises intriguing questions concerning their roles in bacteria and the origin and evolution of reverse transcriptases and whether the bacterial reverse transcriptases are older than eukaryotic reverse transcriptases [PMID: 8828137], Several crystal structures of the reverse transcriptase (RT) domain have been determined [PMID: 1377403], IPR043502 InterPro DNA/RNA This entry represents the DNA/RNA polymerase polymerase superfamily, which includes DNA superfamily polymerase I, reverse transcriptase, T7 RNA polymerase, lesion bypass DNA polymerase (Y-family), RNA-dependent RNA-polymerase and dsRNA phage RNA-dependent RNA- polymerase. These enzymes share a similar protein fold at their active site, which resembles the palm subdomain of the right- hand-shaped polymerases. [PMID: 26931141] SSF56672 Superfamily DNA/RNA This superfamily comprises DNA polymerases polymerases and RNA polymerases PF06817 Pfam RVT_thumb This domain is known as the thumb domain. It is composed of a four helix bundle [PMID: 1377403], IPR010661 InterPro RVT thumb This domain is known as the thumb domain. It is composed of a four helix bundle. Reverse transcriptase converts the viral RNA genome into double-stranded viral DNA. Reverse transcriptase often occurs in a polyprotein; with integrase, ribonuclease H and/or protease, which is cleaved before the enzyme takes action. The impact of antiretroviral treatment on the first 400 amino acids of HIV reverse transcriptase is good. Little is known, however, of the antiretroviral drug impact on the C-terminal domains of Pol, which includes the thumb, connection and RNase H. Evidence suggests that these might be well conserved domains. [PMID: 1377403, PMID: 18335052] PF06815 Pfam RVT_connect This domain is known as the connection domain. This domain lies between the thumb and palm domains [PMID: 1377403], IPR010659 InterPro RVT connect This domain is known as the connection domain. This domain lies between the thumb and palm domains [PMID: 1377403], cd03715 CDD RT ZFREV like RT_ZFREV_like: A subfamily of reverse transcriptases (RTs) found in sequences similar to the intact endogenous retrovirus ZFERV from zebrafish and to Moloney murine leukemia virus RT. An RT gene is usually indicative of a mobile element such as a retrotransposon or retrovirus. RTs occur in a variety of mobile elements, including retrotransposons, retroviruses, group II introns, bacterial msDNAs, hepadnaviruses, and caulimoviruses. These elements can be divided into two major groups. One group contains retroviruses and DNA viruses whose propagation involves an RNA intermediate. They are grouped together with transposable elements containing long terminal repeats (LTRs). The other group, also called poly(A)- type retrotransposons, contain fungal mitochondrial introns and transposable elements that lack LTRs. Phylogenetic analysis suggests that ZFERV belongs to a distinct group of retroviruses. [PMID: 14694121, PMID: 2410413, PMID: 9684890, PMID: 10669612, PMID: 1698615, PMID: 8828137]

Lengthy table referenced here US20230272430A1-20230831-T00002 Please refer to the end of the specification for access instructions. Table 44 provides Retroviral reverse transcriptase domains for use in Gene Writer polypeptides. Wild-type reverse transcriptase enzymes were collected and prioritized as according to the descriptions herein (see Example 33). The Type column indicates whether the sequence corresponds to a wild-type sequence (“root”) or comprises mutations that may improve the activity of the enzyme (“derivative”).

TABLE 44 Retroviral reverse transcriptase domains for use in Gene Writer polypeptides. In some embodiments, a system or method described herein involves a reverse transcriptase domain having an amino acid sequence according to a reverse transcriptase domain of Table 44, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, or functional fragment thereof. SEQ Virus_ Uniprot_ ID name name ID type NO: peptide AVIRE_ AVIRE P03360 root 3136 TAPLEEEYRLFLEAPIQNVTLLEQWKREIPKVWAEINPPGLASTQAPIHV P03360 QLLSTALPVRVRQYPITLEAKRSLRETIRKFRAAGILRPVHSPWNTPLLP VRKSGTSEYRMVQDLREVNKRVETIHPTVPNPYTLLSLLPPDRIWYSVLD LKDAFFCIPLAPESQLIFAFEWADAEEGESGQLTWTRLPQGFKNSPTLFD EALNRDLQGFRLDHPSVSLLQYVDDLLIAADTQAACLSATRDLLMTLAEL GYRVSGKKAQLCQEEVTYLGFKIHKGSRSLSNSRTQAILQIPVPKTKRQV REFLGTIGYCRLWIPGFAELAQPLYAATRGGNDPLVWGEKEEEAFQSLKL ALTQPPALALPSLDKPFQLFVEETSGAAKGVLTQALGPWKRPVAYLSKRL DPVAAGWPRCLRAIAAAALLTREASKLTFGQDIEITSSHNLESLLRSPPD KWLTNARITQYQVLLLDPPRVRFKQTAALNPATLLPETDDTLPIHHCLDT LDSLTSTRPDLTDQPLAQAEATLFTDGSSYIRDGKRYAGAAVVTLDSVIW AEPLPIGTSAQKAELIALTKALEWSKDKSVNIYTDSRYAFATLHVHGMIY RERGLLTAGGKAIKNAPEILALLTAVWLPKRVAVMHCKGHQKDDAPTSTG NRRADEVAREVAIRPLSTQATIS AVIRE_ AVIRE P03360 derivative 3137 TAPLEEEYRLFLEAPIQNVTLLEQWKREIPKVWAEINPPGLASTQAPIHV P03360_ QLLSTALPVRVRQYPITLEAKRSLRETIRKFRAAGILRPVHSPWNTPLLP 3mut VRKSGTSEYRMVQDLREVNKRVETIHPTVPNPYTLLSLLPPDRIWYSVLD LKDAFFCIPLAPESQLIFAFEWADAEEGESGQLTWTRLPQGFKNSPTLFN EALNRDLQGFRLDHPSVSLLQYVDDLLIAADTQAACLSATRDLLMTLAEL GYRVSGKKAQLCQEEVTYLGFKIHKGSRSLSNSRTQAILQIPVPK TKRQVREFLGTIGYCRLWIPGFAELAQPLYAATRPGNDPLVWGEKEEEAF QSLKLALTQPPALALPSLDKPFQLFVEETSGAAKGVLTQALGPWKRPVAY LSKRLDPVAAGWPRCLRAIAAAALLTREASKLTFGQDIEITSSHNLESLL RSPPDKWLTNARITQYQVLLLDPPRVRFKQTAALNPATLLPETDDTLPIH HCLDTLDSLTSTRPDLTDQPLAQAEATLFTDGSSYIRDGKRYAGAAVVTL DSVIWAEPLPIGTSAQKAELIALTKALEWSKDKSVNIYTDSRYAFATLHV HGMIYRERGWLTAGGKAIKNAPEILALLTAVWLPKRVAVMHCKGHQKDDA PTSTGNRRADEVAREVAIRPLSTQATIS AVIRE_ AVIRE P03360 derivative 3138 TAPLEEEYRLFLEAPIQNVTLLEQWKREIPKVWAEINPPGLASTQAPIHV P03360_ QLLSTALPVRVRQYPITLEAKRSLRETIRKFRAAGILRPVHSPWNTPLLP 3mutA VRKSGTSEYRMVQDLREVNKRVETIHPTVPNPYTLLSLLPPDRIWYSVLD LKDAFFCIPLAPESQLIFAFEWADAEEGESGQLTWTRLPQGFKNSPTLFN EALNRDLQGFRLDHPSVSLLQYVDDLLIAADTQAACLSATRDLLMTLAEL GYRVSGKKAQLCQEEVTYLGFKIHKGSRSLSNSRTQAILQIPVPKTKRQV REFLGKIGYCRLFIPGFAELAQPLYAATRPGNDPLVWGEKEEEAFQSLKL ALTQPPALALPSLDKPFQLFVEETSGAAKGVLTQALGPWKRPVAYLSKRL DPVAAGWPRCLRAIAAAALLTREASKLTFGQDIEITSSHNLESLLRSPPD KWLTNARITQYQVLLLDPPRVRFKQTAALNPATLLPETDDTLPIHHCLDT LDSLTSTRPDLTDQPLAQAEATLFTDGSSYIRDGKRYAGAAVVTLDSVIW AEPLPIGTSAQKAELIALTKALEWSKDKSVNIYTDSRY AFATLHVHGMIYRERGWLTAGGKAIKNAPEILALLTAVWLPKRVAVMHCK GHQKDDAPTSTGNRRADEVAREVAIRPLSTQATIS BAEVM_ BAEVM P10272 root 3139 TVSLQDEHRLFDIPVTTSLPDVWLQDFPQAWAETGGLGRAKCQAPIIIDL P10272 KPTAVPVSIKQYPMSLEAHMGIRQHIIKFLELGVLRPCRSPWNTPLLPVK KPGTQDYRPVQDLREINKRTVDIHPTVPNPYNLLSTLKPDYSWYTVLDLK DAFFCLPLAPQSQELFAFEWKDPERGISGQLTWTRLPQGFKNSPTLFDEA LHRDLTDFRTQHPEVTLLQYVDDLLLAAPTKKACTQGTRHLLQELGEKGY RASAKKAQICQTKVTYLGYILSEGKRWLTPGRIETVARIPPPRNPREVRE FLGTAGFCRLWIPGFAELAAPLYALTKESTPFTWQTEHQLAFEALKKALL SAPALGLPDTSKPFTLFLDERQGIAKGVLTQKLGPWKRPVAYLSKKLDPV AAGWPPCLRIMAATAMLVKDSAKLTLGQPLTVITPHTLEAIVRQPPDRWI TNARLTHYQALLLDTDRVQFGPPVTLNPATLLPVPENQPSPHDCRQVLAE THGTREDLKDQELPDADHTWYTDGSSYLDSGTRRAGAAVVDGHNTIWAQS LPPGTSAQKAELIALTKALELSKGKKANIYTDSRYAFATAHTHGSIYERR GLLTSEGKEIKNKAEIIALLKALFLPQEVAIIHCPGHQKGQDPVAVGNRQ ADRVARQAAMAEVLTLATEPDNTSHIT BAEVM_ BAEVM P10272 derivative 3140 TVSLQDEHRLFDIPVTTSLPDVWLQDFPQAWAETGGLGRAKCQAPIIIDL P10272_ KPTAVPVSIKQYPMSLEAHMGIRQHIIKFLELGVLRPCRSPWNTPLLPVK 3mut KPGTQDYRPVQDLREINKRTVDIHPTVPNPYNLLSTLKPDYSWYTVLDLK DAFFCLPLAPQSQELFAFEWKDPERGISGQLTWTRLPQGFKNSPTLFNEA LHRDLTDFRTQHPEVTLLQYVDDLLLAAPTKKACTQGTRHLLQELGEKGY RASAKKAQICQTKVTYLGYILSEGKRWLTPGRIETVARIPPPRNPREVRE FLGTAGFCRLWIPGFAELAAPLYALTKPSTPFTWQTEHQLAFEALKKALL SAPALGLPDTSKPFTLFLDERQGIAKGVLTQKLGPWKRPVAYLSKKLDPV AAGWPPCLRIMAATAMLVKDSAKLTLGQPLTVITPHTLEAIVRQPPDRWI TNARLTHYQALLLDTDRVQFGPPVTLNPATLLPVPENQPSPHDCRQVLAE THGTREDLKDQELPDADHTWYTDGSSYLDSGTRRAGAAVVDGHNTIWAQS LPPGTSAQKAELIALTKALELSKGKKANIYTDSRYAFATAHTHGSIYERR GWLTSEGKEIKNKAEIIALLKALFLPQEVAIIHCPGHQKGQDPVAVGNRQ ADRVARQAAMAEVLTLATEPDNTSHIT BAEVM_ BAEVM P10272 derivative 3141 TVSLQDEHRLFDIPVTTSLPDVWLQDFPQAWAETGGLGRAKCQAPIIIDL P10272_ KPTAVPVSIKQYPMSLEAHMGIRQHIIKFLELGVLRPCRSPWNTPLLPVK 3mutA KPGTQDYRPVQDLREINKRTVDIHPTVPNPYNLLSTLKPDYSWYTVLDLK DAFFCLPLAPQSQELFAFEWKDPERGISGQLTWTRLPQGFKNSPTLFNEA LHRDLTDFRTQHPEVTLLQYVDDLLLAAPTKKACTQGTRHLLQELGEKGY RASAKKAQICQTKVTYLGYILSEGKRWLTPGRIETVARIPPPRNPREVRE FLGKAGFCRLFIPGFAELAAPLYALTKPSTPFTWQTEHQLAFEALKKALL SAPALGLPDTSKPFTLFLDERQGIAKGVLTQKLGPWKRPVAYLSKKLDPV AAGWPPCLRIMAATAMLVKDSAKLTLGQPLTVITPHTLEAIVRQPPDRWI TNARLTHYQALLLDTDRVQFGPPVTLNPATLLPVPENQPSPHDCRQVLAE THGTREDLKDQELPDADHTWYTDGSSYLDSGTRRAGAAVVDGHNTIWAQS LPPGTSAQKAELIALTKALELSKGKKANIYTDSRYAFATAHTHGSIYERR GWLTSEGKEIKNKAEIIALLKALFLPQEVAIIHCPGHQKGQDPVAVGNRQ ADRVARQAAMAEVLTLATEPDNTSHIT BLVAU_ BLVA P25059 root 3142 GVLDAPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P25059 DGPGNNPVFPVRKPNGAWRFVHDLRVTNALTKPIPALSPGPPDLTAIPTH LPHIICLDLKDAFFQIPVEDRFRSYFAFTLPTPGGLQPHRRFAWRVLPQG FINSPALFERALQEPLRQVSAAFSQSLLVSYMDDILYVSPTEEQRLQCYQ TMAAHLRDLGFQVASEKTRQTPSPVPFLGQMVHERMVTYQSLPTLQISSP ISLHQLQTVLGDLQWVSRGTPTTRRPLQLLYSSLKGIDDPRAIIHLSPEQ QQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFPLA YFQTPLTDNQASPWGLLLLLGCQYLQAQALSSYAKTILKYYHNLPKTSLD NWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLVTRAEVFLTPQFSPE PIPAALCLFSDGAARRGAYCLWKDHLLDFQAVPAPESA QKGELAGLLAGLAAAPPEPLNIWVDSKYLYSLLRTLVLGAWLQPDPVPSY ALLYKSLLRHPAIFVGHVRSHSSASHPIASLNNYVDQL BLVAU_ BLVAU P25059 derivative 3143 GVLDAPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P25059_ DGPGNNPVFPVRKPNGAWRFVHDLRVTNALTKPIPALSPGPPDLTAIPTH 2mut LPHIICLDLKDAFFQIPVEDRFRSYFAFTLPTPGGLQPHRRFAWRVLPQG FINSPALFQRALQEPLRQVSAAFSQSLLVSYMDDILYVSPTEEQRLQCYQ TMAAHLRDLGFQVASEKTRQTPSPVPFLGQMVHERMVTYQSLPTLQISSP ISLHQLQTVLGDLQWVSRGTPTTRRPLQLLYSSLKPIDDPRAIIHLSPEQ QQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFPLA YFQTPLTDNQASPWGLLLLLGCQYLQAQALSSYAKTILKYYHNLPKTSLD NWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLVTRAEVFLTPQFSPE PIPAALCLFSDGAARRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLAGL AAAPPEPLNIWVDSKYLYSLLRTLVLGAWLQPDPVPSYALLYKSLLRHPA IFVGHVRSHSSASHPIASLNNYVDQL BLVAU_ BLVAU P25059 derivative 3144 GVLDAPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P25059_ DGPGNNPVFPVRKPNGAWRFVHDLRVTNALTKPIPALSPGPPDLTAPPTH 2mutB LPHIICLDLKDAFFQIPVEDRFRSYFAFTLPTPGGLQPHRRFAWRVLPQG FINSPALFQRALQEPLRQVSAAFSQSLLVSYMDDILYVSPTEEQRLQCYQ TMAAHLRDLGFQVASEKTRQTPSPVPFLGQMVHERMVTYQSLPTLQISSP ISLHQLQTVLGDLQWVSRGTPTTRRPLQLLYSSLKPIDDPRAIIHLSPEQ QQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFPLA YFQTPLTDNQASPWGLLLLLGCQYLQAQALSSYAKTILKYYHNLPKTSLD NWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLVTRAEVFLTPQFSPE PIPAALCLFSDGAARRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLAGL AAAPPEPLNIWVDSKYLYSLLRTLVLGAWLQPDPVPSYALLYKSLLRHPA IFVGHVRSHSSASHPIASLNNYVDQL BLVJ_ BLVJ P03361 root 3145 GVLDTPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P03361 DGPGNNPVFPVRKPNGAWRFVHDLRATNALTKPIPALSPGPPDLTAIPTH PPHIICLDLKDAFFQIPVEDRFRFYLSFTLPSPGGLQPHRRFAWRVLPQG FINSPALFERALQEPLRQVSAAFSQSLLVSYMDDILYASPTEEQRSQCYQ ALAARLRDLGFQVASEKTSQTPSPVPFLGQMVHEQIVTYQSLPTLQISSP ISLHQLQAVLGDLQWVSRGTPTTRRPLQLLYSSLKRHHDPRAIIQLSPEQ LQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFPLA YFQTPLTDNQASPWGLLLLLGCQYLQTQALSSYAKPILKYYHNLPKTSLD NWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLITRAEVFLTPQFSPD PIPAALCLFSDGATGRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLAGL AAAPPEPVNIWVDSKYLYSLLRTLVLGAWLQPDPVPSYALLYKSLLRHPA IVVGHVRSHSSASHPIASLNNYVDQL BLVJ_ BLVJ P03361 derivative 3146 GVLDTPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P03361_ DGPGNNPVFPVRKPNGAWRFVHDLRATNALTKPIPALSPGPPDLTAIPTH 2mut PPHIICLDLKDAFFQIPVEDRFRFYLSFTLPSPGGLQPHRRFAWRVLPQG FINSPALFNRALQEPLRQVSAAFSQSLLVSYMDDILYASPTEEQRSQCPE QLQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFPL AYFQTPLTDNQASPWGLLLLLGCQYLQTQALSSYAKPILKYYHNLPKTSL DNWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLITRAEVFLTPQFSP DPIPAALCLFSDGATGRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLAG LAAAPPEPVNIWVDSKYLYSLLRTWVLGAWLQPDPVPSYALLYKSLLRHP AIVVGHVRSHSSASHPIASLNNYVDQL BLVJ_ BLVJ P03361 derivative 3147 GVLDTPPSHIGLEHLPPPPEVPQFPLNLERLQALQDLVHRSLEAGYISPW P03361_ DGPGNNPVFPVRKPNGAWRFVHDLRATNALTKPIPALSPGPPDLTAPP 2mutB THPPHIICLDLKDAFFQIPVEDRFRFYLSFTLPSPGGLQPHRRFAWRVLP QGFINSPALFQRALQEPLRQVSAAFSQSLLVSYMDDILYASPTEEQRSQC YQALAARLRDLGFQVASEKTSQTPSPVPFLGQMVHEQIVTYQSLPTLQIS SPISLHQLQAVLGDLQWVSRGTPTTRRPLQLLYSSLKRHHDPRAIIQLSP EQLQGIAELRQALSHNARSRYNEQEPLLAYVHLTRAGSTLVLFQKGAQFP LAYFQTPLTDNQASPWGLLLLLGCQYLQTQALSSYAKPILKYYHNLPKTS LDNWIQSSEDPRVQELLQLWPQISSQGIQPPGPWKTLITRAEVFLTPQFS PDPIPAALCLFSDGATGRGAYCLWKDHLLDFQAVPAPESAQKGELAGLLA GLAAAPPEPVNIWVDSKYLYSLLRTWVLGAWLQPDPVPSYALLYKSLLRH PAIVVGHVRSHSSASHPIASLNNYVDQL FFV_ FFV O93209 root 3148 MDLLKPLTVERKGVKIKGYWNSQADITCVPKDLLQGEEPVRQQNVTTIHG O93209 TQEGDVYYVNLKIDGRRINTEVIGTTLDYANITPGDVPWILKKPLELTIK LDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQSWENQVGHRRIRPH KIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQGVLIQKESTMNTPVY PVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGILGSLFKGRYKTTIDL SNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFLNSPGLFTGDVVDLL QGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKEAGYIISLKKSNIAN SIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQLQSILGLLNFARNF IPDFTELIAPLYALIPKSTKNYVPWQIEHSTTLETLITKLNGAEYLQGRK GDKTLIMKVNASYTTGYIRYYNEGEKKPISYVSIVFSKTELKFTELEKLL TTVHKGLLKALDLSMGQNIHVYSPIVSMQNIQKTPQTAKKALASRWLSWL SYLEDPRIRFFYDPQMPALKDLPAVDTGKDNKKHPSNFQHIFYTDGSAIT SPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISLGNHTAQFAEIAAFEFA LKKCLPLGGNILVVTDSNYVAKAYNEELDVWASNGFVNNRKKPLKHISKW KSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNNLADQLATQASFKVH FFV_ FFV O93209 derivative 3149 VPWILKKPLELTIKLDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQ O93209- SWENQVGHRRIRPHKIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQG Pro VLIQKESTMNTPVYPVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGIL GSLFKGRYKTTIDLSNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFL NSPGLFTGDVVDLLQGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKE AGYIISLKKSNIANSIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQ LQSILGLLNFARNFIPDFTELIAPLYALIPKSTKNYVPWQIEHSTTLETL ITKLNGAEYLQGRKGDKTLIMKVNASYTTGYIRYYNEGEKKPISYVSIVF SKTELKFTELEKLLTTVHKGLLKALDLSMGQNIHVYSPIVSMQNIQKTPQ TAKKALASRWLSWLSYLEDPRIRFFYDPQMPALKDLPAVDTGKDNKKHPS NFQHIFYTDGSAITSPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISLGN HTAQFAEIAAFEFALKKCLPLGGNILVVTDSNYVAKAYNEELDVWASNGF VNNRKKPLKHISKWKSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNNLA DQLATQASFKVH FFV_ FFV O93209 derivative 3150 VPWILKKPLELTIKLDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQ O93209- SWENQVGHRRIRPHKIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQG Pro_2 VLIQKESTMNTPVYPVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGIL mut GSLFKGRYKTTIDLSNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFL NSPGLFNGDVVDLLQGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKE AGYIISLKKSNIANSIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQ LQSILGLLNFARNFIPDFTELIAPLYALIPKSPKNYVPWQIEHSTTLETL ITKLNGAEYLQGRKGDKTLIMKVNASYTTGYIRYYNEGEKKPISYVSIVF SKTELKFTELEKLLTTVHKGLLKALDLSMGQNIHVYSPIVSMQNIQKTPQ TAKKALASRWLSWLSYLEDPRIRFFYDPQMPALKDLPAVDTGKDNKKHPS NFQHIFYTDGSAITSPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISLGN HTAQFAEIAAFEFALKKCLPLGGNILVVTDSNYVAKAYNEELDVWASNGF VNNRKKPLKHISKWKSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNNLA DQLATQASFKVH FFV_ FFV O93209 derivative 3151 VPWILKKPLELTIKLDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQ O93209- SWENQVGHRRIRPHKIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQG Pro_ VLIQKESTMNTPVYPVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGIL 2mutA GSLFKGRYKTTIDLSNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFL NSPGLFNGDVVDLLQGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKE AGYIISLKKSNIANSIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQ LQSILGKLNFARNFIPDFTELIAPLYALIPKSPKNYVPWQIEHSTTLETL ITKLNGAEYLQGRKGDKTLIMKVNASYTTGYIRYYNEGEKKPTGKDNKKH PSNFQHIFYTDGSAITSPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISL GNHTAQFAEIAAFEFALKKCLPLGGNILVVTDSNYVAKAYNEELDVWASN GFVNNRKKPLKHISKWKSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNN LADQLATQASFKVH FFV_ FFV O93209 derivative 3152 MDLLKPLTVERKGVKIKGYWNSQADITCVPKDLLQGEEPVRQQNVTTIHG O93209_2 TQEGDVYYVNLKIDGRRINTEVIGTTLDYAIITPGDVPWILKKPLELTIK mut LDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQSWENQVGHRRIRPH KIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQGVLIQKESTMNTPVY PVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGILGSLFKGRYKTTIDL SNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFLNSPG LFNGDVVDLLQGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKEAGYI ISLKKSNIANSIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQLQSI LGLLNFARNFIPDFTELIAPLYALIPKSPKNYVPWQIEHSTTLETLITKL NGAEYLQGRKGDKTLIMKVNASYTTGYIRYYNEGEKKPISYVSIVFSKTE LKFTELEKLLTTVHKGLLKALDLSMGQNIHVYSPIVSMQNIQKTPQTAKK ALASRWLSWLSYLEDPRIRFFYDPQMPALKDLPAVDTGKDNKKHPSNFQH IFYTDGSAITSPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISLGNHTAQ FAEIAAFEFALKKCLPLGGNILVVTDSNYVAKAYNEELDVWASNGFVNNR KKPLKHISKWKSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNNLADQLA TQASFKVH FFV_ FFV O93209 derivative 3153 MDLLKPLTVERKGVKIKGYWNSQADITCVPKDLLQGEEPVRQQNVTTIHG O93209_ TQEGDVYYVNLKIDGRRINTEVIGTTLDYAIITPGDVPWILKKPLELTIK 2mutA LDLEEQQGTLLNNSILSKKGKEELKQLFEKYSALWQSWENQVGHRRIRPH KIATGTVKPTPQKQYHINPKAKPDIQIVINDLLKQGVLIQKESTMNTPVY PVPKPNGRWRMVLDYRAVNKVTPLIAVQNQHSYGILGSLFKGRYKTTIDL SNGFWAHPIVPEDYWITAFTWQGKQYCWTVLPQGFLNSPGLFNGDVVDLL QGIPNVEVYVDDVYISHDSEKEHLEYLDILFNRLKEAGYIISLKKSNIAN SIVDFLGFQITNEGRGLTDTFKEKLENITAPTTLKQLQSILGKLNFARNF IPDFTELIAPLYALIPKSPKNYVPWQIEHSTTLETLITKLNGAEYLQGRK GDKTLIMKVNASYTTGYIRYYNEGEKKPISYVSIVFSKTELKFTELEKLL TTVHKGLLKALDLSMGQNIHVYSPIVSMQNIQKTPQTAKKALASRWLSWL SYLEDPRIRFFYDPQMPALKDLPAVDTGKDNKKHPSNFQHIFYTDGSAIT SPTKEGHLNAGMGIVYFINKDGNLQKQQEWSISLGNHTAQFAEIAAFEFA LKKCLPLGGNILVVTDSNYVAKAYNEELDVWASNGFVNNRKKPLKHISKW KSVADLKRLRPDVVVTHEPGHQKLDSSPHAYGNNLADQLATQASFKVH FLV_ FIV P10273 root 3154 TLQLEEEYRLFEPESTQKQEMDIWLKNFPQAWAETGGMGTAHCQAPVLIQ P10273 LKATATPISIRQYPMPHEAYQGIKPHIRRMLDQGILKPCQSPWNTPLLPV KKPGTEDYRPVQDLREVNKRVEDIHPTVPNPYNLLSTLPPSHPWYTVLDL KDAFFCLRLHSESQLLFAFEWRDPEIGLSGQLTWTRLPQGFKNSPTLFDE ALHSDLADFRVRYPALVLLQYVDDLLLAAATRTECLEGTKALLETLGNKG YRASAKKAQICLQEVTYLGYSLKDGQRWLTKARKEAILSIPVPKNSRQVR EFLGTAGYCRLWIPGFAELAAPLYPLTRPGTLFQWGTEQQLAFEDIKKAL LSSPALGLPDITKPFELFIDENSGFAKGVLVQKLGPWKRPVAYLSKKLDT VASGWPPCLRMVAAIAILVKDAGKLTLGQPLTILTSHPVEALVRQPPNKW LSNARMTHYQAMLLDAERVHFGPTVSLNPATLL PLPSGGNHHDCLQILAETHGTRPDLTDQPLPDADLTWYTDGSSFIRNGER EAGAAVTTESEVIWAAPLPPGTSAQRAELIALTQALKMAEGKKLTVYTDS RYAFATTHVHGEIYRRRGLLTSEGKEIKNKNEILALLEALFLPKRLSIIH CPGHQKGDSPQAKGNRLADDTAKKAATETHSSLTVLP FLV_ FLV P10273 derivative 3155 TLQLEEEYRLFEPESTQKQEMDIWLKNFPQAWAETGGMGTAHCQAPVLIQ P10273_ LKATATPISIRQYPMPHEAYQGIKPHIRRMLDQGILKPCQSPWNTPLLPV 3mut KKPGTEDYRPVQDLREVNKRVEDIHPTVPNPYNLLSTLPPSHPWYTVLDL KDAFFCLRLHSESQLLFAFEWRDPEIGLSGQLTWTRLPQGFKNSPTLFNE ALHSDLADFRVRYPALVLLQYVDDLLLAAATRTECLEGTKALLETLGNKG YRASAKKAQICLQEVTYLGYSLKDGQRWLTKARKEAILSIPVPKNSRQVR EFLGTAGYCRLWIPGFAELAAPLYPLTRPGTLFQWGTEQQLAFEDIKKAL LSSPALGLPDITKPFELFIDENSGFAKGVLVQKLGPWKRPVAYLSKKLDT VASGWPPCLRMVAAIAILVKDAGKLTLGQPLTILTSHPVEALVRQPPNKW LSNARMTHYQAMLLDAERVHFGPTVSLNPATLLPLPSGGNHHDCLQILAE THGTRPDLTDQPLPDADLTWYTDGSSFIRNGEREAGAAVTTESEVIWAAP LPPGTSAQRAELIALTQALKMAEGKKLTVYTDSRYAFATTHVHGEIYRRR GWLTSEGKEIKNKNEILALLEALFLPKRLSIIHCPGHQKGDSPQAKGNRL ADDTAKKAATETHSSLTVLP FLV_ FLV P10273 derivative 3156 TLQLEEEYRLFEPESTQKQEMDIWLKNFPQAWAETGGMGTAHCQAPVLIQ P10273_ LKATATPISIRQYPMPHEAYQGIKPHIRRMLDQGILKPCQSPWNTPLLPV 3mutA KKPGTEDYRPVQDLREVNKRVEDIHPTVPNPYNLLSTLPPSHPWYTVLDL KDAFFCLRLHSESQLLFAFEWRDPEIGLSGQLTWTRLPQGFKNSPTLFNE ALHSDLADFRVRYPALVLLQYVDDLLLAAATRTECLEGTKALLETLGNKG YRASAKKAQICLQEVTYLGYSLKDGQRWLTKARKEAILSIPVPKNSRQVR EFLGKAGYCRLFIPGFAELAAPLYPLTRPGTLFQWGTEQQLAFEDIKKAL LSSPALGLPDITKPFELFIDENSGFAKGVLVQKLGPWKRPVAYLSKKLDT VASGWPPCLRMVAAIAILVKDAGKLTLGQPLTILTSHPVEALVRQPPNKW LSNARMTHYQAMLLDAERVHFGPTVSLNPATLLPLPSGGNHHDCLQILAE THGTRPDLTDQPLPDADLTWYTDGSSFIRNGEREAGAAVTTESEVIWAAP LPPGTSAQRAELIALTQALKMAEGKKLTVYTDSRYAFATTHVHGEIYRRR GWLTSEGKEIKNKNEILALLEALFLPKRLSIIHCPGHQKGDSPQAKGNRL ADDTAKKAATETHSSLTVLP FOAMV_ FOAMV P14350 root 3157 MNPLQLLQPLPAEIKGTKLLAHWNSGATITCIPESFLEDEQPIKKTLIKT P14350 IHGEKQQNVYYVTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQL TILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQHWENQVGHRKI RPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNT PVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTT LDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFTADVV DLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQAGYVVSLKKSE IGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQLQSILGLLNFA RNFIPNFAELVQPLYNLIASAKGKYIEWSEENTKQLNMVIEALNTASNLE ERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVFSKAELKFSMLE KLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHPSQYEGVFYTDG SAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGNHTAQMAEIAAV EFACKKALKIPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKKPLKHI SKWKSIAECLSMKPDITIQHEKGISLQIPVFILKGNALADKLATQGSYVV N FOAMV_ FOAMV P14350 derivative 3158 VPWLTQQPLQLTILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQ P14350- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL ATIVRQKYKTTLDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFTADVVDLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQ AGYVVSLKKSEIGQKTVEFLGFNITKEGRGLTDTFKTK LLNITPPKDLKQLQSILGLLNFARNFIPNFAELVQPLYNLIASAKGKYIE WSEENTKQLNMVIEALNTASNLEERLPEQRLVIKVNTSPSAGYVRYYNE  TGKKPIMYLNYVFSKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYS PIVSMTKIQKTPLPERKALPIRWITWMTYLEDPRIQFHYDKTLPELK HI PDVYTSSQSPVKHPSQYEGVFYTDGSAIKSPDPTKSNNAGMGIVHATYKP EYQVLNQWSIPLGNHTAQMAEIAAVEFACKKALKIPGPVLVITDS FYVA ESANKELPYWKSNGFVNNKKKPLKHISKWKSIAECLSMKPDITIQHEKGI SLQIPVFILKGNALADKLATQGSYVVN FOAMV_ FOAMV P14350 derivative 3159 VPWLTQQPLQLTILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQ P14350- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_2 VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL mut ATIVRQKYKTTLDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADVVDLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQ AGYVVSLKKSEIGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQ LQSILGLLNFARNFIPNFAELVQPLYNLIAPAKGKYIEWSEENTKQLNMV IEALNTASNLEERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVF SKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPL PERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHP SQYEGVFYTDGSAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGN HTAQMAEIAAVEFACKKALKIPGPVLVITDSFYVAESANKELPYWKSNGF VNNKKKPLKHISKWKSIAECLSMKPDITIQHEKGISLQIPVFILKGNALA DKLATQGSYVVN FOAMV_ FOAMV P14350 derivative 3160 VPWLTQQPLQLTILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQ P14350- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_2 VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL mutA ATIVRQKYKTTLDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADVVDLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQ AGYVVSLKKSEIGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQ LQSILGKLNFARNFIPNFAELVQPLYNLIAPAKGKYIEWSEENTKQLNMV IEALNTASNLEERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVF SKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPL PERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHP SQYEGVFYTDGSAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGN HTAQMAEIAAVEFACKKALKIPGPVLVITDSFYVAESANKELPYWKSNGF VNNKKKPLKHISKWKSIAECLSMKPDITIQHEKGISLQIPVFILKGNALA DKLATQGSYVVN FOAMV_ FOAMV P14350 derivative 3161 MNPLQLLQPLPAEIKGTKLLAHWNSGATITCIPESFLEDEQPIKKTLIKT P14350_ IHGEKQQNVYYVTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQL 2mut TILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQHWENQVGHRKI RPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNT PVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTT LDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFNADVV DLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQAGYVVSLKKSE IGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQLQSILGLLNFA RNFIPNFAELVQPLYNLIAPAKGKYIEWSEENTKQLNMVIEALNTASNLE ERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVFSKAELKFSMLE KLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHPSQYEGVFYTDG SAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGNHTAQMAEIAAV EFACKKALKIPGPVLVITDSFYVAESANKEL PYWKSNGFVNNKKKPLKHISKWKSIAECLSMKPDITIQHEKGISLQIPVF ILKGNALADKLATQGSYVVN FOAMV_ FOAMV P14350 derivative 3162 MNPLQLLQPLPAEIKGTKLLAHWNSGATITCIPESFLEDEQPIKKTLIKT P14350_ IHGEKQQNVYYVTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQL 2mutA TILVPLQEYQEKILSKTALPEDQKQQLKTLFVKYDNLWQHWENQVGHRKI RPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNT PVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTT LDLANGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFNADVV DLLKEIPNVQVYVDDIYLSHDDPKEHVQQLEKVFQILLQAGYVVSLKKSE IGQKTVEFLGFNITKEGRGLTDTFKTKLLNITPPKDLKQLQSILGKLNFA RNFIPNFAELVQPLYNLIAPAKGKYIEWSEENTKQLNMVIEALNTASNLE ERLPEQRLVIKVNTSPSAGYVRYYNETGKKPIMYLNYVFSKAELKFSMLE KLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSQSPVKHPSQYEGVFYTDG SAIKSPDPTKSNNAGMGIVHATYKPEYQVLNQWSIPLGNHTAQMAEIAAV EFACKKALKIPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKKPLKHI SKWKSIAECLSMKPDITIQHEKGISLQIPVFILKGNALADKLATQGSYVV N GALV_ GALV P21414 root 3163 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P21414 RSGASPVAVRQYPMSKEAREGIRPHIQKFLDLGVLVPCRSPWNTPLLPVK KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSYTWYSVLDLK DAFFCLRLHPNSQPLFAFEWKDPEKGNTGQLTWTRLPQGFKNSPTLFDEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYEDCKKGTQKLLQELSKLGY RVSAKKAQLCQREVTYLGYLLKEGKRWLTPARKATVMKIPVPTTPRQVRE FLGTAGFCRLWIPGFASLAAPLYPLTKESIPFIWTEEHQQAFDHIKKALL SAPALALPDLTKPFTLYIDERAGVARGVLTQTLGPWRRPVAYLSKKLDPV ASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIASHSLESIVRQPPDRWM TNARMTHYQSLLLNERVSFAPPAVLNPATLLPVESEATPVHRCSEILAEE TGTRRDLEDQPLPGVPTWYTDGSSFITEGKRRAGAPIVDGKRTVWASSLP EGTSAQKAELVALTQALRLAEGKNINIYTDSRYAFATAHIHGAIYKQRGL LTSAGKDIKNKEEILALLEAIHLPRRVAIIHCPGHQRGSNPVATGNRRAD EAAKQAALSTRVLAGTTKP GALV_ GALV P21414 derivative 3164 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P21414_ RSGASPVAVRQYPMSKEAREGIRPHIQKFLDLGVLVPCRSPWNTPLLPVK 3mut KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSYTWYSVLDLK DAFFCLRLHPNSQPLFAFEWKDPEKGNTGQLTWTRLPQGFKNSPTLFNEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYEDCKKGTQKLLQELSKLGY RVSAKKAQLCQREVTYLGYLLKEGKRWLTPARKATVMKIPVPTTPRQVRE FLGTAGFCRLWIPGFASLAAPLYPLTKPSIPFIWTEEHQQAFDHIKKALL SAPALALPDLTKPFTLYIDERAGVARGVLTQTLGPWRRPVAYLSKKLDPV ASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIASHSLESIVRQPPDRWM TNARMTHYQSLLLNERVSFAPPAVLNPATLLPVESEATPVHRCSEILAEE TGTRRDLEDQPLPGVPTWYTDGSSFITEGKRRAGAPIVDGKRTVWASSLP EGTSAQKAELVALTQALRLAEGKNINIYTDSRYAFATAHIHGAIYKQRGW LTSAGKDIKNKEEILALLEAIHLPRRVAIIHCPGHQRGSNPVATGNRRAD EAAKQAALSTRVLAGTTKP GALV_ GALV P21414 derivative 3165 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P21414_ RSGASPVAVRQYPMSKEAREGIRPHIQKFLDLGVLVPCRSPWNTPLLPVK 3mutA KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSYTWYSVLDLK DAFFCLRLHPNSQPLFAFEWKDPEKGNTGQLTWTRLPQGFKNSPTLFNEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYEDCKKGTQKLLQELSKLGY RVSAKKAQLCQREVTYLGYLLKEGKRWLTPARKATVMKIPVPTTPRQVRE FLGKAGFCRLFIPGFASLAAPLYPLTKPSIPFIWTEEHQQAFDHIKKALL SAPALALPDLTKPFTLYIDERAGVARGVLTQTLGP wRRPVAYLSKKLDPVASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIAS HSLESIVRQPPDRWMTNARMTHYQSLLLNERVSFAPPAVLNPATL LPVESEATPVHRCSEILAEETGTRRDLEDQPLPGVPTWYTDGSSFITEGK RRAGAPIVDGKRTVWASSLPEGTSAQKAELVALTQALRLAEGKNINIYTD SRYAFATAHIHGAIYKQRGWLTSAGKDIKNKEEILALLEAIHLPRRVAII HCPGHQRGSNPVATGNRRADEAAKQAALSTRVLAGTTKP HTL1A_ HTL1A P03362 root 3166 AVLGLEHLPRPPQISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P03362 VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSLPTTLAHLQTI DLRDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTL FEMQLAHILQPIRQAFPQCTILQYMDDILLASPSHEDLLLLSEATMASLI SHGLPVSENKTQQTPGTIKFLGQIISPNHLTYDAVPTVPIRSRWALPELQ ALLGEIQWVSKGTPTLRQPLHSLYCALQRHTDPRDQIYLNPSQVQSLVQL RQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKEQWPLVWLHAPLP HTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQTSD HPSVPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALMPVFTLSPV IINTAPCLFSDGSTSRAAYILWDKQILSQRSFPLPPPHKSAQRAELLGLL HGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLPRLL SRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTL1A_ HTL1A P03362 derivative 3167 AVLGLEHLPRPPQISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P03362_ VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSLPTTLAHLQTI 2mut DLRDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTL FQMQLAHILQPIRQAFPQCTILQYMDDILLASPSHEDLLLLSEATMASLI SHGLPVSENKTQQTPGTIKFLGQIISPNHLTYDAVPTVPIRSRWALPELQ ALLGEIQWVSKGTPTLRQPLHSLYCALQPHTDPRDQIYLNPSQVQSLVQL RQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKEQWPLVWLHAPLP HTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQTSD HPSVPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALMPVFTLSPV IINTAPCLFSDGSTSRAAYILWDKQILSQRSFPLPPPHKSAQRAELLGLL HGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLPRLL SRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTL1A_ HTL1A P03362 derivative 3168 AVLGLEHLPRPPQISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P03362_ VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSPPTTLAHLQTI 2mutB DLRDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTL FQMQLAHILQPIRQAFPQCTILQYMDDILLASPSHEDLLLLSEATMASVQ LRQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKEQWPLVWLHAPL PHTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQTS DHPSVPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALMPVFTLSP VIINTAPCLFSDGSTSRAAYILWDKQILSQRSFPLPPPHKSAQRAELLGL LHGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLPRL LSRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTLIC_ HTL1C P14078 root 3169 AVLGLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P14078 VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSLPTTLAHLQTI DLKDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWRVLPQGFKNSPTL FEMQLAHILQPIRQAFPQCTILQYMDDILLASPSHADLQLLSEATMASVQ LRQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHAPL PHTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQTS DHPSVPILLHHSHRFKNLGAQTGELWNTFLKTTAPLAPVKALMPVFTLSP VIINTAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQRAELLGL LHGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLPRL LSRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTLIC_ HTL1C P14078 derivative 3170 AVLGLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P14078_2 VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSLPTTLAHLQTI mut DLKDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWRVLPQGFKNSPTL FQMQLAHILQPIRQAFPQCTILQYMDDILLASPSHADLQLLSEATMA SLISHGLPVSENKTQQTPGTIKFLGQIISPNHLTYDAVPKVPIRSRWALP ELQALLGEIQWVSKGTPTLRQPLHSLYCALQPHTDPRDQIYLNPSQVQSL VQLRQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHA PLPHTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQ TSDHPSVPILLHHSHRFKNLGAQTGELWNTFLKTTAPLAPVKALMPVFTL SPVIINTAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQRAELL GLLHGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLP RLLSRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTLIC_ HTL1C P14078 derivative 3171 AVLGLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNP P14078_2 VFPVKKANGTWRFIHDLRATNSLTIDLSSSSPGPPDLSSPPTTLAHLQTI mutB DLKDAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWRVLPQGFKNSPTL FQMQLAHILQPIRQAFPQCTILQYMDDILLASPSHADLQLLSEATMASLI SHGLPVSENKTQQTPGTIKFLGQIISPNHLTYDAVPKVPIRSRWALPELQ ALLGEIQWVSKGTPTLRQPLHSLYCALQPHTDPRDQIYLNPSQVQSLVQL RQALSQNCRSRLVQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHAPLP HTSQCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISTQTFNQFIQTSD HPSVPILLHHSHRFKNLGAQTGELWNTFLKTTAPLAPVKALMPVFTLSPV IINTAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQRAELLGLL HGLSSARSWRCLNIFLDSKYLYHYLRTLALGTFQGRSSQAPFQALLPRLL SRKVVYLHHVRSHTNLPDPISRLNALTDALLITPVLQL HTLIL_ HTL1L POC211 root 3172 GLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNPVFP P0C211 VKKANGTWRFIHDLRATNSLTVDLSSSSPGPPDLSSLPTTLAHLQTIDLK DAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTLFEM QLASILQPIRQAFPQCVILQYMDDILLASPSPEDLQQLSEATMASLISHG LPVSQDKTQQTPGTIKFLGQUISPNHITYDAVPTVPIRSRWALPELQALL GEIQWVSKGTPTLRQPLHSLYCALQGHTDPRDQIYLNPSQVQSLMQLQQA LSQNCRSRLAQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHAPLPHTS QCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISIQTFNQFIQTSDHPS VPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALTPVFTLSPIIIN TAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQQAELLGLLHGL SSARSWHCLNIFLDSKYLYHYLRTLALGTFQGKSSQAPFQALLPRLLAHK VIYLHHVRSHTNLPDPISKLNALTDALLITPIL HTLIL_ HTL1L POC211 derivative 3173 GLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNPVFP P0C211_2 VKKANGTWRFIHDLRATNSLTVDLSSSSPGPPDLSSLPTTLAHLQTIDLK mut DAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTLFQM QLASILQPIRQAFPQCVILQYMDDILLASPSPEDLQQLSEATMASLISHG LPVSQDKTQQTPGTIKFLGQIISPNHITYDAVPTVPIRSRWALPELQALL GEIQWVSKGTPTLRQPLHSLYCALQGHTDPRDQIYLNPSQVQSLMQLQQA LSQNCRSRLAQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHAPLPHTS QCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISIQTFNQFIQTSDHPS VPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALTPVFTLSPIIIN TAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQQAELLGLLHGL SSARSWHCLNIFLDSKYLYHYLRTLAWGTFQGKSSQAPFQALLPRLLAHK VIYLHHVRSHTNLPDPISKLNALTDALLITPIL HTLIL_ HTL1L POC211 derivative 3174 GLEHLPRPPEISQFPLNPERLQALQHLVRKALEAGHIEPYTGPGNNPVFP P0C211_2 VKKANGTWRFIHDLRATNSLTVDLSSSSPGPPDLSSPPTTLAHLQTIDLK mutB DAFFQIPLPKQFQPYFAFTVPQQCNYGPGTRYAWKVLPQGFKNSPTLFQM QLASILQPIRQAFPQCVILQYMDDILLASPSPEDLQQLSEATMASLISHG LPVSQDKTQQTPGTIKFLGQUISPNHITYDAVPTVPIRSRWALPELQALL GEIQWVSKGTPTLRQPLHSLYCALQGHTDPRDQIYLNPSQVQSLMQLQQA LSQNCRSRLAQTLPLLGAIMLTLTGTTTVVFQSKQQWPLVWLHAPLPHTS QCPWGQLLASAVLLLDKYTLQSYGLLCQTIHHNISIQTFNQFIQTSDHPS VPILLHHSHRFKNLGAQTGELWNTFLKTAAPLAPVKALTPVFTLSPIIIN TAPCLFSDGSTSQAAYILWDKHILSQRSFPLPPPHKSAQQAE LLGLLHGLSSARSWHCLNIFLDSKYLYHYLRTLAWGTFQGKSSQAPFQAL LPRLLAHKVIYLHHVRSHTNLPDPISKLNALTDALLITPIL HTL32_ HTL32 Q0R5R2 root 3175 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP QOR5R2 VKKPNGKWRFIHDLRATNSVTRDLASPSPGPPDLTSLPQGLPHLRTIDLT DAFFQIPLPTIFQPYFAFTLPQPNNYGPGTRYSWRVLPQGFKNSPTLFEQ QLSHILTPVRKTFPNSLIIQYMDDILLASPAPGELAALTDKVTNALTKEG LPLSPEKTQATPGPIHFLGQVISQDCITYETLPSINVKSTWSLAELQSML GELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIKLTSIQVQALRTIQKA LTLNCRSRLVNQLPILALIMLRPTGTTAVLFQTKQKWPLVWLHTPHPATS LRPWGQLLANAVIILDKYSLQHYGQVCKSFHHNISNQALTYYLHTSDQSS VAILLQHSHRFHNLGAQPSGPWRSLLQMPQIFQNIDVLRPPFTISPVVIN HAPCLFSDGSASKAAFIIWDRQVIHQQVLSLPSTCSAQAGELFGLLAGLQ KSQPWVALNIFLDSKFLIGHLRRMALGAFPGPSTQCELHTQLLPLLQGKT VYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTL32_ HTL32 Q0R5R2 derivative 3176 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP QOR5R2_2 VKKPNGKWRFIHDLRATNSVTRDLASPSPGPPDLTSLPQGLPHLRTIDLT mut DAFFQIPLPTIFQPYFAFTLPQPNNYGPGTRYSWRVLPQGFKNSPTLFQQ QLSHILTPVRKTFPNSLIIQYMDDILLASPAPGELAALTDKVTNALTKEG LPLSPEKTQATPGPIHFLGQVISQDCITYETLPSINVKSTWSLAELQSML GELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIKLTSIQVQALRTIQKA LTLNCRSRLVNQLPILALIMLRPTGTTAVLFQTKQKWPLVWLHTPHPATS LRPWGQLLANAVIILDKYSLQHYGQVCKSFHHNISNQALTYYLHTSDQSS VAILLQHSHRFHNLGAQPSGPWRSLLQMPQIFQNIDVLRPPFTISPVVIN HAPCLFSDGSASKAAFIIWDRQVIHQQVLSLPSTCSAQAGELFGLLAGLQ KSQPWVALNIFLDSKFLIGHLRRMAWGAFPGPSTQCELHTQLLPLLQGKT VYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTL32_ HTL32 Q0R5R2 derivative 3177 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP QOR5R2_2 VKKPNGKWRFIHDLRATNSVTRDLASPSPGPPDLTSPPQGLPHLRTIDLT mutB DAFFQIPLPTIFQPYFAFTLPQPNNYGPGTRYSWRVLPQGFKNSPTLFQQ QLSHILTPVRKTFPNSLIIQYMDDILLASPAPGELAALTDKVTNALTKEG LPLSPEKTQATPGPIHFLGQVISQDCITYETLPSINVKSTWSLAELQSML GELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIKLTSIQVQALRTIQKA LTLNCRSRLVNQLPILALIMLRPTGTTAVLFQTKQKWPLVWLHTPHPATS LRPWGQLLANAVIILDKYSLQHYGQVCKSFHHNISNQALTYYLHTSDQSS VAILLQHSHRFHNLGAQPSGPWRSLLQMPQIFQNIDVLRPPFTISPVVIN HAPCLFSDGSASKAAFIIWDRQVIHQQVLSLPSTCSAQAGELFGLLAGLQ KSQPWVALNIFLDSKFLIGHLRRMAWGAFPGPSTQCELHTQLLPLLQGKT VYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTL3P_ HTL3P Q4U0X6 root 3178 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP Q4U0X6 VKKPNGKWRFIHDLRATNSLTRDLASPSPGPPDLTSLPQDLPHLRTIDLT DAFFQIPLPAVFQPYFAFTLPQPNNHGPGTRYSWRVLPQGFKNSPTLFEQ QLSHILAPVRKAFPNSLIIQYMDDILLASPALRELTALTDKVTNALTKEG LPMSLEKTQATPGSIHFLGQVISPDCITYETLPSIHVKSIWSLAELQSML GELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIELTSTQVQALKTIQKA LALNCRSRLVSQLPILALIILRPTGTTAVLFQTKQKWPLVWLHTPHPATS LRPWGQLLANAIITLDKYSLQHYGQICKSFHHNISNQALTYYLHTSDQSS VAILLQHSHRFHNLGAQPSGPWRSLLQVPQIFQNIDVLRPPFIISPVVID HAPCLFSDGATSKAAFILWDKQVIHQQVLPLPSTCSAQAGELFGLLAGLQ KSKPWPALNIFLDSKFLIGHLRRMALGAFLGPSTQCDLHARLFPLLQGKT VYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTL3P_ HTL3P Q4U0X6 derivative 3179 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP Q4U0X6_2 VKKPNGKWRFIHDLRATNSLTRDLASPSPGPPDLTSLPQDLPHLRTIDLT mut DAFFQIPLPAVFQPYFAFTLPQPNNHGPGTRYSWRVLPQGFKNSPTLFQQ QLSHILAPVRKAFPNSLIIQYMDDILLASPALRELTALTDKVTNALTKE GLPMSLEKTQATPGSIHFLGQVISPDCITYETLPSIHVKSIWSLAELQSM LGELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIELTSTQVQALKTIQK ALALNCRSRLVSQLPILALIILRPTGTTAVLFQTKQKWPLVWLHTPHPAT SLRPWGQLLANAIITLDKYSLQHYGQICKSFHHNISNQALTYYLHTSDQS SVAILLQHSHRFHNLGAQPSGPWRSLLQVPQIFQNIDVLRPPFIISPVVI DHAPCLFSDGATSKAAFILWDKQVIHQQVLPLPSTCSAQAGELFGLLAGL QKSKPWPALNIFLDSKFLIGHLRRMAWGAFLGPSTQCDLHARLFPLLQGK TVYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTL3P_ HTL3P Q4UOX6 derivative 3180 GLEHLPPPPEVSQFPLNPERLQALTDLVSRALEAKHIEPYQGPGNNPIFP Q4U0X6_ VKKPNGKWRFIHDLRATNSLTRDLASPSPGPPDLTSPPQDLPHLRTIDLT 2mutB DAFFQIPLPAVFQPYFAFTLPQPNNHGPGTRYSWRVLPQGFKNSPTLFQQ QLSHILAPVRKAFPNSLIIQYMDDILLASPALRELTALTDKVTNALTKEG LPMSLEKTQATPGSIHFLGQVISPDCITYETLPSIHVKSIWSLAELQSML GELQWVSKGTPVLRSSLHQLYLALRGHRDPRDTIELTSTQVQALKTIQKA LALNCRSRLVSQLPILALIILRPTGTTAVLFQTKQKWPLVWLHTPHPATS LRPWGQLLANAIITLDKYSLQHYGQICKSFHHNISNQALTYYLHTSDQSS VAILLQHSHRFHNLGAQPSGPWRSLLQVPQIFQNIDVLRPPFIISPVVID HAPCLFSDGATSKAAFILWDKQVIHQQVLPLPSTCSAQAGELFGLLAGLQ KSKPWPALNIFLDSKFLIGHLRRMAWGAFLGPSTQCDLHARLFPLLQGKT VYVHHVRSHTLLQDPISRLNEATDALMLAPLLPL HTLV2_ HTLV2 P03363 root 3181 HLPPPPQVDQFPLNLPERLQALNDLVSKALEAGHIEPYSGPGNNPVFPVK P03363 KPNGKWRFIHDLRATNAITTTLTSPSPGPPDLTSLPTALPHLQTIDLTDA FFQIPLPKQYQPYFAFTIPQPCNYGPGTRYAWTVLPQGFKNSPTLFEQQL AAVLNPMRKMFPTSTIVQYMDDILLASPTNEELQQLSQLTLQALTTHGLP ISQEKTQQTPGQIRFLGQVISPNHITYESTPTIPIKSQWTLTELQVILGE IQWVSKGTPILRKHLQSLYSALHGYRDPRACITLTPQQLHALHAIQQALO HNCRGRLNPALPLLGLISLSTSGTTSVIFQPKQNWPLAWLHTPHPPTSLC PWGHLLACTILTLDKYTLQHYGQLCQSFHHNMSKQALCDFLRNSPHPSVG ILIHHMGRFHNLGSQPSGPWKTLLHLPTLLQEPRLLRPIFTLSPVVLDTA PCLFSDGSPQKAAYVLWDQTILQQDITPLPSHETHSAQKGELLALICGLR AAKPWPSLNIFLDSKYLIKYLHSLAIGAFLGTSAHQTLQAALPPLLQGKT IYLHHVRSHTNLPDPISTFNEYTDSLILAPLVPL HTLV2_ HTLV2 P03363 derivative 3182 HLPPPPQVDQFPLNLPERLQALNDLVSKALEAGHIEPYSGPGNNPVFPVK P03363_ KPNGKWRFIHDLRATNAITTTLTSPSPGPPDLTSLPTALPHLQTIDLTDA 2mut FFQIPLPKQYQPYFAFTIPQPCNYGPGTRYAWTVLPQGFKNSPTLFQQQL AAVLNPMRKMFPTSTIVQYMDDILLASPTNEELQQLSQLTLQALTTHGLP ISQEKTQQTPGQIRFLGQVISPNHITYESTPTIPIKSQWTLTELQVILGE IQWVSKGTPILRKHLQSLYSALHPYRDPRACITLTPQQLHALHAIQQALQ HNCRGRLNPALPLLGLISLSTSGTTSVIFQPKQNWPLAWLHTPHPPTSLC PWGHLLACTILTLDKYTLQHYGQLCQSFHHNMSKQALCDFLRNSPHPSVG ILIHHMGRFHNLGSQPSGPWKTLLHLPTLLQEPRLLRPIFTLSPVVLDTA PCLFSDGSPQKAAYVLWDQTILQQDITPLPSHETHSAQKGELLALICGLR AAKPWPSLNIFLDSKYLIKYLHSLAIGAFLGTSAHQTLQAALPPLLQGKT IYLHHVRSHTNLPDPISTFNEYTDSLILAPLVPL HTLV2_ HTLV2 P03363 derivative 3183 HLPPPPQVDQFPLNLPERLQALNDLVSKALEAGHIEPYSGPGNNPVFPVK P03363_ KPNGKWRFIHDLRATNAITTTLTSPSPGPPDLTSPPTALPHLQTIDLTDA 2mutB FFQIPLPKQYQPYFAFTIPQPCNYGPGTRYAWTVLPQGFKNSPTLFQQQL AAVLNPMRKMFPTSTIVQYMDDILLASPTNEELQQLSQLTLQALTTHGLP ISQEKTQQTPGQIRFLGQVISPNHITYESTPTIPIKSQWTLTELQVILGE IQWVSKGTPILRKHLQSLYSALHPYRDPRACITLTPQQLHALHAIQQALQ HNCRGRLNPALPLLGLISLSTSGTTSVIFQPKQNWPLAWLHTPHPPTSLC PWGHLLACTILTLDKYTLQHYGQLCQSFHHNMSKQALCDFLRNSPHPSVG ILIHHMGRFHNLGSQPSGPWKTLLHLPTLLQEPRLLRPIFTLSPVVLDTA PCLFSDGSPQKAAYVLWDQTILQQDITPLPSHETHSAQKGELL ALICGLRAAKPWPSLNIFLDSKYLIKYLHSLAIGAFLGTSAHQTLQAALP PLLQGKTIYLHHVRSHTNLPDPISTFNEYTDSLILAPLVPL JSRV_ JSRV P31623 root 3184 PLGTSDSPVTHADPIDWKSEEPVWVDQWPLTQEKLSAAQQLVQEQLRLGH P31623 IEPSTSAWNSPIFVIKKKSGKWRLLQDLRKVNETMMHMGALQPGLPTPSA IPDKSYIIVIDLKDCFYTIPLAPQDCKRFAFSLPSVNFKEPMQRYQWRVL PQGMTNSPTLCQKFVATAIAPVRQRFPQLYLVHYMDDILLAHTDEHLLYQ AFSILKQHLSLNGLVIADEKIQTHFPYNYLGFSLYPRVYNTQLVKLQTDH LKTLNDFQKLLGDINWIRPYLKLPTYTLQPLFDILKGDSDPASPRTLSLE GRTALQSIEEAIRQQQITYCDYQRSWGLYILPTPRAPTGVLYQDKPLRWI YLSATPTKHLLPYYELVAKIIAKGRHEAIQYFGMEPPFICVPYALEQQDW LFQFSDNWSIAFANYPGQITHHYPSDKLLQFASSHAFIFPKIVRRQPIPE ATLIFTDGSSNGTAALIINHQTYYAQTSFSSAQVVELFAVHQALLTVPTS FNLFTDSSYVVGALQMIETVPIIGTTSPEVLNLFTLIQQVLHCRQHPCFF GHIRAHSTLPGALVQGNHTADVLTKQVFFQS JSRV_ JSRV P31623 derivative 3185 PLGTSDSPVTHADPIDWKSEEPVWVDQWPLTQEKLSAAQQLVQEQLRLGH P31623_ IEPSTSAWNSPIFVIKKKSGKWRLLQDLRKVNETMMHMGALQPGLPTPSP 2mutB IPDKSYIIVIDLKDCFYTIPLAPQDCKRFAFSLPSVNFKEPMQRYQWRVL PQGMTNSPTLCQKFVATAIAPVRQRFPQLYLVHYMDDILLAHTDEHLLYQ AFSILKQHLSLNGLVIADEKIQTHFPYNYLGFSLYPRVYNTQLVKLQTDH LKTLNDFQKLLGDINWIRPYLKLPTYTLQPLFDILKGDSDPASPRTLSLE GRTALQSIEEAIRQQQITYCDYQRSWGLYILPTPRAPTGVLYQDKPLRWI YLSATPTKHLLPYYELVAKIIAKGRHEAIQYFGMEPPFICVPYALEQQDW LFQFSDNWSIAFANYPGQITHHYPSDKLLQFASSHAFIFPKIVRRQPIPE ATLIFTDGSSNGTAALIINHQTYYAQTSFSSAQVVELFAVHQALLTVPTS FNLFTDSSYVVGALQMIETVPIIGTTSPEVLNLFTLIQQVLHCRQHPCFF GHIRAHSTLPGALVQGNHTADVLTKQVFFQS KORV_ KORV 101160 root 3186 TLGDQGSRGSDPLPEPRVTLTVEGIPTEFLVNTGAEHSVLTKPMGKMGSK Q9TTC1 RTVVAGATGSKVYPWTTKRLLKIGQKQVTHSFLVIPECPAPLLGRDLLTK LKAQIQFSTEGPQVTWEDRPAMCLVLNLEEEYRLHEKPVPPSIDPSWLQL FPMVWAEKAGMGLANQVPPVVVELKSDASPVAVRQYPMSKEAREGIRPHI QRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVQDIHPT VPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNSQPLFAFEWRDPEKG NTGQLTWTRLPQGFKNSPTLFDEALHRDLASFRALNPQVVMLQYVDDLLV AAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCREEVTYLGYLLKGGKR WLTPARKATVMKIPTPTTPRQVREFLGTAGFCRLWIPGFASLAAPLYPLT REKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTKPFALYVDEKEGVAR GVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIAAVALLLKDADKLTL GQNVLVIAPHNLESIVRQPPDRWMTNARMTHYQSLLLNERVSFAPPAILN PATLLPVESDDTPIHICSEILAEETGTRPDLRDQPLPGVPAWYTDGSSFI MDGRRQAGAAIVDNKRTVWASNLPEGTSAQKAELIALTQALRLAEGKSIN IYTDSRYAFATAHVHGAIYKQRGLLTSAGKDIKNKEEILALLEAIHLPKR VAIIHCPGHQRGTDPVATGNRKADEAAKQAAQSTRILTETTKN KORV_ KORV Q9C1 derivative 3187 LLGRDLLTKLKAQIQFSTEGPQVTWEDRPAMCLVLNLEEEYRLHEKPVPP Q9TTC1- SIDPSWLQLFPMVWAEKAGMGLANQVPPVVVELKSDASPVAVRQYPMSKE Pro AREGIRPHIQRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVN KRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNSQPLFA FEWRDPEKGNTGQLTWTRLPQGFKNSPTLFDEALHRDLASFRALNPQVVM LQYVDDLLVAAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCREEVTYL GYLLKGGKRWLTPARKATVMKIPTPTTPRQVREFLGTAGFCRLWIPGFAS LAAPLYPLTREKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTKPFALY VDEKEGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIAAVALL LKDADKLTLGQNVLVIAPHNLESIVRQPPD RWMTNARMTHYQSLLLNERVSFAPPAILNPATLLPVESDDTPIHICSEIL AEETGTRPDLRDQPLPGVPAWYTDGSSFIMDGRRQAGAAIVDNKRTVWAS NLPEGTSAQKAELIALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQ RGLLTSAGKDIKNKEEILALLEAIHLPKRVAIIHCPGHQRGTDPVATGNR KADEAAKQAAQSTRILTETTKN KORV_ KORV Q9TTC1 derivative 3188 PMSKEAREGIRPHIQRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQD Q9TTC1- LREVNKRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNS Pro3 QPLFAFEWRDPEKGNTGQLTWTRLPQGFKNSPTLFNEALHRDLASFRALN mut PQVVMLQYVDDLLVAAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCRE EVTYLGYLLKGGKRWLTPARKATVMKIPTPTTPRQVREFLGTAGFCRLWI PGFASLAAPLYPLTRPKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTK PFALYVDEKEGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIA AVALLLKDADKLTLGQNVLVIAPHNLESIVRQPPDRWMTNARMTHYQSLL LNERVSFAPPAILNPATLLPVESDDTPIHICSEILAEETGTRPDLRDQPL PGVPAWYTDGSSFIMDGRRQAGAAIVDNKRTVWASNLPEGTSAQKAELIA LTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGKDIKNKE EILALLEAIHLPKRVAIIHCPGHQRGTDPVATGNRKADEAAKQAAQSTRI LTETTKN KORV_ KORV Q9TTC1 derivative 3189 LLGRDLLTKLKAQIQFSTEGPQVTWEDRPAMCLVLNLEEEYRLHEKPVPP Q9TTC1- SIDPSWLQLFPMVWAEKAGMGLANQVPPVVVELKSDASPVAVRQYPMSKE Pro3 AREGIRPHIQRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVN mutA KRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNSQPLFA FEWRDPEKGNTGQLTWTRLPQGFKNSPTLFNEALHRDLASFRALNPQVVM LQYVDDLLVAAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCREEVTYL GYLLKGGKRWLTPARKATVMKIPTPTTPRQVREFLGKAGFCRLFIPGFAS LAAPLYPLTRPKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTKPFALY VDEKEGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIAAVALL LKDADKLTLGQNVLVIAPHNLESIVRQPPDRWMTNARMTHYQSLLLNERV SFAPPAILNPATLLPVESDDTPIHICSEILAEETGTRPDLRDQPLPGVPA WYTDGSSFIMDGRRQAGAAIVDNKRTVWASNLPEGTSAQKAELIALTQAL RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGKDIKNKEEILAL LEAIHLPKRVAIIHCPGHQRGTDPVATGNRKADEAAKQAAQSTRILTETT KN KORV_ KORV Q9TTC1 derivative 3190 TLGDQGSRGSDPLPEPRVTLTVEGIPTEFLVNTGAEHSVLTKPMGKMGSK Q9TTC1_ RTVVAGATGSKVYPWTTKRLLKIGQKQVTHSFLVIPECPAPLLGRDLLTK 3mut LKAQIQFSTEGPQVTWEDRPAMCLVLNLEEEYRLHEKPVPPSIDPSWLQL FPMVWAEKAGMGLANQVPPVVVELKSDASPVAVRQYPMSKEAREGIRPHI QRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVQDIHPT VPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNSQPLFAFEWRDPEKG NTGQLTWTRLPQGFKNSPTLFNEALHRDLASFRALNPQVVMLQYVDDLLV AAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCREEVTYLGYLLKGGKR WLTPARKATVMKIPTPTTPRQVREFLGTAGFCRLWIPGFASLAAPLYPLT RPKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTKPFALYVDEKEGVAR GVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIAAVALLLKDADKLTL GQNVLVIAPHNLESIVRQPPDRWMTNARMTHYQSLLLNERVSFAPPAILN PATLLPVESDDTPIHICSEILAEETGTRPDLRDQPLPGVPAWYTDGSSFI MDGRRQAGAAIVDNKRTVWASNLPEGTSAQKAELIALTQALRLAEGKSIN IYTDSRYAFATAHVHGAIYKQRGWLTSAGKDIKNKEEILALLEAIHLPKR VAIIHCPGHQRGTDPVATGNRKADEAAKQAAQSTRILTETTKN KORV_ KORV Q9TTC1 derivative 3191 TLGDQGSRGSDPLPEPRVTLTVEGIPTEFLVNTGAEHSVLTKPMGKMGSK Q9TTC1_  mutA RTVVAGATGSKVYPWTTKRLLKIGQKQVTHSFLVIPECPAPLLGRDL 3 REGIRPHIQRFLDLGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNK RVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLKDAFFCLKLHPNSQPLFAF EWRDPEKGNTGQLTWTRLPQGFKNSPTLFNEALHRDLASFRALNPQVVML QYVDDLLVAAPTYRDCKEGTRRLLQELSKLGYRVSAKKAQLCREEVTYLG YLLKGGKRWLTPARKATVMKIPTPTTPRQVREFLGKAGFCRLFIPGFASL AAPLYPLTRPKVPFTWTEAHQEAFGRIKEALLSAPALALPDLTKPFALYV DEKEGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPTCLKAIAAVALLL KDADKLTLGQNVLVIAPHNLESIVRQPPDRWMTNARMTHYQSLLLNERVS FAPPAILNPATLLPVESDDTPIHICSEILAEETGTRPDLRDQPLPGVPAW YTDGSSFIMDGRRQAGAAIVDNKRTVWASNLPEGTSAQKAELIALTQALR LAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGKDIKNKEEILALL EAIHLPKRVAIIHCPGHQRGTDPVATGNRKADEAAKQAAQSTRILTETTK N MLVAV_ MLVAV P03356 root 3192 TLNLEDEYRLYETSAEPEVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P03356 PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHRWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLLTLGNL GYRASAKKAQLCQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLRKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVAV_ MLVAV P03356 derivative 3193 TLNLEDEYRLYETSAEPEVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P03356_ PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHRWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLLTLGNL GYRASAKKAQLCQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLRKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVAV_ MLVAV P0335 derivative 3194 TLNLEDEYRLYETSAEPEVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P03356_ PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mutA VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHRWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLLTLGNL GYRASAKKAQLCQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLRKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEG KRLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGREIKNKSEILALLKALF LPKRLSIIHCLGHQKGDSAEARGNRLADQAAREAAIKTPPDTSTLL MLVBM_ MLVBM Q7SVK7 root 3195 LGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP Q7SVK7_3 LKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPV mutAWS KKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFNE ALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDLG YRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQ PVPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFSWGPDQQ KAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRP VAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVE ALVKQPPDRWLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGA PHDCLEILAETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVT TETEVIWAGALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATA HIHGEIYRRRGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKG DSAEARGNRLADQAAREAAIKTPPDTSTLLI MLVBM_ MLVBM Q7SVK7 derivative 3196 TLGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII Q7SVK7 PLKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPVPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFSWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAG ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVBM_ MLVBM Q7SVK7 derivative 3197 TLGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII Q7SVK7_ PLKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPVPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFSWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAG ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVBM_ MLVBM Q7SVK7 root 3195 LGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP Q7SVK7_3 LKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPV mutAWS KKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFNE ALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDLG YRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPVPKTPRQLR EFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFSWGPDQQKAYQEIKQAL LTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRW LSNARMTHYQAMLLDTDRVQFGPVVALNP ATLLPLPEEGAPHDCLEILAETHGTRPDLTDQPIPDADHTWYTDGSSFLQ EGQRKAGAAVTTETEVIWAGALPAGTSAQRAELIALTQALKMAEGKRLNV YTDSRYAFATAHIHGEIYRRRGWLTSEGREIKNKSEILALLKALFLPKRL SIIHCLGHQKGDSAEARGNRLADQAAREAAIKTPPDTSTLLI MLVBM_ MLVBM Q7SVK7 derivative 3196 TLGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII Q7SVK7 PLKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPVPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFSWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAG ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVBM_ MLVBM Q7SVK7 derivative 3197 TLGIEDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII Q7SVK7_ PLKATSTPVSIQQYPMSHEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDILLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPVPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFSWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPATLLPLPEEGAPH DCLEILAETHGTRPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTE TEVIWAGALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHI HGEIYRRRGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDS AEARGNRLADQAAREAAIKTPPDTSTLL MLVCB_ MLVCB P08361 root 3198 TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P08361 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLAGFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPIPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAFQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHDCLDILA EAHGTRSDLMDQPLPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNSAEARGNR MADQAAREVATRETPETSTLL MLVCB_ MLVCB P08361 derivative 3199 TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P08361_3 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLAGFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPIPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAFQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLG PATLLPLPEEGLQHDCLDILAEAHGTRSDLMDQPLPDADHTWYTDGSSFL QEGQRKAGAAVTTETEVIWARALPAGTSAQRAELIALTQALKMAEGKKLN VYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKR LSIIHCPGHQKGNSAEARGNRMADQAAREVATRETPETSTLL MLVCB_ MLVCB 3200 TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P08361_3 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP mutA VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLAGFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPIPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAFQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPATLLPLPEEGLQH DCLDILAEAHGTRSDLMDQPLPDADHTWYTDGSSFLQEGQRKAGAAVTTE TEVIWARALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHI HGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNS AEARGNRMADQAAREVATRETPETSTLL MLVF5_ MLVF5 P26810 root 3201 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAFRQAPLII P26810 SLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWKDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGLCRLWIPGFAEMAAPLYPLTKTGTLFKWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDVGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALNPATLLPLPEEGLQHDCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSFLQEGQRRAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAAGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNHAEARGNR MADQAAREVATRETPETSTLL MLVF5_ MLVF5 P26810 derivative 3202 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAFRQAPLII P26810_ SLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWKDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGLCRLWIPGFAEMAAPLYPLTKPGTLFKWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDVGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALNPATLLPLPEEGLQHDCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSFLQEGQRRAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAAGKKLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNHAEARGNR MADQAAREVATRETPETSTLL MLVF5_ MLVF5 P26810 derivative 3203 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAFRQAPLII P26810_3 SLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP mutA VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWKDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGLCRLFIPGFAEMAAPLYPLTKPGTLFKWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDVGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALNP ATLLPLPEEGLQHDCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSFLQ EGQRRAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAAGKKLNV YTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIIHCPGHQKGNHAEARGNRMADQAAREVATRETPETSTLL MLVFF_ MLVFF P26809 root 3204 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLII P26809 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFEWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALNPATLLPLPEEGLQHDCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVVWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNRAEARGNR MADQAAREVATRETPETSTLL MLVFF_ MLVFF P26809 derivative 3205 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLII P26809_ PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFEWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALNPATLLPLPEEGLQHDCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVVWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGNRAEARGNR MADQAAREVATRETPETSTLL MLVFF_ MLVEF P26809 derivative 3206 TLNIEDEYRLHETSKGPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLII P26809_ PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mutA VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQSLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGDL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFEWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPIVALN PATLLPLPEEGLQHDCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSFL QEGQRKAGAAVTTETEVVWAKALPAGTSAQRAELIALTQALKMAEGKKLN VYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKR LSIIHCPGHQKGNRAEARGNRMADQAAREVATRETPETSTLL MLVMS_ MLVMS P03355 root 3207 TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P03355_ PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP PLV919 VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKL GPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVIL APHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLP LPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRK AGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSR YAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHC PGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTA DGSEFE MLVMS_ MLVMS P03355 derivative 1548 TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P03355 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLL MLVMS_ MLVMS P03355 derivative 3208 TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P03355_3 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLL MLVMS_ MLVMS P03355 derivative 3209 TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII P03355_ PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mutA_ VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD WS LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLL MLVRD_ MLVRD P11227 root 3210 TLNIEDEYRLHEISTEPDVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P11227 PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLL PVKKPGTNDYRPVQGLREVNKRVEDIHPTVPNPYNLLSGLPTSHRWYTVL DLKDAFFCLRLHPTSQPLFASEWRDPGMGISGQLTWTRLPQGFKNSPTLF DEALHRGLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLKTLGN LGYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPTPKTPRQ LREFLGTAGFCRLWIPRFAEMAAPLYPLTKTGTLFNWGPDQQKAYHEIKQ ALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKL DPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPD RWLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEIL AETHGTEPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWA RALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYK RRGLLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGN RLADQAAREAAIKTPPDTSTLL MLVRD_ MLVRD P11227 derivative 3211 TLNIEDEYRLHEISTEPDVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P11227_ PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQGLREVNKRVEDIHPTVPNPYNLLSGLPTSHRWYTVLD LKDAFFCLRLHPTSQPLFASEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRGLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLKTLGNL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPRFAEMAAPLYPLTKPGTLFNWGPDQQKAYHEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTEPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYKR RGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MLVRD_ MLVRD P11227 derivative 3212 TLNIEDEYRLHEISTEPDVSPGSTWLSDFPQAWAETGGMGLAVRQAPLII P11227_ PLKATSTPVSIKQYPMSQEAKLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mutA VKKPGTNDYRPVQGLREVNKRVEDIHPTVPNPYNLLSGLPTSHRWYTVLD LKDAFFCLRLHPTSQPLFASEWRDPGMGISGQLTWTRLPQGFKNSPTLFN EALHRGLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLKTLGNL GYRASAKKAQICQKQVKYLGYLLREGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPRFAEMAAPLYPLTKPGTLFNWGPDQQKAYHEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHDCLEILA ETHGTEPDLTDQPIPDADHTWYTDGSSFLQEGQRKAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYKR RGWLTSEGREIKNKSEILALLKALFLPKRLSIIHCLGHQKGDSAEARGNR LADQAAREAAIKTPPDTSTLL MMTVB_ MMTVB P03365 root 3213 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_WS LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMHD MGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSPN FKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDD ILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQGD SVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILNG DSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYTP TACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDPD YIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTAI IFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQAE IVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHLQ RLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILTA MMTVB_ MMTVB P03365 derivative 3214 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365 SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDI KVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQ ALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMH DMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSP NFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMD DILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQG DSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN GDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYT PTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDP DYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTA IIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQA EIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHL QRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3215 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365- PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL Pro RAVNATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKR FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIR PFLKLTTGELKPLFEILNGDSNPISTRKLTPEACKALQLMNERLSTARVK RLDLSQPWSLCILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCT QLIIKGRHRSKELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGE VHFHLPKDPLLTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYI QGREPIIKENTQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEI ETATLSPRTKIYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAY ADSLTRILT MMTVB_ MMTVB P03365 derivative 3216 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365-Pro_ PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL 2mut RAVNATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKR FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGEL KPLFEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSL CILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRS KELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPL LTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKEN TQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTK IYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3217 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365- PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL Pro_ RAVNATMHDMGALQPGLPSPVAPPKGWEIIIIDLQDCFFNIKLHPEDCKR 2mutB FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGEL KPLFEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSL CILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRS KELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPL LTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKEN TQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTK IYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3218 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365_ SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMRAV 2mut NATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAF SVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYI VHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLG THIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPL FEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCIL KTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKEL FSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTF TLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQN TAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYT ELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3219 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365_ SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDI 2mutB KVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQ ALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMH DMGALQPGLPSPVAPPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSP NFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMD DILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQG DSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN PDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYT PTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDP DYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTA IIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQA EIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHL QRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3220 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_ LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK 2mutB_ VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA WS LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMHD MGALQPGLPSPPAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSPN FKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDD ILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQGD SVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILNP DSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYTP TACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDPD YIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTAI IFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQAE IVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHLQ RLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILTA MMTVB_ MMTVB P03365 derivative 3221 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_ LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK 2mut_ VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA WS LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMHD MGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSPN FKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDD ILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQGD SVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILNP DSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYTP TACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDPD YIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTAI IFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREP IIKENTQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATL SPRTKIYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLT  RILTA MMTVB_ MMTVB P03365 root 3213 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_ LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK WS VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMHD MGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSPN FKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDD ILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQGD SVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILNG DSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYTP TACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDPD YIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTAI IFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQAE IVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHLQ RLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILTA MMTVB_ MMTVB P03365 derivative 3214 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365 SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDI KVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQ ALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMH DMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSP NFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMD DILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQG DSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN GDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYT PTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDP DYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTA IIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQA EIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHL QRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3215 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365- PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL Pro RAVNATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKR FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGEL KPLFEILNGDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSL CILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRS KELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPL LTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKEN TQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTK IYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3216 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365- PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL Pro_ RAVNATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKR 2mut FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGEL KPLFEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSL CILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCT QLIIKGRHRSKELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGE VHFHLPKDPLLTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYI QGREPIIKENTQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEI ETATLSPRTKIYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAY ADSLTRILT MMTVB_ MMTVB P03365 derivative 3217 GRDIMKDIKVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQW P03365- PLKQEKLQALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDL Pro_ RAVNATMHDMGALQPGLPSPVAPPKGWEIIIIDLQDCFFNIKLHPEDCKR 2mutB FAFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQD SYIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLK YLGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGEL KPLFEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSL CILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRS KELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPL LTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKEN TQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTK IYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3218 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365_ SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDI 2mut KVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQ ALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMH DMGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSP NFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMD DILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQG DSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN PDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYT PTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDP DYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTA IIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQA EIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHL QRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILT MMTVB_ MMTVB P03365 derivative 3219 WVQEISDSRPMLHIYLNGRRFLGLLNTGADKTCIAGRDWPANWPIHQTES P03365_ SLQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDI 2mutB KVRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNOWPLKQEKLQ ALQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMH DMGALQPGLPSPVAPPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSP NFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMD DILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQG DSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILN PDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYT PTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIK GRHRSKELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHL PKDPLLTFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREP IIKENTQNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATL SPRTKIYTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLT RILT MMTVB_ MMTVB P03365 derivative 3220 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_ LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK 2mutB_ VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA WS LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLR AVNATMHDMGALQPGLPSPPAVPKGWEIIIIDLQDCFFNIKLHPEDCKRF AFSVPSPNFKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDS YIVHYMDDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKY LGTHIQGDSVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELK PLFEILNPDSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLC ILKTEYTPTACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSK ELFSKDPDYIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLL TFTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENT QNTAQQAEIVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKI YTELKHLQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILTA MMTVB_ MMTVB P03365 derivative 3221 VQEISDSRPMLHIYLNGRRFLGLLDTGADKTCIAGRDWPANWPIHQTESS P03365_ LQGLGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPFTLWGRDIMKDIK 2mut_ VRLMTDSPDDSQDLMIGAIESNLFADQISWKSDQPVWLNQWPLKQEKLQA WS LQQLVTEQLQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRAVNATMHD MGALQPGLPSPVAVPKGWEIIIIDLQDCFFNIKLHPEDCKRFAFSVPSPN FKRPYQRFQWKVLPQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDD ILLAHPSRSIVDEILTSMIQALNKHGLVVSTEKIQKYDNLKYLGTHIQGD SVSYQKLQIRTDKLRTLNDFQKLLGNINWIRPFLKLTTGELKPLFEILNP DSNPISTRKLTPEACKALQLMNERLSTARVKRLDLSQPWSLCILKTEYTP TACLWQDGVVEWIHLPHISPKVITPYDIFCTQLIIKGRHRSKELFSKDPD YIVVPYTKVQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLTFTLQTAI IFPHMTSTTPLEKGIVIFTDGSANGRSVTYIQGREPIIKENTQNTAQQAE IVAVITAFEEVSQPFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKHLQ RLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYADSLTRILTA MPMV_ MPMV P07572 root 3222 LTAAIDILAPQQCAEPITWKSDEPVWVDQWPLTNDKLAAAQQLVQEQLEA P07572 GHITESSSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP VAIPQGYLKIIIDLKDCFFSIPLHPSDQKRFAFSLPSTNFKEPMQRFQWK VLPQGMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAGKDGQQV LQCFDQLKQELTAAGLHIAPEKVQLQDPYTYLGFELNGPKITNQKAVIRK DKLQTLNDFQKLLGDINWLRPYLKLTTGDLKPLFDTLKGDSDPNSHRSLS KEALASLEKVETAIAEQFVTHINYSLPLIFLIFNTALTPTGLFWQDNPIM WIHLPASPKKVLLPYYDAIADLIILGRDHSKKYFGIEPSTIIQPYSKSQI DWLMQNTEMWPIACASFVGILDNHYPPNKLIQFCKLHTFVFPQIISKTPL NNALLVFTDGSSTGMAAYTLTDTTIKFQTNLNSAQLVELQALIAVLSAFP NQPLNIYTDSAYLAHSIPLLETVAQIKHISETAKLFLQCQQLIYNRSIPF YIGHVRAHSGLPGPIAQGNQRADLATKIVASNINT MPMV_ MPMV P07572 derivative 3223 LTAAIDILAPQQCAEPITWKSDEPVWVDQWPLTNDKLAAAQQLVQEQLEA P07572_ GHITESSSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP 2mut VAIPQGYLKIIIDLKDCFFSIPLHPSDQKRFAFSLPSTNFKEPMQRFQWK VLPQGMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAGKDGQQV LQCFDQLKQELTAAGLHIAPEKVQLQDPYTYLGFELNGPKITNQKAVIRK DKLQTLNDFQKLLGDINWLRPYLKLTTGDLKPLFDTLKPDSDPNSHRSLS KEALASLEKVETAIAEQFVTHINYSLPLIFLIFNTALTPTGLFWQDNPIM WIHLPASPKKVLLPYYDAIADLIILGRDHSKKYFGIEPSTIIQPYSKSQI DWLMQNTEMWPIACASFVGILDNHYPPNKLIQFCKLHTFVFPQIISKTPL NNALLVFTDGSSTGMAAYTLTDTTIKFQTNLNSAQLVELQALIAVLSAFP NQPLNIYTDSAYLAHSIPLLETVAQIKHISETAKLFLQCQQLIYNRSIPF YIGHVRAHSGLPGPIAQGNQRADLATKIVASNINT MPMV_ MPMV P07572 derivative 3224 LTAAIDILAPQQCAEPITWKSDEPVWVDQWPLTNDKLAAAQQLVQEQLEA P07572_ GHITESSSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP 2mutB VAPPQGYLKIIIDLKDCFFSIPLHPSDQKRFAFSLPSTNFKEPMQRFQWK VLPQGMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIA GKDGQQVLQCFDQLKQELTAAGLHIAPEKVQLQDPYTYLGFELNGPKITN QKAVIRKDKLQTLNDFQKLLGDINWLRPYLKLTTGDLKPLFDTLKPDSDP NSHRSLSKEALASLEKVETAIAEQFVTHINYSLPLIFLIFNTALTPTGLF WQDNPIMWIHLPASPKKVLLPYYDAIADLIILGRDHSKKYFGIEPSTIIQ PYSKSQIDWLMQNTEMWPIACASFVGILDNHYPPNKLIQFCKLHTFVFPQ IISKTPLNNALLVFTDGSSTGMAAYTLTDTTIKFQTNLNSAQLVELQALI AVLSAFPNQPLNIYTDSAYLAHSIPLLETVAQIKHISETAKLFLQCQQLI YNRSIPFYIGHVRAHSGLPGPIAQGNQRADLATKIVASNINT PERV_ PERV Q4VFZ2 root 3225 LDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKA Q4VFZ2_ SATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKP 3mutA_ GTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDA WS FFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALH RDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRA SAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVREFL GKAGFCRLFIPGFATLAAPLYPLTKPKGEFSWAPEHQKAFDAIKKALLSA PALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVAS GWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTN ARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETG VRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPE GTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWL TSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADR VAKQAAQGVNLLP PERV_ PERV Q4VFZ2 derivative 3226 TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQ Q4VFZ2 LKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPV RKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDE ALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLG YRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVR EFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKAL LSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDP VASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRW MTNARMTHYQSLLLTERVTFAPPAALNPATL LPEETDEPVTHDCHQLLIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYT DSRYAFATAHVHGAIYKQRGLLTSAGREIKNKEEILSLLEALHLPKRLAI IHCPGHQKAKDPISRGNQMADRVAKQAAQGVNLL PERV_ PERV Q4VFZ2 derivative 3227 TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQ Q4VFZ2_ LKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPV 3mut RKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNE ALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLG YRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVR EFLGTAGFCRLWIPGFATLAAPLYPLTKPKGEFSWAPEHQKAFDAIKKAL LSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDP VASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRW MTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIE ETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASS LPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQR GWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQM ADRVAKQAAQGVNLL PERV_ PERV Q4VFZ2 root 3225 LDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKA Q4VFZ2_ SATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKP 3mutA_ GTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDA WS FFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSP TIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLE LSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTT AKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKPKGEFSWAPEHQKAFDA IKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLS KKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQ PPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCH QLLIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRT IWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGA IYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPIS RGNQMADRVAKQAAQGVNLLP PERV_ PERV Q4VFZ2 derivative 3226 TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQ Q4VFZ2 LKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPV RKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDE ALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLG YRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVR EFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKAL LSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDP VASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRW MTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIE ETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASS LPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQR GLLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQM ADRVAKQAAQGVNLL PERV_ PERV Q4VFZ2 derivative 3227 TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQ Q4VFZ2_ LKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPV 3mut RKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNE ALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLG YRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVR EFLGTAGFCRLWIPGFATLAAPLYPLTKPKGEFSWAPEHQKAFDAIKKAL LSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDP VASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRW MTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIE ETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASS LPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQR GWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQM ADRVAKQAAQGVNLL SFV1_ SFV1 P23074 root 3228 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPEAFLEDERPIQTMLIKT P23074 IHGEKQQDVYYLTFKVQGRKVEAEVLASPYDYILLNPSDVPWLMKKPLQL TVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQHWENQVGHRRI KPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQGVLIQQNSTMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIYRGKYKTT LDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFTADVV DLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLNAGYVVSLKKSE IAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQLQSILGLLNFA RNFIPNYSELVKPLYTIVANANGKFISWTEDNSNQLQHIISVLNQADNLE ERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIFSKAEAKFTQTE KLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPLPERKALPVRWI TWMTYLEDPRIQFHYDKSLPELQQIPNVTEDVIAKTKHPSEFAMVFYTDG SAIKHPDVNKSHSAGMGIAQVQFIPEYKIVHQWSIPLGDHTAQLAEIAAV EFACKKALKISGPVLIVTDSFYVAESANKELPYWKSNGFLNNKKKPLRHV SKWKSIAECLQLKPDIIIMHEKGHQQPMTTLHTEGNNLADKLATQGSYVV H SFV1_ SFV1 P23074 derivative 3229 VPWLMKKPLQLTVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQ P23074- HWENQVGHRRIKPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro VLIQQNSTMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL SSIYRGKYKTTLDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFTADVVDLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLN AGYVVSLKKSEIAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQ LQSILGLLNFARNFIPNYSELVKPLYTIVANANGKFISWTEDNSNQLQHI ISVLNQADNLEERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIF SKAEAKFTQTEKLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPL PERKALPVRWITWMTYLEDPRIQFHYDKSLPELQQIPNVTEDVIAKTKHP SEFAMVFYTDGSAIKHPDVNKSHSAGMGIAQVQFIPEYKIVHQWSIPLGD HTAQLAEIAAVEFACKKALKISGPVLIVTDSFYVAESANKELPYWKSNGF LNNKKKPLRHVSKWKSIAECLQLKPDIIIMHEKGHQQPMTTLHTEGNNLA DKLATQGSYVVH SFV1_ SFV1 P23074 derivative 3230 VPWLMKKPLQLTVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQ P23074- HWENQVGHRRIKPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_ VLIQQNSTMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL 2mut SSIYRGKYKTTLDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADVVDLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLN AGYVVSLKKSEIAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQ LQSILGLLNFARNFIPNYSELVKPLYTIVAPANGKFISWTEDNSNQLQHI ISVLNQADNLEERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIF SKAEAKFTQTEKLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPL PERKALPVRWITWMTYLEDPRIQFHYDKSLPELQQIPN VTEDVIAKTKHPSEFAMVFYTDGSAIKHPDVNKSHSAGMGIAQVQFIPEY KIVHQWSIPLGDHTAQLAEIAAVEFACKKALKISGPVLIVTDSFYVAESA NKELPYWKSNGFLNNKKKPLRHVSKWKSIAECLQLKPDIIIMHEKGHQQP MTTLHTEGNNLADKLATQGSYVVH SFV1_ SFV1 P23074 derivative 3231 VPWLMKKPLQLTVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQ P23074- HWENQVGHRRIKPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_ VLIQQNSTMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL 2mutA SSIYRGKYKTTLDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADVVDLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLN AGYVVSLKKSEIAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQ LQSILGKLNFARNFIPNYSELVKPLYTIVAPANGKFISWTEDNSNQLQHI ISVLNQADNLEERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIF SKAEAKFTQTEKLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPL PERKALPVRWITWMTYLEDPRIQFHYDKSLPELQQIPNVTEDVIAKTKHP SEFAMVFYTDGSAIKHPDVNKSHSAGMGIAQVQFIPEYKIVHQWSIPLGD HTAQLAEIAAVEFACKKALKISGPVLIVTDSFYVAESANKELPYWKSNGF LNNKKKPLRHVSKWKSIAECLQLKPDIIIMHEKGHQQPMTTLHTEGNNLA DKLATQGSYVVH SFV1_ SFV1 P23074 derivative 3232 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPEAFLEDERPIQTMLIKT P23074_ IHGEKQQDVYYLTFKVQGRKVEAEVLASPYDYILLNPSDVPWLMKKPLQL 2mut TVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQHWENQVGHRRI KPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQGVLIQQNSTMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIYRGKYKTT LDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFNADVV DLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLNAGYVVSLKKSE IAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQLQSILGLLNFA RNFIPNYSELVKPLYTIVAPANGKFISWTEDNSNQLQHIISVLNQADNLE ERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIFSKAEAKFTQTE KLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPLPERKALPVRWI TWMTYLEDPRIQFHYDKSLPELQQIPNVTEDVIAKT KHPSEFAMVFYTDGSAIKHPDVNKSHSAGMGIAQVQFIPEYKIVHQWSIP LGDHTAQLAEIAAVEFACKKALKISGPVLIVTDSFYVAESANKELPYWKS NGFLNNKKKPLRHVSKWKSIAECLQLKPDIIIMHEKGHQQPMTTLHTEGN NLADKLATQGSYVVH SFV1_ SFV1 P23074 derivative 3233 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPEAFLEDERPIQTMLIKT P23074_ IHGEKQQDVYYLTFKVQGRKVEAEVLASPYDYILLNPSDVPWLMKKPLQL 2mutA TVLVPLHEYQERLLQQTALPKEQKELLQKLFLKYDALWQHWENQVGHRRI KPHNIATGTLAPRPQKQYPINPKAKPSIQIVIDDLLKQGVLIQQNSTMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIYRGKYKTT LDLTNGFWAHPITPESYWLTAFTWQGKQYCWTRLPQGFLNSPALFNADVV DLLKEIPNVQAYVDDIYISHDDPQEHLEQLEKIFSILLNAGYVVSLKKSE IAQREVEFLGFNITKEGRGLTDTFKQKLLNITPPKDLKQLQSILGKLNFA RNFIPNYSELVKPLYTIVAPANGKFISWTEDNSNQLQHIISVLNQADNLE ERNPETRLIIKVNSSPSAGYIRYYNEGSKRPIMYVNYIFSKAEAKFTQTE KLLTTMHKGLIKAMDLAMGQEILVYSPIVSMTKIQRTPLPERKALPVRWI TWMTYLEDPRIQFHYDKSLPELQQIPNVTEDVIAKTKHPSEFAMVFYTDG SAIKHPDVNKSHSAGMGIAQVQFIPEYKIVHQWSIPLGDHTAQLAEIAAV EFACKKALKISGPVLIVTDSFYVAESANKELPYWKSNGFLNNKKKPLRHV SKWKSIAECLQLKPDIIIMHEKGHQQPMTTLHTEGNNLADKLATQGSYVV H SFV3L_ SFV3L P27401 root 3234 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPQAFLEEEVPIKNIWIKT P27401 IHGEKEQPVYYLTFKIQGRKVEAEVISSPYDYILVSPSDIPWLMKKPLQL TTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQHWENQVGHRRI KPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQGVLIQQNSIMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIFRGKYKTT LDLSNGFWAHSITPESYWLTAFTWLGQQYCWTRLPQGFLNSPALFTADVV DLLKEVPNVQVYVDDIYISHDDPREHLEQLEKVFSLLLNAGYVVSLKKSE IAQHEVEFLGFNITKEGRGLTETFKQKLLNITPPRDLKQLQSILGLLNFA RNFIPNFSELVKPLYNIIATANGKYITWTTDNSQQLQNIISMLNSAENLE ERNPEVRLIMKVNTSPSAGYIRFYNEFAKRPIMYLNYVYTKAEVKFTNTE KLLTTIHKGLIKALDLGMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMSYLEDPRIQFHYDKTLPELQQVPTVTDDIIAKIKHPSEFSMVFYTDG SAIKHPNVNKSHNAGMGIAQVQFKPEFTVINTWSIPLGDHTAQLAEVAAV EFACKKALKIDGPVLIVTDSFYVAESVNKELPYWQSNGFFNNKKKPLKHV SKWKSIADCIQLKPDIIIIHEKGHQPTASTFHTEGNNLADKLATQGSYVV N SFV3L_ SFV3L P27401 derivative 3235 IPWLMKKPLQLTTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQ P27401= HWENQVGHRRIKPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQG Pro VLIQQNSIMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL SSIFRGKYKTTLDLSNGFWAHSITPESYWLTAFTWLGQQYCWTRLPQGFL NSPALFTADVVDLLKEVPNVQVYVDDIYISHDDPREHLEQLEKVFSLLLN AGYVVSLKKSEIAQHEVEFLGFNITKEGRGLTETFKQKLLNITPPRDLKQ LQSILGLLNFARNFIPNFSELVKPLYNIIATANGKYITWTTDNSQQLQNI ISMLNSAENLEERNPEVRLIMKVNTSPSAGYIRFYNEFAKRPIMYLNYVY TKAEVKFTNTEKLLTTIHKGLIKALDLGMGQEILVYSPIVSMTKIQKTPL PERKALPIRWITWMSYLEDPRIQFHYDKTLPELQQVPTVTDDIIAKIKHP SEFSMVFYTDGSAIKHPNVNKSHNAGMGIAQVQFKPEFTVINTWSIPLGD HTAQLAEVAAVEFACKKALKIDGPVLIVTDSFYVAESVNKELPYWQSNGF FNNKKKPLKHVSKWKSIADCIQLKPDIIIIHEKGHQPTASTFHTEGNNLA DKLATQGSYVVN SFV3L_ SFV3L P27401 derivative 3236 IPWLMKKPLQLTTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQ P27401- HWENQVGHRRIKPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQG Pro_ VLIQQNSIMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL 2mut SSIFRGKYKTTLDLSNGFWAHSITPESYWLTAFTWLGQQYCW TRLPQGFLNSPALFNADVVDLLKEVPNVQVYVDDIYISHDDPREHLEQLE KVFSLLLNAGYVVSLKKSEIAQHEVEFLGFNITKEGRGLTETFKQKLLNI TPPRDLKQLQSILGLLNFARNFIPNFSELVKPLYNIIATAPGKYITWTTD NSQQLQNIISMLNSAENLEERNPEVRLIMKVNTSPSAGYIRFYNEFAKRP IMYLNYVYTKAEVKFTNTEKLLTTIHKGLIKALDLGMGQEILVYSPIVSM TKIQKTPLPERKALPIRWITWMSYLEDPRIQFHYDKTLPELQQVPTVTDD IIAKIKHPSEFSMVFYTDGSAIKHPNVNKSHNAGMGIAQVQFKPEFTVIN TWSIPLGDHTAQLAEVAAVEFACKKALKIDGPVLIVTDSFYVAESVNKEL PYWQSNGFFNNKKKPLKHVSKWKSIADCIQLKPDIIIIHEKGHQPTASTF HTEGNNLADKLATQGSYVVN SFV3L_ SFV3L P27401 derivative 3237 IPWLMKKPLQLTTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQ P27401- HWENQVGHRRIKPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQG Pro_ VLIQQNSIMNTPVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGIL 2mutA SSIFRGKYKTTLDLSNGFWAHSITPESYWLTAFTWLGQQYCWTRLPQGFL NSPALFNADVVDLLKEVPNVQVYVDDIYISHDDPREHLEQLEKVFSLLLN AGYVVSLKKSEIAQHEVEFLGFNITKEGRGLTETFKQKLL NITPPRDLKQLQSILGKLNFARNFIPNFSELVKPLYNIIATAPGKYITWT TDNSQQLQNIISMLNSAENLEERNPEVRLIMKVNTSPSAGYIRFYNEFAK RPIMYLNYVYTKAEVKFTNTEKLLTTIHKGLIKALDLGMGQEILVYSPIV SMTKIQKTPLPERKALPIRWITWMSYLEDPRIQFHYDKTLPELQQVPTVT DDIIAKIKHPSEFSMVFYTDGSAIKHPNVNKSHNAGMGIAQVQFKPEFTV INTWSIPLGDHTAQLAEVAAVEFACKKALKIDGPVLIVTDSFYVAESVNK ELPYWQSNGFFNNKKKPLKHVSKWKSIADCIQLKPDIIIIHEKGHQPTAS TFHTEGNNLADKLATQGSYVVN SFV3L_ SFV3L P27401 derivative 3238 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPQAFLEEEVPIKNIWIKT P27401_ IHGEKEQPVYYLTFKIQGRKVEAEVISSPYDYILVSPSDIPWLMKKPLQL 2mut TTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQHWENQVGHRRI KPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQGVLIQQNSIMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIFRGKYKTT LDLSNGFWAHSITPESYWLTAFTWLGQQYCWTRLPQGFLNSPALFNADVV DLLKEVPNVQVYVDDIYISHDDPREHLEQLEKVFSLLLNAGYVVSLKKSE IAQHEVEFLGFNITKEGRGLTETFKQKLLNITPPRDLKQLQSILGLLNFA RNFIPNFSELVKPLYNIIATAPGKYITWTTDNSQQLQNIISMLNSAENLE ERNPEVRLIMKVNTSPSAGYIRFYNEFAKRPIMYLNYVYTKAEVKFTNTE KLLTTIHKGLIKALDLGMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMSYLEDPRIQFHYDKTLPELQQVPTVTDDIIAKIKHPSEFSMVFYTDG SAIKHPNVNKSHNAGMGIAQVQFKPEFTVINTWSIPLGDHTAQLAEVAAV EFACKKALKIDGPVLIVTDSFYVAESVNKELPYWQSNGFFNNKKKPLKHV SKWKSIADCIQLKPDIIIIHEKGHQPTASTFHTEGNNLADKLATQGSYVV N SFV3L_ SFVL P27401 derivative 3239 MDPLQLLQPLEAEIKGTKLKAHWNSGATITCVPQAFLEEEVPIKNIWIKT P27401_ IHGEKEQPVYYLTFKIQGRKVEAEVISSPYDYILVSPSDIPWLMKKPLQL 2mutA TTLVPLQEYEERLLKQTMLTGSYKEKLQSLFLKYDALWQHWENQVGHRRI KPHHIATGTVNPRPQKQYPINPKAKASIQTVINDLLKQGVLIQQNSIMNT PVYPVPKPDGKWRMVLDYREVNKTIPLIAAQNQHSAGILSSIFRGKYKTT LDLSNGFWAHSITPESYWLTAFTWLGQQYCWTRLPQGFLNSPALFNADVV DLLKEVPNVQVYVDDIYISHDDPREHLEQLEKVFSLLLNAGYVVSLKKSE IAQHEVEFLGFNITKEGRGLTETFKQKLLNITPPRDLKQLQSILGKLNFA RNFIPNFSELVKPLYNIIATAPGKYITWTTDNSQQLQNIISMLNSAENLE ERNPEVRLIMKVNTSPSAGYIRFYNEFAKRPIMYLNYVYTKAEVKFTNTE KLLTTIHKGLIKALDLGMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMSYLEDPRIQFHYDKTLPELQQVPTVTDDIIAKIKHPSEFSMVFYTDG SAIKHPNVNKSHNAGMGIAQVQFKPEFTVINTWSIPLGDHTAQLAEVAAV EFACKKALKIDGPVLIVTDSFYVAESVNKELPY WQSNGFFNNKKKPLKHVSKWKSIADCIQLKPDIIIIHEKGHQPTASTFHT EGNNLADKLATQGSYVVN SFVCP_ SFVCP 087040 root 3240 MNPLQLLQPLPAEVKGTKLLAHWNSGATITCIPESFLEDEQPIKQTLIKT Q87040 IHGEKQQNVYYLTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQL TILVPLQEYQDRILNKTALPEEQKQQLKALFTKYDNLWQHWENQVGHRKI RPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNT PVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTT LDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFLNSPALFTADAV DLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQAGYVVSLKKSE IGQRTVEFLGFNITKEGRGLTDTFKTKLLNVTPPKDLKQLQSILGLLNFA RNFIPNFAELVQTLYNLIASSKGKYIEWTEDNTKQLNKVIEALNTASNLE ERLPDQRLVIKVNTSPSAGYVRYYNESGKKPIMYLNYVFSKAELKFSMLE KLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSIPPLKHPSQYEGVFCTDG SAIKSPDPTKSNNAGMGIVHAIYNPEYKILNQWSIPLGHHTAQMAEIAAV EFACKKALKVPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKEPLKHI SKWKSIAECLSIKPDITIQHEKGHQPINTSIHTEGNALADKLATQGSYVV N SFVCP_ SFVCP Q87040 derivative 3241 VPWLTQQPLQLTILVPLQEYQDRILNKTALPEEQKQQLKALFTKYDNLWQ Q87040- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL ATIVRQKYKTTLDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFL NSPALFTADAVDLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQ AGYVVSLKKSEIGQRTVEFLGFNITKEGRGLTDTFKTKLLNVTPPKDLKQ LQSILGLLNFARNFIPNFAELVQTLYNLIASSKGKYIEWTEDNTKQLNKV IEALNTASNLEERLPDQRLVIKVNTSPSAGYVRYYNESGKKPIMYLNYVF SKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPL PERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSIPPLKHP SQYEGVFCTDGSAIKSPDPTKSNNAGMGIVHAIYNPEYKILNQWSIPLGH HTAQMAEIAAVEFACKKALKVPGPVLVITDSFYVAESANKELPYWKSNGF VNNKKEPLKHISKWKSIAECLSIKPDITIQHEKGHQPINTSIHTEGNALA DKLATQGSYVVN SFVCP_ SFVCP 087040 derivative 3242 VPWLTQQPLQLTILVPLQEYQDRILNKTALPEEQKQQLKALFTKYDNLWQ Q87040- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_ VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL 2mut ATIVRQKYKTTLDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADAVDLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQ AGYVVSLKKSEIGQRTVEFLGFNITKEGRGLTDTFKTKLLNVTPPKDLKQ LQSILGLLNFARNFIPNFAELVQTLYNLIASSPGKYIEWTEDNTKQLNKV IEALNTASNLEERLPDQRLVIKVNTSPSAGYVRYYNESGKKPIMYLNYVF SKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPL PERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSIPPLKHP SQYEGVFCTDGSAIKSPDPTKSNNAGMGIVHAIYNPEYKILNQWSIPLGH HTAQMAEIAAVEFACKKALKVPGPVLVITDSFYVAESANKELPYWKSNGF VNNKKEPLKHISKWKSIAECLSIKPDITIQHEKGHQPINTSIHTEGNALA DKLATQGSYVVN SFVCP_ SFVCP 087040 derivative 3243 VPWLTQQPLQLTILVPLQEYQDRILNKTALPEEQKQQLKALFTKYDNLWQ Q87040- HWENQVGHRKIRPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQG Pro_ VLTPQNSTMNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGIL 2mutA ATIVRQKYKTTLDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFL NSPALFNADAVDLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQ AGYVVSLKKSEIGQRTVEFLGFNITKEGRGLTDTFKTK LLNVTPPKDLKQLQSILGKLNFARNFIPNFAELVQTLYNLIASSPGKYIE WTEDNTKQLNKVIEALNTASNLEERLPDQRLVIKVNTSPSAGYVRYYNES GKKPIMYLNYVFSKAELKFSMLEKLLTTMHKALIKAMDLAMGQEILVYSP IVSMTKIQKTPLPERKALPIRWITWMTYLEDPRIQFHYDKTLPELKHIPD VYTSSIPPLKHPSQYEGVFCTDGSAIKSPDPTKSNNAGMGIVHAIYNPEY KILNQWSIPLGHHTAQMAEIAAVEFACKKALKVPGPVLVITDSFYVAESA NKELPYWKSNGFVNNKKEPLKHISKWKSIAECLSIKPDITIQHEKGHQPI NTSIHTEGNALADKLATQGSYVVN SFVCP_ SFVCP Q87040 derivative 3244 MNPLQLLQPLPAEVKGTKLLAHWNSGATITCIPESFLEDEQPIKQTLIKT Q87040_ IHGEKQQNVYYLTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLQL 2mut TILVPLQEYQDRILNKTALPEEQKQQLKALFTKYDNLWQHWENQVGHRKI RPHNIATGDYPPRPQKQYPINPKAKPSIQIVIDDLLKQGVLTPQNSTMNT PVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKYKTT LDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFLNSPALFNADAV DLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQAGYVVSLKKSE IGQRTVEFLGFNITKEGRGLTDTFKTKLLNVTPPKDLKQLQSILGLLNFA RNFIPNFAELVQTLYNLIASSPGKYIEWTEDNTKQLNKVIEALNTASNLE ERLPDQRLVIKVNTSPSAGYVRYYNESGKKPIMYLNYVFSKAELKFSMLE KLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPIRWI TWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSIPPLKHPSQYEGVFCTDG SAIKSPDPTKSNNAGMGIVHAIYNPEYKILNQWSIPLGHHTAQMAEIAAV EFACKKALKVPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKEPLKHI SKWKSIAECLSIKPDITIQHEKGHQPINTSIHTEGNALADKLATQGSYVV N SFVCP_ SFVCP Q87040 derivative 3245 MNPLQLLQPLPAEVKGTKLLAHWNSGATITCIPESFLEDEQPIKQTLIKT Q87040_ IHGEKQQNVYYLTFKVKGRKVEAEVIASPYEYILLSPTDVPWLTQQPLST 2mutA MNTPVYPVPKPDGRWRMVLDYREVNKTIPLTAAQNQHSAGILATIVRQKY KTTLDLANGFWAHPITPDSYWLTAFTWQGKQYCWTRLPQGFLNSPALFNA DAVDLLKEVPNVQVYVDDIYLSHDNPHEHIQQLEKVFQILLQAGYVVSLK KSEIGQRTVEFLGFNITKEGRGLTDTFKTKLLNVTPPKDLKQLQSILGKL NFARNFIPNFAELVQTLYNLIASSPGKYIEWTEDNTKQLNKVIEALNTAS NLEERLPDQRLVIKVNTSPSAGYVRYYNESGKKPIMYLNYVFSKAELKFS MLEKLLTTMHKALIKAMDLAMGQEILVYSPIVSMTKIQKTPLPERKALPI RWITWMTYLEDPRIQFHYDKTLPELKHIPDVYTSSIPPLKHPSQYEGVFC TDGSAIKSPDPTKSNNAGMGIVHAIYNPEYKILNQWSIPLGHHTAQMAEI AAVEFACKKALKVPGPVLVITDSFYVAESANKELPYWKSNGFVNNKKEPL KHISKWKSIAECLSIKPDITIQHEKGHQPINTSIHTEGNALADKLATQGS YVVN SMRVH_ SMRVH P03364 root 3246 PRSRAIDIPVPHADKISWKITDPVWVDQWPLTYEKTLAAIALVQEQLAAG P03364 HIEPTNSPWNTPIFIIKKKSGSWRLLQDLRAVNKVMVPMGALQPGLPSPV AIPLNYHKIVIDLKDCFFTIPLHPEDRPYFAFSVPQINFQSPMPRYQWKV LPQGMANSPTLCQKFVAAAIAPVRSQWPEAYILHYMDDILLACDSAEAAK ACYAHIISCLTSYGLKIAPDKVQVSEPFSYLGFELHHQQVFTPRVCLKTD HLKTLNDFQKLLGDIQWLRPYLKLPTSALVPLNNILKGDPNPLSVRALTP EAKQSLALINKAIQNQSVQQISYNLPLVLLLLPTPHTPTAVFWQPNGTDP TKNGSPLLWLHLPASPSKVLLTYPSLLAMLIIKGRYTGRQLFGRDPHSII IPYTQDQLTWLLQTSDEWAIALSSFTGDIDNHYPSDPVIQFAKLHQFIFP KITKCAPIPQATLVFTDGSSNGIAAYVIDNQPISIKSPYLSAQLVELYAI LQVFTVLAHQPFNLYTDSAYIAQSVPLLETVPFIKSSTNATPLFSKLQQL ILNRQHPFFIGHLRAHLNLPGPLAEGNALADAATQIFPIISD SMRVH_ SMRVH P03364 derivative 3247 PRSRAIDIPVPHADKISWKITDPVWVDQWPLTYEKTLAAIALVQEQLAAG P03364_ HIEPTNSPWNTPIFIIKKKSGSWRLLQDLRAVNKVMVPMGALQPGLPSPV 2mut AIPLNYHKIVIDLKDCFFTIPLHPEDRPYFAFSVPQINFQSPMPRYQWKV LPQGMANSPTLCQKFVAAAIAPVRSQWPEAYILHYMDDILLACDS AEAAKACYAHIISCLTSYGLKIAPDKVQVSEPFSYLGFELHHQQVFTPRV CLKTDHLKTLNDFQKLLGDIQWLRPYLKLPTSALVPLNNILKPDPNPLSV RALTPEAKQSLALINKAIQNQSVQQISYNLPLVLLLLPTPHTPTAVFWQP NGTDPTKNGSPLLWLHLPASPSKVLLTYPSLLAMLIIKGRYTGRQLFGRD PHSIIIPYTQDQLTWLLQTSDEWAIALSSFTGDIDNHYPSDPVIQFAKLH QFIFPKITKCAPIPQATLVFTDGSSNGIAAYVIDNQPISIKSPYLSAQLV ELYAILQVFTVLAHQPFNLYTDSAYIAQSVPLLETVPFIKSSTNATPLFS KLQQLILNRQHPFFIGHLRAHLNLPGPLAEGNALADAATQIFPIISD SMRVH_ SMRVH P03364 derivative 3248 PRSRAIDIPVPHADKISWKITDPVWVDQWPLTYEKTLAAIALVQEQLAAG P03364_2 HIEPTNSPWNTPIFIIKKKSGSWRLLQDLRAVNKVMVPMGALQPGLPSPV mutB APPLNYHKIVIDLKDCFFTIPLHPEDRPYFAFSVPQINFQSPMPRYQWKV LPQGMANSPTLCQKFVAAAIAPVRSQWPEAYILHYMDDILLACDSAEAAK ACYAHIISCLTSYGLKIAPDKVQVSEPFSYLGFELHHQQVFTPRVCLKTD HLKTLNDFQKLLGDIQWLRPYLKLPTSALVPLNNILKPDPNPLSVRALTP EAKQSLALINKAIQNQSVQQISYNLPLVLLLLPTPHTPTAVFWQPNGTDP TKNGSPLLWLHLPASPSKVLLTYPSLLAMLIIKGRYTGRQLFGRDPHSII IPYTQDQLTWLLQTSDEWAIALSSFTGDIDNHYPSDPVIQFAKLHQFIFP KITKCAPIPQATLVFTDGSSNGIAAYVIDNQPISIKSPYLSAQLVELYAI LQVFTVLAHQPFNLYTDSAYIAQSVPLLETVPFIKSSTNATPLFSKLQQL ILNRQHPFFIGHLRAHLNLPGPLAEGNALADAATQIFPIISD SRV1_ SRV1 P04025 root 3249 LTAAIDMLAPQQCAEPITWKSDEPVWVDQWPLTSEKLAAAQQLVQEQLEA P04025 GHITESNSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP VAIPQGYLKIIIDLKDCFFSIPLHPSDQKRFAFSLPSTNFKEPMQRFQWK VLPQRMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAGKDGQQV LQCFDQLKQELTIAGLHIAPEKIQLQDPYTYLGFELNGPKITNQKAVIRK DKLQTLNDFQKLLGDINWLRPYLKLTTADLKPLFDTLKGDSNPNSHRSLS KEALALLDKVETAIAEQFVTHINYSLPLMFLIFNTALTPTGLFWQNNPIM WVHLPASPKKVLLPYYDAIADLIILGRDHSKKYFGIEPSVIIQPYSKSQI DWLMQNTEMWPIACASYVGILDNHYPPNKLIQFCKLHAFIFPQIISKTPL NNALLVFTDGSSTGMAAYTLADTTIKFQTNLNSAQLVELQALIAVLSAFP NQPLNIYTDSAYLAHSIPLLETVAQIKHISETAKLFLQCQQLIYNRSIPF YIGHVRAHSGLPGPIAHGNQKADLATKTVASNINT SRV1_ SRV1 P04025 derivative 3250 LTAAIDMLAPQQCAEPITWKSDEPVWVDQWPLTSEKLAAAQQLVQEQLEA P04025_ GHITESNSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP 2mutB VAPPQGYLKIIIDLKDCFFSIPLHPSDQKRFAFSLPSTNFKEPMQRFQWK VLPQRMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAGKDGQQV LQCFDQLKQELTIAGLHIAPEKIQLQDPYTYLGFELNGPKITNQKAVIRK DKLQTLNDFQKLLGDINWLRPYLKLTTADLKPLFDTLKGDSNPNSHRSLS KEALALLDKVETAIAEQFVTHINYSLPLMFLIFNTALTPTGLFWQNNPIM WVHLPASPKKVLLPYYDAIADLIILGRDHSKKYFGIEPSVIIQPYSKSQI DWLMQNTEMWPIACASYVGILDNHYPPNKLIQFCKLHAFIFPQIISKTPL NNALLVFTDGSSTGMAAYTLADTTIKFQTNLNSAQLVELQALIAVLSAFP NQPLNIYTDSAYLAHSIPLLETVAQIKHISETAKLFLQCQQLIYNRSIPF YIGHVRAHSGLPGPIAHGNQKADLATKTVASNINT SRV2_ SRV2 P51517 root 3251 LATAVDILAPQRYADPITWKSDEPVWVDQWPLTQEKLAAAQQLVQEQLQA P51517 GHIIESNSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP VAIPQGYFKIVIDLKDCFFTIPLQPVDQKRFAFSLPSTNFKQPMKRYQWK VLPQGMANSPTLCQKYVAAAIEPVRKSWAQMYIIHYMDDILIAGKLGEQV LQCFAQLKQALTTTGLQIAPEKVQLQDPYTYLGFQINGPKITNQKAVIRR DKLQTLNDFQKLLGDINWLRPYLHLTTGDLKPLFDILKGDSNPNSPRSLS EAALASLQKVETAIAEQFVTQIDYTQPLTFLIFNTTLTPTGLFWQNNPVM WVHLPASPKKVLLPYYDAIADLIILGRDNSKKYFGLEPS PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILA PHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALN LQALIAVLSAFPHRALNVYTDSAYLAHSIPLLETVSHIKHISDTAKFFLQ CQQLIYNRSIPFYLGHIRAHSGLPGPLSQGNHITDLATKVVATTLTT SRV2_ SRV2 P51517 derivative 3252 LATAVDILAPQRYADPITWKSDEPVWVDQWPLTQEKLAAAQQLVQEQLQA P51517_ GHIIESNSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVLMGALQPGLPSP 2mutB VAPPQGYFKIVIDLKDCFFTIPLQPVDQKRFAFSLPSTNFKQPMKRYQWK VLPQGMANSPTLCQKYVAAAIEPVRKSWAQMYIIHYMDDILIAGKLGEQV LQCFAQLKQALTTTGLQIAPEKVQLQDPYTYLGFQINGPKITNQKAVIRR DKLQTLNDFQKLLGDINWLRPYLHLTTGDLKPLFDILKGDSNPNSPRSLS EAALASLQKVETAIAEQFVTQIDYTQPLTFLIFNTTLTPTGLFWQNNPVM WVHLPASPKKVLLPYYDAIADLIILGRDNSKKYFGLEPSTIIQPYSKSQI HWLMQNTETWPIACASYAGNIDNHYPPNKLIQFCKLHAVVFPRIISKTPL DNALLVFTDGSSTGIAAYTFEKTTVRFKTSHTSAQLVELQALIAVLSAFP HRALNVYTDSAYLAHSIPLLETVSHIKHISDTAKFFLQCQQLIYNRSIPF YLGHIRAHSGLPGPLSQGNHITDLATKVVATTLTT WDSV_ WDSV O92815 root 3253 SCQTKNTLNIDEYLLQFPDQLWASLPTDIGRMLVPPITIKIKDNASLPSI O92815 RQYPLPKDKTEGLRPLISSLENQGILIKCHSPCNTPIFPIKKAGRDEYRM IHDLRAINNIVAPLTAVVASPTTVLSNLAPSLHWFTVIDLSNAFFSVPIH KDSQYLFAFTFEGHQYTWTVLPQGFIHSPTLFSQALYQSLHKIKFKISSE ICIYMDDVLIASKDRDTNLKDTAVMLQHLASEGHKVSKKKLQLCQQEVVY LGQLLTPEGRKILPDRKVTVSQFQQPTTIRQIRAFLGLVGYCRHWIPEFS IHSKFLEKQLKKDTAEPFQLDDQQVEAFNKLKHAITTAPVLVVPDPAKPF QLYTSHSEHASIAVLTQKHAGRTRPIAFLSSKFDAIESGLPPCLKACASI HRSLTQADSFILGAPLIIYTTHAICTLLQRDRSQLVTASRFSKWEADLLR PELTFVACSAVSPAHLYMQSCENNIPPHDCVLLTHTISRPRPDLSDLPIP DPDMTLFSDGSYTTGRGGAAVVMHRPVTDDFIIIHQQPGGASAQTAELLA LAAACHLATDKTVNIYTDSRYAYGVVHDFGHLWMHRGFVTSAGTPIKNHK EIEYLLKQIMKPKQVSVIKIEAHTKGVSMEVRGNAAADEAAKNAVFLVQR WDSV_ WDSV O92815 derivative 3254 SCQTKNTLNIDEYLLQFPDQLWASLPTDIGRMLVPPITIKIKDNASLPSI O92815_ RQYPLPKDKTEGLRPLISSLENQGILIKCHSPCNTPIFPIKKAGRDEYRM 2mut IHDLRAINNIVAPLTAVVASPTTVLSNLAPSLHWFTVIDLSNAFFSVPIH KDSQYLFAFTFEGHQYTWTVLPQGFIHSPTLFNQALYQSLHKIKFKISSE ICIYMDDVLIASKDRDTNLKDTAVMLQHLASEGHKVSKKKLQLCQQEVVY LGQLLTPEGRKILPDRKVTVSQFQQPTTIRQIRAFLGLVGYCRHWIPEFS IHSKFLEKQLKPDTAEPFQLDDQQVEAFNKLKHAITTAPVLVVPDPAKPF QLYTSHSEHASIAVLTQKHAGRTRPIAFLSSKFDAIESGLPPCLKACASI HRSLTQADSFILGAPLIIYTTHAICTLLQRDRSQLVTASRFSKWEADLLR PELTFVACSAVSPAHLYMQSCENNIPPHDCVLLTHTISRPRPDLSDLPIP DPDMTLFSDGSYTTGRGGAAVVMHRPVTDDFIIIHQQPGGASAQTAELLA LAAACHLATDKTVNIYTDSRYAYGVVHDFGHLWMHRGFVTSAGTPIKNHK EIEYLLKQIMKPKQVSVIKIEAHTKGVSMEVRGNAAADEAAKNAVFLVQR WDSV_ WDSV O92815 derivative 3255 SCQTKNTLNIDEYLLQFPDQLWASLPTDIGRMLVPPITIKIKDNASLPSI O92815_ RQYPLPKDKTEGLRPLISSLENQGILIKCHSPCNTPIFPIKKAGRDEYRM 2mutA IHDLRAINNIVAPLTAVVASPTTVLSNLAPSLHWFTVIDLSNAFFSVPIH KDSQYLFAFTFEGHQYTWTVLPQGFIHSPTLFNQALYQSLHKIKFKISSE ICIYMDDVLIASKDRDTNLKDTAVMLQHLASEGHKVSKKKLQLCQQEVVY LGQLLTPEGRKILPDRKVTVSQFQQPTTIRQIRAFLGKVGYCRHFIPEFS IHSKFLEKQLKPDTAEPFQLDDQQVEAFNKLKHAITTAPVLVVPDPAKPF QLYTSHSEHASIAVLTQKHAGRTRPIAFLSSKFDAIESGLPPCLKACASI HRSLTQADSFILGAPLIIYTTHAICTLLQRDRSQLVTASRFSKWEADLLR PELTFVACSAVSPAHLYMQSCENNIPPHDCVLLTHTISRPRPDLSDLPIP DPDMTLFSDGSYTTGRGGAAVVMHRPVTDDFIIIHQQPGGASAQTAELLA LAAACHLATDKTVNIYTDSRYAYGVVHDFGHLWMHRGFVTSAGTPIKNHK EIEYLLKQIMKPKQVSVIKIEAHTKGVSMEVRGNAAADEAAKNAVFLVQR WMSV_ WMSV P03359 root 3256 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P03359 RSGASPVAVRQYPMSKEAREGIRPHIQRFLDLGVLVPCQSPWNTPLLPVK KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLK DAFFCLKLHPNSQPLFAFEWRDPEKGNTGQLTWTRLPQGFKNSPTLFDEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYRDCKEGTQKLLQELSKLGY RVSAKKAQLCQKEVTYLGYLLKEGKRWLTPARKATVMKIPPPTTPRQVRE FLGTAGFCRLWIPGFASLAAPLYPLTKESIPFIWTEEHQKAFDRIKEALL SAPALALPDLTKPFTLYVDERAGVARGVLTQTLGPWRRPVAYLSKKLDPV ASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIASHSLESIVRQPPDRWM TNARMTHYQSLLLNERVSFAPPAVLNPATLLPVESEATPVHRCSEILAEE TGTRRDLKDQPLPGVPAWYTDGSSFIAEGKRRAGAAIVDGKRTVWASSLP EGTSAQKAELVALTQALRLAEGKDINIYTDSRYAFATAHIHGAIYKQRGL LTSAGKDIKNKEEILALLEAIHLPKRVAIIHCPGHQKGNDPVATGNRRAD EAAKQAALSTRVLAETTKP WMSV_ WMSV P03359 derivative 3257 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P03359_ RSGASPVAVRQYPMSKEAREGIRPHIQRFLDLGVLVPCQSPWNTPLLPVK 3mut KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLK DAFFCLKLHPNSQPLFAFEWRDPEKGNTGQLTWTRLPQGFKNSPTLFNEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYRDCKEGTQKLLQELSKLGY RVSAKKAQLCQKEVTYLGYLLKEGKRWLTPARKATVMKIPPPTTPRQVRE FLGTAGFCRLWIPGFASLAAPLYPLTKPSIPFIWTEEHQKAFDRIKEALL SAPALALPDLTKPFTLYVDERAGVARGVLTQTLGPWRRPVAYLSKKLDPV ASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIASHSLESIVRQPPDRWM TNARMTHYQSLLLNERVSFAPPAVLNPATLLPVESEATPVHRCSEILAEE TGTRRDLKDQPLPGVPAWYTDGSSFIAEGKRRAGAAIVDGKRTVWASSLP EGTSAQKAELVALTQALRLAEGKDINIYTDSRYAFATAHIHGAIYKQRGW LTSAGKDIKNKEEILALLEAIHLPKRVAIIHCPGHQKGNDPVATGNRRAD EAAKQAALSTRVLAETTKP WMSV_ WMSV P03359 derivative 3258 VLNLEEEYRLHEKPVPSSIDPSWLQLFPTVWAERAGMGLANQVPPVVVEL P03359_ RSGASPVAVRQYPMSKEAREGIRPHIQRFLDLGVLVPCQSPWNTPLLPVK 3mutA KPGTNDYRPVQDLREINKRVQDIHPTVPNPYNLLSSLPPSHTWYSVLDLK DAFFCLKLHPNSQPLFAFEWRDPEKGNTGQLTWTRLPQGFKNSPTLFNEA LHRDLAPFRALNPQVVLLQYVDDLLVAAPTYRDCKEGTQKLLQELSKLGY RVSAKKAQLCQKEVTYLGYLLKEGKRWLTPARKATVMKIPPPTTPRQVRE FLGKAGFCRLFIPGFASLAAPLYPLTKPSIPFIWTEEHQKAFDRIKEALL SAPALALPDLTKPFTLYVDERAGVARGVLTQTLGPWRRPVAYLSKKLDPV ASGWPTCLKAVAAVALLLKDADKLTLGQNVTVIASHSLESIVRQPPDRWM TNARMTHYQSLLLNERVSFAPPAVLNPATLLPVESEATPVHRCSEILAEE TGTRRDLKDQPLPGVPAWYTDGSSFIAEGKRRAGAAIVDGKRTVWASSLP EGTSAQKAELVALTQALRLAEGKDINIYTDSRYAFATAHIHGAIYKQRGW LTSAGKDIKNKEEILALLEAIHLPKRVAIIHCPGHQKGNDPVATGNRRAD EAAKQAALSTRVLAETTKP XMRV6_ XMRV6 A1Z651 root 3259 TLNIEDEYRLHETSKEPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLII A1Z651 PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSEQDCQRGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVAL NPATLLPLPEKEAPHDCLEILAETHGTRPDLTDQPIPDADYTWYTDGSSF LQEGQRRAGAAVTTETEVIWARALPAGTSAQRAELIALTQALKMAEGKKL NVYTDSRYAFATAHVHGEIYRRRGLLTSEGREIKNKNEILALLKALFLPK RLSIIHCPGHQKGNSAEARGNRMADQAAREAAMKAVLETSTLL XMRV6_ XMRV6 A1Z651 derivative 3260 TLNIEDEYRLHETSKEPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLII A1Z651_ PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP 3mut VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSEQDCQRGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEKEAPHDCLEILA ETHGTRPDLTDQPIPDADYTWYTDGSSFLQEGQRRAGAAVTTETEVIWAR ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHVHGEIYRR RGWLTSEGREIKNKNEILALLKALFLPKRLSIIHCPGHQKGNSAEARGNR MADQAAREAAMKAVLETSTLL XMRV6_ XMRV6 A1Z651 derivative 3261 TLNIEDEYRLHETSKEPDVPLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP AA1Z651_ LKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPV 3mut KKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNE ALHRDLADFRIQHPDLILLQYVDDLLLAATSEQDCQRGTRALLQTLGNLG YRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLR EFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQAL LTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRW LSNARMTHYQAMLLDTDRVQFGPVVALNPATLLPLPEKEAPHDCLEILAE THGTRPDLTDQPIPDADYTWYTDGSSFLQEGQRRAGAAVTTETEVIWARA LPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHVHGEIYRRR GWLTSEGREIKNKNEILALLKALFLPKRLSIIHCPGHQKGNSAEARGNRM ADQAAREAAMKAVLETSTLL

In some embodiments, reverse transcriptase domains are modified, for example by site-specific mutation. In some embodiments, reverse transcriptase domains are engineered to have improved properties, e.g. SuperScript IV (SSIV) reverse transcriptase derived from the MMLV RT. In some embodiments, the reverse transcriptase domain may be engineered to have lower error rates, e.g., as described in WO2001068895, incorporated herein by reference. In some embodiments, the reverse transcriptase domain may be engineered to be more thermostable. In some embodiments, the reverse transcriptase domain may be engineered to be more processive. In some embodiments, the reverse transcriptase domain may be engineered to have tolerance to inhibitors. In some embodiments, the reverse transcriptase domain may be engineered to be faster. In some embodiments, the reverse transcriptase domain may be engineered to better tolerate modified nucleotides in the RNA template. In some embodiments, the reverse transcriptase domain may be engineered to insert modified DNA nucleotides. In some embodiments, the reverse transcriptase domain is engineered to bind a template RNA. In some embodiments, one or more mutations are chosen from D200N, L603W, T330P, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R, E302K, F309N, W313F, L435G, N454K, H594Q, L671P, E69K, or D653N in the RT domain of murine leukemia virus reverse transcriptase or a corresponding mutation at a corresponding position of another RT domain. In some embodiments, one or more mutations are chosen as described in WO2018089860A1, incorporated herein by reference (e.g., a C952S, and/or C956S, and/or C952S, C956S (double mutant), and/or C969S, and/or H970Y, and/or R979Q, and/or R976Q, and/or R1071S, and/or R328A, and/or R329A, and/or Q336A, and/or R328A, R329A, Q336A (triple mutant), and/or G426A, and/or D428A, and/or G426A,D428A (double mutant) mutation, and/or any combination thereof, positions relative to WO2018089860A1 SEQ ID NO: 52), in the RT domain of R2Bm retrotransposase or a corresponding mutation at a corresponding position of another RT domain.

In some embodiments, the RT domain possesses proofreading activity. In some embodiments, the RT domain is evolved from a DNA-dependent DNA polymerase and has gained RNA-dependent DNA polymerase activity. The synthetic evolved proofreading RT known as reverse transcription xenopolymerase (RTX, Genbank: QFN49000.1) was previously generated by taking a DNA-dependent DNA polymerase (KOD, Genbank: ABN15964.1) and selecting for RNA-dependent DNA polymerase activity (Ellefson et al 2016). In some embodiments, the engineered RT may comprise DNA-dependent DNA polymerase signatures as the result of the wild-type enzyme, e.g., IPR006134, PF00136, cd05536.

In some embodiments, the reverse transcription domain only recognizes and reverse transcribes a specific template. In some embodiments, the template comprises of specific sequences. In some embodiments, the template comprises inclusion of a UTR that associates the nucleic acid with the reverse transcriptase domain (e.g. an untranslated region (UTR) from a retrotransposon, e.g. the 3′ UTR of an R2 retrotransposon).

The writing domain may also comprise DNA-dependent DNA polymerase activity, e.g., comprise enzymatic activity capable of writing DNA into the genome from a template DNA sequence. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a DNA polymerase domain in the polypeptide. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a reverse transcriptase domain that is also capable of DNA-dependent DNA polymerization, e.g., second strand synthesis.

In some embodiments, a writing domain (e.g., RT domain) comprises an RNA-binding domain, e.g., that specifically binds to an RNA sequence. In some embodiments, a template RNA comprises an RNA sequence that is specifically bound by the RNA-binding domain of the writing domain.

In contrast to other types of reverse transcription machines, e.g., retroviral RTs and LTR retrotransposons, reverse transcription in non-LTR retrotransposons like R2 is performed only on RNA templates containing specific recognition sequences. The R2 retrotransposase requires its template to contain a minimal 3′ UTR region in order to initiate TPRT (Luan and Eickbush Mol Cell Biol 15, 3882-91 (1995)). In some embodiments, the Gene Writer polypeptide is derived from a retrotransposase with a required binding motif and the template RNA is designed to contain said binding motif, such that there is specific retrotransposition of only the desired template. In some embodiments, the Gene Writer polypeptide is derived from a retrotransposon selected from Table 3 and the 3′ UTR on the RNA template comprises the 3′ UTR from the same retrotransposon in Table 3.

Template Nucleic Acid Binding Domain:

The Gene Writer™ polypeptide typically contains regions capable of associating with the Gene Writer™ template nucleic acid (e.g., template RNA). In some embodiments, the template nucleic acid binding domain is an RNA binding domain. In some embodiments, the RNA binding domain is a modular domain that can associate with RNA molecules containing specific signatures, e.g., structural motifs, e.g., secondary structures present in the 3′ UTR in non-LTR retrotransposons. In other embodiments, the template nucleic acid binding domain (e.g., RNA binding domain) is contained within the reverse transcription domain, e.g., the reverse transcriptase-derived component has a known signature for RNA preference, e.g., secondary structures present in the 3′ UTR in non-LTR retrotransposons. In other embodiments, the template nucleic acid binding domain (e.g., RNA binding domain) is contained within the DNA binding domain. For example, in some embodiments, the DNA binding domain is a CRISPR-associated protein that recognizes the structure of a template nucleic acid (e.g., template RNA) comprising a gRNA. In some embodiments, the gRNA is a short synthetic RNA composed of a scaffold sequence that participates in CRISPR-associated protein binding and a user-defined ˜20 nucleotide targeting sequence for a genomic target. The structure of a complete gRNA was described by Nishimasu et al. Cell 156, P935-949 (2014). The gRNA (also referred to as sgRNA for single-guide RNA) consists of crRNA- and tracrRNA-derived sequences connected by an artificial tetraloop. The crRNA sequence can be divided into guide (20 nt) and repeat (12 nt) regions, whereas the tracrRNA sequence can be divided into anti-repeat (14 nt) and three tracrRNA stem loops (Nishimasu et al. Cell 156, P935-949 (2014)). In practice, guide RNA sequences are generally designed to have a length of between 17-24 nucleotides (e.g., 19, 20, or 21 nucleotides) and be complementary to a targeted nucleic acid sequence. Custom gRNA generators and algorithms are available commercially for use in the design of effective guide RNAs. In some embodiments, the gRNA comprises two RNA components from the native CRISPR system, e.g. crRNA and tracrRNA. As is well known in the art, the gRNA may also comprise a chimeric, single guide RNA (sgRNA) containing sequence from both a tracrRNA (for binding the nuclease) and at least one crRNA (to guide the nuclease to the sequence targeted for editing/binding). Chemically modified sgRNAs have also been demonstrated to be effective for use with CRISPR-associated proteins; see, for example, Hendel et al. (2015) Nature Biotechnol., 985-991. In some embodiments, a gRNA comprises a nucleic acid sequence that is complementary to a DNA sequence associated with a target gene. In some embodiments, a polypeptide comprises a DNA-binding domain comprising a CRISPR-associated protein that associates with a gRNA that allows the DNA-binding domain to bind a target genomic DNA sequence. In some embodiments, the gRNA is comprised within the template nucleic acid (e.g., template RNA), thus the DNA-binding domain is also the template nucleic acid binding domain. In some embodiments, the polypeptide possesses RNA binding function in multiple domains, e.g., can bind a gRNA structure in a CRISPR-associated DNA binding domain and a 3′ UTR structure in a non-LTR retrotransposon derived reverse transcription domain.

Endonuclease Domain:

In some embodiments, a Gene Writer™ polypeptide possesses the function of DNA target site cleavage via an endonuclease domain. In some embodiments, the endonuclease domain is also a DNA-binding domain. In some embodiments, the endonuclease domain is also a template nucleic acid (e.g., template RNA) binding domain. For example, in some embodiments a polypeptide comprises a CRISPR-associated endonuclease domain that binds a template RNA comprising a gRNA, binds a target DNA sequence (e.g., with complementarity to a portion of the gRNA), and cuts the target DNA sequence. In certain embodiments, the endonuclease/DNA binding domain of an APE-type retrotransposon or the endonuclease domain of an RLE-type retrotransposon can be used or can be modified (e.g., by insertion, deletion, or substitution of one or more residues) in a Gene Writer™ system described herein. In some embodiments the endonuclease domain or endonuclease/DNA binding domain is altered from its natural sequence to have altered codon usage, e.g. improved for human cells. In some embodiments the endonuclease element is a heterologous endonuclease element, such as Fok1 nuclease, a type-II restriction 1-like endonuclease (RLE-type nuclease), or another RLE-type endonuclease (also known as REL). In some embodiments the heterologous endonuclease activity has nickase activity and does not form double stranded breaks. The amino acid sequence of an endonuclease domain of a Gene Writer™ system described herein may be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% identical to the amino acid sequence of an endonuclease domain of a retrotransposon whose DNA sequence is referenced in Table 1 or 3. A person having ordinary skill in the art is capable of identifying endonuclease domains based upon homology to other known endonuclease domains using tools such as Basic Local Alignment Search Tool (BLAST). In certain embodiments, the heterologous endonuclease is Fok1 or a functional fragment thereof. In certain embodiments, the heterologous endonuclease is a Holliday junction resolvase or homolog thereof, such as the Holliday junction resolving enzyme from Sulfolobus solfataricus-Ssol Hje (Govindaraju et al., Nucleic Acids Research 44:7, 2016). In certain embodiments, the heterologous endonuclease is the endonuclease of the large fragment of a spliceosomal protein, such as Prp8 (Mahbub et al., Mobile DNA 8:16, 2017). In certain embodiments, the heterologous endonuclease is derived from a CRISPR-associated protein, e.g., Cas9. In certain embodiments, the heterologous endonuclease is engineered to have only ssDNA cleavage activity, e.g., only nickase activity, e.g., be a Cas9 nickase. For example, a Gene Writer™ polypeptide described herein may comprise a reverse transcriptase domain from an APE- or RLE-type retrotransposon and an endonuclease domain that comprises Fok1 or a functional fragment thereof. In still other embodiments, homologous endonuclease domains are modified, for example by site-specific mutation, to alter DNA endonuclease activity. In still other embodiments, endonuclease domains are modified to remove any latent DNA-sequence specificity.

In some embodiments the endonuclease domain has nickase activity and does not form double stranded breaks. In some embodiments, the endonuclease domain forms single stranded breaks at a higher frequency than double stranded breaks, e.g., at least 90%, 95%, 96%, 97%, 98%, or 99% of the breaks are single stranded breaks, or less than 10%, 5%, 4%, 3%, 2%, or 1% of the breaks are double stranded breaks. In some embodiments, the endonuclease forms substantially no double stranded breaks. In some embodiments, the enonuclease does not form detectable levels of double stranded breaks.

In some embodiments, the endonuclease domain has nickase activity that nicks the target site DNA of the first strand; e.g., in some embodiments, the endonuclease domain cuts the genomic DNA of the target site near to the site of alteration on the strand that will be extended by the writing domain. In some embodiments, the endonuclease domain has nickase activity that nicks the target site DNA of the first strand and does not nick the target site DNA of the second strand. For example, when a polypeptide comprises a CRISPR-associated endonuclease domain having nickase activity and that does not form double stranded breaks, in some embodiments said CRISPR-associated endonuclease domain nicks the target site DNA strand containing the PAM site (e.g., and does not nick the target site DNA strand that does not contain the PAM site). As a further example, when a polypeptide comprises a CRISPR-associated endonuclease domain having nickase activity and that does not form double stranded breaks, in some embodiments said CRISPR-associated endonuclease domain nicks the target site DNA strand not containing the PAM site (e.g., and does not nick the target site DNA strand that contains the PAM site).

In some other embodiments, the endonuclease domain has nickase activity that nicks the target site DNA of the first strand and the second strand. Without wishing to be bound by theory, after a writing domain (e.g., RT domain) of a polypeptide described herein polymerizes (e.g., reverse transcribes) from the heterologous object sequence of a template nucleic acid (e.g., template RNA), the cellular DNA repair machinery must repair the nick on the first DNA strand. The target site DNA now contains two different sequences for the first DNA strand: one corresponding to the original genomic DNA and a second corresponding to that polymerized from the heterologous object sequence. It is thought that the two different sequences equilibrate with one another, first one hybridizing the second strand, then the other, and which the cellular DNA repair apparatus incorporates into its repaired target site is thought to be random. Without wishing to be bound by theory, it is thought that introducing an additional nick to the second strand may bias the cellular DNA repair machinery to adopt the heterologous object sequence-based sequence more frequently than the original genomic sequence. In some embodiments, the additional nick is positioned at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 nucleotides 5′ or 3′ of the target site modification (e.g., the insertion, deletion, or substitution) or to the nick on the first strand.

Alternatively or additionally, without wishing to be bound by theory, it is thought that an additional nick to the second strand may promote second strand synthesis. In some embodiments, where the Gene Writer™ has inserted or substituted a portion of the first strand, synthesis of a new sequence corresponding to the insertion/substitution in the second strand is necessary.

In some embodiments, the polypeptide comprises a single domain having endonuclease activity (e.g., a single endonuclease domain) and said domain nicks both the first strand and the second strand. For example, in such an embodiment the endonuclease domain may be a CRISPR-associated endonuclease domain, and the template nucleic acid (e.g., template RNA) comprises a gRNA that directs nicking of the first strand and an additional gRNA that directs nicking of the second strand. In some embodiments, the polypeptide comprises a plurality of domains having endonuclease activity, and a first endonuclease domain nicks the first strand and a second endonuclease domain nicks the second strand (optionally, the first endonuclease domain does not (e.g., cannot) nick the second strand and the second endonuclease domain does not (e.g., cannot) nick the first strand).

In some embodiments, the endonuclease domain is capable of nicking a first strand and a second strand. In some embodiments, the first and second strand nicks occur at the same position in the target site but on opposite strands. In some embodiments, the second strand nick occurs in a staggered location, e.g., upstream or downstream, from the first nick. In some embodiments, the endonuclease domain generates a target site deletion if the second strand nick is upstream of the first strand nick. In some embodiments, the endonuclease domain generates a target site duplication if the second strand nick is downstream of the first strand nick. In some embodiments, the endonuclease domain generates no duplication and/or deletion if the first and second strand nicks occur in the same position of the target site (e.g., as described in Gladyshev and Arkhipova Gene 2009, incorporated by reference herein in its entirety). In some embodiments, the endonuclease domain has altered activity depending on protein conformation or RNA-binding status, e.g., which promotes the nicking of the first or second strand (e.g., as described in Christensen et al. PNAS 2006; incorporated by reference herein in its entirety).

In some embodiments, a Gene Writer polypeptide comprises a modification to an endonuclease domain, e.g., relative to the wild-type polypeptide. In some embodiments, the endonuclease domain comprises an addition, deletion, replacement, or modification to the amino acid sequence of the original endonuclease domain. In some embodiments, the endonuclease domain is modified to include a heterologous functional domain that binds specifically to and/or induces endonuclease cleavage of a target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, the endonuclease domain comprises a zinc finger. In some embodiments, the endonuclease domain comprises a Cas domain (e.g., a Cas9 or a mutant or variant thereof). In embodiments, the endonuclease domain comprising the Cas domain is associated with a guide RNA (gRNA), e.g., as described herein. In some embodiments, the endonuclease domain is modified to include a functional domain that does not target a specific target nucleic acid (e.g., DNA) sequence. In embodiments, the endonuclease domain comprises a Fok1 domain.

In some embodiments, the endonuclease domain comprises a meganuclease, or a functional fragment thereof. In some embodiments, the endonuclease domain comprises a homing endonuclease, or a functional fragment thereof. In some embodiments, the endonuclease domain comprises a meganuclease from the LAGLIDADG (SEQ ID NO: 1577), GIY-YIG, HNH, His-Cys Box, or PD-(D/E) XK families, or a functional fragment or variant thereof, e.g., which possess conserved amino acid motifs, e.g., as indicated in the family names. In some embodiments, the endonuclease domain comprises a meganuclease, or fragment thereof, chosen from, e.g., I-SmaMI (Uniprot F7WD42), I-SceI (Uniprot P03882), I-Anil (Uniprot P03880), I-DmoI (Uniprot P21505), I-CreI (Uniprot P05725), I-TevI (Uniprot P13299), I-OnuI (Uniprot Q4VWW5), or I-BmoI (Uniprot Q9ANR6). In some embodiments, the meganuclease is naturally monomeric, e.g., I-SceI, I-TevI, or dimeric, e.g., I-CreI, in its functional form. For example, the LAGLIDADG (SEQ ID NO: 1577) meganucleases with a single copy of the LAGLIDADG motif (SEQ ID NO: 1577) generally form homodimers, whereas members with two copies of the LAGLIDADG motif (SEQ ID NO: 1577) are generally found as monomers. In some embodiments, a meganuclease that normally forms as a dimer is expressed as a fusion, e.g., the two subunits are expressed as a single ORF and, optionally, connected by a linker, e.g., an I-CreI dimer fusion (Rodriguez-Fornes et al. Gene Therapy 2020; incorporated by reference herein in its entirety). In some embodiments, a meganuclease, or a functional fragment thereof, is altered to favor nickase activity for one strand of a double-stranded DNA molecule, e.g., I-SceI (K122I and/or K223I) (Niu et al. J Mol Biol 2008), I-Anil (K227M) (McConnell Smith et al. PNAS 2009), I-DmoI (Q42A and/or K120M) (Molina et al. J Biol Chem 2015). In some embodiments, a meganuclease or functional fragment thereof possessing this preference for single-strand cleavage is used as an endonuclease domain, e.g., with nickase activity. In some embodiments, an endonuclease domain comprises a meganuclease, or a functional fragment thereof, which naturally targets or is engineered to target a safe harbor site, e.g., an I-CreI targeting SH6 site (Rodriguez-Fornes et al., supra). In some embodiments, an endonuclease domain comprises a meganuclease, or a functional fragment thereof, with a sequence tolerant catalytic domain, e.g., I-TevI recognizing the minimal motif CNNNG (Kleinstiver et al. PNAS 2012). In some embodiments, a target sequence tolerant catalytic domain is fused to a DNA binding domain, e.g., to direct activity, e.g., by fusing I-TevI to: (i) zinc fingers to create Tev-ZFEs (Kleinstiver et al. PNAS 2012), (ii) other meganucleases to create MegaTevs (Wolfs et al. Nucleic Acids Res 2014), and/or (iii) Cas9 to create TevCas9 (Wolfs et al. PNAS 2016).

In some embodiments, the endonuclease domain comprises a restriction enzyme, e.g., a Type IIS or Type IIP restriction enzyme. In some embodiments, the endonuclease domain comprises a Type IIS restriction enzyme, e.g., FokI, or a fragment or variant thereof. In some embodiments, the endonuclease domain comprises a Type IIP restriction enzyme, e.g., PvuII, or a fragment or variant thereof. In some embodiments, a dimeric restriction enzyme is expressed as a fusion such that it functions as a single chain, e.g., a FokI dimer fusion (Minczuk et al. Nucleic Acids Res 36(12):3926-3938 (2008)).

The use of additional endonuclease domains is described, for example, in Guha and Edgell Int J Mol Sci 18(22):2565 (2017), which is incorporated herein by reference in its entirety.

In some embodiments, an endonuclease domain comprises a CRISPR/Cas domain (also referred to herein as a CRISPR-associated protein). In some embodiments, a DNA-binding domain comprises a CRISPR/Cas domain. In some embodiments, a CRISPR/Cas domain comprises a protein involved in the clustered regulatory interspaced short palindromic repeat (CRISPR) system, e.g., a Cas protein, and optionally binds a guide RNA, e.g., single guide RNA (sgRNA).

CRISPR systems are adaptive defense systems originally discovered in bacteria and archaea. CRISPR systems use RNA-guided nucleases termed CRISPR-associated or “Cas” endonucleases (e.g., Cas9 or Cpf1) to cleave foreign DNA. For example, in a typical CRISPR/Cas system, an endonuclease is directed to a target nucleotide sequence (e.g., a site in the genome that is to be sequence-edited) by sequence-specific, non-coding “guide RNAs” that target single- or double-stranded DNA sequences. Three classes (I-III) of CRISPR systems have been identified. The class II CRISPR systems use a single Cas endonuclease (rather than multiple Cas proteins). One class II CRISPR system includes a type II Cas endonuclease such as Cas9, a CRISPR RNA (“crRNA”), and a trans-activating crRNA (“tracrRNA”). The crRNA contains a “guide RNA”, typically about 20-nucleotide RNA sequence that corresponds to a target DNA sequence. In the wild-type system, and in some engineered systems, crRNA also contains a region that binds to the tracrRNA to form a partially double-stranded structure which is cleaved by RNase III, resulting in a crRNA/tracrRNA hybrid. A crRNA/tracrRNA hybrid then directs Cas9 endonuclease to recognize and cleave a target DNA sequence. A target DNA sequence is generally adjacent to a “protospacer adjacent motif” (“PAM”) that is specific for a given Cas endonuclease; however, PAM sequences appear throughout a given genome. CRISPR endonucleases identified from various prokaryotic species have unique PAM sequence requirements; examples of PAM sequences include 5′-NGG (Streptococcus pyogenes), 5′-NNAGAA (Streptococcus thermophilus CRISPR1), 5′-NGGNG (Streptococcus thermophilus CRISPR3), and 5′-NNNGATT (Neisseria meningiditis). Some endonucleases, e.g., Cas9 endonucleases, are associated with G-rich PAM sites, e.g., 5′-NGG, and perform blunt-end cleaving of the target DNA at a location 3 nucleotides upstream from (5′ from) the PAM site. Another class II CRISPR system includes the type V endonuclease Cpf1, which is smaller than Cas9; examples include AsCpf1 (from Acidaminococcus sp.) and LbCpf1 (from Lachnospiraceae sp.). Cpf1-associated CRISPR arrays are processed into mature crRNAs without the requirement of a tracrRNA; in other words, a Cpf1 system, in some embodiments, comprises only Cpf1 nuclease and a crRNA to cleave a target DNA sequence. Cpf1 endonucleases, are typically associated with T-rich PAM sites, e.g., 5′-TTN. Cpf1 can also recognize a 5′-CTA PAM motif. Cpf1 typically cleaves a target DNA by introducing an offset or staggered double-strand break with a 4- or 5-nucleotide 5′ overhang, for example, cleaving a target DNA with a 5-nucleotide offset or staggered cut located 18 nucleotides downstream from (3′ from) from a PAM site on the coding strand and 23 nucleotides downstream from the PAM site on the complimentary strand; the 5-nucleotide overhang that results from such offset cleavage allows more precise genome editing by DNA insertion by homologous recombination than by insertion at blunt-end cleaved DNA. See, e.g., Zetsche et al. (2015) Cell, 163:759-771.

A variety of CRISPR associated (Cas) genes or proteins can be used in the technologies provided by the present disclosure and the choice of Cas protein will depend upon the particular conditions of the method. Specific examples of Cas proteins include class II systems including Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Cpf1, C2C1, or C2C3. In some embodiments, a Cas protein, e.g., a Cas9 protein, may be from any of a variety of prokaryotic species. In some embodiments a particular Cas protein, e.g., a particular Cas9 protein, is selected to recognize a particular protospacer-adjacent motif (PAM) sequence. In some embodiments, a DNA-binding domain or endonuclease domain includes a sequence targeting polypeptide, such as a Cas protein, e.g., Cas9. In certain embodiments a Cas protein, e.g., a Cas9 protein, may be obtained from a bacteria or archaea or synthesized using known methods. In certain embodiments, a Cas protein may be from a gram positive bacteria or a gram negative bacteria. In certain embodiments, a Cas protein may be from a Streptococcus (e.g., a S. pyogenes, or a S. thermophilus), a Francisella (e.g., an F. novicida), a Staphylococcus (e.g., an S. aureus), an Acidaminococcus (e.g., an Acidaminococcus sp. BV3L6), a Neisseria (e.g., an N. meningitidis), a Cryptococcus, a Corynebacterium, a Haemophilus, a Eubacterium, a Pasteurella, a Prevotella, a Veillonella, or a Marinobacter.

In some embodiments, a Cas protein requires a protospacer adjacent motif (PAM) to be present in or adjacent to a target DNA sequence for the Cas protein to bind and/or function. In some embodiments, the PAM is or comprises, from 5′ to 3′, NGG, YG, NNGRRT, NNNRRT, NGA, TYCV, TATV, NTTN, or NNNGATT, where N stands for any nucleotide, Y stands for C or T, R stands for A or G, and V stands for A or C or G. In some embodiments, a Cas protein is a protein listed in Table 4. In some embodiments, a Cas protein comprises one or more mutations altering its PAM. In some embodiments, a Cas protein comprises E1369R, E1449H, and R1556A mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises E782K, N968K, and R1015H mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises D1135V, R1335Q, and T1337R mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises S542R and K607R mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises S542R, K548V, and N552R mutations or analogous substitutions to the amino acids corresponding to said positions.

TABLE 4 CRISPR/Cas Proteins, Species, and Mutations # of Mutations to alter Mutations to make Name Enzyme Species AAs PAM PAM recognition catalytically dead FnCas9 Cas9 Francisella 1629 5′-NGG-3′ Wt D11A/H969A/N995A novicida FnCas9 Cas9 Francisella 1629 5′-YG-3′ E1369R/E1449H/ D11A/H969A/N995A RHA novicida R1556A SaCas9 Cas9 Staphylococcus 1053 5′-NNGRRT-3′ Wt D10A/H557A aureus SaCas9 Cas9 Staphylococcus 1053 5′-NNNRRT-3′ E782K/N968K/ D10A/H557A KKH aureus R1015H SpCas9 Cas9 Streptococcus 1368 5′-NGG-3′ Wt D10A/D839A/H840A/ pyogenes N863A SpCas9 Cas9 Streptococcus 1368 5′-NGA-3′ D1135V/R1335Q/ D10A/D839A/H840A/ VQR pyogenes T1337R N863A AsCpf1 Cpf1 Acidaminococcus 1307 5′-TYCV-3′ S542R/K607R E993A RR sp. BV3L6 AsCpf1 Cpf1 Acidaminococcus 1307 5′-TATV-3′ S542R/K548V/ E993A RVR sp. BV3L6 N552R FnCpf1 Cpf1 Francisella 1300 5′-NTTN-3′ Wt D917A/E1006A/ novicida D1255A NmCas9 Cas9 Neisseria 1082 5′-NNNGATT-3′ Wt D16A/D587A/H588A/ meningitidis N611A

In some embodiments, the Cas protein is catalytically active and cuts one or both strands of the target DNA site. In some embodiments, cutting the target DNA site is followed by formation of an alteration, e.g., an insertion or deletion, e.g., by the cellular repair machinery.

In some embodiments, the Cas protein is modified to deactivate or partially deactivate the nuclease, e.g., nuclease-deficient Cas9. Whereas wild-type Cas9 generates double-strand breaks (DSBs) at specific DNA sequences targeted by a gRNA, a number of CRISPR endonucleases having modified functionalities are available, for example: a “nickase” version of Cas9 that has been partially deactivated generates only a single-strand break; a catalytically inactive Cas9 (“dCas9”) does not cut target DNA. In some embodiments, dCas9 binding to a DNA sequence may interfere with transcription at that site by steric hindrance. In some embodiments, dCas9 binding to an anchor sequence may interfere with (e.g., decrease or prevent) genomic complex (e.g., ASMC) formation and/or maintenance. In some embodiments, a DNA-binding domain comprises a catalytically inactive Cas9, e.g., dCas9. Many catalytically inactive Cas9 proteins are known in the art. In some embodiments, dCas9 comprises mutations in each endonuclease domain of the Cas protein, e.g., D10A and H840A or N863A mutations. In some embodiments, a catalytically inactive or partially inactive CRISPR/Cas domain comprises a Cas protein comprising one or more mutations, e.g., one or more of the mutations listed in Table 4. In some embodiments, a Cas protein described on a given row of Table 4 comprises one, two, three, or all of the mutations listed in the same row of Table 4. In some embodiments, a Cas protein, e.g., not described in Table 4, comprises one, two, three, or all of the mutations listed in a row of Table 4 or a corresponding mutation at a corresponding site in that Cas protein.

In some embodiments, a catalytically inactive, e.g., dCas9, or partially deactivated Cas9 protein comprises a D11 mutation (e.g., D11A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H969 mutation (e.g., H969A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a N995 mutation (e.g., N995A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises mutations at one, two, or three of positions D11, H969, and N995 (e.g., D11A, H969A, and N995A mutations) or analogous substitutions to the amino acids corresponding to said positions.

In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D10 mutation (e.g., a D10A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H557 mutation (e.g., a H557A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a D10 mutation (e.g., a D10A mutation) and a H557 mutation (e.g., a H557A mutation) or analogous substitutions to the amino acids corresponding to said positions.

In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D839 mutation (e.g., a D839A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H840 mutation (e.g., a H840A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a N863 mutation (e.g., a N863A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a D10 mutation (e.g., D10A), a D839 mutation (e.g., D839A), a H840 mutation (e.g., H840A), and a N863 mutation (e.g., N863A) or analogous substitutions to the amino acids corresponding to said positions.

In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a E993 mutation (e.g., a E993A mutation) or an analogous substitution to the amino acid corresponding to said position.

In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D917 mutation (e.g., a D917A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a E1006 mutation (e.g., a E1006A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D1255 mutation (e.g., a D1255A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a D917 mutation (e.g., D917A), a E1006 mutation (e.g., E1006A), and a D1255 mutation (e.g., D1255A) or analogous substitutions to the amino acids corresponding to said positions.

In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D16 mutation (e.g., a D16A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D587 mutation (e.g., a D587A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H588 mutation (e.g., a H588A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a N611 mutation (e.g., a N611A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a D16 mutation (e.g., D16A), a D587 mutation (e.g., D587A), a H588 mutation (e.g., H588A), and a N611 mutation (e.g., N611A) or analogous substitutions to the amino acids corresponding to said positions.

In some embodiments, a DNA-binding domain or endonuclease domain may comprise a Cas molecule comprising or linked (e.g., covalently) to a gRNA (e.g., a template nucleic acid, e.g., template RNA, comprising a gRNA).

In some embodiments, an endonuclease domain or DNA binding domain comprises a Streptococcus pyogenes Cas9 (SpCas9) or a functional fragment or variant thereof. In some embodiments, the endonuclease domain or DNA binding domain comprises a modified SpCas9. In embodiments, the modified SpCas9 comprises a modification that alters protospacer-adjacent motif (PAM) specificity. In embodiments, the PAM has specificity for the nucleic acid sequence 5′-NGT-3′. In embodiments, the modified SpCas9 comprises one or more amino acid substitutions, e.g., at one or more of positions L1111, D1135, G1218, E1219, A1322, of R1335, e.g., selected from L1111R, D1135V, G1218R, E1219F, A1322R, R1335V. In embodiments, the modified SpCas9 comprises the amino acid substitution T1337R and one or more additional amino acid substitutions, e.g., selected from L1111, D1135L, S1136R, G1218S, E1219V, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, R1335Q, T1337, T1337L, T1337Q, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337H, T1337Q, and T1337M, or corresponding amino acid substitutions thereto. In embodiments, the modified SpCas9 comprises: (i) one or more amino acid substitutions selected from D1135L, S1136R, G1218S, E1219V, A1322R, R1335Q, and T1337; and (ii) one or more amino acid substitutions selected from L1111R, G1218R, E1219F, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, and T1337M, or corresponding amino acid substitutions thereto.

In some embodiments, a Gene Writer may comprise a Cas protein as listed in Table 40A. The predicted or validated nickase mutations for installing Nickase activity in the Cas protein as shown in Table 40A, are based on the signature of the SpCas9(N863A) mutation. In some embodiments, system described herein comprises a GeneWriter protein of Table 3 and a Cas protein of Table 40A. In some embodiments, a protein or domain of Table 3, 41, or 44 is fused to a Cas protein of Table 40A.

TABLE 40A CRISPR/Cas Proteins, Species, and Mutations SEQ ID Nickase Variant Parental Host NO: Protein Sequence Mutation Nme2Cas9 Neisseria 3262 MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLAR N611A meningitidis SVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVL LHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQR GDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFE PAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGL EDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKT DEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKN TEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEE NRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHAL PFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQ KFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAEN DRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQE VMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDN PFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYA WQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHD KGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR PpnCas9 Pasteurella 3263 MQNNPLNYILGLDLGIASIGWAVVEIDEESSPIRLIDVGVRTFERAEVAKTGESLALSRRLARSSRR N605A pneumotropica LIKRRAERLKKAKRLLKAEKILHSIDEKLPINVWQLRVKGLKEKLERQEWAAVLLHLSKHRGYLS QRKNEGKSDNKELGALLSGIASNHQMLQSSEYRTPAEIAVKKFQVEEGHIRNQRGSYTHTFSRLDL LAEMELLFORQAELGNSYTSTTLLENLTALLMWQKPALAGDAILKMLGKCTFEPSEYKAAKNSY SAERFVWLTKLNNLRILENGTERALNDNERFALLEQPYEKSKLTYAQVRAMLALSDNAIFKGVRY LGEDKKTVESKTTLIEMKFYHQIRKTLGSAELKKEWNELKGNSDLLDEIGTAFSLYKTDDDICRYL EGKLPERVLNALLENLNFDKFIQLSLKALHQILPLMLQGQRYDEAVSAIYGDHYGKKSTETTRLLP TIPADEIRNPVVLRTLTQARKVINAVVRLYGSPARIHIETAREVGKSYQDRKKLEKQQEDNRKQRE SAVKKFKEMFPHFVGEPKGKDILKMRLYELQQAKCLYSGKSLELHRLLEKGYVEVDHALPFSRT WDDSFNNKVLVLANENQNKGNLTPYEWLDGKNNSERWQHFVVRVQTSGFSYAKKQRILNHKLD EKGFIERNLNDTRYVARFLCNFIADNMLLVGKGKRNVFASNGQITALLRHRWGLQKVREQNDRH HALDAVVVACSTVAMQQKITRFVRYNEGNVFSGERIDRETGEIIPLHFPSPWAFFKENVEIRIFSEN PKLELENRLPDYPQYNHEWVQPLFVSRMPTRKMTGQGHMETVKSAKRLNEGLSVLKVPLTQLKL SDLERMVNRDREIALYESLKARLEQFGNDPAKAFAEPFYKKGGALVKAVRLEQTQKSGVLVRDG NGVADNASMVRVDVFTKGGKYFLVPIYTWQVAKGILPNRAATQGKDENDWDIMDEMATFQFSL CQNDLIKLVTKKKTIFGYFNGLNRATSNINIKEHDLDKSKGKLGIYLEVGVKLAISLEKYQVDELG KNIRPCRPTKRQHVR SauCas9 Staphylococcus 3264 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGN TLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETG NYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFV TVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRI EVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG SauCas9- Staphylococcus 3265 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A KKH aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKG NTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEET GNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKF VTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNNDLLNR IEVNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG SauriCas9 Staphylococcus 3266 MQENQQKQNYILGLDIGITSVGYGLIDSKTREVIDAGVRLFPEADSENNSNRRSKRGARRLKRRRI N588A auricularis HRLNRVKDLLADYQMIDLNNVPKSTDPYTIRVKGLREPLTKEEFAIALLHIAKRRGLHNISVSMGD EEQDNELSTKQQLQKNAQQLQDKYVCELQLERLTNINKVRGEKNRFKTEDFVKEVKQLCETQRQ YHNIDDQFIQQYIDLVSTRREYFEGPGNGSPYGWDGDLLKWYEKLMGRCTYFPEELRSVKYAYS ADLFNALNDLNNLVVTRDDNPKLEYYEKYHIIENVFKQKKNPTLKQIAKEIGVQDYDIRGYRITKS GKPQFTSFKLYHDLKNIFEQAKYLEDVEMLDEIAKILTIYQDEISIKKALDQLPELLTESEKSQIAQL TGYTGTHRLSLKCIHIVIDELWESPENQMEIFTRLNLKPKKVEMSEIDSIPTTLVDEFILSPVVKRAFI KIKLHDMQEGKCLYSLEAIPLEDLLSNPTHYEVDHIIPRSVSFDNSLNNKVLVKQSENSKKGNRTP YQYLSSNESKISYNQFKQHILNLSKAKDRISKKKRDMLLEERDINKFEVQKEFINRNLVDTRYATR ELSNLLKTYFSTHDYAVKVKTINGGFTNHLRKVWDFKKHRNHGYKHHAEDALVIANADFLFKTH KALRRTDKILEQPGLEVNDTTVKVDTEEKYQELFETPKQVKNIKQFRDFKYSHRVDKKPNRQLIN DTLYSTREIDGETYVVQTLKDLYAKDNEKVKKLFTERPQKILMYQHDPKTFEKLMTILNQYAEAK NPLAAYYEDKGEYVTKYAKKGNGPAIHKIKYIDKKLGSYLDVSNKYPETQNKLVKLSLKSFRFDI YKCEQGYKMVSIGYLDVLKKDNYYYIPKDKYEAEKQKKKIKESDLFVGSFYYNDLIMYEDELFR VIGVNSDINNLVELNMVDITYKDFCEVNNVTGEKRIKKTIGKRVVLIEKYTTDILGNLYKTPLPKKP QLIFKRGEL SauriCas9- Staphylococcus 3267 MQENQQKQNYILGLDIGITSVGYGLIDSKTREVIDAGVRLFPEADSENNSNRRSKRGARRLKRRRI N588A KKH auricularis HRLNRVKDLLADYQMIDLNNVPKSTDPYTIRVKGLREPLTKEEFAIALLHIAKRRGLHNISVSMGD EEQDNELSTKQQLQKNAQQLQDKYVCELQLERLTNINKVRGEKNRFKTEDFVKEVKQLCETQRQ YHNIDDQFIQQYIDLVSTRREYFEGPGNGSPYGWDGDLLKWYEKLMGRCTYFPEELRSVKYAYS ADLFNALNDLNNLVVTRDDNPKLEYYEKYHIIENVFKQKKNPTLKQIAKEIGVQDYDIRGYRITKS GKPQFTSFKLYHDLKNIFEQAKYLEDVEMLDEIAKILTIYQDEISIKKALDQLPELLTESEKSQIAQL TGYTGTHRLSLKCIHIVIDELWESPENQMEIFTRLNLKPKKVEMSEIDSIPTTLVDEFILSPVVKRAFI QSIKVINAVINRFGLPEDITIELAREKNSKDRRKFINKLQKQNEATRKKIEQLLAKYGNTNAKYMIE KIKLHDMQEGKCLYSLEAIPLEDLLSNPTHYEVDHIIPRSVSFDNSLNNKVLVKQSENSKKGNRTP YQYLSSNESKISYNQFKQHILNLSKAKDRISKKKRDMLLEERDINKFEVQKEFINRNLVDTRYATR ELSNLLKTYFSTHDYAVKVKTINGGFTNHLRKVWDFKKHRNHGYKHHAEDALVIANADFLFKTH KALRRTDKILEQPGLEVNDTTVKVDTEEKYQELFETPKQVKNIKQFRDFKYSHRVDKKPNRKLIN DTLYSTREIDGETYVVQTLKDLYAKDNEKVKKLFTERPQKILMYQHDPKTFEKLMTILNQYAEAK NPLAAYYEDKGEYVTKYAKKGNGPAIHKIKYIDKKLGSYLDVSNKYPETQNKLVKLSLKSFRFDI YKCEQGYKMVSIGYLDVLKKDNYYYIPKDKYEAEKQKKKIKESDLFVGSFYKNDLIMYEDELFR VIGVNSDINNLVELNMVDITYKDFCEVNNVTGEKHIKKTIGKRVVLIEKYTTDILGNLYKTPLPKK PQLIFKRGEL ScaCas9- Streptococcus 3268 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETAEATRLK N872A Sc++ canis RTARRRYTRRKNRIRYLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFGNLADEVAYHRN YPTIYHLRKKLADSPEKADLRLIYLALAHIIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEE SPLDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGNIIALALGLTPNFKSNFDLTEDAKLQL SKDTYDDDLDELLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQD LALLKTLVRQQFPEKYAEIFKDDTKNGYAGYVGADKKLRKRSGKLATEEEFYKFIKPILEKMDGA EELLAKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFYPFLKENREKIEKILTFRIPYYVGP LARGNSRFAWLTRKSEEAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPKHSLLYEYFT VYNELTKVKYVTERMRKPEFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRHYTGWGRLSRKMINGIRDKQSGKTILDFLKSDGFSNRNFMQLIHDDSLTFKEEIEKAQVSGQG DSLHEQIADLAGSPAIKKGILQTVKIVDELVKVMGHKPENIVIEMARENQTTTKGLQQSRERKKRI EEGIKELESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIKDD SIDNKVLTRSVENRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEADKA GFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIREVKVITLKSKLVSDFRKDFQLYKVRDINN YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKRFFYSNIMN FFKTEVKLANGEIRKRPLIETNGETGEVVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKES ILSKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEKGKAKKLKSVKVLVGITIMEKGSY EKDPIGFLEAKGYKDIKKELIFKLPKYSLFELENGRRRMLASAKELQKANELVLPQHLVRLLYYTQ NISATTGSNNLGYIEQHREEFKEIFEKIIDFSEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLL KYTSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSITGLYETRTDLSQLGGD SpyCas9 Streptococcus 3269 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3270 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A NG pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDK LIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASARFLQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPRAFKYFDTTIDRKVYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3271 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAERTRLKR N863A SpRY pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDK LIARKKDWDPKKYGGFLWPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLE AKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAKQLQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT RLGAPRAFKYFDTTIDPKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD St1Cas9 Streptococcus 3272 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRVRL N622A thermophilus NRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDASDDGNSSVG DYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQT QQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFR AAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVA DIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFAD GSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSSSNK TKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANK DEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQF EVDHILPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKK KEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRH WGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNTLVSYSEDQLLDIETGELISDDEYKESVFKAP YQHFVDTLKSKEFEDSILFSYQVDSKFNRKISDATIYATROAKVGKDKADETYVLGKIKDIYTQDG YDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYIRKY SKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQSVSPWRADVYFNKTTGKYEILGLKYADL QFEKGTGTYKISQEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQQLFRFLSRTMPKQK HYVELKPYDKQKFEGGEALIKVLGNVANSGQCKKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPK LDF BlatCas9 Brevibacillus 3273 MAYTMGIDVGIASCGWAIVDLERQRIIDIGVRTFEKAENPKNGEALAVPRREARSSRRRLRRKKHR N607A laterosporus IERLKHMFVRNGLAVDIQHLEQTLRSQNEIDVWQLRVDGLDRMLTQKEWLRVLIHLAQRRGFQS NRKTDGSSEDGQVLVNVTENDRLMEEKDYRTVAEMMVKDEKFSDHKRNKNGNYHGVVSRSSL LVEIHTLFETQRQHHNSLASKDFELEYVNIWSAQRPVATKDQIEKMIGTCTFLPKEKRAPKASWHF QYFMLLQTINHIRITNVQGTRSLNKEEIEQVVNMALTKSKVSYHDTRKILDLSEEYQFVGLDYGKE DEKKKVESKETIIKLDDYHKLNKIFNEVELAKGETWEADDYDTVAYALTFFKDDEDIRDYLQNKY KDSKNRLVKNLANKEYTNELIGKVSTLSFRKVGHLSLKALRKIIPFLEQGMTYDKACQAAGFDFQ GISKKKRSVVLPVIDQISNPVVNRALTQTRKVINALIKKYGSPETIHIETARELSKTFDERKNITKDY KENRDKNEHAKKHLSELGIINPTGLDIVKYKLWCEQQGRCMYSNQPISFERLKESGYTEVDHIIPY SRSMNDSYNNRVLVMTRENREKGNQTPFEYMGNDTQRWYEFEQRVTTNPQIKKEKRONLLLKG FTNRRELEMLERNLNDTRYITKYLSHFISTNLEFSPSDKKKKVVNTSGRITSHLRSRWGLEKNRGQ NDLHHAMDAIVIAVTSDSFIQQVTNYYKRKERRELNGDDKFPLPWKFFREEVIARLSPNPKEQIEA LPNHFYSEDELADLQPIFVSRMPKRSITGEAHQAQFRRVVGKTKEGKNITAKKTALVDISYDKNGD FNMYGRETDPATYEAIKERYLEFGGNVKKAFSTDLHKPKKDGTKGPLIKSVRIMENKTLVHPVNK GKGVVYNSSIVRTDVFQRKEKYYLLPVYVTDVTKGKLPNKVIVAKKGYHDWIEVDDSFTFLFSLY PNDLIFIRQNPKKKISLKKRIESHSISDSKEVQEIHAYYKGVDSSTAAIEFIIHDGSYYAKGVGVQNL DCFEKYQVDILGNYFKVKGEKRLELETSDSNHKGKDVNSIKSTSR cCas9- Staphylococcus 3274 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A v16 aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN DLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLK VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKG NTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEET GNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKF VTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNSDKNNL IEVNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG cCas9- Staphylococcus 3275 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A v17 aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN DLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLK VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKG NTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEET GNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKF VTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNNSTRNI VELNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG cCas9- Staphylococcus 3276 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A v21 aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN DLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLK VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKG NTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEET GNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKF VTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNSDDRNII ELNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG cCas9- Staphylococcus 3277 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQR N580A v42 aureus VKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNE LSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQS FIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALN VYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSL KAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIK KYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGK CLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQ MFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKG NTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEET GNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKF VTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNNNRLNK IELNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG CdiCas9 Corynebacterium 3278 MKYHVGIDVGTFSVGLAAIEVDDAGMPIKTLSLVSHIHDSGLDPDEIKSAVTRLASSGIARRTRRL H573A diphtheriae YRRKRRRLQQLDKFIQRQGWPVIELEDYSDPLYPWKVRAELAASYIADEKERGEKLSVALRHIAR (Alternate) HRGWRNPYAKVSSLYLPDGPSDAFKAIREEIKRASGQPVPETATVGQMVTLCELGTLKLRGEGGV LSARLQQSDYAREIQEICRMQEIGQELYRKIIDVVFAAESPKGSASSRVGKDPLQPGKNRALKASD AFQRYRIAALIGNLRVRVDGEKRILSVEEKNLVFDHLVNLTPKKEPEWVTIAEILGIDRGQLIGTAT MTDDGERAGARPPTHDTNRSIVNSRIAPLVDWWKTASALEQHAMVKALSNAEVDDFDSPEGAK VQAFFADLDDDVHAKLDSLHLPVGRAAYSEDTLVRLTRRMLSDGVDLYTARLQEFGIEPSWTPPT PRIGEPVGNPAVDRVLKTVSRWLESATKTWGAPERVIIEHVREGFVTEKRAREMDGDMRRRAAR NAKLFQEMQEKLNVQGKPSRADLWRYQSVQRQNCQCAYCGSPITFSNSEMDHIVPRAGQGSTNT RENLVAVCHRCNQSKGNTPFAIWAKNTSIEGVSVKEAVERTRHWVTDTGMRSTDFKKFTKAVVE RFQRATMDEEIDARSMESVAWMANELRSRVAQHFASHGTTVRVYRGSLTAEARRASGISGKLKF FDGVGKSRLDRRHHAIDAAVIAFTSDYVAETLAVRSNLKQSQAHRQEAPQWREFTGKDAEHRAA WRVWCQKMEKLSALLTEDLRDDRVVVMSNVRLRLGNGSAHKETIGKLSKVKLSSQLSVSDIDKA SSEALWCALTREPGFDPKEGLPANPERHIRVNGTHVYAGDNIGLFPVSAGSIALRGGYAELGSSFH HARVYKITSGKKPAFAMLRVYTIDLLPYRNQDLFSVELKPQTMSMRQAEKKLRDALATGNAEYL GWLVVDDELVVDTSKIATDQVKAVEAELGTIRRWRVDGFFSPSKLRLRPLQMSKEGIKKESAPEL SKIIDRPGWLPAVNKLFSDGNVTVVRRDSLGRVRLESTAHLPVTWKVQ CjeCas9 Campylobacter 3279 MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARRKARLN N582A jejuni HLKHLIANEFKLNYEDYQSFDESLAKAYKGSLISPYELRFRALNELLSKQDFARVILHIAKRRGYD DIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSKEFTNVRNKKESYERCIAQ SFLKDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALKDFSHLVGNCSFFTDEKRAPKNSPLAFM FVALTRIINLLNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYEFKGEKGTYFI EFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNIS FKALKLVTPLMLEGKKYDEACNELNLKVAINEDKKDFLPAFNETYYKDEVTNPVVLRAIKEYRK VLNALLKKYGKVHKINIELAREVGKNHSQRAKIEKEQNENYKAKKDAELECEKLGLKINSKNILK LRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHIYPYSRSFDDSYMNKVLVFTKQNQEKLNQTPFE AFGNDSAKWQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVLNYTKDYLD FLPLSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVIIAYANNSI VKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKIDEIFVSKPERKKPSGALH EETFRKEEEFYQSYGGKEGVLKALELGKIRKVNGKIVKNGDMFRVDIFKHKKTNKFYAVPIYTMD FALKVLPNKAVARSKKGEIKDWILMDENYEFCFSLYKDSLILIQTKDMQEPEFVYYNAFTSSTVSLI VSKHDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK GeoCas9 Geobacillus 3280 MRYKIGLDIGITSVGWAVMNLDIPRIEDLGVRIFDRAENPQTGESLALPRRLARSARRRLRRRKHR N605A stearother LERIRRLVIREGILTKEELDKLFEEKHEIDVWQLRVEALDRKLNNDELARVLLHLAKRRGFKSNRK mophilus SERSNKENSTMLKHIEENRAILSSYRTVGEMIVKDPKFALHKRNKGENYTNTIARDDLEREIRLIFS KQREFGNMSCTEEFENEYITIWASQRPVASKDDIEKKVGFCTFEPKEKRAPKATYTFQSFIAWEHIN KLRLISPSGARGLTDEERRLLYEQAFQKNKITYHDIRTLLHLPDDTYFKGIVYDRGESRKQNENIRF LELDAYHQIRKAVDKVYGKGKSSSFLPIDFDTFGYALTLFKDDADIHSYLRNEYEQNGKRMPNLA NKVYDNELIEELLNLSFTKFGHLSLKALRSILPYMEQGEVYSSACERAGYTFTGPKKKQKTMLLPN IPPIANPVVMRALTQARKVVNAIIKKYGSPVSIHIELARDLSQTFDERRKTKKEQDENRKKNETAIR QLMEYGLTLNPTGHDIVKFKLWSEQNGRCAYSLQPIEIERLLEPGYVEVDHVIPYSRSLDDSYTNK VLVLTRENREKGNRIPAEYLGVGTERWQQFETFVLTNKQFSKKKRDRLLRLHYDENEETEFKNRN LNDTRYISRFFANFIREHLKFAESDDKQKVYTVNGRVTAHLRSRWEFNKNREESDLHHAVDAVIV ACTTPSDIAKVTAFYQRREQNKELAKKTEPHFPQPWPHFADELRARLSKHPKESIKALNLGNYDD QKLESLQPVFVSRMPKRSVTGAAHQETLRRYVGIDERSGKIQTVVKTKLSEIKLDASGHFPMYGK ESDPRTYEAIRQRLLEHNNDPKKAFQEPLYKPKKNGEPGPVIRTVKIIDTKNQVIPLNDGKTVAYN SNIVRVDVFEKDGKYYCVPVYTMDIMKGILPNKAIEPNKPYSEWKEMTEDYTFRFSLYPNDLIRIE LPREKTVKTAAGEEINVKDVFVYYKTIDSANGGLELISHDHRFSLRGVGSRTLKRFEKYQVDVLG NIYKVRGEKRVGLASSAHSKPGKTIRPLQSTRD iSpyMac Streptococcus 3281 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A Cas9 spp. TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEIQTVGQNGGLFDDNPKSPL EVTPSKLVPLKKELNPKKYGGYQKPTTAYPVLLITDTKQLIPISVMNKKQFEQNPVKFLRDRGYQQ VGKNDFIKLPKYTLVDIGDGIKRLWASSKEIHKGNQLVVSKKSQILLYHAHHLDSDLSNDYLQNH NQQFDVLFNEIISFSKKCKLGKEHIQKIENVYSNKKNSASIEELAESFIKLLGFTQLGATSPFNFLGV KLNQKQYKGKKDYILPCTEGTLIRQSITGLYETRVDLSKIGEDSGGSGGSKRTADGSEFES NmeCas9 Neisseria 3282 MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLAR N611A meningitidis SVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVL LHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQR SDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEP AEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLE DTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTD EDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTE EKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENR KDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFS RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKF DEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAEND RHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEV MIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVK SAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDK AGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGIL PDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDH KIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR ScaCas9 Streptococcus 3283 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETAEATRLK N872A canis RTARRRYTRRKNRIRYLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFGNLADEVAYHRN YPTIYHLRKKLADSPEKADLRLIYLALAHIIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEE SPLDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGNIIALALGLTPNFKSNFDLTEDAKLQL SKDTYDDDLDELLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQD LALLKTLVRQQFPEKYAEIFKDDTKNGYAGYVGIGIKHRKRTTKLATQEEFYKFIKPILEKMDGAE ELLAKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFYPFLKENREKIEKILTFRIPYYVGPL ARGNSRFAWLTRKSEEAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPKHSLLYEYFTV YNELTKVKYVTERMRKPEFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVEDR FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLK RRHYTGWGRLSRKMINGIRDKQSGKTILDFLKSDGFSNRNFMQLIHDDSLTFKEEIEKAQVSGQGD SLHEQIADLAGSPAIKKGILQTVKIVDELVKVMGHKPENIVIEMARENQTTTKGLQQSRERKKRIEE GIKELESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIKDDSI DNKVLTRSVENRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEADKAG FIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIREVKVITLKSKLVSDFRKDFQLYKVRDINNY HHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKRFFYSNIMNF FKTEVKLANGEIRKRPLIETNGETGEVVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKESI LSKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEKGKAKKLKSVKVLVGITIMEKGSYE KDPIGFLEAKGYKDIKKELIFKLPKYSLFELENGRRRMLASATELQKANELVLPQHLVRLLYYTQN ISATTGSNNLGYIEQHREEFKEIFEKIIDFSEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLLK YTSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSITGLYETRTDLSQLGGD ScaCas9- Streptococcus 3284 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETAEATRLK N872A HiFi- canis RTARRRYTRRKNRIRYLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFGNLADEVAYHRN Sc++ YPTIYHLRKKLADSPEKADLRLIYLALAHIIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEE SPLDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGNIIALALGLTPNFKSNFDLTEDAKLQL SKDTYDDDLDELLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQD LALLKTLVRQQFPEKYAEIFKDDTKNGYAGYVGADKKLRKRSGKLATEEEFYKFIKPILEKMDGA EELLAKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFYPFLKENREKIEKILTFRIPYYVGP LARGNSRFAWLTRKSEEAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPKHSLLYEYFT VYNELTKVKYVTERMRKPEFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRHYTGWGRLSRKMINGIRDKQSGKTILDFLKSDGFSNANFMQLIHDDSLTFKEEIEKAQVSGQ GDSLHEQIADLAGSPAIKKGILQTVKIVDELVKVMGHKPENIVIEMARENQTTTKGLQQSRERKKR IEEGIKELESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIKD DSIDNKVLTRSVENRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEADK AGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIREVKVITLKSKLVSDFRKDFQLYKVRDIN NYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKRFFYSNIM NFFKTEVKLANGEIRKRPLIETNGETGEVVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKE SILSKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEKGKAKKLKSVKVLVGITIMEKGSY EKDPIGFLEAKGYKDIKKELIFKLPKYSLFELENGRRRMLASAKELQKANELVLPQHLVRLLYYTQ NISATTGSNNLGYIEQHREEFKEIFEKIIDFSEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLL KYTSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSITGLYETRTDLSQLGGD SpyCas9- Streptococcus 3285 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A 3var- pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY NRRH PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMVKRYDEHHQ DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRE DLLRKQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRLRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGGHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDK LIARKKDWDPKKYGGFNSPTAAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIGFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGVLHKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGVPAAFKYFDTTIDKKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3286 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A 3var- pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY NRTH PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMVKRYDEHHQ DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRE DLLRKQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRLRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGGHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDK LIARKKDWDPKKYGGFNSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIGFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASASVLHKGNELALPSKYVNFLYLASHYEKLKGSS EDNKQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGASAAFKYFDTTIGRKLYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3287 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A 3var- pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY NRCH PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMVKRYDEHHQ DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRE DLLRKQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRLRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGGHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDK LIARKKDWDPKKYGGFNSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGVLQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTINRKQYNTTKEVLDATLIRQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3269 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A HF1 pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3288 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A QQR1 pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASARELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADAQLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTFKQKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3289 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A SpG pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFLWPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLE AKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAKQLQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3290 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A VQR pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3291 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A VRER pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASARELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3292 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A xCas pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDTKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKLYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGIIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEKVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGDQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFIQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELG SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGVLQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3293 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR N863A xCas-NG pyogenes TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY PTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDTKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKLYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED LLRKQRTFDNGIIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEKVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGDQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFIQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL SQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETROITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDK LIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEA KGYKEVKKDLIIKLPKYSLFELENGRKRMLASARFLQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPRAFKYFDTTIDRKVYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD St1Cas9- Streptococcus 3294 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRVRL N622A CNRZ1066 thermophilus NRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDASDDGNSSVG DYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQT QQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFR AAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVA DIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFAD GSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSSSNK TKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANK DEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQF EVDHILPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKK KEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRH WGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNTLVSYSEEQLLDIETGELISDDEYKESVFKAP YQHFVDTLKSKEFEDSILFSYQVDSKFNRKISDATIYATROAKVGKDKKDETYVLGKIKDIYTQDG YDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNKQMNEKGKEVPCNPFLKYKEEHGYIRK YSKKGNGPEIKSLKYYDSKLLGNPIDITPENSKNKVVLQSLKPWRTDVYFNKATGKYEILGLKYA DLQFEKGTGTYKISQEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQQLFRFLSRTLPKQ KHYVELKPYDKQKFEGGEALIKVLGNVANGGQCIKGLAKSNISIYKVRTDVLGNQHIIKNEGDKP KLDF St1Cas9- Streptococcus 3295 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRVRL N622A LMG1831 thermophilus NRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDASDDGNSSVG DYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQT QQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFR AAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVA DIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFAD GSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSSSNK TKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANK DEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQF EVDHILPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKK KEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRH WGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNTLVSYSEEQLLDIETGELISDDEYKESVFKAP YQHFVDTLKSKEFEDSILFSYQVDSKFNRKISDATIYATROAKVGKDKKDETYVLGKIKDIYTQDG YDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNKQMNEKGKEVPCNPFLKYKEEHGYIRK YSKKGNGPEIKSLKYYDSKLLGNPIDITPENSKNKVVLQSLKPWRTDVYFNKNTGKYEILGLKYA DLQFEKKTGTYKISQEKYNGIMKEEGVDSDSEFKFTLYKNDLLLVKDTETKEQQLFRFLSRTMPN VKYYVELKPYSKDKFEKNESLIEILGSADKSGRCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPK LDF St1Cas9- Streptococcus 3296 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRVRL N622A MTH17C thermophilus NRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDASDDGNSSVG L396 DYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQT QQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFR AAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVA DIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFAD GSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSSSNK TKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANK DEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQF EVDHILPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKK KEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRH WGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNTLVSYSEDQLLDIETGELISDDEYKESVFKAP YQHFVDTLKSKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKADETYVLGKIKDIYTQDG YDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYIRKY SKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQSLKPWRTDVYFNKNTGKYEILGLKYSDM QFEKGTGKYSISKEQYENIKVREGVDENSEFKFTLYKNDLLLLKDSENGEQILLRFTSRNDTSKHY VELKPYNRQKFEGSEYLIKSLGTVAKGGQCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKLDF St1Cas9- Streptococcus 3297 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQAENNLVRRTNRQGRRLARRKKHRRVRL N622A TH1477 thermophilus NRLFEESGLITDFTKISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISYLDDASDDGNSSVG DYAQIVKENSKQLETKTPGQIQLERYQTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQT QQEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGRYRTSGETLDNIFGILIGKCTFYPDEFR AAKASYTAQEFNLLNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLFKYIAKLLSCDVA DIKGYRIDKSGKAEIHTFEAYRKMKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFAD GSFSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELYETSEEQMTILTRLGKQKTTSSSNK TKYIDEKLLTEEIYNPVVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEKKAIQKIQKANK DEKDAAMLKAANQYNGKAELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLINNSNQF EVDHILPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTLSNKK KEYLLTEEDISKFDVRKKFIERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTSQLRRH WGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNTLVSYSEDQLLDIETGELISDDEYKESVFKAP YQHFVDTLKSKEFEDSILFSYQVDSKFNRKISDATIYATROAKVGKDKADETYVLGKIKDIYTQDG YDAFMKIYKKDKSKFLMYRHDPQTFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYIRKY SKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQSLKPWRTDVYFNKNTGKYEILGLKYSDM QFEKGTGKYSISKEQYENIKVREGVDENSEFKFTLYKNDLLLLKDSENGEQILLRFTSRNDTSKHY VELKPYNRQKFEGSEYLIKSLGTVVKGGRCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKLDF

In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas domain, e.g., a Cas9 domain. In embodiments, the endonuclease domain or DNA binding domain comprises a nuclease-active Cas domain, a Cas nickase (nCas) domain, or a nuclease-inactive Cas (dCas) domain. In embodiments, the endonuclease domain or DNA binding domain comprises a nuclease-active Cas9 domain, a Cas9 nickase (nCas9) domain, or a nuclease-inactive Cas9 (dCas9) domain. In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas9 domain of Cas9 (e.g., dCas9 and nCas9), Cas12a/Cpf1, Cas12b/C2c1, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, or Cas12i. In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas9 (e.g., dCas9 and nCas9), Cas12a/Cpf1, Cas12b/C2c1, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, or Cas12i. In some embodiments, the endonuclease domain or DNA binding domain comprises an S. pyogenes or an S. thermophilus Cas9, or a functional fragment thereof. In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas9 sequence, e.g., as described in Chylinski, Rhun, and Charpentier (2013) RNA Biology 10:5, 726-737; incorporated herein by reference. In some embodiments, the endonuclease domain or DNA binding domain comprises the HNH nuclease subdomain and/or the RuvC1 subdomain of a Cas, e.g., Cas9, e.g., as described herein, or a variant thereof. In some embodiments, the endonuclease domain or DNA binding domain comprises Cas12a/Cpf1, Cas12b/C2c1, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, or Cas12i. In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas polypeptide (e.g., enzyme), or a functional fragment thereof. In embodiments, the Cas polypeptide (e.g., enzyme) is selected from Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (e.g., Csn1 or Csx12), Cas10, Cas10d, Cas12a/Cpf1, Cas12b/C2c1, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, Cas12i, Csy1, Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Type II Cas effector proteins, Type V Cas effector proteins, Type VI Cas effector proteins, CARF, DinG, Cpf1, Cas12b/C2c1, Cas12c/C2c3, Cas12b/C2c1, Cas12c/C2c3, SpCas9(K855A), eSpCas9(1.1), SpCas9-HF1, hyper accurate Cas9 variant (HypaCas9), homologues thereof, modified or engineered versions thereof, and/or functional fragments thereof. In embodiments, the Cas9 comprises one or more substitutions, e.g., selected from H840A, D10A, P475A, W476A, N477A, D1125A, W1126A, and D1127A. In embodiments, the Cas9 comprises one or more mutations at positions selected from: D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or A987, e.g., one or more substitutions selected from D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and/or D986A. In some embodiments, the endonuclease domain or DNA binding domain comprises a Cas (e.g., Cas9) sequence from Corynebacterium ulcerans, Corynebacterium diphtheria, Spiroplasma syrphidicola, Prevotella intermedia, Spiroplasma taiwanense, Streptococcus iniae, Belliella baltica, Psychroflexus torquis, Streptococcus thermophilus, Listeria innocua, Campylobacter jejuni, Neisseria meningitidis, Streptococcus pyogenes, or Staphylococcus aureus, or a fragment or variant thereof.

In some embodiments, the endonuclease domain or DNA binding domain comprises a Cpf1 domain, e.g., comprising one or more substitutions, e.g., at position D917, E1006A, D1255 or any combination thereof, e.g., selected from D917A, E1006A, D1255A, D917A/E1006A, D917A/D1255A, E1006A/D1255A, and D917A/E1006A/D1255A.

In some embodiments, the endonuclease domain or DNA binding domain comprises spCas9, spCas9-VRQR, spCas9-VRER, xCas9 (sp), saCas9, saCas9-KKH, spCas9-MQKSER, spCas9-LRKIQK, or spCas9-LRVSQL.

In some embodiments, the endonuclease domain or DNA-binding domain comprises an amino acid sequence as listed in Table 37 below, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. In some embodiments, the endonuclease domain or DNA-binding domain comprises an amino acid sequence that has no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 differences (e.g., mutations) relative to any of the amino acid sequences described herein.

TABLE 37 Each of the Reference Sequences are incorporated by reference in their entirety. Name Amino Acid Sequence or Reference Sequence Streptococcus pyogenes Cas9 Exemplary Linker SGSETPGTSESATPES (SEQ ID NO: 1023) Exemplary Linker Motif (SGGS)_(n) (SEQ ID NO: 1583) Exemplary Linker Motif (GGGS)_(n) (SEQ ID NO: 1584) Exemplary Linker Motif (GGGGS)_(n) (SEQ ID NO: 1535) Exemplary Linker Motif (G)_(n) Exemplary Linker Motif (EAAAK)_(n) (SEQ ID NO: 1534) Exemplary Linker Motif (GGS)_(n) Exemplary Linker Motif (XP)_(n) Cas9 from Streptococcus NCBI Reference Sequence: NC_002737.2 and Uniprot pyogenes Reference Sequence: Q99ZW2 Cas9 from Corynebacterium NCBI Refs: NC_015683.1, NC_017317.1 ulcerans Cas9 from Corynebacterium NCBI Refs: NC_016782.1, NC_016786.1 diphtheria Cas9 from Spiroplasma NCBI Ref: NC_021284.1 syrphidicola Cas9 from Prevotella NCBI Ref: NC_017861.1 intermedia Cas9 from Spiroplasma NCBI Ref: NC_021846.1 taiwanense Cas9 from Streptococcus NCBI Ref: NC_021314.1 iniae Cas9 from Belliella baltica NCBI Ref: NC_018010.1 Cas9 from Psychroflexus NCBI Ref: NC_018721.1 torquisI Cas9 from Streptococcus NCBI Ref: YP_820832.1 thermophilus Cas9 from Listeria innocua NCBI Ref: NP_472073.1 Cas9 from Campylobacter NCBI Ref: YP_002344900.1 jejuni Cas9 from Neisseria NCBI Ref: YP_002342100.1 meningitidis dCas9 (D10A and H840A) Catalytically inactive Cas9 (dCas9) Cas9 nickase (nCas9) Catalytically active Cas9 CasY ((ncbi.nlm.nih.gov/protein/APG80656.1) >APG80656.1 CRISPR-associated protein CasY [uncultured Parcubacteria group bacterium]) CasX uniprot.org/uniprot/F0NN87; uniprot.org/uniprot/F0NH53 CasX >tr|F0NH53|F0NH53_SULIR CRISPR associated protein, Casx OS = Sulfolobus islandicus (strain REY15A) GN = SiRe_0771 PE = 4 SV = 1 Deltaproteobacteria CasX Cas12b/C2c1 ((uniprot.org/uniprot/T0D7A2#2) sp|T0D7A2|C2C1_ALIAG CRISPR- associated endonuclease C2c1 OS = Alicyclobacillus acido-terrestris (strain ATCC 49025/DSM 3922/CIP 106132/ NCIMB 13137/GD3B) GN = c2c1 PE = 1 SV = 1) BhCas12b ((Bacillus NCBI Reference Sequence: WP_095142515 hisashii) BvCas12b (Bacillus sp. V3- NCBI Reference Sequence: WP_101661451.1 13) Wild-type Francisella novicida Cpf1 Francisella novicida Cpf1 D917A Francisella novicida Cpf1 E1006A Francisella novicida Cpf1 D1255A Francisella novicida Cpf1 D917A/E1006A Francisella novicida Cpf1 D917A/D1255A Francisella novicida Cpf1 E1006A/D1255A Francisella novicida Cpf1 D917A/E1006A SaCas9 SaCas9n PAM-binding SpCas9 PAM-binding SpCas9n PAM-binding SpEQR Cas9 PAM-binding SpVQR Cas9 PAM-binding SpVRER Cas9 PAM-binding SpVRQR Cas9 SpyMacCas9

In some embodiments, a Gene Writing polypeptide has an endonuclease domain comprising a Cas9 nickase, e.g., Cas9 H840A. In embodiments, the Cas9 H840A has the following amino acid sequence:

Cas9 nickase (H840A): (SEQ ID NO: 1585) DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEA TRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGN IVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDV DKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLI ALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAG YIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAI LRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVV DKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDV DAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRK FDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYK VYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWD KGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGG FDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKK FTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

In some embodiments, a Gene Writing polypeptide comprises the RT domain from a retroviral reverse transcriptase, e.g., a wild-type M-MLV RT, e.g., comprising the following sequence:

M-MLV (WT): (SEQ ID NO: 1586) TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLI 

In some embodiments, a Gene Writing polypeptide comprises the RT domain from a retroviral reverse transcriptase, e.g., an M-MLV RT, e.g., comprising the following sequence:

(SEQ ID NO: 1548) TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLL

In some embodiments, a Gene Writing polypeptide comprises the RT domain from a retroviral reverse transcriptase comprising the sequence of amino acids 659-1329 of NP_057933. In embodiments, the Gene Writing polypeptide further comprises one additional amino acid at the N-terminus of the sequence of amino acids 659-1329 of NP_057933, e.g., as shown below:

(SEQ ID NO: 1587) TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAA Core RT (bold), annotated per above RNAseH (underlined), annotated per above In embodiments, the Gene Writing polypeptide further comprises one additional amino acid at the C-terminus of the sequence of amino acids 659-1329 of NP_057933. In embodiments, the Gene Writing polypeptide comprises an RNaseH1 domain (e.g., amino acids 1178-1318 of NP_057933).

In some embodiments, a retroviral reverse transcriptase domain, e.g., M-MLV RT, may comprise one or more mutations from a wild-type sequence that may improve features of the RT, e.g., thermostability, processivity, and/or template binding. In some embodiments, an M-MLV RT domain comprises, relative to the M-MLV (WT) sequence above, one or more mutations, e.g., selected from D200N, L603W, T330P, T306K, W313F, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R, E302K, F309N, L435G, N454K, H594Q, D653N, R110S, K103L, e.g., a combination of mutations, such as D200N, L603W, and T330P, optionally further including T306K and W313F. In some embodiments, an M-MLV RT used herein comprises the mutations D200N, L603W, T330P, T306K and W313F. In embodiments, the mutant M-MLV RT comprises the following amino acid sequence:

M-MLV (PE2): (SEQ ID NO: 1588) TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLII PLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP VKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNL GYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQL REFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDR WLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRR RGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLI 

In some embodiments, a Gene Writer polypeptide may comprise a linker, e.g., a peptide linker, e.g., a linker as described in Table 38. In some embodiments, a Gene Writer polypeptide comprises a flexible linker between the endonuclease and the RT domain, e.g., a linker comprising the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 1589). In some embodiments, an RT domain of a Gene Writer polypeptide may be located C-terminal to the endonuclease domain. In some embodiments, an RT domain of a Gene Writer polypeptide may be located N-terminal to the endonuclease domain.

TABLE 38 Exemplary linker sequences SEQ ID Amino Acid Sequence NO: GGS GGSGGS 3298 GGSGGSGGS 3299 GGSGGSGGSGGS 3300 GGSGGSGGSGGSGGS 3301 GGSGGSGGSGGSGGSGGS 3302 GGGGS 1535 GGGGSGGGGS 3303 GGGGSGGGGSGGGGS 3304 GGGGSGGGGSGGGGSGGGGS 3305 GGGGSGGGGSGGGGSGGGGSGGGGS 3306 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 3307 GGG GGGG 3308 GGGGG 3309 GGGGGG 3310 GGGGGGG 3311 GGGGGGGG 3312 GSS GSSGSS 1736 GSSGSSGSS 3313 GSSGSSGSSGSS 3314 GSSGSSGSSGSSGSS 3315 GSSGSSGSSGSSGSSGSS 3316 EAAAK 1534 EAAAKEAAAK 3317 EAAAKEAAAKEAAAK 3318 EAAAKEAAAKEAAAKEAAAK 3319 EAAAKEAAAKEAAAKEAAAKEAAAK 3320 EAAAKEAAAKEAAAKEAAAKEAAAKEAAAK 3321 PAP PAPAP 3322 PAPAPAP 3323 PAPAPAPAP 3324 PAPAPAPAPAP 3325 PAPAPAPAPAPAP 3326 GGSGGG 3327 GGGGGS 3328 GGSGSS 3329 GSSGGS 3330 GGSEAAAK 3331 EAAAKGGS 3332 GGSPAP 3333 PAPGGS 3334 GGGGSS 3335 GSSGGG 3336 GGGEAAAK 3337 EAAAKGGG 3338 GGGPAP 3339 PAPGGG 3340 GSSEAAAK 3341 EAAAKGSS 3342 GSSPAP 3343 PAPGSS 3344 EAAAKPAP 3345 PAPEAAAK 3346 GGSGGGGSS 3347 GGSGSSGGG 3348 GGGGGSGSS 3349 GGGGSSGGS 3350 GSSGGSGGG 3351 GSSGGGGGS 3352 GGSGGGEAAAK 3353 GGSEAAAKGGG 3354 GGGGGSEAAAK 3355 GGGEAAAKGGS 3356 EAAAKGGSGGG 3357 EAAAKGGGGGS 3358 GGSGGGPAP 3359 GGSPAPGGG 3360 GGGGGSPAP 3361 GGGPAPGGS 3362 PAPGGSGGG 3363 PAPGGGGGS 3364 GGSGSSEAAAK 3365 GGSEAAAKGSS 3366 GSSGGSEAAAK 3367 GSSEAAAKGGS 3368 EAAAKGGSGSS 3369 EAAAKGSSGGS 3370 GGSGSSPAP 3371 GGSPAPGSS 3372 GSSGGSPAP 3373 GSSPAPGGS 3374 PAPGGSGSS 3375 PAPGSSGGS 3376 GGSEAAAKPAP 3377 GGSPAPEAAAK 3378 EAAAKGGSPAP 3379 EAAAKPAPGGS 3380 PAPGGSEAAAK 3381 PAPEAAAKGGS 3382 GGGGSSEAAAK 3383 GGGEAAAKGSS 3384 GSSGGGEAAAK 3385 GSSEAAAKGGG 3386 EAAAKGGGGSS 3387 EAAAKGSSGGG 3388 GGGGSSPAP 3389 GGGPAPGSS 3390 GSSGGGPAP 3391 GSSPAPGGG 3392 PAPGGGGSS 3393 PAPGSSGGG 3394 GGGEAAAKPAP 3395 GGGPAPEAAAK 3396 EAAAKGGGPAP 3397 EAAAKPAPGGG 3398 PAPGGGEAAAK 3399 PAPEAAAKGGG 3400 GSSEAAAKPAP 3401 GSSPAPEAAAK 3402 EAAAKGSSPAP 3403 EAAAKPAPGSS 3404 PAPGSSEAAAK 3405 PAPEAAAKGSS 3406 AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA 3407 GGGGSEAAAKGGGGS 3408 EAAAKGGGGSEAAAK 3409 SGSETPGTSESATPES 1023 GSAGSAAGSGEF 3410 SGGSSGGSSGSETPGTSESATPESSGGSSGGSS 1589

In some embodiments, a Gene Writer polypeptide comprises a dCas9 sequence comprising a D10A and/or H840A mutation, e.g., the following sequence:

(SEQ ID NO: 1590) SMDKKYSIGLAIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFH RLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKA DLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEEN PINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDA ILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKE IFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLL RKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIP YYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFD KNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIV DLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLK IIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMK QLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHD DSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEH PVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKD DSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDN LTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIK KYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTE ITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTE VQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKV EKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLP KYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRD KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIH QSITGLYETRIDLSQLGGD

In some embodiments, a template RNA molecule for use in the system comprises, from 5′ to 3′ (1) a gRNA spacer; (2) a gRNA scaffold; (3) heterologous object sequence (4) 3′ homology domain. In some embodiments:

-   -   (1) Is a Cas9 spacer of ˜18-22 nt, e.g., is 20 nt     -   (2) Is a gRNA scaffold comprising one or more hairpin loops,         e.g., 1, 2, of 3 loopd for associating the template with a         nickase Cas9 domain. In some embodiments, the gRNA scaffold         carries the sequence, from 5′ to 3′,

(SEQ ID NO: 1591) GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC TTGAAAAAGTGGGACCGAGTCGGTCC

-   -   (3) In some embodiments, the heterologous object sequence is,         e.g., 7-74, e.g., 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, or         70-80 nt or, 80-90 nt in length. In some embodiments, the first         (most 5′) base of the sequence is not C.     -   (4) In some embodiments, the 3′ homology domain that binds the         target priming sequence after nicking occurs is e.g., 3-20 nt,         e.g., 7-15 nt, e.g., 12-14 nt. In some embodiments, the 3′         homology domain has 40-60% GC content.

A second gRNA associated with the system may help drive complete integration. In some embodiments, the second gRNA may target a location that is 0-200 nt away from the first-strand nick, e.g., 0-50, 50-100, 100-200 nt away from the first-strand nick. In some embodiments, the second gRNA can only bind its target sequence after the edit is made, e.g., the gRNA binds a sequence present in the heterologous object sequence, but not in the initial target sequence.

In some embodiments, a Gene Writing system described herein is used to make an edit in HEK293, K562, U2OS, or HeLa cells. In some embodiment, a Gene Writing system is used to make an edit in primary cells, e.g., primary cortical neurons from E18.5 mice.

In some embodiments, a reverse transcriptase or RT domain (e.g., as described herein) comprises a MoMLV RT sequence or variant thereof. In embodiments, the MoMLV RT sequence comprises one or more mutations selected from D200N, L603W, T330P, T306K, W313F, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R, E302K, F309N, L435G, N454K, H594Q, D653N, R110S, and K103L. In embodiments, the MoMLV RT sequence comprises a combination of mutations, such as D200N, L603W, and T330P, optionally further including T306K and/or W313F.

In some embodiments, an endonuclease domain (e.g., as described herein) comprises nCAS9, e.g., comprising the H840A mutation.

In some embodiments, the heterologous object sequence (e.g., of a system as described herein) is about 1-50, 50-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, or more, nucleotides in length.

In some embodiments, the RT and endonuclease domains are joined by a flexible linker, e.g., comprising the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 1589).

In some embodiments, the endonuclease domain is N-terminal relative to the RT domain. In some embodiments, the endonuclease domain is C-terminal relative to the RT domain.

In some embodiments, the system incorporates a heterologous object sequence into a target site by TPRT, e.g., as described herein.

In some embodiments, a system or method described herein involves a CRISPR DNA targeting enzyme or system described in US Pat. App. Pub. No. 20200063126, 20190002889, or 20190002875 (each of which is incorporated by reference herein in its entirety) or a functional fragment or variant thereof. For instance, in some embodiments, a GeneWriter polypeptide or Cas endonuclease described herein comprises a polypeptide sequence of any of the applications mentioned in this paragraph, and in some embodiments a template RNA or guide RNA comprises a nucleic acid sequence of any of the applications mentioned in this paragraph.

In some embodiments, an endonuclease domain or DNA-binding domain comprises a TAL effector molecule. A TAL effector molecule, e.g., a TAL effector molecule that specifically binds a DNA sequence, typically comprises a plurality of TAL effector domains or fragments thereof, and optionally one or more additional portions of naturally occurring TAL effectors (e.g., N- and/or C-terminal of the plurality of TAL effector domains). Many TAL effectors are known to those of skill in the art and are commercially available, e.g., from Thermo Fisher Scientific.

Naturally occurring TALEs are natural effector proteins secreted by numerous species of bacterial pathogens including the plant pathogen Xanthomonas which modulates gene expression in host plants and facilitates bacterial colonization and survival. The specific binding of TAL effectors is based on a central repeat domain of tandemly arranged nearly identical repeats of typically 33 or 34 amino acids (the repeat-variable di-residues, RVD domain).

Members of the TAL effectors family differ mainly in the number and order of their repeats. The number of repeats typically ranges from 1.5 to 33.5 repeats and the C-terminal repeat is usually shorter in length (e.g., about 20 amino acids) and is generally referred to as a “half-repeat”. Each repeat of the TAL effector generally features a one-repeat-to-one-base-pair correlation with different repeat types exhibiting different base-pair specificity (one repeat recognizes one base-pair on the target gene sequence). Generally, the smaller the number of repeats, the weaker the protein-DNA interactions. A number of 6.5 repeats has been shown to be sufficient to activate transcription of a reporter gene (Scholze et al., 2010).

Repeat to repeat variations occur predominantly at amino acid positions 12 and 13, which have therefore been termed “hypervariable” and which are responsible for the specificity of the interaction with the target DNA promoter sequence, as shown in Table 5 listing exemplary repeat variable diresidues (RVD) and their correspondence to nucleic acid base targets.

TABLE 5 RVDs and Nucleic Acid Base Specificity Target Possible RVD Amino Acid Combinations A NI NN CI HI KI G NN GN SN VN LN DN QN EN HN RH NK AN FN C HD RD KD ND AD T NG HG VG IG EG MG YG AA EP VA QG KG RG

Accordingly, it is possible to modify the repeats of a TAL effector to target specific DNA sequences. Further studies have shown that the RVD NK can target G. Target sites of TAL effectors also tend to include a T flanking the 5′ base targeted by the first repeat, but the exact mechanism of this recognition is not known. More than 113 TAL effector sequences are known to date. Non-limiting examples of TAL effectors from Xanthomonas include, Hax2, Hax3, Hax4, AvrXa7, AvrXa10 and AvrBs3.

Accordingly, the TAL effector domain of a TAL effector molecule described herein may be derived from a TAL effector from any bacterial species (e.g., Xanthomonas species such as the African strain of Xanthomonas oryzae pv. Oryzae (Yu et al. 2011), Xanthomonas campestris pv. raphani strain 756C and Xanthomonas oryzae pv. oryzicolastrain BLS256 (Bogdanove et al. 2011). In some embodiments, the TAL effector domain comprises an RVD domain as well as flanking sequence(s) (sequences on the N-terminal and/or C-terminal side of the RVD domain) also from the naturally occurring TAL effector. It may comprise more or fewer repeats than the RVD of the naturally occurring TAL effector. The TAL effector molecule can be designed to target a given DNA sequence based on the above code and others known in the art. The number of TAL effector domains (e.g., repeats (monomers or modules)) and their specific sequence can be selected based on the desired DNA target sequence. For example, TAL effector domains, e.g., repeats, may be removed or added in order to suit a specific target sequence. In an embodiment, the TAL effector molecule of the present invention comprises between 6.5 and 33.5 TAL effector domains, e.g., repeats. In an embodiment, TAL effector molecule of the present invention comprises between 8 and 33.5 TAL effector domains, e.g., repeats, e.g., between 10 and 25 TAL effector domains, e.g., repeats, e.g., between 10 and 14 TAL effector domains, e.g., repeats.

In some embodiments, the TAL effector molecule comprises TAL effector domains that correspond to a perfect match to the DNA target sequence. In some embodiments, a mismatch between a repeat and a target base-pair on the DNA target sequence is permitted as along as it allows for the function of the polypeptide comprising the TAL effector molecule. In general, TALE binding is inversely correlated with the number of mismatches. In some embodiments, the TAL effector molecule of a polypeptide of the present invention comprises no more than 7 mismatches, 6 mismatches, 5 mismatches, 4 mismatches, 3 mismatches, 2 mismatches, or 1 mismatch, and optionally no mismatch, with the target DNA sequence. Without wishing to be bound by theory, in general the smaller the number of TAL effector domains in the TAL effector molecule, the smaller the number of mismatches will be tolerated and still allow for the function of the polypeptide comprising the TAL effector molecule. The binding affinity is thought to depend on the sum of matching repeat-DNA combinations. For example, TAL effector molecules having 25 TAL effector domains or more may be able to tolerate up to 7 mismatches.

In addition to the TAL effector domains, the TAL effector molecule of the present invention may comprise additional sequences derived from a naturally occurring TAL effector. The length of the C-terminal and/or N-terminal sequence(s) included on each side of the TAL effector domain portion of the TAL effector molecule can vary and be selected by one skilled in the art, for example based on the studies of Zhang et al. (2011). Zhang et al., have characterized a number of C-terminal and N-terminal truncation mutants in Hax3 derived TAL-effector based proteins and have identified key elements, which contribute to optimal binding to the target sequence and thus activation of transcription. Generally, it was found that transcriptional activity is inversely correlated with the length of N-terminus. Regarding the C-terminus, an important element for DNA binding residues within the first 68 amino acids of the Hax 3 sequence was identified. Accordingly, in some embodiments, the first 68 amino acids on the C-terminal side of the TAL effector domains of the naturally occurring TAL effector is included in the TAL effector molecule. Accordingly, in an embodiment, a TAL effector molecule comprises 1) one or more TAL effector domains derived from a naturally occurring TAL effector; 2) at least 70, 80, 90, 100, 110, 120, 130, 140, 150, 170, 180, 190, 200, 220, 230, 240, 250, 260, 270, 280 or more amino acids from the naturally occurring TAL effector on the N-terminal side of the TAL effector domains; and/or 3) at least 68, 80, 90, 100, 110, 120, 130, 140, 150, 170, 180, 190, 200, 220, 230, 240, 250, 260 or more amino acids from the naturally occurring TAL effector on the C-terminal side of the TAL effector domains.

In some embodiments, an endonuclease domain or DNA-binding domain is or comprises a Zn finger molecule. A Zn finger molecule comprises a Zn finger protein, e.g., a naturally occurring Zn finger protein or engineered Zn finger protein, or fragment thereof. Many Zn finger proteins are known to those of skill in the art and are commercially available, e.g., from Sigma-Aldrich.

In some embodiments, a Zn finger molecule comprises a non-naturally occurring Zn finger protein that is engineered to bind to a target DNA sequence of choice. See, for example, Beerli, et al. (2002) Nature Biotechnol. 20:135-141; Pabo, et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan, et al. (2001) Nature Biotechnol. 19:656-660; Segal, et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo, et al. (2000) Curr. Opin. Struct. Biol. 10:411-416; U.S. Pat. Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent Publication Nos. 2005/0064474; 2007/0218528; 2005/0267061, all incorporated herein by reference in their entireties.

An engineered Zn finger protein may have a novel binding specificity, compared to a naturally-occurring Zn finger protein. Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual Zn finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, U.S. Pat. Nos. 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.

Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in U.S. Pat. Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as International Patent Publication Nos. WO 98/37186; WO 98/53057; WO 00/27878; and WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger proteins has been described, for example, in International Patent Publication No. WO 02/077227.

In addition, as disclosed in these and other references, zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Pat. Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned International Patent Publication No. WO 02/077227.

Zn finger proteins and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U.S. patent Ser. Nos. 6,140,0815; 789,538; 6,453,242; 6,534,261; 5,925,523; 6,007,988; 6,013,453; and 6,200,759; International Patent Publication Nos. WO 95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970; WO 01/88197; WO 02/099084; WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536; and WO 03/016496.

In addition, as disclosed in these and other references, Zn finger proteins and/or multi-fingered Zn finger proteins may be linked together, e.g., as a fusion protein, using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Pat. Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The Zn finger molecules described herein may include any combination of suitable linkers between the individual zinc finger proteins and/or multi-fingered Zn finger proteins of the Zn finger molecule.

In certain embodiments, the DNA-binding domain or endonuclease domain comprises a Zn finger molecule comprising an engineered zinc finger protein that binds (in a sequence-specific manner) to a target DNA sequence. In some embodiments, the Zn finger molecule comprises one Zn finger protein or fragment thereof. In other embodiments, the Zn finger molecule comprises a plurality of Zn finger proteins (or fragments thereof), e.g., 2, 3, 4, 5, 6 or more Zn finger proteins (and optionally no more than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 Zn finger proteins). In some embodiments, the Zn finger molecule comprises at least three Zn finger proteins. In some embodiments, the Zn finger molecule comprises four, five or six fingers. In some embodiments, the Zn finger molecule comprises 8, 9, 10, 11 or 12 fingers. In some embodiments, a Zn finger molecule comprising three Zn finger proteins recognizes a target DNA sequence comprising 9 or 10 nucleotides. In some embodiments, a Zn finger molecule comprising four Zn finger proteins recognizes a target DNA sequence comprising 12 to 14 nucleotides. In some embodiments, a Zn finger molecule comprising six Zn finger proteins recognizes a target DNA sequence comprising 18 to 21 nucleotides.

In some embodiments, a Zn finger molecule comprises a two-handed Zn finger protein. Two handed zinc finger proteins are those proteins in which two clusters of zinc finger proteins are separated by intervening amino acids so that the two zinc finger domains bind to two discontinuous target DNA sequences. An example of a two handed type of zinc finger binding protein is SIP1, where a cluster of four zinc finger proteins is located at the amino terminus of the protein and a cluster of three Zn finger proteins is located at the carboxyl terminus (see Remade, et al. (1999) EMBO Journal 18(18):5073-5084). Each cluster of zinc fingers in these proteins is able to bind to a unique target sequence and the spacing between the two target sequences can comprise many nucleotides.

DNA Binding Domain:

In certain aspects, the DNA-binding domain of a Gene Writer™ polypeptide described herein is selected, designed, or constructed for binding to a desired host DNA target sequence.

In some embodiments, a Gene Writer polypeptide comprises a modification to a DNA-binding domain, e.g., relative to the wild-type polypeptide. In some embodiments, the DNA-binding domain comprises an addition, deletion, replacement, or modification to the amino acid sequence of the original DNA-binding domain. In some embodiments, the DNA-binding domain is modified to include a heterologous functional domain that binds specifically to a target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, the functional domain replaces at least a portion (e.g., the entirety of) the prior DNA-binding domain of the polypeptide. In some embodiments, the functional domain comprises a zinc finger (e.g., a zinc finger that specifically binds to the target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, the functional domain comprises a Cas domain (e.g., a Cas domain that specifically binds to the target nucleic acid (e.g., DNA) sequence of interest. In embodiments, the Cas domain comprises a Cas9 or a mutant or variant thereof (e.g., as described herein). In embodiments, the Cas domain is associated with a guide RNA (gRNA), e.g., as described herein. In embodiments, the Cas domain is directed to a target nucleic acid (e.g., DNA) sequence of interest by the gRNA. In embodiments, the Cas domain is encoded in the same nucleic acid (e.g., RNA) molecule as the gRNA. In embodiments, the Cas domain is encoded in a different nucleic acid (e.g., RNA) molecule from the gRNA.

In certain embodiments, the DNA-binding domain of the polypeptide is a heterologous DNA-binding protein or domain relative to a native retrotransposon sequence. In some embodiments the heterologous DNA binding element is a zinc-finger element or a TAL effector element, e.g., a zinc-finger or TAL polypeptide or functional fragment thereof. In some embodiments the heterologous DNA binding element is a sequence-guided DNA binding element, such as Cas9, Cpf1, or other CRISPR-related protein that has been altered to have no endonuclease activity. In some embodiments the heterologous DNA binding element retains endonuclease activity. In some embodiments, the heterologous DNA binding element retains partial endonuclease activity to cleave ssDNA, e.g., possesses nickase activity. In some embodiments the heterologous DNA binding element replaces the endonuclease element of the polypeptide. In specific embodiments, the heterologous DNA-binding domain can be any one or more of Cas9, TAL domain, ZF domain, Myb domain, combinations thereof, or multiples thereof. In certain embodiments, the heterologous DNA-binding domain is a DNA binding domain of a retrotransposon or virus described in Table 1 or Table 3. A person having ordinary skill in the art is capable of identifying DNA binding domains based upon homology to other known DNA binding domains using tools as Basic Local Alignment Search Tool (BLAST). In still other embodiments, DNA-binding domains are modified, for example by site-specific mutation, increasing or decreasing DNA-binding elements (for example, number and/or specificity of zinc fingers), etc., to alter DNA-binding specificity and affinity. In some embodiments the DNA binding domain is altered from its natural sequence to have altered codon usage, e.g. improved for human cells In some embodiments, the DNA binding domain comprises a meganuclease domain (e.g., as described herein, e.g., in the endonuclease domain section), or a functional fragment thereof.

In some embodiments, the meganuclease domain possesses endonuclease activity, e.g., double-strand cleavage and/or nickase activity. In other embodiments, the meganuclease domain has reduced activity, e.g., lacks endonuclease activity, e.g., the meganuclease is catalytically inactive. In some embodiments, a catalytically inactive meganuclease is used as a DNA binding domain, e.g., as described in Fonfara et al. Nucleic Acids Res 40(2):847-860 (2012), incorporated herein by reference in its entirety. In embodiments, the DNA binding domain comprises one or more modifications relative to a wild-type DNA binding domain, e.g., a modification via directed evolution, e.g., phage-assisted continuous evolution (PACE).

In certain aspects of the present invention, the host DNA-binding site integrated into by the Gene Writer™ system can be in a gene, in an intron, in an exon, an ORF, outside of a coding region of any gene, in a regulatory region of a gene, or outside of a regulatory region of a gene. In other aspects, the polypeptide may bind to one or more than one host DNA sequence.

In some embodiments, a Gene Writing system is used to edit a target locus in multiple alleles. In some embodiments, a Gene Writing system is designed to edit a specific allele. For example, a Gene Writing polypeptide may be directed to a specific sequence that is only present on one allele, e.g., comprises a template RNA with homology to a target allele, e.g., a gRNA or annealing domain, but not to a second cognate allele. In some embodiments, a Gene Writing system can alter a haplotype-specific allele. In some embodiments, a Gene Writing system that targets a specific allele preferentially targets that allele, e.g., has at least a 2, 4, 6, 8, or 10-fold preference for a target allele.

In certain embodiments, a Gene Writer™ gene editor system RNA further comprises an intracellular localization sequence, e.g., a nuclear localization sequence. The nuclear localization sequence may be an RNA sequence that promotes the import of the RNA into the nucleus. In certain embodiments the nuclear localization signal is located on the template RNA. In certain embodiments, the retrotransposase polypeptide is encoded on a first RNA, and the template RNA is a second, separate, RNA, and the nuclear localization signal is located on the template RNA and not on an RNA encoding the retrotransposase polypeptide. While not wishing to be bound by theory, in some embodiments, the RNA encoding the retrotransposase is targeted primarily to the cytoplasm to promote its translation, while the template RNA is targeted primarily to the nucleus to promote its retrotransposition into the genome. In some embodiments the nuclear localization signal is at the 3′ end, 5′ end, or in an internal region of the template RNA. In some embodiments the nuclear localization signal is 3′ of the heterologous sequence (e.g., is directly 3′ of the heterologous sequence) or is 5′ of the heterologous sequence (e.g., is directly 5′ of the heterologous sequence). In some embodiments the nuclear localization signal is placed outside of the 5′ UTR or outside of the 3′ UTR of the template RNA. In some embodiments the nuclear localization signal is placed between the 5′ UTR and the 3′ UTR, wherein optionally the nuclear localization signal is not transcribed with the transgene (e.g., the nuclear localization signal is an anti-sense orientation or is downstream of a transcriptional termination signal or polyadenylation signal). In some embodiments the nuclear localization sequence is situated inside of an intron. In some embodiments a plurality of the same or different nuclear localization signals are in the RNA, e.g., in the template RNA. In some embodiments the nuclear localization signal is less than 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900 or 1000 bp in legnth. Various RNA nuclear localization sequences can be used. For example, Lubelsky and Ulitsky, Nature 555 (107-111), 2018 describe RNA sequences which drive RNA localization into the nucleus. In some embodiments, the nuclear localization signal is a SINE-derived nuclear RNA localization (SIRLOIN) signal. In some embodiments the nuclear localization signal binds a nuclear-enriched protein. In some embodiments the nuclear localization signal binds the HNRNPK protein. In some embodiments the nuclear localization signal is rich in pyrimidines, e.g., is a C/T rich, C/U rich, C rich, T rich, or U rich region. In some embodiments the nuclear localization signal is derived from a long non-coding RNA. In some embodiments the nuclear localization signal is derived from MALAT1 long non-coding RNA or is the 600 nucleotide M region of MALAT1 (described in Miyagawa et al., RNA 18, (738-751), 2012). In some embodiments the nuclear localization signal is derived from BORG long non-coding RNA or is a AGCCC motif (described in Zhang et al., Molecular and Cellular Biology 34, 2318-2329 (2014). In some embodiments the nuclear localization sequence is described in Shukla et al., The EMBO Journal e98452 (2018). In some embodiments the nuclear localization signal is derived from a non-LTR retrotransposon, an LTR retrotransposon, retrovirus, or an endogenous retrovirus.

In some embodiments, a polypeptide described herein comprises one or more (e.g., 2, 3, 4, 5) nuclear targeting sequences, for example a nuclear localization sequence (NLS). In some embodiments, the NLS is a bipartite NLS. In some embodiments, an NLS facilitates the import of a protein comprising an NLS into the cell nucleus. In some embodiments, the NLS is fused to the N-terminus of a Gene Writer described herein. In some embodiments, the NLS is fused to the C-terminus of the Gene Writer. In some embodiments, the NLS is fused to the N-terminus or the C-terminus of a Cas domain. In some embodiments, a linker sequence is disposed between the NLS and the neighboring domain of the Gene Writer.

In some embodiments, an NLS comprises the amino acid sequence MD SLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 1592), PKKRKVEGADKRTADGSEFESPKKKRKV (SEQ ID NO: 1593), RKSGKIAAIWKRPRKPKKKRKV (SEQ ID NO: 1594), KRTADGSEFESPKKKRKV (SEQ ID NO: 1595), KKTELQTTNAENKTKKL (SEQ ID NO: 1596), or KRGINDRNFWRGENGRKTR (SEQ ID NO: 1597), KRPAATKKAGQAKKKK (SEQ ID NO: 1598), or a functional fragment or variant thereof. Exemplary NLS sequences are also described in PCT/EP2000/011690, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, an NLS comprises an amino acid sequence as disclosed in Table 39. An NLS of this table may be utilized with one or more copies in a polypeptide in one or more locations in a polypeptide, e.g., 1, 2, 3 or more copies of an NLS in an N-terminal domain, between peptide domains, in a C-terminal domain, or in a combination of locations, in order to improve subcellular localization to the nucleus. Multiple unique sequences may be used within a single polypeptide. Sequences may be naturally monopartite or bipartite, e.g., having one or two stretches of basic amino acids, or may be used as chimeric bipartite sequences. Sequence references correspond to UniProt accession numbers, except where indicated as SeqNLS for sequences mined using a subcellular localization prediction algorithm (Lin et al BMC Bioinformat 13:157 (2012), incorporated herein by reference in its entirety).

TABLE 39 Exemplary nuclear localization signals for use in Gene Writing systems SEQ ID Sequence NO: Sequence References AHFKISGEKRPSTDPGKKAK 3411 Q76IQ7 NPKKKKKKDP AHRAKKMSKTHA 3412 P21827 ASPEYVNLPINGNG 3413 SeqNLS CTKRPRW 3414 088622, Q86W56, Q9QYM2, 002776 DKAKRVSRNKSEKKRR 3415 015516, Q5RAK8, Q91YB2, Q91YB0, Q8QGQ6, 008785, Q9WVS9, Q6YGZ4 EELRLKEELLKGIYA 3416 Q9QY16, Q9UHL0, Q2TBP1, Q9QY15 EEQLRRRKNSRLNNTG 3417 G5EFF5 EVLKVIRTGKRKKKAWKR 3418 SeqNLS MVTKVC HHHHHHHHHHHHQPH 3419 Q63934, G3V7L5, Q12837 HKKKHPDASVNFSEFSK 3420 P10103, Q4R844, P12682, B0CM99, A9RA84, Q6YKA4, P09429, P63159, Q08IE6, P63158, Q9YH06, B1MTB0 HKRTKK 3421 Q2R2D5 IINGRKLKLKKSRRRSSQTS 3422 SeqNLS NNSFTSRRS KAEQERRK 3423 Q8LH59 KEKRKRREELFIEQKKRK 3424 SeqNLS KKGKDEWFSRGKKP 3425 P30999 KKGPSVQKRKKT 3426 Q6ZN17 KKKTVINDLLHYKKEK 3427 SeqNLS, P32354 KKNGGKGKNKPSAKIKK 3428 SeqNLS KKPKWDDFKKKKK 3429 Q15397, Q8BKS9, Q562C7 KKRKKD 3430 SeqNLS, Q91Z62, Q1A730, Q969P5, Q2KHT6, Q9CPU7 KKRRKRRRK 3431 SeqNLS KKRRRRARK 3432 Q9UMS6, D4A702, Q91YE8 KKSKRGR 3433 Q9UBS0 KKSRKRGS 3434 B4FG96 KKSTALSRELGKIMRRR 3435 SeqNLS, P32354 KKSYQDPEIIAHSRPRK 3436 Q9U7C9 KKTGKNRKLKSKRVKTR 3437 Q9Z301, 054943, Q8K3T2 KKVSIAGQSGKLWRWKR 3438 Q6YUL8 KKYENVVIKRSPRKRGRPRK 3439 SeqNLS KNKKRK 3440 SeqNLS KPKKKR 3441 SeqNLS KRAMKDDSHGNSTSPKRRK 3442 Q0E671 KRANSNLVAAYEKAKKK 3443 P23508 KRASEDTTSGSPPKKSSAGPKR 3444 Q9BZZ5, Q5R644 KRFKRRWMVRKMKTKK 3445 SeqNLS KRGLNSSFETSPKKVK 3446 Q8IV63 KRGNSSIGPNDLSKRKQRKK 3447 SeqNLS KRIHSVSLSQSQIDPSKKVK 3448 SeqNLS RAK KRKGKLKNKGSKRKK 3449 015381 KRRRRRRREKRKR 3450 Q96GM8 KRSNDRTYSPEEEKQRRA 3451 Q91ZF2 KRTVATNGDASGAHRAKK 3452 SeqNLS MSK KRVYNKGEDEQEHLPKGKK 3453 SeqNLS R KSGKAPRRRAVSMDNSNK 3454 Q9WVH4, 043524 KVNFLDMSLDDIIIYKELE 3455 Q9P127 KVQHRIAKKTTRRRR 3456 Q9DXE6 LSPSLSPL 3457 Q9Y261, P32182, P35583 MDSLLMNRRKFLYQFKNVR 1735 Q9GZX7 WAKGRRETYLC MPQNEYIELHRKRYGYRLD 3458 SeqNLS YHEKKRKKESREAHERSKK AKKMIGLKAKLYHK MVQLRPRASR 3459 SeqNLS NNKLLAKRRKGGASPKDDP 3460 Q965G5 MDDIK NYKRPMDGTYGPPAKRHEG 3461 O14497, A2BH40 E PDTKRAKLDSSETTMVKKK 3462 SeqNLS PEKRTKI 3463 SeqNLS PGGRGKKK 3464 Q719N1, Q9UBP0, A2VDN5 PGKMDKGEHRQERRDRPY 3465 Q01844, Q61545 PKKGDKYDKTD 3466 Q45FA5 PKKKSRK 3467 035914, Q01954 PKKNKPE 3468 Q22663 PKKRAKV 3469 P04295, P89438 PKPKKLKVE 3470 P55263, P55262, P55264, Q64640 PKRGRGR 3471 Q9FYS5, Q43386 PKRRLVDDA 3472 POC797 PKRRRTY 3473 SeqNLS PLFKRR 3474 A8X6H4, Q9TXJO PLRKAKR 3475 Q86WB0, Q5R8V9 PPAKRKCIF 3476 Q6AZ28, 075928, Q8C5D8 PPARRRRL 3477 Q8NAG6 PPKKKRKV 3478 Q3L6L5, P03070, P14999, P03071 PPNKRMKVKH 3479 Q8BN78 PPRIYPQLPSAPT 3480 POC799 PQRSPFPKSSVKR 3481 SeqNLS PRPRKVPR 3482 POC799 PRRRVQRKR 3483 SeqNLS, Q5R448, Q5TAQ9 PRRVRLK 3484 Q58DJ0, P56477, Q13568 PSRKRPR 3485 Q62315, Q5F363, Q92833 PSSKKRKV 3486 SeqNLS PTKKRVK 3487 P07664 QRPGPYDRP 3488 SeqNLS RGKGGKGLGKGGAKRHRK 3489 SeqNLS RKAGKGGGGHKTTKKRSA 3490 B4FG96 KDEKVP RKIKLKRAK 3491 A1L3G9 RKIKRKRAK 3492 B9X187 RKKEAPGPREELRSRGR 3493 035126, P54258, Q5IS70, P54259 RKKRKGK 3494 SeqNLS, Q29243, Q62165, Q28685, 018738, Q9TSZ6, Q14118 RKKRRQRRR 3495 P04326, P69697, P69698, P05907, P20879, P04613, P19553, POC1J9, P20893, P12506, P04612, Q73370, POC1K0, P05906, P35965, P04609, P04610, P04614, P04608, P05905 RKKSIPLSIKNLKRKHKRKK 3496 Q9C0C9 NKITR RKLVKPKNTKMKTKLRTNP 3497 Q14190 Y RKRLILSDKGQLDWKK 3498 SeqNLS, Q91Z62, Q1A730, Q2KHT6, Q9CPU7 RKRLKSK 3499 Q13309 RKRRVRDNM 3500 Q8QPH4, Q809M7, A8C8X1, Q2VNC5, Q38SQ0, 089749, Q6DNQ9, Q809L9, Q0A429, Q20NV3, P16509, P16505, Q6DNQ5, P16506, Q6XT06, P26118, Q2ICQ2, Q2RCG8, Q0A2D0, Q0A2H9, Q9IQ46, Q809M3, Q6J847, Q6J856, B4URE4, A4GCM7, Q0A440, P26120, P16511, RKRSPKDKKEKDLDGAGKR 3501 Q7RTP6 RKT RKRTPRVDGQTGENDMNK 3502 094851 RRRK RLPVRRRRRR 3503 P04499, P12541, P03269, P48313, P03270 RLRFRKPKSK 3504 P69469 RQQRKR 3505 Q14980 RRDLNSSFETSPKKVK 3506 Q8K3G5 RRDRAKLR 3507 Q9SLB8 RRGDGRRR 3508 Q80WE1, Q5R9B4, Q06787, P35922 RRGRKRKAEKQ 3509 Q812D1, Q5XXA9, Q99JF8, Q8MJG1, Q66T72, 075475 RRKKRR 3510 Q0VD86, Q58DS6, Q5R6G2, Q9ERI5, Q6AYK2, Q6NYC1 RRKRSKSEDMDSVESKRRR 3511 Q7TT18 RRKRSR 3512 Q99PU7, D3ZHS6, Q92560, A2VDM8 RRPKGKTLQKRKPK 3513 Q6ZN17 RRRGFERFGPDNMGRKRK 3514 Q63014, Q9DBR0 RRRGKNKVAAQNCRK 3515 SeqNLS RRRKRR 3516 Q5FVH8, Q6MZT1, Q08DH5, Q8BQP9 RRRQKQKGGASRRR 3517 SeqNLS RRRREGPRARRRR 3518 P08313, P10231 RRTIRLKLVYDKCDRSCKIQ 3519 SeqNLS KKNRNKCQYCRFHKCLSVG MSHNAIRFGRMPRSEKAKL KAE RRVPQRKEVSRCRKCRK 3520 Q5RJN4, Q32L09, Q8CAK3, Q9NUL5 RVGGRRQAVECIEDLLNEP 3521 P03255 GQPLDLSCKRPRP RVVKLRIAP 3522 P52639, Q8JMNO RVVRRR 3523 P70278 SKRKTKISRKTR 3524 Q5RAY1, 000443 SYVKTVPNRTRTYIKL 3525 P21935 TGKNEAKKRKIA 3526 P52739, Q8K3J5, Q5RAU9 TLSPASSPSSVSCPVIPASTD 3527 SeqNLS ESPGSALNI VSKKQRTGKKIH 3528 P52739, Q8K3J5, Q5RAU9 SPKKKRKVE 3529 KRTAD GSEFE SPKKKRKVE 3530 PAAKRVKLD 3531 PKKKRKV 3532 MDSLLMNRRKFLYQFKNVR 1735 WAKGRRETYLC SPKKKRKVEAS 3533 MAPKKKRKVGIHRGVP 3534

In some embodiments, the NLS is a bipartite NLS. A bipartite NLS typically comprises two basic amino acid clusters separated by a spacer sequence (which may be, e.g., about 10 amino acids in length). A monopartite NLS typically lacks a spacer. An example of a bipartite NLS is the nucleoplasmin NLS, having the sequence KR[PAATKKAGQA]KKKK (SEQ ID NO: 1598), wherein the spacer is bracketed. Another exemplary bipartite NLS has the sequence PKKKRKVEGADKRTADGSEFESPKKKRKV (SEQ ID NO: 1600). Exemplary NLSs are described in International Application WO2020051561, which is herein incorporated by reference in its entirety, including for its disclosures regarding nuclear localization sequences.

In certain embodiments, a Gene Writer™ gene editor system polypeptide further comprises an intracellular localization sequence, e.g., a nuclear localization sequence and/or a nucleolar localization sequence. The nuclear localization sequence and/or nucleolar localization sequence may be amino acid sequences that promote the import of the protein into the nucleus and/or nucleolus, where it can promote integration of heterologous sequyence into the genome. In certain embodiments, a Gene Writer™ gene editor system polypeptide (e.g., a retrotransposase, e.g., a polypeptide according to any of Tables 1 or 3 herein) further comprises a nucleolar localization sequence. In certain embodiments, the retrotransposase polypeptide is encoded on a first RNA, and the template RNA is a second, separate, RNA, and the nucleolar localization signal is encoded on the RNA encoding the retrotransposase polypeptide and not on the template RNA. In some embodiments, the nucleolar localization signal is located at the N-terminus, C-terminus, or in an internal region of the polypeptide. In some embodiments, a plurality of the same or different nucleolar localization signals are used. In some embodiments, the nuclear localization signal is less than 5, 10, 25, 50, 75, or 100 amino acids in length. Various polypeptide nucleolar localization signals can be used. For example, Yang et al., Journal of Biomedical Science 22, 33 (2015), describe a nuclear localization signal that also functions as a nucleolar localization signal. In some embodiments, the nucleolar localization signal may also be a nuclear localization signal. In some embodiments, the nucleolar localization signal may overlap with a nuclear localization signal. In some embodiments, the nucleolar localization signal may comprise a stretch of basic residues. In some embodiments, the nucleolar localization signal may be rich in arginine and lysine residues. In some embodiments, the nucleolar localization signal may be derived from a protein that is enriched in the nucleolus. In some embodiments, the nucleolar localization signal may be derived from a protein enriched at ribosomal RNA loci. In some embodiments, the nucleolar localization signal may be derived from a protein that binds rRNA. In some embodiments, the nucleolar localization signal may be derived from MSP58. In some embodiments, the nucleolar localization signal may be a monopartite motif. In some embodiments, the nucleolar localization signal may be a bipartite motif. In some embodiments, the nucleolar localization signal may consist of a multiple monopartite or bipartite motifs. In some embodiments, the nucleolar localization signal may consist of a mix of monopartite and bipartite motifs. In some embodiments, the nucleolar localization signal may be a dual bipartite motif. In some embodiments, the nucleolar localization motif may be a KRASSQALGTIPKRRSSSRFIKRKK (SEQ ID NO: 1530). In some embodiments, the nucleolar localization signal may be derived from nuclear factor-KB-inducing kinase. In some embodiments, the nucleolar localization signal may be an RKKRKKK motif (SEQ ID NO: 1531) (described in Birbach et al., Journal of Cell Science, 117 (3615-3624), 2004).

In some embodiments, a nucleic acid described herein (e.g., an RNA encoding a Gene Writer™ polypeptide, or a DNA encoding the RNA) comprises a microRNA binding site. In some embodiments, the microRNA binding site is used to increase the target-cell specificity of a Gene Writer™ system. For instance, the microRNA binding site can be chosen on the basis that is recognized by a miRNA that is present in a non-target cell type, but that is not present (or is present at a reduced level relative to the non-target cell) in a target cell type. Thus, when the RNA encoding the Gene Writer™ polypeptide is present in a non-target cell, it would be bound by the miRNA, and when the RNA encoding the Gene Writer™ polypeptide is present in a target cell, it would not be bound by the miRNA (or bound but at reduced levels relative to the non-target cell). While not wishing to be bound by theory, binding of the miRNA to the RNA encoding the Gene Writer™ polypeptide may reduce production of the Gene Writer™ polypeptide, e.g., by degrading the mRNA encoding the polypeptide or by interfering with translation. Accordingly, in such embodiments the Gene Writer would add to/edit the genome of target cells more efficiently than it edits the genome of non-target cells, e.g., the heterologous object sequence would be inserted into the genome of target cells more efficiently than into the genome of non-target cells, or an insertion or deletion is produced more efficiently in target cells than in non-target cells. A system having a microRNA binding site in the RNA encoding the Gene Writer™ polypeptide (or encoded in the DNA encoding the RNA) may also be used in combination with a template RNA that is regulated by a second microRNA binding site, e.g., as described herein in the section entitled “Template RNA component of Gene Writer™ gene editor system.” In some embodiments, e.g., for liver indications, a miRNA is selected from Table 4 of WO2020014209, incorporated herein by reference.

In some embodiments, the DNA encoding a Gene Writer polypeptide comprises a promoter sequence, e.g., a tissue specific promoter sequence. In some embodiments, the tissue-specific promoter is used to increase the target-cell specificity of a Gene Writer™ system. For instance, the promoter can be chosen on the basis that it is active in a target cell type but not active in (or active at a lower level in) a non-target cell type. A system having a tissue-specific promoter sequence in the DNA of the polypeptide may also be used in combination with a microRNA binding site, e.g., in the template RNA or a nucleic acid encoding a Gene Writer™ protein, e.g., as described herein. A system having a tissue-specific promoter sequence in the DNA encoding the Gene Writer polypeptide may also be used in combination with a DNA encoding the RNA template driven by a tissue-specific promoter, e.g., to achieve higher levels of RNA template in target cells than in non-target cells. In some embodiments, e.g., for liver indications, a tissue-specific promoter is selected from Table 3 of WO2020014209, incorporated herein by reference.

A skilled artisan can, based on the Accession numbers and/or sequences provided in Tables 1 and 3, determine the nucleic acid and corresponding polypeptide sequences of each retrotransposon or virus, and domains thereof, e.g., by using routine sequence analysis tools as Basic Local Alignment Search Tool (BLAST) or CD-Search for conserved domain analysis. Other sequence analysis tools are known and can be found, e.g., at https://molbiol-tools.ca, for example, at https://molbiol-tools.ca/Motifs.htm.

Tables 1 and 3 herein provide the sequences of exemplary transposons or viruses, including the amino acid sequence(s) of the retrotransposase, reverse transcriptase, DNA-binding domain, and/or endonuclease domain; sequences of 5′ and 3′ untranslated regions to allow a polypeptide, e.g., the retrotransposase to bind the template RNA; and/or the full transposon nucleic acid sequence. In some embodiments, a 5′ UTR contained in or referenced by Tables 1 or 3 allows a polypeptide, e.g., the retrotransposase, to bind the template RNA. In some embodiments, a 3′ UTR contained in or referenced by Tables 1 or 3 allows a polypeptide, e.g., the retrotransposase, to bind the template RNA. Thus, in some embodiments, a polypeptide for use in any of the systems described herein can be a polypeptide of any of Tables 1 or 3 herein, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the system further comprises one or both of a 5′ or 3′ untranslated region contained in or referenced by Tables 1 or 3 (or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto), e.g., from the same transposon as the polypeptide referred to in the preceding sentence, as indicated in the same row of the same table. In some embodiments, the system comprises one or both of a 5′ or 3′ untranslated region contained in or referenced by Tables 1 or 3, e.g., a segment of the full transposon sequence that encodes an RNA that is capable of binding a retrotransposase, and/or the sub-sequence provided in the column entitled Predicted 5′ UTR or Predicted 3′ UTR.

In some embodiments, a system or method described herein involves a 3′ UTR, 5′ UTR, or both from a retrotransposon of Table 3. In some embodiments, the 3′ UTR, 5′ UTR, or both, has a sequence comprising a portion of the full retrotransposon DNA sequence shown in column 5 of Table 3 of International Application PCT/US2019/048607, which is incorporated by reference herein in its entirety, including Table 3. In some embodiments, the nucleic acid sequence or amino acid sequence has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the sequence in Table 3 of PCT/US2019/048607.

In some embodiments, a system or method described herein involves a nucleic acid sequence or amino acid sequence of a retrotransposon described in Table 1 or Table 2 of International Application PCT/US2019/048607, which is incorporated by reference herein in its entirety, including Tables 1 and 2. In some embodiments, the nucleic acid sequence or amino acid sequence has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the sequence of a retrotransposon described in said Table 1 or Table 2 of PCT/US2019/048607.

In some embodiments, a polypeptide for use in any of the systems described herein can be a molecular reconstruction or ancestral reconstruction based upon the aligned polypeptide sequence of multiple retrotransposons. In some embodiments, a 5′ or 3′ untranslated region for use in any of the systems described herein can be a molecular reconstruction based upon the aligned 5′ or 3′ untranslated region of multiple retrotransposons. A skilled artisan can, based on the Accession numbers provided herein, align polypeptides or nucleic acid sequences, e.g., by using routine sequence analysis tools as Basic Local Alignment Search Tool (BLAST) or CD-Search for conserved domain analysis. Molecular reconstructions can be created based upon sequence consensus, e.g. using approaches described in Ivics et al., Cell 1997, 501-510; Wagstaff et al., Molecular Biology and Evolution 2013, 88-99. In some embodiments, the retrotransposon from which the 5′ or 3′ untranslated region or polypeptide is derived is a young or a recently active mobile element, as assessed via phylogenetic methods such as those described in Boissinot et al., Molecular Biology and Evolution 2000, 915-928.

Thermostable Gene Writer™ Systems

While not wishing to be bound by theory, in some embodiments, retrotransposases that evolved in cold environments may not function as well at human body temperature. This application provides a number of thermostable Gene Writer™ systems, including proteins derived from avian retrotransposases. Exemplary avian transposase sequences in Table 3 include those of Taeniopygia guttata (zebra finch; transposon name R2-1_TG), Geospiza fortis (medium ground finch; transposon name R2-1_Gfo), Zonotrichia albicollis (white-throated sparrow; transposon name R2-1_ZA), and Tinamus guttatus (white-throated tinamou; transposon name R2-1_TGut).

Thermostability may be measured, e.g., by testing the ability of a Gene Writer™ to polymerize DNA in vitro at a high temperature (e.g., 37° C.) and a low temperature (e.g., 25° C.). Suitable conditions for assaying in vitro DNA polymerization activity (e.g., processivity) are described, e.g., in Bibillo and Eickbush, “High Processivity of the Reverse Transcriptase from a Non-long Terminal Repeat Retrotransposon” (2002) JBC 277, 34836-34845. In some embodiments, the thermostable Gene Writer™ polypeptide has an activity, e.g., a DNA polymerization activity, at 37° C. that is no less than 70%, 75%, 80%, 85%, 90%, or 95% of its activity at 25° C. under otherwise similar conditions.

In some embodiments, a Gene Writer™ polypeptide (e.g., a sequence of Table 1 or 3 or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto) is stable in a subject chosen from a mammal (e.g., human) or a bird. In some embodiments, a Gene Writer™ polypeptide described herein is functional at 37° C. In some embodiments, a Gene Writer™ polypeptide described herein has greater activity at 37° C. than it does at a lower temperature, e.g., at 30° C., 25° C., or 20° C. In some embodiments, a Gene Writer™ polypeptide described herein has greater activity in a human cell than in a zebrafish cell.

In some embodiments, a Gene Writer™ polypeptide is active in a human cell cultured at 37° C., e.g., using an assay of Example 6 or Example 7 of PCT/US2019/048607 which are hereby incorporated by reference.

In some embodiments, the assay comprises steps of: (1) introducing HEK293T cells into one or more wells of 6.4 mm diameter, at 10,000 cells/well, (2) incubating the cells at 37° C. for 24 hr, (3) providing a transfection mixture comprising 0.5 μl if FuGENE® HD transfection reagent and 80 ng DNA (wherein the DNA is a plasmid comprising, in order, (a) CMV promoter, (b) 100 bp of sequence homologous to the 100 bp upstream of the target site, (c) sequence encoding a 5′ untranslated region that binds the Gene Writer™ protein, (d) sequence encoding the Gene Writer™ protein, (e) sequence encoding a 3′ untranslated region that binds the Gene Writer™ protein (f) 100 bp of sequence homologous to the 100 bp downstream of the target site, and (g) BGH polyadenylation sequence) and 10 μl Opti-MEM and incubating for 15 min at room temperature, (4) adding the transfection mixture to the cells, (5) incubating the cells for 3 days, and (6) assaying integration of the exogenous sequence into a target locus (e.g., rDNA) in the cell genome, e.g., wherein one or more of the preceding steps are performed as described in Example 6 of PCT/US2019/048607 which is hereby incorporated by reference.

In some embodiments, the Gene Writer™ polypeptide results in insertion of the heterologous object sequence (e.g., the GFP gene) into the target locus (e.g., rDNA) at an average copy number of at least 0.01, 0.025, 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, or 5 copies per genome. In some embodiments, a cell described herein (e.g., a cell comprising a heterologous sequence at a target insertion site) comprises the heterologous object sequence at an average copy number of at least 0.01, 0.025, 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, or 5 copies per genome.

In some embodiments, a Gene Writer™ causes integration of a sequence in a target RNA with relatively few truncation events at the terminus. For instance, in some embodiments, a Gene Writer™ protein (e.g., of SEQ ID NO: 1016) results in about 25-100%, 50-100%, 60-100%, 70-100%, 75-95%, 80%-90%, or 86.17% of integrants into the target site being non-truncated, as measured by an assay described herein, e.g., an assay of Example 6 and FIG. 8 of PCT/US2019/048607 which are hereby incorporated by reference. In some embodiments, a Gene Writer™ protein (e.g., of SEQ ID NO: 1016) results in at least about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of integrants into the target site being non-truncated, as measured by an assay described herein. In some embodiments, an integrant is classified as truncated versus non-truncated using an assay comprising amplification with a forward primer situated 565 bp from the end of the element (e.g., a wild-type transposon sequence, e.g., of Taeniopygia guttata) and a reverse primer situated in the genomic DNA of the target insertion site, e.g., rDNA. In some embodiments, the number of full-length integrants in the target insertion site is greater than the number of integrants truncated by 300-565 nucleotides in the target insertion site, e.g., the number of full-length integrants is at least 1.1×, 1.2×, 1.5×, 2×, 3×, 4×, 5×, 6×, 7×, 8×, 9×, or 10× the number of the truncated integrants, or the number of full-length integrants is at least 1.1×-10×, 2×-10×, 3×-10×, or 5×-10× the number of the truncated integrants.

In some embodiments, a system or method described herein results in insertion of the heterologous object sequence only at one target site in the genome of the target cell. Insertion can be measured, e.g., using a threshold of above 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, e.g., as described in Example 8 of PCT/US2019/048607 which is hereby incorporated by reference. In some embodiments, a system or method described herein results in insertion of the heterologous object sequence wherein less than 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 10%, 20%, 30%, 40%, or 50% of insertions are at a site other than the target site, e.g., using an assay described herein, e.g., an assay of Example 8 of PCT/US2019/048607.

In some embodiments, a system or method described herein results in “scarless” insertion of the heterologous object sequence, while in some embodiments, the target site can show deletions or duplications of endogenous DNA as a result of insertion of the heterologous sequence. The mechanisms of different retrotransposons could result in different patterns of duplications or deletions in the host genome occurring during retrotransposition at the target site. In some embodiments, the system results in a scarless insertion, with no duplications or deletions in the surrounding genomic DNA. In some embodiments, the system results in a deletion of less than 1, 2, 3, 4, 5, 10, 50, or 100 bp of genomic DNA upstream of the insertion. In some embodiments, the system results in a deletion of less than 1, 2, 3, 4, 5, 10, 50, or 100 bp of genomic DNA downstream of the insertion. In some embodiments, the system results in a duplication of less than 1, 2, 3, 4, 5, 10, 50, or 100 bp of genomic DNA upstream of the insertion. In some embodiments, the system results in a duplication of less than 1, 2, 3, 4, 5, 10, 50, or 100 bp of genomic DNA downstream of the insertion.

In some embodiments, a Gene Writer™ described herein, or a DNA-binding domain thereof, binds to its target site specifically, e.g., as measured using an assay of Example 21 of PCT/US2019/048607 which is hereby incorporated by reference. In some embodiments, the Gene Writer™ or DNA-binding domain thereof binds to its target site more strongly than to any other binding site in the human genome. For example, in some embodiments, in an assay of Example 21 of PCT/US2019/048607, the target site represents more than 50%, 60%, 70%, 80%, 90%, or 95% of binding events of the Gene Writer™ or DNA-binding domain thereof to human genomic DNA.

Genetically Engineered, e.g., Dimerized Gene Writer™ Systems

Some non-LTR retrotransposons utilize two subunits to complete retrotransposition (Christensen et al PNAS 2006). In some embodiments, a retrotransposase described herein comprises two connected subunits as a single polypeptide. For instance, two wild-type retrotransposases could be joined with a linker to form a covalently “dimerized” protein. In some embodiments, the nucleic acid coding for the retrotransposase codes for two retrotransposase subunits to be expressed as a single polypeptide. In some embodiments, the subunits are connected by a peptide linker, such as has been described herein in the section entitled “Linker” and, e.g., in Chen et al Adv Drug Deliv Rev 2013. In some embodiments, the two subunits in the polypeptide are connected by a rigid linker. In some embodiments, the rigid linker consists of the motif (EAAAK)_(n)(SEQ ID NO: 1534). In other embodiments, the two subunits in the polypeptide are connected by a flexible linker. In some embodiments, the flexible linker consists of the motif (Gly)_(n). In some embodiments, the flexible linker consists of the motif (GGGGS)_(n)(SEQ ID NO: 1535). In some embodiments, the rigid or flexible linker consists of 1, 2, 3, 4, 5, 10, 15, or more amino acids in length to enable retrotransposition. In some embodiments, the linker consists of a combination of rigid and flexible linker motifs.

Based on mechanism, not all functions are required from both retrotransposase subunits. In some embodiments, the fusion protein may consist of a fully functional subunit and a second subunit lacking one or more functional domains. In some embodiments, one subunit may lack reverse transcriptase functionality. In some embodiments, one subunit may lack the reverse transcriptase domain. In some embodiments, one subunit may possess only endonuclease activity. In some embodiments, one subunit may possess only an endonuclease domain. In some embodiments, the two subunits comprising the single polypeptide may provide complimentary functions.

In some embodiments, one subunit may lack endonuclease functionality. In some embodiments, one subunit may lack the endonuclease domain. In some embodiments, one subunit may possess only reverse transcriptase activity. In some embodiments, one subunit may possess only a reverse transcriptase domain. In some embodiments, one subunit may possess only DNA-dependent DNA synthesis functionality.

Linkers

In some embodiments, domains of the compositions and systems described herein (e.g., the endonuclease and reverse transcriptase domains of a polypeptide or the DNA binding domain and reverse transcriptase domains of a polypeptide) may be joined by a linker. A composition described herein comprising a linker element has the general form S1-L-S2, wherein S1 and S2 may be the same or different and represent two domain moieties (e.g., each a polypeptide or nucleic acid domain) associated with one another by the linker. In some embodiments, a linker may connect two polypeptides. In some embodiments, a linker may connect two nucleic acid molecules. In some embodiments, a linker may connect a polypeptide and a nucleic acid molecule. A linker may be a chemical bond, e.g., one or more covalent bonds or non-covalent bonds. A linker may be flexible, rigid, and/or cleavable. In some embodiments, the linker is a peptide linker. Generally, a peptide linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids in length, e.g., 2-50 amino acids in length, 2-30 amino acids in length.

The most commonly used flexible linkers have sequences consisting primarily of stretches of Gly and Ser residues (“GS” linker). Flexible linkers may be useful for joining domains that require a certain degree of movement or interaction and may include small, non-polar (e.g. Gly) or polar (e.g. Ser or Thr) amino acids. Incorporation of Ser or Thr can also maintain the stability of the linker in aqueous solutions by forming hydrogen bonds with the water molecules, and therefore reduce unfavorable interactions between the linker and the other moieties. Examples of such linkers include those having the structure [GGS]^(≥1) or [GGGS]^(≥1) (SEQ ID NO: 1536). Rigid linkers are useful to keep a fixed distance between domains and to maintain their independent functions. Rigid linkers may also be useful when a spatial separation of the domains is critical to preserve the stability or bioactivity of one or more components in the agent. Rigid linkers may have an alpha helix-structure or Pro-rich sequence, (XP)_(n), with X designating any amino acid, preferably Ala, Lys, or Glu. Cleavable linkers may release free functional domains in vivo. In some embodiments, linkers may be cleaved under specific conditions, such as the presence of reducing reagents or proteases. In vivo cleavable linkers may utilize the reversible nature of a disulfide bond. One example includes a thrombin-sensitive sequence (e.g., PRS) between the two Cys residues. In vitro thrombin treatment of CPRSC (SEQ ID NO: 1537) results in the cleavage of the thrombin-sensitive sequence, while the reversible disulfide linkage remains intact. Such linkers are known and described, e.g., in Chen et al. 2013. Fusion Protein Linkers: Property, Design and Functionality. Adv Drug Deliv Rev. 65(10): 1357-1369. In vivo cleavage of linkers in compositions described herein may also be carried out by proteases that are expressed in vivo under pathological conditions (e.g. cancer or inflammation), in specific cells or tissues, or constrained within certain cellular compartments. The specificity of many proteases offers slower cleavage of the linker in constrained compartments.

In some embodiments the amino acid linkers are (or are homologous to) the endogenous amino acids that exist between such domains in a native polypeptide. In some embodiments the endogenous amino acids that exist between such domains are substituted but the length is unchanged from the natural length. In some embodiments, additional amino acid residues are added to the naturally existing amino acid residues between domains.

In some embodiments, the amino acid linkers are designed computationally or screened to maximize protein function (Anad et al., FEBS Letters, 587:19, 2013).

Additional Domains:

The Gene Writer™ polypeptide comprises the functions necessary to bind a target DNA sequence and template nucleic acid (e.g., template RNA), nick the target site, and write (e.g., reverse transcribe) the template into DNA, resulting in a modification of the target site. In some embodiments, additional domains may be added to the polypeptide to enhance the efficiency of the process. In some embodiments, the Gene Writer™ polypeptide may contain an additional DNA ligation domain to join reverse transcribed DNA to the DNA of the target site. In some embodiments, the polypeptide may comprise a heterologous RNA-binding domain. In some embodiments, the polypeptide may comprise a domain having 5′ to 3′ exonuclease activity (e.g., wherein the 5′ to 3′ exonuclease activity increases repair of the alteration of the target site, e.g., in favor of alteration over the original genomic sequence). In some embodiments, the polypeptide may comprise a domain having 3′ to 5′ exonuclease activity, e.g., proof-reading activity. In some embodiments, the writing domain, e.g., RT domain, has 3′ to 5′ exonuclease activity, e.g., proof-reading activity.

In some embodiments, the polypeptide does not comprise an RNase H domain. In some embodiments, the polypeptide comprises an RNaseH domain endogenous to one of the other domains. In some embodiments, the polypeptide comprises an RNase H domain that is heterologous to the other domains. In some embodiments, the polypeptide comprises an inactivated endogenous RNaseH domain.

In some embodiments, a Gene Writer as described herein comprises a polypeptide associated with a guide RNA (gRNA). In certain embodiments, the gRNA is comprised in the template nucleic acid molecule. In other embodiments, the gRNA is separate from the template nucleic acid molecule. In some embodiments wherein the gRNA is comprised in the template nucleic acid molecule, the template nucleic acid molecule further comprises a gRNA spacer sequence (e.g., at or within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides of its 5′ end). In embodiments, the gRNA spacer comprises a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a nucleic acid sequence comprised in the target nucleic acid molecule. In embodiments, the gRNA spacer directs Cas domain (e.g., Cas9) activity at the nucleic acid sequence comprised in the target nucleic acid molecule. In some embodiments wherein the gRNA is comprised in the template nucleic acid molecule, the template nucleic acid molecule further comprises a primer binding site (e.g., at or within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides of its 3′ end). In embodiments, the primer binding site comprises a nucleic acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a nucleic acid sequence positioned at the 5′ end (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, or 50 nucleotides) of a nick site on the target nucleic acid molecule. In embodiments, binding of the primer binding site to the target nucleic acid molecule operates to prime TPRT.

Template Nucleic Acid Component of Gene Writer™ Gene Editor System

The Gene Writer™ systems described herein can modify a host target DNA site using a template nucleic acid sequence. In some embodiments, the Gene Writer™ systems described herein transcribe an RNA sequence template into host target DNA sites by target-primed reverse transcription (TPRT). By writing DNA sequence(s) via reverse transcription of the RNA sequence template directly into the host genome, the Gene Writer™ system can insert an object sequence into a target genome without the need for exogenous DNA sequences to be introduced into the host cell (unlike, for example, CRISPR systems), as well as eliminate an exogenous DNA insertion step. The Gene Writer™ system can also delete a sequence from the target genome or introduce a substitution using an object sequence. Therefore, the Gene Writer™ system provides a platform for the use of customized RNA sequence templates containing object sequences, e.g., sequences comprising heterologous gene coding and/or function information.

In some embodiments, a Gene Writer system comprises a template nucleic acid (e.g., RNA or DNA) molecule. In some embodiments, the template nucleic acid molecule comprises a 5′ homology region and/or a 3′ homology region. In some embodiments, the 5′ homology region comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity with a nucleic acid sequence comprised in a target nucleic acid molecule. In embodiments, the nucleic acid sequence in the target nucleic acid molecule is within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 nucleotides of (e.g., 5′ relative to) a target insertion site, e.g., for a heterologous object sequence, e.g., comprised in the template nucleic acid molecule.

In some embodiments, the 3′ homology region comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a nucleic acid sequence comprised in a target nucleic acid molecule. In embodiments, the nucleic acid sequence in the target nucleic acid molecule is within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 nucleotides of (e.g., 3′ relative to) a target insertion site, e.g., for a heterologous object sequence, e.g., comprised in the template nucleic acid molecule. In some embodiments, the 5′ homology region is heterologous to the remainder of the template nucleic acid molecule. In some embodiments, the 3′ homology region is heterologous to the remainder of the template nucleic acid molecule.

In some embodiments, a template nucleic acid (e.g., template RNA) comprises a 3′ target homology domain. In some embodiments, a 3′ target homology domain is disposed 3′ of the heterologous object sequence and is complementary to a sequence adjacent to a site to be modified by a system described herein, or comprises no more than 1, 2, 3, 4, or 5 mismatches to a sequence complementary to the sequence adjacent to a site to be modified by the system/Gene Writer™. In some embodiments, the 3′ homology region binds within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides of a nick site in the target nucleic acid molecule. In some embodiments, binding of the 3′ homology region to the target nucleic acid molecule permits initiation of target-primed reverse transcription (TPRT), e.g., with the 3′ homology region acting as a primer for TPRT. In some embodiments, the 3′ target homology domain anneals to the target site, which provides a binding site and the 3′ hydroxyl for the initiation of TPRT by a Gene Writer polypeptide. In some embodiments, the 3′ target homology domain is 3-5, 5-10, 10-30, 10-25, 10-20, 10-19, 10-18, 10-17, 10-16, 10-15, 10-14, 10-13, 10-12, 10-11, 11-30, 11-25, 11-20, 11-19, 11-18, 11-17, 11-16, 11-15, 11-14, 11-13, 11-12, 12-30, 12-25, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 12-14, 12-13, 13-30, 13-25, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 13-14, 14-30, 14-25, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, 15-30, 15-25, 15-20, 15-19, 15-18, 15-17, 15-16, 16-30, 16-25, 16-20, 16-19, 16-18, 16-17, 17-30, 17-25, 17-20, 17-19, 17-18, 18-30, 18-25, 18-20, 18-19, 19-30, 19-25, 19-20, 20-30, 20-25, or 25-30 nt in length, e.g., 10-17, 12-16, or 12-14 nt in length.

In some embodiments, a template nucleic acid (e.g., template RNA) comprises a heterologous object sequence. In some embodiments, the heterologous object sequence may be transcribed by the RT domain of a Gene Writer™ polypeptide, e.g., thereby introducing an alteration into a target site in genomic DNA. In some embodiments, the heterologous object sequence is at least 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 120, 140, 160, 180, 200, 500, or 1,000 nucleotides (nts) in length, or at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 kilobases in length. In some embodiments, the heterologous object sequence is no more than 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 120, 140, 160, 180, 200, 500, 1,000, or 2000 nucleotides (nts) in length, or no more than 20, 15, 10, 9, 8, 7, 6, 5, 4, or 3 kilobases in length. In some embodiments, the heterologous object sequence is 30-1000, 40-1000, 50-1000, 60-1000, 70-1000, 74-1000, 75-1000, 76-1000, 77-1000, 78-1000, 79-1000, 80-1000, 85-1000, 90-1000, 100-1000, 120-1000, 140-1000, 160-1000, 180-1000, 200-1000, 500-1000, 30-500, 40-500, 50-500, 60-500, 70-500, 74-500, 75-500, 76-500, 77-500, 78-500, 79-500, 80-500, 85-500, 90-500, 100-500, 120-500, 140-500, 160-500, 180-500, 200-500, 30-200, 40-200, 50-200, 60-200, 70-200, 74-200, 75-200, 76-200, 77-200, 78-200, 79-200, 80-200, 85-200, 90-200, 100-200, 120-200, 140-200, 160-200, 180-200, 30-100, 40-100, 50-100, 60-100, 70-100, 74-100, 75-100, 76-100, 77-100, 78-100, 79-100, 80-100, 85-100, or 90-100 nucleotides (nts) in length, or 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-20, 2-15, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-20, 3-15, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-20, 4-15, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-20, 5-15, 5-10, 5-9, 5-8, 5-7, 5-6, 6-20, 6-15, 6-10, 6-9, 6-8, 6-7, 7-20, 7-15, 7-10, 7-9, 7-8, 8-20, 8-15, 8-10, 8-9, 9-20, 9-15, 9-10, 10-15, 10-20, or 15-20 kilobases in length. In some embodiments, the heterologous object sequence is 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, or 10-20 nt in length, e.g., 10-80, 10-50, or 10-20 nt in length, e.g., about 10-20 nt in length. In some embodiments, a template RNA comprises a sequence as listed in Table 43, or a sequence with at lest 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto.

In certain embodiments, the template nucleic acid comprises a customized RNA sequence template which can be identified, designed, engineered and constructed to contain sequences altering or specifying host genome function, for example by introducing a heterologous coding region into a genome; affecting or causing exon structure/alternative splicing; causing disruption of an endogenous gene; causing transcriptional activation of an endogenous gene; causing epigenetic regulation of an endogenous DNA; causing up- or down-regulation of operably liked genes, etc. In certain embodiments, a customized RNA sequence template can be engineered to contain sequences coding for exons and/or transgenes, provide for binding sites to transcription factor activators, repressors, enhancers, etc., and combinations of thereof. In other embodiments, the coding sequence can be further customized with splice acceptor sites, poly-A tails. In certain embodiments the RNA sequence can contain sequences coding for an RNA sequence template homologous to the RLE retrotransposase, be engineered to contain heterologous coding sequences, or combinations thereof.

The template nucleic acid (e.g., template RNA) may have some homology to the target DNA. In some embodiments, the template nucleic acid (e.g., template RNA) 3′ target homology domain may serve as an annealing region to the target DNA, such that the target DNA is positioned to prime the reverse transcription of the template nucleic acid (e.g., template RNA). In some embodiments the template nucleic acid (e.g., template RNA) has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175, 200 or more bases of exact homology to the target DNA at the 3′ end of the RNA. In some embodiments the template nucleic acid (e.g., template RNA) has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 175, 180, or 200 or more bases of at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% homology to the target DNA, e.g., at the 5′ end of the template nucleic acid (e.g., template RNA). In some embodiments the template nucleic acid (e.g., template RNA) has a 3′ region of at least 10, 15, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200 or more bases of at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% homology to the 3′ sequence of a non-LTR retrotransposon, e.g., a non-LTR retrotransposon described herein, e.g. a non-LTR retrotransposon in Table 1 or 3.

The template nucleic acid (e.g., template RNA) component of a Gene Writer™ genome editing system described herein typically is able to bind the Gene Writer™ genome editing protein of the system. In some embodiments the template nucleic acid (e.g., template RNA) has a 3′ region that is capable of binding a Gene Writer™ genome editing protein. The binding region, e.g., 3′ region, may be a structured RNA region, e.g., having at least 1, 2 or 3 hairpin loops, capable of binding the Gene Writer™ genome editing protein of the system. The binding region may associate the template nucleic acid (e.g., template RNA) with any of the polypeptide modules. In some embodiments, the binding region of the template nucleic acid (e.g., template RNA) may associate with an RNA-binding domain in the polypeptide. In some embodiments, the binding region of the template nucleic acid (e.g., template RNA) may associate with the reverse transcription domain of the polypeptide (e.g., specifically bind to the RT domain). For example, where the reverse transcription domain is derived from a non-LTR retrotransposon, the template nucleic acid (e.g., template RNA) may contain a binding region derived from a non-LTR retrotransposon, e.g., a 3′ UTR from a non-LTR retrotransposon. In some embodiments, the template nucleic acid (e.g., template RNA) may associate with the DNA binding domain of the polypeptide, e.g., a gRNA associating with a Cas9-derived DNA binding domain. In some embodiments, the binding region may also provide DNA target recognition, e.g., a gRNA hybridizing to the target DNA sequence and binding the polypeptide, e.g., a Cas9 domain. In some embodiments, the template nucleic acid (e.g., template RNA) may associate with multiple components of the polypeptide, e.g., DNA binding domain and reverse transcription domain. For example, the template nucleic acid (e.g., template RNA) may comprise a gRNA region that associates with a Cas9-derived DNA binding domain and a 3′ UTR from a non-LTR retrotransposon that associated with a non-LTR retrotransposon-derived reverse transcription domain.

In some embodiments the template RNA has a poly-A tail at the 3′ end. In some embodiments the template RNA does not have a poly-A tail at the 3′ end. In some embodiments the template nucleic acid (e.g., template RNA) has a 5′ region of at least 10, 15, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200 or more bases of at least 40%, 50%, 60%, 70%, 80%, 90%, 95% or greater homology to the 5′ sequence of a non-LTR retrotransposon, e.g., a non-LTR retrotransposon described herein.

The template nucleic acid (e.g., template RNA) of the system typically comprises an object sequence (e.g., a heterologous object sequence) for insertion into a target DNA. The object sequence may be coding or non-coding.

In some embodiments a system or method described herein comprises a single template nucleic acid (e.g., template RNA). In some embodiments a system or method described herein comprises a plurality of template nucleic acids (e.g., template RNAs). For example, a system described herein comprises a first RNA comprising (e.g., from 5′ to 3′) a sequence that binds the Gene Writer™ polypeptide (e.g., the DNA-binding domain and/or the endonuclease domain, e.g., a gRNA) and a sequence that binds a target site (e.g., a second strand of a site in a target genome), and a second RNA (e.g., a template RNA) comprising (e.g., from 5′ to 3′) optionally a sequence that binds the Gene Writer™ polypeptide (e.g., that specifically binds the RT domain), a heterologous object sequence, and a 3′ target homology domain. In some embodiments, when the system comprises a plurality of nucleic acids, each nucleic acid comprises a conjugating domain. In some embodiments, a conjugating domain enables association of nucleic acid molecules, e.g., by hybridization of complementary sequences. For example, in some embodiments a first RNA comprises a first conjugating domain and a second RNA comprises a second conjugating domain, and the first and second conjugating domains are capable of hybridizing to one another, e.g., under stringent conditions. In some embodiments, the stringent conditions for hybridization include hybridization in 4×sodium chloride/sodium citrate (SSC), at about 65° C., followed by a wash in 1×SSC, at about 65° C.

In some embodiments, the object sequence may contain an open reading frame. In some embodiments the template nucleic acid (e.g., template RNA) has a Kozak sequence. In some embodiments the template RNA has an internal ribosome entry site. In some embodiments the template RNA has a self-cleaving peptide such as a T2A or P2A site. In some embodiments the template RNA has a start codon. In some embodiments the template RNA has a splice acceptor site. In some embodiments the template RNA has a splice donor site. Exemplary splice acceptor and splice donor sites are described in WO2016044416, incorporated herein by reference in its entirety. Exemplary splice acceptor site sequences are known to those of skill in the art and include, by way of example only, CTGACCCTTCTCTCTCTCCCCCAGAG (SEQ ID NO: 1601) (from human HBB gene) and TTTCTCTCCCACAAG (SEQ ID NO: 1602) (from human immunoglobulin-gamma gene). In some embodiments the template RNA has a microRNA binding site downstream of the stop codon. In some embodiments the template RNA has a polyA tail downstream of the stop codon of an open reading frame. In some embodiments the template RNA comprises one or more exons. In some embodiments the template RNA comprises one or more introns. In some embodiments the template RNA comprises a eukaryotic transcriptional terminator. In some embodiments the template RNA comprises an enhanced translation element or a translation enhancing element. In some embodiments the RNA comprises the human T-cell leukemia virus (HTLV-1) R region. In some embodiments the RNA comprises a posttranscriptional regulatory element that enhances nuclear export, such as that of Hepatitis B Virus (HPRE) or Woodchuck Hepatitis Virus (WPRE).

In some embodiments, a nucleic acid described herein (e.g., a template RNA or a DNA encoding a template RNA) comprises a microRNA binding site. In some embodiments, the microRNA binding site is used to increase the target-cell specificity of a Gene Writer™ system. For instance, the microRNA binding site can be chosen on the basis that is recognized by a miRNA that is present in a non-target cell type, but that is not present (or is present at a reduced level relative to the non-target cell) in a target cell type. Thus, when the template RNA is present in a non-target cell, it would be bound by the miRNA, and when the template RNA is present in a target cell, it would not be bound by the miRNA (or bound but at reduced levels relative to the non-target cell). While not wishing to be bound by theory, binding of the miRNA to the template RNA may interfere with its activity, e.g., may interfere with insertion of the heterologous object sequence into the genome. Accordingly, the system would edit the genome of target cells more efficiently than it edits the genome of non-target cells, e.g., the heterologous object sequence would be inserted into the genome of target cells more efficiently than into the genome of non-target cells, or an insertion or deletion is produced more efficiently in target cells than in non-target cells. A system having a microRNA binding site in the template RNA (or DNA encoding it) may also be used in combination with a nucleic acid encoding a Gene Writer™ polypeptide, wherein expression of the Gene Writer™ polypeptide is regulated by a second microRNA binding site, e.g., as described herein, e.g., in the section entitled “Polypeptide component of Gene Writer™ gene editor system”. In some embodiments, e.g., for liver indications, a miRNA is selected from Table 4 of WO2020014209, incorporated herein by reference.

In some embodiments, the object sequence may contain a non-coding sequence. For example, the template nucleic acid (e.g., template RNA) may comprise a regulatory element, e.g., a promoter or enhancer sequence or miRNA binding site. In some embodiments, integration of the object sequence at a target site will result in upregulation of an endogenous gene. In some embodiments, integration of the object sequence at a target site will result in downregulation of an endogenous gene. In some embodiments the template nucleic acid (e.g., template RNA) comprises a tissue specific promoter or enhancer, each of which may be unidirectional or bidirectional. In some embodiments the promoter is an RNA polymerase I promoter, RNA polymerase II promoter, or RNA polymerase III promoter. In some embodiments the promoter comprises a TATA element. In some embodiments the promoter comprises a B recognition element. In some embodiments the promoter has one or more binding sites for transcription factors.

In some embodiments, a nucleic acid described herein (e.g., a template RNA or a DNA encoding a template RNA) comprises a promoter sequence, e.g., a tissue specific promoter sequence. In some embodiments, the tissue-specific promoter is used to increase the target-cell specificity of a Gene Writer™ system. For instance, the promoter can be chosen on the basis that it is active in a target cell type but not active in (or active at a lower level in) a non-target cell type. Thus, even if the promoter integrated into the genome of a non-target cell, it would not drive expression (or only drive low level expression) of an integrated gene. A system having a tissue-specific promoter sequence in the template RNA may also be used in combination with a microRNA binding site, e.g., in the template RNA or a nucleic acid encoding a Gene Writer™ protein, e.g., as described herein. A system having a tissue-specific promoter sequence in the template RNA may also be used in combination with a DNA encoding a Gene Writer™ polypeptide, driven by a tissue-specific promoter, e.g., to achieve higher levels of Gene Writer™ protein in target cells than in non-target cells. In some embodiments, e.g., for liver indications, a tissue-specific promoter is selected from Table 3 of WO2020014209, incorporated herein by reference.

In some embodiments, a Gene Writer system, e.g., DNA encoding a Gene Writer polypeptide, DNA encoding a template RNA, or DNA or RNA encoding a heterologous object sequence, is designed such that one or more elements is operably linked to a tissue-specific promoter, e.g., a promoter that is active in T-cells. In further embodiments, the T-cell active promoter is inactive in other cell types, e.g., B-cells, NK cells. In some embodiments, the T-cell active promoter is derived from a promoter for a gene encoding a component of the T-cell receptor, e.g., TRAC, TRBC, TRGC, TRDC. In some embodiments, the T-cell active promoter is derived from a promoter for a gene encoding a component of a T-cell-specific cluster of differentiation protein, e.g., CD3, e.g., CD3D, CD3E, CD3G, CD3Z. In some embodiments, T-cell-specific promoters in Gene Writer systems are discovered by comparing publicly available gene expression data across cell types and selecting promoters from the genes with enhanced expression in T-cells. In some embodiments, promoters may be selecting depending on the desired expression breadth, e.g., promoters that are active in T-cells only, promoters that are active in NK cells only, promoters that are active in both T-cells and NK cells.

In some embodiments the template RNA comprises a microRNA sequence, a siRNA sequence, a guide RNA sequence, a piwi RNA sequence.

In some embodiments the template nucleic acid (e.g., template RNA) comprises a site that coordinates epigenetic modification. In some embodiments the template nucleic acid (e.g., template RNA) comprises a chromatin insulator. For example, the template nucleic acid (e.g., template RNA) comprises a CTCF site or a site targeted for DNA methylation.

In some embodiments the template nucleic acid (e.g., template RNA) comprises a gene expression unit composed of at least one regulatory region operably linked to an effector sequence. The effector sequence may be a sequence that is transcribed into RNA (e.g., a coding sequence or a non-coding sequence such as a sequence encoding a micro RNA).

In some embodiments the object sequence of the template nucleic acid (e.g., template RNA) is inserted into a target genome in an endogenous intron. In some embodiments the object sequence of the template nucleic acid (e.g., template RNA) is inserted into a target genome and thereby acts as a new exon. In some embodiments the insertion of the object sequence into the target genome results in replacement of a natural exon or the skipping of a natural exon.

In some embodiments, the object sequence of the template nucleic acid (e.g., template RNA) is inserted into the target genome in a genomic safe harbor site, such as AAVS1, CCR5, ROSA26, or albumin locus. In some embodiments, a Gene Writer is used to integrate a CAR into the T-cell receptor a constant (TRAC) locus (Eyquem et al Nature 543, 113-117 (2017)). In some embodiments, a Gene Writer is used to integrate a CAR into a T-cell receptor R constant (TRBC) locus. Many other safe harbors have been identified by computational approaches (Pellenz et al Hum Gen Ther 30, 814-828 (2019)) and could be used for Gene Writer-mediated integration. In some embodiments, the object sequence of the template nucleic acid (e.g., template RNA) is added to the genome in an intergenic or intragenic region. In some embodiments, the object sequence of the template nucleic acid (e.g., template RNA) is added to the genome 5′ or 3′ within 0.1 kb, 0.25 kb, 0.5 kb, 0.75, kb, 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 7.5 kb, 10 kb, 15 kb, 20 kb, 25 kb, 50, 75 kb, or 100 kb of an endogenous active gene. In some embodiments, the object sequence of the template nucleic acid (e.g., template RNA) is added to the genome 5′ or 3′ within 0.1 kb, 0.25 kb, 0.5 kb, 0.75, kb, 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 7.5 kb, 10 kb, 15 kb, 20 kb, 25 kb, 50, 75 kb, or 100 kb of an endogenous promoter or enhancer. In some embodiments, the object sequence of the template nucleic acid (e.g., template RNA) can be, e.g., 50-50,000 base pairs (e.g., between 50-40,000 bp, between 500-30,000 bp between 500-20,000 bp, between 100-15,000 bp, between 500-10,000 bp, between 50-10,000 bp, between 50-5,000 bp.

The template nucleic acid (e.g., template RNA) can be designed to result in insertions, mutations, or deletions at the target DNA locus. In some embodiments, the template nucleic acid (e.g., template RNA) may be designed to cause an insertion in the target DNA. For example, the template nucleic acid (e.g., template RNA) may contain a heterologous sequence, wherein the reverse transcription will result in insertion of the heterologous sequence into the target DNA. In other embodiments, the RNA template may be designed to write a deletion into the target DNA. For example, the template nucleic acid (e.g., template RNA) may match the target DNA upstream and downstream of the desired deletion, wherein the reverse transcription will result in the copying of the upstream and downstream sequences from the template nucleic acid (e.g., template RNA) without the intervening sequence, e.g., causing deletion of the intervening sequence. In other embodiments, the template nucleic acid (e.g., template RNA) may be designed to write an edit into the target DNA. For example, the template RNA may match the target DNA sequence with the exception of one or more nucleotides, wherein the reverse transcription will result in the copying of these edits into the target DNA, e.g., resulting in mutations, e.g., transition or transversion mutations.

In some embodiments, the template possesses one or more sequences aiding in association of the template with the Gene Writer™ polypeptide. In some embodiments, these sequences may be derived from retrotransposon UTRs. In some embodiments, the UTRs may be located flanking the desired insertion sequence. In some embodiments, a sequence with target site homology may be located outside of one or both UTRs. In some embodiments, the sequence with target site homology can anneal to the target sequence to prime reverse transcription. In some embodiments, the 5′ and/or 3′ UTR may be located terminal to the target site homology sequence, e.g., such that target primed reverse transcription excludes reverse transcription of the 5′ and/or 3′ UTR. In some embodiments, the Gene Writer™ system may result in the insertion of a desired payload without any additional sequence (e.g. gene expression unit without UTRs used to bind the Gene Writer™ protein).

Alternative orientations of the template RNA motifs can be employed, e.g., to limit target site integration to the desired genetic payload. In some embodiments, the polypeptide association domains may be located 5′ of the desired template sequence. For example, the heterologous object sequence may be located downstream of the 5′ UTR and 3′ UTR, giving the 5′-3′ orientation 5′UTR-3′UTR-(heterologous object sequence). In other embodiments, only the 3′ UTR is added upstream of the heterologous object sequence. For example, giving the 5′-3′ orientation 3′UTR-(heterologous object sequence). In certain embodiments, the polypeptide coding region and the heterologous object sequence may be encoded on the same molecule, but where the 5′ UTR (e.g., 5′ UTR from R2 retrotransposon) occurs between the two regions, e.g., giving the 5′-3′ orientation (polypeptide coding sequence)-5′UTR-(heterologous object sequence).

In some embodiments, the template nucleic acid, e.g., template RNA, may comprise a gRNA (e.g., pegRNA). In some embodiments, the template nucleic acid, e.g., template RNA, may bind to the Gene Writer™ polypeptide by interaction of a gRNA portion of the template nucleic acid with a template nucleic acid binding domain, e.g., a RNA binding domain (e.g., a heterologous RNA binding domain). In some embodiments, the heterologous RNA binding domain is a CRISPR/Cas protein, e.g., Cas9.

In some embodiments, the region of the template nucleic acid, e.g., template RNA, comprising the gRNA adopts an underwound ribbon-like structure of gRNA bound to target DNA (e.g., as described in Mulepati et al. Science 19 Sep. 2014:Vol. 345, Issue 6203, pp. 1479-1484). Without wishing to be bound by theory, this non-canonical structure is thought to be facilitated by rotation of every sixth nucleotide out of the RNA-DNA hybrid. Thus, in some embodiments, the region of the template nucleic acid, e.g., template RNA, comprising the gRNA may tolerate increased mismatching with the target site at some interval, e.g., every sixth base. In some embodiments, the region of the template nucleic acid, e.g., template RNA, comprising the gRNA comprising homology to the target site may possess wobble positions at a regular interval, e.g., every sixth base, that do not need to base pair with the target site.

gRNAs with Inducible Activity

In some embodiments, a template nucleic acid, e.g., template RNA, comprises a gRNA with inducible activity. Inducible activity may be achieved by the template nucleic acid, e.g., template RNA, further comprising (in addition to the gRNA) a blocking domain, wherein the sequence of a portion of or all of the blocking domain is at least partially complementary to a portion or all of the gRNA. The blocking domain is thus capable of hybridizing or substantially hybridizing to a portion of or all of the gRNA. In some embodiments, the blocking domain and inducibly active gRNA are disposed on the template nucleic acid, e.g., template RNA, such that the gRNA can adopt a first conformation where the blocking domain is hybridized or substantially hybridized to the gRNA, and a second conformation where the blocking domain is not hybridized or not substantially hybridized to the gRNA. In some embodiments, in the first conformation the gRNA is unable to bind to the Gene Writer polypeptide (e.g., the template nucleic acid binding domain, DNA binding domain, or endonuclease domain (e.g., a CRISPR/Cas protein)) or binds with substantially decreased affinity compared to an otherwise similar template RNA lacking the blocking domain. In some embodiments, in the second conformation the gRNA is able to bind to the Gene Writer polypeptide (e.g., the template nucleic acid binding domain, DNA binding domain, or endonuclease domain (e.g., a CRISPR/Cas protein)). In some embodiments, whether the gRNA is in the first or second conformation can influence whether the DNA binding or endonuclease activities of the Gene Writer polypeptide (e.g., of the CRISPR/Cas protein the Gene Writer polypeptide comprises) are active. In some embodiments, hybridization of the gRNA to the blocking domain can be disrupted using an opener molecule. In some embodiments, an opener molecule comprises an agent that binds to a portion or all of the gRNA or blocking domain and inhibits hybridization of the gRNA to the blocking domain. In some embodiments, the opener molecule comprises a nucleic acid, e.g., comprising a sequence that is partially or wholly complementary to the gRNA, blocking domain, or both. By choosing or designing an appropriate opener molecule, providing the opener molecule can promote a change in the conformation of the gRNA such that it can associate with a CRISPR/Cas protein and provide the associated functions of the CRISPR/Cas protein (e.g., DNA binding and/or endonuclease activity). Without wishing to be bound by theory, providing the opener molecule at a selected time and/or location may allow for spatial and temporal control of the activity of the gRNA, CRISPR/Cas protein, or Gene Writer system comprising the same. In some embodiments, a Gene Writer may comprise a Cas protein as listed in Table 40 or Table 37 or a functional fragment thereof, or a sequence having at least 70%, 75% 80%, 85%, 90%, 95% 96%, 97% 98%, 99% identity thereto.

TABLE 40 CRISPR/Cas Proteins, Species, and Mutations SEQ Parental ID Nickase Variant Host NO: Protein Sequence Mutation Nme2Cas9 Neisseria 3262 MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLID N611A meningitidis LGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLL RARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDR KLTPLEWSAVLGDYSHTFSRKDLQAELILLFEKQKEFGNP HVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEP KAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATL MDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEAS TLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTA FSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLP PIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIET AREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFV GEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVE IDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNG KDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKEC NLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNL LRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFV RYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMI RVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYV TPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVW LTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQ AFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTI ADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPD IDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYI NCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNE LGKEIRPCRLKKRPPVR PpnCas9 Pasteurella 3263 MQNNPLNYILGLDLGIASIGWAVVEIDEESSPIRLIDVGV N605A pneumotropica RTFERAEVAKTGESLALSRRLARSSRRLIKRRAERLKKAK RLLKAEKILHSIDEKLPINVWQLRVKGLKEKLERQEWAAV LLHLSKHRGYLSQRKNEGKSDNKELGALLSGIASNHQMLQ SSEYRTPAEIAVKKFQVEEGHIRNQRGSYTHTFSRLDLLA EMELLFQRQAELGNSYTSTTLLENLTALLMWQKPALAGDA ILKMLGKCTFEPSEYKAAKNSYSAERFVWLTKLNNLRILE NGTERALNDNERFALLEQPYEKSKLTYAQVRAMLALSDNA IFKGVRYLGEDKKTVESKTTLIEMKFYHQIRKTLGSAELK KEWNELKGNSDLLDEIGTAFSLYKTDDDICRYLEGKLPER VLNALLENLNFDKFIQLSLKALHQILPLMLQGQRYDEAVS AIYGDHYGKKSTETTRLLPTIPADEIRNPVVLRTLTQARK VINAVVRLYGSPARIHIETAREVGKSYQDRKKLEKQQEDN RKQRESAVKKFKEMFPHFVGEPKGKDILKMRLYELQQAKC LYSGKSLELHRLLEKGYVEVDHALPFSRTWDDSFNNKVLV LANENQNKGNLTPYEWLDGKNNSERWQHFVVRVQTSGFSY AKKQRILNHKLDEKGFIERNLNDTRYVARFLCNFIADNML LVGKGKRNVFASNGQITALLRHRWGLQKVREQNDRHHALD AVVVACSTVAMQQKITRFVRYNEGNVFSGERIDRETGEII PLHFPSPWAFFKENVEIRIFSENPKLELENRLPDYPQYNH EWVQPLFVSRMPTRKMTGQGHMETVKSAKRLNEGLSVLKV PLTQLKLSDLERMVNRDREIALYESLKARLEQFGNDPAKA FAEPFYKKGGALVKAVRLEQTQKSGVLVRDGNGVADNASM VRVDVFTKGGKYFLVPIYTWQVAKGILPNRAATQGKDEND WDIMDEMATFQFSLCQNDLIKLVTKKKTIFGYFNGLNRAT SNINIKEHDLDKSKGKLGIYLEVGVKLAISLEKYQVDELG KNIRPCRPTKRQHVR SauCas9 Staphylococcus 3264 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKK DGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYF PEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEK FQUIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGK PEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQS SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAI NLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTL VDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAR EKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYL IEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIP RSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKIS YETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKD FINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGF TSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKK LDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQI KHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTL IVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKL KLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKI KYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDN GVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQA EFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDIT YREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYE VKSKKHPQIIKKG SauCas9- Staphylococcus 3265 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A KKH aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKK DGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYF PEELRSVKYAYNADLYNALNVYHDIKDITARKEIIENAEL LDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLK GYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKK VDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKK YGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEE IIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLL NNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRT PFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLL EERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALI IANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETE QEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDT LYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKL LMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTK YSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKL SLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCY EEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNND LLNRIEVNMIDITYREYLENMNDKRPPHIIKTIASKTQSI KKYSTDILGNLYEVKSKKHPQIIKKG SauriCas9 Staphylococcus 3266 MQENQQKQNYILGLDIGITSVGYGLIDSKTREVIDAGVRL N588A auricularis FPEADSENNSNRRSKRGARRLKRRRIHRLNRVKDLLADYQ MIDLNNVPKSTDPYTIRVKGLREPLTKEEFAIALLHIAKR RGLHNISVSMGDEEQDNELSTKQQLQKNAQQLQDKYVCEL QLERLTNINKVRGEKNRFKTEDFVKEVKQLCETQRQYHNI DDQFIQQYIDLVSTRREYFEGPGNGSPYGWDGDLLKWYEK LMGRCTYFPEELRSVKYAYSADLFNALNDLNNLVVTRDDN PKLEYYEKYHIIENVFKQKKNPTLKQIAKEIGVQDYDIRG YRITKSGKPQFTSFKLYHDLKNIFEQAKYLEDVEMLDEIA KILTIYQDEISIKKALDQLPELLTESEKSQIAQLTGYTGT HRLSLKCIHIVIDELWESPENQMEIFTRLNLKPKKVEMSE IDSIPTTLVDEFILSPVVKRAFIQSIKVINAVINRFGLPE DIIIELAREKNSKDRRKFINKLQKQNEATRKKIEQLLAKY GNTNAKYMIEKIKLHDMQEGKCLYSLEAIPLEDLLSNPTH YEVDHIIPRSVSFDNSLNNKVLVKQSENSKKGNRTPYQYL SSNESKISYNQFKQHILNLSKAKDRISKKKRDMLLEERDI NKFEVQKEFINRNLVDTRYATRELSNLLKTYFSTHDYAVK VKTINGGFTNHLRKVWDFKKHRNHGYKHHAEDALVIANAD FLFKTHKALRRTDKILEQPGLEVNDTTVKVDTEEKYQELF ETPKQVKNIKQFRDFKYSHRVDKKPNRQLINDTLYSTREI DGETYVVQTLKDLYAKDNEKVKKLFTERPQKILMYQHDPK TFEKLMTILNQYAEAKNPLAAYYEDKGEYVTKYAKKGNGP AIHKIKYIDKKLGSYLDVSNKYPETQNKLVKLSLKSFRFD IYKCEQGYKMVSIGYLDVLKKDNYYYIPKDKYEAEKQKKK IKESDLFVGSFYYNDLIMYEDELFRVIGVNSDINNLVELN MVDITYKDFCEVNNVTGEKRIKKTIGKRVVLIEKYTTDIL GNLYKTPLPKKPQLIFKRGEL SauriCas9 Staphylococcus 3267 MQENQQKQNYILGLDIGITSVGYGLIDSKTREVIDAGVRL N588A -KKH auricularis FPEADSENNSNRRSKRGARRLKRRRIHRLNRVKDLLADYQ MIDLNNVPKSTDPYTIRVKGLREPLTKEEFAIALLHIAKR RGLHNISVSMGDEEQDNELSTKQQLQKNAQQLQDKYVCEL QLERLTNINKVRGEKNRFKTEDFVKEVKQLCETQRQYHNI DDQFIQQYIDLVSTRREYFEGPGNGSPYGWDGDLLKWYEK LMGRCTYFPEELRSVKYAYSADLFNALNDLNNLVVTRDDN PKLEYYEKYHIIENVFKQKKNPTLKQIAKEIGVQDYDIRG YRITKSGKPQFTSFKLYHDLKNIFEQAKYLEDVEMLDEIA KILTIYQDEISIKKALDQLPELLTESEKSQIAQLTGYTGT HRLSLKCIHIVIDELWESPENQMEIFTRLNLKPKKVEMSE IDSIPTTLVDEFILSPVVKRAFIQSIKVINAVINRFGLPE DIIIELAREKNSKDRRKFINKLQKQNEATRKKIEQLLAKY GNTNAKYMIEKIKLHDMQEGKCLYSLEAIPLEDLLSNPTH YEVDHIIPRSVSFDNSLNNKVLVKQSENSKKGNRTPYQYL SSNESKISYNQFKQHILNLSKAKDRISKKKRDMLLEERDI NKFEVQKEFINRNLVDTRYATRELSNLLKTYFSTHDYAVK VKTINGGFTNHLRKVWDFKKHRNHGYKHHAEDALVIANAD FLFKTHKALRRTDKILEQPGLEVNDTTVKVDTEEKYQELF ETPKQVKNIKQFRDFKYSHRVDKKPNRKLINDTLYSTREI DGETYVVQTLKDLYAKDNEKVKKLFTERPQKILMYQHDPK TFEKLMTILNQYAEAKNPLAAYYEDKGEYVTKYAKKGNGP AIHKIKYIDKKLGSYLDVSNKYPETQNKLVKLSLKSFRFD IYKCEQGYKMVSIGYLDVLKKDNYYYIPKDKYEAEKQKKK IKESDLFVGSFYKNDLIMYEDELFRVIGVNSDINNLVELN MVDITYKDFCEVNNVTGEKHIKKTIGKRVVLIEKYTTDIL GNLYKTPLPKKPQLIFKRGEL ScaCas9- Streptococcus 3268 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNR N872A Sc++ canis KSIKKNLMGALLFDSGETAEATRLKRTARRRYTRRKNRIR YLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFG NLADEVAYHRNYPTIYHLRKKLADSPEKADLRLIYLALAH IIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEESP LDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGN IIALALGLTPNFKSNFDLTEDAKLQLSKDTYDDDLDELLG QIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSAS MVKRYDEHHQDLALLKTLVRQQFPEKYAEIFKDDTKNGYA GYVGADKKLRKRSGKLATEEEFYKFIKPILEKMDGAEELL AKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFY PFLKENREKIEKILTFRIPYYVGPLARGNSRFAWLTRKSE EAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPK HSLLYEYFTVYNELTKVKYVTERMRKPEFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVEDRFNAS LGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRE MIEERLKTYAHLFDDKVMKQLKRRHYTGWGRLSRKMINGI RDKQSGKTILDFLKSDGFSNRNFMQLIHDDSLTFKEEIEK AQVSGQGDSLHEQIADLAGSPAIKKGILQTVKIVDELVKV MGHKPENIVIEMARENQTTTKGLQQSRERKKRIEEGIKEL ESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDIN RLSDYDVDHIVPQSFIKDDSIDNKVLTRSVENRGKSDNVP SEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEA DKAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR EVKVITLKSKLVSDFRKDFQLYKVRDINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKRFFYSNIMNFFKTEVKLANGEIRKRPLIETNGETGE VVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKESIL SKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEK GKAKKLKSVKVLVGITIMEKGSYEKDPIGFLEAKGYKDIK KELIFKLPKYSLFELENGRRRMLASAKELQKANELVLPQH LVRLLYYTQNISATTGSNNLGYIEQHREEFKEIFEKIIDF SEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLLKY TSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSIT GLYETRTDLSQLGGD SpyCas9 Streptococcus 3269 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3270 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A NG pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDKLI ARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASARFLQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PRAFKYFDTTIDRKVYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3271 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A SpRY pyogenes HSIKKNLIGALLFDSGETAERTRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDKLI ARKKDWDPKKYGGFLWPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAKQLQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTRLGA PRAFKYFDTTIDPKQYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD St1Cas9 Streptococcus 3272 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQA N622A thermophilus ENNLVRRTNRQGRRLARRKKHRRVRLNRLFEESGLITDFT KISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISY LDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQ TYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQ QEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGR YRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNL LNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLE TLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFADGS FSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELY ETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNP VVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEK KAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHK QLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHI LPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFI ERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTS QLRRHWGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNT LVSYSEDQLLDIETGELISDDEYKESVFKAPYQHFVDTLK SKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKA DETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQ TFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYI RKYSKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQ SVSPWRADVYFNKTTGKYEILGLKYADLQFEKGTGTYKIS QEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQQ LFRFLSRTMPKQKHYVELKPYDKQKFEGGEALIKVLGNVA NSGQCKKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKLD F BlatCas9 Brevibacillus 3273 MAYTMGIDVGIASCGWAIVDLERQRIIDIGVRTFEKAENP N607A laterosporus KNGEALAVPRREARSSRRRLRRKKHRIERLKHMFVRNGLA VDIQHLEQTLRSQNEIDVWQLRVDGLDRMLTQKEWLRVLI HLAQRRGFQSNRKTDGSSEDGQVLVNVTENDRLMEEKDYR TVAEMMVKDEKFSDHKRNKNGNYHGVVSRSSLLVEIHTLF ETQRQHHNSLASKDFELEYVNIWSAQRPVATKDQIEKMIG TCTFLPKEKRAPKASWHFQYFMLLQTINHIRITNVQGTRS LNKEEIEQVVNMALTKSKVSYHDTRKILDLSEEYQFVGLD YGKEDEKKKVESKETIIKLDDYHKLNKIFNEVELAKGETW EADDYDTVAYALTFFKDDEDIRDYLQNKYKDSKNRLVKNL ANKEYTNELIGKVSTLSFRKVGHLSLKALRKIIPFLEQGM TYDKACQAAGFDFQGISKKKRSVVLPVIDQISNPVVNRAL TQTRKVINALIKKYGSPETIHIETARELSKTFDERKNITK DYKENRDKNEHAKKHLSELGIINPTGLDIVKYKLWCEQQG RCMYSNQPISFERLKESGYTEVDHIIPYSRSMNDSYNNRV LVMTRENREKGNQTPFEYMGNDTQRWYEFEQRVTTNPQIK KEKRQNLLLKGFTNRRELEMLERNLNDTRYITKYLSHFIS TNLEFSPSDKKKKVVNTSGRITSHLRSRWGLEKNRGQNDL HHAMDAIVIAVTSDSFIQQVTNYYKRKERRELNGDDKFPL PWKFFREEVIARLSPNPKEQIEALPNHFYSEDELADLQPI FVSRMPKRSITGEAHQAQFRRVVGKTKEGKNITAKKTALV DISYDKNGDFNMYGRETDPATYEAIKERYLEFGGNVKKAF STDLHKPKKDGTKGPLIKSVRIMENKTLVHPVNKPNDLIF IRQNPKKKISLKKRIESHSISDSKEVQEIHAYYKGVDSST AAIEFIIHDGSYYAKGVGVQNLDCFEKYQVDILGNYFKVK GEKRLELETSDSNHKGKDVNSIKSTSR cCas9- Staphylococcus 3274 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A v16 aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKK DGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYF PEELRSVKYAYNADLYNALNVYHDIKDITARKEIIENAEL LDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLK GYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKK VDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKK YGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEE IIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLL NNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGNRT PFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLL EERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVN NLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALI IANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETE QEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLINDT LYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKL LMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTK YSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKL SLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCY EEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVNSD KNNLIEVNMIDITYREYLENMNDKRPPHIIKTIASKTQSI KKYSTDILGNLYEVKSKKHPQIIKKG cCas9- Staphylococcus 3275 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A v17 aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNEFIDTYIDLLETRRTYYEGPGEGSPFGWKD IKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNL VITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILV NEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENA ELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISN LKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVP KKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAII KKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERI EEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLED LLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEENSKKGN RTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEY LLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFR VNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDA LIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIE TEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRKLIN DTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPE KLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYL TKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVV KLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSK CYEEAKKLKKISNQAEFIASFYKNDLIKINGELYRVIGVN NSTRNIVELNMIDITYREYLENMNDKRPPHIIKTIASKTQ SIKKYSTDILGNLYEVKSKKHPQIIKKG cCas9- Staphylococcus 3276 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A v21 aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKK DGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYF PEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEK FQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGK PEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQS SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAI NLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTL VDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAR EKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYL IEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIP RSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKIS YETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKD FINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGF TSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKK LDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQI KHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKGNTL IVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKL KLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKI KYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDN GVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQA EFIASFYKNDLIKINGELYRVIGVNSDDRNIIELNMIDIT YREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYE VKSKKHPQIIKKG cCas9- Staphylococcus 3277 MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEAN N580A v42 aureus VENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDH SELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKK DGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDT YIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYF PEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEK FQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGK PEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQS SEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAI NLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTL VDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAR EKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYL IEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIP RSVSFDNSFNNKVLVKQEENSKKGNRTPFQYLSSSDSKIS YETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKD FINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGF TSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKK LDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQI KHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKGNTL IVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKL KLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKI KYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDN GVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQA EFIASFYKNDLIKINGELYRVIGVNNNRLNKIELNMIDIT YREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYE VKSKKHPQIIKKG CdiCas9 Corynebacterium 3278 MKYHVGIDVGTFSVGLAAIEVDDAGMPIKTLSLVSHIHDS H573A diphtheriae GLDPDEIKSAVTRLASSGIARRTRRLYRRKRRRLQQLDKF (Alternat IQRQGWPVIELEDYSDPLYPWKVRAELAASYIADEKERGE e) KLSVALRHIARHRGWRNPYAKVSSLYLPDGPSDAFKAIRE EIKRASGQPVPETATVGQMVTLCELGTLKLRGEGGVLSAR LQQSDYAREIQEICRMQEIGQELYRKIIDVVFAAESPKGS ASSRVGKDPLQPGKNRALKASDAFQRYRIAALIGNLRVRV DGEKRILSVEEKNLVFDHLVNLTPKKEPEWVTIAEILGID RGQLIGTATMTDDGERAGARPPTHDTNRSIVNSRIAPLVD WWKTASALEQHAMVKALSNAEVDDFDSPEGAKVQAFFADL DDDVHAKLDSLHLPVGRAAYSEDTLVRLTRRMLSDGVDLY TARLQEFGIEPSWTPPTPRIGEPVGNPAVDRVLKTVSRWL ESATKTWGAPERVIIEHVREGFVTEKRAREMDGDMRRRAA RNAKLFQEMQEKLNVQGKPSRADLWRYQSVQRQNCQCAYC GSPITFSNSEMDHIVPRAGQGSTNTRENLVAVCHRCNQSK GNTPFAIWAKNTSIEGVSVKEAVERTRHWVTDTGMRSTDF KKFTKAVVERFQRATMDEEIDARSMESVAWMANELRSRVA QHFASHGTTVRVYRGSLTAEARRASGISGKLKFFDGVGKS RLDRRHHAIDAAVIAFTSDYVAETLAVRSNLKQSQAHRQE APQWREFTGKDAEHRAAWRVWCQKMEKLSALLTEDLRDDR VVVMSNVRLRLGNGSAHKETIGKLSKVKLSSQLSVSDIDK ASSEALWCALTREPGFDPKEGLPANPERHIRVNGTHVYAG DNIGLFPVSAGSIALRGGYAELGSSFHHARVYKITSGKKP AFAMLRVYTIDLLPYRNQDLFSVELKPQTMSMRQAEKKLR DALATGNAEYLGWLVVDDELVVDTSKIATDQVKAVEAELG TIRRWRVDGFFSPSKLRLRPLQMSKEGIKKESAPELSKII DRPGWLPAVNKLFSDGNVTVVRRDSLGRVRLESTAHLPVT WKVQ CjeCas9 Campylobacter 3279 MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKT N582A jejuni GESLALPRRLARSARKRLARRKARLNHLKHLIANEFKLNY EDYQSFDESLAKAYKGSLISPYELRFRALNELLSKQDFAR VILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQ SVGEYLYKEYFQKFKENSKEFTNVRNKKESYERCIAQSFL KDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALKDFS HLVGNCSFFTDEKRAPKNSPLAFMFVALTRIINLLNNLKN TEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYE FKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAKDIT LIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNISFKA LKLVTPLMLEGKKYDEACNELNLKVAINEDKKDFLPAFNE TYYKDEVTNPVVLRAIKEYRKVLNALLKKYGKVHKINIEL AREVGKNHSQRAKIEKEQNENYKAKKDAELECEKLGLKIN SKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHI YPYSRSFDDSYMNKVLVFTKQNQEKLNQTPFEAFGNDSAK WQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDT RYIARLVLNYTKDYLDFLPLSDDENTKLNDTQKGSKVHVE AKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVIIAYANNS IVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFS GFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEEFYQ SYGGKEGVLKALELGKIRKVNGKIVKNGDMFRVDIFKHKK TNKFYAVPIYTMDFALKVLPNKAVARSKKGEIKDWILMDE NYEFCFSLYKDSLILIQTKDMQEPEFVYYNAFTSSTVSLI VSKHDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVF EKYIVSALGEVTKAEFRQREDFKK GeoCas9 Geobacillus 3280 MRYKIGLDIGITSVGWAVMNLDIPRIEDLGVRIFDRAENP N605A stearother QTGESLALPRRLARSARRRLRRRKHRLERIRRLVIREGIL mophilus TKEELDKLFEEKHEIDVWQLRVEALDRKLNNDELARVLLH LAKRRGFKSNRKSERSNKENSTMLKHIEENRAILSSYRTV GEMIVKDPKFALHKRNKGENYTNTIARDDLEREIRLIFSK QREFGNMSCTEEFENEYITIWASQRPVASKDDIEKKVGFC TFEPKEKRAPKATYTFQSFIAWEHINKLRLISPSGARGLT DEERRLLYEQAFQKNKITYHDIRTLLHLPDDTYFKGIVYD RGESRKQNENIRFLELDAYHQIRKAVDKVYGKGKSSSFLP IDFDTFGYALTLFKDDADIHSYLRNEYEQNGKRMPNLANK VYDNELIEELLNLSFTKFGHLSLKALRSILPYMEQGEVYS SACERAGYTFTGPKKKQKTMLLPNIPPIANPVVMRALTQA RKVVNAIIKKYGSPVSIHIELARDLSQTFDERRKTKKEQD ENRKKNETAIRQLMEYGLTLNPTGHDIVKFKLWSEQNGRC AYSLQPIEIERLLEPGYVEVDHVIPYSRSLDDSYTNKVLV LTRENREKGNRIPAEYLGVGTERWQQFETFVLTNKQFSKK KRDRLLRLHYDENEETEFKNRNLNDTRYISRFFANFIREH LKFAESDDKQKVYTVNGRVTAHLRSRWEFNKNREESDLHH AVDAVIVACTTPSDIAKVTAFYQRREQNKELAKKTEPHFP QPWPHFADELRARLSKHPKESIKALNLGNYDDQKLESLQP VFVSRMPKRSVTGAAHQETLRRYVGIDERSGKIQTVVKTK LSEIKLDASGHFPMYGKESDPRTYEAIRQRLLEHNNDPKK AFQEPLYKPKKNGEPGPVIRTVKIIDTKNQVIPLNDGKTV AYNSNIVRVDVFEKDGKYYCVPVYTMDIMKGILPNKAIEP NKPYSEWKEMTEDYTFRFSLYPNDLIRIELPREKTVKTAA GEEINVKDVFVYYKTIDSANGGLELISHDHRFSLRGVGSR TLKRFEKYQVDVLGNIYKVRGEKRVGLASSAHSKPGKTIR PLQSTRD iSpyMac Streptococcus 3281 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A Cas9 spp. HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRKLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEIQTVGQNGGLFDDNPKSPLEV TPSKLVPLKKELNPKKYGGYQKPTTAYPVLLITDTKQLIP ISVMNKKQFEQNPVKFLRDRGYQQVGKNDFIKLPKYTLVD IGDGIKRLWASSKEIHKGNQLVVSKKSQILLYHAHHLDSD LSNDYLQNHNQQFDVLFNEIISFSKKCKLGKEHIQKIENV YSNKKNSASIEELAESFIKLLGFTQLGATSPFNFLGVKLN QKQYKGKKDYILPCTEGTLIRQSITGLYETRVDLSKIGED SGGSGGSKRTADGSEFES NmeCas9 Neisseria 3282 MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLID N611A meningitidis LGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLL RTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDR KLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLK GVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYS HTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLM TQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWL TKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRAL EKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLK DRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKR YDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRA LSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIE KRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYE QQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSF NNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVE TSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQF VADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAEND RHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDK ETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEA DTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSG QGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNRER EPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQV KAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYY LVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFS LHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHK IGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPP VR ScaCas9 Streptococcus 3283 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNR N872A canis KSIKKNLMGALLFDSGETAEATRLKRTARRRYTRRKNRIR YLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFG NLADEVAYHRNYPTIYHLRKKLADSPEKADLRLIYLALAH IIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEESP LDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGN IIALALGLTPNFKSNFDLTEDAKLQLSKDTYDDDLDELLG QIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSAS MVKRYDEHHQDLALLKTLVRQQFPEKYAEIFKDDTKNGYA GYVGIGIKHRKRTTKLATQEEFYKFIKPILEKMDGAEELL AKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFY PFLKENREKIEKILTFRIPYYVGPLARGNSRFAWLTRKSE EAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPK HSLLYEYFTVYNELTKVKYVTERMRKPEFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVEDRFNAS LGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRE MIEERLKTYAHLFDDKVMKQLKRRHYTGWGRLSRKMINGI RDKQSGKTILDFLKSDGFSNRNFMQLIHDDSLTFKEEIEK AQVSGQGDSLHEQIADLAGSPAIKKGILQTVKIVDELVKV MGHKPENIVIEMARENQTTTKGLQQSRERKKRIEEGIKEL ESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDIN RLSDYDVDHIVPQSFIKDDSIDNKVLTRSVENRGKSDNVP SEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEA DKAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR EVKVITLKSKLVSDFRKDFQLYKVRDINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKRFFYSNIMNFFKTEVKLANGEIRKRPLIETNGETGE VVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKESIL SKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEK GKAKKLKSVKVLVGITIMEKGSYEKDPIGFLEAKGYKDIK KELIFKLPKYSLFELENGRRRMLASATELQKANELVLPQH LVRLLYYTQNISATTGSNNLGYIEQHREEFKEIFEKIIDF SEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLLKY TSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSIT GLYETRTDLSQLGGD ScaCas9- Streptococcus 3284 MEKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNR N872A HiFi- canis KSIKKNLMGALLFDSGETAEATRLKRTARRRYTRRKNRIR Sc++ YLQEIFANEMAKLDDSFFQRLEESFLVEEDKKNERHPIFG NLADEVAYHRNYPTIYHLRKKLADSPEKADLRLIYLALAH IIKFRGHFLIEGKLNAENSDVAKLFYQLIQTYNQLFEESP LDEIEVDAKGILSARLSKSKRLEKLIAVFPNEKKNGLFGN IIALALGLTPNFKSNFDLTEDAKLQLSKDTYDDDLDELLG QIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSAS MVKRYDEHHQDLALLKTLVRQQFPEKYAEIFKDDTKNGYA GYVGADKKLRKRSGKLATEEEFYKFIKPILEKMDGAEELL AKLNRDDLLRKQRTFDNGSIPHQIHLKELHAILRRQEEFY PFLKENREKIEKILTFRIPYYVGPLARGNSRFAWLTRKSE EAITPWNFEEVVDKGASAQSFIERMTNFDEQLPNKKVLPK HSLLYEYFTVYNELTKVKYVTERMRKPEFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVEDRFNAS LGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRE MIEERLKTYAHLFDDKVMKQLKRRHYTGWGRLSRKMINGI RDKQSGKTILDFLKSDGFSNANFMQLIHDDSLTFKEEIEK AQVSGQGDSLHEQIADLAGSPAIKKGILQTVKIVDELVKV MGHKPENIVIEMARENQTTTKGLQQSRERKKRTEEGIKEL ESQILKENPVENTQLQNEKLYLYYLQNGRDMYVDQELDIN RLSDYDVDHIVPQSFIKDDSIDNKVLTRSVENRGKSDNVP SEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEA DKAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR EVKVITLKSKLVSDFRKDFQLYKVRDINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKRFFYSNIMNFFKTEVKLANGEIRKRPLIETNGETGE VVWNKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKESIL SKRESAKLIPRKKGWDTRKYGGFGSPTVAYSILVVAKVEK GKAKKLKSVKVLVGITIMEKGSYEKDPIGFLEAKGYKDIK KELIFKLPKYSLFELENGRRRMLASAKELQKANELVLPQH LVRLLYYTQNISATTGSNNLGYIEQHREEFKEIFEKIIDF SEKYILKNKVNSNLKSSFDEQFAVSDSILLSNSFVSLLKY TSFGASGGFTFLDLDVKQGRLRYQTVTEVLDATLIYQSIT GLYETRTDLSQLGGD SpyCas9- Streptococcus 3285 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A 3var- pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC NRRH YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MVKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRLRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGGHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDKLI ARKKDWDPKKYGGFNSPTAAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIGFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGVLHKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGV PAAFKYFDTTIDKKRYTSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3286 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A 3var- pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC NRTH YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MVKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRLRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGGHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDKLI ARKKDWDPKKYGGFNSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIGFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASASVLHKGNELALPSKYVNFLYLAS HYEKLKGSSEDNKQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA SAAFKYFDTTIGRKLYTSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3287 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A 3var- pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC NRCH YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MVKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGIIPHQIHLGELHAILRRQGDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRLRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGGHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKGNSDKLI ARKKDWDPKKYGGFNSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGVLQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTINRKQYNTTKEVLDATLIRQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3269 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A HF1 pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPNLGAPAAFKYFDTTIDRKRYTSTKEVLDATL IHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3288 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A QQR1 pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASARELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADAQLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTFKQKQYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3289 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A SpG pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFLWPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAKQLQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3290 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A VOR pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3291 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A VRER pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASARELQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD SpyCas9- Streptococcus 3292 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A xCas pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDTKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKLYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGIIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEK VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGDQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFIQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGVLQKGNELALPSKYVNFLYLAS HYEKLKGSPNLGAPAAFKYFDTTIDRKRYTSTKEVLDATL IHQSITGLYETRIDLSQLGGD SpyCas9- Streptococcus 3293 MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR N863A xCas-NG pyogenes HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDTKLQLSKDTYDDDLDNLLA QIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKLYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGIIPHQIHLGELHAILRRQEDFYPFLKDNREKI EKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEK VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGDQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFIQLIHDDSLTFKEDIQKAQVSGQGDSL HEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDH IVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMK NYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDF ATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDKLI ARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSV KELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASARFLQKGNELALPSKYVNFLYLAS HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PRAFKYFDTTIDRKVYRSTKEVLDATLIHQSITGLYETRI DLSQLGGD St1Cas9- Streptococcus 3294 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQA N622A CNRZ106 thermophilus ENNLVRRTNRQGRRLARRKKHRRVRLNRLFEESGLITDFT 6 KISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISY LDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQ TYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQ QEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGR YRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNL LNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLE TLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFADGS FSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELY ETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNP VVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEK KAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHK QLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHI LPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFI ERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTS QLRRHWGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNT LVSYSEEQLLDIETGELISDDEYKESVFKAPYQHFVDTLK SKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKK DETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQ TFEKVIEPILENYPNKQMNEKGKEVPCNPFLKYKEEHGYI RKYSKKGNGPEIKSLKYYDSKLLGNPIDITPENSKNKVVL QSLKPWRTDVYFNKATGKYEILGLKYADLQFEKGTGTYKI SQEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQ QLFRFLSRTLPKQKHYVELKPYDKQKFEGGEALIKVLGNV ANGGQCIKGLAKSNISIYKVRTDVLGNQHIIKNEGDKPKL DF St1Cas9- Streptococcus 3295 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQA N622A LMG1831 thermophilus ENNLVRRTNRQGRRLARRKKHRRVRLNRLFEESGLITDFT KISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISY LDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQ TYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQ QEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGR YRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNL LNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLE TLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFADGS FSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELY ETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNP VVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEK KAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHK QLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHI LPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFI ERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTS QLRRHWGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNT LVSYSEEQLLDIETGELISDDEYKESVFKAPYQHFVDTLK SKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKK DETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQ TFEKVIEPILENYPNKQMNEKGKEVPCNPFLKYKEEHGYI RKYSKKGNGPEIKSLKYYDSKLLGNPIDITPENSKNKVVL QSLKPWRTDVYFNKNTGKYEILGLKYADLQFEKKTGTYKI SQEKYNGIMKEEGVDSDSEFKFTLYKNDLLLVKDTETKEQ QLFRFLSRTMPNVKYYVELKPYSKDKFEKNESLIEILGSA DKSGRCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKL DF St1Cas9- Streptococcus 3296 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQA N622A MTH17C thermophilus ENNLVRRTNRQGRRLARRKKHRRVRLNRLFEESGLITDFT L396 KISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISY LDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQ TYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQ QEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGR YRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNL LNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLE TLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFADGS FSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELY ETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNP VVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEK KAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHK QLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHI LPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFI ERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTS QLRRHWGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNT LVSYSEDQLLDIETGELISDDEYKESVFKAPYQHFVDTLK SKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKA DETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQ TFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYI RKYSKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQ SLKPWRTDVYFNKNTGKYEILGLKYSDMQFEKGTGKYSIS KEQYENIKVREGVDENSEFKFTLYKNDLLLLKDSENGEQI LLRFTSRNDTSKHYVELKPYNRQKFEGSEYLIKSLGTVAK GGQCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKLDF St1Cas9- Streptococcus 3297 MSDLVLGLDIGIGSVGVGILNKVTGEIIHKNSRIFPAAQA N622A TH1477 thermophilus ENNLVRRTNRQGRRLARRKKHRRVRLNRLFEESGLITDFT KISINLNPYQLRVKGLTDELSNEELFIALKNMVKHRGISY LDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLERYQ TYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQ QEFNPQITDEFINRYLEILTGKRKYYHGPGNEKSRTDYGR YRTSGETLDNIFGILIGKCTFYPDEFRAAKASYTAQEFNL LNDLNNLTVPTETKKLSKEQKNQIINYVKNEKAMGPAKLF KYIAKLLSCDVADIKGYRIDKSGKAEIHTFEAYRKMKTLE TLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHEFADGS FSQKQVDELVQFRKANSSIFGKGWHNFSVKLMMELIPELY ETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNP VVAKSVRQAIKIVNAAIKEYGDFDNIVIEMARETNEDDEK KAIQKIQKANKDEKDAAMLKAANQYNGKAELPHSVFHGHK QLATKIRLWHQQGERCLYTGKTISIHDLINNSNQFEVDHI LPLSITFDDSLANKVLVYATANQEKGQRTPYQALDSMDDA WSFRELKAFVRESKTLSNKKKEYLLTEEDISKFDVRKKFI ERNLVDTRYASRVVLNALQEHFRAHKIDTKVSVVRGQFTS QLRRHWGIEKTRDTYHHHAVDALIIAASSQLNLWKKQKNT LVSYSEDQLLDIETGELISDDEYKESVFKAPYQHFVDTLK SKEFEDSILFSYQVDSKFNRKISDATIYATRQAKVGKDKA DETYVLGKIKDIYTQDGYDAFMKIYKKDKSKFLMYRHDPQ TFEKVIEPILENYPNKQINEKGKEVPCNPFLKYKEEHGYI RKYSKKGNGPEIKSLKYYDSKLGNHIDITPKDSNNKVVLQ SLKPWRTDVYFNKNTGKYEILGLKYSDMQFEKGTGKYSIS KEQYENIKVREGVDENSEFKFTLYKNDLLLLKDSENGEQI LLRFTSRNDTSKHYVELKPYNRQKFEGSEYLIKSLGTVVK GGRCIKGLGKSNISIYKVRTDVLGNQHIIKNEGDKPKLDF Table 9B provides parameters to define the necessary components for designing gRNA and/or Template RNAs to apply Cas variants listed in Table 3A for Gene Writing. Tier indicates preferred Cas variants if they are available for use at a given locus. The cut site indicates the validated or predicted protospacer adjacent motif (PAM) requirements, validated or predicted location of cut site (relative to the most upstream base of the PAM site). The gRNA for a given enzyme can be assembled by concatenating the crRNA, Tetraloop, and tracrRNA sequences, and further adding a 5′ spacer of a length within Spacer (min) and Spacer (max) that matches a protospacer at a target site. Further, the predicted location of the ssDNA nick at the target is important for designing the 3′ region of a Template RNA that needs to anneal to the sequence immediately 5′ of the nick in order to initiate target primed reverse transcription.

TABLE 9B parameters to define the necessary components for designing gRNA and/or Template RNAs to apply Cas variants listed in Table 9A for Gene Writing SEQ SEQ Spacer Spacer ID Tetra ID Variant PAM(s) Cut Tier (min) (max) crRNA NO: loop tracrRNA NO: Nme2Cas9 NNNNC −3 1 22 24 GTTG 3535 GAA CGAAATGA 3536 C TAGC A GAACCGTT TCCCT GCTACAAT TTCTC AAGGCCGT ATTTC CTGAAAAG G ATGTGCCG CAACGCTC TGCCCCTT AAAGCTTC TGCTTTAA GGGGCATC GTTTA PpnCas9 NNNNR 1 21 24 GTTG 3537 GAA GCGAAATG 3538 TT TAGC A AAAAACGT TCCCT TGTTACAA TTTTC TAAGAGAT ATTTC GAATTTCT GC CGCAAAGC TCTGCCTC TTGAAATT TCGGTTTC AAGAGGCA TCTTTTT SauCas9 NNGRR; −3 1 21 23 GTTTT 3539 GAA CAGAATCT 3540 NNGRRT AGTA A ACTAAAAC CTCT AAGGCAAA G ATGCCGTG TTTATCTC GTCAACTT GTTGGCGA GA SauCas9 NNNRR; −3 1 21 21 GTTTT 3541 GAA ATTACAGA 3542 -KKH NNNRRT AGTA A ATCTACTA CTCT AAACAAGG GTAA CAAAATGC T CGTGTTTA TCTCGTCA ACTTGTTG GCGAGA SauriCas NNGG −3 1 21 21 GTTTT 3539 GAA CAGAATCT 3543 9 AGTA A ACTAAAAC CTCT AAGGCAAA G ATGCCGTG TTTATCTC GTCAACTT GTTGGCGA GATTTTT SauriCas NNRG −3 1 21 21 GTTTT 3539 GAA CAGAATCT 3543 9-KKH AGTA A ACTAAAAC CTCT AAGGCAAA G ATGCCGTG TTTATCTC GTCAACTT GTTGGCGA GATTTTT ScaCas9 NNG 3 1 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -Sc++ AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NGG 3 1 20 20 GTTTT 3544 GAA TAGCAAGT 3545 AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NG −3 1 20 20 GTTT 3546 GAA CAGCATAG 3547 -NG (NGG = N AAGA A CAAGTTTA GA = NGT GCTA AATAAGGC > NGC) TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C SpyCas9 NRN > N −3 1 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -SpRY YN AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC St1Cas9 NNAGA −3 1 20 20 GTCTT 3548 GTA CAGAAGCT 3549 AW > NN TGTA C ACAAAGAT AGGAW CTCT AAGGCTTC = NNGG G ATGCCGAA AAW ATCAACAC CCTGTCAT TTTATGGC AGGGTGTT TT BlatCas NNNNC −3 1 19 23 GCTA 3550 GAA GGTAAGTT 3551 9 NAA > N TAGT A GCTATAGT NNNCN TCCTT AAGGGCAA DD > NN ACT CAGACCCG NNC AGGCGTTG GGGATCGC CTAGCCCG TGTTTACG GGCTCTCC CCATATTC AAAATAAT GACAGACG AGCACCTT GGAGCATT TATCTCCG AGGTGCT cCas9- NNVAC −3 2 21 21 GUCU 3552 GAA CAGAAUCU 3553 v16 T; NNVA UAGU A ACUAAGAC TGM; NN ACUC AAGGCAAA VATT; N UG AUGCCGUG NVGCT; UUUAUCUC NNVGT GUCAACUU G; NNVG GUUGGCGA TT GAUUUUUU U cCas9- NNVRR −3 2 21 21 GUCU 3552 GAA CAGAAUCU 3553 v17 N UAGU A ACUAAGAC ACUC AAGGCAAA UG AUGCCGUG UUUAUCUC GUCAACUU GUUGGCGA GAUUUUUU U cCas9- NNVAC −3 2 21 21 GUCU 3552 GAA CAGAAUCU 3553 v21 T; NNVA UAGU A ACUAAGAC TGM; NN ACUC AAGGCAAA VATT; N UG AUGCCGUG NVGCT; UUUAUCUC NNVGT GUCAACUU G; NNVG GUUGGCGA TT GAUUUUUU U cCas9- NNVRR −3 2 21 21 GUCU 3552 GAA CAGAAUCU 3553 v42 N UAGU A ACUAAGAC ACUC AAGGCAAA UG AUGCCGUG UUUAUCUC GUCAACUU GUUGGCGA GAUUUUUU U CdiCas9 NNRHH 2 22 22 ACUG 3554 GAA CUGAACCU 3555 HY; NNR GGGU A CAGUAAGC AAAY UCAG AUUGGCUC GUUUCCAA UGUUGAUU GCUCCGCC GGUGCUCC UUAUUUUU AAGGGCGC CGGC CjeCas9 NNNNR −3 2 21 23 GTTTT 3556 GAA AGGGACTA 3557 YAC AGTC A AAATAAAG CCT AGTTTGCG GGACTCTG CGGGGTTA CAATCCCC TAAAACCG CTTTTTT GeoCas NNNNC 2 21 23 GUCA 3558 GAA UCAGGGUU 3559 9 RAA UAGU A ACUAUGAU UCCC AAGGGCUU CUGA UCUGCCUA AGGCAGAC UGACCCGC GGCGUUGG GGAUCGCC UGUCGCCC GCUUUUGG CGGGCAUU CCCCAUCC UU iSpyMac NAAN −3 2 19 2. GTTTT 3544 GAA TAGCAAGT 3545 Cas9 AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC NmeCas NNNNG −3 2 20 24 GTTG 3535 GAA CGAAATGA 3536 9 AYT; NN TAGC A GAACCGTT NNGYTT; TCCCT GCTACAAT NNNNG TTCTC AAGGCCGT AYA; NN ATTTC CTGAAAAG NNGTCT G ATGTGCCG CAACGCTC TGCCCCTT AAAGCTTC TGCTTTAA GGGGCATC GTTTA ScaCas9 NNG −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC ScaCas9 NNG −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -HiFi- AGAG A TAAAATAA Sc++ CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NRRH −3 2 20 20 GTTT 3546 GAA CAGCATAG 3547 -3var- AAGA A CAAGTTTA NRRH GCTA AATAAGGC TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C SpyCas9 NRTH −3 2 20 20 GTTT 3546 GAA CAGCATAG 3547 -3var- AAGA A CAAGTTTA NRTH GCTA AATAAGGC TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C SpyCas9 NRCH −3 2 20 20 GTTT 3546 GAA CAGCATAG 3547 -3var- AAGA A CAAGTTTA NRCH GCTA AATAAGGC TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C SpyCas9 NGG −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -HF1 AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NAAG −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -QQR1 AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NGN −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -SpG AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NGAN −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -VOR AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NGCG −3 2 20 20 GTTTT 3544 GAA TAGCAAGT 3545 -VRER AGAG A TAAAATAA CTA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC SpyCas9 NG; GAA; −3 2 20 20 GTTT 3546 GAA CAGCATAG 3547 -xCas GAT AAGA A CAAGTTTA GCTA AATAAGGC TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C SpyCas9 NG −3 2 20 20 GTTT 3546 GAA CAGCATAG 3547 -xCas- AAGA A CAAGTTTA NG GCTA AATAAGGC TGCT TAGTCCGT G TATCAACT TGAAAAAG TGGCACCG AGTCGGTG C St1Cas9 NNACA −3 2 20 20 GTCTT 3548 GTA CAGAAGCT 3549 CNRZ1 A TGTA C ACAAAGAT 066 CTCT AAGGCTTC G ATGCCGAA ATCAACAC CCTGTCAT TTTATGGC AGGGTGTT TT St1Cas9 NNGCA −3 2 20 20 GTCTT 3548 GTA CAGAAGCT 3549 LMG18 A TGTA C ACAAAGAT 31 CTCT AAGGCTTC G ATGCCGAA ATCAACAC CCTGTCAT TTTATGGC AGGGTGTT TT St1Cas9 NNAAA −3 2 20 20 GTCTT 3548 GTA CAGAAGCT 3549 - A TGTA C ACAAAGAT MTH17 CTCT AAGGCTTC CL396 G ATGCCGAA ATCAACAC CCTGTCAT TTTATGGC AGGGTGTT TT St1Cas9 NNGAA −3 2 20 20 GTCTT 3548 GTA CAGAAGCT 3549 - A TGTA C ACAAAGAT TH1477 CTCT AAGGCTTC G ATGCCGAA ATCAACAC CCTGTCAT TTTATGGC AGGGTGTT TT

In some embodiments, the opener molecule is exogenous to the cell comprising the Gene Writer polypeptide and or template nucleic acid. In some embodiments, the opener molecule comprises an endogenous agent (e.g., endogenous to the cell comprising the Gene Writer polypeptide and or template nucleic acid comprising the gRNA and blocking domain). For example, an inducible gRNA, blocking domain, and opener molecule may be chosen such that the opener molecule is an endogenous agent expressed in a target cell or tissue, e.g., thereby ensuring activity of a Gene Writer system in the target cell or tissue. As a further example, an inducible gRNA, blocking domain, and opener molecule may be chosen such that the opener molecule is absent or not substantially expressed in one or more non-target cells or tissues, e.g., thereby ensuring that activity of a Gene Writer system does not occur or substantially occur in the one or more non-target cells or tissues, or occurs at a reduced level compared to a target cell or tissue. Exemplary blocking domains, opener molecules, and uses thereof are described in PCT App. Publication WO2020044039A1, which is incorporated herein by reference in its entirety. In some embodiments, the template nucleic acid, e.g., template RNA, may comprise one or more UTRs (e.g. from an R2-type retrotransposon) and a gRNA. In some embodiments, the UTR facilitates interaction of the template nucleic acid (e.g., template RNA) with the writing domain, e.g., reverse transcriptase domain, of the Gene Writer polypeptide. In some embodiments, the gRNA facilitates interaction with the template nucleic acid binding domain (e.g., RNA binding domain) of the polypeptide. In some embodiments, the gRNA directs the polypeptide to the matching target sequence, e.g., in a target cell genome. In some embodiments, the template nucleic acid may contain only the reverse transcriptase binding motif (e.g. 3′ UTR from R2) and the gRNA may be provided as a second nucleic acid molecule (e.g., second RNA molecule) for target site recognition. In some embodiments, the template nucleic acid containing the RT-binding motif may exist on the same molecule as the gRNA, but be processed into two RNA molecules by cleavage activity (e.g. ribozyme).

In some embodiments, a template RNA may be customized to correct a given mutation in the genomic DNA of a target cell (e.g., ex vivo or in vivo, e.g., in a target tissue or organ, e.g., in a subject). For example, the mutation may be a disease-associated mutation relative to the wild-type sequence. Without wishing to be bound by theory, sets of empirical parameters help ensure optimal initial in silico designs of template RNAs or portions thereof. As a non-limiting illustrative example, for a selected mutation, the following design parameters may be employed. In some embodiments, design is initiated by acquiring approximately 500 bp (e.g., up to 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, or 700 bp, and optionally at least 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, or 650 bp) flanking sequence on either side of the mutation to serve as the target region. In some embodiments, a template nucleic acid comprises a gRNA. Methodology for designing gRNAs is known to those of skill in the art. In some embodiments, a gRNA comprises a sequence (e.g., a CRISPR spacer) that binds a target site. In some embodiments, the sequence (e.g., a CRISPR spacer) that binds a target site for use in targeting a template nucleic acid to a target region is selected by considering the particular Gene Writer polypeptide (e.g., endonuclease domain or writing domain, e.g., comprising a CRISPR/Cas domain) being used (e.g., for Cas9, a protospacer-adjacent motif (PAM) of NGG immediately 3′ of a 20 nt gRNA binding region). In some embodiments, the CRISPR spacer is selected by ranking first by whether the PAM will be disrupted by the Gene Writing induced edit. In some embodiments, disruption of the PAM may increase edit efficiency. In some embodiments, the PAM can be disrupted by also introducing (e.g., as part of or in addition to another modification to a target site in genomic DNA) a silent mutation (e.g., a mutation that does not alter an amino acid residue encoded by the target nucleic acid sequence, if any) in the target site during Gene Writing. In some embodiments, the CRISPR spacer is selected by ranking sequences by the proximity of their corresponding genomic site to the desired edit location. In some embodiments, the gRNA comprises a gRNA scaffold. In some embodiments, the gRNA scaffold used may be a standard scaffold (e.g., for Cas9, 5′-GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAA AGTGGGACCGAGTCGGTCC-3′ (SEQ ID NO: 1591)), or may contain one or more nucleotide substitutions. In some embodiments, the heterologous object sequence has at least 90% identity, e.g., at least 90%, 95%, 98%, 99%, or 100% identity, or comprises no more than 1, 2, 3, 4, or 5 positions of non-identity to the target site 3′ of the first strand nick (e.g., immediately 3′ of the first strand nick or up to 1, 2, 3, 4, or 5 nucleotides 3′ of the first strand nick), with the exception of any insertion, substitution, or deletion that may be written into the target site by the Gene Writer. In some embodiments, the 3′ target homology domain contains at least 90% identity, e.g., at least 90%, 95%, 98%, 99%, or 100% identity, or comprises no more than 1, 2, 3, 4, or 5 positions of non-identity to the target site 5′ of the first strand nick (e.g., immediately 5′ of the first strand nick or up to 1, 2, 3, 4, or 5 nucleotides 3′ of the first strand nick).

Methods and Compositions for Modified RNA (e.g., gRNA or Template RNA)

In some embodiments, an RNA component of the system (e.g., a template RNA or a gRNA) comprises one or more nucleotide modifications. In some embodiments, the modification pattern of a gRNA can significantly affect in vivo activity compared to unmodified or end-modified guides (e.g., as shown in FIG. 1D from Finn et al. Cell Rep 22(9):2227-2235 (2018); incorporated herein by reference in its entirety). Without wishing to be bound by theory, this process may be due, at least in part, to a stabilization of the RNA conferred by the modifications. Non-limiting examples of such modifications may include 2′-O-methyl (2′-O-Me), 2′-O-(2-methoxyethyl) (2′-O-MOE), 2′-fluoro (2′-F), phosphorothioate (PS) bond between nucleotides, G-C substitutions, and inverted abasic linkages between nucleotides and equivalents thereof.

In some embodiments, the template RNA (e.g., at the portion thereof that binds a target site) or the guide RNA comprises a 5′ terminus region. In some embodiments, the template RNA or the guide RNA does not comprise a 5′ terminus region. In some embodiments, the 5′ terminus region comprises a CRISPR spacer region, e.g., as described with respect to sgRNA in Briner A E et al, Molecular Cell 56: 333-339 (2014) (incorporated herein by reference in its entirety; applicable herein, e.g., to all guide RNAs). In some embodiments, the 5′ terminus region comprises a 5′ end modification. In some embodiments, a 5′ terminus region with or without a spacer region may be associated with a crRNA, trRNA, sgRNA and/or dgRNA. The CRISPR spacer region can, in some instances, comprise a guide region, guide domain, or targeting domain. In some embodiments, a target domain or target sequence may comprise a sequence of nucleic acid to which the guide region/domain directs a nuclease for cleavage. In some embodiments, a spyCas9 protein may be directed by a guide region/domain to a target sequence of a target nucleic acid molecule by the nucleotides present in the CRISPR spacer region.

In some embodiments, the template RNAs (e.g., at the portion thereof that binds a target site) or guide RNAs described herein comprises any of the sequences shown in Table 4 of WO2018107028A1, incorporated herein by reference in its entirety. In some embodiments, where a sequence shows a guide and/or spacer region, the composition may comprise this region or not. In some embodiments, a guide RNA comprises one or more of the modifications of any of the sequences shown in Table 4 of WO2018107028A1, e.g., as identified therein by a SEQ ID NO. In embodiments, the nucleotides may be the same or different, and/or the modification pattern shown may be the same or similar to a modification pattern of a guide sequence as shown in Table 4 of WO2018107028A1. In some embodiments, a modification pattern includes the relative position and identity of modifications of the gRNA or a region of the gRNA (e.g. 5′ terminus region, lower stem region, bulge region, upper stem region, nexus region, hairpin 1 region, hairpin 2 region, 3′ terminus region). In some embodiments, the modification pattern contains at least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the modifications of any one of the sequences shown in the sequence column of Table 4 of WO2018107028A1, and/or over one or more regions of the sequence. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the modification pattern of any one of the sequences shown in the sequence column of Table 4 of WO2018107028A1. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over one or more regions of the sequence shown in Table 4 of WO2018107028A1, e.g., in a 5′ terminus region, lower stem region, bulge region, upper stem region, nexus region, hairpin 1 region, hairpin 2 region, and/or 3′ terminus region. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the modification pattern of a sequence over the 5′ terminus region. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the lower stem. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the bulge. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the upper stem. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the nexus. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the hairpin 1. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the hairpin 2. In some embodiments, the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the 3′terminus. In some embodiments, the modification pattern differs from the modification pattern of a sequence of Table 4 of WO2018107028A1, or a region (e.g. 5′ terminus, lower stem, bulge, upper stem, nexus, hairpin 1, hairpin 2, 3′ terminus) of such a sequence, e.g., at 0, 1, 2, 3, 4, 5, 6, or more nucleotides. In some embodiments, the gRNA comprises modifications that differ from the modifications of a sequence of Table 4 of WO2018107028A1, e.g., at 0, 1, 2, 3, 4, 5, 6, or more nucleotides. In some embodiments, the gRNA comprises modifications that differ from modifications of a region (e.g. 5′terminus, lower stem, bulge, upper stem, nexus, hairpin 1, hairpin 2, 3′ terminus) of a sequence of Table 4 of WO2018107028A1, e.g., at 0, 1, 2, 3, 4, 5, 6, or more nucleotides.

In some embodiments, the template RNAs (e.g., at the portion thereof that binds a target site) or the gRNA comprises a 2′-O-methyl (2′-O-Me) modified nucleotide. In some embodiments, the gRNA comprises a 2′-O-(2-methoxy ethyl) (2′-O-moe) modified nucleotide. In some embodiments, the gRNA comprises a 2′-fluoro (2′-F) modified nucleotide. In some embodiments, the gRNA comprises a phosphorothioate (PS) bond between nucleotides. In some embodiments, the gRNA comprises a 5′ end modification, a 3′ end modification, or 5′ and 3′ end modifications. In some embodiments, the 5′ end modification comprises a phosphorothioate (PS) bond between nucleotides. In some embodiments, the 5′ end modification comprises a 2′-O-methyl (2′-O-Me), 2′-O-(2-methoxy ethyl) (2′-O-MOE), and/or 2′-fluoro (2′-F) modified nucleotide. In some embodiments, the 5′ end modification comprises at least one phosphorothioate (PS) bond and one or more of a 2′-O-methyl (2′-O-Me), 2′-O-(2-methoxyethyl) (2′-O-MOE), and/or 2′-fluoro (2′-F) modified nucleotide. The end modification may comprise a phosphorothioate (PS), 2′-O-methyl (2′-O-Me), 2′-O-(2-methoxyethyl) (2′-O-MOE), and/or 2′-fluoro (2′-F) modification. Equivalent end modifications are also encompassed by embodiments described herein. In some embodiments, the template RNA or gRNA comprises an end modification in combination with a modification of one or more regions of the template RNA or gRNA. Additional exemplary modifications and methods for protecting RNA, e.g., gRNA, and formulae thereof, are described in WO2018126176A1, which is incorporated herein by reference in its entirety.

In some embodiments, structure-guided and systematic approaches are used to introduce modifications (e.g., 2′-OMe-RNA, 2′-F-RNA, and PS modifications) to a template RNA or guide RNA, for example, as described in Mir et al. Nat Commun 9:2641 (2018) (incorporated by reference herein in its entirety). In some embodiments, the incorporation of 2′-F-RNAs increases thermal and nuclease stability of RNA:RNA or RNA:DNA duplexes, e.g., while minimally interfering with C3′-endo sugar puckering. In some embodiments, 2′-F may be better tolerated than 2′-OMe at positions where the 2′-OH is important for RNA:DNA duplex stability. In some embodiments, a crRNA comprises one or more modifications that do not reduce Cas9 activity, e.g., C10, C20, or C21 (fully modified), e.g., as described in Supplementary Table 1 of Mir et al. Nat Commun 9:2641 (2018), incorporated herein by reference in its entirety. In some embodiments, a tracrRNA comprises one or more modifications that do not reduce Cas9 activity, e.g., T2, T6, T7, or T8 (fully modified) of Supplementary Table 1 of Mir et al. Nat Commun 9:2641 (2018). In some embodiments, a crRNA comprises one or more modifications (e.g., as described herein) may be paired with a tracrRNA comprising one or more modifications, e.g., C20 and T2. In some embodiments, a gRNA comprises a chimera, e.g., of a crRNA and a tracrRNA (e.g., Jinek et al. Science 337(6096):816-821 (2012)). In embodiments, modifications from the crRNA and tracrRNA are mapped onto the single-guide chimera, e.g., to produce a modified gRNA with enhanced stability.

In some embodiments, gRNA molecules may be modified by the addition or subtraction of the naturally occurring structural components, e.g., hairpins. In some embodiments, a gRNA may comprise a gRNA with one or more 3′ hairpin elements deleted, e.g., as described in WO2018106727, incorporated herein by reference in its entirety. In some embodiments, a gRNA may contain an added hairpin structure, e.g., an added hairpin structure in the spacer region, which was shown to increase specificity of a CRISPR-Cas system in the teachings of Kocak et al. Nat Biotechnol 37(6):657-666 (2019). Additional modifications, including examples of shortened gRNA and specific modifications improving in vivo activity, can be found in US20190316121, incorporated herein by reference in its entirety.

In some embodiments, structure-guided and systematic approaches (e.g., as described in Mir et al. Nat Commun 9:2641 (2018); incorporated herein by reference in its entirety) are employed to find modifications for the template RNA. In embodiments, the modifications are identified with the inclusion or exclusion of a guide region of the template RNA. In some embodiments, a structure of polypeptide bound to template RNA is used to determine non-protein-contacted nucleotides of the RNA that may then be selected for modifications, e.g., with lower risk of disrupting the association of the RNA with the polypeptide. Secondary structures in a template RNA can also be predicted in silico by software tools, e.g., the RNAstructure tool available at rna.urmc.rochester.edu/RNAstructureWeb (Bellaousov et al. Nucleic Acids Res 41:W471-W474 (2013); incorporated by reference herein in its entirety), e.g., to determine secondary structures for selecting modifications, e.g., hairpins, stems, and/or bulges.

Further included here are compositions and methods for the assembly of full or partial template RNA molecules (e.g., Gene Writing template RNA molecules optionally comprising a gRNA, or separate gRNA molecules). In some embodiments, RNA molecules may be assembled by the connection of two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) RNA segments with each other. In an aspect, the disclosure provides methods for producing nucleic acid molecules, the methods comprising contacting two or more linear RNA segments with each other under conditions that allow for the 5′ terminus of a first RNA segment to be covalently linked with the 3′ terminus of a second RNA segment. In some embodiments, the joined molecule may be contacted with a third RNA segment under conditions that allow for the 5′ terminus of the joined molecule to be covalently linked with the 3′ terminus of the third RNA segment. In embodiments, the method further comprises joining a fourth, fifth, or additional RNA segments to the elongated molecule. This form of assembly may, in some instances, allow for rapid and efficient assembly of RNA molecules.

The present disclosure also provides compositions and methods for the connection (e.g., covalent connection) of crRNA molecules and tracrRNA molecules. In some embodiments, guide RNA molecules with specificity for different target sites can be generated using a single tracrRNA molecule/segment connected to a target site specific crRNA molecule/segment (e.g., as shown in FIG. 10 of US20160102322A1; incorporated herein by reference in its entirety). For example, FIG. 10 of US20160102322A1 shows four tubes with different crRNA molecules with crRNA molecule 3 being connected to a tracrRNA molecule to form a guide RNA molecule, thereby depicting an exemplary connection of two RNA segments to form a product RNA molecule.

The disclosure also provides compositions and methods for the production of template RNA molecules with specificity for a Gene Writer polypeptide and/or a genomic target site. In an aspect, the method comprises: (1) identification of the target site and desired modification thereto, (2) production of RNA segments including an upstream homology segment, a heterologous object sequence segment, a Gene Writer polypeptide binding motif, and a gRNA segment, and/or (3) connection of the four or more segments into at least one molecule, e.g., into a single RNA molecule. In some embodiments, some or all of the template RNA segments comprised in (2) are assembled into a template RNA molecule, e.g., one, two, three, or four of the listed components. In some embodiments, the segments comprised in (2) may be produced in further segmented molecules, e.g., split into at least 2, at least 3, at least 4, or at least 5 or more sub-segments, e.g., that are subsequently assembled, e.g., by one or more methods described herein.

In some embodiments, RNA segments may be produced by chemical synthesis. In some embodiments, RNA segments may be produced by in vitro transcription of a nucleic acid template, e.g., by providing an RNA polymerase to act on a cognate promoter of a DNA template to produce an RNA transcript. In some embodiments, in vitro transcription is performed using, e.g., a T7, T3, or SP6 RNA polymerase, or a derivative thereof, acting on a DNA, e.g., dsDNA, ssDNA, linear DNA, plasmid DNA, linear DNA amplicon, linearized plasmid DNA, e.g., encoding the RNA segment, e.g., under transcriptional control of a cognate promoter, e.g., a T7, T3, or SP6 promoter. In some embodiments, a combination of chemical synthesis and in vitro transcription is used to generate the RNA segments for assembly. In embodiments, the gRNA, upstream target homology, and Gene Writer polypeptide binding segments are produced by chemical synthesis and the heterologous object sequence segment is produced by in vitro transcription. Without wishing to be bound by theory, in vitro transcription may be better suited for the production of longer RNA molecules. In some embodiments, reaction temperature for in vitro transcription may be lowered, e.g., be less than 37° C. (e.g., between 0-10C, 10-20C, or 20-30C), to result in a higher proportion of full-length transcripts (Krieg Nucleic Acids Res 18:6463 (1990)). In some embodiments, a protocol for improved synthesis of long transcripts is employed to synthesize a long template RNA, e.g., a template RNA greater than 5 kb, such as the use of e.g., T7 RiboMAX Express, which can generate 27 kb transcripts in vitro (Thiel et al. J Gen Virol 82(6):1273-1281 (2001)). In some embodiments, modifications to RNA molecules as described herein may be incorporated during synthesis of RNA segments (e.g., through the inclusion of modified nucleotides or alternative binding chemistries), following synthesis of RNA segments through chemical or enzymatic processes, following assembly of one or more RNA segments, or a combination thereof.

In some embodiments, an mRNA of the system (e.g., an mRNA encoding a Gene Writer polypeptide) is synthesized in vitro using T7 polymerase-mediated DNA-dependent RNA transcription from a linearized DNA template, where UTP is optionally substituted with 1-methylpseudoUTP. In some embodiments, the transcript incorporates 5′ and 3′ UTRs, e.g., GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 1603) and UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCC AGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGA (SEQ ID NO: 1604), or functional fragments or variants thereof, and optionally includes a poly-A tail, which can be encoded in the DNA template or added enzymatically following transcription. In some embodiments, a donor methyl group, e.g., S-adenosylmethionine, is added to a methylated capped RNA with cap 0 structure to yield a cap 1 structure that increases mRNA translation efficiency (Richner et al. Cell 168(6): P1114-1125 (2017)).

In some embodiments, the transcript from a T7 promoter starts with a GGG motif. In some embodiments, a transcript from a T7 promoter does not start with a GGG motif. It has been shown that a GGG motif at the transcriptional start, despite providing superior yield, may lead to T7 RNAP synthesizing a ladder of poly(G) products as a result of slippage of the transcript on the three C residues in the template strand from +1 to +3 (Imburgio et al. Biochemistry 39(34):10419-10430 (2000). For tuning transcription levels and altering the transcription start site nucleotides to fit alternative 5′ UTRs, the teachings of Davidson et al. Pac Symp Biocomput 433-443 (2010) describe T7 promoter variants, and the methods of discovery thereof, that fulfill both of these traits.

In some embodiments, RNA segments may be connected to each other by covalent coupling. In some embodiments, an RNA ligase, e.g., T4 RNA ligase, may be used to connect two or more RNA segments to each other. When a reagent such as an RNA ligase is used, a 5′ terminus is typically linked to a 3′ terminus. In some embodiments, if two segments are connected, then there are two possible linear constructs that can be formed (i.e., (1) 5′-Segment 1-Segment 2-3′ and (2) 5′-Segment 2-Segment 1-3′). In some embodiments, intramolecular circularization can also occur. Both of these issues can be addressed, for example, by blocking one 5′ terminus or one 3′ terminus so that RNA ligase cannot ligate the terminus to another terminus. In embodiments, if a construct of 5′-Segment 1-Segment 2-3′ is desired, then placing a blocking group on either the 5′ end of Segment 1 or the 3′ end of Segment 2 may result in the formation of only the correct linear ligation product and/or prevent intramolecular circularization. Compositions and methods for the covalent connection of two nucleic acid (e.g., RNA) segments are disclosed, for example, in US20160102322A1 (incorporated herein by reference in its entirety), along with methods including the use of an RNA ligase to directionally ligate two single-stranded RNA segments to each other.

One example of an end blocker that may be used in conjunction with, for example, T4 RNA ligase, is a dideoxy terminator. T4 RNA ligase typically catalyzes the ATP-dependent ligation of phosphodiester bonds between 5′-phosphate and 3′-hydroxyl termini. In some embodiments, when T4 RNA ligase is used, suitable termini must be present on the termini being ligated. One means for blocking T4 RNA ligase on a terminus comprises failing to have the correct terminus format. Generally, termini of RNA segments with a 5-hydroxyl or a 3′-phosphate will not act as substrates for T4 RNA ligase.

Additional exemplary methods that may be used to connect RNA segments is by click chemistry (e.g., as described in U.S. Pat. Nos. 7,375,234 and 7,070,941, and US Patent Publication No. 2013/0046084, the entire disclosures of which are incorporated herein by reference). For example, one exemplary click chemistry reaction is between an alkyne group and an azide group (see FIG. 11 of US20160102322A1, which is incorporated herein by reference in its entirety). Any click reaction may potentially be used to link RNA segments (e.g., Cu-azide-alkyne, strain-promoted-azide-alkyne, staudinger ligation, tetrazine ligation, photo-induced tetrazole-alkene, thiol-ene, NHS esters, epoxides, isocyanates, and aldehyde-aminooxy). In some embodiments, ligation of RNA molecules using a click chemistry reaction is advantageous because click chemistry reactions are fast, modular, efficient, often do not produce toxic waste products, can be done with water as a solvent, and/or can be set up to be stereospecific.

In some embodiments, RNA segments may be connected using an Azide-Alkyne Huisgen Cycloaddition. reaction, which is typically a 1,3-dipolar cycloaddition between an azide and a terminal or internal alkyne to give a 1,2,3-triazole for the ligation of RNA segments. Without wishing to be bound by theory, one advantage of this ligation method may be that this reaction can initiated by the addition of required Cu(I) ions. Other exemplary mechanisms by which RNA segments may be connected include, without limitation, the use of halogens (F—, Br—, I—)/alkynes addition reactions, carbonyls/sulfhydryls/maleimide, and carboxyl/amine linkages. For example, one RNA molecule may be modified with thiol at 3′ (using disulfide amidite and universal support or disulfide modified support), and the other RNA molecule may be modified with acrydite at 5′ (using acrylic phosphoramidite), then the two RNA molecules can be connected by a Michael addition reaction. This strategy can also be applied to connecting multiple RNA molecules stepwise. Also provided are methods for linking more than two (e.g., three, four, five, six, etc.) RNA molecules to each other. Without wishing to be bound by theory, this may be useful when a desired RNA molecule is longer than about 40 nucleotides, e.g., such that chemical synthesis efficiency degrades, e.g., as noted in US20160102322A1 (incorporated herein by reference in its entirety).

By way of illustration, a tracrRNA is typically around 80 nucleotides in length. Such RNA molecules may be produced, for example, by processes such as in vitro transcription or chemical synthesis. In some embodiments, when chemical synthesis is used to produce such RNA molecules, they may be produced as a single synthesis product or by linking two or more synthesized RNA segments to each other. In embodiments, when three or more RNA segments are connected to each other, different methods may be used to link the individual segments together. Also, the RNA segments may be connected to each other in one pot (e.g., a container, vessel, well, tube, plate, or other receptacle), all at the same time, or in one pot at different times or in different pots at different times. In a non-limiting example, to assemble RNA Segments 1, 2 and 3 in numerical order, RNA Segments 1 and 2 may first be connected, 5′ to 3′, to each other. The reaction product may then be purified for reaction mixture components (e.g., by chromatography), then placed in a second pot, for connection of the 3′ terminus with the 5′ terminus of RNA Segment 3. The final reaction product may then be connected to the 5′ terminus of RNA Segment 3.

In another non-limiting example, RNA Segment 1 (about 30 nucleotides) is the target locus recognition sequence of a crRNA and a portion of Hairpin Region 1. RNA Segment 2 (about 35 nucleotides) contains the remainder of Hairpin Region 1 and some of the linear tracrRNA between Hairpin Region 1 and Hairpin Region 2. RNA Segment 3 (about 35 nucleotides) contains the remainder of the linear tracrRNA between Hairpin Region 1 and Hairpin Region 2 and all of Hairpin Region 2. In this example, RNA Segments 2 and 3 are linked, 5′ to 3′, using click chemistry. Further, the 5′ and 3′ end termini of the reaction product are both phosphorylated. The reaction product is then contacted with RNA Segment 1, having a 3′ terminal hydroxyl group, and T4 RNA ligase to produce a guide RNA molecule.

A number of additional linking chemistries may be used to connect RNA segments according to method of the invention. Some of these chemistries are set out in Table 6 of US20160102322A1, which is incorporated herein by reference in its entirety.

Template Nucleic Acid Composition

In some embodiments, the template nucleic acid is a template RNA. In some embodiments, the template RNA comprises one or more modified nucleotides. For example, in some embodiments, the template RNA comprises one or more deoxyribonucleotides. In some embodiments, regions of the template RNA are replaced by DNA nucleotides, e.g., to enhance stability of the molecule. For example, the 3′ end of the template may comprise DNA nucleotides, while the rest of the template comprises RNA nucleotides that can be reverse transcribed. For instance, in some embodiments, the heterologous object sequence is primarily or wholly made up of RNA nucleotides (e.g., at least 90%, 95%, 98%, or 99% RNA nucleotides). In some embodiments, one or both of the 3′ UTR and the 3′ target homology domain are primarily or wholly made up of DNA nucleotides (e.g., at least 90%, 95%, 98%, or 99% DNA nucleotides). In other embodiments, the template region for writing into the genome may comprise DNA nucleotides. In some embodiments, the DNA nucleotides in the template are copied into the genome by a domain capable of DNA-dependent DNA polymerase activity. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a DNA polymerase domain in the polypeptide. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a reverse transcriptase domain that is also capable of DNA-dependent DNA polymerization, e.g., second strand synthesis. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a DNA polymerase. In some embodiments, the DNA-dependent DNA polymerase activity provided by a DNA polymerase domain in the polypeptide is not capable of reverse transcription activity. In some embodiments, the template molecule is composed of only DNA nucleotides. In some embodiments, the DNA template is polymerized into the genome by a DNA polymerase. In some embodiments, the template composed of DNA nucleotides comprises modified DNA nucleotides. In some embodiments, the template composed of DNA nucleotides comprises a modified backbone.

The nucleotides comprising the template of the Gene Writer™ system can be natural or modified bases, or a combination thereof. For example, the template may contain pseudouridine, dihydrouridine, inosine, 7-methylguanosine, or other modified bases. In some embodiments, the template may contain locked nucleic acid nucleotides. In some embodiments, the modified bases used in the template do not inhibit the reverse transcription of the template. In some embodiments, the modified bases used in the template may improve reverse transcription, e.g., specificity or fidelity.

Additional Functional Characteristics for Gene Writers™

A Gene Writer as described herein may, in some instances, be characterized by one or more functional measurements or characteristics. In some embodiments, the DNA binding domain has one or more of the functional characteristics described below. In some embodiments, the RNA binding domain has one or more of the functional characteristics described below. In some embodiments, the endonuclease domain has one or more of the functional characteristics described below. In some embodiments, the reverse transcriptase domain has one or more of the functional characteristics described below. In some embodiments, the template (e.g., template RNA) has one or more of the functional characteristics described below. In some embodiments, the target site bound by the Gene Writer has one or more of the functional characteristics described below.

Gene Writer Polypeptide

DNA Binding Domain

In some embodiments, the DNA binding domain is capable of binding to a target sequence (e.g., a dsDNA target sequence) with greater affinity than a reference DNA binding domain. In some embodiments, the reference DNA binding domain is a DNA binding domain from R2_BM of B. mori. In some embodiments, the DNA binding domain is capable of binding to a target sequence (e.g., a dsDNA target sequence) with an affinity between 100 pM-10 nM (e.g., between 100 pM-1 nM or 1 nM-10 nM).

In some embodiments, the affinity of a DNA binding domain for its target sequence (e.g., dsDNA target sequence) is measured in vitro, e.g., by thermophoresis, e.g., as described in Asmari et al. Methods 146:107-119 (2018) (incorporated by reference herein in its entirety).

In embodiments, the DNA binding domain is capable of binding to its target sequence (e.g., dsDNA target sequence), e.g, with an affinity between 100 pM-10 nM (e.g., between 100 pM-1 nM or 1 nM-10 nM) in the presence of a molar excess of scrambled sequence competitor dsDNA, e.g., of about 100-fold molar excess.

In some embodiments, the DNA binding domain is found associated with its target sequence (e.g., dsDNA target sequence) more frequently than any other sequence in the genome of a target cell, e.g., human target cell, e.g., as measured by ChIP-seq (e.g., in HEK293T cells), e.g., as described in He and Pu (2010) Curr. Protoc Mol Biol Chapter 21 (incorporated herein by reference in its entirety). In some embodiments, the DNA binding domain is found associated with its target sequence (e.g., dsDNA target sequence) at least about 5-fold or 10-fold, more frequently than any other sequence in the genome of a target cell, e.g., as measured by ChIP-seq (e.g., in HEK293T cells), e.g., as described in He and Pu (2010), supra.

RNA Binding Domain

In some embodiments, the RNA binding domain is capable of binding to a template RNA with greater affinity than a reference RNA binding domain. In some embodiments, the reference RNA binding domain is an RNA binding domain from R2_BM of B. mori. In some embodiments, the RNA binding domain is capable of binding to a template RNA with an affinity between 100 pM-10 nM (e.g., between 100 pM-1 nM or 1 nM-10 nM). In some embodiments, the affinity of a RNA binding domain for its template RNA is measured in vitro, e.g., by thermophoresis, e.g., as described in Asmari et al. Methods 146:107-119 (2018) (incorporated by reference herein in its entirety). In some embodiments, the affinity of a RNA binding domain for its template RNA is measured in cells (e.g., by FRET or CLIP-Seq).

In some embodiments, the RNA binding domain is associated with the template RNA in vitro at a frequency at least about 5-fold or 10-fold higher than with a scrambled RNA. In some embodiments, the frequency of association between the RNA binding domain and the template RNA or scrambled RNA is measured by CLIP-seq, e.g., as described in Lin and Miles (2019) Nucleic Acids Res 47(11):5490-5501 (incorporated by reference herein in its entirety). In some embodiments, the RNA binding domain is associated with the template RNA in cells (e.g., in HEK293T cells) at a frequency at least about 5-fold or 10-fold higher than with a scrambled RNA. In some embodiments, the frequency of association between the RNA binding domain and the template RNA or scrambled RNA is measured by CLIP-seq, e.g., as described in Lin and Miles (2019), supra.

Endonuclease Domain

In some embodiments, the endonuclease domain is associated with the target dsDNA in vitro at a frequency at least about 5-fold or 10-fold higher than with a scrambled dsDNA. In some embodiments, the endonuclease domain is associated with the target dsDNA in vitro at a frequency at least about 5-fold or 10-fold higher than with a scrambled dsDNA, e.g., in a cell (e.g., a HEK293T cell). In some embodiments, the frequency of association between the endonuclease domain and the target DNA or scrambled DNA is measured by ChIP-seq, e.g., as described in He and Pu (2010) Curr. Protoc Mol Biol Chapter 21 (incorporated by reference herein in its entirety).

In some embodiments, the endonuclease domain can catalyze the formation of a nick at a target sequence, e.g., to an increase of at least about 5-fold or 10-fold relative to a non-target sequence (e.g., relative to any other genomic sequence in the genome of the target cell). In some embodiments, the level of nick formation is determined using NickSeq, e.g., as described in Elacqua et al. (2019) bioRxiv doi.org/10.1101/867937 (incorporated herein by reference in its entirety).

In some embodiments, the endonuclease domain is capable of nicking DNA in vitro. In embodiments, the nick results in an exposed base. In embodiments, the exposed base can be detected using a nuclease sensitivity assay, e.g., as described in Chaudhry and Weinfeld (1995) Nucleic Acids Res 23(19):3805-3809 (incorporated by reference herein in its entirety). In embodiments, the level of exposed bases (e.g., detected by the nuclease sensitivity assay) is increased by at least 10%, 50%, or more relative to a reference endonuclease domain. In some embodiments, the reference endonuclease domain is an endonuclease domain from R2_BM of B. mori.

In some embodiments, the endonuclease domain is capable of nicking DNA in a cell. In embodiments, the endonuclease domain is capable of nicking DNA in a HEK293T cell. In embodiments, an unrepaired nick that undergoes replication in the absence of Rad51 results in increased NHEJ rates at the site of the nick, which can be detected, e.g., by using a Rad51 inhibition assay, e.g., as described in Bothmer et al. (2017) Nat Commun 8:13905 (incorporated by reference herein in its entirety). In embodiments, NHEJ rates are increased above 0-5%. In embodiments, NHEJ rates are increased to 20-70% (e.g., between 30%-60% or 40-50%), e.g., upon Rad51 inhibition.

In some embodiments, the endonuclease domain releases the target after cleavage. In some embodiments, release of the target is indicated indirectly by assessing for multiple turnovers by the enzyme, e.g., as described in Yourik at al. RNA 25(1):35-44 (2019) (incorporated herein by reference in its entirety) and shown in FIG. 2 . In some embodiments, the k_(exp) of an endonuclease domain is 1×10⁻³-1×10⁻⁵ min-1 as measured by such methods.

In some embodiments, the endonuclease domain has a catalytic efficiency (k_(cat)/K_(m)) greater than about 1×10⁻⁸ s⁻¹ M⁻¹ in vitro. In embodiments, the endonuclease domain has a catalytic efficiency greater than about 1×10⁵, 1×10⁶, 1×10⁷, or 1×10⁸, s⁻¹ M⁻¹ in vitro. In embodiments, catalytic efficiency is determined as described in Chen et al. (2018) Science 360(6387):436-439 (incorporated herein by reference in its entirety). In some embodiments, the endonuclease domain has a catalytic efficiency (k_(cat)/K_(m)) greater than about 1×10⁸ s⁻¹ M⁻¹ in cells. In embodiments, the endonuclease domain has a catalytic efficiency greater than about 1×10⁵, 1×10⁶, 1×10⁷, or 1×10⁸ s⁻¹ M⁻¹ in cells.

Reverse Transcriptase Domain

In some embodiments, the reverse transcriptase domain has a lower probability of premature termination rate (P_(off)) in vitro relative to a reference reverse transcriptase domain. In some embodiments, the reference reverse transcriptase domain is a reverse transcriptase domain from R2_BM of B. mori or a viral reverse transcriptase domain, e.g., the RT domain from M-MLV.

In some embodiments, the reverse transcriptase domain has a lower probability of premature termination rate (P_(off)) in vitro of less than about 5×10⁻³/nt, 5×10⁻⁴/nt, or 5×10⁻⁶/nt, e.g., as measured on a 1094 nt RNA. In embodiments, the in vitro premature termination rate is determined as described in Bibillo and Eickbush (2002) J Biol Chem 277(38):34836-34845 (incorporated by reference herein its entirety).

In some embodiments, the reverse transcriptase domain is able to complete at least about 30% or 50% of integrations in cells. The percent of complete integrations can be measured by dividing the number of substantially full-length integration events (e.g., genomic sites that comprise at least 98% of the expected integrated sequence) by the number of total (including substantially full-length and partial) integration events in a population of cells. In embodiments, the integrations in cells is determined (e.g., across the integration site) using long-read amplicon sequencing, e.g., as described in Karst et al. (2020) bioRxiv doi.org/10.1101/645903 (incorporated by reference herein its in entirety).

In embodiments, quantifying integrations in cells comprises counting the fraction of integrations that contain at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the DNA sequence corresponding to the template RNA (e.g., a template RNA having a length of at least 0.05, 0.1, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, or 5 kb, e.g., a length between 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 1.0-1.2, 1.2-1.4, 1.4-1.6, 1.6-1.8, 1.8-2.0, 2-3, 3-4, or 4-5 kb).

In some embodiments, the reverse transcriptase domain is capable of polymerizing dNTPs in vitro. In embodiments, the reverse transciptase domain is capable of polymerizing dNTPs in vitro at a rate between 0.1-50 nt/sec (e.g., between 0.1-1, 1-10, or 10-50 nt/sec). In embodiments, polymerization of dNTPs by the reverse transcriptase domain is measured by a single-molecule assay, e.g., as described in Schwartz and Quake (2009) PNAS 106(48):20294-20299 (incorporated by reference in its entirety).

In some embodiments, the reverse transcriptase domain has an in vitro error rate (e.g., misincorporation of nucleotides) of between 1×10⁻³-1×10⁻⁴ or 1×10⁻⁴-1×10⁻⁵ substitutions/nt, e.g., as described in Yasukawa et al. (2017) Biochem Biophys Res Commun 492(2):147-153 (incorporated herein by reference in its entirety). In some embodiments, the reverse transcriptase domain has an error rate (e.g., misincorporation of nucleotides) in cells (e.g., HEK293T cells) of between 1×10⁻³-1×10⁻⁴ or 1×10⁻⁴-1×10⁻⁵ substitutions/nt, e.g., by long-read amplicon sequencing, e.g., as described in Karst et al. (2020) bioRxiv doi.org/10.1101/645903 (incorporated by reference herein in its entirety).

In some embodiments, the reverse transcriptase domain is capable of performing reverse transcription of a target RNA in vitro. In some embodiments, the reverse transcriptase requires a primer of at least 3 nt to initiate reverse transcription of a template. In some embodiments, reverse transcription of the target RNA is determined by detection of cDNA from the target RNA (e.g., when provided with a ssDNA primer, e.g., which anneals to the target with at least 3, 4, 5, 6, 7, 8, 9, or 10 nt at the 3′ end), e.g., as described in Bibillo and Eickbush (2002) J Biol Chem 277(38):34836-34845 (incorporated herein by reference in its entirety).

In some embodiments, the reverse transcriptase domain performs reverse transcription at least 5 or 10 times more efficiently (e.g., by cDNA production), e.g., when converting its RNA template to cDNA, for example, as compared to an RNA template lacking the protein binding motif (e.g., a 3′ UTR). In embodiments, efficiency of reverse transcription is measured as described in Yasukawa et al. (2017) Biochem Biophys Res Commun 492(2):147-153 (incorporated by reference herein in its entirety).

In some embodiments, the reverse transcriptase domain specifically binds a specific RNA template with higher frequency (e.g., about 5 or 10-fold higher frequency) than any endogenous cellular RNA, e.g., when expressed in cells (e.g., HEK293T cells). In embodiments, frequency of specific binding between the reverse transcriptase domain and the template RNA are measured by CLIP-seq, e.g., as described in Lin and Miles (2019) Nucleic Acids Res 47(11):5490-5501 (incorporated herein by reference in its entirety).

In some embodiments, a reverse transcriptase domain may comprise a mutation, e.g., as listed in Table 45. In embodiments, the mutation modifies, e.g., increases the stability and functionality of the RT domain. In some embodiments, the mutation modifies, e.g., increases processivity and template affinity of the RT domain. In some embodiments, the mutated RT domain may show at least 5 fold, at least 10 fold, at least 15 fold, at least 20 fold, at least 25 fold, at least 30 fold, at least 40 fold, at least 45 fold, at least 50 fold, at least 55 fold, at least 60 fold, at least 65 fold, at least 70 fold, at least 80 fold, at least 100 fold increase to processivity compared to an unmutated RT domain. In embodiments, a mutated RT domain may show at least at least 5 fold, at least 10 fold, at least 15 fold, at least 20 fold, at least 25 fold, at least 30 fold, at least 40 fold, at least 45 fold, at least 50 fold, at least 55 fold, at least 60 fold, at least 65 fold, at least 70 fold, at least 80 fold, at least 100 fold increase in template affinity compared to an unmutated RT domain. In some embodiments, a mutant RT domain may comprise one or more mutations selected from D200N/T330P/L603W, T306K, W313F, L139P, E607K.

Table 45 discloses mutations improve the properties of various reverse transcriptases. Core mutations expected to be the most impactful were applied across groups of retroviruses. Conservation of sequence across a group of viruses at one of these core mutations led to the installation of the mutation across that group (see Example 33, FIGS. 36A and B). Sequence positions refer to the positions in MMLV RT. In some embodiments, a RT domain described herein comprises a mutation as described in Table 45.

TABLE 45 List of exemplary RT domain mutations Group L139 D200 T306 W313 T330 L603 E607 Gamma D200N T306K W313F T330P L603W Epsilon D200N T306K W313F T330P L603W Delta L139P D200N X X T330P L603W* X Beta L139P X X X T330P X X Spuma D200N T306K X T330P L603W

Cas-RT Fusions

In some embodiments, a GeneWriter polypeptide comprises a RT domain fused to a Cas molecule. In some embodiments, the Cas molecule is the DBD and/or the endonuclease domain of the GeneWriter polypeptide. In some embodiments, the an RT domain comprises Cas9. In some embodiments, the Cas9 may comprise a mutation, e.g., a disclosed in Table 40A. Table 46 discloses a list of exemplary Cas-RT fusion proteins.

In some embodiments, a Cas molecule in a GeneWriter polypeptide has a similar activity to an otherwise similar Cas molecule that is not fused to a RT domain. In some embodiments, the activity is at least 40%, 50%, 60%, 70%, 80%, or 90% of that of the otherwise similar Cas molecule. In some embodiments, the Cas molecule in the GeneWriter polypeptide may have an indel formation activity at least 40%, 50%, 60%, 70%, 80%, or 90% of that of an otherwise similar Cas molecule that is not fused to a RT domain, e.g., in an assay according to Example 32.

In some embodiments, a GeneWriter polypeptide comprises an amino acid sequence according to Table 46 below, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, a nucleic acid encoding a GeneWriter polypeptide comprises a nucleic acid sequence according to Table 47, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto.

TABLE 46 List of exemplary Gene Writer polypeptides comprising Cas-RT fusions RT Cas retroviral RT source Name domain Linker source polypeptide Gene Writer polypeptide sequence Cas- Cas9 SGGSS Moloney P03355 MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVG RT(MMLV) (N863A) GGSSG murine WAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALL SETPG leukemia FDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS TSESA virus NEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNI TPESS (MMLV VDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLA GGSSG or LAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTY GSS MLVMS) NQLFEENPINASGVDAKAILSARLSKSRRLENLIA (SEQ QLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDA ID NO: KLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLS 1589) DAILLSDILRVNTEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGA SQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ RTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNR EKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEET ITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKV LPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSG EQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDS VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEEN EDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF LKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQG DSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMG RHKPENIVIEMARENQTTQKGQKNSRERMKRIEEG IKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKARGKSDNVPSEEVVKKMKNYWRQLLNAKLI TQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKL VSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAL IKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKA TAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNG ETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQT GGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSP TVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERS SFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHY EKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFS KRVILADANLDKVLSAYNKHRDKPIREQAENIIHL FTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATL IHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETP GTSESATPESSGGSSGGSSTLNIEDEYRLHETSKE PDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP LKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGI LVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKR VEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFF CLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQG FKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDL LLAATSELDCQQGTRALLQTLGNLGYRASAKKAQI CQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKT PRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPG TLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPF ELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILA PHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTR PDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVT TETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEI KNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEA RGNRMADQAARKAAITETPDTSTLLIENSSPSGGS KRTADGSEFEPKKKRKV (SEQ ID NO: 3560) Cas- Cas9 SGGSS Porcine Q4VFZ2 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWA RT(PERV) (N863A) GGSSG endogenous VITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD SETPG retrovirus SGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE TSESA (PERV) MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD TPESS EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALA GGSSG HMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQ GSS LFEENPINASGVDAKAILSARLSKSRRLENLIAQL (SEQ PGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKL ID NO: QLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDA 1589) ILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREK IEKILTFRIPYYVGPLARGNSRFAWMTRKSEETIT PWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLP KHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENED ILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMK QLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIK ELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYV DQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR SDKARGKSDNVPSEEVVKKMKNYWRQLLNAKLITQ RKFDNLTKAERGGLSELDKAGFIKRQLVETRQITK HVAQILDSRMNTKYDENDKLIREVKVITLKSKLVS DFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIK KYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGET GEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGG FSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENG RKRMLASAGELQKGNELALPSKYVNFLYLASHYEK LKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKR VILADANLDKVLSAYNKHRDKPIREQAENIIHLFT LTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIH QSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGT SESATPESSGGSSGGSSLDDEYRLYSPLVKPDQNI QFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASAT PVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQS PWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHP TVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHP TSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPT IFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGAT KQDCLEGTKALLLELSDLGYRASAKKAQICRREVT YLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVRE FLGKAGFCRLFIPGFATLAAPLYPLTKPKGEFSWA PEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDE RKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWP VCLKAIAAVAILVKDADKLTLGQNITVIAPHALEN IVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAAL NPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDI PLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTI WASSLPEGTSAQKAELMALTQALRLAEGKSINIYT DSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEI LSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMA DRVAKQAAQGVNLLP (SEQ ID NO: 3561) Cas- Cas9 SGGSS Murine Q7SVK7 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWA RT(MLVB (N863A) GGSSG leukemia VITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD M) SETPG virus SGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE TSESA (MLVBM) MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD TPESS EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALA GGSSG HMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQ GSS LFEENPINASGVDAKAILSARLSKSRRLENLIAQL (SEQ PGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKL ID NO: QLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDA 1589) ILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREK IEKILTFRIPYYVGPLARGNSRFAWMTRKSEETIT PWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLP KHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENED ILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMK QLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMGRDMYVDQELDINRLSDYDVDHIVPQ SFLKDDSIDNKVLTRSDKARGKSDNVPSEEVVKKM KNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSKLVSDFRKDFQFYKVREINNYHHA HDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVR KMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLAN GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKK DWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKS VKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL IIKLPKYSLFELENGRKRMLASAGELQKGNELALP SKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH YLDEIIEQISEFSKRVILADANLDKVLSAYNKHRD KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK RYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDS GGSSGGSSGSETPGTSESATPESSGGSSGGSSLGI EDEYRLHETSTEPDVSLGSTWLSDFPQAWAETGGM GLAVRQAPLIIPLKATSTPVSIQQYPMSHEARLGI KPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDY RPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQ WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGMGI SGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQH PDLILLQYVDDILLAATSELDCQQGTRALLQTLGD LGYRASAKKAQICQKQVKYLGYLLREGQRWLTEAR KETVMGQPVPKTPRQLREFLGKAGFCRLFIPGFAE MAAPLYPLTKPGTLFSWGPDQQKAYQEIKQALLTA PALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWR RPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAG KLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTH YQAMLLDTDRVQFGPVVALNPATLLPLPEEGAPHD CLEILAETHGTRPDLTDQPIPDADHTWYTDGSSFL QEGQRKAGAAVTTETEVIWAGALPAGTSAQRAELI ALTQALKMAEGKRLNVYTDSRYAFATAHIHGEIYR RRGWLTSEGREIKNKSEILALLKALFLPKRLSIIH CLGHQKGDSAEARGNRLADQAAREAAIKTPPDTST LLI (SEQ ID NO:3562) Cas- Cas9 SGGSS Mouse P03365 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWA RT (N863A) GGSSG mammary VITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD (MMTVB) SETPG tumor SGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE TSESA virus MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD TPESS (MMTVB EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALA GGSSG HMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQ GSS LFEENPINASGVDAKAILSARLSKSRRLENLIAQL (SEQ PGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKL ID NO: QLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDA 1589) ILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREK IEKILTFRIPYYVGPLARGNSRFAWMTRKSEETIT PWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLP KHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENED ILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMK QLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIK ELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYV DQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR SDKARGKSDNVPSEEVVKKMKNYWRQLLNAKLITQ RKFDNLTKAERGGLSELDKAGFIKRQLVETRQITK HVAQILDSRMNTKYDENDKLIREVKVITLKSKLVS DFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIK KYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGET GEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGG FSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENG RKRMLASAGELQKGNELALPSKYVNFLYLASHYEK LKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKR VILADANLDKVLSAYNKHRDKPIREQAENIIHLFT LTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIH QSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGT SESATPESSGGSSGGSSVQEISDSRPMLHIYLNGR RFLGLLDTGADKTCIAGRDWPANWPIHQTESSLQG LGMACGVARSSQPLRWQHEDKSGIIHPFVIPTLPF TLWGRDIMKDIKVRLMTDSPDDSQDLMIGAIESNL FADQISWKSDQPVWLNQWPLKQEKLQALQQLVTEQ LQLGHLEESNSPWNTPVFVIKKKSGKWRLLQDLRA VNATMHDMGALQPGLPSPVAVPKGWEIIIIDLQDC FFNIKLHPEDCKRFAFSVPSPNFKRPYQRFQWKVL PQGMKNSPTLCQKFVDKAILTVRDKYQDSYIVHYM DDILLAHPSRSIVDEILTSMIQALNKHGLVVSTEK IQKYDNLKYLGTHIQGDSVSYQKLQIRTDKLRTLN DFQKLLGNINWIRPFLKLTTGELKPLFEILNGDSN PISTRKLTPEACKALQLMNERLSTARVKRLDLSQP WSLCILKTEYTPTACLWQDGVVEWIHLPHISPKVI TPYDIFCTQLIIKGRHRSKELFSKDPDYIVVPYTK VQFDLLLQEKEDWPISLLGFLGEVHFHLPKDPLLT FTLQTAIIFPHMTSTTPLEKGIVIFTDGSANGRSV TYIQGREPIIKENTQNTAQQAEIVAVITAFEEVSQ PFNLYTDSKYVTGLFPEIETATLSPRTKIYTELKH LQRLIHKRQEKFYIGHIRGHTGLPGPLAQGNAYAD SLTRILTA(SEQ ID NO: 3563) Cas- Cas9 SGGSS Mason- P07572 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWA RT (N863A) GGSSG Pfizer VITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD (MPMV) SETPG monkey SGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE TSESA virus MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD TPESS (MPMV) EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALA GGSSG HMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQ GSS LFEENPINASGVDAKAILSARLSKSRRLENLIAQL (SEQ PGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKL ID NO: QLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDA 1589) ILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ EEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREK IEKILTFRIPYYVGPLARGNSRFAWMTRKSEETIT PWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLP KHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQ KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENED ILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMK QLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIK ELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYV DQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR SDKARGKSDNVPSEEVVKKMKNYWRQLLNAKLITQ RKFDNLTKAERGGLSELDKAGFIKRQLVETRQITK HVAQILDSRMNTKYDENDKLIREVKVITLKSKLVS DFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIK KYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGET GEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGG FSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENG RKRMLASAGELQKGNELALPSKYVNFLYLASHYEK LKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKR VILADANLDKVLSAYNKHRDKPIREQAENIIHLFT LTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIH QSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGT SESATPESSGGSSGGSSTAAIDILAPQQCAEPITW KSDEPVWVDQWPLTNDKLAAAQQLVQEQLEAGHIT ESSSPWNTPIFVIKKKSGKWRLLQDLRAVNATMVL MGALQPGLPSPVAIPQGYLKIIIDLKDCFFSIPLH PSDQKRFAFSLPSTNFKEPMQRFQWKVLPQGMANS PTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAG KDGQQVLQCFDQLKQELTAAGLHIAPEKVQLQDPY TYLGFELNGPKITNQKAVIRKDKLQTLNDFQKLLG DINWLRPYLKLTTGDLKPLFDTLKGDSDPNSHRSL SKEALASLEKVETAIAEQFVTHINYSLPLIFLIFN TALTPTGLFWQDNPIMWIHLPASPKKVLLPYYDAI ADLIILGRDHSKKYFGIEPSTIIQPYSKSQIDWLM QNTEMWPIACASFVGILDNHYPPNKLIQFCKLHTF VFPQIISKTPLNNALLVFTDGSSTGMAAYTLTDTT IKFQTNLNSAQLVELQALIAVLSAFPNQPLNIYTD SAYLAHSIPLLETVAQIKHISETAKLFLQCQQLIY NRSIPFYIGHVRAHSGLPGPIAQGNQRADLATKIV ASNINTN (SEQ ID NO: 3564)

TABLE 47 Exemplary Gene Writer polypeptide coding mRNAs sequences Name mRNA (5′ to 3′) Tail Cas9- AGGAAAUAAGAGAGAAAAGAAGAGU (A)80 RT(MMLV) AAGAAGAAAUAUAAGAGCCACCAUG (SEQ AAACGGACAGCCGACGGAAGCGAGU ID UCGAGUCACCAAAGAAGAAGCGGAA NO: AGUCGACAAGAAGUACAGCAUCGGC 3666) CUGGACAUCGGCACCAACUCUGUGG GCUGGGCCGUGAUCACCGACGAGUA CAAGGUGCCCAGCAAGAAAUUCAAG GUGCUGGGCAACACCGACCGGCACA GCAUCAAGAAGAACCUGAUCGGAGC CCUGCUGUUCGACAGCGGCGAAACA GCCGAGGCCACCCGGCUGAAGAGAA CCGCCAGAAGAAGAUACACCAGACG GAAGAACCGGAUCUGCUAUCUGCAA GAGAUCUUCAGCAACGAGAUGGCCA AGGUGGACGACAGCUUCUUCCACAG ACUGGAAGAGUCCUUCCUGGUGGAA GAGGAUAAGAAGCACGAGCGGCACC CCAUCUUCGGCAACAUCGUGGACGA GGUGGCCUACCACGAGAAGUACCCC ACCAUCUACCACCUGAGAAAGAAAC UGGUGGACAGCACCGACAAGGCCGA CCUGCGGCUGAUCUAUCUGGCCCUG GCCCACAUGAUCAAGUUCCGGGGCC ACUUCCUGAUCGAGGGCGACCUGAA CCCCGACAACAGCGACGUGGACAAG CUGUUCAUCCAGCUGGUGCAGACCU ACAACCAGCUGUUCGAGGAAAACCC CAUCAACGCCAGCGGCGUGGACGCC AAGGCCAUCCUGUCUGCCAGACUGA GCAAGAGCAGACGGCUGGAAAAUCU GAUCGCCCAGCUGCCCGGCGAGAAG AAGAAUGGCCUGUUCGGAAACCUGA UUGCCCUGAGCCUGGGCCUGACCCC CAACUUCAAGAGCAACUUCGACCUG GCCGAGGAUGCCAAACUGCAGCUGA GCAAGGACACCUACGACGACGACCU GGACAACCUGCUGGCCCAGAUCGGC GACCAGUACGCCGACCUGUUUCUGG CCGCCAAGAACCUGUCCGACGCCAU CCUGCUGAGCGACAUCCUGAGAGUG AACACCGAGAUCACCAAGGCCCCCC UGAGCGCCUCUAUGAUCAAGAGAUA CGACGAGCACCACCAGGACCUGACC CUGCUGAAAGCUCUCGUGCGGCAGC AGCUGCCUGAGAAGUACAAAGAGAU UUUCUUCGACCAGAGCAAGAACGGC UACGCCGGCUACAUUGACGGCGGAG CCAGCCAGGAAGAGUUCUACAAGUU CAUCAAGCCCAUCCUGGAAAAGAUG GACGGCACCGAGGAACUGCUCGUGA AGCUGAACAGAGAGGACCUGCUGCG GAAGCAGCGGACCUUCGACAACGGC AGCAUCCCCCACCAGAUCCACCUGG GAGAGCUGCACGCCAUUCUGCGGCG GCAGGAAGAUUUUUACCCAUUCCUG AAGGACAACCGGGAAAAGAUCGAGA AGAUCCUGACCUUCCGCAUCCCCUA CUACGUGGGCCCUCUGGCCAGGGGA AACAGCAGAUUCGCCUGGAUGACCA GAAAGAGCGAGGAAACCAUCACCCC CUGGAACUUCGAGGAAGUGGUGGAC AAGGGCGCUUCCGCCCAGAGCUUCA UCGAGCGGAUGACCAACUUCGAUAA GAACCUGCCCAACGAGAAGGUGCUG CCCAAGCACAGCCUGCUGUACGAGU ACUUCACCGUGUAUAACGAGCUGAC CAAAGUGAAAUACGUGACCGAGGGA AUGAGAAAGCCCGCCUUCCUGAGCG GCGAGCAGAAAAAGGCCAUCGUGGA CCUGCUGUUCAAGACCAACCGGAAA GUGACCGUGAAGCAGCUGAAAGAGG ACUACUUCAAGAAAAUCGAGUGCUU CGACUCCGUGGAAAUCUCCGGCGUG GAAGAUCGGUUCAACGCCUCCCUGG GCACAUACCACGAUCUGCUGAAAAU UAUCAAGGACAAGGACUUCCUGGAC AAUGAGGAAAACGAGGACAUUCUGG AAGAUAUCGUGCUGACCCUGACACU GUUUGAGGACAGAGAGAUGAUCGAG GAACGGCUGAAAACCUAUGCCCACC UGUUCGACGACAAAGUGAUGAAGCA GCUGAAGCGGCGGAGAUACACCGGC UGGGGCAGGCUGAGCCGGAAGCUGA UCAACGGCAUCCGGGACAAGCAGUC CGGCAAGACAAUCCUGGAUUUCCUG AAGUCCGACGGCUUCGCCAACAGAA ACUUCAUGCAGCUGAUCCACGACGA CAGCCUGACCUUUAAAGAGGACAUC CAGAAAGCCCAGGUGUCCGGCCAGG GCGAUAGCCUGCACGAGCACAUUGC CAAUCUGGCCGGCAGCCCCGCCAUU AAGAAGGGCAUCCUGCAGACAGUGA AGGUGGUGGACGAGCUCGUGAAAGU GAUGGGCCGGCACAAGCCCGAGAAC AUCGUGAUCGAAAUGGCCAGAGAGA ACCAGACCACCCAGAAGGGACAGAA GAACAGCCGCGAGAGAAUGAAGCGG AUCGAAGAGGGCAUCAAAGAGCUGG GCAGCCAGAUCCUGAAAGAACACCC CGUGGAAAACACCCAGCUGCAGAAC GAGAAGCUGUACCUGUACUACCUGC AGAAUGGGCGGGAUAUGUACGUGGA CCAGGAACUGGACAUCAACCGGCUG UCCGACUACGAUGUGGACCAUAUCG UGCCUCAGAGCUUUCUGAAGGACGA CUCCAUCGACAACAAGGUGCUGACC AGAAGCGACAAGGCCCGGGGCAAGA GCGACAACGUGCCCUCCGAAGAGGU CGUGAAGAAGAUGAAGAACUACUGG CGGCAGCUGCUGAACGCCAAGCUGA UUACCCAGAGAAAGUUCGACAAUCU GACCAAGGCCGAGAGAGGCGGCCUG AGCGAACUGGAUAAGGCCGGCUUCA UCAAGAGACAGCUGGUGGAAACCCG GCAGAUCACAAAGCACGUGGCACAG AUCCUGGACUCCCGGAUGAACACUA AGUACGACGAGAAUGACAAGCUGAU CCGGGAAGUGAAAGUGAUCACCCUG AAGUCCAAGCUGGUGUCCGAUUUCC GGAAGGAUUUCCAGUUUUACAAAGU GCGCGAGAUCAACAACUACCACCAC GCCCACGACGCCUACCUGAACGCCG UCGUGGGAACCGCCCUGAUCAAAAA GUACCCUAAGCUGGAAAGCGAGUUC GUGUACGGCGACUACAAGGUGUACG ACGUGCGGAAGAUGAUCGCCAAGAG CGAGCAGGAAAUCGGCAAGGCUACC GCCAAGUACUUCUUCUACAGCAACA UCAUGAACUUUUUCAAGACCGAGAU UACCCUGGCCAACGGCGAGAUCCGG AAGCGGCCUCUGAUCGAGACAAACG GCGAAACCGGGGAGAUCGUGUGGGA UAAGGGCCGGGAUUUUGCCACCGUG CGGAAAGUGCUGAGCAUGCCCCAAG UGAAUAUCGUGAAAAAGACCGAGGU GCAGACAGGCGGCUUCAGCAAAGAG UCUAUCCUGCCCAAGAGGAACAGCG AUAAGCUGAUCGCCAGAAAGAAGGA CUGGGACCCUAAGAAGUACGGCGGC UUCGACAGCCCCACCGUGGCCUAUU CUGUGCUGGUGGUGGCCAAAGUGGA AAAGGGCAAGUCCAAGAAACUGAAG AGUGUGAAAGAGCUGCUGGGGAUCA CCAUCAUGGAAAGAAGCAGCUUCGA GAAGAAUCCCAUCGACUUUCUGGAA GCCAAGGGCUACAAAGAAGUGAAAA AGGACCUGAUCAUCAAGCUGCCUAA GUACUCCCUGUUCGAGCUGGAAAAC GGCCGGAAGAGAAUGCUGGCCUCUG CCGGCGAACUGCAGAAGGGAAACGA ACUGGCCCUGCCCUCCAAAUAUGUG AACUUCCUGUACCUGGCCAGCCACU AUGAGAAGCUGAAGGGCUCCCCCGA GGAUAAUGAGCAGAAACAGCUGUUU GUGGAACAGCACAAGCACUACCUGG ACGAGAUCAUCGAGCAGAUCAGCGA GUUCUCCAAGAGAGUGAUCCUGGCC GACGCUAAUCUGGACAAAGUGCUGU CCGCCUACAACAAGCACCGGGAUAA GCCCAUCAGAGAGCAGGCCGAGAAU AUCAUCCACCUGUUUACCCUGACCA AUCUGGGAGCCCCUGCCGCCUUCAA GUACUUUGACACCACCAUCGACCGG AAGAGGUACACCAGCACCAAAGAGG UGCUGGACGCCACCCUGAUCCACCA GAGCAUCACCGGCCUGUACGAGACA CGGAUCGACCUGUCUCAGCUGGGAG GUGACUCUGGAGGAUCUAGCGGAGG AUCCUCUGGCAGCGAGACACCAGGA ACAAGCGAGUCAGCAACACCAGAGA GCAGUGGCGGCAGCAGCGGCGGCAG CAGCACCCUAAAUAUAGAAGAUGAG UAUCGGCUACAUGAGACCUCAAAAG AGCCAGAUGUUUCUCUAGGGUCCAC AUGGCUGUCUGAUUUUCCUCAGGCC UGGGCGGAAACCGGGGGCAUGGGAC UGGCAGUUCGCCAAGCUCCUCUGAU CAUACCUCUGAAAGCAACCUCUACC CCCGUGUCCAUAAAACAAUACCCCA UGUCACAAGAAGCCAGACUGGGGAU CAAGCCCCACAUACAGAGACUGUUG GACCAGGGAAUACUGGUACCCUGCC AGUCCCCCUGGAACACGCCCCUGCU ACCCGUUAAGAAACCAGGGACUAAU GAUUAUAGGCCUGUCCAGGAUCUGA GAGAAGUCAACAAGCGGGUGGAAGA CAUCCACCCCACCGUGCCCAACCCU UACAACCUCUUGAGCGGGCUCCCAC CGUCCCACCAGUGGUACACUGUGCU UGAUUUAAAGGAUGCCUUUUUCUGC CUGAGACUCCACCCCACCAGUCAGC CUCUCUUCGCCUUUGAGUGGAGAGA UCCAGAGAUGGGAAUCUCAGGACAA UUGACCUGGACCAGACUCCCACAGG GUUUCAAAAACAGUCCCACCCUGUU UAAUGAGGCACUGCACAGAGACCUA GCAGACUUCCGGAUCCAGCACCCAG ACUUGAUCCUGCUACAGUACGUGGA UGACUUACUGCUGGCCGCCACUUCU GAGCUAGACUGCCAACAAGGUACUC GGGCCCUGUUACAAACCCUAGGGAA CCUCGGGUAUCGGGCCUCGGCCAAG AAAGCCCAAAUUUGCCAGAAACAGG UCAAGUAUCUGGGGUAUCUUCUAAA AGAGGGUCAGAGAUGGCUGACUGAG GCCAGAAAAGAGACUGUGAUGGGGC AGCCUACUCCGAAGACCCCUCGACA ACUAAGGGAGUUCCUAGGGAAGGCA GGCUUCUGUCGCCUCUUCAUCCCUG GGUUUGCAGAAAUGGCAGCCCCCCU GUACCCUCUCACCAAACCGGGGACU CUGUUUAAUUGGGGCCCAGACCAAC AAAAGGCCUAUCAAGAAAUCAAGCA AGCUCUUCUAACUGCCCCAGCCCUG GGGUUGCCAGAUUUGACUAAGCCCU UUGAACUCUUUGUCGACGAGAAGCA GGGCUACGCCAAAGGUGUCCUAACG CAAAAACUGGGACCUUGGCGUCGGC CGGUGGCCUACCUGUCCAAAAAGCU AGACCCAGUAGCAGCUGGGUGGCCC CCUUGCCUACGGAUGGUAGCAGCCA UUGCCGUACUGACAAAGGAUGCAGG CAAGCUAACCAUGGGACAGCCACUA GUCAUUCUGGCCCCCCAUGCAGUAG AGGCACUAGUCAAACAACCCCCCGA CCGCUGGCUUUCCAACGCCCGGAUG ACUCACUAUCAGGCCUUGCUUUUGG ACACGGACCGGGUCCAGUUCGGACC GGUGGUAGCCCUGAACCCGGCUACG CUGCUCCCACUGCCUGAGGAAGGGC UGCAACACAACUGCCUUGAUAUCCU GGCCGAAGCCCACGGAACCCGACCC GACCUAACGGACCAGCCGCUCCCAG ACGCCGACCACACCUGGUACACGGA UGGAAGCAGUCUCUUACAAGAGGGA CAGCGUAAGGCGGGAGCUGCGGUGA CCACCGAGACCGAGGUAAUCUGGGC UAAAGCCCUGCCAGCCGGGACAUCC GCUCAGCGGGCUGAACUGAUAGCAC UCACCCAGGCCCUAAAGAUGGCAGA AGGUAAGAAGCUAAAUGUUUAUACU GAUAGCCGUUAUGCUUUUGCUACUG CCCAUAUCCAUGGAGAAAUAUACAG AAGGCGUGGGUGGCUCACAUCAGAA GGCAAAGAGAUCAAAAAUAAAGACG AGAUCUUGGCCCUACUAAAAGCCCU CUUUCUGCCCAAAAGACUUAGCAUA AUCCAUUGUCCAGGACAUCAAAAGG GACACAGCGCCGAGGCUAGAGGCAA CCGGAUGGCUGACCAAGCGGCCCGA AAGGCAGCCAUCACAGAGACUCCAG ACACCUCUACCCUCCUCAUAGAAAA UUCAUCACCCUCUGGCGGCUCAAAA AGAACCGCCGACGGCAGCGAAUUCG AGCCCAAGAAGAAGAGGAAAGUCUG AUUAAUUAAGCUGCCUUCUGCGGGG CUUGCCUUCUGGCCAUGCCCUUCUU CUCUCCCUUGCACCUGUACCUCUUG GUCUUUGAAUAAAGCCUGAGUAGGA AGUCUAG (SEQ ID NO: 3565) Cas9- AGGAAAUAAGAGAGAAAAGAAGAGU (A)80 RT(PERV) AAGAAGAAAUAUAAGAGCCACCAUG (SEQ GCUCCCAAAAAGAAAAGGAAGGUGG ID GCAUUCACGGCGUGCCUGCGGCCGA NO: CAAAAAGUACAGCAUCGGCCUUGAU 3666) AUCGGCACCAAUAGCGUGGGCUGGG CCGUUAUCACAGACGAAUACAAGGU ACCCAGCAAGAAGUUCAAGGUGCUG GGGAAUACAGACAGGCACUCUAUCA AGAAAAACCUUAUCGGGGCUCUGCU GUUUGACUCAGGCGAGACCGCCGAG GCCACCAGGUUGAAGAGGACCGCAA GGCGAAGGUACACCCGGAGGAAGAA CAGGAUCUGCUAUCUGCAGGAGAUC UUCAGCAACGAGAUGGCCAAGGUGG ACGACAGCUUCUUCCACAGGCUGGA GGAGAGCUUCCUUGUCGAGGAGGAU AAGAAGCACGAACGACACCCCAUCU UCGGCAACAUAGUCGACGAGGUCGC UUAUCACGAGAAGUACCCCACCAUC UACCACCUGCGAAAGAAAUUGGUGG AUAGCACCGAUAAAGCCGACUUGCG ACUUAUCUACUUGGCUCUGGCGCAC AUGAUUAAGUUCAGGGGCCACUUCC UGAUCGAGGGCGACCUUAACCCCGA CAACAGUGACGUAGACAAAUUGUUC AUCCAGCUUGUACAGACCUAUAACC AGCUGUUCGAGGAAAACCCUAUUAA CGCCAGCGGGGUGGAUGCGAAGGCC AUACUUAGCGCCAGGCUGAGCAAAA GCAGGCGCUUGGAGAACCUGAUAGC CCAGCUGCCCGGUGAAAAGAAGAAC GGCCUCUUCGGUAAUCUGAUUGCCC UGAGCCUGGGCCUGACCCCCAACUU CAAGAGCAACUUCGACCUGGCAGAA GAUGCCAAGCUGCAGUUGAGUAAGG ACACCUAUGACGACGACUUGGACAA UCUGCUCGCCCAAAUCGGCGACCAG UACGCUGACCUGUUCCUCGCCGCCA AGAACCUUUCUGACGCAAUCCUGCU UAGCGAUAUCCUUAGGGUGAACACA GAGAUCACCAAGGCCCCCCUGAGCG CCAGCAUGAUCAAGAGGUACGACGA GCACCAUCAGGACCUGACCCUUCUG AAGGCCCUGGUGAGGCAGCAACUGC CCGAGAAGUACAAGGAGAUCUUUUU CGACCAGAGCAAGAACGGCUACGCC GGCUACAUCGACGGCGGAGCCAGCC AAGAGGAGUUCUACAAGUUCAUCAA GCCCAUCCUGGAGAAGAUGGAUGGC ACCGAGGAGCUGCUGGUGAAGCUGA ACAGGGAAGAUUUGCUCCGGAAGCA GAGGACCUUUGACAACGGUAGCAUC CCCCACCAGAUCCACCUGGGCGAGC UGCACGCAAUACUGAGGCGACAGGA GGAUUUCUACCCCUUCCUCAAGGAC AAUAGGGAGAAAAUCGAAAAGAUUC UGACCUUCAGGAUCCCCUACUACGU GGGCCCUCUUGCCAGGGGCAACAGC CGAUUCGCUUGGAUGACAAGAAAGA GCGAGGAGACCAUCACCCCCUGGAA CUUCGAGGAAGUGGUGGACAAAGGA GCAAGCGCGCAGUCUUUCAUCGAAC GGAUGACCAAUUUCGACAAAAACCU GCCUAACGAGAAGGUGCUGCCCAAG CACAGCCUGCUUUACGAGUACUUCA CCGUGUACAACGAGCUCACCAAGGU GAAAUAUGUGACCGAGGGCAUGCGA AAACCCGCUUUCCUGAGCGGCGAGC AGAAGAAGGCCAUCGUGGACCUGCU GUUCAAGACCAACAGGAAGGUGACC GUGAAGCAGCUGAAGGAGGACUACU UCAAGAAGAUCGAGUGCUUUGAUAG CGUGGAAAUAAGCGGCGUGGAGGAC AGGUUCAACGCCAGCCUGGGCACCU ACCACGACUUGUUGAAGAUAAUCAA AGACAAGGAUUUCCUGGAUAAUGAG GAGAACGAGGAUAUACUCGAGGACA UCGUGCUGACUUUGACCCUGUUUGA GGACCGAGAGAUGAUUGAAGAAAGG CUCAAAACCUACGCCCACCUGUUCG ACGACAAAGUGAUGAAACAACUGAA GAGACGAAGAUACACCGGCUGGGGC AGACUGUCCAGGAAGCUCAUCAACG GCAUUAGGGACAAGCAGAGCGGCAA GACCAUCCUGGAUUUCCUGAAGUCC GACGGCUUCGCCAACCGAAACUUCA UGCAGCUGAUUCACGAUGACAGCUU GACCUUCAAGGAGGACAUCCAGAAG GCCCAGGUUAGCGGCCAGGGCGACU CCCUGCACGAACAUAUUGCAAACCU GGCAGGCUCCCCUGCGAUCAAGAAG GGCAUACUGCAGACCGUUAAGGUUG UGGACGAAUUGGUCAAGGUCAUGGG CAGGCACAAGCCCGAAAACAUAGUU AUAGAGAUGGCCAGAGAGAACCAGA CCACCCAAAAGGGCCAGAAGAACAG CCGGGAGCGCAUGAAAAGGAUCGAG GAGGGUAUCAAGGAACUCGGAAGCC AGAUCCUCAAAGAGCACCCCGUGGA GAAUACCCAGCUCCAGAACGAGAAG CUGUACCUGUACUACCUGCAGAACG GCAGGGACAUGUACGUUGACCAGGA GUUGGACAUCAACAGGCUUUCAGAC UAUGACGUGGAUCACAUAGUGCCCC AGAGCUUUCUUAAAGACGAUAGCAU CGACAACAAGGUCCUGACCCGCUCC GACAAAGCCAGGGGCAAAAGCGACA ACGUGCCAAGCGAAGAGGUGGUUAA AAAGAUGAAGAACUACUGGAGGCAA CUGCUCAACGCGAAAUUGAUCACCC AGAGAAAGUUCGAUAACCUGACCAA GGCCGAGAGGGGCGGACUCUCCGAA CUUGACAAAGCGGGCUUCAUAAAGA GGCAGCUGGUCGAGACCCGACAGAU CACGAAGCACGUGGCCCAAAUCCUC GACAGCAGAAUGAAUACCAAGUACG AUGAGAAUGACAAACUCAUCAGGGA AGUGAAAGUGAUUACCCUGAAGAGC AAGUUGGUGUCCGACUUUCGCAAAG AUUUCCAGUUCUACAAGGUGAGGGA GAUCAACAACUACCACCAUGCCCAC GACGCAUACCUGAACGCCGUGGUCG GCACCGCCCUGAUUAAGAAGUAUCC AAAGCUGGAGUCCGAAUUUGUCUAC GGCGACUACAAAGUUUACGAUGUGA GGAAGAUGAUCGCUAAGAGCGAACA GGAGAUCGGCAAGGCCACCGCUAAG UAUUUCUUCUACAGCAACAUCAUGA ACUUUUUCAAGACCGAGAUCACACU UGCCAACGGCGAAAUCAGGAAGAGG CCGCUUAUCGAGACCAACGGUGAGA CCGGCGAGAUCGUGUGGGACAAGGG CAGGGACUUCGCCACCGUGAGGAAA GUCCUGAGCAUGCCCCAGGUGAAUA UUGUGAAAAAAACUGAGGUGCAGAC AGGCGGCUUUAGCAAGGAAUCCAUC CUGCCCAAGAGGAACAGCGACAAGC UGAUCGCCCGGAAGAAGGACUGGGA CCCUAAGAAGUAUGGAGGCUUCGAC AGCCCCACCGUAGCCUACAGCGUGC UGGUGGUCGCGAAGGUAGAGAAGGG GAAGAGCAAGAAACUGAAGAGCGUG AAGGAGCUGCUCGGCAUAACCAUCA UGGAGAGGUCCAGCUUUGAGAAGAA CCCCAUUGACUUUUUGGAAGCCAAG GGCUACAAAGAGGUCAAAAAGGACC UGAUCAUCAAACUCCCCAAGUACUC CCUGUUUGAAUUGGAGAACGGCAGA AAGAGGAUGCUGGCGAGCGCUGGGG AACUGCAAAAGGGCAACGAACUGGC GCUGCCCAGCAAGUACGUGAAUUUU CUGUACCUGGCGUCCCACUACGAAA AGCUGAAAGGCAGCCCCGAGGACAA CGAGCAGAAGCAGCUGUUCGUGGAG CAGCACAAGCAUUACCUGGACGAGA UAAUCGAGCAAAUCAGCGAGUUCAG CAAGAGGGUGAUUCUGGCCGACGCG AACCUGGAUAAGGUCCUCAGCGCCU ACAACAAGCACCGAGACAAACCCAU CAGGGAGCAGGCCGAGAAUAUCAUA CACCUGUUCACCCUGACAAAUCUGG GCGCACCUGCGGCAUUCAAAUACUU CGAUACCACCAUCGACAGGAAAAGG UACACUAGCACUAAGGAGGUGCUGG AUGCCACCUUGAUCCACCAGUCCAU UACCGGCCUGUAUGAGACCAGGAUC GACCUGAGCCAGCUUGGAGGCGACU CUGGAGGAUCUAGCGGAGGAUCCUC UGGCAGCGAGACACCAGGAACAAGC GAGUCAGCAACACCAGAGAGCAGUG GCGGCAGCAGCGGCGGCAGCAGCCU GGACGACGAGUACAGACUGUAUAGC CCUCUGGUGAAGCCAGAUCAGAACA UUCAGUUCUGGCUGGAACAGUUUCC ACAGGCCUGGGCCGAAACAGCCGGA AUGGGCCUGGCCAAGCAGGUGCCUC CUCAGGUGAUCCAGCUGAAGGCCAG CGCCACACCUGUGUCCGUGCGGCAG UACCCUCUGUCCAAGGAGGCUCAGG AGGGCAUCAGACCUCACGUCCAGCG GCUGAUCCAGCAGGGGAUCCUGGUG CCCGUGCAAAGCCCUUGGAACACCC CUCUUCUGCCCGUGAGAAAACCCGG CACAAACGACUACCGGCCUGUGCAG GACCUGAGAGAAGUGAACAAGCGGG UGCAGGACAUCCACCCCACAGUGCC AAAUCCUUACAACCUGCUUUGUGCC CUGCCCCCCCAGCGCAGCUGGUACA CCGUUCUGGACCUGAAAGAUGCCUU UUUCUGUCUGAGACUUCAUCCUACA AGCCAGCCCCUGUUCGCCUUCGAGU GGCGGGAUCCUGGCACCGGCCGGAC AGGCCAGCUGACAUGGACCAGACUG CCUCAGGGCUUCAAGAACAGCCCUA CCAUCUUCAACGAGGCCCUGCACAG AGACCUUGCCAACUUCAGAAUCCAA CACCCACAGGUGACCCUGCUCCAGU ACGUGGAUGACCUGCUGCUGGCCGG CGCCACAAAACAAGAUUGCCUGGAA GGCACCAAGGCCCUUCUGCUGGAGC UGAGCGACCUGGGAUAUCGGGCCUC UGCUAAGAAAGCUCAGAUCUGCAGG AGAGAGGUGACCUACCUGGGCUACU CUCUGAGAGAUGGCCAAAGAUGGCU GACCGAGGCCAGAAAGAAAACCGUG GUGCAAAUCCCCGCUCCUACAACAG CCAAGCAGGUUAGAGAGUUCCUGGG AAAGGCUGGAUUUUGCAGACUGUUC AUCCCAGGCUUUGCCACCCUGGCCG CCCCUCUGUACCCCCUGACCAAACC UAAGGGCGAGUUCAGCUGGGCCCCA GAGCACCAGAAGGCAUUCGACGCGA UCAAGAAGGCUCUGCUGUCUGCCCC UGCCCUGGCUCUGCCCGACGUGACA AAGCCCUUCACCCUGUACGUGGACG AACGGAAGGGCGUGGCUAGAGGCGU UCUGACCCAGACCCUGGGUCCUUGG AGAAGGCCUGUGGCCUACCUCAGUA AGAAGCUGGAUCCUGUGGCCUCUGG CUGGCCUGUGUGCCUGAAGGCCAUC GCCGCCGUGGCCAUUCUGGUCAAGG AUGCCGAUAAGCUGACCCUAGGCCA GAAUAUCACCGUGAUCGCCCCUCAC GCCCUCGAGAACAUCGUGCGGCAGC CUCCCGACAGAUGGAUGACCAACGC CAGAAUGACCCACUACCAGAGCCUG UUGCUGACCGAGAGAGUGACCUUCG CCCCUCCAGCUGCCCUGAAUCCCGC CACUCUGCUGCCCGAGGAAACCGAC GAGCCUGUGACCCACGACUGCCACC AGCUGCUGAUCGAGGAAACCGGCGU CAGAAAGGACCUGACAGAUAUCCCU CUGACCGGAGAGGUGCUGACAUGGU UCACCGACGGCAGCAGCUACGUCGU GGAAGGCAAGCGGAUGGCCGGCGCC GCUGUGGUCGACGGCACAAGAACCA UCUGGGCUUCCAGCCUGCCUGAGGG CACCAGCGCCCAGAAGGCCGAGCUG AUGGCCCUCACACAGGCCCUGCGGC UGGCUGAGGGCAAAAGCAUCAACAU CUAUACAGACAGCCGUUACGCCUUC GCCACAGCGCACGUGCACGGCGCCA UCUACAAGCAGAGAGGAUGGCUGAC CUCUGCCGGAAGAGAAAUCAAGAAC AAGGAAGAAAUCCUGAGCCUGCUGG AAGCCCUGCAUCUCCCAAAGAGACU GGCCAUCAUCCACUGCCCCGGCCAC CAGAAGGCCAAAGACCCUAUCAGCA GAGGCAACCAGAUGGCCGACCGGGU GGCCAAGCAAGCCGCCCAAGGCGUG AAUCUGCUGCCUUAGUUAAUUAAGC UGCCUUCUGCGGGGCUUGCCUUCUG GCCAUGCCCUUCUUCUCUCCCUUGC ACCUGUACCUCUUGGUCUUUGAAUA AAGCCUGAGUAGGAAGUCUAG (SEQ ID NO: 3566)

In some embodiments, a fusion protein may comprise a Cas molecule, e.g., a mutated Cas9, e.g., a Cas-nuclease containing a mutation inhibiting (e.g., inactivating) one endonuclease active site, e.g., the Cas9 nickase Cas9(N863A). In some embodiments, the fusion protein comprises a peptide linker, e.g., a glycine serine rich flexible peptide linker, e.g., a linker as disclosed in Tables 38 and/or 42, e.g., linker 10, in Table 42. In some embodiments, the fusion protein comprises a RT domain, e.g., a RT domain comprising a sequence from Table 1, Table 3, Table 30, Table 31, Table 41, Table 44, Table 50, or a fragment or variant thereof. In some embodiments, the Cas-RT fusion protein (or nucleic acid encoding the same) is formulated with a gRNA. In some embodiments, the linker length is between 2-40 amino acids, between 5-30 amino acids, between 5-20 amino acids, between 10-20 amino acids, or between 10-15 amino acids. In some embodiments, the Cas-RT fusion proteins has similar DNA binding activity to a Cas molecule that is not fused with a RT domain. In some embodiments, a Cas-RT may comprise a RT domain comprising a mutation. In embodiments, the mutant RT domain shows increased processivility and template affinity compared to an unmutated RT domain. Target Site

In some embodiments, after Gene Writing, the target site surrounding the integrated sequence contains a limited number of insertions or deletions, for example, in less than about 50% or 10% of integration events, e.g., as determined by long-read amplicon sequencing of the target site, e.g., as described in Karst et al. (2020) bioRxiv doi.org/10.1101/645903 (incorporated by reference herein in its entirety). In some embodiments, the target site does not show multiple insertion events, e.g., head-to-tail or head-to-head duplications, e.g., as determined by long-read amplicon sequencing of the target site, e.g., as described in Karst et al. bioRxiv doi.org/10.1101/645903 (2020) (incorporated herein by reference in its entirety). In some embodiments, the target site contains an integrated sequence corresponding to the template RNA. In some embodiments, the target site does not contain insertions resulting from endogenous RNA in more than about 1% or 10% of events, e.g., as determined by long-read amplicon sequencing of the target site, e.g., as described in Karst et al. bioRxiv doi.org/10.1101/645903 (2020) (incorporated herein by reference in its entirety). In some embodiments, the target site contains the integrated sequence corresponding to the template RNA.

Second Strand Nicking

In some embodiments, a Gene Writer system described herein comprises nickase activity that nicks the first strand and the second strand of target DNA. As discussed herein, without wishing to be bound by theory, nicking of the first strand of the target site DNA is thought to provide a 3′ OH that can be used by an RT domain to reverse transcribe a sequence of a template RNA, e.g., a heterologous object sequence. Without wishing to be bound by theory, it is thought that introducing an additional nick to the second strand may bias the cellular DNA repair machinery to adopt the heterologous object sequence-based sequence more frequently than the original genomic sequence. In some embodiments, the additional nick to the second strand is made by the same endonuclease domain (e.g., nickase domain) as the nick to the first strand. In some embodiments, the same Gene Writer polypeptide performs both the nick to the first strand and the nick to the second strand. In some embodiments, the Gene Writer polypeptide comprises a CRISPR/Cas domain and the additional nick to the second strand is directed by an additional nucleic acid, e.g., comprising a second gRNA directing the CRISPR/Cas domain to nick the second strand. In other embodiments, the additional second strand nick is made by a different endonuclease domain (e.g., nickase domain) than the nick to the first strand. In some embodiments, that different endonuclease domain is situated in an additional polypeptide (e.g., a system of the invention further comprises the additional polypeptide), separate from the Gene Writer polypeptide. In some embodiments, the additional polypeptide comprises an endonuclease domain (e.g., nickase domain) described herein. In some embodiments, the additional polypeptide comprises a DNA binding domain, e.g., described herein.

It is contemplated herein that the position at which the second strand nick occurs relative to the first strand nick may influence the extent to which one or more of: desired Gene Writing DNA modifications are obtained, undesired double-strand breaks (DSBs) occur, undesired insertions occur, or undesired deletions occur. Without wishing to be bound by theory, second strand nicking may occur in two general orientations: inward nicks and outward nicks.

In some embodiments, in the inward nick orientation, the RT domain polymerizes (e.g., using the template RNA (e.g., the heterologous object sequence)) away the second strand nick. In some embodiments, in the inward nick orientation, the location of the nick to the first strand and the location of the nick to the second strand are positioned between the first PAM site and second PAM site (e.g., in a scenario wherein both nicks are made by a polypeptide (e.g., a Gene Writer polypeptide) comprising a CRISPR/Cas domain). In some embodiments, in the inward nick orientation, the location of the nick to the first strand and the location of the nick to the second strand are between the sites where the polypeptide and the additional polypeptide bind to the target DNA. In some embodiments, in the inward nick orientation, the location of the nick to the second strand is positioned on the same side of the binding sites of the polypeptide and additional polypeptide relative to the location of the nick to the first strand. In some embodiments, in the inward nick orientation, the location of the nick to the first strand and the location of the nick to the second strand are positioned between the PAM site and the site at a distance from the target site.

An example of a Gene Writer system that provides an inward nick orientation comprises a Gene Writer polypeptide comprising a CRISPR/Cas domain, a template RNA comprising a gRNA that directs nicking of the target site DNA on the first strand, and an additional nucleic acid comprising an additional gRNA that directs nicking at a site a distance from the location of the first nick, wherein the location of the first nick and the location of the second nick are between the PAM sites of the sites to which the two gRNAs direct the Gene Writer polypeptide. As a further example, another Gene Writer system that provides an inward nick orientation comprises a Gene Writer polypeptide comprising a zinc finger molecule and a first nickase domain wherein the zinc finger molecule binds to the target DNA in a manner that directs the first nickase domain to nick the first strand of the target site; an additional polypeptide comprising a CRISPR/Cas domain, and an additional nucleic acid comprising a gRNA that directs the additional polypeptide to nick a site a distance from the target site DNA on the second strand, wherein the location of the first nick and the location of the second nick are between the PAM site and the site to which the zinc finger molecule binds. As a further example, another Gene Writer system that provides an inward nick orientation comprises a Gene Writer polypeptide comprising a zinc finger molecule and a first nickase domain wherein the zinc finger molecule binds to the target DNA in a manner that directs the first nickase domain to nick the first strand of the target site; an additional polypeptide comprising a TAL effector molecule and a second nickase domain wherein the TAL effector molecule binds to a site a distance from the target site in a manner that directs the additional polypeptide to nick the second strand, wherein the location of the first nick and the location of the second nick are between the site to which the TAL effector molecule binds and the site to which the zinc finger molecule binds.

In some embodiments, in the outward nick orientation, the RT domain polymerizes (e.g., using the template RNA (e.g., the heterologous object sequence)) toward the second strand nick. In some embodiments, in the inward nick orientation when both the first and second nicks are made by a polypeptide comprising a CRISPR/Cas domain (e.g., a Gene Writer polypeptide), the first PAM site and second PAM site are positioned between the location of the nick to the first strand and the location of the nick to the second strand. In some embodiments, in the inward nick orientation, the polypeptide (e.g., the Gene Writer polypeptide) and the additional polypeptide bind to sites on the target DNA between the location of the nick to the first strand and the location of the nick to the second. In some embodiments, in the inward nick orientation, the location of the nick to the second strand is positioned on the opposite side of the binding sites of the polypeptide and additional polypeptide relative to the location of the nick to the first strand. In some embodiments, in the inward orientation, the PAM site and the site at a distance from the target site are positioned between the location of the nick to the first strand and the location of the nick to the second strand.

An example of a Gene Writer system that provides an outward nick orientation comprises a Gene Writer polypeptide comprising a CRISPR/Cas domain, a template RNA comprising a gRNA that directs nicking of the target site DNA on the first strand, and an additional nucleic acid comprising an additional gRNA that directs nicking at a site a distance from the location of the first nick, wherein the location of the first nick and the location of the second nick are outside of the PAM sites of the sites to which the two gRNAs direct the Gene Writer polypeptide (i.e., the PAM sites are between the location of the first nick and the location of the second nick). As a further example, another Gene Writer system that provides an outward nick orientation comprises a Gene Writer polypeptide comprising a zinc finger molecule and a first nickase domain wherein the zinc finger molecule binds to the target DNA in a manner that directs the first nickase domain to nick the first strand of the target site; an additional polypeptide comprising a CRISPR/Cas domain, and an additional nucleic acid comprising a gRNA that directs the additional polypeptide to nick a site a distance from the target site DNA on the second strand, wherein the location of the first nick and the location of the second nick are outside the PAM site and the site to which the zinc finger molecule binds (i.e., the PAM site and the site to which the zinc finger molecule binds are between the location of the first nick and the location of the second nick). As a further example, another Gene Writer system that provides an outward nick orientation comprises a Gene Writer polypeptide comprising a zinc finger molecule and a first nickase domain wherein the zinc finger molecule binds to the target DNA in a manner that directs the first nickase domain to nick the first strand of the target site; an additional polypeptide comprising a TAL effector molecule and a second nickase domain wherein the TAL effector molecule binds to a site a distance from the target site in a manner that directs the additional polypeptide to nick the second strand, wherein the location of the first nick and the location of the second nick are outside the site to which the TAL effector molecule binds and the site to which the zinc finger molecule binds (i.e., the site to which the TAL effector molecule binds and the site to which the zinc finger molecule binds are between the location of the first nick and the location of the second nick).

Without wishing to be bound by theory, it is thought that, for Gene Writer systems where a second strand nick is provided, an outward nick orientation is preferred in some embodiments. As is described herein, an inward nick may produce a higher number of double-strand breaks (DSBs) than an outward nick orientation. DSBs may be recognized by the DSB repair pathways in the nucleus of a cell, which can result in undesired insertions and deletions. An outward nick orientation may provide a decreased risk of DSB formation, and a corresponding lower amount of undesired insertions and deletions. In some embodiments, undesired insertions and deletions are insertions and deletions not encoded by the heterologous object sequence, e.g., an insertion or deletion produced by the double-strand break repair pathway unrelated to the modification encoded by the heterologous object sequence. In some embodiments, a desired Gene Writing modification comprises a change to the target DNA (e.g., a substitution, insertion, or deletion) encoded by the heterologous object sequence (e.g., and achieved by the Gene Writer writing the heterologous object sequence into the target site). In some embodiments, the first strand nick and the second strand nick are in an outward orientation.

In addition, the distance between the first strand nick and second strand nick may influence the extent to which one or more of: desired Gene Writing DNA modifications are obtained, undesired double-strand breaks (DSBs) occur, undesired insertions occur, or undesired deletions occur. Without wishing to be bound by theory, it is thought the second strand nick benefit, the biasing of DNA repair toward incorporation of the heterologous object sequence into the target DNA, increases as the distance between the first strand nick and second strand nick decreases. However, it is thought that the risk of DSB formation also increases as the distance between the first strand nick and second strand nick decreases. Correspondingly, it is thought that the number of undesired insertions and/or deletions may increase as the distance between the first strand nick and second strand nick decreases. In some embodiments, the distance between the first strand nick and second strand nick is chosen to balance the benefit of biasing DNA repair toward incorporation of the heterologous object sequence into the target DNA and the risk of DSB formation and of undesired deletions and/or insertions. In some embodiments, a system where the first strand nick and the second strand nick are at least a threshold distance apart has an increased level of desired Gene Writing modification outcomes, a decreased level of undesired deletions, and/or a decreased level of undesired insertions relative to an otherwise similar inward nick orientation system where the first nick and the second nick are less than the a threshold distance apart. In some embodiments the threshold distance(s) is given below.

In some embodiments, the first nick and the second nick are at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nucleotides apart. In some embodiments, the first nick and the second nick are no more than 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, or 250 nucleotides apart. In some embodiments, the first nick and the second nick are 20-200, 30-200, 40-200, 50-200, 60-200, 70-200, 80-200, 90-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 160-200, 170-200, 180-200, 190-200, 20-190, 30-190, 40-190, 50-190, 60-190, 70-190, 80-190, 90-190, 100-190, 110-190, 120-190, 130-190, 140-190, 150-190, 160-190, 170-190, 180-190, 20-180, 30-180, 40-180, 50-180, 60-180, 70-180, 80-180, 90-180, 100-180, 110-180, 120-180, 130-180, 140-180, 150-180, 160-180, 170-180, 20-170, 30-170, 40-170, 50-170, 60-170, 70-170, 80-170, 90-170, 100-170, 110-170, 120-170, 130-170, 140-170, 150-170, 160-170, 20-160, 30-160, 40-160, 50-160, 60-160, 70-160, 80-160, 90-160, 100-160, 110-160, 120-160, 130-160, 140-160, 150-160, 20-150, 30-150, 40-150, 50-150, 60-150, 70-150, 80-150, 90-150, 100-150, 110-150, 120-150, 130-150, 140-150, 20-140, 30-140, 40-140, 50-140, 60-140, 70-140, 80-140, 90-140, 100-140, 110-140, 120-140, 130-140, 20-130, 30-130, 40-130, 50-130, 60-130, 70-130, 80-130, 90-130, 100-130, 110-130, 120-130, 20-120, 30-120, 40-120, 50-120, 60-120, 70-120, 80-120, 90-120, 100-120, 110-120, 20-110, 30-110, 40-110, 50-110, 60-110, 70-110, 80-110, 90-110, 100-110, 20-100, 30-100, 40-100, 50-100, 60-100, 70-100, 80-100, 90-100, 20-90, 30-90, 40-90, 50-90, 60-90, 70-90, 80-90, 20-80, 30-80, 40-80, 50-80, 60-80, 70-80, 20-70, 30-70, 40-70, 50-70, 60-70, 20-60, 30-60, 40-60, 50-60, 20-50, 30-50, 40-50, 20-40, 30-40, or 20-30 nucleotides apart. In some embodiments, the first nick and the second nick are 40-100 nucleotides apart.

Without wishing to be bound by theory, it is thought that, for Gene Writer systems where a second strand nick is provided and an inward nick orientation is selected, increasing the distance between the first strand nick and second strand nick may be preferred. As is described herein, an inward nick orientation may produce a higher number of DSBs than an outward nick orientation, and may result in a higher amount of undesired insertions and deletions than an outward nick orientation, but increasing the distance between the nicks may mitigate that increase in DSBs, undesired deletions, and/or undesired insertions. In some embodiments, an inward nick orientation wherein the first nick and the second nick are at least a threshold distance apart has an increased level of desired Gene Writing modification outcomes, a decreased level of undesired deletions, and/or a decreased level of undesired insertions relative to an otherwise similar inward nick orientation system where the first nick and the second nick are less than the a threshold distance apart. In some embodiments the threshold distance is given below.

In some embodiments, the first strand nick and the second strand nick are in an inward orientation. In some embodiments, the first strand nick and the second strand nick are in an inward orientation and the first strand nick and second strand nick are at least 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 220, 240, 260, 280, 300, 350, 400, 450, or 500 nucleotides apart, e.g., at least 100 nucleotides apart, (and optionally no more than 500, 400, 300, 200, 190, 180, 170, 160, 150, 140, 130, or 120 nucleotides apart). In some embodiments, the first strand nick and the second strand nick are in an inward orientation and the first strand nick and second strand nick are 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 160-200, 170-200, 180-200, 190-200, 100-190, 110-190, 120-190, 130-190, 140-190, 150-190, 160-190, 170-190, 180-190, 100-180, 110-180, 120-180, 130-180, 140-180, 150-180, 160-180, 170-180, 100-170, 110-170, 120-170, 130-170, 140-170, 150-170, 160-170, 100-160, 110-160, 120-160, 130-160, 140-160, 150-160, 100-150, 110-150, 120-150, 130-150, 140-150, 100-140, 110-140, 120-140, 130-140, 100-130, 110-130, 120-130, 100-120, 110-120, or 100-110 nucleotides apart.

Evolved Variants of Gene Writers

In some embodiments, the invention provides evolved variants of Gene Writers. Evolved variants can, in some embodiments, be produced by mutagenizing a reference Gene Writer, or one of the fragments or domains comprised therein. In some embodiments, one or more of the domains (e.g., the reverse transcriptase, DNA binding (including, for example, sequence-guided DNA binding elements), RNA-binding, or endonuclease domain) is evolved, One or more of such evolved variant domains can, in some embodiments, be evolved alone or together with other domains. An evolved variant domain or domains may, in some embodiments, be combined with unevolved cognate component(s) or evolved variants of the cognate component(s), e.g., which may have been evolved in either a parallel or serial manner.

In some embodiments, the process of mutagenizing a reference Gene Writer, or fragment or domain thereof, comprises mutagenizing the reference Gene Writer or fragment or domain thereof. In embodiments, the mutagenesis comprises a continuous evolution method (e g., PACE) or non-contious evolution method (e.g., PANCE), e.g., as described herein. In some embodiments, the evolved Gene Writer, or a fragment or domain thereof, comprises one or more amino acid variations introduced into its amino acid sequence relative to the amino acid sequence of the reference Gene Writer, or fragment or domain thereof. In embodiments, amino acid sequence variations may include one or more mutated residues (e.g., conservative substitutions, non-conservative substitutions, or a combination thereof) within the amino acid sequence of a reference Gene Writer, e.g., as a result of a change in the nucleotide sequence encoding the gene writer that results in, e.g., a change in the codon at any particular position in the coding sequence, the deletion of one or more amino acids (e.g., a truncated protein), the insertion of one or more amino acids, or any combination of the foregoing. The evolved variant (Gene Writer may include variants in one or more components or domains of the Gene Writer (e.g., variants introduced into a reverse transcriptase domain, endonuclease domain, DNA binding domain, RNA binding domain, or combinations thereof).

In some aspects, the invention provides Gene Writers, systems, kits, and methods using or comprising an evolved variant of a Gene Writer, e.g., employs an evolved variant of a Gene Writer or a Gene Writer produced or produceable by PACE or PANCE. In embodiments, the unevolved reference Gene Writer is a Gene Writer as disclosed herein.

The term “phage-assisted continuous evolution (PACE),” as used herein, generally refers to continuous evolution that employs phage as viral vectors. Examples of PACE technology have been described, for example, in International PCT Application No. PCT/US 2009/056194, filed Sep. 8, 2009, published as WO 2010/028347 on Mar. 11, 2010; International PCT Application, PCT/US2011/066747, filed Dec. 22, 2011, published as WO2012/088381 on Jun. 28, 2012; U.S. patent Ser. No. 9,023,594 issued May 5, 2015; U.S. patent Ser. No. 9,771,574, issued Sep. 26, 2017; U.S. patent Ser. No. 9,394,537, issued Jul. 19, 2016; International PCT Application, PCT/US2015/012022, filed Jan. 20, 2015, published as WO 2015/134121 on Sep. 11, 2015; U.S. patent Ser. No. 10,179,911, issued Jan. 15, 2019; and International PCT Application, PCT/US2016/027795, filed Apr. 15, 2016, published as WO 2016/168631 on Oct. 20, 2016, the entire contents of each of which are incorporated herein by reference.

The term “phage-assisted non-continuous evolution (PANCE),” as used herein, generally refers to non-continuous evolution that employs phage as viral vectors. Examples of PANCE technology have been described, for example, in Suzuki T. et al, Crystal structures reveal an elusive functional domain of pyrrolysyl-tRNA synthetase, Nat Chem Biol. 13(12): 1261-1266 (2017), incorporated herein by reference in its entirety. Briefly, PANCE is a technique for rapid in vivo directed evolution using serial flask transfers of evolving selection phage (SP), which contain a gene of interest to be evolved, across fresh host cells (e.g, E. coli cells) Genes inside the host cell may be held constant while genes contained in the SP continuously evolve. Following phage growth, an aliquot of infected cells may be used to transfect a subsequent flask containing host E. coli. This process can be repeated and/or continued until the desired phenotype is evolved, e.g., for as many transfers as desired.

Methods of applying PACE and PANCE to Gene Writers may be readily appreciated by the skilled artisan by reference to, inter alia, the foregoing references. Additional exemplary methods for directing continuous evolution of genome-modifying proteins or systems, e.g., in a population of host cells, e.g., using phage particles, can be applied to generate evolved variants of Gene Writers, or fragments or subdomains thereof. Non-limiting examples of such methods are described in International PCT Application, PCT/US2009/056194, filed Sep. 8, 2009, published as WO 2010/028347 on Mar. 11, 2010; international PCT Application, PCT/US2011/066747, filed Dec. 22, 2011, published as WO 2012/088381 on Jun. 28, 2012, U.S. patent Ser. No. 9,023,594, issued May 5, 2015; U.S. patent Ser. No. 9,771,574, issued Sep. 26, 2017; U.S. patent Ser. No. 9,394,537, issued Jul. 19, 2016; International PCT Application, PCT/US2015/012022, filed Jan. 20, 2015, published as WO 2015/134121 on Sep. 11, 2015; U.S. patent Ser. No. 10,179,911, issued Jan. 15, 2019; International Application No. PCT/US2019/37216, filed Jun. 14, 2019, International Patent Publication WO 2019/023680, published Jan. 31, 2019, International PCT Application, PCT/US2016/027795, filed Apr. 15, 2016, published as WO 2016/168631 on Oct. 20, 2016, and International Patent Publication No. PCT/US2019/47996, filed Aug. 23, 2019, each of which is incorporated herein by reference in its entirety.

In some non-limiting illustrative embodiments, a method of evolution of a evolved variant Gene Writer, of a fragment or domain thereof, comprises: (a) contacting a population of host cells with a population of viral vectors comprising the gene of interest (the starting Gene Writer or fragment or domain thereof), wherein: (1) the host cell is amenable to infection by the viral vector; (2) the host cell expresses viral genes required for the generation of viral particles; (3) the expression of at least one viral gene required for the production of an infectious viral particle is dependent on a function of the gene of interest; and/or (4) the viral vector allows for expression of the protein in the host cell, and can be replicated and packaged into a viral particle by the host cell. In some embodiments, the method comprises (b) contacting the host cells with a mutagen, using host cells with mutations that elevate mutation rate (e.g., either by carrying a mutation plasmid or some genome modification—e.g., proofing-impaired DNA polymerase, SOS genes, such as UmuC, UmuD′, and/or RecA, which mutations, if plasmid-bound, may be under control of an inducible promoter), or a combination thereof. In some embodiments, the method comprises (c) incubating the population of host cells under conditions allowing for viral replication and the production of viral particles, wherein host cells are removed from the host cell population, and fresh, uninfected host cells are introduced into the population of host cells, thus replenishing the population of host cells and creating a flow of host cells. In some embodiments, the cells are incubated under conditions allowing for the gene of interest to acquire a mutation. In some embodiments, the method further comprises (d) isolating a mutated version of the viral vector, encoding an evolved gene product (e.g., an evolved variant Gene Writer, or fragment or domain thereof), from the population of host cells.

The skilled artisan will appreciate a variety of features employable within the above-described framework. For example, in some embodiments, the viral vector or the phage is a filamentous phage, for example, an M13 phage, e.g., an M13 selection phage. In certain embodiments, the gene required for the production of infectious viral particles is the M13 gene III (gIII). In embodiments, the phage may lack a functional gIII, but otherwise comprise gI, gII, gIV, gV, gVI, VII, gVIII, gIX, and a gX. In some embodiments, the generation of infectious VSV particles involves the envelope protein VSV-G. Various embodiments can use different retroviral vectors, for example, Murine Leukemia Virus vectors, or Lentiviral vectors. In embodiments, the retroviral vectors can efficiently be packaged with VSV-G envelope protein, e.g., as a substitute for the native envelope protein of the virus.

In some embodiments, host cells are incubated according to a suitable number of viral life cycles, e.g., at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least, 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1250, at least 1500, at least 1750, at least 2000, at least 2500, at least 3000, at least 4000, at least 5000, at least 7500, at least 10000, or more consecutive viral life cycles, which in on illustrative and non-limiting examples of M13 phage is 10-20 minutes per virus life cycle. Similarly, conditions can be modulated to adjust the time a host cell remains in a population of host cells, e.g., about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 70, about 80, about 90, about 100, about 120, about 150, or about 180 minutes. Host cell populations can be controlled in part by density of the host cells, or, in some embodiments, the host cell density in an inflow, e.g., 10³ cells/ml, about 10⁴ cells/ml, about 10⁵ cells/ml, about 5-10⁵ cells/ml, about 10⁶ cells/ml, about 5-10⁶ cells/ml, about 10⁷ cells/ml, about 5-10⁷ cells/ml, about 10⁸ cells/ml, about 5-10⁸ cells/ml, about 10⁹ cells/ml, about 5 10⁹ cells/ml about 10¹⁰ cells/ml, or about 5 10¹⁰ cells/ml.

Promoters

In some embodiments, one or more promoter or enhancer elements are operably linked to a nucleic acid encoding a Gene Writer protein or a template nucleic acid, e.g., that controls expression of the heterologous object sequence. In certain embodiments, the one or more promoter or enhancer elements comprise cell-type or tissue specific elements. In some embodiments, the promoter or enhancer is the same or derived from the promoter or enhancer that naturally controls expression of the heterologous object sequence. For example, the ornithine transcarbamylase promoter and enhancer may be used to control expression of the ornithine transcarbamylase gene in a system or method provided by the invention for correcting ornithine transcarbamylase deficiencies. In some embodiments, a promoter for use in the invention is for a gene described in any one of Tables 9-22, e.g., which may be used with an allele of the reference gene, or, in other embodiments, with a heterologous gene. In some embodiments, the promoter is a promoter of Table 33 or a functional fragment or variant thereof.

Exemplary tissue specific promoters that are commercially available can be found, for example, at a uniform resource locator (e.g., https://www.invivogen.com/tissue-specific-promoters). In some embodiments, a promoter is a native promoter or a minimal promoter, e.g, which consists of a single fragment from the 5′ region of a given gene. In some embodiments, a native promoter comprises a core promoter and its natural 5′ UTR. In some embodiments, the 5′ UTR comprises an intron. In other embodiments, these include composite promoters, which combine promoter elements of different origins or were generated by assembling a distal enhancer with a minimal promoter of the same origin.

Exemplary cell or tissue specific promoters are provided in the tables, below, and exemplary nucleic acid sequences encoding them are known in the art and can be readily accessed using a variety of resources, such as the NCBI database, including RefSeq, as well as the Eukaryotic Promoter Database (//epd.epfl.ch//index.php).

TABLE 33 Exemplary cell or tissue-specific promoters Promoter Target cells B29 Promoter B cells CD14 Promoter Monocytic Cells CD43 Promoter Leukocytes and platelets CD45 Promoter Hematopoeitic cells CD68 promoter macrophages Desmin promoter muscle cells Elastase-1 promoter pancreatic acinar cells Endoglin promoter endothelial cells fibronectin promoter differentiating cells, healing tissue Flt-1 promoter endothelial cells GFAP promoter Astrocytes GPIIB promoter megakaryocytes ICAM-2 Promoter Endothelial cells INF-Beta promoter Hematopoeitic cells Mb promoter muscle cells Nphs1 promoter podocytes OG-2 promoter Osteoblasts, Odonblasts SP-B promoter Lung Syn1 promoter Neurons WASP promoter Hematopoeitic cells SV40/bAlb promoter Liver SV40/bAlb promoter Liver SV40/Cd3 promoter Leukocytes and platelets SV40/CD45 promoter hematopoeitic cells NSE/RU5′ promoter Mature Neurons

TABLE 34 Additional exemplary cell or tissue-specific promoters Promoter Gene Description Gene Specificity APOA2 Apolipoprotein A-II Hepatocytes (from hepatocyte progenitors) SERPINA1 Serpin peptidase inhibitor, clade A Hepatocytes (hAAT) (alpha-1 antiproteinase, antitrypsin), (from definitive endoderm member 1 (also named alpha 1 anti-tryps in) stage) CYP3A Cytochrome P450, family 3, Mature Hepatocytes subfamily A, polypeptide MIR122 MicroRNA 122 Hepatocytes (from early stage embryonic liver cells) and endoderm Pancreatic specific promoters INS Insulin Pancreatic beta cells (from definitive endoderm stage) IRS2 Insulin receptor substrate 2 Pancreatic beta cells Pdx1 Pancreatic and duodenal Pancreas homeobox 1 (from definitive endoderm stage) Alx3 Aristaless-like homeobox 3 Pancreatic beta cells (from definitive endoderm stage) Ppy Pancreatic polypeptide PP pancreatic cells (gamma cells) Cardiac specific promoters Myh6 Myosin, heavy chain 6, cardiac Late differentiation marker of cardiac (aMHC) muscle, alpha muscle cells (atrial specificity) MYL2 Myosin, light chain 2, regulatory, Late differentiation marker of cardiac (MLC-2v) cardiac, slow muscle cells (ventricular specificity) ITNN13 Troponin I type 3 (cardiac) Cardiomyocytes (cTnl) (from immature state) ITNN13 Troponin I type 3 (cardiac) Cardiomyocytes (cTnl) (from immature state) NPPA Natriuretic peptide precursor A (also Atrial specificity in adult cells (ANF) named Atrial Natriuretic Factor) Slc8a1 Solute carrier family 8 Cardiomyocytes from early (Ncx1) (sodium/calcium exchanger), member developmental stages 1 CNS specific promoters SYN1 Synapsin I Neurons (hSyn) GFAP Glial fibrillary acidic protein Astrocytes INA lntemexin neuronal intermediate Neuroprogenitors filament protein, alpha (a-internexin) NES Nestin Neuroprogenitors and ectoderm MOBP Myelin-associated oligodendrocyte Oligodendrocytes basic protein MBP Myelin basic protein Oligodendrocytes TH Tyrosine hydroxylase Dopaminergic neurons FOXA2 Forkhead box A2 Dopaminergic neurons (also used as a (HNF3 marker of endoderm) beta) Skin specific promoters FLG Filaggrin Keratinocytes from granular layer K14 Keratin 14 Keratinocytes from granular and basal layers TGM3 Transglutaminase 3 Keratinocytes from granular layer Immune cell specific promoters ITGAM lntegrin, alpha M (complement Monocytes, macrophages, granulocytes, (CD11B) component 3 receptor 3 subunit) natural killer cells Urogential cell specific promoters Pbsn Probasin Prostatic epithelium Upk2 Uroplakin 2 Bladder Sbp Spermine binding protein Prostate Ferl14 Fer-1-like 4 Bladder Endothelial cell specific promoters ENG Endoglin Endothelial cells Pluripotent and embryonic cell specific promoters Oct4 POU class 5 homeobox 1 Pluripotent cells (POU5F1) (germ cells, ES cells, iPS cells) NANOG Nanog homeobox Pluripotent cells (ES cells, iPS cells) Synthetic Synthetic promoter based on a Oct-4 Pluripotent cells (ES cells, iPS cells) Oct4 core enhancer element T Brachyury Mesoderm brachyury NES Nestin Neuroprogenitors and Ectoderm SOX17 SRY (sex determining region Y)-box Endoderm 17 FOXA2 Forkhead box A2 Endoderm (also used as a marker of (HNFJ dopaminergic neurons) beta) MIR122 MicroRNA 122 Endoderm and hepatocytes (from early stage embryonic liver cells~

Depending on the host/vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see e.g., Bitter et al. (1987) Methods in Enzymology, 153:516-541; incorporated herein by reference in its entirety).

In some embodiments, a nucleic acid encoding a Gene Writer or template nucleic acid is operably linked to a control element, e.g, a transcriptional control elements, such as a promoter. The transcriptional control element may, in some embodiment, be functional in either a eukaryotic cell, e.g., a mammalian cell; or a prokaryotic cell (e.g., bacterial or archaeal cell). In some embodiments, a nucleotide sequence encoding a polypeptide is operably linked to multiple control elements, e.g., that allow expression of the nucleotide sequence encoding the polypeptide in both prokaryotic and eukaryotic cells.

For illustration purposes, examples of spatially restricted promoters include, but are not limited to, neuron-specific promoters, adipocyte-specific promoters, cardiomyocyte-specific promoters, smooth muscle-specific promoters, photoreceptor-specific promoters, etc. Neuron-specific spatially restricted promoters include, but are not limited to, a neuron-specific enolase (NSE) promoter (see, e.g, EMBL HSENO2, X51956); an aromatic amino acid decarboxylase (AADC) promoter, a neurofilament promoter (see, e.g., GenBank HUMNFL, L04147); a synapsin promoter (see, e.g., Gen-Bank HUMSYNIB, M55301); a thy-1 promoter (see, e.g., Chen et al. (1987) Cell 51:7-19; and Llewellyn, et al, (2010) Nat. Med, 16(10):1161-1166); a serotonin receptor promoter (see, e.g., GenBank S62283); a tyrosine hydroxylase promoter (TH) (see, e.g., Oh et al. (2009) Gene Ther 16:437; Sasaoka et al. (1992) Mol. Brain Res. 16:274; Boundy et al. (1998) J. Neurosci. 18:9989; and Kaneda et al. (1991) Neuron 6:583-594); a GnRH promoter (see, e g., Radovick et al. (1991) Proc. Natl. Acad. Sci. USA 88:3402-3406); an L7 promoter (see, e.g., Oberdick et al. (1990) Science 248:223-226); a DNMT promoter (see, e.g., Bartge et al. (1988) Proc. Natl. Acad. Sci. USA 85:3648-3652); an enkephalin promoter (see, e.g., Comb et al. (1988) EMBO J. 17:3793-3805); a myelin basic protein (MBP) promoter; a Ca2+-calmodulin-dependent protein kinase II-alpha (CamKIIα) promoter (see, e.g., Mayford et al, (1996) Proc. Natl. Acad. Sci. USA 93:13250; and Casanova et al. (2001) Genesis 31:37); a CMV enhancer/platelet-derived growth factor-β promoter (see, e.g., Liu et al. (2004) Gene Therapy 11:52-60); and the like.

Adipocyte-specific spatially restricted promoters include, but are not limited to, the aP2 gene promoter/enhancer, e.g., a region from −5.4 kb to +21 bp of a human aP2 gene (see, e.g., Tozzo et al. (1997) Endocrinol. 138:1604; Ross et al. (1990) Proc. Natl. Acad. Sci. USA 87:9590; and Pavjani et al. (2005) Nat. Med. 1:797); a glucose transporter-4 (GLUT4) promoter (see, e.g., Knight et al. (2003) Proc. Natl. Acad. Sci. USA 100:14725); a fatty acid translocase (FAT/CD36) promoter (see, e g., Kuriki et al (2002) Biol Pharm. Bull. 25:1476; and Sato et al. (2002) J. Bio. Chem. 277:15703); a stearoyl-CoA desaturase-1 (SCDI) promoter (Tabor et al. (1999) J. Biol. Chem. 274:20603); a leptin promoter (see, e.g., Mason et al. (1998) Endocrinol. 139:1013; and Chen et al. (1999) Biochem. Biophys. Res, Comm. 262:187); an adiponectin promoter (see, e.g., Kita et al. (2005) Biochem. Biophys. Res. Comm. 331:484; and Chakrabarti (2010) Endocrinol. 151:2408); an adipsin promoter (see, e g., Platt et al, (1989) Proc. Natl. Acad, Sci. USA 86:7490); a resistin promoter (see, e.g., Sec et al. (2003) Molec. Endocrinol. 17:1522); and the like.

Cardiomyocyte-specific spatially restricted promoters include, but are not limited to, control sequences derived from the following genes: myosin light chain-2, α-myosin heavy chain, AE3, cardiac troponin C, cardiac actin, and the like. Franz et al. (1997) Cardiovasc. Res. 35:560-566; Robbins et al. (1995) Ann. N.Y. Acad. Sci. 752:492-505; Linn et al. (1995) Circ. Res. 76:584-591; Parmacek et al. (1994) Mol. Cell Biol 14:1870-1885; Hunter et al (1993) Hypertension 22:608-617; and Sartorelli et al. (1992) Proc. Natl. Acad. Sci. USA 89:447-4051.

Smooth muscle-specific spatially restricted promoters include, but are not limited to, an SM22α, promoter (see, e.g., Akyürek et al. (2000) Mol. Med. 6:983; and U.S. Pat. No. 7,169,874); a smoothelin promoter (see, e.g., WO 2001/018048); an α-smooth muscle actin promoter; and the like. For example, a 0.4 kb region of the SM22, promoter, within which lie two CArG elements, has been shown to mediate vascular smooth muscle cell-specific expression (see, e.g., Kim, et al (1997) Mol. Cell. Biol. 17, 2266-2278; Li, et al., (1996) J. Cell Biol. 132, 849-859; and Moessler, et al. (1996) Development 122, 2415-2425).

Photoreceptor-specific spatially restricted promoters include, but are not limited to, a rhodopsin promoter; a rhodopsin kinase promoter (Young et al. (2003) Ophthalmol. Vis. Sci. 44:4076); a beta phosphodiesterase gene promoter (Nicoud et al. (2007) J. Gene Med. 9:1015); a retinitis pigmentosa gene promoter (Nicoud et al. (2007) supra), an interphotoreceptor retinoid-binding protein (IRBP) gene enhancer (Nicoud et al. (2007) supra); an IRBP gene promoter (Yokoyama et al (1992) Exp Eye Res. 55:225); and the like.

Nonlimiting Exemplary Cells-Specific Promoters

Cell-specific promoters known in the art may be used to direct expression of a Gene Writer protein, e.g., as described herein. Nonlimiting exemplary mammalian cell-specific promoters have been characterized and used in mice expressing Cre recombinase in a cell-specific manner. Certain nonlimiting exemplary mammalian cell-specific promoters are listed in Table 1 of U.S. Pat. No. 9,845,481, incorporated herein by reference.

In some embodiments, a cell-specific promoters is a promoter that is active in plants. Many exemplary cell-specific plant promoters are known in the art. See, e.g., U.S. Pat. Nos. 5,097,025; 5,783,393; 5,880,330; 5,981,727; 7,557,264; 6,291,666; 7,132,526; and 7,323,622; and U.S. Publication Nos. 2010/0269226; 2007/0180580; 2005/0034192; and 2005/0086712, which are incorporated by reference herein in their entireties for any purpose.

In some embodiments, a vector as described herein comprises an expression cassette. The term “expression cassette”, as used herein, refers to a nucleic acid construct comprising nucleic acid elements sufficient for the expression of the nucleic acid molecule of the instant invention, Typically, an expression cassette comprises the nucleic acid molecule of the instant invention operatively linked to a promoter sequence. The term “operatively linked” refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operatively linked with a coding sequence when it is capable of affecting the expression of that coding sequence (e.g., the coding sequence is under the transcriptional control of the promoter). Encoding sequences can be operatively linked to regulatory sequences in sense or antisense orientation. In certain embodiments, the promoter is a heterologous promoter. The term“heterologous promoter”, as used herein, refers to a promoter that is not found to be operatively linked to a given encoding sequence in nature. In certain embodiments, an expression cassette may comprise additional elements, for example, an intron, an enhancer, a polyadenylation site, a woodchuck response element (WRE), and/or other elements known to affect expression levels of the encoding sequence A “promoter” typically controls the expression of a coding sequence or functional RNA. In certain embodiments, a promoter sequence comprises proximal and more distal upstream elements and can further comprise an enhancer element. An “enhancer” can typically stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. In certain embodiments, the promoter is derived in its entirety from a native gene. In certain embodiments, the promoter is composed of different elements derived from different naturally occurring promoters. In certain embodiments, the promoter comprises a synthetic nucleotide sequence. It will be understood by those skilled in the art that different promoters will direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions or to the presence or the absence of a drug or transcriptional co-factor. Ubiquitous, cell-type-specific, tissue-specific, developmental stage-specific, and conditional promoters, for example, drug-responsive promoters (e.g., tetracycline-responsive promoters) are well known to those of skill in the art. Examples of promoter include, but are not limited to, the phosphoglycerate kinase (PKG) promoter, CAG (composite of the CMV enhancer the chicken beta actin promoter (CBA) and the rabbit beta globin intron.), NSE (neuronal specific enolase), synapsin or NeuN promoters, the SV40 early promoter, mouse mammary tumor virus LTR promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE) SFFV promoter, rous sarcoma virus (RSV) promoter, synthetic promoters, hybrid promoters, and the like. Other promoters can be of human origin or from other species, including from mice. Common promoters include, e.g., the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat, [beta]-actin, rat insulin promoter, the phosphoglycerate kinase promoter, the human alpha- 1 antitrypsin (hAAT) promoter, the transthyretin promoter, the TBG promoter and other liver-specific promoters, the desmin promoter and similar muscle-specific promoters, the EF1-alpha promoter, the CAG promoter and other constitutive promoters, hybrid promoters with multi-tissue specificity, promoters specific for neurons like synapsin and glyceraldehyde-3-phosphate dehydrogenase promoter, all of which are promoters well known and readily available to those of skill in the art, can be used to obtain high-level expression of the coding sequence of interest. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, will also find use herein. Such promoter sequences are commercially available from, e g, Stratagene (San Diego, Calif.). Additional exemplary promoter sequences are described, for example, in WO2018213786A1 (incorporated by reference herein in its entirety).

In some embodiments, the apolipoprotein E enhancer (ApoE) or a functional fragment thereof is used, e.g., to drive expression in the liver. In some embodiments, two copies of the ApoE enhancer or a functional fragment thereof is used. In some embodiments, the ApoE enhancer or functional fragment thereof is used in combination with a promoter, e.g., the human alpha-1 antitrypsin (hAAT) promoter.

In some embodiments, the regulatory sequences impart tissue-specific gene expression capabilities. In some cases, the tissue-specific regulatory sequences bind tissue-specific transcription factors that induce transcription in a tissue specific manner. Various tissue-specific regulatory sequences (e.g., promoters, enhancers, etc.) are known in the art. Exemplary tissue-specific regulatory sequences include, but are not limited to, the following tissue-specific promoters: a liver-specific thyroxin binding globulin (TBG) promoter, a insulin promoter, a glucagon promoter, a somatostatin promoter, a pancreatic polypeptide (PPY) promoter, a synapsin-1 (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a α-myosin heavy chain (a-MIC) promoter, or a cardiac Troponin T (cTnT) promoter. Other exemplary promoters include Beta-actin promoter, hepatitis B virus core promoter, Sandig et al., Gene Ther, 3:1002-9 (1996); alpha-fetoprotein (AFP) promoter, Arbuthnot et al., Hum. Gene Ther., 7:1503-14 (1996)), bone osteocalcin promoter (Stein et al., Mol. Biol, Rep., 24:185-96 (1997)); bone sialoprotein promoter (Chen et al., J Bone Miner. Res., 11:654-64 (1996)), CD2 promoter (Hansal et al., J. Immunol., 161:1063-8 (1998); immunoglobulin heavy chain promoter; T cell receptor ca-chain promoter, neuronal such as neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., 13:503-15 (1993)), neurofilament light-chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron-specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)), and others Additional exemplary promoter sequences are described, for example, in U.S. patent Ser. No. 10/300,146 (incorporated herein by reference in its entirety). In some embodiments, a tissue-specific regulatory element, e.g., a tissue-specific promoter, is selected from one known to be operably linked to a gene that is highly expressed in a given tissue, e.g., as measured by RNA-seq or protein expression data, or a combination thereof. Methods for analyzing tissue specificity by expression are taught in Fagerberg et al. Mol Cell Proteomics 13(2):397-406 (2014), which is incorporated herein by reference in its entirety.

In some embodiments, a vector described herein is a multicistronic expression construct. Multicistronic expression constructs include, for example, constructs harboring a first expression cassette, e.g. comprising a first promoter and a first encoding nucleic acid sequence, and a second expression cassette, e.g. comprising a second promoter and a second encoding nucleic acid sequence. Such multicistronic expression constructs may, in some instances, be particularly useful in the delivery of ion-translated gene products, such as hairpin RNAs, together with a polypeptide, for example, a gene writer and gene writer template. In some embodiments, multicistronic expression constructs may exhibit reduced expression levels of one or more of the included transgenes, for example, because of promoter interference or the presence of incompatible nucleic acid elements in close proximity. If a multicistronic expression construct is part of a viral vector, the presence of a self-complementary nucleic acid sequence may, in some instances, interfere with the formation of structures necessary for viral reproduction or packaging.

In some embodiments, the sequence encodes an RNA with a hairpin. In some embodiments, the hairpin RNA is an a guide RNA, a template RNA, shRNA, or a microRNA. In some embodiments, the first promoter is an RNA polymerase I promoter. In some embodiments, the first promoter is an RNA polymerase II promoter. In some embodiments, the second promoter is an RNA polymerase III promoter in some embodiments, the second promoter is a U6 or H1 promoter. In some embodiments, the nucleic acid construct comprises the structure of AAV construct B1 or 132.

Without wishing to be bound by theory, multicistronic expression constructs may not achieve optimal expression levels as compared to expression systems containing only one cistron. One of the suggested causes of lower expression levels achieved with multicistronic expression constructs comprising two ore more promoter elements is the phenomenon of promoter interference (see, e.g., Curtin J A, Dane A P, Swanson A, Alexander I E, Ginn S L. Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct. Gene Ther 2008 March; 15(5):384-90 and Martin-Duque P, Jezzard S, Kaftansis L, Vassaux G. Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther. 2004 Oct.; 15(10):995-1002; both references incorporated herein by reference for disclosure of promoter interference phenomenon). In some embodiments, the problem of promoter interference may be overcome, e.g., by producing multicistronic expression constructs comprising only one promoter driving transcription of multiple encoding nucleic acid sequences separated by internal ribosomal entry sites, or by separating cistrons comprising their own promoter with transcriptional insulator elements. In some embodiments, single-promoter driven expression of multiple cistrons may result in uneven expression levels of the cistrons. In some embodiments, a promoter cannot efficiently be isolated and isolation elements may not be compatible with some gene transfer vectors, for example, some retroviral vectors.

MicroRNAs

miRNAs and other small interfering nucleic acids generally regulate gene expression via target RNA transcript cleavage/degradation or translational repression of the target messenger RNA (mRNA). miRNAs may, in some instances, be natively expressed, typically as final 19-25 non-translated RNA products. miRNAs generally exhibit their activity through sequence-specific interactions with the 3′ untranslated regions (UTR) of target mRNAs. These endogenously expressed miRNAs may form hairpin precursors that are subsequently processed into an miRNA duplex, and further into a mature single stranded miRNA molecule. This mature miRNA generally guides a multiprotein complex, miRISC, which identifies target 3′ UTR regions of target mRNAs based upon their complementarity to the mature mniRNA. Useful transgene products may include, for example, miRNAs or miRNA binding sites that regulate the expression of a linked polypeptide A non-limiting list of miRNA genes; the products of these genes and their homologues are useful as transgenes or as targets for small interfering nucleic acids (e.g., miRNA sponges, antisense oligonucleotides), e.g., in methods such as those listed in U.S. Ser. No. 10/300,146, 22:25-25:48, incorporated by reference. In some embodiments, one or more binding sites for one or more of the foregoing miRNAs are incorporated in a transgene, e.g., a transgene delivered by a rAAV vector, e.g., to inhibit the expression of the transgene in one or more tissues of an animal harboring the transgene. In some embodiments, a binding site may be selected to control the expression of a transgene in a tissue specific manner. For example, binding sites for the liver-specific miR-122 may be incorporated into a transgene to inhibit expression of that transgene in the liver. Additional exemplary miRNA sequences are described, for example, in U.S. patent Ser. No. 10/300,146 (incorporated herein by reference in its entirety). For liver-specific Gene Writing, however, overexpression of miR-122 may be utilized instead of using binding sites to effect miR-122-specific degradation. This miRNA is positively associated with hepatic differentiation and maturation, as well as enhanced expression of liver specific genes. Thus, in some embodiments, the coding sequence for mniR-122 may be added to a component of a Gene Writing system to enhance a liver-directed therapy.

A miR inhibitor or miRNA inhibitor is generally an agent that blocks miRNA expression and/or processing. Examples of such agents include, but are not limited to, microRNA antagonists, microRNA specific antisense, microRNA sponges, and microRNA oligonucleotides (double-stranded, short oligonucleotides) that inhibit miRNA interaction with a Drosha complex. MicroRNA inhibitors, e.g., miRNA sponges, can be expressed in cells from transgenes (e.g., as described in Ebert, M. S. Nature Methods, Epub Aug. 12, 2007; incorporated by reference herein in its entirety). In some embodiments, microRNA sponges, or other miR inhibitors, are used with the AAVs. microRNA sponges generally specifically inhibit miRNAs through a complementary heptameric seed sequence. In some embodiments, an entire family of miRNAs can be silenced using a single sponge sequence. Other methods for silencing miRNA function (derepression of miRNA targets) in cells will be apparent to one of ordinary skill in the art.

In some embodiments, a miRNA as described herein comprises a sequence listed in Table 4 of PCT Publication No. WO2020014209, incorporated herein by reference. Also incorporated herein by reference are the listing of exemplary miRNA sequences from WO2020014209.

In some embodiments, it is advantageous to silence one or more components of a Gene Writing system (e.g., mRNA encoding a Gene Writer polypeptide, a Gene Writer Template RNA, or a heterologous object sequence expressed from the genome after successful Gene Writing) in a portion of cells. In some embodiments, it is advantageous to restrict expression of a component of a Gene Writing system to select cell types within a tissue of interest.

For example, it is known that in a given tissue, e.g., liver, macrophages and immune cells, e.g., Kupffer cells in the liver, may engage in uptake of a delivery vehicle for one or more components of a Gene Writing system. In some embodiments, at least one binding site for at least one miRNA highly expressed in macrophages and immune cells, e.g., Kupffer cells, is included in at least one component of a Gene Writing system, e.g., nucleic acid encoding a Gene Writing polypeptide or a transgene. In some embodiments, a miRNA that targets the one or more binding sites is listed in a table referenced herein, e.g., miR-142, e.g., mature miRNA hsa-miR-142-5p or hsa-miR-142-3p.

In some embodiments, there may be a benefit to decreasing Gene Writer levels and/or Gene Writer activity in cells in which Gene Writer expression or overexpression of a transgene may have a toxic effect. For example, it has been shown that delivery of a transgene overexpression cassette to dorsal root ganglion neurons may result in toxicity of a gene therapy (see Hordeaux et al Sci Transl Med 12(569):eaba9188 (2020), incorporated herein by reference in its entirety). In some embodiments, at least one miRNA binding site may be incorporated into a nucleic acid component of a Gene Writing system to reduce expression of a system component in a neuron, e.g., a dorsal root ganglion neuron. In some embodiments, the at least one miRNA binding site incorporated into a nucleic acid component of a Gene Writing system to reduce expression of a system component in a neuron is a binding site of miR-182, e.g., mature miRNA hsa-miR-182-5p or hsa-miR-182-3p. In some embodiments, the at least one miRNA binding site incorporated into a nucleic acid component of a Gene Writing system to reduce expression of a system component in a neuron is a binding site of miR-183, e.g., mature miRNA hsa-miR-183-5p or hsa-miR-183-3p. In some embodiments, combinations of miRNA binding sites may be used to enhance the restriction of expression of one or more components of a Gene Writing system to a tissue or cell type of interest.

Table A5 below provides exemplary miRNAs and corresponding expressing cells, e.g., a miRNA for which one can, in some embodiments, incorporate binding sites (complementary sequences) in the transgene or polypeptide nucleic acid, e.g., to decrease expression in that off-target cell.

TABLE A5 Exemplary miRNA from off-target cells and tissues Silenced SEQ cell miRNA Mature miRNA ID type name miRNA sequence NO: Kupffer miR-142 hsa-miR- cauaaaguaga 3567 cells 142-5p aagcacuacu Kupffer miR-142 hsa-miR- uguaguguuuc 1684 cells 142-3p cuacuuuaugga Dorsal miR-182 hsa-miR- uuuggcaauggu 3568 root 182-5p agaacucacacu ganglion neurons Dorsal miR-182 hsa-miR- ugguucuagacu 3569 root 182-3p ugccaacua ganglion neurons Dorsal miR-183 hsa-miR- uauggcacuggu 3570 root 183-5p agaauucacu ganglion neurons Dorsal miR-183 hsa-miR- gugaauuaccga 3571 root 183-3p agggccauaa ganglion neurons Hepatocytes miR-122 hsa-miR- uggagugugaca 3572 122-5p augguguuug Hepatocytes miR-122 hsa-miR- aacgccauuauc 3573 122-3p acacuaaaua

Anticrispr Systems for Regulating GeneWriter Activity

Various approaches for modulating Cas molecule activity may be used in conjunction with the systems and methods described herein. For instance, in some embodiments, a polypeptide described herein (e.g., a Cas molecule or a GeneWriter comprising a Cas domain) can be regulated using an anticrispr agent (e.g., an anticrispr protein or anticrispr small molecule). In some embodiments, the Cas molecule or Cas domain comprises a responsive intein such as, for example, a 4-hydroxytamoxifen (4-HT)-responsive intein, an iCas molecule (e.g., iCas9); a 4-HT-responsive Cas (e.g., allosterically regulated Cas9 (arC9) or dead Cas9 (dC9)). The systems and methods described herein can also utilize a chemically-induced dimerization system of split protein fragments (e.g., rapamycin-mediated dimerization of FK506 binding protein 12 (FKBP) and FKBP rapamycin binding domain (FRB), an abscisic acid-inducible ABI-PYL1 and gibberellin-inducible GID1-GAI heterodimerization domains); a dimer of BCL-xL peptide and BH3 peptides, a A385358 (A3) small molecule, a degron system (e.g., a FKBP-Cas9 destabilized system, an auxin-inducible degron (AID) or an E.coliDHFR degron system), an aptamer or aptazyme fused with gRNA (e.g., tetracycline- and theophylline-responsive bioswitches), AcrIIA2 and AcrIIA4 proteins, and BRD0539.

In some embodiments, a small molecule-responsive intein (e.g., 4-hydroxytamoxifen (4-HT)-responsive intein) is inserted at specific sites within a Cas molecule (e.g., Cas9). In some embodiments, the insertion of a 4HT-responsive intein disrupts Cas9 enzymatic activity. In some embodiments, a Cas molecule (e.g., iCas9) is fused to the hormone binding domain of the estrogen receptor (ERT2). In some embodiments, the ligand binding domain of the human estrogen receptor-α can be inserted into a Cas molecule (e.g., Cas9 or dead Cas9 (dC9)), e.g., at position 231, yielding a 4HT-responsive anticrispr Cas9 (e.g., arC9 or dC9). In some embodiments, dCas9 can provide 4-HT dose-dependent repression of Cas9 function. In some embodiments, arC9 can provide 4-HT dose-dependent control of Cas9 function. In some embodiments, a Cas molecule (e.g., Cas9) is fused to split protein fragments. In some embodiments, chemically-induced dimerization of split protein fragments (e.g., rapamycin-mediated dimerization of FK506 binding protein 12 (FKBP) and FKBP rapamycin binding domain (FRB)) can induce low levels of Cas9 molecule activity. In some embodiments, a chemically-induced dimerization system (e.g., abscisic acid-inducible ABI-PYL1 and gibberellin-inducible GID1-GAI heterodimerization domains) can induce a dose-dependent and reversible transcriptional activation/repression of Cas9. In some embodiments, a Cas9 inducible system (ciCas9) comprises the replacement of a Cas molecule (e.g., Cas9) REC2 domain with a BCL-xl peptide and attachment of a BH3 peptide to the N- and C-termini of the modified Cas9.BCL. In some embodiments, the interaction between BCL-xL and BH3 peptides can keep Cas9 in an inactive state. In some embodiments, a small molecule (e.g., A-385358 (A3)) can disrupt the interaction between BLC-x1 and BH3 peptides to activate Cas9. In some embodiments, a Cas9 inducible system can exhibit dose-dependent control of nuclease activity. In some embodiments, a degron system can induce degradation of a Cas molecule (e.g., Cas9) upon activation or deactivation by an external factor (e.g., small-molecule ligand, light, temperature, or a protein). In some embodiments, a small molecule BRD0539 inhibits a Cas molecule (e.g., Cas9) reversibly. Additional information on anticrispr proteins or anticrispr small molecules can be found, for example, in Gangopadhyay, S. A. et al. Precision control of CRISPR-Cas9 using small molecules and light, Biochemistry, 2019, Maji, B. et al. A high-throughput platform to identify small molecule inhibitors of CRISPR-Cas9, and Pawluk Anti-CRISPR: discovery, mechanism and function Nature Reviews Microbiology volume 16, pages 12-17(2018), each of which is incorporated by reference in its entirety.

Self-Inactivating Modules for Regulating GeneWriter Activity

In some embodiments the Gene Writer systems described herein includes a self-inactivating module. The self-inactivating module leads to a decrease of expression of the Gene Writer polypeptide, the Gene Writer template, or both. Without wishing to be bound by the theory, the self-inactivating module provides for a temporary period of Gene Writer expression prior to inactivation. Without wishing to be bound by theory, the activity of the Gene Writer polypeptide at a target site introduces a mutation (e.g. a substitution, insertion, or deletion) into the DNA encoding the Gene Writer polypeptide or Gene Writer template which results in a decrease of Gene Writer polypeptide or template expression. In some embodiments of the self-inactivating module, a target site for the Gene Writer polypeptide is included in the DNA encoding the Gene Writer polypeptide or Gene Writer template. In some embodiments, one, two, three, four, five, or more copies of the target site are included in the DNA encoding the Gene Writer polypeptide or Gene Writer template. In some embodiments, the target site in the DNA encoding the Gene Writer polypeptide or Gene Writer template is the same target site as the target site on the genome. In some embodiments, the target site is a different target site than the target site on the genome. In some embodiments, the self-inactivation module target site uses the same or a different template RNA or guide RNA as the genome target site. In some embodiments, the target site is modified via target primed reverse transcription based upon a template RNA. In some embodiments the target side is nicked. The target site may be incorporated into an enhancer, a promoter, an untranslated region, an exon, an intron, an open reading frame, or a stuffer sequence.

In some embodiments, upon inactivation, the decrease of expression is 25%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, or more lower than a Gene Writing system that does not contain the self-inactivating module. In some embodiments, a Gene Writer system that contains the self-inactivating module has a 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% 99%, or higher rate of integrations in target sites than off-target sites compared to a Gene Writing system that does not contain the self-inactivation module. a Gene Writer system that contains the self-inactivating module has a 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% 99%, or higher efficiency of target site modification compared to a Gene Writing system that does not contain the self-inactivation module. In some embodiments, the self-inactivating module is included when the Gene Writer polypeptide is delivered as DNA, e.g. via a viral vector.

Self-inactivating modules have been described for nucleases. See, e.g. in Li et al A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing, Mol Ther Methods Clin Dev. 2019 Mar. 15; 12: 111-122, P. Singhal, Self-Inactivating Cas9: a method for reducing exposure while maintaining efficacy in virally delivered Cas9 applications (available at www.editasmedicine.com/wp-content/uploads/2019/10/aef_asgct_poster_2017_final_-_present_5-11-17_515pm1_1494537387_1494558495_1497467403.pdf), and Epstein and Schaffer Engineering a Self-Inactivating CRISPR System for AAV Vectors Targeted Genome Editing I|Volume 24, SUPPLEMENT 1, S50, May 1, 2016, and WO2018106693A1.

Small Molecules

In some embodiments a polypeptide described herein (e.g., a Gene Writer polypeptide) is controllable via a small molecule. In some embodiments the polypeptide is dimerized via a small molecule.

In some embodiment, the polypeptide is controllable via Chemical Induction of Dimerization (CID) with small molecules. CID is generally used to generate switches of protein function to alter cell physiology. An exemplary high specificity, efficient dimerizer is rimiducid (AP1903), which has two identical, protein-binding surfaces arranged tail-to-tail, each with high affinity and specificity for a mutant of FKBP12: FKBP12(F36V) (FKBP12v36, F_(v36) or F_(v)), Attachment of one or more F_(v) domains onto one or more cell signaling molecules that normally rely on homodimerization can convert that protein to rimiducid control. Homodimerization with rimiducid is used in the context of an inducible caspase safety switch. This molecular switch that is controlled by a distinct dimerizer ligand, based on the heterodimerizing small molecule, rapamycin, or rapamycin analogs (“rapalogs”). Rapamycin binds to FKBP12, and its variants, and can induce heterodimerization of signaling domains that are fused to FKBP12 by binding to both FKBP12 and to polypeptides that contain the FKBP-rapamycin-binding (FRB) domain of mTOR. Provided in some embodiments of the present application are molecular switches that greatly augment the use of rapamycin, rapalogs and rimiducid as agents for therapeutic applications.

In some embodiments of the dual switch technology, a homodimerizer, such as AP1903 (rimiducid), directly induces dimerization or multimerization of polypeptides comprising an FKBP12 multimerizing region. In other embodiments, a polypeptide comprising an FKBP12 multimerization is multimerized, or aggregated by binding to a heterodimerizer, such as rapamycin or a rapalog, which also binds to an FRB or FRB variant multimerizing region on a chimeric polypeptide, also expressed in the modified cell, such as, for example, a chimeric antigen receptor. Rapamycin is a natural product macrolide that binds with high affinity (<1 nM) to FKBP12 and together initiates the high-affinity, inhibitory interaction with the FKBP-Rapamycin-Binding (FRB) domain of mTOR. FRB is small (89 amino acids) and can thereby be used as a protein “tag” or “handle” when appended to many proteins. Coexpression of a FRB-fused protein with a FKBP12-fused protein renders their approximation rapamycin-inducible (12-16). This can serve as the basis for a cell safety switch regulated by the orally available ligand, rapamycin, or derivatives of rapamycin (rapalogs) that do not inhibit mTOR at a low, therapeutic dose but instead bind with selected, Caspase-9-fused mutant FRB domains. (see Sabatini D M, et al., Cell. 1994; 78(l):35-43; Brown E J, et al., Nature. 1994; 369(6483):756-8; Chen 3, et al., Proc Natl Acad Sci USA. 1995; 92(11):4947-51; and Choi J, Science. 1996; 273(5272)239-42)

In some embodiments, two levels of control are provided in the therapeutic cells. In embodiments, the first level of control may be tunable, i.e., the level of removal of the therapeutic cells may be controlled so that it results in partial removal of the therapeutic cells. In some embodiments, the chimeric antigen polypeptide comprises a binding site for rapamycin, or a rapamycin analog. In embodiments, also present in the therapeutic cell is a suicide gene, such as, for example, one encoding a caspase polypeptide. Using this controllable first level, the need for continued therapy may, in some embodiments, be balanced with the need to eliminate or reduce the level of negative side effects. In some embodiments, a rapamycin analog, a rapalog is administered to the patient, which then binds to both the caspase polypeptide and the chimeric antigen receptor, thus recruiting the caspase polypeptide to the location, and aggregating the caspase polypeptide. Upon aggregation, the caspase polypeptide induces apoptosis. The amount of rapamycin or rapamycin analog administered to the patient may vary; if the removal of a lower level of cells by apoptosis is desired, a lower level of rapamycin or rapamycin may be administered to the patient. In some embodiments, the second level of control may be designed to achieve the maximum level of cell elimination. This second level may be based, for example, on the use of rimiducid, or AP1903. If there is a need to rapidly eliminate up to 100% of the therapeutic cells, the AP1903 may be administered to the patient. The multimeric AP1903 binds to the caspase poly peptide, leading to multimerization of the caspase poly peptide and apoptosis. In certain examples, second level may also be tunable, or controlled, by the level of AP1903 administered to the subject.

In certain embodiments, small molecules can be used to control genes, as described in for example, U.S. Ser. No. 10/584,351 at 47:53-56:47 (incorporated by reference herein in its entirety), together suitable ligands for the control features, e.g., in U.S. Ser. No. 10/584,351 at 56:48, et seq. as well as U10046049 at 43:27-52:20, incorporated by reference as well as the description of ligands for such control systems at 52:21, et seq.

Resolution of Gene Writing™ Events

After writing of the template nucleic acid into the target site, additional activities may be performed to increase the overall efficiency of incorporation. In some embodiments, a nick may be initiated in the genome on the non-written DNA strand to encourage copying of the newly written DNA onto the second strand. In some embodiments, the nick may be within at least 10, 20, 30, 40, 50, 60, 70 80, 90, or 100 bases of the target site. In some embodiments, this second nick is performed by the same polypeptide performing the writing. In other embodiments, the second nick may be performed by an additional polypeptide encoding nickase activity, e.g. a Cas9 nickase.

For some Gene Writer™ systems, the writing process may leave a 3′ flap containing the newly written DNA that must displace the flanking target sequence to anneal to the second genomic strand to complete the edit. In some embodiments, the 3′ flap is designed to have enhanced strand invasion capability. In some embodiments, 5′-3′ exonuclease activity is supplemented to chew back the exposed 5′ end of the displaced strand. In some embodiments, DNA ligase activity is supplemented to complete the reaction. In some embodiments, the exonuclease and/or ligase activities are optionally provided on the Gene Writer™ polypeptide. In some embodiments, the exonuclease and/or ligase activities are optionally provided separately from the Gene Writer™ polypeptide.

Based on the published mechanism of non-LTR retrotransposons, Gene Writing™ systems derived therefrom may not require supplementation of additional functions for resolution of the writing event. In some embodiments, the system may result in complete writing without requiring endogenous host factors. In some embodiments, the system may result in complete writing without the need for DNA repair. In some embodiments, the system may result in complete writing without eliciting a DNA damage response.

Chemically Modified Nucleic Acids and Nucleic Acid End Features

A nucleic acid described herein (e.g., a template nucleic acid, e.g., a template RNA; or a nucleic acid (e.g., mRNA) encoding a GeneWriter; or a gRNA) can comprise unmodified or modified nucleobases. Naturally occurring RNAs are synthesized from four basic ribonucleotides: ATP, CTP, UTP and GTP, but may contain post-transcriptionally modified nucleotides. Further, approximately one hundred different nucleoside modifications have been identified in RNA (Rozenski, J, Crain, P, and McCloskey, J. (1999). The RNA Modification Database: 1999 update. Nucl Acids Res 27: 196-197). An RNA can also comprise wholly synthetic nucleotides that do not occur in nature.

In some embodiments, the chemically modification is one provided in PCT/US2016/032454, US Pat. Pub. No. 20090286852, of International Application No. WO/2012/019168, WO/2012/045075, WO/2012/135805, WO/2012/158736, WO/2013/039857, WO/2013/039861, WO/2013/052523, WO/2013/090648, WO/2013/096709, WO/2013/101690, WO/2013/106496, WO/2013/130161, WO/2013/151669, WO/2013/151736, WO/2013/151672, WO/2013/151664, WO/2013/151665, WO/2013/151668, WO/2013/151671, WO/2013/151667, WO/2013/151670, WO/2013/151666, WO/2013/151663, WO/2014/028429, WO/2014/081507, WO/2014/093924, WO/2014/093574, WO/2014/113089, WO/2014/144711, WO/2014/144767, WO/2014/144039, WO/2014/152540, WO/2014/152030, WO/2014/152031, WO/2014/152027, WO/2014/152211, WO/2014/158795, WO/2014/159813, WO/2014/164253, WO/2015/006747, WO/2015/034928, WO/2015/034925, WO/2015/038892, WO/2015/048744, WO/2015/051214, WO/2015/051173, WO/2015/051169, WO/2015/058069, WO/2015/085318, WO/2015/089511, WO/2015/105926, WO/2015/164674, WO/2015/196130, WO/2015/196128, WO/2015/196118, WO/2016/011226, WO/2016/011222, WO/2016/011306, WO/2016/014846, WO/2016/022914, WO/2016/036902, WO/2016/077125, or WO/2016/077123, each of which is herein incorporated by reference in its entirety. It is understood that incorporation of a chemically modified nucleotide into a polynucleotide can result in the modification being incorporated into a nucleobase, the backbone, or both, depending on the location of the modification in the nucleotide. In some embodiments, the backbone modification is one provided in EP 2813570, which is herein incorporated by reference in its entirety. In some embodiments, the modified cap is one provided in US Pat. Pub. No. 20050287539, which is herein incorporated by reference in its entirety.

In some embodiments, the chemically modified nucleic acid (e.g., RNA, e.g., mRNA) comprises one or more of ARCA: anti-reverse cap analog (m27.3′-OGP3G), GP3G (Unmethylated Cap Analog), m7GP3G (Monomethylated Cap Analog), m32.2.7GP3G (Trimethylated Cap Analog), m5CTP (5′-methyl-cytidine triphosphate), m6ATP (N6-methyl-adenosine-5′-triphosphate), s2UTP (2-thio-uridine triphosphate), and Ψ (pseudouridine triphosphate).

In some embodiments, the chemically modified nucleic acid comprises a 5′ cap, e.g.: a 7-methylguanosine cap (e.g., a 0-Me-m7G cap); a hypermethylated cap analog; an NAD+-derived cap analog (e.g., as described in Kiledjian, Trends in Cell Biology 28, 454-464 (2018)); or a modified, e.g., biotinylated, cap analog (e.g., as described in Bednarek et al., Phil Trans R Soc B 373, 20180167 (2018)).

In some embodiments, the chemically modified nucleic acid comprises a 3′ feature selected from one or more of: a polyA tail; a 16-nucleotide long stem-loop structure flanked by unpaired 5 nucleotides (e.g., as described by Mannironi et al., Nucleic Acid Research 17, 9113-9126 (1989)); a triple-helical structure (e.g., as described by Brown et al., PNAS 109, 19202-19207 (2012)); a tRNA, Y RNA, or vault RNA structure (e.g., as described by Labno et al., Biochemica et Biophysica Acta 1863, 3125-3147 (2016)); incorporation of one or more deoxyribonucleotide triphosphates (dNTPs), 2′O-Methylated NTPs, or phosphorothioate-NTPs; a single nucleotide chemical modification (e.g., oxidation of the 3′ terminal ribose to a reactive aldehyde followed by conjugation of the aldehyde-reactive modified nucleotide); or chemical ligation to another nucleic acid molecule.

In some embodiments, the nucleic acid (e.g., template nucleic acid) comprises one or more modified nucleotides, e.g., selected from dihydrouridine, inosine, 7-methylguanosine, 5-methylcytidine (5mC), 5′ Phosphate ribothymidine, 2′-O-methyl ribothymidine, 2′-O-ethyl ribothymidine, 2′-fluoro ribothymidine, C-5 propynyl-deoxycytidine (pdC), C-5 propynyl-deoxyuridine (pdU), C-5 propynyl-cytidine (pC), C-5 propynyl-uridine (pU), 5-methyl cytidine, 5-methyl uridine, 5-methyl deoxycytidine, 5-methyl deoxyuridine methoxy, 2,6-diaminopurine, 5′-Dimethoxytrityl-N4-ethyl-2′-deoxycytidine, C-5 propynyl-f-cytidine (pfC), C-5 propynyl-f-uridine (pfU), 5-methyl f-cytidine, 5-methyl f-uridine, C-5 propynyl-m-cytidine (pmC), C-5 propynyl-f-uridine (pmU), 5-methyl m-cytidine, 5-methyl m-uridine, LNA (locked nucleic acid), MGB (minor groove binder) pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), or 5-methoxyuridine (5-MO-U).

In some embodiments, the nucleic acid comprises a backbone modification, e.g., a modification to a sugar or phosphate group in the backbone. In some embodiments, the nucleic acid comprises a nucleobase modification.

In some embodiments, the nucleic acid comprises one or more chemically modified nucleotides of Table 6, one or more chemical backbone modifications of Table 7, one or more chemically modified caps of Table 7. For instance, in some embodiments, the nucleic acid comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 or more) different types of chemical modifications. As an example, the nucleic acid may comprise two or more (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 or more) different types of modified nucleobases, e.g., as described herein, e.g., in Table 6. Alternatively or in combination, the nucleic acid may comprise two or more (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 or more) different types of backbone modifications, e.g., as described herein, e.g., in Table 7. Alternatively or in combination, the nucleic acid may comprise one or more modified cap, e.g., as described herein, e.g., in Table 8. For instance, in some embodiments, the nucleic acid comprises one or more type of modified nucleobase and one or more type of backbone modification; one or more type of modified nucleobase and one or more modified cap; one or more type of modified cap and one or more type of backbone modification; or one or more type of modified nucleobase, one or more type of backbone modification, and one or more type of modified cap.

In some embodiments, the nucleic acid comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, or more) modified nucleobases. In some embodiments, all nucleobases of the nucleic acid are modified. In some embodiments, the nucleic acid is modified at one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, or more) positions in the backbone. In some embodiments, all backbone positions of the nucleic acid are modified.

TABLE 6 Modified nucleotides 5-aza-uridine N2-methyl-6-thio-guanosine 2-thio-5-aza-midine N2,N2-dimethyl-6-thio-guanosine 2-thiouridine pyridin-4-one ribonucleoside 4-thio-pseudouridine 2-thio-5-aza-uridine 2-thio-pseudouridine 2-thiomidine 5-hydroxyuridine 4-thio-pseudomidine 3-methyluridine 2-thio-pseudowidine 5-carboxymethyl-uridine 3-methylmidine 1-carboxymethyl-pseudouridine 1-propynyl-pseudomidine 5-propynyl-uridine 1-methyl-1-deaza-pseudomidine 1-propynyl-pseudouridine 2-thio-1-methyl-1-deaza-pseudouridine 5-taurinomethyluridine 4-methoxy-pseudomidine 1-taurinomethyl-pseudouridine 5′-O-(1-Thiophosphate)-Adenosine 5-taurinomethyl-2-thio-uridine 5′-O-(1-Thiophosphate)-Cytidine 1-taurinomethyl-4-thio-uridine 5′-O-(1-thiophosphate)-Guanosine 5-methyl-uridine 5′-O-(1-Thiophophate)-Uridine 1-methyl-pseudouridine 5′-O-(1-Thiophosphate)-Pseudouridine 4-thio-1-methyl-pseudouridine 2′-O-methyl-Adenosine 2-thio-1-methyl-pseudouridine 2′-O-methyl-Cytidine 1-methyl-1-deaza-pseudouridine 2′-O-methyl-Guanosine 2-thio-1-methyl-1-deaza-pseudomidine 2′-O-methyl-Uridine dihydrouridine 2′-O-methyl-Pseudouridine dihydropseudouridine 2′-O-methyl-Inosine 2-thio-dihydromidine 2-methyladenosine 2-thio-dihydropseudouridine 2-methylthio-N6-methyladenosine 2-methoxyuridine 2-methylthio-N6 isopentenyladenosine 2-methoxy-4-thio-uridine 2-methylthio-N6-(cis- 4-methoxy-pseudouridine hydroxyisopentenyl)adenosine 4-methoxy-2-thio-pseudouridine N6-methyl-N6-threonylcarbamoyladenosine 5-aza-cytidine N6-hydroxynorvalylcarbamoyladenosine pseudoisocytidine 2-methylthio-N6-hydroxynorvalyl 3-methyl-cytidine carbamoyladenosine N4-acetylcytidine 2′-O-ribosyladenosine (phosphate) 5-formylcytidine 1,2′-O-dimethylinosine N4-methylcytidine 5,2′-O-dimethylcytidine 5-hydroxymethylcytidine N4-acetyl-2′-O-methylcytidine 1-methyl-pseudoisocytidine Lysidine pyrrolo-cytidine 7-methylguanosine pyrrolo-pseudoisocytidine N2,2′-O-dimethylguanosine 2-thio-cytidine N2,N2,2′-O-trimethylguanosine 2-thio-5-methyl-cytidine 2′-O-ribosylguanosine (phosphate) 4-thio-pseudoisocytidine Wybutosine 4-thio-1-methyl-pseudoisocytidine Peroxywybutosine 4-thio-1-methyl-1-deaza-pseudoisocytidine Hydroxywybutosine 1-methyl-1-deaza-pseudoisocytidine undermodified hydroxywybutosine zebularine methylwyosine 5-aza-zebularine queuosine 5-methyl-zebularine epoxyqueuosine 5-aza-2-thio-zebularine galactosyl-queuosine 2-thio-zebularine mannosyl-queuosine 2-methoxy-cytidine 7-cyano-7-deazaguanosine 2-methoxy-5-methyl-cytidine 7-aminomethyl-7-deazaguanosine 4-methoxy-pseudoisocytidine archaeosine 4-methoxy-l-methyl-pseudoisocytidine 5,2′-O-dimethyluridine 2-aminopurine 4-thiouridine 2,6-diaminopurine 5-methyl-2-thiouridine 7-deaza-adenine 2-thio-2′-O-methyluridine 7-deaza-8-aza-adenine 3-(3-amino-3-carboxypropyl)uridine 7-deaza-2-aminopurine 5-methoxyuridine 7-deaza-8-aza-2-aminopurine uridine 5-oxyacetic acid 7-deaza-2,6-diaminopurine uridine 5-oxyacetic acid methyl ester 7-deaza-8-aza-2,6-diarninopurine 5-(carboxyhydroxymethyl)uridine) 1-methyladenosine 5-(carboxyhydroxymethyl)uridine methyl ester N6-isopentenyladenosine 5-methoxycarbonylmethyluridine N6-(cis-hydroxyisopentenyl)adenosine 5-methoxycarbonylmethyl-2′-O-methyluridine 2-methylthio-N6-(cis-hydroxyisopentenyl) 5-methoxycarbonylmethyl-2-thiouridine adenosine 5-aminomethyl-2-thiouridine N6-glycinylcarbamoyladenosine 5-methylaminomethyluridine N6-threonylcarbamoyladenosine 5-methylaminomethyl-2-thiouridine 2-methylthio-N6-threonyl 5-methylaminomethyl-2-selenouridine carbamoyladenosine 5-carbamoylmethyluridine N6,N6-dimethyladenosine 5-carbamoylmethyl-2′-O-methyluridine 7-methyladenine 5-carboxymethylaminomethyluridine 2-methylthio-adenine 5-carboxymethylaminomethyl-2′-O- 2-methoxy-adenine methyluridine inosine 5-carboxymethylaminomethyl-2-thiouridine 1-methyl-inosine N4,2′-O-dimethylcytidine wyosine 5-carboxymethyluridine wybutosine N6,2′-O-dimethyladenosine 7-deaza-guanosine N,N6,O-2′-trimethyladenosine 7-deaza-8-aza-guanosine N2,7-dimethylguanosine 6-thio-guanosine N2,N2,7-trimethylguanosine 6-thio-7-deaza-guanosine 3,2′-O-dimethyluridine 6-thio-7-deaza-8-aza-guanosine 5-methyldihydrouridine 7-methyl-guanosine 5-formyl-2′-O-methylcytidine 6-thio-7-methyl-guanosine 1,2′-O-dimethylguanosine 7-methylinosine 4-demethylwyosine 6-methoxy-guanosine Isowyosine 1-methylguanosine N6-acetyladenosine N2-methylguanosine N2,N2-dimethylguanosine 8-oxo-guanosine 7-methyl-8-oxo-guanosine 1-methyl-6-thio-guanosine

TABLE 7 Backbone modifications 2′-O-Methyl backbone Peptide Nucleic Acid (PNA) backbone phosphorothioate backbone morpholino backbone carbamate backbone siloxane backbone sulfide backbone sulfoxide backbone sulfone backbone formacetyl backbone thioformacetyl backbone methyleneformacetyl backbone riboacetyl backbone alkene containing backbone sulfamate backbone sulfonate backbone sulfonamide backbone methyleneimino backbone methylenehydrazino backbone amide backbone

TABLE 8 Modified caps m7GpppA m7GpppC m2,7GpppG m2,2,7GpppG m7Gpppm7G m7,2′OmeGpppG m72′dGpppG m7,3′OmeGpppG m7,3′dGpppG GppppG m7GppppG m7GppppA m7GppppC m2,7GppppG m2,2,7GppppG m7Gppppm7G m7,2′OmeGppppG m72′dGppppG m7,3′OmeGppppG m7,3′dGppppG

Production of Compositions and Systems

As will be appreciated by one of skill, methods of designing and constructing nucleic acid constructs and proteins or polypeptides (such as the systems, constructs and polypeptides described herein) are routine in the art. Generally, recombinant methods may be used. See, in general, Smales & James (Eds.), Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology), Humana Press (2005); and Crommelin, Sindelar & Meibohm (Eds.), Pharmaceutical Biotechnology: Fundamentals and Applications, Springer (2013). Methods of designing, preparing, evaluating, purifying and manipulating nucleic acid compositions are described in Green and Sambrook (Eds.), Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press (2012).

The disclosure provides, in part, a nucleic acid, e.g., vector, encoding a Gene Writer polypeptide described herein, a template nucleic acid described herein, or both. In some embodiments, a vector comprises a selective marker, e.g., an antibiotic resistance marker. In some embodiments, the antibiotic resistance marker is a kanamycin resistance marker. In some embodiments, the antibiotic resistance marker does not confer resistance to beta-lactam antibiotics. In some embodiments, the vector does not comprise an ampicillin resistance marker. In some embodiments, the vector comprises a kanamycin resistance marker and does not comprise an ampicillin resistance marker. In some embodiments, a vector encoding a Gene Writer polypeptide is integrated into a target cell genome (e.g., upon administration to a target cell, tissue, organ, or subject). In some embodiments, a vector encoding a Gene Writer polypeptide is not integrated into a target cell genome (e.g., upon administration to a target cell, tissue, organ, or subject). In some embodiments, a vector encoding a template nucleic acid (e.g., template RNA) is not integrated into a target cell genome (e.g., upon administration to a target cell, tissue, organ, or subject). In some embodiments, if a vector is integrated into a target site in a target cell genome, the selective marker is not integrated into the genome. In some embodiments, if a vector is integrated into a target site in a target cell genome, genes or sequences involved in vector maintenance (e.g., plasmid maintenance genes) are not integrated into the genome. In some embodiments, if a vector is integrated into a target site in a target cell genome, transfer regulating sequences (e.g., inverted terminal repeats, e.g., from an AAV) are not integrated into the genome. In some embodiments, administration of a vector (e.g., encoding a Gene Writer polypeptide described herein, a template nucleic acid described herein, or both) to a target cell, tissue, organ, or subject results in integration of a portion of the vector into one or more target sites in the genome(s) of said target cell, tissue, organ, or subject. In some embodiments, less than 99, 95, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, or 1% of target sites (e.g., no target sites) comprising integrated material comprise a selective marker (e.g., an antibiotic resistance gene), a transfer regulating sequence (e.g., an inverted terminal repeat, e.g., from an AAV), or both from the vector.

Exemplary methods for producing a therapeutic pharmaceutical protein or polypeptide described herein involve expression in mammalian cells, although recombinant proteins can also be produced using insect cells, yeast, bacteria, or other cells under control of appropriate promoters. Mammalian expression vectors may comprise non-transcribed elements such as an origin of replication, a suitable promoter, and other 5′ or 3′ flanking non-transcribed sequences, and 5′ or 3′ non-translated sequences such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and termination sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, splice, and polyadenylation sites may be used to provide other genetic elements required for expression of a heterologous DNA sequence. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described in Green & Sambrook, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press (2012).

Various mammalian cell culture systems can be employed to express and manufacture recombinant protein. Examples of mammalian expression systems include CHO, COS, HEK293, HeLA, and BHK cell lines. Processes of host cell culture for production of protein therapeutics are described in Zhou and Kantardjieff (Eds.), Mammalian Cell Cultures for Biologics Manufacturing (Advances in Biochemical Engineering/Biotechnology), Springer (2014). Compositions described herein may include a vector, such as a viral vector, e.g., a lentiviral vector, encoding a recombinant protein. In some embodiments, a vector, e.g., a viral vector, may comprise a nucleic acid encoding a recombinant protein.

Purification of protein therapeutics is described in Franks, Protein Biotechnology: Isolation, Characterization, and Stabilization, Humana Press (2013); and in Cutler, Protein Purification Protocols (Methods in Molecular Biology), Humana Press (2010).

In some embodiments, a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) conforms to certain quality standards. In some embodiments, a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) produced by a method described herein conforms to certain quality standards. Accordingly, the disclosure is directed in part to methods of manufacturing a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) that conforms to certain quality standards, e.g., in which said quality standards are assayed. The disclosure is further directed to methods of assaying said quality standards in a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA). In some embodiments, quality standards include, but are not limited to:

-   -   (i) the length of the template RNA, e.g., whether the template         RNA has a length that is above a reference length or within a         reference length range, e.g., whether at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present is greater than         100, 125, 150, 175, or 200 nucleotides long;     -   (ii) the presence, absence, and/or length of a polyA tail on the         template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the template RNA present contains a polyA tail (e.g.,         a polyA tail that is at least 5, 10, 20, 30, 50, 70, 100         nucleotides in length (SEQ ID NO: 3665));     -   (iii) the presence, absence, and/or type of a 5′ cap on the         template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the template RNA present contains a 5′ cap, e.g.,         whether that cap is a 7-methylguanosine cap, e.g., a O-Me-m7G         cap;     -   (iv) the presence, absence, and/or type of one or more modified         nucleotides (e.g., selected from pseudouridine, dihydrouridine,         inosine, 7-methylguanosine, 1-N-methylpseudouridine (1-Me-Ψ),         5-methoxyuridine (5-MO-U), 5-methylcytidine (5mC), or a locked         nucleotide) in the template RNA, e.g., whether at least 80, 85,         90, 95, 96, 97, 98, or 99% of the template RNA present contains         one or more modified nucleotides;     -   (v) the stability of the template RNA (e.g., over time and/or         under a pre-selected condition), e.g., whether at least 80, 85,         90, 95, 96, 97, 98, or 99% of the template RNA remains intact         (e.g., greater than 100, 125, 150, 175, or 200 nucleotides long)         after a stability test;     -   (vi) the potency of the template RNA in a system for modifying         DNA, e.g., whether at least 1% of target sites are modified         after a system comprising the template RNA is assayed for         potency;     -   (vii) the length of the polypeptide, first polypeptide, or         second polypeptide, e.g., whether the polypeptide, first         polypeptide, or second polypeptide has a length that is above a         reference length or within a reference length range, e.g.,         whether at least 80, 85, 90, 95, 96, 97, 98, or 99% of the         polypeptide, first polypeptide, or second polypeptide present is         greater than 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050,         1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1600,         1700, 1800, 1900, or 2000 amino acids long (and optionally, no         larger than 2500, 2000, 1500, 1400, 1300, 1200, 1100, 1000, 900,         800, 700, or 600 amino acids long);     -   (viii) the presence, absence, and/or type of post-translational         modification on the polypeptide, first polypeptide, or second         polypeptide, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the polypeptide, first polypeptide, or second         polypeptide contains phosphorylation, methylation, acetylation,         myristoylation, palmitoylation, isoprenylation, glipyatyon, or         lipoylation, or any combination thereof,     -   (ix) the presence, absence, and/or type of one or more         artificial, synthetic, or non-canonical amino acids (e.g.,         selected from ornithine, β-alanine, GABA, S-Aminolevulinic acid,         PABA, a D-amino acid (e.g., D-alanine or D-glutamate),         aminoisobutyric acid, dehydroalanine, cystathionine,         lanthionine, Djenkolic acid, Diaminopimelic acid, Homoalanine,         Norvaline, Norleucine, Homonorleucine, homoserine,         O-methyl-homoserine and O-ethyl-homoserine, ethionine,         selenocysteine, selenohomocysteine, selenomethionine,         selenoethionine, tellurocysteine, or telluromethionine) in the         polypeptide, first polypeptide, or second polypeptide, e.g.,         whether at least 80, 85, 90, 95, 96, 97, 98, or 99% of the         polypeptide, first polypeptide, or second polypeptide present         contains one or more artificial, synthetic, or non-canonical         amino acids;     -   (x) the stability of the polypeptide, first polypeptide, or         second polypeptide (e.g., over time and/or under a pre-selected         condition), e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the polypeptide, first polypeptide, or second         polypeptide remains intact (e.g., greater than 600, 650, 700,         750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250,         1300, 1350, 1400, 1450, 1500, 1600, 1700, 1800, 1900, or 2000         amino acids long (and optionally, no larger than 2500, 2000,         1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, or 600 amino         acids long)) after a stability test;     -   (xi) the potency of the polypeptide, first polypeptide, or         second polypeptide in a system for modifying DNA, e.g., whether         at least 1% of target sites are modified after a system         comprising the polypeptide, first polypeptide, or second         polypeptide is assayed for potency; or     -   (xii) the presence, absence, and/or level of one or more of a         pyrogen, virus, fungus, bacterial pathogen, or host cell         protein, e.g., whether the system is free or substantially free         of pyrogen, virus, fungus, bacterial pathogen, or host cell         protein contamination.

In some embodiments, quality standards include, but are not limited to:

-   -   (i) the length of mRNA encoding the GeneWriter polypeptide,         e.g., whether the mRNA has a length that is above a reference         length or within a reference length range, e.g., whether at         least 80, 85, 90, 95, 96, 97, 98, or 99% of the mRNA present is         greater than 3000, 4000, or 5000 nucleotides long;     -   (ii) the presence, absence, and/or length of a polyA tail on the         mRNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98, or 99%         of the mRNA present contains a polyA tail (e.g., a polyA tail         that is at least 5, 10, 20, 30, 50, 70, 100 nucleotides in         length (SEQ ID NO: 3665));     -   (iii) the presence, absence, and/or type of a 5′ cap on the         mRNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98, or 99%         of the mRNA present contains a 5′ cap, e.g., whether that cap is         a 7-methylguanosine cap, e.g., a O-Me-m7G cap;     -   (iv) the presence, absence, and/or type of one or more modified         nucleotides (e.g., selected from pseudouridine, dihydrouridine,         inosine, 7-methylguanosine, 1-N-methylpseudouridine (1-Me-Ψ),         5-methoxyuridine (5-MO-U), 5-methylcytidine (5mC), or a locked         nucleotide) in the mRNA, e.g., whether at least 80, 85, 90, 95,         96, 97, 98, or 99% of the mRNA present contains one or more         modified nucleotides;     -   (v) the stability of the mRNA (e.g., over time and/or under a         pre-selected condition), e.g., whether at least 80, 85, 90, 95,         96, 97, 98, or 99% of the mRNA remains intact (e.g., greater         than 100, 125, 150, 175, or 200 nucleotides long) after a         stability test; or     -   (vi) the potency of the mRNA in a system for modifying DNA,         e.g., whether at least 1% of target sites are modified after a         system comprising the mRNA is assayed for potency.

Circular RNAs in Gene Writing System

Circular RNAs (circRNA) have been found to occur naturally in cells and have been found to have diverse functions, including both non-coding and protein coding roles in human cells. It has been shown that a circRNA can be engineered by incorporating a self-splicing intron into an RNA molecule (or DNA encoding the RNA molecule) that results in circularization of the RNA, and that an engineered circRNA can have enhanced protein production and stability (Wesselhoeft et al. Nature Communications 2018). It is contemplated that it may be useful to employ circular and/or linear RNA states during the formulation, delivery, or Gene Writing reaction within the target cell. Thus, in some embodiments of any of the aspects described herein, a Gene Writing system comprises one or more circular RNAs (circRNAs). In some embodiments of any of the aspects described herein, a Gene Writing system comprises one or more linear RNAs. In some embodiments, a nucleic acid as described herein (e.g., a nucleic acid molecule encoding a Gene Writer polypeptide, or both) is a circRNA. In some embodiments, a circular RNA molecule encodes the Gene Writer™ polypeptide. In some embodiments, the circRNA molecule encoding the Gene Writer™ polypeptide is delivered to a host cell. In some embodiments, a circular RNA molecule encodes a recombinase, e.g., as described herein. In some embodiments, the circRNA molecule encoding the recombinase is delivered to a host cell. In some embodiments, the circRNA molecule encoding the Gene Writer polypeptide is linearized (e.g., in the host cell) prior to translation. Circular RNAs (circRNA) have been found to occur naturally in cells and have been found to have diverse functions, including both non-coding and protein coding roles in human cells. It has been shown that a circRNA can be engineered by incorporating a self-splicing intron into an RNA molecule (or DNA encoding the RNA molecule) that results in circularization of the RNA, and that an engineered circRNA can have enhanced protein production and stability (Wesselhoeft et al. Nature Communications 2018). In some embodiments, the Gene Writer™ polypeptide is encoded as circRNA.

In some embodiments, the Gene Writer™ polypeptide is encoded as circRNA. While in certain embodiments the template nucleic acid is a DNA, such as a ssDNA, in some embodiments it can be provided as an RNA, e.g., with a reverse transcriptase.

In some embodiments, the circRNA comprises one or more ribozyme sequences. In some embodiments, the ribozyme sequence is activated for autocleavage, e.g., in a host cell, e.g., thereby resulting in linearization of the circRNA. In some embodiments, the ribozyme is activated when the concentration of magnesium reaches a sufficient level for cleavage, e.g., in a host cell. In some embodiments the circRNA is maintained in a low magnesium environment prior to delivery to the host cell. In some embodiments, the ribozyme is a protein-responsive ribozyme. In some embodiments, the ribozyme is a nucleic acid-responsive ribozyme.

In some embodiments, the circRNA is linearized in the nucleus of a target cell. In some embodiments, linearization of a circRNA in the nucleus of a cell involves components present in the nucleus of the cell, e.g., to activate a cleavage event. For example, the B2 and ALU retrotransposons contain self-cleaving ribozymes whose activity is enhanced by interaction with the Polycomb protein, EZH2 (Hernandez et al. PNAS 117(1):415-425 (2020)). Thus, in some embodiments, a ribozyme, e.g., a ribozyme from a B2 or ALU element, that is responsive to a nuclear element, e.g., a nuclear protein, e.g., a genome-interacting protein, e.g., an epigenetic modifier, e.g., EZH2, is incorporated into a circRNA, e.g., of a Gene Writing system. In some embodiments, nuclear localization of the circRNA results in an increase in autocatalytic activity of the ribozyme and linearization of the circRNA.

In some embodiments, an inducible ribozyme (e.g., in a circRNA as described herein) is created synthetically, for example, by utilizing a protein ligand-responsive aptamer design. A system for utilizing the satellite RNA of tobacco ringspot virus hammerhead ribozyme with an MS2 coat protein aptamer has been described (Kennedy et al. Nucleic Acids Res 42(19):12306-12321 (2014), incorporated herein by reference in its entirety) that results in activation of the ribozyme activity in the presence of the MS2 coat protein. In embodiments, such a system responds to protein ligand localized to the cytoplasm or the nucleus. In some embodiments the protein ligand is not MS2. Methods for generating RNA aptamers to target ligands have been described, for example, based on the systematic evolution of ligands by exponential enrichment (SELEX) (Tuerk and Gold, Science 249(4968):505-510 (1990); Ellington and Szostak, Nature 346(6287):818-822 (1990); the methods of each of which are incorporated herein by reference) and have, in some instances, been aided by in silico design (Bell et al. PNAS 117(15):8486-8493, the methods of which are incorporated herein by reference). Thus, in some embodiments, an aptamer for a target ligand is generated and incorporated into a synthetic ribozyme system, e.g., to trigger ribozyme-mediated cleavage and circRNA linearization, e.g., in the presence of the protein ligand. In some embodiments, circRNA linearization is triggered in the cytoplasm, e.g., using an aptamer that associates with a ligand in the cytoplasm. In some embodiments, circRNA linearization is triggered in the nucleus, e.g., using an aptamer that associates with a ligand in the nucleus. In embodiments, the ligand in to the nucleus comprises an epigenetic modifier or a transcription factor. In some embodiments the ligand that triggers linearization is present at higher levels in on-target cells than off-target cells.

It is further contemplated that a nucleic acid-responsive ribozyme system can be employed for circRNA linearization. For example, biosensors that sense defined target nucleic acid molecules to trigger ribozyme activation are described, e.g., in Penchovsky (Biotechnology Advances 32(5):1015-1027 (2014), incorporated herein by reference). By these methods, a ribozyme naturally folds into an inactive state and is only activated in the presence of a defined target nucleic acid molecule (e.g., an RNA molecule). In some embodiments, a circRNA of a Gene Writing system comprises a nucleic acid-responsive ribozyme that is activated in the presence of a defined target nucleic acid, e.g., an RNA, e.g., an mRNA, miRNA, guide RNA, gRNA, sgRNA, ncRNA, lncRNA, tRNA, snRNA, or mtRNA. In some embodiments the nucleic acid that triggers linearization is present at higher levels in on-target cells than off-target cells.

In some embodiments of any of the aspects herein, a Gene Writing system incorporates one or more ribozymes with inducible specificity to a target tissue or target cell of interest, e.g., a ribozyme that is activated by a ligand or nucleic acid present at higher levels in a target tissue or target cell of interest. In some embodiments, the Gene Writing system incorporates a ribozyme with inducible specificity to a subcellular compartment, e.g., the nucleus, nucleolus, cytoplasm, or mitochondria. In some embodiments, the ribozyme that is activated by a ligand or nucleic acid present at higher levels in the target subcellular compartment. In some embodiments, an RNA component of a Gene Writing system is provided as circRNA, e.g., that is activated by linearization. In some embodiments, linearization of a circRNA encoding a Gene Writing polypeptide activates the molecule for translation. In some embodiments, a signal that activates a circRNA component of a Gene Writing system is present at higher levels in on-target cells or tissues, e.g., such that the system is specifically activated in these cells.

In some embodiments, an RNA component of a Gene Writing system is provided as a circRNA that is inactivated by linearization. In some embodiments, a circRNA encoding the Gene Writer polypeptide is inactivated by cleavage and degradation. In some embodiments, a circRNA encoding the Gene Writing polypeptide is inactivated by cleavage that separates a translation signal from the coding sequence of the polypeptide. In some embodiments, a signal that inactivates a circRNA component of a Gene Writing system is present at higher levels in off-target cells or tissues, such that the system is specifically inactivated in these cells.

In some embodiments, nucleic acid (e.g., encoding a polypeptide, or a template DNA, or both) delivered to cells is covalently closed linear DNA, or so-called “doggybone” DNA. During its lifecycle, the bacteriophage N15 employs protelomerase to convert its genome from circular plasmid DNA to a linear plasmid DNA (Ravin et al. J Mol Biol 2001). This process has been adapted for the production of covalently closed linear DNA in vitro (see, for example, WO2010086626A1). In some embodiments, a protelomerase is contacted with a DNA containing one or more protelomerase recognition sites, wherein protelomerase results in a cut at the one or more sites and subsequent ligation of the complementary strands of DNA, resulting in the covalent linkage between the complementary strands. In some embodiments, nucleic acid (e.g., encoding a transposase, or a template DNA, or both) is first generated as circular plasmid DNA containing a single protelomerase recognition site that is then contacted with protelomerase to yield a covalently closed linear DNA. In some embodiments, nucleic acid (e.g., encoding a transposase, or a template DNA, or both) flanked by protelomerase recognition sites on plasmid or linear DNA is contacted with protelomerase to generate a covalently closed linear DNA containing only the DNA contained between the protelomerase recognition sites. In some embodiments, the approach of flanking the desired nucleic acid sequence by protelomerase recognition sites results in covalently closed circular DNA lacking plasmid elements used for bacterial cloning and maintenance. In some embodiments, the plasmid or linear DNA containing the nucleic acid and one or more protelomerase recognition sites is optionally amplified prior to the protelomerase reaction, e.g., by rolling circle amplification or PCR.

In some embodiments, nucleic acid (e.g., encoding a polypeptide, or a template nucleic acid, or both) delivered to cells is designed as minicircles, where plasmid backbone sequences not pertaining to Gene Writing™ are removed before administration to cells. For example, a minicircle may lack a bacterial origin of replication and a selectable marker. In some embodiments, the minicircle does not comprise any bacterial sequence. Minicircles have been shown to result in higher transfection efficiencies and gene expression as compared to plasmids with backbones containing bacterial parts (e.g., bacterial origin of replication, antibiotic selection cassette) and have been used to improve the efficiency of transposition (Sharma et al Mol Ther Nucleic Acids 2013). In some embodiments, the DNA vector encoding the Gene Writer™ polypeptide is delivered as a minicircle. In some embodiments, the DNA vector containing the Gene Writer™ template nucleic acid (e.g., template RNA) is delivered as a minicircle. In some embodiments, the bacterial parts are flanked by recombination sites, e.g., attP/attB, loxP, FRT sites. In some embodiments, the addition of a cognate recombinase results in intramolecular recombination and excision of the bacterial parts. In some embodiments, the recombinase sites are recognized by phiC31 recombinase. In some embodiments, the recombinase sites are recognized by Cre recombinase. In some embodiments, the recombinase sites are recognized by FLP recombinase. In addition to plasmid DNA, minicircles can be generated by excising the desired construct, e.g., transposase expression cassettes or therapeutic expression cassette, from a viral backbone. Previously, it has been shown that excision and circularization of the donor sequence from a viral backbone may be important for transposase-mediated integration efficiency (Yant et al Nat Biotechnol 2002). In some embodiments, minicircles are first formulated and then delivered to target cells. In other embodiments, minicircles are formed from a DNA vector (e.g., plasmid DNA, rAAV, scAAV, ceDNA, doggybone DNA) intracellularly by co-delivery of a recombinase, resulting in excision and circularization of the recombinase recognition site-flanked nucleic acid, e.g., a nucleic acid encoding the Gene Writer™ polypeptide, template nucleic acid (e.g., template RNA) or nucleic acid encoding same, or both.

For optimizing protein expression, it can be helpful to provide tunable controls that can be used to modulate protein activity. In some embodiments, a tunable system may comprise at least one effector module that is responsive to at least one stimulus. The system may be, but is not limited to, a destabilizing domain (DD) system. This system is further taught in PCT/US2018/020704, as well as U.S. Provisional Patent Application No. 62/320,864 filed Apr. 11, 2016, 62/466,596 filed Mar. 3, 2017 and the International Publication WO2017/180587 (the contents each of which are herein incorporated by reference in their entirety). In some embodiments, the tunable system may comprise a first effector module. In some embodiments, the effector module may comprise a first stimulus response element (SRE) operably linked to at least one payload. In one aspect, the payload may be an immunotherapeutic agent. In one aspect, the first SRE of the composition may be responsive to or interact with at least one stimulus. In some embodiments, the first SRE may comprise a destabilizing domain (DD). The DD may be derived from a parent protein or from a mutant protein having one, two, three, or more amino acid mutations compared to the parent protein. In some embodiments, the parent protein may be selected from, but is not limited to, human protein FKBP, comprising the amino acid sequence of PCT/US2018/020704 SEQ. ID NO. 3; human DHFR (hDHFR), comprising the amino acid sequence of PCT/US2018/020704 SEQ. ID NO. 2; E. coli DHFR, comprising the amino acid sequence of PCT/US2018/020704 SEQ. ID NO. 1; PDE5, comprising the amino acid sequence of PCT/US2018/020704 SEQ. ID NO. 4; PPAR, gamma comprising the amino acid sequence of PCT/US2018/020704 SEQ. ID NO. 5; CA2, comprising the amino acid sequence of PCT/US2018/0207041 SEQ. ID NO. 6; or NQ02, comprising the amino acid sequence of PCT/US2018/20704 SEQ. ID NO. 7. In some embodiments, the tunable controls are applied to the Gene Writer polypeptide, such that, e.g., a DD and stimulus can be used to modulate template integration efficiency. In some embodiments, the tunable controls are applied to one or more peptides encoded within the heterologous object sequence of the template, such that, e.g., a DD and stimulus can be used to modulate activity of a genomically integrated payload. In certain embodiments, the payload comprising the DD may be a therapeutic protein, e.g., a functional copy of an endogenously mutated gene. In certain embodiments, the payload comprising the DD may be a heterologous protein, e.g., a CAR.

Kits, Articles of Manufacture, and Pharmaceutical Compositions

In an aspect the disclosure provides a kit comprising a Gene Writer or a Gene Writing system, e.g., as described herein. In some embodiments, the kit comprises a Gene Writer polypeptide (or a nucleic acid encoding the polypeptide) and a template RNA (or DNA encoding the template RNA). In some embodiments, the kit further comprises a reagent for introducing the system into a cell, e.g., transfection reagent, LNP, and the like. In some embodiments, the kit is suitable for any of the methods described herein. In some embodiments, the kit comprises one or more elements, compositions (e.g., pharmaceutical compositions), Gene Writers, and/or Gene Writer systems, or a functional fragment or component thereof, e.g., disposed in an article of manufacture. In some embodiments, the kit comprises instructions for use thereof.

In an aspect, the disclosure provides an article of manufacture, e.g., in which a kit as described herein, or a component thereof, is disposed.

In an aspect, the disclosure provides a pharmaceutical composition comprising a Gene Writer or a Gene Writing system, e.g., as described herein. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises a template RNA and/or an RNA encoding the polypeptide. In embodiments, the pharmaceutical composition has one or more (e.g., 1, 2, 3, or 4) of the following characteristics:

-   -   (a) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) DNA template relative to the template RNA and/or the RNA         encoding the polypeptide, e.g., on a molar basis;     -   (b) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) uncapped RNA relative to the template RNA and/or the RNA         encoding the polypeptide, e.g., on a molar basis;     -   (c) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) partial length RNAs relative to the template RNA and/or         the RNA encoding the polypeptide, e.g., on a molar basis;     -   (d) substantially lacks unreacted cap dinucleotides.

Chemistry, Manufacturing, and Controls (CMC)

Purification of protein therapeutics is described, for example, in Franks, Protein Biotechnology: Isolation, Characterization, and Stabilization, Humana Press (2013); and in Cutler, Protein Purification Protocols (Methods in Molecular Biology), Humana Press (2010).

In some embodiments, a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) conforms to certain quality standards. In some embodiments, a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) produced by a method described herein conforms to certain quality standards. Accordingly, the disclosure is directed, in some aspects, to methods of manufacturing a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA) that conforms to certain quality standards, e.g., in which said quality standards are assayed. The disclosure is also directed, in some aspects, to methods of assaying said quality standards in a Gene Writer™ system, polypeptide, and/or template nucleic acid (e.g., template RNA). In some embodiments, quality standards include, but are not limited to, one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) of the following:

-   -   (i) the length of the template RNA, e.g., whether the template         RNA has a length that is above a reference length or within a         reference length range, e.g., whether at least 80, 85, 90, 95,         96, 97, 98, or 99% of the template RNA present is greater than         100, 125, 150, 175, or 200 nucleotides long;     -   (ii) the presence, absence, and/or length of a polyA tail on the         template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the template RNA present contains a polyA tail (e.g.,         a polyA tail that is at least 5, 10, 20, 30, 50, 70, 100         nucleotides in length (SEQ ID NO: 3665));     -   (iii) the presence, absence, and/or type of a 5′ cap on the         template RNA, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the template RNA present contains a 5′ cap, e.g.,         whether that cap is a 7-methylguanosine cap, e.g., a O-Me-m7G         cap;     -   (iv) the presence, absence, and/or type of one or more modified         nucleotides (e.g., selected from pseudouridine, dihydrouridine,         inosine, 7-methylguanosine, 1-N-methylpseudouridine (1-Me-Ψ),         5-methoxyuridine (5-MO-U), 5-methylcytidine (5mC), or a locked         nucleotide) in the template RNA, e.g., whether at least 80, 85,         90, 95, 96, 97, 98, or 99% of the template RNA present contains         one or more modified nucleotides;     -   (v) the stability of the template RNA (e.g., over time and/or         under a pre-selected condition), e.g., whether at least 80, 85,         90, 95, 96, 97, 98, or 99% of the template RNA remains intact         (e.g., greater than 100, 125, 150, 175, or 200 nucleotides long)         after a stability test;     -   (vi) the potency of the template RNA in a system for modifying         DNA, e.g., whether at least 1% of target sites are modified         after a system comprising the template RNA is assayed for         potency;     -   (vii) the length of the polypeptide, first polypeptide, or         second polypeptide, e.g., whether the polypeptide, first         polypeptide, or second polypeptide has a length that is above a         reference length or within a reference length range, e.g.,         whether at least 80, 85, 90, 95, 96, 97, 98, or 99% of the         polypeptide, first polypeptide, or second polypeptide present is         greater than 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050,         1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1600,         1700, 1800, 1900, or 2000 amino acids long (and optionally, no         larger than 2500, 2000, 1500, 1400, 1300, 1200, 1100, 1000, 900,         800, 700, or 600 amino acids long);     -   (viii) the presence, absence, and/or type of post-translational         modification on the polypeptide, first polypeptide, or second         polypeptide, e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the polypeptide, first polypeptide, or second         polypeptide contains phosphorylation, methylation, acetylation,         myristoylation, palmitoylation, isoprenylation, glipyatyon, or         lipoylation, or any combination thereof,     -   (ix) the presence, absence, and/or type of one or more         artificial, synthetic, or non-canonical amino acids (e.g.,         selected from ornithine, β-alanine, GABA, δ-Aminolevulinic acid,         PABA, a D-amino acid (e.g., D-alanine or D-glutamate),         aminoisobutyric acid, dehydroalanine, cystathionine,         lanthionine, Djenkolic acid, Diaminopimelic acid, Homoalanine,         Norvaline, Norleucine, Homonorleucine, homoserine,         O-methyl-homoserine and O-ethyl-homoserine, ethionine,         selenocysteine, selenohomocysteine, selenomethionine,         selenoethionine, tellurocysteine, or telluromethionine) in the         polypeptide, first polypeptide, or second polypeptide, e.g.,         whether at least 80, 85, 90, 95, 96, 97, 98, or 99% of the         polypeptide, first polypeptide, or second polypeptide present         contains one or more artificial, synthetic, or non-canonical         amino acids;     -   (x) the stability of the polypeptide, first polypeptide, or         second polypeptide (e.g., over time and/or under a pre-selected         condition), e.g., whether at least 80, 85, 90, 95, 96, 97, 98,         or 99% of the polypeptide, first polypeptide, or second         polypeptide remains intact (e.g., greater than 600, 650, 700,         750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250,         1300, 1350, 1400, 1450, 1500, 1600, 1700, 1800, 1900, or 2000         amino acids long (and optionally, no larger than 2500, 2000,         1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, or 600 amino         acids long)) after a stability test;     -   (xi) the potency of the polypeptide, first polypeptide, or         second polypeptide in a system for modifying DNA, e.g., whether         at least 1% of target sites are modified after a system         comprising the polypeptide, first polypeptide, or second         polypeptide is assayed for potency; or     -   (xii) the presence, absence, and/or level of one or more of a         pyrogen, virus, fungus, bacterial pathogen, or host cell         protein, e.g., whether the system is free or substantially free         of pyrogen, virus, fungus, bacterial pathogen, or host cell         protein contamination.

In some embodiments, a system or pharmaceutical composition described herein is endotoxin free.

In some embodiments, the presence, absence, and/or level of one or more of a pyrogen, virus, fungus, bacterial pathogen, and/or host cell protein is determined. In embodiments, whether the system is free or substantially free of pyrogen, virus, fungus, bacterial pathogen, and/or host cell protein contamination is determined.

In some embodiments, a pharmaceutical composition or system as described herein has one or more (e.g., 1, 2, 3, or 4) of the following characteristics:

-   -   (a) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) DNA template relative to the template RNA and/or the RNA         encoding the polypeptide, e.g., on a molar basis;     -   (b) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) uncapped RNA relative to the template RNA and/or the RNA         encoding the polypeptide, e.g., on a molar basis;     -   (c) less than 1% (e.g., less than 0.5%, 0.4%, 0.3%, 0.2%, or         0.1%) partial length RNAs relative to the template RNA and/or         the RNA encoding the polypeptide, e.g., on a molar basis;     -   (d) substantially lacks unreacted cap dinucleotides.

Applications

By integrating coding genes into a RNA sequence template, the Gene Writer™ system can address therapeutic needs, for example, by providing expression of a therapeutic transgene in individuals with loss-of-function mutations, by replacing gain-of-function mutations with normal transgenes, by providing regulatory sequences to eliminate gain-of-function mutation expression, and/or by controlling the expression of operably linked genes, transgenes and systems thereof. In certain embodiments, the RNA sequence template encodes a promotor region specific to the therapeutic needs of the host cell, for example a tissue specific promotor or enhancer. In still other embodiments, a promotor can be operably linked to a coding sequence. In embodiments, the Gene Writer™ gene editor system can provide therapeutic transgenes expressing, e.g., replacement blood factors or replacement enzymes, e.g., lysosomal enzymes. For example, the compositions, systems and methods described herein are useful to express, in a target human genome, agalsidase alpha or beta for treatment of Fabry Disease; imiglucerase, taliglucerase alfa, velaglucerase alfa, or alglucerase for Gaucher Disease; sebelipase alpha for lysosomal acid lipase deficiency (Wolman disease/CESD); laronidase, idursulfase, elosulfase alpha, or galsulfase for mucopolysaccharidoses; alglucosidase alpha for Pompe disease. For example, the compositions, systems and methods described herein are useful to express, in a target human genome factor I, II, V, VII, X, XI, XII or XIII for blood factor deficiencies.

In some embodiments, the heterologous object sequence encodes an intracellular protein (e.g., a cytoplasmic protein, a nuclear protein, an organellar protein such as a mitochondrial protein or lysosomal protein, or a membrane protein). In some embodiments, the heterologous object sequence encodes a membrane protein, e.g., a membrane protein other than a CAR, and/or an endogenous human membrane protein. In some embodiments, the heterologous object sequence encodes an extracellular protein. In some embodiments, the heterologous object sequence encodes an enzyme, a structural protein, a signaling protein, a regulatory protein, a transport protein, a sensory protein, a motor protein, a defense protein, or a storage protein. Other proteins include an immune receptor protein, e.g. a synthetic immune receptor protein such as a chimeric antigen receptor protein (CAR), a T cell receptor, a B cell receptor, or an antibody.

A Gene Writing™ system may be used to modify immune cells. In some embodiments, a Gene Writing™ system may be used to modify T cells. In some embodiments, T-cells may include any subpopulation of T-cells, e.g., CD4+, CD8+, gamma-delta, naïve T cells, stem cell memory T cells, central memory T cells, or a mixture of subpopulations. In some embodiments, a Gene Writing™ system may be used to deliver or modify a T-cell receptor (TCR) in a T cell. In some embodiments, a Gene Writing™ system may be used to deliver at least one chimeric antigen receptor (CAR) to T-cells. In some embodiments, a Gene Writing™ system may be used to deliver at least one CAR to natural killer (NK) cells. In some embodiments, a Gene Writing™ system may be used to deliver at least one CAR to natural killer T (NKT) cells. In some embodiments, a Gene Writing™ system may be used to deliver at least one CAR to a progenitor cell, e.g., a progenitor cell of T, NK, or NKT cells. In some embodiments, cells modified with at least one CAR (e.g., CAR-T cells, CAR-NK cells, CAR-NKT cells), or a combination of cells modified with at least one CAR (e.g., a mixture of CAR-NK/T cells) are used to treat a condition as identified in the targetable landscape of CAR therapies in MacKay, et al. Nat Biotechnol 38, 233-244 (2020), incorporated by reference herein in its entirety. In some embodiments, the immune cells comprise a CAR specific to a tumor or a pathogen antigen selected from a group consisting of AChR (fetal acetylcholine receptor), ADGRE2, AFP (alpha fetoprotein), BAFF-R, BCMA, CAIX (carbonic anhydrase IX), CCR1, CCR4, CEA (carcinoembryonic antigen), CD3, CD5, CD8, CD7, CD10, CD13, CD14, CD15, CD19, CD20, CD22, CD30, CD33, CLLI, CD34, CD38, CD41, CD44, CD49f, CD56, CD61, CD64, CD68, CD70, CD74, CD99, CD117, CD123, CD133, CD138, CD44v6, CD267, CD269, CDS, CLEC12A, CS1, EGP-2 (epithelial glycoprotein-2), EGP-40 (epithelial glycoprotein-40), EGFR(HER1), EGFR-VIII, EpCAM (epithelial cell adhesion molecule), EphA2, ERBB2 (HER2, human epidermal growth factor receptor 2), ERBB3, ERBB4, FBP (folate-binding protein), Flt3 receptor, folate receptor-a, GD2 (ganglioside G2), GD3 (ganglioside G3), GPC3 (glypican-3), GPI00, hTERT (human telomerase reverse transcriptase), ICAM-1, integrin B7, interleukin 6 receptor, IL13Ra2 (interleukin-13 receptor 30 subunit alpha-2), kappa-light chain, KDR (kinase insert domain receptor), LeY (Lewis Y), L1CAM (LI cell adhesion molecule), LILRB2 (leukocyte immunoglobulin like receptor B2), MARTI, MAGE-A1 (melanoma associated antigen A1), MAGE-A3, MSLN (mesothelin), MUC16 (mucin 16), MUCI (mucin I), KG2D ligands, NY-ESO-1 (cancer-testis antigen), PRI (proteinase 3), TRBCI, TRBC2, TFM-3, TACI, tyrosinase, survivin, hTERT, oncofetal antigen (h5T4), p53, PSCA (prostate stem cell antigen), PSMA (prostate-specific membrane antigen), hROR1, TAG-72 (tumor-associated glycoprotein 72), VEGF-R2 (vascular endothelial growth factor R2), WT-1 (Wilms tumor protein), and antigens of HIV (human immunodeficiency virus), hepatitis B, hepatitis C, CMV (cytomegalovirus), EBV (Epstein-Barr virus), HPV (human papilloma virus).

In some embodiments, immune cells, e.g., T-cells, NK cells, NKT cells, or progenitor cells are modified ex vivo and then delivered to a patient. In some embodiments, a Gene Writer™ system is delivered by one of the methods mentioned herein, and immune cells, e.g., T-cells, NK cells, NKT cells, or progenitor cells are modified in vivo in the patient.

In some embodiments, a Gene Writer™ system described herein is delivered to a tissue or cell from the cerebrum, cerebellum, adrenal gland, ovary, pancreas, parathyroid gland, hypophysis, testis, thyroid gland, breast, spleen, tonsil, thymus, lymph node, bone marrow, lung, cardiac muscle, esophagus, stomach, small intestine, colon, liver, salivary gland, kidney, prostate, blood, or other cell or tissue type. In some embodiments, a Gene Writer™ system described herein is used to treat a disease, such as a cancer, inflammatory disease, infectious disease, genetic defect, or other disease. A cancer can be cancer of the cerebrum, cerebellum, adrenal gland, ovary, pancreas, parathyroid gland, hypophysis, testis, thyroid gland, breast, spleen, tonsil, thymus, lymph node, bone marrow, lung, cardiac muscle, esophagus, stomach, small intestine, colon, liver, salivary gland, kidney, prostate, blood, or other cell or tissue type, and can include multiple cancers.

In some embodiments, a Gene Writer™ system described herein described herein is administered by enteral administration (e.g. oral, rectal, gastrointestinal, sublingual, sublabial, or buccal administration). In some embodiments, a Gene Writer™ system described herein is administered by parenteral administration (e.g., intravenous, intramuscular, subcutaneous, intradermal, epidural, intracerebral, intracerebroventricular, epicutaneous, nasal, intra-arterial, intra-articular, intracavernous, intraocular, intraosseous infusion, intraperitoneal, intrathecal, intrauterine, intravaginal, intravesical, perivascular, or transmucosal administration). In some embodiments, a Gene Writer™ system described herein is administered by topical administration (e.g., transdermal administration).

In some embodiments, a Gene Writing system can be used to make an insertion, deletion, substitution, or combination thereof in a cell, tissue, or subject. In some embodiments, an insertion, deletion, substitution, or combination thereof, increases or decreases expression (e.g. transcription or translation) of a gene. In some embodiments, an insertion, deletion, substitution, or combination thereof, increases or decreases expression (e.g. transcription or translation) of a gene by altering, adding, or deleting sequences in a promoter or enhancer, e.g. sequences that bind transcription factors. In some embodiments, an insertion, deletion, substitution, or combination thereof alters translation of a gene (e.g. alters an amino acid sequence), inserts or deletes a start or stop codon, alters or fixes the translation frame of a gene. In some embodiments, an insertion, deletion, substitution, or combination thereof alters splicing of a gene, e.g. by inserting, deleting, or altering a splice acceptor or donor site. In some embodiments, an insertion, deletion, substitution, or combination thereof alters transcript or protein half-life. In some embodiments, an insertion, deletion, substitution, or combination thereof alters protein localization in the cell (e.g. from the cytoplasm to a mitochondria, from the cytoplasm into the extracellular space (e.g. adds a secretion tag)). In some embodiments, an insertion, deletion, substitution, or combination thereof alters (e.g. improves) protein folding (e.g. to prevent accumulation of misfolded proteins). In some embodiments, an insertion, deletion, substitution, or combination thereof, alters, increases, decreases the activity of a gene, e.g. a protein encoded by the gene.

In some embodiments, a Gene Writing system can be used to make multiple modifications (e.g., multiple insertions, deletions, or substitutions, and all combinations thereof) to a target cell, either simultaneously or sequentially. In some embodiments, a Gene Writing system can be used to further modify an already modified cell. In some embodiments, a Gene Writing system can be use to modify a cell edited by a complementary technology, e.g., a gene edited cell, e.g., a cell with one or more CRISPR knockouts. In some embodiments, the previously edited cell is a T-cell. In some embodiments, the previous modifications comprise gene knockouts in a T-cell, e.g., endogenous TCR (e.g., TRAC, TRBC), HLA Class I (B2M), PD1, CD52, CTLA-4, TIM-3, LAG-3, DGK. In some embodiments, a Gene Writing system is used to insert a TCR or CAR into a T-cell that has been previously modified.

In some embodiments, a Gene Writer™ system as described herein can be used to modify an animal cell, plant cell, or fungal cell. In some embodiments, a Gene Writer™ system as described herein can be used to modify a mammalian cell (e.g., a human cell). In some embodiments, a Gene Writer™ system as described herein can be used to modify a cell from a livestock animal (e.g., a cow, horse, sheep, goat, pig, llama, alpaca, camel, yak, chicken, duck, goose, or ostrich). In some embodiments, a Gene Writer™ system as described herein can be used as a laboratory tool or a research tool, or used in a laboratory method or research method, e.g., to modify an animal cell, e.g., a mammalian cell (e.g., a human cell), a plant cell, or a fungal cell.

In some embodiments, a Gene Writer™ system as described herein can be used to express a protein, template, or heterologous object sequence (e.g., in an animal cell, e.g., a mammalian cell (e.g., a human cell), a plant cell, or a fungal cell). In some embodiments, a Gene Writer™ system as described herein can be used to express a protein, template, or heterologous object sequence under the control of an inducible promoter (e.g., a small molecule inducible promoter). In some embodiments, a Gene Writing system or payload thereof is designed for tunable control, e.g., by the use of an inducible promoter. For example, a promoter, e.g., Tet, driving a gene of interest may be silent at integration, but may, in some instances, activated upon exposure to a small molecule inducer, e.g., doxycycline. In some embodiments, the tunable expression allows post-treatment control of a gene (e.g., a therapeutic gene), e.g., permitting a small molecule-dependent dosing effect. In embodiments, the small molecule-dependent dosing effect comprises altering levels of the gene product temporally and/or spatially, e.g., by local administration. In some embodiments, a promoter used in a system described herein may be inducible, e.g., responsive to an endogenous molecule of the host and/or an exogenous small molecule administered thereto.

In some embodiments, a Gene Writing system is used to make changes to non-coding and/or regulatory control regions, e.g., to tune the expression of endogenous genes. In some embodiments, a Gene Writing system is used to induce upregulation or downregulation of gene expression. In some embodiments, a regulatory control region comprises one or more of a promoter, enhancer, UTR, CTCF site, and/or a gene expression control region.

In some embodiments, a Gene Writing system may be used to treat or prevent a repeat expansion disease (e.g., a disease of Table 26), or to reduce the severity or a symptom thereof. In some embodiments, the repeat expansion disease comprises expansion of a trinucleotide repeat. In some embodiments, the subject has at least 10, 20, 30, 40, or 50 copies of the repeat. In embodiments, the repeat expansion disease is an inherited disease. Non-limiting examples of repeat expansion diseases include Huntington's disease (HD) and myotonic dystrophy. For example, healthy individuals may possess between 10 and 35 tandem copies of the CAG trinucleotide repeat, while Huntington's patients frequently possess >40 copies, which can result, e.g., in an elongated and dysfunctional Huntingtin protein. In some embodiments, a Gene Writer corrects a repeat expansion, e.g., by recognizing DNA at the terminus of the repeat region and nicking one strand (FIG. 30 ). In some embodiments, the template RNA component of the Gene Writer comprises a region with a number of repeats characteristic of a healthy subject, e.g., about 20 repeats (e.g., between 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, or 35-40 repeats). In some embodiments, the template RNA component of the Gene Writer is copied by TPRT into the target site. In some embodiments, a second strand nick and second strand synthesis then results in the integration of the newly copied DNA comprising a correct number of repeats (e.g., as described herein). In some embodiments, the system recognizes DNA at the terminus of the repeat region and the template carries the information for the new number of repeats. In embodiments, a Gene Writer can be used in this way regardless of the number of repeats present in an individual and/or in an individual cell. Owing to the presence of multiple repeats, an alternative non-GeneWriter therapeutic (e.g., a CRISPR-based homologous recombination therapeutic) might, in some embodiments, result in unpredictable repair behavior. Further non-limiting examples of repeat expansion diseases and the causative repeats can be found, for example, in La Spada and Taylor Nat Rev Genet 11(4):247-258 (2010), which is incorporated herein by reference in its entirety.

In some embodiments, a Gene Writing system may be used to treat a healthy individual, e.g., as a preventative therapy. Gene Writing systems can, in some embodiments, be targeted to generate mutations, e.g., that have been shown to be protective towards a disease of interest. An exemplary list of such diseases and protective mutation targets can be found in Table 22.

In some embodiments, a Gene Writer system described herein is used to treat an indication of any of Tables 9-12. For instance, in some embodiments the GeneWriter system modifies a target site in genomic DNA in a cell, wherein the target site is in a gene of any of Tables 9-12, e.g., in a subject having the corresponding indication listed in any of Tables 9-12. In some embodiments, the cell is a liver cell and the target site is in a gene of Table 9, e.g., in a subject having the corresponding indication listed in Table 9. In some embodiments, the cell is an HSC and the target site is in a gene of Table 10, e.g., in a subject having the corresponding indication listed in Table 10. In some embodiments, the cell is a CNS cell and the target site is in a gene of Table 11, e.g., in a subject having the corresponding indication listed in Table 11. In some embodiments, the cell is a cell of the eye and the target site is in a gene of Table 12, e.g., in a subject having the corresponding indication listed in Table 12. In some embodiments, the target site is in a coding region in the gene. In some embodiments, the target site is in a promoter. In some embodiments, the target site is in a 5′ UTR or a 3′ UTR of the gene of any of Tables 9-12. In some embodiments, the target site is in an intron or exon of the gene. In some embodiments, the GeneWriter corrects a mutation in the gene. In some embodiments, the GeneWriter inserts a sequence that had been deleted from the gene (e.g., through a disease-causing mutation). In some embodiments, the GeneWriter deletes a sequence that had been duplicated in the gene (e.g., through a disease-causing mutation). In some embodiments, the GeneWriter replaces a mutation (e.g., a disease-causing mutation) with the corresponding wild-type sequence. In some embodiments, the mutation is a substitution, insertion, deletion, or inversion.

TABLE 9 Indications and genetic targets, e.g., in the liver Disease Gene Affected Acute intermittent porphyria HMBS Alpha-1-antitrypsin deficiency (AAT) SERPINA1 Arginase deficiency ARG1 Argininosuccinate lyase deficiency ASL Carbamoyl phosphate synthetase I deficiency CPS1 Citrin deficiency SLC25A13 Citrullinemia type I ASS1 Crigler-Najjar syndrome (Hyperbilirubinemia) UGT1A1 Fabry disease GLA Familial hypercholesterolemia 4 (homozygous LDLRAP1 familial cholesterolemia) Glutaric aciduria I GCDH Glutaric aciduria II (multiple acyl-CoA GA IIA: ETFA dehydrogenase deficiency) GA IIB: ETFB GA IIC: ETFDH Glycogen storage disease type IV GBE1 Hemophilia A F8 Hemophilia B F9 Hereditary hemochromatosis HFE Homocystinuria CBS Maple syrup urine disease (MSUD) Type Ia: BCKDHA Type Ib: BCKDHB Type II: DBT Methylmalonic acidemia (methylmalonyl-CoA MMUT mutase deficiency) MPS 1S (Scheie syndrome) IDUA MPS2 IDS MPS3 (San Filippo Syndrome) Type IIIa: SGSH Type IIIb: NAGLU Type IIIc: HGSNAT Type IIId: GNS MPS4 Type IVA: GALNS Type IVB: GLB1 MPS6 ARSB MPS7 GUSB Ornithine transcarbamylase deficiency OTC Phenylketonuria (phenylalanine hydroxylase PAH deficiency) Polycystic Liver Disease PCLD1: PRKCSH PCLD2: SEC63 PLCD3: ALG8 PCLD4: LRP5 Pompe disease GAA Primary Hyperoxaluria 1 (oxalosis) AGXT Progressive familial intrahepatic cholestasis type 1 ATP8B1 Progressive familial intrahepatic cholestasis type 2 ABCB11 Progressive familial intrahepatic cholestasis type 3 ABCB4 Propionic acidemia PCCB; PCCA Pyruvate carboxylase deficiency PC Tyrosinemia type I FAH Wilson's disease ATP7B

TABLE 10 Indications and genetic targets for HSCs Disease Gene Affected Adrenoleukodystrophy (CALD) ABCD1 Alpha-mannosidosis MAN2B1 Blackfan-Diamond Anemia Congenital amegakaryocytic thrombocytopenia MPL Dyskeratosis Congenita TERC Fanconi anemia FANC Gaucher disease GBA Globoid cell leukodystrophy (Krabbe disease) GALC Hemophagocytic lymphohistiocytosis PRF1; STX11; STXBP2; UNC13D Malignant infantile osteopetrosis- autosomal Many genes recessive osteopetrosis implicated Metachromatic leukodystrophy PSAP MPS 1S (Scheie syndrome) IDUA MPS2 IDS MPS7 GUSB Mucolipidosis II GNPTAB Niemann-Pick disease A and B SMPD1 Niemann-Pick disease C NPC1 Pompe disease GAA Pyruvate kinase deficiency (PKD) PKLR Sickle cell disease (SCD) HBB Tay Sachs HEXA Thalassemia HBB

TABLE 11 Indications and genetic targets for the CNS Disease Gene Affected Alpha-mannosidosis MAN2B1 Ataxia-telangiectasia ATM CADASIL NOTCH3 Canavan disease ASPA Carbamoyl-phosphate synthetase 1 deficiency CPS1 CLN1 disease PPT1 CLN2 Disease TPP1 CLN3 Disease (Juvenile neuronal ceroid CLN3 lipofuscinosis, Batten Disease) Coffin-Lowry syndrome RPS6KA3 Congenital myasthenic syndrome 5 COLQ Cornelia de Lange syndrome (NIPBL) NIPBL Cornelia de Lange syndrome (SMC1A) SMC1A Dravet syndrome (SCN1A) SCN1A Glycine encephalopathy (GLDC) GLDC GM1 gangliosidosis GLB1 Huntington's Disease HTT Hydrocephalus with stenosis of the aqueduct L1CAM of Sylvius Leigh Syndrome SURF1 Metachromatic leukodystrophy (ARSA) ARSA MPS type 2 IDS MPS type 3 Type 3a: SGSH Type 3b: NAGLU Mucolipidosis IV MCOLN1 Neurofibromatosis Type 1 NF1 Neurofibromatosis type 2 NF2 Pantothenate kinase-associated neurodegeneration PANK2 Pyridoxine-dependent epilepsy ALDH7A1 Rett syndrome (MECP2) MECP2 Sandhoff disease HEXB Semantic dementia (Frontotemporal dementia) MAPT Spinocerebellar ataxia with axonal neuropathy SETX (Ataxia with Oculomotor Apraxia) Tay-Sachs disease HEXA X-linked Adrenoleukodystrophy ABCD1

TABLE 12 Indications and genetic targets for the eye Disease Gene Affected Achromatopsia CNGB3 Amaurosis Congenita (LCA1) GUCY2D Amaurosis Congenita (LCA10) CEP290 Amaurosis Congenita (LCA2) RPE65 Amaurosis Congenita (LCA8) CRB1 Choroideremia CHM Cone Rod Dystrophy (ABCA4) ABCA4 Cone Rod Dystrophy (GUCY2D) GUCY2D Cystinosis, Ocular Nonnephropathic CTNS Doyne Honeycomb Retinal Dystrophy (DHRD) EFEMP1 Familial Oculoleptomeningeal Amyloidosis TTR Keratitis-ichthyosis-deafness (KID) GJB2 Lattice corneal dystrophy type I TGFBI Macular Corneal Dystrophy (MCD) CHST6 Meesmann Corneal Dystrophy KRT12; KRT3 Optic Atrophy OPA1 Retinitis Pigmentosa (AR) USH2A Retinitis Rigmentosa (AD) RHO Sorsby Fundus Dystrophy TIMP3 Stargardt Disease ABCA4

Additional Suitable Indications

Exemplary suitable diseases and disorders that can be treated by the systems or methods provided herein, for example, those comprising Gene Writers, include, without limitation: Baraitser-Winter syndromes 1 and 2; Diabetes mellitus and insipidus with optic atrophy and deafness; Alpha-1-antitrypsin deficiency; Heparin cofactor II deficiency; Adrenoleukodystrophy; Keppen-Lubinsky syndrome; Treacher collins syndrome 1; Mitochondrial complex I, II, 111, III (nuclear type 2, 4, or 8) deficiency; Hypermanganesemia with dystonia, polycythemia and cirrhosis; Carcinoid tumor of intestine; Rhabdoid tumor predisposition syndrome 2; Wilson disease; Hyperphenylalaninemia, bh4-deficient, a, due to partial pts deficiency, B14-deficient, D, and non-pku; Hyperinsulinemic hypoglycemia familial 3, 4, and 5; Keratosis follicularis; Oral-facial-digital syndrome; SeSAME syndrome; Deafness, nonsyndromic sensorineural, mitochondrial; Proteinuria; Insulin-dependent diabetes mellitus secretory diarrhea syndrome; Moyamoya disease 5; Diamond-Blackfan anemia 1, 5, 8, and 10; Pseudoachondroplastic spondyloepiphyseal dysplasia syndrome; Brittle cornea syndrome 2; Methylmalonic acidemia with homocystinuria, ; Adams-Oliver syndrome 5 and 6; autosomal recessive Agammaglobulinemia 2; Cortical malformations, occipital; Febrile seizures, familial, 11; Mucopolysaccharidosis type VI, type VI (severe), and type VII; Marden Walker like syndrome; Pseudoneonatal adrenoleukodystrophy; Spheroid body myopathy; Cleidocranial dysostosis; Multiple Cutaneous and Mucosal Venous Malformations; Liver failure acute infantile; Neonatal intrahepatic cholestasis caused by citrin deficiency; Ventricular septal defect 1; Oculodentodigital dysplasia; Wilms tumor 1; Weill-Marchesani-like syndrome; Renal adysplasia; Cataract 1, 4, autosomal dominant, autosomal dominant, multiple types, with microcornea, coppock-like, juvenile, with microcomea and glucosuria, and nuclear diffuse nonprogressive; Odontohypophosphatasia; Cerebro-oculo-facio-skeletal syndrome; Schizophrenia 15; Cerebral amyloid angiopathy, APP-related; Hemophagocytic lymphohistiocytosis, familial, 3; Porphobilinogen synthase deficiency; Episodic ataxia type 2; Trichorhinophalangeal syndrome type 3; Progressive familial heart block type IB; Glioma susceptibility 1; Lichtenstein-Knorr Syndrome; Hypohidrotic X-linked ectodermal dysplasia; Bartter syndrome types 3, 3 with hypocalciuria, and 4; Carbonic anhydrase VA deficiency, hyperammonemia due to; Cardiomyopathy; Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis; Combined d-2- and 1-2-hydroxyglutaric aciduria; Arginase deficiency; Cone-rod dystrophy 2 and 6; Smith-Lemli-Opitz syndrome; Mucolipidosis III Gamma; Blau syndrome; Wemer syndrome; Meningioma; Iodotyrosyl coupling defect; Dubin-Johnson syndrome; 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency; Boucher Neubauser syndrome; Iron accumulation in brain; Mental Retardation, X-Linked 102 and syndromic 13; familial, Pituitary adenoma predisposition; Hypoplasia of the corpus callosum; Hyperalphalipoproteinemia 2; Deficiency of ferroxidase; Growth hormone insensitivity with immunodeficiency; Marinesco-Sj\xc3\xb6gren syndrome; Martsolf syndrome; Gaze palsy, familial horizontal, with progressive scoliosis; Mitchell-Riley syndrome; Hypocalciuric hypercalcemia, familial, types 1 and 3; Rubinstein-Taybi syndrome; Epstein syndrome; Juvenile retinoschisis; Becker muscular dystrophy; Loeys-Dietz syndrome 1, 2, 3; Congenital muscular hypertrophy-cerebral syndrome; Familial juvenile gout; Spermatogenic failure 11, 3, and 8; Orofacial cleft 11 and 7, Cleft lip/palate-ectodermal dysplasia syndrome; Mental retardation, X-linked, nonspecific, syndromic, Hedera type, and syndromic, wu type; Combined oxidative phosphorylation deficiencies 1, 3, 4, 12, 15, and 25; Frontotemporal dementia; Kniest dysplasia; Familial cardiomyopathy; Benign familial hematuria; Pheochromocytoma; Aminoglycoside-induced deafness; Gamma-aminobutyric acid transaminase deficiency; Oculocutaneous albinism type IB, type 3, and type 4; Renal coloboma syndrome; CNS hypomyelination; Hennekam lymphangiectasia-lymphedema syndrome 2; Migraine, familial basilar; Distal spinal muscular atrophy, X-linked 3; X-linked periventricular heterotopia; Microcephaly; Mucopolysaccharidosis, MIPS-I-H/S, MPS-II, MPS-III-A, MPS-III-B, MPS-III-C, MPS-IV-A, MPS-IV-B; Infantile Parkinsonism-dystonia; Frontotemporal dementia with TDP43 inclusions, TARDBP-related; Hereditary diffuse gastric cancer; Sialidosis type I and II; Microcephaly-capillary malformation syndrome; Hereditary breast and ovarian cancer syndrome; Brain small vessel disease with hemorrhage; Non-ketotic hyperglycinemia; Navajo neurohepatopathy; Auriculocondylar syndrome 2; Spastic paraplegia 15, 2, 3, 35, 39, 4, autosomal dominant, 55, autosomal recessive, and SA; Autosomal recessive cutis laxa type IA and IB Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency; Hutchinson-Gilford syndrome; Familial amyloid nephropathy with urticaria and deafness; Supravalvar aortic stenosis; Diffuse palmoplantar keratoderma, Bothnian type; Holt-Oram syndrome; Coffin Siris/Intellectual Disability; Left-right axis malformations; Rapadilino syndrome; Nanophthalmos 2; Craniosynostosis and dental anomalies; Paragangliomas 1; Snyder Robinson syndrome; Ventricular fibrillation; Activated P13K-delta syndrome; Howel-Evans syndrome; Larsen syndrome, dominant type; Van Maldergem syndrome 2; MYH-associated polyposis; 6-pymvoyl-tetrahydropterin synthase deficiency; Alagille syndromes 1 and 2; Lymphangiomyomatosis; Muscle eye brain disease; WFSI-Related Disorders; Primary hypertrophic osteoarthropathy, autosomal recessive 2; Infertility; Nestor-Guillermo progeria syndrome; Mitochondrial trifunctional protein deficiency; Hypoplastic left heart syndrome 2; Primary dilated cardiomyopathy; Retinitis pigmentosa; Hirschsprung disease 3; Upshaw-Schulman syndrome; Desbuquois dysplasia 2; Diarrhea 3 (secretory sodium, congenital, syndromic) and 5 (with tufting enteropathy, congenital); Pachyonychia congenita 4 and type 2; Cerebral autosomal dominant and recessive arteriopathy with subcortical infarcts and leukoencephalopathy; Vi tel Ii form dystrophy; type II, type IV, IV (combined hepatic and myopathic), type V, and type VI; Atypical Rett syndrome; Atrioventricular septal defect 4; Papillon-Lef\xc3\xa8vre syndrome; Leber amaurosis; X-linked hereditary motor and sensory neuropathy; Progressive sclerosing poliodystrophy; Goldmann-Favre syndrome; Renal-hepatic-pancreatic dysplasia; Pallister-Hall syndrome; Amyloidogenic transthyretin amyloidosis; Melnick-Needles syndrome; Hyperimmunoglobulin E syndrome; Posterior column ataxia with retinitis pigmentosa; Chondrodysplasia punctata 1, X-linked recessive and 2 X-linked dominant; Ectopia lentis, isolated autosomal recessive and dominant; Familial cold urticarial; Familial adenomatous polyposis 1 and 3; Porokeratosis 8, disseminated superficial actinic type; PIK3CA Related Overgrowth Spectrum; Cerebral cavernous malformations 2; Exudative vitreoretinopathy 6; Megalencephaly cutis marmorata telangiectatica congenital; TARP syndrome; Diabetes mellitus, permanent neonatal, with neurologic features; Short-rib thoracic dysplasia II or 3 with or without polydactyly; Hypertrichotic osteochondrodysplasia; beta Thalassemia; Niemann-Pick disease type C1, C2, type A, and type C1, adult form; Charcot-Marie-Tooth disease types IB, 2B2, 2C, 2F, 21, 2U (axonal), 1C (demyelinating), dominant intermediate C, recessive intermediate A, 2A2, 4C, 4D, 4H, IF, IVF, and X; Tyrosinemia type I; Paroxysmal atrial fibrillation; UV-sensitive syndrome; Tooth agenesis, selective, 3 and 4; Merosin deficient congenital muscular dystrophy; Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; Congenital aniridia; Left ventricular noncompaction 5; Deficiency of aromatic-L-amino-acid decarboxylase; Coronary heart disease; Leukonychia totalis; Distal arthrogryposis type 2B; Retinitis pigmentosa 10, i1, 12, 14, 15, 17, and 19; Robinow Sorauf syndrome; Tenorio Syndrome; Prolactinoma; Neurofibromatosis, type land type 2; Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, types A2, A7, A8, A11, and A14; Heterotaxy, visceral, 2, 4, and 6, autosomal; Jankovic Rivera syndrome; Lipodystrophy, familial partial, type 2 and 3; Hemoglobin 1 disease, nondeletional; Multicentric osteolysis, nodulosis and arthropathy; Thyroid agenesis; deficiency of Acyl-CoA dehydrogenase family, member 9; Alexander disease; Phytanic acid storage disease, Breast-ovarian cancer, familial 1, 2, and 4; Proline dehydrogenase deficiency; Childhood hypophosphatasia; Pancreatic agenesis and congenital heart disease; Vitamin D-dependent rickets, types land 2; Iridogoniodysgenesis dominant type and type 1; Autosomal recessive hypohidrotic ectodermal dysplasia syndrome; Mental retardation, X-linked, 3, 21, 30, and 72; Hereditary hemorrhagic telangiectasia type 2; Blepharophimosis, ptosis, and epicanthus inversus; Adenine phosphoribosyltransferase deficiency; Seizures, benign familial infantile, 2; Acrodysostosis 2, with or without hormone resistance; Tetralogy of Fallot; Retinitis pigmentosa 2, 20, 25, 35, 36, 38, 39, 4, 40, 43, 45, 48, 66, 7, 70, 72; Lysosomal acid lipase deficiency; Eichsfeld type congenital muscular dystrophy; Walker-Warburg congenital muscular dystrophy; TNF receptor-associated periodic fever syndrome (TRAPS); Progressive myoclonus epilepsy with ataxia; Epilepsy, childhood absence 2, 12 (idiopathic generalized, susceptibility to) 5 (nocturnal frontal lobe), nocturnal frontal lobe type 1, partial, with variable foci, progressive myoclonic 3, and X-linked, with variable learning disabilities and behavior disorders; Long QT syndrome; Dicarboxylic aminoaciduria; Brachydactyly types A1 and A2; Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency; Multisystem smooth muscle dysfunction syndrome; Syndactyly Cenani Lenz type; Joubert syndrome 1, 6, 7, 9/15 (digenic), 14, 16, and 17, and Orofaciodigital syndrome xiv; Digitorenocerebral syndrome; Retinoblastoma; Dyskinesia, familial, with facial myokymia; Hereditary sensory and autonomic neuropathy type IIB amd IIA; familial hyperinsulinism; Megalencephalic leukoencephalopathy with subcortical cysts land 2a; Aase syndrome; Wiedemann-Steiner syndrome; Ichthyosis exfoliativa; Myotonia congenital; Granulomatous disease, chronic, X-linked, variant; Deficiency of 2-methylbutyryl-CoA dehydrogenase; Sarcoidosis, early-onset; Glaucoma, congenital and Glaucoma, congenital, Coloboma; Breast cancer, susceptibility to; Ceroid lipofuscinosis neuronal 2, 6, 7, and 10; Congenital generalized lipodystrophy type 2; Fructose-biphosphatase deficiency; Congenital contractural arachnodactyly; Lynch syndrome I and II, Phosphoglycerate dehydrogenase deficiency; Burn-Mckeown syndrome; Myocardial infarction 1; Achromatopsia 2 and 7; Retinitis Pigmentosa 73; Protan defect; Polymicrogyria, asymmetric, bilateral frontoparietal; Spinal muscular atrophy, distal, autosomal recessive, 5; Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency; Familial porencephaly; Hurler syndrome; Oto-palato-digital syndrome, types I and II; Sotos syndrome 1 or 2; Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency; Parastremmatic dwarfism; Thyrotropin releasing hormone resistance, generalized; Diabetes mellitus, type 2, and insulin-dependent, 20; Thoracic aortic aneurysms and aortic dissections; Estrogen resistance; Maple syrup urine disease type 1A and type 3; Hypospadias 1 and 2, X-linked; Metachromatic leukodystrophy juvenile, late infantile, and adult types; Early T cell progenitor acute lymphoblastic leukemia; Neuropathy, Hereditary Sensory, Type IC; Mental retardation, autosomal dominant 31; Retinitis pigmentosa 39; Breast cancer, early-onset; May-Hegglin anomaly; Gaucher disease type I and Subacute neuronopathic; Temtamy syndrome; Spinal muscular atrophy, lower extremity predominant 2, autosomal dominant; Fanconi anemia, complementation group E, I, N, and O; Alkaptonuria; Hirschsprung disease; Combined malonic and methylmalonic aciduria; Arrhythmogenic right ventricular cardiomyopathy types 5, 8, and 10; Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi; Timothy syndrome; Deficiency of guanidinoacetate methyltransferase; Myoclonic dystonia; Kanzaki disease; Neutral 1 amino acid transport defect; Neurohypophyseal diabetes insipidus; Thyroid hormone metabolism, abnormal; Benign scapuloperoneal muscular dystrophy with cardiomyopathy; I-Hypoglycemia with deficiency of glycogen synthetase in the liver; Hypertrophic cardiomyopathy; Myasthenic Syndrome, Congenital, 11, associated with acetylcholine receptor deficiency; Mental retardation X-linked syndromic 5; Stormorken syndrome; Aplastic anemia; Intellectual disability; Normokalemic periodic paralysis, potassium-sensitive; Danon disease; Nephronophthisis 13, 15 and 4; Thyrotoxic periodic paralysis and Thyrotoxic periodic paralysis 2; Infertility associated with multi-tailed spermatozoa and excessive DNA; Glaucoma, primary open angle, juvenile-onset; Afibrinogenemia and congenital Afibrinogenemia; Polycystic kidney disease 2, adult type, and infantile type; Familial porphyria cutanea tarda; Cerebello-oculo-renal syndrome (nephronophthisis, oculomotor apraxia and cerebellar abnormalities); Frontotemporal Dementia Chromosome 3-Linked and Frontotemporal dementia ubiquitin-positive; Metatrophic dysplasia; Immunodeficiency-centromeric instability-facial anomalies syndrome 2; Anemia, nonspherocytic hemolytic, due to G6PD deficiency; Bronchiectasis with or without elevated sweat chloride 3; Congenital myopathy with fiber type disproportion; Carney complex, type I; Cryptorchidism, unilateral or bilateral; Ichthyosis bullosa of Siemens; Isolated lutropin deficiency; DFNA 2 Nonsyndromic Hearing Loss; Klein-Waardenberg syndrome; Gray platelet syndrome; Bile acid synthesis defect, congenital, 2; 46, XY sex reversal, type 1, 3, and 5; Acute intermittent porphyria; Cornelia de Fange syndromes 1 and 5; Hyperglycinuria; Cone-rod dystrophy 3; Dysfibrinogenemia; Karak syndrome; Congenital muscular dystrophy-dystroglycanopathy without mental retardation, type B5; Infantile nystagmus, X-linked; Dyskeratosis congenita, autosomal recessive, 1, 3, 4, and 5; Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation; Hyperlysinemia; Bardet-Biedl syndromes 1, 11, 16, and 19; Autosomal recessive centronuclear myopathy; Frasier syndrome; Caudal regression syndrome; Fibrosis of extraocular muscles, congenital, 1, 2, 3a (with or without extraocular involvement), 3b; Prader-Willi-like syndrome; Malignant melanoma; Bloom syndrome; Darier disease, segmental; Multicentric osteolysis nephropathy; Hemochromatosis type 1, 2B, and 3; Cerebellar ataxia infantile with progressive external ophthalmoplegi and Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2; Hypoplastic left heart syndrome; Epilepsy, Hearing Loss, And Mental Retardation Syndrome; Transferrin serum level quantitative trait locus 2; Ocular albinism, type I; Marfan syndrome; Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A14 and B14; Hyperammonemia, type III; Cryptophthalmos syndrome; Alopecia universalis congenital; Adult hypophosphatasia; Mannose-binding protein deficiency; Bull eye macular dystrophy; Autosomal dominant torsion dystonia 4; Nephrotic syndrome, type 3, type 5, with or without ocular abnormalities, type 7, and type 9; Seizures, Early infantile epileptic encephalopathy 7; Persistent hyperinsulinemic hypoglycemia of infancy; Thrombocytopenia, X-linked; Neonatal hypotonia; Orstavik Lindemann Solberg syndrome; Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia; Pituitary dependent hypercortisolism; Epidermodysplasia verruciformis; Epidermolysis bullosa, junctional, localisata variant; Cytochrome c oxidase i deficiency; Kindler syndrome; Myosclerosis, autosomal recessive; Truncus arteriosus; Duane syndrome type 2; ADULT syndrome; Zellweger syndrome spectrum; Leukoencephalopathy with ataxia, with Brainstem and Spinal Cord Involvement and Lactate Elevation, with vanishing white matter, and progressive, with ovarian failure; Antithrombin III deficiency; Holoprosencephaly 7; Roberts-SC phocomelia syndrome; Mitochondrial DNA-depletion syndrome 3 and 7, hepatocerebral types, and 13 (encephalomyopathic type); Porencephaly 2; Microcephaly, normal intelligence and immunodeficiency; Giant axonal neuropathy; Sturge-Weber syndrome, Capillary malformations, congenital, 1; Fabry disease and Fabry disease, cardiac variant; Glutamate formiminotransferase deficiency; Fanconi-Bickel syndrome; Acromicric dysplasia; Epilepsy, idiopathic generalized, susceptibility to, 12; Basal ganglia calcification, idiopathic, 4; Polyglucosan body myopathy 1 with or without immunodeficiency; Malignant tumor of prostate; Congenital ectodermal dysplasia of face; Congenital heart disease; Age-related macular degeneration 3, 6, 11, and 12; Congenital myotonia, autosomal dominant and recessive forms; Hypomagnesemia 1, intestinal; Sulfite oxidase deficiency, isolated; Pick disease; Plasminogen deficiency, type L; Syndactyly type 3; Cone-rod dystrophy amelogenesis imperfecta; Pseudoprimary hyperaldosteronism; Terminal osseous dysplasia; Bartter syndrome antenatal type 2; Congenital muscular dystrophy-dystroglycanopathy with mental retardation, types 32, B3, B5, and B15; Familial infantile myasthenia; Lymphoproliferative syndrome 1, 1 (X-linked), and 2; Hypercholesterolaemnia and Hypercholesterolemia, autosomal recessive; Neoplasm of ovary; Infantile GM1 gangliosidosis; Syndromic X-linked mental retardation 16; Deficiency of ribose-5-phosphate isomerase; Alzheimer disease, types, 1, 3, and 4; Andersen Tawil syndrome; Multiple synostoses syndrome 3; Chilbain lupus 1; Hemophagocytic lymphohistiocytosis, familial, 2; Axenfeld-Rieger syndrome type 3; Myopathy, congenital with cores; Osteoarthritis with mild chondrodysplasia; Peroxisome biogenesis disorders; Severe congenital neutropenia; Hereditary neuralgic amyotrophy; Palmoplantar keratoderma, nonepidermolytic, focal or diffuse; Dysplasminogenemia; Familial colorectal cancer; Spastic ataxia 5, autosomal recessive, Charlevoix-Saguenay type, 1, 10, or 11, autosomal recessive; Frontometaphyseal dysplasia land 3; Hereditary factors II, IX, VIII deficiency disease; Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, with immune dysregulation, Aggrecan type, with congenital joint dislocations, short lib-hand type, Sedaghatian type, with cone-rod dystrophy, and Kozlowski type; ichthyosis prematurity syndrome; Stickler syndrome type 1; Focal segmental glomerulosclerosis 5; 5-Oxoprolinase deficiency; Microphthalmia syndromic 5, 7, and 9; Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome; Deficiency of butyryl-CoA dehydrogenase; Maturity-onset diabetes of the young, type 2; Mental retardation, syndromic, Claes-Jensen type, X-linked; Deafness, cochlear, with myopia and intellectual impairment, without vestibular involvement, autosomal dominant, X-linked 2; Spondylocarpotarsal synostosis syndrome; Sting-associated vasculopathy, infantile-onset; Neutral lipid storage disease with myopathy; Immune dysfunction with T-cell inactivation due to calcium entry defect 2; Cardiofaciocutaneous syndrome; Corticosterone methyloxidase type 2 deficiency; Hereditary myopathy with early respiratory failure; Interstitial nephritis, karyomegalic; Trimethylaminuria; Hyperimmunoglobulin D with periodic fever; Malignant hyperthermia susceptibility type 1; Trichomegaly with mental retardation, dwarfism and pigmentary degeneration of retina; Breast adenocarcinoma; Complement factor B deficiency; Ulrich congenital muscular dystrophy; Left ventricular noncompaction cardiomyopathy; Fish-eye disease; Finnish congenital nephrotic syndrome; Limb-girdle muscular dystrophy, type IB, 2A, 2B, 2D, C1, C5, C9, C14; Idiopathic fibrosing alveolitis, chronic form; Primary familial hypertrophic cardiomyopathy; Angiotensin i-converting enzyme, benign serum increase; Cd8 deficiency, familial; Proteus syndrome; Glucose-6-phosphate transport defect; Borjeson-Forssman-Lehmann syndrome; Zellweger syndrome; Spinal muscular atrophy, type II; Prostate cancer, hereditary, 2; Thrombocytopenia, platelet dysfunction, hemolysis, and imbalanced globin synthesis; Congenital disorder of glycosylation types IB, ID, 1G, 1H, 1 J, 1K, IN, IP, 2C, 2J, 2K, Ilm; Junctional epidermolysis bullosa gravis of Herlitz; Generalized epilepsy with febrile seizures plus 3, type 1, type 2; Schizophrenia 4; Coronary artery disease, autosomal dominant 2; Dyskeratosis congenita, autosomal dominant, 2 and 5; Subcortical laminar heterotopia, X-linked; Adenylate kinase deficiency; X-linked severe combined immunodeficiency; Coproporphyria; Amyloid Cardiomyopathy, Transthyretin-related; Hypocalcemia, autosomal dominant 1; Brugada syndrome; Congenital myasthenic syndrome, acetazolamide-responsive; Primary hypomagnesemia; Sclerosteosis; Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 and 4; Mevalonic aciduria; Schwannomatosis 2; Hereditary motor and sensory neuropathy with optic atrophy; Porphyria cutanea tarda; Osteochondritis dissecans; Seizures, benign familial neonatal, 1, and/or myokymia; Long QT syndrome, LQT1 subtype; Mental retardation, anterior maxillary protrusion, and strabismus; Idiopathic hypercalcemia of infancy; Hypogonadotropic hypogonadism 11 with or without anosmia; Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; Primary autosomal recessive microcephaly 10, 2, 3, and 5; Interrupted aortic arch; Congenital amegakaryocytic thrombocytopenia; Hermansky-Pudlak syndrome 1, 3, 4, and 6; Long QT syndrome 1, 2, 2/9, 2/5, (digenic), 3, 5 and 5, acquired, susceptibility to; Andermann syndrome; Retinal cone dystrophy 3B; Erythropoietic protoporphyria; Sepiapterin reductase deficiency; Very long chain acyl-CoA dehydrogenase deficiency; Hyperferritinemia cataract syndrome; Silver spastic paraplegia syndrome; Charcot-Made-Tooth disease; Atrial septal defect 2; Carnevale syndrome; Hereditary insensitivity to pain with anhidrosis; Catecholaminergic polymorphic ventricular tachycardia; Hypokalenmic periodic paralysis 1 and 2; Sudden infant death syndrome; Hypochromic microcytic anemia with iron overload; GLUT1 deficiency syndrome 2; Leukodystrophy, Hypomyelinating, 11 and 6; Cone monochromatism; Osteopetrosis autosomal dominant type 1 and 2, recessive 4, recessive 1, recessive 6; Severe congenital neutropenia 3, autosomal recessive or dominant; Methionine adenosyltransferase deficiency, autosomal dominant; Paroxysmal familial ventricular fibrillation; Pyruvate kinase deficiency of red cells; Schneckenbecken dysplasia; Torsades de pointes; Distal myopathy Markesbery-Griggs type; Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase; Sudden cardiac death; Neu-Laxova syndrome 1; Atransferrinemia; Hyperparathyroidism 1 and 2; Cutaneous malignant melanoma 1; Symphalangism, proximal, 1b; Progressive pseudorheumatoid dysplasia; Werdnig-Hoffmann disease; Achondrogenesis type 2; Holoprosencephaly 2, 3, 7, and 9; Schindler disease, type 1; Cerebroretinal microangiopathy with calcifications and cysts; Heterotaxy, visceral, X-linked; Tuberous sclerosis syndrome; Kartagener syndrome; Thyroid hormone resistance, generalized, autosomal dominant; Bestrophinopathy, autosomal recessive; Nail disorder, nonsyndromic congenital, 8; Mohr-Tranebjaerg syndrome; Cone-rod dystrophy 12; Hearing impairment; Ovarioleukodystrophy; Renal tubular acidosis, proximal, with ocular abnormalities and mental retardation; Dihydropteridine reductase deficiency; Focal epilepsy with speech disorder with or without mental retardation; Ataxia-telangiectasia syndrome; Brown-Vialetto-Van laere syndrome and Brown-Vialetto-Van Laere syndrome 2; Cardiomyopathy; Peripheral demyelinating neuropathy, central dysmyelination; Comeal dystrophy, Fuchs endothelial, 4; Cowden syndrome 3; Dystonia 2 (torsion, autosomal recessive), 3 (torsion, X-linked), 5 (Dopa-responsive type), 10, 12, 16, 25, 26 (Myoclonic); Epiphyseal dysplasia, multiple, with myopia and conductive deafness; Cardiac conduction defect, nonspecific; Branchiootic syndromes 2 and 3; Peroxisome biogenesis disorder 14B, 2A, 4A, 5B, 6A, 7A, and 7B; Familial renal glucosuria; Candidiasis, familial, 2, 5, 6, and 8; Autoimmune disease, multisystem, infantile-onset; Early infantile epileptic encephalopathy 2, 4, 7, 9, 10, 11, 13, and 14; Segawa syndrome, autosomal recessive; Deafness, autosomal dominant 3a, 4, 12, 13, 15, autosomal dominant nonsyndromic sensorineural 17, 20, and 65; Congenital dyserythropoietic anemia, type I and II; Enhanced s-cone syndrome; Adult neuronal ceroid lipofuscinosis; Atrial fibrillation, familial, i1, 12, 13, and 16; Norum disease; Osteosarcoma; Partial albinism; Biotinidase deficiency; Combined cellular and humoral immune defects with granulomas; Alpers encephalopathy; Holocarboxylase synthetase deficiency; Maturity-onset diabetes of the young, type 1, type 2, type 11, type 3, and type 9; Variegate porphyria; Infantile cortical hyperostosis; Testosterone 17-beta-dehydrogenase deficiency; L-2-hydroxyglutaric aciduria; Tyrosinase-negative oculocutaneous albinism; Primary ciliary dyskinesia 24; Pontocerebellar hypoplasia type 4; Ciliary dyskinesia, primary, 7, 11, 15, 20 and 22; Idiopathic basal ganglia calcification 5; Brain atrophy; Craniosynostosis 1 and 4; Keratoconus 1; Rasopathy; Congenital adrenal hyperplasia and Congenital adrenal hypoplasia, X-linked; Mitochondrial DNA depletion syndrome 11, 12 (cardiomyopathy type), 2, 4B (MNGIE type), 8B (MNGIE type); Brachydactyly with hypertension; Cornea plana 2; Aarskog syndrome; Multiple epiphyseal dysplasia 5 or Dominant; Comeal endothelial dystrophy type 2; Aminoacylase 1 deficiency; Delayed speech and language development; Nicolaides-Baraitser syndrome; Enterokinase deficiency; Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 Arthrogryposis multiplex congenita, distal, X-linked; Perrault syndrome 4; Jervell and Lange-Nielsen syndrome 2; Hereditary Nonpolyposis Colorectal Neoplasms; Robinow syndrome, autosomal recessive, autosomal recessive, with brachy-syn-polydactyly; Neurofibrosarcoma; Cytochrome-c oxidase deficiency; Vesicoureteral reflux 8; Dopamine beta hydroxylase deficiency; Carbohydrate-deficient glycoprotein syndrome type I and II; Progressive familial intrahepatic cholestasis 3; Benign familial neonatal-infantile seizures; Pancreatitis, chronic, susceptibility to; Rhizomelic chondrodysplasia punctata type 2 and type 3; Disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency; Deafness with labyrinthine aplasia microtia and microdontia (FAMM); Rothmund-Thomson syndrome; Cortical dysplasia, complex, with other brain malformations 5 and 6; Myasthenia, familial infantile, 1; Trichorhinophalangeal dysplasia type I; Worth disease; Splenic hypoplasia; Molybdenum cofactor deficiency, complementation group A; Sebastian syndrome; Progressive familial intrahepatic cholestasis 2 and 3; Weill-Marchesani syndrome 1 and 3; Microcephalic osteodysplastic primordial dwarfism type 2; Surfactant metabolism dysfunction, pulmonary, 2 and 3; Severe X-linked myotubular myopathy; Pancreatic cancer 3; Platelet-type bleeding disorder 15 and 8; Tyrosinase-positive oculocutaneous albinism; Borrone Di Rocco Crovato syndrome; ATR-X syndrome; Sucrase-isomaltase deficiency; Complement component 4, partial deficiency of, due to dysfunctional c1 inhibitor; Congenital central hypoventilation; Infantile hypophosphatasia; Plasminogen activator inhibitor type I deficiency; Malignant lymphoma, non-Hodgkin; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome; Schwartz Jampel syndrome type 1; Fetal hemoglobin quantitative trait locus 1; Myopathy, distal, with anterior tibial onset; Noonan syndrome 1 and 4, LEOPARD syndrome 1; Glaucoma 1, open angle, e, F, and G; Kenny-Caffey syndrome type 2; PTEN hamartoma tumor syndrome; Duchenne muscular dystrophy; insulin-resistant diabetes mellitus and acanthosis nigricans; Microphthalmia, isolated 3, 5, 6, 8, and with coloboma 6; Raine syndrome; Premature ovarian failure 4, 5, 7, and 9; Allan-Hemdon-Dudley syndrome; Citrullinemia type I; Alzheimer disease, familial, 3, with spastic paraparesis and apraxia; Familial hemiplegic migraine types 1 and 2; Ventriculomegaly with cystic kidney disease; Pseudoxanthoma elasticum; Homocysteinemia due to MTHFR deficiency, CBS deficiency, and Homocystinuria, pyridoxine-responsive; Dilated cardiomyopathy 1A, 1AA, 1C, 1G, 1BB, 1DD, 1FF, 1HH, II, IKK, IN, IS, 1Y, and 3B; Muscle AMP guanine oxidase deficiency; Familial cancer of breast; Hereditary sideroblastic anemia; Myoglobinuria, acute recurrent, autosomal recessive; Neuroferritinopathy; Cardiac arrhythmia; Glucose transporter type 1 deficiency syndrome; Holoprosencephaly sequence; Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps; Isovaleryl-CoA dehydrogenase deficiency; Kallmann syndrome 1, 2, and 6; Permanent neonatal diabetes mellitus; Acrocallosal syndrome, Schinzel type; Gordon syndrome; MYH9 related disorders; Donnai Barrow syndrome; Severe congenital neutropenia and 6, autosomal recessive; Charcot-Marie-Tooth disease, types ID and IVF; Coffin-Lowry syndrome; mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency; Hypomagnesemia, seizures, and mental retardation; Ischiopatellar dysplasia; Multiple congenital anomalies-hypotonia-seizures syndrome 3; Spastic paraplegia 50, autosomal recessive; Short stature with nonspecific skeletal abnormalities; Severe myoclonic epilepsy in infancy; Propionic academia; Adolescent nephronophthisis; Macrocephaly, macrosomia, facial dysmorphism syndrome; Stargardt disease 4; Ehlers-Danlos syndrome type 7 (autosomal recessive), classic type, type 2 (progeroid), hydroxylysine-deficient, type 4, type 4 variant, and due to tenascin-X deficiency; Myopia 6; Coxa plana; Familial cold autoinflammatory syndrome 2; Malformation of the heart and great vessels; von Willebrand disease type 2M and type 3; Deficiency of galactokinase; Brugada syndrome 1; X-linked ichthyosis with steryl-sulfatase deficiency; Congenital ocular coloboma; Histiocytosis-lymphadenopathy plus syndrome; Aniridia, cerebellar ataxia, and mental retardation; Left ventricular noncompaction 3; Amyotrophic lateral sclerosis types 1, 6, 15 (with or without frontotemporal dementia), 22 (with or without frontotemporal dementia), and 10; Osteogenesis imperfecta type 12, type 5, type 7, type 8, type IL, type III, with normal sclerae, dominant form, recessive perinatal lethal; Hematologic neoplasm; Favism, susceptibility to; Pulmonary Fibrosis And/Or Bone Marrow Failure, Telomere-Related, 1 and 3; Dominant hereditary optic atrophy; Dominant dystrophic epidermolysis bullosa with absence of skin; Muscular dystrophy, congenital, megaconial type; Multiple gastrointestinal atresias; McCune-Albright syndrome; Nail-patella syndrome; McLeod neuroacanthocytosis syndrome; Common variable immunodeficiency 9; Partial hypoxanthine-guanine phosphoribosyltransferase deficiency; Pseudohypoaldosteronism type 1 autosomal dominant and recessive and type 2; Urocanate hydratase deficiency; Heterotopia; Meckel syndrome type 7; Ch\xc3\xa9diak-Higashi syndrome, Chediak-Higashi syndrome, adult type; Severe combined immunodeficiency due to ADA deficiency, with microcephaly, growth retardation, and sensitivity to ionizing radiation, atypical, autosomal recessive, T cell-negative, 1B cell-positive, NK cell-negative of NK-positive; insulin resistance; Deficiency of steroid 11-beta-monooxygenase; Popliteal pterygium syndrome; Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia; Deafness, autosomal recessive 1A, 2, 3, 6, 8, 9, 12, 15, 16, 18b, 22, 28, 31, 44, 49, 63, 77, 86, and 89; Primary hyperoxaluria, type 1, type, and type III; Paramyotonia congenita of von Eulenburg; Desbuquois syndrome; Carnitine palmitoyltransferase I, II, II (late onset), and II (infantile) deficiency; Secondary hypothyroidism; Mandibulofacial dysostosis, Treacher Collins type, autosomal recessive; Cowden syndrome 1; Li-Fraumeni syndrome 1; Asparagine synthetase deficiency; Malattia leventinese; Optic atrophy 9; Infantile convulsions and paroxysmal choreoathetosis, familial; Ataxia with vitamin E deficiency; islet cell hyperplasia; Miyoshi muscular dystrophy 1; Thrombophilia, hereditary, due to protein C deficiency, autosomal dominant and recessive; Fechtner syndrome; Properdin deficiency, X-linked; Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, Creatine deficiency, X-linked; Pilomatrixoma; Cyanosis, transient neonatal and atypical nephropathic; Adult onset alaxia with oculomotor apraxia; Hemangioma, capillary infantile; PC-K6a; Generalized dominant dystrophic epidermolysis bullosa; Pelizaeus-Merzbacher disease, Myopathy, centronuclear, 1, congenital, with excess of muscle spindles, distal, 1, lactic acidosis, and sideroblastic anemia 1, mitochondrial progressive with congenital cataract, hearing loss, and developmental delay, and tubular aggregate, 2; Benign familial neonatal seizures 1 and 2; Primary pulmonary hypertension; Lymphedema, primary, with myelodysplasia; Congenital long QT syndrome; Familial exudative vitreoretinopathy, X-linked; Autosomal dominant hypohidrotic ectodermal dysplasia; Primordial dwarfism; Familial pulmonary capillary hemangiomatosis; Carnitine acylcarnitine translocase deficiency, Visceral myopathy; Familial Mediterranean fever and Familial Mediterranean fever, autosomal dominant; Combined partial and complete 17-alpha-hydroxylase/17, 20-lyase deficiency; Oto-palato-digital syndrome, type I; Nephrolithiasis/osteoporosis, hypophosphatemic, 2; Familial type 1 and 3 hyperlipoproteinemia; Phenotypes; CHARGE association; Fuhrmann syndrome; Hypotrichosis-lymphedema-telangiectasia syndrome; Chondrodysplasia Blomstrand type; Acroerythrokeratoderma; Slowed nerve conduction velocity, autosomal dominant; Hereditary cancer-predisposing syndrome; Craniodiaphyseal dysplasia, autosomal dominant; Spinocerebellar ataxia autosomal recessive 1 and 16; Proprotein convertase ⅓ deficiency; D-2-hydroxyglutaric aciduria 2; Hyperekplexia 2 and Hyperekplexia hereditary; Central core disease; Opitz G/BBB syndrome; Cystic fibrosis; Thiel-Behnke comeal dystrophy; Deficiency of bisphosphoglycerate mutase; Mitochondrial short-chain Enoyl-CoA Hydratase 1 deficiency; Ectodermal dysplasia skin fragility syndrome; Wolfram-like syndrome, autosomal dominant; Microcytic anemia; Pyruvate carboxylase deficiency; Leukocyte adhesion deficiency type I and III; Multiple endocrine neoplasia, types land 4; Transient bullous dermolysis of the newborn; Primrose syndrome; Non-small cell lung cancer; Congenital muscular dystrophy; Lipase deficiency combined; COLE-CARPENTER SYNDROME 2, Atrioventricular septal defect and common atrioventricular junction; Deficiency of xanthine oxidase; Waardenburg syndrome type 1, 4C, and 2E (with neurologic involvement); Stickler syndrome, types 1(nonsyndromic ocular) and 4; Comeal fragility keratoglobus, blue sclerae and joint hypermobility; Microspherophakia; Chudley-McCullough syndrome; Epidermolysa bullosa simplex and limb girdle muscular dystrophy, simplex with mottled pigmentation, simplex with pyloric atresia, simplex, autosomal recessive, and with pyloric atresia; Rett disorder; Abnormality of neuronal migration; Growth hormone deficiency with pituitary anomalies; Leigh disease; Keratosis palmoplantaris striata 1; Weissenbacher-Zweymuller syndrome; Medium-chain acyl-coenzyme A dehydrogenase deficiency; UDPglucose-4-epimerase deficiency; susceptibility to Autism, X-linked 3; Rhegmatogenous retinal detachment, autosomal dominant; Familial febrile seizures 8; Ulna and fibula absence of with severe limb deficiency; Left ventricular noncompaction 6; Centromeric instability of chromosomes 1, 9 and 16 and immunodeficiency; Hereditary diffuse leukoencephalopathy with spheroids; Cushing syndrome; Dopamine receptor d2, reduced brain density of; C-like syndrome; Renal dysplasia, retinal pigmentary dystrophy, cerebellar ataxia and skeletal dysplasia; Ovarian dysgenesis 1; Pierson syndrome; Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract; Progressive intrahepatic cholestasis; autosomal dominant, autosomal recessive, and X-linked recessive Alport syndromes; Angelman syndrome; Amish infantile epilepsy syndrome; Autoimmune lymphoproliferative syndrome, type 1a; Hydrocephalus; Marfanoid habitus; Bare lymphocyte syndrome type 2, complementation group E; Recessive dystrophic epidermolysis bullosa; Factor H, VII, X, v and factor viii, combined deficiency of 2, xiii, a subunit, deficiency; Zonular pulverulent cataract 3; Warts, hypogammaglobulinemia, infections, and myelokathexis; Benign hereditary chorea; Deficiency of hyaluronoglucosaminidase; Microcephaly, hiatal hernia and nephrotic syndrome; Growth and mental retardation, mandibulofacial dysostosis, microcephaly, and cleft palate; Lymphedema, hereditary, id; Delayed puberty; Apparent mineralocorticoid excess; Generalized arterial calcification of infancy 2; METHYLMALONIC ACIDURIA, mut(0) TYPE; Congenital heart disease, multiple types, 2; Familial hypoplastic, glomerulocystic kidney; Cerebrooculofacioskeletal syndrome 2; Stargardt disease 1; Mental retardation, autosomal recessive 15, 44, 46, and 5; Prolidase deficiency; Methylmalonic aciduria cblB type, ; Oguchi disease; Endocrine-cerebroosteodysplasia; Lissencephaly 1, 2 (X-linked), 3, 6 (with microcephaly), X-linked; Somatotroph adenoma; Gamstorp-Wohlfart syndrome; Lipid proteinosis; Inclusion body myopathy 2 and 3; Enlarged vestibular aqueduct syndrome; Osteoporosis with pseudoglioma; Acquired long QT syndrome; Phenylketonuria; CHOPS syndrome; Global developmental delay; Bietti crystalline corneoretinal dystrophy; Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia; Congenital erythropoietic porphyria; Atrophia bulborum hereditaria; Paragangliomas 3; Van der Woude syndrome; Aromatase deficiency; Birk Barel mental retardation dysmorphism syndrome; Amyotrophic lateral sclerosis type 5; Methemoglobinemia types I 1 and 2; Congenital stationary night blindness, type 1A, 1B, 1C, 1E, 1F, and 2A; Seizures; Thyroid cancer, follicular; Lethal congenital contracture syndrome 6; Distal hereditary motor neuronopathy type 2B; Sex cord-stromal tumor; Epileptic encephalopathy, childhood-onset, early infantile, 1, 19, 23, 25, 30, and 32; Myofibrillar myopathy 1 and ZASP-related; Cerebellar ataxia infantile with progressive external ophthalmoplegia; Purine-nucleoside phosphorylase deficiency; Forebrain defects; Epileptic encephalopathy Lennox-Gastaut type; Obesity; 4, Left ventricular noncompaction 10; Verheij syndrome; Mowat-Wilson syndrome; Odontotrichomelic syndrome; Patterned dystrophy of retinal pigment epithelium; Lig4 syndrome; Barakat syndrome; IRAK4 deficiency; Somatotroph adenoma; Branched-chain ketoacid dehydrogenase kinase deficiency; Cystinuria; Familial aplasia of the vermis; Succinyl-CoA acetoacetate transferase deficiency; Scapuloperoneal spinal muscular atrophy; Pigmentary retinal dystrophy; Glanzmann thrombasthenia; Primary open angle glaucoma juvenile onset 1; Aicardi Goutieres syndromes 1, 4, and 5; Renal dysplasia; intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies; Beaded hair; Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis; Metachromatic leukodystrophy; Cholestanol storage disease; Three M syndrome 2; Leber congenital amaurosis 11, 12, 13, 16, 4, 7, and 9; Mandibuloacral dysplasia with type A or B lipodystrophy, atypical; Meier-Gorlin syndromes land 4; Hypotrichosis 8 and 12; Short QT syndrome 3; Ectodermal dysplasia 1 ib; Anonychia; Pseudohypoparathyroidism type IA, Pseudopseudohypoparathyroidism; Leber optic atrophy; Bainbridge-Ropers syndrome; Weaver syndrome; Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities; Deficiency of alpha-mannosidase; Macular dystrophy, vitelliform, adult-onset; Glutaric aciduria, type 1; (Gangliosidosis GM1 type1 (with cardiac involvement) 3; Mandibuloacral dysostosis; Hereditary lymphedema type 1; Atrial standstill 2; Kabuki make-up syndrome; Bethlem myopathy and Bethlem myopathy 2; Myeloperoxidase deficiency; Fleck comeal dystrophy; Hereditary acrodermatitis enteropathica; Hypobetalipoproteinemia, familial, associated with apob32; Cockayne syndrome type A, Hyperparathyroidisim, neonatal severe; Ataxia-telangiectasia-like disorder; Pendred syndrome; I blood group system; Familial benign pemphigus; Visceral heterotaxy 5, autosomal; Nephrogenic diabetes insipidus, Nephrogenic diabetes insipidus, X-linked; Minicore myopathy with external ophthalmoplegia; Perry syndrome; hypohidrotic/hair/tooth type, autosomal recessive; Hereditary pancreatitis; Mental retardation and microcephaly with pontine and cerebellar hypoplasia; Glycogen storage disease 0 (muscle), II (adult form), IXa2, IXc, type 1A; Osteopathia striata with cranial sclerosis; Gluthathione synthetase deficiency; Brugada syndrome and Brugada syndrome 4; Endometrial carcinoma; Hypohidrotic ectodermal dysplasia with immune deficiency; Cholestasis, intrahepatic, of pregnancy 3; Bemard-Soulier syndrome, types A1 and A2 (autosomal dominant); Salla disease; Ornithine aminotransferase deficiency; PTEN hamartoma tumor syndrome; Distichiasis-lymphedema syndrome; Corticosteroid-binding globulin deficiency; Adult neuronal ceroid lipofuscinosis; Dejerine-Sottas disease; Tetraamelia, autosomal recessive; Senior-Loken syndrome 4 and 5, ; Glutaric acidemia IIA and IIB; Aortic aneurysm, familial thoracic 4, 6, and 9′ Hyperphosphatasia with mental retardation syndrome 2, 3, and 4; Dyskeratosis congenita X-linked; Arthrogryposis, renal dysfunction, and cholestasis 2; Bannayan-Riley-Ruvalcaba syndrome; 3-Methylglutaconic aciduria; Isolated 17,20-lyase deficiency; Gorlin syndrome; Hand foot uterus syndrome; Tay-Sachs disease, B1 variant, Gm2-gangliosidosis (adult), m2-gangliosidosis (adult-onset); Dowling-degos disease 4; Parkinson disease 14, 15, 19 (juvenile-onset), 2, 20 (early-onset), 6, (autosomal recessive early-onset, and 9; Ataxia, sensory, autosomal dominant; Congenital microvillous atrophy; Myoclonic-Atonic Epilepsy; Tangier disease; 2-methyl-3-hydroxybutyric aciduria; Familial renal hypouricemia; Schizencephaly; Mitochondrial DNA depletion syndrome 4B, MNGIE type; Feingold syndrome 1; Renal carnitine transport defect; Familial hypercholesterolemia; Townes-Brocks-branchiootorenal-like syndrome; Griscelli syndrome type 3; Meckel-Gruber syndrome; Bullous ichthyosiform erythroderma; Neutrophil immunodeficiency syndrome; Myasthenic Syndrome, Congenital, 17, 2A (slow-channel), 4B (fast-channel), and without tubular aggregates; Microvascular complications of diabetes 7; McKusick Kaufman syndrome; Chronic granulomatous disease, autosomal recessive cytochrome b-positive, types 1 and 2; Arginino succinate lyase deficiency; Mitochondrial phosphate carrier and pyruvate carrier deficiency; Lattice corneal dystrophy Type II; Ectodermal dysplasia-syndactyly syndrome 1; Hypomyelinating leukodystrophy 7; Mental retardation, autosomal dominant 12, 13, 15, 24, 3, 30, 4, 5, 6, and 9; Generalized epilepsy with febrile seizures plus, types 1 and 2; Psoriasis susceptibility 2; Frank Ter Haar syndrome; Thoracic aortic aneurysms and aortic dissections; Crouzon syndrome; Granulosa cell tumor of the ovary; Epidermolytic palmoplantar keratoderma; Leri Weill dyschondrosteosis; 3 beta-Hydroxysteroid dehydrogenase deficiency; Familial restrictive cardiomyopathy 1; Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 1 and 3; Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis; Hajdu-Cheney syndrome; Pigmented nodular adrenocortical disease, primary, 1; Episodic pain syndrome, familial, 3; Dejerine-Sottas syndrome, autosomal dominant; FG syndrome and FG syndrome 4; Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency; Hypothyroidism, congenital, nongoitrous, 1; Miller syndrome; Nemaline myopathy 3 and 9; Oligodontia-colorectal cancer syndrome; Cold-induced sweating syndrome 1; Van Buchem disease type 2; Glaucoma 3, primary congenital, d; Citrullinemia type I and 11; Nonaka myopathy; Congenital muscular dystrophy due to partial LAMA2 deficiency; Myoneural gastrointestinal encephalopathy syndrome; Leigh syndrome due to mitochondrial complex 1 deficiency; Medulloblastoma; Pyruvate dehydrogenase El-alpha deficiency; Carcinoma of colon; Nance-Horan syndrome; Sandhoff disease, adult and infantil types; Arthrogryposis renal dysfunction cholestasis syndrome; Autosomal recessive hypophosphatemic bone disease; Doyne boney comb retinal dystrophy; Spinocerebellar ataxia 14, 21, 35, 40, and 6; Lewy body dementia; RRM2B-related mitochondrial disease; Brody myopathy; Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2; Usher syndrome, types 1, 113, ID, 1C, 2A, 2C, and 2D; hypocalcification type and hypomaturation type, IIA1 Amelogenesis imperfecta; Pituitary hormone deficiency, combined 1, 2, 3, and 4; Cushing Symphalangism; Renal tubular acidosis, distal, autosomal recessive, with late-onset sensorineural hearing loss, or with hemolytic anemia; Infantile nephronophthisis; Juvenile polyposis syndrome; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Deficiency of 3-hydroxyacyl-CoA dehydrogenase; Parathyroid carcinoma; X-linked agammaglobulinemia; Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness; Multiple sulfatase deficiency; Neurodegeneration with brain iron accumulation 4 and 6; Cholesterol monooxygenase (side-chain cleaving) deficiency; hemolytic anemia due to Adenylosuccinate lyase deficiency; Myoclonus with epilepsy with ragged red fibers; Pitt-Hopkins syndrome; Multiple pterygium syndrome Escobar type; Homocystinuria-Megaloblastic anemia due to defect in cobalamin metabolism, cblE complementation type; Cholecystitis; Spherocytosis types 4 and 5; Multiple congenital anomalies; Xeroderma pigmentosum, complementation group b, group D, group E, and group G; Leiner disease; Groenouw comeal dystrophy type I; Coenzyme Q10 deficiency, primary 1, 4, and 7; Distal spinal muscular atrophy, congenital nonprogressive; Warburg micro syndrome 2 and 4; Bile acid synthesis defect, congenital, 3; Acth-independent macronodular adrenal hyperplasia 2; Acrocapitofemoral dysplasia; Paget disease of bone, familial; Severe neonatal-onset encephalopathy with microcephaly; Zimmermann-Laband syndrome and Zimmermann-Laband syndrome 2; Reifenstein syndrome; Familial hypokalemia-hypomagnesemia; Photosensitive trichothiodystrophy; Adult junctional epidermolysis bullosa; Lung cancer; Freeman-Sheldon syndrome; Hyperinsulinism-hyperammonemia syndrome; Posterior polar cataract type 2; Sclerocornea, autosomal recessive; Juvenile (GM>1<gangliosidosis; Cohen syndrome; Hereditary Paraganglioma-Pheochromocytoma Syndromes; Neonatal insulin-dependent diabetes mellitus; Hypochondrogenesis; Floating-Harbor syndrome; Cutis laxa with osteodystrophy and with severe pulmonary, gastrointestinal, and urinary abnormalities; Congenital contractures of the limbs and face, hypotonia, and developmental delay; Dyskeratosis congenita autosomal dominant and autosomal dominant, 3; Histiocytic medullary reticulosis; Costello syndrome; Immunodeficiency 15, 16, 19, 30, 31C, 38, 40, 8, due to defect in cd3-zeta, with hyper IgM type 1 and 2, and X-Linked, with magnesium defect, Epstein-Barr vims infection, and neoplasia; Atrial septal defects 2, 4, and 7 (with or without atrioventricular conduction defects); GTP cyclohydrolase I deficiency; Talipes equinovarus; Phosphoglycerate kinase 1 deficiency; Tuberous sclerosis 1 and 2; Autosomal recessive congenital ichthyosis 1, 2, 3, 4A, and 4B; and Familial hypertrophic cardiomyopathy 1, 2, 3, 4, 7, 10, 23 and 24.

Indications by Tissue

Additional suitable diseases and disorders that can be treated by the systems and methods provided herein include, without limitation, diseases of the central nervous system (CNS) (see exemplary diseases and affected genes in Table 13), diseases of the eye (see exemplary diseases and affected genes in Table 14), diseases of the heart (see exemplary diseases and affected genes in Table 15), diseases of the hematopoietic stem cells (HSC) (see exemplary diseases and affected genes in Table 16), diseases of the kidney (see exemplary diseases and affected genes in Table 17), diseases of the liver (see exemplary diseases and affected genes in Table 18), diseases of the lung (see exemplary diseases and affected genes in Table 19), diseases of the skeletal muscle (see exemplary diseases and affected genes in Table 20), and diseases of the skin (see exemplary diseases and affected genes in Table 21). Table 22 provides exemplary protective mutations that reduce risks of the indicated diseases. In some embodiments, a Gene Writer system described herein is used to treat an indication of any of Tables 13-21. In some embodiments, the GeneWriter system modifies a target site in genomic DNA in a cell, wherein the target site is in a gene of any of Tables 13-21, e.g., in a subject having the corresponding indication listed in any of Tables 13-21. In some embodiments, the GeneWriter corrects a mutation in the gene. In some embodiments, the GeneWriter inserts a sequence that had been deleted from the gene (e.g., through a disease-causing mutation). In some embodiments, the GeneWriter deletes a sequence that had been duplicated in the gene (e.g., through a disease-causing mutation). In some embodiments, the GeneWriter replaces a mutation (e.g., a disease-causing mutation) with the corresponding wild-type sequence. In some embodiments, the mutation is a substitution, insertion, deletion, or inversion.

TABLE 13 CNS diseases and genes affected. Gene Disease Affected Alpha-mannosidosis MAN2B1 Ataxia-telangiectasia ATM CADASIL NOTCH3 Canavan disease ASPA Carbamoyl-phosphate synthetase 1 deficiency CPS1 CLN1 disease PPT1 CLN2 Disease TPP1 CLN3 Disease (Juvenile neuronal ceroid lipofuscinosis, CLN3 Batten Disease) Coffin-Lowry syndrome RPS6KA3 Congenital myasthenic syndrome 5 COLQ Cornelia de Lange syndrome (NIPBL) NIPBL Cornelia de Lange syndrome (SMC1A) SMC1A Dravet syndrome (SCN1A) SCN1A Glycine encephalopathy (GLDC) GLDC GM1 gangliosidosis GLB1 Huntington's Disease HTT Hydrocephalus with stenosis of the aqueduct of Sylvius L1CAM Leigh Syndrome SURF1 Metachromatic leukodystrophy (ARSA) ARSA MPS type 2 IDS MPS type 3 SGSH Mucolipidosis IV MCOLN1 Neurofibromatosis Type 1 NF1 Neurofibromatosis type 2 NF2 Pantothenate kinase-associated neurodegeneration PANK2 Pyridoxine-dependent epilepsy ALDH7A1 Rett syndrome (MECP2) MECP2 Sandhoff disease HEXB Semantic dementia (Frontotemporal dementia) MAPT Spinocerebellar ataxia with axonal neuropathy (Ataxia with SETX Oculomotor Apraxia) Tay-Sachs disease HEXA X-linked Adrenoleukodystrophy ABCD1

TABLE 14 Eye diseases and genes affected. Disease Gene Affected Achromatopsia CNGB3 Amaurosis Congenita (LCA1) GUCY2D Amaurosis Congenita (LCA10) CEP290 Amaurosis Congenita (LCA2) RPE65 Amaurosis Congenita (LCA8) CRB1 Choroideremia CHM Cone Rod Dystrophy (ABCA4) ABCA4 Cone Rod Dystrophy (CRX) CRX Cone Rod Dystrophy (GUCY2D) GUCY2D Cystinosis, Ocular Nonnephropathic CTNS Lattice corneal dystrophy type I TGFBI Macular Corneal Dystrophy (MCD) CHST6 Optic Atrophy OPA1 Retinitis Pigmentosa (AR) USH2A Retinitis Rigmentosa (AD) RHO Stargardt Disease ABCA4 Vitelliform Macular Dystrophy BEST1; PRPH2

TABLE 15 Heart diseases and genes affected. Gene Disease Affected Arrhythmogenic right ventricular cardiomyopathy (ARVC) PKP2 Barth syndrome TAZ Becker muscular dystrophy DMD Brugada syndrome SCN5A Catecholaminergic polymorphic ventricular tachycardia RYR2 (RYR2) Dilated cardiomyopathy (LMNA) LMNA Dilated cardiomyopathy (TTN) TTN Duchenne muscular dystrophy DMD Emery-Dreifuss Muscular Dystrophy Type I EMD Familial hypertrophic cardiomyopathy MYH7 Familial hypertrophic cardiomyopathy MYBPC3 Jervell Lange-Nielsen syndrome KCNQ1 LCHAD deficiency HADHA Limb-girdle muscular dystrophy type IB (Emery-Dreifuss LMNA EDMD2) Limb-girdle muscular dystrophy, type 2D SGCA Long QT syndrome 1 (Romano Ward) KCNQ1

TABLE 16 HSC diseases and genes affected. Gene Disease Affected ADA-SCID ADA Adrenoleukodystrophy (CALD) ABCD1 Alpha-mannosidosis MAN2B1 Chronic granulomatous disease CYBB; CYBA; NCF1; NCF2; NCF4 Common variable immunodeficiency TNFRSF13B Fanconi anemia FANCA; FANCC; FANCG Gaucher disease GBA Globoid cell leukodystrophy (Krabbe disease) GALC Hemophagocyti c lymphohi sti ocytosi s PRF1; STX11; STXBP2; UNC13D IL-7R SCID IL7R JAK-3 SCID JAK3 Malignant infantile osteopetrosis- autosomal TCIRG1; recessive osteopetrosis Many genes implicated Metachromatic leukodystrophy ARSA; PSAP MPS 1S (Scheie syndrome) IDUA MPS2 IDS MPS7 GUSB Mucolipidosis II GNPTAB Niemann-Pick disease A and B SMPD1 Niemann-Pick disease C NPC1 Paroxysmal Nocturnal Hemoglobinuria PIGA Pompe disease GAA Pyruvate kinase deficiency (PKD) PKLR RAG 1/2 Deficiency (SCID with granulomas) RAG1/RAG2 Severe Congenital Neutropenia ELANE; HAX1 Sickle cell disease (SCD) HBB Tay Sachs HEXA Thalassemia HBB Wiskott-Aldrich Syndrome WAS X-linked agammaglobulinemia BTK X-linked SCID IL2RG

TABLE 17 Kidney diseases and genes affected. Gene Disease Affected Alport syndrome COL4A5 Autosomal dominant polycystic kidney disease (PKD1) PKD1 Autosomal dominant polycystic kidney disease (PKD2) PDK2 Autosomal dominant tubulointerstitial kidney disease MUC1 (MUC1) Autosomal dominant tubulointerstitial kidney disease UMOD (UMOD) Autosomal recessive polycystic kidney disease PKHD1 Congenital nephrotic syndrome NPHS2 Cystinosis CTNS

TABLE 18 Liver diseases and genes affected. Gene Disease Affected Acute intermittent porphyria HMBS Alagille syndrome JAG1 Alpha-1-antitrypsin deficiency SERPINA1 Carbamoyl phosphate synthetase I deficiency CPS1 Citrullinemia I ASS1 Crigler-Najjar UGT1A1 Fabry LPL Familial chylomicronemia syndrome GLA Gaucher GBE1 GSD IV GBA Heme A F8 Heme B F9 Hereditary amyloidosis (hTTR) TTR Hereditary angioedema SERPING1 (KLKB1 for CRISPR) HoFH LDLRAP1 Hypercholesterolemia PCSK9 Methylmalonic acidemia MMUT MPS II IDS MPS III Type IIIa: SGSH Type IIIb: NAGLU Type IIIc: HGSNAT Type IIId: GNS MPS IV Type IVA: GALNS Type IVB: GLB1 MPS VI ARSB MSUD Type Ia: BCKDHA Type Ib: BCKDHB Type II: DBT OTC Deficiency OTC Polycystic Liver Disease PRKCSH Pompe GAA Primary Hyperoxaluria 1 AGXT (HAO1 or LDHA for CRISPR) Progressive familial intrahepatic cholestasis type 1 ATP8B1 Progressive familial intrahepatic cholestasis type 2 ABCB11 Progressive familial intrahepatic cholestasis type 3 ABCB4 Propionic acidemia PCCB; PCCA Wilson's Disease ATP7B Glycogen storage disease, Type la G6PC Glycogen storage disease, Type IHb AGL Isovaleric acidemia IVD Wolman disease LIPA

TABLE 19 Lung diseases and genes affected. Gene Disease Affected Alpha-1 antitrypsin deficiency SERPINA1 Cystic fibrosis CFTR Primary ciliary dyskinesia DNAI1 Primary ciliary dyskinesia DNAH5 Primary pulmonary hypertension I BMPR2 Surfactant Protein B (SP-B) Deficiency (pulmonary SFTPB surfactant metabolism dysfunction 1)

TABLE 20 Skeletal muscle diseases and genes affected. Gene Disease Affected Becker muscular dystrophy DMD Becker myotonia CLCN1 Bethlem myopathy COL6A2 Centronuclear myopathy, X-linked (myotubular) MTM1 Congenital myasthenic syndrome CHRNE Duchenne muscular dystrophy DMD Emery-Dreifuss muscular dystrophy, AD LMNA Facioscapulohumeral Muscular Dystrophy DUX4 - D4Z4 chromosomal region Hyperkalemic periodic paralysis SCN4A Hypokalemic periodic paralysis CACNA1S Limb-girdle muscular dystrophy 2A CAPN3 Limb-girdle muscular dystrophy 2B DYSF Limb-girdle muscular dystrophy, type 2D SGCA Miyoshi muscular dystrophy 1 DYSF Paramyotonia congenita SCN4A Thomsen myotonia CLCN1 VCP myopathy (IBMPFD) 1 VCP

TABLE 21 Skin diseases and genes affected. Gene Disease Affected Epidermolysis Bullosa Dystrophica Dominant COL7A1 Epidermolysis Bullosa Dystrophica Recessive COL7A1 (Hallopeau-Siemens) Epidermolysis Bullosa Junctional LAMB3 Epidermolysis Bullosa Simplex KRT5; KRT14 Epidermolytic Ichthyosis KRT1; KRT10 Hailey-Hailey Disease ATP2C1 Lamellar Ichthyosis/Nonbullous Congenital TGM1 Ichthyosiform Erythroderma (ARCI) Netherton Syndrome SPINK5

TABLE 22 Exemplary protective mutations that reduce disease risk. Disease Gene Exemplary Protective Mutation Alzheimer's APP A673T Parkinson's SGK1 Diabetes (Type II) SLC30A8 p.Arg138X; p.Lys34SerfsX50 Cardiovascular PCSK9 R46L Disease Cardiovascular ASGR1 NM_001671.4, c.284-36_283 + 33delCTGGGGCTGGGG Disease (SEQ ID NO: 1605); NP_001662.1, p.W158X Cardiovascular NPC1L1 p.Arg406X Disease Cardiovascular APOC3 R19X; IVS2 + 1G→A; A43T Disease Cardiovascular LPA Disease Cardiovascular ANGPTL4 E40K Disease Cardiovascular ANGPTL3 p.Ser17Ter; p.Asn121fs; p.Asn147fs; c.495 + 6T→C Disease HIV infection CCR5 CCR5-delta32

Pathogenic Mutations

In some embodiments, the systems or methods provided herein can be used to correct a pathogenic mutation. The pathogenic mutation can be a genetic mutation that increases an individual's susceptibility or predisposition to a certain disease or disorder. In some embodiments, the pathogenic mutation is a disease-causing mutation in a gene associated with a disease or disorder. In some embodiments, the systems or methods provided herein can be used to revert the pathogenic mutation to its wild-type counterpart. In some embodiments, the systems or method provided herein can be used to change the pathogenic mutation to a sequence not causing the disease or disorder.

Table 23 provides exemplary indications (column 1), underlying genes (column 2), and pathogenic mutations that can be corrected using the systems or methods described herein (column 3).

TABLE 23 Indications, genes, and causitive pathogenic mutations. Disease Gene Pathogenic Mutation^(#) Achromatopsia CNGB3 1148delC Alpha-1 Antitrypsin Deficiency SERPINA1 E342K Alpha-1 Antitrypsin Deficiency SERPINA1 E342K Alpha-1 Antitrypsin Deficiency SERPINA1 R48C (R79C) Amaurosis Congenita (LCA10) CEP290 2991 + 1655A > G Andersen- Tawil syndrome KCNJ2 R218W Arrhythmogenic right ventricular cardiomyopathy PKP2 c.235C > T (ARVC) associated with congenital factor XI deficiency F11 E117* associated with congenital factor XI deficiency F11 F283L ATTR amyloidosis TTR V50M/N30M autosomal dominant deafness COCH G88E autosomal dominant deafness TECTA Y1870C autosomal dominant Parkinson's disease SNCA A53T autosomal dominant Parkinson's disease SNCA A30P Autosomal dominant rickets FGF23 R176Q autosomal recessive deafness CX30 T5M autosomal recessive deafness DFNB59 R183W autosomal recessive deafness TMC1 Y182C autosomal recessive hypercholesterolemia ARH Q136* Blackfan-Diamond anemia RPS19 R62Q blue-cone monochromatism OPN.ILW C203R Brugada syndrome SCN5A E1784K CADASIL syndrome NOTCH3 gene R90C C ADA SIL. syndrome NOTCH3 gene R141C Canavan disease ASPA E285A Canavan disease ASPA Y231X Canavan disease ASPA A305E carnitine palmitoyltransferase II deficiency CPT2 S113L choroideremia CHM R293* choroideremia CHM R270* choroideremia CHM A117A Citrullinemia Type I ASS G390R classic galactosemia GALT Q188R classic horoocystoinuria CBS T191M classic homocystemuria CBS G307S CLN2 Disease TPP1 c.509 − 1 G > C CLN2 Disease TPP1 c.622 C < T CLN2 Disease TPP1 c.851 G > T cone-rod dystrophy GUCY2D R838C congenital factor V deficiency F5 R506Q congenital factor V deficiency F5 R534Q congenital factor VII deficiency F7 A294V congenital factor VII deficiency F7 C310F congenital factor VII deficiency F7 R304Q congenital factor VII deficiency F7 QI00R Creutzfeldt- Jakob disease (CJD) PRNP E200K Creutzfeldt- Jakob disease (CJD) PRNP M129V Creutzfeldt- Jakob disease (CJD) PRNP P102L Creutzfeldt- Jakob disease (CJD) PRNP D178N cystic fibrosis CFTR G551D cystic fibrosis CFTR W1282* cystic fibrosis CFTR R553* cystic fibrosis CFTR R117H cystic fibrosis CFTR delta F508 eystinosis CTNS W138* Darier disease ATP2A2 N767S Darier disease ATP2A2 N767S Darier disease ATP2A2 N767S Epidermolysis Bullosa Junctional LAMB3 R42X Epidermolysis Bullosa Junctional LAMB3 R635X familial amyotrophic lateral sclerosis (ALS) SOD! A4V familial amyotrophic lateral sclerosis (ALS) SOD1 H46R familial amyotrophic lateral sclerosis (ALS) SOD I G37R Gaucher disease GBA N370S Gaucher disease GBA N370S Gaucher disease GBA L444P Gaucher disease GBA L444P Gaucher disease GBA L483P glutarvl-CoA dehydrogenase deficiency GCDH R138G glutaryl-CoA dehydrogenase deficiency GCDH M263V glutaryl-Co A dehydrogenase deficiency GCDH R402W glycine encephalopathy GLDC A389V glycine encephalopathy GLDC G771R glycine encephalopathy GLDC T269M hemophilia A F8 R2178C hemophilia A F8 R550C hemophilia A F8 R2169H hemophilia A F8 R1985Q hemophilia B F9 T342M hemophilia B F9 R294Q hemophilia B F9 R43Q hemophilia B F9 R191H hemophilia B F9 G106S hemophilia B F9 A279T hemophilia B F9 P75* hemophilia B F9 R294* hemophilia B F9 R379Q Hereditary antithrombin deficiency type I SERPINCI R48C (R79C) hereditary chronic pancreatitis PRSS1 R122H Hunter syndrome IDS R88C Hunter syndrome IDS G374G Hurler syndrome (MPS1) IDUA Q70* Hurler syndrome (MPS1) IDUA W402* Hyperkalemic periodic paralysis SCN4A T704M Hyperkalemic periodic paralysis SCN4A M1592V Hyperkalemic periodic paralysis CACNA1S p.Arg528X Hyperkalemic periodic paralysis CACNA1S p.Arg1239 intermittent porphyria HMBS R173W isolated agammaglobulin em ia E47 E555K Lattice corneal dystrophy type I TGFBI Arg124Cys LCHAD deficiency HADHA Glu474Gln Leber congenital amaurosis 2 RPE65 R44* Leber congenital amaurosis 2 RPE65 IVS1 Leber congenital amaurosis 2 RPE65 G-A, + 5 Lesch -Nyhan syndrome HPRTI R51* Le sch -N yhan syndrome HPRTI R170* Limb-girdle muscular dystrophy, type 2D SGCA Arg77Cys Marteauz- Lamy Syndrome (MSPVI) ARSB Y210C Mediterranean G6PD deficiency G6PD S188D medium-chain acyl-CoA dehydrogenase deficiency ACADM K329E medium-chain. acyl-CoA dehydrogenase deficiency ACADM K329E medium-chain acyl-CoA dehydrogenase deficiency ACADM K329E Meesmann epithelial corneal dystrophy KRT12 L132P metachfoniatic leukodystrophy ARSA P426L metachromatic leukodystrophy ARSA c.459 + 1G > A Morquio Syndrome (MPSIVA) GALNS R386C Mucolipidosis IV MC0LN1 406-2A > G Mucolipidosis IV MC0LN1 511_6943del Neimann-Pick disease type A SMPDI L302P Neuronal ceroid lipofuscinosis (NCL) CLN2 R208* neuronal ceroid lipofuscinosis 1 PPT1 R151* Parkinsons disease LRRK2 G2019S Pendred syndrome PDS T461P Pendred syndrome PDS L236P Pendred syndrome PDS c.1001 + 1G > A Pendred syndrome PDS IVS8, + 1 G > A, phenylketonuria PAH R408W phenylketonuria PAH 165T phenylketonuria PAH R261Q phenylketonuria PAH IVS10-HG > A phenylketonuria PCDH15 R245* phenylketonuria PCDH15 R245* Pompe disease GAA c.−32 − 13T > G Primary ciliary dyskinesia DNAI1 IVS1 + 2 3insT Primary ciliary dyskinesia DNAH5 10815delT primary' hypoxalimia AGXT G170R Progressive familial intrahepatic cholestasis type 2 ABCB11 D482G (c.1445A > G) Progressive familial intrahepatic cholestasis type 2 ABCB11 E297G Propionic acidemia PCCB;PCCA c.1218_1231del14ins12 pseudoxanthoma, eiasticum ABCC6 R1141* Pyruvate kinase deficiency (PKD) PKLR c.1456c −> T retinitis pignientos USH2a C759F retinitis pigmentosa IMPDHI D226N retinitis pigmentosa PDE6A V685M retinitis pigmentosa PDE6A D670G retinitis pigmentosa PRPF3 T494M retinitis pigmentosa PRPF8 H2309R retinitis pigmentosa RHO P23H retinitis pigmentosa RHO P347L retinitis pigmentosa RHO P347L retinitis pigmentosa RHO D190N retinitis pigmentosa RPI R667* retinitis pigmentosa/Usher syndrome type 1C USH1C V72V Rett syndrome MECP2 R106W Rett syndrome MECP2 R133C Rett syndrome MECP2 R306C Rett syndrome MECP2 R168* Rett syndrome MECP2 R255* Sanfilippo syndrome A (MPSIIIA) SGSH R74C Sanfilippo syndrome A (MPSIIIA) SGSH R245H Sanfilippo syndrome B (MPSIIIB) NAGLU R297* Sanfilippo syndrome B (MPSIIIB) NAGLU Y140C severe combined immunodeficiency ADA G216R severe combined immunodeficiency ADA G216R severe combined immunodeficiency ADA Q3* sickle cell disease HBB E6V sickle cell disease HBB E6V sickle cell disease HBB E6V sickle cell disease HBB E26K sickle cell disease HBB E26K sickle cell disease HBB E7K sickle cell disease HBB c.−138C > T sickle cell disease HBB IVS2 sickle cell disease HBB 654 C > T Sly Syndrome (MPSVH) GUSB L175F Stargardt disease ABCA4 A1038V Stargardt disease ABCA4 A1038V Stargardt disease ABCA4 L541P Stargardt disease ABCA4 G1961E Stargardt disease ABCA4 G1961E Stargardt disease ABCA4 G1961E Stargardt disease ABCA4 G1961E Stargardt disease ABCA4 c.2588G > C Stargardt disease ABCA4 c.5461 − 10 T > C Stargardt disease ABCA4 c.5714 + 5G > A Tay Sachs HEXA InsTATC1278 tyrosinemia type 1 FAH P261L Usher syndrome type 1F PCDH15 R245* variegate porphyria PPOX R59W VCP myopathy (IBMPFD) 1 VCP R1555X von Gierke disease G6PC Q347* von Gierke disease G6PC Q347* von Gierke disease G6PC Q347* von Gierke disease G6PC R83C Wilson's Disease ATP7B E297G X-linked myotubular myopathy MTMI c.1261 − 10A > G X-linked retinoschisis RS1 R102W X-linked retinoschisis RS1 R141C ^(#)See J T den Dunnen and S E Antonarakis, Hum Mutat. 2000; 15(1): 7-12, herein incorporated by reference in its entirety, for details of the nomenclatures of gene mutations. *means a stop codon.

Compensatory Edits

In some embodiments, the systems or methods provided herein can be used to introduce a compensatory edit. In some embodiments, the compensatory edit is at a position of a gene associated with a disease or disorder, which is different from the position of a disease-causing mutation. In some embodiments, the compensatory mutation is not in the gene containing the causative mutation. In some embodiments, the compensatory edit can negate or compensate for a disease-causing mutation. In some embodiments, the compensatory edit can be introduced by the systems or methods provided herein to suppress or reverse the mutant effect of a disease-causing mutation.

Table 24 provides exemplary indications (column 1), genes (column 2), and compensatory edits that can be introduced using the system is or methods described herein (column 3). In some embodiments, the compensatory edits provided in Table 24 can be introduced to suppress or reverse the mutant effect of a disease-causing mutation.

TABLE 24 Indications, genes, compensatory edits, and exemplary design features. Disease Gene Nucleotide Change^(#) Alpha-1 Antitrypsin Deficiency SERPINAI F51L Alpha-1 Antitrypsin Deficiency SERPINAI M3741 Alpha-1 Antitrypsin Deficiency SERPINAI A348V/A347V Alpha-1 Antitrypsin Deficiency SERPINAI K387R Alpha-1 Antitrypsin Deficiency SERPINAI T59A Alpha-1 Antitiypsin Deficiency SERPINAI T68A ATTR amyloidosis TTR A108V ATTR amyloidosis TTR R104H ATTR amyloidosis TTR T119M Cystic fibroses CFTR R555K Cystic fibrosis CFTR F409L Cystic fibrosis CFTR F433L Cystic fibrosis CFTR H667R Cystic fibrosis CFTR R1070W Cystic fibrosis CFTR R29K Cystic fibrosis CFTR R553Q Cystic fibrosis CFTR 1539T Cystic fibrosis CFTR G550E Cystic fibroses CFTR F429S Cystic fibrosis CFTR Q637R Sickle cell disease HBB A70T Sickle cell disease HBB A70V Sickle cell disease HBB L88P Sickle cell disease HBB F85L and/or F85P Sickle cell disease HBB E22G Sickle cell disease HBB G16D and/or G16N ^(#)See J T den Dunnen and S E Antonarakis, Hum Mutat. 2000; 15(1): 7-12, herein incorporated by reference in its entirety, for details of the nomenclatures of gene mutations.

Regulatory Edits

In some embodiments, the systems or methods provided herein can be used to introduce a regulatory edit. In some embodiments, the regulatory edit is introduced to a regulatory sequence of a gene, for example, a gene promoter, gene enhancer, gene repressor, or a sequence that regulates gene splicing. In some embodiments, the regulatory edit increases or decreases the expression level of a target gene. In some embodiments, the target gene is the same as the gene containing a disease-causing mutation. In some embodiment, the target gene is different from the gene containing a disease-causing mutation. For example, the systems or methods provided herein can be used to upregulate the expression of fetal hemoglobin by introducing a regulatory edit at the promoter of bcl11a, thereby treating sickle cell disease.

Table 25 provides exemplary indications (column 1), genes (column 2), and regulatory edits that can be introduced using the systems or methods described herein (column 3).

TABLE 25 Indications, genes, and compensatory regulatory edits. Disease Gene Nucleotide Change^(#) homozygous familial hypercholesterolaemia LDLR c.81C > T Porphyrias ALAS1 c.3G > A Porphyrias ALAS1 c.2T > C Porphyrias ALAS1 c.46C > T Porphyrias ALAS1 c.91C > T Porphyrias ALAS1 c.91C > T Porphyrias ALAS1 c.226C > T Porphyrias ALAS1 c.226C > T Porphyrias ALAS1 c.226C > T Porphyrias ALAS1 c.229C > T Porphyrias ALAS1 c.247C > T Porphyrias ALAS1 c.247C > T Porphyrias ALAS1 c.250C > T Porphyrias ALAS1 c.250C > T Porphyrias ALAS1 c.340C > T Porphyrias ALAS1 c.340C > T Porphyrias ALAS1 c.349C > T Porphyrias ALAS1 c.391C > T Porphyrias ALAS1 c.391C > T Porphyrias ALAS1 c.403C > T Porphyrias ALAS1 c.403C > T Porphyrias ALAS1 c.199 + 1G > A Porphyrias ALAS1 c.199 + 1G > A Porphyrias ALAS1 c.199 + 1G > A Porphyrias ALAS1 c.199 + 1G > A Porphyrias ALAS1 c.199 + 2T > C Porphyrias ALAS1 c.199 + 2T > C Porphyrias ALAS1 c.199 + 2T > C Porphyrias ALAS1 c.199 + 2T > C Porphyrias ALAS1 c.200 − 2A > G Porphyrias ALAS1 C.427 + 1G > A Porphyrias ALAS1 c.427 + 2T > C Porphyrias ALAS1 c.1165 + 1G > A Porphyrias ALAS1 c.1165 + 2T > C Porphyrias ALAS1 c.1166 − 1A > G Porphyrias ALAS1 c.1331 − 2A > G sickle cell disease BCL11A c.386-24278G > A sickle cell disease BCL11A c.386-24983T > C sickle cell disease HBG1 c.−167C > T sickle cell disease HBG1 c.−170G > A sickle cell disease HBG1 c.−249C > T sickle cell disease HBG2 c.−211C > T sickle cell disease HBG2 c.−228T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−198 T > C sickle cell disease HBG1/2 C.−175 T > C sickle cell disease HBG1/2 C.−175 T > C sickle cell disease HBG1/2 C.−175 T > C sickle cell disease HBG1/2 C.−175 T > C sickle cell disease HBG1/2 C.−175 T > C sickle cell disease HBG1/2 C.−114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 C. −114~−102 deletion sickle cell disease HBG1/2 c. −90 BCL11A Binding sickle cell disease HBG1/2 c. −90 BCL11A Binding sickle cell disease HBG1/2 C. −202 C > T, −201 C > T, −198 T > C, −197 C > T, −196 C > T, −195 C > G sickle cell disease HBG1/2 C. −197 C > T, −196 C > T, −195 C > G ^(#)See J T den Dunnen and S E Antonarakis, Hum Mutat. 2000; 15(1): 7-12, herein incorporated by reference in its entirety, for details of the nomenclatures of gene mutations.

Repeat Expansion Diseases

In some embodiments, the systems or methods provided herein can be used to treat a repeat expansion disease, for example, a repeat expansion disease provided in Table 26. Table 26 provides the indication (column 1), the gene (column 2), minimal repeat sequence of the repeat that is expanded in the condition (column 3), and the location of the repeat relative to the listed gene for each indication (column 4). In some embodiments, the systems or methods provided herein, for example, those comprising Gene Writers, can be used to treat repeat expansion diseases by resetting the number of repeats at the locus according to a customized RNA template (see, e.g., Example 24).

TABLE 26 Exemplary repeat expansion diseases, genes,  causal repeats, and repeat locations. Causal Repeat Disease Gene repeat location myotonic DMPK/DM1 CTG 3′ UTR dystrophy 1 myotonic ZNF9/CNBP CCTG Intron 1 dystrophy 2 dentatorubral- ATN1 CAG Coding pallidoluysian atrophy fragile X mental FMR1 CGG 5′ UTR retardation syndrome fragile X E mental FMR2 GCC 5′ UTR retardation Friedreich's ataxia FXN GAA Intron fragile X tremor FMR1 CGG 5′ UTR ataxia syndrome Huntington's HTT CAG Coding disease Huntington's JPH3 CTG 3′ UTR, disease-like 2 coding myoclonic CSTB CCCC Promoter epilepsy of GCCC Unverricht CGCG and Lundborg (SEQ ID NO: 1606) oculopharyngeal PABPN1 GCG Coding muscular dystrophy spinal and bulbar AR CAG Coding muscular atrophy spinocerebellar ATXN1 CAG Coding ataxia 1 spinocerebellar ATXN2 CAG Coding ataxia 2 spinocerebellar ATXN3 CAG Coding ataxia 3 spinocerebellar CACNA1A CAG Coding ataxia 6 spinocerebellar ATXN7 CAG Coding  ataxia 7 spinocerebellar ATXN8 CTG/CAG CTG/CAG ataxia 8 (ATXN8) spinocerebellar ATXN10 ATTCT Intron ataxia 10 spinocerebellar PPP2R2B CAG Promoter, ataxia 12 5′ UTR? spinocerebellar TBP CAG Coding ataxia 17 Syndromic/non- ARX GCG Coding syndromic X- linked mental retardation

Exemplary Templates

In some embodiments, the systems or methods provided herein use the template sequences listed in Table 27. Table 27 provides exemplary template RNA sequences (column 5) and optional second-nick gRNA sequences (column 6) designed to be paired with a Gene Writing polypeptide to correct the indicated pathogenic mutations (column 4). All the templates in Table 27 are meant to exemplify the total sequence of (1) targeting gRNA for first strand nick, (2) polypeptide binding domain, (3) heterologous object sequence, and (4) target homology domain for setting up TPRT at first strand nick.

TABLE 27 Exemplary diseases, tissues, genes, pathogenic mutations, template RNA sequences, and second nick gRNA sequences. Second nick Disease Tissue Gene Mutation Template RNA gRNA Alpha-1 Liver SERP PIZ TCCCCTCCAGGCCGTGCATAGTTTT TTTGTT antitrypsin INA1 AGAGCTAGAAATAGCAAGTTAAAA GAACTT TAAGGCTAGTCCGTTATCAACTTGA GACCTC AAAAGTGGGACCGAGTCGGTCCTcG GG (SEQ TCGATGGTCAGCACAGCCTTATGCA ID NO: CGGCCTGGA (SEQ ID NO: 1607) 1608) Cystic Lung CFTR deltaF508 ACCATTAAAGAAAATATCATGTTTT AaagAT fibrosis AGAGCTAGAAATAGCAAGTTAAAA GATATT TAAGGCTAGTCCGTTATCAACTTGA TTCTTT AAAAGTGGGACCGAGTCGGTCCAC AA (SEQ CAaagATGATATTTTCTTTA (SEQ ID ID NO: NO: 1609) 1610) Sickle cell HSC HBB HbS GTAACGGCAGACTTCTCCACGTTTT TGGTGA AGAGCTAGAAATAGCAAGTTAAAA GGCCCT TAAGGCTAGTCCGTTATCAACTTGA GGGCA AAAAGTGGGACCGAGTCGGTCCGA GGT CTCCTGaGGAGAAGTCTGCC (SEQ ID (SEQ ID NO: 1611) NO: 1612) Wilson's Liver ATP7 H1069Q TTGGTGACTGCCACGCCCAAGTTTT GGCCA Disease B AGAGCTAGAAATAGCAAGTTAAAA GCAGT TAAGGCTAGTCCGTTATCAACTTGA GAACAc AAAAGTGGGACCGAGTCGGTCCAC CCCT AcCCCTTGGGCGTGGCAGTC (SEQ ID (SEQ ID NO: 1613) NO: 1614) ARVC Heart PKP2 235C>T ACTCAGGAACACTGCTGGTTGTTTT TTGGTT AGAGCTAGAAATAGCAAGTTAAAA GAAAA TAAGGCTAGTCCGTTATCAACTTGA TGATTT AAAAGTGGGACCGAGTCGGTCCTTC TGT ACtGAACCAGCAGTGTTCC (SEQ ID (SEQ ID NO: 1615) NO: 1616) Long QT Heart KCN P343S CCAGGGAAAACGCACCCACGGTTTT CTCCTT syndrome 1 Q1 AGAGCTAGAAATAGCAAGTTAAAA CTTTGC TAAGGCTAGTCCGTTATCAACTTGA GCTCcC AAAAGTGGGACCGAGTCGGTCCTCc AG (SEQ CAGCGGTAGGTGCCCCGTGGGTGC ID NO: GTTTTC (SEQ ID NO: 1617) 1618) Mucolipidosis CNS MCO 406-2A>G GCCCTCCCCTTCTCTGCCCAGTTTTA TCAGGC IV LN1 GAGCTAGAAATAGCAAGTTAAAAT AACGC AAGGCTAGTCCGTTATCAACTTGAA CAGGT AAAGTGGGACCGAGTCGGTCCGGT ACtG ACtGTGGGCAGAGAAGGGG (SEQ ID (SEQ ID NO: 1619) NO: 1620)

In some embodiments, the systems or methods provided herein use the template sequences listed in Table 35. Table 35 provides exemplary template RNA sequences (column 5) and optional second-nick gRNA sequences (column 6) designed to be paired with a Gene Writing polypeptide to correct the indicated pathogenic mutations (column 4). All the templates in Table 35 are meant to exemplify the total sequence of: (1) targeting gRNA for first strand nick, (2) polypeptide binding domain, (3) heterologous object sequence, and (4) target homology domain for setting up TPRT at first strand nick.

TABLE 35 Exemplary Gene Writing templates and second nick gRNA sequences for the correction of exemplary repeat expansion diseases. The region of the template spanning the repeat(s) is indicated in lowercase. Second Reference -nick Disease Gene Accession Repeat Location Template RNA gRNA myotonic DMPK NC_00019.10 CTG 3′ UTR CTCGAAGGGTC ATCA dystrophy (45769709 . . . CTTGTAGCCGTT CAGG 1 45782490, TTAGAGCTAGA ACTG complement) AATAGCAAGTT GAGC AAAATAAGGCT TGGG AGTCCGTTATCA (SEQ ACTTGAAAAAG ID NO: TGGGACCGAGT 1622) CGGTCCGTGAT CCCCCcagcagcagc agcagcagcagcagcag cagcagcagcagcagca gcagcagcagcagcag CATTCCCGGCTA CAAGGACCCT (SEQ ID NO: 1621) myotonic CNBP NC_00003.12 CCTG Intron 1 ACCACTGCACT GCCT dystrophy (129167827 . . . CCAGCCTAGGT CAGC 2 129183896, TTTAGAGCTAG CTCC complement) AAATAGCAAGT TGAG TAAAATAAGGC TAGC TAGTCCGTTATC (SEQ AACTTGAAAAA ID NO: GTGGGACCGAG 1624) TCGGTCCGTGTC TGTCTGTCTGTC TGTCTGTCTGTC TGTCTGTCTGTC TGcctgcctgcctgcctg cctgcctgcctgcctggct gcctgtctgcctgtctgcct gcctgcctgcctgcctgcc tgcctgTCTGTCTC ACTTTGTCCCCT AGGCTGGAGTG CA (SEQ ID NO: 1623) fragile X FMR1 NC_00023.11 CGG 5′ UTR GGGGGCGTGCG GCTC mental (147911919 . . . GCAGCGCGGGT AGAG retardation 147951127) TTTAGAGCTAG GCGG syndrome AAATAGCAAGT CCCT TAAAATAAGGC CCAC TAGTCCGTTATC (SEQ AACTTGAAAAA ID NO: GTGGGACCGAG 1626) TCGGTCCTGCG GGCGCTCGAGG CCCAGccgccgccgc cgccgccgccgccgccg cctccgccgccgccgcc gccgccgccgccgccg CGCTGCCGCAC G (SEQ ID NO: 1625) Friedreich's FXN NC_00009.12 GAA Intron CAGGCGCGCGA CGCT ataxia (69035752 . . . CACCACGCCGT TGAG 69079076) TTTAGAGCTAG CCCG AAATAGCAAGT GGAG TAAAATAAGGC GCAG TAGTCCGTTATC (SEQ AACTTGAAAAA ID NO: GTGGGACCGAG 1628) TCGGTCCAACC CAGTATCTACTA AAAAATACAAA AAAAAAAAAAA AAgaagaagaagaaga agaaAATAAAGA AAAGTTAGCCG GGCGTGGTGTC GCGC (SEQ ID NO: 1627) Huntington HTT NC_00004.12 CAG Coding GGCGGCTGAGG CGCT disease (3074681 . . . AAGCTGAGGGT GCAC 3243960) TTTAGAGCTAG CGAC AAATAGCAAGT CGTG TAAAATAAGGC AGTT TAGTCCGTTATC (SEQ AACTTGAAAAA ID NO: GTGGGACCGAG 1630) TCGGTCCAGTCC CTCAAGTCCTTC cagcagcagcagcagca gcagcagcagcagcage agcagcagcagcagcag cagcagcaacagccgcc accgccgccgccgccgc cgccgcctcctCAGCT TCCTCAG (SEQ ID NO: 1629) spinocerebellar ATXN NC_00006.12 CAG Coding TGAGCCCCGGA TCCA ataxia 1 (16299112 . . . GCCCTGCTGGTT GTTC 16761490, TTAGAGCTAGA TCCG complement) AATAGCAAGTT CAGA AAAATAAGGCT ACAC AGTCCGTTATCA (SEQ ACTTGAAAAAG ID NO: TGGGACCGAGT 1632) CGGTCCACAAG GCTGAGcagcagca gcagcagcagcagcagc agcagcagcagcatcag catcagcagcagcagca gcagcagcagcagcagc agcagcagcagCACC TCAGCAGGGCT CCGGG (SEQ ID NO: 1631)

Exemplary Heterologous Object Sequences

In some embodiments, the systems or methods provided herein comprise a heterologous object sequence, wherein the heterologous object sequence or a reverse complementary sequence thereof, encodes a protein (e.g., an antibody) or peptide. In some embodiments, the therapy is one approved by a regulatory agency such as FDA.

In some embodiments, the protein or peptide is a protein or peptide from the THPdb database (Usmani et al. PLoS One 12(7):e0181748 (2017), herein incorporated by reference in its entirety. In some embodiments, the protein or peptide is a protein or peptide disclosed in Table 28. In some embodiments, the systems or methods disclosed herein, for example, those comprising Gene Writers, may be used to integrate an expression cassette for a protein or peptide from Table 28 into a host cell to enable the expression of the protein or peptide in the host. In some embodiments, the sequences of the protein or peptide in the first column of Table 28 can be found in the patents or applications provided in the third column of Table 28, incorporated by reference in their entireties.

In some embodiments, the protein or peptide is an antibody disclosed in Table 1 of Lu et al. J Biomed Sci 27(1):1 (2020), herein incorporated by reference in its entirety. In some embodiments, the protein or peptide is an antibody disclosed in Table 29. In some embodiments, the systems or methods disclosed herein, for example, those comprising Gene Writers, may be used to integrate an expression cassette for an antibody from Table 29 into a host cell to enable the expression of the antibody in the host. In some embodiments, a system or method described herein is used to express an agent that binds a target of column 2 of Table 29 (e.g., a monoclonal antibody of column 1 of Table 29) in a subject having an indication of column 3 of Table 29.

TABLE 28 Exemplary protein and peptide therapeutics. Therapeutic peptide Category Patent Number Lepirudin Antithrombins and Fibrinolytic CA1339104 Agents Cetuximab Antineoplastic Agents CA1340417 Dor se alpha Enzymes CA2184581 Denileukin diftitox Antineoplastic Agents Etanercept Immunosuppressive Agents CA2476934 Bivalirudin Antithrombins U.S. Pat. No. 7,582,727 Leuprolide Antineoplastic Agents Peginterferon alpha-2a Immunosuppressive Agents CA2203480 Alteplase Thrombolytic Agents Interferon alpha-n1 Antiviral Agents Darbepoetin alpha Anti-anemic Agents CA2165694 Reteplase Fibrinolytic Agents CA2107476 Epoetin alpha Hematinics CA1339047 Salmon Calcitonin Bone Density Conservation U.S. Pat. No. 6,440,392 Agents Interferon alpha-n3 Immunosuppressive Agents Pegfilgrastim Immunosuppressive Agents CA1341537 Sargramostim Immunosuppressive Agents CA1341150 Secretin Diagnostic Agents Peginterferon alpha-2b Immunosuppressive Agents CA1341567 Asparagi se Antineoplastic Agents Thyrotropin alpha Diagnostic Agents U.S. Pat. No. 5,840,566 Antihemophilic Factor Coagulants and Thrombotic agents CA2124690 A kinra Antirheumatic Agents CA2141953 Gramicidin D Anti-Bacterial Agents Intravenous Immunologic Factors Immunoglobulin Anistreplase Fibrinolytic Agents Insulin Regular Antidiabetic Agents Tenecteplase Fibrinolytic Agents CA2129660 Menotropins Fertility Agents Interferon gamma-1b Immunosuppressive Agents U.S. Pat. No. 6,936,695 Interferon alpha-2a, CA2172664 Recombi nt Coagulation factor Vila Coagulants Oprelvekin Antineoplastic Agents Palifermin Anti-Mucositis Agents Glucagon recombi nt Hypoglycemic Agents Aldesleukin Antineoplastic Agents Botulinum Toxin Type B Antidystonic Agents Omalizumab Anti-Allergic Agents CA2113813 Lutropin alpha Fertility Agents U.S. Pat. No. 5,767,251 Insulin Lispro Hypoglycemic Agents U.S. Pat. No. 5,474,978 Insulin Glargine Hypoglycemic Agents U.S. Pat. No. 7,476,652 Collage se Rasburicase Gout Suppressants CA2175971 Adalimumab Antirheumatic Agents CA2243459 Imiglucerase Enzyme Replacement Agents U.S. Pat. No. 5,549,892 Abciximab Anticoagulants CA1341357 Alpha-1-protei se inhibitor Serine Protei se Inhibitors Pegaspargase Antineoplastic Agents Interferon beta-1a Antineoplastic Agents CA1341604 Pegademase bovine Enzyme Replacement Agents Human Serum Albumin Serum substitutes U.S. Pat. No. 6,723,303 Eptifibatide Platelet Aggregation Inhibitors U.S. Pat. No. 6,706,681 Serum albumin iodo ted Diagnostic Agents Infliximab Antirheumatic Agents, Anti- CA2106299 Inflammatory Agents, Non- Steroidal, Dermatologic Agents, Gastrointesti 1 Agents and Immunosuppressive Agents Follitropin beta Fertility Agents U.S. Pat. No. 7,741,268 Vasopressin Anti diuretic Agents Interferon beta-1b Adjuvants, Immunologic and CA1340861 Immunosuppressive Agents Interferon alphacon-1 Antiviral Agents and CA1341567 Immunosuppressive Agents Hyaluronidase Adjuvants, Anesthesia and Permeabilizing Agents Insulin, porcine Hypoglycemic Agents Trastuzumab Antineoplastic Agents CA2103059 Rituximab Antineoplastic Agents, CA2149329 Immunologic Factors and Antirheumatic Agents Basiliximab Immunosuppressive Agents CA2038279 Muromo b Immunologic Factors and Immunosuppressive Agents Digoxin Immune Fab Antidotes (Ovine) Ibritumomab CA2149329 Daptomycin U.S. Pat. No. 6,468,967 Tositumomab Pegvisomant Hormone Replacement Agents U.S. Pat. No. 5,849,535 Botulinum Toxin Type A Neuromuscular Blocking Agents, CA2280565 Anti-Wrinkle Agents and Anti dystonic Agents Pancrelipase Gastrointesti 1 Agents and Enzyme Replacement Agents Streptoki se Fibrinolytic Agents and Thrombolytic Agents Alemtuzumab CA1339198 Alglucerase Enzyme Replacement Agents Capromab Indicators, Reagents and Diagnostic Agents Laronidase Enzyme Replacement Agents Urofollitropin Fertility Agents U.S. Pat. No. 5,767,067 Efalizumab Immunosuppressive Agents Serum albumin Serum substitutes U.S. Pat. No. 6,723,303 Choriogo dotropin alpha Fertility Agents and Go dotropins U.S. Pat. No. 6,706,681 Antithymocyte globulin Immunologic Factors and Immunosuppressive Agents Filgrastim Immunosuppressive Agents, CA1341537 Antineutropenic Agents and Hematopoietic Agents Coagulation factor ix Coagulants and Thrombotic Agents Becaplermin Angiogenesis Inducing Agents CA1340846 Agalsidase beta Enzyme Replacement Agents CA2265464 Interferon alpha-2b Immunosuppressive Agents CA1341567 Oxytocin Oxytocics, Anti-tocolytic Agents and Labor Induction Agents Enfuvirtide HIV Fusion Inhibitors U.S. Pat. No. 6,475,491 Palivizumab Antiviral Agents CA2197684 Daclizumab Immunosuppressive Agents Bevacizumab Angiogenesis Inhibitors CA2286330 Arcitumomab Diagnostic Agents U.S. Pat. No. 8,420,081 Arcitumomab Diagnostic Agents U.S. Pat. No. 7,790,142 Eculizumab CA2189015 Panitumumab Ranibizumab Ophthalmics CA2286330 Idursulfase Enzyme Replacement Agents Alglucosidase alpha Enzyme Replacement Agents CA2416492 Exe tide Hypoglycemic Agents U.S. Pat. No. 6,872,700 Mecasermin U.S. Pat. No. 5,681,814 Pramlintide U.S. Pat. No. 5,686,411 Galsulfase Enzyme Replacement Agents Abatacept Antirheumatic Agents and CA2110518 Immunosuppressive Agents Cosyntropin Hormones and Diagnostic Agents Corticotropin Insulin aspart Hypoglycemic Agents and U.S. Pat. No. 5,866,538 Antidiabetic Agents Insulin detemir Antidiabetic Agents U.S. Pat. No. 5,750,497 Insulin glulisine Antidiabetic Agents U.S. Pat. No. 6,960,561 Pegaptanib Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Nesiritide Thymalphasin Defibrotide Antithrombins tural alpha interferon OR multiferon Glatiramer acetate Preotact Teicoplanin Anti-Bacterial Agents Ca kinumab Anti-Inflammatory Agents and Monoclo 1 antibodies Ipilimumab Antineoplastic Agents and CA2381770 Monoclo 1 antibodies Sulodexide Antithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents Tocilizumab CA2201781 Teriparatide Bone Density Conservation US6977077 Agents Pertuzumab Monoclo 1 antibodies CA2376596 Rilo cept Immunosuppressive Agents U.S. Pat. No. 5,844,099 Denosumab Bone Density Conservation CA2257247 Agents and Monoclo 1 antibodies Liraglutide U.S. Pat. No. 6,268,343 Golimumab Antipsoriatic Agents and Monoclo 1 antibodies and TNF inhibitor Belatacept Antirheumatic Agents and Immunosuppressive Agents Buserelin Velaglucerase alpha Enzymes U.S. Pat. No. 7,138,262 Tesamorelin U.S. Pat. No. 5,861,379 Brentuximab vedotin Taliglucerase alpha Enzymes Belimumab Monoclo 1 antibodies Aflibercept Antineoplastic Agents and U.S. Pat. No. 7,306,799 Ophthalmics Asparagi se erwinia Enzymes chrysanthemi Ocriplasmin Ophthalmics Glucarpidase Enzymes Teduglutide U.S. Pat. No. 5,789,379 Raxibacumab Anti-Infective Agents and Monoclo 1 antibodies Certolizumab pegol TNF inhibitor CA2380298 Insulin,isophane Hypoglycemic Agents and Antidiabetic Agents Epoetin zeta Obinutuzumab Antineoplastic Agents Fibrinolysin aka plasmin U.S. Pat. No. 3,234,106 Follitropin alpha Romiplostim Colony-Stimulating Factors and Thrombopoietic Agents Luci ctant Pulmo ry surfactants U.S. Pat. No. 5,407,914 talizumab Immunosuppressive agents Aliskiren Renin inhibitor Ragweed Pollen Extract Secukinumab Inhibitor US20130202610 Somatotropin Recombi nt Hormone Replacement Agents CA1326439 Drotrecogin alpha Antisepsis CA2036894 Alefacept Dermatologic and Immunosupressive agents OspA lipoprotein Vaccines Uroki se U.S. Pat. No. 4,258,030 Abarelix Anti-Testosterone Agents U.S. Pat. No. 5,968,895 Sermorelin Hormone Replacement Agents Aprotinin U.S. Pat. No. 5,198,534 Gemtuzumab ozogamicin Antineoplastic agents and U.S. Pat. No. 5,585,089 Immunotoxins Satumomab Pendetide Diagnostic Agents Albiglutide Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. Alirocumab Ancestim Antithrombin alpha Antithrombin III human Asfotase alpha Enzymes Alimentary Tract and Metabolism Atezolizumab Autologous cultured chondrocytes B er actant Bli tumomab Antineoplastic Agents US20120328618 Immunosuppressive Agents Monoclo 1 antibodies Antineoplastic and Immunomodulating Agents Cl Esterase Inhibitor (Human) Coagulation Factor XIIIA- Subunit (Recombi nt) Conestat alpha Daratumumab Antineoplastic Agents Desirudin Dulaglutide Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins Elosulfase alpha Enzymes; Alimentary Tract and Metabolism Elotuzumab US2014055370 Evolocumab Lipid Modifying Agents, Plain; Cardiovascular System Fibrinogen Concentrate (Human) Filgrastim-sndz Gastric intrinsic factor Hepatitis B immune globulin Human calcitonin Human Clostridium tetani toxoid immune globulin Human rabies virus immune globulin Human Rho(D) immune globulin Hyaluronidase (Human U.S. Pat. No. 7,767,429 Recombi nt) Idarucizumab Anticoagulant Immune Globulin Human Immunologic Factors; Immunosuppressive Agents; Anti- Infective Agents Vedolizumab Immunosupressive agent, US2012151248 Antineoplastic agent Ustekinumab Deramtologic agent, Immunosuppressive agent, antineoplastic agent Turoctocog alpha Tuberculin Purified Protein Derivative Simoctocog alpha Antihaemorrhagics: blood coagulation factor VIII Siltuximab Antineoplastic and U.S. Pat. No. 7,612,182 Immunomodulating Agents, Immunosuppressive Agents Sebelipase alpha Enzymes Sacrosidase Enzymes Ramucirumab Antineoplastic and US2013067098 Immunomodulating Agents Prothrombin complex concentrate Poractant alpha Pulmo ry Surfactants Pembrolizumab Antineoplastic and US2012135408 Immunomodulating Agents Peginterferon beta-la Ofatumumab Antineoplastic and U.S. Pat. No. 8,337,847 Immunomodulating Agents Obiltoxaximab Nivolumab Antineoplastic and US2013173223 Immunomodulating Agents Necitumumab Metreleptin US20070099836 Methoxy polyethylene glycol-epoetin beta Mepolizumab Antineoplastic and US2008134721 Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors Ixekizumab Insulin Pork Hypoglycemic Agents, Antidiabetic Agents Insulin Degludec Insulin Beef Thyroglobulin Hormone therapy U.S. Pat. No. 5,099,001 Anthrax immune globulin Plasma derivative human Anti-inhibitor coagulant Blood Coagulation Factors, complex Antihemophilic Agent Anti-thymocyte Globulin Antibody (Equine) Anti-thymocyte Globulin Antibody (Rabbit) Brodalumab Antineoplastic and Immunomodulating Agents C1 Esterase Inhibitor Blood and Blood Forming Organs (Recombi nt) Ca kinumab Antineoplastic and Immunomodulating Agents Chorionic Go dotropin Hormones U.S. Pat. No. 6,706,681 (Human) Chorionic Go dotropin Hormones U.S. Pat. No. 5,767,251 (Recombi nt) Coagulation factor X Blood Coagulation Factors human Dinutuximab Antibody, Immunosuppresive US20140170155 agent, Antineoplastic agent Efmoroctocog alpha Antihemophilic Factor Factor IX Complex Antihemophilic agent (Human) Hepatitis A Vaccine Vaccine Human Varicella-Zoster Antibody Immune Globulin Ibritumomab tiuxetan Antibody, Immunosuppressive CA2149329 Agents Lenograstim Antineoplastic and Immunomodulating Agents Pegloticase Enzymes Protamine sulfate Heparin Antagonists, Hematologic Agents Protein S human Anticoagulant plasma protein Sipuleucel-T Antineoplastic and U.S. Pat. No. 8,153,120 Immunomodulating Agents Somatropin recombi nt Hormones, Hormone Substitutes, CA1326439, CA2252535, and Hormone Antagonists U.S. Pat. No. 5,288,703, U.S. Pat. No. 5,849,700, U.S. Pat. No. 5,849,704, U.S. Pat. No. 5,898,030, U.S. Pat. No. 6,004,297, U.S. Pat. No. 6,152,897, U.S. Pat. No. 6,235,004, U.S. Pat. No. 6,899,699 Susoctocog alpha Blood coagulation factors, Antihaemorrhagics Thrombomodulin alpha Anticoagulant agent, Antiplatelet agent

TABLE 29 Exemplary monoclonal antibody therapies. mAb Target Indication Muromonab-CD3 CD3 Kidney transplant rejection Abciximab GPIIb/IIIa Prevention of blood dots in angioplasty Rituximab CD20 Non-Hodgkin lymphoma Palivizumab RSV Prevention of respiratory syncytial virus infection Infliximab TNFα Crohn's disease Trastuzumab HER2 Breast cancer Alemtuzumab CD52 Chronic myeloid leukemia Adalimumab TNFα Rheumatoid arthritis Ibritumomab CD20 Non-Hodgkin lymphoma tiuxetan Omalizumab IgE Asthma Cetuximab EGER Colorectal cancer Bevacizumab VEGF-A Colorectal cancer Natalizumab ITGA4 Multiple sclerosis Panitumumab EGFR Colorectal cancer Ranibizumab VEGF-A Macular degeneration Eculizumab C5 Paroxysmal nocturnal hemoglobinuria Certolizumab TNFα Crohn's disease pegol Ustekinumab IL-12/23 Psoriasis Canakinumab IL-1β Muckle-Wells syndrome Golimumab TNFα Rheumatoid and psoriatic arthritis, ankylosing spondylitis Ofatumumab CD20 Chronic lymphocytic leukemia Tocilizumab IL-6R Rheumatoid arthritis Denosumab RANKE Bone loss Belimumab BLyS Systemic lupus erythematosus Ipilimumab CTLA-4 Metastatic melanoma Brentuximab CD30 Hodgkin lymphoma, systemic anaplastic large vedotin cell lymphoma Pertuzumab HER2 Breast Cancer Trastuzumab HER2 Breast cancer emtansine Raxibacumab B. anthrasis PA Anthrax infection Obinutuzumab CD20 Chronic lymphocytic leukemia Siltuximab IL-6 Castleman disease Ramucirumab VEGFR2 Gastric cancer Vedolizumab α4β7 integrin Ulcerative colitis, Crohn disease Blinatumomab CD19, CD3 Acute lymphoblastic leukemia Nivolumab PD-1 Melanoma, non-small cell lung cancer Pembrolizumab PD-1 Melanoma Idarucizumab Dabigatran Reversal of dabigatran-induced anticoagulation Necitumumab EGFR Non-small cell lung cancer Dinutuximab GD2 Neuroblastoma Secukinumab IL-17α Psoriasis Mepolizumab IL-5 Severe eosinophilic asthma Alirocurnab PCSK9 High cholesterol Evoloeumab PCSK9 High cholesterol Daratumumab CD38 Multiple myeloma Elotuzumab SLAMF7 Muitiple myeloma Ixekizumab IL-17α Psoriasis Reslizumab IL-5 Asthma Olaratumab PDGFRα Soft tissue sarcoma Bezlotoxumab Clostridium Prevention of Clostridium difficile infection difficile enterotoxin B recurrence Atezoiizumab PD-L1 Bladder cancer Obiltoxaximab B. anthrasis PA Prevention of inhalational anthrax Inotuzumab CD22 Acute lymphoblastic leukemia ozogamicin Brodalumab IL-17R Plaque psoriasis Guselkumab IL-23 p19 Plaque psoriasis Dupilumab IL-4Rα Atopic dermatitis Sarilumab IL-6R Rheumatoid arthritis Avelumab PD-L1 Merkel cell carcinoma Ocrelizumab CD20 Multiple sclerosis Emicizumab Factor IXa, X Hemophilia A Benralizumab IL-5Rα Asthma Gemtuzumab CD33 Acute myeloid leukemia ozogamicin Durvalumab PD-L1 Bladder cancer Burosumab FGF23 X-linked hypophosphatemia Lanadelumab Plasma kallikrein Hereditary angioedema attacks Mogamulizumab CCR4 Mycosis fungoides or Sézary syndrome Erenumab CGRPR Migraine prevention Galcanezumab CGRP Migraine prevention Tildrakizumab IL-23 p19 Plaque psoriasis Cemiplimab PD-1 Cutaneous squamous cell carcinoma Emapalumab IFNγ Primary hemophagocytic lymphohistiocytosis Fremanezumab CGRP Migraine prevention Ibalizumab CD4 HIV infection Moxetumomab CD22 Hairy cell leukemia pasudodox Ravulizuniab C5 Paroxysmal nocturnal hemoglobinuria Caplacizumab von Willebrand factor Acquired thrombotic thrombocytopenic purpura Romosozurnab Sclerostin Osteoporosis in postmenopausal women at increased risk of fracture Risankizumab IL-23 p19 Plaque psoriasis Polatuzumab CD79P Diffuse large B-cell lymphoma vedotin Brolucizumab VEGF-A Macular degeneration Crizanlizumab P-selectin Sickle cell disease

Plant-Modification Methods

Gene Writer systems described herein may be used to modify a plant or a plant part (e.g., leaves, roots, flowers, fruits, or seeds), e.g., to increase the fitness of a plant.

A. Delivery to a Plant

Provided herein are methods of delivering a Gene Writer system described herein to a plant. Included are methods for delivering a Gene Writer system to a plant by contacting the plant, or part thereof, with a Gene Writer system. The methods are useful for modifying the plant to, e.g., increase the fitness of a plant.

More specifically, in some embodiments, a nucleic acid described herein (e.g., a nucleic acid encoding a GeneWriter) may be encoded in a vector, e.g., inserted adjacent to a plant promoter, e.g., a maize ubiquitin promoter (ZmUBI) in a plant vector (e.g., pHUC411). In some embodiments, the nucleic acids described herein are introduced into a plant (e.g., japonica rice) or part of a plant (e.g., a callus of a plant) via agrobacteria. In some embodiments, the systems and methods described herein can be used in plants by replacing a plant gene (e.g., hygromycin phosphotransferase (HPT)) with a null allele (e.g., containing a base substitution at the start codon). Systems and methods for modifying a plant genome are described in Xu et. al. Development of plant prime editing systems for precise genome editing, 2020, Plant Communications.

In one aspect, provided herein is a method of increasing the fitness of a plant, the method including delivering to the plant the Gene Writer system described herein (e.g., in an effective amount and duration) to increase the fitness of the plant relative to an untreated plant (e.g., a plant that has not been delivered the Gene Writer system).

An increase in the fitness of the plant as a consequence of delivery of a Gene Writer system can manifest in a number of ways, e.g., thereby resulting in a better production of the plant, for example, an improved yield, improved vigor of the plant or quality of the harvested product from the plant, an improvement in pre- or post-harvest traits deemed desirable for agriculture or horticulture (e.g., taste, appearance, shelf life), or for an improvement of traits that otherwise benefit humans (e.g., decreased allergen production). An improved yield of a plant relates to an increase in the yield of a product (e.g., as measured by plant biomass, grain, seed or fruit yield, protein content, carbohydrate or oil content or leaf area) of the plant by a measurable amount over the yield of the same product of the plant produced under the same conditions, but without the application of the instant compositions or compared with application of conventional plant-modifying agents. For example, yield can be increased by at least about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or more than 100%. In some instances, the method is effective to increase yield by about 2×-fold, 5×-fold, 10×-fold, 25×-fold, 50×-fold, 75×-fold, 100×-fold, or more than 100×-fold relative to an untreated plant. Yield can be expressed in terms of an amount by weight or volume of the plant or a product of the plant on some basis. The basis can be expressed in terms of time, growing area, weight of plants produced, or amount of a raw material used. For example, such methods may increase the yield of plant tissues including, but not limited to: seeds, fruits, kernels, bolls, tubers, roots, and leaves.

An increase in the fitness of a plant as a consequence of delivery of a Gene Writer system can also be measured by other means, such as an increase or improvement of the vigor rating, the stand (the number of plants per unit of area), plant height, stalk circumference, stalk length, leaf number, leaf size, plant canopy, visual appearance (such as greener leaf color), root rating, emergence, protein content, increased tillering, bigger leaves, more leaves, less dead basal leaves, stronger tillers, less fertilizer needed, less seeds needed, more productive tillers, earlier flowering, early grain or seed maturity, less plant verse (lodging), increased shoot growth, earlier germination, or any combination of these factors, by a measurable or noticeable amount over the same factor of the plant produced under the same conditions, but without the administration of the instant compositions or with application of conventional plant-modifying agents.

Accordingly, provided herein is a method of modifying a plant, the method including delivering to the plant an effective amount of any of the Gene Writer systems provided herein, wherein the method modifies the plant and thereby introduces or increases a beneficial trait in the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant. In particular, the method may increase the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In some instances, the increase in plant fitness is an increase (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) in disease resistance, drought tolerance, heat tolerance, cold tolerance, salt tolerance, metal tolerance, herbicide tolerance, chemical tolerance, water use efficiency, nitrogen utilization, resistance to nitrogen stress, nitrogen fixation, pest resistance, herbivore resistance, pathogen resistance, yield, yield under water-limited conditions, vigor, growth, photosynthetic capability, nutrition, protein content, carbohydrate content, oil content, biomass, shoot length, root length, root architecture, seed weight, or amount of harvestable produce.

In some instances, the increase in fitness is an increase (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) in development, growth, yield, resistance to abiotic stressors, or resistance to biotic stressors. An abiotic stress refers to an environmental stress condition that a plant or a plant part is subjected to that includes, e.g., drought stress, salt stress, heat stress, cold stress, and low nutrient stress. A biotic stress refers to an environmental stress condition that a plant or plant part is subjected to that includes, e.g. nematode stress, insect herbivory stress, fungal pathogen stress, bacterial pathogen stress, or viral pathogen stress. The stress may be temporary, e.g. several hours, several days, several months, or permanent, e.g. for the life of the plant.

In some instances, the increase in plant fitness is an increase (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) in quality of products harvested from the plant. For example, the increase in plant fitness may be an improvement in commercially favorable features (e.g., taste or appearance) of a product harvested from the plant. In other instances, the increase in plant fitness is an increase in shelf-life of a product harvested from the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%).

Alternatively, the increase in fitness may be an alteration of a trait that is beneficial to human or animal health, such as a reduction in allergen production. For example, the increase in fitness may be a decrease (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) in production of an allergen (e.g., pollen) that stimulates an immune response in an animal (e.g., human).

The modification of the plant (e.g., increase in fitness) may arise from modification of one or more plant parts. For example, the plant can be modified by contacting leaf, seed, pollen, root, fruit, shoot, flower, cells, protoplasts, or tissue (e.g., meristematic tissue) of the plant. As such, in another aspect, provided herein is a method of increasing the fitness of a plant, the method including contacting pollen of the plant with an effective amount of any of the plant-modifying compositions herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In yet another aspect, provided herein is a method of increasing the fitness of a plant, the method including contacting a seed of the plant with an effective amount of any of the Gene Writer systems disclosed herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In another aspect, provided herein is a method including contacting a protoplast of the plant with an effective amount of any of the Gene Writer systems described herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In a further aspect, provided herein is a method of increasing the fitness of a plant, the method including contacting a plant cell of the plant with an effective amount of any of the Gene Writer system described herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In another aspect, provided herein is a method of increasing the fitness of a plant, the method including contacting meristematic tissue of the plant with an effective amount of any of the plant-modifying compositions herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

In another aspect, provided herein is a method of increasing the fitness of a plant, the method including contacting an embryo of the plant with an effective amount of any of the plant-modifying compositions herein, wherein the method increases the fitness of the plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%) relative to an untreated plant.

B. Application Methods

A plant described herein can be exposed to any of the Gene Writer system compositions described herein in any suitable manner that permits delivering or administering the composition to the plant. The Gene Writer system may be delivered either alone or in combination with other active (e.g., fertilizing agents) or inactive substances and may be applied by, for example, spraying, injection (e.g., microinjection), through plants, pouring, dipping, in the form of concentrated liquids, gels, solutions, suspensions, sprays, powders, pellets, briquettes, bricks and the like, formulated to deliver an effective concentration of the plant-modifying composition. Amounts and locations for application of the compositions described herein are generally determined by the habitat of the plant, the lifecycle stage at which the plant can be targeted by the plant-modifying composition, the site where the application is to be made, and the physical and functional characteristics of the plant-modifying composition.

In some instances, the composition is sprayed directly onto a plant, e.g., crops, by e.g., backpack spraying, aerial spraying, crop spraying/dusting etc. In instances where the Gene Writer system is delivered to a plant, the plant receiving the Gene Writer system may be at any stage of plant growth. For example, formulated plant-modifying compositions can be applied as a seed-coating or root treatment in early stages of plant growth or as a total plant treatment at later stages of the crop cycle. In some instances, the plant-modifying composition may be applied as a topical agent to a plant.

Further, the Gene Writer system may be applied (e.g., in the soil in which a plant grows, or in the water that is used to water the plant) as a systemic agent that is absorbed and distributed through the tissues of a plant. In some instances, plants or food organisms may be genetically transformed to express the Gene Writer system.

Delayed or continuous release can also be accomplished by coating the Gene Writer system or a composition with the plant-modifying composition(s) with a dissolvable or bioerodable coating layer, such as gelatin, which coating dissolves or erodes in the environment of use, to then make the plant-modifying com Gene Writer system position available, or by dispersing the agent in a dissolvable or erodable matrix. Such continuous release and/or dispensing means devices may be advantageously employed to consistently maintain an effective concentration of one or more of the plant-modifying compositions described herein.

In some instances, the Gene Writer system is delivered to a part of the plant, e.g., a leaf, seed, pollen, root, fruit, shoot, or flower, or a tissue, cell, or protoplast thereof. In some instances, the Gene Writer system is delivered to a cell of the plant. In some instances, the Gene Writer system is delivered to a protoplast of the plant. In some instances, the Gene Writer system is delivered to a tissue of the plant. For example, the composition may be delivered to meristematic tissue of the plant (e.g., apical meristem, lateral meristem, or intercalary meristem). In some instances, the composition is delivered to permanent tissue of the plant (e.g., simple tissues (e.g., parenchyma, collenchyma, or sclerenchyma) or complex permanent tissue (e.g., xylem or phloem)). In some instances, the Gene Writer system is delivered to a plant embryo.

C. Plants

A variety of plants can be delivered to or treated with a Gene Writer system described herein. Plants that can be delivered a Gene Writer system (i.e., “treated”) in accordance with the present methods include whole plants and parts thereof, including, but not limited to, shoot vegetative organs/structures (e.g., leaves, stems and tubers), roots, flowers and floral organs/structures (e.g., bracts, sepals, petals, stamens, carpels, anthers and ovules), seed (including embryo, endosperm, cotyledons, and seed coat) and fruit (the mature ovary), plant tissue (e.g., vascular tissue, ground tissue, and the like) and cells (e.g., guard cells, egg cells, and the like), and progeny of same. Plant parts can further refer parts of the plant such as the shoot, root, stem, seeds, stipules, leaves, petals, flowers, ovules, bracts, branches, petioles, internodes, bark, pubescence, tillers, rhizomes, fronds, blades, pollen, stamen, and the like.

The class of plants that can be treated in a method disclosed herein includes the class of higher and lower plants, including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns, horsetails, psilophytes, lycophytes, bryophytes, and algae (e.g., multicellular or unicellular algae). Plants that can be treated in accordance with the present methods further include any vascular plant, for example monocotyledons or dicotyledons or gymnosperms, including, but not limited to alfalfa, apple, Arabidopsis, banana, barley, canola, castor bean, chrysanthemum, clover, cocoa, coffee, cotton, cottonseed, corn, crambe, cranberry, cucumber, dendrobium, dioscorea, eucalyptus, fescue, flax, gladiolus, liliacea, linseed, millet, muskmelon, mustard, oat, oil palm, oilseed rape, papaya, peanut, pineapple, ornamental plants, Phaseolus, potato, rapeseed, rice, rye, ryegrass, safflower, sesame, sorghum, soybean, sugarbeet, sugarcane, sunflower, strawberry, tobacco, tomato, turfgrass, wheat and vegetable crops such as lettuce, celery, broccoli, cauliflower, cucurbits; fruit and nut trees, such as apple, pear, peach, orange, grapefruit, lemon, lime, almond, pecan, walnut, hazel; vines, such as grapes (e.g., a vineyard), kiwi, hops; fruit shrubs and brambles, such as raspberry, blackberry, gooseberry; forest trees, such as ash, pine, fir, maple, oak, chestnut, popular; with alfalfa, canola, castor bean, corn, cotton, crambe, flax, linseed, mustard, oil palm, oilseed rape, peanut, potato, rice, safflower, sesame, soybean, sugarbeet, sunflower, tobacco, tomato, and wheat. Plants that can be treated in accordance with the methods of the present invention include any crop plant, for example, forage crop, oilseed crop, grain crop, fruit crop, vegetable crop, fiber crop, spice crop, nut crop, turf crop, sugar crop, beverage crop, and forest crop. In certain instances, the crop plant that is treated in the method is a soybean plant. In other certain instances, the crop plant is wheat. In certain instances, the crop plant is corn. In certain instances, the crop plant is cotton. In certain instances, the crop plant is alfalfa. In certain instances, the crop plant is sugarbeet. In certain instances, the crop plant is rice. In certain instances, the crop plant is potato. In certain instances, the crop plant is tomato.

In certain instances, the plant is a crop. Examples of such crop plants include, but are not limited to, monocotyledonous and dicotyledonous plants including, but not limited to, fodder or forage legumes, ornamental plants, food crops, trees, or shrubs selected from Acer spp., Allium spp., Amaranthus spp., Ananas comosus, Apium graveolens, Arachis spp, Asparagus officinalis, Beta vulgaris, Brassica spp. (e.g., Brassica napus, Brassica rapa ssp. (canola, oilseed rape, turnip rape), Camellia sinensis, Canna indica, Cannabis saliva, Capsicum spp., Castanea spp., Cichorium endivia, Citrullus lanatus, Citrus spp., Cocos spp., Coffea spp., Coriandrum sativum, Corylus spp., Crataegus spp., Cucurbita spp., Cucumis spp., Daucus carota, Fagus spp., Ficus carica, Fragaria spp., Ginkgo biloba, Glycine spp. (e.g., Glycine max, Soja hispida or Soja max), Gossypium hirsutum, Helianthus spp. (e.g., Helianthus annuus), Hibiscus spp., Hordeum spp. (e.g., Hordeum vulgare), Ipomoea batatas, Juglans spp., Lactuca sativa, Linum usitatissimum, Litchi chinensis, Lotus spp., Luffa acutangula, Lupinus spp., Lycopersicon spp. (e.g., Lycopersicon esculenturn, Lycopersicon lycopersicum, Lycopersicon pyriforme), Malus spp., Medicago sativa, Mentha spp., Miscanthus sinensis, Morus nigra, Musa spp., Nicotiana spp., Olea spp., Oryza spp. (e.g., Oryza sativa, Oryza latifolia), Panicum miliaceum, Panicum virgatum, Passiflora edulis, Petroselinum crispum, Phaseolus spp., Pinus spp., Pistacia vera, Pisum spp., Poa spp., Populus spp., Prunus spp., Pyrus communis, Quercus spp., Raphanus sativus, Rheum rhabarbarum, Ribes spp., Ricinus communis, Rubus spp., Saccharum spp., Salix sp., Sambucus spp., Secale cereale, Sesamum spp., Sinapis spp., Solanum spp. (e.g., Solanum tuberosum, Solanum integrifolium or Solanum lycopersicum), Sorghum bicolor, Sorghum halepense, Spinacia spp., Tamarindus indica, Theobroma cacao, Trifolium spp., Triticosecale rimpaui, Triticum spp. (e.g., Triticum aestivum, Triticum durum, Triticum turgidum, Triticum hybernum, Triticum macha, Triticum sativum or Triticum vulgare), Vaccinium spp., Vicia spp., Vigna spp., Viola odorata, Vitis spp., and Zea mays. In certain embodiments, the crop plant is rice, oilseed rape, canola, soybean, corn (maize), cotton, sugarcane, alfalfa, sorghum, or wheat.

The plant or plant part for use in the present invention include plants of any stage of plant development. In certain instances, the delivery can occur during the stages of germination, seedling growth, vegetative growth, and reproductive growth. In certain instances, delivery to the plant occurs during vegetative and reproductive growth stages. In some instances, the composition is delivered to pollen of the plant. In some instances, the composition is delivered to a seed of the plant. In some instances, the composition is delivered to a protoplast of the plant. In some instances, the composition is delivered to a tissue of the plant. For example, the composition may be delivered to meristematic tissue of the plant (e.g., apical meristem, lateral meristem, or intercalary meristem). In some instances, the composition is delivered to permanent tissue of the plant (e.g., simple tissues (e.g., parenchyma, collenchyma, or sclerenchyma) or complex permanent tissue (e.g., xylem or phloem)). In some instances, the composition is delivered to a plant embryo. In some instances, the composition is delivered to a plant cell. The stages of vegetative and reproductive growth are also referred to herein as “adult” or “mature” plants.

In instances where the Gene Writer system is delivered to a plant part, the plant part may be modified by the plant-modifying agent. Alternatively, the Gene Writer system may be distributed to other parts of the plant (e.g., by the plant's circulatory system) that are subsequently modified by the plant-modifying agent.

Administration

The composition and systems described herein may be used in vitro or in vivo. In some embodiments the system or components of the system are delivered to cells (e.g., mammalian cells, e.g., human cells), e.g., in vitro or in vivo. In some embodiments, the cells are eukaryotic cells, e.g., cells of a multicellular organism, e.g., an animal, e.g., a mammal (e.g., human, swine, bovine) a bird (e.g., poultry, such as chicken, turkey, or duck), or a fish. In some embodiments, the cells are non-human animal cells (e.g., a laboratory animal, a livestock animal, or a companion animal). In some embodiments, the cell is a stem cell (e.g., a hematopoietic stem cell), a fibroblast, or a T cell. In some embodiments, the cell is a non-dividing cell, e.g., a non-dividing fibroblast or non-dividing T cell. In some embodiments, the cell is an HSC and p53 is not upregulated or is upregulated by less than 10%, 5%, 2%, or 1%, e.g., as determined according to the method described in Example 30 of PCT/US2019/048607 which is hereby incorporated by reference. The skilled artisan will understand that the components of the Gene Writer™ system may be delivered in the form of polypeptide, nucleic acid (e.g., DNA, RNA), and combinations thereof.

For instance, delivery can use any of the following combinations for delivering the retrotransposase (e.g., as DNA encoding the retrotransposase protein, as RNA encoding the retrotransposase protein, or as the protein itself) and the template RNA (e.g., as DNA encoding the RNA, or as RNA):

-   -   1. Retrotransposase DNA+template DNA     -   2. Retrotransposase RNA+template DNA     -   3. Retrotransposase DNA+template RNA     -   4. Retrotransposase RNA+template RNA     -   5. Retrotransposase protein+template DNA     -   6. Retrotransposase protein+template RNA     -   7. Retrotransposase virus+template virus     -   8. Retrotransposase virus+template DNA     -   9. Retrotransposase virus+template RNA     -   10. Retrotransposase DNA+template virus     -   11. Retrotransposase RNA+template virus     -   12. Retrotransposase protein+template virus

As indicated above, in some embodiments, the DNA or RNA that encodes the retrotransposase protein is delivered using a virus, and in some embodiments, the template RNA (or the DNA encoding the template RNA) is delivered using a virus.

In one embodiments the system and/or components of the system are delivered as nucleic acid. For example, the Gene Writer™ polypeptide may be delivered in the form of a DNA or RNA encoding the polypeptide, and the template RNA may be delivered in the form of RNA or its complementary DNA to be transcribed into RNA. In some embodiments the system or components of the system are delivered on 1, 2, 3, 4, or more distinct nucleic acid molecules. In some embodiments the system or components of the system are delivered as a combination of DNA and RNA. In some embodiments the system or components of the system are delivered as a combination of DNA and protein. In some embodiments the system or components of the system are delivered as a combination of RNA and protein. In some embodiments the Gene Writer™ genome editor polypeptide is delivered as a protein.

In some embodiments the system or components of the system are delivered to cells, e.g. mammalian cells or human cells, using a vector. The vector may be, e.g., a plasmid or a virus. In some embodiments delivery is in vivo, in vitro, ex vivo, or in situ. In some embodiments the virus is an adeno associated virus (AAV), a lentivirus, an adenovirus. In some embodiments the system or components of the system are delivered to cells with a viral-like particle or a virosome. In some embodiments the delivery uses more than one virus, viral-like particle or virosome.

In one embodiment, the compositions and systems described herein can be formulated in liposomes or other similar vesicles. Liposomes are spherical vesicle structures composed of a uni- or multilamellar lipid bilayer surrounding internal aqueous compartments and a relatively impermeable outer lipophilic phospholipid bilayer. Liposomes may be anionic, neutral or cationic. Liposomes are biocompatible, nontoxic, can deliver both hydrophilic and lipophilic drug molecules, protect their cargo from degradation by plasma enzymes, and transport their load across biological membranes and the blood brain barrier (BBB) (see, e.g., Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi:10.1155/2011/469679 for review).

Vesicles can be made from several different types of lipids; however, phospholipids are most commonly used to generate liposomes as drug carriers. Methods for preparation of multilamellar vesicle lipids are known in the art (see for example U.S. Pat. No. 6,693,086, the teachings of which relating to multilamellar vesicle lipid preparation are incorporated herein by reference). Although vesicle formation can be spontaneous when a lipid film is mixed with an aqueous solution, it can also be expedited by applying force in the form of shaking by using a homogenizer, sonicator, or an extrusion apparatus (see, e.g., Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi:10.1155/2011/469679 for review). Extruded lipids can be prepared by extruding through filters of decreasing size, as described in Templeton et al., Nature Biotech, 15:647-652, 1997, the teachings of which relating to extruded lipid preparation are incorporated herein by reference.

A variety of nanoparticles can be used for delivery, such as a liposome, a lipid nanoparticle, a cationic lipid nanoparticle, an ionizable lipid nanoparticle, a polymeric nanoparticle, a gold nanoparticle, a dendrimer, a cyclodextrin nanoparticle, a micelle, or a combination of the foregoing.

Lipid nanoparticles are an example of a carrier that provides a biocompatible and biodegradable delivery system for the pharmaceutical compositions described herein. Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid-polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, may also be employed. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core-shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. For a review, see, e.g., Li et al. 2017, Nanomaterials 7, 122; doi:10.3390/nano7060122.

Exosomes can also be used as drug delivery vehicles for the compositions and systems described herein. For a review, see Ha et al. July 2016. Acta Pharmaceutica Sinica B. Volume 6, Issue 4, Pages 287-296; https://doi.org/10.1016/j.apsb.2016.02.001.

Fusosomes interact and fuse with target cells, and thus can be used as delivery vehicles for a variety of molecules. They generally consist of a bilayer of amphipathic lipids enclosing a lumen or cavity and a fusogen that interacts with the amphipathic lipid bilayer. The fusogen component has been shown to be engineerable in order to confer target cell specificity for the fusion and payload delivery, allowing the creation of delivery vehicles with programmable cell specificity (see for example Patent Application WO2020014209, the teachings of which relating to fusosome design, preparation, and usage are incorporated herein by reference).

In some embodiments, the protein component(s) of the Gene Writing™ system may be pre-associated with the template nucleic acid (e.g., template RNA). For example, in some embodiments, the Gene Writer™ polypeptide may be first combined with the template nucleic acid (e.g., template RNA) to form a ribonucleoprotein (RNP) complex. In some embodiments, the RNP may be delivered to cells via, e.g., transfection, nucleofection, virus, vesicle, LNP, exosome, fusosome.

A Gene Writer™ system can be introduced into cells, tissues and multicellular organisms. In some embodiments the system or components of the system are delivered to the cells via mechanical means or physical means.

Formulation of protein therapeutics is described in Meyer (Ed.), Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic, Woodhead Publishing Series (2012).

Tissue Specific Activity/Administration

In some embodiments, a system, template RNA, or polypeptide described herein is administered to or is active in (e.g., is more active in) a target tissue, e.g., a first tissue. In some embodiments, the system, template RNA, or polypeptide is not administered to or is less active in (e.g., not active in) a non-target tissue. In some embodiments, a system, template RNA, or polypeptide described herein is useful for modifying DNA in a target tissue, e.g., a first tissue, (e.g., and not modifying DNA in a non-target tissue).

In some embodiments, a system comprises (a) a polypeptide described herein or a nucleic acid encoding the same, (b) a template nucleic acid (e.g., template RNA) described herein, and (c) one or more first tissue-specific expression-control sequences specific to the target tissue, wherein the one or more first tissue-specific expression-control sequences specific to the target tissue are in operative association with (a), (b), or (a) and (b), wherein, when associated with (a), (a) comprises a nucleic acid encoding the polypeptide.

In some embodiments, the nucleic acid in (b) comprises RNA.

In some embodiments, the nucleic acid in (b) comprises DNA.

In some embodiments, the nucleic acid in (b): (i) is single-stranded or comprises a single-stranded segment, e.g., is single-stranded DNA or comprises a single-stranded segment and one or more double stranded segments; (ii) has inverted terminal repeats; or (iii) both (i) and (ii).

In some embodiments, the nucleic acid in (b) is double-stranded or comprises a double-stranded segment.

In some embodiments, (a) comprises a nucleic acid encoding the polypeptide.

In some embodiments, the nucleic acid in (a) comprises RNA.

In some embodiments, the nucleic acid in (a) comprises DNA.

In some embodiments, the nucleic acid in (a): (i) is single-stranded or comprises a single-stranded segment, e.g., is single-stranded DNA or comprises a single-stranded segment and one or more double stranded segments; (ii) has inverted terminal repeats; or (iii) both (i) and (ii).

In some embodiments, the nucleic acid in (a) is double-stranded or comprises a double-stranded segment.

In some embodiments, the nucleic acid in (a), (b), or (a) and (b) is linear.

In some embodiments, the nucleic acid in (a), (b), or (a) and (b) is circular, e.g., a plasmid or minicircle.

In some embodiments, the heterologous object sequence is in operative association with a first promoter.

In some embodiments, the one or more first tissue-specific expression-control sequences comprises a tissue specific promoter.

In some embodiments, the tissue-specific promoter comprises a first promoter in operative association with: i. the heterologous object sequence, ii. a nucleic acid encoding the transposase, or iii. (i) and (ii).

In some embodiments, the one or more first tissue-specific expression-control sequences comprises a tissue-specific microRNA recognition sequence in operative association with: i. the heterologous object sequence, ii. a nucleic acid encoding the transposase, or iii. (i) and (ii).

In some embodiments, a system comprises a tissue-specific promoter, and the system further comprises one or more tissue-specific microRNA recognition sequences, wherein: i. the tissue specific promoter is in operative association with: I. the heterologous object sequence, II. a nucleic acid encoding the transposase, or III. (I) and (II); and/or ii. the one or more tissue-specific microRNA recognition sequences are in operative association with: I. the heterologous object sequence, II. a nucleic acid encoding the transposase, or III.(I) and (II).

In some embodiments, wherein (a) comprises a nucleic acid encoding the polypeptide, the nucleic acid comprises a promoter in operative association with the nucleic acid encoding the polypeptide.

In some embodiments, the nucleic acid encoding the polypeptide comprises one or more second tissue-specific expression-control sequences specific to the target tissue in operative association with the polypeptide coding sequence.

In some embodiments, the one or more second tissue-specific expression-control sequences comprises a tissue specific promoter.

In some embodiments, the tissue-specific promoter is the promoter in operative association with the nucleic acid encoding the polypeptide.

In some embodiments, the one or more second tissue-specific expression-control sequences comprises a tissue-specific microRNA recognition sequence.

In some embodiments, the promoter in operative association with the nucleic acid encoding the polypeptide is a tissue-specific promoter, the system further comprising one or more tissue-specific microRNA recognition sequences.

In some embodiments, a nucleic acid component of a system provided by the invention a sequence (e.g., encoding the polypeptide or comprising a heterologous object sequence) is flanked by untranslated regions (UTRs) that modify protein expression levels. Various 5′ and 3′ UTRs can affect protein expression. For example, in some embodiments, the coding sequence may be preceded by a 5′ UTR that modifies RNA stability or protein translation. In some embodiments, the sequence may be followed by a 3′ UTR that modifies RNA stability or translation. In some embodiments, the sequence may be preceded by a 5′ UTR and followed by a 3′ UTR that modify RNA stability or translation. In some embodiments, the 5′ and/or 3′ UTR may be selected from the 5′ and 3′ UTRs of complement factor 3 (C3) (cactcctccccatcctctccctctgtccctctgtccctctgaccctgcactgtcccagcacc (SEQ ID NO: 1633)) or orosomucoid 1 (ORM1) (caggacacagccttggatcaggacagagacttgggggccatcctgcccctccaacccgacatgtgtacctcagctttttccctcacttgcat caataaagcttctgtgtttggaacagctaa (SEQ ID NO: 1634)) (Asrani et al. RNA Biology 2018). In certain embodiments, the 5′ UTR is the 5′ UTR from C3 and the 3′ UTR is the 3′ UTR from ORM1. In certain embodiments, a 5′ UTR and 3′ UTR for protein expression, e.g., mRNA (or DNA encoding the RNA) for a Gene Writer polypeptide or heterologous object sequence, comprise optimized expression sequences. In some embodiments, the 5′ UTR comprises GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 1603) and/or the 3′ UTR comprising UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCC AGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGA (SEQ ID NO: 1604), e.g., as described in Richner et al. Cell 168(6): P1114-1125 (2017), the sequences of which are incorporated herein by reference.

In some embodiments, a 5′ and/or 3′ UTR may be selected to enhance protein expression. In some embodiments, a 5′ and/or 3′ UTR may be selected to modify protein expression such that overproduction inhibition is minimized. In some embodiments, UTRs are around a coding sequence, e.g., outside the coding sequence and in other embodiments proximal to the coding sequence, In some embodiments additional regulatory elements (e.g., miRNA binding sites, cis-regulatory sites) are included in the UTRs.

In some embodiments, an open reading frame of a Gene Writer system, e.g., an ORF of an mRNA (or DNA encoding an mRNA) encoding a Gene Writer polypeptide or one or more ORFs of an mRNA (or DNA encoding an mRNA) of a heterologous object sequence, is flanked by a 5′ and/or 3′ untranslated region (UTR) that enhances the expression thereof. In some embodiments, the 5′ UTR of an mRNA component (or transcript produced from a DNA component) of the system comprises the sequence 5′-GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC-3′ (SEQ ID NO: 1603). In some embodiments, the 3′ UTR of an mRNA component (or transcript produced from a DNA component) of the system comprises the sequence 5′-UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCC AGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGA-3′ (SEQ ID NO: 1604). This combination of 5′ UTR and 3′ UTR has been shown to result in desirable expression of an operably linked ORF by Richner et al. Cell 168(6): P1114-1125 (2017), the teachings and sequences of which are incorporated herein by reference. In some embodiments, a system described herein comprises a DNA encoding a transcript, wherein the DNA comprises the corresponding 5′ UTR and 3′ UTR sequences, with T substituting for U in the above-listed sequence). In some embodiments, a DNA vector used to produce an RNA component of the system further comprises a promoter upstream of the 5′ UTR for initiating in vitro transcription, e.g, a T7, T3, or SP6 promoter. The 5′ UTR above begins with GGG, which is a suitable start for optimizing transcription using T7 RNA polymerase. For tuning transcription levels and altering the transcription start site nucleotides to fit alternative 5′ UTRs, the teachings of Davidson et al. Pac Symp Biocomput 433-443 (2010) describe T7 promoter variants, and the methods of discovery thereof, that fulfill both of these traits.

Viral Vectors and Components Thereof

Viruses are a useful source of delivery vehicles for the systems described herein, in addition to a source of relevant enzymes or domains as described herein, e.g., as sources of polymerases and polymerase functions used herein, e.g., DNA-dependent DNA polymerase, RNA-dependent RNA polymerase, RNA-dependent DNA polymerase, DNA-dependent RNA polymerase, reverse transcriptase. Some enzymes, e.g., reverse transcriptases, may have multiple activities, e.g., be capable of both RNA-dependent DNA polymerization and DNA-dependent DNA polymerization, e.g., first and second strand synthesis. In some embodiments, the virus used as a Gene Writer delivery system or a source of components thereof may be selected from a group as described by Baltimore Bacteriol Rev 35(3):235-241 (1971).

In some embodiments, the virus is selected from a Group I virus, e.g., is a DNA virus and packages dsDNA into virions. In some embodiments, the Group I virus is selected from, e.g., Adenoviruses, Herpesviruses, Poxviruses.

In some embodiments, the virus is selected from a Group II virus, e.g., is a DNA virus and packages ssDNA into virions. In some embodiments, the Group II virus is selected from, e.g., Parvoviruses. In some embodiments, the parvovirus is a dependoparvovirus, e.g., an adeno-associated virus (AAV).

In some embodiments, the virus is selected from a Group III virus, e.g., is an RNA virus and packages dsRNA into virions. In some embodiments, the Group III virus is selected from, e.g., Reoviruses. In some embodiments, one or both strands of the dsRNA contained in such virions is a coding molecule able to serve directly as mRNA upon transduction into a host cell, e.g., can be directly translated into protein upon transduction into a host cell without requiring any intervening nucleic acid replication or polymerization steps.

In some embodiments, the virus is selected from a Group IV virus, e.g., is an RNA virus and packages ssRNA(+) into virions. In some embodiments, the Group IV virus is selected from, e.g., Coronaviruses, Picornaviruses, Togaviruses. In some embodiments, the ssRNA(+) contained in such virions is a coding molecule able to serve directly as mRNA upon transduction into a host cell, e.g., can be directly translated into protein upon transduction into a host cell without requiring any intervening nucleic acid replication or polymerization steps.

In some embodiments, the virus is selected from a Group V virus, e.g., is an RNA virus and packages ssRNA(−) into virions. In some embodiments, the Group V virus is selected from, e.g., Orthomyxoviruses, Rhabdoviruses. In some embodiments, an RNA virus with an ssRNA(−) genome also carries an enzyme inside the virion that is transduced to host cells with the viral genome, e.g., an RNA-dependent RNA polymerase, capable of copying the ssRNA(−) into ssRNA(+) that can be translated directly by the host.

In some embodiments, the virus is selected from a Group VI virus, e.g., is a retrovirus and packages ssRNA(+) into virions. In some embodiments, the Group VI virus is selected from, e.g., Retroviruses. In some embodiments, the retrovirus is a lentivirus, e.g., HIV-1, HIV-2, SIV, BIV. In some embodiments, the retrovirus is a spumavirus, e.g., a foamy virus, e.g., HFV, SFV, BFV. In some embodiments, the ssRNA(+) contained in such virions is a coding molecule able to serve directly as mRNA upon transduction into a host cell, e.g., can be directly translated into protein upon transduction into a host cell without requiring any intervening nucleic acid replication or polymerization steps. In some embodiments, the ssRNA(+) is first reverse transcribed and copied to generate a dsDNA genome intermediate from which mRNA can be transcribed in the host cell. In some embodiments, an RNA virus with an ssRNA(+) genome also carries an enzyme inside the virion that is transduced to host cells with the viral genome, e.g., an RNA-dependent DNA polymerase, capable of copying the ssRNA(+) into dsDNA that can be transcribed into mRNA and translated by the host. In some embodiments, the reverse transcriptase from a Group VI retrovirus is incorporated as the reverse transcriptase domain of a Gene Writer polypeptide.

In some embodiments, the virus is selected from a Group VII virus, e.g., is a retrovirus and packages dsRNA into virions. In some embodiments, the Group VII virus is selected from, e.g., Hepadnaviruses. In some embodiments, one or both strands of the dsRNA contained in such virions is a coding molecule able to serve directly as mRNA upon transduction into a host cell, e.g., can be directly translated into protein upon transduction into a host cell without requiring any intervening nucleic acid replication or polymerization steps. In some embodiments, one or both strands of the dsRNA contained in such virions is first reverse transcribed and copied to generate a dsDNA genome intermediate from which mRNA can be transcribed in the host cell. In some embodiments, an RNA virus with a dsRNA genome also carries an enzyme inside the virion that is transduced to host cells with the viral genome, e.g., an RNA-dependent DNA polymerase, capable of copying the dsRNA into dsDNA that can be transcribed into mRNA and translated by the host. In some embodiments, the reverse transcriptase from a Group VII retrovirus is incorporated as the reverse transcriptase domain of a Gene Writer polypeptide.

In some embodiments, virions used to deliver nucleic acid in this invention may also carry enzymes involved in the process of Gene Writing. For example, a retroviral virion may contain a reverse transcriptase domain that is delivered into a host cell along with the nucleic acid. In some embodiments, an RNA template may be associated with a Gene Writer polypeptide within a virion, such that both are co-delivered to a target cell upon transduction of the nucleic acid from the viral particle. In some embodiments, the nucleic acid in a virion may comprise DNA, e.g., linear ssDNA, linear dsDNA, circular ssDNA, circular dsDNA, minicircle DNA, dbDNA, ceDNA. In some embodiments, the nucleic acid in a virion may comprise RNA, e.g., linear ssRNA, linear dsRNA, circular ssRNA, circular dsRNA. In some embodiments, a viral genome may circularize upon transduction into a host cell, e.g., a linear ssRNA molecule may undergo a covalent linkage to form a circular ssRNA, a linear dsRNA molecule may undergo a covalent linkage to form a circular dsRNA or one or more circular ssRNA. In some embodiments, a viral genome may replicate by rolling circle replication in a host cell. In some embodiments, a viral genome may comprise a single nucleic acid molecule, e.g., comprise a non-segmented genome. In some embodiments, a viral genome may comprise two or more nucleic acid molecules, e.g., comprise a segmented genome. In some embodiments, a nucleic acid in a virion may be associated with one or proteins. In some embodiments, one or more proteins in a virion may be delivered to a host cell upon transduction. In some embodiments, a natural virus may be adapted for nucleic acid delivery by the addition of virion packaging signals to the target nucleic acid, wherein a host cell is used to package the target nucleic acid containing the packaging signals.

In some embodiments, a virion used as a delivery vehicle may comprise a commensal human virus. In some embodiments, a virion used as a delivery vehicle may comprise an anellovirus, the use of which is described in WO2018232017A1, which is incorporated herein by reference in its entirety.

AAV Administration

In some embodiments, an adeno-associated virus (AAV) is used in conjunction with the system, template nucleic acid, and/or polypeptide described herein. In some embodiments, an AAV is used to deliver, administer, or package the system, template nucleic acid, and/or polypeptide described herein. In some embodiments, the AAV is a recombinant AAV (rAAV).

In some embodiments, a system comprises (a) a polypeptide described herein or a nucleic acid encoding the same, (b) a template nucleic acid (e.g., template RNA) described herein, and (c) one or more first tissue-specific expression-control sequences specific to the target tissue, wherein the one or more first tissue-specific expression-control sequences specific to the target tissue are in operative association with (a), (b), or (a) and (b), wherein, when associated with (a), (a) comprises a nucleic acid encoding the polypeptide.

In some embodiments, a system described herein further comprises a first recombinant adeno-associated virus (rAAV) capsid protein; wherein the at least one of (a) or (b) is associated with the first rAAV capsid protein, wherein at least one of (a) or (b) is flanked by AAV inverted terminal repeats (ITRs).

In some embodiments, (a) and (b) are associated with the first rAAV capsid protein.

In some embodiments, (a) and (b) are on a single nucleic acid.

In some embodiments, the system further comprises a second rAAV capsid protein, wherein at least one of (a) or (b) is associated with the second rAAV capsid protein, and wherein the at least one of (a) or (b) associated with the second rAAV capsid protein is different from the at least one of (a) or (b) is associated with the first rAAV capsid protein.

In some embodiments, the at least one of (a) or (b) is associated with the first or second rAAV capsid protein is dispersed in the interior of the first or second rAAV capsid protein, which first or second rAAV capsid protein is in the form of an AAV capsid particle.

In some embodiments, the system further comprises a nanoparticle, wherein the nanoparticle is associated with at least one of (a) or (b).

In some embodiments, (a) and (b), respectively are associated with: a) a first rAAV capsid protein and a second rAAV capsid protein; b) a nanoparticle and a first rAAV capsid protein; c) a first rAAV capsid protein; d) a first adenovirus capsid protein; e) a first nanoparticle and a second nanoparticle; or f) a first nanoparticle.

Viral vectors are useful for delivering all or part of a system provided by the invention, e.g., for use in methods provided by the invention. Systems derived from different viruses have been employed for the delivery of polypeptides, nucleic acids, or transposons; for example: integrase-deficient lentivirus, adenovirus, adeno-associated virus (AAV), herpes simplex virus, and baculovirus (reviewed in Hodge et al. Hum Gene Ther 2017; Narayanavari et al. Crit Rev Biochem Mol Biol 2017; Boehme et al. Curr Gene Ther 2015).

Adenoviruses are common viruses that have been used as gene delivery vehicles given well-defined biology, genetic stability, high transduction efficiency, and ease of large-scale production (see, for example, review by Lee et al. Genes & Diseases 2017). They possess linear dsDNA genomes and come in a variety of serotypes that differ in tissue and cell tropisms. In order to prevent replication of infectious virus in recipient cells, adenovirus genomes used for packaging are deleted of some or all endogenous viral proteins, which are provided in trans in viral production cells. This renders the genomes helper-dependent, meaning they can only be replicated and packaged into viral particles in the presence of the missing components provided by so-called helper functions. A helper-dependent adenovirus system with all viral ORFs removed may be compatible with packaging foreign DNA of up to ˜37 kb (Parks et al. J Virol 1997). In some embodiments, an adenoviral vector is used to deliver DNA corresponding to the polypeptide or template component of the Gene Writing™ system, or both are contained on separate or the same adenoviral vector. In some embodiments, the adenovirus is a helper-dependent adenovirus (HD-AdV) that is incapable of self-packaging. In some embodiments, the adenovirus is a high-capacity adenovirus (HC-AdV) that has had all or a substantial portion of endogenous viral ORFs deleted, while retaining the necessary sequence components for packaging into adenoviral particles. For this type of vector, the only adenoviral sequences required for genome packaging are noncoding sequences: the inverted terminal repeats (ITRs) at both ends and the packaging signal at the 5′-end (Jager et al. Nat Protoc 2009). In some embodiments, the adenoviral genome also comprises stuffer DNA to meet a minimal genome size for optimal production and stability (see, for example, Hausl et al. Mol Ther 2010). Adenoviruses have been used in the art for the delivery of transposons to various tissues. In some embodiments, an adenovirus is used to deliver a Gene Writing™ system to the liver.

In some embodiments, an adenovirus is used to deliver a Gene Writing™ system to HSCs, e.g., HDAd5/35++. HDAd5/35++ is an adenovirus with modified serotype 35 fibers that de-target the vector from the liver (Wang et al. Blood Adv 2019). In some embodiments, the adenovirus that delivers a Gene Writing™ system to HSCs utilizes a receptor that is expressed specifically on primitive HSCs, e.g., CD46.

Adeno-associated viruses (AAV) belong to the parvoviridae family and more specifically constitute the dependoparvovirus genus. The AAV genome is composed of a linear single-stranded DNA molecule which contains approximately 4.7 kilobases (kb) and consists of two major open reading frames (ORFs) encoding the non-structural Rep (replication) and structural Cap (capsid) proteins. A second ORF within the cap gene was identified that encodes the assembly-activating protein (AAP). The DNAs flanking the AAV coding regions are two cis-acting inverted terminal repeat (ITR) sequences, approximately 145 nucleotides in length, with interrupted palindromic sequences that can be folded into energetically stable hairpin structures that function as primers of DNA replication. In addition to their role in DNA replication, the ITR sequences have been shown to be involved in viral DNA integration into the cellular genome, rescue from the host genome or plasmid, and encapsidation of viral nucleic acid into mature virions (Muzyczka, (1992) Curr. Top. Micro. Immunol. 158:97-129). In some embodiments, one or more Gene Writing™ nucleic acid components is flanked by ITRs derived from AAV for viral packaging. See, e.g., WO2019113310.

In some embodiments, one or more components of the Gene Writing™ system are carried via at least one AAV vector. In some embodiments, the at least one AAV vector is selected for tropism to a particular cell, tissue, organism. In some embodiments, the AAV vector is pseudotyped, e.g., AAV2/8, wherein AAV2 describes the design of the construct but the capsid protein is replaced by that from AAV8. It is understood that any of the described vectors could be pseudotype derivatives, wherein the capsid protein used to package the AAV genome is derived from that of a different AAV serotype. In some embodiments, an AAV to be employed for Gene Writing™ may be evolved for novel cell or tissue tropism as has been demonstrated in the literature (e.g., Davidsson et al. Proc Natl Acad Sci USA 2019).

In some embodiments, the AAV delivery vector is a vector which has two AAV inverted terminal repeats (ITRs) and a nucleotide sequence of interest (for example, a sequence coding for a Gene Writer™ polypeptide or a DNA template, or both), each of said ITRs having an interrupted (or noncontiguous) palindromic sequence, i.e., a sequence composed of three segments: a first segment and a last segment that are identical when read 5′→3′ but hybridize when placed against each other, and a segment that is different that separates the identical segments. Such sequences, notably the ITRs, form hairpin structures. See, for example, WO2012123430.

Conventionally, AAV virions with capsids are produced by introducing a plasmid or plasmids encoding the rAAV or scAAV genome, Rep proteins, and Cap proteins (Grimm et al, 1998). Upon introduction of these helper plasmids in trans, the AAV genome is “rescued” (i.e., released and subsequently recovered) from the host genome, and is further encapsidated to produce infectious AAV. In some embodiments, one or more Gene Writing™ nucleic acids are packaged into AAV particles by introducing the ITR-flanked nucleic acids into a packaging cell in conjunction with the helper functions.

In some embodiments, the AAV genome is a so called self-complementary genome (referred to as scAAV), such that the sequence located between the ITRs contains both the desired nucleic acid sequence (e.g., DNA encoding the Gene Writer™ polypeptide or template, or both) in addition to the reverse complement of the desired nucleic acid sequence, such that these two components can fold over and self-hybridize. In some embodiments, the self-complementary modules are separated by an intervening sequence that permits the DNA to fold back on itself, e.g., forms a stem-loop. An scAAV has the advantage of being poised for transcription upon entering the nucleus, rather than being first dependent on ITR priming and second-strand synthesis to form dsDNA. In some embodiments, one or more Gene Writing™ components is designed as an scAAV, wherein the sequence between the AAV ITRs contains two reverse complementing modules that can self-hybridize to create dsDNA.

In some embodiments, nucleic acid (e.g., encoding a polypeptide, or a template, or both) delivered to cells is closed-ended, linear duplex DNA (CELiD DNA or ceDNA). In some embodiments, ceDNA is derived from the replicative form of the AAV genome (Li et al. PLoS One 2013). In some embodiments, the nucleic acid (e.g., encoding a polypeptide, or a template DNA, or both) is flanked by ITRs, e.g., AAV ITRs, wherein at least one of the ITRs comprises a terminal resolution site and a replication protein binding site (sometimes referred to as a replicative protein binding site). In some embodiments, the ITRs are derived from an adeno-associated virus, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or a combination thereof. In some embodiments, the ITRs are symmetric. In some embodiments, the ITRs are asymmetric. In some embodiments, at least one Rep protein is provided to enable replication of the construct. In some embodiments, the at least one Rep protein is derived from an adeno-associated virus, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or a combination thereof. In some embodiments, ceDNA is generated by providing a production cell with (i) DNA flanked by ITRs, e.g., AAV ITRs, and (ii) components required for ITR-dependent replication, e.g., AAV proteins Rep78 and Rep52 (or nucleic acid encoding the proteins). In some embodiments, ceDNA is free of any capsid protein, e.g., is not packaged into an infectious AAV particle. In some embodiments, ceDNA is formulated into LNPs (see, for example, WO2019051289A1).

In some embodiments, the ceDNA vector consists of two self complementary sequences, e.g., asymmetrical or symmetrical or substantially symmetrical ITRs as defined herein, flanking said expression cassette, wherein the ceDNA vector is not associated with a capsid protein. In some embodiments, the ceDNA vector comprises two self-complementary sequences found in an AAV genome, where at least one ITR comprises an operative Rep-binding element (RBE) (also sometimes referred to herein as “RBS”) and a terminal resolution site (trs) of AAV or a functional variant of the RBE. See, for example, WO2019113310.

In some embodiments, the AAV genome comprises two genes that encode four replication proteins and three capsid proteins, respectively. In some embodiments, the genes are flanked on either side by 145-bp inverted terminal repeats (ITRs). In some embodiments, the virion comprises up to three capsid proteins (Vp1, Vp2, and/or Vp3), e.g., produced in a 1:1:10 ratio. In some embodiments, the capsid proteins are produced from the same open reading frame and/or from differential splicing (Vp1) and alternative translational start sites (Vp2 and Vp3, respectively). Generally, Vp3 is the most abundant subunit in the virion and participates in receptor recognition at the cell surface defining the tropism of the virus. In some embodiments, Vp1 comprises a phospholipase domain, e.g., which functions in viral infectivity, in the N-terminus of Vp1.

In some embodiments, packaging capacity of the viral vectors limits the size of the base editor that can be packaged into the vector. For example, the packaging capacity of the AAVs can be about 4.5 kb (e.g., about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0 kb), e.g., including one or two inverted terminal repeats (ITRs), e.g., 145 base ITRs.

In some embodiments, recombinant AAV (rAAV) comprises cis-acting 145-bp ITRs flanking vector transgene cassettes, e.g., providing up to 4.5 kb for packaging of foreign DNA. Subsequent to infection, rAAV can, in some instances, express a fusion protein of the invention and persist without integration into the host genome by existing episomally in circular head-to-tail concatemers. rAAV can be used, for example, in vitro and in vivo. In some embodiments, AAV-mediated gene delivery requires that the length of the coding sequence of the gene is equal or greater in size than the wild-type AAV genome.

AAV delivery of genes that exceed this size and/or the use of large physiological regulatory elements can be accomplished, for example, by dividing the protein(s) to be delivered into two or more fragments. In some embodiments, the N-terminal fragment is fused to a split intein-N. In some embodiments, the C-terminal fragment is fused to a split intein-C. In embodiments, the fragments are packaged into two or more AAV vectors.

In some embodiments, dual AAV vectors are generated by splitting a large transgene expression cassette in two separate halves (5 and 3 ends, or head and tail), e.g., wherein each half of the cassette is packaged in a single AAV vector (of <5 kb). The re-assembly of the full-length transgene expression cassette can, in some embodiments, then be achieved upon co-infection of the same cell by both dual AAV vectors. In some embodiments, co-infection is followed by one or more of: (1) homologous recombination (HR) between 5 and 3 genomes (dual AAV overlapping vectors); (2) ITR-mediated tail-to-head concatemerization of 5 and 3 genomes (dual AAV trans-splicing vectors); and/or (3) a combination of these two mechanisms (dual AAV hybrid vectors). In some embodiments, the use of dual AAV vectors in vivo results in the expression of full-length proteins. In some embodiments, the use of the dual AAV vector platform represents an efficient and viable gene transfer strategy for transgenes of greater than about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 kb in size. In some embodiments, AAV vectors can also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides. In some embodiments, AAV vectors can be used for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest.94:1351 (1994); each of which is incorporated herein by reference in their entirety). The construction of recombinant AAV vectors is described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989) (incorporated by reference herein in their entirety).

In some embodiments, a Gene Writer described herein (e.g., with or without one or more guide nucleic acids) can be delivered using AAV, lentivirus, adenovirus or other plasmid or viral vector types, in particular, using formulations and doses from, for example, U.S. Pat. No. 8,454,972 (formulations, doses for adenovirus), U.S. Pat. No. 8,404,658 (formulations, doses for AAV) and U.S. Pat. No. 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivirus, AAV and adenovirus. For example, for AAV, the route of administration, formulation and dose can be as described in U.S. Pat. No. 8,454,972 and as in clinical trials involving AAV. For Adenovirus, the route of administration, formulation and dose can be as described in U.S. Pat. No. 8,404,658 and as in clinical trials involving adenovirus. For plasmid delivery, the route of administration, formulation and dose can be as described in U.S. Pat. No. 5,846,946 and as in clinical studies involving plasmids. Doses can be based on or extrapolated to an average 70 kg individual (e.g. a male adult human), and can be adjusted for patients, subjects, mammals of different weight and species. Frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), depending on usual factors including the age, sex, general health, other conditions of the patient or subject and the particular condition or symptoms being addressed. In some embodiments, the viral vectors can be injected into the tissue of interest. For cell-type specific Gene Writing, the expression of the Gene Writer and optional guide nucleic acid can, in some embodiments, be driven by a cell-type specific promoter.

In some embodiments, AAV allows for low toxicity, for example, due to the purification method not requiring ultracentrifugation of cell particles that can activate the immune response. In some embodiments, AAV allows low probability of causing insertional mutagenesis, for example, because it does not substantially integrate into the host genome.

In some embodiments, AAV has a packaging limit of about 4.4, 4.5, 4.6, 4.7, or 4.75 kb. In some embodiments, a Gene Writer, promoter, and transcription terminator can fit into a single viral vector. SpCas9 (4.1 kb) may, in some instances, be difficult to package into AAV. Therefore, in some embodiments, a Gene Writer is used that is shorter in length than other Gene Writers or base editors. In some embodiments, the Gene Writers are less than about 4.5 kb, 4.4 kb, 4.3 kb, 4.2 kb, 4.1 kb, 4 kb, 3.9 kb, 3.8 kb, 3.7 kb, 3.6 kb, 3.5 kb, 3.4 kb, 3.3 kb, 3.2 kb, 3.1 kb, 3 kb, 2.9 kb, 2.8 kb, 2.7 kb, 2.6 kb, 2.5 kb, 2 kb, or 1.5 kb.

An AAV can be AAV1, AAV2, AAV5 or any combination thereof. In some embodiments, the type of AAV is selected with respect to the cells to be targeted; e.g., AAV serotypes 1, 2, 5 or a hybrid capsid AAV1, AAV2, AAV5 or any combination thereof can be selected for targeting brain or neuronal cells; or AAV4 can be selected for targeting cardiac tissue. In some embodiments, AAV8 is selected for delivery to the liver. Exemplary AAV serotypes as to these cells are described, for example, in Grimm, D. et al, J. Virol. 82: 5887-5911 (2008) (incorporated herein by reference in its entirety). In some embodiments, AAV refers all serotypes, subtypes, and naturally-occurring AAV as well as recombinant AAV. AAV may be used to refer to the virus itself or a derivative thereof. In some embodiments, AAV includes AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV6.2, AAV7, AAVrh.64R1, AAVhu.37, AAVrh.8, AAVrh.32.33, AAV8, AAV9, AAV-DJ, AAV2/8, AAVrh1O, AAVLK03, AV10, AAV11, AAV 12, rh1O, and hybrids thereof, avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, nonprimate AAV, and ovine AAV. The genomic sequences of various serotypes of AAV, as well as the sequences of the native terminal repeats (TRs), Rep proteins, and capsid subunits are known in the art. Such sequences may be found in the literature or in public databases such as Genflank. Additional exemplary AAV serotypes are listed in Table 36.

TABLE 36 Exemplary AAV serotypes. Target Tissue Vehicle Reference Liver AAV (AAV8¹, AAVrh.8¹, 1. Wang et al., Mol. Ther. 18, AAVhu.37¹, AAV2/8, 118-25 (2010) AAV2/rh10², AAV9, AAV2, 2. Ginn et al., JHEP Reports, NP40³, NP59^(2, 3), AAV3B⁵, 100065 (2019) AAV-DJ⁴, AAV-LK01⁴, 3. Paulk et al., Mol. Ther. 26, AAV-LK02⁴, AAV-LK03⁴, 289-303 (2018). AAV-LK19⁴ 4. L. Lisowski et al., Nature. Adenovirus (Ad5, HC-AdV⁶) 506, 382-6 (2014). 5. L. Wang et al., Mol. Ther. 23, 1877-87 (2015). 6. Hausl Mol Ther (2010) Lung AAV (AAV4, AAV5, 1. Duncan et al., Mol Ther AAV6¹, AAV9, H22²) Methods Clin Dev (2018) Adenovirus (Ad5, Ad3, 2. Cooney et al., Am J Respir Ad21, Ad14)³ Cell Mol Biol (2019) 3. Li et al., Mol Ther Methods Clin Dev (2019) Skin AAV (AAV6¹, AAV-LK19²) 1. Petek et al., Mol. Ther. (2010) 2. L. Lisowski et al., Nature. 506, 382-6 (2014). HSCs Adenovirus (HDAd5/35⁺⁺) Wang et al. Blood Adv (2019)

In some embodiments, a pharmaceutical composition (e.g., comprising an AAV as described herein) has less than 10% empty capsids, less than 8% empty capsids, less than 7% empty capsids, less than 5% empty capsids, less than 3% empty capsids, or less than 1% empty capsids. In some embodiments, the pharmaceutical composition has less than about 5% empty capsids. In some embodiments, the number of empty capsids is below the limit of detection. In some embodiments, it is advantageous for the pharmaceutical composition to have low amounts of empty capsids, e.g., because empty capsids may generate an adverse response (e.g., immune response, inflammatory response, liver response, and/or cardiac response), e.g., with little or no substantial therapeutic benefit.

In some embodiments, the residual host cell protein (rHCP) in the pharmaceutical composition is less than or equal to 100 ng/ml rHCP per 1×10¹³ vg/ml, e.g., less than or equal to 40 ng/ml rHCP per 1×10¹³ vg/ml or 1-50 ng/ml rHCP per 1×10¹³ vg/ml. In some embodiments, the pharmaceutical composition comprises less than 10 ng rHCP per 1.0×10¹³ vg, or less than 5 ng rHCP per 1.0×10¹³ vg, less than 4 ng rHCP per 1.0×10¹³ vg, or less than 3 ng rHCP per 1.0×10¹³ vg, or any concentration in between. In some embodiments, the residual host cell DNA (hcDNA) in the pharmaceutical composition is less than or equal to 5×10⁶ μg/ml hcDNA per 1×10¹³ vg/ml, less than or equal to 1.2×10⁶ μg/ml hcDNA per 1×10¹³ vg/ml, or 1×10⁵ μg/ml hcDNA per 1×10¹³ vg/ml. In some embodiments, the residual host cell DNA in said pharmaceutical composition is less than 5.0×10⁵ pg per 1×10¹³ vg, less than 2.0×10⁵ pg per 1.0×10¹³ vg, less than 1.1×10⁵ pg per 1.0×10¹³ vg, less than 1.0×10⁵ pg hcDNA per 1.0×10¹³ vg, less than 0.9×10⁵ pg hcDNA per 1.0×10¹³ vg, less than 0.8×10⁵ pg hcDNA per 1.0×10¹³ vg, or any concentration in between.

In some embodiments, the residual plasmid DNA in the pharmaceutical composition is less than or equal to 1.7×10⁵ μg/ml per 1.0×10¹³ vg/ml, or 1×10⁵ μg/ml per 1×1.0×10¹³ vg/ml, or 1.7×10⁶ μg/ml per 1.0×10¹³ vg/ml. In some embodiments, the residual DNA plasmid in the pharmaceutical composition is less than 10.0×10⁵ pg by 1.0×10¹³ vg, less than 8.0×10⁵ pg by 1.0×10¹³ vg or less than 6.8×10⁵ pg by 1.0×10¹³ vg. In embodiments, the pharmaceutical composition comprises less than 0.5 ng per 1.0×10¹³ vg, less than 0.3 ng per 1.0×10¹³ vg, less than 0.22 ng per 1.0×10¹³ vg or less than 0.2 ng per 1.0×10¹³ vg or any intermediate concentration of bovine serum albumin (BSA). In embodiments, the benzonase in the pharmaceutical composition is less than 0.2 ng by 1.0×10¹³ vg, less than 0.1 ng by 1.0×10¹³ vg, less than 0.09 ng by 1.0×10¹³ vg, less than 0.08 ng by 1.0×10¹³ vg or any intermediate concentration. In embodiments, Poloxamer 188 in the pharmaceutical composition is about 10 to 150 ppm, about 15 to 100 ppm or about 20 to 80 ppm. In embodiments, the cesium in the pharmaceutical composition is less than 50 pg/g (ppm), less than 30 pg/g (ppm) or less than 20 pg/g (ppm) or any intermediate concentration.

In embodiments, the pharmaceutical composition comprises total impurities, e.g., as determined by SDS-PAGE, of less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or any percentage in between. In embodiments, the total purity, e.g., as determined by SDS-PAGE, is greater than 90%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, or any percentage in between. In embodiments, no single unnamed related impurity, e.g., as measured by SDS-PAGE, is greater than 5%, greater than 4%, greater than 3% or greater than 2%, or any percentage in between. In embodiments, the pharmaceutical composition comprises a percentage of filled capsids relative to total capsids (e.g., peak 1+peak 2 as measured by analytical ultracentrifugation) of greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91%, greater than 91.9%, greater than 92%, greater than 93%, or any percentage in between. In embodiments of the pharmaceutical composition, the percentage of filled capsids measured in peak 1 by analytical ultracentrifugation is 20-80%, 25-75%, 30-75%, 35-75%, or 37.4-70.3%. In embodiments of the pharmaceutical composition, the percentage of filled capsids measured in peak 2 by analytical ultracentrifugation is 20-80%, 20-70%, 22-65%, 24-62%, or 24.9-60.1%.

In one embodiment, the pharmaceutical composition comprises a genomic titer of 1.0 to 5.0×10¹³ vg/mL, 1.2 to 3.0×10¹³ vg/mL or 1.7 to 2.3×10¹³ vg/ml. In one embodiment, the pharmaceutical composition exhibits a biological load of less than 5 CFU/mL, less than 4 CFU/mL, less than 3 CFU/mL, less than 2 CFU/mL or less than 1 CFU/mL or any intermediate contraction. In embodiments, the amount of endotoxin according to USP, for example, USP <85> (incorporated by reference in its entirety) is less than 1.0 EU/mL, less than 0.8 EU/mL or less than 0.75 EU/mL. In embodiments, the osmolarity of a pharmaceutical composition according to USP, for example, USP <785> (incorporated by reference in its entirety) is 350 to 450 mOsm/kg, 370 to 440 mOsm/kg or 390 to 430 mOsm/kg. In embodiments, the pharmaceutical composition contains less than 1200 particles that are greater than 25 m per container, less than 1000 particles that are greater than 25 m per container, less than 500 particles that are greater than 25 m per container or any intermediate value. In embodiments, the pharmaceutical composition contains less than 10,000 particles that are greater than 10 m per container, less than 8000 particles that are greater than 10 m per container or less than 600 particles that are greater than 10 pm per container.

In one embodiment, the pharmaceutical composition has a genomic titer of 0.5 to 5.0×10¹³ vg/mL, 1.0 to 4.0×10¹³ vg/mL, 1.5 to 3.0×10¹³ vg/ml or 1.7 to 2.3×10¹³ vg/ml. In one embodiment, the pharmaceutical composition described herein comprises one or more of the following: less than about 0.09 ng benzonase per 1.0×10¹³ vg, less than about 30 pg/g (ppm) of cesium, about 20 to 80 ppm Poloxamer 188, less than about 0.22 ng BSA per 1.0×10¹³ vg, less than about 6.8×10⁵ pg of residual DNA plasmid per 1.0×10¹³ vg, less than about 1.1×10⁵ pg of residual hcDNA per 1.0×10¹³ vg, less than about 4 ng of rHCP per 1.0×10¹³ vg, pH 7.7 to 8.3, about 390 to 430 mOsm/kg, less than about 600 particles that are >25 m in size per container, less than about 6000 particles that are >10 m in size per container, about 1.7×10¹³-2.3×10¹³ vg/mL genomic titer, infectious titer of about 3.9×10⁸ to 8.4×10¹⁰ IU per 1.0×10¹³ vg, total protein of about 100-300 pg per 1.0×10¹³ vg, mean survival of >24 days in A7SMA mice with about 7.5×10¹³ vg/kg dose of viral vector, about 70 to 130% relative potency based on an in vitro cell based assay and/or less than about 5% empty capsid. In various embodiments, the pharmaceutical compositions described herein comprise any of the viral particles discussed here, retain a potency of between ±20%, between +15%, between ±10% or within +5% of a reference standard. In some embodiments, potency is measured using a suitable in vitro cell assay or in vivo animal model.

Additional methods of preparation, characterization, and dosing AAV particles are taught in WO2019094253, which is incorporated herein by reference in its entirety.

Additional rAAV constructs that can be employed consonant with the invention include those described in Wang et al 2019, available at: //doi.org/10.1038/s41573-019-0012-9, including Table 1 thereof, which is incorporated by reference in its entirety.

Inteins

In some embodiments, as described in more detail below, Intein-N may be fused to the N-terminal portion of a first domain described herein, and intein-C may be fused to the C-terminal portion of a second domain described herein for the joining of the N-terminal portion to the C-terminal portion, thereby joining the first and second domains. In some embodiments, the first and second domains are each independent chosen from a DNA binding domain, an RNA binding domain, an RT domain, and an endonuclease domain.

As used herein, “intein” refers to a self-splicing protein intron (e.g., peptide), e.g., which ligates flanking N-terminal and C-terminal exteins (e.g., fragments to be joined). An intein may, in some instances, comprise a fragment of a protein that is able to excise itself and join the remaining fragments (the exteins) with a peptide bond in a process known as protein splicing. Inteins are also referred to as “protein introns.” The process of an intein excising itself and joining the remaining portions of the protein is herein termed “protein splicing” or “intein-mediated protein splicing.” In some embodiments, an intein of a precursor protein (an intein containing protein prior to intein-mediated protein splicing) comes from two genes. Such intein is referred to herein as a split intein (e.g., split intein-N and split intein-C). For example, in cyanobacteria, DnaE, the catalytic subunit a of DNA polymerase III, is encoded by two separate genes, dnaE-n and dnaE-c. The intein encoded by the dnaE-n gene may be herein referred as “intein-N.” The intein encoded by the dnaE-c gene may be herein referred as “intein-C.”

Use of inteins for joining heterologous protein fragments is described, for example, in Wood et al., J. Biol. Chem. 289(21); 14512-9 (2014) (incorporated herein by reference in its entirety). For example, when fused to separate protein fragments, the inteins IntN and IntC may recognize each other, splice themselves out, and/or simultaneously ligate the flanking N- and C-terminal exteins of the protein fragments to which they were fused, thereby reconstituting a full-length protein from the two protein fragments.

In some embodiments, a synthetic intein based on the dnaE intein, the Cfa-N (e.g., split intein-N) and Cfa-C (e.g., split intein-C) intein pair, is used. Examples of such inteins have been described, e.g., in Stevens et al., J Am Chem Soc. 2016 Feb. 24; 138(7):2162-5 (incorporated herein by reference in its entirety). Non-limiting examples of intein pairs that may be used in accordance with the present disclosure include: Cfa DnaE intein, Ssp GyrB intein, Ssp DnaX intein, Ter DnaE3 intein, Ter ThyX intein, Rma DnaB intein and Cne Prp8 intein (e.g., as described in U.S. Pat. No. 8,394,604, incorporated herein by reference.

In some embodiments, Intein-N and intein-C may be fused to the N-terminal portion of the split Cas9 and the C-terminal portion of a split Cas9, respectively, for the joining of the N-terminal portion of the split Cas9 and the C-terminal portion of the split Cas9. For example, in some embodiments, an intein-N is fused to the C-terminus of the N-terminal portion of the split Cas9, i.e., to form a structure of N [N-terminal portion of the split Cas9]-[intein-N]˜ C. In some embodiments, an intein-C is fused to the N-terminus of the C-terminal portion of the split Cas9, i.e., to form a structure of N-[intein-C]˜[C-terminal portion of the split Cas9]-C. The mechanism of intein-mediated protein splicing for joining the proteins the inteins are fused to (e.g., split Cas9) is described in Shah et al., Chem Sci. 2014; 5(1):446-461, incorporated herein by reference. Methods for designing and using inteins are known in the art and described, for example by WO2020051561, WO2014004336, WO2017132580, US20150344549, and US20180127780, each of which is incorporated herein by reference in their entirety.

In some embodiments, a split refers to a division into two or more fragments. In some embodiments, a split Cas9 protein or split Cas9 comprises a Cas9 protein that is provided as an N-terminal fragment and a C-terminal fragment encoded by two separate nucleotide sequences. The polypeptides corresponding to the N-terminal portion and the C-terminal portion of the Cas9 protein may be spliced to form a reconstituted Cas9 protein. In embodiments, the Cas9 protein is divided into two fragments within a disordered region of the protein, e.g., as described in Nishimasu et al., Cell, Volume 156, Issue 5, pp. 935-949, 2014, or as described in Jiang et al. (2016) Science 351: 867-871 and PDB file: 5F9R (each of which is incorporated herein by reference in its entirety). A disordered region may be determined by one or more protein structure determination techniques known in the art, including, without limitation, X-ray crystallography, NMR spectroscopy, electron microscopy (e.g., cryoEM), and/or in silico protein modeling. In some embodiments, the protein is divided into two fragments at any C, T, A, or S, e.g., within a region of SpCas9 between amino acids A292-G364, F445-K483, or E565-T637, or at corresponding positions in any other Cas9, Cas9 variant (e.g., nCas9, dCas9), or other napDNAbp. In some embodiments, protein is divided into two fragments at SpCas9 T310, T313, A456, S469, or C574. In some embodiments, the process of dividing the protein into two fragments is referred to as splitting the protein.

In some embodiments, a protein fragment ranges from about 2-1000 amino acids (e.g., between 2-10, 10-50, 50-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, or 900-1000 amino acids) in length. In some embodiments, a protein fragment ranges from about 5-500 amino acids (e.g., between 5-10, 10-50, 50-100, 100-200, 200-300, 300-400, or 400-500 amino acids) in length. In some embodiments, a protein fragment ranges from about 20-200 amino acids (e.g., between 20-30, 30-40, 40-50, 50-100, or 100-200 amino acids) in length.

In some embodiments, a portion or fragment of a Gene Writer (e.g., Cas9-R2Tg) is fused to an intein. The nuclease can be fused to the N-terminus or the C-terminus of the intein. In some embodiments, a portion or fragment of a fusion protein is fused to an intein and fused to an AAV capsid protein. The intein, nuclease and capsid protein can be fused together in any arrangement (e.g., nuclease-intein-capsid, intein-nuclease-capsid, capsid-intein-nuclease, etc.). In some embodiments, the N-terminus of an intein is fused to the C-terminus of a fusion protein and the C-terminus of the intein is fused to the N-terminus of an AAV capsid protein.

In some embodiments, an endonuclease domain (e.g., a nickase Cas9 domain) is fused to intein-N and a polypeptide comprising an RT domain is fused to an intein-C.

Exemplary nucleotide and amino acid sequences of interns are provided below:

DnaE Intein-N DNA: (SEQ ID NO: 1637) TGCCTGTCATACGAAACCGAGATACTGACAGTAGAA TATGGCCTTCTGCCAATCGGGAAGATTGTGGAGAAA CGGATAGAATGCACAGTTTACTCTGTCGATAACAAT GGTAACATTTATACTCAGCCAGTTGCCCAGTGGCAC GACCGGGGAGAGCAGGAAGTATTCGAATACTGTCTG GAGGATGGAAGTCTCATTAGGGCCACTAAGGACCAC AAATTTATGACAGTCGATGGCCAGATGCTGCCTATA GACGAAATCTTTGAGCGAGAGTTGGACCTCATGCGA GTTGACAACCTTCCTAAT DnaE Intein-N Protein: (SEQ ID NO: 1638) CLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNN GNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDH KFMTVDGQMLPIDEIFERELDLMRVDNLPN DnaE Intein-C DNA: (SEQ ID NO: 1639) ATGATCAAGATAGCTACAAGGAAGTATCTTGGCAAA CAAAACGTTTATGATATTGGAGTCGAAAGAGATCAC AACTTTGCTCTGAAGAACGGATTCATAGCTTCTAAT Intein-C: (SEQ ID NO: 1640) MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN Cfa-N DNA: (SEQ ID NO: 1641) TGCCTGTCTTATGATACCGAGATACTTACCGTTGAA TATGGCTTCTTGCCTATTGGAAAGATTGTCGAAGAG AGAATTGAATGCACAGTATATACTGTAGACAAGAAT GGTTTCGTTTACACACAGCCCATTGCTCAATGGCAC AATCGCGGCGAACAAGAAGTATTTGAGTACTGTCTC GAGGATGGAAGCATCATACGAGCAACTAAAGATCAT AAATTCATGACCACTGACGGGCAGATGTTGCCAATA GATGAGATATTCGAGCGGGGCTTGGATCTCAAACAA GTGGATGGATTGCCA Cfa-N Protein: (SEQ ID NO: 1642) CLSYDTEILTVEYGFLPIGKIVEERIECTVYTVDKN GFVYTQPIAQWHNRGEQEVFEYCLEDGSIIRATKDH KFMTTDGQMLPIDEIFERGLDLKQVDGLP Cfa-C DNA: (SEQ ID NO: 1643) ATGAAGAGGACTGCCGATGGATCAGAGTTTGAATCT CCCAAGAAGAAGAGGAAAGTAAAGATAATATCTCGA AAAAGTCTTGGTACCCAAAATGTCTATGATATTGGA GTGGAGAAAGATCACAACTTCCTTCTCAAGAACGGT CTCGTAGCCAGCAAC Cfa-C Protein: (SEQ ID NO: 1644) MKRTADGSEFESPKKKRKVKIISRKSLGTQNVYDIG VEKDHNFLLKNGLVASN

Lipid Nanoparticles

The methods and systems provided by the invention, may employ any suitable carrier or delivery modality, including, in certain embodiments, lipid nanoparticles (LNPs). Lipid nanoparticles, in some embodiments, comprise one or more ionic lipids, such as non-cationic lipids (e.g., neutral or anionic, or zwitterionic lipids); one or more conjugated lipids (such as PEG-conjugated lipids or lipids conjugated to polymers described in Table 5 of WO2019217941; incorporated herein by reference in its entirety); one or more sterols (e.g., cholesterol); and, optionally, one or more targeting molecules (e.g., conjugated receptors, receptor ligands, antibodies); or combinations of the foregoing.

Lipids that can be used in nanoparticle formations (e.g., lipid nanoparticles) include, for example those described in Table 4 of WO2019217941, which is incorporated by reference e.g., a lipid-containing nanoparticle can comprise one or more of the lipids in table 4 of WO2019217941. Lipid nanoparticles can include additional elements, such as polymers, such as the polymers described in table 5 of WO2019217941, incorporated by reference.

In some embodiments, conjugated lipids, when present, can include one or more of PEG-diacylglycerol (DAG) (such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG)), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), a pegylated phosphatidylethanoloamine (PEG-PE), PEG succinate diacylglycerol (PEGS-DAG) (such as 4-0-(2′,3′-di(tetradecanoyloxy)propyl-1-0-(w-methoxy(polyethoxy)ethyl) butanedioate (PEG-S-DMG)), PEG dialkoxypropylcarbam, N-(carbonyl-methoxypoly ethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, and those described in Table 2 of WO2019051289 (incorporated by reference), and combinations of the foregoing.

In some embodiments, sterols that can be incorporated into lipid nanoparticles include one or more of cholesterol or cholesterol derivatives, such as those in WO2009/127060 or US2010/0130588, which are incorporated by reference. Additional exemplary sterols include phytosterols, including those described in Eygeris et al (2020), dx.doi.org/10.1021/acs.nanolett.0c01386, incorporated herein by reference.

In some embodiments, the lipid particle comprises an ionizable lipid, a non-cationic lipid, a conjugated lipid that inhibits aggregation of particles, and a sterol. The amounts of these components can be varied independently and to achieve desired properties. For example, in some embodiments, the lipid nanoparticle comprises an ionizable lipid is in an amount from about 20 mol % to about 90 mol % of the total lipids (in other embodiments it may be 20-70% (mol), 30-60% (mol) or 40-50% (mol); about 50 mol % to about 90 mol % of the total lipid present in the lipid nanoparticle), a non-cationic lipid in an amount from about 5 mol % to about 30 mol % of the total lipids, a conjugated lipid in an amount from about 0.5 mol % to about 20 mol % of the total lipids, and a sterol in an amount from about 20 mol % to about 50 mol % of the total lipids. The ratio of total lipid to nucleic acid (e.g., encoding the Gene Writer or template nucleic acid) can be varied as desired. For example, the total lipid to nucleic acid (mass or weight) ratio can be from about 10:1 to about 30:1.

In some embodiments, an ionizable lipid may be a cationic lipid, a ionizable cationic lipid, e.g., a cationic lipid that can exist in a positively charged or neutral form depending on pH, or an amine-containing lipid that can be readily protonated. In some embodiments, the cationic lipid is a lipid capable of being positively charged, e.g., under physiological conditions. Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. In some embodiments, the lipid particle comprises a cationic lipid in formulation with one or more of neutral lipids, ionizable amine-containing lipids, biodegradable alkyn lipids, steroids, phospholipids including polyunsaturated lipids, structural lipids (e.g., sterols), PEG, cholesterol and polymer conjugated lipids. In some embodiments, the cationic lipid may be an ionizable cationic lipid. An exemplary cationic lipid as disclosed herein may have an effective pKa over 6.0. In embodiments, a lipid nanoparticle may comprise a second cationic lipid having a different effective pKa (e.g., greater than the first effective pKa), than the first cationic lipid. A lipid nanoparticle may comprise between 40 and 60 mol percent of a cationic lipid, a neutral lipid, a steroid, a polymer conjugated lipid, and a therapeutic agent, e.g., a nucleic acid (e.g., RNA) described herein (e.g., a template nucleic acid or a nucleic acid encoding a GeneWriter), encapsulated within or associated with the lipid nanoparticle. In some embodiments, the nucleic acid is co-formulated with the cationic lipid. The nucleic acid may be adsorbed to the surface of an LNP, e.g., an LNP comprising a cationic lipid. In some embodiments, the nucleic acid may be encapsulated in an LNP, e.g., an LNP comprising a cationic lipid. In some embodiments, the lipid nanoparticle may comprise a targeting moiety, e.g., coated with a targeting agent. In embodiments, the LNP formulation is biodegradable. In some embodiments, a lipid nanoparticle comprising one or more lipid described herein, e.g., Formula (i), (ii), (ii), (vii) and/or (ix) encapsulates at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98% or 100% of an RNA molecule, e.g., template RNA and/or a mRNA encoding the Gene Writer polypeptide.

In some embodiments, the lipid to nucleic acid ratio (mass/mass ratio; w/w ratio) can be in the range of from about 1:1 to about 25:1, from about 10:1 to about 14:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. The amounts of lipids and nucleic acid can be adjusted to provide a desired N/P ratio, for example, N/P ratio of 3, 4, 5, 6, 7, 8, 9, 10 or higher. Generally, the lipid nanoparticle formulation's overall lipid content can range from about 5 mg/ml to about 30 mg/mL.

Exemplary ionizable lipids that can be used in lipid nanoparticle formulations include, without limitation, those listed in Table 1 of WO2019051289, incorporated herein by reference. Additional exemplary lipids include, without limitation, one or more of the following formulae: X of US2016/0311759; I of US20150376115 or in US2016/0376224; I, II or III of US20160151284; I, IA, II, or IIA of US20170210967; I-c of US20150140070; A of US2013/0178541; I of US2013/0303587 or US2013/0123338; I of US2015/0141678; II, III, IV, or V of US2015/0239926; I of US2017/0119904; I or II of WO2017/117528; A of US2012/0149894; A of US2015/0057373; A of WO2013/116126; A of US2013/0090372; A of US2013/0274523; A of US2013/0274504; A of US2013/0053572; A of WO2013/016058; A of WO2012/162210; I of US2008/042973; I, II, III, or IV of US2012/01287670; I or II of US2014/0200257; I, II, or III of US2015/0203446; I or III of US2015/0005363; I, IA, IB, IC, ID, II, IIA, IIB, IIC, IID, or III-XXIV of US2014/0308304; of US2013/0338210; I, II, III, or IV of WO2009/132131; A of US2012/01011478; I or XXXV of US2012/0027796; XIV or XVII of US2012/0058144; of US2013/0323269; I of US2011/0117125; I, II, or III of US2011/0256175; I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII of US2012/0202871; I, II, III, IV, V, VI, VII, VIII, X, XII, XIII, XIV, XV, or XVI of US2011/0076335; I or II of US2006/008378; I of US2013/0123338; I or X-A-Y-Z of US2015/0064242; XVI, XVII, or XVIII of US2013/0022649; I, II, or III of US2013/0116307; I, II, or III of US2013/0116307; I or II of US2010/0062967; I-X of US2013/0189351; I of US2014/0039032; V of US2018/0028664; I of US2016/0317458; I of US2013/0195920; 5, 6, or 10 of U.S. Pat. No. 10,221,127; I11-3 of WO2018/081480; I-5 or I-8 of WO2020/081938; 18 or 25 of U.S. Pat. No. 9,867,888; A of US2019/0136231; II of WO2020/219876; 1 of US2012/0027803; OF-02 of US2019/0240349; 23 of U.S. Pat. No. 10,086,013; cKK-E12/A6 of Miao et al (2020); C12-200 of WO2010/053572; 7C1 of Dahlman et al (2017); 304-013 or 503-013 of Whitehead et al; TS-P4C2 of U.S. Pat. No. 9,708,628; I of WO2020/106946; I of WO2020/106946.

In some embodiments, the ionizable lipid is MC3 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate (DLin-MC3-DMA or MC3), e.g., as described in Example 9 of WO2019051289A9 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is the lipid ATX-002, e.g., as described in Example 10 of WO2019051289A9 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is (13Z,16Z)-A,A-dimethyl-3-nonyldocosa-13, 16-dien-1-amine (Compound 32), e.g., as described in Example 11 of WO2019051289A9 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is Compound 6 or Compound 22, e.g., as described in Example 12 of WO2019051289A9 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102); e.g., as described in Example 1 of U.S. Pat. No. 9,867,888 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is 9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate (LPO1) e.g., as synthesized in Example 13 of WO2015/095340 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is Di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g. as synthesized in Example 7, 8, or 9 of US2012/0027803 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is 1,1′-((2-(4-(2-((2-(Bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), e.g., as synthesized in Examples 14 and 16 of WO2010/053572 (incorporated by reference herein in its entirety). In some embodiments, the ionizable lipid is; Imidazole cholesterol ester (ICE) lipid (3S, 10R, 13R, 17R)-10, 13-dimethyl-17-((R)-6-methylheptan-2-yl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-(1H-imidazol-4-yl)propanoate, e.g., Structure (I) from WO2020/106946 (incorporated by reference herein in its entirety).

Some non-limiting example of lipid compounds that may be used (e.g., in combination with other lipid components) to form lipid nanoparticles for the delivery of compositions described herein, e.g., nucleic acid (e.g., RNA) described herein (e.g., a template nucleic acid or a nucleic acid encoding a GeneWriter) includes,

In some embodiments an LNP comprising Formula (i) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (ii) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (iii) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (v) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (vi) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

(viii)

In some embodiments an LNP comprising Formula (viii) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (ix) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

-   -   wherein     -   X¹ is O, NR¹, or a direct bond, X² is C2-5 alkylene, X³ is C(=0)         or a direct bond, R¹ is H or Me, R³ is Ci-3 alkyl, R² is Ci-3         alkyl, or R² taken together with the nitrogen atom to which it         is attached and 1-3 carbon atoms of X² form a 4-, 5-, or         6-membered ring, or X¹ is NR¹, R¹ and R² taken together with the         nitrogen atoms to which they are attached form a 5- or         6-membered ring, or R² taken together with R³ and the nitrogen         atom to which they are attached form 5-, 6-, or 7-membered ring,         Y¹ is C2-12 alkylene, Y² is selected from

-   -   n is 0 to 3 R⁴ is Ci-15 alkyl, Z¹ is Ci-6 alkylene or a direct         bond,     -   Z² is

-   -   (in either orientation) or absent, provided that if Z¹ is a         direct bond, Z² is absent;     -   R⁵ is C5-9 alkyl or C6-10 alkoxy, R⁶ is C5-9 alkyl or C6-10         alkoxy, W is methylene or a direct bond, and R⁷ is H or Me, or a         salt thereof, provided that if R³ and R² are C2 alkyls, X¹ is O,         X² is linear C3 alkylene, X³ is C(=0, Y¹ linear Ce alkylene,         (Y²)_(n)-R⁴ is

-   -   R⁴ is linear C5 alkyl, Z¹ is C2 alkylene, Z² is absent, W is         methylene, and R⁷ is H, then R⁵ and R⁶ are not Cx alkoxy.

In some embodiments an LNP comprising Formula (xii) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising Formula (xi) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

where R=

In some embodiments, a lipid of Formula (xii) can be represented by the following structure

In some embodiments an LNP comprises a compound of Formula (xiii) and a compound of Formula (xiv).

In some embodiments an LNP comprising Formula (xv) is used to deliver a GeneWriter composition described herein to the liver and/or hepatocyte cells.

In some embodiments an LNP comprising a formulation of Formula (xvi) is used to deliver a GeneWriter composition described herein to the lung endothelial cells.

where X=

(a)

In some embodiments, a lipid compound used to form lipid nanoparticles for the delivery of compositions described herein, e.g., nucleic acid (e.g., RNA) described herein (e.g., a template nucleic acid or a nucleic acid encoding a GeneWriter) is made by one of the following reactions:

Exemplary non-cationic lipids include, but are not limited to, distearoyl-sn-glycero-phosphoethanolamine, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine (such as 16-O-monomethyl PE), dimethyl-phosphatidylethanolamine (such as 16-O-dimethyl PE), 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylserine (DOPS), sphingomyelin (SM), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dierucoylphosphatidylcholine (DEPC), palmitoyloleyolphosphatidylglycerol (POPG), dielaidoyl-phosphatidylethanolamine (DEPE), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidicacid, cerebrosides, dicetylphosphate, lysophosphatidylcholine, dilinoleoylphosphatidylcholine, or mixtures thereof. It is understood that other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. The acyl groups in these lipids are preferably acyl groups derived from fatty acids having C10-C24 carbon chains, e.g., lauroyl, myristoyl, paimitoyl, stearoyl, or oleoyl. Additional exemplary lipids, in certain embodiments, include, without limitation, those described in Kim et al. (2020) dx.doi.org/10.1021/acs.nanolett.0c01386, incorporated herein by reference. Such lipids include, in some embodiments, plant lipids found to improve liver transfection with mRNA (e.g., DGTS). In some embodiments, the non-cationic lipid may have the following structure

Other examples of non-cationic lipids suitable for use in the lipid nanoparticles include, without limitation, nonphosphorous lipids such as, e.g., stearylamine, dodeeylamine, hexadecylamine, acetyl palmitate, glycerol ricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyl dimethyl ammonium bromide, ceramide, sphingomyelin, and the like. Other non-cationic lipids are described in WO2017/099823 or US patent publication US2018/0028664, the contents of which is incorporated herein by reference in their entirety.

In some embodiments, the non-cationic lipid is oleic acid or a compound of Formula I, II, or IV of US2018/0028664, incorporated herein by reference in its entirety. The non-cationic lipid can comprise, for example, 0-30% (mol) of the total lipid present in the lipid nanoparticle. In some embodiments, the non-cationic lipid content is 5-20% (mol) or 10-15% (mol) of the total lipid present in the lipid nanoparticle. In embodiments, the molar ratio of ionizable lipid to the neutral lipid ranges from about 2:1 to about 8:1 (e.g., about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, or 8:1).

In some embodiments, the lipid nanoparticles do not comprise any phospholipids.

In some aspects, the lipid nanoparticle can further comprise a component, such as a sterol, to provide membrane integrity. One exemplary sterol that can be used in the lipid nanoparticle is cholesterol and derivatives thereof. Non-limiting examples of cholesterol derivatives include polar analogues such as 5a-choiestanol, 53-coprostanol, choiesteryl-(2′-hydroxy)-ethyl ether, choiesteryl-(4′-hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5p-cholestanone, and cholesteryl decanoate; and mixtures thereof. In some embodiments, the cholesterol derivative is a polar analogue, e.g., choiesteryl-(4′-hydroxy)-butyl ether. Exemplary cholesterol derivatives are described in PCT publication WO2009/127060 and US patent publication US2010/0130588, each of which is incorporated herein by reference in its entirety.

In some embodiments, the component providing membrane integrity, such as a sterol, can comprise 0-50% (mol) (e.g., 0-10%, 10-20%, 20-30%, 30-40%, or 40-50%) of the total lipid present in the lipid nanoparticle. In some embodiments, such a component is 20-50% (mol) 30-40% (mol) of the total lipid content of the lipid nanoparticle.

In some embodiments, the lipid nanoparticle can comprise a polyethylene glycol (PEG) or a conjugated lipid molecule. Generally, these are used to inhibit aggregation of lipid nanoparticles and/or provide steric stabilization. Exemplary conjugated lipids include, but are not limited to, PEG-lipid conjugates, polyoxazoline (POZ)-lipid conjugates, polyamide-lipid conjugates (such as ATTA-lipid conjugates), cationic-polymer lipid (CPL) conjugates, and mixtures thereof. In some embodiments, the conjugated lipid molecule is a PEG-lipid conjugate, for example, a (methoxy polyethylene glycol)-conjugated lipid.

Exemplary PEG-lipid conjugates include, but are not limited to, PEG-diacylglycerol (DAG) (such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG)), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), a pegylated phosphatidylethanoloamine (PEG-PE), PEG succinate diacylglycerol (PEGS-DAG) (such as 4-0-(2′,3′-di(tetradecanoyloxy)propyl-1-0-(w-methoxy(polyethoxy)ethyl) butanedioate (PEG-S-DMG)), PEG dialkoxypropylcarbam, N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, 1,2-dimyristoyl-sn-glycerol, methoxypoly ethylene glycol (DMG-PEG-2K), or a mixture thereof. Additional exemplary PEG-lipid conjugates are described, for example, in U.S. Pat. Nos. 5,885,613, 6,287,591, US2003/0077829, US2003/0077829, US2005/0175682, US2008/0020058, US2011/0117125, US2010/0130588, US2016/0376224, US2017/0119904, and US/099823, the contents of all of which are incorporated herein by reference in their entirety. In some embodiments, a PEG-lipid is a compound of Formula III, III-a-I, III-a-2, III-b-1, III-b-2, or V of US2018/0028664, the content of which is incorporated herein by reference in its entirety. In some embodiments, a PEG-lipid is of Formula II of US20150376115 or US2016/0376224, the content of both of which is incorporated herein by reference in its entirety. In some embodiments, the PEG-DAA conjugate can be, for example, PEG-dilauryloxypropyl, PEG-dimyristyloxypropyl, PEG-dipalmityloxypropyl, or PEG-distearyloxypropyl. The PEG-lipid can be one or more of PEG-DMG, PEG-dilaurylglycerol, PEG-dipalmitoylglycerol, PEG-disterylglycerol, PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglycamide, PEG-disterylglycamide, PEG-cholesterol (1-[8′-(Cholest-5-en-3[beta]-oxy)carboxamido-3′,6′-dioxaoctanyl] carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-Ditetradecoxylbenzyl-[omega]-methyl-poly(ethylene glycol) ether), and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. In some embodiments, the PEG-lipid comprises PEG-DMG, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. In some embodiments, the PEG-lipid comprises a structure selected from:

In some embodiments, lipids conjugated with a molecule other than a PEG can also be used in place of PEG-lipid. For example, polyoxazoline (POZ)-lipid conjugates, polyamide-lipid conjugates (such as ATTA-lipid conjugates), and cationic-polymer lipid (GPL) conjugates can be used in place of or in addition to the PEG-lipid.

Exemplary conjugated lipids, i.e., PEG-lipids, (POZ)-lipid conjugates, ATTA-lipid conjugates and cationic polymer-lipids are described in the PCT and LIS patent applications listed in Table 2 of WO2019051289A9 and in WO2020106946A1, the contents of all of which are incorporated herein by reference in their entirety.

In some embodiments an LNP comprises a compound of Formula (xix), a compound of Formula (xxi) and a compound of Formula (xxv). In some embodiments a LNP comprising a formulation of Formula (xix), Formula (xxi) and Formula (xxv) is used to deliver a GeneWriter composition described herein to the lung or pulmonary cells.

In some embodiments, the PEG or the conjugated lipid can comprise 0-20% (mol) of the total lipid present in the lipid nanoparticle. In some embodiments, PEG or the conjugated lipid content is 0.5-10% or 2-5% (mol) of the total lipid present in the lipid nanoparticle. Molar ratios of the ionizable lipid, non-cationic-lipid, sterol, and PEG/conjugated lipid can be varied as needed. For example, the lipid particle can comprise 30-70% ionizable lipid by mole or by total weight of the composition, 0-60% cholesterol by mole or by total weight of the composition, 0-30% non-cationic-lipid by mole or by total weight of the composition and 1-10% conjugated lipid by mole or by total weight of the composition. Preferably, the composition comprises 30-40% ionizable lipid by mole or by total weight of the composition, 40-50% cholesterol by mole or by total weight of the composition, and 10-20% non-cationic-lipid by mole or by total weight of the composition. In some other embodiments, the composition is 50-75% ionizable lipid by mole or by total weight of the composition, 20-40% cholesterol by mole or by total weight of the composition, and 5 to 10% non-cationic-lipid, by mole or by total weight of the composition and 1-10% conjugated lipid by mole or by total weight of the composition. The composition may contain 60-70% ionizable lipid by mole or by total weight of the composition, 25-35% cholesterol by mole or by total weight of the composition, and 5-10% non-cationic-lipid by mole or by total weight of the composition. The composition may also contain up to 90% ionizable lipid by mole or by total weight of the composition and 2 to 15% non-cationic lipid by mole or by total weight of the composition. The formulation may also be a lipid nanoparticle formulation, for example comprising 8-30% ionizable lipid by mole or by total weight of the composition, 5-30% non-cationic lipid by mole or by total weight of the composition, and 0-20% cholesterol by mole or by total weight of the composition; 4-25% ionizable lipid by mole or by total weight of the composition, 4-25% non-cationic lipid by mole or by total weight of the composition, 2 to 25% cholesterol by mole or by total weight of the composition, 10 to 35% conjugate lipid by mole or by total weight of the composition, and 5% cholesterol by mole or by total weight of the composition; or 2-30% ionizable lipid by mole or by total weight of the composition, 2-30% non-cationic lipid by mole or by total weight of the composition, 1 to 15% cholesterol by mole or by total weight of the composition, 2 to 35% conjugate lipid by mole or by total weight of the composition, and 1-20% cholesterol by mole or by total weight of the composition; or even up to 90% ionizable lipid by mole or by total weight of the composition and 2-10% non-cationic lipids by mole or by total weight of the composition, or even 100% cationic lipid by mole or by total weight of the composition. In some embodiments, the lipid particle formulation comprises ionizable lipid, phospholipid, cholesterol and a PEG-ylated lipid in a molar ratio of 50:10:38.5:1.5. In some other embodiments, the lipid particle formulation comprises ionizable lipid, cholesterol and a PEG-ylated lipid in a molar ratio of 60:38.5:1.5.

In some embodiments, the lipid particle comprises ionizable lipid, non-cationic lipid (e.g. phospholipid), a sterol (e.g., cholesterol) and a PEG-ylated lipid, where the molar ratio of lipids ranges from 20 to 70 mole percent for the ionizable lipid, with a target of 40-60, the mole percent of non-cationic lipid ranges from 0 to 30, with a target of 0 to 15, the mole percent of sterol ranges from 20 to 70, with a target of 30 to 50, and the mole percent of PEG-ylated lipid ranges from 1 to 6, with a target of 2 to 5.

In some embodiments, the lipid particle comprises ionizable lipid/non-cationic-lipid/sterol/conjugated lipid at a molar ratio of 50:10:38.5:1.5.

In an aspect, the disclosure provides a lipid nanoparticle formulation comprising phospholipids, lecithin, phosphatidylcholine and phosphatidylethanolamine.

In some embodiments, one or more additional compounds can also be included. Those compounds can be administered separately or the additional compounds can be included in the lipid nanoparticles of the invention. In other words, the lipid nanoparticles can contain other compounds in addition to the nucleic acid or at least a second nucleic acid, different than the first. Without limitations, other additional compounds can be selected from the group consisting of small or large organic or inorganic molecules, monosaccharides, disaccharides, trisaccharides, oligosaccharides, polysaccharides, peptides, proteins, peptide analogs and derivatives thereof, peptidomimetics, nucleic acids, nucleic acid analogs and derivatives, an extract made from biological materials, or any combinations thereof.

In some embodiments, a lipid nanoparticle (or a formulation comprising lipid nanoparticles) lacks reactive impurities (e.g., aldehydes or ketones), or comprises less than a preselected level of reactive impurities (e.g., aldehydes or ketones). While not wishing to be bound by theory, in some embodiments, a lipid reagent is used to make a lipid nanoparticle formulation, and the lipid reagent may comprise a contaminating reactive impurity (e.g., an aldehyde or ketone). A lipid regent may be selected for manufacturing based on having less than a preselected level of reactive impurities (e.g., aldehydes or ketones). Without wishing to be bound by theory, in some embodiments, aldehydes can cause modification and damage of RNA, e.g., cross-linking between bases and/or covalently conjugating lipid to RNA (e.g., forming lipid-RNA adducts). This may, in some instances, lead to failure of a reverse transcriptase reaction and/or incorporation of inappropriate bases, e.g., at the site(s) of lesion(s), e.g., a mutation in a newly synthesized target DNA.

In some embodiments, a lipid nanoparticle formulation is produced using a lipid reagent comprising less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. In some embodiments, a lipid nanoparticle formulation is produced using a lipid reagent comprising less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. In some embodiments, a lipid nanoparticle formulation is produced using a lipid reagent comprising: (i) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content; and (ii) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. In some embodiments, the lipid nanoparticle formulation is produced using a plurality of lipid reagents, and each lipid reagent of the plurality independently meets one or more criterion described in this paragraph. In some embodiments, each lipid reagent of the plurality meets the same criterion, e.g., a criterion of this paragraph.

In some embodiments, the lipid nanoparticle formulation comprises less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. In some embodiments, the lipid nanoparticle formulation comprises less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. In some embodiments, the lipid nanoparticle formulation comprises: (i) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content; and (ii) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species.

In some embodiments, one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content. In some embodiments, one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species. In some embodiments, one or more, or optionally all, of the lipid reagents used for a lipid nanoparticle as described herein or a formulation thereof comprise: (i) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% total reactive impurity (e.g., aldehyde) content; and (ii) less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of any single reactive impurity (e.g., aldehyde) species.

In some embodiments, total aldehyde content and/or quantity of any single reactive impurity (e.g., aldehyde) species is determined by liquid chromatography (LC), e.g., coupled with tandem mass spectrometry (MS/MS), e.g., according to the method described in Example 40. In some embodiments, reactive impurity (e.g., aldehyde) content and/or quantity of reactive impurity (e.g., aldehyde) species is determined by detecting one or more chemical modifications of a nucleic acid molecule (e.g., an RNA molecule, e.g., as described herein) associated with the presence of reactive impurities (e.g., aldehydes), e.g., in the lipid reagents. In some embodiments, reactive impurity (e.g., aldehyde) content and/or quantity of reactive impurity (e.g., aldehyde) species is determined by detecting one or more chemical modifications of a nucleotide or nucleoside (e.g., a ribonucleotide or ribonucleoside, e.g., comprised in or isolated from a template nucleic acid, e.g., as described herein) associated with the presence of reactive impurities (e.g., aldehydes), e.g., in the lipid reagents, e.g., as described in Example 41. In embodiments, chemical modifications of a nucleic acid molecule, nucleotide, or nucleoside are detected by determining the presence of one or more modified nucleotides or nucleosides, e.g., using LC-MS/MS analysis, e.g., as described in Example 41.

In some embodiments, a nucleic acid (e.g., RNA) described herein (e.g., a template nucleic acid or a nucleic acid encoding a GeneWriter) does not comprise an aldehyde modification, or comprises less than a preselected amount of aldehyde modifications. In some embodiments, on average, a nucleic acid has less than 50, 20, 10, 5, 2, or 1 aldehyde modifications per 1000 nucleotides, e.g., wherein a single cross-linking of two nucleotides is a single aldehyde modification. In some embodiments, the aldehyde modification is an RNA adduct (e.g., a lipid-RNA adduct). In some embodiments, the aldehyde-modified nucleotide is cross-linking between bases. In some embodiments, a nucleic acid (e.g., RNA) described herein comprises less than 50, 20, 10, 5, 2, or 1 cross-links between nucleotide.

In some embodiments, LNPs are directed to specific tissues by the addition of targeting domains. For example, biological ligands may be displayed on the surface of LNPs to enhance interaction with cells displaying cognate receptors, thus driving association with and cargo delivery to tissues wherein cells express the receptor. In some embodiments, the biological ligand may be a ligand that drives delivery to the liver, e.g., LNPs that display GalNAc result in delivery of nucleic acid cargo to hepatocytes that display asialoglycoprotein receptor (ASGPR). The work of Akinc et al. Mol Ther 18(7):1357-1364 (2010) teaches the conjugation of a trivalent GalNAc ligand to a PEG-lipid (GalNAc-PEG-DSG) to yield LNPs dependent on ASGPR for observable LNP cargo effect (see, e.g., FIG. 6 ). Other ligand-displaying LNP formulations, e.g., incorporating folate, transferrin, or antibodies, are discussed in WO2017223135, which is incorporated herein by reference in its entirety, in addition to the references used therein, namely Kolhatkar et al., Curr Drug Discov Technol. 2011 8:197-206; Musacchio and Torchilin, Front Biosci. 2011 16:1388-1412; Yu et al., Mol Membr Biol. 2010 27:286-298; Patil et al., Crit Rev Ther Drug Carrier Syst. 2008 25:1-61; Benoit et al., Biomacromolecules. 2011 12:2708-2714; Zhao et al., Expert Opin Drug Deliv. 2008 5:309-319; Akinc et al., Mol Ther. 2010 18:1357-1364; Srinivasan et al., Methods Mol Biol. 2012 820:105-116; Ben-Arie et al., Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release. 20:63-68; Peer et al., Proc Natl Acad Sci USA. 2007 104:4095-4100; Kim et al., Methods Mol Biol. 2011 721:339-353; Subramanya et al., Mol Ther. 2010 18:2028-2037; Song et al., Nat Biotechnol. 2005 23:709-717; Peer et al., Science. 2008 319:627-630; and Peer and Lieberman, Gene Ther. 2011 18:1127-1133.

In some embodiments, LNPs are selected for tissue-specific activity by the addition of a Selective ORgan Targeting (SORT) molecule to a formulation comprising traditional components, such as ionizable cationic lipids, amphipathic phospholipids, cholesterol and poly(ethylene glycol) (PEG) lipids. The teachings of Cheng et al. Nat Nanotechnol 15(4):313-320 (2020) demonstrate that the addition of a supplemental “SORT” component precisely alters the in vivo RNA delivery profile and mediates tissue-specific (e.g., lungs, liver, spleen) gene delivery and editing as a function of the percentage and biophysical property of the SORT molecule.

In some embodiments, the LNPs comprise biodegradable, ionizable lipids. In some embodiments, the LNPs comprise (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, also called 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate) or another ionizable lipid. See, e.g, lipids of WO2019/067992, WO/2017/173054, WO2015/095340, and WO2014/136086, as well as references provided therein. In some embodiments, the term cationic and ionizable in the context of LNP lipids is interchangeable, e.g., wherein ionizable lipids are cationic depending on the pH.

In some embodiments, multiple components of a Gene Writer system may be prepared as a single LNP formulation, e.g., an LNP formulation comprises mRNA encoding for the Gene Writer polypeptide and an RNA template. Ratios of nucleic acid components may be varied in order to maximize the properties of a therapeutic. In some embodiments, the ratio of RNA template to mRNA encoding a Gene Writer polypeptide is about 1:1 to 100:1, e.g., about 1:1 to 20:1, about 20:1 to 40:1, about 40:1 to 60:1, about 60:1 to 80:1, or about 80:1 to 100:1, by molar ratio. In other embodiments, a system of multiple nucleic acids may be prepared by separate formulations, e.g., one LNP formulation comprising a template RNA and a second LNP formulation comprising an mRNA encoding a Gene Writer polypeptide. In some embodiments, the system may comprise more than two nucleic acid components formulated into LNPs. In some embodiments, the system may comprise a protein, e.g., a Gene Writer polypeptide, and a template RNA formulated into at least one LNP formulation.

In some embodiments, the average LNP diameter of the LNP formulation may be between 10⁸ of nm and 100s of nm, e.g., measured by dynamic light scattering (DLS). In some embodiments, the average LNP diameter of the LNP formulation may be from about 40 nm to about 150 nm, such as about 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In some embodiments, the average LNP diameter of the LNP formulation may be from about 50 nm to about 100 nm, from about 50 nm to about 90 nm, from about 50 nm to about 80 nm, from about 50 nm to about 70 nm, from about 50 nm to about 60 nm, from about 60 nm to about 100 nm, from about 60 nm to about 90 nm, from about 60 nm to about 80 nm, from about 60 nm to about 70 nm, from about 70 nm to about 100 nm, from about 70 nm to about 90 nm, from about 70 nm to about 80 nm, from about 80 nm to about 100 nm, from about 80 nm to about 90 nm, or from about 90 nm to about 100 nm. In some embodiments, the average LNP diameter of the LNP formulation may be from about 70 nm to about 100 nm. In a particular embodiment, the average LNP diameter of the LNP formulation may be about 80 nm. In some embodiments, the average LNP diameter of the LNP formulation may be about 100 nm. In some embodiments, the average LNP diameter of the LNP formulation ranges from about 1 mm to about 500 mm, from about 5 mm to about 200 mm, from about 10 mm to about 100 mm, from about 20 mm to about 80 mm, from about 25 mm to about 60 mm, from about 30 mm to about 55 mm, from about 35 mm to about 50 mm, or from about 38 mm to about 42 mm.

A LNP may, in some instances, be relatively homogenous. A polydispersity index may be used to indicate the homogeneity of a LNP, e.g., the particle size distribution of the lipid nanoparticles. A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. A LNP may have a polydispersity index from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of a LNP may be from about 0.10 to about 0.20.

The zeta potential of a LNP may be used to indicate the electrokinetic potential of the composition. In some embodiments, the zeta potential may describe the surface charge of a LNP. Lipid nanoparticles with relatively low charges, positive or negative, are generally desirable, as more highly charged species may interact undesirably with cells, tissues, and other elements in the body. In some embodiments, the zeta potential of a LNP may be from about −10 mV to about +20 mV, from about −10 mV to about +15 mV, from about −10 mV to about +10 mV, from about −10 mV to about +5 mV, from about −10 mV to about 0 mV, from about −10 mV to about −5 mV, from about −5 mV to about +20 mV, from about −5 mV to about +15 mV, from about −5 mV to about +10 mV, from about −5 mV to about +5 mV, from about −5 mV to about 0 mV, from about 0 mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV to about +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about +20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about +10 mV.

The efficiency of encapsulation of a protein and/or nucleic acid, e.g., Gene Writer polypeptide or mRNA encoding the polypeptide, describes the amount of protein and/or nucleic acid that is encapsulated or otherwise associated with a LNP after preparation, relative to the initial amount provided. The encapsulation efficiency is desirably high (e.g., close to 100%). The encapsulation efficiency may be measured, for example, by comparing the amount of protein or nucleic acid in a solution containing the lipid nanoparticle before and after breaking up the lipid nanoparticle with one or more organic solvents or detergents. An anion exchange resin may be used to measure the amount of free protein or nucleic acid (e.g., RNA) in a solution. Fluorescence may be used to measure the amount of free protein and/or nucleic acid (e.g., RNA) in a solution. For the lipid nanoparticles described herein, the encapsulation efficiency of a protein and/or nucleic acid may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency may be at least 80%. In some embodiments, the encapsulation efficiency may be at least 90%. In some embodiments, the encapsulation efficiency may be at least 95%.

A LNP may optionally comprise one or more coatings. In some embodiments, a LNP may be formulated in a capsule, film, or table having a coating. A capsule, film, or tablet including a composition described herein may have any useful size, tensile strength, hardness or density.

Additional exemplary lipids, formulations, methods, and characterization of LNPs are taught by WO2020061457, which is incorporated herein by reference in its entirety.

In some embodiments, in vitro or ex vivo cell lipofections are performed using Lipofectamine MessengerMax (Thermo Fisher) or TransIT-mRNA Transfection Reagent (Mirus Bio). In certain embodiments, LNPs are formulated using the GenVoy_ILM ionizable lipid mix (Precision NanoSystems). In certain embodiments, LNPs are formulated using 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA) or dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA or MC3), the formulation and in vivo use of which are taught in Jayaraman et al. Angew Chem Int Ed Engl 51(34):8529-8533 (2012), incorporated herein by reference in its entirety.

LNP formulations optimized for the delivery of CRISPR-Cas systems, e.g., Cas9-gRNA RNP, gRNA, Cas9 mRNA, are described in WO2019067992 and WO2019067910, both incorporated by reference.

Additional specific LNP formulations useful for delivery of nucleic acids are described in U.S. Pat. Nos. 8,158,601 and 8,168,775, both incorporated by reference, which include formulations used in patisiran, sold under the name ONPATTRO.

Exemplary dosing of Gene Writer LNP may include about 0.1, 0.25, 0.3, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, or 100 mg/kg (RNA). Exemplary dosing of AAV comprising a nucleic acid encoding one or more components of the system may include an MOI of about 10¹¹, 10¹², 10¹³, and 10¹⁴ vg/kg.

All publications, patent applications, patents, and other publications and references (e.g., sequence database reference numbers) cited herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences referred to herein, e.g., in any Table herein, are incorporated by reference. Unless otherwise specified, the sequence accession numbers specified herein, including in any Table herein, refer to the database entries current as of Mar. 4, 2020. When one gene or protein references a plurality of sequence accession numbers, all of the sequence variants are encompassed.

EXAMPLES

The invention is further illustrated by the following examples. The examples are provided for illustrative purposes only and are not to be construed as limiting the scope or content of the invention in any way.

Example 1: Gene Writer™ Enabling Nucleotide Substitution in Genomic DNA to Correct Alpha-1 Antitrypsin Deficiency Mutation in Human Cells

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence at a single nucleotide.

In this example, the Gene Writer™ polypeptide and writing template are provided as DNA transfected into HEK293T cells that possess the PiZ genotype (E342K), a common allele associated with alpha-1 antitrypsin deficiency. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The writing template is designed to have homology to the target sequence, while incorporating additional nucleotides at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand containing the substitution.

To create the transversion in the affected human SERPINAI gene that restores the GAG triplet coding for glutamate in healthy patients, the Gene Writer™ polypeptide is used with a specific template nucleic acid, which encodes a gRNA scaffold for polypeptide binding, a spacer for polypeptide homing, target homology domain to set up TPRT, and a template sequence for reverse transcription that includes the required substitution. An exemplary template RNA carries the sequence (1)TCCCCTCCAGGCCGTGCATA(2)GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG GCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCC(3)TcGTCGATGGTC AGCACAGCCTTAT(4)GCACGGCCTGGA (SEQ ID NO: 1607), where numbers are used to delineate the modules of the template in the order (5′-3′) (1) gRNA spacer, (2) gRNA scaffold, (3) heterologous object sequence, (4) 3′ homology priming domain, and the lowercase “c” indicates the position in the template carrying the nucleotide substitution to be written into the target site to correct the E342K mutation. An exemplary gRNA for providing a second nick as described in embodiments of this system comprises the spacer sequence TTTGTTGAACTTGACCTCGG (SEQ ID NO: 1608) and directs a Cas9 nickase to nick the second strand of the target site within the homologous region. In some embodiments, this second nick improves the efficiency of the edit.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target, and genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit.

Example 2: Gene Writer™ Enabling Short Insertion in Genomic DNA to Correct CFTR

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by insertion of a short string of nucleotides.

In this example, the Gene Writer™ polypeptide and writing template are provided as DNA transfected into HEK293T cells that possess the CFTR delta-F508 mutation, a common allele associated with cystic fibrosis. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The writing template is designed to have homology to the target sequence, while incorporating additional nucleotides at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand containing the short insertion.

To create a short insertion in the affected human CFTR locus that restores the TTT triplet coding for phenylalanine in healthy patients, the Gene Writer™ polypeptide is used with a specific template, which encodes a spacer for polypeptide homing, target homology domain to set up TPRT, and a template sequence for reverse transcription that includes the 3-nt insertion.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target. After the incubation period, genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit.

Example 3: Gene Writer™ Enabling Deletion of Genomic DNA to Correct Duchenne Muscular Dystrophy (DMD)

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by deletion of nucleotides.

One of the most common mutations found in patients with DMD is a deletion that eliminates exon 50 in the rod domain of dystrophin, which places exon 51 out of frame with preceding exons. Such a mutation results in production of truncated dystrophin, leading to the pathological effects of the disease. In order to ameliorate disease, the remainder of the 79 total exons, the splice acceptor site is deleted from exon 51, resulting in restoration of the full-length protein, an approach known as exon skipping.

In this example, the Gene Writer™ polypeptide and writing template are provided as RNA nucleofected into cells containing a deletion in exon 50 that results in a truncated dystrophin product, as described above. Target cells are either patient-derived iPSCs containing the mutation or are synthetically engineered using CRISPR-Cas to generate the deletion. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The writing template is designed to have homology to the target sequence, while incorporating a deletion at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand lacking the deleted nucleotides.

To create a short deletion that removes the exon 51 5′ splice acceptor site, the Gene Writer™ polypeptide is used with a specific template that encodes a spacer for polypeptide homing, target homology domain to set up TPRT, and a template sequence for reverse transcription that includes a 5-nt deletion proximal to the Gene Writer™ polypeptide-induced nick, which includes the splice acceptor site.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target. After the incubation period, genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit. Protein analysis by Western blot is used to further confirm the expression of the restored dystrophin, as compared to the truncated dystrophin produced in non-edited cells.

Example 4: Gene Writer™ Enabling Large Insertion into Genomic DNA

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by insertion of a large string of nucleotides.

In this example, the Gene Writer™ polypeptide, gRNA, and writing template are provided as DNA transfected into HEK293T cells. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The reverse transcriptase function is derived from the highly processive RT domain of an R2 retrotransposase. The writing template is designed to have homology to the target sequence, while incorporating the genetic payload at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand containing the desired insertion.

To create a large insertion in the human HEK293T cell DNA, the Gene Writer™ polypeptide is used in conjunction with a specific gRNA, which targets the Cas9-containing Gene Writer™ to the target locus, and a template RNA for reverse transcription, which contains an RT-binding motif (3′ UTR from an R2 element) for associating with the reverse transcriptase, a region of homology to the target site for priming reverse transcription, and a genetic payload (GFP expression unit). This complex nicks the target site and then performs TPRT on the template, initiating the reaction by using priming regions on the template that are complementary to the sequence immediately adjacent to the site of the nick and copying the GFP payload into the genomic DNA.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target. After the incubation period, genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit.

Example 5: Gene Writer™ Edits not Incorporating Binding Sequences from the Template RNA

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by insertion of a genetic payload without causing the insertion of additional sequence from the template molecule.

In this example, the Gene Writer™ polypeptide and writing template are provided as DNA transfected into HEK293T cells. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The writing template is designed to have homology to the target sequence, while incorporating the genetic payload (e.g. GFP gene expression unit) at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand containing the desired insertion.

To accomplish specific insertion of a genetic payload without also incorporating extraneous template motifs (e.g. protein binding motif), the layout of the template RNA molecule is such that the protein binding sequences (e.g. UTRs) are terminal to the homology sequences used to write the new payload into the genomic target site.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target. After the incubation period, genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit.

Example 6: Gene Writer™ Genome Editing in the Presence of DNA Repair Inhibitors

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by insertion of a genetic payload without causing the insertion of additional sequence from the template molecule.

In this example, experiments will test the effect of different DNA repair pathways on Gene Writing™ via the application of DNA repair pathway inhibitors or DNA repair pathway deficient cell lines. When applying DNA repair pathway inhibitors, PrestoBlue cell viability assay is performed first to determine the toxicity of the inhibitors and whether any normalization should be applied for following assays. SCR7 is an inhibitor for NHEJ, which is applied at a series of dilutions during Gene Writer™ delivery. PARP protein is a nuclear enzyme that binds as homodimers to both single- and double-strand breaks. Thus, its inhibitors are be used in the test of relevant DNA repair pathways, including homologous recombination repair pathway and base excision repair pathway. The experiment procedure is the same with that of SCR7. Cell lines with deficient core proteins of nucleotide excision repair (NER) pathway are used to test the effect of NER on Gene Writing™. After the delivery of the Gene Writer™ system into the cell, ddPCR is used to evaluate the retrotransposition in the context of inhibition of DNA repair pathways. Sequencing analysis is also performed to evaluate whether certain DNA repair pathways play a role in the alteration of the integration junction. In some embodiments, Gene Writing™ into the genome will not be decreased by the knockdown of DNA repair pathways, suggesting that the system does not utilize host cell repair pathways for DNA integration. In some embodiments, Gene Writing™ into the genome will not be decreased by more than 50% by the knockdown of DNA repair pathways, suggesting that the system does not rely on host cell repair pathways for DNA integration.

Example 7: Internal Gene Writer Deletions Demonstrating Protein Domain Modularity

This example describes deletions in a Gene Writer polypeptide that retain functionality and further demonstrate the modularity of the DNA binding domain.

In this example, a series of experiments were performed to test the activity of various mutant retrotransposases, as well as gaining structural knowledge about the protein modularity. This experiment tested removing a polypeptide stretch after the c-myb motif in the DNA binding domain (DBD) and replacing it with a flexible linker (FIG. 8 a ). The polypeptide stretch removed is referred to as the “natural linker” since it is the intervening region between the DNA binding motifs and the RNA binding domain. The polypeptide region removed spans the following: on the N terminal side at either, location A (predicted random coil following c-myb motif) or location B (end of predicted alpha helix that contains part of the c-myb motif) and the removed region ends at either location vi (alpha helical region of R2Tg that preceded the predicted −1 RNA binding motif or at location v2 (C-terminal side of an alpha helical region of R2Tg that preceded the predicted −1 RNA binding motif). In place of the polypeptide stretch removed, “natural linker”, is the either of two linkers (Linker A, XTEN: SGSETPGTSESATPES (SEQ ID NO: 1023), and Linker B, 3GS: GGGS (SEQ ID NO: 1024)). For each of these mutant retrotransposases that contain different removed regions (location A-v1, location A-v2, location B-v1, or location B-v2) they were replaced with either linker A or linker B by PCR to a DNA plasmid that expressed R2Tg, thereby yielding these sequences: c-mybA-v1 replaced with 3GS linker (SEQ ID NO: 1024), c-mybA-v2 replaced with 3GS linker (SEQ ID NO: 1024), c-mybA-v1 replaced with XTEN linker, c-mybA-v2 replaced with XTEN linker, c-mybB-v1 replaced with 3GS linker (SEQ ID NO: 1024), c-mybB-v2 replaced with 3GS linker (SEQ ID NO: 1024), c-mybB-v1 replaced with XTEN linker, c-mybB-v2 replaced with XTEN linker, as shown in Table E1 below. The insertion of the linkers was verified by Sanger sequencing and the DNA plasmids were purified for transfection.

Table E1. Amino acid sequences of R2Tg mutants with linkers in place of the “natural linker” region that intervenes the DNA binding domain (DBD) and RNA binding domain.

The N-terminal DNA-binding domain is italicized and the linker connecting to the rest of the protein is in bold and underlined.

R2Tg SEQ ID Mutant Amino Acid Sequence NO: R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1646 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybA FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v1 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE 3GS linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR (SEQ ID NO: CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRK 1024) PAEEPREEPGTCHHTRRAA GGGS CFGCLESISQIRTATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDI PLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNV QEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGC RTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNP RQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQ HIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQ GDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLSDS WENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTI NGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLK PLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPP CTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFME KEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPH RKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNC PVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIF VKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDV TFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDI VHMFASRARKSMVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1647 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybA FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v2 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE 3GS linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR (SEQ ID NO: CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRK 1024) PAEEPREEPGTCHHTRRAA GGGS TATRDKKDTVTREKHPKKPFQKWMKD RAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTR WETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPD GITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCS ENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVD PHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLA MDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILE TFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGE SEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYT IPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTR DGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLW IQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRK NEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRAN VYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHN YICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVT VRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGK WHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSM VM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1648 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybA FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v1 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE XTEN linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRK PAEEPREEPGTCHHTRRAA SGSETPGTSESATPES CFGCLESISQIRTA TRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKI ILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFR ELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWL TTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSRIV TARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFV DIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTH TDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAM AFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKD SYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLD FWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKI RTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIA QSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNN VSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKIS NHWIQYYRRIPHRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDA DIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIRD SNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLE TEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAET FSTVALFSSVDIVHMFASRARKSMVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1649 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybA FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v2 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE XTEN linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRK PAEEPREEPGTCHHTRRAA SGSETPGTSESATPES TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDI PLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNV QEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGC RTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNP RQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQ HIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQ GDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLSDS WENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTI NGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLK PLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPP CTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFME KEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPH RKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNC PVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIF VKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDV TFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDI VHMFASRARKSMVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1650 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybB FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v1 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE 3GS linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR (SEQ ID NO: CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRL GGGS 1024) CFGCLESISQIRTATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRF QRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLG DFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMD PEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPI TIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIW SAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEES GKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQ GQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDP WIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHS EVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAG LIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIP SIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLAS QGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLARG RQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAK KKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLE EAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTE LGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1651 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybB FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v2 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE 3GS linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR (SEQ ID NO: CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRL GGGS 1024) TATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLA KIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTA FRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNL WLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSR IVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVV FVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRN THTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSIT AMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPT KDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTK LDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQ KIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHR IAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPP NNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDK ISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLARGRQDQYIKACRHC DADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHI RDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKH LETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKMA ETFSTVALFSSVDIVHMFASRARKSMVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1652 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybB FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v1 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE XTEN linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRL SGSE TPGTSESATPES CFGCLESISQIRTATRDKKDTVTREKHPKKPFQKWMK DRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKT RWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGP DGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKP DRLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGC SENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREV DPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNL AMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISIL ETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPG ESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTY TIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSST RDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKL WIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWR KNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRA NVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRH NYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDV TVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKS MVM R2Tg with MASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNSLANSGSDFGGGGL 1653 natural linker GLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDLVSLFPKHRV deletion c- DLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHVYECVH mybB FAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEKE location-v2 SEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNL replaced with IEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGE XTEN linker WICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKR CWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRL SGSE TPGTSESATPES TATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRF QRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLG DFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMD PEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPI TIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIW SAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEES GKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQ GQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDP WIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHS EVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAG LIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIP SIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLAS QGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLARG RQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAK KKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLE EAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTE LGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM

HEK293T cells were plated in 96-well plates and grown overnight at 37° C., 5% CO2. The HEK293T cells were transfected with plasmids that expressed R2Tg (wild-type), R2 endonuclease mutant, and natural linker mutants. The transfection was carried out using the Fugene HD transfection reagent according to the manufacturer recommendations, where each well received 80 ng of plasmid DNA and 0.5 μL of transfection reagent. All transfections were performed in duplicate and the cells were incubated for 72 h prior to genomic DNA extraction.

Activity of the mutants was measured by a ddPCR assay that quantified the copy number of R2Tg integrations by measuring the number of 3′ junction amplicons (FIG. 8 b ).

Deletions that begin after the random coil following the c-myb DNA binding motif (location A, c-mybA) are well-tolerated with integration activity near that of wild-type R2Tg. The natural linker region deletion end point is nearly the same for either location v1 (N-terminal to the alpha helix preceding the −1 RNA binding motif) or v2 (C-terminal to the alpha helix preceding the −1 RNA binding motif). For the deletion beginning at location A and ending at location v1 or v2, replacement of this polypeptide stretch with the XTEN linker (SEQ ID NO: 1023) seems to retain the most amount of activity whereas replacement with the 3GS linker (SEQ ID NO: 1024) has approximately a 50% reduction in integration activity. For natural linker deletions that begin at location B (c-mybB), these configurations show a more marked reduction in integration activity when compared to wild-type or location A (c-mybA). The difference in activity may be related to the structure of the protein based on the position of the deletion that creates a non-optimal three dimensional structure of the retrotransposase through the location of the linker, length of the linker, or amino acid combination of the linker that is not optimal to connect location B to locations v1 or v2. Even though the N-terminal natural linker deletion start location mybB is a sub-optimal, the C-terminal end of the deletion was most tolerated at v2 with either the 3GS (SEQ ID NO: 1024) or XTEN linker and appears to be the preferential location for having a polypeptide preceding the RBD −1 region.

Example 8: Determination of Target Specificity of a Gene Writer Endonuclease Domain

This example describes using a custom genomic landing pad in human cells to determine whether there is a sequence requirement for target cleavage and subsequent integration by a Gene Writer system.

In this example, cell lines were created to have “landing pads” or stable integrations that mimic a region of rDNA that contain the R2 position to which R2 retrotransposases target for retrotransposition (see FIG. 9 ). The integrants or landing pads were designed to either have the wild-type region sequence in and around the R2 site found in rDNA, 12-bp of sequence mutation at and around the R2 cleavage site, or 75-bp of sequence mutation at and around the R2 cleavage site (Table E2). The DNA for these different landing pads was chemically synthesized and cloned into the pLenti-N-tGFP vector. The cloned landing pads into the lentiviral expression vector were confirmed and sequence verified by Sanger sequencing of the landing pad. The sequence verified plasmids (9 μg) along with the lentiviral packaging mix (9 μg, obtained from Biosettia) were transfected using Lipofectamine2000™ according the manufacturer instructions into a packaging cell line, LentiX-293T (Takara Bio). The transfected cells were incubated at 37° C., 10% CO₂ for 48 hours (including one medium change at 24 hrs) and the viral particle containing medium was collected from the cell culture dish. The collected medium was filtered through a 0.2 pm filter to remove cell debris and prepared for transduction of U2OS cells. The viral containing medium was diluted in DMEM and mixed with polybrene to prepare a dilution series for transduction of U2OS cells where the final concentration of polybrene was 8 μg/ml. The U2OS cells were grown in viral containing medium for 48 hour and then split with fresh medium. The split cells were grown to confluence and transduction efficiency of the different dilutions of virus were measured by GFP expression via flow cytometry and ddPCR detection of the genomic integrated lentivirus that contained GFP and the different rDNA landing pads (WT, 12-bp mutation, or 75-bp mutation). The GFP positive cell line from the 1:10 viral medium dilution (>99% GFP+) was chosen for subsequent experiments and cryopreserved.

To test if mutations in and around the R2 cleavage position can impact the Gene Writer system activity, the R2Tg Gene Writer Driver along with a plasmid that expressed a Gene Writer transgene molecule were electroporated into the different landing pad cell lines. In order to test if the sequence in and around the cleavage site impacted the Gene Writer polypeptide sequence activity to integrate, the homology arms for the Gene Writer template molecule were designed to have 100% homology 100 bp to the left (Gene Writer molecule module A) and 100 bp to the right (Gene Writer molecule module F) of the cleavage position for each of the landing pads. The changes to the homology arms of the Gene Writer template molecule expression plasmid were introduced by PCR and were confirmed by Sanger Sequencing. Either 73 ng of the WT R2Tg Gene Writer Driver or the Endonuclease domain mutant R2Tg Gene Writer Driver expression plasmids were co-nucleofected) using nucleofection program DN100 into each of the different U2OS landing pad cell lines (WT, 12-bp mutant, or 75-bp mutant) with 177 ng of plasmids that expressed the Gene Writer template molecules that had 100% homology to either the WT landing pad, 12-bp mutant landing pad, or 75-bp mutant landing pad. After nucleofection, cells were grown at 37° C., 10% CO₂ for 3 days prior to cell lysis and genomic DNA extraction. The extracted gDNA was measured for Gene Writer template molecule integration at the landing pad site by ddPCR. The DNA nicking activity was measured by detection of insertions, deletions, and/or a combination of both insertions and deletions at the landing pad through next-generation sequence analysis of an amplicon that was generated from the landing pad found in the gDNA.

The integration activity of the R2Tg Gene Writer is greatly reduced when the cleavage region is mutated where there is no integration of a Gene Writer template molecule in either of the 12-bp or 75-bp landing pad cell lines (FIG. 10 a ). Furthermore, integration is not detected with Gene Writer template molecules that have homology arms that correspond to either the 12-bp or 75-bp mutant landing pads. To rule out that the lost integration activity is due to incompatible homology arms, DNA nicking activity was measured by NGS analysis of the landing pad. The nicking activity is independent of the Gene Writer template molecule as the WT R2Tg Gene Writer driver had comparable indels at the WT landing pad with the WT, 12-bp mutant, or 75-bp mutant Gene Writer template molecule (FIG. 10 b ). The 12-bp and 75-bp landing pads, regardless of Gene Writer template molecule co-nucleofected with the WT R2Tg Gene Writer did not show any reads above background that contained indels. The level of indels was similar to the Gene Writer template driver containing endonuclease mutations.

TABLE E2 Exemplary Landing Pads Landing Pad Sequence 5′-> 3′ Sequence (rDNA, underline; cleavage region, bold; Name mutated sequence, bold-italic WT GCTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTGTTGACG CGATGTGATTTCTGCCCAGTGCTCTGAATGTCAAAGTGAAGAAATTCA ATGAAGCGCGGGTAAACGGCGGGAGTAACTATGACTCTCTTAAGGTAG CCAAATGCCTCGTCATCTAATTAGTGACGCGCATGAATGGATGAACGA GATTCCCACTGTCCCTACCTACTATCCAGCGAAACCACAGCCAAGGGA AATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGC GTTACCCAACTTAATCGCCTTGCAGCACATCC (SEQ ID NO: 1654) 12-bp GCTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTGTTGACG Mutant CGATGTGATTTCTGCCCAGTGCTCTGAATGTCAAAGTGAAGAAATTCA ATGAAGCGCGGGTAAACGGCGGGAGTAACTATGACTCTCTT TCCAATA TGATT TGCCTCGTCATCTAATTAGTGACGCGCATGAATGGATGAACGA GATTCCCACTGTCCCTACCTACTATCCAGCGAAACCACAGCCAAGGGA AATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGC GTTACCCAACTTAATCGCCTTGCAGCACATCC (SEQ ID NO: 1655) 75-bp getcacacaggaaacagctatgaccatgattacgccaagctgttgacg Mutant cgatgtgatttctgcccagtgctctgaatgtcaaagtgaagaaattca atgaagcgcgggtaaacggcgggagtaactatgactctcttt ccaata tgattccacccatggcaaattccatggcaccgtcaaggctgagaacgg gaagcttgtcatcaatggaa actatccagcgaaaccacagccaaggga aattcactggccgtcgttttacaacgtcgtgactgggaaaaccctggc gttacccaacttaatcgccttgcagcacatcc (SEQ ID NO: 1656)

In some embodiments, a Gene Writer is derived from a retrotransposase with some level of target sequence specificity in the endonuclease domain. Thus, it may be desirable to retarget the Gene Writer to a location in the genome that possesses homology to the natural target sequence recognized by an endonuclease domain, referred to as the endonuclease recognition motif (ERM). In some embodiments, this sub-target sequence may be contained in the region surrounding the nick site. In specific embodiments, a 13 nt sequence (TAAGGTAGCCAAA (SEQ TD NO: 1657)) based on the nick site of an R2 element, e.g., R2Tg, is used to search the human genome for suitable locations for retargeting the Gene Writer, wherein a heterologous DNA-binding domain is designed to localize the Gene Writer to an endogenous ERM to direct endonuclease activity and subsequent retrotransposition of a template RNA. In some embodiments, the human genome site possesses 100% identity to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 nucleotides in the 13 nt motif. In further embodiments, the human genome site containing the ERM is selected from Table E3, and a DNA-binding domain fusion, e.g., ZF, TAL, or dCas9 with a custom gRNA, is designed to localize the polypeptide to the site (e.g., see Example 9). In preferred embodiments, the genome site possesses a safe harbor score of at least 5, 6, 7, 8 as defined in Pellenz et al Hum Gene Ther 30, 814-282 (2019) and shown in Table E3. In some embodiments, the template RNA (or DNA encoding the template RNA) is designed such that the homology arms match the flanking genomic sequences surrounding the expected nick site at the new target.

Table E36 Human genome sites matching a 13 nt stretch around the nicking site of R2 elements.

The human genome was searched for 1000 identity to the full 13 nt match or 12 consecutive nucleotides (“Match”). Chromosomal location and start and end coordinates are provided for each match. Score (“Score”) is a metric evaluating each site for eight desirable safe harbor characteristics.

Chro- mosome Start End Source Match Score chr06 123749082 123749094 NC_000006.12 13 8 chr02 5035294 5035305 NC_000002.12 12 8 chr02 145760352 145760341 NC_000002.12 12 8 chr02 147034635 147034624 NC_000002.12 12 8 chr02 181792104 181792115 NC_000002.12 12 8 chr03 34017171 34017182 NC_000003.12 12 8 chr03 74784684 74784695 NC_000003.12 12 8 chr03 110093351 110093362 NC_000003.12 12 8 chr06 14459104 14459093 NC_000006.12 12 8 chr06 119620936 119620947 NC_000006.12 12 8 chr06 145123473 145123462 NC_000006.12 12 8 chr07 12024654 12024665 NC_000007.14 12 8 chr07 52001436 52001447 NC_000007.14 12 8 chr07 115339421 115339410 NC_000007.14 12 8 chr08 126384299 126384310 NC_000008.11 12 8 chr12 84083562 84083573 NC_000012.12 12 8 chrX 117646432 117646421 NC_000023.11 12 8 chr02 106547509 106547521 NC_000002.12 13 7 chr02 226038592 226038604 NC_000002.12 13 7 chr03 102522532 102522520 NC_000003.12 13 7 chr03 110933592 110933604 NC_000003.12 13 7 chr03 119752575 119752563 NC_000003.12 13 7 chr03 172868603 172868615 NC_000003.12 13 7 chr03 191985222 191985210 NC_000003.12 13 7 chr05 6213503 6213515 NC_000005.10 13 7 chr05 58295578 58295566 NC_000005.10 13 7 chr05 129844500 129844512 NC_000005.10 13 7 chr06 1454372 1454360 NC_000006.12 13 7 chr06 48973921 48973909 NC_000006.12 13 7 chr08 18663054 18663066 NC_000008.11 13 7 chr08 93499020 93499032 NC_000008.11 13 7 chr08 119753973 119753985 NC_000008.11 13 7 chr09 86856907 86856919 NC_000009.12 13 7 chr12 29955571 29955583 NC_000012.12 13 7 chr12 118529104 118529092 NC_000012.12 13 7 chr13 65656029 65656041 NC_000013.11 13 7 chr22 34266611 34266623 NC_000022.11 13 7 chrX 26651640 26651628 NC_000023.11 13 7 chrX 119194351 119194363 NC_000023.11 13 7 chrX 139180620 139180608 NC_000023.11 13 7 chr01 106465846 106465857 NC_000001.11 12 7 chr02 964160 964171 NC_000002.12 12 7 chr02 40018947 40018936 NC_000002.12 12 7 chr02 62845403 62845392 NC_000002.12 12 7 chr02 64834920 64834909 NC_000002.12 12 7 chr02 67969608 67969619 NC_000002.12 12 7 chr02 76183118 76183129 NC_000002.12 12 7 chr02 81819286 81819297 NC_000002.12 12 7 chr02 119597238 119597249 NC_000002.12 12 7 chr02 122897376 122897365 NC_000002.12 12 7 chr02 123603423 123603412 NC_000002.12 12 7 chr02 144644206 144644217 NC_000002.12 12 7 chr02 145221757 145221746 NC_000002.12 12 7 chr02 158367531 158367520 NC_000002.12 12 7 chr02 160092083 160092072 NC_000002.12 12 7 chr02 192245037 192245048 NC_000002.12 12 7 chr02 195223552 195223563 NC_000002.12 12 7 chr02 200351999 200351988 NC_000002.12 12 7 chr02 237068525 237068514 NC_000002.12 12 7 chr03 18724351 18724340 NC_000003.12 12 7 chr03 23969399 23969388 NC_000003.12 12 7 chr03 25177339 25177350 NC_000003.12 12 7 chr03 34880863 34880852 NC_000003.12 12 7 chr03 66233879 66233890 NC_000003.12 12 7 chr03 74527939 74527950 NC_000003.12 12 7 chr03 98583025 98583014 NC_000003.12 12 7 chr03 99278452 99278463 NC_000003.12 12 7 chr03 116060228 116060239 NC_000003.12 12 7 chr03 139468578 139468589 NC_000003.12 12 7 chr03 140064054 140064043 NC_000003.12 12 7 chr03 140438138 140438127 NC_000003.12 12 7 chr03 152457330 152457341 NC_000003.12 12 7 chr03 160950736 160950725 NC_000003.12 12 7 chr03 167207758 167207769 NC_000003.12 12 7 chr03 167722472 167722483 NC_000003.12 12 7 chr03 180475661 180475672 NC_000003.12 12 7 chr04 121590786 121590775 NC_000004.12 12 7 chr04 133719599 133719588 NC_000004.12 12 7 chr05 11564132 11564121 NC_000005.10 12 7 chr05 11970221 11970210 NC_000005.10 12 7 chr05 32814431 32814420 NC_000005.10 12 7 chr05 38003029 38003018 NC_000005.10 12 7 chr05 39758118 39758129 NC_000005.10 12 7 chr05 41221615 41221604 NC_000005.10 12 7 chr05 74838717 74838728 NC_000005.10 12 7 chr05 86444529 86444518 NC_000005.10 12 7 chr05 86617117 86617106 NC_000005.10 12 7 chr05 89438360 89438349 NC_000005.10 12 7 chr05 108102395 108102406 NC_000005.10 12 7 chr05 110231750 110231761 NC_000005.10 12 7 chr05 113996496 113996485 NC_000005.10 12 7 chr05 117233050 117233039 NC_000005.10 12 7 chr05 121622921 121622932 NC_000005.10 12 7 chr05 122520704 122520693 NC_000005.10 12 7 chr05 142330490 142330479 NC_000005.10 12 7 chr05 156359105 156359094 NC_000005.10 12 7 chr06 19187842 19187831 NC_000006.12 12 7 chr06 41103469 41103458 NC_000006.12 12 7 chr06 49856872 49856883 NC_000006.12 12 7 chr06 54896309 54896298 NC_000006.12 12 7 chr06 64416107 64416096 NC_000006.12 12 7 chr06 104438997 104439008 NC_000006.12 12 7 chr06 109349688 109349677 NC_000006.12 12 7 chr06 110631149 110631160 NC_000006.12 12 7 chr06 114751383 114751372 NC_000006.12 12 7 chr06 116514339 116514350 NC_000006.12 12 7 chr06 121606126 121606137 NC_000006.12 12 7 chr06 126139788 126139777 NC_000006.12 12 7 chr06 130852449 130852460 NC_000006.12 12 7 chr06 136843057 136843068 NC_000006.12 12 7 chr06 155559692 155559681 NC_000006.12 12 7 chr06 158099232 158099221 NC_000006.12 12 7 chr07 24339208 24339219 NC_000007.14 12 7 chr07 39519736 39519725 NC_000007.14 12 7 chr07 72228733 72228722 NC_000007.14 12 7 chr07 82955239 82955228 NC_000007.14 12 7 chr07 104990180 104990191 NC_000007.14 12 7 chr07 107698186 107698197 NC_000007.14 12 7 chr07 111002449 111002438 NC_000007.14 12 7 chr07 115191852 115191841 NC_000007.14 12 7 chr07 115572755 115572766 NC_000007.14 12 7 chr08 21126162 21126151 NC_000008.11 12 7 chr08 25928055 25928066 NC_000008.11 12 7 chr08 45036535 45036524 NC_000008.11 12 7 chr08 45248484 45248473 NC_000008.11 12 7 chr08 45502096 45502085 NC_000008.11 12 7 chr08 45763984 45763973 NC_000008.11 12 7 chr08 53335054 53335043 NC_000008.11 12 7 chr08 55581238 55581227 NC_000008.11 12 7 chr08 63169546 63169557 NC_000008.11 12 7 chr08 66553887 66553898 NC_000008.11 12 7 chr08 86283378 86283367 NC_000008.11 12 7 chr08 113060704 113060715 NC_000008.11 12 7 chr08 114537195 114537206 NC_000008.11 12 7 chr08 114886082 114886071 NC_000008.11 12 7 chr08 127206415 127206426 NC_000008.11 12 7 chr08 133590421 133590410 NC_000008.11 12 7 chr08 135425161 135425150 NC_000008.11 12 7 chr10 7034863 7034852 NC_000010.11 12 7 chr10 124304797 124304786 NC_000010.11 12 7 chr10 131502495 131502506 NC_000010.11 12 7 chr11 5557203 5557192 NC_000011.10 12 7 chr11 31242576 31242565 NC_000011.10 12 7 chr11 31419537 31419526 NC_000011.10 12 7 chr11 33169689 33169678 NC_000011.10 12 7 chr11 55948947 55948958 NC_000011.10 12 7 chr11 85654901 85654890 NC_000011.10 12 7 chr11 92588724 92588735 NC_000011.10 12 7 chr11 105227927 105227938 NC_000011.10 12 7 chr11 106302916 106302927 NC_000011.10 12 7 chr11 110594096 110594085 NC_000011.10 12 7 chr11 125228337 125228326 NC_000011.10 12 7 chr12 8769205 8769194 NC_000012.12 12 7 chr12 30438984 30438973 NC_000012.12 12 7 chr12 33556205 33556216 NC_000012.12 12 7 chr12 39419629 39419640 NC_000012.12 12 7 chr12 88509246 88509257 NC_000012.12 12 7 chr12 92878719 92878708 NC_000012.12 12 7 chr12 107034133 107034144 NC_000012.12 12 7 chr12 109455187 109455176 NC_000012.12 12 7 chr13 88827671 88827660 NC_000013.11 12 7 chr14 48126959 48126948 NC_000014.9 12 7 chr20 851155 851166 NC_000020.11 12 7 chr22 17367227 17367238 NC_000022.11 12 7 chrX 20420571 20420582 NC_000023.11 12 7 chrX 22545830 22545819 NC_000023.11 12 7 chrX 28899719 28899708 NC_000023.11 12 7 chrX 33013952 33013963 NC_000023.11 12 7 chrX 103880419 103880408 NC_000023.11 12 7 chrX 105612448 105612459 NC_000023.11 12 7 chrX 107929443 107929454 NC_000023.11 12 7 chrX 112571297 112571286 NC_000023.11 12 7 chrX 127584278 127584267 NC_000023.11 12 7 chrX 130836800 130836811 NC_000023.11 12 7 chrX 140554200 140554211 NC_000023.11 12 7 chrX 146697583 146697572 NC_000023.11 12 7 chr01 97461481 97461469 NC_000001.11 13 6 chr01 104600535 104600547 NC_000001.11 13 6 chr02 12589473 12589461 NC_000002.12 13 6 chr02 187173643 187173631 NC_000002.12 13 6 chr03 29181713 29181701 NC_000003.12 13 6 chr04 32171549 32171537 NC_000004.12 13 6 chr04 116646904 116646916 NC_000004.12 13 6 chr04 164205821 164205833 NC_000004.12 13 6 chr04 170244792 170244780 NC_000004.12 13 6 chr05 15818439 15818451 NC_000005.10 13 6 chr05 174059501 174059489 NC_000005.10 13 6 chr06 94936128 94936140 NC_000006.12 13 6 chr06 98142018 98142006 NC_000006.12 13 6 chr06 151814731 151814719 NC_000006.12 13 6 chr07 14490189 14490201 NC_000007.14 13 6 chr07 53075165 53075153 NC_000007.14 13 6 chr07 87815318 87815306 NC_000007.14 13 6 chr07 103485572 103485584 NC_000007.14 13 6 chr08 35951572 35951560 NC_000008.11 13 6 chr08 39327231 39327219 NC_000008.11 13 6 chr08 69690270 69690258 NC_000008.11 13 6 chr08 117816166 117816154 NC_000008.11 13 6 chr08 123134654 123134666 NC_000008.11 13 6 chr09 68817454 68817466 NC_000009.12 13 6 chr09 68894040 68894028 NC_000009.12 13 6 chr09 80470190 80470178 NC_000009.12 13 6 chr10 1642234 1642222 NC_000010.11 13 6 chr10 73077072 73077060 NC_000010.11 13 6 chr10 110134589 110134601 NC_000010.11 13 6 chr11 9150979 9150991 NC_000011.10 13 6 chr11 9153635 9153623 NC_000011.10 13 6 chr11 13413693 13413705 NC_000011.10 13 6 chr11 41773900 41773912 NC_000011.10 13 6 chr11 77886545 77886557 NC_000011.10 13 6 chr11 79988166 79988154 NC_000011.10 13 6 chr11 108008162 108008150 NC_000011.10 13 6 chr12 30847723 30847735 NC_000012.12 13 6 chr12 86693014 86693026 NC_000012.12 13 6 chr12 122128926 122128914 NC_000012.12 13 6 chr13 29622714 29622726 NC_000013.11 13 6 chr14 39336522 39336510 NC_000014.9 13 6 chr15 94819443 94819431 NC_000015.10 13 6 chr17 10951262 10951250 NC_000017.11 13 6 chr19 30854506 30854518 NC_000019.10 13 6 chr20 42688485 42688473 NC_000020.11 13 6 chrX 38138789 38138801 NC_000023.11 13 6 chrX 86361231 86361243 NC_000023.11 13 6 chrX 107051786 107051798 NC_000023.11 13 6 chrX 109054235 109054247 NC_000023.11 13 6 chr01 32830533 32830522 NC_000001.11 12 6 chr01 56714138 56714127 NC_000001.11 12 6 chr01 79950536 79950547 NC_000001.11 12 6 chr01 81600862 81600851 NC_000001.11 12 6 chr01 88351333 88351344 NC_000001.11 12 6 chr01 100720346 100720335 NC_000001.11 12 6 chr01 103153587 103153598 NC_000001.11 12 6 chr01 163679268 163679279 NC_000001.11 12 6 chr01 178138239 178138228 NC_000001.11 12 6 chr01 202443386 202443375 NC_000001.11 12 6 chr01 214381798 214381787 NC_000001.11 12 6 chr01 239483920 239483909 NC_000001.11 12 6 chr02 5995932 5995921 NC_000002.12 12 6 chr02 14869774 14869785 NC_000002.12 12 6 chr02 37466261 37466250 NC_000002.12 12 6 chr02 38845623 38845634 NC_000002.12 12 6 chr02 38849877 38849866 NC_000002.12 12 6 chr02 52660534 52660523 NC_000002.12 12 6 chr02 55372861 55372872 NC_000002.12 12 6 chr02 62005199 62005210 NC_000002.12 12 6 chr02 70287567 70287556 NC_000002.12 12 6 chr02 79359701 79359712 NC_000002.12 12 6 chr02 84655638 84655627 NC_000002.12 12 6 chr02 126324776 126324787 NC_000002.12 12 6 chr02 149537132 149537143 NC_000002.12 12 6 chr02 169529510 169529521 NC_000002.12 12 6 chr02 175817135 175817124 NC_000002.12 12 6 chr02 180079693 180079682 NC_000002.12 12 6 chr02 206324011 206324000 NC_000002.12 12 6 chr02 206814054 206814043 NC_000002.12 12 6 chr02 224807794 224807805 NC_000002.12 12 6 chr02 229238864 229238853 NC_000002.12 12 6 chr02 236280053 236280064 NC_000002.12 12 6 chr03 154343 154354 NC_000003.12 12 6 chr03 8511973 8511984 NC_000003.12 12 6 chr03 16880365 16880376 NC_000003.12 12 6 chr03 18087857 18087846 NC_000003.12 12 6 chr03 47168148 47168137 NC_000003.12 12 6 chr03 47937628 47937617 NC_000003.12 12 6 chr03 48992978 48992989 NC_000003.12 12 6 chr03 82163078 82163067 NC_000003.12 12 6 chr03 103449909 103449898 NC_000003.12 12 6 chr03 120049593 120049604 NC_000003.12 12 6 chr03 143783076 143783065 NC_000003.12 12 6 chr03 149601763 149601752 NC_000003.12 12 6 chr03 167891194 167891183 NC_000003.12 12 6 chr03 181054638 181054627 NC_000003.12 12 6 chr03 191545181 191545170 NC_000003.12 12 6 chr03 197899144 197899155 NC_000003.12 12 6 chr04 668375 668364 NC_000004.12 12 6 chr04 19382020 19382031 NC_000004.12 12 6 chr04 19484541 19484552 NC_000004.12 12 6 chr04 26997338 26997349 NC_000004.12 12 6 chr04 55658608 55658619 NC_000004.12 12 6 chr04 70437852 70437841 NC_000004.12 12 6 chr04 79981798 79981809 NC_000004.12 12 6 chr04 94968197 94968208 NC_000004.12 12 6 chr04 102674459 102674470 NC_000004.12 12 6 chr04 124485434 124485445 NC_000004.12 12 6 chr04 126123159 126123148 NC_000004.12 12 6 chr04 137124764 137124753 NC_000004.12 12 6 chr04 160702860 160702849 NC_000004.12 12 6 chr04 167052375 167052386 NC_000004.12 12 6 chr04 179139043 179139032 NC_000004.12 12 6 chr04 179161408 179161397 NC_000004.12 12 6 chr04 187143772 187143761 NC_000004.12 12 6 chr05 10200709 10200720 NC_000005.10 12 6 chr05 33225853 33225842 NC_000005.10 12 6 chr05 76255175 76255186 NC_000005.10 12 6 chr05 82855245 82855256 NC_000005.10 12 6 chr05 84139572 84139561 NC_000005.10 12 6 chr05 88198462 88198473 NC_000005.10 12 6 chr05 102501084 102501073 NC_000005.10 12 6 chr05 109583817 109583806 NC_000005.10 12 6 chr05 128180682 128180671 NC_000005.10 12 6 chr05 136190403 136190392 NC_000005.10 12 6 chr05 154189555 154189566 NC_000005.10 12 6 chr05 171957271 171957282 NC_000005.10 12 6 chr05 175317578 175317567 NC_000005.10 12 6 chr06 4853151 4853162 NC_000006.12 12 6 chr06 16133021 16133032 NC_000006.12 12 6 chr06 26103447 26103436 NC_000006.12 12 6 chr06 35947570 35947581 NC_000006.12 12 6 chr06 68279419 68279430 NC_000006.12 12 6 chr06 79806546 79806557 NC_000006.12 12 6 chr06 85260407 85260418 NC_000006.12 12 6 chr06 136633874 136633885 NC_000006.12 12 6 chr06 137931054 137931043 NC_000006.12 12 6 chr06 139739984 139739973 NC_000006.12 12 6 chr06 140341418 140341429 NC_000006.12 12 6 chr06 145869806 145869795 NC_000006.12 12 6 chr06 146731539 146731528 NC_000006.12 12 6 chr06 168728425 168728436 NC_000006.12 12 6 chr07 51771646 51771635 NC_000007.14 12 6 chr07 137082304 137082315 NC_000007.14 12 6 chr07 141052267 141052278 NC_000007.14 12 6 chr08 17556548 17556537 NC_000008.11 12 6 chr08 30097319 30097308 NC_000008.11 12 6 chr08 68502659 68502670 NC_000008.11 12 6 chr08 86697209 86697198 NC_000008.11 12 6 chr08 91622182 91622171 NC_000008.11 12 6 chr08 92498179 92498168 NC_000008.11 12 6 chr08 124481608 124481597 NC_000008.11 12 6 chr08 129563081 129563092 NC_000008.11 12 6 chr08 131305462 131305451 NC_000008.11 12 6 chr09 14627274 14627285 NC_000009.12 12 6 chr09 15151836 15151847 NC_000009.12 12 6 chr09 22322306 22322295 NC_000009.12 12 6 chr09 23783142 23783153 NC_000009.12 12 6 chr09 26318093 26318104 NC_000009.12 12 6 chr09 31054959 31054970 NC_000009.12 12 6 chr09 79007585 79007596 NC_000009.12 12 6 chr09 88239264 88239253 NC_000009.12 12 6 chr09 96543680 96543669 NC_000009.12 12 6 chr09 99112802 99112813 NC_000009.12 12 6 chr09 123836553 123836564 NC_000009.12 12 6 chr10 33633573 33633562 NC_000010.11 12 6 chr10 65551995 65551984 NC_000010.11 12 6 chr10 66717930 66717941 NC_000010.11 12 6 chr10 74291798 74291787 NC_000010.11 12 6 chr10 82621770 82621781 NC_000010.11 12 6 chr10 91090519 91090530 NC_000010.11 12 6 chr10 99682921 99682910 NC_000010.11 12 6 chr10 107653284 107653273 NC_000010.11 12 6 chr10 127387876 127387887 NC_000010.11 12 6 chr11 10330421 10330410 NC_000011.10 12 6 chr11 21052051 21052062 NC_000011.10 12 6 chr11 56948810 56948799 NC_000011.10 12 6 chr11 91992913 91992902 NC_000011.10 12 6 chr11 96712150 96712139 NC_000011.10 12 6 chr11 99478699 99478710 NC_000011.10 12 6 chr11 103284503 103284514 NC_000011.10 12 6 chr11 110624774 110624763 NC_000011.10 12 6 chr11 118226686 118226697 NC_000011.10 12 6 chr11 121927186 121927175 NC_000011.10 12 6 chr11 127371998 127372009 NC_000011.10 12 6 chr12 21742376 21742387 NC_000012.12 12 6 chr12 33375091 33375102 NC_000012.12 12 6 chr12 79305333 79305322 NC_000012.12 12 6 chr12 87018030 87018041 NC_000012.12 12 6 chr12 97027085 97027074 NC_000012.12 12 6 chr12 97030674 97030685 NC_000012.12 12 6 chr12 97794786 97794775 NC_000012.12 12 6 chr12 99326334 99326345 NC_000012.12 12 6 chr12 100617295 100617284 NC_000012.12 12 6 chr12 106997614 106997603 NC_000012.12 12 6 chr12 114419769 114419758 NC_000012.12 12 6 chr13 29428703 29428714 NC_000013.11 12 6 chr13 34838980 34838991 NC_000013.11 12 6 chr13 68672648 68672637 NC_000013.11 12 6 chr13 68677576 68677565 NC_000013.11 12 6 chr13 79534292 79534303 NC_000013.11 12 6 chr13 83374368 83374357 NC_000013.11 12 6 chr13 91208120 91208131 NC_000013.11 12 6 chr13 92057240 92057251 NC_000013.11 12 6 chr13 105912154 105912165 NC_000013.11 12 6 chr14 37970959 37970948 NC_000014.9 12 6 chr14 40492006 40491995 NC_000014.9 12 6 chr14 44782915 44782926 NC_000014.9 12 6 chr14 48758306 48758317 NC_000014.9 12 6 chr14 88004548 88004537 NC_000014.9 12 6 chr15 56610753 56610764 NC_000015.10 12 6 chr15 70757589 70757578 NC_000015.10 12 6 chr15 96964230 96964219 NC_000015.10 12 6 chr16 66442829 66442818 NC_000016.10 12 6 chr16 74623964 74623975 NC_000016.10 12 6 chr16 75189302 75189291 NC_000016.10 12 6 chr17 9332911 9332900 NC_000017.11 12 6 chr18 32474384 32474373 NC_000018.10 12 6 chr18 34128952 34128963 NC_000018.10 12 6 chr18 55039826 55039815 NC_000018.10 12 6 chr18 78931519 78931508 NC_000018.10 12 6 chr19 31065225 31065236 NC_000019.10 12 6 chr19 32434028 32434017 NC_000019.10 12 6 chr19 51221292 51221303 NC_000019.10 12 6 chr20 1361969 1361958 NC_000020.11 12 6 chr20 4448895 4448906 NC_000020.11 12 6 chr20 13696489 13696478 NC_000020.11 12 6 chr20 20275384 20275395 NC_000020.11 12 6 chr20 26367536 26367525 NC_000020.11 12 6 chr21 37223237 37223248 NC_000021.9 12 6 chr21 46496495 46496484 NC_000021.9 12 6 chr22 39560335 39560346 NC_000022.11 12 6 chrX 986645 986656 NC_000023.11 12 6 chrX 5921242 5921253 NC_000023.11 12 6 chrX 6765829 6765840 NC_000023.11 12 6 chrX 15504137 15504126 NC_000023.11 12 6 chrX 22546280 22546269 NC_000023.11 12 6 chrX 41199361 41199372 NC_000023.11 12 6 chrX 43885293 43885282 NC_000023.11 12 6 chrX 67874307 67874296 NC_000023.11 12 6 chrX 110216026 110216037 NC_000023.11 12 6 chrX 110566890 110566879 NC_000023.11 12 6 chrX 111357390 111357379 NC_000023.11 12 6 chrX 150589443 150589454 NC_000023.11 12 6 chr01 23207589 23207577 NC_000001.11 13 5 chr01 25897408 25897420 NC_000001.11 13 5 chr01 65491478 65491490 NC_000001.11 13 5 chr01 154831168 154831180 NC_000001.11 13 5 chr02 35254361 35254349 NC_000002.12 13 5 chr02 207969171 207969159 NC_000002.12 13 5 chr03 185371630 185371642 NC_000003.12 13 5 chr04 46469891 46469879 NC_000004.12 13 5 chr04 105058847 105058835 NC_000004.12 13 5 chr04 124730032 124730044 NC_000004.12 13 5 chr04 158619352 158619364 NC_000004.12 13 5 chr06 85949972 85949960 NC_000006.12 13 5 chr06 109604972 109604960 NC_000006.12 13 5 chr10 59089285 59089273 NC_000010.11 13 5 chr10 99263586 99263598 NC_000010.11 13 5 chr11 96315922 96315934 NC_000011.10 13 5 chr15 33186727 33186715 NC_000015.10 13 5 chr15 87091718 87091706 NC_000015.10 13 5 chr16 16972153 16972165 NC_000016.10 13 5 chr16 59986446 59986458 NC_000016.10 13 5 chr18 12587445 12587457 NC_000018.10 13 5 chr18 78691060 78691048 NC_000018.10 13 5 chr19 39627504 39627492 NC_000019.10 13 5 chr19 54674561 54674573 NC_000019.10 13 5 chr20 30512867 30512855 NC_000020.11 13 5 chr20 45173430 45173442 NC_000020.11 13 5 chr21 35062647 35062659 NC_000021.9 13 5 chrX 77412877 77412889 NC_000023.11 13 5 chrX 130349739 130349727 NC_000023.11 13 5 chr01 8663054 8663065 NC_000001.11 12 5 chr01 26335998 26336009 NC_000001.11 12 5 chr01 42582606 42582595 NC_000001.11 12 5 chr01 47032830 47032819 NC_000001.11 12 5 chr01 69196253 69196264 NC_000001.11 12 5 chr01 70300023 70300034 NC_000001.11 12 5 chr01 82771042 82771053 NC_000001.11 12 5 chr01 100102957 100102946 NC_000001.11 12 5 chr01 107996202 107996213 NC_000001.11 12 5 chr01 162211653 162211642 NC_000001.11 12 5 chr01 208646365 208646354 NC_000001.11 12 5 chr01 215734460 215734449 NC_000001.11 12 5 chr01 234143991 234144002 NC_000001.11 12 5 chr01 241045297 241045286 NC_000001.11 12 5 chr02 140780861 140780872 NC_000002.12 12 5 chr02 149162575 149162586 NC_000002.12 12 5 chr02 162692841 162692852 NC_000002.12 12 5 chr02 222738270 222738259 NC_000002.12 12 5 chr03 67248099 67248110 NC_000003.12 12 5 chr03 174292637 174292648 NC_000003.12 12 5 chr04 12331297 12331308 NC_000004.12 12 5 chr04 21504937 21504948 NC_000004.12 12 5 chr04 43962965 43962976 NC_000004.12 12 5 chr04 57433948 57433937 NC_000004.12 12 5 chr04 85682861 85682872 NC_000004.12 12 5 chr04 106114290 106114301 NC_000004.12 12 5 chr04 113028283 113028294 NC_000004.12 12 5 chr04 151151805 151151794 NC_000004.12 12 5 chr04 152051162 152051173 NC_000004.12 12 5 chr04 179052931 179052920 NC_000004.12 12 5 chr05 6661409 6661420 NC_000005.10 12 5 chr05 93549147 93549158 NC_000005.10 12 5 chr05 148916732 148916721 NC_000005.10 12 5 chr05 153193520 153193531 NC_000005.10 12 5 chr05 169165696 169165685 NC_000005.10 12 5 chr06 99056822 99056833 NC_000006.12 12 5 chr07 21203640 21203651 NC_000007.14 12 5 chr07 27364344 27364355 NC_000007.14 12 5 chr07 45331667 45331656 NC_000007.14 12 5 chr08 28102047 28102036 NC_000008.11 12 5 chr08 64148089 64148078 NC_000008.11 12 5 chr08 121058238 121058249 NC_000008.11 12 5 chr08 134902692 134902681 NC_000008.11 12 5 chr09 26814924 26814935 NC_000009.12 12 5 chr09 35739632 35739643 NC_000009.12 12 5 chr09 77017601 77017612 NC_000009.12 12 5 chr09 83041777 83041788 NC_000009.12 12 5 chr09 87072669 87072658 NC_000009.12 12 5 chr09 134613617 134613628 NC_000009.12 12 5 chr10 7938397 7938408 NC_000010.11 12 5 chr10 59688277 59688266 NC_000010.11 12 5 chr10 91834373 91834384 NC_000010.11 12 5 chr10 106036664 106036653 NC_000010.11 12 5 chr11 1648239 1648228 NC_000011.10 12 5 chr11 28286474 28286485 NC_000011.10 12 5 chr11 59609982 59609993 NC_000011.10 12 5 chr11 82154773 82154784 NC_000011.10 12 5 chr12 56884436 56884425 NC_000012.12 12 5 chr12 65309897 65309908 NC_000012.12 12 5 chr12 70312802 70312791 NC_000012.12 12 5 chr12 108169798 108169809 NC_000012.12 12 5 chr13 41643771 41643782 NC_000013.11 12 5 chr13 43730188 43730177 NC_000013.11 12 5 chr13 66772070 66772081 NC_000013.11 12 5 chr13 67266239 67266250 NC_000013.11 12 5 chr13 70438394 70438405 NC_000013.11 12 5 chr13 72462904 72462915 NC_000013.11 12 5 chr13 73589220 73589209 NC_000013.11 12 5 chr13 114256981 114256970 NC_000013.11 12 5 chr14 53548116 53548105 NC_000014.9 12 5 chr14 91128016 91128005 NC_000014.9 12 5 chr15 55623598 55623609 NC_000015.10 12 5 chr15 59650410 59650421 NC_000015.10 12 5 chr15 67895787 67895798 NC_000015.10 12 5 chr15 75030887 75030898 NC_000015.10 12 5 chr15 80376611 80376600 NC_000015.10 12 5 chr17 2259971 2259960 NC_000017.11 12 5 chr17 13599804 13599793 NC_000017.11 12 5 chr17 49970374 49970385 NC_000017.11 12 5 chr17 74411987 74411998 NC_000017.11 12 5 chr18 6692184 6692173 NC_000018.10 12 5 chr18 26936361 26936372 NC_000018.10 12 5 chr18 32164785 32164796 NC_000018.10 12 5 chr18 57372141 57372152 NC_000018.10 12 5 chr18 76028676 76028665 NC_000018.10 12 5 chr18 79860251 79860240 NC_000018.10 12 5 chr20 2767508 2767497 NC_000020.11 12 5 chr20 32334864 32334853 NC_000020.11 12 5 chr20 42969400 42969411 NC_000020.11 12 5 chr21 15405882 15405871 NC_000021.9 12 5 chr21 27128817 27128828 NC_000021.9 12 5 chr21 27724878 27724889 NC_000021.9 12 5 chr21 33775512 33775523 NC_000021.9 12 5 chr22 40201219 40201208 NC_000022.11 12 5 chrX 24583713 24583724 NC_000023.11 12 5 chrX 53003928 53003939 NC_000023.11 12 5 chrX 75537169 75537180 NC_000023.11 12 5 chrX 91187582 91187593 NC_000023.11 12 5 chr01 237603124 237603136 NC_000001.11 13 4 chr02 132279864 132279852 NC_000002.12 13 4 chr02 176672291 176672279 NC_000002.12 13 4 chr04 47096940 47096952 NC_000004.12 13 4 chr05 170123837 170123825 NC_000005.10 13 4 chr10 97944808 97944796 NC_000010.11 13 4 chr10 114226626 114226614 NC_000010.11 13 4 chr13 67884795 67884783 NC_000013.11 13 4 chr14 59591410 59591398 NC_000014.9 13 4 chr16 3659076 3659088 NC_000016.10 13 4 chr18 25418784 25418772 NC_000018.10 13 4 chrX 45634061 45634049 NC_000023.11 13 4 chr01 3217976 3217987 NC_000001.11 12 4 chr01 92837827 92837816 NC_000001.11 12 4 chr01 112701651 112701662 NC_000001.11 12 4 chr01 166000671 166000660 NC_000001.11 12 4 chr01 178801277 178801288 NC_000001.11 12 4 chr02 177290177 177290166 NC_000002.12 12 4 chr02 218084695 218084706 NC_000002.12 12 4 chr02 236494650 236494639 NC_000002.12 12 4 chr04 42894460 42894471 NC_000004.12 12 4 chr04 66200304 66200315 NC_000004.12 12 4 chr06 35644009 35643998 NC_000006.12 12 4 chr06 35671520 35671531 NC_000006.12 12 4 chr09 95179956 95179945 NC_000009.12 12 4 chr09 122078420 122078431 NC_000009.12 12 4 chr09 132891241 132891252 NC_000009.12 12 4 chr09 134244101 134244112 NC_000009.12 12 4 chr10 46934395 46934384 NC_000010.11 12 4 chr10 48117437 48117448 NC_000010.11 12 4 chr10 102716315 102716304 NC_000010.11 12 4 chr12 31614069 31614080 NC_000012.12 12 4 chr13 18693215 18693204 NC_000013.11 12 4 chr14 30845671 30845660 NC_000014.9 12 4 chr14 94062711 94062722 NC_000014.9 12 4 chr17 10363532 10363543 NC_000017.11 12 4 chr17 59667014 59667025 NC_000017.11 12 4 chr17 68278027 68278038 NC_000017.11 12 4 chr18 44686796 44686785 NC_000018.10 12 4 chr18 55570049 55570060 NC_000018.10 12 4 chr20 37099530 37099519 NC_000020.11 12 4 chr21 14473970 14473981 NC_000021.9 12 4 chr21 28191101 28191112 NC_000021.9 12 4 chr01 85362838 85362827 NC_000001.11 12 3 chr14 106817445 106817434 NC_000014.9 12 3 chr17 12074729 12074718 NC_000017.11 12 3 chr21 8217645 8217657 NC_000021.9 13 2 chr21 8400683 8400695 NC_000021.9 13 2 chr21 8444915 8444927 NC_000021.9 13 2 chr01 65227883 65227872 NC_000001.11 12 2 chr17 31347890 31347879 NC_000017.11 12 1

Example 9: Retargeting of a Gene Writer to a Genomic Safe Harbor Site

This example describes a Gene Writer comprising a heterologous DNA binding domain that redirects its activity to a genomic safe harbor site.

In this example, the Gene Writer polypeptide sequence is altered to where its natural DNA binding domain is replaced, mutated/inactivated, and/or joined with another polypeptide sequence that can redirect the Gene Writer system to another genomic location that is not its endogenous or natural binding site. In some instances, the polypeptide sequence that redirects the Gene Writer system to a non-natural genomic location may also be attached and/or inserted to any module of the Gene Writer polypeptide sequence.

In some embodiments, the polypeptide sequence used to redirect the Gene Writer system to a non-natural genomic target encodes for: a zinc finger, a series of adjacent, regularly, or irregularly spaced zinc fingers, a transcription activator-like effector (TALE), a series of adjacent, regularly, or irregularly spaced a transcription activator-like effectors (TALEs), Cas9, Cas9 with mutations to its catalytic residues inactivating the double-stranded DNA endonuclease activity (referred to as catalytically-dead Cas9 (dCas9)), Cas9 with a point mutation or multiple point mutations in a single catalytic domain in order to render Cas9 endonuclease only able to cleave one strand of double-stranded DNA (referred to as Cas9 nickase) (see FIG. 12 ).

In some embodiments, the polypeptide sequence used to re-direct the Gene Writer system targets a genomic safe-harbor location (e.g., AAVS1 site on human chromosome 19) (Pellenz, S., et. al., Human Gene Therapy, 30(7), 814-828, 2019), see FIGS. 11 and 13 . In further embodiments, the polypeptide sequence used to re-direct the Gene Writer polypeptide sequence is used in conjunction with a nucleic acid that targets the genomic safe harbor location (e.g., the polypeptide sequence for catalytic dead Cas9 along with a single-guide RNA targeting the AAVS1 site on chromosome 19).

TABLE E4 Re-targeted Gene Writer constructs. Examples shown are to re-target R2Tg Gene Writer polypeptide sequence to the AAVS1 site using ZF or Cas9 domains. Gene Writer Polypeptide Sequence (Re-targeting polypeptide sequence, italic; Polypeptide Name Linker, bold underline) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached at v2 RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG location of DBD of RKFAQNSTRIGHTKIHLRGS GGGS TATRDKKDTVTREKHPKKPFQKWMKDRAI R2Tg with 3GS KKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSF linker (SEQ ID NO: KSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMD 1024) PEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGS ILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRP LGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRN THTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAF ADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTIND CAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAP LKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCT CDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQ LHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNW RKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVY PTREFLARGRODQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELL EEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGL SKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1658) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached at v2 RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG location of DBD of RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES TATRDKKDTVTREKHPK R2Tg with XTEN KPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYS linker VFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGP DGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLK DINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQ TIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGY HRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFY IKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTK LDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRT AVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDT MKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAP TQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRK LLTALQLRANVYPTREFLARGRODQYIKACRHCDADIESCAHIIGNCPVTQDA RIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVD VTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWH QDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1659) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached at v1 RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG location of DBD of RKFAQNSTRIGHTKIHLRGS GGGS CFGCLESISQIRTATRDKKDTVTREKHPK R2Tg with 3GS KPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYS linker (SEQ ID NO: VFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGP 1024) DGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLK DINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQ TIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGY HRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFY IKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTK LDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRT AVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDT MKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAP TQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRK LLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDA RIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVD VTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWH QDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1660) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached at v1 RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG location of DBD of RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES CFGCLESISQIRTATRD R2Tg with XTEN KKDTVTREKHPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIEC linker LSCDIPLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKN VQEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTV LIPKSSKPDRLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIR AAGCSENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREV DPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDP LLCKLEESGKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTG LKTQGQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDP WIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKT ALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQAR RLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPP NNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNH WIQYYRRIPHRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCA HIIGNCPVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDL IFVKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTF VGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFAS RARKSMVM (SEQ ID NO: 1661) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached at v2 RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG location of DBD of RKFAQGYNLAGHTKIHLRGS GGGS TATRDKKDTVTREKHPKKPFQKWMKDRAI R2Tg with 3GS KKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSF linker (SEQ ID NO: KSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMD 1024) PEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGS ILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRP LGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRN THTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAF ADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTIND CAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAP LKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCT CDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQ LHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNW RKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVY PTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELL LEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSL EEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGL SKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1662) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached at v2 RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG location of DBD of RKFAQGYNLAGHTKIHLRGS SGSETPGTSESATPES TATRDKKDTVTREKHPK R2Tg with XTEN KPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYS linker VFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGP DGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLK DINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQ TIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGY HRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFY IKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTK LDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRT AVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDT MKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAP TQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRK LLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDA RIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVD VTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWH QDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1663) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached at v1 RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG location of DBD of RKFAQGYNLAGHTKIHLRGS GGGS CFGCLESISQIRTATRDKKDTVTREKHPK R2Tg with 3GS KPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYS linker (SEQ ID NO: VFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGP 1024) DGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLK DINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQ TIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMY ENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGY HRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFY IKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTK LDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRT AVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDT MKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAP TQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRK LLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDA RIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVD VTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWH QDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1664) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached at v1 RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG location of DBD of RKFAQGYNLAGHTKIHLRGS SGSETPGTSESATPES CFGCLESISQIRTATRD R2Tg with XTEN KKDTVTREKHPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIEC linker LSCDIPLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKN VQEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTV LIPKSSKPDRLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIR AAGCSENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHITHALQQREV DPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDP LLCKLEESGKGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTG LKTQGQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDP WIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKT ALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQAR RLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPP NNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNH WIQYYRRIPHRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCA HIIGNCPVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDL IFVKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTF VGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFAS RARKSMVM (SEQ ID NO: 1665) AAVS1 Left and MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA Right ZFP RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG (separated by XTEN RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES GIHGVPAAMAERPFQCR linker) attached at ICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFARTDYLVDHTKIHTGSQKP v2 location of DBD FQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICGRKFAQGYNLAGHTKIHLR of R2Tg with 3GS GS GGGS TATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGK linker (SEQ ID NO: LAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDFKTYGKADNTAFR 1024) ELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGK IPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSRIVTARLSKAC PLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQ HIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKIQIRVGVKQGDPM SPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLSDSWENMNTNI SILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTINGTPLNMIDPGE SEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQKTDILKTYTIPRL IYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSSTRDGGLGITK LAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPS IWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGI VNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLARGRQDQYIKAC RHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKKKDWVVFKEPHIR DSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEV RHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKMAETFSTVALF SSVDIVHMFASRARKSMVM (SEQ ID NO: 1666) AAVS1 Left and MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA Right ZFP RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG (separated by XTEN RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES GIHGVPAAMAERPFQCR linker) attached at ICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFARTDYLVDHTKIHTGSQKP v2 location of DBD FQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICGRKFAQGYNLAGHTKIHLR of R2Tg with XTEN GS SGSETPGTSESATPES TATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYL linker RFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDF KTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRT MEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLF SRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFV DIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKI QIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVL LSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTI NGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQK TDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILY SSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLW IQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFK KWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFL ARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKK KDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLEEAAAE KVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQV KMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1667) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached to N- RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG terminus of R2Tg RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES ASCPKPGPPVSAGAMSL with XTEN linker ESGLTTHSVLAIERGPNSLANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVD LVSWSHPGPTSKSQQVDLVSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAE NDLALLVNLEFYRSDLHVYECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHS SLPRDSELFVPEEGSSEKESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNP PCPCCGTRVNSVLNLIEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCR GPETEKAPAGEWICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETS NRGAHKRCWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLL SRKPAEEPREEPGTCHHTRRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRA AAGGRTMDEIRRHPDKGNGQQRPTKQKSEEQLQAYYKKTLEERLSAGALNTFP RAFKQVMEGRDIKLVINQTAQDCFGCLESISQIRTATRDKKDTVTREKHPKKP FQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVF KTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDG ITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDI NNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTI IWSAKREHRPLGVVFVDIAKAFDTVSHQHITHALQQREVDPHIVGLVSNMYEN ISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHR GQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIK PTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLD FWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAV KEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMK CFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLL TALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARI VRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQD NFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1668) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached to N- RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG terminus of R2Tg RKFAQGYNLAGHTKIHLRGS SGSETPGTSESATPES ASCPKPGPPVSAGAMSL with XTEN linker ESGLTTHSVLAIERGPNSLANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVD LVSWSHPGPTSKSQQVDLVSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAE NDLALLVNLEFYRSDLHVYECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHS SLPRDSELFVPEEGSSEKESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNP PCPCCGTRVNSVLNLIEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCR GPETEKAPAGEWICEVCNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETS NRGAHKRCWTKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLL SRKPAEEPREEPGTCHHTRRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRA AAGGRTMDEIRRHPDKGNGQQRPTKQKSEEQLQAYYKKTLEERLSAGALNTFP RAFKQVMEGRDIKLVINQTAQDCFGCLESISQIRTATRDKKDTVTREKHPKKP FQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVF KTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDG ITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDI NNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTI IWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYEN ISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHR GOSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIK PTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLD FWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAV KEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMK CFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLL TALQLRANVYPTREFLARGRODQYIKACRHCDADIESCAHIIGNCPVTQDARI VRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQD NFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1669) AAVS1 Left and MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA Right ZFP attached RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG to N-terminus of RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES GIHGVPAAMAERPFQCR R2Tg with XTEN ICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFARTDYLVDHTKIHTGSQKP linker FQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICGRKFAQGYNLAGHTKIHLR GS SGSETPGTSESATPES ASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNS LANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDL VSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHV YECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEK ESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPCPCCGTRVNSVLNLIEH LKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGEWICEVCN RDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKRCWTKEEEELLI RLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRKPAEEPREEPGTCHHT RRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRAAAGGRTMDEIRRHPDKGN GQQRPTKQKSEEQLQAYYKKTLEERLSAGALNTFPRAFKQVMEGRDIKLVINQ TAQDCFGCLESISQIRTATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRF QRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDFKT YGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRTME IFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSR IVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFVDI AKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKIQI RVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLS DSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTING TPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQKTD ILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSS TRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQ AGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKW TKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLAR GRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKKKD RKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKM AETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1670) AAVS1 Left ZFP MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA attached to N- RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG terminus of R2Tg RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES ASCPKPGPPVSAGAMSL containing DBD ESGLTTHSVLAIERGPNSLANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVD inactivation LVSWSHPGPTSKSQQVDLVSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAE mutations with NDLALLVNLEFYRSDLHVYECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHS XTEN linker SLPRDSELFVPEEGSSEKESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNP PSPSSGTRVNSVLNLIEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCR GPETEKAPAGEWISEVSNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETS NRGAHKACATKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLL SRKPAEEPREEPGTCHHTRRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRA AAGGRTMDEIRRHPDKGNGQQRPTKQKSEEQLQAYYKKTLEERLSAGALNTFP RAFKQVMEGRDIKLVINQTAQDCFGCLESISQIRTATRDKKDTVTREKHPKKP FQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVF KTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDG ITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDI NNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTI IWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYEN ISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHR GOSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIK PTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLD FWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAV KEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMK CFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLL TALQLRANVYPTREFLARGRODQYIKACRHCDADIESCAHIIGNCPVTQDARI VRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQD NFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1671) AAVS1 Right ZFP MGIHGVPAAMAERPFQCRICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFA attached to N- RTDYLVDHTKIHTGSQKPFQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICG terminus of R2Tg RKFAQGYNLAGHTKIHLRGS SGSETPGTSESATPES ASCPKPGPPVSAGAMSL containing DBD ESGLTTHSVLAIERGPNSLANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVD inactivation LVSWSHPGPTSKSQQVDLVSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAE mutations with NDLALLVNLEFYRSDLHVYECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHS XTEN linker SLPRDSELFVPEEGSSEKESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNP PSPSSGTRVNSVLNLIEHLKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCR GPETEKAPAGEWISEVSNRDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETS NRGAHKACATKEEEELLIRLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLL SRKPAEEPREEPGTCHHTRRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRA AAGGRTMDEIRRHPDKGNGQQRPTKQKSEEQLQAYYKKTLEERLSAGALNTFP RAFKQVMEGRDIKLVINQTAQDCFGCLESISQIRTATRDKKDTVTREKHPKKP FQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVF KTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDG ITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDI NNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTI IWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYEN ISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHR GQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCHGFYIK PTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLD FWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAV KEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMK CFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQ KDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLL TALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVTQDARI KRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVT VRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQD NFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1672) AAVS1 Left and MGIHGVPAAMAERPFQCRICMRNFSYNWHLQRHIRTHTGEKPFACDICGRKFA Right ZFP attached RSDHLTTHTKIHTGSQKPFQCRICMRNFSHNYARDCHIRTHTGEKPFACDICG to N-terminus of RKFAQNSTRIGHTKIHLRGS SGSETPGTSESATPES GIHGVPAAMAERPFQCR R2Tg containing ICMRNFSQSSNLARHIRTHTGEKPFACDICGRKFARTDYLVDHTKIHTGSQKP DBD inactivation FQCRICMRNFSYNTHLTRHIRTHTGEKPFACDICGRKFAQGYNLAGHTKIHLR mutations with GS SGSETPGTSESATPES ASCPKPGPPVSAGAMSLESGLTTHSVLAIERGPNS XTEN linker LANSGSDFGGGGLGLPLRLLRVSVGTQTSRSDWVDLVSWSHPGPTSKSQQVDL VSLFPKHRVDLLSKNDQVDLVAQFLPSKFPPNLAENDLALLVNLEFYRSDLHV YECVHFAAHWEGLSGLPEVYEQLAPQPCVGETLHSSLPRDSELFVPEEGSSEK ESEDAPKTSPPTPGKHGLEQTGEEKVMVTVPDKNPPSPSSGTRVNSVLNLIEH LKVSHGKRGVCFRCAKCGKENSNYHSVVCHFPKCRGPETEKAPAGEWISEVSN RDFTTKIGLGQHKRLAHPAVRNQERIVASQPKETSNRGAHKACATKEEEELLI RLEAQFEGNKNINKLIAEHITTKTAKQISDKRRLLSRKPAEEPREEPGTCHHT RRAAASLRTEPEMSHHAQAEDRDNGPGRRPLPGRAAAGGRTMDEIRRHPDKGN GQQRPTKOKSEEQLQAYYKKTLEERLSAGALNTFPRAFKQVMEGRDIKLVINQ TAQDCFGCLESISQIRTATRDKKDTVTREKHPKKPFQKWMKDRAIKKGNYLRF QRLFYLDRGKLAKIILDDIECLSCDIPLSEIYSVFKTRWETTGSFKSLGDFKT YGKADNTAFRELITAKEIEKNVQEMSKGSAPGPDGITLGDVVKMDPEFSRTME IFNLWLTTGKIPDMVRGCRTVLIPKSSKPDRLKDINNWRPITIGSILLRLFSR IVTARLSKACPLNPRQRGFIRAAGCSENLKLLQTIIWSAKREHRPLGVVFVDI AKAFDTVSHQHIIHALQQREVDPHIVGLVSNMYENISTYITTKRNTHTDKIQI RVGVKQGDPMSPLLFNLAMDPLLCKLEESGKGYHRGQSSITAMAFADDLVLLS DSWENMNTNISILETFCNLTGLKTQGQKCHGFYIKPTKDSYTINDCAAWTING TPLNMIDPGESEKYLGLQFDPWIGIARSGLSTKLDFWLQRIDQAPLKPLQKTD ILKTYTIPRLIYIADHSEVKTALLETLDQKIRTAVKEWLHLPPCTCDAILYSS TRDGGLGITKLAGLIPSVQARRLHRIAQSSDDTMKCFMEKEKMEQLHKKLWIQ AGGDRENIPSIWEAPPSSEPPNNVSTNSEWEAPTQKDKFPKPCNWRKNEFKKW TKLASQGRGIVNFERDKISNHWIQYYRRIPHRKLLTALQLRANVYPTREFLAR GRQDQYIKACRHCDADIESCAHIIGNCPVTQDARIKRHNYICELLLEEAKKKD WVVFKEPHIRDSNKELYKPDLIFVKDARALVVDVTVRYEAAKSSLEEAAAEKV RKYKHLETEVRHLTNAKDVTFVGFPLGARGKWHQDNFKLLTELGLSKSRQVKM AETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1673) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGN attached at v2 TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM location of DBD of AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV R2Tg with DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF XTEN33aa linker EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLK LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1674) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGN containing catalytic TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM mutations (dCas9) AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV attached at v2 DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF location of DBD of EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT R2Tg with PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL XTEN33aa linker SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1675) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGN D10A nickase TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM mutant attached at AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV v2 location of DBD DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF of R2Tg with EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT XTEN33aa linker PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLK LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1676) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGN N863A nickase TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM mutant attached at AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV v2 location of DBD DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF of R2Tg with EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT XTEN33aa linker PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPDLIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1677) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGN D10A nickase TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM mutant attached at AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV v2 location of DBD DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF of R2Tg containing EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL EN mutation with SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS XTEN33aa linker KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE LSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLK LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPALIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1678) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGN N863A nickase TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM mutant attached at AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV v2 location of DBD DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF of R2Tg containing EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT EN mutation with PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL XTEN33aa linker SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLK LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPALIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1679) S. pyogenes Cas9 MAPKKKRKVGIHGVPAADKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGN attached at v2 TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM location of DBD of AKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV R2Tg containing EN DSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF mutation with EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT XTEN33aa linker PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILL SDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS KNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIAN LAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINR LSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGD SGGSSGGSSGSETPGTSESATPESSGGSSGGSS TATRDKKDTVTREK HPKKPFQKWMKDRAIKKGNYLRFQRLFYLDRGKLAKIILDDIECLSCDIPLSE IYSVFKTRWETTGSFKSLGDFKTYGKADNTAFRELITAKEIEKNVQEMSKGSA PGPDGITLGDVVKMDPEFSRTMEIFNLWLTTGKIPDMVRGCRTVLIPKSSKPD RLKDINNWRPITIGSILLRLFSRIVTARLSKACPLNPRQRGFIRAAGCSENLK LLQTIIWSAKREHRPLGVVFVDIAKAFDTVSHQHIIHALQQREVDPHIVGLVS NMYENISTYITTKRNTHTDKIQIRVGVKQGDPMSPLLFNLAMDPLLCKLEESG KGYHRGQSSITAMAFADDLVLLSDSWENMNTNISILETFCNLTGLKTQGQKCH GFYIKPTKDSYTINDCAAWTINGTPLNMIDPGESEKYLGLQFDPWIGIARSGL STKLDFWLQRIDQAPLKPLQKTDILKTYTIPRLIYIADHSEVKTALLETLDQK IRTAVKEWLHLPPCTCDAILYSSTRDGGLGITKLAGLIPSVQARRLHRIAQSS DDTMKCFMEKEKMEQLHKKLWIQAGGDRENIPSIWEAPPSSEPPNNVSTNSEW EAPTQKDKFPKPCNWRKNEFKKWTKLASQGRGIVNFERDKISNHWIQYYRRIP HRKLLTALQLRANVYPTREFLARGRQDQYIKACRHCDADIESCAHIIGNCPVT QDARIKRHNYICELLLEEAKKKDWVVFKEPHIRDSNKELYKPALIFVKDARAL VVDVTVRYEAAKSSLEEAAAEKVRKYKHLETEVRHLTNAKDVTFVGFPLGARG KWHQDNFKLLTELGLSKSRQVKMAETFSTVALFSSVDIVHMFASRARKSMVM (SEQ ID NO: 1680)

Example 10: Inactivation of an Endogenous Nucleolar Localization Signal in a Gene Writer

This example describes a Gene Writer in which an endogenous nucleolar localization signal has been inactivated to reduce intracellular targeting of the protein to the nucleolus.

In this example, the nucleolar localization signal (NoLS) of a retrotransposase is computationally predicted using a published algorithm that was trained on validated proteins that localize to the nucleolus (Scott, M. S., et al, Nucleic Acids Research, 38(21), 7388-7399 (2010)). The predicted NoLS sequence is based on both amino acid sequence, amino acid sequence context, and predicted secondary structure of the retrotransposase. The identified sequence is typically rich with basic amino acids (Scott, M. S., et al, Nucleic Acids Research, 38(21), 7388-7399 (2010)) and when these residues are mutated to a simple side-chain, non-basic, amino acids or removed from the retrotransposase polypeptide chain then it can prevent localization to the nucleolus (Yang, C. P., et. al., Journal of Biomedical Science, 22(1), 1-15. (2015), Martin, R. M., et. al., Nucleus, 6(4), 314-325 (2015)). In some embodiments, the NoLS sequence is located in the amino acid region of a retrotransposase that is between the reverse transcriptase polymerase motif and the restriction-like endonuclease motifs. The predicted NoLS region contains lysine, arginine, histidine, and/or glutamine amino acids where nucleolar localization is inactivated by mutation of one or more of these residues to an alanine amino acid residue and/or one or more of these amino acids are removed from the polypeptide chain of the retrotransposase. In some embodiments, the amino acid sequence of the Gene Writer driver of R2Tg found upstream of the RLE is mutated such that lysines (K) are substituted for alanines (A), e.g., the predicted NoLS of R2Tg (amino acids 1,128-1,154 of polypeptide sequence), (APTQKDKFPKPCNWRKNEFKKWTKLAS (SEQ ID NO: 1681)) is mutated at 1, 2, 3, 4, 5, 6, or 7 residues to produce an inactivated NoLS (APTQADAFPAPCNWRANEFAAWTALAS (SEQ ID NO: 1682)).

Example 11: Application of Second-Strand Nicking in a Gene Writer System

This example describes a Gene Writer system in which retrotransposition is paired with targeted second-strand nicking activity in order to increase the efficiency of integration events. The second strand nick can be achieved by (1) a Cas9 nickase fused to a gene writer system, in which the Gene Writer introduces one nick through its endonuclease domain (EN), and the fused nickase Cas9 μlaces another nick on either the top and bottom DNA strands (FIG. 7A), or (2) a GeneWriter system in which the active EN domain introduces a nick, and a Cas9 nickase introduces a second nick on either top or bottom strand of the DNA, upstream or downstream of the Gene Writer induced nick (FIG. 7B).

In the first part of this example, a Cas9 nickase is fused to a Gene Writer protein (FIG. 7A). The Cas9 is targeted to a DNA sequence through a gRNA. The Gene Writer protein introduces a DNA nick through its EN domain, and an additional nick is generated through the nickase Cas9 activity. This additional nick can be targeted to the top or bottom strands of the DNA surrounding the Gene Writer introduced nick (FIG. 8A). Constructs designed and tested include (see schematic FIG. 14A):

-   -   Cas9-N863A-R2tg (RBD*, RT, EN)     -   Cas9-H840A-R2tg (RBD*, RT, EN)     -   Cas9-D10A-R2tg (RBD*, RT, EN)     -   dCas9-R2tg (RBD*, RT, EN)         The DNA binding domain is the nickase Cas9 that directs the Gene         Writer molecule to a DNA target through a gRNA. The RNA binding         domain (RBD) in this set of Gene Writer constructs is         inactivated with a point mutation (RBD*). As a donor for         insertion, constructs in which the R2Tg RNA binding domain is         inactive use a gRNA that is extended at its 3′ end to include         donor sequence for genome modification (FIG. 14B). These         modifications include nucleotide substitutions, nucleotide         deletions and nucleotide insertions. In this first set of         experiments, the above constructs-R2Tg(RBD*, RT, EN) and         dCas9-R2Tg(RBD*, RT, EN) fusions with a 3′ extended gRNA         template targeting the AAVS1 locus are delivered to U2OS cells         through nucleofection in SE buffer using program DN100. gRNAs         used include gRNAs for each construct that target either the         bottom or top strand of DNA. After nucleofection, cells are         grown in complete medium for 3 days. gDNA is harvested on day 3,         and amplicon sequencing followed by computational analysis using         CRISPResso (indel analysis tool) are performed. 3′ extended gRNA         mediated insertions, deletions or nucleotide substitutions are         observed upon delivery of dCas9-R2Tg(RBD*, RT, EN), and         increased in frequency when delivering Nickase-Cas9-R2Tg(RBD*,         RT, EN) constructs.

In the second part of this example, a Cas9 nickase is fused to a Gene Writer protein (FIG. 7A). The Cas9 is targeted to a DNA sequence through a gRNA. The Gene Writer protein introduces a DNA nick through its EN domain, and an additional nick is generated through the nickase Cas9 activity. This additional nick can be targeted to the top or bottom strands of the DNA surrounding the Gene Writer introduced nick (FIG. 7A). In contrast to the constructs listed above, the RNA binding domain of R2Tg is active (FIG. 15A), and the template used for genome modification is a transgene flanked by UTRs (FIG. 15B). Constructs include (see schematic FIG. 15A):

-   -   Cas9-N863A-R2tg (RBD, RT, EN)     -   Cas9-H840A-R2tg (RBD, RT, EN)     -   Cas9-D10A-R2tg (RBD, RT, EN)     -   dCas9-R2tg (RBD, RT, EN)         The transgene flanked by UTRs requires homology arms at the site         of nicking. To determine the site of nicking for the accurate         design of homology arms for the donor transgene DNA, the above         listed constructs are nucleofected into 200 k U2OS cells with a         gRNA targeting the AAVS1 locus using pulse code DN100. After         nucleofection, cells are grown in complete medium for 3 days.         gDNA is harvested on day 3, and amplicon sequencing followed by         computational analysis using CRISPResso as an indel analysis         tool are performed. The nicking site of the EN domain is         identified from the indels the EN domain produces at the AAVS1         site. Homology arms of 100 bp flanking the EN nicking site are         designed and included in the transgene. To achieve genome         modification, Cas9-R2Tg fusion constructs listed above are         nucleofected into U2OS cells, along with a gRNA targeting either         the top or bottom strand of the AAVS1 locus, and the appropriate         transgenes harboring homology to the previously determined         nicking site. After nucleofection, cells are grown in complete         medium for 3 days. gDNA is harvested on day 3, and ddPCR is         performed to detect transgene integration at the AAVS1 site.         Integrations are observed upon delivery of dCas9-R2Tg(RBD, RT,         EN), and increased in frequency when delivering         Nickase-Cas9-R2Tg(RBD, RT, EN) constructs.

In another example, a Gene Writer protein is targeted to DNA through its DNA binding domain (FIG. 7B). The Gene Writer protein will introduce a DNA nick at a DNA strand. In addition, a Cas9 nickase is used to generate a second nick either on the top or bottom strands of the DNA, upstream or downstream of the first nick. In this example, a Gene Writer plasmid targeting the AAVS1 site (FIG. 16A) and with a UTR flanked transgene with homology to the AAVS1 site (FIG. 16B) is nucleofected into 200 k U2OS cells using pulse code DN100. The following Cas9 constructs are transfected alongside the Gene Writer plasmids (FIG. 16C):

-   -   Cas9-N863A     -   Cas9-H840A     -   Cas9-D10A     -   dCas9         All Cas9 constructs are co-nucleofected with gRNAs targeting the         AAVS1 locus on either the top or bottom strands, upstream or         downstream of the Gene Writer introduced nick. After         nucleofection, cells are grown in complete medium for 3 days.         gDNA is harvested on day 3, and ddPCR is performed to detect         transgene integration at the AAVS1 site. Integrations are         observed upon delivery of dCas9 and increased in frequency when         delivering Nickase-Cas9 constructs.

Example 12: Improved Expression of Gene Writer Polypeptide by Heterologous UTRs

This example describes the use of heterologous UTRs to enhance the intracellular expression of the Gene Writer polypeptide.

In this example, the Gene Writer polypeptide was expressed from mRNA (FIG. 17 ). In the plasmid template for the mRNA production, the native retrotransposon UTRs were replaced with UTRs optimized for the protein expression (C3 5′UTR and ORM 3′ UTR from Asrani et al., RNA biology 15, 756-762 (2018) or 5′ and 3′ UTRs from Richter et al., Cell 168, 1114-1125 (2017)). The plasmid included the T7 promoter followed by the 5′UTR, the retrotransposon coding sequence, the 3′ UTR, 3GS linker (SEQ ID NO: 1024), SV40 nuclear localization signal (NLS), XTEN linker, HiBit sequence and 96-100 nucleotide long poly(A) tail (SEQ ID NO: 1683). The plasmid was linearized by enzymatic restriction resulting in blunt end or 5′ overhang downstream of poly(A) tail and used for in vitro transcription (IVT) using T7 polymerase (NEB). Following the IVT step the RNA was treated with DNase I (NEB). After the buffer exchange step the enzymatic capping reaction was performed using Vaccinia capping enzyme (NEB) and 2′-O-methyltransferase (NEB) in the presence of GTP and SAM (NEB). The capped RNA was concentrated and buffer exchanged. 50,000 HEK293T cells were transfected with 0.5 pg with the Gene Writer mRNA in the presence or in the absence of the RNA template in 1:1 molar ratio using Neon transfection system (1150 V per pulse, 20 msec per pulse, 2 pulses in 10 μL tips in 96 well format). The RNA template was in vitro transcribed from plasmid as described in Example 14 (Improved Gene Writer components for RNA-based delivery).

After transfection HEK293T cells were grown for 5 hours before assaying the Gene Writer expression by probing its HiBit tag expression using standard protocol https://www.promega.com/-/media/files/resources/protocols/technical-manuals/500/nano-glo-hibit-lytic-detection-system-technical-manual.pdf?la=en. Protein expression was found to be greatly improved by the use of 5′ and 3′ UTRex_(p) from C3-ORM as compared to using the native UTRs from R2Tg (FIG. 17 ). The genome integration was assayed 3 days post-transfection using 3′ ddPCR (FIG. 18 ).

Example 13: Improved Gene Writer Components for Mixed RNA and DNA Delivery

This example describes improvements to the RNA molecule encoding a Gene Writer polypeptide that enhance expression and allow for increased efficiency of retrotransposition when used with a Gene Writer template encoded on plasmid DNA.

In this example, the polypeptide component of the Gene Writer™ system is expressed from mRNA described in Example 12 (Improved expression of Gene Writer polypeptide by heterologous UTRs). The plasmid template was synthesized such that the reporter gene (eGFP) was flanked by R2Tg untranslated regions (UTRs) and 100 bp of homology to its rDNA target. The tempate expression was driven by the mammalian CMV promoter. We introduced the plasmid into HEK393T cells using the FuGENE® HD transfection reagent. HEK293T cells were seeded in 96-well plates at 10,000 cells/well 24 hours before transfection. On the transfection day, 0.5 μl transfection reagent and 80 ng DNA was mixed in 10 μl Opti-MEM and incubated for 15 minutes at room temperature. The transfection mixture was then added to the medium of the seeded cells. Cells were detached and used for the electroporation of 0.5 pg of mRNA per well using Neon transfection system (1150 V per pulse, 20 msec per pulse, 2 pulses in 10 μL tips in 96 well format).

HEK293T cells were transfected with the following test agents:

-   -   1. mRNA coding for the polypeptide described above     -   2. Plasmid encoding template RNA described above     -   3. Combination of 1 and 2. The plasmid was pre-lipofected 24 hrs         before mRNA transfection as described above.         After transfection, HEK293T cells were cultured for 1-3 days and         then assayed for site-specific genome editing. Genomic DNA was         isolated from each group of HEK293 cells. ddPCR was performed to         confirm integration and assess integration efficiency. Taqman         probes and primers were designed as described in         PCT/US2019/048607 to amplify the expected product across 5′ and         3′ ends of integration junctions. The results of the ddPCR copy         number analysis (in comparison to reference gene RPP30) are         shown in FIG. 19 . The genome integration in the presence of the         mRNA and the template plasmid achieved a mean copy number of         0.683 integrants/genome when targeting 3′ junction and of 0.249         integrants/genome when targeting 5′ junction. The mRNA only         transfection resulted in a mean copy number of 0.002         integrants/genome, in comparison to 0.0004 integrants/genome for         the plasmid only transfection.

Example 14: Improved Gene Writer Components for RNA-Based Delivery

This example describes improvements to the RNA molecule encoding a Gene Writer polypeptide that enhance expression and allow for increased efficiency of retrotransposition when co-delivered with a Gene Writer RNA template.

In this example, the polypeptide component of the Gene Writer™ system is expressed from mRNA described in Example 12 (Improved expression of Gene Writer polypeptide by heterologous UTRs). The plasmid template for the RNA template production included T7 promoter followed by the IRES-expressing reporter gene (eGFP) flanked by R2Tg untranslated regions (UTRs) and 100 bp of homology to its rDNA target. The plasmid template was linearized by enzymatic restriction resulting in blunt end or 5′ overhang downstream of the RNA template sequence and used for in vitro transcription (IVT) using T7 RNA polymerase (NEB). Following the IVT step the RNA was treated with DNase I (NEB) and either enzymatically polyadenylated by poly(A) polymerase (NEB) or not. After the buffer exchange step the enzymatic capping reaction was performed using Vaccinia capping enzyme (NEB) and 2′-O-methyltransferase (NEB) in the presence of GTP and SAM (NEB). The capped RNA was concentrated and buffer exchanged. 50,000 HEK293T cells were co-transfected with 0.5 to 1 pg of the GeneWriter mRNA and the RNA template in 1:4 to 1:12 molar ratios. The Neon transfection system was used for the RNA transfection (1150 V per pulse, 20 msec per pulse, 2 pulses in 10 μL tips in 96 well format).

After transfection, HEK293T cells were cultured for at least 1 day and then assayed for site-specific genome editing. Genomic DNA was isolated from each group of HEK293 cells. ddPCR was performed to confirm integration and assess integration efficiency. Taqman probes and primers were designed as described in PCT/US2019/048607 to amplify the expected product across 5′ and 3′ ends of integration junctions. The mean copy number of 0.498 integrants/genome was achieved in the presence of the 0.5 pg of mRNA and 1:8 molar ratio of Gene Writer mRNA to the RNA template when the RNA template was enzymatically polyadenylated, in comparison to that of 0.031 integrants/genome when the RNA transgene was not polyadenylated.

Example 15: Gene Writers that Deliver Genetic Cargo Containing Introns

This example describes the use of a Gene Writer system to integrate genetic cargo that contains introns by using RNA-based delivery to tune expression of the gene of interest from its newly introduced genomic locus.

In this example, Gene writing technology uses an RNA template encoding a protein of interest including its native or non-native introns. For example, intron 6 of the triose phosphate isomerase (TPI) gene (Nott et al., 2003) will be used as one of the non-native introns in these experiments.

The presence of introns in the genomic copy of a gene and their removal by splicing has been reported to affect nearly every aspect of the gene expression, including its transcription rate, the mRNA processing, export, cell localization, translation and decay (reviewed in Shaul International Journal of Biochemistry and Cell Biology 91B, 145-155 (2017)). The introns can be inserted into different parts of the RNA template (FIG. 21 ) and depending on the intron location their role in gene expression can differ.

An intron in the 5′ UTR_(exp), close to the transcription start site, introduces activating chromatin modifications (Bieberstein et al., Cell Reports 2, 62-68 (2012)), improves accuracy of transcription start site recognition and facilitates PolII recruitment (Laxa et al., Plant Physiology 172, 313-327 (2016)), increases rates of transcription initiation (Kwek et al., Nature Structural Biology 9, 800-805 (2002)) and elongation (Lin et al., Nature Structural and Molecular Biology 15, 819-826 (2008)), and improve the productive elongation in the sense relative to the antisense orientation (Almada et al., Nature 499, 360-363 (2013)).

An intron in the 3′ UTR_(exp) limits the mRNA expression to one protein molecule per mRNA: the exon junction complex (EJC) left by spliceosome downstream of stop codon is recognized by the nonsense-mediated decay (NMD) machinery and therefore the mRNA is marked for deletion at the end of the pioneering round of translation (Zhang et al., RNA 4, 801-815 (1998)).

The ability to employ introns in a therapeutic gene may, however, be limited by splicing that occurs prior to integration of the template. For example, an intron in the forward orientation would be spliced out when an RNA template was encoded and delivered on a DNA plasmid, since transcription in the same direction would yield a template RNA that would be spliced prior to integration, thus failing to incorporate the intron in the genome. Additionally, lentivirus constructs designed to deliver a transgene must encode a sequence with an intron in the reverse orientation, since the viral packaging process would result in intron splicing and absence of the intron in packaged viral particles (Miller et al. J Virol 62, 4337-45 (1988)). However, the reverse orientation has also been thought to result in a reduction in viral titer and transduction (Uchida et al., Nat Commun 10, 4479 (2019)). It is worth noting that since the Gene Writer template can be generated through in vitro transcription and delivered directly as RNA, the problem of pre-integration splicing of desired introns can be avoided. In some embodiments, the Gene Writer template may thus contain one or more introns in same-sense orientation with the transcript, which is generated by IVT and delivered to the target cell as RNA.

An intron in any location depicted in FIG. 21 will recruit U1 snRNP that protects mRNA from the premature cleavage and polyadenylation (Kaida et al., Nature 468 664-681 (2010); Berg et al., Cell 150, 53-64 (2012)). In addition, the EJC interacts with components of the TREX (transcription-export) complex and increases the rate of mRNA export from nucleus to cytoplasm 6-10-fold in comparison to the constructs lacking introns (Valencia et al., PNAS 105, 3386-3391 (2008)). It was also demonstrated that the binding of the polypyrimidine tract-binding protein, a splicing regulator protein, mediates a significant increase in the half-life of the spliced transcripts (Lu & Cullen, RNA 9, 618-630 (2003); Millevoi et al., Nucleic Acid Research 37, 4672-4683 (2009)). The efficiency of the mRNA translation was shown to be increased by the presence of the SR proteins (serine-arginine rich proteins, involved in RNA splicing) (Sanford et al., Genes & Development 18, 755-768 (2004); Sato et al., Molecular Cell 29, 255-262 (2008)) and the EJC proteins and its peripheral factors (Nott et al., Genes & Development 18, 210-222 (2004)).

In this example both the template RNAs harboring an intron or introns and Gene Writer polypeptide are delivered to the cells as in vitro transcribed capped RNAs as described in Example 14 (Improved Gene Writer components for RNA-based delivery). One to three days post-transfection the GOI expression and the genomic integration are assayed. In some embodiments, the genome integration and/or protein expression will be higher for the intron-containing RNA template.

Example 16: Engineering of the Retrotransposon 5′ UTR to Improve Efficiency of Integration

This example describes the deletion, replacement, or mutation of the 5′UTR of a retrotransposon to increase integration efficiency.

The 5′UTR region of non-LTR retrotransposons has multiple functions including self-cleaving ribozyme activity, which has been shown in certain elements and is predicted in additional retrotransposons (see modules B and C of FIG. 27-28 ) (Ruminski et al. J Biol Chem 286, 41286-41295 (2011)). Ribozymal activity is predicted to cleave the RNA within or upstream of the 5′UTR. Either increasing or restricting this activity and structural component of the 5′UTR may benefit retrotransposition efficiency. A prediction of the ribozyme structure of R2Tg is provided in FIG. 29 .

In order to evaluate engineering of the 5′UTR, constructs were designed to enhance or diminish these activities (FIG. 20 ). In case (A), the natural 5′UTR of R2Tg is used to integrate in trans as in previous experiments. Case (B) illustrates deletion of the 5′UTR. (C) and (D) represent cases in which the 5′UTR from the original species (in this case R2Tg from T. guttata) has been replaced by the 5′UTR of a retrotransposon from a distinct species. Case (C) provides an example in which the 5′UTR from A. maritima R2 has replaced that of R2Tg. (D) represents the generic case in which UTRs from additional species may be substituted (“Rx”), such as that from B. mori, D. ananasse, F. auricularia, L. polyphemus, N. giraulti, or O. latipes, or from a retrotransposon selected from a Table herein, or any of Tables 1-3 of PCT/US2019/048607, herein incorporated by reference in its entirety. Case (E) represents the substitution of a ribozyme, such as a hammerhead ribozyme, e.g., RiboJ (Lou et al Nat Biotechnol 30, 1137-1142 (2012)). Case (F) represents the inactivation of the 5′UTR of R2Tg through point mutations, e.g., 75C>T in the 5′ UTR (FIG. 20 .B, position indicated by shaded box). 5′UTR sequences are expected to be modular to any insertion sequence mediated by the retrotransposon.

Each case is evaluated as in previous examples by transfection of Gene Writer polypeptide plasmid with template plasmid and evaluation of integration frequency via ddPCR. In some embodiments, substitution or mutation of the 5′ UTR results in increased efficiency of integration.

Example 17: Modifying the 5′ and 3′ Ends of Gene Writer RNA Components to Improve RNA Stability

This example describes the addition of non-coding sequences to the 5′ and 3′ ends of RNA in order to improve stability in a mammalian cell.

The decay of eukaryotic RNAs in cells are mostly carried out by exoribonucleases. In this example, the half-life of RNAs is prolonged by introducing protective sequences and/or modifications at their 5′ and 3′ ends. The most common natural way of protecting the RNA ends is by introduction of 5′ cap structure and 3′ poly(A) tail. In this example, the polypeptide component of the Gene Writer™ system is expressed from mRNA described in Example 12 (Improved expression of Gene Writer polypeptide by heterologous UTRs). The plasmid template for the RNA template production included T7 promoter followed by the IRES-expressing reporter gene (eGFP) flanked by R2Tg untranslated regions (UTRs) and 100 bp of homology to its rDNA target. The plasmid template was linearized by enzymatic restriction resulting in blunt end or 5′ overhang downstream of the RNA template sequence and used for in vitro transcription (IVT) using T7 polymerase (NEB). Following the IVT step the RNA was treated with DNase I (NEB) and either enzymatically polyadenylated by poly(A) polymerase (NEB) or not. After the buffer exchange step the enzymatic capping reaction resulting in cap 1 structure was performed as described in Example 14 (Improved Gene Writer components for RNA-based delivery) or not performed. The template RNA was concentrated and buffer exchanged. 50,000 HEK293T cells were co-transfected with 0.5 pg with the GeneWriter mRNA and the RNA template in 1:1 to 1:8 molar ratios using Neon transfection system (1150 V per pulse, 20 msec per pulse, 2 pulses in 10 μL tips in 96 well format).

After transfection, HEK293T cells were cultured for 1-3 days and then assayed for site-specific genome editing. Genomic DNA was isolated from each group of HEK293 cells. ddPCR was performed to confirm integration and assess integration efficiency. Taqman probes and primers were designed as described in PCT/US2019/048607 to amplify the expected product across 3′ end of integration junctions. The genome integration was improved when the enzymatically capped and poly(A) tailed template was used (FIG. 22 ).

The mean copy number of 0.498 integrants/genome was achieved in the presence of the 0.5 pg of mRNA and 1:8 molar ratio of mRNA:RNA template when the RNA template was enzymatically polyadenylated, in comparison to that of 0.031 integrants/genome when the RNA transgene was not enzymatically polyadenylated.

3′ End Modifications of RNAs.

It has been reported that the interactions between poly(A) tail shorter than 15-20 nts and the poly(A) binding protein (PABP) are destabilized resulting in the fast degradation of the RNA (Chang et al., Molecular Cell 53, 1044-1052 (2014); Subtelny et al., Nature 508, 66-71 (2014)). To determine the suitable lengths of the poly(A) tail of the template RNA we will test its lengths of 30, 40, 50, 60, 70, 80, 90 and 100 nucleotides. The IVT templates will be produced by PCR using reverse primers encoding the poly(A) tails of the abovementioned length. The IVT, DNase I treatment and capping of Gene Writer and the RNA template will be performed as described in Example 14 (Improved Gene Writer components for RNA-based delivery). After one to three days post-transfection the genomic integration will be assayed. In some embodiments, the genome integration will be higher for the RNA template tailed with a poly(A) tail of a suitable length.

In a cell the RNA degradation is initiated by shortening its poly(A) tail by deadenylases. Since the deadenylases are 3′-5′ exoribonucleases favoring the poly(A) stretches, the terminal uridine, cytidine and most often guanine detected in the natural poly(A) tails of many mRNA were proposed to protect the poly(A) tail from its shortening (Chang et al., Molecular Cell 53, 1044-1052 (2014)). We will assay the Gene Writer and template RNAs with the encoded poly(A) tail with terminal G or C, or intermittent Gs or Cs (similar to that used in Lim et al., Science 361, 701-704 (2018)) according as described before.

Some of the RNAs have been described to evolve alternative ways of protections their 3′ ends. A specific 16-nucleotide long stem-loop structure flanked with unpaired 5 nucleotides on both sides has been reported to protect the 3′ end of mRNA encoding H2a.X histone (Mannironi et al., Nucleic Acid Research 17, 9113-9126 (1989)). It has been shown that the heterologous mRNA ending with the histone stem-loop structure is cell cycle-regulated (Harris et al., Molecular Cellular Biology 11, 2416-2424 (1991); Stauber et al., EMBO Journal 5, 3297-3303 (1986)). The stem-loop structure is recognized and protected by the Stem-Loop Binding Protein (SLBP). The protein accumulates shortly before cells enter S-phase and is rapidly degraded at the end of S-phase (Whifield et al., Molecular Cellular Biology 20, 4188-4198 (2000)). The stem-loop element will be inserted to the 3′ end of the Gene Writer mRNA and the RNA templates and tested as described above to induce cell-cycle specific genome integration events.

Some viral and long non-coding RNAs have evolved to protect their 3′ ends with triple-helical structures (Brown et al., PNAS 109, 19202-19207 (2012)). Additionally, the structural elements of tRNA, Y RNA and vault RNA (reviewed in Labno et al., Biochemica et Biophysica Acta 1863, 3125-3147 (2016)) have been reported to extend half-life of these non-coding RNAs. We will insert the structures to protect the 3′ end of the RNA templates and probe their efficiencies in Gene Writing system as described above.

Finally, we will incorporate dNTP, 2′O-Methylated NTPs or phosphorothioate-NTP at the 3′ of the RNA transgenes to increase the half-life of these molecules by protecting the 3′ end of the RNA from exoribonucleases. We will incorporate single modified nucleotides or their stretches by extending the 3′end of the RNA by the DNA polymerases (for example, Klenow fragment) capable of extending an RNA sequence by adding modified nucleotides (Shcherbakova & Brenowitz, Nature Protocols 3, 288-302 (2008)).

A single nucleotide chemical modification of the 3′ end of the RNA can be done by first oxidation of 3′ terminal end of ribose sugar with sodium periodate to form a reactive aldehyde followed by conjugation of an aldehyde-reactive modified nucleotide. Alternatively, T4 DNA or T4 RNA ligases can be used for the splinted ligation (Moore & Query, Methods in Enzymology 317, 109-123 (2000)) of the stretches of modified nucleotides to the 3′ end of the RNAs.

Chemical ligation of two fragments is also possible. The phosphodiester bond linkage between two RNA substrates can be formed either by activating the phosphomonoester group using a reactive imidazolide or by using a condensing reagent such as cyanogen bromide. A disadvantage of chemical ligation is that it can also result in the creation of a 2′-5′ phosphodiester linkage, together with the desired 3′-5′ phosphodiester linkages.

5′ End Modifications of RNAs

In addition to the cap 1 structure described in Example 14 (Improved Gene Writer components for RNA-based delivery) other 5′ end protection groups will be explored. Particularly, we will use hypermethylated (Wurth et al. Nucleic Acid Res 42, 8663-8677 (2014)), phosphorothioate (Kuhn et al., Gene Therapy 17, 961-971 (2010)), NAD+-derived (Kiledjian, Trends in Cell Biology 28, 454-464 (2018)) and modified (for example, biotinylated: Bednarek et al., Phil Trans R Soc B 373, 20180167 (2018)) cap analogs for co-transcriptional capping.

We will also label the 5′ of the RNA with 5′-[γ-thio]triphosphate to create a reactive sulfur group and chemically modify the 5′ end with the protective modifications using a haloacetamide derivative of the modified group.

The proposed modifications to protect 3′ and 5′ end of the RNA will be introduced in RNA templates and/or Gene Writer mRNA (if compatible with translation). The genome integration efficiencies of the RNAs will be tested as described in Example 14 (Improved Gene Writer components for RNA-based delivery).

Example 18: Use of Modified RNA Bases in a Gene Writer System

This example describes Gene Writer systems comprising modified RNA bases to potentially improve features of the system, e.g., increase efficiency of integration, decrease cellular response to foreign nucleic acids. For the Gene Writer polypeptide, the proposed modifications pertaining to the coding region are compatible with translation. For the RNA template, the proposed modifications are compatible with reverse transcription.

In this example, mRNA encoding the Gene Writer polypeptide was in vitro transcribed with a 100% replacement of the corresponding rNTP with one of the modified rNTPs: pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), 5-methoxyuridine (5-MO-U) or 5-methylcytidine (5mC). Otherwise, the RNA preparation, purification and cell transfections were performed as described in the Example 14 (Improved Gene Writer components for RNA-based delivery). The gene integration capacity of the modified mRNAs was compared with that of the non-modified mRNA (G0) using ddPCR, with all polypeptide mRNAs being paired with an unmodified template RNA (FIG. 23 ). Integration was detected when the polypeptide was encoded using each modified rNTP, with the highest signal coming from 5-MO-U and the lowest from 5mC. This demonstrates that the Gene Writer polypeptide component is functional when expressed from mRNA containing modified bases.

Further, this example describes the modularity of the Gene Writer template molecule where it is composed of all or a subset of exemplary modules listed in FIG. 6 and illustrated in FIG. 5 . Individual modules can be produced by chemical or in vitro syntheses as a contiguous nucleic acid molecule or in separate pieces that are later combined together. The individual modules of the Gene Writer template molecule can be chemically modified nucleic acids, be comprised in part or in entirety of non-nucleic acids, re-arranged in order, and/or omitted to form the Gene Writer template molecule.

In some embodiments, the Gene Writer template molecule (all modules, A-F) is synthesized by in vitro transcription where 0-100% replacement of a corresponding rNTP (adenosine, cytidine, guanosine, and/or uridine) is with one or more modified rNTPs (base or ribose modification), e.g., 5′ hydroxyl, 5′ Phosphate, 2′-O-methyl, 2′-O-ethyl, 2′-fluoro, ribothymidine, C-5 propynyl-dC (pdC), C-5 propynyl-dU (pdU), C-5 propynyl-C(pC), C-5 propynyl-U (pU), 5-methyl C, 5-methyl U, 5-methyl dC, 5-methyl dU methoxy, (2,6-diaminopurine), 5′-Dimethoxytrityl-N4-ethyl-2′-deoxyCytidine, C-5 propynyl-fC (pfC), C-5 propynyl-fU (pfU), 5-methyl fC, 5-methyl fU, C-5 propynyl-mC (pmC), C-5 propynyl-fU (pmU), 5-methyl mC, 5-methyl mU, LNA (locked nucleic acid), MGB (minor groove binder) pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), 5-methoxyuridine (5-MO-U). The modified nucleotides in this embodiment rely on incorporation through a transcription reaction which utilizes a natural or mutant polypeptide sequence of a RNA polymerase that readily incorporates modified nucleotides into a RNA transcript that is made in vitro (Padilla, R., Nucleic Acids Research, 30(24), 138e-138, 2002; Ibach, J., et. al., Journal of Biotechnology, 167(3), 287-295, 2013; Meyer, A. J., et. al., Nucleic Acids Research, 43(15), 7480-7488, 2015). The modified Gene Writer template molecule is typically in whole or in part compatible with the reverse transcriptase activity of the Gene Writer polypeptide sequence; for modules or parts of modules of the Gene Writer template molecule used as a template for reverse transcription, preference is given to modifications that are compatible with reverse transcription (Motorin et al., Methods in Enzymology 425 21-53, 2007; Mauger et al., PNAS 116, 24075-24083, 2019). Gene Writer systems with template molecules containing modified rNTPs are tested as described above and in Example 14 (Improved Gene Writer components for RNA-based delivery).

In some embodiments, individual modules are chemically synthesized containing modified nucleotides, e.g., 5′ hydroxyl, 5′ Phosphate, 2′-O-methyl, 2′-O-ethyl, 2′-fluoro, ribothymidine, C-5 propynyl-dC (pdC), C-5 propynyl-dU (pdU), C-5 propynyl-C(pC), C-5 propynyl-U (pU), 5-methyl C, 5-methyl U, 5-methyl dC, 5-methyl dU methoxy, (2,6-diaminopurine), 5′-Dimethoxytrityl-N4-ethyl-2′-deoxyCytidine, C-5 propynyl-fC (pfC), C-5 propynyl-fU (pfU), 5-methyl fC, 5-methyl fU, C-5 propynyl-mC (pmC), C-5 propynyl-fU (pmU), 5-methyl mC, 5-methyl mU, LNA (locked nucleic acid), MGB (minor groove binder) pseudouridine (Ψ), 1-N-methylpseudouridine (1-Me-Ψ), 5-methoxyuridine (5-MO-U), where the individual modules are then ligated together through enzymatic (e.g., splint ligation using T4 DNA ligase, Moore, M. J., & Query, C. C. Methods in Enzymology, 317, 109-123, 2000) or chemical processes (e.g., Fedorova, O. A., et. al., Nucleosides and Nucleotides, 15(6), 1137-1147, 1996) to form a complete Gene Writer template molecule.

An example of a modified Gene Writer template molecule is where modules A and F are each 100 nt of chemically synthesized RNA with cytidine and uridine nucleotides containing 2′-O-methyl ribose modifications and module A contains (3) phosphorothioate linkages between the first 3 nucleotides on the 5′ end and module F contains (3) phosphorothioate linkages between the last 3 nucleotides on the 3′ end of the module. Modules B-E are synthesized by in vitro transcription using an RNA polymerase (RNAP), e.g., T7 RNAP, T3 RNAP, or SP6 RNAP (NEB), or derivatives thereof that possess enhanced properties, e.g., increased fidelity, increased processivity, or increased efficiency of incorporating modified nucleotides. Module A is ligated to the 5′ end of the in vitro transcribed module B-E molecule and module F is ligated on to the 3′ end of the in vitro transcribed module B-E molecule by splint ligation (described by Moore, M. J., & Query, C. C. Methods in Enzymology, 317, 109-123, 2000). This fully assembled template RNA (all modules, A-F) is then used with a Gene Writer polypeptide (or nucleic acid encoding the polypeptide) in a target cell to assess genomic integration as in previous examples. In some embodiments, RNA modifications do not decrease the efficiency of integration greater than 50%, e.g., as measured by ddPCR. In some embodiments, RNA modifications improve the efficiency of integration, e.g., as measured by ddPCR. In some embodiments, RNA modifications improve the reverse transcription reaction, e.g., improve the processivity or fidelity as measured by sequencing of integration events.

Example 19: Gene Writer Templates that do not Incorporate UTRs

This example describes a configuration of the Gene Writer template molecule that results in an exclusion of the UTRs, such that these regions used in retrotransposition are not integrated into the host cell.

In this example, we describe the positioning, omission, and/or substitution of the UTR modules of the Gene Writer template molecule (FIGS. 5 and 6 ) to result in the Gene Writer driver to not incorporate the UTR modules into the genome as a part of retrotransposition. In some embodiments, the Gene Writer template molecule modules for the 5′ and 3′ UTRs (modules B+C and E of Gene Writer template molecule) are moved to the ends of the molecule so that their function of interacting with the Gene Writer driver does not change but the homology arm is now located adjacent to the heterologous object sequence (module D) where complementarity of the homology arms act as a primer for reverse transcription. In some cases, modules B and/or C are omitted from the Gene Writer template molecule with module E following module F.

Additional examples of not incorporating the UTRs into the genome are removing modules B and C from the Gene Writer template molecule, re-positioning module F (3′ homology arm) to follow module D (heterologous object sequence) and have module E be substituted with a binding ligand such as biotin. This Gene Writer template molecule would now consist of module A (5′ homology arm)-module D (heterologous object sequence)-module F (3′ homology arm)-module E comprised of biotin. The Gene Writer driver polypeptide sequence would be modified to incorporate the amino acid sequence for monomeric streptavidin. This example illustrates how the utility of mediating a non-nucleic acid mediated association of the Gene Writer template molecule with the Gene Writer driver polypeptide sequence.

Example 20: Gene Writers can Integrate Genetic Cargo Independently of the Homology Directed Repair Pathway

This example describes the use of a Gene Writer system in a human cell wherein the homologous recombination repair pathway is inhibited.

In this example, U2OS cells were treated with 30 pmols (1.5 μM) non-targeting control siRNA (Ctrl) or a siRNA against Rad51, a core component of the homologous recombination repair pathway. SiRNAs were co-delivered with R2Tg driver and transgene plasmid in trans (see FIG. 24 for driver and transgene configuration schematic). Specifically, Plasmid expressing R2Tg, control R2Tg with a mutation in the RT domain, or control R2Tg with an endonuclease inactivating mutation were used in conjunction with transgene (FIG. 25A, B). A total of 250 ng DNA plasmids with a 1:4 molar ration of driver to transgene, along with 30 pmol of siRNAs were nucleofected into 200 k U2OS cells resuspended in 20 μL of nucleofection buffer SE using pulse code DN100. Protein lysates collected on day 3 showed the absence of Rad51 in the siRad51 treated condition (FIG. 25C). gDNA was extracted at day 3 and ddPCR assays to detect transgene integration at the rDNA locus was performed. The results of the ddPCR copy number analysis (in comparison to reference gene RPP30) are shown in FIG. 26 . The absence of Rad51 leads to a ˜20% reduction in R2Tg mediated transgene integration at the rDNA locus both at the 3′ and 5′ junctions (FIG. 26 ), indicating that R2TG mediated transgene insertion is not wholly dependent on the presence of the homologous recombination pathway, and can occur in the absence of the endogenous HR pathway. In some embodiments, HR independence enables Gene Writing to work in cells and tissues with endogenously low levels of HR, e.g., liver, brain, retina, muscle, bone, nerve, cells in G₀ or G₁ phase, non-dividing cells, senescent cells, terminally differentiated cells. In some embodiments, HR independence enables Gene Writing to work in cells or in patients or tissues containing cells with mutations in genes involved in the HR pathway, e.g., BRCA1, BRCA2, P53, RAD51.

Example 21: Gene Writers can Integrate Genetic Cargo Independently of the Single-Stranded Template Repair Pathway

This example describes the use of a Gene Writer system in a human cell wherein the single-stranded template repair (SSTR) pathway is inhibited.

In this example, the SSTR pathway will be inhibited using siRNAs against the core components of the pathway: FANCA, FANCD2, FANCE, USP1. Control siRNAs of a non-target control will also be included. 200 k U2OS cells will be nucleofected with 30 pmols (1.5 μM) siRNAs, as well as R2Tg driver and transgene plasmids (trans configuration). Specifically, 250 ng of Plasmids expressing R2Tg, control R2Tg with a mutation in the RT domain, or control R2Tg with an endonuclease inactivating mutation) are used in conjunction with transgene at a 1:4 molar ratio (driver to transgene). Transfections of U2OS cells is performed in SE buffer using program DN100. After nucleofection, cells are grown in complete medium for 3 days. gDNA is harvested on day 3 and ddPCR is performed to assess integration at the rDNA site. Transgene integration at rDNA is detected in the absence of core SSTR pathway components.

Example 22: Gene Writer Systems with Enhanced Activity for Target Vs Non-Target Cells

This example describes the incorporation of regulatory sequences into Gene Writer systems in order to decrease integration activity in non-target cells.

In this example, genetic regulation is accomplished through (i) using tissue-specific promoters to upregulate component expression and integration in target cells and (ii) using miRNA binding sites to decrease integration in non-target cells that have increased endogenous levels of the corresponding miRNA. Target cells used are human hepatocytes and non-target cells are hematopoetic stem cells (HSCs). The driver of integration here is a plasmid encoding the Gene Writer polypeptide (e.g., R2Tg retrotransposase) driven by different promoters and with scrambled or specific miRNA binding sites after the coding sequence. The template for integration is encoded on plasmid DNA, such that transcription results in a homology- and UTR-flanked heterologous object sequence. The heterologous object sequence may comprise a reporter gene that is driven by different promoters and with scrambled or specific miRNA binding sites after the coding sequence. The control promoter used here is CMV and the control for miRNA binding site is a randomly scrambled version of the binding site for miR-142. The target tissue-specific promoter used here is ApoE.HCR.hAAT, which is expressed in liver cells, and the off-target tissue-specific miRNA binding site is complementary to miR-142 (uguaguguuuccuacuuuaugga (SEQ ID NO: 1684)), which is expressed in HSCs.

Target cells and non-target cells are nucleofected with a combination of Gene Writer polypeptide (1) and template (2) selected from:

-   -   Gene Writer polypeptide constructs (1):         -   a. Non-specific driver: CMV-R2Tg         -   b. Non-specific inactivated driver: CMV-R2Tg(EN*)         -   c. Tissue-specific driver: ApoE.HCR.hAAT-R2Tg-miR142         -   d. Tissue-specific inactivated driver:             ApoE.HCR.hAAT-R2Tg(EN*)-miR142     -   Gene Writer template constructs (2):         -   a. Non-specific transgene: CMV-gfp         -   b. Tissue-specific transgene: ApoE.HCR.hAAT-gfp-miR142             Cells are incubated for at least three days and subsequently             evaluated for integration efficiency and reporter             expression. For integration efficiency, ddPCR is performed             to quantify the average number of integrations per genome             for each sample. In some embodiments, the ratio between the             integration efficiency in target cells and non-target cells             is higher when using a template paired with the             tissue-specific driver (la) vs a non-specific driver (1c).             To assess reporter expression, cells are analyzed by flow             cytometry to detect GFP fluorescence and RT-qPCR to detect             transcription. In some embodiments, the ratio between             fluorescence in target cells and non-target cells is higher             when using a driver paired with a tissue-specific transgene             cassette (2b) vs a non-specific transgene cassette (2a). In             some embodiments, the ratio between transcript levels in             target cells and non-target cells is higher when using a             driver paired with a tissue-specific transgene cassette (2b)             vs a non-specific transgene cassette (2a). In some             embodiments, the combination of a tissue-specific driver             (la) with a tissue-specific transgene cassette (2b) results             in the highest ratio of transcription or expression between             target and non-target cells. Alternatively, a screening             assay can be performed in the same cell line artificially             expressing or not expressing a given miRNA, e.g., the             on-target screening cell is a HEK293T cell and the             non-target cell is mimicked by introducing overexpression of             miR-142 in HEK293T cells.

Example 23: Correction of Alpha-1 Antitrypsin Deficiency Using Lipid Nanoparticles Comprising Gene Writers

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence at a single nucleotide in vivo. More specifically, the Gene Writer™ polypeptide and writing template are delivered to mouse liver cells via lipid nanoparticles to correct the SERPINA1 PiZ mutation causing alpha-1 antitrypsin deficiency.

Formulation and treatment of murine models with LNPs (LNP-INT01 system) carrying Cas9 and gRNA are taught by Finn et al. Cell Reports 22:2227-2235 (2018), the methods of which are incorporated herein by reference.

Capped and polyadenylated Gene Writer polypeptide mRNA containing N1-methyl pseudo-U is generated by in vitro transcription using a linearized plasmid DNA template and T7 RNA polymerase. The polypeptide mRNA is purified from enzyme and nucleotides using a MegaClear Transcription Clean-up Kit, in accordance with the manufacturer's protocol (ThermoFisher). The transcript concentration is determined by measuring the light absorbance at 260 nm (Nanodrop), and the transcript is analyzed by capillary electrophoresis by TapeStation (Agilent). Template RNA comprising the mutation correcting sequence is also prepared by in vitro transcription and translation using similar methods. In this example, the template RNA comprises the sequence as exemplified in Example 1.

LNPs are formulated with an amine-to-RNA-phosphate (N:P) ratio of 4.5. The lipid nanoparticle components are dissolved in 100% ethanol with the following molar ratios: 45 mol % LPO1 lipid, 44 mol % cholesterol, 9 mol % DSPC, and 2 mol % PEG2k-DMG. The RNA cargo (1:40 molar ratio of polypeptide mRNA:template RNA) is dissolved in 50 mM acetate buffer (pH 4.5), resulting in a concentration of RNA cargo of approximately 0.45 mg/mL. LNPs are formed by microfluidic mixing of the lipid and RNA solutions using a Precision Nanosystems NanoAssemblr Benchtop Instrument, in accordance with the manufacturer's protocol. After mixing, the LNPs are collected and diluted in PBS (approximately 1:1), and then the remaining buffer is exchanged into PBS (100-fold excess of sample volume) overnight at 4C under gentle stirring using a 10 kDa Slide-a-Lyzer G2 Dialysis Cassette (ThermoFisher Scientific). The resultant mixture is then filtered using a 0.2-mm sterile filter. The filtrate is stored at 2C-8C. Multi-dose formulations may be formulated using 25 mM citrate, 100 mM NaCl cargo buffer (pH 5), and buffer exchanged by TFF into tris-saline sucrose buffer (TSS) buffer (5% sucrose, 45 mM NaCl, and 50 mM Tris). Formulated LNPs have an average size of 105 nm. Encapsulation efficiencies are determined by ribogreen assay (Leung et al., 2012). Particle size and polydispersity are measured by dynamic light scattering (DLS) using a Malvern Zetasizer DLS instrument.

NSG-PiZ mice carrying the human SERPINA1 PiZ allele (E342K) are acquired from The Jackson Laboratory. To assess the ability of Gene Writing to edit the mutant allele in vivo, LNPs are dosed via the lateral tail vein at 3 mg/kg in a volume of 0.2 mL per animal. Excipient-treated animals are used as negative controls for all studies. Animals are euthanized at various time points by exsanguination via cardiac puncture under isoflurane anesthesia. In some embodiments, animals are euthanized at one week post-treatment to be analyzed for Gene Writing. Liver tissue is collected from the median or left lateral lobe from each animal for DNA extraction and analysis.

For NGS analysis of editing efficiency, PCR primers are designed around the target site, and the region of interest is amplified from extracted genomic DNA. Additional PCR is performed in accordance with the manufacturer's protocols (Illumina) to add the appropriate chemistry for sequencing, and amplicons are then sequenced on an Illumina MiSeq. Sequencing reads are aligned to the mouse reference genome after eliminating those having low quality scores. The resultant files containing the reads are mapped to the reference genome (BAM files), where reads that overlap the target region of interest are selected, and the number of wild-type reads versus the number of reads that contain the SERPINA1 reversion mutation encoded in the template RNA are calculated. The editing percentage (e.g., the “editing efficiency” or “percent editing”) is defined as the total number of reversion sequence reads over the total number of sequence reads.

In some embodiments, this example is repeated with additional groups of mice and a redosing regimen is used to analyze dose-to-effect properties of the system. In these experiments, mice are assigned to groups for weekly dosing up to 4 weeks, with euthanasia and tissue analysis as described herein being performed each week. In some embodiments, mice that receive more doses of the LNP formulation demonstrate higher Gene Writing efficiency by sequencing, e.g., mice receiving 2 doses one week apart that are analyzed at week three show a higher fraction of gene corrected reads by NGS of liver tissue samples as compared to mice receiving a single dose and analyzed at week three. In application, dosing in this manner may allow tuning of therapeutic intervention after evaluating patient response to one or more doses.

Example 24: Using Gene Writing to Address Repeat Expansion Diseases

This example describes the use of a Gene Writer™ gene editing system to treat a repeat expansion disease by rewriting a normal number of repeats into the locus. More specifically, the Gene Writer™ polypeptide and writing template are delivered to mouse CNS via AAV to reset the CAG repeats in HTT as per the custom template RNA to cure Huntington Disease. Healthy humans tend to carry between 10 and 35 CAG repeats within the huntingtin gene (HTT), while those with Huntington Disease may possess between 36 to greater than 120 repeats.

In this example, the template RNA is designed to correct the CAG repeat region of the HTT gene by encoding a sequence with 10 such repeats and homology to the flanking target sequence to fully write across the target locus. Multiple examples of such template RNAs could be designed, with an exemplary template RNA, as encoded in DNA, comprising the sequence (1)GGCGGCTGAGGAAGCTGAGG(2)GTTTTAGAGCTAGAAATAGCAAGTTAAAATAA GGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCC(3)AGTCCCTCAAG TCCTTCcagcagcagcagcagcagcagcagcagcagccgccaccgccgccgccgccgccgccgcctcct(4)CAGCTTCC TCAG (SEQ ID NO: 1685), where numbers are used to delineate the modules of the template in the order (5′-3′) (1) gRNA spacer, (2) gRNA scaffold, (3) heterologous object sequence, (4) 3′ homology priming domain, with the repeat correction being encoded in (3). The CAG repeat region is followed by a short repeat region encoding for 11 proline residues (8 residues being encoded by CCG triplets). Without wishing to be bound by theory, this region is included in (3) to place (4) in a more unique region to prevent mispriming. An exemplary gRNA for providing a second nick as described in embodiments of this system comprises the spacer sequence CGCTGCACCGACCGTGAGTT (SEQ ID NO: 1630) and directs a Cas9 nickase to nick the second strand of the target site within the homologous region. In some embodiments, this second nick improves the efficiency of the edit.

In order to deliver a complete Gene Writing system to the CNS, in this example, the Gene Writer is split across two AAV genomes, with the first encoding the nickase Cas9 domain fused to intein-N of a split intein pair (DnaE Intein-N: CLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCL EDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN (SEQ ID NO: 1638)) and the second encoding the RT domain fused to an intein-C of a split intein pair (DnaE Intein-C, MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN (SEQ ID NO: 1640)) and the template RNA. The two polypeptide components are expressed from a polymerase II promoter, e.g. a neuronal cell-specific promoter described herein, and the template RNA and gRNA for providing a second nick are expressed from a polymerase III promoter, e.g. a U6 promoter. When co-infecting a cell, the two polypeptide components reconstitute a complete Gene Writer polypeptide with N-terminal Cas9 and C-terminal RT and the template RNA is expressed and reverse transcribed into the target locus. To achieve delivery for cells of the CNS (specifically the claudate nucleus and the putamen of the basal ganglia), the pseudotyped system rAAV2/1 is used here, where the AAV2 ITRs are used to package the described nucleic acids into particles with AAV1 capsid. AAV preparation and mouse injection and harvesting protocols used here follow the teachings of Monteys et al. Mol Ther 25(1):12-23 (2017).

FVB-Tg(YAC128)53Hay/J mice are acquired from The Jackson Laboratory. These transgenic mice express the full-length human huntingtin protein with ˜118 glutamine repeats (CAG trinucleotide repeats) and develop hyperkinesis at three months of age. At 8 weeks of age, mice are treated with a combination 1:1 of rAAV2/1-Cas9 virus and rAAV-MMLV_RT/hU6templateRNA virus. For rAAV injections, mice are anesthetized with isoflurane and 5 μL of rAAV mixture injected unilaterally into the right striata at 0.2 μL/min. After three weeks, mice are sacrificed and brain tissue taken for genomic DNA extraction and NGS analysis.

For NGS analysis of editing efficiency, PCR primers are designed flanking the target site, and the region of interest is amplified from extracted genomic DNA. Additional PCR is performed in accordance with the manufacturer's protocols (Illumina) to add the necessary chemistry for sequencing, and amplicons are then sequenced on an Illumina MiSeq. Sequencing reads are aligned to the mouse reference genome after eliminating those having low quality scores. The resultant files containing the reads are mapped to the reference genome (BAM files), where reads that overlap the target region of interest are selected, and the number of diseased allele (>35 CAG repeats) reads versus the number of repaired allele (10-35 CAG repeats) reads are calculated. The editing percentage (e.g., the “editing efficiency” or “percent editing”) is defined as the total number of repaired reads, as defined above, over the total number of sequence reads.

Example 25: Delivery of a Gene Writing System by LNP and AAV Vehicles

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence at a single nucleotide in vivo. More specifically, the Gene Writer™ polypeptide and writing template are delivered to mouse liver cells via a combination of lipid nanoparticles (mRNA encoding polypeptide) and AAV (DNA encoding the RNA template) to correct the SERPINA1 PiZ mutation causing alpha-1 antitrypsin deficiency.

Capped and tailed mRNA encoding the Gene Writer polypeptide are prepared by in vitro transcription and formulated into LNP-INTO1 as described in Example 23, but without template RNA co-formulation.

In this example, the template RNA is encoded as DNA and delivered via AAV. The teachings of Cunningham et al. Mol Ther 16(6):1081-1088 (2008) describe the use of rAAV2/8 with the human alpha-1 antitrypsin (hAAT) promoter and two copies of the hepatic control region of the apolipoprotein E enhancer (ApoE) to effectively transduce and drive expression of cargo in juvenile mouse liver. Accordingly, rAAV2/8.ApoE-hAAT.PiZ (rAAV2/8.PiZ) as described here comprises the above described AAV and promoter system driving expression of an RNA template for correcting the PiZ mutation, in addition to a second nick-directing gRNA being driven by a U6 promoter (RNA sequences previously described in Example 1).

NGS-PiZ mice carrying the human SERPINA1 PiZ allele (E342K) are acquired from The Jackson Laboratory. To assess the activity of Gene Writing to edit the mutant allele in vivo, 8-week-old mice are dosed i.p. with ˜10¹¹ vg of rAAV2/8.PiZ to express the template RNA and via the lateral tail vein with formulated LNPs at 3 mg/kg in a volume of 0.2 mL per animal to express the Gene Writer polypeptide. Animals are euthanized at various time points by exsanguination via cardiac puncture under isoflurane anesthesia. In some embodiments, animals are euthanized at one week post-treatment to be analyzed for Gene Writing. Liver tissue is collected from the median or left lateral lobe from each animal for DNA extraction and analysis.

For NGS analysis of editing efficiency, PCR primers are designed around the target site, and the region of interest is amplified from extracted genomic DNA. Additional PCR is performed in accordance with the manufacturer's protocols (Illumina) to add the necessary chemistry for sequencing, and amplicons are then sequenced on an Illumina MiSeq. Sequencing reads are aligned to the mouse reference genome after eliminating those having low quality scores. The resultant files containing the reads are mapped to the reference genome (BAM files), where reads that overlap the target region of interest are selected, and the number of wild-type reads versus the number of reads that contain the SERPINA1 reversion mutation encoded in the template RNA are calculated. The editing percentage is defined as the total number of reversion sequence reads over the total number of sequence reads.

Example 26: Application of a Gene Writer™ System for Delivering Therapeutic Gene to Liver in a Human Chimeric Liver Mouse Model

This example describes a Gene Writer™ genome editing system delivered to the liver in vivo for integration and stable expression of a genetic payload. Specifically, LNPs are used to deliver a Gene Writing system capable of integrating a complete OTC expression cassette to treat a humanized mouse model of OTC-deficiency.

In this example, a Gene Writing system is used to treat a humanized mouse model of OTC deficiency, in which human hepatocytes derived from patients with OTC deficiency are engrafted into a mouse model (Ginn et al JHEP Reports 2019). An exemplary Gene Writing system for large payload integration comprises a Cas9-directed reverse transcriptase system utilizing a highly processive reverse transcriptase, e.g., MarathonRT. An exemplary template RNA component comprises, from 5′ to 3′, (1) a gRNA spacer with homology to the AAVS1 safe harbor site, (2) a gRNA scaffold, (3) a heterologous object sequence, and (4) a 3′ target homology region for annealing to the genomic DNA immediately upstream of the first strand nick to prime TPRT of the heterologous object sequence. An exemplary sequence for (1) is GGGGCCACTAGGGACAGGAT (SEQ ID NO: 1689). Region (2) carries the gRNA scaffold as described in this application, generally comprising the sequence GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAA AGTGGGACCGAGTCGGTCC (SEQ ID NO: 1591). In this example, (3) comprises a complete OTC expression cassette, where a liver-codon-optimized sequence encoding human OTC (UniProt P00480) is in operable association with the ApoE.hAAT promoter system as described in Example 25. An exemplary sequence for (4) is CTGTCCCTAGTG (SEQ ID NO: 1690). An exemplary sequence of an additional gRNA spacer for generating a second strand nick to improve the efficiency of integration is AGAGAGATGGCTCCAGGAAA (SEQ ID NO: 1691).

Eight to 12-week-old female Fah^(−/−)Rag2^(−/−)I12^(−/−) (FRG) mice are engrafted with human hepatocytes, isolated from pediatric donors or purchased from Lonza (Basel, Switzerland), as described previously (Azuma et al Nat Biotechnol 2007). Engrafted mice are cycled on and off 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC) in drinking water to promote liver repopulation. Blood is collected every two weeks and at the end of the experiment to measure the levels of human albumin, used as a marker to estimate the level of engraftment, in serum by enzyme-linked immunosorbent assay (ELISA; Bethyl Laboratories, Inc., Montgomery, Tex.). Eleven weeks after engraftment, mice are treated with the Gene Writer™s formulated as in Example 23. For treatment, LNPs are delivered via the lateral tail vein at 3 mg/kg in a volume of 0.2 mL per animal.

After vector injection, mice are cycled on NTBC for another 5 weeks before being euthanized. DNA and RNA are subsequently extracted from liver lysates by standard methods. OTC expression is subsequently assayed by performing RT-qPCR on isolated RNA samples using sequence-specific primers. Levels of human OTC are also measured throughout the experiment by using a human OTC ELISA kit (e.g., Aviva Systems Biology OTC ELISA Kit (Human) (OKCD07437)) on serum at Days −7, 0, 2, 4, 7, 14, 21, 28, and 35 post-injection, following the manufacturer's recommended protocol.

For analysis of editing efficiency, a ddPCR assay is performed using a pair of primers that anneal across either the 5′ junction or the 3′ junction of integration, with one primer in each set annealing to the heterologous object sequence, and the other to an appropriate region of the AAVS1 site on the genome. The assay is normalized to a reference gene to quantify the number of target site integrations per genome.

To analyze integrations at the target site, long-read sequencing across the integration site is performed. PCR primers are designed flanking the target site, and the region of interest is amplified from extracted genomic DNA. Additional PCR is performed in accordance with the manufacturer's protocols (PacBio) to add the necessary chemistry for sequencing, and amplicons are then sequenced via PacBio. Sequencing reads are aligned to the mouse reference genome after eliminating those having low quality scores. The resultant files containing the reads are mapped to the reference genome (BAM files), where reads that contain an insertion sequence relative to the reference genome are selected for further analysis to determine completeness of integration, defined in this example as containing the complete promoter and coding sequence of OTC.

Example 27: Gene Writers for Integration of a CAR in T-Cells Ex Vivo

This example describes delivery of a Gene Writer™ genome editing system to T-cells ex vivo for integration and stable expression of a genetic payload. Specifically, LNPs are used to deliver a Gene Writing system capable of integrating a chimeric antigen receptor (CAR) into the TRAC locus to generate CAR-T cells for treating B-cell lymphoma.

In this example, a Gene Writing system comprises a Gene Writing polypeptide, e.g., a nickase Cas9 and R2Tg reverse transcriptase domain, as described herein, a gRNA for directing nickase activity to the target locus, and a template RNA comprising, from 5′ to 3′:

-   -   (1) 100 nt homology to target site 3′ of first strand nick     -   (2) 5′ UTR from R2Tg     -   (3) Heterologous object sequence     -   (4) 3′ UTR from R2Tg     -   (5) 100 nt homology to target site 5′ of first strand nick         Wherein (3) comprises the coding sequence for the CD19-specific         Hu19-CD828Z (Genbank MN698642; Brudno et al. Nat Med 26:270-280         (2020)) CAR molecule. The Gene Writer in this example is guided         to the 5′ end of the first exon of TRAC by using a targeted         gRNA, e.g., TCAGGGTTCTGGATATCTGT (SEQ ID NO: 1692), in order to         place the cargo under endogenous expression control from that         locus while disrupting the endogenous TCR, as taught by Eyquem         et al. Nature 543:113-117 (2017). These three components         (polypeptide, gRNA, and template) all comprise RNA, which is         synthesized by in vitro transcription (e.g., polypeptide mRNA,         template RNA) or chemical synthesis (gRNA).

The LNP formulation used in this example has been screened and validated for delivery to T-cells ex vivo, being taught in Billingsley et al. Nano Lett 20(3):1578-1589 (2020), which is incorporated herein by reference in its entirety. Specifically, the LNP formulation C14-4, comprising cholesterol, phospholipid, lipid-anchored PEG, and the ionizable lipid C14-4 (FIG. 2C of Billingsley et al. Nano Lett 20(3):1578-1589 (2020)) was used to encapsulate all three RNA components in a molar ratio of polypeptide mRNA:gRNA:template RNA of about 1:40:40.

Additional edits can be performed on T-cells in order to improve activity of the CAR-T cells against their cognate target. In some embodiments, a second LNP formulation of C14-4 as described comprises a Cas9/gRNA preformed RNP complex, wherein the gRNA targets the Pdcd1 exon 1 for PD-1 inactivation, which can enhance anti-tumor activity of CAR-T cells by disruption of this inhibitory checkpoint that can otherwise trigger suppression of the cells (see Rupp et al. Sci Rep 7:737 (2017)). The application of both nanoparticle formulation thus enables lymphoma targeting by providing the anti-CD19 cargo, while simultaneously boosting efficacy by knocking out the PD-1 checkpoint inhibitor. In some embodiments, cells may be treated with the nanoparticles simultaneously. In some embodiments, the cells may be treated with the nanoparticles in separate steps, e.g., first deliver the RNP for generating the PD-1 knockout, and subsequently treat cells with the nanoparticles carrying the anti-CD19 CAR. In some embodiments, the second component of the system that improves T cell efficacy may result in the knockout of PD-1, TCR, CTLA-4, HLA-I, HLA-II, CS1, CD52, B2M, MHC-I, MHC-II, CD3, FAS, PDC1, CISH, TRAC, or a combination thereof. In some embodiments, knockdown of PD-1, TCR, CTLA-4, HLA-I, HLA-II, CS1, CD52, B2M, MHC-I, MHC-II, CD3, FAS, PDC1, CISH, or TRAC may be preferred, e.g., using siRNA targeting PD-1. In some embodiments, siRNA targeting PD-1 may be achieved using self-delivering RNAi as described by Ligtenberg et al. Mol Ther 26(6):1482-1493 (2018) and in WO2010033247, incorporated herein by reference in its entirety, in which extensive chemical modifications of siRNAs, conferring the resulting hydrophobically modified siRNA molecules the ability to penetrate all cell types ex vivo and in vivo and achieve long-lasting specific target gene knockdown without any additional delivery formulations or techniques. In some embodiments, one or more components of the system may be delivered by other methods, e.g., electroporation. In some embodiments, additional regulators are knocked in to the cells for overexpression to control T cell- and NK cell-mediated immune responses and macrophage engulfment, e.g., PD-L1, HLA-G, CD47 (Han et al. PNAS 116(21):10441-10446 (2019)). Knock-in may be accomplished through application of an additional Gene Writing system with a template carrying an expression cassette for one or more such factors (3) with targeting to a safe harbor locus, e.g., AAVS1, e.g., using gRNA GGGGCCACTAGGGACAGGAT (SEQ ID NO: 1689) to target the Gene Writer polypeptide to AAVS1.

LNPs are used to treat primary T cells activated by Dynabeads at a 1:1 CD4⁺:CD8⁺ ratio at 450 ng/μL total mRNA concentrations. The resulting T cell populations are analyzed for integration, expression, and effect. For assessing integration, ddPCR is used with primers producing an amplicon extending from within the integrated CAR to the flanking genomic TRAC sequence. Comparing signal to a reference gene (e.g., RPP30), allows quantification of the average copy number per genome and integration efficiency. To analyze expression, flow cytometry with immunological probes is used to assess the level and percent of cells displaying surface CAR expression. To analyze activity of the CAR-T cells, treated cells are assessed via a co-plated cancer cell killing assay. By engineering Nalm6 ALL cells to express luciferase, cancer cell killing can be assessed by change in luminescence after co-culture with CAR-T cells as compared to signal from Nalm6 cells alone Billingsley et al. Nano Lett 20(3):1578-1589 (2020). Thus, a Gene Writing system can be used to generate CAR-T cells ex vivo with the desired cytotoxic activity.

Example 28: Gene Writers for Integration of a CAR in T-Cells In Vivo

This example describes a Gene Writer™ genome editing system delivered to T-cells in vivo for integration and stable expression of a genetic payload. Specifically, targeted nanoparticles are used to deliver a Gene Writing system capable of integrating a chimeric antigen receptor (CAR) expression cassette into the murine Rosa26 locus to generate CAR-T cells in a murine model.

In this example, a Gene Writing system comprises a Gene Writing polypeptide, e.g., a nickase Cas9 and R2Tg reverse transcriptase domain, as described herein, a gRNA for directing nickase activity to the target locus, and a template RNA comprising, from 5′ to 3′:

-   -   (1) 100 nt homology to target site 3′ of first strand nick     -   (2) 5′ UTR from R2Tg     -   (3) Heterologous object sequence     -   (4) 3′ UTR from R2Tg     -   (5) 100 nt homology to target site 5′ of first strand nick         Wherein (3) comprises the coding sequence for the CD19-specific         m194-1BBz CAR driven by the EF1a promoter (Smith et al. Nat         Nanotechnol 12(8):813-820 (2017)). The Gene Writer in this         example is guided to the murine Rosa26 locus using a gRNA, e.g.,         ACTCCAGTCTTTCTAGAAGA (SEQ ID NO: 1693) (Chu et al. Nat         Biotechnol 33(5):543-548 (2015)). Production of RNA molecules is         as according to examples provided herein, e.g., by in vitro         transcription (e.g., Gene Writer polypeptide mRNA, template RNA)         and by chemical synthesis (e.g., gRNA). Modifications to the RNA         components of the system are as described elsewhere. For Gene         Writer mRNA, the sequence additionally comprises a 5′ UTR (e.g.,         GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO:         1603)) and a 3′ UTR (e.g.,         UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCC         AGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGA (SEQ ID         NO: 1604)) flanking the coding sequence. This combination of 5′         UTR and 3′ UTR has been shown to result in good expression of an         operably linked ORF (Richner et al. Cell 168(6): P1114-1125         (2017)).

In order to achieve delivery specifically to T-cells, targeted LNPs (tLNPs) are generated that carry a conjugated mAb against CD4. See, e.g., Ramishetti et al. ACS Nano 9(7):6706-6716 (2015). Alternatively, conjugating a mAb against CD3 can be used to target both CD4⁺ and CD8⁺ T-cells (Smith et al. Nat Nanotechnol 12(8):813-820 (2017)). In other embodiments, the nanoparticle used to deliver to T-cells in vivo is a constrained nanoparticle that lacks a targeting ligand, as taught by Lokugamage et al. Adv Mater 31(41):e1902251 (2019).

The tLNP can be made by first preparing the nucleic acid mix (e.g., polypeptide mRNA:gRNA:template RNA molar ratio of 1:40:40) with a mixture of lipids (cholesterol, DSPC, PEG-DMG, Dlin-MC3-DMA, and DSPE-PEG-maleimide) and then chemically conjugating the desired DTT-reduced mAb (e.g., anti-CD4, e.g., clone YTS.177) to the maleimide functional group on the LNPs. See Ramishetti et al. ACS Nano 9(7):6706-6716 (2015).

Six to 8 week old C57BL6/J mice are injected intravenously with formulated LNP at a dose of 1 mg RNA/kg body weight. Blood is collected at one day and three days post-administration in heparin-coated collection tubes, and the leukocytes are isolated by density centrifugation using Ficoll-Paque PLUS (GE Healthcare). Five days post-administration, animals are euthanized and blood and organs (spleen, lymph nodes, bone marrow cells) are harvested for T-cell analysis. Expression of the anti-CD19 CAR is detected by FACS using specific immunological sorting. Positive cells are confirmed for integration by ddPCR on the sorted population, where primers are used that flank an integration junction, e.g., one primer of the pair annealing to the integrated cargo and the other to genomic DNA from the Rosa26 target site.

Example 29: Assessment of Distance and PAM Orientation Between the First and Second Nicks to Reduce Non-Templated Indel Formation During Gene Writing

This examples describes how the placement of a second nick used in a Gene Writing system can be optimized to (1) increase the frequency of installation of a desired edit using a Gene Writer polypeptide with a template RNA, while (2) decreasing undesired insertions and/or deletions that may arise as a byproduct of the second nick.

An exemplary Gene Writing system can install a desired genomic modification (e.g., an insertion, deletion, or point mutation) using 1) a template RNA that comprises a gRNA and a heterologous object sequence comprising the desired genomic modification, and 2) a Gene Writing polypeptide comprising a nickase Cas9 (e.g., Cas9 N863A) fused to a reverse transcriptase (RT) (e.g., an RT domain from MMLV). In said exemplary Gene Writing system, the Cas9-RT fusion introduces a first nick, which exposes an available 3′OH to initiate the reverse transcriptase reaction using the template RNA as a template for target primed reverse transcription. The placement of a second nick adjacent to, but on the opposite strand as the first nick, enhances the installation of the desired genome modification.

In this experiment, a 3 nt insertion (CTT) is directed to the HEK3 locus. The template RNA for the insertion comprises (1) a gRNA spacer with homology to the HEK3 site, (2) a gRNA scaffold, (3) a heterologous object sequence including the CTT insertion, and (4) a 3′ target homology region for annealing to the genomic DNA immediately upstream of the first strand nick to set up target-primed reverse transcription of the heterologous object sequence. The sequence of the template RNA used is (5′-3′) GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCT AGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTCTGCCATCA<AAG>CG TGCTCAGTCTG (SEQ ID NO: 1694), where “< >” is used to denote the insertion sequence.

In addition, a set of second nick gRNAs, targeting a nick to the opposite DNA strand as the first nick, were designed that place a second nick either upstream or downstream of the location of the desired CTT insertion at various distances ranging from 26 to 257 bp. The upstream second nick creates a set of nicks with an inward orientation, with the PAM sites out (PAM-out), while the downstream second nick creates a set of nicks with an outward orientation, with the PAM sites inside the nicks (PAM-in), as described herein. Second nick gRNAs were designed using a web-based tool and are listed in Tables E5 and E6. The distance between dual nicks indicates the distance between the first nick directed by the template RNA and the second nick directed by the second nick gRNA, and the PAM orientation (e.g., “PAM-in” and thus outward orientation, or “PAM-out” and thus inward orientation) is provided with respect to the first nick as depicted in FIG. 31 .

TABLE E5 gRNA targeting the second nick upstream of the first nick in “PAM-out” orientation Distance PAM between orientation dual to first nicks PAM nick Orientation  (nts) sgRNA Sequence Sequence out antisense 28 TGGGCCCCAAGGATTGACCC AGG (SEQ ID NO: 1695) out antisense 33 CCCAAGGATTGACCCAGGCC AGG (SEQ ID NO: 1696) out antisense 34 CCAAGGATTGACCCAGGCCA GGG (SEQ ID NO: 1697) out antisense 38 GGATTGACCCAGGCCAGGGC TGG (SEQ ID NO: 1698) out antisense 108 GCAGAAATAGACTAATTGCA TGG (SEQ ID NO: 1699) out antisense 109 CAGAAATAGACTAATTGCAT GGG (SEQ ID NO: 1700) out antisense 120 TAATTGCATGGGCGTTTCCC TGG (SEQ ID NO: 1701) out antisense 121 AATTGCATGGGCGTTTCCCT GGG (SEQ ID NO: 1702) out antisense 136 TCCCTGGGATCCCTGTCTCC AGG (SEQ ID NO: 1703) out antisense 161 TCTCTCATCCATGCCTTTCT AGG (SEQ ID NO: 1704) out antisense 197 CCCTTGCTTAAAACTCTCCA AGG (SEQ ID NO: 1705) out antisense 222 TCTCATGCCAAGCTCCCTGC AGG (SEQ ID NO: 1706) out antisense 232 AGCTCCCTGCAGGACATCCC AGG (SEQ ID NO: 1707) out antisense 240 GCAGGACATCCCAGGCCCTC TGG (SEQ ID NO: 1708) out antisense 241 CAGGACATCCCAGGCCCTCT GGG (SEQ ID NO: 1709) out antisense 255 CCCTCTGGGACAGCAGCTCA CGG (SEQ ID NO: 1710) out antisense 256 CCTCTGGGACAGCAGCTCAC GGG (SEQ ID NO: 1711)

TABLE E6 gRNA targeting the second nick downstream of the first nick in “PAM-in” orientation Distance PAM between orientation dual to first nicks PAM nick Orientation (nts) sgRNA Sequence Sequence In antisense 26 GACGCCCTCTGGAGGAAGCA GGG (SEQ ID NO: 1712) In antisense 27 CGACGCCCTCTGGAGGAAGC AGG (SEQ ID NO: 1713) In antisense 34 TGTCCTGCGACGCCCTCTGG AGG (SEQ ID NO: 1714) Ir antisense 37 AGCTGTCCTGCGACGCCCTC TGG (SEQ ID NO: 1715) In antisense 63 GCACATACTAGCCCCTGTCT AGG (SEQ ID NO: 1716) In antisense 90 GTCAACCAGTATCCCGGTGC AGG (SEQ ID NO: 1717) In antisense 96 AAACTTGTCAACCAGTATCC CGG (SEQ ID NO: 1718) In antisense 133 CCAGGGACCTCCCTAGGTGC TGG (SEQ ID NO: 1719) In antisense 139 CCCCTTCCAGGGACCTCCCT AGG (SEQ ID NO: 1720) In antisense 150 GGTGAGGCTGGCCCCTTCCA GGG (SEQ ID NO: 1721) In antisense 151 TGGTGAGGCTGGCCCCTTCC AGG (SEQ ID NO: 1722) In antisense 162 CCCTCCTCTCCTGGTGAGGC TGG (SEQ ID NO: 1723) In antisense 166 AGGTCCCTCCTCTCCTGGTG AGG (SEQ ID NO: 1724) In antisense 171 GGGCCAGGTCCCTCCTCTCC TGG (SEQ ID NO: 1725) In antisense 186 GAGCTCGACCCTGAAGGGCC AGG (SEQ ID NO: 1726) I1 antisense 191 CTGTTGAGCTCGACCCTGAA GGG (SEQ ID NO: 1727) In antisense 192 TCTGTTGAGCTCGACCCTGA AGG (SEQ ID NO: 1728) In antisense 233 GCTGAAAGCCACTGGGCTCT GGG (SEQ ID NO: 1729) In antisense 234 TGCTGAAAGCCACTGGGCTC TGG (SEQ ID NO: 1730) In antisense 240 TGCAGGTGCTGAAAGCCACT GGG (SEQ ID NO: 1731) In antisense 241 ATGCAGGTGCTGAAAGCCAC TGG (SEQ ID NO: 1732) In antisense 257 TTGATCTCTGATTTTCATGC AGG (SEQ ID NO: 1733)

To conduct the experiment, 200,000 U2OS cells in 20 μL SE buffer are nucleofected with 800 ng of plasmid encoding the Gene Writer polypeptide (N863ACas9-RT), 200 ng of template RNA, and 83 ng of a second nick gRNA listed in Tables E5 and E6. The Lonza Amaxa nucleofection system is used with the nucleofection code DN100. After nucleofection, 80 μL of DMEM+10% FBS medium are added to the cell suspension and the cells are plate in a 24 well plate with 500 μL of DMEM+10% FBS. Genomic DNA is extracted at day 3 post-nucleofection.

To analyze extracted DNA for the desired CTT insertion, amplicon sequencing is performed as described herein by amplifying the HEK locus using primers surrounding the first nick. The anticipated 300-350 bp amplicon is then sequenced on an Illumina MiSeq. The frequency of the desired CCT insertions is determined using the CRISPResso computational analysis pipeline (Clement et al. Nat Biotechnol 37(3):224-226 (2019)).

To measure undesired insertions and/or deletions arising as byproducts of the reaction, long-range amplification is performed with primers located >1.5 kb upstream and downstream of the first nick site, producing an amplicon >3 kb. This amplicon is sequenced using long-read sequencing (e.g., PacBio) and analyzed for the presence of insertions and deletions resulting from the dual nicking.

In some embodiments, a reaction using a second nick gRNA that cuts downstream of the first nick and provides a “PAM in” or outward orientation results in fewer unintended mutations (e.g., mutations in the target site other than the targeted CTT insertion) as compared to gRNAs placed upstream of the first nick at a similar distance but providing a “PAM-out” or inward orientation, as measured by the methods described herein. In other embodiments, a second nick gRNA that cuts upstream of the first nick and provides a “PAM-out” or inward orientation results in fewer undesired mutations (e.g., mutations in the target site other than the targeted CTT insertion) when the distance between the first and second nick is at least 100 nt as compared to a second nick gRNA providing a distance between the first and second nick of less than 100 nt, as measured by the methods described herein.

Thus, in some embodiments, a preferred design for a second nick gRNA is one resulting in 1) a “PAM-in” or outward orientation, or 2) a “PAM-out” or inward orientation with at least 100 nt separation between the first and second nicks (FIG. 32 ).

Example 30: Design and Human Cell Expression of Gene Writing Systems Utilizing Various Cas-RT Fusions

This example describes the construction and expression of Gene Writing polypeptides comprising fusions of Cas and reverse transcriptase domains in mammalian cells. Gene Writing polypeptides with these domains have been shown herein to enable the precise, site-specific modification of a DNA target from an RNA template molecule. Here, we describe the expression of a library of domains to create novel systems that may have diverse functional characteristics. More specifically, described here are fusion proteins comprising 1) a Cas-nuclease containing a mutation inactivating one endonuclease active site, e.g., the Cas9 nickase Cas9(N863A); 2) a peptide-linker to connect the functional protein domains, e.g., a sequence from Table 38 or 42, e.g., SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 1589); and 3) a reverse transcriptase (RT), e.g., an RT domain described in this application, e.g., an RT domain comprising a sequence from Table 1, Table 3, Table 30, Table 31, or Table 41, or a derivative thereof may be used in such an assay, collectively referred to in this Example as Cas-RT. Accordingly, Cas-RT fusion proteins are assembled on a plasmid and co-delivered with a single guide RNA (sgRNA) expression plasmid to validate system expression in human cells.

Gene Writer polypeptides generated by Cas-RT domain fusions assayed here comprised: (1) a Cas9 wild-type or Cas9(N863A) nickase domain; (2) a peptide linker (SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 1589)); (3) a selection of RT domains from Table 1 and Table 30 taken from diverse sources; and (4) at least one nuclear localization signal. U2OS or HEK293T cells were transfected by Lonza Amaxa nucleofection of 250,000 cells/well with ˜800 ng of Cas9(N863A)-RT fusion plasmid with 200 ng of a sgRNA plasmid. To assess the expression level of Cas9-RT fusions, cell lysates were collected on day 2 post-transfection and analyzed by Western blot using a primary antibody against Cas9. Several Cas9-RT fusions showed appreciable protein expression (FIG. 33 ), suggestive of expression levels sufficient for Gene Writing activity. Notably, a wide range of expression levels is observed for the different Cas9-RT constructs, demonstrating the impact of the fusion design and RT selection on expression level of Cas-RT in cells.

Example 31: Improvement of Expression of Cas-RT Fusions Through Linker Selection

This example demonstrates the optimization of Cas-RT fusions to improve protein expression in mammalian cells. As described in Example 30, construction of novel Cas-RT fusions by the simple substitution of new functional domains may result in low or moderate expression of the Gene Writer polypeptide. Thus, it is contemplated here that modified configurations of the fusion may be advantageous in the context of different domains. Without wishing to be limited by the example, one such approach for improving the expression and stability of new fusions is through the use of a linker library. Here, the peptide linker sequence between the Cas and RT domains of the Cas-RT fusion is varied using a library of linker sequences. More specifically, linkers from Table 42 were used to generate new variants of a Cas9-RT fusion construct previously demonstrating low protein expression (see Example 30 and FIG. 33 ) and delivered to human cells to screen for improved Cas-RT protein expression.

A set of 22 peptide linkers (Table 42) with varying degrees of length, flexibility, hydrophobicity, and secondary structure was first used to generate variants of a Cas-RT fusion protein by substitution of the original linker (see Example 30). HEK293T cells were transfected by electroporation of 250,000 cells/well with ˜800 ng of each Cas9-RT fusion plasmid along with 200 ng of a single-guide RNA plasmid. To assess the expression level of Cas9-RT fusions, cell lysates were collected on day 2 post-transfection and analyzed by Western blot using a primary antibody against Cas9. Linker 10 listed in Table 42 significantly improved Cas-RT fusion expression (FIG. 34 ), demonstrating the potentially profound impact of the peptide linker sequence on Cas-RT expression.

TABLE 42 Peptide sequences used as linkers between the Cas and RT domains in Gene Writer polypeptides comprising Cas-RT fusions SEQ ID # Linker sequence NO: Notes 1 GGS Short 2 GGGGS 1535 Flexible, short 3 (GGGGS)₂ 3303 Flexible 4 (GGGGS)₃ 3304 Flexible, long 5 (GGGGS)₄ 3305 Flexible, very long 6 (G)₆ 3310 Flexible 7 (G)₈ 3312 Flexible 8 GSAGSAAG 3410 Flexible SGEF 9 (GSSGSS) 1736 Mid 10 (GSSGSS)₂ 3314 Mid, Flexible 11 (GSSGSS)₃ 3316 Mid 12 SGSETPGTS 1023 XTEN ESATPES 13 (EAAAK) 1534 Rigid helix, short 14 (EAAAK)₂ 3317 Rigid helix, mid 15 (EAAAK)₃ 3318 Rigid helix, long 16 PAP Rigid, short 17 PAPAP 3322 Rigid, short 18 PAPAPAPAP 3324 Rigid, mid 19 A(EAAAK)₄AL 3407 Rigid, very EA(EAAAK)₄A long with helices 20 GGGGS(EAAAK) 3408 Flexible- GGGGS helix-flex 21 (EAAAK)GGGGS 3409 Helix-flex- (EAAAK) helix 22 SGGSSGGSSGS 1589 Flexible- ETPGTSESATP XTEN- ESSGGSSGGSS flexible

Example 32: Cas-Mediated Cleavage Activity of Gene Writers Comprising Cas-RT Fusions

This example demonstrates the ability of Cas-RT fusions to retain functionality of the protein domains. Specifically, by assaying cells treated with Gene Writer polypeptides comprising a cleavage-competent Cas domain (cleavase), DNA binding can be read by target site analysis to demonstrate activity of Cas in the context of the fusions. Here, such Cas-RT cleavase fusions in which both nuclease active sites are functional, e.g., Cas9(wild-type)-RT, were co-delivered on plasmid vectors along with a sgRNA-expression plasmid to target the Cas to the AAVS1 site in human cells. Analysis of indel formation at the predicted cleavage site in AAVS1 by Cas-RT cleavase fusions functioned as a readout of both DNA binding activity and endonuclease activity, thereby confirming effective DNA targeting by the Cas-RT fusions.

Cas-RT fusions with fully functional endonuclease domains, e.g., comprising wild-type Cas9 with both nuclease active sites intact, e.g., Cas9(N863), were generated from Cas-RT fusion proteins described herein, e.g., comprising a Cas9 nickase, e.g., Cas9(N863A), in order to increase the sensitivity of detection of DNA binding and cleavage. Since the intact Cas9 nuclease can cut both strands to generate a double-stranded cleavage event in the genome, repair of these sites generates a higher mutation (indel) signal than repair of a single-stranded DNA nick. Thus, the frequency of indel formation of the fusions was compared to that of unfused, wild-type Cas9 in order to assess the maintenance of Cas functionality when placed in the context of the novel Cas-RT fusions.

U2OS or HEK293T cells were transfected by Lonza Amaxa nucleofection of 250,000 cells/well with ˜800 ng of Cas9(WT)-RT fusion plasmid along with 200 ng of a sgRNA plasmid to produce the gRNA targeting Cas9 to AAVS1 (Table 43 gRNA P7). To assess the DNA binding and cleavage activity of Cas9-RT cleavase fusions, genomic DNA (gDNA) was collected on day 3 post-transfection. Indel patterns in the gDNA were analyzed by amplicon sequencing at loci targeted by the sgRNA. Sequencing results were analyzed by the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)). All tested Cas-RT cleavase fusions showed indel formation commensurate to their respective protein expression levels (FIG. 33 ), indicating that Cas-mediated DNA binding activity is retained in Cas-RT fusions (FIG. 35 ).

Example 33: Gene Writers Comprising Cas-RT Fusions with Various RT Domains Enable Precise Editing in Human Cells

This example demonstrates the ability of multiple tested Cas-RT fusions to programmably install mutations in genomic DNA in human cells. More specifically, the reverse transcriptase domain of Cas-RT fusions, e.g., an RT domain described in this application, was varied to determine the genome editing capacity of Cas-RT fusions employing novel RT combinations. Template RNAs were co-delivered on plasmid vectors along with Cas-RT expression plasmids in human cells to determine the Rewriting activity of Cas-RT fusions.

In order to generate domain libraries for Gene Writer polypeptides, Cas effector proteins were selected; see in Table 37 and Table 40A. Additional Cas9 domains were further selected for use in the Gene Writer polypeptides described herein, as features including PAM requirements of a target sequence, predicted mutations for conferring nickase activity (e.g., D10A, H840A, or N863A for SpCas9), and gRNA features including single-guide composition, e.g., specific spacer parameters and gRNA scaffold sequence for conferring polypeptide binding for the cognate Cas enzyme, were able to be determined (Table 40A). Linker sequences to connect Cas and RT domains were collected based on a search for diversity of length, flexibility, and composition in order to optimize fusion proteins (Tables 38 and 42). Optimization of fusion expression by linker screening is further described in Example 31. Reverse transcriptase domains were mined from a variety of sources using literature and RT protein domain signatures as described in this application, including from non-LTR retrotransposons, LTR retrotransposons, group II introns, diversity-generating elements, retrons, telomerases, retroplasmids, retroviruses, and polymerases with evolved RNA-dependent DNA polymerase activity (e.g., an RT domain comprising a sequence from Table 1, Table 3, Table 30, Table 31, Table 44, or Table N41, or a derivative thereof may be used in such an assay).

Specifically, to assess the use of novel RT domains in the context of a Gene Writer polypeptide to successfully edit the genome, a subset of exemplary RT domains from retroviruses was selected for fusion to a Cas9(N863A) nickase. Briefly, a database of POL proteins from Retroviridae was first generated and then prioritized (see The UniProt Consortium Nucleic Acids Res 47(D1):D506-D515 (2019); Mitchell et al. Nucleic Acids Res 47(D1):D351-D360 (2019)). Though not wishing to be limited by such example, retroviral RTs from the genera Betaretrovirus, Deltaretrovirus, Gammaretrovirus, and Spumavirus may function as monomeric proteins (see, for example, Table 1 from Herschhorn et al Cell Mol Life Sci 67(16):2717-2747 (2010)) and thus may be advantageous for use in a fusion protein, as described herein. A selection of retroviral monomeric RT sequences emerging from the analysis with these criteria is shown in Table 44. Further, mutations that have been shown to stabilize RT domains, as described in this application and in the literature (Table 45) (Anzalone et al Nat Biotechnol 38(7):824-844 (2020); Baranauskas et al Protein Eng Des Sel 25(10):657-668 (2012); Arezi and Hogrefe Nucleic Acids Res 37(2):473-481 (2009); Yasukawa et al J Biotechnol 150(3):299-306 (2010); the findings of which as they relate to improving RT stability and function are incorporated herein in their entirety), were analyzed for application to candidate RT domains (positions provided here based on the MMLV RT amino acid sequence as reference). As examples, MMLV RT with the mutational profile L139P/D200N/T330P/L603W/E607K showed an approximately 65-fold increase in processivity and 48-fold increase in template affinity (Baranauskas et al Protein Eng Des Sel 25(10):657-668 (2012)) and increased efficiency of prime editing of genomic DNA by a range of 1.6-5.1-fold with mutational profile D200N/T306K/W313F/T330P/L603W (Anzalone et al Nat Biotechnol 38(7):824-844 (2020)). From these studies, the core set of D200N/T330P/L603W was identified and an alignment of RT domains from the retroviral genera described here was used to predict the relevant amino acid positions where conserved (FIG. 36A). The additional mutations T306K and/or W313F were also applied where relevant and L139P and/or E607K was used when neither mutation of the T306K/W313F set was able to be applied (FIG. 36B). Cas9 nickase fusions with these wild-type RT domains or mutational variants with potentially improved activity were generated and exemplary fusions are described in Table 46.

To generate precise edits using Gene Writer Cas-RT fusions, Template RNAs were constructed to template reverse transcription of an edit into the genomic target site by the RT domain. Template RNAs were designed to comprise (i) a gRNA spacer sequence for guiding the Cas-RT to the target region, e.g., a sequence complementary to a 20-nucleotide sequence in the HEK3 locus; (ii) a primer-binding sequence capable of complementary base pairing with a single strand of the nicked DNA for target-primed reverse transcription; (iii) a heterologous object sequence providing a template for reverse transcription that further comprises the intended final target sequence; and (iv) a gRNA scaffold sequence to associate with the Cas9 domain of the Cas9-RT polypeptide fusion. The constructs employed here specifically followed the 5′ to 3′ orientation (i), (iv), (iii), (ii). Template RNAs encoded on plasmids were cloned such that expression was driven by the U6 promoter and transcription termination controlled by a 7 nt polyT stretch following the primer-binding sequence at the 3′ end of the Template RNA cassette. Template compositions are described in Table 43 (Templates P1, P2, P3).

U2OS or HEK293T cells were transfected by electroporation of 250,000 cells/well with ˜800 ng of Cas9-RT(MMLV) fusion expression plasmid, 200 ng of a Template RNA expression plasmid, and 83 ng of an additional second-nick gRNA (2gRNA P5) expression plasmid (Table 43). To assess the genome editing capacity of Cas-RT fusions, genomic DNA (gDNA) was collected on day 3 post-transfection. The frequency of intended (exact and scarless edit as designed) versus unintended (any non-intended changes to the target sequence) edits (“Activity ratio”) at target loci were analyzed by amplicon sequencing. As used herein, amplicon sequencing of a target site comprises the use of site-specific primers in PCR amplification of the target site, sequencing of amplicons on an Illumina MiSeq, and detection and characterization of editing events using the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)). Several Cas-RT fusions showed appreciable genome editing activity, with multiple Cas-RT fusions having Activity Ratios of ˜3 (FIG. 37 ), demonstrating that various Cas-RT fusions drawing from reverse transcriptase domains described herein can efficiently and precisely encode edits into the human genome.

TABLE 43 List of Template RNA and gRNA used in select examples. Name Description spacer scaffold RT+ins PBS Template RNA Template HEK3_8PBS GGCCCAGACTGA GTTTTAGA TCTGCCATCAA CGTG GGCCCAGACTGAG P1 _10RT GCACGTGA (SEQ GCTAGAAA AG (SEQ ID NO: CTCA CACGTGAGTTTTAG (CTTat1) ID NO: 3574) TAGCAAGT 3576) AGCTAGAAATAGC TAAAATAA AAGTTAAAATAAG GGCTAGTC GCTAGTCCGTTATC CGTTATCA AACTTGAAAAAGT ACTTGAAA GGCACCGAGTCGGT AAGTGGCA GCTCTGCCATCAAA CCGAGTCG GCGTGCTCA (SEQ GTGC (SEQ ID NO: 3577) ID NO: 3575) Template HEK3_13PB GGCCCAGACTGA GTTTTAGA TCTGCCATCAA CGTG GGCCCAGACTGAG P2 S_10RT GCACGTGA (SEQ GCTAGAAA AG (SEQ ID NO: CTCA CACGTGAGTTTTAG (CTTat1) ID NO: 3574) TAGCAAGT 3576) GTCT AGCTAGAAATAGC TAAAATAA G AAGTTAAAATAAG GGCTAGTC (SEQ GCTAGTCCGTTATC CGTTATCA ID AACTTGAAAAAGT ACTTGAAA NO: GGCACCGAGTCGGT AAGTGGCA 3578) GCTCTGCCATCAAA CCGAGTCG GCGTGCTCAGTCTG GTGC (SEQ (SEQ ID NO: 3579) ID NO: 3575) Template HEK3_17PB GGCCCAGACTGA GTTTTAGA TCTGCCATCAA CGTG GGCCCAGACTGAG P3 S_10RT GCACGTGA (SEQ GCTAGAAA AG (SEQ ID NO: CTCA CACGTGAGTTTTAG (CTTat1) ID NO: 3574) TAGCAAGT 3576) GTCT AGCTAGAAATAGC TAAAATAA GGGC AAGTTAAAATAAG GGCTAGTC C GCTAGTCCGTTATC CGTTATCA (SEQ AACTTGAAAAAGT ACTTGAAA ID GGCACCGAGTCGGT AAGTGGCA NO: GCTCTGCCATCAAA CCGAGTCG 3580) GCGTGCTCAGTCTG GTGC (SEQ GGCC (SEQ ID NO: ID NO: 3575) 3581) Template HBB_13PBS_ GCATGGTGCACC GTTTTAGA AGACTTCTCCA GAGT GCATGGTGCACCTG P4 10RT TGACTCCTG GCTAGAAA CAG (SEQ ID CAGG ACTCCTGGTTTTAG (TtoAat4) (SEQ ID NO: 3582) TAGCAAGT NO: 3583) TGCA AGCTAGAAATAGC TAAAATAA C AAGTTAAAATAAG GGCTAGTC (SEQ GCTAGTCCGTTATC CGTTATCA ID AACTTGAAAAAGT ACTTGAAA NO: GGCACCGAGTCGGT AAGTGGCA 3584) GCAGACTTCTCCAC CCGAGTCG AGGAGTCAGGTGC GTGC (SEQ AC (SEQ ID NO: ID NO: 3575) 3585) 2gRNA HEK3_+90 GTCAACCAGTAT GTTTTAGA NA NA NA P5 CCCGGTGC (SEQ GCTAGAAA ID NO: 1717) TAGCAAGT TAAAATAA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC (SEQ ID NO: 3575) 2gRNA HBB_+72 GCCTTGATACCA GTTTTAGA NA NA NA P6 ACCTGCCCA GCTAGAAA (SEQ ID NO: 3586) TAGCAAGT TAAAATAA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC (SEQ ID NO: 3575) gRNA g19_AAVS1 GTCCCCTCCACC GTTTTAGA NA NA NA P7 CCACAGTG (SEQ GCTAGAAA ID NO: 3587) TAGCAAGT TAAAATAA GGCTAGTC CGTTATCA ACTTGAAA AAGTGGCA CCGAGTCG GTGC (SEQ ID NO: 3575)

Example 34: Multiplexing of a Gene Writer System to Simultaneously Edit Multiple Loci in a Human Cell

This example demonstrates the use of a Gene Writer system to edit multiple sites in the genome. In some applications, it may be of high value to be able to engineer multiple locations in the genome, e.g., to correct multiple genetic mutations or to optimize an engineered cell for cell therapy by performing multiple simultaneous modifications ex vivo or in vivo. In this example, a 3-plasmid system is utilized comprising: 1) a Gene Writer polypeptide expression plasmid, e.g., a plasmid encoding a Cas9 nickase fused to a reverse transcriptase (Cas-RT); 2) a Template plasmid, e.g., a plasmid encoding an expression cassette for a Template RNA that determines the genome site and the edit to instill at that site; and 3) a second-nick gRNA expression plasmid, e.g., a plasmid encoding an additional gRNA sequence to direct a second-strand nick for Cas9 at a location proximal to the target site.

In this example, two genome loci, the HBB gene and the human HEK3 locus, were targeted using gRNA comprising spacer sequences with identity to these sites to determine the ability to target multiple loci in parallel. To assess targeting of either locus separately or both simultaneously, cells were treated with different compositions of the Template plasmids to enable targeting of: 1) HEK3 alone, 2) HBB alone, or 3) both HBB and the HEK3 locus. Specifically, 800 ng of plasmid encoding the Cas9-RT(MMLV) fusion (Table 46), 200 ng of plasmid encoding the HEK3-modifying Template (Template P2, Table 43) and/or plasmid encoding the HBB-modifying Template (Template P4, Table 43), and 83 ng of plasmid encoding the HEK3 second-nick gRNA (2gRNA P5, Table 43) and/or plasmid encoding the HBB second-nick gRNA (2gRNA P6, Table 43) were nucleofected using nucleofection program DS_150 into HEK293T cells. After nucleofection, cells were grown at 37° C., 5% C02 for 3 days prior to cell lysis and genomic DNA extraction. Primers specific to each locus were used to amplify the region and amplicons were sequenced using an Illumina MiSeq. Perfect correction and indel rates were analyzed using the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)) to determine Gene Writing efficacy. Table 51 lists the components of the Gene Writer System used in this example.

TABLE 51 Name Description spacer scaffold RT+ins PBS Template RNA Template HEK GGCCCA GTTTTAGAGCT TCTGC CGTGCTC GGCCCAGACTGAGCACGT P1 3_8P GACTGA AGAAATAGCA CATCA A GAGTTTTAGAGCTAGAAA BS_1 GCACGT AGTTAAAATA AAG TAGCAAGTTAAAATAAGG ORT GA (SEQ AGGCTAGTCC (SEQ CTAGTCCGTTATCAACTTG (CTTa ID NO: GTTATCAACTT ID NO: AAAAAGTGGCACCGAGTC t1) 3574) GAAAAAGTGG 3576) GGTGCTCTGCCATCAAAG CACCGAGTCG CGTGCTCA (SEQ ID NO: GTGC (SEQ ID 3577) NO: 3575) Template HEK GGCCCA GTTTTAGAGCT TCTGC CGTGCTC GGCCCAGACTGAGCACGT P2 3_13 GACTGA AGAAATAGCA CATCA AGTCTG GAGTTTTAGAGCTAGAAA PBS_ GCACGT AGTTAAAATA AAG (SEQ ID TAGCAAGTTAAAATAAGG 10RT GA (SEQ AGGCTAGTCC (SEQ NO: 3578) CTAGTCCGTTATCAACTTG (CTT ID NO: GTTATCAACTT ID NO: AAAAAGTGGCACCGAGTC at1) 3574) GAAAAAGTGG 3576) GGTGCTCTGCCATCAAAG CACCGAGTCG CGTGCTCAGTCTG (SEQ ID GTGC (SEQ ID NO: 3579) NO: 3575) Template HEK GGCCCA GTTTTAGAGCT TCTGC CGTGCTC GGCCCAGACTGAGCACGT P3 3_17 GACTGA AGAAATAGCA CATCA AGTCTG GAGTTTTAGAGCTAGAAA PBS_ GCACGT AGTTAAAATA AAG GGCC TAGCAAGTTAAAATAAGG 10RT GA (SEQ AGGCTAGTCC (SEQ (SEQ ID CTAGTCCGTTATCAACTTG (CTT ID NO: GTTATCAACTT ID NO: NO: 3580) AAAAAGTGGCACCGAGTC at1) 3574) GAAAAAGTGG 3576) GGTGCTCTGCCATCAAAG CACCGAGTCG CGTGCTCAGTCTGGGCC GTGC (SEQ ID (SEQ ID NO: 3581) NO: 3575) Template HBB_ GCATGG GTTTTAGAGCT AGAC GAGTCA GCATGGTGCACCTGACTC P4 13P TGCACC AGAAATAGCA TTCTC GGTGCA CTGGTTTTAGAGCTAGAA BS_1 TGACTC AGTTAAAATA CACA C (SEQ ID ATAGCAAGTTAAAATAAG ORT CTG AGGCTAGTCC G (SEQ NO: 3584) GCTAGTCCGTTATCAACTT (TtoA (SEQ ID GTTATCAACTT ID NO: GAAAAAGTGGCACCGAGT at4) NO: 3582) GAAAAAGTGG 3583) CGGTGCAGACTTCTCCAC CACCGAGTCG AGGAGTCAGGTGCAC GTGC (SEQ ID (SEQ ID NO: 3585) NO: 3575) 2gRNA HEK3_+90 GTCAAC GTTTTAGAGCT NA NA NA P5 CAGTAT AGAAATAGCA CCCGGT AGTTAAAATA GC (SEQ AGGCTAGTCC ID NO: GTTATCAACTT 1717) GAAAAAGTGG CACCGAGTCG GTGC (SEQ ID NO: 3575) 2gRNA HBB_+72 GCCTTG GTTTTAGAGCT NA NA NA P6 ATACCA AGAAATAGCA ACCTGC AGTTAAAATA CCA AGGCTAGTCC (SEQ ID GTTATCAACTT NO: 3586) GAAAAAGTGG CACCGAGTCG GTGC (SEQ ID NO: 3575) gRNA g19_ GTCCCC GTTTTAGAGCT NA NA NA P7 AAV TCCACC AGAAATAGCA S1 CCACAG AGTTAAAATA TG (SEQ AGGCTAGTCC ID NO: GTTATCAACTT 3587) GAAAAAGTGG CACCGAGTCG GTGC (SEQ ID NO: 3575) When tested independently, both targets saw a high degree of precise correction, with approximately 36% editing in HEK3 and 23% editing in HBB (FIG. 38 ). Further, when targeted at the same time, approximately 34% editing of HEK3 and 14% editing of HBB target sites was achieved with precise correction conferred by the respective Template RNAs. Additionally, insertions and deletions were observed with low frequency in all conditions, with indels for each locus reaching similar levels when tested alone or in combination. Though not the express intent of this example, the lack of increase in indels during simultaneous editing is a positive indicator for the potential to increase the number of loci targetable in parallel without compromising the precision of each individual edit.

Example 35: Delivery of DNA-Free Gene Writer Systems Through Nucleofection of Human Cells

This example describes the application of a Gene Writer system to edit the genome in human cells via delivery of RNA components, e.g., mRNA encoding the Gene Writer polypeptide and an RNA template. Without wishing to be bound by theory, the ability to deliver only RNA components in the absence of DNA is expected to confer major advantages to this system, including a reduction in immunogenicity and cellular toxicity linked to the detection of DNA in the cytoplasm and the availability of lipid nanoparticles systems described herein, the majority of which are optimized for RNA delivery, that can circumvent issues associated with viral delivery of nucleic acid therapeutics (e.g., manufacturing challenges, pre-existing immunity, immunogenic response to viral proteins). The reduction in cellular toxicity through use of an RNA system may be especially important for the modification of more sensitive cell types, such as primary cells. Further, nucleofection may be an effective method of delivering these systems to a patient's cells, e.g., for ex vivo cell engineering. Thus, it is of significant value to demonstrate the capacity of a Gene Writing system to function appropriately when delivered as all RNA and in the absence of DNA. Specifically, this example demonstrates delivery of an all-RNA Gene Writing system to modify the genome of HEK293T cells. To demonstrate RNA-based Gene Writing is not limited to a single composition, two versions of a Cas-RT fusion polypeptide are employed that comprise an RT domain derived from either Moloney murine leukemia virus (Cas9-RT(MMLV)) or porcine endogenous retrovirus (Cas9-RT(PERV)) (Table 46).

Gene Writer polypeptide-encoding mRNAs (1) were generated using T7 polymerase-driven in vitro transcription. In general, plasmids encoding the mRNA constructs comprised a transcriptional cassette comprising the following components: T7 promoter, 5′UTR, Gene Writer coding sequence (Cas9 nickase fused with a reverse transcriptase by a peptide linker and further comprising a nuclear localization signal), 3′UTR, and an 80 nt polyA tail (SEQ ID NO: 3666). In this example, RNA molecules were prepared using unmodified nucleotides from linearized plasmid template. The mRNAs encoding Cas9-RT(MMLV) or Cas9-RT(PERV) (Table47) were co-transcriptionally capped with CleanCap AG (TriLink BioTechnologies).

Gene Writer Template RNAs (2) encoding genomic edits were generated by chemical synthesis and purified by standard desalting. The first and last three bases of each Template RNA comprised 2′-O-methyl phosphorothioate modifications. Template RNAs of varying length were designed to introduce different mutations into the human HEK3 locus (Table 48).

Where indicated, second nick gRNAs (3) were generated by chemical synthesis and comprised the following sequence modifications:

(SEQ ID NO: 3588) mG*mC*mA*rGrArArArUrArGrArCrUrArArUrUr GrCrArGrUrUrUrUrArGrArGrCrUrArGrArArAr UrArGrCrArArGrUrUrArArArArUrArArGrGrCr UrArGrUrCrCrGrUrUrArUrCrArArCrUrUrGrAr ArArArArGrUrGrGrCrArCrCrGrArGrUrCrGrGr UrGrCmU*mU*mU*rU.

To assay the RNA Gene Writing systems described herein, HEK293T cells were plated 2 days before nucleofection to obtain 70-80% confluency on the day of nucleofection. RNAs were mixed according to the following combinations: i) Cas9-RT mRNA (1) only; ii) Cas9-RT mRNA (1), template RNA (2), and second nick gRNA (3); or iii) Cas9-RT mRNA (1) and template RNA (2). RNA mixes comprised 4.5 μg of the Cas9-RT mRNA (1), 5 μM final concentration of template RNA (2), and 1.3 μM final concentration of second nick gRNA (3). Mixes were nucleofected into approximately 200,000 cells using the Lonza Amaxa Nucleofector 96 Well Shuttle System, as according to manufacturer's protocols. Cells were then lysed and genomic DNA was collected 72 hours after nucleofection. Amplicon sequencing libraries were prepared using primers to amplify across the target site and Illumina sequencing was performed. Precise correction and indel rates were analyzed using the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)).

In these experiments, approximately 20% precise Writing activity was achieved with Cas9-RT(MMLV) using Template 1 (Table 48). A drop in activity was observed for templates that were longer than 120 nt in length; Template 4, which encoded the same edit as Template 1, but with an addition of 20 nt at the 3′ end of the RT template, showed an approximately 3.1-fold drop in precise Writing activity and an approximately 2.4-fold drop in the ratio of precise corrections to indels (FIG. 39 ). The use of Cas9-RT-encoding mRNAs with different UTRs and capping approaches produced similar levels of activity, though there was a slight increase with mRNA-5 (Table 49; FIG. 40 ). The all-RNA nucleofection of the Gene Writer Cas9-RT(PERV) with Template 1 and the second-nick gRNA further resulted in a precise Writing efficiency of approximately 7% (FIG. 41 ). Across the experiments of this example, the addition of the second-nick gRNA resulted in an increase in Writing activity.

Table 48 provides sequences of Template RNA molecules used in all-RNA Gene Writing Examples. The spacer sequence of each Template RNA described here was kept constant and comprised 20 nt (5′-GGCCCAGACTGAGCACGTGA-3′ (SEQ ID NO: 3574)) of 100% identity to a target site in the human HEK3 locus (also known as LINC01509) (sequence maps to NC_000009.12:107422339..107422358, assembly GRCh38.p13). A Template RNA will typically comprise the components shown in the table, such that spacer+scaffold+RT+edit+PBS+Tail can yield the complete molecule.

TABLE 48 Template RNAs used in various Examples disclosed herein Descrip- TemplateRNA RNA Name tion spacer scaffold RT+edit PBS Tail Combined Sequence Length Template HEK3_13P GGCC GTTT TCTG CGT TTTT GGCC mG*mG*mC*r 126 1 BS_10RT(C CAGA TAGA CCAT GCT CAGA CrCrArGrAr TTat1) CTGA GCTA CAAA CA CTGA CrUrGrArGr GCAC GAAA G GTC GCAC CrArCrGrUr GTGA TAGC (SEQ ID TG GTGA GrArGrUrUr (SEQ AAGT NO: 3576) (SEQ GTTT UrUrArGrAr ID TAAA ID TAGA GrCrUrArGr NO: ATAA NO:  GCTA ArArArUrAr 3574) GGCT 3578) GAAA GrCrArArGr AGTC TAGC UrUrArArAr CGTT AAGT ÅrUrArArGr ATCA TAAA GrCrUrArGr ACTT ATAA UrCrCrGrUr GAAA GGCT UrArUrCrAr AAGT AGTC ArCrUrUrGr GGCA CGTT ArArArArAr CCGA ATCA GrUrGrGrCr GTCG ACTT ArCrCrGrAr GTGC GAAA GrUrCrGrGr (SEQ ID AAGT UrGrCrUrCr NO: 3575) GGCA UrGrCrCrAr CCGA UrCrArArAr GTCG GrCrGrUrGr GTGC CrUrCrArGr TCTG UrCrUrGrU* CCAT mU*mU*mU CAAA (SEQ ID  GCGT NO: 3590) GCTC AGTC TGTT TT  (SEQ ID NO: 3589) Template HEK3_13P GGCC GTTT TCTG CGT TTTT GGCC mG*mG*mC*r 133 2 BS_10RT CAGA TAGA CCAT GCT CAGA CrCrArGrAr (10 CTGA GCTA CACA CA CTGA CrUrGrArGr nts at1) GCAC GAAA TGTA GTC GCAC CrArCrGrUr GTGA TAGC GTTG TG GTGA GrArGrUrUr (SEQ AAGT (SEQ ID (SEQ GTTT UrUrArGrAr ID TAAA NO: 3591) ID TAGA GrCrUrArGr NO: ATAA NO:  GCTA ArArArUrAr 3574) GGCT 3578) GAAA GrCrArArGr AGTC TAGC UrUrArArAr CGTT AAGT ArUrArArGr ATCA TAAA GrCrUrArGr ACTT ATAA UrCrCrGrUr GAAA GGCT UrArUrCrAr AAGT AGTC ArCrUrUrGr GGCA CGTT ArArArArAr CCGA ATCA GrUrGrGrCr GTCG ACTT ArCrCrGrAr GTGC GAAA GrUrCrGrGr (SEQ ID AAGT UrGrCrUrCr NO: 3575) GGCA UrGrCrCrAr CCGA UrCrArCrAr GTCG UrGrUrArGr GTGC UrUrGrCrGr TCTG UrGrCrUrCr CCAT ArGrUrCrUr CACA GrU*mU*mU* TGTA mU (SEQ ID GTTG NO: 3593) CGTG CTCA GTCT GTTT T  (SEQ ID NO: 3592) Template HEK3_13P GGCC GTTT TCTG CGT TTTT GGCC mG*mG*mC* 143 3 BS_10RT CAGA TAGA CCAT GCT CAGA rCrC (20 CTGA GCTA CACA CA CTGA rArGrArCrU nts at1) GCAC GAAA TGTA GTC GCAC rGrArGrCrA GTGA TAGC GTTG TG GTGA rCrGrUrGrA (SEQ AAGT AGGT (SEQ GTTT rGrUrUrUrU NO: TAAA CAAT ID TAGA rArGrArGrC 3574) ATAA GA  NO:  GCTA rUrArGrArA GGCT (SEQ ID 3578) GAAA rArUrArGrC AGTC NO:3594) TAGC rArArGrUrU CGTT AAGT rArArArArU ATCA TAAA rArArGrGrC ACTT ATAA rUrArGrUrC GAAA GGCT rCrGrUrUrA AAGT AGTC rUrCrArArC GGCA CGTT rUrUrGrArA CCGA ATCA rArArArGrU GTCG ACTT rGrGrCrArC GTGC GAAA rCrGrArGrU (SEQ ID AAGT rCrGrGrUrG NO: 3575) GGCA rCrUrCrUrG CCGA rCrCrArUrC GTCG rArCrArUrG GTGC rUrArGrUrU TCTG rGrArGrGrU CCAT rCrArArUrG CACA rArCrGrUrG TGTA rCrUrCrArG GTTG rUrCrUrGrU AGGT *mU*mU*mU  CAAT (SEQ GACG ID NO: TGCT 3596) CAGT CTGT TTT  (SEQ  ID NO: 3595) Template HEK3 13P GGCC GTTT GGAA CGT TTTT GGCC mG*mG*mC*r 146 4 BS_30RT CAGA TAGA GCAG GCT CAGA CrCrArGrAr (CTTat1) CTGA GCTA GGCT CA CTGA CrUrGrArGr GCAC GAAA TCCT GTC GCAC CrArCrGrUr GTGA TAGC TTCC TG GTGA GrArGrUrUr (SEQ AAGT TCTG (SEQ GTTT UrUrArGrAr ID TAAA CCAT ID TAGA GrCrUrArGr NO: ATAA CAAA NO:  GCTA ArArArUrAr 3574) GGCT G  3578) GAAA GrCrArArGr AGTC (SEQ ID TAGC UrUrArArAr CGTT NO: 3597) AAGT ÅrUrArArGr ATCA TAAA GrCrUrArGr ACTT ATAA UrCrCrGrUr GAAA GGCT UrArUrCrAr AAGT AGTC ArCrUrUrGr GGCA CGTT ArArArArAr CCGA ATCA GrUrGrGrCr GTCG ACTT ArCrCrGrAr GTGC GAAA GrUrCrGrGr (SEQ ID AAGT UrGrCrGrGr NO: 3575) GGCA ArArGrCrAr CCGA GrGrGrCrUr GTCG UrCrCrUrUr GTGC UrCrCrUrCr GGAA UrGrCrCrAr GCAG UrCrArArAr GGCT GrCrGrUrGr TCCT CrUrCrArGr TTCC UrCrUtGrU* TCTG mU*mU*mU CCAT (SEQ ID NO: CAAA 3599) GCGT GCTC AGTC TGTT TT  (SEQ ID NO: 3598) Template HEK3 13P GGCC GTTT GGAA CGT TTTT GGCC mG*mG*mC*r 153 5 BS_30RT CAGA TAGA GCAG GCT CAGA CrCrArGrAr (10 CTGA GCTA GGCT CA CTGA CrUrGrArGr nts at1) GCAC GAAA TCCT GTC GCAC CrArCrGrUr GTGA TAGC TTCC TG GTGA GrArGrUrUr (SEQ AAGT TCTG (SEQ GTTT UrUrArGrAr ID TAAA CCAT ID TAGA GrCrUrArGr NO: ATAA CACA NO:  GCTA ArArArUrAr 3574) GGCT TGTA 3578) GAAA GrCrArArGr AGTC GTTG TAGC UrUrArArAr CGTT (SEQ ID AAGT ArUrArArGr ATCA NO: 3600) TAAA GrCrUrArGr ACTT ATAA UrCrCrGrUr GAAA GGCT UrArUrCrAr AAGT AGTC ArCrUrUrGr GGCA CGTT ArArArArAr CCGA ATCA GrUrGrGrCr GTCG ACTT ArCrCrGrAr GTGC GAAA GrUrCrGrGr (SEQ ID AAGT UrGrCrGrGr NO: 3575) GGCA ArArGrCrAr CCGA GrGrGrCrUr GTCG UrCrCrUrUr GTGC UrCrCrUrCr GGAA UrGrCrCrAr GCAG UrCrArCrAr GGCT UrGrUrArGr TCCT UrUrGrCrGr TTCC UrGrCrUrCr TCTG ArGrUrCrUr CCAT GrU*mU*mU* CACA mU (SEQ ID TGTA NO: 3602) GTTG CGTG CTCA GTCT GTTT T  (SEQ ID NO: 3601) Template HEK3 13P GGCC GTTT GGAA CGT TTTT GGCC mG*mG*mC*r 163 6 BS_30RT CAGA TAGA GCAG GCT CAGA CrCrArGrAr (20 CTGA GCTA GGCT CA CTGA CrUrGrArGr nts at1) GCAC GAAA TCCT GTC GCAC CrArCrGrUr GTGA TAGC TTCC TG GTGA GrArGrUrUr (SEQ AAGT TCTG (SEQ GTTT UrUrArGrAr ID TAAA CCAT ID TAGA GrCrUrArGr NO: ATAA CACA NO:  GCTA ArArArUrAr 3574) GGCT TGTA 3578) GAAA GrCrArArGr AGTC GTTG TAGC UrUrArArAr CGTT AGGT AAGT ArUrArArGr ATCA CAAT TAAA GrCrUrArGr ACTT GA ATAA UrCrCrGrUr GAAA (SEQ ID GGCT UrArUrCrAr AAGT NO: 3603) AGTC ArCrUrUrGr GGCA CGTT ArArArArAr CCGA ATCA GrUrGrGrCr GTCG ACTT ArCrCrGrAr GTGC GAAA GrUrCrGrGr (SEQ ID AAGT UrGrCrGrGr NO: 3575) GGCA ArArGrCrAr CCGA GrGrGrCrUr GTCG UrCrCrUrUr GTGC UrCrCrUrCr GGAA UrGrCrCrAr GCAG UrCrArCrAr GGCT UrGrUrArGr TCCT UrUrGrArGr TTCC GrUrCrArAr TCTG UrGrArCrGr CCAT UrGrCrUrCr CACA ArGrUrCrUr TGTA GrU*mU*mU* GTTG mU(SEQ ID  AGGT NO: 3605) CAAT GACG TGCT CAGT CTGT TTT (SEQ ID NO: 3604)

TABLE 49 Different production and compositions of Gene Writer polypeptide mRNAs used in various Examples Transcription Modified Name template Capping Poly A NTPs 5′ UTR 3′ UTR mRNA-1 PCR CleanCap Added None AGGAAA GCTGGAGCCTCG amplicon (AG); co- during TAAGAG GTGGCCATGCTTC transcrip- amplifi- AGAAAA TTGCCCCTTGGGC tional cation GAAGAG CTCCCCCCAGCCC TAAGAA CTCCTCCCCTTCC GAAATA TGCACCCGTACCC TAAGAG CCGTGGTCTTTGA CCACC ATAAAGTCTGA (SEQ ID (SEQ ID NO: 3606) NO: 3607) mRNA-2 PCR CleanCap Added 5moU AGGAAA GCTGGAGCCTCG amplicon (AG); co- during TAAGAG GTGGCCATGCTTC transcrip- amplifi- AGAAAA TTGCCCCTTGGGC tional cation GAAGAG CTCCCCCCAGCCC TAAGAA CTCCTCCCCTTCC GAAATA TGCACCCGTACCC TAAGAG CCGTGGTCTTTGA CCACC ATAAAGTCTGA (SEQ ID (SEQ ID NO: 3606) NO: 3607) mRNA-3 PCR Enzymatic, Added None GGGAAA GCTGGAGCCTCG amplicon 2′O during TAAGAG GTGGCCATGCTTC Methylated amplifi- AGAAAA TTGCCCCTTGGGC (Cap1); cation GAAGAG CTCCCCCCAGCCC post- TAAGAA CTCCTCCCCTTCC transcrip- GAAATA TGCACCCGTACCC tional TAAGAG CCGTGGTCTTTGA CCACC ATAAAGTCTGA (SEQ ID (SEQ ID NO: 3608) NO: 3607) mRNA-4 PCR Enzymatic, Added 5moU GGGAAA GCTGGAGCCTCG amplicon 2′O during TAAGAG GTGGCCATGCTTC Methylated amplifi- AGAAAA TTGCCCCTTGGGC (Cap1); cation GAAGAG CTCCCCCCAGCCC post- TAAGAA CTCCTCCCCTTCC transcrip- GAAATA TGCACCCGTACCC tional TAAGAG CCGTGGTCTTTGA CCACC ATAAAGTCTGA (SEQ ID (SEQ ID NO: 3608) NO: 3607) mRNA-5 Linearized CleanCap Plasmid None AGGAAA GCTGCCTTCTGCG plasmid (AG); co- - TAAGAG GGGCTTGCCTTCT transcrip- encoded AGAAAA GGCCATGCCCTTC tional GAAGAG TTCTCTCCCTTGC TAAGAA ACCTGTACCTCTT GAAATA GGTCTTTGAATAA TAAGAG AGCCTGAGTAGG CCACC AAGTCTA (SEQ ID (SEQ ID NO: 3606) NO: 3609)

Example 36: Use of Modified Nucleotides in an all-RNA Gene Writer System

This example describes the application of a Gene Writer system to edit the genome in human cells via delivery of RNA components, e.g., mRNA encoding the Gene Writer polypeptide and an RNA template. Further to the demonstration of the DNA-free system in Example 35, this example describes the incorporation of modified nucleotides, e.g., 5-methoxyuridine, into the mRNA encoding the Gene Writer polypeptide, and the incorporation of modified nucleotides, e.g. 2′-O-methyl phosphorothioate, into the Gene Writer template RNA.

Gene Writer polypeptide-encoding mRNAs (1) were generated using T7 polymerase-driven in vitro transcription of an amplicon generated from a plasmid by PCR. The plasmid encoding the mRNA construct comprised a transcriptional cassette comprising the following components: T7 promoter, 5′UTR, Gene Writer coding sequence (Cas9 nickase fused with a reverse transcriptase by a peptide linker and further comprising a bipartite SV40 NLS), and a 3′UTR. A poly A tail component was added such that it was encoded in the amplicon serving as the template for RNA transcription. In this example, mRNA molecules were prepared by incorporating one modified nucleotide, 5-methoxyuridine (5moU), into the transcription reaction. The mRNA encoding Cas9-RT(MMLV) (Table 47) was capped either co-transcriptionally with CleanCap AG (TriLink BioTechnologies) or post-transcriptionally via enzymatic capping (2′O methylated, Cap1) (Table 49).

Gene Writer Template RNAs (2) encoding genomic edits were generated by chemical synthesis and purified by standard desalting. The first and last three bases of each Template RNA comprised 2′-O-methyl phosphorothioate modifications. Here, Template 1 was used to introduce a CTT insertion into the human HEK3 locus (Table 48).

Where indicated, second nick gRNAs (3) were generated by chemical synthesis and comprised the following sequence modifications:

(SEQ ID NO: 3588) mG*mC*mA*rGrArArArUrArGrArCrUrArArUrUrGr CrArGrUrUrUrUrArGrArGrCrUrArGrArArArUrAr GrCrArArGrUrUrArArArArUrArArGrGrCrUrArGr UrCrCrGrUrUrArUrCrArArCrUrUrGrArArArArAr GrUrGrGrCrArCrCrGrArGrUrCrGrGrUrGrCmU*mU *mU*rU.

To assay the RNA Gene Writing systems described herein, HEK293T cells were plated 2 days before nucleofection to obtain 70-80% confluency on the day of nucleofection. RNAs were mixed according to the following combinations: i) Cas9-RT mRNA (1) only; ii) Cas9-RT mRNA (1), template RNA (2), and second nick gRNA (3); or iii) Cas9-RT mRNA (1) and template RNA (2). RNA mixes comprised 4.5 μg of the Cas9-RT mRNA (1), 5 μM final concentration of template RNA (2), and 1.3 μM final concentration of second nick gRNA (3). Mixes were nucleofected into approximately 200,000 cells using the Lonza Amaxa Nucleofector 96 Well Shuttle System, as according to manufacturer's protocols. Cells were then lysed and genomic DNA was collected 72 hours after nucleofection. Amplicon sequencing libraries were prepared using primers to amplify across the target site and Illumina sequencing was performed. Precise correction and indel rates were analyzed using the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)).

In these experiments, approximately 20% precise Writing activity was achieved using an all RNA Gene Writing system that incorporated modified nucleotides (5moU) in the mRNA encoding the Gene Writer polypeptide (FIG. 42 ). Notably, the incorporation of the modified nucleotide 5moU did not result in an observable inhibitory effect on Writing efficiency. Similar efficiencies resulted from the mRNA capping methods assayed here (see Table 49). A slight decrease in efficiency was observed in the absence of a second nick gRNA (FIG. 42 ).

Example 37: Delivery of DNA-Free Gene Writer Systems Through Lipid-Based Transfection of Human Cells

This example describes the application of a Gene Writer system to edit the genome in human cells via delivery of RNA components, e.g., mRNA encoding the Gene Writer polypeptide and an RNA template. Without wishing to be bound by theory, the ability to deliver only RNA components in the absence of DNA is expected to confer major advantages to this system, including a reduction in immunogenicity and cellular toxicity linked to the detection of DNA in the cytoplasm and the availability of lipid nanoparticles systems described herein, the majority of which are optimized for RNA delivery, that can circumvent issues associated with viral delivery of nucleic acid therapeutics (e.g., manufacturing challenges, pre-existing immunity, immunogenic response to viral proteins). The reduction in cellular toxicity through use of an RNA system may be especially important for the modification of more sensitive cell types, such as primary cells. Lipid transfection reagents may be utilized directly for ex vivo cell engineering and lipid-based nanoparticles are suitable for in vivo RNA delivery to a patient's cells. Thus, it is of significant value to demonstrate the capacity of a Gene Writing system to function appropriately when delivered as all RNA and in the absence of DNA. Specifically, this example demonstrates delivery of an all RNA Gene Writing system to modify the genome of HEK293T cells using the lipid-based transfection reagents Lipofectamine 3000 and MessengerMAX (Invitrogen). To demonstrate RNA-based Gene Writing is not limited to a single composition, two versions of a Cas-RT fusion polypeptide are employed that comprise an RT domain derived from either Moloney murine leukemia virus (Cas9-RT(MMLV)) or porcine endogenous retrovirus (Cas9-RT(PERV)) (Table 46).

Gene Writer polypeptide-encoding mRNAs (1) were generated using T7 polymerase-driven in vitro transcription. In general, plasmids encoding the mRNA constructs comprised a transcriptional cassette comprising the following components: T7 promoter, 5′UTR, Gene Writer coding sequence (Cas9 nickase fused with a reverse transcriptase by a peptide linker and further comprising a nuclear localization signal), 3′UTR, and an 80 nt polyA tail (SEQ ID NO: 3666). In this example, RNA molecules were prepared using unmodified nucleotides from either linearized plasmid template or using a PCR amplicon of the transcriptional cassette described above. The mRNA encoding Cas9-RT(MMLV) was capped either co-transcriptionally with CleanCap AG (TriLink BioTechnologies) or post-transcriptionally via enzymatic capping (2′O methylated, Cap1) (Table 49). The mRNA encoding Cas9-RT(PERV) was generated from plasmid template and co-transcriptionally capped with CleanCap AG (TriLink BioTechnologies) (Table 47).

Gene Writer Template RNAs (2) encoding genomic edits were generated by chemical synthesis and purified by standard desalting. The first and last three bases of each Template RNA comprised 2′-O-methyl phosphorothioate modifications. Here, Template 1 was used to introduce a CTT insertion into the human HEK3 locus (Table 48).

Where indicated, second nick gRNAs (3) were generated by chemical synthesis and comprised the following sequence modifications:

(SEQ ID NO: 3588) mG*mC*mA*rGrArArArUrArGrArCrUrArArUrUrGr CrArGrUrUrUrUrArGrArGrCrUrArGrArArArUrAr GrCrArArGrUrUrArArArArUrArArGrGrCrUrArGr UrCrCrGrUrUrArUrCrArArCrUrUrGrArArArArAr GrUrGrGrCrArCrCrGrArGrUrCrGrGrUrGrCmU*mU *mU*rU.

To assay the RNA Gene Writing systems described herein, approximately 50,000 HEK293T cells were plated in 24-well plates 1 day before lipofection. RNAs were mixed according to the following combinations: i) Cas9-RT mRNA (1) only; ii) Cas9-RT mRNA (1), template RNA (2), and second nick gRNA (3); or iii) Cas9-RT mRNA (1) and template RNA (2). RNA mixes comprised 0.45 μg of the Cas9-RT mRNA (1), 2.5 pM final concentration of template RNA (2), and 1.0 pM final concentration of second nick gRNA (3). RNAs were mixed with Opti-MEM media (Gibco) and Lipofectamine 3000 or MessengerMAX reagent (Invitrogen) and added to cells. Cells were then lysed and genomic DNA was collected 72 hours after nucleofection. Amplicon sequencing libraries were prepared using primers to amplify across the target site and Illumina sequencing was performed. Precise correction and indel rates were analyzed using the CRISPResso2 pipeline (Clement et al Nat Biotechnol 37(3):224-226 (2019)).

In these experiments, up to approximately 17% precise Writing activity was achieved using an all RNA Gene Writing system delivered by lipid-based transfection, approaching efficiencies similar to nucleofection (FIG. 43B; see Example 35 for nucleofection). Lipofectamine 3000 was also used (FIG. 43A). In contrast to nucleofection (Example 35), there was not an observable reduction when utilizing the 20 nt longer Template 4 as compared to Template 1 (Table 48; FIG. 43C). Further, the all-RNA lipofection of the Gene Writer Cas9-RT(PERV) with Template 1 resulted in precise Writing of the desired edit with an efficiency of approximately 3.5% (FIG. 44 ).

Example 38: RNA Gene Writing Enables DNA-Free Precise Editing of Primary T Cells

This example describes the use of a Cas9-RT fusion polypeptide-based Gene Writer system for the genomic editing of target DNA sequences. More specifically, this example describes nucleofection of an all-RNA system into primary CD4+ T cells for Gene Rewriting in primary human cells, e.g., as a means of demonstrating the Gene Rewriter system for ex vivo application.

The all RNA system described here comprised: 1) Gene Writer polypeptide-encoding mRNA, e.g., an RNA encoding the Cas9-RT fusion polypeptide as a driver for programmed gene editing through a targeted nicking and reverse transcription process as described in this invention; 2) a template RNA molecule, e.g., an RNA comprising (i) a gRNA spacer sequence for guiding the driver to the targeted region, e.g., a sequence complementary to a 20-nucleotide sequence in the HEK3 locus; (ii) a primer-binding sequence capable of complementary base pairing with a single strand of the nicked DNA for target-primed reverse transcription; (iii) a heterologous object sequence providing a template for reverse transcription that further comprises the intended final target sequence; and (iv) a gRNA scaffold sequence to associate with the Cas9 domain of the Cas9-RT polypeptide fusion; and 3) an optional additional gRNA to promote second-strand nicking near the target site, e.g., an RNA comprising (i) a spacer sequence for targeting the driver to induce a second nick, on the opposite strand of the first nick guided by the template RNA, at a site proximal to the target site (e.g., within 50-150 nt from the first nick); and (ii) a gRNA scaffold sequence mediating an association with the Cas9 domain of the driver. In this example, the Cas-RT fusion polypeptide (1) (Table 46) comprises a Cas9(N863A) nickase fused to an MMLV reverse transcriptase domain. The template RNAs (2) employed here specifically follow the 5′ to 3′ orientation (i), (iv), (iii), (ii), as listed in the description thereof and are detailed in Table 48 and Example 35.

To deliver the RNA Gene Writer system into primary human CD4+ T cells and validate protein expression, 1,000,000 cells (Human Peripheral Blood CD4+ T Cells, Lonza catalog #2W-200) were stimulated by CD3/CD28 for two days and then nucleofected with 0, 2.5, 5, or 10 pg of mRNA encoding the Cas-RT polypeptide using a Nucleofector 96-well Shuttle System (Lonza) with the EO-115 nucleofection program, as according to manufacturer's protocols. One day post-nucleofection, the efficiency of delivery was assessed by immunoblotting with a Cas9 antibody (Cell Signaling) to measure protein expression of the Gene Writer polypeptide from the nucleofected mRNA (FIG. 45A).

Subsequently, primary human CD4+ T cells were nucleofected with either: (1) 5 pg Gene Writer polypeptide mRNA (Writer only control); (2) 5 pg Gene Writer polypeptide mRNA and 5 pM template RNA, e.g., one of six template RNAs from Table 48 that target the same site of the HEK3 locus, but differ in editing result or design; or (3) 5 pg Gene Writer polypeptide mRNA, 5 pM template RNA, e.g., one of six template RNAs from Table 48, and 2.075 μM of an additional gRNA for generating a second-strand nick, e.g., the second-nick gRNA targeting a sequence 10⁸ nt upstream of the HEK3 target site described in Example 35. Three days post-nucleofection, cells were harvested to examine 1) cell viability after RNA delivery of the Gene Writer system, and 2) editing efficiency on the target site of the genome. To assess the cell viability, the percentage of live cells was measured by flow cytometry after staining cells with a fluorescent live/dead dye (BioLegend). Cell viability was comparable in experimental conditions and in the absence of nucleofection (Untreated control) (FIG. 45B). To evaluate efficiency of editing by the Gene Writing systems, genomic DNA was analyzed by PCR-based amplicon sequencing assay, as described in Example 35. The efficiency of the desired editing (Perfect Write) reached approximately 6.3% using Template 1 (Table 48) with the Gene Writer polypeptide mRNA (FIGS. 46A and B). Here, the addition of a second-nick gRNA (FIG. 46B) resulted in similar levels of editing. Thus, this example demonstrates the use of Gene Writing systems for highly specific editing in primary T cells and further shows the successful application of DNA-free, all-RNA Gene Writing in these cells.

Example 39: Detection of Retrotransposase-Mediated Integration in Human Cells

This example describes the identification of retrotransposons demonstrating functionality in human cells. By assaying native or modified retrotransposons for integration activity, this example demonstrates a method for the selection of retrotransposases comprising protein domains that can be used to recreate retrotransposases in their native domain composition or as components of chimeric or synthetic Gene Writers for engineering the genome of human cells. For example, a retrotransposon successfully producing an integration signal is expected to comprise functional DNA binding, endonuclease, reverse transcriptase, and, optionally, second-strand synthesis activities. In some embodiments, a reverse transcriptase domain from a retrotransposon that has been shown to demonstrate activity as described in this example is used to provide the reverse transcriptase activity in a Gene Writer polypeptide, e.g., as the RT of a Cas-RT fusion polypeptide. The screen described here employs the nucleofection of a two-plasmid system comprising a retrotransposon polypeptide and an inactivated reporter template into human cells to characterize the RT-dependent retrotransposition efficiency of computationally selected retrotransposons.

In this example, a two-plasmid system was employed comprising: 1) a retrotransposon-encoded protein expression driver plasmid, e.g., a plasmid encoding a retrotransposase polypeptide from Table 50, comprising a human codon-optimized retrotransposase coding sequence fused with a HiBit tag for detection of protein expression and driven by the mammalian CMV promoter, and 2) a template plasmid, e.g., a plasmid comprising (i) a promoter for expression in mammalian cells to drive transcription of the RNA template molecule, e.g., a CMV promoter, with the template molecule further comprising (ii) a reporter cassette that is inactive in the context of plasmid-derived expression, e.g., an EGFP expression cassette with coding sequence disrupted by an intron encoded in the opposite orientation (GFPai) flanked by (iii) the untranslated regions (UTRs) of the native retrotransposon that naturally comprises the retrotransposase of (1) (see FIG. 48 ). Here, the GFP reporter is encoded in the absence of a promoter to drive its expression to avoid any loss of signal due to GFP toxicity (see FIG. 48 ).

To deliver the two-plasmid system into U2OS cells, ˜400,000 cells were nucleofected with 88.3 ng driver plasmid (1) and 161.7 ng template plasmid (2) using the Lonza SE Cell Line 96-well Nucleofector™ Kit as per manufacturer's instructions. Three days post-nucleofection, integration efficiency was measured using ddPCR to determine the copy number of integrations per genome. Reverse transcription-dependent retrotransposition activity was measured by using a ddPCR approach that utilized the antisense intron as described below. Expression of the driver protein was measured by HiBit-based bioluminescence assay.

When employing an antisense intron reporter containing intronic sequence within the reporter cassette of the template plasmid, e.g., the GFPai system described here, the intron is present in the plasmid but is spliced out during transcription, thus only reporter DNA derived from the transcript by reverse transcription would lack the intron sequence (FIG. 48 ). To limit detection to only events derived from reverse transcription, a ddPCR Taqman probe was designed to span the splicing junction to hybridize to DNA lacking the intron but not to plasmid DNA still containing the intact intron. The forward and reverse primers were designed upstream and downstream of the probe and within the GFP sequence. This design avoids the possible background from template plasmid directly recombined into the genome without a first transcription step, or from intact template plasmid contaminating the gDNA extraction samples.

Gene Writing systems derived from retrotransposases in Table 50 were assayed as following this example to determine activity in human cells. Analysis of the integration efficiency of 163 candidate retrotransposon systems by ddPCR is shown in FIG. 49 . From the assay described in this example, 25 retrotransposase candidates demonstrated successful trans-integration of the retrotransposon UTR-flanked Template sequence at greater than 0.01 copies/genome on average.

Example 40: Selection of Lipid Reagents with Reduced Aldehyde Content

In this example, lipids are selected for downstream use in lipid nanoparticle formulations containing Gene Writing component nucleic acid(s), and lipids are selected based at least in part on having an absence or low level of contaminating aldehydes. Reactive aldehyde groups in lipid reagents may cause chemical modifications to component nucleic acid(s), e.g., RNA, e.g., template RNA, during LNP formulation. Thus, in some embodiments, the aldehyde content of lipid reagents is minimized.

Liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS) can be used to separate, characterize, and quantify the aldehyde content of reagents, e.g., as described in Zurek et al. The Analyst 124(9):1291-1295 (1999), incorporated herein by reference. Here, each lipid reagent is subjected to LC-MS/MS analysis. The LC/MS-MS method first separates the lipid and one or more impurities with a C8 HPLC column and follows with the detection and structural determination of these molecules with the mass spectrometer. If an aldehyde is present in a lipid reagent, it is quantified using a staple-isotope labeled (SIL) standard that is structurally identical to the aldehyde, but is heavier due to C13 and N15 labeling. An appropriate amount of the SIL standard is spiked into the lipid reagent. The mixture is then subjected to LC-MS/MS analysis. The amount of contaminating aldehyde is determined by multiplying the amount of SIL standard and the peak ratio (unknown/SIL). Any identified aldehyde(s) in the lipid reagents is quantified as described. In some embodiments, lipid raw materials selected for LNP formulation are not found to contain any contaminating aldehyde content above a chosen level. In some embodiments, one or more, and optionally all, lipid reagents used for formulation comprise less than 3% total aldehyde content. In some embodiments, one or more, and optionally all, lipid reagents used for formulation comprise less than 0.3% of any single aldehyde species. In some embodiments, one or more, and optionally all, lipid reagents used in formulation comprise less than 0.3% of any single aldehyde species and less than 3% total aldehyde content.

Example 41: Quantification of RNA Modification Caused by Aldehydes During Formulation

In this example, the RNA molecules are analyzed post-formulation to determine the extent of any modifications that may have happened during the formulation process, e.g., to detect chemical modifications caused by aldehyde contamination of the lipid reagents (see, e.g., Example 40).

RNA modifications can be detected by analysis of ribonucleosides, e.g., as according to the methods of Su et al. Nature Protocols 9:828-841 (2014), incorporated herein by reference in its entirety. In this process, RNA is digested to a mix of nucleosides, and then subjected to LC-MS/MS analysis. RNA post-formulation is contained in LNPs and must first be separated from lipids by coprecipitating with GlycoBlue in 80% isopropanol. After centrifugation, the pellets containing RNA are carefully transferred to a new Eppendorf tube, to which a cocktail of enzymes (benzonase, Phosphodiesterase type 1, phosphatase) is added to digest the RNA into nucleosides. The Eppendorf tube is placed on a preheated Thermomixer at 37° C. for 1 hour. The resulting nucleosides mix is directly analyzed by a LC-MS/MS method that first separates nucleosides and modified nucleosides with a C18 column and then detects them with mass spectrometry.

If aldehyde(s) in lipid reagents have caused chemical modification, data analysis will associate the modified nucleoside(s) with the aldehyde(s). A modified nucleoside can be quantified using a SIL standard which is structurally identical to the native nucleoside except heavier due to C13 and N15 labeling. An appropriate amount of the SIL standard is spiked into the nucleoside digest, which is then subjected to LC-MS/MS analysis. The amount of the modified nucleoside is obtained by multiplying the amount of SIL standard and the peak ratio (unknown/SIL). LC-MS/MS is capable of quantifying all the targeted molecules simultaneously. In some embodiments, the use of lipid reagents with higher contaminating aldehyde content results in higher levels of RNA modification as compared to the use of higher purity lipid reagents as materials during the lipid nanoparticle formulation process. Thus, in preferred embodiments, higher purity lipid reagents are used that result in RNA modification below an acceptable level.

Example 42: Gene Writer™ Enabling Large Insertion into Genomic DNA

This example describes the use of a Gene Writer™ gene editing system to alter a genomic sequence by insertion of a large string of nucleotides.

In this example, the Gene Writer™ polypeptide, gRNA, and writing template are provided as DNA transfected into HEK293T cells. The Gene Writer™ polypeptide uses a Cas9 nickase for both DNA-binding and endonuclease functions. The reverse transcriptase function is derived from the highly processive RT domain of an R2 retrotransposase. The writing template is designed to have homology to the target sequence, while incorporating the genetic payload at the desired position, such that reverse transcription of the template RNA results in the generation of a new DNA strand containing the desired insertion.

To create a large insertion in the human HEK293T cell DNA, the Gene Writer™ polypeptide is used in conjunction with a specific gRNA, which targets the Cas9-containing Gene Writer™ to the target locus, and a template RNA for reverse transcription, which contains an RT-binding motif (3′ UTR from an R2 element) for associating with the reverse transcriptase, a region of homology to the target site for priming reverse transcription, and a genetic payload (GFP expression unit). This complex nicks the target site and then performs TPRT on the template, initiating the reaction by using priming regions on the template that are complementary to the sequence immediately adjacent to the site of the nick and copying the GFP payload into the genomic DNA.

After transfection, cells are incubated for three days to allow for expression of the Gene Writing™ system and conversion of the genomic DNA target. After the incubation period, genomic DNA is extracted from cells. Genomic DNA is then subjected to PCR-based amplification using site-specific primers and amplicons are sequenced on an Illumina MiSeq according to manufacturer's protocols. Sequence analysis is then performed to determine the frequency of reads containing the desired edit.

Example 43: Gene Writers can Integrate Genetic Cargo Independently of the Single-Stranded Template Repair Pathway

This example describes the use of a Gene Writer system in a human cell wherein the single-stranded template repair (SSTR) pathway is inhibited.

In this example, the SSTR pathway will be inhibited using siRNAs against the core components of the pathway: FANCA, FANCD2, FANCE, USP1. Control siRNAs of a non-target control will also be included. 200 k U2OS cells will be nucleofected with 30 pmols (1.5 μM) siRNAs, as well as R2Tg driver and transgene plasmids (trans configuration). Specifically, 250 ng of Plasmids expressing R2Tg, control R2Tg with a mutation in the RT domain, or control R2Tg with an endonuclease inactivating mutation) are used in conjunction with transgene at a 1:4 molar ratio (driver to transgene). Transfections of U2OS cells is performed in SE buffer using program DN100. After nucleofection, cells are grown in complete medium for 3 days. gDNA is harvested on day 3 and ddPCR is performed to assess integration at the rDNA site. Transgene integration at rDNA is detected in the absence of core SSTR pathway components.

Example 44: Formulation of Lipid Nanoparticles Encapsulating Firefly Luciferase mRNA

In this example, a reporter mRNA encoding firefly luciferase was formulated into lipid nanoparticles comprising different ionizable lipids. Lipid nanoparticle (LNP) components (ionizable lipid, helper lipid, sterol, PEG) were dissolved in 100% ethanol with the lipid component. These were then prepared at molar ratios of 50:10:38.5:1.5 using ionizable lipid LIPIDV004 or LIPIDV005 (Table A1), DSPC, cholesterol, and DMG-PEG 2000, respectively. Firefly Luciferase mRNA-LNPs containing the ionizable lipid LIPIDV003 (Table A1) were prepared at a molar ratio of 45:9:44:2 using LIPIDV003, DSPC, cholesterol, and DMG-PEG 2000, respectively. Firefly luciferase mRNA used in these formulations was produced by in vitro transcription and encoded the Firefly Luciferase protein, further comprising a 5′ cap, 5′ and 3′ UTRs, and a polyA tail. The mRNA was synthesized under standard conditions for T7 RNA polymerase in vitro transcription with co-transcriptional capping, but with the nucleotide triphosphate UTP 100% substituted with N1-methyl-pseudouridine triphosphate in the reaction. Purified mRNA was dissolved in 25 mM sodium citrate, pH 4 to a concentration of 0.1 mg/mL.

Firefly Luciferase mRNA was formulated into LNPs with a lipid amine to RNA phosphate (N:P) molar ratio of 6. The LNPs were formed by microfluidic mixing of the lipid and RNA solutions using a Precision Nanosystems NanoAssemblr™ Benchtop Instrument, using the manufacturer's recommended settings. A 3:1 ratio of aqueous to organic solvent was maintained during mixing using differential flow rates. After mixing, the LNPs were collected and dialyzed in 15 mM Tris, 5% sucrose buffer at 4° C. overnight. The Firefly Luciferase mRNA-LNP formulation was concentrated by centrifugation with Amicon 10 kDa centrifugal filters (Millipore). The resulting mixture was then filtered using a 0.2 m sterile filter. The final LNP was stored at −80° C. until further use.

TABLE A1 Ionizable Lipids used in Example 44 (Formula (ix), (vii), and (iii)) Molecular LIPID ID Chemical Name Weight Structure LIPIDV003 (9Z,12Z)-3-((4,4- bis(octyloxy)butanoyl) oxy)-2-((((3-(diethylamino) propoxy)carbonyl)oxy) methyl)propyl octadeca-9,12-dienoate 852.29

LIPIDV004 Heptadecan-9-yl 8-((2- hydroxyethyl)(8-(nonyloxy)-8- oxooctyl)amino)octanoate 710.18

LIPIDV005 919.56

Prepared LNPs were analyzed for size, uniformity, and % RNA encapsulation. The size and uniformity measurements were performed by dynamic light scattering using a Malvern Zetasizer DLS instrument (Malvern Panalytical). LNPs were diluted in PBS prior to being measured by DLS to determine the average particle size (nanometers, nm) and polydispersity index (pdi). The particle sizes of the Firefly Luciferase mRNA-LNPs are shown in Table A2.

TABLE A2 LNP particle size and uniformity LNP ID Ionizable Lipid Particle Size (nm) pdi LNPV019-002 LIPIDV005 77 0.04 LNPV006-006 LIPIDV004 71 0.08 LNPV011-003 LIPIDV003 87 0.08

The percent encapsulation of luciferase mRNA was measured by the fluorescence-based RNA quantification assay Ribogreen (ThermoFisher Scientific). LNP samples were diluted in 1×TE buffer and mixed with the Ribogreen reagent per manufacturer's recommendations and measured on a i3 SpectraMax spectrophotomer (Molecular Devices) using 644 nm excitation and 673 nm emission wavelengths. To determine the percent encapsulation, LNPs were measured using the Ribogreen assay with intact LNPs and disrupted LNPs, where the particles were incubated with 1×TE buffer containing 0.2% (w/w) Triton-X100 to disrupt particles to allow encapsulated RNA to interact with the Ribogreen reagent. The samples were again measured on the i3 SpectraMax spectrophotometer to determine the total amount of RNA present. Total RNA was subtracted from the amount of RNA detected when the LNPs were intact to determine the fraction encapsulated. Values were multiplied by 100 to determine the percent encapsulation. The Firefly Luciferase mRNA-LNPs that were measured by Ribogreen and the percent RNA encapsulation is reported in Table A3.

TABLE A3 RNA encapsulation after LNP formulation LNP ID Ionizable Lipid % mRNA encapsulation LNPV019-002 LIPIDV005 98 LNPV006-006 LIPIDV004 92 LNPV011-003 LIPIDV003 97

Example 45: In Vitro Activity Testing of mRNA-LNPs in Primary Hepatocytes

In this example, LNPs comprising the luciferase reporter mRNA were used to deliver the RNA cargo into cells in culture. Primary mouse or primary human hepatocytes were thawed and plated in collagen-coated 96-well tissue culture plates at a density of 30,000 or 50,000 cells per well, respectively. The cells were plated in 1×William's Media E with no phenol red and incubated at 37° C. with 5% C02. After 4 hours, the medium was replaced with maintenance medium (1× William's Media E with no phenol containing Hepatocyte Maintenance Supplement Pack (ThermoFisher Scientific)) and cells were grown overnight at 37° C. with 5% C02. Firefly Luciferase mRNA-LNPs were thawed at 4° C. and gently mixed. The LNPs were diluted to the appropriate concentration in maintenance media containing 7.5% fetal bovine serum. The LNPs were incubated at 37° C. for 5 minutes prior to being added to the plated primary hepatocytes. To assess delivery of RNA cargo to cells, LNPs were incubated with primary hepatocytes for 24 hours and cells were then harvested and lysed for a Luciferase activity assay. Briefly, medium was aspirated from each well followed by a wash with 1×PBS. The PBS was aspirated from each well and 200 μL passive lysis buffer (PLB) (Promega) was added back to each well and then placed on a plate shaker for 10 minutes. The lysed cells in PLB were frozen and stored at −80° C. until luciferase activity assay was performed.

To perform the luciferase activity assay, cellular lysates in passive lysis buffer were thawed, transferred to a round bottom 96-well microtiter plate and spun down at 15,000 g at 4° C. for 3 min to remove cellular debris. The concentration of protein was measured for each sample using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific) according to the manufacturer's instructions. Protein concentrations were used to normalize for cell numbers and determine appropriate dilutions of lysates for the luciferase assay. The luciferase activity assay was performed in white-walled 96-well microtiter plates using the luciferase assay reagent (Promega) according to manufacturer's instructions and luminescence was measured using an i3X SpectraMax plate reader (Molecular Devices). The results of the dose-response of Firefly luciferase activity mediated by the Firefly mRNA-LNPs are shown in FIGS. 50A and B and indicate successful LNP-mediated delivery of RNA into primary cells in culture. As shown in FIG. 50A, LNPs formulated as according to Example 44 were analyzed for delivery of cargo to primary human (A) and mouse (B) hepatocytes, as according to Example 45. The luciferase assay revealed dose-responsive luciferase activity from cell lysates, indicating successful delivery of RNA to the cells and expression of Firefly luciferase from the mRNA cargo.

Example 46: LNP-Mediated Delivery of RNA to the Mouse Liver

To measure the effectiveness of LNP-mediated delivery of firefly luciferase containing particles to the liver, LNPs were formulated and characterized as described in Example 44 and tested in vitro prior (Example 45) to administration to mice. C57BL/6 male mice (Charles River Labs) at approximately 8 weeks of age were dosed with LNPs via intravenous (i.v.) route at 1 mg/kg. Vehicle control animals were dosed i.v. with 300 μL phosphate buffered saline. Mice were injected via intraperitoneal route with dexamethasone at 5 mg/kg 30 minutes prior to injection of LNPs. Tissues were collected at necropsy at or 6, 24, 48 hours after LNP administration with a group size of 5 mice per time point. Liver and other tissue samples were collected, snap-frozen in liquid nitrogen, and stored at −80° C. until analysis. Frozen liver samples were pulverized on dry ice and transferred to homogenization tubes containing lysing matrix D beads (MP Biomedical). Ice-cold 1× luciferase cell culture lysis reagent (CCLR) (Promega) was added to each tube and the samples were homogenized in a Fast Prep-24 5G Homogenizer (MP Biomedical) at 6 m/s for 40 seconds. The samples were transferred to a clean microcentrifuge tube and clarified by centrifugation. Prior to luciferase activity assay, the protein concentration of liver homogenates was determined for each sample using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific) according to the manufacturer's instructions. Luciferase activity was measured with 200 pg (total protein) of liver homogenate using the luciferase assay reagent (Promega) according to manufacturer's instructions using an i3X SpectraMax plate reader (Molecular Devices). Liver samples revealed successful delivery of mRNA by all lipid formulations, with reporter activity following the ranking LIPIDV005>LIPIDV004>LIPIDV003 (FIG. 51 ). As shown in FIG. 51 , Firefly luciferase mRNA-containing LNPs were formulated and delivered to mice by iv, and liver samples were harvested and assayed for luciferase activity at 6, 24, and 48 hours post administration. Reporter activity by the various formulations followed the ranking LIPIDV005>LIPIDV004>LIPIDV003. RNA expression was transient and enzyme levels returned near vehicle background by 48 hours. Post-administration. This assay validated the use of these ionizable lipids and their respective formulations for RNA systems for delivery to the liver.

Without wishing to be limited by example, the lipids and formulations described in this example are support the efficacy for the in vivo delivery of other RNA molecules beyond a reporter mRNA. All-RNA Gene Writing systems can be delivered by the formulations described herein. For example, all-RNA systems employing a Gene Writer polypeptide mRNA, Template RNA, and an optional second-nick gRNA are described for editing the genome in vitro by nucleofection, by using modified nucleotides, by lipofection), and editing cells, e.g., primary T cells. As described in this application, these all-RNA systems have many unique advantages in cellular immunogenicity and toxicity, which is of importance when dealing with more sensitive primary cells, especially immune cells, e.g., T cells, as opposed to immortalized cell culture cell lines. Further, it is contemplated that these all RNA systems could be targeted to alternate tissues and cell types using novel lipid delivery systems as referenced herein, e.g., for delivery to the liver, the lungs, muscle, immune cells, and others, given the function of Gene Writing systems has been validated in multiple cell types in vitro here, and the function of other RNA systems delivered with targeted LNPs is known in the art. The in vivo delivery of Gene Writing systems has potential for great impact in many therapeutic areas, e.g., correcting pathogenic mutations), instilling protective variants, and enhancing cells endogenous to the body, e.g., T cells. Given an appropriate formulation, all-RNA Gene Writing is conceived to enable the manufacture of cell-based therapies in situ in the patient.

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20230272430A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1-108. (canceled)
 109. A polypeptide or a nucleic acid encoding the polypeptide, wherein the polypeptide comprises (i) a reverse transcriptase (RT) domain, (ii) a DNA-binding domain (DBD); and (iii) an endonuclease domain, wherein the RT domain has a sequence of Table 30 or 44, or a sequence having at least 90% identity thereto.
 110. A system for modifying DNA comprising: (a) the polypeptide or a nucleic acid encoding the polypeptide of claim 109; and (b) a template RNA (or DNA encoding the template RNA) comprising, from 5′ to 3′, (i) optionally a sequence that binds a target site, (ii) optionally a sequence that binds the polypeptide, (iii) a heterologous object sequence, and (iv) a 3′ target homology domain.
 111. The system of claim 110, wherein the DBD comprises a CRISPR/Cas domain.
 112. The system of claim 110, wherein the endonuclease domain is a nickase domain.
 113. The system of claim 110, wherein the RT domain comprises one or more mutations relative to a naturally occurring RT domain or an RT domain or functional fragment chosen from Table 30 or
 44. 114. The system of claim 112, wherein the RT domain is positioned C-terminal of the nickase domain in the polypeptide.
 115. The system of claim 110, wherein the polypeptide comprises a linker positioned between the RT domain and the DBD.
 116. The system of claim 110, wherein the linker is between 2-50 amino acids in length.
 117. The system of claim 110, wherein the 3′ target homology domain is complementary to a sequence adjacent to a site to be modified by the system.
 118. The system of claim 110, wherein the heterologous object sequence is complementary to a site to be modified by the system except at a position or positions to be modified.
 119. The system of claim 110, wherein the heterologous object sequence inserts at least 1 nucleotide into the target site.
 120. The system of claim 110, wherein the sequence that binds the polypeptide comprises a gRNA scaffold.
 121. The system of claim 110, wherein the sequence that binds a target site is at least 18 nucleotides long.
 122. The system of claim 110, wherein the sequence that binds a target site is complementary to the second strand of the target site.
 123. The system of claim 110, further comprising a second strand-targeting gRNA that directs the endonuclease domain to nick the second strand.
 124. The system of claim 123, wherein the template RNA further comprises the second strand-targeting gRNA.
 125. The system of claim 123, wherein the second strand-targeting gRNA is disposed on a separate nucleic acid from the template RNA.
 126. The system of claim 110, wherein the template RNA comprises a 2′-O-methyl modified nucleotide.
 127. The system of claim 110, wherein the nucleic acid encoding the polypeptide comprises 5-methoxyuridine.
 128. The system of claim 110, wherein at least 80% of the template RNA present contains one or more modified nucleotides.
 129. The system of claim 110, wherein the polypeptide and/or template RNA are packaged into a virus, viral-like particle, virosome, liposome, vesicle, exosome, or LNP.
 130. The system of claim 110, which is substantially free of pyrogen, virus, fungus, bacterial pathogen, and/or host cell protein contamination.
 131. A method for modifying a target site in genomic DNA in a cell, the method comprising contacting the cell with a system of claim 110, thereby modifying the target site in genomic DNA in a cell.
 132. A method for treating a subject having a disease or condition associated with a genetic defect, the method comprising administering to the subject the system of claim 110, thereby treating the subject having a disease or condition associated with a genetic defect. 